BackgroundUsing	O
antibodies	O
to	O
specific	O
protein	O
antigens	O
is	O
the	O
method	O
of	O
choice	O
to	O
assign	O
and	O
identify	O
cell	O
lineage	O
through	O
simultaneous	O
analysis	O
of	O
surface	O
molecules	O
and	O
intracellular	O
markers	O
.	O

Embryonic	O
stem	O
cell	O
research	O
can	O
be	O
benefited	O
from	O
using	O
antibodies	O
specific	O
to	O
transcriptional	O
factors	O
/	O
markers	O
that	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
or	O
critical	O
for	O
cell	O
lineage	O
.	O

ResultsIn	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
validated	O
antibodies	O
(	O
either	O
monoclonal	O
or	O
polyclonal	O
)	O
specific	O
to	O
human	O
embryonic	O
stem	O
cell	O
antigens	O
and	O
early	O
differentiation	O
transcriptional	O
factors	O
/	O
markers	O
that	O
are	O
critical	O
for	O
cell	O
differentiation	O
into	O
definite	O
lineage	O
.	O

ConclusionThese	O
antibodies	O
enable	O
stem	O
cell	O
biologists	O
to	O
conveniently	O
identify	O
stem	O
cell	O
characteristics	O
and	O
to	O
quantitatively	O
assess	O
differentiation	O
.	O

Although	O
the	O
stem	O
cell	O
concept	O
was	O
introduced	O
decades	O
ago	O
,	O
to	O
date	O
,	O
stem	O
cells	O
can	O
only	O
be	O
defined	O
functionally	O
,	O
not	O
morphologically	O
or	O
phenotypically	O
.	O

Two	O
functions	O
define	O
stem	O
cells	O
.	O

Firstly	O
,	O
they	O
are	O
self	O
-	O
renewing	O
,	O
thus	O
able	O
to	O
propagate	O
to	O
generate	O
additional	O
stem	O
cells	O
.	O

Secondly	O
they	O
can	O
differentiate	O
into	O
various	O
progenitor	O
cells	O
,	O
which	O
commit	O
to	O
further	O
maturation	O
along	O
a	O
specific	O
lineage	O
.	O

While	O
stem	O
cells	O
can	O
be	O
best	O
defined	O
functionally	O
,	O
a	O
good	O
number	O
of	O
molecular	O
markers	O
have	O
been	O
used	O
to	O
prospectively	O
identify	O
various	O
stem	O
cell	O
populations	O
.	O

Although	O
the	O
functional	O
importance	O
of	O
many	O
of	O
these	O
antigens	O
remains	O
unknown	O
,	O
their	O
unique	O
expression	O
pattern	O
and	O
timing	O
of	O
expression	O
provide	O
a	O
useful	O
tool	O
for	O
scientists	O
to	O
identify	O
as	O
well	O
as	O
isolate	O
stem	O
cells	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESC	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
earliest	O
stem	O
cell	O
population	O
[	O
1,2	O
]	O
.	O

This	O
pluripotent	O
population	O
can	O
differentiate	O
into	O
all	O
somatic	O
tissue	O
including	O
germ	O
cells	O
.	O

In	O
the	O
case	O
of	O
human	O
ESC	O
,	O
they	O
can	O
differentiate	O
into	O
some	O
extra	O
-	O
embryonic	O
derivatives	O
as	O
well	O
.	O

Like	O
mouse	O
ESC	O
,	O
human	O
ES	O
cells	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
3	O
]	O
.	O

Gene	O
expression	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
has	O
been	O
investigated	O
among	O
several	O
ES	O
cell	O
lines	O
by	O
a	O
variety	O
of	O
techniques	O
.	O

They	O
include	O
comparison	O
with	O
databases	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
.	O

A	O
list	O
of	O
molecules	O
comprised	O
of	O
known	O
ES	O
-	O
specific	O
or	O
-highly	O
expressed	O
genes	O
and	O
candidates	O
that	O
can	O
serve	O
as	O
markers	O
for	O
human	O
ESCs	O
and	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
has	O
been	O
established	O
[	O
3	O
-	O
11	O
]	O
.	O

For	O
example	O
,	O
pluripotent	O
ESC	O
can	O
be	O
characterized	O
by	O
high	O
level	O
expression	O
of	O
Oct3	O
/	O
4	O
(	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
,	O
Pou5f1	O
)	O
and	O
Nanog	O
,	O
which	O
are	O
a	O
member	O
of	O
POU	O
domain	O
and	O
homeobox	O
transcription	O
factors	O
respectively	O
.	O

A	O
critical	O
amount	O
of	O
Oct3	O
/	O
4	O
and	O
Nanog	O
expression	O
is	O
required	O
to	O
sustain	O
stem	O
-	O
cell	O
pluripotency	O
and	O
both	O
of	O
these	O
markers	O
are	O
downregulated	O
as	O
cells	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
-	O
9	O
]	O
.	O

Antibodies	O
to	O
Oct3	O
/	O
4	O
which	O
cross	O
react	O
with	O
human	O
Oct	O
3	O
/	O
4	O
have	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
presence	O
of	O
undifferentiated	O
ESC	O
.	O

No	O
single	O
marker	O
however	O
is	O
sufficient	O
or	O
unique	O
for	O
identifying	O
ESCs	O
.	O

Oct3	O
/	O
4	O
for	O
example	O
is	O
expressed	O
by	O
germ	O
cells	O
and	O
may	O
be	O
expressed	O
by	O
specific	O
populations	O
later	O
in	O
development	O
.	O

Likewise	O
,	O
Nanog	O
has	O
been	O
shown	O
to	O
express	O
in	O
other	O
tissues	O
.	O

We	O
and	O
other	O
have	O
noted	O
however	O
,	O
that	O
while	O
no	O
single	O
marker	O
is	O
sufficient	O
a	O
constellation	O
of	O
positive	O
and	O
negative	O
markers	O
can	O
in	O
concert	O
unambiguously	O
allow	O
one	O
to	O
define	O
the	O
state	O
of	O
ESC	O
cultures	O
and	O
that	O
surface	O
markers	O
in	O
combination	O
can	O
be	O
used	O
to	O
prospectively	O
sort	O
for	O
ESC	O
.	O

Based	O
on	O
published	O
data	O
at	O
the	O
level	O
of	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
a	O
number	O
of	O
candidate	O
marker	O
genes	O
.	O

We	O
have	O
also	O
expressed	O
the	O
recombinant	O
protein	O
and	O
generated	O
a	O
panel	O
of	O
monoclonal	O
or	O
polyclonal	O
antibodies	O
to	O
these	O
proteins	O
.	O

Using	O
these	O
antibodies	O
we	O
have	O
confirmed	O
the	O
specificity	O
and	O
selectivity	O
of	O
these	O
antibodies	O
on	O
several	O
ESC	O
lines	O
and	O
established	O
their	O
utility	O
as	O
stem	O
cells	O
markers	O
.	O

Our	O
results	O
confirm	O
the	O
expression	O
pattern	O
and	O
timing	O
of	O
these	O
cell	O
markers	O
at	O
the	O
protein	O
level	O
,	O
whereas	O
previous	O
data	O
reported	O
at	O
the	O
level	O
of	O
gene	O
expression	O
.	O

Characterization	O
of	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
by	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
initially	O
selected	O
for	O
their	O
abilities	O
to	O
recognize	O
recombinant	O
proteins	O
in	O
direct	O
ELISAs	O
.	O

A	O
subset	O
were	O
also	O
tested	O
by	O
Western	O
Blot	O
analysis	O
using	O
recombinant	O
proteins	O
and	O
cell	O
lysate	O
to	O
confirm	O
binding	O
to	O
a	O
single	O
epitope	O
.	O

The	O
best	O
clone	O
was	O
later	O
screened	O
for	O
its	O
applications	O
for	O
immunocytochemistry	O
and	O
flow	O
cytometry	O
using	O
various	O
cell	O
lines	O
.	O

Human	O
peripheral	O
blood	O
platelets	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
CD9	O
antibody	O
.	O

MCF-7	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
E	O
-	O
Cadherin	O
and	O
PODXL	O
(	O
podocalyxin	O
-	O
like	O
)	O
antibodies	O
.	O

MG-63	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
GATA1	O
(	O
GATA	O
binding	O
protein	O
1	O
)	O
antibody	O
.	O

Beta	B
-	I
TC6	I
cells	O
were	O
used	O
for	O
screening	O
for	O
mouse	O
anti	O
-	O
human	O
/	O
mouse	O
PDX-1	O
(	O
pancreatic	O
duodenal	O
homeobox-1	O
)	O
antibody	O
.	O

NTERA-2	B
cells	O
were	O
used	O
for	O
screening	O
mouse	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
and	O
SOX2	O
(	O
sex	O
-	O
determining	O
region	O
Y	O
-	O
box	O
2	O
)	O
antibodies	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
affinity	O
-	O
purified	O
using	O
recombinant	O
proteins	O
and	O
validated	O
by	O
direct	O
ELISAs	O
and	O
Western	O
.	O

Caco-2	B
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
GATA6	O
antibody	O
and	O
NTERA-2	B
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	O
Nanog	O
and	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
antibodies	O
(	O
Summarized	O
in	O
Table	O
1	O
)	O
.Table	O
1Summary	O
list	O
of	O
antibody	O
verification	O
by	O
western	O
blot	O
.	O

AntibodySample	O
used	O
for	O
analysisMol	O
.	O

Wt	O
.	O

(	O
KD	O
)	O
Gt	O
×	O
hBrachyurymouse	O
ES	O
-	O
derived	O
EB	O
lysate48Ms	O
×	O
hDPPA5N	O
/	O
AN	O
/	O
AGt	O
×	O
hGATA6Caco2	O
cell	B
lysate65Gt	O
×	O
hNanogNTERA-2	O
cell	O
lysate33Gt	O
×	O
hOct	O
3	O
/	O
4NTERA-2	O
cell	O
lysate39Gt	O
×	O
hPDX1beta	O
-	B
TC	I
6	I
cell	O
lysate32Gt	O
×	O
hSOX17mouse	O
ES	O
-	O
derived	O
EB	O
lysate45Ms	O
×	O
hCD9PBMC25Rt	O
×	O
hGATA-1N	O
/	O
AN	O
/	O
AMs	O
×	O
hE	O
-	O
CadherinMCF-7	O
cell	B
lysate97Ms	O
×	O
hPODXLMCF-7	O
cell	B
lysate57Ms	O
×	O
hSOX2NTERA-2	O
cell	O
lysate36N	O
/	O
A	O
:	O
1	O
.	O

DPPA5	O
is	O
still	O
being	O
subcloned	O
.	O

Only	O
Elisa	O
verification	O
is	O
available.2	O
.	O

The	O
clone	O
for	O
GATA-1	O
(	O
MAB1779	O
)	O
does	O
not	O
work	O
for	O
Western	O
blot	O
application	O
but	O
is	O
useful	O
for	O
IHC	O
,	O
The	O
clone	O
picked	O
for	O
Western	O
blot	O
analysis	O
does	O
not	O
work	O
for	O
IHC	O
(	O
MAB17791	O
,	O
see	O
data	O
in	O
)	O
.After	O

antibodies	O
were	O
validated	O
in	O
direct	O
ELISAs	O
,	O
Western	O
blot	O
or	O
cell	O
lines	O
(	O
Fig.	O
1	O
and	O
data	O
not	O
shown	O
)	O
,	O
they	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
individual	O
molecules	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

When	O
examined	O
by	O
immunohistochemistry	O
,	O
high	O
level	O
of	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
SOX2	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
Fig.	O
2A	O
,	O
2B	O
and	O
2C	O
)	O
.	O

DPPA5	O
(	O
developmental	O
pluripotency	O
associated	O
5	O
)	O
expression	O
was	O
also	O
observed	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
noted	O
that	O
a	O
subset	O
of	O
the	O
proteins	O
used	O
were	O
membrane	O
bound	O
proteins	O
.	O

To	O
test	O
if	O
any	O
of	O
the	O
antibodies	O
generated	O
could	O
recognize	O
an	O
extracellular	O
epitope	O
and	O
thus	O
be	O
used	O
for	O
live	O
cell	O
sorting	O
,	O
we	O
repeated	O
staining	O
of	O
live	O
cells	O
as	O
previously	O
described	O
.	O

The	O
CD9	O
,	O
E	O
-	O
Cadherin	O
and	O
PODXL	O
antibodies	O
recognized	O
an	O
extracellular	O
epitope	O
and	O
their	O
ability	O
to	O
select	O
cells	O
by	O
FACS	O
was	O
confirmed	O
(	O
Fig.	O
3	O
)	O
.	O

Minimal	O
or	O
no	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
detected	O
in	O
the	O
differentiated	O
EBs	O
(	O
Fig.	O
2D	O
,	O
2E	O
and	O
2F	O
)	O
.	O

However	O
,	O
SOX2	O
expression	O
,	O
which	O
is	O
observed	O
in	O
neural	O
progenitor	O
cells	O
,	O
is	O
persistent	O
in	O
subsets	O
of	O
EBs	O
.	O

Figure	O
1Western	O
blot	O
analysis	O
for	O
Gt	O
×	O
hOct3	O
/	O
4	O
(	O
A	O
)	O
,	O
Gt	O
×	O
hNanog	O
(	O
B	O
)	O
and	O
Ms	O
×	O
hSOX2	O
(	O
C	O
)	O
in	O
NTERA-2	B
cell	O
lysate	O
,	O
Ms	O
×	O
hE	O
-	O
Cadherin	O
(	O
D	O
)	O
in	O
MCF-7	B
cell	O
lysate	O
,	O
Ms	O
×	O
hCD9	O
(	O
E	O
)	O
in	O
PBMC	O
lysate	O
and	O
Ms	O
×	O
hPDX-1	O
(	O
F	O
)	O
in	O
β	B
-	I
TC-6	I
cell	B
lysate	O
.	O

Numbers	O
indicate	O
the	O
positions	O
of	O
molecular	O
weight	O
markers	O
.	O

Figure	O
2Undifferentiated	O
human	O
ES	O
cells	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
and	O
differentiated	O
EBs	O
(	O
D	O
,	O
E	O
and	O
F	O
)	O
were	O
analyzed	O
using	O
antibodies	O
to	O
indicated	O
molecular	O
markers	O
.	O

Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
Oct3	O
/	O
4	O
(	O
Red	O
in	O
A	O
and	O
D	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
SOX2	O
(	O
Green	O
in	O
A	O
and	O
D	O
)	O
,	O
goat	O
anti	O
-	O
human	O
E	O
-	O
Cadherin	O
(	O
Red	O
in	O
B	O
and	O
E	O
)	O
,	O
mouse	O
anti	O
-	O
human	O
PODXL	O
(	O
Green	O
in	O
B	O
and	O
E	O
)	O
,	O
and	O
goat	O
anti	O
-	O
human	O
Nanog	O
(	O
Red	O
in	O
C	O
and	O
F	O
)	O
,	O
are	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
in	O
C	O
-	O
F	O
)	O
.	O

Note	O
the	O
dramatic	O
downregulation	O
of	O
ESC	O
specific	O
markers	O
(	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
,	O
and	O
Nanog	O
)	O
in	O
EBs	O
.	O

However	O
,	O
SOX2	O
expression	O
is	O
persistent	O
in	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

Figure	O
3Human	O
embryonic	O
stem	O
cells	O
stained	O
with	O
anti	O
-	O
CD9	O
(	O
A	O
)	O
,	O
anti	O
-	O
E	O
-	O
Cadherin	O
(	O
B	O
)	O
,	O
and	O
anti	O
-	O
PODXL	O
(	O
C	O
)	O
and	O
antigen	O
expression	O
detected	O
by	O
a	O
flow	O
cytometer	O
.	O

The	O
specific	O
staining	O
is	O
indicated	O
by	O
green	O
histogram	O
and	O
corresponding	O
isotype	O
control	O
is	O
indicated	O
by	O
black	O
histogram	O
.	O

Suspension	O
culture	O
with	O
FGF	O
withdrawal	O
is	O
known	O
to	O
induce	O
differentiation	O
of	O
ES	O
cells	O
to	O
all	O
three	O
germ	O
layer	O
precursors	O
[	O
12	O
]	O
.	O

The	O
differentiation	O
status	O
of	O
the	O
EB	O
used	O
here	O
was	O
detected	O
to	O
contain	O
all	O
germ	O
cell	O
markers	O
by	O
RT	O
-	O
PCR	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
order	O
to	O
examine	O
how	O
more	O
antibodies	O
can	O
be	O
used	O
for	O
characterization	O
of	O
early	O
differentiation	O
events	O
from	O
human	O
ES	O
cells	O
,	O
we	O
examined	O
the	O
expressions	O
of	O
endodermal	O
markers	O
,	O
SOX17	O
,	O
GATA6	O
and	O
PDX-1	O
,	O
and	O
mesodermal	O
markers	O
,	O
Brachyury	O
and	O
GATA1	O
,	O
in	O
the	O
undifferentiated	O
human	O
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

Expressions	O
of	O
SOX17	O
,	O
GATA6	O
,	O
PDX-1	O
,	O
Brachyury	O
and	O
GATA1	O
were	O
not	O
detected	O
in	O
undifferentiated	O
human	O
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
to	O
the	O
undifferentiated	O
ES	O
cells	O
,	O
subpopulations	O
of	O
SOX17-	O
,	O
GATA6-	O
,	O
Brachyury-	O
and	O
GATA1-positive	O
cells	O
were	O
observed	O
(	O
Fig	O
4	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
endodermal	O
and	O
mesodermal	O
precursors	O
exist	O
in	O
EBs	O
with	O
FGF	O
withdrawal	O
for	O
8	O
days	O
.	O

However	O
,	O
no	O
PDX-1-positive	O
cells	O
were	O
seen	O
in	O
EBs	O
differentiated	O
with	O
the	O
same	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.Figure	O
4Differentiated	O
EBs	O
were	O
analyzed	O
by	O
either	O
immunocytochemistry	O
or	O
RT	O
-	O
PCR	O
to	O
the	O
indicated	O
molecular	O
markers	O
.	O

(	O
A	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
SOX17	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
Fluoro	O
Nissl	O
nuclear	O
staining	O
(	O
Green	O
)	O
.	O

(	O
B	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
GATA6	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
C	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	O
brachyury	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
D	O
)	O
Immunostaining	O
with	O
mouse	O
anti	O
-	O
human	O
GATA1	O
(	O
Red	O
)	O
.	O

Note	O
that	O
each	O
antibody	O
recognizes	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

(	O
E	O
)	O
The	O
differentiation	O
status	O
of	O
EB	O
is	O
detected	O
by	O
RT	O
-	O
PCR	O
using	O
different	O
germ	O
layer	O
cell	O
markers	O
.	O

Selected	O
endoderm	O
markers	O
AFP	O
,	O
FoxA2	O
;	O
mesoderm	O
markers	O
Hand1	O
,	O
MSX1	O
and	O
ectoderm	O
marker	O
Msl1	O
were	O
all	O
highly	O
expressed	O
in	O
the	O
EB	O
samples	O
while	O
their	O
expression	O
was	O
either	O
undetectable	O
or	O
at	O
low	O
level	O
in	O
the	O
ES	O
samples	O
.	O

G3PDH	O
was	O
a	O
positive	O
control	O
showing	O
similar	O
amount	O
of	O
RNA	O
samples	O
were	O
used	O
for	O
analysis	O
.	O

Examination	O
of	O
cross	O
-	O
reactivity	O
of	O
antibodies	O
on	O
mouse	O
ES	O
and	O
differentiated	O
cellsWe	O
have	O
also	O
examined	O
the	O
cross	O
-	O
reactivities	O
of	O
these	O
antibodies	O
to	O
mouse	O
ES	O
cells	O
using	O
mouse	O
D3	B
ES	O
cell	O
line	O
and	O
mouse	O
fetal	O
endodermal	O
tissue	O
.	O

Cross	O
-	O
reactivity	O
to	O
mouse	O
of	O
goat	O
anti	O
-	O
Oct3	O
/	O
4	O
,	O
goat	O
anti	O
-	O
PDX-1	O
,	O
goat	O
anti	O
-	O
SOX17	O
and	O
mouse	O
anti	O
-	O
SOX2	O
was	O
detected	O
.	O

Minimal	O
cross	O
-	O
reactivity	O
to	O
mouse	O
,	O
measured	O
by	O
10	O
%	O
intensity	O
to	O
human	O
by	O
higher	O
than	O
control	O
cells	O
,	O
was	O
observed	O
in	O
mouse	O
anti	O
-	O
CD9	O
and	O
mouse	O
anti	O
-	O
E	O
-	O
cadherin	O
antibodies	O
.	O

Goat	O
anti	O
-	O
Nanog	O
and	O
mouse	O
anti	O
-	O
PODXL	O
antibodies	O
appear	O
to	O
be	O
human	O
-	O
specific	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
subtypes	O
of	O
monoclonal	O
antibodies	O
were	O
also	O
identified	O
in	O
the	O
best	O
clones	O
.	O

These	O
results	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Summary	O
of	O
antibodies	O
detection	O
in	O
ES	O
and	O
EB	O
samples	O
.	O

AntibodyESEBReactivity	O
to	O
mouseIsotype	O
of	O
monoclonal	O
antibody	O
(	O
Clone	O
No.	O
)	O
Gt	O
×	O
hBrachyuryNoYesNT*Ms	O
×	O
hDPPA5YesNT*NT*ND*Gt	O
×	O
hGATA6NoYesNT*Gt	O
×	O
hNanogYesDownNoGt	O
×	O
hOct	O
3	O
/	O
4YesDownYesGt	O
×	O
hPDX-1NoNoYesGt	O
×	O
hSOX17NoYesYesMs	O
×	O
hCD9YesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
209306	O
)	O
Ms	O
×	O
hE	O
-	O
cadherinYesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
180224	O
)	O
Ms	O
×	O
hGATA1NoYesNT*Rat	O
IgG2B	O
(	O
clone	O
234732	O
)	O
Ms	O
×	O
hPODXLYesNoNoMouse	O
IgG2A	O
(	O
clone	O
222328	O
)	O
Ms	O
×	O
hSOX2YesYesYesMouse	O
IgG2A	O
(	O
clone	O
245610	O
)	O
*NT	O
,	O
Not	O
tested	O
;	O
ND	O
,	O
Not	O
determined	O
.	O

The	O
expression	O
patterns	O
detected	O
using	O
antibodies	O
developed	O
in	O
our	O
facility	O
are	O
consistent	O
with	O
data	O
reported	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
or	O
cDNA	O
microarrays	O
.	O

Moreover	O
several	O
of	O
the	O
monoclonal	O
antibodies	O
have	O
differing	O
heavy	O
chain	O
subunits	O
allowing	O
double	O
labeling	O
using	O
subtype	O
specific	O
markers	O
to	O
be	O
performed	O
.	O

In	O
summary	O
,	O
we	O
have	O
developed	O
a	O
useful	O
collection	O
of	O
antibodies	O
that	O
would	O
be	O
useful	O
for	O
identification	O
of	O
stem	O
cell	O
characteristics	O
and	O
assessment	O
of	O
differentiation	O
.	O

Several	O
additional	O
antibodies	O
to	O
the	O
molecules	O
that	O
have	O
been	O
identified	O
as	O
potential	O
cell	O
lineage	O
markers	O
[	O
13	O
]	O
are	O
currently	O
under	O
development	O
using	O
the	O
same	O
approach	O
.	O

Cloning	O
and	O
expression	O
of	O
Brachyury	O
,	O
DPPA5	O
,	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
GATA1	O
,	O
GATA6	O
,	O
Nanog	O
,	O
Oct3	O
/	O
4	O
,	O
PDX-1	O
,	O
PODXL	O
,	O
SOX2	O
and	O
SOX17Brachyury	O
(	O
aa	O
.	O

1–202	O
)	O
,	O
DPPA5	O
(	O
a.a	O
.	O

1–116	O
)	O
,	O
GATA1	O
(	O
a.a	O
.	O
1–413	O
)	O
,	O
GATA6	O
(	O
aa	O
.	O

1–449	O
)	O
,	O
Nanog	O
(	O
aa	O
.	O

153–305	O
)	O
,	O
Oct3	O
/	O
4	O
(	O
aa	O
.	O
1–265	O
)	O
,	O
PDX-1	O
(	O
aa	O
.	O

1–283	O
)	O
,	O
SOX2	O
(	O
aa	O
.	O
135–317	O
)	O
and	O
SOX17	O
(	O
aa	O
.	O
177–414	O
)	O
were	O
expressed	O
in	O
E.	O
Coli	O
and	O
extracellular	O
domains	O
of	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
were	O
expressed	O
in	O
mouse	O
NSO	O
cells	O
.	O

All	O
proteins	O
were	O
purified	O
and	O
sequenced	O
before	O
they	O
were	O
used	O
as	O
antigens	O
for	O
immunizations	O
and	O
as	O
substrate	O
for	O
antibody	O
screening	O
and	O
subcloning	O
.	O

Production	O
and	O
purification	O
of	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
derived	O
from	O
fusions	O
of	O
mouse	O
myeloma	O
with	O
B	O
cells	O
obtained	O
from	O
BALB	O
/	O
c	O
mice	O
which	O
had	O
been	O
immunized	O
with	O
purified	O
antigen	O
.	O

The	O
IgG	O
fraction	O
of	O
the	O
culture	O
supernatant	O
was	O
purified	O
by	O
Protein	O
G	O
affinity	O
chromatography	O
(	O
Sigma	O
)	O
.	O

Each	O
panel	O
of	O
antibodies	O
was	O
screened	O
and	O
selected	O
for	O
their	O
abilities	O
to	O
detect	O
purified	O
recombinant	O
antigen	O
in	O
direct	O
ELISA	O
and	O
Western	O
blot	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
derived	O
from	O
sera	O
of	O
goats	O
which	O
had	O
been	O
immunized	O
and	O
boost	O
it	O
with	O
purified	O
antigen	O
.	O

Antibody	O
was	O
purified	O
from	O
the	O
sera	O
by	O
an	O
antigen	O
-	O
affinity	O
chromatography	O
.	O

Cells	O
and	O
cell	O
cultureHuman	O
Caco-2	B
,	O
MG-63	B
,	O
MCF-7	B
,	O
NTERA-2	B
and	O
mouse	O
D3	B
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
.	O

Cells	O
were	O
cultured	O
according	O
to	O
the	O
ATCC	O
instructions	O
.	O

Information	O
regarding	O
human	O
ES	O
cell	O
line	O
HSF-6	B
(	O
NIH	O
code	O
UC06	B
)	O
can	O
be	O
obtained	O
at	O
the	O
website	O
[	O
14	O
]	O
.	O

Undifferentiated	O
human	O
ES	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
in	O
human	O
ES	O
culture	O
medium	O
[	O
DMEM	O
supplemented	O
with	O
20	O
%	O
KnockOut	O
Serum	O
Replacement	O
(	O
Invitrogen	O
)	O
and	O
5	O
ng	O
/	O
mL	O
of	O
bFGF	O
(	O
R&D	O
Systems	O
)	O
]	O
.	O

To	O
induce	O
formation	O
of	O
embryoid	O
bodies	O
(	O
EBs	O
)	O
,	O
ES	O
colonies	O
were	O
harvested	O
,	O
separated	O
from	O
the	O
MEF	O
feeder	O
cells	O
by	O
gravity	O
,	O
gently	O
resuspended	O
in	O
ES	O
culture	O
medium	O
and	O
transferred	O
to	O
non	O
-	O
adherent	O
suspension	O
culture	O
dishes	O
(	O
Corning	O
)	O
.	O

Unless	O
otherwise	O
noted	O
,	O
EBs	O
derived	O
from	O
human	O
ES	O
cell	O
aggregates	O
were	O
cultured	O
for	O
8	O
days	O
in	O
ES	O
culture	O
medium	O
deprived	O
of	O
bFGF	O
and	O
used	O
for	O
analysis	O
by	O
immunohistochemistry	O
as	O
described	O
.	O

Western	O
blotCells	O
are	O
solubilized	O
in	O
hot	O
2	O
×	O
SDS	O
gel	O
sample	O
buffer	O
(	O
20	O
mM	O
dithiothreitol	O
,	O
6	O
%	O
SDS	O
,	O
0.25	O
M	O
Tris	O
,	O
pH	O
6.8	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
NaF	O
and	O
bromophenyl	O
blue	O
)	O
at	O
2	O
×	O
106	O
per	O
mL.	O
The	O
extracts	O
are	O
heated	O
in	O
a	O
boiling	O
water	O
bath	O
for	O
5	O
minutes	O
and	O
sonicated	O
with	O
a	O
probe	O
sonicator	O
with	O
3–4	O
bursts	O
of	O
5–10	O
seconds	O
each	O
.	O

Samples	O
are	O
diluted	O
with	O
1	O
×	O
SDS	O
sample	O
buffer	O
to	O
the	O
desired	O
loading	O
of	O
1–5	O
×	O
103	O
per	O
lane	O
.	O

Lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
Immobilon	O
-	O
P	O
membrane	O
,	O
and	O
immunoblotted	O
with	O
0.5	O
μg	O
/	O
mL	O
primary	O
Abs	O
as	O
described	O
in	O
R&D	O
Systems	O
Website	O
[	O
15	O
]	O
.	O

ImmunohistochemistryAntibodies	O
were	O
used	O
with	O
the	O
appropriate	O
secondary	O
reagents	O
at	O
a	O
concentration	O
of	O
5	O
to	O
10	O
μg	O
/	O
ml	O
.	O

Cells	O
or	O
sections	O
of	O
EBs	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
20	O
min	O
,	O
then	O
blocked	O
and	O
permeabilized	O
with	O
0.1	O
%	O
Triton	O
X-100	O
,	O
1	O
%	O
BSA	O
,	O
10	O
%	O
normal	O
donkey	O
serum	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
45	O
min	O
.	O

After	O
blocking	O
,	O
cells	O
were	O
incubated	O
with	O
diluted	O
primary	O
antibody	O
overnight	O
at	O
4	O
°	O
C	O
followed	O
by	O
coupled	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	O
(	O
Molecular	O
Probes	O
)	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
for	O
an	O
hour	O
.	O

Between	O
each	O
step	O
cells	O
were	O
washed	O
with	O
PBS	O
with	O
0.1	O
%	O
BSA	O
.	O

RT	O
-	O
PCRTotal	O
RNA	O
was	O
extracted	O
from	O
EBs	O
using	O
Trizol	O
LS	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
synthesized	O
by	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

The	O
PCR	O
primers	O
are	O
available	O
upon	O
request	O
.	O

Flow	O
cytometryAntibodies	O
were	O
prepared	O
at	O
the	O
concentration	O
of	O
0.1	O
mg	O
/	O
mL.	O
10	O
μL	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
1	O
–	O
2.5	O
×	O
105	O
cells	O
in	O
a	O
total	O
reaction	O
volume	O
not	O
exceeding	O
200	O
μL.	O
The	O
sample	O
was	O
then	O
incubated	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
excess	O
antibody	O
was	O
removed	O
by	O
washing	O
cells	O
twice	O
with	O
FACS	O
buffer	O
(	O
2	O
%	O
FCS	O
and	O
0.1	O
%	O
sodium	O
azide	O
in	O
Hank	O
's	O
buffer	O
)	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
200	O
μL	O
of	O
FACS	O
buffer	O
and	O
the	O
binding	O
of	O
unlabeled	O
monoclonal	O
antibodies	O
was	O
visualized	O
by	O
adding	O
10	O
μL	O
of	O
a	O
25	O
μg	O
/	O
mL	O
stock	O
solution	O
of	O
a	O
secondary	O
developing	O
reagent	O
such	O
as	O
goat	O
anti	O
-	O
mouse	O
IgG	O
conjugated	O
to	O
a	O
fluorochrome	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
cells	O
were	O
washed	O
once	O
with	O
FACS	O
buffer	O
,	O
once	O
with	O
PBS	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
400	O
μL	O
of	O
PBS	O
and	O
analyzed	O
on	O
a	O
FACScant	O
flow	O
cytometer	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
.	O

Five	O
thousand	O
events	O
were	O
collected	O
and	O
analyzed	O
using	O
CELL	O
Quest	O
software	O
.	O

BackgroundIn	O
order	O
to	O
compare	O
the	O
gene	O
expression	O
profiles	O
of	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
lines	O
and	O
their	O
differentiated	O
progeny	O
and	O
to	O
monitor	O
feeder	O
contaminations	O
,	O
we	O
have	O
examined	O
gene	O
expression	O
in	O
seven	O
hESC	O
lines	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
using	O
Illumina	O
®	O
bead	O
arrays	O
that	O
contain	O
probes	O
for	O
24,131	O
transcript	O
probes	O
.	O

ResultsA	O
total	O
of	O
48	O
different	O
samples	O
(	O
including	O
duplicates	O
)	O
grown	O
in	O
multiple	O
laboratories	O
under	O
different	O
conditions	O
were	O
analyzed	O
and	O
pairwise	O
comparisons	O
were	O
performed	O
in	O
all	O
groups	O
.	O

Hierarchical	O
clustering	O
showed	O
that	O
blinded	O
duplicates	O
were	O
correctly	O
identified	O
as	O
the	O
closest	O
related	O
samples	O
.	O

hESC	O
lines	O
clustered	O
together	O
irrespective	O
of	O
the	O
laboratory	O
in	O
which	O
they	O
were	O
maintained	O
.	O

hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
differentiated	O
from	O
them	O
and	O
the	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	B
.	O

The	O
embryonal	O
carcinoma	O
(	O
EC	O
)	O
line	O
NTera2	B
is	O
a	O
useful	O
model	O
for	O
evaluating	O
characteristics	O
of	O
hESCs	O
.	O

Expression	O
of	O
subsets	O
of	O
individual	O
genes	O
was	O
validated	O
by	O
comparing	O
with	O
published	O
databases	O
,	O
MPSS	O
(	O
Massively	O
Parallel	O
Signature	O
Sequencing	O
)	O
libraries	O
,	O
and	O
parallel	O
analysis	O
by	O
microarray	O
and	O
RT	O
-	O
PCR.Conclusionwe	O
show	O
that	O
Illumina	O
's	O
bead	O
array	O
platform	O
is	O
a	O
reliable	O
,	O
reproducible	O
and	O
robust	O
method	O
for	O
developing	O
base	O
global	O
profiles	O
of	O
cells	O
and	O
identifying	O
similarities	O
and	O
differences	O
in	O
large	O
number	O
of	O
samples	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
most	O
pluripotent	O
stem	O
cell	O
population	O
.	O

Human	O
ES	O
cells	O
(	O
hESCs	O
)	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	O
or	O
human	O
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
1	O
-	O
4	O
]	O
while	O
retaining	O
the	O
ability	O
to	O
differentiate	O
into	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
as	O
well	O
as	O
trophoectoderm	O
and	O
germ	O
cells	O
.	O

Gene	O
expression	O
in	O
hESC	O
has	O
been	O
investigated	O
by	O
a	O
variety	O
of	O
techniques	O
including	O
massively	O
parallel	O
signature	O
sequencing	O
(	O
MPSS	O
)	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
scan	O
,	O
large	O
scale	O
microarrays	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
[	O
5	O
-	O
7	O
]	O
.	O

Markers	O
for	O
hESCs	O
that	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
have	O
been	O
established	O
and	O
markers	O
that	O
distinguish	O
ESCs	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
have	O
been	O
developed	O
.	O

Novel	O
stage	O
-	O
specific	O
genes	O
that	O
distinguish	O
between	O
hESCs	O
and	O
EBs	O
have	O
been	O
identified	O
and	O
allelic	O
differences	O
between	O
ESC	O
have	O
begun	O
to	O
be	O
recognized	O
[	O
8	O
-	O
10	O
]	O
.	O

As	O
the	O
potential	O
of	O
hESCs	O
and	O
their	O
derivatives	O
for	O
regenerative	O
medicine	O
is	O
being	O
evaluated	O
,	O
it	O
has	O
become	O
clear	O
that	O
the	O
overall	O
state	O
of	O
the	O
cells	O
,	O
degree	O
of	O
contamination	O
and	O
comparisons	O
of	O
the	O
more	O
than	O
a	O
hundred	O
different	O
newly	O
derived	O
lines	O
will	O
need	O
to	O
be	O
performed	O
.	O

It	O
will	O
be	O
necessary	O
to	O
develop	O
methods	O
to	O
monitor	O
and	O
assess	O
hESC	O
and	O
their	O
derivatives	O
on	O
a	O
routine	O
basis	O
.	O

Since	O
differentiated	O
cells	O
are	O
often	O
scattered	O
within	O
or	O
at	O
the	O
edge	O
of	O
colonies	O
[	O
11	O
]	O
and	O
the	O
differentiation	O
is	O
so	O
subtle	O
that	O
morphological	O
characteristics	O
and	O
even	O
immunohistochemistry	O
are	O
insufficient	O
to	O
detect	O
it	O
,	O
larger	O
scale	O
methods	O
of	O
analysis	O
need	O
to	O
be	O
developed	O
.	O

Our	O
strategy	O
was	O
to	O
compare	O
a	O
variety	O
of	O
different	O
hESC	O
lines	O
that	O
were	O
derived	O
and	O
expanded	O
by	O
three	O
different	O
institutions	O
(	O
WiCell	O
Research	O
Institute	O
,	O
BresaGen	O
,	O
Inc.	O
,	O
and	O
Technion	O
-	O
Israel	O
Institute	O
of	O
Technology	O
)	O
,	O
and	O
cultured	O
in	O
two	O
separate	O
laboratories	O
(	O
Burnham	O
Institute	O
and	O
NIA	O
)	O
to	O
a	O
baseline	O
set	O
of	O
data	O
against	O
which	O
cell	O
samples	O
can	O
be	O
compared	O
.	O

By	O
using	O
cells	O
grown	O
in	O
different	O
conditions	O
we	O
expected	O
to	O
be	O
able	O
to	O
identify	O
core	O
commonalities	O
and	O
by	O
comparing	O
feeders	O
and	O
embryoid	O
bodies	O
(	O
EB	O
)	O
with	O
hESC	O
identify	O
measures	O
of	O
contamination	O
and	O
early	O
markers	O
of	O
differentiation	O
.	O

Further	O
,	O
by	O
comparing	O
embryonal	O
carcinoma	O
cell	O
(	O
EC	O
)	O
and	O
karyotypically	O
variant	O
lines	O
with	O
hESC	O
,	O
we	O
would	O
be	O
able	O
to	O
directly	O
assess	O
their	O
utility	O
as	O
surrogates	O
(	O
for	O
quality	O
control	O
purposes	O
)	O
for	O
hESC	O
.	O

We	O
employed	O
a	O
pre	O
-	O
commercial	O
prototype	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
[	O
12	O
]	O
,	O
a	O
genome	O
-	O
scale	O
bead	O
based	O
array	O
technology	O
that	O
combines	O
the	O
sensitivity	O
and	O
low	O
cost	O
of	O
a	O
focused	O
array	O
with	O
the	O
coverage	O
of	O
a	O
large	O
scale	O
array	O
,	O
while	O
requiring	O
much	O
smaller	O
sample	O
sizes	O
than	O
MPSS	O
,	O
EST	O
scan	O
or	O
SAGE	O
.	O

We	O
show	O
that	O
the	O
Illumina	O
bead	O
based	O
array	O
correctly	O
identified	O
blinded	O
duplicates	O
as	O
the	O
closest	O
related	O
samples	O
and	O
readily	O
distinguished	O
between	O
hESC	O
lines	O
,	O
as	O
well	O
as	O
between	O
ESCs	O
and	O
EBs	O
derived	O
from	O
them	O
.	O

This	O
array	O
allowed	O
us	O
to	O
estimate	O
the	O
degree	O
of	O
feeder	O
contamination	O
present	O
in	O
the	O
cultures	O
.	O

Similarities	O
and	O
differences	O
between	O
EC	O
line	O
NTera2	B
and	O
hESC	O
lines	O
could	O
be	O
determined	O
and	O
verified	O
,	O
and	O
the	O
database	O
comparisons	O
allowed	O
us	O
to	O
identify	O
core	O
self	O
-	O
renewal	O
pathways	O
that	O
regulate	O
hESC	O
propagation	O
.	O

Multiple	O
hESC	O
lines	O
can	O
be	O
assessed	O
by	O
Illumina	O
bead	O
arrayForty	O
-	O
eight	O
samples	O
were	O
selected	O
from	O
multiple	O
laboratories	O
and	O
gene	O
expression	O
profiles	O
were	O
examined	O
using	O
a	O
bead	O
array	O
containing	O
24,131	O
transcripts	O
derived	O
from	O
the	O
Human	O
RefSeq	O
database	O
that	O
included	O
full	O
length	O
and	O
splice	O
variants	O
.	O

Each	O
gene	O
was	O
represented	O
by	O
sequences	O
containing	O
an	O
average	O
of	O
thirty	O
beads	O
to	O
provide	O
an	O
internal	O
measure	O
of	O
reliability	O
.	O

Samples	O
included	O
7	O
hESC	O
lines	O
BG01	B
,	O
BG02	B
,	O
BG03	B
,	O
I6	B
,	O
H1	B
,	O
H7	B
and	O
H9	B
,	O
EBs	O
that	O
were	O
differentiated	O
from	O
hESCs	O
of	O
the	O
three	O
BG	O
lines	O
,	O
human	O
fibroblast	O
feeder	O
HS27	B
(	O
ATCC	O
)	O
,	O
hESC	O
-	O
derived	O
fibroblasts	O
,	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01	B
Variant	I
(	O
BG01V	B
)	O
[	O
13	O
]	O
and	O
EC	O
line	O
NTera2	B
[	O
14	O
]	O
.	O

Samples	O
were	O
blinded	O
and	O
biological	O
and	O
technical	O
repeats	O
were	O
examined	O
at	O
the	O
same	O
time	O
.	O

A	O
single	O
slide	O
contained	O
eight	O
replicates	O
and	O
six	O
such	O
slides	O
were	O
used	O
for	O
the	O
present	O
set	O
of	O
samples	O
.	O

Results	O
were	O
normalized	O
to	O
average	O
following	O
Illumina	O
Beadstudio	O
manual	O
and	O
the	O
quality	O
of	O
each	O
sample	O
was	O
assessed	O
by	O
immunocytochemitsry	O
and	O
RT	O
-	O
PCR	O
prior	O
to	O
subjecting	O
them	O
for	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Results	O
from	O
the	O
entire	O
sample	O
set	O
are	O
available	O
for	O
download	O
as	O
an	O
excel	O
spreadsheet	O
(	O
Additional	O
file	O
1	O
)	O
and	O
a	O
CD	O
of	O
the	O
results	O
is	O
available	O
upon	O
request	O
.	O

The	O
total	O
number	O
of	O
genes	O
identified	O
as	O
expressed	O
at	O
>	O
0.99	O
confidence	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

Intensity	O
results	O
are	O
reported	O
in	O
arbitrary	O
units	O
and	O
ranged	O
from	O
10	O
to	O
20,000	O
(	O
a	O
two	O
thousand	O
fold	O
range	O
)	O
.	O

Although	O
the	O
sensitivity	O
of	O
the	O
array	O
has	O
been	O
reported	O
to	O
be	O
high	O
,	O
in	O
the	O
present	O
report	O
we	O
have	O
restricted	O
our	O
analysis	O
to	O
expression	O
of	O
at	O
least	O
100	O
units	O
in	O
any	O
one	O
sample	O
.	O

Using	O
this	O
cutoff	O
,	O
on	O
average	O
cells	O
expressed	O
approximately	O
8,000	O
transcripts	O
(	O
Table	O
1	O
,	O
2	O
)	O
,	O
a	O
number	O
similar	O
to	O
the	O
number	O
detected	O
by	O
SAGE	O
,	O
MPSS	O
and	O
EST	O
analysis	O
[	O
5	O
-	O
7,10,15,16	O
]	O
.	O

As	O
with	O
other	O
analysis	O
,	O
genes	O
with	O
the	O
highest	O
abundance	O
were	O
housekeeping	O
genes	O
,	O
ribosomal	O
genes	O
and	O
structural	O
genes	O
(	O
Table	O
2	O
and	O
Additional	O
file	O
1	O
)	O
.	O

These	O
genes	O
were	O
similar	O
in	O
most	O
samples	O
though	O
relative	O
levels	O
varied	O
.	O

Table	O
1Correlation	O
coefficients	O
of	O
paired	O
samples	O
in	O
this	O
bead	O
array	O
In	O
order	O
to	O
test	O
the	O
reproducibility	O
and	O
reliability	O
of	O
the	O
bead	O
array	O
,	O
duplicate	O
samples	O
of	O
hESC	O
lines	O
H9	B
,	O
I6	B
,	O
and	O
EC	O
line	O
NTera2	B
and	O
human	O
fibroblast	O
feeders	O
(	O
HS27	B
)	O
were	O
run	O
at	O
the	O
same	O
time	O
and	O
correlation	O
coefficients	O
(	O
R2	O
)	O
of	O
duplicates	O
were	O
generated	O
using	O
the	O
entire	O
data	O
of	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
§	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
*	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
and	O
expression	O
level	O
>	O
100	O
arbitrary	O
units	O
(	O
#	O
)	O
.	O

Note	O
that	O
the	O
correlation	O
coefficients	O
are	O
in	O
the	O
range	O
of	O
0.9382–0.9761	O
and	O
the	O
number	O
of	O
genes	O
was	O
in	O
the	O
range	O
of	O
10,000–14,000.Duplicate	O
SamplesNo	O
.	O
of	O
all	O
genes	O
(	O
expr.>0	O
)	O
§R2of	O
all	O
genes	O
(	O
expr	O
.	O

>	O
0	O
)	O
No	O
.	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*R2	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*No	O
.	O
(	O
>	O
0.99	O
,	O
level>100	O
)	O
#H918,8990.868113,6720.97087,408I619,1390.866312,5700.97616,826NTera219,1620.874114,0360.93827,147Feeder18,1570.872410,6060.97517,021Table	O
2Distribution	O
of	O
genes	O
with	O
expression	O
levels	O
<	O
50	O
and	O
>	O
50–10,000	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
in	O
8	O
hESC	O
populations	O
All	O
human	O
ESC	O
samples	O
were	O
hybridized	O
in	O
one	O
experiment	O
and	O
the	O
relative	O
detection	O
levels	O
of	O
genes	O
were	O
binned	O
to	O
obtain	O
a	O
global	O
overview	O
of	O
transcription	O
,	O
approximately	O
8	O
,	O
000	O
genes	O
(	O
~50	O
%	O
)	O
were	O
greater	O
than	O
100	O
arbitrary	O
units	O
.	O

The	O
numbers	O
are	O
similar	O
to	O
results	O
obtained	O
by	O
other	O
large	O
scale	O
analysis	O
such	O
as	O
MPSS.Abundance	O
(	O
relative	O
detection	O
levels	O
)	O
H9H9	B
on	O
human	O
feedersI6BG01BG02BG03BG01VPooled	O
(	O
H1	B
,	O
H7	B
,	O
H9	B
)	O
No.%No.%No.%No.%No.%No.%No.%No.%<502,90921.26,06738.43,55925.34,52830.74,25630.54,70632.24194.35,80334.4>5010,81778.89,74761.610,48474.710,23269.39,69469.59,91567.89,43895.711,08565.6>1008,12659.27,53947.77,40952.87,70352.27,49653.77,43050.87,23073.38,21748.7>5003,07722.42,94718.62,62618.73,06520.82,95021.12,85219.52,85128.92,94117.4>10001,62911.91,62510.31,49010.61,63811.11,58911.41,51710.41,56615.91,5549.2>50002481.82571.62561.82561.72631.92621.82752.82511.5>10000900.7940.61120.8920.61000.71070.71011.0940.6Total	O
No.	O
of	O
genes	O
detected	O
at	O
>	O
0.99	O
confidence13,72615,81414,04314,76013,95014,6219,85716,888One	O
of	O
the	O
advantages	O
of	O
the	O
Illumina	O
arrays	O
is	O
the	O
ability	O
of	O
running	O
multiple	O
samples	O
simultaneously	O
thus	O
allowing	O
multiple	O
pairwise	O
comparisons	O
to	O
be	O
performed	O
readily	O
.	O

To	O
show	O
the	O
similarity	O
of	O
relative	O
gene	O
expression	O
between	O
samples	O
,	O
we	O
have	O
used	O
Illumina	O
Beadstudio	O
and	O
clustering	O
software	O
packages	O
Pcluster	O
[	O
17	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
to	O
generate	O
a	O
heat	O
-	O
map	O
(	O
Figure	O
1	O
)	O
and	O
a	O
dendrogram	O
(	O
Figure	O
2	O
)	O
.	O

Based	O
on	O
their	O
properties	O
,	O
we	O
classified	O
some	O
of	O
our	O
samples	O
into	O
four	O
groups	O
,	O
(	O
A	O
)	O
undifferentiated	O
hESCs	O
(	O
including	O
a	O
sample	O
from	O
karyotypically	O
abnormal	O
variant	O
,	O
designated	O
as	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
;	O
(	O
B	O
)	O
differentiated	O
ES	O
cells	O
and	O
EBs	O
(	O
designated	O
as	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
;	O
(	O
C	O
)	O
hESC	O
derived	O
neural	O
cells	O
(	O
designated	O
as	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
;	O
and	O
(	O
D	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
designated	O
as	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
and	O
these	O
groups	O
were	O
shown	O
in	O
the	O
heat	O
-	O
map	O
.	O

Comparing	O
the	O
overall	O
pattern	O
of	O
expression	O
,	O
we	O
made	O
several	O
important	O
observations	O
:	O
1	O
)	O
Duplicates	O
clustered	O
close	O
to	O
each	O
other	O
and	O
were	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
any	O
other	O
sample	O
;	O
2	O
)	O
ESCs	O
appeared	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
EBs	O
;	O
3	O
)	O
NTera2	B
cells	O
appeared	O
more	O
similar	O
to	O
ESCs	O
while	O
differentiated	O
NTera2	B
and	O
EBs	O
can	O
be	O
readily	O
distinguished	O
from	O
their	O
parent	O
populations	O
(	O
Figure	O
2	O
)	O
;	O
4	O
)	O
BG01V	B
appeared	O
similar	O
to	O
undifferentiated	O
BG01	B
cells	O
;	O
5	O
)	O
In	O
general	O
ESC	O
lines	O
grown	O
in	O
one	O
laboratory	O
appeared	O
more	O
similar	O
than	O
samples	O
grown	O
in	O
other	O
laboratories	O
,	O
suggesting	O
that	O
culture	O
conditions	O
affected	O
gene	O
expression	O
but	O
that	O
this	O
effect	O
was	O
much	O
smaller	O
than	O
the	O
effect	O
of	O
differentiation	O
.	O

Figure	O
1Unsupervised	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
illustrated	O
in	O
a	O
heat	O
-	O
map	O
.	O

Each	O
row	O
represents	O
the	O
relative	O
levels	O
of	O
expression	O
of	O
a	O
single	O
gene	O
.	O

Each	O
column	O
represents	O
a	O
sample	O
.	O

The	O
samples	O
include	O
four	O
groups	O
of	O
cells	O
,	O
ES	O
designates	O
11	O
samples	O
of	O
hESCs	O
,	O
EB	O
contains	O
6	O
samples	O
of	O
differentiated	O
ESCs	O
and	O
EBs	O
,	O
NS	O
consists	O
of	O
3	O
hESC	O
derived	O
neural	O
cells	O
and	O
FB	O
is	O
a	O
collection	O
of	O
hESC	O
derived	O
mesenchyme	O
and	O
fibroblasts	O
.	O

High	O
expressions	O
relative	O
to	O
mean	O
are	O
colored	O
red	O
.	O

Low	O
expressions	O
are	O
colored	O
green	O
.	O

Black	O
represents	O
no	O
significant	O
change	O
in	O
expression	O
level	O
between	O
mean	O
and	O
sample	O
.	O

Samples	O
cluster	O
closer	O
within	O
their	O
own	O
group	O
than	O
samples	O
from	O
other	O
groups	O
.	O

Figure	O
2Dendrogram	O
of	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
of	O
relative	O
expression	O
of	O
genes	O
in	O
selected	O
samples	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
p	O
<	O
0.05	O
)	O
.	O

hESCs	O
clustered	O
together	O
and	O
BG	O
lines	O
cultured	O
in	O
the	O
same	O
laboratory	O
shared	O
the	O
largest	O
similarities	O
.	O

EBs	O
were	O
separated	O
from	O
hESCs	O
from	O
which	O
they	O
were	O
derived	O
.	O

EC	O
line	O
NTera2	B
and	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
respectively	O
.	O

The	O
global	O
analysis	O
suggested	O
that	O
the	O
bead	O
arrays	O
used	O
were	O
sufficiently	O
sensitive	O
such	O
that	O
individual	O
subsets	O
of	O
genes	O
could	O
be	O
analyzed	O
,	O
different	O
populations	O
of	O
cells	O
could	O
be	O
readily	O
distinguished	O
and	O
that	O
a	O
subset	O
of	O
candidate	O
genes	O
could	O
be	O
sufficient	O
to	O
distinguish	O
between	O
groups	O
of	O
cells	O
.	O

The	O
comparison	O
across	O
multiple	O
samples	O
will	O
allow	O
a	O
set	O
of	O
core	O
stem	O
cell	O
markers	O
to	O
be	O
identified	O
.	O

In	O
subsequent	O
sections	O
we	O
have	O
performed	O
such	O
analysis	O
.	O

Readers	O
are	O
urged	O
to	O
analyze	O
the	O
expression	O
of	O
desired	O
genes	O
directly	O
as	O
it	O
is	O
impossible	O
to	O
test	O
every	O
gene	O
given	O
the	O
large	O
body	O
of	O
data	O
generated	O
.	O

Comparison	O
between	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
resultsWe	O
have	O
previously	O
used	O
EST	O
scan	O
and	O
MPSS	O
to	O
analyze	O
pooled	O
samples	O
of	O
ESCs	O
and	O
EBs	O
from	O
three	O
different	O
WiCell	O
lines	O
(	O
H1	B
,	O
H7	B
and	O
H9	B
)	O
[	O
5	O
]	O
.	O

Comparison	O
between	O
the	O
two	O
methodologies	O
indicated	O
that	O
while	O
there	O
is	O
good	O
concordance	O
for	O
genes	O
expressed	O
at	O
high	O
levels	O
,	O
this	O
does	O
not	O
hold	O
for	O
genes	O
expressed	O
at	O
lower	O
levels	O
.	O

As	O
a	O
test	O
of	O
the	O
quality	O
of	O
the	O
data	O
generated	O
in	O
these	O
experiments	O
and	O
to	O
evaluate	O
whether	O
comparisons	O
can	O
be	O
made	O
across	O
different	O
methodologies	O
,	O
we	O
re	O
-	O
ran	O
the	O
identical	O
samples	O
on	O
the	O
bead	O
array	O
platform	O
.	O

The	O
complete	O
comparison	O
of	O
gene	O
expression	O
is	O
shown	O
in	O
Additional	O
file	O
2	O
and	O
is	O
summarized	O
in	O
Tables	O
3	O
and	O
Table	O
4	O
.	O

Overall	O
,	O
concordance	O
in	O
Illumina	O
array	O
was	O
better	O
than	O
that	O
evident	O
between	O
EST	O
scan	O
and	O
MPSS	O
datasets	O
[	O
9	O
]	O
,	O
but	O
clearly	O
showed	O
much	O
wider	O
differences	O
than	O
that	O
seen	O
with	O
running	O
duplicates	O
in	O
the	O
same	O
assay	O
format	O
.	O

Nevertheless	O
,	O
this	O
comparison	O
provides	O
an	O
independent	O
verification	O
of	O
the	O
data	O
and	O
suggests	O
that	O
if	O
a	O
sample	O
is	O
detected	O
in	O
more	O
than	O
one	O
large	O
-	O
scale	O
analysis	O
,	O
the	O
reliability	O
of	O
the	O
gene	O
expression	O
detection	O
is	O
high	O
,	O
which	O
also	O
reduces	O
the	O
number	O
of	O
individual	O
genes	O
needed	O
to	O
be	O
verified	O
.	O

Caution	O
should	O
be	O
observed	O
in	O
comparing	O
different	O
samples	O
run	O
on	O
different	O
platforms	O
,	O
especially	O
when	O
there	O
has	O
not	O
been	O
rigorous	O
bioinformatic	O
matching	O
of	O
the	O
source	O
sequences	O
used	O
to	O
identify	O
genes	O
in	O
the	O
platforms	O
.	O

Often	O
genes	O
called	O
by	O
the	O
same	O
symbol	O
originate	O
from	O
different	O
database	O
records	O
,	O
which	O
may	O
originate	O
from	O
different	O
splice	O
variants	O
or	O
contain	O
sequence	O
differences	O
due	O
to	O
polymorphisms	O
or	O
outright	O
error	O
[	O
19	O
]	O
.Table	O
3Expression	O
of	O
hESC	O
specific	O
markers	O
in	O
pooled	O
hESC	O
sample	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
The	O
expression	O
of	O
previously	O
identified	O
hESC	O
markers	O
was	O
examined	O
in	O
all	O
hESC	O
samples	O
(	O
the	O
values	O
displayed	O
represent	O
the	O
expression	O
level	O
of	O
pooled	O
H1	B
,	O
H7	B
and	O
H9	B
)	O
.	O

Most	O
of	O
the	O
genes	O
were	O
also	O
identified	O
using	O
Illumina	O
bead	O
array	O
in	O
all	O
8	O
hESC	O
populations	O
in	O
this	O
study	O
(	O
1	O
*	O
)	O
,	O
the	O
gene	O
CER1	O
was	O
detected	O
in	O
all	O
except	O
one	O
duplicate	O
of	O
H9	B
(	O
2	O
*	O
)	O
,	O
Nanog	O
was	O
not	O
detected	O
in	O
all	O
populations	O
(	O
3	O
*	O
)	O
and	O
Sox2	O
,	O
Lin41	O
,	O
NR6A1	O
and	O
FoxD3	O
were	O
not	O
detected	O
in	O
the	O
array	O
although	O
they	O
were	O
present	O
in	O
the	O
chips	O
for	O
hybridization	O
(	O
4*	O
)	O
.AccessionSymbolPooled	O
ES	O
(	O
H1	B
,	O
7	B
,	O
9	B
)	O
CommentsNM_003641.1IFITM188441*NM_020997.2LEFTB6579.61*NM_024674.3LIN283944.11*NM_175849.1DNMT3B33911*NM_003212.1TDGF131691*NM_001769.2CD92930.81*NM_000165.2GJA12404.41*NM_021195.2CLDN62247.21*NM_004360.2CDH11972.91*NM_021127.1PMAIP11601.51*NM_032805.1ZNF2061504.51*NM_003577.1UTF11444.11*XM_050625.2SFRP21353.91*NM_006548.3IMP-212061*NM_152312.2GYLTL1B1066.61*NM_015973.2GAL1043.31*NM_003240.2EBAF944.11*NM_054023.2SCGB3A2890.51*NM_020990.2CKMT1742.41*NM_033668.1ITGB1694.71*NM_003744.3NUMB618.31*NM_007015.1LECT1597.41*NM_021912.2GABRB3482.71*NM_006729.2DIAPH2467.11*NM_000222.1KIT188.91*NM_005454.1CER1151.52*NM_024865.1NANOG56.93*NM_002701.1POU5F1694.41*NM_003106SOX2ND4*NM_006458.2LIN41ND4*NM_001489.3NR6A1ND4*NM_012183FOXD3ND4*Table	O
4Comparison	O
of	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
results	O
The	O
samples	O
were	O
analyzed	O
by	O
MPSS	O
and	O
bead	O
array	O
.	O

The	O
number	O
of	O
genes	O
detected	O
by	O
each	O
method	O
and	O
the	O
degree	O
of	O
overlap	O
is	O
summarized	O
.	O

Note	O
much	O
higher	O
degree	O
of	O
overlap	O
when	O
the	O
top	O
2000	O
hits	O
were	O
compared	O
.	O

*	O
:	O
Most	O
of	O
the	O
genes	O
detected	O
by	O
MPSS	O
were	O
novel	O
genes	O
not	O
included	O
in	O
the	O
bead	O
array	O
.	O

ESNo.%Common	O
in	O
both	O
(	O
Top	O
2000	O
hits	O
)	O
1,62281.1Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,07146.0By	O
bead	O
array	O
only3,46231.4By	O
MPSS	O
only	O
*	O
2,50422.7Total11,037100EBNo.%Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,16843.1By	O
bead	O
array	O
only4,13134.4By	O
MPSS	O
only	O
*	O
2,69422.5Total11,993100	O
Human	O
feeders	O
and	O
hESCs	O
can	O
be	O
readily	O
distinguished	O
and	O
contamination	O
can	O
be	O
readily	O
assessedFor	O
all	O
samples	O
,	O
we	O
conducted	O
an	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
analysis	O
revealed	O
the	O
underlying	O
features	O
and	O
variation	O
patterns	O
of	O
gene	O
expression	O
in	O
each	O
cell	O
types	O
.	O

Figure	O
2	O
shows	O
results	O
of	O
the	O
cluster	O
analysis	O
of	O
relative	O
gene	O
expression	O
in	O
selected	O
samples	O
.	O

As	O
one	O
of	O
our	O
purposes	O
of	O
this	O
study	O
was	O
to	O
distinguish	O
between	O
human	O
fibroblast	O
feeders	O
cells	O
and	O
hESCs	O
and	O
hEBs	O
,	O
wishing	O
to	O
readily	O
detect	O
feeder	O
contamination	O
in	O
hESCs	O
,	O
we	O
included	O
one	O
of	O
the	O
human	O
feeder	O
cells	O
HS27	B
(	O
ATCC	O
)	O
in	O
this	O
study	O
.	O

We	O
have	O
been	O
using	O
HS27	B
as	O
feeder	O
cells	O
for	O
H9	B
hESCs	O
for	O
more	O
than	O
two	O
years	O
and	O
all	O
hESCs	O
grown	O
on	O
HS27	B
had	O
normal	O
karyotype	O
,	O
expressed	O
all	O
undifferentiated	O
markers	O
,	O
and	O
made	O
teratomas	O
with	O
all	O
germ	O
layers	O
(	O
data	O
not	O
show	O
)	O
.	O

The	O
global	O
pairwise	O
comparison	O
clearly	O
showed	O
that	O
human	O
feeders	O
were	O
far	O
more	O
dissimilar	O
to	O
hESCs	O
than	O
hESCs	O
grown	O
in	O
different	O
laboratories	O
,	O
hESCs	O
compared	O
to	O
their	O
differentiated	O
EBs	O
that	O
contained	O
mesodermal	O
tissue	O
,	O
and	O
hESCs	O
compared	O
to	O
the	O
karyotypically	O
variant	O
hESC	O
line	O
BG01V	B
.	O

Pairwise	O
comparisons	O
of	O
human	O
feeders	O
with	O
hESCs	O
resulted	O
in	O
a	O
correlation	O
coefficient	O
of	O
0.66	O
,	O
which	O
was	O
less	O
than	O
the	O
correlation	O
coefficient	O
of	O
0.71–0.74	O
observed	O
between	O
hESCs	O
and	O
their	O
corresponding	O
EBs	O
.	O

The	O
large	O
difference	O
between	O
human	O
feeders	O
and	O
hESCs	O
suggested	O
that	O
it	O
would	O
be	O
possible	O
to	O
identify	O
markers	O
that	O
were	O
robust	O
and	O
reliable	O
in	O
distinguishing	O
the	O
two	O
populations	O
,	O
and	O
these	O
markers	O
would	O
be	O
sufficiently	O
sensitive	O
in	O
detecting	O
contamination	O
of	O
feeders	O
.	O

We	O
examined	O
the	O
data	O
to	O
develop	O
a	O
list	O
of	O
genes	O
that	O
had	O
high	O
levels	O
of	O
expression	O
in	O
human	O
feeder	O
cells	O
maintained	O
in	O
hESC	O
medium	O
but	O
whose	O
expression	O
was	O
low	O
or	O
absent	O
in	O
either	O
ESCs	O
or	O
EBs	O
.	O

The	O
absence	O
of	O
expression	O
in	O
EBs	O
was	O
used	O
as	O
a	O
control	O
for	O
spontaneous	O
differentiation	O
of	O
ESC	O
colonies	O
(	O
including	O
mesodermal	O
differentiation	O
)	O
which	O
may	O
occur	O
and	O
the	O
markers	O
selected	O
should	O
be	O
able	O
to	O
distinguish	O
between	O
these	O
two	O
events	O
.	O

A	O
complete	O
list	O
of	O
genes	O
expressed	O
at	O
least	O
ten	O
-	O
fold	O
higher	O
in	O
human	O
feeders	O
is	O
provided	O
in	O
Figure	O
3	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
(	O
qPCR	O
)	O
was	O
used	O
to	O
verify	O
the	O
fold	O
change	O
of	O
the	O
expression	O
of	O
4	O
genes	O
,	O
including	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTHA4	O
(	O
Figure	O
3C	O
)	O
.	O

Further	O
confirmation	O
can	O
also	O
be	O
done	O
using	O
immunocytochemistry	O
,	O
as	O
antibodies	O
against	O
these	O
genes	O
are	O
commercially	O
available	O
.	O

Figure	O
3Human	O
fibroblast	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
and	O
EBs	O
.	O

Bead	O
array	O
identified	O
lists	O
of	O
genes	O
that	O
were	O
uniquely	O
expressed	O
in	O
human	O
fibroblast	O
feeders	O
as	O
compared	O
to	O
hESCs	O
(	O
A	O
)	O
and	O
hEBs	O
(	O
B	O
)	O
.	O

The	O
four	O
genes	O
whose	O
expression	O
was	O
confirmed	O
by	O
qPCR	O
(	O
C	O
)	O
were	O
in	O
bold	O
.	O

In	O
the	O
graph	O
(	O
C	O
)	O
,	O
gene	O
expression	O
of	O
each	O
gene	O
in	O
feeder	O
cells	O
was	O
designated	O
as	O
1	O
fold	O
and	O
the	O
bars	O
represented	O
fold	O
decrease	O
for	O
each	O
gene	O
.	O

Thus	O
this	O
comparison	O
allowed	O
us	O
to	O
distinguish	O
between	O
hESCs	O
and	O
human	O
feeders	O
and	O
identify	O
candidate	O
markers	O
that	O
could	O
detect	O
feeder	O
cell	O
contamination	O
should	O
human	O
feeders	O
be	O
used	O
in	O
the	O
propagation	O
of	O
hESCs	O
.	O

hESCs	O
and	O
EBs	O
can	O
be	O
distinguished	O
from	O
each	O
otherIllumina	O
bead	O
array	O
analysis	O
confirmed	O
that	O
hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
EBs	O
by	O
global	O
analysis	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
specific	O
subsets	O
of	O
markers	O
could	O
be	O
identified	O
.	O

We	O
and	O
others	O
have	O
used	O
MPSS	O
and	O
EST	O
scan	O
and	O
generated	O
array	O
data	O
to	O
make	O
lists	O
of	O
hESC	O
-	O
specific	O
genes	O
[	O
5,9,10,20	O
]	O
.	O

As	O
discussed	O
above	O
,	O
most	O
hESC	O
markers	O
identified	O
by	O
MPSS	O
have	O
been	O
detected	O
in	O
the	O
present	O
bead	O
array	O
analysis	O
(	O
Table	O
3	O
)	O
,	O
confirming	O
the	O
utility	O
of	O
these	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
assessing	O
undifferentiated	O
status	O
of	O
hESCs	O
.	O

In	O
addition	O
,	O
we	O
have	O
generated	O
a	O
list	O
of	O
genes	O
differentially	O
expressed	O
at	O
higher	O
level	O
in	O
EBs	O
than	O
in	O
hESCs	O
,	O
a	O
subset	O
of	O
which	O
is	O
shown	O
in	O
Table	O
5	O
.	O

These	O
markers	O
were	O
common	O
to	O
all	O
EB	O
samples	O
tested	O
and	O
included	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
.	O

The	O
entire	O
set	O
of	O
differentially	O
expressed	O
genes	O
is	O
provided	O
in	O
Additional	O
file	O
3	O
.	O

Thus	O
,	O
the	O
bead	O
array	O
format	O
,	O
which	O
allows	O
multiple	O
pairwise	O
comparisons	O
,	O
can	O
be	O
used	O
to	O
identify	O
genes	O
that	O
are	O
expressed	O
by	O
all	O
differentiating	O
EB	O
samples	O
in	O
the	O
present	O
study	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
core	O
set	O
of	O
limited	O
markers	O
might	O
be	O
sufficient	O
to	O
monitor	O
the	O
process	O
of	O
differentiation	O
.	O

By	O
suitable	O
selection	O
of	O
different	O
germ	O
cell	O
layer	O
specific	O
markers	O
one	O
may	O
also	O
assess	O
the	O
overall	O
quality	O
of	O
differentiation	O
toward	O
germ	O
cells	O
.	O

Table	O
5Genes	O
which	O
are	O
differentially	O
expressed	O
at	O
higher	O
levels	O
in	O
EBs	O
than	O
in	O
hESCsSymbolAll	O
EBAll	O
ESEB	O
/	O
ESRELN11120.52224.0SST1394.25.5253.5SLC40A11210.19.1133.0IGF24896.938.4127.5SLN2017.817118.7DCN7588.176.299.6ANXA84048.941.996.6AQP11665.420.581.2APOB1256.415.879.5AHSG1414.320.868.0NID21476.731.447.0FGB221052.442.2LUM8439.4205.441.1MGP2772.469.839.7THBD1206.434.435.1SERPINA11255.643.728.7HAND112294437.428.1HBE11106.542.626.0TTR7661.2347.122.1HBG21601.185.618.7COL2A11636.291.817.8KIAA09771370.87817.6AFP8941552.316.2COL3A11355796714.0IGFBP38446.3603.414.0PAX61577.8118.213.3APOA19398.1709.813.2FRZB3523.7315.711.2SPON21548.7159.49.7CEBPD1100.2122.79.0DLK13355.8374.89.0RDC11589.7192.18.3BMP41851.5227.38.1PITX21057.9131.28.1ACTA25045629.88.0GAS11215.61547.9AGTRL11053.8135.17.8COL5A15876.4765.47.7CDKN1C3134.1412.97.6CXCL142220.5312.67.1DOK41011.1145.27.0ARHGDIB1635.3246.56.6FLRT21879.5314.36.0MSX12771.8499.75.5	O
Smaller	O
but	O
distinct	O
differences	O
among	O
undifferentiated	O
hESC	O
linesOur	O
cluster	O
analysis	O
indicated	O
that	O
BG01	B
,	O
BG02	B
and	O
BG03	B
cell	O
lines	O
were	O
overall	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
lines	O
(	O
Figure	O
1	O
and	O
2	O
)	O
,	O
but	O
nevertheless	O
showed	O
additional	O
differences	O
than	O
technical	O
or	O
biological	O
repeats	O
of	O
the	O
same	O
sample	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
this	O
microarray	O
strategy	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
identify	O
relatively	O
cell	O
type	O
specific	O
candidate	O
genes	O
that	O
could	O
be	O
used	O
to	O
distinguish	O
one	O
hESC	O
population	O
from	O
another	O
or	O
to	O
identify	O
differences	O
that	O
were	O
due	O
to	O
varied	O
isolation	O
and	O
growth	O
conditions	O
.	O

As	O
a	O
test	O
we	O
looked	O
for	O
differences	O
between	O
BG01	B
,	O
BG02	B
and	O
BG03	B
,	O
which	O
were	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
the	O
same	O
conditions	O
.	O

Lists	O
of	O
candidate	O
genes	O
are	O
shown	O
in	O
Figure	O
4A	O
,	O
C	O
and	O
4E	O
and	O
the	O
comparison	O
of	O
these	O
three	O
lines	O
are	O
shown	O
in	O
scatter	O
plots	O
in	O
Figure	O
4B	O
,	O
D	O
and	O
4F.Figure	O
4BG	O
lines	O
show	O
small	O
but	O
distinct	O
differences	O
as	O
assessed	O
by	O
bead	O
array	O
.	O

These	O
three	O
hESC	O
lines	O
share	O
high	O
similarities	O
as	O
shown	O
by	O
the	O
scatterplots	O
of	O
BG01	B
vs	O
BG02	B
(	O
B	O
)	O
,	O
BG01	B
vs	O
BG03	B
(	O
D	O
)	O
and	O
BG02	B
vs	O
BG03	B
(	O
F	O
)	O
.	O

Comparisons	O
of	O
all	O
three	O
lines	O
were	O
made	O
and	O
lists	O
of	O
selected	O
genes	O
that	O
were	O
specifically	O
expressed	O
in	O
BG01	B
(	O
A	O
)	O
,	O
BG02	B
(	O
C	O
)	O
and	O
BG03	B
(	O
F	O
)	O
are	O
shown	O
.	O

Correlation	O
coefficients	O
(	O
R2	O
)	O
were	O
generated	O
using	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
black	O
and	O
blue	O
dots	O
)	O
,	O
or	O
all	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
blue	O
dots	O
)	O
.	O

Genes	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

We	O
reasoned	O
as	O
well	O
that	O
such	O
a	O
global	O
comparison	O
should	O
allow	O
us	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
if	O
genes	O
present	O
on	O
the	O
Y	O
chromosome	O
were	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
undifferentiated	O
state	O
and	O
were	O
detected	O
by	O
the	O
bead	O
array	O
.	O

Several	O
such	O
candidate	O
genes	O
were	O
identified	O
.	O

The	O
most	O
robust	O
were	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
and	O
EIF1AY	O
(	O
Figure	O
5	O
)	O
.	O

To	O
confirm	O
that	O
these	O
were	O
useful	O
markers	O
,	O
we	O
designed	O
RT	O
-	O
PCR	O
primers	O
and	O
tested	O
their	O
expression	O
in	O
a	O
male	O
(	O
BG01	B
)	O
and	O
a	O
female	O
(	O
BG03	B
)	O
line	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
noted	O
that	O
several	O
of	O
these	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
ESCs	O
differentiated	O
to	O
form	O
EBs	O
and	O
upon	O
further	O
differentiation	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
markers	O
might	O
be	O
used	O
in	O
adult	O
stem	O
cell	O
and	O
germ	O
cell	O
populations	O
as	O
well	O
.	O

Figure	O
5Male	O
and	O
female	O
hESC	O
lines	O
can	O
be	O
distinguished	O
by	O
genes	O
identified	O
by	O
bead	O
array	O
.	O

Five	O
potential	O
genes	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
EIF1AY	O
,	O
VCY	O
,	O
and	O
AMELY	O
are	O
located	O
in	O
the	O
Y	O
chromosome	O
.	O

By	O
comparing	O
the	O
expression	O
level	O
of	O
these	O
genes	O
in	O
all	O
hESC	O
lines	O
,	O
we	O
have	O
found	O
that	O
3	O
out	O
of	O
5	O
were	O
specifically	O
expressed	O
in	O
male	O
hESC	O
lines	O
I6	B
,	O
BG01	B
and	O
BG02	B
(	O
A	O
)	O
and	O
this	O
was	O
verified	O
by	O
RT	O
-	O
PCR	O
in	O
male	O
line	O
BG01	B
and	O
female	O
line	O
BG03	B
(	O
B	O
)	O
.	O

G3PDH	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

*	O
:	O
represents	O
the	O
gene	O
expression	O
level	O
is	O
detected	O
at	O
<	O
0.99	O
confidence	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
the	O
bead	O
array	O
format	O
is	O
sufficiently	O
sensitive	O
and	O
global	O
that	O
it	O
can	O
distinguish	O
one	O
cell	O
line	O
from	O
another	O
even	O
if	O
those	O
two	O
cell	O
lines	O
are	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
virtually	O
identical	O
conditions	O
.	O

Bead	O
array	O
can	O
also	O
be	O
used	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
.	O

Comparison	O
of	O
diploid	O
pluripotent	O
cells	O
with	O
NTera2	B
and	O
BG01	B
variantOur	B
previous	O
results	O
have	O
suggested	O
that	O
EC	O
lines	O
share	O
many	O
of	O
the	O
properties	O
of	O
hESCs	O
and	O
can	O
be	O
used	O
as	O
a	O
useful	O
model	O
for	O
initial	O
testing	O
of	O
biological	O
questions	O
[	O
21	O
]	O
.	O

More	O
recently	O
we	O
have	O
identified	O
BG01V	B
as	O
a	O
karyotypically	O
abnormal	O
variant	O
that	O
behaves	O
much	O
like	O
its	O
normal	O
counterpart	O
BG01	B
,	O
but	O
is	O
not	O
subject	O
to	O
the	O
same	O
constraints	O
of	O
use	O
as	O
karyotypically	O
normal	O
hESCs	O
[	O
13	O
]	O
.	O

Given	O
the	O
sensitivity	O
of	O
the	O
bead	O
array	O
analysis	O
,	O
we	O
tested	O
its	O
ability	O
to	O
detect	O
the	O
overall	O
similarities	O
and	O
differences	O
between	O
NTera2	B
and	O
a	O
pooled	O
ESC	O
sample	O
or	O
between	O
the	O
karyotypically	O
abnormal	O
BG01V	B
and	O
its	O
normal	O
parent	O
line	O
(	O
Figure	O
6	O
)	O
.Figure	O
6Diploid	O
pluripotent	O
EC	O
cell	O
line	O
NTera2	B
and	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	B
can	O
be	O
distinguished	O
from	O
normal	O
hESCs	O
using	O
Illumina	O
array	O
.	O

Comparison	O
of	O
NTera2	B
and	O
pooled	O
hESC	O
sample	O
resulted	O
a	O
correlation	O
coefficient	O
of	O
0.8997	O
.	O

Two	O
lists	O
of	O
genes	O
,	O
which	O
were	O
specifically	O
expressed	O
in	O
NTera2	B
(	O
C	O
)	O
or	O
in	O
hESCs	O
(	O
E	O
)	O
were	O
identified	O
.	O

Likewise	O
,	O
while	O
sharing	O
similarities	O
with	O
BG01	B
(	O
B	O
,	O
correlation	O
coefficient=	O
0.9043	O
)	O
,	O
BG01V	B
was	O
different	O
from	O
BG01	B
in	O
expression	O
for	O
many	O
genes	O
,	O
particularly	O
genes	O
from	O
the	O
TGFβ	O
pathway	O
(	O
D	O
,	O
F	O
)	O
.	O

Black	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
at	O
>	O
0	O
expression	O
level	O
,	O
blue	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
both	O
at	O
>	O
0	O
expression	O
level	O
and	O
at	O
>	O
0.99	O
confidence	O
.	O

Genes	O
plotted	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

Our	O
results	O
showed	O
that	O
,	O
while	O
NTera2	B
shared	O
a	O
high	O
similarity	O
with	O
hESCs	O
[	O
21	O
]	O
,	O
it	O
did	O
have	O
important	O
differences	O
with	O
hESC	O
lines	O
.	O

Examining	O
these	O
differences	O
(	O
summarized	O
in	O
Figure	O
6C	O
and	O
6E	O
)	O
,	O
we	O
noted	O
that	O
some	O
reflected	O
the	O
origin	O
of	O
the	O
tumor	O
cells	O
from	O
which	O
this	O
line	O
was	O
derived	O
[	O
14	O
]	O
.	O

Several	O
germ	O
cell	O
markers	O
such	O
as	O
GAGE2	O
,	O
GAGE7	O
and	O
GAGE8	O
were	O
highly	O
expressed	O
in	O
NTera2	B
but	O
were	O
absent	O
(	O
or	O
present	O
at	O
low	O
levels	O
)	O
in	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
(	O
See	O
Figure	O
6C	O
and	O
Additional	O
file	O
1	O
.	O

Note	O
that	O
the	O
GAGE	O
genes	O
are	O
highly	O
similar	O
in	O
sequence	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
one	O
family	O
member	O
from	O
another	O
through	O
hybridization	O
;	O
thus	O
,	O
while	O
all	O
of	O
these	O
GAGE	O
gene	O
probes	O
gave	O
positive	O
signal	O
,	O
it	O
is	O
difficult	O
to	O
say	O
if	O
the	O
signal	O
came	O
from	O
the	O
specific	O
gene	O
itself	O
or	O
from	O
cross	O
-	O
hybridization	O
from	O
one	O
of	O
the	O
other	O
family	O
members	O
)	O
.	O

None	O
of	O
these	O
were	O
present	O
in	O
BG01V	B
,	O
indicating	O
that	O
the	O
karyotypically	O
abnormal	O
variant	O
is	O
not	O
the	O
equivalent	O
of	O
a	O
teratocarcinoma	O
line	O
such	O
as	O
NTera2	B
.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
,	O
we	O
noticed	O
a	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
genes	O
in	O
the	O
TGFβ	O
pathway	O
,	O
such	O
as	O
GDF3	O
(	O
Figure	O
6C	O
)	O
,	O
TGFBI	O
,	O
CDKN1A	O
,	O
IGFBP7	O
,	O
IGFBP3	O
,	O
NODAL	O
,	O
CER1	O
and	O
BMP2	O
(	O
Figure	O
6E	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
postulated	O
role	O
of	O
this	O
pathway	O
in	O
germ	O
cell	O
differentiation	O
[	O
22,23	O
]	O
and	O
suggests	O
that	O
TGFβ	O
pathway	O
can	O
not	O
be	O
reliably	O
tested	O
using	O
NTera2	B
as	O
a	O
model	O
for	O
hESC.The	O
BG01V	B
showed	O
clear	O
differences	O
from	O
its	O
normal	O
counterpart	O
and	O
some	O
major	O
changes	O
are	O
summarized	O
in	O
Figure	O
6D	O
and	O
6F	O
.	O

Early	O
markers	O
of	O
differentiation	O
appeared	O
to	O
be	O
present	O
at	O
higher	O
levels	O
in	O
BG01V	B
as	O
compared	O
to	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
,	O
although	O
hESC	O
specific	O
genes	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
(	O
see	O
Additional	O
file	O
4	O
)	O
.	O

In	O
particular	O
,	O
the	O
Wnt	O
pathway	O
and	O
the	O
TGFβ	O
signaling	O
pathway	O
(	O
Figure	O
6D	O
)	O
,	O
both	O
of	O
which	O
involved	O
in	O
the	O
early	O
process	O
of	O
differentiation	O
[	O
24,25	O
]	O
,	O
appeared	O
to	O
be	O
activated	O
(	O
Additional	O
file	O
4	O
)	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
growth	O
factors	O
and	O
signaling	O
in	O
these	O
early	O
events	O
can	O
not	O
be	O
readily	O
studied	O
in	O
this	O
cell	O
line	O
.	O

In	O
summary	O
,	O
the	O
analysis	O
highlighted	O
the	O
utility	O
of	O
the	O
potential	O
reference	O
standards	O
NTera2	B
and	O
BG01V	B
,	O
demonstrated	O
their	O
general	O
similarity	O
and	O
provided	O
detail	O
on	O
potential	O
caveats	O
to	O
their	O
application	O
.	O

Global	O
arrays	O
provide	O
a	O
snapshot	O
of	O
the	O
state	O
of	O
the	O
cells	O
and	O
identify	O
core	O
self	O
-	O
renewal	O
pathwaysWe	O
have	O
utilized	O
a	O
small	O
fraction	O
of	O
the	O
data	O
to	O
demonstrate	O
the	O
overall	O
utility	O
of	O
this	O
approach	O
and	O
its	O
sensitivity	O
in	O
identifying	O
small	O
differences	O
in	O
cell	O
populations	O
.	O

An	O
additional	O
potential	O
application	O
of	O
such	O
an	O
analysis	O
is	O
the	O
ability	O
to	O
examine	O
the	O
general	O
state	O
of	O
a	O
particular	O
signaling	O
pathway	O
and	O
determine	O
whether	O
it	O
is	O
active	O
.	O

By	O
comparing	O
across	O
many	O
samples	O
,	O
a	O
procedure	O
previously	O
expensive	O
and	O
difficult	O
in	O
terms	O
of	O
the	O
RNA	O
and	O
replicate	O
requirement	O
,	O
one	O
can	O
rapidly	O
identify	O
key	O
regulatory	O
pathways	O
.	O

To	O
test	O
whether	O
we	O
could	O
use	O
such	O
multiple	O
pairwise	O
comparisons	O
to	O
elucidate	O
the	O
major	O
regulatory	O
pathways	O
that	O
may	O
be	O
required	O
for	O
hESC	O
self	O
-	O
renewal	O
,	O
we	O
examined	O
several	O
metabolic	O
pathways	O
.	O

The	O
results	O
of	O
the	O
analysis	O
of	O
the	O
insulin	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
signaling	O
pathway	O
are	O
shown	O
in	O
Figure	O
7	O
.	O

Using	O
the	O
same	O
4	O
groups	O
of	O
samples	O
as	O
in	O
Figure	O
1	O
,	O
we	O
conducted	O
PAM	O
(	O
Prediction	O
Analysis	O
of	O
Microarray	O
)	O
[	O
26	O
]	O
,	O
in	O
search	O
for	O
biomarkers	O
used	O
in	O
diagnostic	O
identification	O
of	O
these	O
four	O
groups	O
,	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
.	O

In	O
PAM	O
,	O
a	O
list	O
of	O
significant	O
IGF	O
pathway	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
was	O
obtained	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
each	O
class	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
took	O
the	O
gene	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
and	O
compared	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
.	O

For	O
cross	O
-	O
validation	O
of	O
prediction	O
results	O
,	O
multiple	O
classification	O
processes	O
were	O
performed	O
on	O
two	O
data	O
sets	O
randomly	O
constructed	O
each	O
time	O
from	O
the	O
entire	O
gene	O
expression	O
dataset	O
.	O

The	O
first	O
dataset	O
,	O
consisting	O
of	O
70	O
%	O
of	O
the	O
total	O
data	O
,	O
was	O
used	O
as	O
the	O
training	O
dataset	O
,	O
and	O
the	O
other	O
dataset	O
,	O
containing	O
the	O
remaining	O
30	O
%	O
of	O
data	O
,	O
was	O
used	O
for	O
the	O
data	O
prediction	O
and	O
verification	O
process	O
.	O

The	O
final	O
biomarkers	O
were	O
determined	O
in	O
such	O
a	O
way	O
that	O
the	O
misclassification	O
error	O
rate	O
was	O
minimal	O
.	O

The	O
resulting	O
graph	O
(	O
Figure	O
7	O
)	O
showed	O
the	O
shrunken	O
class	O
centroids	O
for	O
genes	O
that	O
had	O
at	O
least	O
one	O
nonzero	O
difference	O
in	O
each	O
diagnostic	O
class	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
represented	O
candidate	O
biomarkers	O
for	O
the	O
diagnosis	O
of	O
each	O
class	O
.	O

All	O
data	O
analyses	O
were	O
performed	O
using	O
the	O
bioconductor	O
package	O
[	O
17	O
]	O
.Figure	O
7Identification	O
of	O
diagnostic	O
markers	O
by	O
PAM	O
.	O

The	O
shrunken	O
class	O
centroids	O
for	O
genes	O
which	O
have	O
at	O
least	O
one	O
nonzero	O
difference	O
are	O
shown	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
were	O
the	O
candidate	O
molecular	O
markers	O
for	O
the	O
diagnosis	O
of	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
,	O
including	O
,	O
(	O
from	O
left	O
to	O
right	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	O
fibroblast	O
feeder	O
cells	O
(	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
,	O
undifferentiated	O
hESCs	O
(	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
,	O
hESC	O
derived	O
neural	O
cells	O
(	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
,	O
and	O
differentiated	O
ES	O
cells	O
and	O
EB	O
,	O
(	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
identified	O
biomarkers	O
can	O
be	O
used	O
to	O
distinguish	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
.	O

Undifferentiated	O
hESCs	O
have	O
been	O
analyzed	O
by	O
EST	O
scan	O
,	O
MPSS	O
,	O
SAGE	O
and	O
microarray	O
[	O
5,10,16	O
]	O
.	O

The	O
goal	O
of	O
these	O
experiments	O
including	O
our	O
own	O
is	O
to	O
develop	O
a	O
low	O
cost	O
reliable	O
method	O
to	O
assess	O
multiple	O
samples	O
to	O
generate	O
a	O
global	O
database	O
of	O
markers	O
and	O
to	O
provide	O
a	O
method	O
of	O
identifying	O
core	O
measures	O
of	O
similarities	O
and	O
differences	O
across	O
multiple	O
laboratories	O
.	O

We	O
and	O
others	O
have	O
proposed	O
three	O
alternative	O
methods	O
of	O
assessment	O
:	O
Quantitative	O
RT	O
-	O
PCR	O
[	O
9,20	O
]	O
,	O
focused	O
arrays	O
[	O
27	O
]	O
or	O
a	O
large	O
scale	O
array	O
with	O
bioinformatics	O
tools	O
being	O
utilized	O
to	O
focus	O
on	O
appropriate	O
subsets	O
of	O
genes	O
[	O
5,7,15,16,28	O
]	O
.	O

Each	O
of	O
these	O
methods	O
has	O
its	O
advantages	O
and	O
disadvantages	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
global	O
Illumina	O
bead	O
array	O
retains	O
the	O
advantages	O
of	O
low	O
cost	O
per	O
sample	O
associated	O
with	O
focused	O
arrays	O
yet	O
still	O
has	O
the	O
strength	O
of	O
the	O
global	O
attributes	O
of	O
MPSS	O
or	O
EST	O
scan	O
while	O
requiring	O
much	O
less	O
RNA	O
and	O
turnaround	O
time	O
.	O

To	O
test	O
this	O
array	O
format	O
we	O
examined	O
samples	O
from	O
a	O
variety	O
of	O
laboratories	O
in	O
a	O
blinded	O
fashion	O
to	O
determine	O
whether	O
the	O
array	O
was	O
sufficiently	O
sensitive	O
and	O
rapid	O
for	O
routine	O
assessment	O
.	O

Duplicates	O
using	O
100	O
ng	O
of	O
RNA	O
were	O
run	O
and	O
results	O
obtained	O
forty	O
-	O
eight	O
hours	O
later	O
.	O

The	O
resolution	O
was	O
sufficient	O
that	O
ESC	O
samples	O
could	O
be	O
distinguished	O
from	O
one	O
another	O
and	O
a	O
variant	O
karyotypically	O
abnormal	O
subclone	O
could	O
be	O
distinguished	O
from	O
the	O
parent	O
population	O
(	O
correlation	O
coefficient	O
=	O
0.9043	O
)	O
.	O

Aliquots	O
of	O
the	O
pooled	O
ES	O
and	O
pooled	O
EB	O
samples	O
,	O
which	O
we	O
had	O
prepared	O
for	O
MPSS	O
,	O
were	O
included	O
in	O
this	O
run	O
to	O
compare	O
these	O
two	O
methods	O
directly	O
.	O

The	O
current	O
analysis	O
confirms	O
that	O
comparison	O
across	O
platforms	O
is	O
difficult	O
and	O
that	O
only	O
positive	O
results	O
can	O
be	O
treated	O
with	O
any	O
reliability	O
.	O

The	O
absence	O
of	O
expression	O
can	O
not	O
be	O
readily	O
interpreted	O
.	O

In	O
particular	O
,	O
genes	O
expressed	O
at	O
low	O
levels	O
(	O
greater	O
than	O
70	O
%	O
of	O
all	O
genes	O
detected	O
)	O
should	O
not	O
be	O
assessed	O
in	O
cross	O
platform	O
comparisons	O
.	O

The	O
limited	O
concordance	O
at	O
low	O
levels	O
raises	O
a	O
question	O
as	O
to	O
how	O
many	O
genes	O
are	O
actually	O
expressed	O
by	O
any	O
one	O
cell	O
line	O
and	O
whether	O
the	O
cutoff	O
of	O
3	O
tpm	O
used	O
for	O
MPSS	O
or	O
100	O
intensity	O
units	O
for	O
bead	O
arrays	O
is	O
a	O
reasonable	O
cutoff	O
.	O

We	O
used	O
100	O
units	O
for	O
our	O
analysis	O
and	O
we	O
would	O
suggest	O
that	O
readers	O
exercise	O
similar	O
caution	O
.	O

Nevertheless	O
even	O
at	O
this	O
higher	O
cutoff	O
the	O
arrays	O
were	O
remarkably	O
sensitive	O
and	O
allowed	O
us	O
to	O
readily	O
distinguish	O
between	O
samples	O
including	O
cells	O
grown	O
in	O
the	O
same	O
laboratory	O
.	O

The	O
basis	O
of	O
the	O
sensitivity	O
could	O
be	O
attributed	O
to	O
a	O
limited	O
set	O
of	O
genes	O
and	O
those	O
genes	O
could	O
be	O
identified	O
for	O
future	O
use	O
.	O

For	O
example	O
BG01V	B
,	O
while	O
much	O
more	O
similar	O
to	O
BG01	B
than	O
to	O
any	O
other	O
cell	O
type	O
,	O
could	O
still	O
be	O
distinguished	O
from	O
a	O
biological	O
replicate	O
of	O
BG01	B
by	O
the	O
expression	O
of	O
a	O
particular	O
subset	O
of	O
differentiation	O
markers	O
(	O
Figure	O
6	O
)	O
.	O

EC	O
cells	O
such	O
as	O
NTera2	B
could	O
be	O
distinguished	O
from	O
hESCs	O
by	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
and	O
the	O
presence	O
of	O
a	O
partially	O
inactivated	O
TGFβ	O
(	O
BMP	O
)	O
signaling	O
pathway	O
(	O
Figure	O
6	O
)	O
.	O

Distinguishing	O
ESCs	O
from	O
EBs	O
was	O
relatively	O
straightforward	O
.	O

We	O
have	O
confirmed	O
the	O
utility	O
of	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
this	O
platform	O
as	O
well	O
as	O
identified	O
an	O
additional	O
set	O
of	O
markers	O
that	O
can	O
serve	O
as	O
biomarkers	O
to	O
distinguish	O
between	O
the	O
hESC	O
and	O
EB	O
states	O
.	O

A	O
subset	O
of	O
these	O
markers	O
have	O
been	O
used	O
to	O
develop	O
a	O
qPCR	O
assay	O
that	O
shows	O
such	O
a	O
high	O
sensitivity	O
that	O
changes	O
in	O
cell	O
behavior	O
can	O
be	O
detected	O
after	O
as	O
little	O
as	O
twenty	O
-	O
four	O
hours	O
and	O
the	O
development	O
of	O
EBs	O
can	O
be	O
reliably	O
staged	O
[	O
10,20	O
]	O
.	O

During	O
the	O
identification	O
of	O
ES	O
and	O
EB	O
specific	O
markers	O
,	O
we	O
have	O
noticed	O
that	O
some	O
known	O
hESC	O
markers	O
,	O
such	O
as	O
Nanog	O
,	O
was	O
not	O
detected	O
in	O
all	O
populations	O
of	O
hESCs	O
that	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Several	O
ESC	O
-	O
specific	O
gene	O
,	O
including	O
Lin41	O
,	O
Sox2	O
and	O
FoxD3	O
,	O
were	O
not	O
detected	O
in	O
the	O
array	O
either	O
(	O
Table	O
3	O
)	O
.	O

We	O
believe	O
that	O
the	O
problem	O
with	O
Lin	O
41	O
,	O
Sox2	O
and	O
FoxD3	O
is	O
a	O
technical	O
one	O
as	O
we	O
were	O
able	O
to	O
confirm	O
expression	O
using	O
alternate	O
methods	O
.	O

We	O
are	O
in	O
progress	O
of	O
redesigning	O
appropriate	O
probes	O
for	O
these	O
genes	O
.	O

In	O
the	O
case	O
of	O
the	O
gene	O
Nanog	O
,	O
there	O
are	O
several	O
pseudo	O
genes	O
in	O
the	O
genome	O
for	O
Nanog	O
and	O
it	O
has	O
been	O
a	O
major	O
technical	O
challenge	O
designing	O
primers	O
or	O
probes	O
that	O
are	O
specific	O
and	O
sensitive	O
.	O

We	O
believe	O
that	O
a	O
partial	O
explanation	O
for	O
the	O
variability	O
in	O
Nanog	O
expression	O
is	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
to	O
this	O
gene	O
.	O

However	O
,	O
immunocytochemistry	O
while	O
not	O
strictly	O
quantitative	O
shows	O
similar	O
variability	O
when	O
used	O
to	O
assess	O
Nanog	O
expression	O
in	O
different	O
cell	O
lines	O
[	O
9,27,28	O
]	O
.	O

This	O
large	O
comparison	O
between	O
samples	O
allowed	O
us	O
to	O
identify	O
markers	O
that	O
distinguish	O
human	O
feeder	O
cells	O
from	O
hESC	O
.	O

While	O
we	O
have	O
listed	O
19	O
potential	O
markers	O
(	O
Figure	O
3	O
)	O
and	O
identified	O
several	O
hundred	O
potential	O
markers	O
as	O
shown	O
in	O
Additional	O
file	O
5	O
,	O
we	O
suggest	O
that	O
as	O
few	O
as	O
3–4	O
genes	O
may	O
be	O
sufficient	O
.	O

Previously	O
we	O
found	O
that	O
as	O
few	O
as	O
four	O
were	O
satisfactory	O
to	O
distinguish	O
between	O
hESCs	O
and	O
hEBs	O
,	O
which	O
are	O
two	O
much	O
more	O
closely	O
related	O
samples	O
[	O
9	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
confirmed	O
by	O
qPCR	O
the	O
differential	O
expression	O
of	O
four	O
genes	O
,	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTH4	O
,	O
to	O
separate	O
human	O
fibroblast	O
feeders	O
and	O
hESCs	O
(	O
Figure	O
3	O
)	O
.	O

Several	O
markers	O
such	O
as	O
MMP3	O
and	O
TNFRSF11B	O
have	O
commercially	O
available	O
antibodies	O
(	O
R&D	O
systems	O
)	O
that	O
may	O
be	O
used	O
to	O
further	O
confirm	O
contamination	O
of	O
feeder	O
cells	O
by	O
immunocytochemistry	O
.	O

Efforts	O
to	O
identify	O
other	O
useful	O
antibodies	O
based	O
on	O
these	O
results	O
continue	O
[	O
29	O
]	O
.	O

While	O
we	O
have	O
focused	O
on	O
the	O
immediate	O
utility	O
of	O
the	O
Illumina	O
array	O
platform	O
,	O
it	O
is	O
important	O
to	O
remember	O
that	O
this	O
array	O
provides	O
a	O
global	O
snapshot	O
of	O
cell	O
state	O
and	O
the	O
data	O
obtained	O
can	O
be	O
readily	O
compared	O
in	O
order	O
to	O
determine	O
key	O
signaling	O
pathways	O
.	O

The	O
ability	O
to	O
compare	O
multiple	O
samples	O
in	O
one	O
run	O
enhances	O
data	O
selectivity	O
and	O
reliability	O
.	O

To	O
make	O
such	O
analysis	O
more	O
readily	O
available	O
,	O
we	O
utilized	O
several	O
software	O
tools	O
including	O
the	O
software	O
package	O
available	O
through	O
Illumina	O
.	O

The	O
BeadStudio	O
software	O
provided	O
with	O
the	O
BeadLab	O
and	O
BeadStudio	O
genetic	O
analysis	O
systems	O
for	O
use	O
with	O
the	O
bead	O
array	O
datasets	O
provides	O
a	O
useful	O
set	O
of	O
analytical	O
and	O
presentation	O
tools	O
that	O
allow	O
straightforward	O
comparisons	O
,	O
which	O
are	O
sufficient	O
for	O
average	O
users	O
.	O

For	O
detailed	O
analysis	O
we	O
recommend	O
using	O
more	O
specific	O
commercial	O
tools	O
or	O
software	O
packages	O
developed	O
by	O
NCBI	O
.	O

In	O
summary	O
,	O
the	O
Illumina	O
bead	O
array	O
has	O
several	O
key	O
strengths	O
including	O
high	O
throughput	O
,	O
low	O
cost	O
and	O
high	O
sensitivity	O
.	O

By	O
using	O
this	O
array	O
,	O
we	O
can	O
readily	O
detect	O
contaminating	O
feeders	O
and	O
spontaneous	O
differentiation	O
,	O
differentiate	O
male	O
and	O
female	O
lines	O
and	O
distinguish	O
between	O
one	O
undifferentiated	O
population	O
and	O
another	O
.	O

Such	O
a	O
global	O
analysis	O
allows	O
us	O
to	O
assess	O
context	O
dependent	O
signaling	O
and	O
identify	O
biomarkers	O
of	O
particular	O
states	O
of	O
cells	O
.	O

Our	O
future	O
efforts	O
will	O
focus	O
on	O
data	O
mining	O
and	O
developing	O
better	O
cross	O
platform	O
comparison	O
tools	O
and	O
generating	O
focused	O
high	O
throughput	O
arrays	O
for	O
quality	O
control	O
in	O
clinical	O
and	O
research	O
settings	O
.	O

hESC	O
cultureThe	O
hESC	O
lines	O
H1	B
,	O
H7	B
and	O
H9	B
(	O
WiCell	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
cultured	O
on	O
feeder	O
layers	O
derived	O
from	O
mitotically	O
inactivated	O
HS27	B
human	O
fibroblast	O
cells	O
(	O
HS27	B
,	O
ATCC	O
)	O
,	O
or	O
mouse	O
embryonic	O
fibroblsts	O
or	O
under	O
feeder	O
-	O
free	O
conditions	O
on	O
Matrigel	O
(	O
BD	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
coated	O
plates	O
for	O
at	O
least	O
10	O
passages	O
.	O

Culture	O
medium	O
for	O
all	O
cultures	O
was	O
composed	O
of	O
DMEM	O
/	O
F12-Glutamax	O
1:1	O
,	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
nonessential	O
amino	O
acids	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
(	O
all	O
from	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
and	O
4	O
ng	O
/	O
ml	O
human	O
recombinant	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
/	O
FGF2	O
;	O
PeproTech	O
Inc.	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
.	O
)	O

Feeder	O
-	O
free	O
cultures	O
were	O
prepared	O
for	O
gene	O
expression	O
analysis	O
by	O
manually	O
harvesting	O
individual	O
colonies	O
with	O
uniform	O
typical	O
undifferentiated	O
ESC	O
morphology	O
.	O

BG01	B
(	O
46	O
,	O
XY	O
)	O
,	O
BG02	B
(	O
46	O
,	O
XY	O
)	O
,	O
BG03	B
(	O
46	O
,	O
XX	O
)	O
,	O
I6	B
(	O
46	O
,	O
XY	O
)	O
and	O
BG01V	B
(	O
BG01	B
karyotypic	O
variant	O
:	O
49	O
,	O
XXY	O
,	O
+	O
12	O
,	O
+	O
17	O
)	O
:	O
Cells	O
were	O
maintained	O
for	O
3	O
(	O
BG01V	B
)	O
,	O
7	O
(	O
BG02	B
)	O
,	O
8	O
(	O
BG01	B
)	O
,	O
or	O
21	O
(	O
BG03	B
)	O
passages	O
under	O
feeder	O
-	O
free	O
condition	O
on	O
fibronectin	O
-	O
coated	O
plates	O
in	O
medium	O
that	O
had	O
been	O
conditioned	O
by	O
mouse	O
embryonic	O
fibroblasts	O
for	O
24	O
hours	O
.	O

Culture	O
medium	O
was	O
DMEM	O
/	O
F12	O
,	O
1:1	O
supplemented	O
with	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
4	O
ng	O
/	O
ml	O
of	O
bFGF.Different	O
hESC	O
lines	O
were	O
grown	O
in	O
slightly	O
different	O
culture	O
conditions	O
as	O
described	O
above	O
.	O

H	O
lines	O
were	O
grown	O
on	O
Matrigel	O
coated	O
dishes	O
,	O
while	O
BG	O
lines	O
on	O
fibronectin	O
treated	O
dishes	O
.	O

These	O
coating	O
substrata	O
supported	O
the	O
growth	O
of	O
hESCs	O
similarly	O
,	O
as	O
evaluated	O
by	O
colony	O
morphology	O
,	O
immunocytochemistry	O
and	O
proliferation	O
rate	O
(	O
data	O
not	O
shown	O
)	O
.Embryoid	O
bodies	O
(	O
EBs	O
)	O
were	O
prepared	O
from	O
BG	O
lines	O
as	O
described	O
in	O
[	O
5	O
]	O
.	O

Cells	O
were	O
aggregated	O
and	O
cultured	O
on	O
non	O
-	O
adherent	O
substrata	O
for	O
fourteen	O
days	O
.	O

Other	O
cellsNTera2	O
cells	O
were	O
purchased	O
from	O
ATCC	O
and	O
cultured	O
in	O
parallel	O
with	O
hESCssamples	O
using	O
protocols	O
described	O
previously	O
[	O
21	O
]	O
.	O

HS27	B
embryonic	O
human	O
newborn	O
foreskin	O
cells	O
(	O
ATCC	O
CRL-1634	O
)	O
were	O
grown	O
in	O
DMEM	O
with	O
10%FBS.All	O
samples	O
included	O
in	O
this	O
study	O
can	O
be	O
found	O
in	O
Additional	O
file	O
6.Bead	O
array	O
gene	O
expression	O
analysisRNA	O
was	O
isolated	O
from	O
cultured	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
(	O
Qiagen	O
,	O
Inc	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Sample	O
amplification	O
was	O
performed	O
using	O
100	O
ng	O
of	O
total	O
RNA	O
as	O
input	O
material	O
by	O
the	O
method	O
of	O
Van	O
Gelder	O
et	O
al	O
[	O
30	O
]	O
.	O

Amplified	O
RNA	O
synthesized	O
from	O
limited	O
quantities	O
of	O
heterogenous	O
cDNA	O
[	O
30	O
]	O
was	O
performed	O
using	O
the	O
Illumina	O
RNA	O
Amplification	O
kit	O
(	O
Ambion	O
,	O
Inc.	O
,	O
Austin	O
,	O
TX	O
)	O
following	O
the	O
Manufacturer	O
instructions	O
.	O

Labeling	O
was	O
achieved	O
by	O
use	O
of	O
the	O
incorporation	O
of	O
biotin-16-UTP	O
(	O
Perkin	O
Elmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Boston	O
,	O
MA	O
)	O
present	O
at	O
a	O
ratio	O
of	O
1:1	O
with	O
unlabeled	O
UTP	O
.	O

Labeled	O
,	O
amplified	O
material	O
(	O
700	O
ng	O
per	O
array	O
)	O
was	O
hybridized	O
to	O
a	O
pilot	O
version	O
of	O
the	O
Illumina	O
HumanRef-8	O
BeadChip	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
(	O
Illumina	O
,	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Amersham	O
fluorolink	O
streptavidin	O
-	O
Cy3	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
following	O
the	O
BeadChip	O
manual	O
.	O

Arrays	O
were	O
scanned	O
with	O
an	O
Illumina	O
Bead	O
array	O
Reader	O
confocal	O
scanner	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
.	O

Array	O
data	O
processing	O
and	O
analysis	O
was	O
performed	O
using	O
Illumina	O
BeadStudio	O
software	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
and	O
clustering	O
analysisDifferentially	O
expressed	O
genes	O
between	O
ES	O
and	O
EB	O
were	O
identified	O
by	O
ANOVA	O
at	O
p	O
value	O
0.05	O
using	O
bioconductor	O
[	O
17	O
]	O
.	O

Unsupervised	O
hierarchical	O
clustering	O
analysis	O
and	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
were	O
conducted	O
using	O
software	O
Pcluster	O
[	O
31	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
.Identification	O
of	O
diagnostic	O
markersPAM	O
(	O
prediction	O
analysis	O
of	O
microarray	O
)	O
was	O
employed	O
for	O
the	O
identification	O
of	O
diagnostic	O
markers	O
from	O
insulin	O
pathway	O
genes	O
by	O
using	O
the	O
software	O
package	O
bioconductor	O
[	O
17	O
]	O
.	O

PAM	O
is	O
a	O
class	O
prediction	O
method	O
for	O
expression	O
data	O
mining	O
.	O

It	O
can	O
provide	O
a	O
list	O
of	O
significant	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
multiple	O
classes	O
,	O
such	O
as	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
,	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
for	O
that	O
gene	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
by	O
PAM	O
takes	O
the	O
protein	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
,	O
and	O
compares	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
[	O
26	O
]	O
.RT	O
-	O
PCR	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysisTotal	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
(	O
Invitrogen	O
.	O

cDNA	O
was	O
synthesized	O
using	O
2.5	O
μg	O
total	O
RNA	O
in	O
a	O
20-μl	O
reaction	O
with	O
Superscript	O
II	O
(	O
Invitrogen	O
)	O
and	O
oligo	O
(	O
dT	O
)	O
12–18	O
(	O
Promega	O
;	O
Madison	O
,	O
WI	O
)	O
.	O

One	O
microliter	O
RNase	O
H	O
(	O
Invitrogen	O
)	O
was	O
added	O
to	O
each	O
tube	O
and	O
incubated	O
for	O
20	O
minutes	O
at	O
37	O
°	O
C	O
before	O
proceeding	O
to	O
the	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
PCR	O
primers	O
are	O
:	O
RPS4Y	O
-	O
forward	O
:	O
5	O
'	O
AGATTCTCTTCCGTCGCAG	O
3	O
'	O
,	O
RPS4Y	O
-	O
reverse	O
,	O
5	O
'	O
CTCCACCAATCACCATACAC	O
3	O
'	O
;	O
EIFAY	O
-	O
forward	O
,	O
5	O
'	O
CTGCTGCATCTTAGTTCAGTC	O
3	O
'	O
;	O
EIFAY	O
-	O
reverse	O
5	O
'	O
CTTCCAATCGTCCATTTCCC	O
3	O
'	O
.	O

Quantitative	O
real	O
time	O
PCR	O
gene	O
specific	O
primer	O
pairs	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
(	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
the	O
following	O
genes	O
:	O
MMP3	O
(	O
Hs00233962_m1	O
)	O
,	O
TFRSF11B	O
(	O
Hs00171068_m1	O
)	O
,	O
THBS1	O
(	O
Hs00170236_m1	O
)	O
,	O
KRTHA4	O
(	O
Hs00606019_gH	O
)	O
,	O
and	O
for	O
internal	O
control	O
β	O
-	O
actin	O
(	O
ACTB	O
,	O
Hs99999903_m1	O
)	O
.	O

This	O
work	O
uncovers	O
novel	O
mechanisms	O
of	O
aging	O
within	O
stem	O
cell	O
niches	O
that	O
are	O
evolutionarily	O
conserved	O
between	O
mice	O
and	O
humans	O
and	O
affect	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
.	O

Specifically	O
,	O
we	O
have	O
examined	O
the	O
effects	O
of	O
aged	O
muscle	O
and	O
systemic	O
niches	O
on	O
key	O
molecular	O
identifiers	O
of	O
regenerative	O
potential	O
of	O
human	O
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
and	O
post	O
-	O
natal	O
muscle	O
stem	O
cells	O
(	O
satellite	O
cells	O
)	O
.	O

Our	O
results	O
reveal	O
that	O
aged	O
differentiated	O
niches	O
dominantly	O
inhibit	O
the	O
expression	O
of	O
Oct4	O
in	O
hESCs	O
and	O
Myf-5	O
in	O
activated	O
satellite	O
cells	O
,	O
and	O
reduce	O
proliferation	O
and	O
myogenic	O
differentiation	O
of	O
both	O
embryonic	O
and	O
tissue	O
-	O
specific	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
.	O

Therefore	O
,	O
despite	O
their	O
general	O
neoorganogenesis	O
potential	O
,	O
the	O
ability	O
of	O
hESCs	O
,	O
and	O
the	O
more	O
differentiated	O
myogenic	O
ASCs	O
to	O
contribute	O
to	O
tissue	O
repair	O
in	O
the	O
old	O
will	O
be	O
greatly	O
restricted	O
due	O
to	O
the	O
conserved	O
inhibitory	O
influence	O
of	O
aged	O
differentiated	O
niches	O
.	O

Significantly	O
,	O
this	O
work	O
establishes	O
that	O
hESC	O
-	O
derived	O
factors	O
enhance	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
,	O
importantly	O
,	O
aged	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
;	O
thus	O
,	O
suggesting	O
that	O
the	O
regenerative	O
outcome	O
of	O
stem	O
cell	O
-	O
based	O
replacement	O
therapies	O
will	O
be	O
determined	O
by	O
a	O
balance	O
between	O
negative	O
influences	O
of	O
aged	O
tissues	O
on	O
transplanted	O
cells	O
and	O
positive	O
effects	O
of	O
embryonic	O
cells	O
on	O
the	O
endogenous	O
regenerative	O
capacity	O
.	O

Comprehensively	O
,	O
this	O
work	O
points	O
toward	O
novel	O
venues	O
for	O
in	O
situ	O
restoration	O
of	O
tissue	O
repair	O
in	O
the	O
old	O
and	O
identifies	O
critical	O
determinants	O
of	O
successful	O
cell	O
-	O
replacement	O
therapies	O
for	O
aged	O
degenerating	O
organs	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
are	O
distinguished	O
by	O
their	O
ability	O
to	O
self	O
-	O
renew	O
and	O
to	O
differentiate	O
into	O
any	O
other	O
cell	O
type	O
via	O
asymmetric	O
cell	O
divisions	O
,	O
in	O
which	O
one	O
daughter	O
cell	O
maintains	O
'	O
stemness	O
'	O
while	O
the	O
other	O
daughter	O
cell	O
differentiates	O
into	O
a	O
particular	O
tissue	O
type	O
.	O

ESCs	O
,	O
including	O
those	O
of	O
human	O
origin	O
(	O
hESCs	O
)	O
,	O
are	O
derived	O
from	O
the	O
blastocyst	O
and	O
can	O
be	O
propagated	O
in	O
vitro	O
(	O
Evans	O
&	O
Kaufman	O
,	O
1981	O
;	O
Thomson	O
et	O
al.	O
,	O
1998	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

Their	O
tremendous	O
potential	O
for	O
organogenesis	O
has	O
created	O
a	O
great	O
interest	O
in	O
using	O
hESCs	O
for	O
replacing	O
tissues	O
and	O
organs	O
lost	O
to	O
disease	O
,	O
or	O
old	O
age	O
(	O
reviewed	O
in	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
.	O

As	O
such	O
,	O
the	O
use	O
of	O
hESCs	O
is	O
particularly	O
important	O
,	O
due	O
to	O
the	O
fact	O
that	O
adult	O
organ	O
stem	O
cells	O
are	O
often	O
limited	O
in	O
number	O
,	O
cell	O
-	O
fate	O
plasticity	O
,	O
expansion	O
capacity	O
,	O
telomere	O
length	O
,	O
and	O
lifespan	O
(	O
Mayhall	O
et	O
al.	O
,	O
2004	O
)	O
.	O

The	O
general	O
goal	O
behind	O
most	O
cell	O
-	O
replacement	O
approaches	O
is	O
to	O
expand	O
and	O
then	O
differentiate	O
hESCs	O
in	O
vitro	O
,	O
thus	O
producing	O
a	O
cell	O
type	O
of	O
interest	O
,	O
such	O
as	O
neuronal	O
,	O
blood	O
,	O
endothelial	O
,	O
pancreatic	O
,	O
bone	O
,	O
and	O
others	O
.	O

These	O
differentiated	O
cells	O
are	O
expected	O
to	O
replace	O
their	O
dysfunctional	O
counterparts	O
in	O
vivo	O
.	O

The	O
scope	O
of	O
disorders	O
that	O
can	O
be	O
potentially	O
treated	O
with	O
a	O
neoorganogenesis	O
approach	O
is	O
large	O
and	O
includes	O
many	O
that	O
are	O
currently	O
incurable	O
,	O
such	O
as	O
muscle	O
atrophy	O
,	O
diabetes	O
,	O
Alzheimer	O
's	O
disease	O
,	O
Parkinson	O
's	O
disease	O
,	O
and	O
other	O
degenerative	O
diseases	O
that	O
often	O
accompany	O
human	O
aging	O
(	O
McDonald	O
et	O
al.	O
,	O
1999	O
;	O
Liu	O
et	O
al.	O
,	O
2000	O
;	O
Hori	O
et	O
al.	O
,	O
2002	O
;	O
Kim	O
et	O
al.	O
,	O
2002	O
;	O
Blyszczuk	O
et	O
al.	O
,	O
2003	O
)	O
.	O

While	O
many	O
studies	O
have	O
focused	O
on	O
the	O
derivation	O
,	O
propagation	O
,	O
and	O
in	O
vitro	O
differentiation	O
of	O
hESCs	O
(	O
reviewed	O
in	O
Hoffman	O
&	O
Carpenter	O
,	O
2005	O
;	O
Wobus	O
&	O
Boheler	O
,	O
2005	O
)	O
,	O
relatively	O
few	O
have	O
examined	O
the	O
properties	O
of	O
these	O
cells	O
and	O
their	O
more	O
differentiated	O
progeny	O
in	O
the	O
aged	O
,	O
as	O
opposed	O
to	O
the	O
young	O
,	O
systemic	O
and	O
local	O
organ	O
environments	O
.	O

Recently	O
published	O
data	O
suggest	O
that	O
these	O
extrinsic	O
cues	O
become	O
altered	O
with	O
age	O
in	O
ways	O
that	O
preclude	O
activation	O
of	O
organ	O
stem	O
cells	O
(	O
such	O
as	O
satellite	O
cells	O
)	O
,	O
inhibit	O
repair	O
-	O
specific	O
molecular	O
signaling	O
(	O
such	O
as	O
delta	O
-	O
Notch	O
)	O
,	O
and	O
interfere	O
with	O
productive	O
tissue	O
repair	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Janzen	O
et	O
al.	O
,	O
2006	O
;	O
Krishnamurthy	O
et	O
al.	O
,	O
2006	O
;	O
Molofsky	O
et	O
al.	O
,	O
2006	O
)	O
.	O

Furthermore	O
,	O
at	O
least	O
two	O
lines	O
of	O
evidence	O
suggest	O
that	O
stem	O
cell	O
-	O
based	O
tissue	O
-	O
replacement	O
therapies	O
might	O
be	O
hindered	O
in	O
the	O
elderly	O
,	O
because	O
all	O
cells	O
along	O
the	O
developmental	O
lineage	O
(	O
e.g.	O
,	O
stem	O
cells	O
,	O
more	O
differentiated	O
progenitor	O
cells	O
or	O
even	O
tissues	O
containing	O
a	O
pool	O
of	O
precursors	O
)	O
might	O
rapidly	O
'	O
age	O
'	O
and	O
fail	O
to	O
contribute	O
to	O
organ	O
repair	O
when	O
introduced	O
into	O
the	O
old	O
organism	O
in	O
vivo	O
.	O

First	O
,	O
in	O
heterochronic	O
tissue	O
-	O
transplantation	O
studies	O
,	O
the	O
age	O
of	O
the	O
host	O
environment	O
determined	O
the	O
regenerative	O
outcome	O
,	O
as	O
both	O
young	O
and	O
old	O
skeletal	O
muscle	O
explants	O
containing	O
differentiated	O
and	O
precursor	O
cells	O
effectively	O
regenerated	O
in	O
young	O
,	O
but	O
not	O
in	O
old	O
animals	O
(	O
Zacks	O
&	O
Sheff	O
,	O
1982	O
;	O
Carlson	O
&	O
Faulkner	O
,	O
1989	O
)	O
.	O

Second	O
,	O
using	O
parabiotically	O
paired	O
young	O
and	O
old	O
mice	O
,	O
the	O
regenerative	O
potential	O
of	O
muscle	O
and	O
liver	O
was	O
shown	O
to	O
be	O
influenced	O
by	O
the	O
age	O
of	O
the	O
systemic	O
environment	O
(	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
key	O
molecular	O
identifiers	O
of	O
stem	O
cell	O
properties	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
myogenic	O
capacity	O
would	O
be	O
influenced	O
by	O
the	O
age	O
of	O
extrinsic	O
milieu	O
,	O
regardless	O
of	O
whether	O
stem	O
cells	O
are	O
embryonic	O
or	O
the	O
more	O
differentiated	O
,	O
muscle	O
-	O
specific	O
satellite	O
cells	O
.	O

Satellite	O
cells	O
are	O
muscle	O
stem	O
cells	O
situated	O
in	O
direct	O
contact	O
with	O
myofibers	O
,	O
the	O
differentiated	O
muscle	O
cells	O
.	O

When	O
myofibers	O
are	O
damaged	O
,	O
quiescent	O
satellite	O
cells	O
are	O
activated	O
to	O
proliferate	O
and	O
then	O
differentiate	O
into	O
fusion	O
-	O
competent	O
myoblasts	O
that	O
continue	O
to	O
proliferate	O
and	O
can	O
form	O
primary	O
cultures	O
,	O
but	O
are	O
also	O
capable	O
of	O
producing	O
new	O
,	O
multinucleated	O
myofibers	O
or	O
myotubes	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
Morgan	O
et	O
al.	O
,	O
2002	O
;	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Activated	O
satellite	O
cells	O
express	O
myogenic	O
markers	O
,	O
such	O
as	O
Myf5	O
,	O
M	O
-	O
cadherin	O
,	O
and	O
Paired	O
box	O
gene	O
7	O
(	O
Pax7	O
)	O
;	O
fusion	O
-	O
competent	O
myoblasts	O
express	O
high	O
levels	O
of	O
desmin	O
,	O
and	O
de	O
novo	O
generated	O
myofibers	O
or	O
myotubes	O
express	O
embryonic	O
myosin	O
heavy	O
chain	O
(	O
eMyHC	O
)	O
and	O
continue	O
to	O
express	O
desmin	O
(	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

While	O
desmin	O
can	O
be	O
also	O
present	O
in	O
smooth	O
and	O
cardiac	O
muscle	O
cells	O
,	O
the	O
isolation	O
of	O
hind	O
limb	O
skeletal	O
muscle	O
with	O
subsequent	O
purification	O
of	O
myofibers	O
away	O
from	O
all	O
interstitial	O
cells	O
,	O
as	O
well	O
as	O
purification	O
of	O
associated	O
muscle	O
stem	O
cells	O
results	O
in	O
primary	O
cultures	O
that	O
are	O
uniformly	O
of	O
skeletal	O
muscle	O
lineage	O
.	O

Every	O
desmin+	O
cell	O
in	O
such	O
cultures	O
is	O
a	O
fusion	O
-	O
competent	O
myoblast	O
,	O
and	O
is	O
able	O
to	O
produce	O
multinucleated	O
myotubes	O
after	O
48	O
h	O
of	O
culture	O
in	O
differentiation	O
-	O
promoting	O
medium	O
[	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
with	O
2	O
%	O
horse	O
serum	O
]	O
.	O

Some	O
of	O
these	O
myogenic	O
cells	O
fuse	O
into	O
myotubes	O
,	O
even	O
in	O
the	O
mitogen	O
-	O
rich	O
medium	O
[	O
(	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
with	O
5–10	O
%	O
mouse	O
serum	O
or	O
DMEM	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
FBS	O
]	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
;	O
and	O
see	O
below	O
)	O
.	O

An	O
experimental	O
system	O
was	O
developed	O
that	O
(	O
i	O
)	O
provided	O
the	O
ability	O
to	O
study	O
the	O
regenerative	O
response	O
of	O
hESCs	O
and	O
of	O
muscle	O
stem	O
cells	O
in	O
various	O
heterochronic	O
environments	O
in	O
vitro	O
;	O
and	O
(	O
ii	O
)	O
allowed	O
examination	O
of	O
the	O
effects	O
of	O
hESCs	O
on	O
muscle	O
repair	O
,	O
in	O
vivo	O
,	O
after	O
transplantation	O
into	O
young	O
vs.	O
old	O
hosts	O
.	O

This	O
model	O
allowed	O
us	O
to	O
address	O
both	O
the	O
negative	O
effects	O
of	O
the	O
aged	O
niche	O
on	O
key	O
stem	O
cell	O
properties	O
and	O
the	O
positive	O
effects	O
of	O
hESCs	O
on	O
the	O
aged	O
muscle	O
-	O
specific	O
organ	O
progenitor	O
cells	O
in	O
vitro	O
,	O
and	O
on	O
the	O
regenerative	O
capacity	O
of	O
old	O
muscle	O
in	O
vivo	O
.	O

The	O
resulting	O
data	O
demonstrate	O
that	O
the	O
composition	O
of	O
conserved	O
extrinsic	O
cues	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
becomes	O
altered	O
with	O
age	O
in	O
ways	O
that	O
inhibit	O
both	O
hESCs	O
and	O
adult	O
stem	O
cell	O
regenerative	O
potential	O
.	O

Specifically	O
,	O
molecular	O
markers	O
of	O
stem	O
cell	O
functionality	O
,	O
e.g.	O
Oct4	O
(	O
in	O
hESCs	O
)	O
and	O
Myf5	O
(	O
in	O
muscle	O
stem	O
cells	O
)	O
,	O
the	O
rate	O
of	O
cell	O
proliferation	O
,	O
and	O
the	O
capacity	O
for	O
myogenic	O
differentiation	O
are	O
all	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieu	O
,	O
and	O
by	O
the	O
old	O
differentiated	O
muscle	O
tissue	O
.	O

However	O
,	O
while	O
satellite	O
cells	O
are	O
unable	O
to	O
deter	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
and	O
local	O
niches	O
,	O
hESCs	O
are	O
capable	O
of	O
antagonizing	O
the	O
aged	O
environments	O
,	O
thereby	O
enhancing	O
the	O
regenerative	O
potential	O
of	O
both	O
young	O
and	O
old	O
muscle	O
stem	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
a	O
complex	O
interplay	O
between	O
negative	O
regulation	O
of	O
hESCs	O
and	O
adult	O
muscle	O
stem	O
cells	O
by	O
the	O
aged	O
niche	O
,	O
and	O
positive	O
regulation	O
of	O
the	O
host	O
's	O
regenerative	O
responses	O
by	O
hESCs	O
will	O
likely	O
determine	O
the	O
success	O
of	O
hESC	O
-	O
based	O
cell	O
-	O
replacement	O
therapies	O
in	O
the	O
old	O
.	O

Regenerative	O
responses	O
of	O
adult	O
muscle	O
stem	O
cells	O
and	O
hESCs	O
are	O
dominantly	O
inhibited	O
by	O
the	O
aged	O
systemic	O
milieuPrevious	O
work	O
established	O
that	O
the	O
upregulation	O
of	O
repair	O
-	O
specific	O
molecular	O
signaling	O
mechanisms	O
,	O
such	O
as	O
Notch	O
,	O
and	O
successful	O
engagement	O
of	O
resident	O
muscle	O
stem	O
cells	O
in	O
tissue	O
repair	O
are	O
largely	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
rather	O
than	O
by	O
the	O
cell	O
-	O
autonomous	O
age	O
of	O
muscle	O
cells	O
,	O
or	O
by	O
the	O
differences	O
in	O
their	O
numbers	O
(	O
Conboy	O
&	O
Rando	O
,	O
2005	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
these	O
experiments	O
also	O
hinted	O
at	O
a	O
small	O
but	O
persistent	O
inhibitory	O
effect	O
of	O
the	O
aged	O
systemic	O
milieu	O
on	O
the	O
performance	O
of	O
young	O
stem	O
cells	O
.	O

Exploring	O
this	O
further	O
,	O
we	O
found	O
that	O
young	O
serum	O
permits	O
satellite	O
cells	O
to	O
be	O
myogenic	O
,	O
while	O
old	O
serum	O
inhibits	O
the	O
satellite	O
cell	O
regenerative	O
potential	O
not	O
only	O
alone	O
,	O
but	O
also	O
when	O
mixed	O
with	O
young	O
serum	O
,	O
suggesting	O
a	O
dominant	O
over	O
-	O
riding	O
of	O
'	O
young	O
'	O
serum	O
factors	O
(	O
Fig.	O
1	O
)	O
.	O

Myofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
have	O
been	O
activated	O
by	O
injury	O
in	O
vivo	O
,	O
were	O
established	O
from	O
young	O
(	O
2–3	O
months	O
)	O
and	O
old	O
(	O
22–24	O
months	O
)	O
C57-BL	O
/	O
6	O
male	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

As	O
previously	O
shown	O
,	O
this	O
method	O
is	O
well	O
suited	O
for	O
the	O
assessment	O
of	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

Isolated	O
myofiber	O
explants	O
with	O
associated	O
satellite	O
cells	O
were	O
cultured	O
overnight	O
in	O
the	O
presence	O
of	O
young	O
or	O
old	O
serum	O
(	O
alone	O
at	O
5	O
%	O
and	O
10	O
%	O
,	O
and	O
mixed	O
at	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
)	O
;	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

The	O
effects	O
of	O
heterochronic	O
systemic	O
milieu	O
on	O
myogenic	O
potential	O
were	O
examined	O
as	O
generation	O
of	O
proliferating	O
myoblasts	O
that	O
express	O
desmin	O
and	O
Myf5	O
,	O
and	O
that	O
spontaneously	O
form	O
multinucleated	O
nascent	O
myotubes	O
.	O

As	O
shown	O
in	O
Fig.	O
1A	O
and	O
quantified	O
in	O
Fig.	O
1B	O
,	O
the	O
age	O
of	O
sera	O
clearly	O
determined	O
satellite	O
cell	O
regenerative	O
potential	O
and	O
old	O
serum	O
strongly	O
inhibited	O
the	O
myogenic	O
potential	O
of	O
young	O
satellite	O
cells	O
either	O
when	O
present	O
alone	O
,	O
or	O
when	O
mixed	O
with	O
young	O
sera	O
.	O

Similar	O
data	O
was	O
obtained	O
by	O
using	O
another	O
myogenic	O
marker	O
,	O
Pax7	O
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Additionally	O
,	O
there	O
were	O
two	O
to	O
three	O
times	O
fewer	O
total	O
cells	O
generated	O
in	O
the	O
presence	O
of	O
aged	O
serum	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

1The	O
age	O
of	O
sera	O
determined	O
the	O
regenerative	O
potential	O
of	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Young	O
satellite	O
cells	O
were	O
cultured	O
either	O
in	O
5	O
%	O
or	O
10	O
%	O
young	O
(	O
Young	O
)	O
,	O
10	O
%	O
old	O
(	O
Old	O
)	O
,	O
or	O
in	O
a	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Cells	O
were	O
analyzed	O
by	O
immunofluorescence	O
microscopy	O
,	O
using	O
anti	O
-	O
BrdU	O
(	O
red	O
)	O
,	O
antidesmin	O
(	O
green	O
)	O
or	O
anti	O
-	O
Myf5	O
antibodies	O
(	O
green	O
,	O
small	O
panels	O
)	O
.	O

Similar	O
results	O
are	O
shown	O
for	O
Pax7	O
immunodetection	O
(	O
Supplementary	O
Fig.	O
S1	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labeled	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
were	O
quantified	O
[	O
300	O
young	O
myofibers	O
per	O
experiment	O
]	O
as	O
percentage	O
of	O
desmin+	O
/	O
Myf5+	O
/	O
BrdU+	O
de	O
novo	O
generated	O
cells	O
for	O
each	O
age	O
and	O
culture	O
condition	O
.	O

On	O
average	O
,	O
two	O
to	O
three	O
fewer	O
cells	O
were	O
generated	O
when	O
cultured	O
in	O
the	O
presence	O
of	O
old	O
.	O

Shown	O
are	O
identical	O
microscope	O
fields	O
at	O
×40	O
magnification	O
.	O

At	O
least	O
three	O
independent	O
experiments	O
produced	O
similar	O
results	O
.	O

(	O
*	O
)	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
sera	O
.	O

Importantly	O
,	O
it	O
was	O
not	O
simply	O
the	O
dilution	O
of	O
young	O
serum	O
factors	O
that	O
resulted	O
in	O
diminished	O
myogenic	O
capacity	O
when	O
young	O
and	O
old	O
sera	O
were	O
mixed	O
,	O
because	O
young	O
sera	O
promoted	O
robust	O
myogenesis	O
both	O
at	O
10	O
%	O
and	O
5	O
%	O
.	O

Thus	O
,	O
old	O
serum	O
factors	O
dominantly	O
inhibited	O
the	O
myogenic	O
capacity	O
of	O
young	O
satellite	O
cells	O
even	O
in	O
the	O
presence	O
of	O
young	O
serum	O
.	O

This	O
observation	O
suggests	O
that	O
satellite	O
cells	O
of	O
young	O
mice	O
engage	O
in	O
efficient	O
myogenic	O
responses	O
,	O
in	O
part	O
,	O
because	O
the	O
inhibitory	O
influence	O
of	O
old	O
circulatory	O
milieu	O
is	O
absent	O
.	O

These	O
data	O
reveal	O
that	O
the	O
regenerative	O
potential	O
of	O
young	O
muscle	O
stem	O
cells	O
is	O
determined	O
by	O
the	O
age	O
of	O
the	O
systemic	O
milieu	O
,	O
prompting	O
us	O
to	O
investigate	O
whether	O
hESCs	O
would	O
similarly	O
succumb	O
to	O
inhibitory	O
factors	O
present	O
in	O
the	O
aged	O
circulation	O
.	O

To	O
determine	O
the	O
effects	O
of	O
aged	O
serum	O
on	O
stem	O
cell	O
self	O
-	O
renewal	O
/	O
pluripotency	O
,	O
we	O
analyzed	O
hESC	O
expression	O
of	O
Oct4	O
and	O
studied	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
by	O
assessing	O
BrdU	O
incorporation	O
(	O
Fig.	O
2	O
)	O
and	O
Ki67	O
expression	O
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Specifically	O
,	O
these	O
determinants	O
of	O
hESC	O
regenerative	O
potential	O
were	O
examined	O
in	O
the	O
presence	O
of	O
heterochronic	O
(	O
young	O
vs.	O
old	O
)	O
mouse	O
sera	O
added	O
to	O
typical	O
hESC	O
medium	O
,	O
e.g.	O
,	O
MEF	O
-	O
conditioned	O
medium	O
(	O
MCM	O
)	O
.	O

Oct4	O
is	O
expressed	O
by	O
self	O
-	O
renewing	O
,	O
pluripotent	O
ESCs	O
in	O
culture	O
,	O
by	O
the	O
totipotent	O
inner	O
cell	O
mass	O
of	O
the	O
blastocyst	O
and	O
by	O
the	O
germ	O
cells	O
(	O
Nichols	O
et	O
al.	O
,	O
1998	O
;	O
Pesce	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Most	O
cells	O
in	O
control	O
cultures	O
or	O
young	O
conditions	O
expressed	O
high	O
levels	O
of	O
this	O
marker	O
of	O
'	O
stemness	O
'	O
,	O
and	O
maintained	O
their	O
normal	O
phenotype	O
and	O
morphology	O
throughout	O
the	O
various	O
co	O
-	O
culture	O
experiments	O
performed	O
in	O
this	O
study	O
(	O
see	O
below	O
)	O
.Fig	O
.	O

2The	O
regenerative	O
potential	O
of	O
embryonic	O
stem	O
cells	O
was	O
negatively	O
affected	O
by	O
aged	O
mouse	O
sera	O
.	O

(	O
A	O
)	O
hESCs	O
were	O
cultured	O
in	O
MCM	O
with	O
10	O
%	O
young	O
(	O
young	O
)	O
or	O
old	O
(	O
old	O
)	O
mouse	O
serum	O
,	O
or	O
in	O
three	O
control	O
media	O
:	O
MCM	O
without	O
mouse	O
sera	O
;	O
GM	O
(	O
myoblast	O
medium	O
of	O
Ham	O
's	O
F10	O
with	O
20	O
%	O
FBS	O
)	O
and	O
DMEM	O
/	O
FBS	O
(	O
hESC	O
differentiation	O
medium	O
of	O
DMEM	O
with	O
10	O
%	O
FBS	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
assays	O
were	O
performed	O
for	O
BrdU	O
(	O
red	O
)	O
,	O
Oct4	O
(	O
red	O
)	O
,	O
and	O
Ki67	O
(	O
Supplementary	O
Fig.	O
S2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

A	O
high	O
rate	O
of	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
is	O
displayed	O
in	O
all	O
control	O
media	O
and	O
in	O
the	O
presence	O
of	O
young	O
mouse	O
serum	O
.	O

In	O
contrast	O
,	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
are	O
inhibited	O
in	O
the	O
presence	O
of	O
old	O
mouse	O
serum	O
,	O
either	O
alone	O
or	O
when	O
mixed	O
with	O
young	O
serum	O
.	O

MCM	O
with	O
mouse	O
sera	O
at	O
5	O
%	O
gave	O
results	O
similar	O
to	O
those	O
observed	O
with	O
10	O
%	O
young	O
mouse	O
sera	O
or	O
in	O
control	O
media	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
and	O
Oct4	O
+	O
cells	O
for	O
each	O
culture	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
young	O
serum	O
.	O

Importantly	O
,	O
at	O
10	O
%	O
aged	O
serum	O
dramatically	O
inhibited	O
the	O
self	O
-	O
renewal	O
and	O
proliferative	O
potential	O
of	O
hESCs	O
,	O
as	O
judged	O
by	O
highly	O
diminished	O
Oct4	O
expression	O
and	O
a	O
lack	O
of	O
BrdU	O
incorporation	O
.	O

Again	O
,	O
the	O
inhibitory	O
factors	O
in	O
the	O
aged	O
milieu	O
were	O
dominant	O
over	O
the	O
young	O
,	O
as	O
evidenced	O
by	O
a	O
decline	O
in	O
Oct4	O
expression	O
,	O
the	O
low	O
rate	O
of	O
BrdU	O
incorporation	O
,	O
and	O
Ki67	O
expression	O
in	O
young	O
and	O
old	O
mixed	O
environments	O
(	O
5	O
%	O
young	O
+	O
5	O
%	O
old	O
sera	O
in	O
MCM	O
)	O
.	O

Similar	O
to	O
the	O
data	O
shown	O
for	O
adult	O
stem	O
cells	O
(	O
ASCs	O
)	O
(	O
Fig.	O
1	O
)	O
,	O
it	O
was	O
not	O
simply	O
a	O
dilution	O
of	O
young	O
serum	O
factors	O
as	O
hESCs	O
robustly	O
proliferated	O
and	O
expressed	O
high	O
levels	O
of	O
Oct4	O
when	O
cultured	O
with	O
5	O
%	O
young	O
sera	O
in	O
MCM	O
(	O
Supplementary	O
Fig.	O
S3	O
)	O
.	O

Quantification	O
of	O
multiple	O
independent	O
experiments	O
has	O
demonstrated	O
that	O
hESC	O
expression	O
of	O
Oct4	O
and	O
BrdU	O
incorporation	O
have	O
been	O
reduced	O
by	O
two-	O
to	O
threefold	O
in	O
the	O
aged	O
milieu	O
(	O
Fig.	O
2B	O
)	O
.As	O
expected	O
,	O
hESCs	O
cultured	O
in	O
control	O
media	O
,	O
including	O
MCM	O
alone	O
that	O
does	O
not	O
contain	O
either	O
young	O
or	O
old	O
serum	O
,	O
also	O
displayed	O
a	O
high	O
rate	O
of	O
proliferation	O
and	O
Oct4	O
expression	O
(	O
Fig.	O
2	O
,	O
control	O
medium	O
)	O
.	O

Additionally	O
,	O
in	O
this	O
experimental	O
set	O
-	O
up	O
there	O
was	O
no	O
general	O
inhibitory	O
effect	O
of	O
sera	O
per	O
se	O
on	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
,	O
as	O
10	O
%	O
young	O
mouse	O
sera	O
(	O
young	O
)	O
and	O
10–20	O
%	O
of	O
FBS	O
(	O
growth	O
medium	O
and	O
DMEM	O
/	O
FBS	O
)	O
allowed	O
for	O
a	O
high	O
rate	O
of	O
cell	O
proliferation	O
and	O
for	O
uniformly	O
high	O
Oct4	O
levels	O
(	O
Fig.	O
2	O
)	O
.When	O
instead	O
of	O
immediate	O
exposure	O
to	O
aged	O
mouse	O
serum	O
,	O
hESCs	O
were	O
first	O
cultured	O
overnight	O
in	O
MCM	O
,	O
these	O
cells	O
were	O
no	O
longer	O
susceptible	O
to	O
the	O
negative	O
effects	O
of	O
old	O
systemic	O
milieu	O
(	O
Fig.	O
3	O
)	O
,	O
suggesting	O
that	O
hESC	O
-	O
produced	O
factors	O
established	O
an	O
embryonic	O
microniche	O
that	O
may	O
provide	O
temporary	O
protection	O
from	O
the	O
aged	O
environment	O
.	O

It	O
appears	O
that	O
satellite	O
cells	O
do	O
not	O
have	O
such	O
anti	O
-	O
aging	O
ability	O
,	O
because	O
despite	O
an	O
initial	O
activation	O
in	O
entirely	O
young	O
environments	O
,	O
e.g.	O
,	O
after	O
muscle	O
injury	O
to	O
young	O
muscle	O
,	O
isolated	O
satellite	O
cells	O
remain	O
susceptible	O
to	O
inhibition	O
by	O
the	O
old	O
mouse	O
serum	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
.	O

Similarly	O
,	O
culturing	O
satellite	O
cells	O
isolated	O
from	O
noninjured	O
muscle	O
in	O
growth	O
-	O
promoting	O
medium	O
for	O
1–2	O
days	O
does	O
not	O
protect	O
against	O
the	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
milieu	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

3Embryonic	O
stem	O
cells	O
produce	O
youthful	O
microniche	O
in	O
culture	O
.	O

(	O
A	O
)	O
As	O
opposed	O
to	O
immediate	O
exposure	O
to	O
old	O
mouse	O
serum	O
after	O
passaging	O
(	O
10	O
%	O
old	O
)	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
feeder	O
-	O
free	O
conditions	O
,	O
e.g.	O
,	O
Matrigel	O
™	O
+	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
,	O
resulted	O
in	O
continuously	O
high	O
BrdU	O
incorporation	O
and	O
Oct4	O
expression	O
(	O
embryonic	O
microniche	O
+	O
10	O
%	O
old	O
)	O
.	O

BrdU	O
was	O
added	O
for	O
the	O
last	O
2	O
h	O
of	O
culture	O
to	O
measure	O
the	O
rate	O
of	O
cell	O
proliferation	O
.	O

Immunodetection	O
of	O
BrdU	O
and	O
Oct4	O
(	O
both	O
in	O
red	O
)	O
was	O
performed	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

(	O
B	O
)	O
Three	O
independent	O
experiments	O
yielded	O
similar	O
results	O
and	O
were	O
quantified	O
as	O
percentage	O
of	O
BrdU+	O
/	O
Oct4	O
+	O
for	O
each	O
condition	O
.	O

*	O
indicates	O
P	O
<	O
0.001	O
as	O
compared	O
to	O
'	O
old	O
+	O
MCM'.Fig	O
.	O

4Aged	O
muscle	O
niche	O
inhibits	O
the	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
satellite	O
cells	O
.	O

(	O
A	O
)	O
Immunodetection	O
of	O
a	O
mouse	O
-	O
specific	O
M	O
-	O
cadherin	O
(	O
green	O
)	O
or	O
desmin	O
(	O
red	O
;	O
both	O
human	O
and	O
mouse	O
proteins	O
are	O
detected	O
)	O
revealed	O
that	O
hESCs	O
underwent	O
muscle	O
lineage	O
differentiation	O
when	O
co	O
-	O
cultured	O
with	O
young	O
,	O
but	O
not	O
old	O
myofibers	O
.	O

The	O
myogenic	O
progeny	O
of	O
hESCs	O
appears	O
M	O
-	O
cadherin−	O
/	O
desmin+	O
(	O
white	O
arrow	O
in	O
young	O
)	O
,	O
as	O
opposed	O
to	O
M	O
-	O
cadherin−	O
/	O
desmin−	O
hESCs	O
that	O
lack	O
myogenic	O
commitment	O
(	O
white	O
arrow	O
in	O
old	O
)	O
.	O

M	O
-	O
cadherin+	O
/	O
desmin+	O
cells	O
are	O
the	O
myogenic	O
progeny	O
of	O
mouse	O
satellite	O
cells	O
(	O
yellow	O
arrows	O
)	O
.	O

To	O
assess	O
the	O
effects	O
of	O
secreted	O
factors	O
produced	O
by	O
young	O
vs.	O
old	O
myofibers	O
on	O
the	O
rate	O
of	O
hESC	O
proliferation	O
,	O
transient	O
,	O
2	O
h	O
BrdU	O
incorporation	O
was	O
examined	O
in	O
hESCs	O
cultured	O
for	O
48	O
h	O
with	O
supernatants	O
produced	O
by	O
heterochronic	O
myofiber	O
explants	O
(	O
See	O
Experimental	O
procedures	O
for	O
details	O
)	O
.	O

As	O
compared	O
to	O
young	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
young	O
myofiber	O
supernant	O
)	O
,	O
exposure	O
to	O
old	O
myofiber	O
-	O
derived	O
supernatants	O
(	O
old	O
myofiber	O
supernant	O
)	O
inhibited	O
hESCs	O
proliferation	O
,	O
as	O
judged	O
by	O
BrdU	O
immunodetection	O
(	O
red	O
)	O
.	O

As	O
expected	O
,	O
the	O
rate	O
of	O
hESCs	O
proliferation	O
was	O
high	O
in	O
control	O
media	O
(	O
shown	O
in	O
Fig.	O
2	O
)	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
in	O
all	O
experiments	O
.	O

Quantification	O
of	O
desmin+	O
/	O
BrdU+	O
hESCs	O
in	O
direct	O
myofiber	O
cocultures	O
,	O
or	O
with	O
muscle	O
supernatants	O
,	O
is	O
shown	O
in	O
(	O
B	O
)	O
.	O

*	O
indicates	O
P≤	O
0.001	O
as	O
compared	O
to	O
young	O
.	O

(	O
C	O
)	O
Transwell	O
co	O
-	O
cultures	O
between	O
purified	O
young	O
satellite	O
cells	O
and	O
myofibers	O
isolated	O
from	O
uninjured	O
young	O
(	O
young	O
myofiber	O
)	O
and	O
old	O
(	O
old	O
myofiber	O
)	O
muscle	O
demonstrated	O
that	O
satellite	O
cell	O
regenerative	O
myogenic	O
capacity	O
was	O
inhibited	O
by	O
the	O
aged	O
differentiated	O
muscle	O
.	O

Myogenic	O
potential	O
was	O
determined	O
by	O
the	O
ability	O
of	O
satellite	O
cells	O
to	O
generate	O
proliferating	O
desmin+	O
myoblasts	O
(	O
immunodetection	O
shown	O
in	O
green	O
)	O
and	O
by	O
rate	O
of	O
proliferation	O
(	O
2	O
h	O
BrdU	O
incorporation	O
;	O
immunodetection	O
shown	O
in	O
red	O
)	O
.	O

(	O
D	O
)	O
Satellite	O
cell	O
regenerative	O
potential	O
was	O
quantified	O
as	O
percentage	O
of	O
desmin+	O
/	O
BrdU+	O
cells	O
for	O
transwell	O
co	O
-	O
cultures	O
with	O
young	O
or	O
old	O
uninjured	O
myofibers	O
(	O
i.e.	O
,	O
RM	O
,	O
resting	O
muscle	O
)	O
.	O

n	O
=	O
3	O
;	O
*	O
indicates	O
P≤	O
0.05	O
as	O
compared	O
to	O
young	O
.	O

Comprehensively	O
,	O
these	O
data	O
establish	O
that	O
the	O
inhibition	O
of	O
stem	O
cell	O
regenerative	O
potential	O
by	O
the	O
aged	O
systemic	O
milieu	O
is	O
conserved	O
between	O
species	O
(	O
mouse	O
vs.	O
human	O
)	O
and	O
cell	O
types	O
(	O
adult	O
vs.	O
embryonic	O
stem	O
cells	O
)	O
.	O

As	O
summarized	O
in	O
Table	O
1	O
,	O
aged	O
mouse	O
sera	O
similarly	O
affected	O
the	O
expression	O
of	O
key	O
molecular	O
identifiers	O
of	O
both	O
embryonic	O
and	O
adult	O
stem	O
cells	O
,	O
e.g.	O
,	O
Oct4	O
in	O
hESCs	O
and	O
Myf5	O
in	O
mouse	O
ASCs	O
.	O

As	O
expected	O
,	O
adult	O
mouse	O
stem	O
cells	O
did	O
not	O
express	O
Oct4	O
,	O
and	O
hESCs	O
did	O
not	O
express	O
Myf5	O
in	O
these	O
experimental	O
conditions	O
(	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
aged	O
systemic	O
milieu	O
had	O
similar	O
inhibitory	O
effects	O
on	O
proliferation	O
of	O
hESCs	O
and	O
ASCs	O
,	O
suggesting	O
that	O
not	O
only	O
the	O
regenerative	O
capacity	O
,	O
but	O
also	O
the	O
presence	O
and	O
expansion	O
of	O
stem	O
cells	O
will	O
be	O
significantly	O
restricted	O
in	O
aged	O
organs	O
.	O

Intriguingly	O
,	O
prolonged	O
culturing	O
of	O
hESCs	O
in	O
their	O
preferred	O
in	O
vitro	O
conditions	O
enables	O
generation	O
of	O
an	O
embryonic	O
microniche	O
that	O
antagonizes	O
the	O
inhibitory	O
influences	O
of	O
aged	O
circulatory	O
factors	O
.	O

Table	O
1Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
systemic	O
environmentRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Call	O
-	O
fate	O
identifier	O
ESC	O
(	O
percentage	O
of	O
Oct4	O
)	O
/	O
ASC	O
(	O
percentage	O
of	O
Myf5	O
)	O
10	O
%	O
young59.5	O
±	O
0.8	O
,	O
59.3	O
±	O
4.099.0	O
±	O
0.1	O
,	O
50.7	O
±	O
9.510	O
%	O
old32.7	O
±	O
2.1	O
,	O
27.3	O
±	O
3.517.6	O
±	O
3.2	O
,	O
18.1	O
±	O
5.95	O
%	O
young	O
+	O
5	O
%	O
old31.0	O

±	O
2.6	O
,	O
38.0	O
±	O
2.020.6	O
±	O
3.5	O
,	O
17.1	O
±	O
4.2Quantified	O
results	O
from	O
Figs	O
1	O
,	O
2	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
cell	O
-	O
fate	O
identifier	O
(	O
Oct4	O
or	O
Myf5	O
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
cultured	O
in	O
heterochronic	O
systemic	O
conditions	O
of	O
10	O
%	O
young	O
(	O
young	O
)	O
,	O
10	O
%	O
old	O
(	O
old	O
)	O
or	O
in	O
5%+	O
5	O
%	O
mouse	O
sera	O
combination	O
(	O
young	O
+	O
old	O
)	O
.	O

Results	O
for	O
5	O
%	O
young	O
mouse	O
sera	O
are	O
very	O
similar	O
to	O
those	O
for	O
10	O
%	O
young	O
mouse	O
sera	O
and	O
are	O
shown	O
in	O
Fig.	O
1	O
(	O
ASCs	O
)	O
and	O
Supplementary	O
Fig.	O
S3	O
(	O
hESCs	O
)	O
.	O

The	O
regenerative	O
potential	O
of	O
hESCs	O
and	O
ASCs	O
is	O
inhibited	O
by	O
aged	O
differentiated	O
muscleAfter	O
establishing	O
that	O
the	O
aged	O
systemic	O
niche	O
negatively	O
affects	O
the	O
regenerative	O
capacity	O
of	O
hESCs	O
and	O
of	O
ASCs	O
,	O
we	O
then	O
assessed	O
whether	O
myogenic	O
potential	O
and	O
the	O
rate	O
of	O
cell	O
proliferation	O
would	O
be	O
inhibited	O
in	O
hESCs	O
and	O
ASCs	O
by	O
the	O
aged	O
local	O
muscle	O
niche	O
.	O

Myofibers	O
with	O
associated	O
satellite	O
cells	O
were	O
isolated	O
from	O
young	O
and	O
old	O
injured	O
muscle	O
,	O
and	O
were	O
directly	O
co	O
-	O
cultured	O
with	O
hESCs	O
in	O
typical	O
hESC	O
differentiation	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
.	O

Similar	O
to	O
Fig.	O
1	O
,	O
the	O
myogenic	O
potential	O
in	O
these	O
co	O
-	O
cultures	O
was	O
assayed	O
by	O
the	O
expression	O
of	O
desmin	O
,	O
which	O
is	O
present	O
in	O
both	O
fusion	O
-	O
competent	O
myoblasts	O
and	O
newly	O
formed	O
myotubes	O
.	O

To	O
analyze	O
whether	O
hESCs	O
,	O
mouse	O
myogenic	O
progenitor	O
cells	O
or	O
both	O
could	O
express	O
desmin	O
in	O
direct	O
co	O
-	O
cultures	O
,	O
we	O
costained	O
these	O
cells	O
with	O
a	O
mouse	O
-	O
specific	O
antibody	O
to	O
a	O
myogenic	O
marker	O
,	O
M	O
-	O
cadherin	O
,	O
which	O
does	O
not	O
react	O
with	O
human	O
protein	O
,	O
and	O
a	O
desmin	O
-	O
specific	O
antibody	O
that	O
recognizes	O
both	O
mouse	O
and	O
human	O
proteins	O
.	O

As	O
shown	O
in	O
Fig.	O
4A	O
,	O
hESCs	O
underwent	O
myogenic	O
differentiation	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
(	O
M	O
-	O
cadherin−	O
/	O
desmin+	O
mononucleated	O
cells	O
,	O
white	O
arrow	O
in	O
young	O
)	O
.	O

These	O
myogenic	O
progeny	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
young	O
myofibers	O
could	O
be	O
of	O
skeletal	O
,	O
smooth	O
or	O
cardiac	O
muscle	O
lineages	O
(	O
Debus	O
et	O
al.	O
,	O
1983	O
;	O
Fischman	O
&	O
Danto	O
,	O
1985	O
;	O
Schultz	O
&	O
McCormick	O
,	O
1994	O
)	O
.	O

As	O
expected	O
,	O
the	O
young	O
mouse	O
muscle	O
progenitor	O
cells	O
(	O
M	O
-	O
cadherin+	O
/	O
desmin+	O
)	O
were	O
more	O
advanced	O
in	O
their	O
degree	O
of	O
myogenic	O
differentiation	O
,	O
which	O
was	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
as	O
judged	O
by	O
the	O
formation	O
of	O
large	O
,	O
multinucleated	O
de	O
novo	O
myotubes	O
(	O
yellow	O
arrow	O
in	O
young	O
)	O
.	O

In	O
addition	O
to	O
the	O
myogenically	O
differentiated	O
human	O
cells	O
,	O
co	O
-	O
cultures	O
with	O
young	O
myofiber	O
explants	O
also	O
contained	O
some	O
small	O
undifferentiated	O
hESC	O
colonies	O
,	O
as	O
determined	O
by	O
immunoreactivity	O
to	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
the	O
nuclear	O
mitotic	O
apparatus	O
protein	O
,	O
NuMA	O
and	O
Oct4	O
expression	O
(	O
Supplementary	O
Fig.	O
S4	O
)	O
.In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
the	O
aged	O
mouse	O
myofibers	O
,	O
only	O
mouse	O
cells	O
appeared	O
desmin+	O
(	O
Fig.	O
4A	O
,	O
yellow	O
arrow	O
in	O
old	O
)	O
.	O

These	O
aged	O
myogenic	O
cells	O
were	O
of	O
skeletal	O
muscle	O
lineage	O
,	O
based	O
on	O
spontaneous	O
generation	O
of	O
multinucleated	O
myotubes	O
(	O
see	O
Fig.	O
5B	O
)	O
and	O
based	O
on	O
induced	O
differentiation	O
into	O
myotubes	O
in	O
DMEM	O
+	O
2	O
%	O
horse	O
serum	O
(	O
not	O
shown	O
)	O
.	O

Importantly	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
failed	O
in	O
the	O
aged	O
co	O
-	O
cultures	O
(	O
Fig.	O
4A	O
,	O
white	O
arrow	O
in	O
old	O
)	O
.	O

Furthermore	O
,	O
colonies	O
of	O
hESCs	O
in	O
co	O
-	O
cultures	O
with	O
aged	O
myofibers	O
typically	O
differentiated	O
into	O
cells	O
with	O
fibroblast	O
morphology	O
,	O
which	O
lacked	O
Oct4	O
expression	O
(	O
not	O
shown	O
)	O
.	O

Spontaneous	O
production	O
of	O
desmin+	O
myogenic	O
cells	O
in	O
control	O
hESC	O
cultures	O
without	O
myofibers	O
,	O
or	O
with	O
young	O
/	O
old	O
mouse	O
sera	O
was	O
less	O
than	O
0.1	O
%	O
(	O
not	O
shown	O
)	O
.Fig	O
.	O

5In	O
vitro	O
co	O
-	O
culture	O
with	O
hESCs	O
enhanced	O
myogenesis	O
of	O
mouse	O
cells	O
.	O

(	O
A	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
5	O
×	O
106	O
primary	O
mouse	O
myoblasts	O
.	O

hESCs	O
expressing	O
Oct4	O
(	O
immunodetection	O
shown	O
in	O
red	O
)	O
dramatically	O
enhanced	O
myotube	O
formation	O
of	O
co	O
-	O
cultured	O
mouse	O
myoblasts	O
(	O
immunodetection	O
of	O
eMyHC	O
is	O
shown	O
in	O
green	O
)	O
,	O
as	O
compared	O
to	O
co	O
-	O
cultures	O
between	O
mouse	O
myoblasts	O
and	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
Mb	O
+	O
hMSCs	O
)	O
or	O
myoblasts	O
alone	O
(	O
Mb	O
alone	O
)	O
.	O

Experiments	O
were	O
carried	O
out	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
throughout	O
this	O
figure	O
.	O

(	O
B	O
)	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
young	O
or	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
as	O
described	O
in	O
Experimental	O
procedures	O
.	O

Co	O
-	O
culture	O
with	O
hESCs	O
(	O
myofiber	O
+	O
hESC	O
)	O
,	O
but	O
not	O
hMSCs	O
(	O
myofiber	O
+	O
hMSC	O
)	O
or	O
control	O
medium	O
(	O
DMEM	O
/	O
FBS	O
)	O
,	O
greatly	O
enhanced	O
the	O
myogenic	O
potential	O
of	O
both	O
young	O
and	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
,	O
based	O
on	O
immunodetection	O
of	O
percentage	O
of	O
desmin+	O
de	O
novo	O
generated	O
myoblasts	O
and	O
multinucleated	O
myotubes	O
.	O

These	O
experiments	O
were	O
carried	O
out	O
in	O
GM	O
.	O

Shown	O
are	O
myogenic	O
responses	O
of	O
mouse	O
cells	O
only	O
,	O
judged	O
by	O
lack	O
of	O
immunoreactivity	O
to	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
antigens	O
,	O
such	O
as	O
NuMA	O
and	O
Oct4	O
;	O
and	O
presence	O
of	O
mouse	O
-	O
specific	O
immunoreactivity	O
,	O
e.g.	O
,	O
M	O
-	O
cadherin	O
(	O
not	O
shown	O
)	O
.	O

Both	O
young	O
and	O
old	O
myofiber	O
associated	O
satellite	O
cells	O
exhibited	O
considerable	O
myogenic	O
improvement	O
over	O
control	O
conditions	O
.	O

n	O
=	O
3.In	O
concert	O
with	O
the	O
conservation	O
of	O
inhibitory	O
affects	O
of	O
aged	O
systemic	O
niche	O
,	O
the	O
negative	O
influence	O
of	O
local	O
muscle	O
niche	O
was	O
also	O
found	O
to	O
be	O
conserved	O
in	O
its	O
inhibition	O
of	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
.	O

Specifically	O
,	O
the	O
myogenic	O
capacity	O
(	O
generation	O
of	O
desmin+	O
myoblasts	O
)	O
was	O
inhibited	O
in	O
young	O
satellite	O
cells	O
co	O
-	O
cultured	O
in	O
a	O
transwell	O
system	O
with	O
aged	O
myofibers	O
(	O
Fig.	O
4B	O
)	O
.	O

In	O
addition	O
,	O
hESC	O
and	O
ASC	O
proliferation	O
(	O
BrdU	O
incorporation	O
)	O
was	O
also	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
(	O
Fig.	O
4A	O
,	O
C	O
)	O
.	O

These	O
data	O
suggest	O
that	O
not	O
only	O
systemic	O
but	O
also	O
local	O
organ	O
niches	O
would	O
inhibit	O
key	O
stem	O
cell	O
properties	O
,	O
e.g.	O
,	O
myogenic	O
capacity	O
and	O
the	O
rate	O
of	O
proliferation	O
in	O
the	O
aged	O
organism	O
.	O

The	O
conserved	O
inhibitory	O
influences	O
of	O
the	O
differentiated	O
muscle	O
niche	O
on	O
hESC	O
and	O
ASC	O
regenerative	O
responses	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Conservation	O
of	O
stem	O
cell	O
aging	O
in	O
the	O
local	O
organ	O
nicheRate	O
of	O
proliferation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
BrdU	O
)	O
Myogenic	O
differentiation	O
ESC	O
/	O
ASC	O
(	O
percentage	O
of	O
desmin	O
)	O
Young	O
myofiber60.2	O
±	O
2.5	O
,	O
40.5	O
±	O
2.67.4	O
±	O
0.9	O
,	O
47.6	O
±	O
5.0Old	O
myofiber30.1	O
±	O
4.3	O
,	O
21.5	O
±	O
4.11.3	O
±	O
0.7	O
,	O
19.7	O
±	O
4.7Quantified	O
results	O
from	O
Fig.	O
4	O
are	O
summarized	O
and	O
presented	O
as	O
mean	O
percentages	O
from	O
experimental	O
replicates	O
±	O
SE	O
.	O

Rate	O
of	O
proliferation	O
(	O
BrdU	O
)	O
and	O
myogenic	O
differentiation	O
(	O
desmin	O
)	O
are	O
shown	O
for	O
both	O
ESCs	O
and	O
ASCs	O
,	O
in	O
the	O
presence	O
of	O
young	O
vs.	O
old	O
differentiated	O
muscle	O
environments	O
(	O
young	O
myofiber	O
or	O
old	O
myofiber	O
)	O
.	O

hESCs	O
indirectly	O
enhance	O
and	O
rejuvenate	O
the	O
regeneration	O
of	O
skeletal	O
muscleWhile	O
hESC	O
properties	O
were	O
inhibited	O
by	O
aged	O
differentiated	O
muscle	O
,	O
the	O
myogenic	O
potential	O
of	O
aged	O
satellite	O
cells	O
seemed	O
to	O
be	O
enhanced	O
by	O
co	O
-	O
cultures	O
with	O
hESCs	O
(	O
Fig.	O
4A	O
)	O
.	O

Therefore	O
,	O
we	O
further	O
explored	O
the	O
enhancing	O
and	O
rejuvenating	O
effects	O
of	O
hESCs	O
on	O
myogenic	O
potential	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
using	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSCs	O
)	O
as	O
a	O
negative	O
control	O
.	O

First	O
,	O
we	O
examined	O
the	O
effects	O
of	O
hESCs	O
on	O
myotube	O
generation	O
by	O
co	O
-	O
culture	O
with	O
primary	O
myoblasts	O
freshly	O
derived	O
from	O
activated	O
-	O
by	O
-	O
injury	O
satellite	O
cells	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
5A	O
(	O
Mb	O
+	O
hESC	O
)	O
,	O
primary	O
myoblasts	O
underwent	O
very	O
rapid	O
and	O
robust	O
nascent	O
myotube	O
formation	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h	O
in	O
myoblast	O
differentiation	O
medium	O
.	O

Namely	O
,	O
remarkably	O
large	O
fused	O
myotubes	O
containing	O
approximately	O
50–70	O
nuclei	O
formed	O
around	O
hESCs	O
colonies	O
(	O
Fig.	O
5A	O
)	O
.	O

In	O
contrast	O
,	O
when	O
co	O
-	O
cultured	O
with	O
hMSCs	O
,	O
myotube	O
formation	O
was	O
no	O
greater	O
than	O
in	O
myoblast	O
cultures	O
alone	O
(	O
Fig.	O
5A	O
,	O
Mb	O
+	O
hMSC	O
and	O
Mb	O
alone	O
)	O
.	O

Encouraged	O
by	O
these	O
data	O
,	O
we	O
analyzed	O
the	O
myogenic	O
potential	O
of	O
young	O
and	O
old	O
satellite	O
cells	O
co	O
-	O
cultured	O
with	O
hESCs	O
for	O
48	O
h.	O
As	O
shown	O
in	O
Fig.	O
5B	O
,	O
hESCs	O
conferred	O
a	O
much	O
-	O
enhanced	O
myogenic	O
capacity	O
on	O
both	O
young	O
and	O
,	O
importantly	O
,	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
(	O
rapid	O
formation	O
of	O
desmin+	O
myogenic	O
cells	O
,	O
many	O
of	O
which	O
formed	O
de	O
novo	O
multinucleated	O
myotubes	O
)	O
.	O

Control	O
co	O
-	O
cultures	O
of	O
these	O
satellite	O
cells	O
with	O
hMSCs	O
displayed	O
no	O
enhanced	O
myogenicity	O
.	O

In	O
summary	O
,	O
while	O
the	O
myogenic	O
potential	O
(	O
production	O
of	O
desmin+	O
fusion	O
-	O
competent	O
cells	O
)	O
was	O
more	O
pronounced	O
in	O
young	O
vs.	O
old	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
under	O
all	O
experimental	O
conditions	O
,	O
a	O
finding	O
that	O
is	O
consistent	O
with	O
previous	O
data	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
a	O
clear	O
increase	O
in	O
myogenic	O
potential	O
of	O
old	O
satellite	O
cells	O
was	O
noted	O
in	O
co	O
-	O
cultures	O
with	O
hESCs	O
,	O
as	O
compared	O
to	O
control	O
cultures	O
devoid	O
of	O
hESCs	O
(	O
Fig.	O
4A	O
,	O
B	O
)	O
.Interestingly	O
,	O
in	O
addition	O
to	O
the	O
rejuvenating	O
effects	O
of	O
direct	O
co	O
-	O
cultures	O
shown	O
in	O
Fig.	O
5	O
,	O
soluble	O
factors	O
present	O
in	O
hESC	O
-	O
conditioned	O
culture	O
supernatants	O
were	O
also	O
able	O
to	O
enhance	O
myogenesis	O
of	O
aged	O
satellite	O
cells	O
(	O
Supplementary	O
Fig.	O
S5	O
)	O
.	O

Thus	O
,	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
an	O
established	O
embryonic	O
microniche	O
antagonizes	O
the	O
inhibitory	O
effects	O
of	O
the	O
aged	O
environment	O
on	O
stem	O
cell	O
responses	O
(	O
Fig.	O
3	O
)	O
,	O
the	O
hESC	O
-	O
produced	O
factors	O
enhanced	O
myogenic	O
capacity	O
of	O
even	O
old	O
mouse	O
satellite	O
cells	O
.	O

Establishing	O
that	O
hESC	O
-	O
produced	O
factors	O
enhance	O
adult	O
myogenesis	O
and	O
rejuvenate	O
the	O
regenerative	O
capacity	O
of	O
even	O
aged	O
satellite	O
cells	O
in	O
vitro	O
prompted	O
us	O
to	O
examine	O
whether	O
the	O
regeneration	O
of	O
old	O
injured	O
muscle	O
will	O
be	O
improved	O
by	O
hESC	O
transplantation	O
in	O
vivo	O
.	O

Additionally	O
,	O
based	O
on	O
the	O
data	O
shown	O
above	O
,	O
we	O
speculated	O
that	O
even	O
if	O
the	O
host	O
's	O
repair	O
capacity	O
is	O
improved	O
,	O
hESCs	O
themselves	O
will	O
not	O
be	O
efficiently	O
maintained	O
or	O
expanded	O
in	O
the	O
context	O
of	O
old	O
systemic	O
and	O
local	O
organ	O
environments	O
,	O
and	O
will	O
not	O
directly	O
contribute	O
to	O
the	O
repair	O
of	O
aged	O
skeletal	O
muscle	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
injected	O
5	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
into	O
the	O
tibialis	O
anterior	O
(	O
TA	O
)	O
and	O
gastrocnemius	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
at	O
24	O
h	O
after	O
cardiotoxin	O
-	O
induced	O
injury	O
,	O
when	O
activation	O
/	O
proliferation	O
of	O
endogenous	O
satellite	O
cells	O
normally	O
begins	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
.	O

To	O
avoid	O
immune	O
response	O
against	O
hESC	O
antigens	O
,	O
mice	O
were	O
immunosuppressed	O
using	O
FK506	O
(	O
Ito	O
&	O
Tanaka	O
,	O
1997	O
;	O
Dumont	O
,	O
2000	O
)	O
.	O

Muscle	O
was	O
isolated	O
5	O
days	O
post	O
-	O
injury	O
,	O
when	O
nascent	O
differentiated	O
myofibers	O
normally	O
replace	O
the	O
damaged	O
tissue	O
(	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
,	O
and	O
10	O
µm	O
cryosections	O
were	O
analyzed	O
for	O
the	O
success	O
in	O
tissue	O
repair	O
using	O
hematoxylin	O
and	O
eosin	O
(	O
H&E	O
)	O
histochemistry	O
and	O
eMyHC	O
immunodetection	O
.	O

H&E	O
analysis	O
reveals	O
newly	O
formed	O
myofibers	O
,	O
based	O
on	O
their	O
smaller	O
size	O
and	O
centrally	O
located	O
nuclei	O
.	O

Additionally	O
,	O
de	O
novo	O
myofibers	O
in	O
the	O
damaged	O
area	O
appear	O
positive	O
for	O
eMyHC	O
,	O
while	O
undamaged	O
myofibers	O
remain	O
negative	O
.	O

As	O
shown	O
in	O
Fig.	O
6A	O
and	O
quantified	O
in	O
6B	O
,	O
injection	O
of	O
hESCs	O
significantly	O
enhanced	O
regeneration	O
of	O
skeletal	O
muscle	O
.	O

Remarkably	O
,	O
this	O
positive	O
embryonic	O
effect	O
was	O
especially	O
pronounced	O
in	O
old	O
tissue	O
.	O

Fig.	O

6Skeletal	O
muscle	O
regeneration	O
following	O
hESC	O
transplantation	O
is	O
a	O
balance	O
between	O
the	O
inhibitory	O
influence	O
of	O
aged	O
niches	O
and	O
the	O
rejuvenating	O
effects	O
of	O
hESCs	O
.	O

Young	O
and	O
old	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
were	O
injured	O
by	O
cardiotoxin	O
injection	O
.	O

hESCs	O
or	O
hMSCs	O
were	O
transplanted	O
at	O
the	O
site	O
of	O
injury	O
and	O
were	O
analyzed	O
by	O
cryosectioning	O
at	O
Day	O
5	O
after	O
injury	O
(	O
as	O
described	O
in	O
Experimental	O
procedures	O
)	O
.	O

(	O
A	O
)	O
Newly	O
regenerated	O
myofibers	O
were	O
detected	O
using	O
eMyHC	O
-	O
specific	O
antibody	O
(	O
green	O
)	O
and	O
staining	O
with	O
H&E.	O
In	O
H&E	O
staining	O
,	O
newly	O
regenerated	O
areas	O
contain	O
smaller	O
,	O
immature	O
myofibers	O
with	O
centrally	O
located	O
nuclei	O
.	O

Uninjured	O
myofibers	O
are	O
much	O
larger	O
,	O
by	O
comparison	O
,	O
with	O
peripherally	O
restricted	O
nuclei	O
.	O

Poorly	O
regenerated	O
areas	O
lack	O
new	O
myofibers	O
and	O
contain	O
areas	O
of	O
fibrosis	O
and	O
inflammation	O
.	O

eMyHC	O
immunodetection	O
is	O
specific	O
for	O
regenerating	O
areas	O
of	O
muscle	O
only	O
.	O

Both	O
assays	O
showed	O
dramatic	O
enhancement	O
of	O
muscle	O
regeneration	O
in	O
'	O
old	O
+	O
hESC	O
'	O
vs.	O
'	O
old	O
+	O
hMSC	O
'	O
.	O

Regeneration	O
improvement	O
was	O
also	O
seen	O
in	O
young	O
+	O
hESC	O
,	O
as	O
compared	O
to	O
young	O
+	O
hMSC	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
muscle	O
regeneration	O
was	O
performed	O
by	O
analyzing	O
the	O
density	O
of	O
newly	O
formed	O
myofibers	O
per	O
mm2	O
of	O
injury	O
site	O
,	O
which	O
is	O
the	O
volume	O
that	O
typically	O
covers	O
the	O
whole	O
injured	O
area	O
.	O

Multiple	O
,	O
10	O
µm	O
H&E	O
sections	O
were	O
examined	O
through	O
the	O
entire	O
volume	O
of	O
injury	O
in	O
multiple	O
,	O
independently	O
injured	O
muscles	O
.	O

n	O
=	O
20	O
;	O

*	O
indicates	O
P	O
<	O
0.001	O
(	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
young	O
+	O
hMSC	O
and	O
'	O
old	O
+	O
hMSC	O
'	O
compared	O
to	O
'	O
old	O
+	O
hESC	O
'	O
.	O

(	O
C	O
)	O
H&E	O
and	O
immunofluoresence	O
staining	O
for	O
Oct4	O
,	O
and	O
a	O
human	O
-	O
specific	O
antibody	O
to	O
NuMA	O
,	O
revealed	O
the	O
failure	O
of	O
hESCs	O
to	O
expand	O
or	O
persist	O
in	O
old	O
,	O
but	O
the	O
presence	O
of	O
hESCs	O
in	O
young	O
muscle	O
at	O
5	O
days	O
post	O
-	O
transplantation	O
.	O

Hoechst	O
(	O
blue	O
)	O
labels	O
nuclei	O
.	O

Importantly	O
,	O
such	O
enhanced	O
and	O
rejuvenated	O
muscle	O
repair	O
stems	O
from	O
an	O
indirect	O
induction	O
,	O
as	O
hESCs	O
themselves	O
(	O
or	O
control	O
hMSCs	O
)	O
did	O
not	O
physically	O
contribute	O
to	O
the	O
mouse	O
myofibers	O
,	O
as	O
judged	O
by	O
near	O
absence	O
(	O
less	O
than	O
0.1	O
%	O
)	O
of	O
human	O
-	O
specific	O
NuMA+	O
nuclei	O
in	O
de	O
novo	O
desmin+	O
myofibers	O
,	O
analyzed	O
through	O
multiple	O
injury	O
sites	O
.	O

An	O
example	O
of	O
one	O
regenerated	O
myofiber	O
from	O
young	O
muscle	O
injected	O
with	O
hESCs	O
,	O
with	O
NuMA+	O
nucleus	O
in	O
a	O
field	O
of	O
NuMA−	O
/	O
desmin+	O
mouse	O
myofibers	O
,	O
is	O
shown	O
in	O
Supplementary	O
Fig.	O
S6	O
.	O

No	O
such	O
NuMA+	O
/	O
desmin+	O
myofibers	O
were	O
detected	O
in	O
aged	O
regenerated	O
muscle	O
(	O
not	O
shown	O
)	O
.In	O
agreement	O
with	O
the	O
in	O
vitro	O
data	O
,	O
establishing	O
that	O
aged	O
systemic	O
and	O
local	O
niches	O
inhibit	O
hESC	O
proliferation	O
and	O
Oct4	O
expression	O
(	O
Figs	O
2	O
and	O
4	O
and	O
Supplementary	O
Fig.	O
S2	O
)	O
,	O
hESCs	O
failed	O
to	O
expand	O
or	O
even	O
persist	O
in	O
old	O
muscle	O
,	O
as	O
judged	O
by	O
the	O
absence	O
of	O
NuMA+	O
/	O
Oct4	O
+	O
hESC	O
-	O
derived	O
cells	O
in	O
the	O
aged	O
tissue	O
.	O

In	O
contrast	O
,	O
colonies	O
of	O
Numa+	O
/	O
Oct4	O
+	O
hESC	O
-	O
derived	O
cells	O
that	O
did	O
not	O
undergo	O
myogenic	O
differentiation	O
were	O
easily	O
detected	O
in	O
young	O
regenerating	O
muscle	O
(	O
Fig.	O
6C	O
)	O
.	O

This	O
finding	O
validates	O
several	O
technical	O
aspects	O
of	O
these	O
experiments	O
,	O
and	O
confirms	O
the	O
contrasting	O
effects	O
of	O
young	O
and	O
old	O
systemic	O
and	O
local	O
organ	O
niches	O
on	O
hESC	O
self	O
-	O
renewal	O
.	O

These	O
data	O
further	O
confirm	O
and	O
extrapolate	O
our	O
findings	O
and	O
demonstrate	O
that	O
when	O
exposed	O
to	O
both	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
,	O
hESCs	O
fail	O
to	O
persist	O
and	O
do	O
not	O
contribute	O
to	O
tissue	O
repair	O
directly	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
embryonic	O
cells	O
indirectly	O
but	O
significantly	O
improve	O
the	O
repair	O
of	O
aged	O
injured	O
muscle	O
in	O
vivo	O
.	O

The	O
data	O
presented	O
here	O
establish	O
for	O
the	O
first	O
time	O
that	O
both	O
the	O
local	O
environment	O
of	O
old	O
differentiated	O
organ	O
,	O
e.g.	O
,	O
skeletal	O
muscle	O
and	O
the	O
systemic	O
milieu	O
dramatically	O
affect	O
the	O
regenerative	O
potential	O
of	O
both	O
hESCs	O
and	O
mouse	O
post	O
-	O
natal	O
myogenic	O
progenitor	O
cells	O
.	O

Not	O
only	O
are	O
the	O
factors	O
promoting	O
myogenic	O
differentiation	O
and	O
proliferation	O
of	O
hESCs	O
likely	O
to	O
become	O
depleted	O
with	O
age	O
,	O
but	O
the	O
aged	O
systemic	O
and	O
local	O
organ	O
niches	O
are	O
likely	O
to	O
contain	O
dominant	O
inhibitors	O
of	O
ASC	O
and	O
hESC	O
regenerative	O
potential	O
(	O
Figs	O
1	O
,	O
2	O
,	O
and	O
4	O
,	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
)	O
.	O

Importantly	O
,	O
the	O
similar	O
inhibitory	O
effects	O
of	O
old	O
mouse	O
serum	O
and	O
old	O
myofibers	O
on	O
satellite	O
cell	O
(	O
Figs	O
1	O
and	O
4C	O
)	O
and	O
hESC	O
(	O
Figs	O
2	O
and	O
4A	O
)	O
proliferation	O
and	O
regenerative	O
capacity	O
suggest	O
the	O
conservation	O
of	O
elements	O
in	O
age	O
-	O
specific	O
extrinsic	O
regulatory	O
mechanisms	O
between	O
evolutionarily	O
distinct	O
species	O
and	O
stem	O
cell	O
types	O
.	O

Additionally	O
,	O
a	O
similarity	O
in	O
the	O
inhibitory	O
properties	O
between	O
systemic	O
and	O
local	O
organ	O
niches	O
is	O
also	O
of	O
interest	O
and	O
may	O
indicate	O
that	O
molecules	O
produced	O
by	O
old	O
tissues	O
have	O
circulatory	O
/	O
endocrine	O
activity	O
;	O
and/or	O
that	O
age	O
-	O
specific	O
systemic	O
inhibitory	O
components	O
become	O
deposited	O
in	O
the	O
old	O
tissues	O
.	O

Humans	O
display	O
broad	O
genetic	O
polymorphisms	O
and	O
behavioral	O
variations	O
,	O
which	O
makes	O
the	O
identification	O
of	O
age	O
-	O
specific	O
molecular	O
changes	O
complicated	O
.	O

In	O
contrast	O
,	O
laboratory	O
mice	O
are	O
genetically	O
and	O
environmentally	O
controlled	O
.	O

Establishing	O
that	O
age	O
-	O
specific	O
signals	O
,	O
regulating	O
stem	O
cell	O
responses	O
,	O
are	O
evolutionarily	O
conserved	O
and	O
soluble	O
enables	O
the	O
formation	O
of	O
rational	O
approaches	O
for	O
the	O
identification	O
and	O
characterization	O
of	O
the	O
inhibitors	O
involved	O
,	O
and	O
for	O
revealing	O
the	O
precise	O
timing	O
of	O
their	O
first	O
appearance	O
in	O
serum	O
and	O
differentiated	O
tissues	O
with	O
advancing	O
age	O
.	O

Significantly	O
,	O
these	O
experiments	O
have	O
also	O
revealed	O
that	O
not	O
only	O
are	O
hESCs	O
able	O
to	O
protect	O
themselves	O
against	O
the	O
negative	O
influences	O
of	O
aged	O
mouse	O
sera	O
(	O
Fig.	O
3	O
)	O
,	O
but	O
these	O
cells	O
also	O
produce	O
factors	O
that	O
dramatically	O
enhance	O
the	O
myogenic	O
capacity	O
of	O
primary	O
myoblasts	O
and	O
young	O
and	O
old	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
,	O
and	O
also	O
significantly	O
improve	O
repair	O
of	O
young	O
and	O
old	O
injured	O
muscle	O
in	O
vivo	O
(	O
Fig.	O
6	O
)	O
.	O

Identification	O
of	O
these	O
embryonic	O
factors	O
would	O
allow	O
us	O
to	O
potentially	O
enrich	O
the	O
arsenal	O
of	O
therapeutic	O
tools	O
for	O
combating	O
age	O
-	O
specific	O
degenerative	O
disorders	O
.	O

The	O
interactions	O
between	O
hESCs	O
and	O
heterochronic	O
differentiated	O
niches	O
,	O
initially	O
identified	O
in	O
vitro	O
,	O
have	O
been	O
confirmed	O
by	O
in	O
vivo	O
experiments	O
.	O

Namely	O
,	O
while	O
the	O
regenerative	O
capacity	O
,	O
or	O
presence	O
,	O
of	O
hESCs	O
is	O
greatly	O
restricted	O
in	O
aged	O
,	O
as	O
compared	O
to	O
young	O
skeletal	O
muscle	O
(	O
where	O
transplanted	O
cells	O
experience	O
both	O
old	O
systemic	O
and	O
local	O
environments	O
)	O
,	O
embryonic	O
cells	O
indirectly	O
enhance	O
and	O
rejuvenate	O
muscle	O
repair	O
when	O
introduced	O
at	O
the	O
time	O
of	O
muscle	O
stem	O
cell	O
activation	O
in	O
the	O
host	O
,	O
e.g.	O
,	O
at	O
Day	O
1	O
after	O
the	O
injury	O
(	O
Fig.	O
6	O
)	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
the	O
percentage	O
of	O
hESCs	O
direct	O
contribution	O
to	O
desmin+	O
myofibers	O
in	O
young	O
muscle	O
will	O
be	O
increased	O
by	O
transplanting	O
these	O
cells	O
at	O
a	O
different	O
time	O
-	O
point	O
after	O
muscle	O
injury	O
,	O
e.g.	O
,	O
at	O
Days	O
3–5	O
(	O
as	O
in	O
co	O
-	O
cultures	O
with	O
myofibers	O
pre	O
-	O
injured	O
for	O
3	O
days	O
,	O
Fig.	O
4A	O
)	O
.	O

In	O
any	O
case	O
,	O
the	O
virtual	O
lack	O
of	O
hESC	O
and	O
hMSC	O
direct	O
contribution	O
to	O
the	O
newly	O
regenerated	O
skeletal	O
muscle	O
,	O
when	O
small	O
numbers	O
of	O
these	O
cells	O
were	O
injected	O
into	O
injured	O
tissue	O
,	O
is	O
completely	O
consistent	O
with	O
the	O
body	O
of	O
previous	O
data	O
demonstrating	O
that	O
myofiber	O
-	O
associated	O
satellite	O
cells	O
conduct	O
rapid	O
and	O
robust	O
muscle	O
repair	O
and	O
greatly	O
outnumber	O
injected	O
human	O
cells	O
(	O
Collins	O
et	O
al.	O
,	O
2005	O
;	O
Wagers	O
&	O
Conboy	O
,	O
2005	O
)	O
;	O
that	O
compared	O
to	O
muscle	O
-	O
specific	O
satellite	O
cells	O
,	O
the	O
myogenic	O
differentiation	O
of	O
hESCs	O
in	O
vitro	O
remains	O
very	O
small	O
(	O
Fig.	O
5	O
,	O
Table	O
2	O
)	O
,	O
and	O
that	O
control	O
hMSCs	O
are	O
not	O
normally	O
myogenic	O
unless	O
these	O
cells	O
overexpress	O
exogenous	O
constitutively	O
active	O
domain	O
of	O
Notch	O
(	O
Dezawa	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Intriguingly	O
,	O
the	O
failure	O
of	O
hESCs	O
to	O
strive	O
in	O
old	O
skeletal	O
muscle	O
might	O
represent	O
a	O
therapeutically	O
desirable	O
outcome	O
.	O

For	O
example	O
,	O
while	O
in	O
young	O
tissue	O
hESC	O
derivatives	O
putatively	O
would	O
go	O
on	O
to	O
produce	O
teratomas	O
,	O
it	O
is	O
unlikely	O
that	O
teratoma	O
formation	O
would	O
occur	O
after	O
hESC	O
transplantation	O
into	O
aged	O
skeletal	O
muscle	O
.	O

Thus	O
,	O
the	O
indirect	O
beneficial	O
effects	O
of	O
hESCs	O
on	O
tissue	O
repair	O
are	O
unlikely	O
to	O
be	O
compromised	O
by	O
the	O
oncogenic	O
properties	O
of	O
these	O
embryonic	O
cells	O
in	O
the	O
context	O
of	O
old	O
skeletal	O
muscle	O
.	O

Comprehensively	O
,	O
the	O
results	O
of	O
this	O
work	O
increase	O
our	O
understanding	O
of	O
aging	O
as	O
a	O
process	O
,	O
reveal	O
evolutionary	O
conserved	O
age	O
-	O
specific	O
interactions	O
between	O
stem	O
cells	O
and	O
their	O
differentiated	O
niches	O
,	O
and	O
suggest	O
novel	O
therapeutic	O
approaches	O
for	O
improving	O
the	O
regenerative	O
responses	O
of	O
endogenous	O
or	O
transplanted	O
stem	O
cells	O
in	O
old	O
individuals	O
.	O

Animal	O
strainsYoung	O
(	O
2–3	O
months	O
)	O
,	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
pathogen	O
-	O
free	O
breeding	O
colonies	O
at	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
.	O

Aged	O
22–24	O
months	O
C57-BL	O
/	O
6	O
male	O
mice	O
were	O
obtained	O
from	O
the	O
National	O
Institute	O
on	O
Aging	O
(	O
NIH	O
)	O
.	O

Animals	O
were	O
maintained	O
in	O
the	O
North	O
-	O
West	O
Animal	O
Facility	O
of	O
the	O
University	O
of	O
California	O
,	O
Berkeley	O
,	O
CA	O
,	O
USA	O
,	O
and	O
handled	O
in	O
accordance	O
with	O
the	O
Administrative	O
Panel	O
on	O
Laboratory	O
Animal	O
Care	O
at	O
UC	O
Berkeley	O
.	O

Muscle	O
injury	O
and	O
isolationMyofiber	O
cultures	O
,	O
in	O
which	O
satellite	O
cells	O
were	O
activated	O
by	O
in	O
vivo	O
injury	O
,	O
were	O
set	O
up	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2005	O
)	O
.	O

Briefly	O
,	O
mice	O
were	O
injured	O
by	O
direct	O
injection	O
with	O
5	O
ng	O
cardiotoxin	O
(	O
CTX-1	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
into	O
the	O
tibialis	O
anterior	O
and	O
gastrocnemius	O
muscles	O
using	O
a	O
28-gauge	O
needle	O
.	O

After	O
1–5	O
days	O
post	O
-	O
injection	O
,	O
injured	O
or	O
uninjured	O
muscle	O
tissue	O
was	O
dissected	O
out	O
.	O

Once	O
isolated	O
,	O
whole	O
muscle	O
was	O
prepared	O
for	O
cryosectioning	O
(	O
see	O
below	O
)	O
or	O
myofiber	O
fragments	O
were	O
obtained	O
from	O
hind	O
limb	O
muscles	O
by	O
enzymatic	O
digestion	O
(	O
see	O
below	O
)	O
,	O
trituration	O
,	O
and	O
multiple	O
sedimentation	O
and	O
washing	O
procedures	O
.	O

Additionally	O
,	O
blood	O
was	O
collected	O
from	O
mice	O
for	O
the	O
isolation	O
of	O
sera	O
.	O

Briefly	O
,	O
blood	O
cells	O
were	O
coagulated	O
at	O
37	O
°	O
C	O
for	O
15	O
'	O
and	O
then	O
were	O
centrifuged	O
repeatedly	O
at	O
5900	O
g	O
,	O
4	O
°	O
C	O
in	O
a	O
microfuge	O
for	O
3	O
'	O
to	O
isolate	O
sera	O
.	O

Mixtures	O
of	O
young	O
and	O
old	O
sera	O
were	O
made	O
1	O
:	O
1	O
.	O

For	O
example	O
,	O
in	O
5%+	O
5	O
%	O
conditions	O
,	O
50	O
µL	O
of	O
young	O
and	O
50	O
µL	O
old	O
serum	O
were	O
added	O
to	O
900	O
µL	O
of	O
culture	O
medium	O
(	O
Opti	O
-	O
MEM	O
or	O
MCM	O
,	O
see	O
co	O
-	O
culture	O
procedures	O
below	O
)	O
.	O

Myofiber	O
explant	O
culturesExplant	O
and	O
primary	O
cell	O
cultures	O
were	O
generated	O
from	O
C57-BL	O
/	O
6	O
mice	O
,	O
as	O
previously	O
described	O
(	O
Conboy	O
&	O
Rando	O
,	O
2002	O
;	O
Conboy	O
et	O
al.	O
,	O
2003	O
)	O
.	O

Dissected	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
underwent	O
enzymatic	O
digestion	O
at	O
37	O
°	O
C	O
in	O
DMEM	O
(	O
Invitrogen	O
)	O
/	O
Pen	O
-	O
Strep	O
(	O
Invitrogen	O
)	O
/	O
0.2	O
%	O
Collagenase	O
Type	O
IIA	O
(	O
Sigma	O
)	O
solution	O
.	O

Isolated	O
fibers	O
were	O
resuspended	O
in	O
GM	O
(	O
Ham	O
's	O
F10	O
nutrient	O
mixture	O
(	O
Mediatech	O
,	O
Inc.	O
,	O
Herndon	O
,	O
VA	O
,	O
USA	O
)	O
,	O
20	O
%	O
FBS	O
(	O
Mediatech	O
)	O
,	O
5	O
ng	O
mL−1	O
bFGF	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
and	O
1	O
%	O
Pen	O
-	O
Strep	O
,	O
and	O
cultured	O
on	O
ECM	O
-	O
coated	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
plates	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
)	O
.	O

Cultures	O
of	O
primary	O
myoblasts	O
were	O
derived	O
from	O
isolated	O
fibers	O
,	O
through	O
repeated	O
passaging	O
,	O
and	O
were	O
maintained	O
in	O
GM	O
.	O

Myoblast	O
differentiation	O
medium	O
[	O
DMEM	O
,	O
supplemented	O
with	O
2	O
%	O
horse	O
serum	O
(	O
Mediatech	O
)	O
]	O
was	O
used	O
to	O
promote	O
rapid	O
formation	O
of	O
myotubes	O
from	O
cultured	O
myoblasts	O
(	O
Morgan	O
&	O
Partridge	O
,	O
2003	O
)	O
.	O

Human	O
embryonic	O
and	O
mesenchymal	O
stem	O
cell	O
cultureThe	O
federally	O
approved	O
hESC	O
line	O
,	O
H7	B
(	O
NIH	O
no.	O
WA07	B
,	O
obtained	O
from	O
WiCell	O
Research	O
Institue	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
,	O
was	O
used	O
in	O
accordance	O
with	O
the	O
UC	O
Berkeley	O
and	O
UC	O
San	O
Francisco	O
Committee	O
on	O
Human	O
Research	O
guidelines	O
,	O
and	O
in	O
accordance	O
with	O
NIH	O
guidelines	O
.	O

To	O
propagate	O
hESCs	O
,	O
routine	O
culturing	O
and	O
maintenance	O
was	O
performed	O
using	O
standard	O
in	O
vitro	O
conditions	O
for	O
both	O
feeder	O
-	O
dependent	O
and	O
feeder	O
-	O
free	O
cultures	O
(	O
Geron	O
Corporation	O
,	O
2002	O
)	O
.	O

Briefly	O
,	O
hESCs	O
grown	O
on	O
MEFs	O
were	O
cultured	O
in	O
standard	O
hESC	O
medium	O
[	O
Knockout	O
™	O
DMEM	O
,	O
20	O
%	O
KSR	O
,	O
1	O
%	O
NEAA	O
,	O
1	O
mm	O
l	O
-	O
glutamine	O
(	O
Invitrogen	O
)	O
,	O
0.1	O
mmβ	O
-	O
mercaptoethanol	O
(	O
Sigma	O
)	O
]	O
and	O
were	O
supplemented	O
with	O
4	O
ng	O
mL−1	O
hbFGF	O
(	O
Invitrogen	O
)	O
.	O

Feeder	O
-	O
free	O
hESC	O
cultures	O
were	O
maintained	O
in	O
MEF	O
-	O
conditioned	O
hESC	O
medium	O
(	O
MCM	O
)	O
,	O
4	O
ng	O
mL−1	O
hbFGF	O
.	O

Differentiation	O
medium	O
for	O
hESCs	O
(	O
DMEM	O
/	O
FBS	O
)	O
was	O
made	O
by	O
replacing	O
KSR	O
with	O
20	O
%	O
FBS	O
(	O
Hyclone	O
,	O
Logan	O
,	O
UH	O
,	O
USA	O
)	O
.	O

hMSCs	O
were	O
maintained	O
in	O
mesenchymal	O
stem	O
cell	O
GM	O
,	O
MSC	O
-	O
GM	O
™	O
and	O
were	O
cultured	O
according	O
to	O
supplier	O
recommendations	O
(	O
Cambrex	O
Walkersville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
typically	O
seeded	O
onto	O
chambered	O
slides	O
coated	O
with	O
a	O
3	O
%	O
GFR	O
Matrigel	O
™	O
(	O
BD	O
Biosciences	O
)	O
substrate	O
in	O
PBS	O
.	O

Cells	O
were	O
typically	O
incubated	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
under	O
the	O
various	O
experimental	O
conditions	O
employed	O
,	O
then	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
.	O

hESCs	O
and	O
hMSCs	O
were	O
analyzed	O
24–48	O
h	O
after	O
experimental	O
treatments	O
,	O
during	O
which	O
no	O
apoptosis	O
-	O
related	O
differences	O
in	O
cell	O
numbers	O
were	O
observed	O
.	O

Heterochronic	O
co	O
-	O
culture	O
systemsHeterochronic	O
systemic	O
cultures	O
were	O
established	O
by	O
culturing	O
myofiber	O
explants	O
(	O
in	O
GM	O
)	O
or	O
hESCs	O
(	O
in	O
MCM	O
)	O
in	O
the	O
presence	O
of	O
young	O
,	O
old	O
or	O
young	O
+	O
old	O
sera	O
for	O
48	O
h	O
(	O
Figs	O
1	O
and	O
2	O
and	O
Supplementary	O
Figs	O
S1–3	O
)	O
.	O

In	O
such	O
cultures	O
,	O
hESCs	O
were	O
passaged	O
immediately	O
prior	O
to	O
sera	O
exposure	O
.	O

In	O
contrast	O
,	O
preculturing	O
of	O
hESCs	O
for	O
24	O
h	O
in	O
MCM	O
,	O
prior	O
to	O
replacing	O
MCM	O
with	O
MCM	O
+	O
10	O
%	O
old	O
mouse	O
sera	O
was	O
done	O
for	O
embryonic	O
microniche	O
experiments	O
(	O
Fig.	O
3	O
)	O
.	O

For	O
heterochronic	O
local	O
organ	O
niche	O
cultures	O
,	O
hESCs	O
were	O
co	O
-	O
cultured	O
directly	O
with	O
myofiber	O
explants	O
for	O
48	O
h	O
in	O
GM	O
,	O
or	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
supernatants	O
derived	O
from	O
cultured	O
myofiber	O
explants	O
for	O
48	O
h	O
(	O
Figs	O
4A	O
and	O
5	O
)	O
.	O

Specifically	O
,	O
1	O
×	O
105	O
hESCs	O
or	O
control	O
hMSCs	O
were	O
co	O
-	O
cultured	O
with	O
identical	O
volume	O
,	O
e.g.	O
,	O
100	O
µL	O
,	O
of	O
young	O
or	O
old	O
myofiber	O
fragments	O
with	O
their	O
associated	O
satellite	O
cells	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
experiments	O
shown	O
in	O
Supplementary	O
Fig.	O
S5	O
,	O
culture	O
-	O
conditioned	O
supernatant	O
produced	O
by	O
hESCs	O
grown	O
in	O
MCM	O
was	O
used	O
as	O
a	O
medium	O
in	O
which	O
1	O
×	O
105	O
of	O
myofiber	O
-	O
associated	O
young	O
or	O
old	O
satellite	O
cells	O
were	O
cultured	O
for	O
48	O
h.	O
In	O
direct	O
co	O
-	O
cultures	O
,	O
mouse	O
vs.	O
human	O
cells	O
were	O
distinguished	O
by	O
immunodetection	O
with	O
human	O
-	O
specific	O
/	O
hESC	O
-	O
specific	O
and	O
mouse	O
-	O
specific	O
antibodies	O
(	O
Supplementary	O
Fig.	O
S4	O
and	O
see	O
below	O
)	O
.	O

To	O
prepare	O
muscle	O
supernatants	O
,	O
explants	O
were	O
cultured	O
for	O
24	O
h	O
in	O
GM	O
and	O
cellular	O
debris	O
was	O
removed	O
from	O
conditioned	O
media	O
by	O
multiple	O
rounds	O
of	O
centrifugation	O
.	O

The	O
absence	O
of	O
cells	O
was	O
confirmed	O
by	O
microscopic	O
examination	O
.	O

To	O
mimic	O
the	O
local	O
organ	O
niche	O
for	O
satellite	O
cell	O
assays	O
(	O
Fig.	O
4B	O
)	O
,	O
1.0	O
µm	O
transwell	O
(	O
Corning	O
,	O
NY	O
,	O
USA	O
)	O
co	O
-	O
cultures	O
of	O
uninjured	O
explants	O
with	O
activated	O
satellite	O
cells	O
were	O
established	O
.	O

Activated	O
-	O
by	O
-	O
injury	O
(	O
24	O
h	O
post	O
-	O
injury	O
)	O
satellite	O
cells	O
were	O
seeded	O
onto	O
ECM	O
-	O
coated	O
12-well	O
plates	O
in	O
Opti	O
-	O
MEM	O
(	O
Invitrogen	O
)	O
and	O
5	O
%	O
FBS	O
.	O

Transwells	O
were	O
placed	O
over	O
satellite	O
cells	O
and	O
contained	O
isolated	O
myofiber	O
explants	O
from	O
uninjured	O
young	O
or	O
old	O
muscle	O
(	O
i.e.	O
,	O
resting	O
muscle	O
)	O
.	O

Satellite	O
cells	O
were	O
cultured	O
for	O
72–96	O
h	O
in	O
the	O
presence	O
of	O
myofiber	O
explants	O
and	O
were	O
fixed	O
for	O
immunodetection	O
,	O
as	O
described	O
above	O
.	O

Cell	O
transplantationhESCs	O
were	O
grown	O
on	O
MEFs	O
and	O
expanded	O
in	O
6-well	O
plates	O
.	O

Cells	O
were	O
treated	O
with	O
1	O
mg	O
mL−1	O
Collagenase	O
Type	O
IV	O
(	O
Invitrogen	O
)	O
for	O
5–10	O
min	O
,	O
were	O
washed	O
and	O
then	O
incubated	O
with	O
0.5	O
mg	O
mL−1	O
Dispase	O
(	O
Invitrogen	O
)	O
to	O
lift	O
only	O
human	O
cell	O
colonies	O
.	O

Isolated	O
hESCs	O
were	O
washed	O
several	O
times	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Similarly	O
,	O
hMSCs	O
were	O
expanded	O
in	O
6-well	O
plates	O
,	O
lifted	O
with	O
Trypsin	O
/	O
EDTA	O
(	O
Invitrogen	O
)	O
,	O
washed	O
and	O
resuspended	O
in	O
100	O
µL	O
hESC	O
medium	O
.	O

Approximately	O
5	O
×	O
105	O
hESCs	O
or	O
hMSCs	O
were	O
injected	O
into	O
24	O
h	O
post	O
-	O
injured	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
muscles	O
of	O
young	O
and	O
old	O
mice	O
,	O
using	O
a	O
21-gauge	O
needle	O
.	O

Immunosuppression	O
of	O
animals	O
was	O
achieved	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
mg	O
kg−1	O
FK506	O
(	O
Sigma	O
)	O
at	O
48	O
h	O
prior	O
to	O
cell	O
transplantation	O
,	O
and	O
on	O
each	O
day	O
following	O
transplantation	O
.	O

Immunodetection	O
and	O
histological	O
analysisTo	O
assay	O
the	O
affects	O
of	O
heterochronic	O
local	O
and	O
systemic	O
environments	O
on	O
stem	O
cell	O
regenerative	O
potential	O
,	O
hESC	O
,	O
hMSC	O
,	O
and	O
myofiber	O
-	O
derived	O
precursor	O
cell	O
cultures	O
were	O
fixed	O
with	O
70	O
%	O
EtOH	O
/	O
PBS	O
at	O
4	O
°	O
C	O
,	O
and	O
were	O
analyzed	O
by	O
indirect	O
immunofluorescence	O
.	O

Combinations	O
of	O
antibodies	O
were	O
used	O
to	O
co	O
-	O
stain	O
cultures	O
and	O
histosections	O
,	O
in	O
order	O
to	O
determine	O
the	O
percentages	O
of	O
cells	O
that	O
proliferated	O
or	O
differentiated	O
and	O
to	O
distinguish	O
hESCs	O
from	O
mouse	O
cells	O
.	O

Antibodies	O
to	O
the	O
myogenic	O
transcription	O
factors	O
,	O
Myf5	O
/	O
Pax7	O
,	O
the	O
intermediate	O
filament	O
protein	O
,	O
desmin	O
,	O
and	O
the	O
marker	O
of	O
newly	O
formed	O
myotubes	O
,	O
eMyHC	O
,	O
were	O
used	O
to	O
reveal	O
commitment	O
to	O
myogenic	O
differentiation	O
.	O

Cell	O
commitment	O
to	O
this	O
differentiation	O
program	O
was	O
assessed	O
by	O
the	O
efficiency	O
of	O
myotube	O
formation	O
,	O
estimated	O
by	O
the	O
number	O
of	O
nuclei	O
per	O
myotube	O
.	O

Ki67	O
,	O
a	O
cell	O
cycle	O
related	O
nuclear	O
protein	O
consistently	O
absent	O
in	O
quiescent	O
cells	O
,	O
was	O
used	O
as	O
a	O
marker	O
for	O
proliferation	O
.	O

Whereas	O
Ki67	O
appears	O
in	O
all	O
active	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
BrdU	O
staining	O
allowed	O
exclusive	O
detection	O
of	O
cells	O
in	O
S	O
-	O
phase	O
,	O
thereby	O
enabling	O
accurate	O
quantification	O
of	O
DNA	O
synthesis	O
.	O

In	O
select	O
cultures	O
,	O
10	O
µm	O
BrdU	O
was	O
added	O
for	O
2	O
h	O
prior	O
to	O
fixation	O
.	O

BrdU	O
-	O
specific	O
immunostaining	O
required	O
nuclear	O
permeabilization	O
with	O
treatment	O
of	O
4N	O
HCl	O
.	O

hESCs	O
were	O
distinguished	O
from	O
mouse	O
cells	O
by	O
using	O
a	O
species	O
-	O
specific	O
antibody	O
to	O
the	O
cell	O
-	O
surface	O
marker	O
M	O
-	O
cadherin	O
for	O
murine	O
and	O
the	O
nuclear	O
marker	O
NuMA	O
for	O
human	O
cells	O
.	O

Antibodies	O
to	O
Oct4	O
were	O
used	O
as	O
a	O
marker	O
of	O
hESC	O
self	O
-	O
renewal	O
/	O
pluripotency	O
.	O

Following	O
permeabilization	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
+	O
0.25	O
%	O
Triton	O
X-100	O
,	O
cells	O
were	O
incubated	O
with	O
primary	O
antibodies	O
(	O
concentration	O
determined	O
as	O
per	O
manufacturer	O
's	O
recommendations	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
in	O
PBS	O
,	O
+	O
1	O
%	O
FBS	O
,	O
washed	O
several	O
times	O
,	O
and	O
then	O
incubated	O
with	O
fluorophore	O
-	O
conjugated	O
,	O
species	O
-	O
specific	O
secondary	O
antibodies	O
(	O
diluted	O
1	O
:	O
500	O
in	O
PBS	O
+	O
1	O
%	O
FBS	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

For	O
histological	O
analysis	O
,	O
dissected	O
muscle	O
was	O
treated	O
in	O
a	O
25	O
%	O
sucrose	O
/	O
PBS	O
solution	O
,	O
frozen	O
in	O
OCT	O
compound	O
(	O
Tissue	O
Tek	O
)	O
and	O
cryosectioned	O
at	O
10	O
µm	O
.	O

Immunostaining	O
was	O
performed	O
in	O
the	O
manner	O
described	O
above	O
,	O
or	O
H&E	O
staining	O
of	O
cryosections	O
was	O
performed	O
.	O

Nuclei	O
were	O
visualized	O
by	O
Hoechst	O
staining	O
for	O
all	O
immunostains	O
.	O

Samples	O
were	O
analyzed	O
at	O
room	O
temperature	O
by	O
using	O
a	O
Zeiss	O
Axioscope	O
40	O
fluorescent	O
microscope	O
,	O
and	O
imaged	O
with	O
an	O
Axiocan	O
MRc	O
camera	O
and	O
AxioVision	O
software	O
.	O

All	O
images	O
depict	O
identical	O
microscope	O
fields	O
at	O
×20	O
magnification	O
,	O
unless	O
otherwise	O
noted	O
.	O

ReagentsAntibodies	O
to	O
Oct4	O
(	O
ab18976	O
)	O
,	O
BrdU	O
(	O
BU1	O
/	O
75	O
(	O
ICR1	O
)	O
,	O
and	O
Ki67	O
(	O
ab15580	O
)	O
were	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
M	O
-	O
cadherin	O
(	O
clone	O
12G4	O
)	O
was	O
acquired	O
from	O
Upstate	O
Biotechnology	O
(	O
Lake	O
Placid	O
,	O
NY	O
,	O
USA	O
)	O
,	O
and	O
NuMA	O
antibody	O
(	O
Catalog	O
number	O
NA09L	O
)	O
from	O
EMD	O
Biosciences	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Antibody	O
to	O
developmental	O
eMyHC	O
(	O
clone	O
RNMy2	O
/	O
9D2	O
)	O
was	O
acquired	O
from	O
Vector	O
Laboratories	O
(	O
Burlingame	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Myf5	O
(	O
GTX77876	O
)	O
and	O
Pax7	O
(	O
GTX77888	O
)	O
antibodies	O
were	O
obtained	O
from	O
GeneTex	O
(	O
San	O
Antonio	O
,	O
TX	O
,	O
USA	O
)	O
.	O

Desmin	O
antibodies	O
(	O
clone	O
DE	O
-	O
U-10	O
and	O
Catalog	O
number	O
D8281	O
)	O
,	O
BrdU	O
labeling	O
reagent	O
and	O
FK506	O
(	O
Catalog	O
number	O
F4679	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

Fluorophore	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
Alexa	O
Fluor	O
)	O
were	O
obtained	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
,	O
USA	O
)	O
.	O

Statistical	O
analysesA	O
minimum	O
of	O
three	O
replicates	O
were	O
undertaken	O
for	O
each	O
experimental	O
condition	O
.	O

Quantified	O
data	O
are	O
presented	O
as	O
means	O
±	O
SE	O
.	O

Significance	O
testing	O
was	O
performed	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
anova	O
)	O
to	O
compare	O
data	O
from	O
different	O
experimental	O
groups	O
.	O

P	O
values	O
of	O
<	O
0.05	O
were	O
considered	O
as	O
statistically	O
significant	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
the	O
expression	O
of	O
IL	O
-	O
6	O
mRNA	O
was	O
significantly	O
decreased	O
in	O
NUGC3	B
,	O
GBK	B
-	I
1	I
,	O
and	O
RERF	B
-	I
LCOK	I
cells	O
but	O
was	O
increased	O
in	O
GaCa	O
cells	O
.	O

In	O
this	O
study	O
,	O
6	O
different	O
cryoprotector	O
combinations	O
[	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
,	O
ethylene	O
glycol	O
,	O
and	O
hydroxyethylstarch	O
(	O
HES	O
)	O
]	O
combined	O
with	O
2	O
different	O
application	O
methods	O
were	O
screened	O
with	O
the	O
VUB01	B
cell	O
line	O
,	O
to	O
establish	O
a	O
new	O
slow	O
-	O
freezing	O
protocol	O
with	O
high	O
recovery	O
rates	O
and	O
a	O
good	O
expansion	O
capacity	O
.	O

Ma01	O
caused	O
highly	O
lethal	O
infection	O
in	O
mice	O
with	O
severe	O
lung	O
pathology	O
and	O
extended	O
tissue	O
tropism	O
.	O

CCL	O
-	O
16	O
was	O
overexpressed	O
by	O
over	O
130	O
-	O
fold	O
in	O
IBS	O
-	O
constipation	O
patients	O
when	O
compared	O
with	O
both	O
controls	O
and	O
IBS	O
-	O
diarrhea	O
patients	O
.	O

The	O
EH	B
-	I
GB2	I
established	O
gallbladder	O
cancer	O
cell	O
line	O
is	O
useful	O
for	O
future	O
studies	O
of	O
gallbladder	O
cancer	O
development	O
,	O
progression	O
,	O
metastasis	O
and	O
therapy	O
.	O

Compound	O
1	O
and	O
the	O
precursors	O
(	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
7	O
)	O
showed	O
antiproliferative	O
activities	O
against	O
human	O
K562	B
leukemia	O
,	O
murine	O
WEHI3	B
leukemia	O
,	O
and	O
murine	O
MEL	B
erythroid	O
progenitor	O
.	O

Concerning	O
both	O
GSH	O
-	O
peroxidase	O
and	O
GSH	O
-	O
reductase	O
no	O
significant	O
differences	O
between	O
the	O
HLac	B
79	I
subpopulations	O
were	O
observed	O
.	O

In	O
two	O
different	O
donors	O
,	O
we	O
identified	O
a	O
unique	O
peptide	O
in	O
the	O
NEF	O
protein	O
that	O
could	O
be	O
recognized	O
in	O
association	O
with	O
two	O
different	O
HLA	O
class	O
I	O
molecules	O
.	O

When	O
the	O
expression	O
of	O
E	O
-	O
cadherin	O
in	O
these	O
cells	O
was	O
examined	O
by	O
immunoblot	O
analysis	O
,	O
the	O
highly	O
metastatic	O
HM	B
-	I
1	I
cells	O
was	O
found	O
to	O
express	O
an	O
extremely	O
small	O
amount	O
of	O
this	O
molecule	O
,	O
as	O
compared	O
with	O
a	O
high	O
level	O
of	O
E	O
-	O
cadherin	O
expression	O
in	O
the	O
weakly	O
metastatic	O
LM	B
-	I
1	I
and	O
LM	B
-	I
3	I
cells	O
.	O

The	O
KU	B
-	I
8	I
cell	O
line	O
was	O
established	O
from	O
a	O
lymph	O
node	O
metastasis	O
of	O
human	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
penis	O
.	O

Speedy	O
restoration	O
of	O
immune	O
responsiveness	O
in	O
bone	O
marrow	O
recipients	O
has	O
been	O
the	O
objective	O
of	O
studies	O
in	O
which	O
the	O
donor	O
was	O
immunized	O
so	O
that	O
specific	O
immunologic	O
memory	O
could	O
be	O
transferred	O
adoptively	O
and	O
selectively	O
.	O

Molecular	O
cloning	O
and	O
expression	O
of	O
T11	O
cDNAs	O
reveal	O
a	O
receptor	O
-	O
like	O
structure	O
on	O
human	O
T	O
lymphocytes	O
.	O

All	O
three	O
react	O
with	O
HL	B
-	I
60	I
(	O
promyelocytic	O
)	O
,	O
RWLeu4	B
(	O
CML	O
promyelocytic	O
)	O
,	O
and	O
U937	B
(	O
monocytic	O
)	O
,	O
but	O
not	O
with	O
KG	B
-	I
1	I
(	O
myeloblastic	O
)	O
or	O
K562	B
(	O
CML	O
erythroid	O
)	O
.	O

Herpes	O
Simplex	O
Virus	O
specified	O
DNA	O
-	O
binding	O
proteins	O
were	O
purified	O
from	O
virus	O
infected	O
VERO	B
and	O
RAJI	B
cells	O
.	O

The	O
human	O
thyroid	O
carcinoma	O
HTh7	B
spheroids	O
and	O
the	O
3	O
types	O
of	O
human	O
glioma	O
spheroids	O
had	O
lower	O
quotients	O
.	O

COMMA	B
-	I
D	I
cells	O
were	O
able	O
to	O
undergo	O
serial	O
passage	O
and	O
continued	O
to	O
exhibit	O
dome	O
formation	O
after	O
20	O
passages	O
in	O
SFM	O
.	O

The	O
mol	O
wt	O
of	O
the	O
abnormal	O
receptors	O
in	O
human	O
leukemia	O
cells	O
was	O
the	O
same	O
as	O
the	O
mol	O
wt	O
of	O
receptors	O
in	O
mutant	O
mouse	O
lymphoma	O
cell	O
lines	O
,	O
S49	B
143R	I
and	O
S49	B
55R	I
,	O
which	O
have	O
the	O
nuclear	O
transfer	O
-	O
increased	O
phenotype	O
of	O
glucocorticoid	O
resistance	O
.	O

Human	O
recombinant	O
interferon	O
alpha	O
A	O
/	O
D	O
(	O
alpha	O
A	O
/	O
D	O
)	O
was	O
examined	O
for	O
its	O
antitumor	O
activity	O
in	O
several	O
mouse	O
tumor	O
models	O
using	O
metastatic	O
tumors	O
,	O
such	O
as	O
B16	B
melanoma	I
F1	I
,	O
BL6	B
and	O
F10	B
,	O
UV2237	B
m	I
fibrosarcoma	O
,	O
and	O
K1735	B
m	I
melanoma	O
.	O

IL	O
-	O
1	O
was	O
measured	O
by	O
its	O
property	O
of	O
promoting	O
the	O
production	O
of	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
by	O
phytohemagglutinin	O
-	O
treated	O
LBRM	B
-	I
33	I
clone	I
1A5	I
cells	O
.	O

To	O
our	O
knowledge	O
,	O
RS4	B
;	I
11	I
is	O
the	O
first	O
cell	O
line	O
established	O
from	O
t	O
(	O
4	O
;	O
11	O
)	O
-	O
associated	O
acute	O
leukemia	O
.	O

These	O
molecules	O
could	O
be	O
very	O
faintly	O
induced	O
in	O
PUTKO	B
and	O
DUTKO	B
hybrids	O
,	O
in	O
contrast	O
with	O
strong	O
HLA	O
class	O
-	O
II	O
expression	O
on	O
the	O
B	O
parental	O
lines	O
.	O

Two	O
human	O
melanoma	O
lines	O
,	O
RPMI	B
-	I
7931	I
and	O
HS	B
-	I
294	I
,	O
respond	O
to	O
mitogenic	O
stimulation	O
by	O
PHA	O
.	O

[	O
Pharmacology	O
:	O
antihistaminics	O
H1	O
receptor	O
blockaders	O
]	O

From	O
analysis	O
of	O
binding	O
patterns	O
in	O
various	O
tissues	O
and	O
in	O
immunoblots	O
,	O
it	O
was	O
found	O
that	O
RBA2	O
cross	O
-	O
reacted	O
strongly	O
with	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
desmin	O
.	O

In	O
limiting	O
dilution	O
cultures	O
,	O
most	O
normal	O
resting	O
splenic	O
B	O
cells	O
or	O
WEHI	B
-	I
279	I
B	O
tumor	O
cells	O
are	O
inducible	O
by	O
BMF	O
.	O

RLD	B
cells	O
are	O
able	O
to	O
differentiate	O
after	O
in	O
vitro	O
stimulation	O
with	O
1	O
%	O
DMSO	O
or	O
with	O
30	O
nM	O
tetradecanoylphorbol	O
-	O
1	O
.	O
3	O
-	O
acetate	O
(	O
TPA	O
)	O
.	O

Human	O
amnion	O
CCL	B
-	I
25	I
cells	O
,	O
human	O
embryonic	O
intestine	O
CCL	B
-	I
6	I
cells	O
,	O
human	O
colon	O
adenocarcinoma	O
LOVO	B
cells	O
,	O
and	O
mouse	O
hepatoma	O
BW	O
-	O
1	O
cells	O
were	O
used	O
.	O

In	O
additional	O
studies	O
,	O
the	O
cytostatic	O
effects	O
of	O
activated	O
macrophages	O
markedly	O
reduced	O
the	O
cytotoxic	O
effects	O
of	O
the	O
chemotherapeutic	O
agent	O
cytosine	O
arabinoside	O
on	O
EMT	B
-	I
6	I
target	O
cells	O
.	O

Six	O
commonly	O
used	O
strains	O
of	O
lymphocytic	O
choriomeningitis	O
virus	O
(	O
LCMV	O
)	O
[	O
Armstrong	O
(	O
Arm	O
)	O
CA	O
1371	O
,	O
Arm	O
E	O
-	O
350	O
,	O
WE	O
,	O
UBC	O
,	O
Traub	O
and	O
Pasteur	O
C1PV	O
76001	O
]	O
were	O
examined	O
for	O
distinctive	O
genetic	O
and	O
biological	O
properties	O
.	O

[	O
Development	O
of	O
leukemia	O
L	B
-	I
1210	I
after	O
treatment	O
with	O
the	O
methionine	O
synthetase	O
inhibitor	O
quinoline	O
dibromide	O
]	O

The	O
expression	O
of	O
the	O
DCC	O
(	O
deleted	O
in	O
colorectal	O
cancer	O
)	O
gene	O
,	O
located	O
on	O
the	O
chromosome	O
18q21	O
,	O
was	O
extremely	O
reduced	O
in	O
KML	B
-	I
1	I
cell	O
line	O
,	O
as	O
compared	O
with	O
that	O
in	O
a	O
normal	O
spleen	O
tissue	O
and	O
other	O
4	O
lymphoma	O
cell	O
lines	O
by	O
the	O
reverse	O
transcription	O
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
method	O
.	O

After	O
a	O
4	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
,	O
228	O
patients	O
were	O
randomized	O
to	O
4	O
weeks	O
of	O
treatment	O
with	O
either	O
NIF	O
CC	O
30	O
mg	O
daily	O
or	O
NIF	O
GITS	O
30	O
mg	O
daily	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
2d	O
-	O
29	O
and	O
2d	O
-	O
35	O
in	O
the	O
brain	O
were	O
lower	O
than	O
that	O
of	O
P450	O
2D4	O
in	O
the	O
liver	O
.	O

Fifteen	O
percent	O
of	O
EGF	O
receptors	O
present	O
on	O
differentiated	O
HT29	B
-	I
D4	I
cells	O
were	O
localized	O
in	O
the	O
apical	O
surface	O
,	O
whereas	O
98	O
%	O
of	O
IGF	O
-	O
I	O
receptors	O
were	O
segregated	O
to	O
the	O
basolateral	O
domain	O
.	O

KE	B
-	I
97	I
is	O
mucinous	O
carcinoma	O
,	O
and	O
it	O
was	O
reported	O
with	O
the	O
belief	O
that	O
it	O
is	O
a	O
useful	O
cell	O
line	O
upon	O
the	O
investigation	O
of	O
its	O
cancer	O
metastasis	O
mechanism	O
and	O
cytological	O
characteristics	O
.	O

The	O
inferred	O
amino	O
acid	O
sequences	O
of	O
rat	O
liver	O
CBS	O
and	O
rat	O
liver	O
hemoprotein	O
H	O
-	O
450	O
are	O
identical	O
.	O

Swine	B
testis	I
cells	O
contain	O
functional	O
heparan	O
sulfate	O
but	O
are	O
defective	O
in	O
entry	O
of	O
herpes	O
simplex	O
virus	O
.	O

The	O
addition	O
of	O
anti	O
-	O
HGF	O
antibodies	O
to	O
cultures	O
of	O
SBC	B
-	I
5	I
cells	O
specifically	O
inhibited	O
spreading	O
and	O
motility	O
of	O
the	O
cells	O
without	O
affecting	O
growth	O
,	O
and	O
the	O
conditioned	O
medium	O
of	O
SBC	B
-	I
5	I
cells	O
also	O
induced	O
scattering	O
of	O
other	O
lineage	O
lung	O
carcinoma	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
beta	O
)	O
(	O
1	O
ng	O
/	O
ml	O
)	O
did	O
not	O
influence	O
whole	O
cell	O
alkaline	O
phosphatase	O
levels	O
in	O
UMR	B
201	I
cells	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
influence	O
of	O
the	O
exposure	O
time	O
and	O
the	O
sequence	O
of	O
modulator	O
administration	O
on	O
the	O
active	O
transport	O
of	O
the	O
fluorescent	O
dye	O
rhodamine	O
123	O
(	O
R123	O
)	O
,	O
a	O
substrate	O
for	O
the	O
P	O
-	O
glycoprotein	O
,	O
in	O
the	O
resistant	O
lymphoblastoid	O
cell	O
line	O
VCR1000	B
and	O
the	O
parental	O
nonresistant	O
cell	O
line	O
CCRF	B
-	I
CEM	I
.	O

No	O
DHT	O
and	O
cyproterone	O
acetate	O
effects	O
on	O
the	O
androgen	O
receptor	O
negative	O
line	O
UM	B
-	I
SCC11B	I
were	O
found	O
.	O

Normal	O
human	O
fibroblasts	O
(	O
the	O
OUMS	B
-	I
24	I
strain	O
)	O
,	O
derived	O
from	O
a	O
6	O
-	O
week	O
-	O
old	O
human	O
embryo	O
,	O
were	O
transformed	O
(	O
into	O
the	O
OUMS	B
-	I
24F	I
line	O
)	O
and	O
immortalized	O
by	O
repeated	O
treatments	O
(	O
59	O
times	O
)	O
with	O
4	O
-	O
nitroquinoline	O
1	O
-	O
oxide	O
(	O
4NQO	O
)	O
.	O

The	O
Kasumi	B
-	I
4	I
cells	O
had	O
the	O
following	O
characteristic	O
features	O
:	O
undifferentiated	O
blasts	O
which	O
were	O
positive	O
from	O
CD34	O
,	O
CD33	O
and	O
CD13	O
surface	O
markers	O
,	O
but	O
negative	O
for	O
myeloperoxidase	O
platelet	O
peroxidase	O
,	O
CD36	O
,	O
CD41	O
and	O
CD42	O
;	O
chromosome	O
abnormalities	O
of	O
t	O
(	O
9	O
;	O
22	O
;	O
11	O
)	O
(	O
q34	O
;	O
q11	O
;	O
q13	O
)	O
,	O
inv	O
(	O
3	O
)	O
(	O
q21q26	O
)	O
;	O
and	O
elevated	O
expression	O
of	O
EVI1	O
gene	O
which	O
is	O
located	O
at	O
chromosome	O
band	O
3q26	O
.	O

The	O
gp130	O
-	O
associated	O
cytokines	O
,	O
IL	O
-	O
11	O
,	O
leukemia	O
inhibitory	O
factor	O
and	O
oncostatin	O
M	O
,	O
stimulated	O
the	O
growth	O
of	O
the	O
KAS	B
-	I
6	I
/	I
1	I
cells	O
,	O
but	O
had	O
minimal	O
effects	O
on	O
the	O
DP	B
-	I
6	I
and	O
KP	B
-	I
6	I
cells	O
.	O

Responses	O
to	O
cisplatin	O
essentially	O
reported	O
low	O
sensitivity	O
of	O
OC	B
314	I
and	O
OC	B
315	I
and	O
resistance	O
of	O
OC	B
316	I
,	O
thus	O
reflecting	O
the	O
original	O
sensitivity	O
at	O
the	O
clinical	O
level	O
.	O

Introduction	O
of	O
a	O
plasmid	O
carrying	O
an	O
fbpA	O
-	O
cat	O
transcriptional	O
fusion	O
in	O
E	O
.	O
coli	O
H1717	O
(	O
Fur	O
+	O
)	O
resulted	O
in	O
an	O
88	O
%	O
induction	O
of	O
chloramphenicol	O
acetyltransferase	O
expression	O
under	O
conditions	O
of	O
iron	O
restriction	O
;	O
however	O
,	O
chloramphenicol	O
acetyltransferase	O
expression	O
was	O
not	O
responsive	O
to	O
iron	O
in	O
E	O
.	O
coli	O
H1745	O
(	O
Fur	O
-	O
)	O
,	O
indicating	O
that	O
transcriptional	O
regulation	O
of	O
fbpA	O
in	O
response	O
to	O
iron	O
occurs	O
via	O
the	O
negative	O
regulator	O
Fur	O
.	O

Transfection	O
analysis	O
in	O
the	O
pancreatic	O
cell	O
line	O
HIT	B
T	I
-	I
15	I
M	O
2	O
.	O
2	O
.	O
2	O
revealed	O
that	O
a	O
DNA	O
fragment	O
containing	O
this	O
region	O
causes	O
a	O
45	O
%	O
reduction	O
in	O
promoter	O
activity	O
when	O
linked	O
to	O
the	O
native	O
insulin	O
promoter	O
and	O
a	O
72	O
%	O
reduction	O
when	O
linked	O
to	O
a	O
heterologous	O
tk	O
promoter	O
.	O

NR6W	B
cells	O
demonstrated	O
a	O
saturation	O
binding	O
curve	O
with	O
125I	O
-	O
labeled	O
EGF	O
(	O
affinity	O
,	O
1	O
.	O
8	O
x	O
10	O
(	O
8	O
)	O
;	O
r2	O
=	O
0	O
.	O
96	O
)	O
.	O

In	O
contrast	O
,	O
no	O
difference	O
in	O
adhesion	O
to	O
LAK	O
cells	O
and	O
susceptibility	O
to	O
LAK	O
cytotoxicity	O
was	O
detected	O
between	O
baseline	O
and	O
TNF	O
-	O
alpha	O
-	O
treated	O
NCI	B
H838	I
cells	O
.	O

A	O
unique	O
immunohistochemical	O
approach	O
of	O
introducing	O
ascites	O
fluid	O
OX	O
-	O
27	O
as	O
the	O
primary	O
antibody	O
intravenously	O
to	O
the	O
PVG	O
-	O
RT1U	O
host	O
demonstrated	O
that	O
in	O
donor	O
PVG	O
-	O
RT1C	O
posterior	O
pituitary	O
allografts	O
,	O
donor	O
and	O
not	O
host	O
vessels	O
predominate	O
and	O
are	O
restricted	O
to	O
the	O
graft	O
.	O

The	O
Lu	B
-	I
134A	I
cells	O
adhered	O
to	O
the	O
substrate	O
and	O
developed	O
elongated	O
cytoplasmic	O
processes	O
which	O
gradually	O
grew	O
into	O
long	O
neuronal	O
-	O
like	O
processes	O
.	O

The	O
galanin	O
receptors	O
expressed	O
in	O
CHP	B
-	I
212	I
cells	O
,	O
like	O
GALR1	O
have	O
high	O
affinity	O
for	O
galanin	O
(	O
Kd	O
=	O
0	O
.	O
07	O
nM	O
)	O
and	O
the	O
potency	O
for	O
inhibition	O
of	O
125I	O
-	O
galanin	O
binding	O
by	O
galanin	O
peptides	O
parallels	O
that	O
of	O
hGALR1	O
expressed	O
in	O
a	O
stable	O
CHO	B
cell	O
line	O
.	O

A	O
single	O
intraperitoneal	O
injection	O
of	O
the	O
replication	O
-	O
deficient	O
adenovirus	O
containing	O
the	O
HST	O
-	O
1	O
gene	O
(	O
Adex1HST	O
-	O
1	O
)	O
into	O
mice	O
caused	O
a	O
two	O
-	O
fold	O
increase	O
in	O
peripheral	O
platelet	O
count	O
for	O
30	O
days	O
,	O
and	O
effectively	O
prevented	O
experimentally	O
induced	O
thrombocytopenia	O
.	O

In	O
a	O
cell	O
clone	O
derived	O
from	O
line	O
VMCub1	B
by	O
stable	O
transfection	O
with	O
wild	O
-	O
type	O
p53	O
under	O
the	O
control	O
of	O
a	O
metallothionein	O
promotor	O
,	O
p21	O
was	O
induced	O
along	O
with	O
p53	O
upon	O
activation	O
of	O
the	O
promoter	O
with	O
zinc	O
chloride	O
.	O

Peptides	O
derived	O
from	O
CDR1	O
of	O
44aacb	O
,	O
CDR2	O
of	O
118	O
.	O
1	O
,	O
and	O
CDRs	O
1	O
and	O
3	O
of	O
MY904	O
heavy	O
chains	O
were	O
found	O
to	O
possess	O
blocking	O
activity	O
at	O
10	O
-	O
100	O
muM	O
.	O

The	O
cell	O
lines	O
OCM	B
-	I
1	I
and	O
OMM	B
-	I
1	I
expressed	O
MAGE	O
-	O
1	O
,	O
-	O
2	O
and	O
-	O
3	O
,	O
whereas	O
EOM	B
-	I
3	I
,	O
MEL202	B
,	O
92	B
-	I
1	I
and	O
OMM	B
-	I
3	I
were	O
negative	O
for	O
these	O
antigens	O
.	O

Parsley	O
cells	O
recognize	O
the	O
fungal	O
phytopathogen	O
Phytophthora	O
sojae	O
through	O
a	O
plasma	O
membrane	O
receptor	O
.	O

Of	O
note	O
,	O
three	O
of	O
the	O
four	O
c	O
-	O
met	O
+	O
lines	O
belonged	O
to	O
the	O
category	O
Hodgkin	O
-	O
ALCL	O
;	O
the	O
Hodgkin	O
cell	O
line	O
SUP	B
-	I
HD	I
-	I
1	I
showed	O
both	O
HGF	O
and	O
c	O
-	O
met	O
mRNA	O
bands	O
suggesting	O
the	O
possibility	O
of	O
an	O
autocrine	O
loop	O
.	O

Single	O
-	O
cell	O
suspensions	O
(	O
UF	B
-	I
1	I
/	O
GMTg	O
SCID	O
cells	O
)	O
were	O
similar	O
in	O
morphological	O
,	O
immunological	O
,	O
cytogenetic	O
and	O
molecular	O
genetic	O
features	O
to	O
parental	O
UF	B
-	I
1	I
cells	O
.	O

A	O
172	O
bp	O
genomic	O
fragment	O
flanking	O
the	O
untranslated	O
exon	O
produced	O
a	O
high	O
level	O
of	O
expression	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfection	O
assays	O
using	O
a	O
human	O
lung	O
adenocarcinoma	O
cell	O
line	O
.	O

Glioma	O
tumor	O
stem	O
-	O
like	O
cells	O
promote	O
tumor	O
angiogenesis	O
and	O
vasculogenesis	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
.	O

Cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
are	O
predicted	O
to	O
be	O
critical	O
drivers	O
of	O
tumor	O
progression	O
due	O
to	O
their	O
self	O
-	O
renewal	O
capacity	O
and	O
limitless	O
proliferative	O
potential	O
.	O

An	O
emerging	O
area	O
of	O
research	O
suggests	O
that	O
CSC	O
may	O
also	O
support	O
tumor	O
progression	O
by	O
promoting	O
tumor	O
angiogenesis	O
.	O

To	O
investigate	O
how	O
CSC	O
contribute	O
to	O
tumor	O
vascular	O
development	O
,	O
we	O
used	O
an	O
approach	O
comparing	O
tumor	O
xenografts	O
of	O
the	O
C6	B
glioma	O
cell	O
line	O
containing	O
either	O
a	O
low	O
or	O
a	O
high	O
fraction	O
of	O
CSC	O
.	O

Compared	O
with	O
CSC	O
-	O
low	O
tumors	O
,	O
CSC	O
-	O
high	O
tumors	O
exhibited	O
increased	O
microvessel	O
density	O
and	O
blood	O
perfusion	O
and	O
induced	O
increased	O
mobilization	O
and	O
tumor	O
recruitment	O
of	O
bone	O
marrow	O
-	O
derived	O
endothelial	O
progenitor	O
cells	O
(	O
EPC	O
)	O
.	O

CSC	O
-	O
high	O
C6	B
cell	O
cultures	O
also	O
induced	O
higher	O
levels	O
of	O
endothelial	O
cell	O
proliferation	O
and	O
tubule	O
organization	O
in	O
vitro	O
compared	O
with	O
CSC	O
-	O
low	O
cultures	O
.	O

CSC	O
-	O
high	O
cultures	O
and	O
tumors	O
expressed	O
increased	O
levels	O
of	O
the	O
proangiogenic	O
factors	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
,	O
and	O
when	O
signaling	O
by	O
either	O
factor	O
was	O
blocked	O
,	O
all	O
aspects	O
of	O
angiogenesis	O
observed	O
in	O
CSC	O
-	O
high	O
cultures	O
and	O
tumors	O
,	O
including	O
microvessel	O
density	O
,	O
perfusion	O
,	O
EPC	O
mobilization	O
/	O
recruitment	O
,	O
and	O
stimulation	O
of	O
endothelial	O
cell	O
activity	O
,	O
were	O
reduced	O
to	O
levels	O
comparable	O
with	O
those	O
observed	O
in	O
CSC	O
-	O
low	O
cultures	O
/	O
tumors	O
.	O

These	O
results	O
suggest	O
that	O
CSC	O
contribute	O
to	O
tumor	O
angiogenesis	O
by	O
promoting	O
both	O
local	O
endothelial	O
cell	O
activity	O
and	O
systemic	O
angiogenic	O
processes	O
involving	O
bone	O
marrow	O
-	O
derived	O
EPC	O
in	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
dependent	O
and	O
stromal	O
-	O
derived	O
factor	O
1	O
-	O
dependent	O
manner	O
.	O

Islet	O
endothelial	O
activation	O
and	O
oxidative	O
stress	O
gene	O
expression	O
is	O
reduced	O
by	O
IL	O
-	O
1Ra	O
treatment	O
in	O
the	O
type	O
2	O
diabetic	O
GK	O
rat	O
.	O

BACKGROUND	O
:	O
Inflammation	O
followed	O
by	O
fibrosis	O
is	O
a	O
component	O
of	O
islet	O
dysfunction	O
in	O
both	O
rodent	O
and	O
human	O
type	O
2	O
diabetes	O
.	O

Because	O
islet	O
inflammation	O
may	O
originate	O
from	O
endothelial	O
cells	O
,	O
we	O
assessed	O
the	O
expression	O
of	O
selected	O
genes	O
involved	O
in	O
endothelial	O
cell	O
activation	O
in	O
islets	O
from	O
a	O
spontaneous	O
model	O
of	O
type	O
2	O
diabetes	O
,	O
the	O
Goto	O
-	O
Kakizaki	O
(	O
GK	O
)	O
rat	O
.	O

We	O
also	O
examined	O
islet	O
endotheliuml	O
/	O
oxidative	O
stress	O
(	O
OS	O
)	O
/	O
inflammation	O
-	O
related	O
gene	O
expression	O
,	O
islet	O
vascularization	O
and	O
fibrosis	O
after	O
treatment	O
with	O
the	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
on	O
islets	O
isolated	O
from	O
10	O
-	O
week	O
-	O
old	O
diabetic	O
GK	O
and	O
control	O
Wistar	O
rats	O
.	O

Furthermore	O
,	O
GK	O
rats	O
were	O
treated	O
s	O
.	O
c	O
twice	O
daily	O
with	O
IL	O
-	O
1Ra	O
(	O
Kineret	O
,	O
Amgen	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
saline	O
,	O
from	O
4	O
weeks	O
of	O
age	O
onwards	O
(	O
onset	O
of	O
diabetes	O
)	O
.	O

Four	O
weeks	O
later	O
,	O
islet	O
gene	O
analysis	O
and	O
pancreas	O
immunochemistry	O
were	O
performed	O
.	O

Thirty	O
-	O
two	O
genes	O
were	O
selected	O
encoding	O
molecules	O
involved	O
in	O
endothelial	O
cell	O
activation	O
,	O
particularly	O
fibrinolysis	O
,	O
vascular	O
tone	O
,	O
OS	O
,	O
angiogenesis	O
and	O
also	O
inflammation	O
.	O

All	O
genes	O
except	O
those	O
encoding	O
angiotensinogen	O
and	O
epoxide	O
hydrolase	O
(	O
that	O
were	O
decreased	O
)	O
,	O
and	O
12	O
-	O
lipoxygenase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
that	O
showed	O
no	O
change	O
)	O
,	O
were	O
significantly	O
up	O
-	O
regulated	O
in	O
GK	O
islets	O
.	O

After	O
IL	O
-	O
1Ra	O
treatment	O
of	O
GK	O
rats	O
in	O
vivo	O
,	O
most	O
selected	O
genes	O
implied	O
in	O
endothelium	O
/	O
OS	O
/	O
immune	O
cells	O
/	O
fibrosis	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

IL	O
-	O
1Ra	O
also	O
improved	O
islet	O
vascularization	O
,	O
reduced	O
fibrosis	O
and	O
ameliorated	O
glycemia	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
GK	O
rat	O
islets	O
have	O
increased	O
mRNA	O
expression	O
of	O
markers	O
of	O
early	O
islet	O
endothelial	O
cell	O
activation	O
,	O
possibly	O
triggered	O
by	O
several	O
metabolic	O
factors	O
,	O
and	O
also	O
some	O
defense	O
mechanisms	O
.	O

The	O
beneficial	O
effect	O
of	O
IL	O
-	O
1Ra	O
on	O
most	O
islet	O
endothelial	O
/	O
OS	O
/	O
immune	O
cells	O
/	O
fibrosis	O
parameters	O
analyzed	O
highlights	O
a	O
major	O
endothelial	O
-	O
related	O
role	O
for	O
IL	O
-	O
1	O
in	O
GK	O
islet	O
alterations	O
.	O

Thus	O
,	O
metabolically	O
-	O
altered	O
islet	O
endothelium	O
might	O
affect	O
the	O
beta	O
-	O
cell	O
microenvironment	O
and	O
contribute	O
to	O
progressive	O
type	O
2	O
diabetic	O
beta	O
-	O
cell	O
dysfunction	O
in	O
GK	O
rats	O
.	O

Counteracting	O
islet	O
endothelial	O
cell	O
inflammation	O
might	O
be	O
one	O
way	O
to	O
ameliorate	O
/	O
prevent	O
beta	O
-	O
cell	O
dysfunction	O
in	O
type	O
2	O
diabetes	O
.	O

Cognitive	O
function	O
and	O
number	O
of	O
teeth	O
in	O
a	O
community	O
-	O
dwelling	O
elderly	O
population	O
without	O
dementia	O
.	O

Although	O
the	O
number	O
of	O
sound	O
or	O
decayed	O
teeth	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
cognitive	O
function	O
in	O
elderly	O
populations	O
with	O
dementia	O
,	O
little	O
is	O
known	O
about	O
this	O
association	O
in	O
elderly	O
populations	O
without	O
dementia	O
.	O

We	O
evaluated	O
this	O
relationship	O
,	O
with	O
adjustment	O
for	O
confounding	O
factors	O
,	O
in	O
Japanese	O
populations	O
of	O
60	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
270	O
;	O
120	O
males	O
and	O
150	O
females	O
)	O
and	O
65	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
123	O
;	O
57	O
males	O
and	O
66	O
females	O
)	O
individuals	O
residing	O
in	O
Fukuoka	O
Prefecture	O
of	O
Japan	O
.	O

Dental	O
examinations	O
were	O
performed	O
in	O
all	O
subjects	O
,	O
along	O
with	O
the	O
Mini	O
-	O
mental	O
state	O
examination	O
(	O
MMSE	O
)	O
for	O
assessing	O
cognitive	O
function	O
.	O

Among	O
the	O
total	O
of	O
393	O
subjects	O
,	O
the	O
mean	O
MMSE	O
score	O
was	O
27	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
and	O
391	O
subjects	O
scored	O
24	O
or	O
higher	O
.	O

The	O
mean	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
were	O
12	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
3	O
and	O
0	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
respectively	O
.	O

Associations	O
were	O
found	O
between	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
and	O
MMSE	O
in	O
total	O
subjects	O
and	O
males	O
,	O
but	O
not	O
in	O
females	O
,	O
by	O
multiple	O
regression	O
analysis	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
level	O
of	O
education	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
working	O
status	O
,	O
systolic	O
blood	O
pressure	O
and	O
blood	O
glucose	O
.	O

An	O
association	O
was	O
also	O
found	O
between	O
MMSE	O
and	O
the	O
number	O
of	O
sound	O
teeth	O
in	O
a	O
logistic	O
regression	O
analysis	O
.	O

In	O
conclusion	O
,	O
associations	O
were	O
found	O
between	O
normal	O
-	O
range	O
cognitive	O
function	O
and	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	O
,	O
after	O
adjustment	O
for	O
various	O
confounding	O
factors	O
,	O
in	O
an	O
elderly	O
Japanese	O
population	O
.	O

Magnesium	O
for	O
treatment	O
of	O
asthma	O
in	O
children	O
.	O

QUESTION	O
:	O
Magnesium	O
is	O
considered	O
adjuvant	O
therapy	O
for	O
moderate	O
to	O
severe	O
asthma	O
exacerbations	O
in	O
adults	O
,	O
but	O
can	O
it	O
be	O
used	O
to	O
treat	O
children	O
?	O

ANSWER	O
:	O
Magnesium	O
seems	O
to	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
asthma	O
in	O
children	O
.	O

It	O
is	O
a	O
safe	O
drug	O
to	O
administer	O
,	O
but	O
there	O
have	O
been	O
minor	O
side	O
effects	O
reported	O
,	O
such	O
as	O
epigastric	O
or	O
facial	O
warmth	O
,	O
flushing	O
,	O
pain	O
and	O
numbness	O
at	O
the	O
infusion	O
site	O
,	O
dry	O
mouth	O
,	O
malaise	O
,	O
and	O
hypotension	O
.	O

Owing	O
to	O
its	O
bronchodilating	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
magnesium	O
is	O
an	O
encouraging	O
adjuvant	O
therapy	O
for	O
pediatric	O
patients	O
who	O
do	O
not	O
respond	O
to	O
conventional	O
treatment	O
in	O
acute	O
severe	O
exacerbations	O
.	O

Future	O
studies	O
should	O
focus	O
on	O
establishing	O
the	O
optimal	O
dosage	O
for	O
maximal	O
benefits	O
and	O
the	O
best	O
route	O
of	O
administration	O
.	O

Magnesium	O
should	O
also	O
be	O
considered	O
as	O
a	O
prophylactic	O
treatment	O
.	O

AVE8062	O
:	O
a	O
new	O
combretastatin	O
derivative	O
vascular	O
disrupting	O
agent	O
.	O

Angiogenesis	O
has	O
an	O
essential	O
role	O
in	O
promoting	O
and	O
supporting	O
tumor	O
growth	O
and	O
it	O
is	O
an	O
important	O
therapeutic	O
target	O
.	O

The	O
tumor	O
vascular	O
network	O
is	O
the	O
result	O
of	O
pro	O
-	O
angiogenic	O
and	O
inhibitory	O
factors	O
as	O
well	O
as	O
of	O
the	O
interaction	O
between	O
endothelial	O
cells	O
and	O
extracellular	O
matrix	O
.	O

Different	O
antiangiogenic	O
therapeutics	O
have	O
been	O
developed	O
to	O
improve	O
tumor	O
control	O
through	O
vascular	O
-	O
targeting	O
agents	O
(	O
VTA	O
)	O
.	O

VTAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
antiangiogenic	O
agents	O
and	O
vascular	O
-	O
disrupting	O
agents	O
(	O
VDAs	O
)	O
.	O

VTAs	O
inhibit	O
specific	O
factors	O
required	O
to	O
induce	O
and	O
direct	O
the	O
angiogenic	O
process	O
,	O
with	O
major	O
activity	O
against	O
small	O
tumor	O
masses	O
and	O
at	O
the	O
tumor	O
periphery	O
,	O
encompassing	O
monoclonal	O
antibodies	O
and	O
small	O
molecules	O
inhibitors	O
of	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
VEGF	O
receptor	O
.	O

VDAs	O
specifically	O
target	O
and	O
destroy	O
well	O
-	O
established	O
tumor	O
vessels	O
with	O
ischemia	O
and	O
destruction	O
of	O
large	O
masses	O
with	O
central	O
hemorrhagic	O
necrosis	O
and	O
survival	O
of	O
a	O
thin	O
peripheral	O
tumor	O
layer	O
.	O

VDAs	O
can	O
be	O
divided	O
into	O
biologics	O
,	O
such	O
as	O
ligand	O
-	O
based	O
,	O
and	O
small	O
-	O
molecule	O
agents	O
;	O
this	O
second	O
group	O
includes	O
small	O
-	O
molecule	O
VDAs	O
like	O
flavonoids	O
,	O
such	O
as	O
5	O
,	O
6	O
-	O
dimethylxanthenone	O
-	O
4	O
-	O
acetic	O
acid	O
(	O
DMXAA	O
)	O
,	O
and	O
microtubule	O
-	O
destabilizing	O
agents	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
mechanism	O
of	O
action	O
,	O
as	O
well	O
as	O
the	O
preclinical	O
and	O
clinical	O
results	O
,	O
of	O
one	O
of	O
the	O
most	O
promising	O
antitubulin	O
agents	O
:	O
the	O
combretastatin	O
A4	O
-	O
phosphate	O
derivative	O
,	O
AVE8062A	O
.	O

Targeting	O
TNF	O
for	O
Treatment	O
of	O
Cancer	O
and	O
Autoimmunity	O
.	O

Tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
was	O
first	O
isolated	O
two	O
decades	O
ago	O
as	O
a	O
macrophageproduced	O
protein	O
that	O
can	O
effectively	O
kill	O
tumor	O
cells	O
.	O

TNF	O
-	O
alpha	O
is	O
also	O
an	O
essential	O
component	O
of	O
the	O
immune	O
system	O
and	O
is	O
required	O
for	O
hematopoiesis	O
,	O
for	O
protection	O
from	O
bacterial	O
infection	O
and	O
for	O
immune	O
cell	O
-	O
mediated	O
cytotoxicity	O
.	O

Extensive	O
research	O
,	O
however	O
,	O
has	O
revealed	O
that	O
TNF	O
-	O
alpha	O
is	O
one	O
of	O
the	O
major	O
players	O
in	O
tumor	O
initiation	O
,	O
proliferation	O
,	O
invasion	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

The	O
proinflammatory	O
activities	O
link	O
TNF	O
-	O
alpha	O
with	O
a	O
wide	O
variety	O
of	O
autoimmune	O
diseases	O
,	O
including	O
psoriasis	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
sclerosis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
multiple	O
sclerosis	O
,	O
diabetes	O
and	O
ankylosing	O
spondylitis	O
.	O

Systemic	O
inhibitors	O
of	O
TNF	O
such	O
as	O
etanercept	O
(	O
Enbrel	O
)	O
(	O
a	O
soluble	O
TNF	O
receptor	O
)	O
and	O
infliximab	O
(	O
Remicade	O
)	O
and	O
adalimumab	O
(	O
Humira	O
)	O
(	O
anti	O
-	O
TNF	O
antibodies	O
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
inflammatory	O
bowel	O
disease	O
,	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

These	O
drugs	O
,	O
however	O
,	O
exhibit	O
severe	O
side	O
effects	O
and	O
are	O
expensive	O
.	O

Hence	O
orally	O
active	O
blockers	O
of	O
TNF	O
-	O
alpha	O
that	O
are	O
safe	O
,	O
efficacious	O
and	O
inexpensive	O
are	O
urgently	O
needed	O
.	O

Numerous	O
products	O
from	O
fruits	O
,	O
vegetable	O
and	O
traditional	O
medicinal	O
plants	O
have	O
been	O
described	O
which	O
can	O
suppress	O
TNF	O
expression	O
and	O
TNF	O
signaling	O
but	O
their	O
clinical	O
potential	O
is	O
yet	O
uncertain	O
.	O

[	O
Prognostic	O
significance	O
of	O
cellular	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
in	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
]	O

INTRODUCTION	O
:	O
Increased	O
angiogenesis	O
in	O
bone	O
marrow	O
is	O
one	O
of	O
the	O
characteristics	O
of	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
,	O
a	O
clonal	O
myeloproliferative	O
disorder	O
that	O
expresses	O
a	O
chimeric	O
bcr	O
/	O
abl	O
protein	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
potent	O
and	O
a	O
specific	O
regulator	O
of	O
angiogenesis	O
which	O
principally	O
targets	O
endothelial	O
cells	O
and	O
regulates	O
several	O
of	O
their	O
functions	O
,	O
including	O
mitogenesis	O
,	O
permeability	O
and	O
migration	O
.	O

The	O
impact	O
of	O
elevated	O
VEGF	O
expression	O
on	O
the	O
course	O
of	O
chronic	O
myeloid	O
leukaemia	O
is	O
unknown	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
the	O
follow	O
-	O
up	O
of	O
VEGF	O
expression	O
during	O
the	O
course	O
of	O
CML	O
.	O

METHODS	O
:	O
We	O
studied	O
VEGF	O
expression	O
of	O
85	O
CML	O
patients	O
(	O
median	O
age	O
50	O
years	O
,	O
range	O
16	O
-	O
75	O
years	O
)	O
.	O

At	O
the	O
commencement	O
of	O
the	O
study	O
,	O
29	O
patients	O
were	O
in	O
chronic	O
phase	O
(	O
CP	O
)	O
,	O
25	O
in	O
an	O
accelerated	O
phase	O
(	O
AP	O
)	O
,	O
and	O
31	O
in	O
the	O
blast	O
crisis	O
(	O
BC	O
)	O
.	O

The	O
temporal	O
expression	O
(	O
percentage	O
positivity	O
per	O
1000	O
analysed	O
cells	O
)	O
VEGF	O
proteins	O
over	O
the	O
course	O
of	O
CML	O
were	O
studied	O
using	O
the	O
immunohistochemical	O
technique	O
utilizing	O
relevant	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
correlated	O
with	O
the	O
laboratory	O
(	O
Hb	O
,	O
WBC	O
and	O
platelet	O
counts	O
,	O
and	O
the	O
percentage	O
of	O
blasts	O
)	O
and	O
clinical	O
parameters	O
(	O
organomegaly	O
,	O
duration	O
of	O
CP	O
,	O
AP	O
,	O
and	O
BC	O
)	O
of	O
disease	O
progression	O
.	O

RESULTS	O
:	O
The	O
expression	O
ofVEGF	O
protein	O
was	O
most	O
pronounced	O
in	O
AP	O
(	O
ANOVA	O
,	O
p	O
=	O
0	O
.	O
033	O
)	O
.	O

The	O
level	O
of	O
VEGF	O
expression	O
correlated	O
inversely	O
with	O
the	O
degree	O
of	O
splenomegaly	O
(	O
Pearson	O
,	O
r	O
=	O
-	O
0	O
.	O
400	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

High	O
expression	O
of	O
VEGF	O
correlated	O
with	O
a	O
shorter	O
overall	O
survival	O
(	O
log	O
rank	O
,	O
p	O
=	O
0	O
.	O
042	O
)	O
.	O

CONCLUSION	O
:	O
Immunohistochemically	O
confirmed	O
significance	O
of	O
the	O
expression	O
of	O
VEGF	O
in	O
dependence	O
of	O
the	O
CML	O
stage	O
could	O
be	O
of	O
clinical	O
importance	O
in	O
deciding	O
on	O
the	O
timing	O
therapy	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
role	O
in	O
the	O
biology	O
of	O
CML	O
and	O
that	O
VEGF	O
inhibitors	O
should	O
be	O
investigated	O
in	O
CML	O
.	O

Pbx1	O
is	O
a	O
downstream	O
target	O
of	O
Evi	O
-	O
1	O
in	O
hematopoietic	O
stem	O
/	O
progenitors	O
and	O
leukemic	O
cells	O
.	O

Ecotropic	O
viral	O
integration	O
site	O
-	O
1	O
(	O
Evi	O
-	O
1	O
)	O
is	O
a	O
nuclear	O
transcription	O
factor	O
,	O
which	O
is	O
essential	O
for	O
the	O
proliferation	O
/	O
maintenance	O
of	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
.	O

Aberrant	O
expression	O
of	O
Evi	O
-	O
1	O
has	O
been	O
frequently	O
found	O
in	O
myeloid	O
leukemia	O
,	O
and	O
is	O
associated	O
with	O
a	O
poor	O
patient	O
survival	O
.	O

Recently	O
,	O
we	O
reported	O
candidate	O
target	O
genes	O
of	O
Evi	O
-	O
1	O
shared	O
in	O
HSCs	O
and	O
leukemic	O
cells	O
using	O
gene	O
expression	O
profiling	O
analysis	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
Pbx1	O
,	O
a	O
proto	O
-	O
oncogene	O
in	O
hematopoietic	O
malignancy	O
,	O
as	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
.	O

Overexpression	O
of	O
Evi	O
-	O
1	O
increased	O
Pbx1	O
expression	O
in	O
hematopoietic	O
stem	O
/	O
progenitor	O
cells	O
.	O

An	O
analysis	O
of	O
the	O
Pbx1	O
promoter	O
region	O
revealed	O
that	O
Evi	O
-	O
1	O
upregulates	O
Pbx1	O
transcription	O
.	O

Furthermore	O
,	O
reduction	O
of	O
Pbx1	O
levels	O
through	O
RNAi	O
-	O
mediated	O
knockdown	O
significantly	O
inhibited	O
Evi	O
-	O
1	O
-	O
induced	O
transformation	O
.	O

In	O
contrast	O
,	O
knockdown	O
of	O
Pbx1	O
did	O
not	O
impair	O
bone	O
marrow	O
transformation	O
by	O
E2A	O
/	O
HLF	O
or	O
AML1	O
/	O
ETO	O
,	O
suggesting	O
that	O
Pbx1	O
is	O
specifically	O
required	O
for	O
the	O
maintenance	O
of	O
bone	O
marrow	O
transformation	O
mediated	O
by	O
Evi	O
-	O
1	O
.	O

These	O
results	O
indicate	O
that	O
Pbx1	O
is	O
a	O
target	O
gene	O
of	O
Evi	O
-	O
1	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
mediated	O
leukemogenesis	O
.	O

Inducible	O
nitric	O
oxide	O
synthase	O
modulates	O
angiogenesis	O
in	O
ischemic	O
hindlimb	O
of	O
rat	O
.	O

BACKGROUND	O
:	O
Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
adequate	O
oxygen	O
delivery	O
,	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
is	O
a	O
potential	O
regulator	O
of	O
angiogenesis	O
.	O

NO	O
is	O
synthesized	O
through	O
three	O
isoforms	O
of	O
NO	O
synthase	O
(	O
NOS	O
)	O
.	O

It	O
is	O
hypothesized	O
that	O
the	O
NO	O
derived	O
from	O
inducible	O
NOS	O
(	O
iNOS	O
)	O
may	O
promote	O
survival	O
of	O
ischemic	O
tissue	O
through	O
angiogenesis	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
iNOS	O
deficiency	O
(	O
by	O
L	O
-	O
NIL	O
)	O
on	O
angiogenesis	O
in	O
a	O
hindlimb	O
ischemia	O
model	O
.	O

METHODS	O
:	O
Thirty	O
-	O
two	O
male	O
wistar	O
rats	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

In	O
groups	O
1	O
&	O
2	O
,	O
hindlimb	O
ischemia	O
was	O
induced	O
by	O
ligation	O
of	O
femoral	O
artery	O
and	O
they	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
.	O

The	O
animals	O
in	O
groups	O
3	O
and	O
4	O
also	O
received	O
L	O
-	O
NIL	O
and	O
saline	O
respectively	O
without	O
surgical	O
procedure	O
.	O

After	O
21	O
days	O
,	O
the	O
serum	O
concentration	O
of	O
nitrite	O
,	O
capillary	O
density	O
and	O
expression	O
of	O
HIF1alpha	O
were	O
determined	O
.	O

RESULTS	O
:	O
Serum	O
nitrite	O
levels	O
were	O
significantly	O
lower	O
in	O
L	O
-	O
NIL	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
capillary	O
density	O
in	O
group	O
1	O
(	O
ischemia	O
+	O
L	O
-	O
NIL	O
)	O
was	O
significantly	O
different	O
from	O
group	O
2	O
(	O
ischemia	O
+	O
saline	O
)	O
;	O
group	O
1	O
:	O
360	O
.	O
33	O
+	O
/	O
-	O
77	O
.	O
02	O
,	O
group	O
2	O
:	O
549	O
+	O
/	O
-	O
81	O
.	O
85	O
/	O
mm2	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
In	O
addition	O
,	O
expression	O
of	O
HIF1alpha	O
was	O
significantly	O
increased	O
in	O
ischemic	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Selective	O
inhibition	O
of	O
iNOS	O
by	O
L	O
-	O
NIL	O
inhibits	O
angiogenesis	O
in	O
a	O
hindlimb	O
ischemic	O
rat	O
model	O
.	O

In	O
addition	O
,	O
ischemia	O
induces	O
expression	O
of	O
HIF1alpha	O
in	O
hypoxic	O
tissue	O
.	O

Tumor	O
Angiogenesis	O
:	O
Initiation	O
and	O
Targeting	O
-	O
Therapeutic	O
Targeting	O
of	O
an	O
FGF	O
-	O
Binding	O
Protein	O
,	O
an	O
Angiogenic	O
Switch	O
Molecule	O
,	O
and	O
Indicator	O
of	O
Early	O
Stages	O
of	O
Gastrointestinal	O
Adenocarcinomas	O
-	O
.	O

Tumor	O
angiogenesis	O
has	O
been	O
related	O
to	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
toward	O
more	O
aggressive	O
behavior	O
of	O
human	O
tumors	O
.	O

In	O
particular	O
,	O
the	O
activity	O
of	O
angiogenic	O
factors	O
is	O
crucial	O
for	O
tumor	O
progression	O
.	O

We	O
previously	O
characterized	O
a	O
secreted	O
fibroblast	O
growth	O
factor	O
-	O
binding	O
protein	O
(	O
FGF	O
-	O
BP	O
)	O
as	O
a	O
chaperone	O
molecule	O
,	O
which	O
binds	O
to	O
various	O
FGFs	O
,	O
enhances	O
FGF	O
-	O
mediated	O
biochemical	O
and	O
biologic	O
events	O
and	O
importantly	O
is	O
a	O
crucial	O
rate	O
-	O
limiting	O
factor	O
for	O
tumor	O
-	O
dependent	O
angiogenesis	O
.	O

We	O
generated	O
monoclonal	O
antibodies	O
that	O
target	O
FGF	O
-	O
BP	O
protein	O
and	O
used	O
them	O
as	O
a	O
tool	O
to	O
evaluate	O
frequency	O
and	O
pattern	O
of	O
FGF	O
-	O
BP	O
expression	O
during	O
the	O
malignant	O
progression	O
of	O
pancreas	O
and	O
colorectal	O
carcinoma	O
in	O
archival	O
tissue	O
samples	O
.	O

We	O
found	O
that	O
FGF	O
-	O
BP	O
is	O
dramatically	O
upregulated	O
during	O
the	O
initiation	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
.	O

Crucial	O
genetic	O
events	O
underlying	O
the	O
initiation	O
and	O
progression	O
of	O
colorectal	O
and	O
pancreatic	O
adenocarcinoma	O
with	O
a	O
particular	O
focus	O
on	O
the	O
modulation	O
of	O
angiogenesis	O
and	O
antiangiogenic	O
therapies	O
are	O
discussed	O
.	O

We	O
propose	O
that	O
the	O
upregulation	O
of	O
the	O
secreted	O
FGF	O
-	O
BP	O
protein	O
during	O
early	O
phases	O
of	O
pancreas	O
and	O
colon	O
cancer	O
could	O
make	O
this	O
protein	O
a	O
possible	O
serum	O
marker	O
indicating	O
the	O
presence	O
of	O
high	O
-	O
risk	O
premalignant	O
lesions	O
.	O

Furthermore	O
,	O
the	O
biological	O
activity	O
of	O
FGF	O
-	O
BP	O
is	O
neutralized	O
by	O
monoclonal	O
antibodies	O
suggesting	O
the	O
potential	O
for	O
antibody	O
-	O
based	O
therapeutic	O
targeting	O
.	O

Range	O
of	O
motion	O
limitation	O
after	O
rotator	O
cuff	O
repair	O
.	O

HYPOTHESIS	O
:	O

This	O
study	O
was	O
conducted	O
to	O
identify	O
preoperative	O
factors	O
correlating	O
with	O
limited	O
motion	O
after	O
rotator	O
cuff	O
repair	O
(	O
RCR	O
)	O
and	O
to	O
evaluate	O
the	O
affect	O
of	O
loss	O
of	O
motion	O
on	O
outcome	O
.	O

We	O
hypothesized	O
that	O
patients	O
with	O
preoperative	O
ROM	O
loss	O
,	O
diabetes	O
,	O
and	O
workman	O
'	O
s	O
compensation	O
claims	O
would	O
exhibit	O
postoperative	O
ROM	O
loss	O
at	O
3	O
months	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O

Preoperative	O
and	O
postoperative	O
evaluations	O
,	O
including	O
outcomes	O
assessment	O
and	O
physical	O
examination	O
parameters	O
,	O
were	O
reviewed	O
for	O
345	O
patients	O
who	O
underwent	O
RCR	O
.	O

Correlations	O
between	O
demographic	O
,	O
physical	O
examination	O
,	O
and	O
surgical	O
variables	O
and	O
postoperative	O
limitation	O
of	O
motion	O
and	O
need	O
for	O
capsular	O
release	O
were	O
determined	O
.	O

RESULTS	O
:	O

At	O
3	O
-	O
month	O
follow	O
-	O
up	O
,	O
mean	O
active	O
forward	O
elevation	O
(	O
AFE	O
)	O
,	O
active	O
external	O
rotation	O
(	O
AER	O
)	O
,	O
and	O
passive	O
internal	O
rotation	O
(	O
PIR	O
)	O
were	O
90	O
%	O
,	O
78	O
%	O
,	O
and	O
80	O
%	O
of	O
the	O
contralateral	O
side	O
.	O

Limitation	O
of	O
preoperative	O
motion	O
correlated	O
with	O
limitation	O
of	O
postoperative	O
AFE	O
,	O
AER	O
,	O
and	O
PIR	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Forty	O
-	O
seven	O
patients	O
considered	O
clinically	O
stiff	O
were	O
followed	O
at	O
1	O
year	O
postoperatively	O
.	O

Three	O
patients	O
required	O
arthroscopic	O
capsular	O
release	O
for	O
persistent	O
range	O
of	O
motion	O
loss	O
.	O

CONCLUSION	O
:	O

Early	O
postoperative	O
limitation	O
of	O
motion	O
after	O
RCR	O
is	O
associated	O
with	O
restricted	O
preoperative	O
motion	O
.	O

Other	O
factors	O
,	O
including	O
diabetes	O
mellitus	O
and	O
worker	O
'	O
s	O
compensation	O
claim	O
,	O
are	O
also	O
associated	O
with	O
range	O
of	O
motion	O
loss	O
.	O

Most	O
shoulders	O
with	O
early	O
motion	O
loss	O
recover	O
motion	O
and	O
rarely	O
require	O
capsular	O
release	O
.	O

[	O
Effect	O
of	O
osteopontin	O
silencing	O
by	O
lentivirus	O
-	O
mediated	O
delivery	O
of	O
siRNA	O
on	O
glioma	O
cell	O
invasion	O
and	O
apoptosis	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
osteopontin	O
silencing	O
on	O
the	O
invasion	O
and	O
apoptosis	O
of	O
U251	B
cells	O
.	O

METHODS	O
:	O
The	O
invasion	O
,	O
apoptosis	O
and	O
levels	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
were	O
determined	O
by	O
invasion	O
assay	O
,	O
flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
respectively	O
.	O

RESULTS	O
:	O
Osteopontin	O
small	O
interference	O
RNA	O
(	O
siRNA	O
)	O
inhibited	O
osteopontin	O
expression	O
and	O
cell	O
invasion	O
,	O
promoted	O
apoptosis	O
in	O
U251	B
cells	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
was	O
decreased	O
,	O
while	O
Bax	O
level	O
was	O
elevated	O
.	O

CONCLUSION	O
:	O
Osteopontin	O
siRNA	O
can	O
inhibit	O
U251	B
cells	O
invasion	O
via	O
the	O
down	O
-	O
regulation	O
of	O
uPA	O
,	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
levels	O
,	O
and	O
promote	O
apoptosis	O
through	O
induction	O
of	O
Bax	O
expression	O
and	O
inhibition	O
of	O
Bcl	O
2	O
level	O
.	O

It	O
suggests	O
that	O
osteopontin	O
plays	O
an	O
important	O
role	O
in	O
human	O
glioma	O
progression	O
.	O

The	O
role	O
of	O
hypoxia	O
in	O
2	O
-	O
butoxyethanol	O
-	O
induced	O
hemangiosarcoma	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
compound	O
-	O
induced	O
hemangiosarcomas	O
in	O
mice	O
,	O
and	O
therefore	O
,	O
their	O
human	O
relevance	O
,	O
a	O
systems	O
biology	O
approach	O
was	O
undertaken	O
using	O
transcriptomics	O
and	O
Causal	O
Network	O
Modeling	O
from	O
mice	O
treated	O
with	O
2	O
-	O
butoxyethanol	O
(	O
2	O
-	O
BE	O
)	O
.	O

2	O
-	O
BE	O
is	O
a	O
hemolytic	O
agent	O
that	O
induces	O
hemangiosarcomas	O
in	O
mice	O
.	O

We	O
hypothesized	O
that	O
the	O
hemolysis	O
induced	O
by	O
2	O
-	O
BE	O
would	O
result	O
in	O
local	O
tissue	O
hypoxia	O
,	O
a	O
well	O
-	O
documented	O
trigger	O
for	O
endothelial	O
cell	O
proliferation	O
leading	O
to	O
hemangiosarcoma	O
.	O

Gene	O
expression	O
data	O
from	O
bone	O
marrow	O
(	O
BM	O
)	O
,	O
liver	O
,	O
and	O
spleen	O
of	O
mice	O
exposed	O
to	O
a	O
single	O
dose	O
(	O
4	O
h	O
)	O
or	O
seven	O
daily	O
doses	O
of	O
2	O
-	O
BE	O
were	O
used	O
to	O
develop	O
a	O
mechanistic	O
model	O
of	O
hemangiosarcoma	O
.	O

The	O
resulting	O
mechanistic	O
model	O
confirms	O
previous	O
work	O
proposing	O
that	O
2	O
-	O
BE	O
induces	O
macrophage	O
activation	O
and	O
inflammation	O
in	O
the	O
liver	O
.	O

In	O
addition	O
,	O
the	O
model	O
supports	O
local	O
tissue	O
hypoxia	O
in	O
the	O
liver	O
and	O
spleen	O
,	O
coupled	O
with	O
increased	O
erythropoeitin	O
signaling	O
and	O
erythropoiesis	O
in	O
the	O
spleen	O
and	O
BM	O
,	O
and	O
suppression	O
of	O
mechanisms	O
that	O
contribute	O
to	O
genomic	O
stability	O
,	O
events	O
that	O
could	O
be	O
contributing	O
factors	O
to	O
hemangiosarcoma	O
formation	O
.	O

Finally	O
,	O
an	O
immunohistochemistry	O
method	O
(	O
Hypoxyprobe	O
)	O
demonstrated	O
that	O
tissue	O
hypoxia	O
was	O
present	O
in	O
the	O
spleen	O
and	O
BM	O
.	O

Together	O
,	O
the	O
results	O
of	O
this	O
study	O
identify	O
molecular	O
mechanisms	O
that	O
initiate	O
hemangiosarcoma	O
,	O
a	O
key	O
step	O
in	O
understanding	O
safety	O
concerns	O
that	O
can	O
impact	O
drug	O
decision	O
processes	O
,	O
and	O
identified	O
hypoxia	O
as	O
a	O
possible	O
contributing	O
factor	O
for	O
2	O
-	O
BE	O
-	O
induced	O
hemangiosarcoma	O
in	O
mice	O
.	O

Magnitude	O
of	O
malate	O
-	O
aspartate	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
shuttle	O
activity	O
in	O
intact	O
respiring	O
tumor	O
cells	O
.	O

Measurements	O
of	O
respiration	O
,	O
CO2	O
and	O
lactate	O
production	O
,	O
and	O
changes	O
in	O
the	O
levels	O
of	O
various	O
key	O
metabolites	O
of	O
the	O
glycolytic	O
sequence	O
and	O
tricarboxylic	O
acid	O
cycle	O
were	O
made	O
on	O
five	O
lines	O
of	O
rodent	O
ascites	O
tumor	O
cells	O
(	O
two	O
strains	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
,	O
Krebs	B
II	I
carcinoma	O
,	O
AS	B
-	I
30D	I
carcinoma	O
,	O
and	O
L1210	B
cells	O
)	O
incubated	O
aerobically	O
in	O
the	O
presence	O
of	O
uniformly	O
labeled	O
D	O
-	O
[	O
14C	O
]	O
glucose	O
.	O

From	O
these	O
data	O
,	O
as	O
well	O
as	O
earlier	O
evidence	O
demonstrating	O
that	O
the	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NADH	O
)	O
shuttle	O
in	O
these	O
cells	O
requires	O
a	O
transaminase	O
step	O
and	O
is	O
thus	O
identified	O
as	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
(	O
W	O
.	O
V	O
.	O
V	O
.	O
Greenhouse	O
and	O
A	O
.	O
L	O
.	O
Lehninger	O
,	O
Cancer	O
Res	O
.	O
,	O
36	O
:	O
1392	O
-	O
1396	O
,	O
1976	O
)	O
,	O
metabolic	O
flux	O
diagrams	O
were	O
constructed	O
for	O
the	O
five	O
cell	O
lines	O
.	O

These	O
diagrams	O
show	O
the	O
relative	O
rates	O
of	O
glycolysis	O
,	O
the	O
tricarboxylic	O
acid	O
cycle	O
,	O
electron	O
transport	O
,	O
and	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
in	O
these	O
tumors	O
.	O

Large	O
amounts	O
of	O
cytosolic	O
NADH	O
were	O
oxidized	O
by	O
the	O
mitochondrial	O
respiratory	O
chain	O
via	O
the	O
NADH	O
shuttle	O
,	O
comprising	O
anywhere	O
from	O
about	O
20	O
to	O
80	O
%	O
of	O
the	O
total	O
flow	O
of	O
reducing	O
equivalents	O
to	O
oxygen	O
in	O
these	O
tumors	O
.	O

Calculations	O
of	O
the	O
sources	O
of	O
energy	O
for	O
adenosine	O
triphosphate	O
synthesis	O
indicated	O
that	O
on	O
the	O
average	O
about	O
one	O
-	O
third	O
of	O
the	O
respiratory	O
adenosine	O
triphosphate	O
is	O
generated	O
by	O
electron	O
flow	O
originating	O
from	O
cytosolic	O
NADH	O
via	O
the	O
malate	O
-	O
aspartate	O
shuttle	O
.	O

AKT2	O
is	O
a	O
downstream	O
target	O
of	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
.	O

We	O
reported	O
earlier	O
on	O
the	O
oncogenic	O
properties	O
of	O
Grm1	O
by	O
demonstrating	O
that	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
clones	O
proliferate	O
in	O
the	O
absence	O
of	O
growth	O
supplement	O
and	O
anchorage	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
these	O
clones	O
also	O
exhibit	O
aggressive	O
tumorigenic	O
phenotypes	O
in	O
vivo	O
with	O
short	O
latency	O
in	O
tumor	O
formation	O
in	O
both	O
immunodeficient	O
and	O
syngeneic	O
mice	O
.	O

We	O
also	O
detected	O
strong	O
activation	O
of	O
AKT	O
in	O
allograft	O
tumors	O
specifically	O
AKT2	O
as	O
the	O
predominant	O
isoform	O
involved	O
.	O

In	O
parallel	O
,	O
we	O
assessed	O
several	O
human	O
melanoma	O
biopsy	O
samples	O
and	O
found	O
again	O
that	O
AKT2	O
was	O
the	O
predominantly	O
activated	O
AKT	O
in	O
these	O
human	O
melanoma	O
biopsies	O
.	O

In	O
cultured	O
stable	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
clones	O
,	O
as	O
well	O
as	O
an	O
metabotropic	O
glutamate	O
receptor	O
1	O
(	O
Grm1	O
)	O
expressing	O
human	O
melanoma	O
cell	O
line	O
,	O
C8161	B
,	O
stimulation	O
of	O
Grm1	O
by	O
its	O
agonist	O
led	O
to	O
the	O
activation	O
of	O
AKT	O
,	O
while	O
preincubation	O
with	O
Grm1	O
-	O
antagonist	O
abolished	O
Grm1	O
-	O
agonist	O
-	O
induced	O
AKT	O
activation	O
.	O

In	O
addition	O
,	O
a	O
reduction	O
in	O
tumor	O
volume	O
of	O
Grm1	O
-	O
mouse	O
-	O
melanocytic	O
-	O
allografts	O
was	O
detected	O
in	O
the	O
presence	O
of	O
small	O
interfering	O
AKT2	O
RNA	O
(	O
siAKT2	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
showed	O
that	O
,	O
in	O
addition	O
to	O
the	O
MAPK	O
pathway	O
previously	O
reported	O
being	O
a	O
downstream	O
target	O
of	O
stimulated	O
Grm1	O
,	O
AKT2	O
is	O
another	O
downstream	O
target	O
in	O
Grm1	O
mediated	O
melanocyte	O
transformation	O
.	O

Pancreatic	O
endocrine	O
tumors	O
:	O
expression	O
profiling	O
evidences	O
a	O
role	O
for	O
AKT	O
-	O
mTOR	O
pathway	O
.	O

PURPOSE	O
:	O
We	O
investigated	O
the	O
global	O
gene	O
expression	O
in	O
a	O
large	O
panel	O
of	O
pancreatic	O
endocrine	O
tumors	O
(	O
PETs	O
)	O
aimed	O
at	O
identifying	O
new	O
potential	O
targets	O
for	O
therapy	O
and	O
biomarkers	O
to	O
predict	O
patient	O
outcome	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Using	O
a	O
custom	O
microarray	O
,	O
we	O
analyzed	O
72	O
primary	O
PETs	O
,	O
seven	O
matched	O
metastases	O
,	O
and	O
10	O
normal	O
pancreatic	O
samples	O
.	O

Relevant	O
differentially	O
expressed	O
genes	O
were	O
validated	O
by	O
either	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
or	O
immunohistochemistry	O
on	O
tissue	O
microarrays	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
:	O
tuberous	O
sclerosis	O
2	O
(	O
TSC2	O
)	O
and	O
phosphatase	O
and	O
tensin	O
homolog	O
(	O
PTEN	O
)	O
were	O
downregulated	O
in	O
most	O
of	O
the	O
primary	O
tumors	O
,	O
and	O
their	O
low	O
expression	O
was	O
significantly	O
associated	O
with	O
shorter	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
;	O
somatostatin	O
receptor	O
2	O
(	O
SSTR2	O
)	O
was	O
absent	O
or	O
very	O
low	O
in	O
insulinomas	O
compared	O
with	O
nonfunctioning	O
tumors	O
;	O
and	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
13	O
(	O
FGF13	O
)	O
gene	O
was	O
significantly	O
associated	O
with	O
the	O
occurrence	O
of	O
liver	O
metastasis	O
and	O
shorter	O
disease	O
-	O
free	O
survival	O
.	O

TSC2	O
and	O
PTEN	O
are	O
two	O
key	O
inhibitors	O
of	O
the	O
Akt	O
/	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
and	O
the	O
specific	O
inhibition	O
of	O
mTOR	O
with	O
rapamycin	O
or	O
RAD001	O
inhibited	O
cell	O
proliferation	O
of	O
PET	O
cell	O
lines	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
strongly	O
support	O
a	O
role	O
for	O
PI3	O
K	O
/	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
PET	O
,	O
which	O
ties	O
in	O
with	O
the	O
fact	O
that	O
mTOR	O
inhibitors	O
have	O
reached	O
phase	O
III	O
trials	O
in	O
neuroendocrine	O
tumors	O
.	O

The	O
finding	O
of	O
differential	O
SSTR	O
expression	O
raises	O
the	O
potential	O
for	O
SSTR	O
expression	O
to	O
be	O
evaluated	O
as	O
a	O
marker	O
of	O
response	O
to	O
somatostatin	O
analogs	O
.	O

Finally	O
,	O
we	O
identified	O
FGF13	O
as	O
a	O
new	O
prognostic	O
marker	O
that	O
predicted	O
poorer	O
outcome	O
in	O
patients	O
who	O
were	O
clinically	O
considered	O
free	O
from	O
disease	O
.	O

Neural	O
network	O
analysis	O
of	O
spectroscopic	O
data	O
of	O
lycopene	O
and	O
beta	O
-	O
carotene	O
content	O
in	O
food	O
samples	O
compared	O
to	O
HPLC	O
-	O
UV	O
-	O
vis	O
.	O

In	O
this	O
study	O
a	O
neural	O
network	O
(	O
NN	O
)	O
model	O
was	O
designed	O
to	O
predict	O
lycopene	O
and	O
beta	O
-	O
carotene	O
concentrations	O
in	O
food	O
samples	O
,	O
combined	O
with	O
a	O
simple	O
and	O
fast	O
technique	O
,	O
such	O
as	O
UV	O
-	O
vis	O
spectroscopy	O
.	O

The	O
measurement	O
of	O
the	O
absorbance	O
at	O
446	O
and	O
502	O
nm	O
of	O
different	O
beta	O
-	O
carotene	O
and	O
lycopene	O
standard	O
mixtures	O
was	O
used	O
to	O
optimize	O
a	O
neural	O
network	O
based	O
on	O
a	O
multilayer	O
perceptron	O
(	O
MLP	O
)	O
(	O
learning	O
and	O
verification	O
process	O
)	O
.	O

Then	O
,	O
for	O
validation	O
purposes	O
,	O
the	O
optimized	O
NN	O
has	O
been	O
applied	O
to	O
determine	O
the	O
concentration	O
of	O
both	O
compounds	O
in	O
food	O
samples	O
(	O
fresh	O
tomato	O
,	O
tomato	O
concentrate	O
,	O
tomato	O
sauce	O
,	O
ketchup	O
,	O
tomato	O
juice	O
,	O
watermelon	O
,	O
medlar	O
,	O
green	O
pepper	O
,	O
and	O
carrots	O
)	O
,	O
comparing	O
the	O
NN	O
results	O
with	O
the	O
known	O
values	O
of	O
these	O
compounds	O
obtained	O
by	O
analytical	O
techniques	O
(	O
UV	O
-	O
vis	O
and	O
HPLC	O
)	O
.	O

It	O
was	O
concluded	O
that	O
when	O
the	O
MLP	O
-	O
NN	O
is	O
used	O
within	O
the	O
range	O
studied	O
,	O
the	O
optimized	O
NN	O
is	O
able	O
to	O
estimate	O
the	O
beta	O
-	O
carotene	O
and	O
lycopene	O
concentrations	O
in	O
food	O
samples	O
with	O
an	O
adequate	O
accuracy	O
,	O
solving	O
the	O
UV	O
-	O
vis	O
interference	O
of	O
beta	O
-	O
carotene	O
and	O
lycopene	O
.	O

Effectiveness	O
of	O
different	O
approaches	O
for	O
establishing	O
cisplatin	O
-	O
induced	O
cochlear	O
lesions	O
in	O
mice	O
.	O

CONCLUSIONS	O
:	O

Mouse	O
cochleae	O
are	O
highly	O
resistant	O
to	O
systemically	O
administered	O
cisplatin	O
.	O

However	O
,	O
cochlear	O
lesions	O
can	O
be	O
produced	O
effectively	O
in	O
mice	O
when	O
cisplatin	O
is	O
applied	O
locally	O
through	O
the	O
round	O
window	O
niche	O
or	O
tympanum	O
.	O

OBJECTIVE	O
:	O

To	O
explore	O
the	O
optimal	O
approach	O
for	O
creating	O
cisplatin	O
-	O
induced	O
cochlear	O
lesions	O
in	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

Cisplatin	O
was	O
administered	O
to	O
adult	O
C57BL	O
/	O
6J	O
mice	O
via	O
four	O
approaches	O
:	O
(	O
1	O
)	O
transtympanic	O
injection	O
,	O
(	O
2	O
)	O
round	O
window	O
niche	O
injection	O
,	O
(	O
3	O
)	O
intraperitoneal	O
injection	O
(	O
i	O
.	O
p	O
.	O
)	O
at	O
4	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
consecutive	O
days	O
,	O
and	O
(	O
4	O
)	O
one	O
15	O
mg	O
/	O
kg	O
dose	O
i	O
.	O
p	O
.	O

The	O
hearing	O
was	O
monitored	O
using	O
frequency	O
-	O
specific	O
auditory	O
brainstem	O
responses	O
(	O
ABRs	O
)	O
and	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
.	O

Cochlear	O
pathology	O
was	O
observed	O
in	O
cochleograms	O
with	O
Harris	O
'	O
hematoxylin	O
staining	O
.	O

RESULTS	O
:	O

Cisplatin	O
applied	O
systemically	O
did	O
not	O
cause	O
any	O
significant	O
ABR	O
threshold	O
elevation	O
across	O
the	O
frequencies	O
tested	O
(	O
2	O
-	O
32	O
kHz	O
)	O
,	O
whereas	O
local	O
application	O
of	O
cisplatin	O
through	O
the	O
round	O
window	O
niche	O
or	O
tympanum	O
resulted	O
in	O
significant	O
ABR	O
threshold	O
elevations	O
from	O
high	O
to	O
medium	O
frequencies	O
.	O

The	O
functional	O
changes	O
were	O
consistent	O
with	O
the	O
cochlear	O
pathology	O
across	O
groups	O
.	O

[	O
Reconstruction	O
of	O
hepatic	O
artery	O
in	O
adult	O
to	O
adult	O
living	O
donor	O
liver	O
transplantation	O
in	O
104	O
patients	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
report	O
the	O
experience	O
of	O
hepatic	O
artery	O
reconstruction	O
with	O
adult	O
-	O
to	O
-	O
adult	O
living	O
donor	O
liver	O
transplantation	O
(	O
ALDLT	O
)	O
using	O
right	O
lobe	O
liver	O
grafts	O
.	O

METHODS	O
:	O

From	O
January	O
2002	O
to	O
August	O
2007	O
,	O
104	O
patients	O
underwent	O
ALDLT	O
using	O
right	O
lobe	O
grafts	O
.	O

Hepatic	O
arteries	O
of	O
donors	O
and	O
recipients	O
were	O
assessed	O
carefully	O
with	O
spiral	O
CT	O
angiography	O
and	O
DSA	O
before	O
ALDLT	O
.	O

All	O
patients	O
underwent	O
reconstruction	O
of	O
hepatic	O
artery	O
between	O
right	O
lobe	O
liver	O
grafts	O
of	O
donor	O
and	O
recipient	O
which	O
included	O
the	O
anastomosis	O
between	O
right	O
hepatic	O
artery	O
of	O
donors	O
and	O
recipients	O
;	O
the	O
reconstruction	O
of	O
right	O
hepatic	O
artery	O
between	O
donor	O
grafts	O
and	O
left	O
hepatic	O
artery	O
of	O
recipients	O
;	O
interpositional	O
bypass	O
using	O
autogenous	O
saphenous	O
vein	O
and	O
cryopreserved	O
iliac	O
artery	O
between	O
right	O
hepatic	O
artery	O
of	O
donors	O
and	O
hepatic	O
artery	O
,	O
common	O
hepatic	O
artery	O
and	O
abdominal	O
aorta	O
of	O
recipients	O
.	O

The	O
microsurgical	O
technique	O
was	O
employed	O
under	O
the	O
magnification	O
of	O
3	O
.	O
5	O
times	O
and	O
operative	O
microscope	O
of	O
5	O
-	O
10	O
times	O
.	O

RESULTS	O
:	O

In	O
these	O
series	O
,	O
HAT	O
occurred	O
in	O
2	O
recipients	O
at	O
Days	O
1	O
and	O
7	O
post	O
-	O
ALDLT	O
(	O
1	O
.	O
9	O
%	O
)	O
.	O

Both	O
were	O
revascularized	O
with	O
autogenous	O
saphenous	O
vein	O
between	O
right	O
hepatic	O
artery	O
of	O
donor	O
and	O
abdominal	O
aorta	O
of	O
recipient	O
.	O

HAT	O
occurred	O
in	O
1	O
recipient	O
at	O
Days	O
90	O
post	O
-	O
ALDLT	O
,	O
but	O
no	O
symptom	O
was	O
presented	O
.	O

There	O
was	O
no	O
severe	O
complication	O
and	O
mortality	O
related	O
to	O
hepatic	O
artery	O
reconstruction	O
in	O
recipients	O
.	O

No	O
HAT	O
,	O
hepatic	O
artery	O
stenosis	O
and	O
aneurysm	O
occurred	O
during	O
the	O
follow	O
-	O
up	O
period	O
of	O
2	O
-	O
60	O
months	O
.	O

The	O
1	O
,	O
2	O
and	O
3	O
-	O
year	O
survival	O
rates	O
were	O
89	O
.	O
3	O
%	O
,	O
76	O
.	O
0	O
%	O
and	O
69	O
.	O
3	O
%	O
respectively	O
.	O

CONCLUSION	O
:	O

Careful	O
evaluation	O
of	O
hepatic	O
artery	O
condition	O
and	O
using	O
microsurgical	O
techniques	O
are	O
important	O
for	O
safer	O
arterial	O
reconstruction	O
and	O
a	O
long	O
-	O
term	O
patency	O
of	O
hepatic	O
artery	O
in	O
living	O
donor	O
liver	O
transplantation	O
in	O
adults	O
using	O
right	O
lobe	O
liver	O
grafts	O
.	O

ICAM	O
-	O
3	O
enhances	O
the	O
migratory	O
and	O
invasive	O
potential	O
of	O
human	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
cells	O
by	O
inducing	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
via	O
Akt	O
and	O
CREB	O
.	O

We	O
have	O
previously	O
reported	O
that	O
intercellular	O
adhesion	O
molecule	O
-	O
3	O
(	O
ICAM	O
-	O
3	O
)	O
is	O
associated	O
with	O
an	O
increase	O
of	O
cellular	O
radio	O
-	O
resistance	O
and	O
cancer	O
cell	O
proliferation	O
.	O

In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
ICAM	O
-	O
3	O
has	O
an	O
additional	O
effect	O
on	O
cancer	O
cell	O
migration	O
and	O
invasion	O
because	O
molecules	O
induced	O
by	O
ICAM	O
-	O
3	O
are	O
known	O
as	O
regulators	O
of	O
cell	O
migration	O
and	O
invasion	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
used	O
NCI	B
-	I
H1299	I
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
cell	O
line	O
(	O
p53	O
and	O
PTEN	O
null	O
cell	O
)	O
and	O
constructed	O
an	O
ICAM	O
-	O
3	O
-	O
over	O
-	O
expressing	O
stable	O
transfectant	O
,	O
which	O
exhibited	O
increased	O
cell	O
migration	O
and	O
invasion	O
.	O

The	O
increased	O
migration	O
and	O
invasion	O
resulted	O
from	O
up	O
-	O
regulation	O
of	O
expression	O
and	O
activities	O
of	O
MMP	O
-	O
2	O
and	O
MMP	O
-	O
9	O
.	O

ICAM	O
-	O
3	O
also	O
increased	O
Akt	O
phosphorylation	O
,	O
which	O
caused	O
an	O
increase	O
in	O
cellular	O
migration	O
/	O
invasion	O
and	O
MMP	O
activities	O
.	O

Activity	O
of	O
several	O
transcriptional	O
factors	O
located	O
downstream	O
in	O
the	O
Akt	O
pathway	O
was	O
also	O
tested	O
,	O
and	O
constitutive	O
activation	O
of	O
adenosine	O
3	O
'	O
,	O
5	O
'	O
-	O
monophosphate	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
by	O
ICAM	O
-	O
3	O
was	O
detected	O
.	O

Blockage	O
of	O
the	O
Akt	O
pathway	O
attenuated	O
CREB	O
activation	O
,	O
and	O
a	O
decrease	O
in	O
CREB	O
expression	O
reduced	O
cellular	O
migration	O
/	O
invasion	O
and	O
activity	O
of	O
MMPs	O
.	O

This	O
result	O
indicates	O
that	O
CREB	O
functions	O
in	O
the	O
signaling	O
pathway	O
between	O
Akt	O
and	O
MMP	O
.	O

We	O
also	O
showed	O
ICAM	O
-	O
3	O
-	O
induced	O
cell	O
migration	O
and	O
invasion	O
in	O
NCI	B
-	I
H460	I
NSCLC	O
cells	O
(	O
wild	O
-	O
type	O
p53	O
and	O
PTEN	O
cell	O
)	O
through	O
the	O
same	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
ICAM	O
-	O
3	O
stimulates	O
cancer	O
cell	O
migration	O
/	O
invasion	O
via	O
ICAM	O
-	O
3	O
/	O
Akt	O
/	O
CREB	O
/	O
MMP	O
pathway	O
regardless	O
of	O
p53	O
and	O
PTEN	O
status	O
,	O
and	O
this	O
reflects	O
the	O
possibility	O
that	O
ICAM	O
-	O
3	O
could	O
be	O
considered	O
as	O
a	O
candidate	O
for	O
anti	O
-	O
cancer	O
drug	O
development	O
and	O
as	O
a	O
cancer	O
diagnostic	O
marker	O
.	O

Phenolic	O
fraction	O
of	O
tobacco	O
smoke	O
condensate	O
potentiates	O
benzo	O
[	O
a	O
]	O
pyerene	O
diol	O
epoxide	O
-	O
induced	O
cell	O
transformation	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
.	O

In	O
this	O
study	O
we	O
separated	O
weakly	O
acidic	O
phenolic	O
components	O
from	O
other	O
neutral	O
,	O
acidic	O
and	O
basic	O
components	O
of	O
tobacco	O
smoke	O
condensate	O
(	O
TSC	O
)	O
and	O
observed	O
that	O
phenolic	O
fraction	O
of	O
TSC	O
significantly	O
increased	O
the	O
number	O
of	O
colonies	O
of	O
promotion	O
-	O
sensitive	O
JB6	B
Cl41	I
cells	O
that	O
showed	O
anchorage	O
-	O
independent	O
growth	O
on	O
soft	O
agar	O
in	O
response	O
to	O
BPDE	O
(	O
an	O
ultimate	O
carcinogen	O
produced	O
by	O
metabolic	O
activation	O
of	O
the	O
PAH	O
benzo	O
[	O
a	O
]	O
pyrene	O
)	O
.	O

Anchorage	O
-	O
independent	O
cell	O
growth	O
is	O
indicative	O
of	O
cell	O
transformation	O
resulting	O
in	O
acquisition	O
of	O
tumorigenic	O
potential	O
.	O

In	O
order	O
to	O
understand	O
the	O
underlying	O
mechanism	O
by	O
which	O
TSC	O
phenolic	O
fraction	O
potentiates	O
BPDE	O
-	O
induced	O
tumorigenicity	O
,	O
we	O
examined	O
its	O
effect	O
on	O
the	O
activation	O
of	O
two	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
which	O
are	O
known	O
to	O
be	O
influenced	O
by	O
established	O
tumor	O
promoter	O
TPA	O
.	O

BPDE	O
treatment	O
caused	O
induction	O
of	O
both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
activity	O
as	O
determined	O
by	O
luciferase	O
reporter	O
assay	O
and	O
only	O
NF	O
-	O
kappaB	O
induction	O
in	O
response	O
to	O
BPDE	O
was	O
significantly	O
attenuated	O
by	O
TSC	O
phenolic	O
fraction	O
whereas	O
AP	O
-	O
1	O
induction	O
remains	O
unaltered	O
.	O

Attenuation	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
TSC	O
phenolic	O
fraction	O
was	O
associated	O
with	O
significant	O
decrease	O
of	O
intracellular	O
PKC	O
substrate	O
phosphorylation	O
in	O
BPDE	O
treated	O
cells	O
.	O

Non	O
-	O
specific	O
PKC	O
inhibitors	O
staurosporine	O
and	O
bisindolylmaleimide	O
II	O
as	O
well	O
as	O
inhibitors	O
specific	O
to	O
conventional	O
PKCs	O
(	O
Go6976	O
)	O
and	O
PKC	O
-	O
delta	O
(	O
rottlerin	O
)	O
attenuated	O
NF	O
-	O
kappaB	O
activation	O
in	O
BPDE	O
treated	O
cells	O
to	O
a	O
varying	O
degree	O
indicating	O
a	O
possible	O
link	O
between	O
PKC	O
down	O
-	O
regulation	O
and	O
the	O
attenuation	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Treatment	O
of	O
cells	O
with	O
PKC	O
inhibitors	O
also	O
potentiated	O
anchorage	O
-	O
independent	O
growth	O
of	O
BPDE	O
treated	O
cells	O
on	O
soft	O
agar	O
.	O

Our	O
data	O
suggest	O
a	O
possible	O
role	O
of	O
PKC	O
down	O
-	O
regulation	O
in	O
potentiation	O
of	O
BPDE	O
-	O
induced	O
tumorogenicity	O
by	O
TSC	O
phenolic	O
fraction	O
.	O

Costs	O
of	O
hip	O
fracture	O
.	O

Rehabilitation	O
of	O
180	O
patients	O
in	O
primary	O
health	O
care	O
.	O

Costs	O
related	O
to	O
functional	O
status	O
were	O
calculated	O
for	O
180	O
consecutive	O
hip	O
fracture	O
patients	O
(	O
mean	O
age	O
78	O
years	O
)	O
who	O
were	O
admitted	O
from	O
their	O
own	O
home	O
and	O
rehabilitated	O
in	O
primary	O
health	O
care	O
.	O

Within	O
4	O
months	O
after	O
the	O
fracture	O
,	O
75	O
percent	O
of	O
the	O
patients	O
had	O
been	O
discharged	O
to	O
their	O
own	O
home	O
,	O
9	O
percent	O
were	O
dead	O
,	O
and	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
per	O
patient	O
were	O
SEK	O
43	O
,	O
000	O
,	O
whereas	O
the	O
total	O
costs	O
including	O
communal	O
help	O
and	O
costs	O
for	O
living	O
accommodations	O
after	O
discharge	O
were	O
twice	O
as	O
high	O
.	O

The	O
total	O
costs	O
per	O
patient	O
for	O
long	O
-	O
term	O
medical	O
treatment	O
(	O
from	O
4	O
months	O
up	O
to	O
3	O
years	O
after	O
fracture	O
)	O
were	O
7	O
percent	O
of	O
the	O
short	O
-	O
term	O
medical	O
treatment	O
costs	O
.	O

Patients	O
with	O
a	O
cervical	O
fracture	O
discharged	O
to	O
their	O
own	O
home	O
and	O
with	O
good	O
functional	O
status	O
consumed	O
only	O
one	O
fifth	O
of	O
the	O
resources	O
that	O
patients	O
with	O
a	O
trochanteric	O
fracture	O
discharged	O
to	O
institutional	O
care	O
and	O
who	O
had	O
reduced	O
functional	O
status	O
consumed	O
.	O

A	O
substantial	O
part	O
of	O
the	O
costs	O
can	O
be	O
saved	O
by	O
improved	O
organization	O
of	O
rehabilitation	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O

A	O
further	O
cost	O
reduction	O
would	O
require	O
a	O
combination	O
of	O
technologic	O
,	O
social	O
,	O
and	O
organizational	O
changes	O
aimed	O
at	O
early	O
discharge	O
and	O
continued	O
follow	O
-	O
up	O
in	O
primary	O
health	O
care	O
.	O

The	O
role	O
of	O
p53	O
in	O
glucose	O
metabolism	O
.	O

The	O
p53	O
protein	O
functions	O
to	O
prevent	O
tumour	O
development	O
by	O
inhibiting	O
the	O
outgrowth	O
of	O
stressed	O
or	O
damaged	O
cells	O
.	O

In	O
addition	O
to	O
well	O
established	O
functions	O
to	O
block	O
cell	O
proliferation	O
,	O
recent	O
studies	O
have	O
revealed	O
a	O
role	O
for	O
p53	O
in	O
the	O
regulation	O
of	O
pathways	O
involved	O
in	O
glucose	O
metabolism	O
.	O

The	O
metabolic	O
functions	O
of	O
p53	O
resist	O
the	O
shift	O
to	O
glycolysis	O
that	O
is	O
characteristically	O
seen	O
in	O
cancers	O
,	O
and	O
also	O
help	O
cells	O
adapt	O
to	O
and	O
survive	O
limited	O
periods	O
of	O
metabolic	O
stress	O
.	O

Such	O
activities	O
of	O
p53	O
would	O
not	O
only	O
help	O
to	O
prevent	O
cancer	O
development	O
,	O
but	O
might	O
also	O
contribute	O
to	O
non	O
-	O
tumour	O
related	O
roles	O
for	O
p53	O
,	O
such	O
as	O
in	O
the	O
regulation	O
of	O
longevity	O
.	O

These	O
new	O
functions	O
of	O
p53	O
are	O
providing	O
interesting	O
possibilities	O
for	O
the	O
development	O
of	O
novel	O
therapies	O
.	O

14	O
-	O
3	O
-	O
3zeta	O
Overexpression	O
and	O
abnormal	O
beta	O
-	O
catenin	O
expression	O
are	O
associated	O
with	O
poor	O
differentiation	O
and	O
progression	O
in	O
stage	O
I	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
14	O
-	O
3	O
-	O
3zeta	O
interacted	O
with	O
other	O
key	O
cellular	O
proteins	O
involved	O
in	O
the	O
tumor	O
development	O
and	O
progression	O
.	O

Knowledge	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
expression	O
and	O
clinical	O
significance	O
in	O
the	O
same	O
tumor	O
tissues	O
is	O
limited	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
significance	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
in	O
stage	O
I	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

Specimens	O
of	O
NSCLC	O
and	O
adjacent	O
normal	O
lung	O
tissues	O
were	O
collected	O
from	O
110	O
patients	O
.	O

The	O
expressions	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
were	O
detected	O
by	O
western	O
blotting	O
,	O
double	O
labeling	O
immunofluorescence	O
,	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
was	O
upregulated	O
in	O
stage	O
I	O
NSCLC	O
.	O

Further	O
,	O
the	O
overexpression	O
of	O
14	O
-	O
3	O
-	O
3zeta	O
correlated	O
with	O
histological	O
grades	O
,	O
lymph	O
node	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
.	O

Abnormal	O
expression	O
of	O
beta	O
-	O
catenin	O
was	O
significantly	O
correlated	O
with	O
poor	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
.	O

Abnormal	O
beta	O
-	O
catenin	O
expression	O
was	O
associated	O
significantly	O
with	O
positive	O
14	O
-	O
3	O
-	O
3zeta	O
expression	O
.	O

In	O
conclusion	O
,	O
14	O
-	O
3	O
-	O
3zeta	O
and	O
beta	O
-	O
catenin	O
might	O
have	O
an	O
important	O
role	O
in	O
development	O
,	O
progression	O
and	O
metastatic	O
process	O
of	O
NSCLC	O
.	O

14	O
-	O
3	O
-	O
3zeta	O
might	O
be	O
used	O
as	O
prognostic	O
biomarkers	O
for	O
NSCLC	O
.	O

A	O
randomized	O
pilot	O
study	O
of	O
the	O
Engaging	O
Moms	O
Program	O
for	O
family	O
drug	O
court	O
.	O

In	O
response	O
to	O
the	O
need	O
for	O
effective	O
drug	O
court	O
interventions	O
,	O
the	O
effectiveness	O
of	O
the	O
Engaging	O
Moms	O
Program	O
(	O
EMP	O
)	O
versus	O
Intensive	O
Case	O
Management	O
Services	O
(	O
ICMS	O
)	O
on	O
multiple	O
outcomes	O
for	O
mothers	O
enrolled	O
in	O
family	O
drug	O
court	O
was	O
investigated	O
.	O

In	O
this	O
intent	O
-	O
to	O
-	O
treat	O
study	O
,	O
mothers	O
(	O
N	O
=	O
62	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
usual	O
drug	O
court	O
care	O
or	O
the	O
Engaging	O
Moms	O
drug	O
court	O
program	O
.	O

Mothers	O
were	O
assessed	O
at	O
intake	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	O
following	O
intake	O
.	O

Results	O
indicated	O
that	O
at	O
18	O
months	O
post	O
drug	O
court	O
enrollment	O
,	O
77	O
%	O
of	O
mothers	O
assigned	O
to	O
EMP	O
versus	O
55	O
%	O
of	O
mothers	O
assigned	O
to	O
ICMS	O
had	O
positive	O
child	O
welfare	O
dispositions	O
.	O

There	O
were	O
statistically	O
significant	O
time	O
effects	O
for	O
both	O
intervention	O
groups	O
on	O
multiple	O
outcomes	O
including	O
substance	O
use	O
,	O
mental	O
health	O
,	O
parenting	O
practices	O
,	O
and	O
family	O
functioning	O
.	O

EMP	O
showed	O
equal	O
or	O
better	O
improvement	O
than	O
ICMS	O
on	O
all	O
outcomes	O
.	O

The	O
results	O
suggest	O
that	O
EMP	O
in	O
family	O
drug	O
court	O
is	O
a	O
viable	O
and	O
promising	O
intervention	O
approach	O
to	O
reduce	O
maternal	O
addiction	O
and	O
child	O
maltreatment	O
.	O

Hormonal	O
regulation	O
and	O
distinct	O
functions	O
of	O
semaphorin	O
-	O
3B	O
and	O
semaphorin	O
-	O
3F	O
in	O
ovarian	O
cancer	O
.	O

Semaphorins	O
comprise	O
a	O
family	O
of	O
molecules	O
that	O
influence	O
neuronal	O
growth	O
and	O
guidance	O
.	O

Class	O
-	O
3	O
semaphorins	O
,	O
semaphorin	O
-	O
3B	O
(	O
SEMA3B	O
)	O
and	O
semaphorin	O
-	O
3F	O
(	O
SEMA3F	O
)	O
,	O
illustrate	O
their	O
effects	O
by	O
forming	O
a	O
complex	O
with	O
neuropilins	O
(	O
NP	O
-	O
1	O
or	O
NP	O
-	O
2	O
)	O
and	O
plexins	O
.	O

We	O
examined	O
the	O
status	O
and	O
regulation	O
of	O
semaphorins	O
and	O
their	O
receptors	O
in	O
human	O
ovarian	O
cancer	O
cells	O
.	O

A	O
significantly	O
reduced	O
expression	O
of	O
SEMA3B	O
(	O
83	O
kDa	O
)	O
,	O
SEMA3F	O
(	O
90	O
kDa	O
)	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
observed	O
in	O
ovarian	O
cancer	O
cell	O
lines	O
when	O
compared	O
with	O
normal	O
human	O
ovarian	O
surface	O
epithelial	O
cells	O
.	O

The	O
expression	O
of	O
NP	O
-	O
1	O
,	O
NP	O
-	O
2	O
,	O
and	O
plexin	O
-	O
A1	O
was	O
not	O
altered	O
in	O
human	O
ovarian	O
surface	O
epithelial	O
and	O
ovarian	O
cancer	O
cells	O
.	O

The	O
decreased	O
expression	O
of	O
SEMA3B	O
,	O
SEMA3F	O
,	O
and	O
plexin	O
-	O
A3	O
was	O
confirmed	O
in	O
stage	O
3	O
ovarian	O
tumors	O
.	O

The	O
treatment	O
of	O
ovarian	O
cancer	O
cells	O
with	O
luteinizing	O
hormone	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
,	O
and	O
estrogen	O
induced	O
a	O
significant	O
upregulation	O
of	O
SEMA3B	O
,	O
whereas	O
SEMA3F	O
was	O
upregulated	O
only	O
by	O
estrogen	O
.	O

Cotreatment	O
of	O
cell	O
lines	O
with	O
a	O
hormone	O
and	O
its	O
specific	O
antagonist	O
blocked	O
the	O
effect	O
of	O
the	O
hormone	O
.	O

Ectopic	O
expression	O
of	O
SEMA3B	O
or	O
SEMA3F	O
reduced	O
soft	O
-	O
agar	O
colony	O
formation	O
,	O
adhesion	O
,	O
and	O
cell	O
invasion	O
of	O
ovarian	O
cancer	O
cell	O
cultures	O
.	O

Forced	O
expression	O
of	O
SEMA3B	O
,	O
but	O
not	O
SEMA3F	O
,	O
inhibited	O
viability	O
of	O
ovarian	O
cancer	O
cells	O
.	O

Overexpression	O
of	O
SEMA3B	O
and	O
SEMA3F	O
reduced	O
focal	O
adhesion	O
kinase	O
phosphorylation	O
and	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
in	O
ovarian	O
cancer	O
cells	O
.	O

Forced	O
expression	O
of	O
SEMA3F	O
,	O
but	O
not	O
SEMA3B	O
in	O
ovarian	O
cancer	O
cells	O
,	O
significantly	O
inhibited	O
endothelial	O
cell	O
tube	O
formation	O
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
that	O
the	O
loss	O
of	O
SEMA3	O
expression	O
could	O
be	O
a	O
hallmark	O
of	O
cancer	O
progression	O
.	O

Furthermore	O
,	O
gonadotropin	O
-	O
and	O
/	O
or	O
estrogen	O
-	O
mediated	O
maintenance	O
of	O
SEMA3	O
expression	O
could	O
control	O
ovarian	O
cancer	O
angiogenesis	O
and	O
metastasis	O
.	O

Tobacco	O
smoke	O
promotes	O
lung	O
tumorigenesis	O
by	O
triggering	O
IKKbeta	O
-	O
and	O
JNK1	O
-	O
dependent	O
inflammation	O
.	O

Chronic	O
exposure	O
to	O
tobacco	O
smoke	O
,	O
which	O
contains	O
over	O
60	O
tumor	O
-	O
initiating	O
carcinogens	O
,	O
is	O
the	O
major	O
risk	O
factor	O
for	O
development	O
of	O
lung	O
cancer	O
,	O
accounting	O
for	O
a	O
large	O
portion	O
of	O
cancer	O
-	O
related	O
deaths	O
worldwide	O
.	O

It	O
is	O
well	O
established	O
that	O
tobacco	O
smoke	O
is	O
a	O
tumor	O
initiator	O
,	O
but	O
we	O
asked	O
whether	O
it	O
also	O
acts	O
as	O
a	O
tumor	O
promoter	O
once	O
malignant	O
initiation	O
,	O
such	O
as	O
caused	O
by	O
K	O
-	O
ras	O
activation	O
,	O
has	O
taken	O
place	O
.	O

Here	O
we	O
demonstrate	O
that	O
repetitive	O
exposure	O
to	O
tobacco	O
smoke	O
promotes	O
tumor	O
development	O
both	O
in	O
carcinogen	O
-	O
treated	O
mice	O
and	O
in	O
transgenic	O
mice	O
undergoing	O
sporadic	O
K	O
-	O
ras	O
activation	O
in	O
lung	O
epithelial	O
cells	O
.	O

Tumor	O
promotion	O
is	O
due	O
to	O
induction	O
of	O
inflammation	O
that	O
results	O
in	O
enhanced	O
pneumocyte	O
proliferation	O
and	O
is	O
abrogated	O
by	O
IKKbeta	O
ablation	O
in	O
myeloid	O
cells	O
or	O
inactivation	O
of	O
JNK1	O
.	O

Killing	O
tumor	O
cells	O
through	O
their	O
surface	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
or	O
major	O
histocompatibility	O
complex	O
class	O
I	O
molecules	O
.	O

Targeted	O
antibody	O
-	O
based	O
therapy	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
cancers	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
tumor	O
cells	O
treated	O
with	O
antibodies	O
specific	O
for	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
(	O
beta	O
(	O
2	O
)	O
M	O
)	O
or	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
mouse	O
models	O
)	O
.	O

Antibodies	O
against	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
induce	O
tumor	O
cell	O
apoptosis	O
by	O
1	O
)	O
recruiting	O
MHC	O
class	O
I	O
molecules	O
to	O
lipid	O
rafts	O
and	O
activating	O
LYN	O
kinase	O
and	O
the	O
signal	O
-	O
transducing	O
enzyme	O
phospholipase	O
C	O
-	O
gamma2	O
-	O
dependent	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
signaling	O
pathway	O
and	O
2	O
)	O
expelling	O
interleukin	O
6	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptors	O
out	O
of	O
lipid	O
rafts	O
and	O
inhibiting	O
the	O
growth	O
and	O
survival	O
factor	O
-	O
induced	O
activation	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
and	O
extracellular	O
signal	O
-	O
related	O
kinase	O
pathways	O
.	O

Consequently	O
,	O
mitochondrial	O
integrity	O
is	O
compromised	O
,	O
and	O
the	O
caspase	O
-	O
9	O
-	O
dependent	O
cascade	O
is	O
activated	O
in	O
treated	O
tumor	O
cells	O
.	O

However	O
,	O
although	O
beta	O
(	O
2	O
)	O
M	O
and	O
MHC	O
class	O
I	O
are	O
expressed	O
on	O
normal	O
hematopoietic	O
cells	O
,	O
which	O
is	O
a	O
potential	O
safety	O
concern	O
,	O
the	O
monoclonal	O
antibodies	O
were	O
selective	O
to	O
tumor	O
cells	O
and	O
did	O
not	O
damage	O
normal	O
cells	O
in	O
vitro	O
or	O
in	O
human	O
-	O
like	O
mouse	O
models	O
.	O

These	O
findings	O
suggest	O
that	O
targeting	O
beta	O
(	O
2	O
)	O
M	O
or	O
MHC	O
class	O
I	O
by	O
using	O
antibodies	O
or	O
other	O
agents	O
offers	O
a	O
potential	O
therapeutic	O
approach	O
for	O
beta	O
(	O
2	O
)	O
M	O
/	O
MHC	O
class	O
I	O
-	O
expressing	O
malignancies	O
.	O

Cancer	O
2010	O
.	O

(	O
c	O
)	O
2010	O
American	O
Cancer	O
Society	O
.	O

Further	O
Characterization	O
of	O
Activin	O
A	O
-	O
induced	O
IgA	O
Response	O
in	O
Murine	O
B	O
Lymphocytes	O
.	O

We	O
have	O
recently	O
shown	O
that	O
activin	O
A	O
,	O
a	O
member	O
of	O
TGF	O
-	O
beta	O
superfamily	O
,	O
stimulates	O
mouse	O
B	O
cells	O
to	O
express	O
IgA	O
isotype	O
but	O
other	O
isotypes	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
effects	O
of	O
activin	O
A	O
on	O
B	O
cell	O
growth	O
and	O
IgA	O
expression	O
.	O

We	O
found	O
that	O
activin	O
A	O
did	O
not	O
have	O
effect	O
on	O
LPS	O
-	O
stimulated	O
cell	O
viability	O
.	O

In	O
parallel	O
,	O
CFSE	O
staining	O
analysis	O
revealed	O
that	O
activin	O
A	O
did	O
not	O
alter	O
cell	O
division	O
.	O

An	O
increase	O
of	O
IgA	O
secretion	O
by	O
activin	O
A	O
was	O
completely	O
abrogated	O
by	O
anti	O
-	O
activin	O
A	O
Ab	O
but	O
not	O
by	O
anti	O
-	O
TGFbeta1	O
Ab	O
.	O

In	O
the	O
same	O
conditions	O
,	O
no	O
other	O
isotypes	O
are	O
significantly	O
affected	O
by	O
each	O
antibody	O
treatment	O
.	O

Finally	O
,	O
activin	O
A	O
,	O
as	O
similar	O
to	O
TGF	O
-	O
beta1	O
,	O
increased	O
IgA	O
secretion	O
by	O
mesenteric	O
lymph	O
node	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
activin	O
A	O
can	O
specifically	O
stimulate	O
IgA	O
response	O
,	O
independent	O
of	O
TGF	O
-	O
beta	O
in	O
the	O
gut	O
.	O

Posterior	O
stabilization	O
of	O
the	O
cervical	O
spine	O
with	O
hook	O
plates	O
.	O

Hook	O
-	O
plate	O
fixation	O
is	O
designed	O
for	O
posterior	O
cervical	O
stabilization	O
from	O
C2	O
to	O
C7	O
.	O

Indications	O
remain	O
the	O
same	O
as	O
for	O
standard	O
posterior	O
fixations	O
.	O

The	O
prime	O
indications	O
are	O
discoligamentous	O
injuries	O
.	O

The	O
plates	O
are	O
hooked	O
under	O
the	O
lower	O
laminas	O
and	O
attached	O
to	O
the	O
articular	O
masses	O
of	O
the	O
upper	O
vertebra	O
by	O
oblique	O
screws	O
.	O

An	O
H	O
-	O
graft	O
is	O
placed	O
between	O
the	O
spinous	O
processes	O
.	O

The	O
vertebrae	O
are	O
compressed	O
together	O
by	O
the	O
plates	O
at	O
three	O
points	O
,	O
the	O
facet	O
joints	O
,	O
and	O
graft	O
.	O

The	O
resulting	O
pre	O
-	O
stressed	O
system	O
is	O
stable	O
in	O
all	O
directions	O
.	O

A	O
protocol	O
for	O
safe	O
reduction	O
of	O
cervical	O
dislocations	O
is	O
observed	O
.	O

Of	O
70	O
patients	O
treated	O
from	O
1979	O
to	O
1986	O
,	O
51	O
were	O
examined	O
12	O
-	O
54	O
months	O
after	O
surgery	O
.	O

All	O
fusions	O
consolidated	O
.	O

Two	O
neurologic	O
complications	O
not	O
attributable	O
to	O
the	O
fixation	O
occurred	O
.	O

Other	O
major	O
complications	O
were	O
not	O
seen	O
.	O

Comment	O
on	O
""""	O
Why	O
reduced	O
-	O
form	O
regression	O
models	O
of	O
health	O
effects	O
versus	O
exposures	O
should	O
not	O
replace	O
QRA	O
:	O
livestock	O
production	O
and	O
infant	O
mortality	O
as	O
an	O
example	O
,	O
""""	O
by	O
Louis	O
Anthony	O
(	O
Tony	O
)	O
Cox	O
,	O
Jr	O
.	O
,	O
Risk	O
Analysis	O
2009	O
,	O
Vol	O
.	O

29	O
,	O
No	O
.	O
12	O
.	O

While	O
a	O
recent	O
paper	O
by	O
Cox	O
in	O
this	O
journal	O
uses	O
as	O
its	O
motivating	O
factor	O
the	O
benefits	O
of	O
quantitative	O
risk	O
assessment	O
,	O
its	O
content	O
is	O
entirely	O
devoted	O
to	O
critiquing	O
Sneeringer	O
'	O
s	O
article	O
in	O
the	O
American	O
Journal	O
of	O
Agricultural	O
Economics	O
.	O

Cox	O
'	O
s	O
two	O
main	O
critiques	O
of	O
Sneeringer	O
are	O
fundamentally	O
flawed	O
and	O
misrepresent	O
the	O
original	O
article	O
.	O

Cox	O
posits	O
that	O
Sneeringer	O
did	O
A	O
and	O
B	O
,	O
and	O
then	O
argues	O
why	O
A	O
and	O
B	O
are	O
incorrect	O
.	O

However	O
,	O
Sneeringer	O
in	O
fact	O
did	O
C	O
and	O
D	O
;	O
thus	O
critiques	O
of	O
A	O
and	O
B	O
are	O
not	O
applicable	O
to	O
Sneeringer	O
'	O
s	O
analysis	O
.	O

Dose	O
-	O
and	O
time	O
-	O
dependent	O
effects	O
of	O
doxorubicin	O
on	O
cytotoxicity	O
,	O
cell	O
cycle	O
and	O
apoptotic	O
cell	O
death	O
in	O
human	O
colon	O
cancer	O
cells	O
.	O

The	O
cytostatic	O
drug	O
doxorubicin	O
is	O
a	O
well	O
-	O
known	O
chemotherapeutic	O
agent	O
which	O
is	O
used	O
in	O
treatment	O
of	O
a	O
wide	O
variety	O
of	O
cancers	O
.	O

A	O
key	O
factor	O
in	O
the	O
response	O
of	O
cancer	O
cells	O
to	O
chemotherapeutic	O
drugs	O
is	O
the	O
activation	O
of	O
the	O
apoptotic	O
pathway	O
,	O
a	O
pathway	O
that	O
is	O
often	O
impaired	O
in	O
chemoresistant	O
colon	O
cancer	O
cells	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
doxorubicin	O
in	O
Hct	B
-	I
116	I
human	O
colon	O
carcinoma	O
cells	O
in	O
order	O
to	O
clarify	O
if	O
a	O
time	O
/	O
concentration	O
range	O
for	O
optimal	O
doxorubicin	O
-	O
induced	O
apoptosis	O
exists	O
.	O

We	O
compared	O
a	O
treatment	O
schedule	O
were	O
cells	O
were	O
bolus	O
incubated	O
for	O
3h	O
with	O
doxorubicin	O
followed	O
by	O
24h	O
in	O
drug	O
-	O
free	O
medium	O
,	O
with	O
a	O
continuous	O
doxorubicin	O
treatment	O
schedule	O
for	O
24h	O
.	O

Bolus	O
incubation	O
was	O
carried	O
out	O
to	O
determine	O
effects	O
of	O
doxorubicin	O
accumulated	O
during	O
the	O
first	O
3h	O
,	O
whereas	O
continuous	O
incubation	O
allowed	O
further	O
(	O
continuous	O
)	O
exposure	O
to	O
doxorubicin	O
.	O

We	O
found	O
that	O
bolus	O
(	O
3h	O
)	O
treatment	O
with	O
doxorubicin	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
decrease	O
of	O
viable	O
cells	O
and	O
concomitant	O
increase	O
of	O
apoptosis	O
.	O

Additionally	O
,	O
bolus	O
(	O
3h	O
)	O
doxorubicin	O
incubation	O
led	O
to	O
phosphorylation	O
of	O
p53	O
at	O
serine	O
392	O
,	O
induction	O
of	O
p21	O
,	O
G2	O
arrest	O
and	O
increase	O
of	O
proapoptotic	O
protein	O
Bax	O
.	O

In	O
contrast	O
,	O
continuous	O
(	O
24h	O
)	O
treatment	O
with	O
doxorubicin	O
reduced	O
the	O
number	O
of	O
living	O
cells	O
with	O
no	O
parallel	O
raise	O
in	O
the	O
amount	O
of	O
dead	O
cells	O
.	O

Continuous	O
(	O
24h	O
)	O
treatment	O
with	O
5	O
microM	O
doxorubicin	O
resulted	O
in	O
cell	O
cycle	O
arrest	O
in	O
G0	O
/	O
G1	O
phase	O
that	O
was	O
neither	O
accompanied	O
by	O
phosphorylation	O
and	O
activation	O
of	O
p53	O
nor	O
enhanced	O
expression	O
of	O
p21	O
.	O

These	O
results	O
suggest	O
that	O
doxorubicin	O
is	O
able	O
to	O
induce	O
cell	O
death	O
by	O
apoptosis	O
only	O
at	O
particular	O
dose	O
and	O
treatment	O
conditions	O
and	O
imply	O
a	O
completely	O
different	O
cellular	O
response	O
following	O
bolus	O
or	O
continuous	O
exposure	O
to	O
doxorubicin	O
.	O

p24	O
family	O
type	O
1	O
transmembrane	O
proteins	O
are	O
required	O
for	O
insulin	O
biosynthesis	O
and	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

The	O
p24	O
protein	O
family	O
have	O
multiple	O
functions	O
in	O
protein	O
transport	O
in	O
the	O
early	O
secretory	O
pathway	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
role	O
of	O
p24	O
proteins	O
in	O
insulin	O
transport	O
.	O

Several	O
members	O
were	O
detected	O
in	O
insulinoma	O
cell	O
lines	O
and	O
rat	O
islets	O
and	O
expression	O
levels	O
positively	O
correlated	O
with	O
insulin	O
abundance	O
,	O
particularly	O
for	O
p24delta1	O
and	O
p24beta1	O
.	O

Knocking	O
down	O
p24delta1	O
in	O
insulinoma	O
cell	O
lines	O
,	O
which	O
also	O
resulted	O
in	O
the	O
concomitant	O
knock	O
-	O
down	O
of	O
other	O
family	O
members	O
,	O
impaired	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
,	O
decreased	O
total	O
cellular	O
insulin	O
content	O
and	O
reduced	O
proinsulin	O
biosynthesis	O
.	O

There	O
was	O
no	O
effect	O
on	O
overall	O
protein	O
biosynthesis	O
or	O
ER	O
stress	O
.	O

These	O
results	O
suggest	O
that	O
p24delta1	O
and	O
possibly	O
other	O
p24	O
family	O
proteins	O
are	O
required	O
for	O
normal	O
insulin	O
biosynthesis	O
and	O
subsequent	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

Absence	O
of	O
microbiota	O
(	O
germ	O
-	O
free	O
conditions	O
)	O
accelerates	O
the	O
atherosclerosis	O
in	O
ApoE	O
-	O
deficient	O
mice	O
fed	O
standard	O
low	O
cholesterol	O
diet	O
.	O

AIM	O
:	O

The	O
aim	O
of	O
our	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
intestinal	O
bacteria	O
on	O
the	O
development	O
of	O
atherosclerotic	O
lesions	O
using	O
apolipoprotein	O
E	O
(	O
ApoE	O
)	O
-	O
deficient	O
knockout	O
mice	O
.	O

METHODS	O
:	O

The	O
experiments	O
were	O
performed	O
on	O
ApoE	O
-	O
/	O
-	O
-	O
deficient	O
mouse	O
strain	O
C57BL	O
/	O
6	O
,	O
bred	O
under	O
germ	O
-	O
free	O
(	O
GF	O
)	O
conditions	O
for	O
two	O
generations	O
or	O
under	O
conventional	O
conditions	O
with	O
defined	O
microflora	O
(	O
CV	O
)	O
.	O

The	O
mice	O
were	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
or	O
cholesterol	O
-	O
rich	O
diet	O
for	O
3	O
-	O
4	O
months	O
.	O

We	O
studied	O
the	O
development	O
of	O
advanced	O
lesions	O
in	O
the	O
thoracic	O
and	O
abdominal	O
aorta	O
by	O
histological	O
,	O
morphometric	O
and	O
immunohistological	O
methods	O
.	O

RESULTS	O
:	O

Conventionally	O
reared	O
ApoE	O
-	O
/	O
-	O
mice	O
(	O
containing	O
no	O
pathogenic	O
intestinal	O
microbiota	O
)	O
and	O
fed	O
a	O
standard	O
low	O
cholesterol	O
diet	O
in	O
contrast	O
to	O
a	O
high	O
cholesterol	O
diet	O
did	O
not	O
develop	O
atherosclerotic	O
aortic	O
plaques	O
.	O

In	O
contrast	O
,	O
ApoE	O
-	O
/	O
-	O
mice	O
reared	O
under	O
germfree	O
conditions	O
for	O
2	O
generations	O
and	O
fed	O
a	O
low	O
cholesterol	O
diet	O
exhibited	O
atherosclerotic	O
plaques	O
in	O
the	O
aorta	O
.	O

Characteristic	O
lipid	O
deposition	O
with	O
foam	O
cells	O
and	O
macrophages	O
was	O
found	O
in	O
their	O
arterial	O
walls	O
.	O

CONCLUSION	O
:	O

In	O
contrast	O
to	O
the	O
absence	O
of	O
atherosclerotic	O
plaques	O
in	O
conventionally	O
reared	O
ApoE	O
-	O
deficient	O
mice	O
,	O
germ	O
-	O
free	O
ApoE	O
-	O
/	O
-	O
mice	O
consuming	O
the	O
same	O
low	O
cholesterol	O
standard	O
diet	O
developed	O
atherosclerotic	O
plaques	O
in	O
the	O
aorta	O
.	O

Differences	O
in	O
atherosclerotic	O
plaques	O
between	O
GF	O
and	O
CV	O
ApoE	O
-	O
/	O
-	O
mice	O
are	O
not	O
so	O
apparent	O
when	O
mice	O
are	O
fed	O
a	O
high	O
cholesterol	O
diet	O
.	O

Our	O
findings	O
thus	O
document	O
the	O
protective	O
effect	O
of	O
microbiota	O
(	O
commensal	O
bacteria	O
)	O
on	O
atherosclerosis	O
development	O
.	O

Lactate	O
-	O
dehydrogenase	O
5	O
is	O
overexpressed	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
correlates	O
with	O
the	O
expression	O
of	O
the	O
transketolase	O
-	O
like	O
protein	O
1	O
.	O

AIMS	O
:	O
As	O
one	O
of	O
the	O
five	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
isoenzymes	O
,	O
LDH5	O
has	O
the	O
highest	O
efficiency	O
to	O
catalyze	O
pyruvate	O
transformation	O
to	O
lactate	O
.	O

LDH5	O
overexpression	O
in	O
cancer	O
cells	O
induces	O
an	O
upregulated	O
glycolytic	O
metabolism	O
and	O
reduced	O
dependence	O
on	O
the	O
presence	O
of	O
oxygen	O
.	O

Here	O
we	O
analyzed	O
LDH5	O
protein	O
expression	O
in	O
a	O
well	O
characterized	O
large	O
cohort	O
of	O
primary	O
lung	O
cancers	O
in	O
correlation	O
to	O
clinico	O
-	O
pathological	O
data	O
and	O
its	O
possible	O
impact	O
on	O
patient	O
survival	O
.	O

METHODS	O
:	O
Primary	O
lung	O
cancers	O
(	O
n	O
=	O
269	O
)	O
and	O
non	O
neoplastic	O
lung	O
tissue	O
(	O
n	O
=	O
35	O
)	O
were	O
tested	O
for	O
LDH5	O
expression	O
by	O
immunohistochemistry	O
using	O
a	O
polyclonal	O
LDH5	O
antibody	O
(	O
ab53010	O
)	O
.	O

The	O
results	O
of	O
LDH5	O
expression	O
were	O
correlated	O
to	O
clinico	O
-	O
pathological	O
data	O
as	O
well	O
as	O
to	O
patient	O
'	O
s	O
survival	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
the	O
previously	O
tested	O
transketolase	O
like	O
1	O
protein	O
(	O
TKTL1	O
)	O
expression	O
were	O
correlated	O
to	O
LDH5	O
expression	O
.	O

RESULTS	O
:	O
89	O
.	O
5	O
%	O
(	O
n	O
=	O
238	O
)	O
of	O
NSCLC	O
revealed	O
LDH5	O
expression	O
whereas	O
LDH5	O
expression	O
was	O
not	O
detected	O
in	O
non	O
neoplastic	O
lung	O
tissues	O
(	O
n	O
=	O
34	O
)	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

LDH5	O
overexpression	O
was	O
associated	O
with	O
histological	O
type	O
(	O
adenocarcinoma	O
=	O
57	O
%	O
,	O
squamous	O
cell	O
carcinoma	O
=	O
45	O
%	O
,	O
large	O
cell	O
carcinoma	O
=	O
46	O
%	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

No	O
significant	O
correlation	O
could	O
be	O
detected	O
with	O
regard	O
to	O
TNM	O
-	O
stage	O
,	O
grading	O
or	O
survival	O
.	O

A	O
two	O
sided	O
correlation	O
between	O
the	O
expression	O
of	O
TKTL1	O
and	O
LDH5	O
could	O
be	O
shown	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
within	O
the	O
overall	O
cohort	O
as	O
well	O
as	O
for	O
each	O
grading	O
and	O
pN	O
group	O
.	O

A	O
significant	O
correlation	O
between	O
LDH5	O
and	O
TKTL1	O
within	O
each	O
histologic	O
tumortype	O
could	O
not	O
be	O
revealed	O
.	O

CONCLUSIONS	O
:	O
LDH5	O
is	O
overexpressed	O
in	O
NSCLC	O
and	O
could	O
hence	O
serve	O
as	O
an	O
additional	O
marker	O
for	O
malignancy	O
.	O

Furthermore	O
,	O
LDH5	O
correlates	O
positively	O
with	O
the	O
prognostic	O
marker	O
TKTL1	O
.	O

Our	O
results	O
confirm	O
a	O
close	O
link	O
between	O
the	O
two	O
metabolic	O
enzymes	O
and	O
indicate	O
an	O
alteration	O
in	O
the	O
glucose	O
metabolism	O
in	O
the	O
process	O
of	O
malignant	O
transformation	O
.	O

Expression	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
survival	O
.	O

KISS1	O
and	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
may	O
play	O
important	O
roles	O
as	O
metastasis	O
suppressor	O
and	O
metastasis	O
promoter	O
genes	O
,	O
respectively	O
,	O
in	O
a	O
variety	O
of	O
malignancies	O
.	O

However	O
,	O
there	O
is	O
little	O
information	O
about	O
their	O
possible	O
roles	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
MMP	O
-	O
9	O
in	O
NSCLC	O
and	O
their	O
relations	O
to	O
metastasis	O
and	O
prognosis	O
.	O

The	O
mRNA	O
and	O
protein	O
expressions	O
of	O
KISS1	O
and	O
of	O
MMP	O
-	O
9	O
protein	O
were	O
detected	O
by	O
in	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
respectively	O
in	O
85	O
cases	O
of	O
NSCLC	O
,	O
and	O
their	O
matched	O
lymph	O
node	O
metastases	O
.	O

Expressions	O
of	O
KISS1	O
mRNA	O
and	O
protein	O
were	O
significantly	O
higher	O
in	O
low	O
TNM	O
stages	O
of	O
NSCLC	O
(	O
I	O
-	O
II	O
)	O
compared	O
to	O
more	O
advanced	O
stages	O
(	O
III	O
-	O
IV	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
in	O
advanced	O
TNM	O
stages	O
,	O
cases	O
without	O
metastasis	O
had	O
higher	O
KISS1	O
gene	O
expression	O
compared	O
to	O
those	O
with	O
lymph	O
node	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
contrast	O
,	O
MMP	O
-	O
9	O
expression	O
was	O
higher	O
in	O
stage	O
III	O
-	O
IV	O
NSCLC	O
cases	O
compared	O
to	O
stage	O
I	O
-	O
II	O
tumors	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
higher	O
in	O
NSCLC	O
cases	O
with	O
metastasis	O
than	O
those	O
without	O
metastasis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
negative	O
correction	O
between	O
KISS1	O
and	O
MMP	O
-	O
9	O
protein	O
expression	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
5	O
-	O
year	O
survival	O
rate	O
in	O
cases	O
with	O
higher	O
KISS1	O
protein	O
expression	O
was	O
significantly	O
higher	O
than	O
in	O
those	O
with	O
low	O
expression	O
(	O
20	O
.	O
9	O
vs	O
.	O
2	O
.	O
4	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
the	O
5	O
-	O
year	O
survival	O
rate	O
of	O
patients	O
with	O
high	O
MMP	O
-	O
9	O
protein	O
expression	O
were	O
lower	O
than	O
those	O
with	O
low	O
expression	O
(	O
19	O
vs	O
.	O
4	O
.	O
7	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
KISS1	O
and	O
MMP	O
-	O
9	O
may	O
serve	O
as	O
potential	O
prognostic	O
and	O
therapeutic	O
markers	O
in	O
lung	O
cancer	O
.	O

Is	O
the	O
elimination	O
of	O
HIV	O
infection	O
within	O
reach	O
in	O
the	O
United	O
States	O
?	O

Lessons	O
from	O
an	O
epidemiologic	O
transmission	O
model	O
.	O

Recent	O
estimates	O
show	O
that	O
the	O
transmission	O
rate	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
the	O
U	O
.	O
S	O
.	O
has	O
substantially	O
decreased	O
.	O

This	O
raises	O
the	O
question	O
,	O
is	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
nation	O
feasible	O
in	O
the	O
foreseeable	O
future	O
?	O

We	O
demonstrate	O
that	O
if	O
the	O
HIV	O
transmission	O
rate	O
were	O
reduced	O
by	O
50	O
%	O
,	O
then	O
the	O
reproductive	O
rate	O
of	O
HIV	O
infection	O
would	O
drop	O
below	O
unity	O
and	O
lead	O
to	O
eventual	O
elimination	O
of	O
infection	O
.	O

In	O
recent	O
congressional	O
testimony	O
,	O
the	O
director	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
others	O
asserted	O
that	O
the	O
HIV	O
transmission	O
rate	O
can	O
be	O
halved	O
by	O
2020	O
,	O
if	O
not	O
earlier	O
,	O
provided	O
sufficient	O
investment	O
is	O
made	O
toward	O
achieving	O
this	O
goal	O
.	O

We	O
assert	O
that	O
if	O
adequate	O
investment	O
is	O
made	O
and	O
the	O
transmission	O
rate	O
is	O
in	O
fact	O
lowered	O
by	O
50	O
%	O
,	O
then	O
the	O
HIV	O
reproductive	O
rate	O
would	O
fall	O
below	O
unity	O
,	O
setting	O
the	O
stage	O
for	O
eventual	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
U	O
.	O
S	O
.	O

Loss	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
carcinoma	O
.	O

BACKGROUND	O
:	O
CDC4	O
/	O
FBXW7	O
,	O
encoding	O
a	O
ubiquitin	O
ligase	O
,	O
maps	O
to	O
4q32	O
and	O
has	O
been	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
gene	O
and	O
therapeutic	O
target	O
in	O
many	O
tumor	O
types	O
.	O

Mutations	O
in	O
colonic	O
adenomas	O
,	O
and	O
the	O
frequent	O
losses	O
on	O
4q	O
described	O
in	O
gastric	O
cancer	O
prompt	O
speculation	O
about	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
carcinogenesis	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
role	O
of	O
CDC4	O
/	O
FBXW7	O
in	O
gastric	O
cancer	O
,	O
through	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
on	O
47	O
flow	O
-	O
sorted	O
gastric	O
carcinomas	O
including	O
early	O
-	O
onset	O
gastric	O
cancers	O
(	O
EOGC	O
)	O
and	O
xenografted	O
conventional	O
gastric	O
carcinomas	O
.	O

Ploidy	O
analysis	O
was	O
carried	O
out	O
on	O
39	O
EOGCs	O
and	O
immunohistochemistry	O
of	O
CDC4	O
/	O
FBXW7	O
and	O
its	O
substrates	O
c	O
-	O
myc	O
,	O
c	O
-	O
jun	O
,	O
Notch	O
and	O
cyclin	O
E	O
was	O
performed	O
on	O
204	O
gastric	O
carcinomas	O
using	O
tissue	O
microarrays	O
(	O
TMAs	O
)	O
.	O

Sequence	O
analysis	O
of	O
CDC4	O
/	O
FBXW7	O
was	O
carried	O
out	O
on	O
gastric	O
carcinoma	O
cell	O
lines	O
and	O
xenografts	O
.	O

RESULTS	O
:	O
Loss	O
of	O
heterozygosity	O
of	O
CDC4	O
/	O
FBXW7	O
occurred	O
in	O
32	O
%	O
of	O
EOGCs	O
,	O
and	O
correlated	O
with	O
loss	O
of	O
expression	O
in	O
26	O
%	O
.	O

Loss	O
of	O
expression	O
was	O
frequent	O
in	O
both	O
EOGC	O
and	O
conventional	O
gastric	O
cancers	O
.	O

No	O
CDC4	O
/	O
FBXW7	O
mutations	O
were	O
found	O
and	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
did	O
not	O
correlate	O
with	O
ploidy	O
status	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
loss	O
of	O
CDC4	O
/	O
FBXW7	O
expression	O
and	O
upregulation	O
of	O
c	O
-	O
myc	O
.	O

CONCLUSION	O
:	O
Loss	O
of	O
CDC4	O
/	O
FBXW7	O
appears	O
to	O
play	O
a	O
role	O
in	O
both	O
EOGC	O
and	O
conventional	O
gastric	O
carcinogenesis	O
,	O
and	O
c	O
-	O
myc	O
overexpression	O
is	O
likely	O
to	O
be	O
an	O
important	O
oncogenic	O
consequence	O
of	O
CDC4	O
/	O
FBXW7	O
loss	O
.	O

Pain	O
assessment	O
by	O
continuous	O
EEG	O
:	O
association	O
between	O
subjective	O
perception	O
of	O
tonic	O
pain	O
and	O
peak	O
frequency	O
of	O
alpha	O
oscillations	O
during	O
stimulation	O
and	O
at	O
rest	O
.	O

Recordings	O
of	O
neurophysiological	O
brain	O
responses	O
to	O
noxious	O
stimuli	O
have	O
been	O
traditionally	O
based	O
on	O
short	O
stimuli	O
,	O
in	O
the	O
order	O
of	O
milliseconds	O
,	O
which	O
induce	O
distinct	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O

However	O
,	O
using	O
such	O
stimuli	O
in	O
the	O
experimental	O
setting	O
is	O
disadvantageous	O
as	O
they	O
are	O
too	O
brief	O
to	O
faithfully	O
simulate	O
clinical	O
pain	O
.	O

We	O
aimed	O
at	O
utilizing	O
continuous	O
EEG	O
to	O
investigate	O
the	O
properties	O
of	O
peak	O
alpha	O
frequency	O
(	O
PAF	O
)	O
as	O
an	O
objective	O
cortical	O
measure	O
associated	O
with	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O

Five	O
minute	O
long	O
continuous	O
EEG	O
was	O
recorded	O
in	O
18	O
healthy	O
volunteers	O
under	O
:	O
(	O
i	O
)	O
resting	O
-	O
state	O
;	O
(	O
ii	O
)	O
innocuous	O
temperature	O
;	O
and	O
(	O
iii	O
)	O
psychophysically	O
-	O
anchored	O
noxious	O
temperature	O
.	O

Numerical	O
pain	O
scores	O
(	O
NPSs	O
)	O
collected	O
during	O
the	O
application	O
of	O
tonic	O
noxious	O
stimuli	O
were	O
tested	O
for	O
correlation	O
with	O
peak	O
frequencies	O
of	O
alpha	O
power	O
-	O
curves	O
derived	O
from	O
central	O
,	O
temporal	O
and	O
frontal	O
electrodes	O
.	O

NPSs	O
and	O
PAFs	O
remained	O
stable	O
throughout	O
the	O
recording	O
conditions	O
(	O
RM	O
-	O
ANOVAs	O
;	O
Ps	O
>	O
0	O
.	O
51	O
)	O
.	O

In	O
the	O
noxious	O
condition	O
,	O
PAFs	O
obtained	O
at	O
the	O
bilateral	O
temporal	O
scalp	O
were	O
correlated	O
with	O
NPSs	O
(	O
Ps	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
recorded	O
at	O
the	O
bilateral	O
temporal	O
scalp	O
were	O
correlated	O
with	O
NPSs	O
reported	O
during	O
the	O
noxious	O
condition	O
(	O
Ps	O
<	O
0	O
.	O
01	O
)	O
.	O

These	O
psychophysical	O
-	O
neurophysiological	O
relations	O
attest	O
to	O
the	O
properties	O
of	O
PAF	O
as	O
a	O
novel	O
cortical	O
objective	O
measure	O
of	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O

Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
might	O
hold	O
inherent	O
pain	O
modulation	O
attributes	O
,	O
possibly	O
enabling	O
the	O
prediction	O
of	O
individual	O
responsiveness	O
to	O
prolonged	O
pain	O
.	O

The	O
relevance	O
of	O
PAF	O
to	O
the	O
neural	O
processing	O
of	O
tonic	O
pain	O
may	O
indicate	O
its	O
potential	O
to	O
advance	O
pain	O
research	O
as	O
well	O
as	O
clinical	O
pain	O
characterization	O
.	O

Acoustic	O
trauma	O
evokes	O
hyperactivity	O
and	O
changes	O
in	O
gene	O
expression	O
in	O
guinea	O
-	O
pig	O
auditory	O
brainstem	O
.	O

Hearing	O
loss	O
from	O
acoustic	O
trauma	O
is	O
a	O
risk	O
factor	O
for	O
tinnitus	O
.	O

Animal	O
models	O
using	O
acoustic	O
trauma	O
have	O
demonstrated	O
hyperactivity	O
in	O
central	O
auditory	O
pathways	O
,	O
which	O
has	O
been	O
suggested	O
as	O
a	O
substrate	O
for	O
tinnitus	O
.	O

We	O
used	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
unilateral	O
acoustic	O
trauma	O
.	O

Within	O
the	O
same	O
animals	O
,	O
measurements	O
of	O
peripheral	O
hearing	O
loss	O
,	O
spontaneous	O
activity	O
of	O
single	O
neurons	O
in	O
the	O
inferior	O
colliculus	O
and	O
gene	O
expression	O
in	O
cochlear	O
nucleus	O
and	O
inferior	O
colliculus	O
were	O
combined	O
,	O
acutely	O
and	O
after	O
recovery	O
from	O
acoustic	O
trauma	O
.	O

Genes	O
investigated	O
related	O
to	O
inhibitory	O
(	O
GABA	O
-	O
A	O
receptor	O
subunit	O
alpha	O
1	O
;	O
glycine	O
receptor	O
subunit	O
alpha	O
1	O
)	O
and	O
excitatory	O
neurotransmission	O
(	O
glutamate	O
decarboxylase	O
1	O
;	O
glutamate	O
receptor	O
AMPA	O
subunit	O
alpha	O
2	O
;	O
glutamate	O
receptor	O
NMDA	O
subunit	O
1	O
)	O
,	O
regulation	O
of	O
transmitter	O
release	O
(	O
member	O
of	O
RAB	O
family	O
of	O
small	O
GTPase	O
;	O
RAB3	O
GTPase	O
activating	O
protein	O
subunit	O
1	O
)	O
and	O
neuronal	O
excitability	O
(	O
potassium	O
channel	O
subfamily	O
K	O
member	O
15	O
)	O
.	O

Acoustic	O
trauma	O
resulted	O
in	O
unilateral	O
hearing	O
loss	O
and	O
hyperactivity	O
bilaterally	O
in	O
inferior	O
colliculus	O
.	O

Changes	O
in	O
expression	O
of	O
different	O
mRNAs	O
were	O
observed	O
in	O
ipsilateral	O
cochlear	O
nucleus	O
and	O
in	O
ipsi	O
-	O
and	O
contralateral	O
inferior	O
colliculus	O
,	O
immediately	O
after	O
acoustic	O
trauma	O
,	O
and	O
after	O
2	O
and	O
4	O
weeks	O
'	O
recovery	O
.	O

Gene	O
expression	O
was	O
generally	O
reduced	O
immediately	O
after	O
trauma	O
,	O
followed	O
by	O
a	O
return	O
to	O
near	O
normal	O
levels	O
or	O
over	O
-	O
expression	O
as	O
recovery	O
time	O
increased	O
.	O

Different	O
mechanisms	O
appear	O
to	O
underlie	O
the	O
spontaneous	O
hyperactivity	O
observed	O
.	O

There	O
is	O
evidence	O
of	O
down	O
-	O
regulation	O
of	O
genes	O
associated	O
with	O
neuronal	O
inhibition	O
in	O
the	O
contralateral	O
inferior	O
colliculus	O
,	O
whereas	O
in	O
ipsilateral	O
cochlear	O
nucleus	O
,	O
competing	O
actions	O
of	O
inhibitory	O
and	O
excitatory	O
systems	O
seem	O
to	O
play	O
a	O
major	O
role	O
in	O
determining	O
overall	O
excitability	O
.	O

Telomere	O
/	O
telomerase	O
interplay	O
in	O
virus	O
-	O
driven	O
and	O
virus	O
-	O
independent	O
lymphomagenesis	O
:	O
pathogenic	O
and	O
clinical	O
implications	O
.	O

Telomerase	O
is	O
a	O
ribonucleoprotein	O
complex	O
critically	O
involved	O
in	O
extending	O
and	O
maintaining	O
telomeres	O
.	O

Unlike	O
the	O
majority	O
of	O
somatic	O
cells	O
,	O
in	O
which	O
hTERT	O
and	O
telomerase	O
activity	O
are	O
generally	O
silent	O
,	O
normal	O
lymphocytes	O
show	O
transient	O
physiological	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
according	O
to	O
their	O
differentiation	O
/	O
activation	O
status	O
.	O

During	O
lymphomagenesis	O
,	O
induction	O
of	O
persistent	O
telomerase	O
expression	O
and	O
activity	O
may	O
occur	O
before	O
or	O
after	O
telomere	O
shortening	O
,	O
as	O
a	O
consequence	O
of	O
the	O
different	O
mechanisms	O
through	O
which	O
transforming	O
factors	O
/	O
agents	O
may	O
activate	O
telomerase	O
.	O

Available	O
data	O
indicate	O
that	O
the	O
timing	O
of	O
telomerase	O
activation	O
may	O
allow	O
the	O
distinction	O
of	O
two	O
different	O
lymphomagenetic	O
models	O
:	O
(	O
i	O
)	O
an	O
early	O
activation	O
of	O
telomerase	O
via	O
exogenous	O
regulators	O
of	O
hTERT	O
,	O
along	O
with	O
an	O
increased	O
lymphocyte	O
growth	O
and	O
a	O
subsequent	O
selection	O
of	O
cells	O
with	O
increased	O
transforming	O
potential	O
may	O
characterize	O
several	O
virus	O
-	O
related	O
lymphoid	O
malignancies	O
;	O
(	O
ii	O
)	O
a	O
progressive	O
shortening	O
of	O
telomeres	O
,	O
leading	O
to	O
genetic	O
instability	O
which	O
favors	O
a	O
subsequent	O
activation	O
of	O
telomerase	O
via	O
endogenous	O
regulators	O
may	O
occur	O
in	O
most	O
virus	O
-	O
unrelated	O
lymphoid	O
tumors	O
.	O

These	O
models	O
may	O
have	O
clinically	O
relevant	O
implications	O
,	O
particularly	O
for	O
the	O
tailoring	O
of	O
therapeutic	O
strategies	O
targeting	O
telomerase	O
.	O

Angiogenesis	O
inhibitors	O
:	O
current	O
strategies	O
and	O
future	O
prospects	O
.	O

Angiogenesis	O
has	O
become	O
an	O
attractive	O
target	O
for	O
drug	O
therapy	O
because	O
of	O
its	O
key	O
role	O
in	O
tumor	O
growth	O
.	O

An	O
extensive	O
array	O
of	O
compounds	O
is	O
currently	O
in	O
preclinical	O
development	O
,	O
with	O
many	O
now	O
entering	O
the	O
clinic	O
and	O
/	O
or	O
achieving	O
approval	O
from	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
.	O

Several	O
regulatory	O
and	O
signaling	O
molecules	O
governing	O
angiogenesis	O
are	O
of	O
interest	O
,	O
including	O
growth	O
factors	O
(	O
eg	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
,	O
fibroblast	O
growth	O
factor	O
,	O
and	O
epidermal	O
growth	O
factor	O
)	O
,	O
receptor	O
tyrosine	O
kinases	O
,	O
and	O
transcription	O
factors	O
such	O
as	O
hypoxia	O
inducible	O
factor	O
,	O
as	O
well	O
as	O
molecules	O
involved	O
in	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
signaling	O
.	O

Pharmacologic	O
agents	O
have	O
been	O
identified	O
that	O
target	O
these	O
pathways	O
,	O
yet	O
for	O
some	O
agents	O
(	O
notably	O
thalidomide	O
)	O
,	O
an	O
understanding	O
of	O
the	O
specific	O
mechanisms	O
of	O
antitumor	O
action	O
has	O
proved	O
elusive	O
.	O

The	O
following	O
review	O
describes	O
key	O
molecular	O
mechanisms	O
and	O
novel	O
therapies	O
that	O
are	O
on	O
the	O
horizon	O
for	O
antiangiogenic	O
tumor	O
therapy	O
.	O

A	O
generative	O
model	O
for	O
image	O
segmentation	O
based	O
on	O
label	O
fusion	O
.	O

We	O
propose	O
a	O
nonparametric	O
,	O
probabilistic	O
model	O
for	O
the	O
automatic	O
segmentation	O
of	O
medical	O
images	O
,	O
given	O
a	O
training	O
set	O
of	O
images	O
and	O
corresponding	O
label	O
maps	O
.	O

The	O
resulting	O
inference	O
algorithms	O
rely	O
on	O
pairwise	O
registrations	O
between	O
the	O
test	O
image	O
and	O
individual	O
training	O
images	O
.	O

The	O
training	O
labels	O
are	O
then	O
transferred	O
to	O
the	O
test	O
image	O
and	O
fused	O
to	O
compute	O
the	O
final	O
segmentation	O
of	O
the	O
test	O
subject	O
.	O

Such	O
label	O
fusion	O
methods	O
have	O
been	O
shown	O
to	O
yield	O
accurate	O
segmentation	O
,	O
since	O
the	O
use	O
of	O
multiple	O
registrations	O
captures	O
greater	O
inter	O
-	O
subject	O
anatomical	O
variability	O
and	O
improves	O
robustness	O
against	O
occasional	O
registration	O
failures	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
manuscript	O
presents	O
the	O
first	O
comprehensive	O
probabilistic	O
framework	O
that	O
rigorously	O
motivates	O
label	O
fusion	O
as	O
a	O
segmentation	O
approach	O
.	O

The	O
proposed	O
framework	O
allows	O
us	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
theoretically	O
and	O
practically	O
.	O

In	O
particular	O
,	O
recent	O
label	O
fusion	O
or	O
multiatlas	O
segmentation	O
algorithms	O
are	O
interpreted	O
as	O
special	O
cases	O
of	O
our	O
framework	O
.	O

We	O
conduct	O
two	O
sets	O
of	O
experiments	O
to	O
validate	O
the	O
proposed	O
methods	O
.	O

In	O
the	O
first	O
set	O
of	O
experiments	O
,	O
we	O
use	O
39	O
brain	O
MRI	O
scans	O
-	O
with	O
manually	O
segmented	O
white	O
matter	O
,	O
cerebral	O
cortex	O
,	O
ventricles	O
and	O
subcortical	O
structures	O
-	O
to	O
compare	O
different	O
label	O
fusion	O
algorithms	O
and	O
the	O
widely	O
-	O
used	O
FreeSurfer	O
whole	O
-	O
brain	O
segmentation	O
tool	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
proposed	O
framework	O
yields	O
more	O
accurate	O
segmentation	O
than	O
FreeSurfer	O
and	O
previous	O
label	O
fusion	O
algorithms	O
.	O

In	O
a	O
second	O
experiment	O
,	O
we	O
use	O
brain	O
MRI	O
scans	O
of	O
282	O
subjects	O
to	O
demonstrate	O
that	O
the	O
proposed	O
segmentation	O
tool	O
is	O
sufficiently	O
sensitive	O
to	O
robustly	O
detect	O
hippocampal	O
volume	O
changes	O
in	O
a	O
study	O
of	O
aging	O
and	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

Yellow	O
-	O
green	O
52	O
.	O
3W	O
laser	O
at	O
556	O
nm	O
based	O
on	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Q	O
-	O
switched	O
Nd	O
:	O
YAG	O
laser	O
.	O

We	O
demonstrate	O
a	O
high	O
-	O
power	O
556	O
nm	O
yellow	O
-	O
green	O
laser	O
generated	O
by	O
intracavity	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Nd	O
:	O
YAG	O
laser	O
at	O
1112	O
nm	O
.	O

A	O
symmetrical	O
L	O
-	O
shaped	O
flat	O
-	O
flat	O
cavity	O
was	O
employed	O
to	O
implement	O
efficient	O
operation	O
of	O
the	O
low	O
-	O
gain	O
1112	O
nm	O
transition	O
and	O
to	O
achieve	O
good	O
power	O
scalability	O
.	O

The	O
coatings	O
of	O
the	O
cavity	O
mirrors	O
were	O
carefully	O
designed	O
to	O
optimize	O
the	O
performance	O
of	O
the	O
laser	O
,	O
and	O
a	O
92W	O
continuous	O
wave	O
laser	O
output	O
at	O
1112	O
nm	O
was	O
achieved	O
when	O
the	O
pumping	O
power	O
of	O
the	O
laser	O
diodes	O
reached	O
960W	O
.	O

By	O
intracavity	O
frequency	O
doubling	O
of	O
the	O
fundamental	O
laser	O
in	O
a	O
lithium	O
triborate	O
crystal	O
,	O
the	O
maximum	O
power	O
of	O
the	O
frequency	O
-	O
doubled	O
output	O
at	O
556	O
nm	O
was	O
found	O
to	O
be	O
as	O
high	O
as	O
52	O
.	O
3W	O
with	O
a	O
pulse	O
repetition	O
frequency	O
of	O
10kHz	O
.	O

This	O
corresponds	O
to	O
an	O
optical	O
-	O
to	O
-	O
optical	O
conversion	O
efficiency	O
of	O
about	O
5	O
.	O
4	O
%	O
.	O

Betulin	O
induces	O
mitochondrial	O
cytochrome	O
c	O
release	O
associated	O
apoptosis	O
in	O
human	O
cancer	O
cells	O
.	O

We	O
examined	O
whether	O
betulin	O
,	O
a	O
naturally	O
abundant	O
compound	O
,	O
has	O
anticancer	O
functions	O
in	O
human	O
cancer	O
cells	O
.	O

The	O
results	O
showed	O
that	O
betulin	O
significantly	O
inhibited	O
cell	O
viability	O
in	O
cervix	O
carcinoma	O
HeLa	B
cells	O
,	O
hepatoma	O
HepG2	B
cells	O
,	O
lung	O
adenocarcinoma	O
A549	B
cells	O
,	O
and	O
breast	O
cancer	O
MCF	B
-	I
7	I
cells	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
10	O
to	O
15	O
microg	O
/	O
mL	O
.	O

While	O
betulin	O
exhibited	O
only	O
moderate	O
anticancer	O
activity	O
in	O
other	O
human	O
cancer	O
cells	O
such	O
as	O
hepatoma	O
SK	B
-	I
HEP	I
-	I
1	I
cells	O
,	O
prostate	O
carcinoma	O
PC	B
-	I
3	I
,	O
and	O
lung	O
carcinoma	O
NCI	B
-	I
H460	I
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
20	O
to	O
60	O
microg	O
/	O
mL	O
,	O
it	O
showed	O
minor	O
growth	O
inhibition	O
in	O
human	O
erythroleukemia	O
K562	B
cells	O
(	O
IC	O
(	O
50	O
)	O
>	O
100	O
microg	O
/	O
mL	O
)	O
.	O

We	O
further	O
investigated	O
the	O
mechanism	O
of	O
anticancer	O
activity	O
by	O
betulin	O
,	O
using	O
HeLa	B
cells	O
as	O
an	O
experimental	O
model	O
.	O

Betulin	O
(	O
10	O
microg	O
/	O
mL	O
)	O
induces	O
apoptotic	O
cell	O
death	O
,	O
as	O
evidenced	O
by	O
morphological	O
characteristics	O
such	O
as	O
membrane	O
phosphatidylserine	O
translocation	O
,	O
nuclear	O
condensation	O
/	O
fragmentation	O
,	O
and	O
apoptotic	O
body	O
formation	O
.	O

A	O
kinetics	O
analysis	O
showed	O
that	O
the	O
depolarization	O
of	O
mitochondrial	O
membrane	O
potential	O
and	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	O
c	O
occurred	O
as	O
early	O
as	O
30	O
min	O
after	O
treatment	O
with	O
betulin	O
.	O

Betulin	O
,	O
unlike	O
its	O
chemical	O
derivative	O
betulinic	O
acid	O
,	O
did	O
not	O
directly	O
trigger	O
mitochondrial	O
cytochrome	O
c	O
release	O
in	O
isolated	O
mitochondria	O
.	O

Importantly	O
,	O
Bax	O
and	O
Bak	O
were	O
rapidly	O
translocated	O
to	O
the	O
mitochondria	O
30	O
min	O
after	O
betulin	O
treatment	O
.	O

The	O
sequential	O
activation	O
of	O
caspase	O
-	O
9	O
and	O
caspase	O
-	O
3	O
/	O
-	O
7	O
and	O
the	O
cleavage	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
were	O
observed	O
behind	O
those	O
mitochondrial	O
events	O
.	O

Furthermore	O
,	O
specific	O
downregulation	O
of	O
either	O
caspase	O
-	O
9	O
,	O
Bax	O
,	O
or	O
Bak	O
by	O
siRNA	O
effectively	O
reduced	O
PARP	O
cleavage	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Taken	O
together	O
,	O
the	O
lines	O
of	O
evidence	O
demonstrate	O
that	O
betulin	O
triggers	O
apoptosis	O
of	O
human	O
cancer	O
cells	O
through	O
the	O
intrinsic	O
apoptotic	O
pathway	O
.	O

Relationship	O
and	O
prognostic	O
significance	O
of	O
SPARC	O
and	O
VEGF	O
protein	O
expression	O
in	O
colon	O
cancer	O
.	O

BACKGROUND	O
:	O
SPARC	O
(	O
secreted	O
protein	O
,	O
acidic	O
and	O
rich	O
in	O
cysteine	O
)	O
is	O
closely	O
related	O
with	O
the	O
progress	O
,	O
invasion	O
and	O
metastasis	O
of	O
malignant	O
tumor	O
and	O
angiogenesis	O
.	O

METHODS	O
:	O
Using	O
human	O
colon	O
adenocarcinoma	O
tissues	O
(	O
hereinafter	O
referred	O
to	O
as	O
colon	O
cancer	O
)	O
and	O
their	O
corresponding	O
non	O
-	O
diseased	O
colon	O
from	O
114	O
patients	O
'	O
biopsies	O
,	O
the	O
expression	O
of	O
SPARC	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
were	O
investigated	O
by	O
immunohistochemistry	O
staining	O
to	O
assessment	O
the	O
relationship	O
between	O
SPARC	O
and	O
VEGF	O
,	O
as	O
well	O
as	O
their	O
prognostic	O
significance	O
in	O
patients	O
.	O

Evaluation	O
of	O
VEGF	O
expression	O
level	O
with	O
the	O
same	O
tissues	O
was	O
used	O
to	O
establish	O
the	O
antigenic	O
profiles	O
,	O
and	O
the	O
marker	O
of	O
CD34	O
staining	O
was	O
used	O
as	O
an	O
indicator	O
of	O
microvessel	O
density	O
(	O
MVD	O
)	O
.	O

RESULTS	O
:	O
SPARC	O
expression	O
was	O
mainly	O
in	O
the	O
stromal	O
cells	O
surrounding	O
the	O
colon	O
cancer	O
,	O
and	O
was	O
significant	O
difference	O
in	O
those	O
tissues	O
with	O
the	O
lymph	O
node	O
metastasis	O
and	O
differentiation	O
degree	O
of	O
tumor	O
.	O

Expression	O
of	O
SPARC	O
was	O
significantly	O
correlated	O
with	O
the	O
expression	O
of	O
VEGF	O
and	O
MVD	O
in	O
colon	O
cancer	O
tissues	O
.	O

Patients	O
with	O
low	O
or	O
absence	O
expressing	O
SPARC	O
had	O
significantly	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
in	O
a	O
Single	O
Factor	O
Analysis	O
;	O
Cox	O
Regression	O
Analysis	O
,	O
SPARC	O
emerged	O
as	O
an	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
independent	O
prognostic	O
factor	O
for	O
colon	O
cancer	O
.	O

CONCLUSION	O
:	O
The	O
low	O
expression	O
or	O
absence	O
of	O
stromal	O
SPARC	O
was	O
an	O
independent	O
prognostic	O
factor	O
for	O
poor	O
prognosis	O
of	O
colon	O
cancer	O
.	O

SPARC	O
maybe	O
involved	O
in	O
the	O
regulation	O
of	O
anti	O
-	O
angiogenesis	O
by	O
which	O
it	O
may	O
serve	O
as	O
a	O
novel	O
target	O
for	O
colon	O
cancer	O
treatment	O
as	O
well	O
as	O
a	O
novel	O
distinctive	O
marker	O
.	O

Prognostic	O
significance	O
of	O
TRAIL	O
signaling	O
molecules	O
in	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
.	O

PURPOSE	O
:	O

We	O
previously	O
found	O
that	O
cellular	O
FLICE	O
-	O
inhibitory	O
protein	O
(	O
c	O
-	O
FLIP	O
)	O
,	O
caspase	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
receptor	O
2	O
(	O
DR5	O
)	O
are	O
major	O
regulators	O
of	O
cell	O
viability	O
and	O
chemotherapy	O
-	O
induced	O
apoptosis	O
in	O
colorectal	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
c	O
-	O
FLIP	O
,	O
caspase	O
8	O
,	O
TRAIL	O
and	O
DR5	O
expression	O
in	O
tissues	O
from	O
patients	O
with	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O

Tissue	O
microarrays	O
were	O
constructed	O
from	O
matched	O
normal	O
and	O
tumor	O
tissue	O
derived	O
from	O
patients	O
(	O
n	O
=	O
253	O
)	O
enrolled	O
in	O
a	O
phase	O
III	O
trial	O
of	O
adjuvant	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
versus	O
postoperative	O
observation	O
alone	O
.	O

TRAIL	O
,	O
DR5	O
,	O
caspase	O
8	O
,	O
and	O
c	O
-	O
FLIP	O
expression	O
levels	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O

Colorectal	O
tumors	O
displayed	O
significantly	O
higher	O
expression	O
levels	O
of	O
c	O
-	O
FLIP	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
caspase	O
8	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
DR5	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
lower	O
levels	O
of	O
TRAIL	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
matched	O
normal	O
tissue	O
.	O

In	O
univariate	O
analysis	O
,	O
higher	O
TRAIL	O
expression	O
in	O
the	O
tumor	O
was	O
associated	O
with	O
worse	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
026	O
)	O
,	O
with	O
a	O
trend	O
to	O
decreased	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
;	O
P	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
higher	O
tumor	O
c	O
-	O
FLIP	O
expression	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
RFS	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

Using	O
multivariate	O
predictive	O
modeling	O
for	O
RFS	O
in	O
all	O
patients	O
and	O
including	O
all	O
biomarkers	O
,	O
age	O
,	O
treatment	O
,	O
and	O
stage	O
,	O
we	O
found	O
that	O
the	O
model	O
was	O
significant	O
when	O
the	O
mean	O
tumor	O
c	O
-	O
FLIP	O
expression	O
score	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

As	O
regards	O
overall	O
survival	O
,	O
the	O
overall	O
model	O
was	O
predictive	O
when	O
both	O
TRAIL	O
expression	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O

High	O
c	O
-	O
FLIP	O
and	O
TRAIL	O
expression	O
may	O
be	O
independent	O
adverse	O
prognostic	O
markers	O
in	O
stage	O
II	O
and	O
III	O
colorectal	O
cancer	O
and	O
might	O
identify	O
patients	O
most	O
at	O
risk	O
of	O
relapse	O
.	O

Overexpression	O
of	O
Bax	O
inhibitor	O
-	O
1	O
(	O
BI	O
-	O
1	O
)	O
induces	O
cell	O
transformation	O
in	O
NIH3T3	B
cells	O
.	O

BI	O
-	O
1	O
(	O
Bax	O
inhibitor	O
-	O
1	O
)	O
,	O
an	O
apoptosis	O
-	O
inhibiting	O
gene	O
belonging	O
to	O
the	O
Bcl	O
-	O
2	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mitochondrial	O
apoptosis	O
pathway	O
to	O
suppress	O
Bax	O
-	O
induced	O
apoptosis	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
BI	O
-	O
1	O
in	O
promoting	O
cell	O
growth	O
and	O
tumorigenesis	O
,	O
in	O
the	O
present	O
study	O
we	O
overexpressed	O
the	O
BI	O
-	O
1	O
gene	O
in	O
NIH3T3	B
cells	O
using	O
the	O
lentivirus	O
-	O
mediated	O
gene	O
expression	O
system	O
.	O

Our	O
in	O
vitro	O
studies	O
showed	O
that	O
NIH3T3	B
cells	O
overexpressing	O
BI	O
-	O
1	O
displayed	O
a	O
significantly	O
higher	O
growth	O
rate	O
and	O
formed	O
more	O
and	O
larger	O
colonies	O
than	O
the	O
control	O
cells	O
.	O

In	O
addition	O
,	O
our	O
in	O
vivo	O
studies	O
indicated	O
that	O
the	O
lenti	O
-	O
BI	O
-	O
1	O
-	O
infected	O
cells	O
formed	O
obvious	O
tumours	O
,	O
while	O
no	O
tumours	O
were	O
formed	O
by	O
the	O
control	O
cells	O
after	O
subcutaneously	O
injected	O
into	O
nude	O
mice	O
.	O

These	O
results	O
strongly	O
suggested	O
that	O
the	O
BI	O
-	O
1	O
gene	O
might	O
play	O
a	O
crucial	O
role	O
in	O
neoplastic	O
genesis	O
and	O
development	O
.	O

Structure	O
of	O
human	O
hemoglobin	O
messenger	O
RNA	O
and	O
its	O
relation	O
to	O
hemoglobinopathies	O
.	O

1	O
.	O

One	O
-	O
fifth	O
to	O
1	O
/	O
4	O
of	O
globin	O
mRNA	O
is	O
untranslated	O
sequence	O
other	O
than	O
polyadenylic	O
acid	O
.	O

2	O
.	O

The	O
untranslated	O
sequences	O
of	O
mRNA	O
vary	O
markedly	O
in	O
their	O
sequence	O
and	O
in	O
their	O
length	O
.	O

3	O
.	O

Globin	O
mRNAs	O
demonstrate	O
a	O
marked	O
bias	O
in	O
codon	O
selection	O
.	O

4	O
.	O

Viral	O
mRNA	O
shows	O
a	O
quite	O
different	O
pattern	O
of	O
codon	O
selection	O
;	O
therefore	O
,	O
the	O
selection	O
of	O
codons	O
is	O
not	O
uniform	O
for	O
all	O
mRNAs	O
functioning	O
in	O
animal	O
cells	O
.	O

5	O
.	O

Elongated	O
hemoglobin	O
chains	O
can	O
be	O
accounted	O
for	O
by	O
frame	O
-	O
shift	O
mutations	O
,	O
or	O
point	O
mutations	O
within	O
the	O
normal	O
termination	O
codon	O
.	O

The	O
additional	O
amino	O
acids	O
are	O
then	O
coded	O
for	O
by	O
sequences	O
that	O
are	O
normally	O
untranslated	O
.	O

6	O
.	O

Certain	O
hemoglobin	O
deletion	O
mutants	O
occur	O
at	O
sites	O
where	O
there	O
are	O
partially	O
reiterated	O
sequences	O
within	O
the	O
heomoglobin	O
messenger	O
RNA	O
.	O

Anti	O
-	O
metastasis	O
effects	O
of	O
gallic	O
acid	O
on	O
gastric	O
cancer	O
cells	O
involves	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
and	O
downregulation	O
of	O
PI3	O
K	O
/	O
AKT	O
/	O
small	O
GTPase	O
signals	O
.	O

Polyphenols	O
are	O
natural	O
antioxidants	O
that	O
are	O
thought	O
to	O
contribute	O
to	O
prevention	O
of	O
cardiovascular	O
disease	O
and	O
malignancy	O
.	O

Although	O
many	O
studies	O
have	O
been	O
carried	O
out	O
to	O
investigate	O
the	O
chemopreventive	O
role	O
of	O
flavonoids	O
,	O
less	O
attention	O
has	O
been	O
focused	O
on	O
phenolic	O
acids	O
.	O

In	O
this	O
study	O
,	O
the	O
aim	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
phenolic	O
acids	O
found	O
abundantly	O
in	O
vegetables	O
,	O
i	O
.	O
e	O
.	O
gallic	O
acid	O
(	O
GA	O
)	O
,	O
caffeic	O
acid	O
(	O
CA	O
)	O
and	O
protocatechuic	O
acid	O
(	O
PCA	O
)	O
,	O
on	O
the	O
inhibition	O
of	O
gastric	O
adenocarcinoma	O
(	O
AGS	O
)	O
cell	O
metastasis	O
.	O

The	O
results	O
showed	O
0	O
.	O
01	O
mM	O
GA	O
induced	O
the	O
same	O
level	O
of	O
cell	O
toxicity	O
as	O
4	O
.	O
0mM	O
PCA	O
.	O

Using	O
wound	O
-	O
healing	O
assay	O
and	O
Boyden	O
chamber	O
assay	O
,	O
GA	O
had	O
potent	O
inhibitory	O
effects	O
on	O
AGS	O
cell	O
migration	O
.	O

The	O
expression	O
of	O
MMP	O
-	O
2	O
/	O
9	O
of	O
AGS	O
cells	O
was	O
inhibited	O
by	O
2	O
.	O
0	O
microM	O
of	O
GA	O
.	O

It	O
is	O
possible	O
that	O
the	O
suppressive	O
effect	O
of	O
GA	O
on	O
MMP	O
-	O
2	O
/	O
9	O
might	O
involve	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

Multiple	O
proteins	O
involved	O
in	O
metastasis	O
and	O
the	O
cytoskeletal	O
reorganization	O
signal	O
pathway	O
,	O
including	O
Ras	O
,	O
Cdc42	O
,	O
Rac1	O
,	O
RhoA	O
,	O
RhoB	O
,	O
PI3	O
K	O
and	O
p38MAPK	O
,	O
were	O
also	O
inhibited	O
by	O
GA	O
.	O

Furthermore	O
,	O
immunoreactivity	O
assay	O
of	O
cytoskeletal	O
F	O
-	O
actin	O
demonstrated	O
a	O
significant	O
inhibitory	O
effect	O
of	O
GA	O
treatment	O
.	O

In	O
conclusion	O
,	O
GA	O
may	O
have	O
the	O
potential	O
to	O
be	O
an	O
effective	O
agent	O
for	O
prevention	O
and	O
treatment	O
of	O
gastric	O
cancer	O
metastasis	O
.	O

1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
,	O
but	O
not	O
selenomethionine	O
,	O
inhibits	O
androgen	O
receptor	O
and	O
Akt	O
signaling	O
in	O
human	O
prostate	O
cancer	O
cells	O
.	O

The	O
lack	O
of	O
treatment	O
for	O
worried	O
-	O
well	O
patients	O
with	O
high	O
-	O
grade	O
prostatic	O
intraepithelial	O
neoplasia	O
combined	O
with	O
issues	O
of	O
recurrence	O
and	O
hormone	O
resistance	O
in	O
prostate	O
cancer	O
survivors	O
remains	O
a	O
major	O
public	O
health	O
obstacle	O
.	O

The	O
long	O
latency	O
of	O
prostate	O
cancer	O
development	O
provides	O
an	O
opportunity	O
to	O
intervene	O
with	O
agents	O
of	O
known	O
mechanisms	O
at	O
various	O
stages	O
of	O
disease	O
progression	O
.	O

A	O
number	O
of	O
signaling	O
cascades	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
prostate	O
cancer	O
development	O
and	O
progression	O
,	O
including	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
and	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathways	O
.	O

Crosstalk	O
between	O
these	O
two	O
pathways	O
is	O
also	O
thought	O
to	O
contribute	O
to	O
progression	O
and	O
hormone	O
-	O
refractory	O
prostate	O
disease	O
.	O

Our	O
initial	O
investigations	O
show	O
that	O
the	O
naturally	O
occurring	O
organoselenium	O
compound	O
selenomethionine	O
(	O
SM	O
)	O
and	O
the	O
synthetic	O
1	O
,	O
4	O
-	O
phenylenebis	O
(	O
methylene	O
)	O
selenocyanate	O
(	O
p	O
-	O
XSC	O
)	O
can	O
inhibit	O
human	O
prostate	O
cancer	O
cell	O
viability	O
;	O
however	O
,	O
in	O
contrast	O
to	O
SM	O
,	O
p	O
-	O
XSC	O
is	O
active	O
at	O
physiologically	O
relevant	O
doses	O
.	O

In	O
the	O
current	O
investigation	O
,	O
we	O
show	O
that	O
p	O
-	O
XSC	O
,	O
but	O
not	O
an	O
equivalent	O
dose	O
of	O
SM	O
,	O
alters	O
molecular	O
targets	O
and	O
induces	O
apoptosis	O
in	O
androgen	O
-	O
responsive	O
LNCaP	B
and	O
androgen	O
-	O
independent	O
LNCaP	B
C4	I
-	I
2	I
human	O
prostate	O
cancer	O
cells	O
.	O

p	O
-	O
XSC	O
effectively	O
inhibits	O
AR	O
expression	O
and	O
transcriptional	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

p	O
-	O
XSC	O
also	O
decreases	O
Akt	O
phosphorylation	O
as	O
well	O
as	O
Akt	O
-	O
specific	O
phosphorylation	O
of	O
the	O
AR	O
.	O

Inhibition	O
of	O
Akt	O
,	O
however	O
,	O
does	O
not	O
fully	O
attenuate	O
p	O
-	O
XSC	O
-	O
mediated	O
downregulation	O
of	O
AR	O
activity	O
,	O
suggesting	O
that	O
inhibition	O
of	O
AR	O
signaling	O
by	O
p	O
-	O
XSC	O
does	O
not	O
occur	O
solely	O
through	O
alterations	O
in	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
/	O
Akt	O
survival	O
pathway	O
.	O

Our	O
data	O
suggest	O
that	O
p	O
-	O
XSC	O
inhibits	O
multiple	O
signaling	O
pathways	O
in	O
prostate	O
cancer	O
,	O
likely	O
accounting	O
for	O
the	O
downstream	O
effects	O
on	O
proliferation	O
and	O
apoptosis	O
.	O

Listerine	O
:	O
past	O
,	O
present	O
and	O
future	O
-	O
-	O
a	O
test	O
of	O
thyme	O
.	O

Listerine	O
,	O
a	O
mouthrinse	O
composed	O
of	O
a	O
mixture	O
of	O
essential	O
oils	O
,	O
was	O
created	O
in	O
1879	O
and	O
was	O
originally	O
formulated	O
as	O
a	O
surgical	O
antiseptic	O
.	O

In	O
spite	O
of	O
its	O
known	O
antimicrobial	O
properties	O
it	O
was	O
thought	O
of	O
as	O
a	O
product	O
in	O
search	O
of	O
a	O
use	O
and	O
promoted	O
as	O
a	O
deterrent	O
for	O
halitosis	O
and	O
as	O
a	O
floor	O
cleaner	O
.	O

In	O
the	O
last	O
several	O
years	O
Listerine	O
has	O
emerged	O
as	O
a	O
bona	O
fide	O
therapeutic	O
agent	O
for	O
reduction	O
of	O
plaque	O
induced	O
oral	O
diseases	O
.	O

In	O
contrast	O
to	O
the	O
inconsistent	O
history	O
of	O
Listerine	O
,	O
systemic	O
antibiotics	O
discovered	O
in	O
the	O
1940	O
'	O
s	O
were	O
heralded	O
as	O
miracle	O
drugs	O
.	O

However	O
,	O
the	O
value	O
of	O
prophylactic	O
usage	O
of	O
antibiotics	O
has	O
come	O
under	O
scrutiny	O
as	O
a	O
result	O
of	O
increasing	O
resistance	O
and	O
adverse	O
reactions	O
.	O

Moreover	O
,	O
reports	O
by	O
both	O
American	O
and	O
British	O
professional	O
societies	O
have	O
led	O
to	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
relative	O
risks	O
associated	O
with	O
plaque	O
induced	O
bacteremia	O
when	O
twice	O
-	O
yearly	O
visits	O
to	O
dental	O
professionals	O
are	O
compared	O
to	O
daily	O
activities	O
.	O

These	O
new	O
recommendations	O
and	O
revelations	O
open	O
the	O
door	O
for	O
local	O
antimicrobial	O
approaches	O
to	O
reduce	O
the	O
challenge	O
of	O
plaque	O
-	O
induced	O
bacteremias	O
.	O

These	O
issues	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
Listerine	O
,	O
its	O
intricate	O
and	O
complicated	O
past	O
,	O
and	O
its	O
connection	O
to	O
current	O
uses	O
in	O
oral	O
health	O
and	O
beyond	O
.	O

Ventral	O
and	O
dorsal	O
striatal	O
dopamine	O
efflux	O
and	O
behavior	O
in	O
rats	O
with	O
simple	O
vs	O
.	O
co	O
-	O
morbid	O
histories	O
of	O
cocaine	O
sensitization	O
and	O
neonatal	O
ventral	O
hippocampal	O
lesions	O
.	O

UNLABELLED	O
:	O

RATIONAL	O
:	O
Exposing	O
animal	O
models	O
of	O
mental	O
illness	O
to	O
addictive	O
drugs	O
provides	O
an	O
approach	O
to	O
understanding	O
the	O
neural	O
etiology	O
of	O
dual	O
diagnosis	O
disorders	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
neonatal	O
ventral	O
hippocampal	O
lesions	O
(	O
NVHL	O
)	O
in	O
rats	O
produce	O
features	O
of	O
both	O
schizophrenia	O
and	O
addiction	O
vulnerability	O
.	O

OBJECTIVE	O
:	O

This	O
study	O
investigated	O
ventral	O
and	O
dorsal	O
striatal	O
dopamine	O
(	O
DA	O
)	O
efflux	O
in	O
NVHL	O
rats	O
combined	O
with	O
behavioral	O
sensitization	O
to	O
cocaine	O
.	O

METHODS	O
:	O

Adult	O
NVHL	O
vs	O
.	O
SHAM	O
-	O
operated	O
rats	O
underwent	O
a	O
5	O
-	O
day	O
injection	O
series	O
of	O
cocaine	O
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
vs	O
.	O
saline	O
.	O

One	O
week	O
later	O
,	O
rats	O
were	O
cannulated	O
in	O
nucleus	O
accumbens	O
SHELL	O
,	O
CORE	O
,	O
or	O
caudate	O
-	O
putamen	O
.	O

Another	O
week	O
later	O
,	O
in	O
vivo	O
microdialysis	O
sampled	O
DA	O
during	O
locomotor	O
testing	O
in	O
which	O
a	O
single	O
cocaine	O
injection	O
(	O
15	O
mg	O
/	O
kg	O
)	O
was	O
delivered	O
.	O

RESULTS	O
:	O

NVHLs	O
and	O
cocaine	O
history	O
significantly	O
increased	O
behavioral	O
activation	O
approximately	O
2	O
-	O
fold	O
over	O
SHAM	O
-	O
saline	O
history	O
rats	O
.	O

DA	O
efflux	O
curves	O
corresponded	O
time	O
dependently	O
with	O
the	O
cocaine	O
injection	O
and	O
locomotor	O
curves	O
and	O
varied	O
significantly	O
by	O
striatal	O
region	O
:	O
Baseline	O
DA	O
levels	O
increased	O
5	O
-	O
fold	O
while	O
cocaine	O
-	O
stimulated	O
DA	O
efflux	O
decreased	O
by	O
half	O
across	O
a	O
ventral	O
to	O
dorsal	O
striatal	O
gradient	O
.	O

However	O
,	O
NVHLs	O
,	O
prior	O
cocaine	O
history	O
,	O
and	O
individual	O
differences	O
in	O
behavior	O
were	O
not	O
underpinned	O
by	O
differential	O
DA	O
efflux	O
overall	O
or	O
within	O
any	O
striatal	O
region	O
.	O

CONCLUSION	O
:	O

Differences	O
in	O
ventral	O
/	O
dorsal	O
striatal	O
DA	O
efflux	O
are	O
not	O
present	O
in	O
and	O
are	O
not	O
required	O
for	O
producing	O
differential	O
levels	O
of	O
acute	O
cocaine	O
-	O
induced	O
behavioral	O
activation	O
in	O
NVHLs	O
with	O
and	O
without	O
a	O
behaviorally	O
sensitizing	O
cocaine	O
history	O
.	O

These	O
findings	O
suggest	O
other	O
neurotransmitter	O
systems	O
,	O
and	O
alterations	O
in	O
striatal	O
network	O
function	O
post	O
-	O
synaptic	O
to	O
DA	O
transmission	O
are	O
more	O
important	O
to	O
understanding	O
the	O
interactive	O
effects	O
of	O
addictive	O
drugs	O
and	O
mental	O
illness	O
.	O

Adenovirus	O
5	O
E1A	O
enhances	O
histone	O
deacetylase	O
inhibitors	O
-	O
induced	O
apoptosis	O
through	O
Egr	O
-	O
1	O
-	O
mediated	O
Bim	O
upregulation	O
.	O

Histone	O
deacetylase	O
inhibitors	O
(	O
HDACi	O
)	O
are	O
potent	O
anti	O
-	O
cancer	O
agents	O
for	O
variety	O
of	O
cancer	O
types	O
.	O

Suberoylanilide	O
hydroxamic	O
acid	O
(	O
SAHA	O
)	O
has	O
been	O
approved	O
as	O
a	O
drug	O
to	O
treat	O
cutaneous	O
T	O
cell	O
lymphoma	O
,	O
and	O
the	O
combination	O
of	O
HDACi	O
and	O
other	O
agents	O
have	O
been	O
actively	O
tested	O
in	O
many	O
clinical	O
trials	O
.	O

Adenovirus	O
5	O
early	O
region	O
1A	O
(	O
E1A	O
)	O
has	O
been	O
shown	O
to	O
exhibit	O
high	O
tumor	O
suppressor	O
activity	O
,	O
and	O
gene	O
therapy	O
using	O
E1A	O
has	O
been	O
tested	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
showed	O
that	O
proapoptotic	O
activity	O
of	O
HDACi	O
was	O
robustly	O
enhanced	O
by	O
E1A	O
in	O
multiple	O
cancer	O
cells	O
,	O
but	O
not	O
in	O
normal	O
cells	O
.	O

Moreover	O
,	O
we	O
showed	O
that	O
combination	O
of	O
E1A	O
gene	O
therapy	O
and	O
SAHA	O
showed	O
high	O
therapeutic	O
efficacy	O
with	O
low	O
toxicity	O
in	O
vivo	O
ovarian	O
and	O
breast	O
xenograft	O
models	O
.	O

SAHA	O
downregulated	O
Bcl	O
-	O
XL	O
and	O
upregulated	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
Bim	O
,	O
whose	O
expression	O
was	O
further	O
enhanced	O
by	O
E1A	O
in	O
cancer	O
cells	O
.	O

These	O
alterations	O
of	O
Bcl	O
-	O
2	O
family	O
proteins	O
were	O
critical	O
for	O
apoptosis	O
induced	O
by	O
the	O
combination	O
in	O
cancer	O
cells	O
.	O

SAHA	O
enhanced	O
acetylation	O
of	O
histone	O
H3	O
in	O
Bim	O
promoter	O
region	O
,	O
while	O
E1A	O
upregulated	O
Egr	O
-	O
1	O
,	O
which	O
was	O
directly	O
involved	O
in	O
Bim	O
transactivation	O
.	O

Together	O
,	O
our	O
results	O
provide	O
not	O
only	O
a	O
novel	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
anti	O
-	O
tumor	O
activity	O
of	O
E1A	O
,	O
but	O
also	O
a	O
rationale	O
for	O
the	O
combined	O
HDACi	O
and	O
E1A	O
gene	O
therapy	O
in	O
future	O
clinical	O
trials	O
.	O

Sanguinarine	O
induces	O
apoptosis	O
of	O
human	O
osteosarcoma	O
cells	O
through	O
the	O
extrinsic	O
and	O
intrinsic	O
pathways	O
.	O

The	O
quaternary	O
benzo	O
[	O
c	O
]	O
phenanthridine	O
alkaloid	O
sanguinarine	O
inhibits	O
the	O
proliferation	O
of	O
cancerous	O
cells	O
from	O
different	O
origins	O
,	O
including	O
lung	O
,	O
breast	O
,	O
pancreatic	O
and	O
colon	O
,	O
but	O
nothing	O
is	O
known	O
of	O
its	O
effects	O
on	O
osteosarcoma	O
,	O
a	O
primary	O
malignant	O
bone	O
tumour	O
.	O

We	O
have	O
found	O
that	O
sanguinarine	O
alters	O
the	O
morphology	O
and	O
reduces	O
the	O
viability	O
of	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
human	O
osteosarcoma	O
cell	O
lines	O
in	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Incubation	O
with	O
1	O
micromol	O
/	O
L	O
sanguinarine	O
for	O
4	O
and	O
24h	O
killed	O
more	O
efficiently	O
MG	B
-	I
63	I
cells	O
than	O
SaOS	B
-	I
2	I
cells	O
,	O
while	O
incubation	O
with	O
5	O
micromol	O
/	O
L	O
sanguinarine	O
killed	O
almost	O
100	O
%	O
of	O
both	O
cell	O
populations	O
within	O
24h	O
.	O

This	O
treatment	O
also	O
changed	O
the	O
mitochondrial	O
membrane	O
potential	O
in	O
both	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
cells	O
within	O
1h	O
,	O
caused	O
chromatin	O
condensation	O
and	O
the	O
formation	O
of	O
apoptotic	O
bodies	O
.	O

It	O
activated	O
multicaspases	O
,	O
and	O
increased	O
the	O
activities	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
in	O
both	O
MG	B
-	I
63	I
and	O
SaOS	B
-	I
2	I
cells	O
.	O

These	O
data	O
highlight	O
sanguinarine	O
as	O
a	O
novel	O
potential	O
agent	O
for	O
bone	O
cancer	O
therapy	O
.	O

Using	O
a	O
web	O
-	O
based	O
orthopaedic	O
clinic	O
in	O
the	O
curricular	O
teaching	O
of	O
a	O
German	O
university	O
hospital	O
:	O
analysis	O
of	O
learning	O
effect	O
,	O
student	O
usage	O
and	O
reception	O
.	O

PURPOSE	O
:	O

Modern	O
teaching	O
concepts	O
for	O
undergraduate	O
medical	O
students	O
in	O
Germany	O
include	O
problem	O
based	O
learning	O
as	O
a	O
major	O
component	O
of	O
the	O
new	O
licensing	O
regulations	O
for	O
physicians	O
.	O

Here	O
we	O
describe	O
the	O
usage	O
of	O
a	O
web	O
-	O
based	O
virtual	O
outpatient	O
clinic	O
in	O
the	O
teaching	O
curriculum	O
of	O
undergraduate	O
medical	O
students	O
,	O
its	O
effect	O
on	O
learning	O
success	O
,	O
and	O
student	O
reception	O
.	O

METHODS	O
:	O

Fifth	O
year	O
medial	O
students	O
were	O
requested	O
to	O
examine	O
7	O
virtual	O
orthopaedic	O
patients	O
which	O
had	O
been	O
created	O
by	O
the	O
authors	O
using	O
the	O
Inmedea	O
-	O
Simulator	O
.	O

They	O
also	O
had	O
to	O
take	O
a	O
multiple	O
-	O
choice	O
examination	O
on	O
two	O
different	O
occasions	O
and	O
their	O
utilisation	O
of	O
the	O
simulator	O
was	O
analysed	O
subjectively	O
and	O
objectively	O
.	O

RESULTS	O
:	O

One	O
hundred	O
and	O
sixty	O
students	O
took	O
part	O
in	O
the	O
study	O
.	O

The	O
average	O
age	O
was	O
24	O
.	O
9	O
years	O
,	O
60	O
%	O
were	O
female	O
.	O

Most	O
of	O
the	O
participants	O
studied	O
on	O
their	O
own	O
using	O
their	O
private	O
computer	O
with	O
a	O
fast	O
internet	O
-	O
connection	O
at	O
home	O
.	O

The	O
average	O
usage	O
time	O
was	O
263	O
min	O
,	O
most	O
of	O
the	O
students	O
worked	O
with	O
the	O
system	O
in	O
the	O
afternoon	O
,	O
although	O
a	O
considerable	O
number	O
used	O
it	O
late	O
in	O
the	O
night	O
.	O

Regarding	O
learning	O
success	O
,	O
we	O
found	O
that	O
the	O
examination	O
results	O
were	O
significantly	O
better	O
after	O
using	O
the	O
system	O
(	O
7	O
.	O
66	O
versus	O
8	O
.	O
37	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Eighty	O
percent	O
of	O
the	O
students	O
enjoyed	O
dealing	O
with	O
the	O
virtual	O
patients	O
emphasizing	O
the	O
completeness	O
of	O
patient	O
cases	O
,	O
the	O
artistic	O
graphic	O
design	O
and	O
the	O
expert	O
comments	O
available	O
,	O
as	O
well	O
as	O
the	O
good	O
applicability	O
to	O
real	O
cases	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
students	O
graded	O
the	O
virtual	O
orthopaedic	O
clinic	O
as	O
appropriate	O
to	O
teach	O
orthopaedic	O
content	O
.	O

CONCLUSION	O
:	O

Using	O
the	O
Inmedea	O
-	O
Simulator	O
is	O
an	O
effective	O
method	O
to	O
enhance	O
students	O
'	O
learning	O
efficacy	O
.	O

The	O
way	O
the	O
system	O
was	O
used	O
by	O
the	O
students	O
emphasises	O
the	O
advantages	O
of	O
the	O
internet	O
-	O
like	O
free	O
time	O
management	O
and	O
the	O
implementation	O
of	O
multimedia	O
-	O
based	O
content	O
.	O

Constitutively	O
nuclear	O
FOXO3a	O
localization	O
predicts	O
poor	O
survival	O
and	O
promotes	O
Akt	O
phosphorylation	O
in	O
breast	O
cancer	O
.	O

BACKGROUND	O
:	O
The	O
PI3	O
K	O
-	O
Akt	O
signal	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
the	O
development	O
of	O
drug	O
-	O
resistance	O
.	O

Cytotoxic	O
chemotherapy	O
resistance	O
is	O
linked	O
to	O
limited	O
therapeutic	O
options	O
and	O
poor	O
prognosis	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Examination	O
of	O
FOXO3a	O
and	O
phosphorylated	O
-	O
Akt	O
(	O
P	O
-	O
Akt	O
)	O
expression	O
in	O
breast	O
cancer	O
tissue	O
microarrays	O
showed	O
nuclear	O
FOXO3a	O
was	O
associated	O
with	O
lymph	O
node	O
positivity	O
(	O
p	O
=	O
0	O
.	O
052	O
)	O
,	O
poor	O
prognosis	O
(	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
and	O
P	O
-	O
Akt	O
expression	O
in	O
invasive	O
ductal	O
carcinoma	O
.	O

Using	O
tamoxifen	O
and	O
doxorubicin	O
-	O
sensitive	O
and	O
-	O
resistant	O
breast	O
cancer	O
cell	O
lines	O
as	O
models	O
,	O
we	O
found	O
that	O
doxorubicin	O
-	O
but	O
not	O
tamoxifen	O
-	O
resistance	O
is	O
associated	O
with	O
nuclear	O
accumulation	O
of	O
FOXO3a	O
,	O
consistent	O
with	O
the	O
finding	O
that	O
sustained	O
nuclear	O
FOXO3a	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O

We	O
also	O
established	O
that	O
doxorubicin	O
treatment	O
induces	O
proliferation	O
arrest	O
and	O
FOXO3a	O
nuclear	O
relocation	O
in	O
sensitive	O
breast	O
cancer	O
cells	O
.	O

Induction	O
of	O
FOXO3a	O
activity	O
in	O
doxorubicin	O
-	O
sensitive	O
MCF	B
-	I
7	I
cells	O
was	O
sufficient	O
to	O
promote	O
Akt	O
phosphorylation	O
and	O
arrest	O
cell	O
proliferation	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
FOXO3a	O
expression	O
reduced	O
PI3	O
K	O
/	O
Akt	O
activity	O
.	O

Using	O
MDA	B
-	I
MB	I
-	I
231	I
cells	O
,	O
in	O
which	O
FOXO3a	O
activity	O
can	O
be	O
induced	O
by	O
4	O
-	O
hydroxytamoxifen	O
,	O
we	O
showed	O
that	O
FOXO3a	O
induction	O
up	O
-	O
regulates	O
PI3	O
K	O
-	O
Akt	O
activity	O
and	O
enhanced	O
doxorubicin	O
resistance	O
.	O

However	O
FOXO3a	O
induction	O
has	O
little	O
effect	O
on	O
cell	O
proliferation	O
,	O
indicating	O
that	O
FOXO3a	O
or	O
its	O
downstream	O
activity	O
is	O
deregulated	O
in	O
the	O
cytotoxic	O
drug	O
resistant	O
breast	O
cancer	O
cells	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
sustained	O
FOXO3a	O
activation	O
can	O
enhance	O
hyperactivation	O
of	O
the	O
PI3	O
K	O
/	O
Akt	O
pathway	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
Together	O
these	O
data	O
suggest	O
that	O
lymph	O
node	O
metastasis	O
and	O
poor	O
survival	O
in	O
invasive	O
ductal	O
breast	O
carcinoma	O
are	O
linked	O
to	O
an	O
uncoupling	O
of	O
the	O
Akt	O
-	O
FOXO3a	O
signaling	O
axis	O
.	O

In	O
these	O
breast	O
cancers	O
activated	O
Akt	O
fails	O
to	O
inactivate	O
and	O
re	O
-	O
localize	O
FOXO3a	O
to	O
the	O
cytoplasm	O
,	O
and	O
nuclear	O
-	O
targeted	O
FOXO3a	O
does	O
not	O
induce	O
cell	O
death	O
or	O
cell	O
cycle	O
arrest	O
.	O

As	O
such	O
,	O
sustained	O
nuclear	O
FOXO3a	O
expression	O
in	O
breast	O
cancer	O
may	O
culminate	O
in	O
cancer	O
progression	O
and	O
the	O
development	O
of	O
an	O
aggressive	O
phenotype	O
similar	O
to	O
that	O
observed	O
in	O
cytotoxic	O
chemotherapy	O
resistant	O
breast	O
cancer	O
cell	O
models	O
.	O

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	O
promotes	O
tumorigenesis	O
and	O
genesis	O
of	O
cells	O
resembling	O
glioma	O
stem	O
cells	O
.	O

A	O
growing	O
body	O
of	O
evidence	O
indicates	O
that	O
deregulation	O
of	O
stem	O
cell	O
fate	O
determinants	O
is	O
a	O
hallmark	O
of	O
many	O
types	O
of	O
malignancies	O
.	O

The	O
neural	O
stem	O
cell	O
fate	O
determinant	O
TLX	O
plays	O
a	O
pivotal	O
role	O
in	O
neurogenesis	O
in	O
the	O
adult	O
brain	O
by	O
maintaining	O
neural	O
stem	O
cells	O
.	O

Here	O
,	O
we	O
report	O
a	O
tumorigenic	O
role	O
of	O
TLX	O
in	O
brain	O
tumor	O
initiation	O
and	O
progression	O
.	O

Increased	O
TLX	O
expression	O
was	O
observed	O
in	O
a	O
number	O
of	O
glioma	O
cells	O
and	O
glioma	O
stem	O
cells	O
,	O
and	O
correlated	O
with	O
poor	O
survival	O
of	O
patients	O
with	O
gliomas	O
.	O

Ectopic	O
expression	O
of	O
TLX	O
in	O
the	O
U87MG	B
glioma	O
cell	O
line	O
and	O
Ink4a	O
/	O
Arf	O
-	O
deficient	O
mouse	O
astrocytes	O
(	O
Ink4a	O
/	O
Arf	O
(	O
-	O
/	O
-	O
)	O
astrocytes	O
)	O
induced	O
cell	O
proliferation	O
with	O
a	O
concomitant	O
increase	O
in	O
cyclin	O
D	O
expression	O
,	O
and	O
accelerated	O
foci	O
formation	O
in	O
soft	O
agar	O
and	O
tumor	O
formation	O
in	O
in	O
vivo	O
transplantation	O
assays	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
TLX	O
in	O
Ink4a	O
/	O
Arf	O
(	O
-	O
/	O
-	O
)	O
astrocytes	O
inhibited	O
cell	O
migration	O
and	O
invasion	O
and	O
promoted	O
neurosphere	O
formation	O
and	O
Nestin	O
expression	O
,	O
which	O
are	O
hallmark	O
characteristics	O
of	O
glioma	O
stem	O
cells	O
,	O
under	O
stem	O
cell	O
culture	O
conditions	O
.	O

Our	O
results	O
indicate	O
that	O
TLX	O
is	O
involved	O
in	O
glioma	O
stem	O
cell	O
genesis	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
this	O
type	O
of	O
malignancy	O
.	O

Actin	O
-	O
sequestering	O
protein	O
,	O
thymosin	O
beta	O
-	O
4	O
,	O
is	O
a	O
novel	O
hypoxia	O
responsive	O
regulator	O
.	O

Angiogenesis	O
is	O
induced	O
by	O
soluble	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
released	O
from	O
tumor	O
cells	O
in	O
hypoxia	O
.	O

It	O
enhances	O
solid	O
tumor	O
growth	O
and	O
provides	O
an	O
ability	O
to	O
establish	O
metastasis	O
at	O
peripheral	O
sites	O
by	O
tumor	O
cell	O
migration	O
.	O

Thymosin	O
beta	O
-	O
4	O
(	O
TB4	O
)	O
is	O
an	O
actin	O
-	O
sequestering	O
protein	O
to	O
control	O
cytoskeletal	O
reorganization	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
angiogenesis	O
and	O
tumor	O
metastasis	O
are	O
dependent	O
on	O
hypoxia	O
conditioning	O
-	O
induced	O
TB4	O
expression	O
in	O
B16F10	B
melanoma	O
cells	O
.	O

TB4	O
expression	O
in	O
B16F10	B
cells	O
was	O
increased	O
by	O
hypoxia	O
conditioning	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
we	O
found	O
an	O
increase	O
of	O
angiogenesis	O
and	O
HIF	O
-	O
1alpha	O
expression	O
in	O
TB4	O
-	O
transgenic	O
(	O
Tg	O
)	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

When	O
wound	O
healing	O
assay	O
was	O
used	O
to	O
assess	O
in	O
vitro	O
tumor	O
cell	O
migration	O
,	O
hypoxia	O
conditioning	O
for	O
1	O
h	O
enhanced	O
B16F10	B
cell	O
migration	O
.	O

When	O
TB4	O
expression	O
in	O
B16F10	B
cells	O
was	O
inhibited	O
by	O
the	O
infection	O
with	O
small	O
hairpin	O
(	O
sh	O
)	O
RNA	O
of	O
TB4	O
cloned	O
in	O
lentiviral	O
vector	O
,	O
tumor	O
cell	O
migration	O
was	O
retarded	O
.	O

In	O
addition	O
,	O
hypoxia	O
conditioning	O
-	O
induced	O
tumor	O
cell	O
migration	O
was	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
.	O

HIF	O
-	O
1alpha	O
stabilization	O
and	O
the	O
expression	O
of	O
VEGF	O
isoform	O
165	O
and	O
121	O
in	O
hypoxia	O
were	O
also	O
reduced	O
by	O
the	O
infection	O
of	O
lentiviral	O
shRNA	O
of	O
TB4	O
in	O
B16F10	B
cells	O
.	O

We	O
also	O
found	O
an	O
increase	O
of	O
tumor	O
growth	O
and	O
lung	O
metastasis	O
count	O
in	O
TB4	O
-	O
Tg	O
mice	O
as	O
compared	O
to	O
wildtype	O
mice	O
.	O

Collectively	O
,	O
hypoxia	O
conditioning	O
induced	O
tumor	O
cell	O
migration	O
by	O
TB4	O
expression	O
-	O
dependent	O
HIF	O
-	O
1alpha	O
stabilization	O
.	O

It	O
suggests	O
that	O
TB4	O
could	O
be	O
a	O
hypoxia	O
responsive	O
regulator	O
to	O
control	O
tumor	O
cell	O
migration	O
in	O
angiogenesis	O
and	O
tumor	O
metastasis	O
.	O

Acute	O
ablation	O
of	O
Langerhans	O
cells	O
enhances	O
skin	O
immune	O
responses	O
.	O

Understanding	O
the	O
function	O
of	O
Langerhans	O
cells	O
(	O
LCs	O
)	O
in	O
vivo	O
has	O
been	O
complicated	O
by	O
conflicting	O
results	O
from	O
LC	O
-	O
deficient	O
mice	O
.	O

Human	O
Langerin	O
-	O
DTA	O
mice	O
constitutively	O
lack	O
LCs	O
and	O
develop	O
exaggerated	O
contact	O
hypersensitivity	O
(	O
CHS	O
)	O
responses	O
.	O

Murine	O
Langerin	O
-	O
diphtheria	O
toxin	O
receptor	O
(	O
DTR	O
)	O
mice	O
allow	O
for	O
the	O
inducible	O
elimination	O
of	O
LCs	O
and	O
Langerin	O
(	O
+	O
)	O
dermal	O
dendritic	O
cells	O
(	O
dDCs	O
)	O
after	O
administration	O
of	O
diphtheria	O
toxin	O
,	O
which	O
results	O
in	O
reduced	O
CHS	O
.	O

When	O
Langerin	O
(	O
+	O
)	O
dDCs	O
have	O
partially	O
repopulated	O
the	O
skin	O
but	O
LCs	O
are	O
still	O
absent	O
,	O
CHS	O
returns	O
to	O
normal	O
.	O

Thus	O
,	O
LCs	O
appear	O
to	O
be	O
suppressive	O
in	O
human	O
Langerin	O
-	O
DTA	O
mice	O
and	O
redundant	O
in	O
murine	O
Langerin	O
-	O
DTR	O
mice	O
.	O

To	O
determine	O
whether	O
inducible	O
versus	O
constitutive	O
LC	O
ablation	O
explains	O
these	O
results	O
,	O
we	O
engineered	O
human	O
Langerin	O
-	O
DTR	O
mice	O
in	O
which	O
diphtheria	O
toxin	O
ablates	O
LCs	O
without	O
affecting	O
Langerin	O
(	O
+	O
)	O
dDCs	O
.	O

The	O
inducible	O
ablation	O
of	O
LCs	O
in	O
human	O
Langerin	O
-	O
DTR	O
mice	O
resulted	O
in	O
increased	O
CHS	O
.	O

Thus	O
,	O
LC	O
-	O
mediated	O
suppression	O
does	O
not	O
require	O
their	O
absence	O
during	O
ontogeny	O
or	O
during	O
the	O
steady	O
-	O
state	O
and	O
is	O
consistent	O
with	O
a	O
model	O
in	O
which	O
LCs	O
actively	O
suppress	O
Ag	O
-	O
specific	O
CHS	O
responses	O
.	O

Skin	O
deep	O
and	O
deeper	O
:	O
multiple	O
pathways	O
in	O
basal	O
cell	O
carcinogenesis	O
.	O

This	O
perspective	O
places	O
the	O
report	O
by	O
Villani	O
et	O
al	O
.	O
that	O
appears	O
in	O
this	O
issue	O
of	O
the	O
journal	O
(	O
beginning	O
on	O
page	O
1222	O
)	O
in	O
the	O
context	O
of	O
recent	O
work	O
showing	O
an	O
intersection	O
between	O
two	O
important	O
developmental	O
pathways	O
implicated	O
in	O
oncogenesis	O
:	O
the	O
hedgehog	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
pathways	O
.	O

Villani	O
et	O
al	O
.	O
define	O
a	O
key	O
role	O
for	O
the	O
IGF	O
regulatory	O
protein	O
Igfbp2	O
in	O
a	O
genetic	O
model	O
of	O
basal	O
cell	O
carcinogenesis	O
driven	O
by	O
targeted	O
constitutive	O
activation	O
of	O
hedgehog	O
signaling	O
.	O

Placed	O
in	O
the	O
framework	O
of	O
other	O
recently	O
published	O
work	O
,	O
the	O
observations	O
of	O
Villani	O
et	O
al	O
.	O
both	O
raise	O
questions	O
about	O
the	O
cell	O
of	O
origin	O
for	O
basal	O
cell	O
cancers	O
and	O
define	O
additional	O
putative	O
therapeutic	O
and	O
preventive	O
targets	O
for	O
this	O
disease	O
.	O

Brick1	O
is	O
an	O
essential	O
regulator	O
of	O
actin	O
cytoskeleton	O
required	O
for	O
embryonic	O
development	O
and	O
cell	O
transformation	O
.	O

Brick1	O
(	O
Brk1	O
)	O
is	O
the	O
less	O
-	O
studied	O
component	O
of	O
the	O
Wave	O
/	O
Scar	O
pathway	O
involved	O
in	O
the	O
branched	O
nucleation	O
of	O
actin	O
fibers	O
.	O

The	O
clinical	O
relevance	O
of	O
Brk1	O
is	O
emphasized	O
by	O
correlative	O
data	O
showing	O
that	O
Von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
patients	O
that	O
also	O
lose	O
the	O
BRK1	O
gene	O
are	O
protected	O
against	O
the	O
development	O
of	O
tumors	O
.	O

This	O
contrasts	O
with	O
recent	O
evidence	O
suggesting	O
that	O
the	O
Wave	O
complex	O
may	O
function	O
as	O
an	O
invasion	O
suppressor	O
in	O
epithelial	O
cancers	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
downregulation	O
of	O
Brk1	O
results	O
in	O
abnormal	O
actin	O
stress	O
fiber	O
formation	O
and	O
vinculin	O
distribution	O
and	O
loss	O
of	O
Arp2	O
/	O
3	O
and	O
Wave	O
proteins	O
at	O
the	O
cellular	O
protrusions	O
.	O

Brk1	O
is	O
required	O
for	O
cell	O
proliferation	O
and	O
cell	O
transformation	O
by	O
oncogenes	O
.	O

In	O
addition	O
,	O
Brk1	O
downregulation	O
results	O
in	O
defective	O
directional	O
migration	O
and	O
invasive	O
growth	O
in	O
renal	O
cell	O
carcinoma	O
cells	O
as	O
well	O
as	O
in	O
other	O
tumor	O
cell	O
types	O
.	O

Finally	O
,	O
genetic	O
ablation	O
of	O
Brk1	O
results	O
in	O
dramatic	O
defects	O
in	O
embryo	O
compaction	O
and	O
development	O
,	O
suggesting	O
an	O
essential	O
role	O
for	O
this	O
protein	O
in	O
actin	O
dynamics	O
.	O

Thus	O
,	O
genetic	O
loss	O
or	O
inhibition	O
of	O
BRK1	O
is	O
likely	O
to	O
be	O
protective	O
against	O
tumor	O
development	O
due	O
to	O
proliferation	O
and	O
motility	O
defects	O
in	O
affected	O
cells	O
.	O

The	O
proenkephalin	O
-	O
A	O
-	O
derivative	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
is	O
not	O
present	O
in	O
the	O
feline	O
species	O
.	O

No	O
opioid	O
octapeptide	O
Met	O
-	O
enkephalin	O
-	O
Arg	O
-	O
Gly	O
-	O
Leu	O
was	O
detected	O
either	O
in	O
the	O
brain	O
or	O
in	O
the	O
adrenal	O
gland	O
of	O
the	O
cat	O
using	O
a	O
specific	O
radioimmunoassay	O
.	O

Whereas	O
it	O
was	O
possible	O
to	O
determine	O
the	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
contents	O
.	O

The	O
Met	O
-	O
enkephalin	O
versus	O
Leu	O
-	O
enkephalin	O
concentration	O
ratio	O
was	O
around	O
five	O
in	O
each	O
area	O
of	O
the	O
brain	O
assayed	O
.	O

The	O
presence	O
of	O
authentic	O
Met	O
-	O
enkephalin	O
and	O
Leu	O
-	O
enkephalin	O
was	O
confirmed	O
by	O
high	O
performance	O
liquid	O
chromatography	O
analysis	O
.	O

All	O
in	O
all	O
,	O
these	O
data	O
seem	O
to	O
indicate	O
that	O
the	O
cat	O
proenkephalin	O
is	O
partly	O
different	O
from	O
that	O
previously	O
analysed	O
in	O
mammalian	O
species	O
including	O
humans	O
,	O
rats	O
and	O
cows	O
.	O

Ras	O
-	O
association	O
domain	O
family	O
1C	O
protein	O
promotes	O
breast	O
cancer	O
cell	O
migration	O
and	O
attenuates	O
apoptosis	O
.	O

BACKGROUND	O
:	O
The	O
Ras	O
association	O
domain	O
family	O
1	O
(	O
RASSF1	O
)	O
gene	O
is	O
a	O
Ras	O
effector	O
encoding	O
two	O
major	O
mRNA	O
forms	O
,	O
RASSF1A	O
and	O
RASSF1C	O
,	O
derived	O
by	O
alternative	O
promoter	O
selection	O
and	O
alternative	O
mRNA	O
splicing	O
.	O

RASSF1A	O
is	O
a	O
tumor	O
suppressor	O
gene	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
RASSF1C	O
both	O
in	O
normal	O
and	O
transformed	O
cells	O
.	O

METHODS	O
:	O
Gene	O
silencing	O
and	O
over	O
-	O
expression	O
techniques	O
were	O
used	O
to	O
modulate	O
RASSF1C	O
expression	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

Affymetrix	O
-	O
microarray	O
analysis	O
was	O
performed	O
using	O
T47D	B
cells	O
over	O
-	O
expressing	O
RASSF1C	O
to	O
identify	O
RASSF1C	O
target	O
genes	O
.	O

RT	O
-	O
PCR	O
and	O
western	O
blot	O
techniques	O
were	O
used	O
to	O
validate	O
target	O
gene	O
expression	O
.	O

Cell	O
invasion	O
and	O
apoptosis	O
assays	O
were	O
also	O
performed	O
.	O

RESULTS	O
:	O
In	O
this	O
article	O
,	O
we	O
report	O
the	O
effects	O
of	O
altering	O
RASSF1C	O
expression	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

We	O
found	O
that	O
silencing	O
RASSF1C	O
mRNA	O
in	O
breast	O
cancer	O
cell	O
lines	O
(	O
MDA	B
-	I
MB231	I
and	O
T47D	B
)	O
caused	O
a	O
small	O
but	O
significant	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Conversely	O
,	O
inducible	O
over	O
-	O
expression	O
of	O
RASSF1C	O
in	O
breast	O
cancer	O
cells	O
(	O
MDA	B
-	I
MB231	I
and	O
T47D	B
)	O
resulted	O
in	O
a	O
small	O
increase	O
in	O
cell	O
proliferation	O
.	O

We	O
also	O
report	O
on	O
the	O
identification	O
of	O
novel	O
RASSF1C	O
target	O
genes	O
.	O

RASSF1C	O
down	O
-	O
regulates	O
several	O
pro	O
-	O
apoptotic	O
and	O
tumor	O
suppressor	O
genes	O
and	O
up	O
-	O
regulates	O
several	O
growth	O
promoting	O
genes	O
in	O
breast	O
cancer	O
cells	O
.	O

We	O
further	O
show	O
that	O
down	O
-	O
regulation	O
of	O
caspase	O
3	O
via	O
overexpression	O
of	O
RASSF1C	O
reduces	O
breast	O
cancer	O
cells	O
'	O
sensitivity	O
to	O
the	O
apoptosis	O
inducing	O
agent	O
,	O
etoposide	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
RASSF1C	O
over	O
-	O
expression	O
enhances	O
T47D	B
cell	O
invasion	O
/	O
migration	O
in	O
vitro	O
.	O

CONCLUSION	O
:	O
Together	O
,	O
our	O
findings	O
suggest	O
that	O
RASSF1C	O
,	O
unlike	O
RASSF1A	O
,	O
is	O
not	O
a	O
tumor	O
suppressor	O
,	O
but	O
instead	O
may	O
play	O
a	O
role	O
in	O
stimulating	O
metastasis	O
and	O
survival	O
in	O
breast	O
cancer	O
cells	O
.	O

Androgen	O
stimulates	O
glycolysis	O
for	O
de	O
novo	O
lipid	O
synthesis	O
by	O
increasing	O
the	O
activities	O
of	O
hexokinase	O
2	O
and	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
2	O
in	O
prostate	O
cancer	O
cells	O
.	O

Up	O
-	O
regulation	O
of	O
lipogenesis	O
by	O
androgen	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
metabolic	O
features	O
of	O
LNCaP	B
prostate	O
cancer	O
cells	O
.	O

The	O
present	O
study	O
revealed	O
that	O
androgen	O
increases	O
glucose	O
utilization	O
for	O
de	O
novo	O
lipogenesis	O
in	O
LNCaP	B
cells	O
through	O
the	O
activation	O
of	O
HK2	O
(	O
hexokinase	O
2	O
)	O
and	O
activation	O
of	O
the	O
cardiac	O
isoform	O
of	O
PFKFB2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
/	O
fructose	O
-	O
2	O
,	O
6	O
-	O
bisphosphatase	O
)	O
.	O

Activation	O
of	O
PKA	O
(	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
)	O
by	O
androgen	O
increased	O
phosphorylation	O
of	O
CREB	O
[	O
CRE	O
(	O
cAMP	O
-	O
response	O
element	O
)	O
-	O
binding	O
protein	O
]	O
,	O
which	O
in	O
turn	O
bound	O
to	O
CRE	O
on	O
the	O
promoter	O
of	O
the	O
HK2	O
gene	O
resulting	O
in	O
transcriptional	O
activation	O
of	O
the	O
HK2	O
gene	O
.	O

Up	O
-	O
regulation	O
of	O
PFKFB2	O
expression	O
was	O
mediated	O
by	O
the	O
direct	O
binding	O
of	O
ligand	O
-	O
activated	O
androgen	O
receptor	O
to	O
the	O
PFKFB2	O
promoter	O
.	O

The	O
activated	O
PI3	O
K	O
(	O
phosphoinositide	O
3	O
-	O
kinase	O
)	O
/	O
Akt	O
signalling	O
pathway	O
in	O
LNCaP	B
cells	O
contributes	O
to	O
the	O
phosphorylation	O
of	O
PFKFB2	O
at	O
Ser466	O
and	O
Ser483	O
,	O
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
PFK	O
-	O
2	O
(	O
6	O
-	O
phosphofructo	O
-	O
2	O
-	O
kinase	O
)	O
activity	O
.	O

Glucose	O
uptake	O
and	O
lipogenesis	O
were	O
severely	O
blocked	O
by	O
knocking	O
-	O
down	O
of	O
PFKFB2	O
using	O
siRNA	O
(	O
small	O
interfering	O
RNA	O
)	O
or	O
by	O
inhibition	O
of	O
PFK	O
-	O
2	O
activity	O
with	O
LY294002	O
treatment	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
de	O
novo	O
lipid	O
synthesis	O
by	O
androgen	O
requires	O
the	O
transcriptional	O
up	O
-	O
regulation	O
of	O
HK2	O
and	O
PFKFB2	O
,	O
and	O
phosphorylation	O
of	O
PFKFB2	O
generated	O
by	O
the	O
PI3	O
K	O
/	O
Akt	O
signalling	O
pathway	O
to	O
supply	O
the	O
source	O
for	O
lipogenesis	O
from	O
glucose	O
in	O
prostate	O
cancer	O
cells	O
.	O

Expression	O
profiling	O
in	O
progressive	O
stages	O
of	O
fumarate	O
-	O
hydratase	O
deficiency	O
:	O
the	O
contribution	O
of	O
metabolic	O
changes	O
to	O
tumorigenesis	O
.	O

Hereditary	O
leiomyomatosis	O
and	O
renal	O
cell	O
carcinoma	O
(	O
HLRCC	O
)	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
Krebs	O
cycle	O
enzyme	O
fumarate	O
hydratase	O
(	O
FH	O
)	O
.	O

It	O
has	O
been	O
proposed	O
that	O
""""	O
pseudohypoxic	O
""""	O
stabilization	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
by	O
fumarate	O
accumulation	O
contributes	O
to	O
tumorigenesis	O
in	O
HLRCC	O
.	O

We	O
hypothesized	O
that	O
an	O
additional	O
direct	O
consequence	O
of	O
FH	O
deficiency	O
is	O
the	O
establishment	O
of	O
a	O
biosynthetic	O
milieu	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
we	O
isolated	O
primary	O
mouse	O
embryonic	O
fibroblast	O
(	O
MEF	O
)	O
lines	O
from	O
Fh1	O
-	O
deficient	O
mice	O
.	O

As	O
predicted	O
,	O
these	O
MEFs	O
upregulated	O
Hif	O
-	O
1alpha	O
and	O
HIF	O
target	O
genes	O
directly	O
as	O
a	O
result	O
of	O
FH	O
deficiency	O
.	O

In	O
addition	O
,	O
detailed	O
metabolic	O
assessment	O
of	O
these	O
MEFs	O
confirmed	O
their	O
dependence	O
on	O
glycolysis	O
,	O
and	O
an	O
elevated	O
rate	O
of	O
lactate	O
efflux	O
,	O
associated	O
with	O
the	O
upregulation	O
of	O
glycolytic	O
enzymes	O
known	O
to	O
be	O
associated	O
with	O
tumorigenesis	O
.	O

Correspondingly	O
,	O
Fh1	O
-	O
deficient	O
benign	O
murine	O
renal	O
cysts	O
and	O
an	O
advanced	O
human	O
HLRCC	O
-	O
related	O
renal	O
cell	O
carcinoma	O
manifested	O
a	O
prominent	O
and	O
progressive	O
increase	O
in	O
the	O
expression	O
of	O
HIF	O
-	O
alpha	O
target	O
genes	O
and	O
in	O
genes	O
known	O
to	O
be	O
relevant	O
to	O
tumorigenesis	O
and	O
metastasis	O
.	O

In	O
accord	O
with	O
our	O
hypothesis	O
,	O
in	O
a	O
variety	O
of	O
different	O
FH	O
-	O
deficient	O
tissues	O
,	O
including	O
a	O
novel	O
murine	O
model	O
of	O
Fh1	O
-	O
deficient	O
smooth	O
muscle	O
,	O
we	O
show	O
a	O
striking	O
and	O
progressive	O
upregulation	O
of	O
a	O
tumorigenic	O
metabolic	O
profile	O
,	O
as	O
manifested	O
by	O
increased	O
PKM2	O
and	O
LDHA	O
protein	O
.	O

Based	O
on	O
the	O
models	O
assessed	O
herein	O
,	O
we	O
infer	O
that	O
that	O
FH	O
deficiency	O
compels	O
cells	O
to	O
adopt	O
an	O
early	O
,	O
reversible	O
,	O
and	O
progressive	O
protumorigenic	O
metabolic	O
milieu	O
that	O
is	O
reminiscent	O
of	O
that	O
driving	O
the	O
Warburg	O
effect	O
.	O

Targets	O
identified	O
in	O
these	O
novel	O
and	O
diverse	O
FH	O
-	O
deficient	O
models	O
represent	O
excellent	O
potential	O
candidates	O
for	O
further	O
mechanistic	O
investigation	O
and	O
therapeutic	O
metabolic	O
manipulation	O
in	O
tumors	O
.	O

Role	O
of	O
stromal	O
myofibroblasts	O
in	O
invasive	O
breast	O
cancer	O
:	O
stromal	O
expression	O
of	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
correlates	O
with	O
worse	O
clinical	O
outcome	O
.	O

BACKGROUND	O
:	O
Recently	O
,	O
the	O
desmoplastic	O
reaction	O
has	O
been	O
implicated	O
as	O
having	O
an	O
important	O
function	O
in	O
epithelial	O
solid	O
tumor	O
biology	O
.	O

There	O
have	O
been	O
no	O
reports	O
showing	O
the	O
relativity	O
of	O
invasive	O
breast	O
cancer	O
and	O
the	O
desmoplastic	O
reaction	O
by	O
a	O
quantitative	O
analysis	O
of	O
the	O
myofibroblasts	O
that	O
were	O
an	O
important	O
player	O
in	O
the	O
desmoplastic	O
reaction	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
immunohistochemically	O
investigate	O
the	O
correlation	O
between	O
the	O
desmoplastic	O
reaction	O
and	O
the	O
clinicopathology	O
of	O
invasive	O
breast	O
cancer	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
60	O
patients	O
with	O
a	O
known	O
prognosis	O
of	O
invasive	O
breast	O
cancer	O
.	O

We	O
quantified	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
as	O
a	O
marker	O
of	O
myofibroblasts	O
in	O
the	O
invasive	O
breast	O
cancer	O
.	O

After	O
staining	O
samples	O
for	O
alpha	O
-	O
SMA	O
,	O
their	O
expression	O
was	O
extracted	O
and	O
quantified	O
as	O
a	O
relative	O
percentage	O
by	O
computer	O
-	O
assisted	O
image	O
analysis	O
.	O

RESULTS	O
:	O
There	O
was	O
relatively	O
wide	O
variation	O
in	O
the	O
expression	O
of	O
alpha	O
-	O
SMA	O
with	O
the	O
percentage	O
of	O
the	O
area	O
from	O
0	O
.	O
68	O
to	O
28	O
.	O
15	O
%	O
(	O
mean	O
8	O
.	O
48	O
+	O
/	O
-	O
5	O
.	O
40	O
%	O
)	O
.	O

The	O
metastasis	O
group	O
showed	O
significantly	O
higher	O
alpha	O
-	O
SMA	O
expression	O
compared	O
with	O
the	O
no	O
metastasis	O
group	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

When	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
their	O
alpha	O
-	O
SMA	O
expression	O
using	O
a	O
cutoff	O
point	O
at	O
the	O
mean	O
value	O
of	O
8	O
.	O
48	O
%	O
,	O
the	O
high	O
alpha	O
-	O
SMA	O
group	O
had	O
a	O
significantly	O
poorer	O
overall	O
survival	O
rate	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Multivariate	O
analysis	O
demonstrated	O
that	O
alpha	O
-	O
SMA	O
and	O
lymph	O
node	O
metastasis	O
were	O
identified	O
as	O
independent	O
predictive	O
factors	O
of	O
metastasis	O
.	O

CONCLUSION	O
:	O
Myofibroblasts	O
represent	O
an	O
important	O
prognostic	O
factor	O
for	O
invasive	O
growth	O
that	O
is	O
translated	O
into	O
a	O
poor	O
clinical	O
prognosis	O
for	O
patients	O
with	O
invasive	O
breast	O
cancer	O
.	O

A	O
STAT3	O
-	O
mediated	O
metabolic	O
switch	O
is	O
involved	O
in	O
tumour	O
transformation	O
and	O
STAT3	O
addiction	O
.	O

The	O
pro	O
-	O
oncogenic	O
transcription	O
factor	O
STAT3	O
is	O
constitutively	O
activated	O
in	O
a	O
wide	O
variety	O
of	O
tumours	O
that	O
often	O
become	O
addicted	O
to	O
its	O
activity	O
,	O
but	O
no	O
unifying	O
view	O
of	O
a	O
core	O
function	O
determining	O
this	O
widespread	O
STAT3	O
-	O
dependence	O
has	O
yet	O
emerged	O
.	O

We	O
show	O
here	O
that	O
constitutively	O
active	O
STAT3	O
acts	O
as	O
a	O
master	O
regulator	O
of	O
cell	O
metabolism	O
,	O
inducing	O
aerobic	O
glycolysis	O
and	O
down	O
-	O
regulating	O
mitochondrial	O
activity	O
both	O
in	O
primary	O
fibroblasts	O
and	O
in	O
STAT3	O
-	O
dependent	O
tumour	O
cell	O
lines	O
.	O

As	O
a	O
result	O
,	O
cells	O
are	O
protected	O
from	O
apoptosis	O
and	O
senescence	O
while	O
becoming	O
highly	O
sensitive	O
to	O
glucose	O
deprivation	O
.	O

We	O
show	O
that	O
enhanced	O
glycolysis	O
is	O
dependent	O
on	O
HIF	O
-	O
1alpha	O
up	O
-	O
regulation	O
,	O
while	O
reduced	O
mitochondrial	O
activity	O
is	O
HIF	O
-	O
1alpha	O
-	O
independent	O
and	O
likely	O
caused	O
by	O
STAT3	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
mitochondrial	O
proteins	O
.	O

The	O
induction	O
of	O
aerobic	O
glycolysis	O
is	O
an	O
important	O
component	O
of	O
STAT3	O
pro	O
-	O
oncogenic	O
activities	O
,	O
since	O
inhibition	O
of	O
STAT3	O
tyrosine	O
phosphorylation	O
in	O
the	O
tumour	O
cell	O
lines	O
down	O
-	O
regulates	O
glycolysis	O
prior	O
to	O
leading	O
to	O
growth	O
arrest	O
and	O
cell	O
death	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
propose	O
that	O
this	O
novel	O
,	O
central	O
metabolic	O
role	O
is	O
at	O
the	O
core	O
of	O
the	O
addiction	O
for	O
STAT3	O
shown	O
by	O
so	O
many	O
biologically	O
different	O
tumours	O
.	O

The	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domains	O
of	O
ADAM	O
-	O
9	O
mediate	O
interactions	O
between	O
melanoma	O
cells	O
and	O
fibroblasts	O
.	O

A	O
characteristic	O
of	O
malignant	O
cells	O
is	O
their	O
capacity	O
to	O
invade	O
their	O
surrounding	O
and	O
to	O
metastasize	O
to	O
distant	O
organs	O
.	O

During	O
these	O
processes	O
,	O
proteolytic	O
activities	O
of	O
tumor	O
and	O
stromal	O
cells	O
modify	O
the	O
extracellular	O
matrix	O
to	O
produce	O
a	O
microenvironment	O
suitable	O
for	O
their	O
growth	O
and	O
migration	O
.	O

In	O
recent	O
years	O
the	O
family	O
of	O
ADAM	O
proteases	O
has	O
been	O
ascribed	O
important	O
roles	O
in	O
these	O
processes	O
.	O

ADAM	O
-	O
9	O
is	O
expressed	O
in	O
human	O
melanoma	O
at	O
the	O
tumor	O
-	O
stroma	O
border	O
where	O
direct	O
or	O
indirect	O
interactions	O
between	O
tumor	O
cells	O
and	O
fibroblasts	O
occur	O
.	O

To	O
analyze	O
the	O
role	O
of	O
ADAM	O
-	O
9	O
for	O
the	O
interaction	O
between	O
melanoma	O
cells	O
and	O
stromal	O
fibroblasts	O
,	O
we	O
produced	O
the	O
recombinant	O
disintegrin	O
-	O
like	O
and	O
cysteine	O
-	O
rich	O
domain	O
of	O
ADAM	O
-	O
9	O
(	O
DC	O
-	O
9	O
)	O
.	O

Melanoma	O
cells	O
and	O
human	O
fibroblasts	O
adhered	O
to	O
immobilized	O
DC	O
-	O
9	O
in	O
a	O
Mn	O
(	O
2	O
+	O
)	O
-	O
dependent	O
fashion	O
suggesting	O
an	O
integrin	O
-	O
mediated	O
process	O
.	O

Inhibition	O
studies	O
showed	O
that	O
adhesion	O
of	O
fibroblasts	O
was	O
mediated	O
by	O
several	O
beta1	O
integrin	O
receptors	O
independent	O
of	O
the	O
RGD	O
and	O
ECD	O
recognition	O
motif	O
.	O

Furthermore	O
,	O
interaction	O
of	O
fibroblasts	O
and	O
high	O
invasive	O
melanoma	O
cells	O
with	O
soluble	O
recombinant	O
DC	O
-	O
9	O
resulted	O
in	O
enhanced	O
expression	O
of	O
MMP	O
-	O
1	O
and	O
MMP	O
-	O
2	O
.	O

Silencing	O
of	O
ADAM	O
-	O
9	O
in	O
melanoma	O
cells	O
significantly	O
reduced	O
cell	O
adhesion	O
to	O
fibroblasts	O
.	O

Ablation	O
of	O
ADAM	O
-	O
9	O
in	O
fibroblasts	O
almost	O
completely	O
abolished	O
these	O
cellular	O
interactions	O
and	O
melanoma	O
cell	O
invasion	O
in	O
vitro	O
.	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
ADAM	O
-	O
9	O
expression	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
cell	O
-	O
cell	O
contacts	O
between	O
fibroblasts	O
and	O
melanoma	O
cells	O
and	O
that	O
these	O
interactions	O
contribute	O
to	O
proteolytic	O
activities	O
required	O
during	O
invasion	O
of	O
melanoma	O
cells	O
.	O

Influences	O
on	O
the	O
pharmacokinetics	O
of	O
oxycodone	O
:	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
in	O
439	O
adult	O
cancer	O
patients	O
.	O

OBJECTIVE	O
:	O

Oxycodone	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
cancer	O
pain	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
pharmacokinetics	O
in	O
cancer	O
pain	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationships	O
between	O
ordinary	O
patient	O
characteristics	O
and	O
serum	O
concentrations	O
of	O
oxycodone	O
and	O
the	O
ratios	O
noroxycodone	O
or	O
oxymorphone	O
/	O
oxycodone	O
in	O
cancer	O
patients	O
.	O

METHODS	O
:	O

Four	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
using	O
oral	O
oxycodone	O
for	O
cancer	O
pain	O
were	O
included	O
.	O

The	O
patients	O
'	O
characteristics	O
(	O
sex	O
,	O
age	O
,	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
,	O
Karnofsky	O
performance	O
status	O
,	O
""""	O
time	O
since	O
starting	O
opioids	O
""""	O
,	O
""""	O
oxycodone	O
total	O
daily	O
dose	O
""""	O
,	O
""""	O
time	O
from	O
last	O
oxycodone	O
dose	O
""""	O
,	O
use	O
of	O
CYP3A4	O
inducer	O
/	O
inhibitor	O
,	O
""""	O
use	O
of	O
systemic	O
steroids	O
""""	O
,	O
""""	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
""""	O
,	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
albumin	O
serum	O
concentrations	O
)	O
influence	O
on	O
oxycodone	O
serum	O
concentrations	O
or	O
metabolite	O
/	O
oxycodone	O
ratios	O
were	O
explored	O
by	O
multiple	O
regression	O
analyses	O
.	O

RESULTS	O
:	O

Sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
total	O
daily	O
dose	O
,	O
and	O
""""	O
time	O
from	O
last	O
oxycodone	O
dose	O
""""	O
predicted	O
oxycodone	O
concentrations	O
.	O

CYP3A4	O
inducers	O
,	O
total	O
daily	O
dose	O
,	O
and	O
""""	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
""""	O
predicted	O
the	O
oxymorphone	O
/	O
oxycodone	O
ratio	O
.	O

Total	O
daily	O
dose	O
,	O
""""	O
time	O
from	O
last	O
dose	O
to	O
blood	O
sample	O
""""	O
,	O
albumin	O
,	O
sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
steroids	O
,	O
BMI	O
and	O
GFR	O
predicted	O
the	O
noroxycodone	O
/	O
oxycodone	O
ratio	O
.	O

CONCLUSION	O
:	O

Women	O
had	O
lower	O
oxycodone	O
serum	O
concentrations	O
than	O
men	O
.	O

CYP3A4	O
inducers	O
/	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
as	O
these	O
are	O
predicted	O
to	O
have	O
a	O
significant	O
impact	O
on	O
oxycodone	O
pharmacokinetics	O
.	O

Other	O
characteristics	O
explained	O
only	O
minor	O
parts	O
of	O
the	O
variability	O
of	O
the	O
outcomes	O
.	O

Emerging	O
metabolic	O
targets	O
in	O
cancer	O
therapy	O
.	O

Cancer	O
cells	O
are	O
different	O
from	O
normal	O
cells	O
in	O
their	O
metabolic	O
properties	O
.	O

Normal	O
cells	O
mostly	O
rely	O
on	O
mitochondrial	O
oxidative	O
phosphorylation	O
to	O
produce	O
energy	O
.	O

In	O
contrast	O
,	O
cancer	O
cells	O
depend	O
mostly	O
on	O
glycolysis	O
,	O
the	O
aerobic	O
breakdown	O
of	O
glucose	O
into	O
ATP	O
.	O

This	O
altered	O
energy	O
dependency	O
is	O
known	O
as	O
the	O
""""	O
Warburg	O
effect	O
""""	O
and	O
is	O
a	O
hallmark	O
of	O
cancer	O
cells	O
.	O

In	O
recent	O
years	O
,	O
investigating	O
the	O
metabolic	O
changes	O
within	O
cancer	O
cells	O
has	O
been	O
a	O
rapidly	O
growing	O
area	O
.	O

Emerging	O
evidence	O
shows	O
that	O
oncogenes	O
that	O
drive	O
the	O
cancer	O
-	O
promoting	O
signals	O
also	O
drive	O
the	O
altered	O
metabolism	O
.	O

Although	O
the	O
exact	O
mechanisms	O
underlying	O
the	O
Warburg	O
effect	O
are	O
unclear	O
,	O
the	O
existing	O
evidence	O
suggests	O
that	O
increased	O
glycolysis	O
plays	O
an	O
important	O
role	O
in	O
support	O
malignant	O
behavior	O
of	O
cancer	O
cells	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
unique	O
metabolism	O
of	O
cancer	O
cells	O
will	O
help	O
to	O
design	O
of	O
more	O
effective	O
drugs	O
targeting	O
metabolic	O
pathways	O
,	O
which	O
will	O
greatly	O
impact	O
the	O
capacity	O
to	O
effectively	O
treat	O
cancer	O
patients	O
.	O

Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
Warburg	O
effect	O
upon	O
tumor	O
cell	O
growth	O
and	O
survival	O
,	O
and	O
discussion	O
on	O
the	O
potential	O
metabolic	O
targets	O
for	O
cancer	O
therapy	O
.	O

MTSS1	O
:	O
a	O
multifunctional	O
protein	O
and	O
its	O
role	O
in	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

MTSS1	O
(	O
metastasis	O
suppressor	O
-	O
1	O
)	O
was	O
first	O
identified	O
as	O
a	O
metastasis	O
suppressor	O
missing	O
in	O
metastatic	O
bladder	O
carcinoma	O
cell	O
lines	O
.	O

The	O
down	O
-	O
regulation	O
of	O
MTSS1	O
that	O
may	O
be	O
caused	O
by	O
DNA	O
methylation	O
was	O
also	O
observed	O
in	O
many	O
other	O
types	O
of	O
cancer	O
.	O

While	O
accumlating	O
evidence	O
for	O
the	O
function	O
of	O
MTSS1	O
support	O
the	O
concept	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
a	O
metastasis	O
suppressor	O
,	O
but	O
actually	O
acts	O
as	O
a	O
scaffold	O
protein	O
that	O
interacts	O
with	O
multiple	O
partners	O
to	O
regulate	O
actin	O
dynamics	O
.	O

It	O
has	O
also	O
been	O
demonstrated	O
that	O
MTSS1	O
is	O
involved	O
in	O
the	O
Shh	O
signaling	O
pathway	O
in	O
the	O
developing	O
hair	O
follicle	O
and	O
in	O
basal	O
cell	O
carcinomas	O
of	O
the	O
skin	O
.	O

Such	O
evidence	O
indicates	O
that	O
MTSS1	O
as	O
a	O
multiple	O
functional	O
molecular	O
player	O
and	O
has	O
an	O
important	O
role	O
in	O
development	O
,	O
carcinogenesis	O
and	O
metastasis	O
.	O

However	O
,	O
the	O
biochemical	O
mechanisms	O
by	O
which	O
MTSS1	O
functions	O
in	O
cells	O
and	O
the	O
physiological	O
role	O
of	O
this	O
protein	O
in	O
animals	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
current	O
knowledge	O
of	O
MTSS1	O
'	O
s	O
role	O
in	O
cancer	O
metastasis	O
,	O
carcinogenesis	O
,	O
and	O
development	O
.	O

The	O
clinical	O
significance	O
of	O
MTSS1	O
will	O
also	O
be	O
discussed	O
.	O

Geometric	O
correlations	O
and	O
breakdown	O
of	O
mesoscopic	O
universality	O
in	O
spin	O
transport	O
.	O

We	O
construct	O
a	O
unified	O
semiclassical	O
theory	O
of	O
charge	O
and	O
spin	O
transport	O
in	O
chaotic	O
ballistic	O
and	O
disordered	O
diffusive	O
mesoscopic	O
systems	O
with	O
spin	O
-	O
orbit	O
interaction	O
.	O

Neglecting	O
dynamic	O
effects	O
of	O
spin	O
-	O
orbit	O
interaction	O
,	O
we	O
reproduce	O
the	O
random	O
matrix	O
theory	O
results	O
that	O
the	O
spin	O
conductance	O
fluctuates	O
universally	O
around	O
zero	O
average	O
.	O

Incorporating	O
these	O
effects	O
into	O
the	O
theory	O
,	O
we	O
show	O
that	O
geometric	O
correlations	O
generate	O
finite	O
average	O
spin	O
conductances	O
,	O
but	O
that	O
they	O
do	O
not	O
affect	O
the	O
charge	O
conductance	O
to	O
leading	O
order	O
.	O

The	O
theory	O
,	O
which	O
is	O
confirmed	O
by	O
numerical	O
transport	O
calculations	O
,	O
allows	O
us	O
to	O
investigate	O
the	O
entire	O
range	O
from	O
the	O
weak	O
to	O
the	O
previously	O
unexplored	O
strong	O
spin	O
-	O
orbit	O
regime	O
,	O
where	O
the	O
spin	O
rotation	O
time	O
is	O
shorter	O
than	O
the	O
momentum	O
relaxation	O
time	O
.	O

Development	O
and	O
validation	O
of	O
an	O
approach	O
to	O
produce	O
large	O
-	O
scale	O
quantities	O
of	O
CpG	O
-	O
methylated	O
plasmid	O
DNA	O
.	O

The	O
prokaryotic	O
CpG	O
-	O
specific	O
DNA	O
methylase	O
from	O
Spiroplasma	O
,	O
SssI	O
methylase	O
,	O
has	O
been	O
extensively	O
used	O
to	O
methylate	O
plasmid	O
DNA	O
in	O
vitro	O
to	O
investigate	O
the	O
effects	O
of	O
methylation	O
in	O
vertebrate	O
systems	O
.	O

Currently	O
available	O
methods	O
to	O
produce	O
CpG	O
-	O
methylated	O
plasmid	O
DNA	O
have	O
certain	O
limitations	O
and	O
can	O
not	O
generate	O
large	O
quantities	O
of	O
methylated	O
DNA	O
without	O
cost	O
or	O
problems	O
of	O
purity	O
.	O

Here	O
we	O
describe	O
an	O
approach	O
in	O
which	O
the	O
SssI	O
methylase	O
gene	O
has	O
been	O
introduced	O
into	O
the	O
Escherichia	O
coli	O
bacterial	O
genome	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Plasmid	O
DNA	O
propagated	O
in	O
this	O
bacterium	O
under	O
conditions	O
which	O
induce	O
the	O
methylase	O
gene	O
result	O
in	O
significant	O
(	O
>	O
90	O
%	O
)	O
CpG	O
methylation	O
.	O

Methylated	O
DNA	O
produced	O
by	O
this	O
approach	O
behaves	O
similarly	O
to	O
methylated	O
DNA	O
produced	O
in	O
vitro	O
using	O
the	O
purified	O
methylase	O
.	O

The	O
approach	O
is	O
scalable	O
allowing	O
for	O
the	O
production	O
of	O
milligram	O
quantities	O
of	O
methylated	O
plasmid	O
DNA	O
.	O

Dissecting	O
genetic	O
networks	O
underlying	O
complex	O
phenotypes	O
:	O
the	O
theoretical	O
framework	O
.	O

Great	O
progress	O
has	O
been	O
made	O
in	O
genetic	O
dissection	O
of	O
quantitative	O
trait	O
variation	O
during	O
the	O
past	O
two	O
decades	O
,	O
but	O
many	O
studies	O
still	O
reveal	O
only	O
a	O
small	O
fraction	O
of	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
,	O
and	O
epistasis	O
remains	O
elusive	O
.	O

We	O
integrate	O
contemporary	O
knowledge	O
of	O
signal	O
transduction	O
pathways	O
with	O
principles	O
of	O
quantitative	O
and	O
population	O
genetics	O
to	O
characterize	O
genetic	O
networks	O
underlying	O
complex	O
traits	O
,	O
using	O
a	O
model	O
founded	O
upon	O
one	O
-	O
way	O
functional	O
dependency	O
of	O
downstream	O
genes	O
on	O
upstream	O
regulators	O
(	O
the	O
principle	O
of	O
hierarchy	O
)	O
and	O
mutual	O
functional	O
dependency	O
among	O
related	O
genes	O
(	O
functional	O
genetic	O
units	O
,	O
FGU	O
)	O
.	O

Both	O
simulated	O
and	O
real	O
data	O
suggest	O
that	O
complementary	O
epistasis	O
contributes	O
greatly	O
to	O
quantitative	O
trait	O
variation	O
,	O
and	O
obscures	O
the	O
phenotypic	O
effects	O
of	O
many	O
'	O
downstream	O
'	O
loci	O
in	O
pathways	O
.	O

The	O
mathematical	O
relationships	O
between	O
the	O
main	O
effects	O
and	O
epistatic	O
effects	O
of	O
genes	O
acting	O
at	O
different	O
levels	O
of	O
signaling	O
pathways	O
were	O
established	O
using	O
the	O
quantitative	O
and	O
population	O
genetic	O
parameters	O
.	O

Both	O
loss	O
of	O
function	O
and	O
""""	O
co	O
-	O
adapted	O
""""	O
gene	O
complexes	O
formed	O
by	O
multiple	O
alleles	O
with	O
differentiated	O
functions	O
(	O
effects	O
)	O
are	O
predicted	O
to	O
be	O
frequent	O
types	O
of	O
allelic	O
diversity	O
at	O
loci	O
that	O
contribute	O
to	O
the	O
genetic	O
variation	O
of	O
complex	O
traits	O
in	O
populations	O
.	O

Downstream	O
FGUs	O
appear	O
to	O
be	O
more	O
vulnerable	O
to	O
loss	O
of	O
function	O
than	O
their	O
upstream	O
regulators	O
,	O
but	O
this	O
vulnerability	O
is	O
apparently	O
compensated	O
by	O
different	O
FGUs	O
of	O
similar	O
functions	O
.	O

Other	O
predictions	O
from	O
the	O
model	O
may	O
account	O
for	O
puzzling	O
results	O
regarding	O
responses	O
to	O
selection	O
,	O
genotype	O
by	O
environment	O
interaction	O
,	O
and	O
the	O
genetic	O
basis	O
of	O
heterosis	O
.	O

Ras	O
p21	O
onco	O
-	O
protein	O
in	O
the	O
sera	O
of	O
mice	O
carrying	O
an	O
experimentally	O
induced	O
tumor	O
and	O
in	O
human	O
cancer	O
patients	O
.	O

We	O
have	O
established	O
a	O
model	O
system	O
to	O
detect	O
the	O
presence	O
of	O
ras	O
p21	O
in	O
the	O
sera	O
of	O
Balb	O
/	O
c	O
mice	O
carrying	O
tumors	O
induced	O
by	O
a	O
mouse	O
cell	O
line	O
transformed	O
with	O
the	O
Harvey	O
murine	O
sarcoma	O
virus	O
in	O
the	O
presence	O
of	O
a	O
helper	O
Friend	O
murine	O
leukemia	O
virus	O
.	O

As	O
determined	O
by	O
ELISA	O
and	O
immunoblot	O
assays	O
,	O
ras	O
p21	O
in	O
the	O
serum	O
increased	O
with	O
increased	O
tumor	O
growth	O
.	O

Since	O
ras	O
genes	O
have	O
been	O
found	O
to	O
be	O
frequently	O
activated	O
in	O
human	O
tumours	O
,	O
we	O
examined	O
the	O
levels	O
of	O
ras	O
p21	O
in	O
the	O
sera	O
of	O
a	O
variety	O
of	O
human	O
cancer	O
patients	O
.	O

In	O
only	O
3	O
out	O
of	O
13	O
cases	O
,	O
representing	O
patients	O
with	O
adenocarcinomas	O
of	O
the	O
stomach	O
receiving	O
chemotherapy	O
,	O
was	O
ras	O
p21	O
detected	O
at	O
elevated	O
levels	O
,	O
whereas	O
in	O
patients	O
with	O
the	O
following	O
types	O
of	O
cancer	O
no	O
substantial	O
change	O
in	O
serum	O
ras	O
p21	O
was	O
observed	O
;	O
nine	O
with	O
breast	O
,	O
5	O
colon	O
,	O
5	O
lung	O
,	O
5	O
ovarian	O
and	O
5	O
hepatocellular	O
carcinomas	O
.	O

Serum	O
soluble	O
vascular	O
adhesion	O
protein	O
-	O
1	O
is	O
a	O
valuable	O
prognostic	O
marker	O
in	O
gastric	O
cancer	O
.	O

BACKGROUND	O
:	O
Vascular	O
adhesion	O
protein	O
-	O
1	O
(	O
VAP	O
-	O
1	O
)	O
regulates	O
leukocyte	O
tissue	O
infiltration	O
.	O

Elevated	O
serum	O
soluble	O
VAP	O
-	O
1	O
(	O
sVAP	O
-	O
1	O
)	O
levels	O
occur	O
in	O
certain	O
diseases	O
having	O
an	O
inflammatory	O
component	O
.	O

We	O
previously	O
showed	O
in	O
colorectal	O
cancer	O
that	O
sVAP	O
-	O
1	O
expression	O
is	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
this	O
decreased	O
expression	O
is	O
associated	O
with	O
poor	O
prognosis	O
and	O
lymph	O
node	O
and	O
liver	O
metastasis	O
.	O

However	O
,	O
sVAP	O
-	O
1	O
expression	O
has	O
not	O
been	O
described	O
for	O
gastric	O
cancer	O
.	O

This	O
study	O
determines	O
the	O
relationship	O
between	O
preoperative	O
serum	O
sVAP	O
-	O
1	O
levels	O
and	O
clinicopathological	O
features	O
and	O
prognosis	O
in	O
gastric	O
cancer	O
.	O

METHODS	O
:	O
Preoperative	O
serum	O
was	O
collected	O
from	O
107	O
gastric	O
cancer	O
patients	O
and	O
33	O
normal	O
controls	O
.	O

sVAP	O
-	O
1	O
levels	O
were	O
assayed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

RESULTS	O
:	O
The	O
mean	O
sVAP	O
-	O
1	O
level	O
for	O
cancer	O
patients	O
was	O
significantly	O
higher	O
relative	O
to	O
controls	O
,	O
and	O
decreased	O
with	O
disease	O
progression	O
.	O

Tumor	O
size	O
,	O
serosal	O
invasion	O
,	O
lymph	O
node	O
metastasis	O
,	O
peritoneal	O
dissemination	O
,	O
and	O
TNM	O
classification	O
was	O
significantly	O
correlated	O
with	O
sVAP	O
-	O
1	O
level	O
.	O

sVAP	O
-	O
1	O
is	O
also	O
an	O
independent	O
predictive	O
marker	O
for	O
lymph	O
node	O
metastasis	O
.	O

Patients	O
having	O
low	O
sVAP	O
-	O
1	O
levels	O
had	O
significantly	O
poorer	O
prognosis	O
relative	O
to	O
patients	O
having	O
elevated	O
sVAP	O
-	O
1	O
in	O
all	O
or	O
stages	O
I	O
-	O
III	O
gastric	O
cancer	O
patients	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
Low	O
sVAP	O
-	O
1	O
levels	O
are	O
associated	O
with	O
poor	O
prognosis	O
in	O
gastric	O
cancer	O
.	O

Determining	O
sVAP	O
-	O
1	O
levels	O
may	O
be	O
valuable	O
for	O
predicting	O
prognosis	O
and	O
lymph	O
node	O
metastasis	O
.	O

Diallyl	O
trisulfide	O
(	O
DATS	O
)	O
inhibits	O
mouse	O
colon	O
tumor	O
in	O
mouse	O
CT	B
-	I
26	I
cells	O
allograft	O
model	O
in	O
vivo	O
.	O

Our	O
earlier	O
studies	O
showed	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
human	O
colon	O
cancer	O
HT29	B
and	O
colo	B
205	I
cell	O
lines	O
in	O
vitro	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
to	O
show	O
that	O
DATS	O
induced	O
apoptosis	O
in	O
vitro	O
and	O
inhibited	O
CT26	B
cancer	O
cells	O
in	O
vivo	O
on	O
a	O
murine	O
allograft	O
animal	O
model	O
.	O

In	O
vitro	O
studies	O
,	O
the	O
results	O
indicated	O
that	O
DATS	O
induced	O
morphological	O
changes	O
and	O
induction	O
of	O
apoptosis	O
in	O
CT26	B
cells	O
.	O

In	O
vivo	O
studies	O
,	O
CT26	B
cancer	O
cells	O
were	O
implanted	O
into	O
BALB	O
/	O
c	O
mice	O
and	O
groups	O
of	O
mice	O
were	O
treated	O
with	O
vehicle	O
,	O
DATS	O
(	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
)	O
.	O

DATS	O
were	O
injected	O
once	O
per	O
four	O
days	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
,	O
with	O
treatment	O
starting	O
4	O
weeks	O
prior	O
to	O
cells	O
inoculation	O
.	O

Treatment	O
with	O
vehicle	O
or	O
with	O
10	O
and	O
50	O
mg	O
/	O
kg	O
of	O
DATS	O
resulted	O
in	O
a	O
reduction	O
in	O
tumor	O
volume	O
and	O
weight	O
.	O

Tumor	O
volume	O
and	O
total	O
hemoglobin	O
in	O
allograft	O
mice	O
treated	O
with	O
50	O
mg	O
/	O
kg	O
DATS	O
were	O
significantly	O
smaller	O
than	O
that	O
in	O
the	O
control	O
group	O
.	O

These	O
findings	O
indicated	O
that	O
DATS	O
inhibits	O
tumor	O
growth	O
in	O
an	O
allograft	O
animal	O
model	O
.	O

Thus	O
,	O
DATS	O
may	O
represent	O
a	O
colon	O
cancer	O
preventive	O
agent	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
.	O

Metabolic	O
regulation	O
by	O
p53	O
.	O

We	O
are	O
increasingly	O
aware	O
that	O
cellular	O
metabolism	O
plays	O
a	O
vital	O
role	O
in	O
diseases	O
such	O
as	O
cancer	O
,	O
and	O
that	O
p53	O
is	O
an	O
important	O
regulator	O
of	O
metabolic	O
pathways	O
.	O

By	O
transcriptional	O
activation	O
and	O
other	O
means	O
,	O
p53	O
is	O
able	O
to	O
contribute	O
to	O
the	O
regulation	O
of	O
glycolysis	O
,	O
oxidative	O
phosphorylation	O
,	O
glutaminolysis	O
,	O
insulin	O
sensitivity	O
,	O
nucleotide	O
biosynthesis	O
,	O
mitochondrial	O
integrity	O
,	O
fatty	O
acid	O
oxidation	O
,	O
antioxidant	O
response	O
,	O
autophagy	O
and	O
mTOR	O
signalling	O
.	O

The	O
ability	O
to	O
positively	O
and	O
negatively	O
regulate	O
many	O
of	O
these	O
pathways	O
,	O
combined	O
with	O
feedback	O
signalling	O
from	O
these	O
pathways	O
to	O
p53	O
,	O
demonstrates	O
the	O
reciprocal	O
and	O
flexible	O
nature	O
of	O
the	O
regulation	O
,	O
facilitating	O
a	O
diverse	O
range	O
of	O
responses	O
to	O
metabolic	O
stress	O
.	O

Intriguingly	O
,	O
metabolic	O
stress	O
triggers	O
primarily	O
an	O
adaptive	O
(	O
rather	O
than	O
pro	O
-	O
apoptotic	O
)	O
p53	O
response	O
,	O
and	O
p53	O
is	O
emerging	O
as	O
an	O
important	O
regulator	O
of	O
metabolic	O
homeostasis	O
.	O

A	O
better	O
understanding	O
of	O
how	O
p53	O
coordinates	O
metabolic	O
adaptation	O
will	O
facilitate	O
the	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
and	O
will	O
also	O
illuminate	O
the	O
wider	O
role	O
of	O
p53	O
in	O
human	O
biology	O
.	O

Use	O
of	O
DNA	O
microarray	O
and	O
small	O
animal	O
positron	O
emission	O
tomography	O
in	O
preclinical	O
drug	O
evaluation	O
of	O
RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
VEGFR	O
-	O
2	O
inhibitor	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
has	O
become	O
a	O
useful	O
tool	O
for	O
assessing	O
early	O
biologic	O
response	O
to	O
cancer	O
therapy	O
and	O
may	O
be	O
particularly	O
useful	O
in	O
the	O
development	O
of	O
new	O
cancer	O
therapeutics	O
.	O

RAF265	O
,	O
a	O
novel	O
B	O
-	O
Raf	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
inhibitor	O
,	O
was	O
evaluated	O
in	O
the	O
preclinical	O
setting	O
for	O
its	O
ability	O
to	O
inhibit	O
the	O
uptake	O
of	O
PET	O
tracers	O
in	O
the	O
A375	B
M	I
(	O
B	O
-	O
Raf	O
(	O
V600E	O
)	O
)	O
human	O
melanoma	O
cell	O
line	O
.	O

RAF265	O
inhibited	O
2	O
-	O
deoxy	O
-	O
2	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluoro	O
-	O
d	O
-	O
glucose	O
(	O
FDG	O
)	O
accumulation	O
in	O
cell	O
culture	O
at	O
28	O
hours	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

RAF265	O
also	O
inhibited	O
FDG	O
accumulation	O
in	O
tumor	O
xenografts	O
after	O
1	O
day	O
of	O
drug	O
treatment	O
.	O

This	O
decrease	O
persisted	O
for	O
the	O
remaining	O
2	O
weeks	O
of	O
treatment	O
.	O

DNA	O
microarray	O
analysis	O
of	O
treated	O
tumor	O
xenografts	O
revealed	O
significantly	O
decreased	O
expression	O
of	O
genes	O
regulating	O
glucose	O
and	O
thymidine	O
metabolism	O
and	O
revealed	O
changes	O
in	O
apoptotic	O
genes	O
,	O
suggesting	O
that	O
the	O
imaging	O
tracers	O
FDG	O
,	O
3	O
-	O
deoxy	O
-	O
3	O
-	O
[	O
(	O
18	O
)	O
F	O
]	O
fluorothymidine	O
,	O
and	O
annexin	O
V	O
could	O
serve	O
as	O
potential	O
imaging	O
biomarkers	O
for	O
RAF265	O
therapy	O
monitoring	O
.	O

We	O
concluded	O
that	O
RAF265	O
is	O
highly	O
efficacious	O
in	O
this	O
xenograft	O
model	O
of	O
human	O
melanoma	O
and	O
decreases	O
glucose	O
metabolism	O
as	O
measured	O
by	O
DNA	O
microarray	O
analysis	O
,	O
cell	O
culture	O
assays	O
,	O
and	O
small	O
animal	O
FDG	O
PET	O
scans	O
as	O
early	O
as	O
1	O
day	O
after	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
use	O
of	O
FDG	O
PET	O
in	O
clinical	O
trials	O
with	O
RAF265	O
to	O
assess	O
early	O
tumor	O
response	O
.	O

DNA	O
microarray	O
analysis	O
and	O
small	O
animal	O
PET	O
studies	O
may	O
be	O
used	O
as	O
complementary	O
technologies	O
in	O
drug	O
development	O
.	O

DNA	O
microarray	O
analysis	O
allows	O
for	O
analysis	O
of	O
drug	O
effects	O
on	O
multiple	O
pathways	O
linked	O
to	O
cancer	O
and	O
can	O
suggest	O
corresponding	O
imaging	O
tracers	O
for	O
further	O
analysis	O
as	O
biomarkers	O
of	O
tumor	O
response	O
.	O

Predictive	O
value	O
of	O
serum	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
in	O
malignant	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
.	O

BACKGROUND	O
:	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
serum	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
(	O
CA	O
19	O
-	O
9	O
)	O
in	O
the	O
diagnosis	O
of	O
malignant	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
of	O
pancreas	O
(	O
IPMNs	O
)	O
.	O

METHODS	O
:	O

Eighty	O
-	O
six	O
patients	O
with	O
pathological	O
diagnosis	O
of	O
IPMNs	O
in	O
Zhongshan	O
Hospital	O
between	O
March	O
1999	O
and	O
November	O
2008	O
were	O
retrospectively	O
reviewed	O
.	O

Data	O
reflecting	O
clinical	O
characteristics	O
,	O
tumor	O
marker	O
level	O
,	O
and	O
prognosis	O
were	O
collected	O
.	O

The	O
potential	O
predictive	O
value	O
of	O
CA	O
19	O
-	O
9	O
was	O
analyzed	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O

RESULTS	O
:	O

Eighty	O
-	O
six	O
consecutive	O
patients	O
with	O
IPMNs	O
all	O
underwent	O
surgical	O
intervention	O
.	O

A	O
high	O
level	O
of	O
CA	O
19	O
-	O
9	O
or	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
was	O
associated	O
with	O
more	O
advanced	O
stage	O
of	O
malignant	O
IPMNs	O
.	O

Carbohydrate	O
antigen	O
19	O
-	O
9	O
was	O
significant	O
for	O
judging	O
malignant	O
IPMNs	O
in	O
the	O
binary	O
logistic	O
regression	O
model	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O

The	O
hazard	O
ratio	O
was	O
1	O
.	O
014	O
,	O
whose	O
95	O
.	O
0	O
%	O
confidence	O
interval	O
was	O
0	O
.	O
91	O
-	O
1	O
.	O
028	O
.	O

Receiver	O
operating	O
characteristic	O
analysis	O
showed	O
that	O
the	O
serum	O
CA	O
19	O
-	O
9	O
level	O
had	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	O
,	O
postoperative	O
survival	O
,	O
and	O
disease	O
-	O
specific	O
recurrence	O
.	O

The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
856	O
,	O
0	O
.	O
893	O
,	O
0	O
.	O
815	O
,	O
and	O
0	O
.	O
857	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

According	O
to	O
the	O
follow	O
-	O
up	O
,	O
mean	O
survival	O
time	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
was	O
dramatically	O
shorter	O
than	O
that	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
<	O
=	O
63	O
.	O
60	O
U	O
/	O
ml	O
(	O
57	O
.	O
38	O
+	O
/	O
-	O
2	O
.	O
85	O
versus	O
29	O
.	O
24	O
+	O
/	O
-	O
5	O
.	O
82	O
[	O
months	O
]	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O

Serum	O
CA	O
19	O
-	O
9	O
level	O
has	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	O
.	O

Patients	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
had	O
poor	O
postoperative	O
prognosis	O
in	O
IPMNs	O
.	O

Preoperative	O
abnormal	O
serum	O
CA	O
19	O
-	O
9	O
might	O
be	O
predictive	O
for	O
an	O
aggressive	O
surgical	O
intervention	O
in	O
IPMNs	O
.	O

Saliva	O
proteins	O
of	O
vector	O
Culicoides	O
modify	O
structure	O
and	O
infectivity	O
of	O
bluetongue	O
virus	O
particles	O
.	O

Bluetongue	O
virus	O
(	O
BTV	O
)	O
and	O
epizootic	O
haemorrhagic	O
disease	O
virus	O
(	O
EHDV	O
)	O
are	O
related	O
orbiviruses	O
,	O
transmitted	O
between	O
their	O
ruminant	O
hosts	O
primarily	O
by	O
certain	O
haematophagous	O
midge	O
vectors	O
(	O
Culicoides	O
spp	O
.	O
)	O
.	O

The	O
larger	O
of	O
the	O
BTV	O
outer	O
-	O
capsid	O
proteins	O
,	O
'	O
VP2	O
'	O
,	O
can	O
be	O
cleaved	O
by	O
proteases	O
(	O
including	O
trypsin	O
or	O
chymotrypsin	O
)	O
,	O
forming	O
infectious	O
subviral	O
particles	O
(	O
ISVP	O
)	O
which	O
have	O
enhanced	O
infectivity	O
for	O
adult	O
Culicoides	O
,	O
or	O
KC	O
cells	O
(	O
a	O
cell	O
-	O
line	O
derived	O
from	O
C	O
.	O
sonorensis	O
)	O
.	O

We	O
demonstrate	O
that	O
VP2	O
present	O
on	O
purified	O
virus	O
particles	O
from	O
3	O
different	O
BTV	O
strains	O
can	O
also	O
be	O
cleaved	O
by	O
treatment	O
with	O
saliva	O
from	O
adult	O
Culicoides	O
.	O

The	O
saliva	O
proteins	O
from	O
C	O
.	O
sonorensis	O
(	O
a	O
competent	O
BTV	O
vector	O
)	O
,	O
cleaved	O
BTV	O
-	O
VP2	O
more	O
efficiently	O
than	O
those	O
from	O
C	O
.	O
nubeculosus	O
(	O
a	O
less	O
competent	O
/	O
non	O
-	O
vector	O
species	O
)	O
.	O

Electrophoresis	O
and	O
mass	O
spectrometry	O
identified	O
a	O
trypsin	O
-	O
like	O
protease	O
in	O
C	O
.	O
sonorensis	O
saliva	O
,	O
which	O
was	O
significantly	O
reduced	O
or	O
absent	O
from	O
C	O
.	O
nubeculosus	O
saliva	O
.	O

Incubating	O
purified	O
BTV	O
-	O
1	O
with	O
C	O
.	O
sonorensis	O
saliva	O
proteins	O
also	O
increased	O
their	O
infectivity	O
for	O
KC	O
cells	O
~	O
10	O
fold	O
,	O
while	O
infectivity	O
for	O
BHK	B
cells	O
was	O
reduced	O
by	O
2	O
-	O
6	O
fold	O
.	O

Treatment	O
of	O
an	O
'	O
eastern	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
with	O
saliva	O
proteins	O
of	O
either	O
C	O
.	O
sonorensis	O
or	O
C	O
.	O
nubeculosus	O
cleaved	O
VP2	O
,	O
but	O
a	O
'	O
western	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
remained	O
unmodified	O
.	O

These	O
results	O
indicate	O
that	O
temperature	O
,	O
strain	O
of	O
virus	O
and	O
protein	O
composition	O
of	O
Culicoides	O
saliva	O
(	O
particularly	O
its	O
protease	O
content	O
which	O
is	O
dependent	O
upon	O
vector	O
species	O
)	O
,	O
can	O
all	O
play	O
a	O
significant	O
role	O
in	O
the	O
efficiency	O
of	O
VP2	O
cleavage	O
,	O
influencing	O
virus	O
infectivity	O
.	O

Saliva	O
of	O
several	O
other	O
arthropod	O
species	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
transmission	O
,	O
infectivity	O
and	O
virulence	O
of	O
certain	O
arboviruses	O
,	O
by	O
modulating	O
and	O
/	O
or	O
suppressing	O
the	O
mammalian	O
immune	O
response	O
.	O

The	O
findings	O
presented	O
here	O
,	O
however	O
,	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
proteases	O
in	O
Culicoides	O
saliva	O
can	O
also	O
directly	O
modify	O
the	O
orbivirus	O
particle	O
structure	O
,	O
leading	O
to	O
increased	O
infectivity	O
specifically	O
for	O
Culicoides	O
cells	O
and	O
,	O
in	O
turn	O
,	O
efficiency	O
of	O
transmission	O
to	O
the	O
insect	O
vector	O
.	O

Systematic	O
proteomic	O
analysis	O
of	O
human	O
hepotacellular	O
carcinoma	O
cells	O
reveals	O
molecular	O
pathways	O
and	O
networks	O
involved	O
in	O
metastasis	O
.	O

Systematic	O
proteomic	O
studying	O
of	O
the	O
mechanism	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
metastasis	O
remains	O
challenging	O
.	O

We	O
performed	O
comparative	O
proteomic	O
and	O
pathway	O
analysis	O
of	O
four	O
human	O
metastatic	O
HCC	O
cell	O
lines	O
to	O
identify	O
metastasis	O
-	O
associated	O
proteins	O
.	O

These	O
HCC	O
cell	O
lines	O
had	O
a	O
similar	O
genetic	O
background	O
but	O
with	O
an	O
increasing	O
potential	O
of	O
metastasis	O
.	O

Using	O
a	O
combination	O
of	O
two	O
dimensional	O
electrophoresis	O
(	O
2	O
-	O
DE	O
)	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
,	O
a	O
total	O
of	O
125	O
proteins	O
and	O
their	O
post	O
-	O
translational	O
modification	O
forms	O
or	O
isoforms	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
the	O
cell	O
lines	O
.	O

Among	O
them	O
,	O
29	O
were	O
gradually	O
up	O
-	O
regulated	O
whereas	O
17	O
were	O
down	O
-	O
regulated	O
with	O
increasing	O
metastatic	O
potential	O
.	O

Instead	O
of	O
a	O
traditional	O
single	O
-	O
gene	O
readout	O
,	O
global	O
bioinformatics	O
analysis	O
was	O
carried	O
out	O
,	O
which	O
revealed	O
that	O
the	O
glycolysis	O
pathway	O
was	O
the	O
most	O
significantly	O
enriched	O
pathway	O
.	O

The	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
centered	O
and	O
NF	O
-	O
kappaB	O
centered	O
networks	O
were	O
also	O
enriched	O
in	O
the	O
result	O
,	O
which	O
may	O
imply	O
the	O
key	O
function	O
of	O
inflaming	O
on	O
metastasis	O
.	O

Meanwhile	O
,	O
knockdown	O
of	O
HDGF	O
,	O
an	O
up	O
-	O
regulated	O
protein	O
and	O
a	O
target	O
of	O
NF	O
-	O
kappaB	O
,	O
induced	O
cell	O
apoptosis	O
in	O
the	O
metastatic	O
HCC	O
cells	O
.	O

This	O
work	O
provides	O
a	O
demonstration	O
that	O
a	O
combination	O
of	O
bioinformatics	O
and	O
comparative	O
proteomics	O
can	O
help	O
in	O
finding	O
out	O
potential	O
biomarkers	O
associated	O
with	O
HCC	O
metastasis	O
on	O
the	O
level	O
of	O
pathways	O
.	O

Roles	O
of	O
brca2	O
(	O
fancd1	O
)	O
in	O
oocyte	O
nuclear	O
architecture	O
,	O
gametogenesis	O
,	O
gonad	O
tumors	O
,	O
and	O
genome	O
stability	O
in	O
zebrafish	O
.	O

Mild	O
mutations	O
in	O
BRCA2	O
(	O
FANCD1	O
)	O
cause	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
when	O
homozygous	O
,	O
while	O
severe	O
mutations	O
cause	O
common	O
cancers	O
including	O
breast	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancers	O
when	O
heterozygous	O
.	O

Here	O
we	O
report	O
a	O
zebrafish	O
brca2	O
insertional	O
mutant	O
that	O
shares	O
phenotypes	O
with	O
human	O
patients	O
and	O
identifies	O
a	O
novel	O
brca2	O
function	O
in	O
oogenesis	O
.	O

Experiments	O
showed	O
that	O
mutant	O
embryos	O
and	O
mutant	O
cells	O
in	O
culture	O
experienced	O
genome	O
instability	O
,	O
as	O
do	O
cells	O
in	O
FA	O
patients	O
.	O

In	O
wild	O
-	O
type	O
zebrafish	O
,	O
meiotic	O
cells	O
expressed	O
brca2	O
;	O
and	O
,	O
unexpectedly	O
,	O
transcripts	O
in	O
oocytes	O
localized	O
asymmetrically	O
to	O
the	O
animal	O
pole	O
.	O

In	O
juvenile	O
brca2	O
mutants	O
,	O
oocytes	O
failed	O
to	O
progress	O
through	O
meiosis	O
,	O
leading	O
to	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O

Adult	O
mutants	O
became	O
sterile	O
males	O
due	O
to	O
the	O
meiotic	O
arrest	O
of	O
spermatocytes	O
,	O
which	O
then	O
died	O
by	O
apoptosis	O
,	O
followed	O
by	O
neoplastic	O
proliferation	O
of	O
gonad	O
somatic	O
cells	O
that	O
was	O
similar	O
to	O
neoplasia	O
observed	O
in	O
ageing	O
dead	O
end	O
(	O
dnd	O
)	O
-	O
knockdown	O
males	O
,	O
which	O
lack	O
germ	O
cells	O
.	O

The	O
construction	O
of	O
animals	O
doubly	O
mutant	O
for	O
brca2	O
and	O
the	O
apoptotic	O
gene	O
tp53	O
(	O
p53	O
)	O
rescued	O
brca2	O
-	O
dependent	O
sex	O
reversal	O
.	O

Double	O
mutants	O
developed	O
oocytes	O
and	O
became	O
sterile	O
females	O
that	O
produced	O
only	O
aberrant	O
embryos	O
and	O
showed	O
elevated	O
risk	O
for	O
invasive	O
ovarian	O
tumors	O
.	O

Oocytes	O
in	O
double	O
-	O
mutant	O
females	O
showed	O
normal	O
localization	O
of	O
brca2	O
and	O
pou5f1	O
transcripts	O
to	O
the	O
animal	O
pole	O
and	O
vasa	O
transcripts	O
to	O
the	O
vegetal	O
pole	O
,	O
but	O
had	O
a	O
polarized	O
rather	O
than	O
symmetrical	O
nucleus	O
with	O
the	O
distribution	O
of	O
nucleoli	O
and	O
chromosomes	O
to	O
opposite	O
nuclear	O
poles	O
;	O
this	O
result	O
revealed	O
a	O
novel	O
role	O
for	O
Brca2	O
in	O
establishing	O
or	O
maintaining	O
oocyte	O
nuclear	O
architecture	O
.	O

Mutating	O
tp53	O
did	O
not	O
rescue	O
the	O
infertility	O
phenotype	O
in	O
brca2	O
mutant	O
males	O
,	O
suggesting	O
that	O
brca2	O
plays	O
an	O
essential	O
role	O
in	O
zebrafish	O
spermatogenesis	O
.	O

Overall	O
,	O
this	O
work	O
verified	O
zebrafish	O
as	O
a	O
model	O
for	O
the	O
role	O
of	O
Brca2	O
in	O
human	O
disease	O
and	O
uncovered	O
a	O
novel	O
function	O
of	O
Brca2	O
in	O
vertebrate	O
oocyte	O
nuclear	O
architecture	O
.	O

Induction	O
of	O
I	O
d	O
-	O
1	O
by	O
FGF	O
-	O
2	O
involves	O
activity	O
of	O
EGR	O
-	O
1	O
and	O
sensitizes	O
neuroblastoma	O
cells	O
to	O
cell	O
death	O
.	O

Inhibitor	O
of	O
differentiation	O
-	O
1	O
(	O
I	O
d	O
-	O
1	O
)	O
is	O
a	O
member	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
family	O
of	O
proteins	O
that	O
regulate	O
gene	O
transcription	O
through	O
their	O
inhibitory	O
binding	O
to	O
basic	O
-	O
HLH	O
transcription	O
factors	O
.	O

Similarly	O
to	O
other	O
members	O
of	O
this	O
family	O
,	O
I	O
d	O
-	O
1	O
is	O
involved	O
in	O
the	O
repression	O
of	O
cell	O
differentiation	O
and	O
activation	O
of	O
cell	O
growth	O
.	O

The	O
dual	O
function	O
of	O
I	O
d	O
-	O
1	O
,	O
inhibition	O
of	O
differentiation	O
,	O
and	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
might	O
be	O
interdependent	O
,	O
as	O
cell	O
differentiation	O
is	O
generally	O
coupled	O
with	O
the	O
exit	O
from	O
the	O
cell	O
cycle	O
.	O

Fibroblast	O
growth	O
factor	O
-	O
2	O
(	O
FGF	O
-	O
2	O
)	O
has	O
been	O
reported	O
to	O
play	O
multiple	O
roles	O
in	O
different	O
biological	O
processes	O
during	O
development	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

In	O
addition	O
,	O
FGF	O
-	O
2	O
has	O
been	O
described	O
to	O
induce	O
""""	O
neuronal	O
-	O
like	O
""""	O
differentiation	O
and	O
trigger	O
apoptosis	O
in	O
neuroblastoma	O
SK	B
-	I
N	I
-	I
MC	I
cells	O
.	O

Although	O
regulation	O
of	O
I	O
d	O
-	O
1	O
protein	O
by	O
several	O
mitogenic	O
factors	O
is	O
well	O
-	O
established	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
FGF	O
-	O
2	O
in	O
the	O
regulation	O
of	O
I	O
d	O
-	O
1	O
.	O

Using	O
human	O
neuroblastoma	O
cell	O
line	O
,	O
SK	B
-	I
N	I
-	I
MC	I
,	O
we	O
found	O
that	O
treatment	O
of	O
these	O
cells	O
with	O
FGF	O
-	O
2	O
resulted	O
in	O
early	O
induction	O
of	O
both	O
I	O
d	O
-	O
1	O
mRNA	O
and	O
protein	O
.	O

The	O
induction	O
occurs	O
within	O
1	O
h	O
from	O
FGF	O
-	O
2	O
treatment	O
and	O
is	O
mediated	O
by	O
ERK1	O
/	O
2	O
pathway	O
,	O
which	O
in	O
turn	O
stimulates	O
expression	O
of	O
the	O
early	O
growth	O
response	O
-	O
1	O
(	O
Egr	O
-	O
1	O
)	O
transcription	O
factor	O
.	O

We	O
also	O
demonstrate	O
direct	O
interaction	O
of	O
Egr	O
-	O
1	O
with	O
I	O
d	O
-	O
1	O
promoter	O
in	O
vitro	O
and	O
in	O
cell	O
culture	O
.	O

Finally	O
,	O
inhibition	O
of	O
I	O
d	O
-	O
1	O
expression	O
results	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
accumulation	O
of	O
FGF	O
-	O
2	O
-	O
treated	O
cells	O
and	O
delayed	O
cell	O
death	O
.	O

Vimentin	O
is	O
preferentially	O
expressed	O
in	O
human	O
breast	O
carcinomas	O
with	O
low	O
estrogen	O
receptor	O
and	O
high	O
Ki	O
-	O
67	O
growth	O
fraction	O
.	O

Vimentin	O
expression	O
,	O
growth	O
fractions	O
(	O
GF	O
)	O
,	O
and	O
estrogen	O
receptor	O
(	O
ER	O
)	O
levels	O
were	O
determined	O
for	O
90	O
untreated	O
primary	O
breast	O
carcinomas	O
.	O

Coexpression	O
of	O
keratin	O
and	O
vimentin	O
was	O
found	O
in	O
approximately	O
20	O
%	O
of	O
the	O
tumors	O
regardless	O
of	O
menopausal	O
status	O
.	O

Vimentin	O
was	O
expressed	O
preferentially	O
in	O
tumor	O
cells	O
of	O
high	O
-	O
grade	O
ductal	O
breast	O
carcinomas	O
(	O
15	O
of	O
28	O
histologic	O
grade	O
3	O
vs	O
.	O
0	O
of	O
40	O
grades	O
1	O
and	O
2	O
)	O
.	O

Vimentin	O
expression	O
was	O
found	O
preferentially	O
in	O
tumors	O
with	O
high	O
GF	O
(	O
greater	O
than	O
15	O
%	O
Ki	O
-	O
67	O
positive	O
by	O
immunoperoxidase	O
staining	O
)	O
and	O
low	O
ER	O
levels	O
(	O
less	O
than	O
60	O
fmols	O
/	O
mg	O
protein	O
by	O
a	O
monoclonal	O
enzyme	O
immunoassay	O
)	O
.	O

Sixty	O
-	O
eight	O
percent	O
of	O
tumors	O
in	O
this	O
group	O
were	O
vimentin	O
positive	O
and	O
88	O
%	O
of	O
all	O
vimentin	O
-	O
positive	O
tumors	O
fell	O
into	O
this	O
category	O
.	O

More	O
than	O
50	O
%	O
of	O
the	O
tumor	O
cells	O
coexpressed	O
vimentin	O
and	O
keratin	O
.	O

Thus	O
,	O
vimentin	O
expression	O
may	O
be	O
helpful	O
in	O
identifying	O
a	O
substantial	O
subset	O
of	O
ER	O
-	O
independent	O
breast	O
carcinomas	O
with	O
poor	O
prognostic	O
indicators	O
.	O

High	O
-	O
mobility	O
group	O
A2	O
protein	O
modulates	O
hTERT	O
transcription	O
to	O
promote	O
tumorigenesis	O
.	O

The	O
high	O
-	O
mobility	O
group	O
A2	O
gene	O
(	O
HMGA2	O
)	O
is	O
one	O
of	O
the	O
most	O
frequently	O
amplified	O
genes	O
in	O
human	O
cancers	O
.	O

However	O
,	O
functions	O
of	O
HMGA2	O
in	O
tumorigenesis	O
are	O
not	O
fully	O
understood	O
due	O
to	O
limited	O
knowledge	O
of	O
its	O
targets	O
in	O
tumor	O
cells	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
link	O
between	O
HMGA2	O
and	O
the	O
regulation	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
,	O
the	O
catalytic	O
subunit	O
of	O
telomerase	O
,	O
which	O
offers	O
critical	O
insight	O
into	O
how	O
HMGA2	O
contributes	O
to	O
tumorigenesis	O
.	O

The	O
expression	O
of	O
HMGA2	O
modulates	O
the	O
expression	O
of	O
hTERT	O
,	O
resulting	O
in	O
cells	O
with	O
enhanced	O
telomerase	O
activities	O
and	O
increased	O
telomere	O
length	O
.	O

Treatment	O
with	O
suberoylanilide	O
hydroxamide	O
(	O
SAHA	O
)	O
,	O
a	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
,	O
causes	O
dose	O
-	O
dependent	O
hTERT	O
reporter	O
activation	O
,	O
mimicking	O
HMGA2	O
overexpression	O
.	O

By	O
interacting	O
with	O
Sp1	O
,	O
HMGA2	O
interferes	O
with	O
the	O
recruitment	O
of	O
HDAC2	O
to	O
the	O
hTERT	O
proximal	O
promoter	O
,	O
enhancing	O
localized	O
histone	O
H3	O
-	O
K9	O
acetylation	O
and	O
thereby	O
stimulating	O
hTERT	O
expression	O
and	O
telomerase	O
activity	O
.	O

Moreover	O
,	O
HMGA2	O
knockdown	O
by	O
short	O
hairpin	O
HMGA2	O
in	O
HepG2	B
cells	O
leads	O
to	O
progressive	O
telomere	O
shortening	O
and	O
a	O
concurrent	O
decrease	O
of	O
steady	O
-	O
state	O
hTERT	O
mRNA	O
levels	O
,	O
attenuating	O
their	O
ability	O
to	O
form	O
colonies	O
in	O
soft	O
agar	O
.	O

Importantly	O
,	O
HMGA2	O
partially	O
replaces	O
the	O
function	O
of	O
hTERT	O
during	O
the	O
tumorigenic	O
transformation	O
of	O
normal	O
human	O
fibroblasts	O
.	O

These	O
findings	O
are	O
potentially	O
clinically	O
relevant	O
,	O
because	O
HMGA2	O
expression	O
is	O
reported	O
to	O
be	O
upregulated	O
in	O
a	O
number	O
of	O
human	O
cancers	O
as	O
telomere	O
maintenance	O
is	O
essential	O
for	O
tumorigenesis	O
.	O

3	O
-	O
[	O
(	O
Methyl	O
-	O
carbamo	O
-	O
yl	O
)	O
amino	O
]	O
-	O
1H	O
-	O
isoindolium	O
chloride	O
.	O

The	O
title	O
compound	O
,	O
C	O
(	O
10	O
)	O
H	O
(	O
12	O
)	O
N	O
(	O
3	O
)	O
O	O
(	O
+	O
)	O
.	O
Cl	O
(	O
-	O
)	O
,	O
is	O
a	O
derivative	O
of	O
o	O
-	O
phthaldehyde	O
and	O
methyl	O
-	O
thio	O
-	O
urea	O
.	O

The	O
mol	O
-	O
ecules	O
form	O
dimers	O
through	O
intra	O
-	O
and	O
inter	O
-	O
molecular	O
N	O
-	O
H	O
.	O
.	O
.	O
O	O
hydrogen	O
bonds	O
.	O

The	O
dimers	O
are	O
further	O
linked	O
into	O
chains	O
through	O
one	O
C	O
-	O
H	O
.	O
.	O
.	O
Cl	O
and	O
two	O
N	O
-	O
H	O
.	O
.	O
.	O
Cl	O
hydrogen	O
bonds	O
.	O

mirAct	O
:	O
a	O
web	O
tool	O
for	O
evaluating	O
microRNA	O
activity	O
based	O
on	O
gene	O
expression	O
data	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
critical	O
regulators	O
in	O
the	O
complex	O
cellular	O
networks	O
.	O

The	O
mirAct	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
sysbio	O
.	O
ustc	O
.	O
edu	O
.	O
cn	O
/	O
software	O
/	O
mirAct	O
)	O
is	O
a	O
tool	O
designed	O
to	O
investigate	O
miRNA	O
activity	O
based	O
on	O
gene	O
-	O
expression	O
data	O
by	O
using	O
the	O
negative	O
regulation	O
relationship	O
between	O
miRNAs	O
and	O
their	O
target	O
genes	O
.	O

mirAct	O
supports	O
multiple	O
-	O
class	O
data	O
and	O
enables	O
clustering	O
analysis	O
based	O
on	O
computationally	O
determined	O
miRNA	O
activity	O
.	O

Here	O
,	O
we	O
describe	O
the	O
framework	O
of	O
mirAct	O
,	O
demonstrate	O
its	O
performance	O
by	O
comparing	O
with	O
other	O
similar	O
programs	O
and	O
exemplify	O
its	O
applications	O
using	O
case	O
studies	O
.	O

Non	O
-	O
heart	O
-	O
beating	O
organ	O
donation	O
in	O
Italy	O
.	O

In	O
2007	O
the	O
non	O
-	O
heart	O
-	O
beating	O
organ	O
donation	O
(	O
NHBD	O
)	O
""""	O
Programma	O
Alba	O
""""	O
(	O
Sunrise	O
Programme	O
)	O
started	O
in	O
Pavia	O
,	O
Italy	O
.	O

The	O
initial	O
plan	O
was	O
to	O
cut	O
down	O
waiting	O
list	O
for	O
kidney	O
transplantation	O
,	O
while	O
its	O
final	O
aim	O
is	O
to	O
shorten	O
organ	O
transplantation	O
waiting	O
lists	O
.	O

When	O
compared	O
to	O
European	O
countries	O
and	O
the	O
USA	O
,	O
the	O
Italian	O
NHBD	O
program	O
has	O
taken	O
longer	O
to	O
get	O
established	O
.	O

Initially	O
Italian	O
physicians	O
were	O
not	O
entirely	O
aware	O
of	O
the	O
NHBD	O
organ	O
viability	O
for	O
transplantation	O
,	O
furthermore	O
ethical	O
issues	O
and	O
the	O
need	O
to	O
regulate	O
medical	O
requirements	O
to	O
Italian	O
law	O
slowed	O
down	O
the	O
NHBD	O
program	O
.	O

In	O
particular	O
,	O
Italian	O
legislation	O
provides	O
for	O
death	O
ascertainment	O
after	O
irreversible	O
cardiac	O
arrest	O
,	O
20	O
-	O
minute	O
flat	O
electrocardiogram	O
.	O

This	O
no	O
-	O
touch	O
period	O
is	O
longer	O
when	O
compared	O
to	O
worldwide	O
legislation	O
,	O
and	O
organ	O
viability	O
has	O
been	O
a	O
main	O
concern	O
for	O
Italian	O
transplant	O
doctors	O
over	O
the	O
years	O
.	O

However	O
,	O
recent	O
data	O
let	O
up	O
to	O
40	O
-	O
minute	O
warm	O
ischemia	O
time	O
to	O
preserve	O
organ	O
viability	O
;	O
this	O
has	O
encouraged	O
Pavia	O
'	O
s	O
group	O
to	O
establish	O
the	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
.	O

It	O
was	O
designed	O
according	O
to	O
Italian	O
legislation	O
from	O
death	O
diagnosis	O
to	O
graft	O
placement	O
,	O
from	O
this	O
perspective	O
must	O
the	O
significant	O
role	O
of	O
the	O
Transplant	O
coordinator	O
be	O
recognized	O
.	O

Since	O
2007	O
seven	O
kidneys	O
have	O
been	O
gathered	O
from	O
seven	O
NHBD	O
.	O

Of	O
these	O
,	O
six	O
NHBD	O
kidneys	O
have	O
been	O
transplanted	O
.	O

Currently	O
,	O
four	O
patients	O
are	O
out	O
of	O
dialysis	O
.	O

This	O
report	O
is	O
a	O
detailed	O
description	O
of	O
NHBD	O
""""	O
Programma	O
Alba	O
""""	O
and	O
its	O
preliminary	O
results	O
.	O

KISS1	O
methylation	O
and	O
expression	O
as	O
tumor	O
stratification	O
biomarkers	O
and	O
clinical	O
outcome	O
prognosticators	O
for	O
bladder	O
cancer	O
patients	O
.	O

KISS1	O
is	O
a	O
metastasis	O
suppressor	O
gene	O
that	O
is	O
lost	O
in	O
several	O
malignancies	O
,	O
including	O
bladder	O
cancer	O
.	O

We	O
tested	O
the	O
epigenetic	O
silencing	O
hypothesis	O
and	O
evaluated	O
the	O
biological	O
influence	O
of	O
KISS1	O
methylation	O
on	O
its	O
expression	O
and	O
clinical	O
relevance	O
in	O
bladder	O
cancer	O
.	O

KISS1	O
hypermethylation	O
was	O
frequent	O
in	O
bladder	O
cancer	O
cells	O
analyzed	O
by	O
methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	O
sequencing	O
and	O
was	O
associated	O
with	O
low	O
gene	O
expression	O
,	O
being	O
restored	O
in	O
vitro	O
by	O
demethylating	O
azacytidine	O
.	O

Hypermethylation	O
was	O
also	O
frequently	O
observed	O
in	O
a	O
large	O
series	O
of	O
bladder	O
tumors	O
(	O
83	O
.	O
1	O
%	O
,	O
n	O
=	O
804	O
)	O
.	O

KISS1	O
methylation	O
was	O
associated	O
with	O
increasing	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
tumor	O
grade	O
(	O
P	O
=	O
0	O
.	O
010	O
)	O
.	O

KISS1	O
methylation	O
was	O
associated	O
with	O
low	O
KISS1	O
transcript	O
expression	O
by	O
quantitative	O
RT	O
-	O
PCR	O
(	O
P	O
=	O
0	O
.	O
037	O
)	O
.	O

KISS1	O
transcript	O
expression	O
was	O
also	O
associated	O
with	O
histopathological	O
tumor	O
stage	O
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

Low	O
transcript	O
expression	O
alone	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
or	O
combined	O
with	O
methylation	O
(	O
P	O
=	O
0	O
.	O
019	O
)	O
was	O
associated	O
with	O
poor	O
disease	O
-	O
specific	O
survival	O
(	O
n	O
=	O
205	O
)	O
.	O

KISS1	O
transcript	O
expression	O
remained	O
an	O
independent	O
prognosticator	O
in	O
multivariate	O
analyses	O
(	O
P	O
=	O
0	O
.	O
017	O
)	O
.	O

KISS1	O
hypermethylation	O
was	O
identified	O
in	O
bladder	O
cancer	O
,	O
providing	O
a	O
potential	O
mechanistic	O
explanation	O
(	O
epigenetic	O
silencing	O
)	O
for	O
the	O
observed	O
loss	O
of	O
KISS1	O
in	O
uroepithelial	O
malignancies	O
.	O

Associations	O
of	O
KISS1	O
methylation	O
and	O
its	O
expression	O
with	O
histopathological	O
variables	O
and	O
poor	O
survival	O
suggest	O
the	O
utility	O
of	O
incorporating	O
KISS1	O
measurement	O
using	O
paraffin	O
-	O
embedded	O
material	O
for	O
tumor	O
stratification	O
and	O
clinical	O
outcome	O
prognosis	O
of	O
patients	O
with	O
uroepithelial	O
neoplasias	O
.	O

Oscillatory	O
alpha	O
-	O
band	O
mechanisms	O
and	O
the	O
deployment	O
of	O
spatial	O
attention	O
to	O
anticipated	O
auditory	O
and	O
visual	O
target	O
locations	O
:	O
supramodal	O
or	O
sensory	O
-	O
specific	O
control	O
mechanisms	O
?	O

Oscillatory	O
alpha	O
-	O
band	O
activity	O
(	O
8	O
-	O
15	O
Hz	O
)	O
over	O
parieto	O
-	O
occipital	O
cortex	O
in	O
humans	O
plays	O
an	O
important	O
role	O
in	O
suppression	O
of	O
processing	O
for	O
inputs	O
at	O
to	O
-	O
be	O
-	O
ignored	O
regions	O
of	O
space	O
,	O
with	O
increased	O
alpha	O
-	O
band	O
power	O
observed	O
over	O
cortex	O
contralateral	O
to	O
locations	O
expected	O
to	O
contain	O
distractors	O
.	O

It	O
is	O
unclear	O
whether	O
similar	O
processes	O
operate	O
during	O
deployment	O
of	O
spatial	O
attention	O
in	O
other	O
sensory	O
modalities	O
.	O

Evidence	O
from	O
lesion	O
patients	O
suggests	O
that	O
parietal	O
regions	O
house	O
supramodal	O
representations	O
of	O
space	O
.	O

The	O
parietal	O
lobes	O
are	O
prominent	O
generators	O
of	O
alpha	O
oscillations	O
,	O
raising	O
the	O
possibility	O
that	O
alpha	O
is	O
a	O
neural	O
signature	O
of	O
supramodal	O
spatial	O
attention	O
.	O

Furthermore	O
,	O
when	O
spatial	O
attention	O
is	O
deployed	O
within	O
vision	O
,	O
processing	O
of	O
task	O
-	O
irrelevant	O
auditory	O
inputs	O
at	O
attended	O
locations	O
is	O
also	O
enhanced	O
,	O
pointing	O
to	O
automatic	O
links	O
between	O
spatial	O
deployments	O
across	O
senses	O
.	O

Here	O
,	O
we	O
asked	O
whether	O
lateralized	O
alpha	O
-	O
band	O
activity	O
is	O
also	O
evident	O
in	O
a	O
purely	O
auditory	O
spatial	O
-	O
cueing	O
task	O
and	O
whether	O
it	O
had	O
the	O
same	O
underlying	O
generator	O
configuration	O
as	O
in	O
a	O
purely	O
visuospatial	O
task	O
.	O

If	O
common	O
to	O
both	O
sensory	O
systems	O
,	O
this	O
would	O
provide	O
strong	O
support	O
for	O
""""	O
supramodal	O
""""	O
attention	O
theory	O
.	O

Alternately	O
,	O
alpha	O
-	O
band	O
differences	O
between	O
auditory	O
and	O
visual	O
tasks	O
would	O
support	O
a	O
sensory	O
-	O
specific	O
account	O
.	O

Lateralized	O
shifts	O
in	O
alpha	O
-	O
band	O
activity	O
were	O
indeed	O
observed	O
during	O
a	O
purely	O
auditory	O
spatial	O
task	O
.	O

Crucially	O
,	O
there	O
were	O
clear	O
differences	O
in	O
scalp	O
topographies	O
of	O
this	O
alpha	O
activity	O
depending	O
on	O
the	O
sensory	O
system	O
within	O
which	O
spatial	O
attention	O
was	O
deployed	O
.	O

Findings	O
suggest	O
that	O
parietally	O
generated	O
alpha	O
-	O
band	O
mechanisms	O
are	O
central	O
to	O
attentional	O
deployments	O
across	O
modalities	O
but	O
that	O
they	O
are	O
invoked	O
in	O
a	O
sensory	O
-	O
specific	O
manner	O
.	O

The	O
data	O
support	O
an	O
""""	O
interactivity	O
account	O
,	O
""""	O
whereby	O
a	O
supramodal	O
system	O
interacts	O
with	O
sensory	O
-	O
specific	O
control	O
systems	O
during	O
deployment	O
of	O
spatial	O
attention	O
.	O

[	O
Expression	O
of	O
Merlin	O
protein	O
in	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
and	O
the	O
clinical	O
significance	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
Merlin	O
protein	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
Merlin	O
protein	O
in	O
45	O
cases	O
of	O
NSCLC	O
and	O
adjacent	O
tissue	O
of	O
NSCLC	O
and	O
normal	O
lung	O
tissue	O
was	O
checked	O
by	O
immunohistochemistry	O
.	O

The	O
relation	O
between	O
the	O
expression	O
of	O
Merlin	O
protein	O
and	O
the	O
multiple	O
factors	O
of	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
expression	O
rates	O
of	O
Merlin	O
protein	O
in	O
NSCLC	O
and	O
normal	O
lung	O
tissue	O
sections	O
were	O
73	O
.	O
33	O
%	O
and	O
15	O
.	O
56	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
expression	O
of	O
Merlin	O
protein	O
was	O
not	O
associated	O
with	O
the	O
pathological	O
type	O
,	O
gender	O
,	O
P	O
-	O
TNM	O
stage	O
,	O
differentiation	O
and	O
lymph	O
node	O
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Merlin	O
protein	O
might	O
contribute	O
to	O
the	O
initiation	O
of	O
metastasis	O
of	O
NSCLC	O
.	O

The	O
members	O
of	O
an	O
Epstein	O
-	O
Barr	O
virus	O
microRNA	O
cluster	O
cooperate	O
to	O
transform	O
B	O
lymphocytes	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforms	O
B	O
lymphocytes	O
through	O
the	O
expression	O
of	O
the	O
latent	O
viral	O
proteins	O
EBNA	O
and	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
.	O

Recently	O
,	O
it	O
has	O
become	O
apparent	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
also	O
contribute	O
to	O
EBV	O
'	O
s	O
oncogenic	O
properties	O
;	O
recombinant	O
EBVs	O
that	O
lack	O
the	O
BHRF1	O
miRNA	O
cluster	O
display	O
a	O
reduced	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
in	O
vitro	O
.	O

Furthermore	O
,	O
infected	O
cells	O
evince	O
a	O
marked	O
upregulation	O
of	O
the	O
EBNA	O
genes	O
.	O

Using	O
recombinant	O
viruses	O
that	O
lack	O
only	O
one	O
member	O
of	O
the	O
cluster	O
,	O
we	O
now	O
show	O
that	O
all	O
three	O
BHRF1	O
miRNAs	O
contribute	O
to	O
B	O
-	O
cell	O
transformation	O
.	O

Recombinants	O
that	O
lacked	O
miR	O
-	O
BHRF1	O
-	O
2	O
or	O
miR	O
-	O
BHRF1	O
-	O
3	O
displayed	O
enhanced	O
EBNA	O
expression	O
initiated	O
at	O
the	O
Cp	O
and	O
Wp	O
promoters	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
the	O
deletion	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
reduced	O
the	O
expression	O
level	O
of	O
miR	O
-	O
BHRF1	O
-	O
3	O
and	O
possibly	O
that	O
of	O
miR	O
-	O
BHRF1	O
-	O
1	O
,	O
demonstrating	O
that	O
the	O
expression	O
of	O
one	O
miRNA	O
can	O
potentiate	O
the	O
expression	O
of	O
other	O
miRNAs	O
located	O
in	O
the	O
same	O
cluster	O
.	O

Therefore	O
,	O
the	O
phenotypic	O
traits	O
of	O
the	O
miR	O
-	O
BHRF1	O
-	O
2	O
null	O
mutant	O
could	O
result	O
partly	O
from	O
reduced	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
expression	O
levels	O
.	O

Nevertheless	O
,	O
using	O
an	O
miR	O
-	O
BHRF1	O
-	O
1	O
and	O
miR	O
-	O
BHRF1	O
-	O
3	O
double	O
mutant	O
,	O
we	O
could	O
directly	O
assess	O
and	O
confirm	O
the	O
contribution	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
to	O
B	O
-	O
cell	O
transformation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
potentiating	O
effect	O
of	O
miR	O
-	O
BHRF1	O
-	O
2	O
on	O
miR	O
-	O
BHRF1	O
-	O
3	O
synthesis	O
can	O
be	O
reproduced	O
with	O
simple	O
expression	O
plasmids	O
,	O
provided	O
that	O
both	O
miRNAs	O
are	O
processed	O
from	O
the	O
same	O
transcript	O
.	O

Therefore	O
,	O
this	O
enhancing	O
effect	O
does	O
not	O
result	O
from	O
an	O
idiosyncrasy	O
of	O
the	O
EBV	O
genome	O
but	O
rather	O
reflects	O
a	O
general	O
property	O
of	O
these	O
miRNAs	O
.	O

This	O
study	O
highlights	O
the	O
advantages	O
of	O
arranging	O
the	O
BHRF1	O
miRNAs	O
in	O
clusters	O
:	O
it	O
allows	O
the	O
synchronous	O
and	O
synergistic	O
expression	O
of	O
genetic	O
elements	O
that	O
cooperate	O
to	O
transform	O
their	O
target	O
cells	O
.	O

Hedgehog	O
signaling	O
:	O
networking	O
to	O
nurture	O
a	O
promalignant	O
tumor	O
microenvironment	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
embryonic	O
development	O
,	O
the	O
Hedgehog	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
participant	O
in	O
cancer	O
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

Although	O
this	O
pathway	O
is	O
activated	O
by	O
autocrine	O
signaling	O
by	O
Hedgehog	O
ligands	O
,	O
it	O
can	O
also	O
initiate	O
paracrine	O
signaling	O
with	O
cells	O
in	O
the	O
microenvironment	O
.	O

This	O
creates	O
a	O
network	O
of	O
Hedgehog	O
signaling	O
that	O
determines	O
the	O
malignant	O
behavior	O
of	O
the	O
tumor	O
cells	O
.	O

As	O
a	O
result	O
of	O
paracrine	O
signal	O
transmission	O
,	O
the	O
effects	O
of	O
Hedgehog	O
signaling	O
most	O
profoundly	O
influence	O
the	O
stromal	O
cells	O
that	O
constitute	O
the	O
tumor	O
microenvironment	O
.	O

The	O
stromal	O
cells	O
in	O
turn	O
produce	O
factors	O
that	O
nurture	O
the	O
tumor	O
.	O

Thus	O
,	O
such	O
a	O
resonating	O
cross	O
-	O
talk	O
can	O
amplify	O
Hedgehog	O
signaling	O
,	O
resulting	O
in	O
molecular	O
chatter	O
that	O
overall	O
promotes	O
tumor	O
progression	O
.	O

Inhibitors	O
of	O
Hedgehog	O
signaling	O
have	O
been	O
the	O
subject	O
of	O
intense	O
research	O
.	O

Several	O
of	O
these	O
inhibitors	O
are	O
currently	O
being	O
evaluated	O
in	O
clinical	O
trials	O
.	O

Here	O
,	O
we	O
review	O
the	O
role	O
of	O
the	O
Hedgehog	O
pathway	O
in	O
the	O
signature	O
characteristics	O
of	O
cancer	O
cells	O
that	O
determine	O
tumor	O
development	O
,	O
progression	O
,	O
and	O
metastasis	O
.	O

This	O
review	O
condenses	O
the	O
latest	O
findings	O
on	O
the	O
signaling	O
pathways	O
that	O
are	O
activated	O
and	O
/	O
or	O
regulated	O
by	O
molecules	O
generated	O
from	O
Hedgehog	O
signaling	O
in	O
cancer	O
and	O
cites	O
promising	O
clinical	O
interventions	O
.	O

Finally	O
,	O
we	O
discuss	O
future	O
directions	O
for	O
identifying	O
the	O
appropriate	O
patients	O
for	O
therapy	O
,	O
developing	O
reliable	O
markers	O
of	O
efficacy	O
of	O
treatment	O
,	O
and	O
combating	O
resistance	O
to	O
Hedgehog	O
pathway	O
inhibitors	O
.	O

Analysis	O
of	O
molecular	O
aberrations	O
of	O
Wnt	O
pathway	O
gladiators	O
in	O
colorectal	O
cancer	O
in	O
the	O
Kashmiri	O
population	O
.	O

The	O
development	O
and	O
progression	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
a	O
multi	O
-	O
step	O
process	O
,	O
and	O
the	O
Wnt	O
pathways	O
with	O
its	O
two	O
molecular	O
gladiators	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
beta	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
transforming	O
a	O
normal	O
tissue	O
into	O
a	O
malignant	O
one	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
aberrations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
the	O
pathogenesis	O
of	O
CRC	O
in	O
the	O
Kashmir	O
valley	O
,	O
and	O
to	O
correlate	O
it	O
with	O
various	O
clinicopathological	O
variables	O
.	O

We	O
examined	O
the	O
paired	O
tumour	O
and	O
normal	O
-	O
tissue	O
specimens	O
of	O
86	O
CRC	O
patients	O
for	O
the	O
occurrence	O
of	O
aberrations	O
in	O
the	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
of	O
the	O
APC	O
gene	O
and	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
and	O
/	O
or	O
PCR	O
-	O
direct	O
sequencing	O
.	O

Analysis	O
of	O
promoter	O
hypermethylation	O
of	O
the	O
APC	O
gene	O
was	O
also	O
carried	O
out	O
using	O
methylation	O
-	O
specific	O
PCR	O
(	O
MS	O
-	O
PCR	O
)	O
.	O

The	O
overall	O
mutation	O
rate	O
of	O
the	O
MCR	O
of	O
the	O
APC	O
gene	O
among	O
86	O
CRC	O
cases	O
was	O
12	O
.	O
8	O
per	O
cent	O
(	O
11	O
of	O
86	O
)	O
.	O

Promoter	O
hypermethylation	O
of	O
APC	O
was	O
observed	O
in	O
54	O
.	O
65	O
per	O
cent	O
(	O
47	O
of	O
86	O
)	O
of	O
cases	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
significant	O
association	O
between	O
tumour	O
location	O
,	O
tumour	O
grade	O
and	O
node	O
status	O
and	O
the	O
methylation	O
status	O
of	O
the	O
APC	O
gene	O
(	O
p	O
<	O
=	O
0	O
.	O
05	O
)	O
.	O

Although	O
the	O
number	O
of	O
mutations	O
in	O
the	O
APC	O
and	O
beta	O
-	O
catenin	O
genes	O
in	O
our	O
CRC	O
cases	O
was	O
very	O
low	O
,	O
the	O
study	O
confirms	O
the	O
role	O
of	O
epigenetic	O
gene	O
silencing	O
of	O
the	O
pivotal	O
molecular	O
gladiator	O
,	O
APC	O
,	O
of	O
the	O
Wnt	O
pathway	O
in	O
the	O
development	O
of	O
CRC	O
in	O
the	O
Kashmiri	O
population	O
.	O

Massive	O
osteolysis	O
in	O
a	O
dog	O
resembling	O
Gorham	O
'	O
s	O
disease	O
in	O
humans	O
.	O

An	O
eight	O
-	O
month	O
-	O
old	O
mixed	O
-	O
breed	O
dog	O
was	O
presented	O
with	O
a	O
history	O
of	O
sudden	O
onset	O
pelvic	O
limb	O
lameness	O
.	O

Radiographic	O
and	O
computed	O
tomographic	O
examinations	O
demonstrated	O
an	O
osteolytic	O
process	O
involving	O
the	O
lumbar	O
spine	O
and	O
pelvis	O
.	O

A	O
comprehensive	O
work	O
-	O
up	O
including	O
serial	O
radiographic	O
skeletal	O
survey	O
,	O
biopsy	O
,	O
routine	O
laboratory	O
investigation	O
and	O
evaluation	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
and	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
levels	O
failed	O
to	O
reveal	O
any	O
underlying	O
cause	O
for	O
the	O
osteolysis	O
.	O

Conservative	O
treatment	O
using	O
the	O
bisphosphonate	O
drug	O
alendronate	O
and	O
oral	O
analgesic	O
medications	O
resulted	O
in	O
a	O
return	O
to	O
nearly	O
normal	O
long	O
-	O
term	O
function	O
,	O
despite	O
massive	O
lumbar	O
and	O
pelvic	O
osteolysis	O
.	O

The	O
clinical	O
,	O
radiological	O
and	O
histopathological	O
features	O
in	O
this	O
dog	O
are	O
reported	O
,	O
and	O
similarities	O
with	O
the	O
human	O
condition	O
known	O
as	O
Gorham	O
'	O
s	O
disease	O
are	O
discussed	O
.	O

Correlation	O
of	O
lymphatic	O
vessel	O
density	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
with	O
nodal	O
metastasis	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
not	O
only	O
the	O
intratumoral	O
and	O
peritumoral	O
lymphatic	O
vessel	O
density	O
(	O
ILD	O
and	O
PLD	O
)	O
but	O
also	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factors	O
(	O
VEGFs	O
)	O
and	O
to	O
test	O
their	O
correlation	O
with	O
regional	O
lymph	O
nodal	O
metastases	O
in	O
papillary	O
thyroid	O
microcarcinoma	O
(	O
PTMC	O
)	O
.	O

METHODS	O
:	O
A	O
clinicopathologic	O
data	O
review	O
was	O
performed	O
in	O
60	O
patients	O
with	O
PTMC	O
treated	O
with	O
total	O
thyroidectomies	O
involving	O
neck	O
dissections	O
.	O

The	O
patterns	O
of	O
lymphatic	O
vessels	O
,	O
the	O
expression	O
of	O
VEGFs	O
,	O
and	O
their	O
correlation	O
with	O
neck	O
metastases	O
were	O
assessed	O
.	O

RESULTS	O
:	O
PLD	O
was	O
significantly	O
higher	O
than	O
ILD	O
(	O
p	O
<	O
.	O
001	O
)	O
.	O

Patients	O
with	O
high	O
PLD	O
(	O
>	O
8	O
.	O
0	O
)	O
showed	O
higher	O
rates	O
of	O
neck	O
metastases	O
than	O
low	O
PLD	O
(	O
<	O
=	O
8	O
.	O
0	O
)	O
(	O
74	O
.	O
0	O
%	O
vs	O
46	O
.	O
8	O
%	O
,	O
p	O
=	O
.	O
03	O
)	O
.	O

Univariate	O
and	O
multivariate	O
analyses	O
revealed	O
high	O
PLD	O
as	O
the	O
only	O
independent	O
variable	O
predictive	O
of	O
neck	O
metastasis	O
.	O

The	O
expression	O
of	O
VEGFs	O
did	O
not	O
correlate	O
with	O
either	O
lymphatic	O
density	O
or	O
neck	O
metastasis	O
.	O

CONCLUSIONS	O
:	O
PLD	O
may	O
be	O
of	O
potential	O
benefit	O
in	O
the	O
prediction	O
of	O
neck	O
metastasis	O
in	O
PTMC	O
.	O

Inhibition	O
of	O
autophagy	O
potentiates	O
the	O
antitumor	O
effect	O
of	O
the	O
multikinase	O
inhibitor	O
sorafenib	O
in	O
hepatocellular	O
carcinoma	O
.	O

Multikinase	O
inhibitor	O
sorafenib	O
inhibits	O
proliferation	O
and	O
angiogenesis	O
of	O
tumors	O
by	O
suppressing	O
the	O
Raf	O
/	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
and	O
VEGF	O
receptor	O
tyrosine	O
kinase	O
.	O

It	O
significantly	O
prolongs	O
median	O
survival	O
of	O
patients	O
with	O
advanced	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
but	O
the	O
response	O
is	O
disease	O
-	O
stabilizing	O
and	O
cytostatic	O
rather	O
than	O
one	O
of	O
tumor	O
regression	O
.	O

To	O
examine	O
the	O
mechanisms	O
underlying	O
the	O
relative	O
resistance	O
in	O
HCC	O
,	O
we	O
investigated	O
the	O
role	O
of	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
self	O
-	O
digestion	O
pathway	O
,	O
in	O
hepatoma	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Sorafenib	O
treatment	O
led	O
to	O
accumulation	O
of	O
autophagosomes	O
as	O
evidenced	O
by	O
conversion	O
from	O
LC3	O
-	O
I	O
to	O
LC3	O
-	O
II	O
observed	O
by	O
immunoblot	O
in	O
Huh7	B
,	O
HLF	B
and	O
PLC	B
/	I
PRF	I
/	I
5	I
cells	O
.	O

This	O
induction	O
was	O
due	O
to	O
activation	O
of	O
autophagic	O
flux	O
,	O
as	O
there	O
was	O
further	O
increase	O
in	O
LC3	O
-	O
II	O
expression	O
upon	O
treatment	O
with	O
lysosomal	O
inhibitors	O
,	O
clear	O
decline	O
of	O
the	O
autophagy	O
substrate	O
p62	O
,	O
and	O
an	O
mRFP	O
-	O
GFP	O
-	O
LC3	O
fluorescence	O
change	O
in	O
sorafenib	O
-	O
treated	O
hepatoma	O
cells	O
.	O

Sorafenib	O
inhibited	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
and	O
its	O
inhibition	O
led	O
to	O
accumulation	O
of	O
LC3	O
-	O
II	O
.	O

Pharmacological	O
inhibition	O
of	O
autophagic	O
flux	O
by	O
chloroquine	O
increased	O
apoptosis	O
and	O
decreased	O
cell	O
viability	O
in	O
hepatoma	O
cells	O
.	O

siRNA	O
-	O
mediated	O
knockdown	O
of	O
the	O
ATG7	O
gene	O
also	O
sensitized	O
hepatoma	O
cells	O
to	O
sorafenib	O
.	O

Finally	O
,	O
sorafenib	O
induced	O
autophagy	O
in	O
Huh7	B
xenograft	O
tumors	O
in	O
nude	O
mice	O
and	O
coadministration	O
with	O
chloroquine	O
significantly	O
suppressed	O
tumor	O
growth	O
compared	O
with	O
sorafenib	O
alone	O
.	O

In	O
conclusion	O
,	O
sorafenib	O
administration	O
induced	O
autophagosome	O
formation	O
and	O
enhanced	O
autophagic	O
activity	O
,	O
which	O
conferred	O
a	O
survival	O
advantage	O
to	O
hepatoma	O
cells	O
.	O

Concomitant	O
inhibition	O
of	O
autophagy	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
unlocking	O
the	O
antitumor	O
potential	O
of	O
sorafenib	O
in	O
HCC	O
.	O

Desensitization	O
of	O
prostaglandin	O
F2	O
alpha	O
-	O
stimulated	O
inositol	O
phosphate	O
generation	O
in	O
NIH	B
-	I
3T3	I
fibroblasts	O
transformed	O
by	O
overexpression	O
of	O
normal	O
c	O
-	O
Ha	O
-	O
ras	O
-	O
1	O
,	O
c	O
-	O
Ki	O
-	O
ras	O
-	O
2	O
and	O
c	O
-	O
N	O
-	O
ras	O
genes	O
.	O

The	O
stimulation	O
of	O
inositol	O
phosphate	O
generation	O
in	O
control	O
and	O
ras	O
-	O
gene	O
-	O
transformed	O
NIH	B
-	I
3T3	I
cells	O
by	O
prostaglandin	O
F2	O
alpha	O
(	O
PGF2	O
alpha	O
)	O
was	O
investigated	O
.	O

Compared	O
with	O
the	O
control	O
cells	O
,	O
a	O
desensitization	O
of	O
the	O
response	O
was	O
observed	O
in	O
cells	O
transformed	O
by	O
the	O
overexpression	O
of	O
N	O
-	O
,	O
Ha	O
-	O
,	O
or	O
Ki	O
-	O
ras	O
genes	O
.	O

This	O
desensitization	O
was	O
without	O
effect	O
upon	O
the	O
concentration	O
causing	O
half	O
-	O
maximal	O
effect	O
(	O
EC50	O
)	O
,	O
dissociation	O
constant	O
(	O
Kd	O
)	O
or	O
number	O
of	O
PGF2	O
alpha	O
receptors	O
.	O

Inhibition	O
of	O
PG	O
synthesis	O
was	O
without	O
effect	O
upon	O
desensitization	O
,	O
demonstrating	O
that	O
the	O
effect	O
was	O
not	O
agonist	O
-	O
induced	O
.	O

Desensitization	O
could	O
be	O
induced	O
in	O
NIH	B
-	I
3T3	I
cells	O
by	O
culturing	O
under	O
conditions	O
where	O
the	O
cells	O
were	O
all	O
in	O
the	O
exponential	O
growth	O
phase	O
,	O
or	O
by	O
a	O
12	O
h	O
exposure	O
to	O
a	O
C	O
-	O
kinase	O
-	O
activating	O
phorbol	O
ester	O
.	O

These	O
results	O
suggest	O
that	O
desensitization	O
of	O
certain	O
agonist	O
-	O
induced	O
inositol	O
phospholipid	O
responses	O
in	O
ras	O
-	O
transformed	O
cells	O
is	O
a	O
consequence	O
of	O
increased	O
cell	O
proliferation	O
and	O
associated	O
amplification	O
in	O
C	O
-	O
kinase	O
activity	O
and	O
is	O
an	O
indirect	O
consequence	O
of	O
transformation	O
by	O
ras	O
.	O

Sunitinib	O
induces	O
apoptosis	O
in	O
pheochromocytoma	O
tumor	O
cells	O
by	O
inhibiting	O
VEGFR2	O
/	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
pathways	O
through	O
modulation	O
of	O
Bcl	O
-	O
2	O
and	O
BAD	O
.	O

Sunitinib	O
is	O
an	O
oral	O
multitargeted	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	O
activity	O
that	O
mainly	O
targets	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
(	O
VEGFRs	O
)	O
.	O

Very	O
recently	O
,	O
sunitinib	O
has	O
been	O
shown	O
to	O
be	O
an	O
active	O
agent	O
for	O
the	O
treatment	O
of	O
malignant	O
pheochromocytomas	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
sunitinib	O
acts	O
only	O
through	O
an	O
antiangiogenic	O
mechanism	O
or	O
whether	O
it	O
may	O
also	O
directly	O
target	O
tumor	O
cells	O
.	O

Sunitinib	O
markedly	O
induced	O
apoptosis	O
of	O
PC12	B
cells	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Furthermore	O
,	O
in	O
support	O
of	O
these	O
findings	O
,	O
we	O
found	O
that	O
sunitinib	O
induced	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
as	O
well	O
as	O
dephosphorylation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
,	O
which	O
results	O
in	O
the	O
activation	O
of	O
BAD	O
in	O
these	O
cells	O
.	O

Consistent	O
with	O
these	O
apoptotic	O
effects	O
,	O
our	O
results	O
showed	O
that	O
sunitinib	O
inhibited	O
phosphorylation	O
of	O
Akt	O
and	O
mTOR	O
and	O
was	O
followed	O
by	O
a	O
reduction	O
of	O
S6K1	O
,	O
which	O
is	O
a	O
well	O
-	O
known	O
target	O
of	O
mTOR	O
.	O

Knockdown	O
of	O
VEGFR	O
-	O
2	O
attenuated	O
the	O
sunitinib	O
-	O
induced	O
effects	O
,	O
including	O
apoptosis	O
and	O
inhibition	O
of	O
signaling	O
pathways	O
such	O
as	O
the	O
phosphorylation	O
of	O
Akt	O
as	O
well	O
as	O
mTOR	O
,	O
and	O
Bcl	O
-	O
2	O
,	O
which	O
confirmed	O
that	O
these	O
effects	O
could	O
be	O
mediated	O
by	O
VEGFR	O
-	O
2	O
.	O

In	O
addition	O
,	O
silencing	O
of	O
S6K1	O
induced	O
apoptosis	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
BAD	O
and	O
Bcl	O
-	O
2	O
,	O
similar	O
to	O
that	O
observed	O
with	O
sunitinib	O
treatment	O
.	O

Thus	O
,	O
these	O
results	O
together	O
suggest	O
that	O
sunitinib	O
initially	O
exerts	O
its	O
apoptotic	O
effect	O
through	O
the	O
inhibition	O
of	O
VEGFR	O
-	O
2	O
,	O
which	O
,	O
when	O
followed	O
by	O
reduction	O
of	O
its	O
downstream	O
effectors	O
,	O
including	O
Akt	O
/	O
mTOR	O
/	O
S6K1	O
,	O
may	O
lead	O
to	O
inhibition	O
of	O
the	O
antiapoptotic	O
molecule	O
Bcl	O
-	O
2	O
and	O
activation	O
of	O
the	O
proapoptotic	O
molecule	O
BAD	O
in	O
PC12	B
cells	O
.	O

However	O
,	O
PC12	B
cells	O
do	O
not	O
precisely	O
reflect	O
the	O
pathogenesis	O
of	O
malignant	O
cells	O
.	O

Therefore	O
,	O
we	O
confirmed	O
the	O
key	O
findings	O
by	O
replicating	O
these	O
experiments	O
in	O
human	O
neuroblastoma	O
SK	B
-	I
N	I
-	I
SH	I
cells	O
.	O

Development	O
of	O
a	O
mouse	O
model	O
for	O
lymph	O
node	O
metastasis	O
with	O
endometrial	O
cancer	O
.	O

Controlling	O
lymph	O
node	O
metastasis	O
is	O
currently	O
a	O
key	O
issue	O
in	O
cancer	O
therapy	O
.	O

Lymph	O
node	O
metastasis	O
is	O
one	O
of	O
the	O
most	O
important	O
prognostic	O
factors	O
in	O
various	O
types	O
of	O
cancers	O
,	O
including	O
endometrial	O
cancer	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
lymphangiogenesis	O
,	O
and	O
is	O
implicated	O
to	O
play	O
an	O
important	O
role	O
in	O
lymph	O
node	O
metastasis	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
VEGF	O
-	O
C	O
in	O
lymph	O
node	O
metastasis	O
,	O
we	O
developed	O
an	O
animal	O
model	O
by	O
using	O
an	O
endometrial	O
cancer	O
cell	O
line	O
,	O
HEC1A	B
.	O

This	O
cell	O
line	O
is	O
not	O
invasive	O
by	O
nature	O
and	O
secretes	O
moderate	O
amounts	O
of	O
VEGF	O
-	O
C	O
;	O
intrauterine	O
injection	O
of	O
HEC1A	B
cells	O
into	O
Balb	O
/	O
c	O
nude	O
mice	O
resulted	O
in	O
uterine	O
cancer	O
with	O
lymph	O
node	O
metastasis	O
after	O
8	O
weeks	O
.	O

To	O
analyze	O
the	O
contribution	O
of	O
VEGF	O
-	O
C	O
to	O
lymph	O
node	O
metastasis	O
,	O
its	O
corresponding	O
gene	O
was	O
stably	O
introduced	O
into	O
HEC1A	B
cells	O
(	O
HEC1A	B
/	O
VEGF	O
-	O
C	O
)	O
,	O
which	O
then	O
produced	O
more	O
than	O
10	O
times	O
the	O
amount	O
of	O
VEGF	O
-	O
C	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
was	O
significantly	O
higher	O
in	O
HEC1A	B
/	I
VEGF	I
-	I
C	I
cells	O
than	O
in	O
HEC1A	B
cells	O
(	O
3	O
.	O
2	O
vs	O
1	O
.	O
1	O
nodes	O
/	O
animal	O
,	O
respectively	O
)	O
.	O

Augmented	O
lymphangiogenesis	O
was	O
observed	O
within	O
tumors	O
when	O
HEC1A	B
/	I
VEGF	I
-	I
C	I
cells	O
were	O
inoculated	O
.	O

These	O
results	O
indicate	O
that	O
VEGF	O
-	O
C	O
plays	O
a	O
critical	O
role	O
in	O
lymph	O
node	O
metastasis	O
,	O
in	O
addition	O
to	O
serving	O
as	O
a	O
platform	O
to	O
test	O
the	O
efficacy	O
of	O
various	O
therapeutic	O
modalities	O
against	O
lymph	O
node	O
metastasis	O
.	O

[	O
Rubella	O
in	O
Poland	O
in	O
2009	O
]	O
.	O

In	O
Poland	O
,	O
7	O
,	O
587	O
cases	O
of	O
rubella	O
were	O
registered	O
in	O
2009	O
(	O
incidence	O
19	O
.	O
9	O
per	O
100	O
,	O
000	O
population	O
)	O
.	O

According	O
to	O
a	O
new	O
rubella	O
case	O
definition	O
,	O
introduced	O
in	O
2009	O
,	O
7	O
(	O
0	O
.	O
1	O
%	O
)	O
cases	O
were	O
classified	O
as	O
confirmed	O
cases	O
,	O
30	O
(	O
0	O
.	O
4	O
%	O
)	O
as	O
probable	O
.	O

One	O
case	O
of	O
congenital	O
rubella	O
syndrome	O
was	O
reported	O
.	O

The	O
incidence	O
in	O
men	O
(	O
26	O
.	O
6	O
)	O
was	O
1	O
.	O
9	O
-	O
times	O
higher	O
than	O
in	O
women	O
(	O
13	O
.	O
6	O
)	O
.	O

The	O
highest	O
incidence	O
was	O
observed	O
in	O
children	O
aged	O
7	O
and	O
8	O
years	O
(	O
180	O
.	O
3	O
and	O
175	O
.	O
6	O
,	O
respectively	O
)	O
.	O

No	O
rubella	O
deaths	O
were	O
registered	O
.	O

An	O
improvement	O
of	O
laboratory	O
diagnosis	O
of	O
reported	O
cases	O
is	O
necessary	O
to	O
assess	O
the	O
impact	O
of	O
2	O
-	O
dose	O
immunization	O
implemented	O
in	O
2003	O
on	O
rubella	O
epidemiology	O
in	O
Poland	O
.	O

Burns	O
from	O
hot	O
wheat	O
bags	O
:	O
a	O
public	O
safety	O
issue	O
.	O

Introduction	O
:	O
Wheat	O
bags	O
are	O
therapeutic	O
devices	O
that	O
are	O
heated	O
in	O
microwaves	O
and	O
commonly	O
used	O
to	O
provide	O
relief	O
from	O
muscle	O
and	O
joint	O
pain	O
.	O

The	O
Royal	O
Adelaide	O
Hospital	O
Burns	O
Unit	O
has	O
observed	O
a	O
number	O
of	O
patients	O
with	O
significant	O
burn	O
injuries	O
resulting	O
from	O
their	O
use	O
.	O

Despite	O
their	O
dangers	O
,	O
the	O
products	O
come	O
with	O
limited	O
safety	O
information	O
.	O

Methods	O
:	O
Data	O
were	O
collected	O
from	O
the	O
Burns	O
Unit	O
database	O
for	O
all	O
patients	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
from	O
2004	O
to	O
2009	O
.	O

This	O
was	O
analyzed	O
to	O
determine	O
the	O
severity	O
of	O
the	O
burn	O
injury	O
and	O
identify	O
any	O
predisposing	O
factors	O
.	O

An	O
experimental	O
study	O
was	O
performed	O
to	O
measure	O
the	O
temperature	O
of	O
wheat	O
bags	O
when	O
heated	O
to	O
determine	O
their	O
potential	O
for	O
causing	O
thermal	O
injury	O
.	O

Results	O
:	O
11	O
patients	O
were	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
.	O

The	O
median	O
age	O
was	O
52	O
years	O
and	O
the	O
mean	O
total	O
body	O
surface	O
area	O
was	O
1	O
.	O
1	O
%	O
.	O

All	O
burns	O
were	O
either	O
deep	O
dermal	O
(	O
45	O
.	O
5	O
%	O
)	O
or	O
full	O
thickness	O
(	O
54	O
.	O
5	O
%	O
)	O
.	O

Ten	O
patients	O
required	O
operative	O
management	O
.	O

Predisposing	O
factors	O
(	O
eg	O
,	O
neuropathy	O
)	O
to	O
thermal	O
injury	O
were	O
identified	O
in	O
7	O
patients	O
.	O

The	O
experimental	O
study	O
showed	O
that	O
hot	O
wheat	O
bags	O
reached	O
temperatures	O
of	O
57	O
.	O
3degreesC	O
(	O
135	O
.	O
1degreesF	O
)	O
when	O
heated	O
according	O
to	O
instructions	O
,	O
63	O
.	O
3degreesC	O
(	O
145	O
.	O
9degreesF	O
)	O
in	O
a	O
1000	O
W	O
microwave	O
and	O
69	O
.	O
6degreesC	O
(	O
157	O
.	O
3degreesF	O
)	O
on	O
reheating	O
.	O

Conclusions	O
:	O
Hot	O
wheat	O
bags	O
cause	O
serious	O
burn	O
injury	O
.	O

When	O
heated	O
improperly	O
,	O
they	O
can	O
reach	O
temperatures	O
high	O
enough	O
to	O
cause	O
epidermal	O
necrosis	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O

Patients	O
with	O
impaired	O
temperature	O
sensation	O
are	O
particularly	O
at	O
risk	O
.	O

There	O
should	O
be	O
greater	O
public	O
awareness	O
of	O
the	O
dangers	O
of	O
wheat	O
bag	O
use	O
and	O
more	O
specific	O
safety	O
warnings	O
on	O
the	O
products	O
.	O

IL	O
-	O
17F	O
deficiency	O
inhibits	O
small	O
intestinal	O
tumorigenesis	O
in	O
ApcMin	O
/	O
+	O
mice	O
.	O

IL	O
-	O
17	O
plays	O
an	O
important	O
role	O
in	O
gut	O
homeostasis	O
.	O

However	O
,	O
the	O
role	O
of	O
IL	O
-	O
17F	O
in	O
intestinal	O
tumorigenesis	O
has	O
not	O
been	O
addressed	O
.	O

Here	O
we	O
demonstrate	O
that	O
ablation	O
of	O
IL	O
-	O
17F	O
significantly	O
inhibits	O
spontaneous	O
intestinal	O
tumorigenesis	O
in	O
the	O
small	O
intestine	O
of	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O

IL	O
-	O
17F	O
ablation	O
decreased	O
IL	O
-	O
1beta	O
and	O
Cox	O
-	O
2	O
expression	O
as	O
well	O
as	O
IL	O
-	O
17	O
receptor	O
C	O
(	O
IL	O
-	O
17RC	O
)	O
expression	O
,	O
which	O
were	O
increased	O
in	O
tumors	O
from	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
.	O

Lack	O
of	O
IL	O
-	O
17F	O
did	O
not	O
reverse	O
the	O
splenomegaly	O
but	O
partially	O
restored	O
thymic	O
atrophy	O
,	O
suggesting	O
a	O
local	O
effect	O
of	O
IL	O
-	O
17F	O
in	O
the	O
intestine	O
.	O

IL	O
-	O
17F	O
deficient	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
showed	O
a	O
significant	O
decrease	O
in	O
immune	O
cell	O
infiltration	O
in	O
the	O
lamina	O
propria	O
.	O

Interestingly	O
,	O
the	O
expression	O
of	O
IL	O
-	O
17A	O
from	O
CD4	O
T	O
cells	O
in	O
the	O
lamina	O
propria	O
remains	O
unchanged	O
in	O
the	O
absence	O
of	O
IL	O
-	O
17F	O
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
the	O
proinflammatory	O
and	O
essential	O
role	O
of	O
IL	O
-	O
17F	O
to	O
develop	O
spontaneous	O
intestinal	O
tumorigenesis	O
in	O
Apc	O
(	O
Min	O
/	O
+	O
)	O
mice	O
in	O
the	O
presence	O
of	O
IL	O
-	O
17A	O
.	O

Curcumin	O
inhibits	O
metastatic	O
progression	O
of	O
breast	O
cancer	O
cell	O
through	O
suppression	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
by	O
NF	O
-	O
kappa	O
B	O
signaling	O
pathways	O
.	O

Curcumin	O
(	O
1	O
,	O
7	O
-	O
bis	O
(	O
4	O
-	O
hydroxy	O
-	O
3	O
-	O
methoxyphenyl	O
)	O
-	O
1	O
,	O
6	O
-	O
heptadiene	O
-	O
3	O
,	O
5	O
-	O
dione	O
)	O
,	O
is	O
extracted	O
from	O
the	O
plant	O
Curcuma	O
longa	O
.	O

It	O
was	O
recently	O
reported	O
for	O
its	O
anticancer	O
effect	O
on	O
several	O
types	O
of	O
cancer	O
cells	O
in	O
vitro	O
however	O
,	O
the	O
molecular	O
mechanisms	O
of	O
this	O
anticancer	O
effect	O
are	O
not	O
fully	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
curcumin	O
on	O
human	O
mammary	O
epithelial	O
carcinoma	O
MCF	B
-	I
7	I
cells	O
.	O

Cells	O
were	O
treated	O
with	O
curcumin	O
and	O
examined	O
for	O
cell	O
viability	O
by	O
MTT	O
assay	O
.	O

The	O
cells	O
invasion	O
was	O
demonstrated	O
by	O
transwell	O
assay	O
.	O

The	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
to	O
DNA	O
was	O
examined	O
in	O
nuclear	O
extracts	O
using	O
Trans	O
-	O
AM	O
NF	O
-	O
kappaB	O
ELISA	O
kit	O
.	O

Western	O
blot	O
was	O
performed	O
to	O
detect	O
the	O
effect	O
of	O
curcumin	O
on	O
the	O
expression	O
of	O
uPA	O
.	O

Our	O
results	O
showed	O
that	O
curcumin	O
dose	O
-	O
dependently	O
inhibited	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
proliferation	O
of	O
MCF	B
-	I
7	I
cells	O
.	O

Meanwhile	O
,	O
the	O
adhesion	O
and	O
invasion	O
ability	O
of	O
MCF	B
-	I
7	I
cells	O
were	O
sharply	O
inhibited	O
when	O
treated	O
with	O
different	O
concentrations	O
of	O
curcumin	O
.	O

Curcumin	O
also	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
expression	O
of	O
uPA	O
and	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
respectively	O
.	O

It	O
is	O
concluded	O
that	O
curcumin	O
inhibits	O
the	O
adhesion	O
and	O
invasion	O
of	O
MCF	B
-	I
7	I
cells	O
through	O
down	O
-	O
regulating	O
the	O
protein	O
expression	O
of	O
uPA	O
via	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Accordingly	O
,	O
the	O
therapeutic	O
potential	O
of	O
curcumin	O
for	O
breast	O
cancer	O
deserves	O
further	O
study	O
.	O

Aglycon	O
of	O
rhizochalin	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
apoptosis	O
via	O
activation	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
in	O
HT	B
-	I
29	I
colon	O
cancer	O
cells	O
.	O

Rhizochalin	O
is	O
a	O
two	O
-	O
headed	O
sphingolipid	O
-	O
like	O
compound	O
isolated	O
from	O
the	O
sponge	O
Rhizochalina	O
incrustata	O
.	O

It	O
has	O
been	O
reported	O
that	O
rhizocalin	O
and	O
its	O
derivates	O
have	O
a	O
chemopreventive	O
and	O
chemotherapeutic	O
effect	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
these	O
effects	O
is	O
not	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
aglycon	O
of	O
rhizochalin	O
(	O
AglRhz	O
)	O
from	O
the	O
Rhizochalina	O
incrustata	O
induces	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
phosphorylation	O
,	O
and	O
thereby	O
inhibits	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
-	O
p70S6	O
kinase	O
-	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
signaling	O
and	O
activator	O
protein	O
1	O
(	O
AP	O
-	O
1	O
)	O
activity	O
via	O
phosphorylation	O
of	O
Raptor	O
in	O
HT	B
-	I
29	I
cells	O
.	O

In	O
addition	O
,	O
AglRhz	O
induced	O
activation	O
of	O
caspase	O
-	O
3	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
,	O
and	O
DNA	O
fragmentation	O
in	O
HT	B
-	I
29	I
cells	O
,	O
leads	O
to	O
induction	O
of	O
apoptosis	O
as	O
well	O
as	O
suppression	O
of	O
tumorigenicity	O
of	O
HT	B
-	I
29	I
cells	O
.	O

Notably	O
,	O
AglRhz	O
inhibits	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-	O
1	O
-	O
induced	O
AP	O
-	O
1	O
activity	O
and	O
cell	O
transformation	O
in	O
JB6	B
Cl41	I
cells	O
.	O

Overall	O
,	O
our	O
findings	O
identify	O
AMPK	O
as	O
an	O
important	O
target	O
protein	O
for	O
mediating	O
the	O
anti	O
-	O
tumor	O
properties	O
of	O
AglRhz	O
in	O
HT	B
-	I
29	I
colon	O
cancer	O
cells	O
and	O
have	O
important	O
implication	O
for	O
sponges	O
,	O
the	O
most	O
important	O
marine	O
source	O
,	O
in	O
colon	O
cancer	O
.	O

Expression	O
of	O
thymidylate	O
synthase	O
and	O
dihydropyrimidine	O
dehydrogenase	O
in	O
primary	O
oral	O
squamous	O
cell	O
carcinoma	O
and	O
corresponding	O
metastases	O
in	O
cervical	O
lymph	O
nodes	O
:	O
association	O
with	O
the	O
metastasis	O
suppressor	O
CD82	O
.	O

Thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
are	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
metabolizing	O
enzymes	O
and	O
are	O
involved	O
in	O
the	O
sensitivity	O
of	O
carcinoma	O
patients	O
to	O
5	O
-	O
FU	O
.	O

Although	O
5	O
-	O
FU	O
is	O
often	O
used	O
for	O
the	O
treatment	O
of	O
oral	O
carcinoma	O
,	O
there	O
has	O
not	O
been	O
any	O
investigation	O
into	O
the	O
expression	O
of	O
these	O
enzymes	O
in	O
metastatic	O
lymph	O
nodes	O
or	O
of	O
their	O
roles	O
in	O
the	O
effectiveness	O
of	O
5	O
-	O
FU	O
in	O
treating	O
lymph	O
node	O
-	O
metastatic	O
cancer	O
.	O

Oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
often	O
metastasizes	O
to	O
the	O
lymph	O
nodes	O
,	O
and	O
these	O
enzymes	O
may	O
be	O
significant	O
in	O
the	O
survival	O
of	O
patients	O
with	O
this	O
disease	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
TS	O
and	O
DPD	O
in	O
cervical	O
lymph	O
node	O
metastases	O
and	O
its	O
relationship	O
with	O
primary	O
OSCC	O
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
these	O
enzymes	O
and	O
Kangai	O
1	O
(	O
KAI1	O
/	O
CD82	O
)	O
which	O
is	O
a	O
metastasis	O
suppressor	O
protein	O
.	O

Surgical	O
specimens	O
from	O
20	O
cases	O
of	O
OSCC	O
with	O
lymph	O
node	O
metastasis	O
,	O
20	O
cases	O
of	O
OSCC	O
without	O
lymph	O
node	O
metastasis	O
,	O
and	O
10	O
cases	O
of	O
normal	O
mucosa	O
were	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
relationship	O
between	O
TS	O
and	O
DPD	O
expression	O
and	O
clinicopathological	O
data	O
was	O
analyzed	O
.	O

TS	O
and	O
DPD	O
proteins	O
were	O
overexpressed	O
in	O
primary	O
OSCC	O
compared	O
to	O
that	O
in	O
normal	O
mucosa	O
.	O

TS	O
expression	O
of	O
the	O
primary	O
oral	O
cancer	O
cells	O
in	O
the	O
group	O
with	O
lymph	O
node	O
metastasis	O
was	O
higher	O
than	O
that	O
of	O
those	O
without	O
.	O

DPD	O
expression	O
did	O
not	O
significantly	O
correlate	O
with	O
the	O
occurrence	O
of	O
lymph	O
node	O
metastasis	O
,	O
nor	O
was	O
it	O
different	O
between	O
primary	O
oral	O
cancer	O
cells	O
and	O
cervical	O
metastases	O
.	O

CD82	O
expression	O
was	O
significantly	O
reduced	O
in	O
lymph	O
node	O
metastases	O
.	O

These	O
findings	O
indicate	O
that	O
TS	O
and	O
CD82	O
may	O
be	O
of	O
great	O
value	O
in	O
assessing	O
lymph	O
node	O
metastasis	O
of	O
OSCC	O
,	O
and	O
could	O
be	O
taken	O
as	O
new	O
targets	O
for	O
therapy	O
of	O
metastatic	O
OSCC	O
.	O

c	O
-	O
MYC	O
functions	O
as	O
a	O
molecular	O
switch	O
to	O
alter	O
the	O
response	O
of	O
human	O
mammary	O
epithelial	O
cells	O
to	O
oncostatin	O
M	O
.	O

Cytokines	O
play	O
an	O
important	O
role	O
in	O
creating	O
an	O
inflammatory	O
microenvironment	O
,	O
which	O
is	O
now	O
considered	O
a	O
hallmark	O
of	O
cancer	O
.	O

Although	O
tumor	O
cells	O
can	O
exploit	O
cytokine	O
signaling	O
to	O
promote	O
growth	O
,	O
invasion	O
,	O
and	O
metastasis	O
,	O
the	O
response	O
of	O
normal	O
and	O
premalignant	O
epithelial	O
cells	O
to	O
cytokines	O
present	O
in	O
a	O
developing	O
tumor	O
microenvironment	O
remains	O
unclear	O
.	O

Oncostatin	O
M	O
(	O
OSM	O
)	O
,	O
an	O
IL	O
-	O
6	O
family	O
cytokine	O
responsible	O
for	O
STAT3	O
activation	O
,	O
has	O
been	O
implicated	O
in	O
cancer	O
development	O
,	O
progression	O
,	O
invasion	O
,	O
and	O
metastasis	O
.	O

Paradoxically	O
,	O
OSM	O
can	O
also	O
suppress	O
the	O
growth	O
of	O
normal	O
cells	O
and	O
certain	O
tumor	O
-	O
derived	O
cell	O
lines	O
.	O

Using	O
isogenic	O
human	O
mammary	O
epithelial	O
cells	O
(	O
HMEC	O
)	O
at	O
different	O
stages	O
of	O
neoplastic	O
transformation	O
,	O
we	O
found	O
that	O
OSM	O
signaling	O
suppressed	O
c	O
-	O
MYC	O
expression	O
and	O
engaged	O
a	O
p16	O
-	O
and	O
p53	O
-	O
independent	O
growth	O
arrest	O
that	O
required	O
STAT3	O
activity	O
.	O

Inhibition	O
of	O
STAT3	O
activation	O
by	O
expressing	O
a	O
dominant	O
-	O
negative	O
STAT3	O
protein	O
or	O
a	O
STAT3	O
-	O
shRNA	O
prevented	O
the	O
OSM	O
-	O
mediated	O
arrest	O
.	O

In	O
addition	O
,	O
expression	O
of	O
c	O
-	O
MYC	O
from	O
a	O
constitutive	O
promoter	O
also	O
abrogated	O
the	O
STAT3	O
-	O
mediated	O
arrest	O
,	O
and	O
strikingly	O
,	O
cooperated	O
with	O
OSM	O
to	O
promote	O
anchorage	O
-	O
independent	O
growth	O
(	O
AIG	O
)	O
,	O
a	O
property	O
associated	O
with	O
malignant	O
transformation	O
.	O

Cooperative	O
transformation	O
by	O
c	O
-	O
MYC	O
and	O
OSM	O
required	O
PI3	O
K	O
and	O
AKT	O
signaling	O
,	O
showing	O
the	O
importance	O
of	O
multiple	O
signaling	O
pathways	O
downstream	O
of	O
the	O
OSM	O
receptor	O
in	O
defining	O
the	O
cellular	O
response	O
to	O
cytokines	O
.	O

These	O
findings	O
identify	O
c	O
-	O
MYC	O
as	O
an	O
important	O
molecular	O
switch	O
that	O
alters	O
the	O
cellular	O
response	O
to	O
OSM	O
-	O
mediated	O
signaling	O
from	O
tumor	O
suppressive	O
to	O
tumor	O
promoting	O
.	O

PTHrP	O
drives	O
breast	O
tumor	O
initiation	O
,	O
progression	O
,	O
and	O
metastasis	O
in	O
mice	O
and	O
is	O
a	O
potential	O
therapy	O
target	O
.	O

Parathyroid	O
hormone	O
-	O
related	O
protein	O
(	O
PTHrP	O
)	O
is	O
a	O
secreted	O
factor	O
expressed	O
in	O
almost	O
all	O
normal	O
fetal	O
and	O
adult	O
tissues	O
.	O

It	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
developmental	O
and	O
physiological	O
processes	O
,	O
including	O
serum	O
calcium	O
regulation	O
.	O

PTHrP	O
is	O
also	O
associated	O
with	O
the	O
progression	O
of	O
skeletal	O
metastases	O
,	O
and	O
its	O
dysregulated	O
expression	O
in	O
advanced	O
cancers	O
causes	O
malignancy	O
-	O
associated	O
hypercalcemia	O
.	O

Although	O
PTHrP	O
is	O
frequently	O
expressed	O
by	O
breast	O
tumors	O
and	O
other	O
solid	O
cancers	O
,	O
its	O
effects	O
on	O
tumor	O
progression	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
demonstrate	O
in	O
mice	O
pleiotropic	O
involvement	O
of	O
PTHrP	O
in	O
key	O
steps	O
of	O
breast	O
cancer	O
-	O
it	O
influences	O
the	O
initiation	O
and	O
progression	O
of	O
primary	O
tumors	O
and	O
metastases	O
.	O

Pthrp	O
ablation	O
in	O
the	O
mammary	O
epithelium	O
of	O
the	O
PyMT	O
-	O
MMTV	O
breast	O
cancer	O
mouse	O
model	O
caused	O
a	O
delay	O
in	O
primary	O
tumor	O
initiation	O
,	O
inhibited	O
tumor	O
progression	O
,	O
and	O
reduced	O
metastasis	O
to	O
distal	O
sites	O
.	O

Mechanistically	O
,	O
it	O
reduced	O
expression	O
of	O
molecular	O
markers	O
of	O
cell	O
proliferation	O
(	O
Ki67	O
)	O
and	O
angiogenesis	O
(	O
factor	O
VIII	O
)	O
,	O
antiapoptotic	O
factor	O
Bcl	O
-	O
2	O
,	O
cell	O
-	O
cycle	O
progression	O
regulator	O
cyclin	O
D1	O
,	O
and	O
survival	O
factor	O
AKT1	O
.	O

PTHrP	O
also	O
influenced	O
expression	O
of	O
the	O
adhesion	O
factor	O
CXCR4	O
,	O
and	O
coexpression	O
of	O
PTHrP	O
and	O
CXCR4	O
was	O
crucial	O
for	O
metastatic	O
spread	O
.	O

Importantly	O
,	O
PTHrP	O
-	O
specific	O
neutralizing	O
antibodies	O
slowed	O
the	O
progression	O
and	O
metastasis	O
of	O
human	O
breast	O
cancer	O
xenografts	O
.	O

Our	O
data	O
identify	O
what	O
we	O
believe	O
to	O
be	O
new	O
functions	O
for	O
PTHrP	O
in	O
several	O
key	O
steps	O
of	O
breast	O
cancer	O
and	O
suggest	O
that	O
PTHrP	O
may	O
constitute	O
a	O
novel	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Aquaporins	O
in	O
human	O
breast	O
cancer	O
:	O
identification	O
and	O
involvement	O
in	O
carcinogenesis	O
of	O
breast	O
cancer	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Aquaporins	O
(	O
AQPs	O
)	O
play	O
important	O
roles	O
in	O
water	O
and	O
glycerol	O
transport	O
.	O

Recently	O
,	O
the	O
role	O
of	O
AQPs	O
in	O
human	O
carcinogenesis	O
has	O
become	O
an	O
area	O
of	O
great	O
interest	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
AQPs	O
in	O
human	O
breast	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
profile	O
of	O
AQPs	O
in	O
human	O
breast	O
cancer	O
and	O
its	O
significance	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
the	O
expression	O
profile	O
of	O
AQP0	O
-	O
12	O
in	O
breast	O
cancer	O
tissues	O
and	O
corresponding	O
normal	O
tissues	O
by	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
AQP1	O
,	O
3	O
-	O
5	O
,	O
and	O
10	O
-	O
12	O
were	O
expressed	O
in	O
human	O
breast	O
cancer	O
and	O
/	O
or	O
normal	O
breast	O
tissues	O
,	O
and	O
AQP1	O
and	O
3	O
-	O
5	O
exhibited	O
differential	O
expression	O
.	O

AQP1	O
was	O
expressed	O
in	O
cell	O
membranes	O
and	O
its	O
expression	O
was	O
higher	O
in	O
cancer	O
than	O
that	O
in	O
normal	O
tissues	O
.	O

AQP4	O
was	O
expressed	O
in	O
the	O
cell	O
membrane	O
and	O
cytoplasm	O
and	O
was	O
detected	O
markedly	O
stronger	O
in	O
normal	O
than	O
in	O
cancer	O
tissues	O
.	O

AQP5	O
was	O
expressed	O
mainly	O
in	O
cell	O
membranes	O
in	O
carcinoma	O
tissues	O
,	O
but	O
was	O
almost	O
absent	O
in	O
normal	O
breast	O
tissues	O
.	O

Expression	O
of	O
AQP5	O
was	O
associated	O
with	O
cellular	O
differentiation	O
,	O
lymph	O
node	O
invasion	O
,	O
and	O
clinicopathological	O
staging	O
.	O

CONCLUSIONS	O
:	O
These	O
observations	O
suggested	O
that	O
several	O
subtypes	O
of	O
the	O
AQP	O
family	O
play	O
a	O
role	O
in	O
human	O
breast	O
carcinogenesis	O
.	O

Absence	O
of	O
antisperm	O
antibodies	O
in	O
anejaculatory	O
men	O
.	O

Antisperm	O
antibodies	O
were	O
assessed	O
in	O
the	O
serum	O
samples	O
of	O
73	O
men	O
unable	O
to	O
ejaculate	O
naturally	O
and	O
on	O
the	O
sperm	O
cells	O
of	O
13	O
of	O
these	O
men	O
.	O

None	O
of	O
the	O
serum	O
samples	O
were	O
found	O
to	O
be	O
positive	O
by	O
sperm	O
agglutination	O
or	O
sperm	O
immobilization	O
methods	O
and	O
antibodies	O
were	O
detected	O
by	O
an	O
immunobead	O
assay	O
on	O
the	O
sperm	O
cells	O
of	O
one	O
of	O
the	O
13	O
men	O
examined	O
.	O

Research	O
and	O
discovery	O
of	O
the	O
first	O
human	O
cancer	O
virus	O
,	O
HTLV	O
-	O
1	O
.	O

Human	O
T	O
-	O
cell	O
lymphoma	O
virus	O
(	O
HTLV	O
)	O
-	O
1	O
was	O
the	O
first	O
human	O
retrovirus	O
to	O
be	O
discovered	O
.	O

It	O
has	O
been	O
recognized	O
as	O
the	O
cause	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

In	O
addition	O
to	O
giving	O
a	O
historical	O
perspective	O
on	O
HTLV	O
-	O
1	O
and	O
other	O
retrovirus	O
research	O
,	O
this	O
paper	O
discusses	O
the	O
origin	O
of	O
HTLV	O
-	O
1	O
;	O
the	O
modes	O
of	O
transmission	O
and	O
global	O
epidemiology	O
of	O
HTLV	O
-	O
1	O
infection	O
;	O
the	O
genome	O
of	O
HTLV	O
-	O
1	O
and	O
the	O
mechanism	O
of	O
HTLV	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
;	O
the	O
role	O
of	O
HTLV	O
-	O
1	O
in	O
other	O
diseases	O
,	O
and	O
recent	O
breakthroughs	O
in	O
ATL	O
therapy	O
.	O

Relationship	O
between	O
of	O
blood	O
flow	O
,	O
glucose	O
metabolism	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
in	O
experimentally	O
-	O
induced	O
glioma	O
(	O
RG1	O
2	O
.	O
2	O
)	O
of	O
rat	O
brain	O
.	O

In	O
experimental	O
RG1	O
2	O
.	O
2	O
glioma	O
of	O
rat	O
brain	O
,	O
local	O
blood	O
flow	O
,	O
glucose	O
utilization	O
,	O
protein	O
synthesis	O
,	O
glucose	O
and	O
ATP	O
content	O
were	O
measured	O
by	O
means	O
of	O
triple	O
tracer	O
autoradiography	O
and	O
bioluminescence	O
technique	O
,	O
respectively	O
,	O
to	O
determine	O
hemodynamic	O
and	O
metabolic	O
thresholds	O
for	O
local	O
tumor	O
energy	O
failure	O
.	O

Perfusion	O
thresholds	O
were	O
estimated	O
at	O
tumor	O
blood	O
flow	O
values	O
of	O
69	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
(	O
estimate	O
+	O
/	O
-	O
standard	O
error	O
)	O
and	O
of	O
69	O
+	O
/	O
-	O
7	O
.	O
1	O
ml	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
beginning	O
of	O
the	O
decline	O
in	O
regional	O
ATP	O
and	O
glucose	O
content	O
,	O
respectively	O
.	O

Metabolic	O
thresholds	O
were	O
derived	O
at	O
tumor	O
glucose	O
utilization	O
values	O
of	O
70	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
3	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
reduced	O
protein	O
synthesis	O
,	O
of	O
55	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
the	O
decrease	O
in	O
glucose	O
content	O
,	O
and	O
34	O
.	O
7	O
+	O
/	O
-	O
4	O
.	O
7	O
mumol	O
/	O
100	O
g	O
/	O
min	O
for	O
decline	O
in	O
ATP	O
content	O
.	O

Our	O
results	O
suggest	O
that	O
blood	O
flow	O
limits	O
glucose	O
supply	O
to	O
tumor	O
tissue	O
at	O
much	O
higher	O
flow	O
rates	O
than	O
in	O
normal	O
brain	O
which	O
,	O
in	O
turn	O
,	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
tumor	O
glucose	O
utilization	O
.	O

A	O
reduction	O
and	O
not	O
an	O
increase	O
in	O
tumor	O
glucose	O
availability	O
could	O
be	O
a	O
more	O
appropriate	O
strategy	O
for	O
the	O
induction	O
of	O
energy	O
failure	O
in	O
tumors	O
.	O

Selective	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
by	O
nuclear	O
factor	O
-	O
kappaB	O
essential	O
modulator	O
-	O
binding	O
domain	O
peptide	O
suppresses	O
the	O
metastasis	O
of	O
highly	O
metastatic	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
contributes	O
to	O
the	O
development	O
of	O
metastasis	O
,	O
thus	O
leading	O
to	O
a	O
poor	O
prognosis	O
in	O
many	O
cancers	O
,	O
including	O
OSCC	O
.	O

However	O
,	O
little	O
in	O
vivo	O
experimental	O
data	O
are	O
available	O
about	O
the	O
effects	O
of	O
NF	O
-	O
kappaB	O
inhibition	O
on	O
OSCC	O
metastasis	O
.	O

OSCC	B
sublines	O
were	O
established	O
from	O
a	O
GFP	O
-	O
expressing	O
parental	O
cell	O
line	O
,	O
GSAS	B
,	O
and	O
designated	O
GSAS	B
/	O
N3	O
and	O
N5	O
according	O
to	O
the	O
in	O
vivo	O
passage	O
number	O
after	O
cervical	O
lymph	O
node	O
metastasis	O
by	O
a	O
serial	O
orthotopic	O
transplantation	O
model	O
.	O

In	O
vitro	O
migration	O
and	O
invasion	O
were	O
assessed	O
in	O
these	O
cells	O
,	O
and	O
the	O
NF	O
-	O
kappaB	O
activities	O
and	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
were	O
also	O
examined	O
.	O

In	O
in	O
vivo	O
experiments	O
,	O
the	O
metastasis	O
and	O
survival	O
of	O
tumor	O
-	O
engrafted	O
mice	O
were	O
monitored	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
a	O
selective	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
NEMO	O
-	O
binding	O
domain	O
(	O
NBD	O
)	O
peptide	O
,	O
on	O
metastasis	O
in	O
GSAS	B
/	O
N5	O
-	O
engrafted	O
mice	O
were	O
assessed	O
,	O
and	O
engrafted	O
tongue	O
tumors	O
were	O
immunohistochemically	O
examined	O
.	O

Highly	O
metastatic	O
GSAS	B
/	O
N3	O
and	O
N5	O
cells	O
showed	O
an	O
enhanced	O
NF	O
-	O
kappaB	O
activity	O
,	O
thus	O
contributing	O
to	O
increased	O
migration	O
,	O
invasion	O
,	O
and	O
a	O
poor	O
prognosis	O
compared	O
with	O
the	O
parent	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
,	O
such	O
as	O
fibronectin	O
,	O
beta1	O
integrin	O
,	O
MMP	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
9	O
,	O
and	O
-	O
14	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
were	O
upregulated	O
in	O
the	O
highly	O
metastatic	O
cells	O
.	O

The	O
NBD	O
peptide	O
suppressed	O
metastasis	O
and	O
tongue	O
tumor	O
growth	O
in	O
GSAS	B
/	O
N5	O
-	O
inoculated	O
mice	O
,	O
and	O
was	O
accompanied	O
by	O
the	O
downregulation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
regulated	O
metastasis	O
-	O
related	O
molecules	O
in	O
engrafted	O
tongue	O
tumors	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
selective	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
NBD	O
peptide	O
may	O
provide	O
an	O
effective	O
approach	O
for	O
the	O
treatment	O
of	O
highly	O
metastatic	O
OSCC	O
.	O

beta	O
-	O
catenin	O
signaling	O
controls	O
metastasis	O
in	O
Braf	O
-	O
activated	O
Pten	O
-	O
deficient	O
melanomas	O
.	O

Malignant	O
melanoma	O
is	O
characterized	O
by	O
frequent	O
metastasis	O
,	O
however	O
,	O
specific	O
changes	O
that	O
regulate	O
this	O
process	O
have	O
not	O
been	O
clearly	O
delineated	O
.	O

Although	O
it	O
is	O
well	O
known	O
that	O
Wnt	O
signaling	O
is	O
frequently	O
dysregulated	O
in	O
melanoma	O
,	O
the	O
functional	O
implications	O
of	O
this	O
observation	O
are	O
unclear	O
.	O

By	O
modulating	O
beta	O
-	O
catenin	O
levels	O
in	O
a	O
mouse	O
model	O
of	O
melanoma	O
that	O
is	O
based	O
on	O
melanocyte	O
-	O
specific	O
Pten	O
loss	O
and	O
Braf	O
(	O
V600E	O
)	O
mutation	O
,	O
we	O
demonstrate	O
that	O
beta	O
-	O
catenin	O
is	O
a	O
central	O
mediator	O
of	O
melanoma	O
metastasis	O
to	O
the	O
lymph	O
nodes	O
and	O
lungs	O
.	O

In	O
addition	O
to	O
altering	O
metastasis	O
,	O
beta	O
-	O
catenin	O
levels	O
control	O
tumor	O
differentiation	O
and	O
regulate	O
both	O
MAPK	O
/	O
Erk	O
and	O
PI3	O
K	O
/	O
Akt	O
signaling	O
.	O

Highly	O
metastatic	O
tumors	O
with	O
beta	O
-	O
catenin	O
stabilization	O
are	O
very	O
similar	O
to	O
a	O
subset	O
of	O
human	O
melanomas	O
.	O

Together	O
these	O
findings	O
establish	O
Wnt	O
signaling	O
as	O
a	O
metastasis	O
regulator	O
in	O
melanoma	O
.	O

Impaired	O
CK1	O
delta	O
activity	O
attenuates	O
SV40	O
-	O
induced	O
cellular	O
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	O
carcinogenesis	O
in	O
vivo	O
.	O

Simian	O
virus	O
40	O
(	O
SV40	O
)	O
is	O
a	O
powerful	O
tool	O
to	O
study	O
cellular	O
transformation	O
in	O
vitro	O
,	O
as	O
well	O
as	O
tumor	O
development	O
and	O
progression	O
in	O
vivo	O
.	O

Various	O
cellular	O
kinases	O
,	O
among	O
them	O
members	O
of	O
the	O
CK1	O
family	O
,	O
play	O
an	O
important	O
role	O
in	O
modulating	O
the	O
transforming	O
activity	O
of	O
SV40	O
,	O
including	O
the	O
transforming	O
activity	O
of	O
T	O
-	O
Ag	O
,	O
the	O
major	O
transforming	O
protein	O
of	O
SV40	O
,	O
itself	O
.	O

Here	O
we	O
characterized	O
the	O
effects	O
of	O
mutant	O
CK1delta	O
variants	O
with	O
impaired	O
kinase	O
activity	O
on	O
SV40	O
-	O
induced	O
cell	O
transformation	O
in	O
vitro	O
,	O
and	O
on	O
SV40	O
-	O
induced	O
mammary	O
carcinogenesis	O
in	O
vivo	O
in	O
a	O
transgenic	O
/	O
bi	O
-	O
transgenic	O
mouse	O
model	O
.	O

CK1delta	O
mutants	O
exhibited	O
a	O
reduced	O
kinase	O
activity	O
compared	O
to	O
wtCK1delta	O
in	O
in	O
vitro	O
kinase	O
assays	O
.	O

Molecular	O
modeling	O
studies	O
suggested	O
that	O
mutation	O
N172D	O
,	O
located	O
within	O
the	O
substrate	O
binding	O
region	O
,	O
is	O
mainly	O
responsible	O
for	O
impaired	O
mutCK1delta	O
activity	O
.	O

When	O
stably	O
over	O
-	O
expressed	O
in	O
maximal	O
transformed	O
SV	B
-	I
52	I
cells	O
,	O
CK1delta	O
mutants	O
induced	O
reversion	O
to	O
a	O
minimal	O
transformed	O
phenotype	O
by	O
dominant	O
-	O
negative	O
interference	O
with	O
endogenous	O
wtCK1delta	O
.	O

To	O
characterize	O
the	O
effects	O
of	O
CK1delta	O
on	O
SV40	O
-	O
induced	O
mammary	O
carcinogenesis	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
mutant	O
CK1delta	O
under	O
the	O
control	O
of	O
the	O
whey	O
acidic	O
protein	O
(	O
WAP	O
)	O
gene	O
promoter	O
,	O
and	O
crossed	O
them	O
with	O
SV40	O
transgenic	O
WAP	O
-	O
T	O
-	O
antigen	O
(	O
WAP	O
-	O
T	O
)	O
mice	O
.	O

Both	O
WAP	O
-	O
T	O
mice	O
as	O
well	O
as	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
mice	O
developed	O
breast	O
cancer	O
.	O

However	O
,	O
tumor	O
incidence	O
was	O
lower	O
and	O
life	O
span	O
was	O
significantly	O
longer	O
in	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
bi	O
-	O
transgenic	O
animals	O
.	O

The	O
reduced	O
CK1delta	O
activity	O
did	O
not	O
affect	O
early	O
lesion	O
formation	O
during	O
tumorigenesis	O
,	O
suggesting	O
that	O
impaired	O
CK1delta	O
activity	O
reduces	O
the	O
probability	O
for	O
outgrowth	O
of	O
in	O
situ	O
carcinomas	O
to	O
invasive	O
carcinomas	O
.	O

The	O
different	O
tumorigenic	O
potential	O
of	O
SV40	O
in	O
WAP	O
-	O
T	O
and	O
WAP	O
-	O
mutCK1delta	O
/	O
WAP	O
-	O
T	O
tumors	O
was	O
also	O
reflected	O
by	O
a	O
significantly	O
different	O
expression	O
of	O
various	O
genes	O
known	O
to	O
be	O
involved	O
in	O
tumor	O
progression	O
,	O
specifically	O
of	O
those	O
involved	O
in	O
wnt	O
-	O
signaling	O
and	O
DNA	O
repair	O
.	O

Our	O
data	O
show	O
that	O
inactivating	O
mutations	O
in	O
CK1delta	O
impair	O
SV40	O
-	O
induced	O
cellular	O
transformation	O
in	O
vitro	O
and	O
mouse	O
mammary	O
carcinogenesis	O
in	O
vivo	O
.	O

Mitochondrial	O
apoptosis	O
and	O
FAK	O
signaling	O
disruption	O
by	O
a	O
novel	O
histone	O
deacetylase	O
inhibitor	O
,	O
HTPB	O
,	O
in	O
antitumor	O
and	O
antimetastatic	O
mouse	O
models	O
.	O

BACKGROUND	O
:	O
Compound	O
targeting	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
represents	O
a	O
new	O
era	O
in	O
molecular	O
cancer	O
therapeutics	O
.	O

However	O
,	O
effective	O
HDAC	O
inhibitors	O
for	O
the	O
treatment	O
of	O
solid	O
tumors	O
remain	O
to	O
be	O
developed	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Here	O
,	O
we	O
propose	O
a	O
novel	O
HDAC	O
inhibitor	O
,	O
N	O
-	O
Hydroxy	O
-	O
4	O
-	O
(	O
4	O
-	O
phenylbutyryl	O
-	O
amino	O
)	O
benzamide	O
(	O
HTPB	O
)	O
,	O
as	O
a	O
potential	O
chemotherapeutic	O
drug	O
for	O
solid	O
tumors	O
.	O

The	O
HDAC	O
inhibition	O
of	O
HTPB	O
was	O
confirmed	O
using	O
HDAC	O
activity	O
assay	O
.	O

The	O
antiproliferative	O
and	O
anti	O
-	O
migratory	O
mechanisms	O
of	O
HTPB	O
were	O
investigated	O
by	O
cell	O
proliferation	O
,	O
flow	O
cytometry	O
,	O
DNA	O
ladder	O
,	O
caspase	O
activity	O
,	O
Rho	O
activity	O
,	O
F	O
-	O
actin	O
polymerization	O
,	O
and	O
gelatin	O
-	O
zymography	O
for	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O

Mice	O
with	O
tumor	O
xenograft	O
and	O
experimental	O
metastasis	O
model	O
were	O
used	O
to	O
evaluate	O
effects	O
on	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Our	O
results	O
indicated	O
that	O
HTPB	O
was	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
in	O
suppressing	O
cell	O
viability	O
specifically	O
of	O
lung	O
cancer	O
cells	O
but	O
not	O
of	O
the	O
normal	O
lung	O
cells	O
.	O

Upon	O
HTPB	O
treatment	O
,	O
cell	O
cycle	O
arrest	O
was	O
induced	O
and	O
subsequently	O
led	O
to	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

HTPB	O
disrupted	O
F	O
-	O
actin	O
dynamics	O
via	O
downregulating	O
RhoA	O
activity	O
.	O

Moreover	O
,	O
HTPB	O
inhibited	O
activity	O
of	O
MMP2	O
and	O
MMP9	O
,	O
reduced	O
integrin	O
-	O
beta1	O
/	O
focal	O
adhesion	O
complex	O
formation	O
and	O
decreased	O
pericellular	O
poly	O
-	O
fibronectin	O
assemblies	O
.	O

Finally	O
,	O
intraperitoneal	O
injection	O
or	O
oral	O
administration	O
of	O
HTPB	O
efficiently	O
inhibited	O
A549	B
xenograft	O
tumor	O
growth	O
in	O
vivo	O
without	O
side	O
effects	O
.	O

HTPB	O
delayed	O
lung	O
metastasis	O
of	O
4T1	B
mouse	O
breast	O
cancer	O
cells	O
.	O

Acetylation	O
of	O
histone	O
and	O
non	O
-	O
histone	O
proteins	O
,	O
induction	O
of	O
apoptotic	O
-	O
related	O
proteins	O
and	O
de	O
-	O
phosphorylation	O
of	O
focal	O
adhesion	O
kinase	O
were	O
confirmed	O
in	O
treated	O
mice	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
results	O
suggested	O
that	O
intrinsic	O
apoptotic	O
pathway	O
may	O
involve	O
in	O
anti	O
-	O
tumor	O
growth	O
effects	O
of	O
HTPB	O
in	O
lung	O
cancer	O
cells	O
.	O

HTPB	O
significantly	O
suppresses	O
tumor	O
metastasis	O
partly	O
through	O
inhibition	O
of	O
integrin	O
-	O
beta1	O
/	O
FAK	O
/	O
MMP	O
/	O
RhoA	O
/	O
F	O
-	O
actin	O
pathways	O
.	O

We	O
have	O
provided	O
convincing	O
preclinical	O
evidence	O
that	O
HTPB	O
is	O
a	O
potent	O
HDAC	O
targeted	O
inhibitor	O
and	O
is	O
thus	O
a	O
promising	O
candidate	O
for	O
lung	O
cancer	O
chemotherapy	O
.	O

Inactivation	O
of	O
androgen	O
-	O
induced	O
regulator	O
ARD1	O
inhibits	O
androgen	O
receptor	O
acetylation	O
and	O
prostate	O
tumorigenesis	O
.	O

Androgen	O
signaling	O
through	O
androgen	O
receptor	O
(	O
AR	O
)	O
is	O
critical	O
for	O
prostate	O
tumorigenesis	O
.	O

Given	O
that	O
AR	O
-	O
mediated	O
gene	O
regulation	O
is	O
enhanced	O
by	O
AR	O
coregulators	O
,	O
inactivation	O
of	O
those	O
coregulators	O
is	O
emerging	O
as	O
a	O
promising	O
therapy	O
for	O
prostate	O
cancer	O
(	O
PCa	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
N	O
-	O
acetyltransferase	O
arrest	O
-	O
defect	O
1	O
protein	O
(	O
ARD1	O
)	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
in	O
PCa	O
cells	O
.	O

ARD1	O
is	O
up	O
-	O
regulated	O
in	O
human	O
PCa	O
cell	O
lines	O
and	O
primary	O
tumor	O
biopsies	O
.	O

The	O
expression	O
of	O
ARD1	O
was	O
augmented	O
by	O
treatment	O
with	O
synthetic	O
androgen	O
(	O
R1881	O
)	O
unless	O
AR	O
is	O
deficient	O
or	O
is	O
inhibited	O
by	O
AR	O
-	O
specific	O
siRNA	O
or	O
androgen	O
inhibitor	O
bicalutamide	O
(	O
Casodex	O
)	O
.	O

Depletion	O
of	O
ARD1	O
by	O
shRNA	O
suppressed	O
PCa	O
cell	O
proliferation	O
,	O
anchorage	O
-	O
independent	O
growth	O
,	O
and	O
xenograft	O
tumor	O
formation	O
in	O
SCID	O
mice	O
,	O
suggesting	O
that	O
AR	O
-	O
dependent	O
ARD1	O
expression	O
is	O
biologically	O
germane	O
.	O

Notably	O
,	O
ARD1	O
was	O
critical	O
for	O
transcriptionally	O
regulating	O
a	O
number	O
of	O
AR	O
target	O
genes	O
that	O
are	O
involved	O
in	O
prostate	O
tumorigenesis	O
.	O

Furthermore	O
,	O
ARD1	O
interacted	O
physically	O
with	O
and	O
acetylated	O
the	O
AR	O
protein	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Because	O
AR	O
-	O
ARD1	O
interaction	O
facilitated	O
the	O
AR	O
binding	O
to	O
its	O
targeted	O
promoters	O
for	O
gene	O
transcription	O
,	O
we	O
propose	O
that	O
ARD1	O
functions	O
as	O
a	O
unique	O
AR	O
regulator	O
and	O
forms	O
a	O
positive	O
feedback	O
loop	O
for	O
AR	O
-	O
dependent	O
prostate	O
tumorigenesis	O
.	O

Disruption	O
of	O
AR	O
-	O
ARD1	O
interactions	O
may	O
be	O
a	O
potent	O
intervention	O
for	O
androgen	O
-	O
dependent	O
PCa	O
therapy	O
.	O

The	O
role	O
of	O
He	O
s	O
genes	O
in	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumor	O
formation	O
.	O

Notch	O
signaling	O
regulates	O
intestinal	O
development	O
,	O
homeostasis	O
and	O
tumorigenesis	O
,	O
but	O
its	O
precise	O
downstream	O
mechanism	O
remains	O
largely	O
unknown	O
.	O

Here	O
we	O
found	O
that	O
inactivation	O
of	O
the	O
Notch	O
effectors	O
Hes1	O
,	O
Hes3	O
and	O
Hes5	O
,	O
but	O
not	O
Hes1	O
alone	O
,	O
led	O
to	O
reduced	O
cell	O
proliferation	O
,	O
increased	O
secretory	O
cell	O
formation	O
and	O
altered	O
intestinal	O
structures	O
in	O
adult	O
mice	O
.	O

However	O
,	O
in	O
Apc	O
mutation	O
-	O
induced	O
intestinal	O
tumors	O
,	O
inactivation	O
of	O
Hes1	O
alone	O
was	O
sufficient	O
for	O
reducing	O
tumor	O
cell	O
proliferation	O
and	O
inducing	O
differentiation	O
of	O
tumor	O
cells	O
into	O
all	O
types	O
of	O
intestinal	O
epithelial	O
cells	O
,	O
but	O
without	O
affecting	O
the	O
homeostasis	O
of	O
normal	O
crypts	O
owing	O
to	O
genetic	O
redundancy	O
.	O

These	O
results	O
indicated	O
that	O
He	O
s	O
genes	O
cooperatively	O
regulate	O
intestinal	O
development	O
and	O
homeostasis	O
and	O
raised	O
the	O
possibility	O
that	O
Hes1	O
is	O
a	O
promising	O
target	O
to	O
induce	O
the	O
differentiation	O
of	O
tumor	O
cells	O
.	O

Activation	O
-	O
induced	O
cytidine	O
deaminase	O
in	O
antibody	O
diversification	O
and	O
chromosome	O
translocation	O
.	O

DNA	O
damage	O
,	O
rearrangement	O
,	O
and	O
mutation	O
of	O
the	O
human	O
genome	O
are	O
the	O
basis	O
of	O
carcinogenesis	O
and	O
thought	O
to	O
be	O
avoided	O
at	O
all	O
costs	O
.	O

An	O
exception	O
is	O
the	O
adaptive	O
immune	O
system	O
where	O
lymphocytes	O
utilize	O
programmed	O
DNA	O
damage	O
to	O
effect	O
antigen	O
receptor	O
diversification	O
.	O

Both	O
B	O
and	O
T	O
lymphocytes	O
diversify	O
their	O
antigen	O
receptors	O
through	O
RAG1	O
/	O
2	O
mediated	O
recombination	O
,	O
but	O
B	O
cells	O
undergo	O
two	O
additional	O
processes	O
-	O
-	O
somatic	O
hypermutation	O
(	O
SHM	O
)	O
and	O
class	O
-	O
switch	O
recombination	O
(	O
CSR	O
)	O
,	O
both	O
initiated	O
by	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
.	O

AID	O
deaminates	O
cytidines	O
in	O
DNA	O
resulting	O
in	O
U	O
:	O
G	O
mismatches	O
that	O
are	O
processed	O
into	O
point	O
mutations	O
in	O
SHM	O
or	O
double	O
-	O
strand	O
breaks	O
in	O
CSR	O
.	O

Although	O
AID	O
activity	O
is	O
focused	O
at	O
Immunoglobulin	O
(	O
Ig	O
)	O
gene	O
loci	O
,	O
it	O
also	O
targets	O
a	O
wide	O
array	O
of	O
non	O
-	O
Ig	O
genes	O
including	O
oncogenes	O
associated	O
with	O
lymphomas	O
.	O

Here	O
,	O
we	O
review	O
the	O
molecular	O
basis	O
of	O
AID	O
regulation	O
,	O
targeting	O
,	O
and	O
initiation	O
of	O
CSR	O
and	O
SHM	O
,	O
as	O
well	O
as	O
AID	O
'	O
s	O
role	O
in	O
generating	O
chromosome	O
translocations	O
that	O
contribute	O
to	O
lymphomagenesis	O
.	O

Expression	O
of	O
HER2	O
and	O
bradykinin	O
B1	O
receptors	O
in	O
precursor	O
lesions	O
of	O
gallbladder	O
carcinoma	O
.	O

AIM	O
:	O
To	O
determine	O
the	O
expression	O
of	O
HER2	O
and	O
bradykinin	O
B	O
(	O
1	O
)	O
receptors	O
(	O
B	O
(	O
1	O
)	O
R	O
)	O
in	O
the	O
two	O
pathogenic	O
models	O
of	O
gallbladder	O
cancer	O
:	O
the	O
metaplasia	O
-	O
dysplasia	O
-	O
carcinoma	O
and	O
the	O
adenoma	O
-	O
carcinoma	O
pathways	O
.	O

METHODS	O
:	O
Receptor	O
proteins	O
were	O
visualized	O
by	O
immunohistochemistry	O
on	O
5	O
-	O
mum	O
sections	O
of	O
paraffin	O
-	O
embedded	O
tissue	O
.	O

Expression	O
of	O
both	O
receptors	O
was	O
studied	O
in	O
biopsy	O
samples	O
from	O
92	O
patients	O
(	O
6	O
males	O
and	O
86	O
females	O
;	O
age	O
ranging	O
from	O
28	O
to	O
86	O
years	O
,	O
mean	O
56	O
years	O
)	O
.	O

High	O
HER2	O
expression	O
in	O
specimens	O
was	O
additionally	O
investigated	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

Cell	O
proliferation	O
in	O
each	O
sample	O
was	O
assessed	O
by	O
using	O
the	O
Ki	O
-	O
67	O
proliferation	O
marker	O
.	O

RESULTS	O
:	O
HER2	O
receptor	O
protein	O
was	O
absent	O
in	O
adenomas	O
and	O
in	O
normal	O
gallbladder	O
epithelium	O
.	O

On	O
the	O
contrary	O
,	O
there	O
was	O
intense	O
staining	O
for	O
HER2	O
on	O
the	O
basolateral	O
membrane	O
of	O
epithelial	O
cells	O
of	O
intestinal	O
metaplasia	O
(	O
22	O
/	O
24	O
;	O
91	O
.	O
7	O
%	O
)	O
and	O
carcinoma	O
in	O
situ	O
(	O
9	O
/	O
10	O
;	O
90	O
%	O
)	O
,	O
the	O
lesions	O
that	O
displayed	O
a	O
significantly	O
high	O
proliferation	O
index	O
.	O

Protein	O
up	O
-	O
regulation	O
of	O
HER2	O
in	O
the	O
epithelium	O
with	O
metaplasia	O
or	O
carcinoma	O
in	O
situ	O
was	O
not	O
accompanied	O
by	O
HER2	O
gene	O
amplification	O
.	O

A	O
similar	O
result	O
was	O
observed	O
in	O
invasive	O
carcinomas	O
(	O
0	O
/	O
12	O
)	O
.	O

The	O
B	O
(	O
1	O
)	O
R	O
distribution	O
pattern	O
mirrored	O
that	O
of	O
HER2	O
except	O
that	O
B	O
(	O
1	O
)	O
R	O
was	O
additionally	O
observed	O
in	O
the	O
adenomas	O
.	O

The	O
B	O
(	O
1	O
)	O
R	O
appeared	O
either	O
as	O
cytoplasmic	O
dots	O
or	O
labeling	O
on	O
the	O
apical	O
cell	O
membrane	O
of	O
the	O
cells	O
composing	O
the	O
epithelia	O
with	O
intestinal	O
metaplasia	O
(	O
24	O
/	O
24	O
;	O
100	O
%	O
)	O
and	O
carcinoma	O
in	O
situ	O
(	O
10	O
/	O
10	O
;	O
100	O
%	O
)	O
and	O
in	O
the	O
epithelial	O
cells	O
of	O
adenomas	O
.	O

In	O
contrast	O
,	O
both	O
HER2	O
(	O
4	O
/	O
12	O
;	O
33	O
%	O
)	O
and	O
B	O
(	O
1	O
)	O
R	O
(	O
1	O
/	O
12	O
;	O
8	O
.	O
3	O
%	O
)	O
showed	O
a	O
low	O
expression	O
in	O
invasive	O
gallbladder	O
carcinomas	O
.	O

CONCLUSION	O
:	O
The	O
up	O
-	O
regulation	O
of	O
HER2	O
and	O
B	O
(	O
1	O
)	O
R	O
in	O
precursor	O
lesions	O
of	O
gallbladder	O
carcinoma	O
suggests	O
cross	O
-	O
talk	O
between	O
these	O
two	O
receptors	O
that	O
may	O
be	O
of	O
importance	O
in	O
the	O
modulation	O
of	O
cell	O
proliferation	O
in	O
gallbladder	O
carcinogenesis	O
.	O

Expression	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
in	O
normal	O
human	O
tissues	O
.	O

The	O
distribution	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
was	O
studied	O
immunohistochemically	O
in	O
fresh	O
frozen	O
sections	O
of	O
normal	O
human	O
tissues	O
.	O

Immunodetection	O
was	O
performed	O
with	O
a	O
specific	O
anti	O
-	O
bFGF	O
mouse	O
monoclonal	O
antibody	O
that	O
was	O
found	O
to	O
react	O
with	O
recombinant	O
human	O
bFGF	O
in	O
Western	O
blot	O
analysis	O
,	O
and	O
to	O
specifically	O
neutralize	O
the	O
mitogenic	O
activity	O
of	O
bFGF	O
on	O
bovine	O
vascular	O
endothelial	O
cells	O
.	O

Expression	O
of	O
bFGF	O
on	O
normal	O
human	O
tissues	O
was	O
ubiquitously	O
detected	O
in	O
the	O
basement	O
membranes	O
of	O
all	O
size	O
blood	O
vessels	O
,	O
but	O
was	O
not	O
found	O
in	O
epidermal	O
or	O
epithelial	O
basement	O
membranes	O
of	O
a	O
variety	O
of	O
tissues	O
tested	O
.	O

Intensity	O
and	O
patterns	O
of	O
localization	O
in	O
blood	O
vessels	O
was	O
consistent	O
in	O
various	O
tissues	O
,	O
but	O
varied	O
among	O
different	O
regions	O
of	O
the	O
vascular	O
bed	O
.	O

Whereas	O
homogeneous	O
and	O
intense	O
immunoreactivity	O
were	O
observed	O
in	O
large	O
and	O
intermediate	O
size	O
blood	O
vessels	O
,	O
heterogeneity	O
of	O
expression	O
was	O
found	O
in	O
capillaries	O
.	O

The	O
most	O
intense	O
immunoreactivity	O
was	O
observed	O
in	O
branching	O
capillaries	O
.	O

Endothelial	O
cell	O
staining	O
was	O
heterogeneous	O
and	O
varied	O
in	O
different	O
regions	O
.	O

Strong	O
staining	O
for	O
bFGF	O
was	O
also	O
found	O
in	O
cardiac	O
muscle	O
fibers	O
,	O
smooth	O
muscle	O
cells	O
of	O
mid	O
-	O
size	O
blood	O
vessels	O
,	O
the	O
gut	O
and	O
the	O
myometrium	O
,	O
in	O
central	O
nervous	O
system	O
neurons	O
and	O
cerebellar	O
Purkinje	O
cells	O
,	O
and	O
on	O
epithelial	O
cells	O
of	O
the	O
bronchi	O
,	O
colon	O
,	O
endometrium	O
,	O
and	O
sweat	O
gland	O
ducts	O
of	O
the	O
skin	O
.	O

The	O
presence	O
of	O
bFGF	O
in	O
the	O
extracellular	O
compartment	O
of	O
a	O
diverse	O
variety	O
of	O
organs	O
may	O
play	O
a	O
role	O
in	O
angiogenesis	O
.	O

However	O
,	O
the	O
function	O
of	O
bFGF	O
in	O
parenchymal	O
cells	O
remains	O
to	O
be	O
determined	O
.	O

Incidence	O
of	O
BRAF	O
p	O
.	O
Val600Glu	O
and	O
p	O
.	O
Val600Lys	O
mutations	O
in	O
a	O
consecutive	O
series	O
of	O
183	O
metastatic	O
melanoma	O
patients	O
from	O
a	O
high	O
incidence	O
region	O
.	O

AIM	O
:	O
Approximately	O
40	O
-	O
60	O
%	O
of	O
melanomas	O
from	O
Caucasian	O
populations	O
carry	O
activating	O
mutations	O
in	O
the	O
BRAF	O
oncogene	O
,	O
with	O
the	O
most	O
common	O
being	O
the	O
p	O
.	O
Val600Glu	O
(	O
V600E	O
)	O
hotspot	O
mutation	O
in	O
exon	O
15	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
frequency	O
of	O
the	O
less	O
common	O
p	O
.	O
Val600Lys	O
(	O
V600	O
K	O
)	O
mutation	O
in	O
metastatic	O
melanoma	O
from	O
a	O
high	O
incidence	O
region	O
.	O

METHOD	O
:	O
Dideoxy	O
sequencing	O
and	O
fluorescent	O
single	O
strand	O
conformation	O
analysis	O
were	O
used	O
to	O
screen	O
for	O
mutations	O
in	O
exon	O
15	O
of	O
BRAF	O
in	O
183	O
cases	O
of	O
metastatic	O
melanoma	O
.	O

RESULTS	O
:	O
The	O
overall	O
incidence	O
of	O
BRAF	O
mutation	O
(	O
89	O
/	O
183	O
,	O
49	O
%	O
)	O
was	O
very	O
similar	O
to	O
other	O
large	O
studies	O
of	O
Caucasian	O
populations	O
.	O

However	O
,	O
the	O
frequency	O
of	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
was	O
higher	O
than	O
in	O
most	O
other	O
studies	O
and	O
comprised	O
almost	O
one	O
-	O
third	O
of	O
all	O
BRAF	O
mutations	O
in	O
our	O
cohort	O
(	O
27	O
/	O
89	O
,	O
30	O
%	O
)	O
.	O

CONCLUSION	O
:	O
BRAF	O
p	O
.	O
Val600Lys	O
mutations	O
were	O
present	O
at	O
a	O
relatively	O
high	O
frequency	O
in	O
this	O
cohort	O
of	O
metastatic	O
melanoma	O
patients	O
(	O
27	O
/	O
183	O
,	O
15	O
%	O
)	O
.	O

Assays	O
used	O
to	O
screen	O
for	O
BRAF	O
mutations	O
in	O
the	O
clinic	O
should	O
be	O
robust	O
enough	O
to	O
detect	O
the	O
p	O
.	O
Val600Lys	O
mutation	O
,	O
as	O
this	O
may	O
have	O
therapeutic	O
implications	O
.	O

[	O
Biotechnological	O
and	O
biomedical	O
aspects	O
of	O
production	O
and	O
study	O
of	O
metal	O
cation	O
-	O
phospholipid	O
complexes	O
]	O
.	O

Problems	O
relating	O
to	O
the	O
technology	O
of	O
a	O
phospholipid	O
preparation	O
from	O
natural	O
materials	O
,	O
liposome	O
production	O
,	O
and	O
studies	O
into	O
the	O
mechanisms	O
of	O
interaction	O
between	O
metal	O
(	O
trace	O
elements	O
)	O
cations	O
and	O
model	O
bilayer	O
lipid	O
membranes	O
are	O
discussed	O
.	O

The	O
proposed	O
technology	O
of	O
extraction	O
allows	O
for	O
preparation	O
of	O
phospholipids	O
utilizable	O
for	O
liposome	O
formation	O
.	O

The	O
cation	O
specificity	O
of	O
lipid	O
bilayers	O
is	O
found	O
to	O
be	O
determined	O
by	O
the	O
presence	O
of	O
anionic	O
phosphate	O
adsorption	O
sites	O
on	O
their	O
surface	O
.	O

Overexpression	O
confers	O
an	O
oncogenic	O
potential	O
upon	O
the	O
eph	O
gene	O
.	O

The	O
eph	O
gene	O
encodes	O
a	O
putative	O
receptor	O
tyrosine	O
kinase	O
for	O
an	O
as	O
yet	O
unknown	O
ligand	O
.	O

Some	O
human	O
cancer	O
cells	O
have	O
been	O
found	O
to	O
overexpress	O
eph	O
mRNAs	O
without	O
gene	O
amplification	O
.	O

We	O
show	O
here	O
that	O
NIH3T3	B
cells	O
acquire	O
tumorigenic	O
ability	O
in	O
nude	O
mice	O
and	O
make	O
colonies	O
in	O
soft	O
agar	O
with	O
a	O
viral	O
LTR	O
(	O
Long	O
Terminal	O
Repeat	O
)	O
-	O
driven	O
artificial	O
expression	O
of	O
the	O
eph	O
gene	O
to	O
a	O
high	O
level	O
.	O

This	O
result	O
supports	O
the	O
alleged	O
contribution	O
of	O
overexpressed	O
receptor	O
tyrosine	O
kinases	O
to	O
cell	O
transformation	O
.	O

The	O
enlarging	O
clinical	O
spectrum	O
of	O
Lyme	O
disease	O
:	O
Lyme	O
cerebral	O
vasculitis	O
,	O
a	O
new	O
disease	O
entity	O
.	O

The	O
case	O
of	O
a	O
patient	O
with	O
cerebral	O
vasculitis	O
with	O
a	O
right	O
thalamic	O
infarct	O
associated	O
with	O
cerebral	O
spinal	O
fluid	O
Lyme	O
disease	O
is	O
presented	O
.	O

This	O
entity	O
has	O
not	O
been	O
described	O
in	O
the	O
United	O
States	O
,	O
and	O
only	O
one	O
similar	O
case	O
in	O
the	O
world	O
literature	O
could	O
be	O
found	O
.	O

The	O
patient	O
presented	O
with	O
a	O
progressive	O
headache	O
and	O
subsequent	O
development	O
of	O
grand	O
mal	O
seizure	O
activity	O
.	O

Lyme	O
disease	O
has	O
been	O
associated	O
with	O
cranial	O
nerve	O
palsies	O
,	O
peripheral	O
and	O
cranial	O
radiculopathies	O
,	O
aseptic	O
meningitis	O
,	O
encephalitic	O
symptoms	O
,	O
chorea	O
,	O
and	O
demyelinating	O
polyneuropathy	O
presenting	O
like	O
Guillain	O
-	O
Barre	O
syndrome	O
.	O

These	O
syndromes	O
can	O
occur	O
separately	O
or	O
in	O
combination	O
.	O

Stroke	O
and	O
strokelike	O
syndromes	O
have	O
been	O
attributed	O
to	O
Lyme	O
disease	O
.	O

The	O
literature	O
concerning	O
the	O
neurologic	O
manifestations	O
of	O
Lyme	O
disease	O
is	O
reviewed	O
.	O

Amplification	O
of	O
mineralocorticoid	O
activity	O
of	O
aldosterone	O
by	O
18	O
-	O
hydroxy	O
-	O
corticosterone	O
and	O
18	O
-	O
hydroxy	O
-	O
19	O
-	O
nor	O
-	O
corticosterone	O
in	O
adrenalectomized	O
rats	O
.	O

A	O
combination	O
of	O
aldosterone	O
(	O
1	O
micrograms	O
)	O
with	O
either	O
18	O
-	O
OH	O
-	O
corticosterone	O
(	O
1	O
micrograms	O
)	O
or	O
18	O
-	O
OH	O
-	O
19	O
-	O
norcorticosterone	O
(	O
1	O
micrograms	O
)	O
injected	O
to	O
adrenalectomized	O
rats	O
indicated	O
an	O
amplification	O
of	O
mineralocorticoid	O
activity	O
as	O
expressed	O
by	O
Na	O
/	O
K	O
ratio	O
in	O
urine	O
.	O

Without	O
aldosterone	O
their	O
mineralocorticoid	O
potency	O
was	O
negligible	O
.	O

Alterations	O
in	O
carbohydrate	O
metabolism	O
in	O
canine	O
lymphoma	O
.	O

Following	O
an	O
overnight	O
fast	O
,	O
blood	O
samples	O
were	O
obtained	O
from	O
14	O
dogs	O
with	O
previously	O
untreated	O
lymphoma	O
before	O
and	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
and	O
90	O
minutes	O
following	O
an	O
intravenous	O
challenge	O
with	O
500	O
mg	O
/	O
kg	O
dextrose	O
.	O

Samples	O
were	O
assayed	O
for	O
glucose	O
,	O
lactate	O
,	O
and	O
insulin	O
concentrations	O
and	O
compared	O
statistically	O
with	O
ten	O
control	O
dogs	O
of	O
similar	O
weight	O
and	O
age	O
undergoing	O
an	O
identical	O
dextrose	O
challenge	O
.	O

Dogs	O
with	O
lymphoma	O
had	O
similar	O
glucose	O
tolerance	O
curves	O
when	O
compared	O
with	O
controls	O
.	O

Lactate	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
all	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
when	O
compared	O
with	O
controls	O
.	O

Rise	O
in	O
lactate	O
concentrations	O
over	O
baseline	O
levels	O
in	O
the	O
first	O
30	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
significantly	O
higher	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Insulin	O
concentrations	O
were	O
significantly	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
at	O
baseline	O
and	O
at	O
the	O
5	O
-	O
,	O
45	O
-	O
,	O
60	O
-	O
,	O
and	O
90	O
-	O
minute	O
time	O
periods	O
of	O
the	O
glucose	O
tolerance	O
test	O
in	O
dogs	O
with	O
lymphoma	O
.	O

Rise	O
in	O
insulin	O
concentrations	O
over	O
baseline	O
in	O
the	O
first	O
5	O
minutes	O
of	O
the	O
glucose	O
tolerance	O
test	O
were	O
also	O
significantly	O
greater	O
in	O
dogs	O
with	O
lymphoma	O
(	O
P	O
=	O
0	O
.	O
021	O
)	O
.	O

These	O
results	O
indicate	O
carbohydrate	O
metabolism	O
is	O
altered	O
in	O
dogs	O
with	O
lymphoma	O
.	O

Many	O
of	O
these	O
alterations	O
parallel	O
those	O
observed	O
in	O
human	O
patients	O
suffering	O
from	O
cancer	O
cachexia	O
making	O
canine	O
lymphoma	O
a	O
potential	O
model	O
for	O
further	O
study	O
of	O
the	O
pathogenesis	O
and	O
therapy	O
of	O
cancer	O
cachexia	O
.	O

Retinal	O
revascularisation	O
in	O
diabetic	O
retinopathy	O
.	O

The	O
case	O
history	O
of	O
a	O
33	O
-	O
year	O
-	O
old	O
diabetic	O
patient	O
who	O
has	O
had	O
diabetes	O
for	O
24	O
years	O
is	O
presented	O
.	O

When	O
first	O
seen	O
in	O
1975	O
he	O
had	O
bilateral	O
proliferative	O
retinopathy	O
with	O
new	O
vessels	O
in	O
the	O
retinal	O
periphery	O
.	O

He	O
had	O
large	O
areas	O
of	O
capillary	O
non	O
-	O
perfusion	O
lateral	O
to	O
the	O
macula	O
in	O
the	O
right	O
eye	O
associated	O
with	O
the	O
new	O
vessels	O
.	O

Nine	O
years	O
later	O
,	O
after	O
extensive	O
repeated	O
photocoagulation	O
,	O
revascularisation	O
of	O
large	O
areas	O
previously	O
not	O
perfused	O
were	O
seen	O
.	O

The	O
vessels	O
are	O
in	O
the	O
plane	O
of	O
the	O
retina	O
and	O
do	O
not	O
have	O
the	O
appearance	O
of	O
new	O
vessels	O
.	O

Members	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
supplant	O
the	O
epidermal	O
growth	O
factor	O
requirement	O
of	O
BALB	O
/	O
MK	O
-	O
2	O
keratinocytes	O
and	O
induce	O
distinct	O
alterations	O
in	O
their	O
terminal	O
differentiation	O
program	O
.	O

BALB	O
-	O
/	O
MK	O
-	O
2	O
mouse	O
epidermal	O
keratinocytes	O
required	O
epidermal	O
growth	O
factor	O
for	O
proliferation	O
and	O
terminally	O
differentiated	O
in	O
response	O
to	O
high	O
Ca2	O
+	O
concentration	O
.	O

Infection	O
with	O
retroviruses	O
containing	O
transforming	O
genes	O
of	O
the	O
src	O
and	O
ras	O
oncogene	O
families	O
led	O
to	O
rapid	O
loss	O
of	O
epidermal	O
growth	O
factor	O
dependence	O
,	O
in	O
some	O
cases	O
,	O
accompanied	O
by	O
alterations	O
in	O
cellular	O
morphology	O
.	O

The	O
virus	O
-	O
altered	O
cells	O
continued	O
to	O
proliferate	O
in	O
the	O
presence	O
of	O
high	O
levels	O
of	O
extracellular	O
calcium	O
but	O
exhibited	O
alterations	O
in	O
normal	O
keratinocyte	O
terminal	O
differentiation	O
that	O
appear	O
to	O
be	O
specific	O
to	O
the	O
particular	O
oncogene	O
.	O

These	O
alterations	O
bore	O
similarities	O
to	O
abnormalities	O
in	O
differentiation	O
observed	O
in	O
naturally	O
occurring	O
squamous	O
epithelial	O
malignancies	O
.	O

Experimental	O
drug	O
therapy	O
of	O
peritumoral	O
brain	O
edema	O
.	O

Four	O
drugs	O
with	O
potential	O
anti	O
-	O
peritumoral	O
brain	O
edema	O
activity	O
were	O
studied	O
using	O
the	O
VX2	O
rabbit	O
brain	O
tumor	O
model	O
.	O

Meclofenamate	O
and	O
indomethacin	O
were	O
tested	O
in	O
an	O
attempt	O
to	O
confirm	O
recent	O
reports	O
of	O
anti	O
-	O
edema	O
activity	O
in	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
'	O
s	O
)	O
.	O

The	O
'	O
angiostatic	O
'	O
steroids	O
17	O
hydroxyprogesterone	O
and	O
epicortisol	O
were	O
tested	O
because	O
of	O
their	O
lack	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
effects	O
and	O
their	O
structural	O
similarity	O
to	O
glucocorticoids	O
.	O

The	O
protein	O
and	O
water	O
component	O
of	O
brain	O
edema	O
were	O
indirectly	O
quantitated	O
.	O

None	O
of	O
the	O
test	O
drugs	O
demonstrated	O
significant	O
anti	O
-	O
edema	O
activity	O
.	O

This	O
work	O
does	O
not	O
confirm	O
reports	O
that	O
NSAID	O
'	O
s	O
have	O
anti	O
-	O
edema	O
activity	O
and	O
suggests	O
that	O
there	O
may	O
be	O
no	O
correlation	O
between	O
'	O
angiostatic	O
'	O
and	O
anti	O
-	O
edema	O
activity	O
in	O
certain	O
steroid	O
compounds	O
.	O

Gastric	O
microcirculatory	O
change	O
and	O
development	O
of	O
acute	O
gastric	O
mucosal	O
lesions	O
(	O
stress	O
ulcer	O
)	O
.	O

Concerning	O
the	O
pathogenesis	O
of	O
acute	O
gastric	O
mucosal	O
lesions	O
,	O
gastric	O
microcirculatory	O
change	O
has	O
drawn	O
attention	O
as	O
an	O
important	O
factor	O
.	O

In	O
view	O
of	O
this	O
fact	O
,	O
gastric	O
mucosal	O
blood	O
flow	O
and	O
microvascular	O
structure	O
were	O
investigated	O
in	O
normal	O
and	O
in	O
burn	O
stressed	O
rats	O
.	O

Moreover	O
,	O
alterations	O
in	O
acid	O
and	O
pepsin	O
activities	O
in	O
by	O
morphological	O
and	O
biochemical	O
procedures	O
in	O
order	O
to	O
evaluate	O
the	O
relationship	O
between	O
defensive	O
and	O
aggressive	O
factors	O
of	O
the	O
gastric	O
mucosa	O
.	O

Gastric	O
mucosal	O
blood	O
flow	O
decreased	O
significantly	O
in	O
early	O
period	O
after	O
induction	O
of	O
stress	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
incidence	O
of	O
ulceration	O
showed	O
a	O
correlative	O
relation	O
with	O
the	O
decrease	O
of	O
mucosal	O
blood	O
flow	O
.	O

Reduction	O
of	O
blood	O
flow	O
in	O
burn	O
was	O
due	O
to	O
opening	O
of	O
arteriovenular	O
shunt	O
and	O
it	O
appeared	O
that	O
this	O
was	O
responsible	O
for	O
mucosal	O
ischemia	O
and	O
congestion	O
.	O

Following	O
the	O
decrease	O
of	O
blood	O
flow	O
,	O
acid	O
output	O
was	O
lower	O
in	O
stress	O
than	O
that	O
in	O
control	O
.	O

Finally	O
,	O
the	O
results	O
of	O
these	O
studies	O
demonstrated	O
the	O
importance	O
of	O
defensive	O
factors	O
.	O

The	O
reduction	O
of	O
mucosal	O
blood	O
flow	O
resulted	O
in	O
the	O
sequence	O
of	O
events	O
that	O
led	O
to	O
formation	O
of	O
acute	O
gastric	O
mucosal	O
lesion	O
.	O

Identification	O
of	O
a	O
small	O
region	O
of	O
the	O
v	O
-	O
fos	O
gene	O
product	O
that	O
is	O
sufficient	O
for	O
transforming	O
potential	O
and	O
growth	O
-	O
stimulating	O
activity	O
.	O

To	O
analyze	O
the	O
structure	O
-	O
function	O
relationship	O
for	O
the	O
v	O
-	O
fos	O
protein	O
,	O
we	O
constructed	O
in	O
-	O
frame	O
insertion	O
and	O
deletion	O
mutants	O
of	O
the	O
v	O
-	O
fos	O
gene	O
carried	O
by	O
FBJ	O
-	O
MuSV	O
,	O
and	O
expressed	O
them	O
in	O
chicken	O
primary	O
cells	O
using	O
retrovirus	O
vectors	O
.	O

We	O
assessed	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
the	O
ability	O
of	O
the	O
v	O
-	O
fos	O
protein	O
to	O
transform	O
chicken	O
embryo	O
fibroblasts	O
and	O
to	O
stimulate	O
cellular	O
proliferation	O
of	O
chicken	O
neuroretinal	O
cells	O
.	O

The	O
mutant	O
which	O
retains	O
only	O
the	O
central	O
region	O
of	O
the	O
v	O
-	O
fos	O
protein	O
(	O
Met111	O
-	O
Ile206	O
)	O
have	O
both	O
activities	O
,	O
but	O
the	O
mutants	O
which	O
have	O
deletions	O
in	O
this	O
region	O
,	O
and	O
one	O
of	O
the	O
mutants	O
that	O
has	O
a	O
four	O
amino	O
acid	O
insertion	O
in	O
it	O
,	O
lost	O
both	O
activities	O
.	O

The	O
central	O
region	O
that	O
is	O
sufficient	O
for	O
these	O
activities	O
includes	O
the	O
evolutionarily	O
highly	O
conserved	O
region	O
among	O
human	O
,	O
mouse	O
and	O
chicken	O
c	O
-	O
fos	O
proteins	O
.	O

Additionally	O
,	O
this	O
sequence	O
shares	O
some	O
homology	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
GCN4	O
and	O
c	O
-	O
jun	O
protein	O
.	O

The	O
truncated	O
fos	O
protein	O
that	O
contains	O
only	O
part	O
of	O
the	O
central	O
region	O
is	O
not	O
phosphorylated	O
in	O
chicken	O
embryo	O
fibroblasts	O
,	O
indicating	O
that	O
phosphorylation	O
of	O
the	O
fos	O
protein	O
is	O
not	O
necessary	O
for	O
the	O
transforming	O
activity	O
.	O

Inhibition	O
by	O
retinoic	O
acid	O
of	O
type	O
IV	O
collagenolysis	O
and	O
invasion	O
through	O
reconstituted	O
basement	O
membrane	O
by	O
metastatic	O
rat	O
mammary	O
adenocarcinoma	O
cells	O
.	O

The	O
activity	O
of	O
type	O
IV	O
collagenase	O
,	O
which	O
enables	O
tumor	O
cells	O
to	O
degrade	O
collagen	O
type	O
IV	O
found	O
in	O
the	O
subendothelial	O
basement	O
membrane	O
,	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
in	O
several	O
tumor	O
types	O
,	O
including	O
the	O
rat	O
13762NF	B
mammary	O
adenocarcinoma	O
cell	O
line	O
and	O
its	O
clones	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
all	O
-	O
trans	O
-	O
RA	O
)	O
and	O
other	O
retinoids	O
,	O
which	O
exhibit	O
antitumor	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
affect	O
the	O
collagenolytic	O
activity	O
of	O
metastatic	O
rat	O
13762NF	B
mammary	O
adenocarcinoma	O
cells	O
.	O

Cells	O
of	O
the	O
highly	O
metastatic	O
lung	O
-	O
colonizing	O
clone	O
MTF7	B
.	I
T35	I
.	I
3	I
,	O
derived	O
from	O
the	O
13762NF	B
cell	O
line	O
,	O
were	O
treated	O
for	O
3	O
days	O
with	O
0	O
.	O
1	O
,	O
1	O
,	O
or	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
,	O
harvested	O
,	O
and	O
seeded	O
on	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
extracellular	O
matrix	O
deposited	O
by	O
cultured	O
rat	O
lung	O
endothelial	O
cells	O
or	O
on	O
a	O
film	O
of	O
purified	O
[	O
3H	O
]	O
proline	O
-	O
labeled	O
type	O
IV	O
collagen	O
.	O

The	O
amount	O
of	O
radioactivity	O
released	O
into	O
the	O
medium	O
during	O
the	O
subsequent	O
24	O
to	O
72	O
h	O
was	O
measured	O
,	O
and	O
it	O
was	O
found	O
that	O
all	O
-	O
trans	O
-	O
RA	O
treatment	O
inhibited	O
degradation	O
of	O
extracellular	O
matrix	O
and	O
type	O
IV	O
collagen	O
by	O
50	O
to	O
60	O
%	O
.	O

This	O
effect	O
was	O
observed	O
whether	O
the	O
cells	O
had	O
been	O
treated	O
with	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
or	O
in	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
or	O
acid	O
-	O
treated	O
fetal	O
bovine	O
serum	O
.	O

The	O
growth	O
of	O
the	O
cells	O
was	O
not	O
inhibited	O
under	O
these	O
conditions	O
,	O
except	O
after	O
treatment	O
with	O
10	O
microM	O
all	O
-	O
trans	O
-	O
RA	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
reduction	O
in	O
collagenolytic	O
activity	O
was	O
observed	O
in	O
viable	O
cells	O
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O

A	O
24	O
-	O
h	O
exposure	O
of	O
cells	O
to	O
all	O
-	O
trans	O
-	O
RA	O
was	O
sufficient	O
to	O
cause	O
a	O
30	O
%	O
decrease	O
in	O
the	O
collagenolytic	O
activity	O
,	O
and	O
this	O
inhibitory	O
effect	O
was	O
reversible	O
.	O

The	O
direct	O
addition	O
of	O
all	O
-	O
trans	O
-	O
RA	O
to	O
conditioned	O
medium	O
had	O
no	O
effect	O
on	O
secreted	O
collagenase	O
activity	O
.	O

The	O
apparent	O
molecular	O
weights	O
of	O
the	O
collagenolytic	O
enzymes	O
were	O
determined	O
by	O
electrophoresis	O
of	O
cell	O
extracts	O
and	O
concentrated	O
conditioned	O
medium	O
in	O
type	O
IV	O
collagen	O
-	O
embedded	O
polyacrylamide	O
gels	O
followed	O
by	O
renaturation	O
and	O
activation	O
of	O
the	O
enzymes	O
within	O
the	O
gels	O
.	O

Two	O
major	O
type	O
IV	O
collagenolytic	O
metalloproteinases	O
exhibiting	O
molecular	O
weights	O
of	O
64	O
,	O
000	O
and	O
88	O
,	O
000	O
,	O
respectively	O
,	O
were	O
detected	O
by	O
this	O
method	O
.	O

These	O
two	O
enzymes	O
were	O
also	O
found	O
to	O
have	O
specificity	O
for	O
gelatin	O
.	O

The	O
Mr	O
64	O
,	O
000	O
enzyme	O
could	O
be	O
extracted	O
from	O
viable	O
cells	O
(	O
presumably	O
from	O
the	O
cell	O
membrane	O
)	O
by	O
2	O
%	O
1	O
-	O
butanol	O
.	O

Treatment	O
with	O
all	O
-	O
trans	O
-	O
RA	O
decreased	O
the	O
level	O
of	O
these	O
enzymes	O
in	O
the	O
cellular	O
,	O
cell	O
membrane	O
,	O
and	O
conditioned	O
medium	O
compartments	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Type	O
-	O
A	O
cholecystokinin	O
receptors	O
in	O
CHP212	B
neuroblastoma	O
cells	O
:	O
evidence	O
for	O
association	O
with	O
G	O
protein	O
and	O
activation	O
of	O
phosphoinositide	O
hydrolysis	O
.	O

125I	O
-	O
Bolton	O
Hunter	O
-	O
cholecystokinin	O
octapeptide	O
(	O
BH	O
-	O
CCK8	O
)	O
and	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
membrane	O
binding	O
assays	O
were	O
used	O
to	O
identify	O
and	O
characterize	O
cholecystokinin	O
(	O
CCK	O
)	O
receptors	O
in	O
CHP212	B
human	O
neuroblastoma	O
cells	O
.	O

The	O
ligand	O
binding	O
properties	O
of	O
CCK	O
receptors	O
in	O
these	O
cells	O
are	O
similar	O
to	O
those	O
found	O
in	O
pancreas	O
(	O
CCK	O
-	O
A	O
sites	O
)	O
and	O
differ	O
from	O
the	O
predominant	O
type	O
of	O
CCK	O
binding	O
site	O
found	O
in	O
brain	O
(	O
CCK	O
-	O
B	O
sites	O
)	O
.	O

The	O
specific	O
binding	O
of	O
125I	O
-	O
BH	O
-	O
CCK8	O
but	O
not	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
was	O
reduced	O
by	O
the	O
metabolically	O
stable	O
GTP	O
analog	O
guanosine	O
5	O
'	O
-	O
(	O
beta	O
-	O
delta	O
-	O
imido	O
)	O
trisphosphate	O
.	O

A	O
substantial	O
difference	O
in	O
the	O
Bmax	O
for	O
the	O
radiolabeled	O
agonist	O
(	O
125I	O
-	O
BH	O
-	O
CCK8	O
)	O
and	O
antagonist	O
[	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
]	O
was	O
noted	O
.	O

These	O
observations	O
are	O
consistent	O
with	O
CCK	O
receptors	O
existing	O
in	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
-	O
coupled	O
and	O
-	O
uncoupled	O
states	O
.	O

Similar	O
to	O
its	O
action	O
in	O
pancreatic	O
acinar	O
cells	O
,	O
CCK8	O
(	O
S	O
)	O
stimulated	O
the	O
accumulation	O
of	O
[	O
3H	O
]	O
inositol	O
phosphates	O
in	O
cells	O
prelabeled	O
with	O
[	O
3H	O
]	O
myo	O
-	O
inositol	O
(	O
EC50	O
=	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
;	O
maximum	O
response	O
=	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
x	O
basal	O
)	O
.	O

The	O
intrinsic	O
activity	O
of	O
CCK	O
analogues	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
was	O
substantially	O
less	O
than	O
their	O
reported	O
intrinsic	O
activity	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
in	O
pancreatic	O
acinar	O
cells	O
.	O

The	O
CHP212	B
neuroblastoma	O
cell	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
the	O
recently	O
reported	O
CCK	O
-	O
A	O
binding	O
site	O
found	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Energy	O
supply	O
of	O
the	O
mitotic	O
cell	O
cycle	O
and	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
in	O
ascites	O
tumors	O
.	O

The	O
activation	O
of	O
Na	O
+	O
transport	O
is	O
due	O
to	O
the	O
exchange	O
of	O
protons	O
formed	O
via	O
glucose	O
conversion	O
into	O
lactate	O
for	O
Na	O
+	O
,	O
i	O
.	O
e	O
.	O
,	O
to	O
the	O
stimulation	O
of	O
the	O
Na	O
+	O
/	O
H	O
+	O
-	O
antiport	O
.	O

Experimental	O
results	O
and	O
theoretical	O
calculations	O
suggest	O
that	O
in	O
glucose	O
-	O
containing	O
medium	O
the	O
Na	O
+	O
transport	O
increases	O
from	O
0	O
.	O
75	O
to	O
1	O
.	O
78	O
pmol	O
/	O
hour	O
per	O
cell	O
.	O

The	O
permeability	O
of	O
plasma	O
membranes	O
for	O
K	O
+	O
increases	O
2	O
.	O
75	O
fold	O
,	O
while	O
the	O
passive	O
flux	O
of	O
Na	O
+	O
diminishes	O
.	O

The	O
intensity	O
of	O
O2	O
adsorption	O
by	O
ascites	O
tumor	O
cells	O
does	O
not	O
practically	O
depend	O
on	O
the	O
monovalent	O
cation	O
concentration	O
gradient	O
between	O
the	O
cells	O
and	O
the	O
culture	O
medium	O
,	O
whereas	O
the	O
rate	O
of	O
glycolysis	O
decreases	O
simultaneously	O
with	O
the	O
diminution	O
of	O
the	O
concentration	O
gradient	O
.	O

In	O
synchronized	O
cultures	O
at	O
the	O
beginning	O
of	O
the	O
mitotic	O
cycle	O
,	O
the	O
bulk	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
the	O
synthesis	O
of	O
biopolymers	O
,	O
whereas	O
that	O
at	O
the	O
end	O
of	O
the	O
S	O
-	O
phase	O
and	O
in	O
the	O
G2	O
-	O
phase	O
is	O
utilized	O
for	O
cation	O
transport	O
across	O
plasma	O
membranes	O
.	O

From	O
35	O
to	O
100	O
%	O
of	O
the	O
whole	O
amount	O
of	O
ATP	O
resynthesized	O
via	O
glycolysis	O
is	O
utilized	O
for	O
transport	O
purposes	O
.	O

It	O
is	O
concluded	O
that	O
the	O
observed	O
increase	O
in	O
the	O
Na	O
+	O
/	O
K	O
+	O
ratio	O
in	O
ascites	O
tumor	O
cells	O
is	O
connected	O
with	O
their	O
enhanced	O
ability	O
to	O
synthesize	O
lactic	O
acid	O
.	O

Presumably	O
,	O
glycolysis	O
is	O
one	O
of	O
the	O
regulatory	O
mechanisms	O
of	O
intracellular	O
ratios	O
of	O
monovalent	O
cations	O
.	O

Endoscopic	O
injection	O
therapy	O
for	O
acute	O
upper	O
GI	O
bleeding	O
.	O

In	O
summary	O
,	O
we	O
have	O
found	O
this	O
technique	O
to	O
be	O
useful	O
in	O
patients	O
in	O
whom	O
coagulation	O
therapy	O
is	O
not	O
possible	O
or	O
effective	O
.	O

It	O
must	O
still	O
be	O
considered	O
a	O
technique	O
which	O
is	O
undergoing	O
evaluation	O
.	O

Prospective	O
randomized	O
trials	O
comparing	O
this	O
therapy	O
with	O
other	O
currently	O
available	O
therapies	O
such	O
a	O
electrocoagulation	O
,	O
laser	O
and	O
conservative	O
management	O
must	O
be	O
completed	O
to	O
firmly	O
define	O
its	O
place	O
in	O
treatment	O
strategy	O
for	O
acute	O
upper	O
GI	O
bleeding	O
.	O

Screening	O
method	O
for	O
insecticidal	O
activity	O
using	O
first	O
instars	O
of	O
black	O
blow	O
fly	O
(	O
Diptera	O
:	O
Calliphoridae	O
)	O
.	O

A	O
bioassay	O
method	O
suitable	O
for	O
rapid	O
mass	O
screening	O
of	O
fermentation	O
and	O
synthetic	O
organic	O
compounds	O
for	O
insecticidal	O
activity	O
is	O
described	O
.	O

The	O
test	O
,	O
which	O
uses	O
first	O
instars	O
of	O
susceptible	O
black	O
blow	O
fly	O
,	O
Phormia	O
regina	O
(	O
Meigen	O
)	O
,	O
in	O
a	O
bovine	O
serum	O
medium	O
,	O
detects	O
insecticidal	O
activity	O
with	O
reproducible	O
results	O
.	O

It	O
is	O
capable	O
of	O
selecting	O
the	O
most	O
active	O
compound	O
in	O
structure	O
-	O
activity	O
relationships	O
by	O
minimum	O
effective	O
dose	O
concentration	O
studies	O
.	O

The	O
bioassay	O
system	O
is	O
easy	O
to	O
operate	O
and	O
requires	O
only	O
a	O
minute	O
quantity	O
of	O
chemical	O
compound	O
.	O

Osteonectin	O
transcript	O
and	O
metastatic	O
behavior	O
in	O
v	O
-	O
Ki	O
-	O
ras	O
transformed	O
fibroblasts	O
.	O

Osteonectin	O
is	O
one	O
of	O
the	O
major	O
non	O
-	O
collagenous	O
proteins	O
of	O
bone	O
.	O

However	O
,	O
its	O
transcript	O
has	O
been	O
found	O
in	O
many	O
soft	O
,	O
extracellular	O
matrix	O
-	O
producing	O
tissues	O
;	O
an	O
osteonectin	O
-	O
related	O
protein	O
was	O
detected	O
in	O
tumor	O
basement	O
membrane	O
.	O

We	O
have	O
investigated	O
the	O
expression	O
of	O
osteonectin	O
gene	O
in	O
fresh	O
BALB	B
/	I
c	I
fibroblasts	O
transformed	O
by	O
v	O
-	O
Ki	O
-	O
ras	O
.	O

Transformed	O
cells	O
exhibited	O
lower	O
levels	O
of	O
RNA	O
as	O
compared	O
with	O
normal	O
fibroblasts	O
.	O

The	O
transformed	O
cells	O
were	O
cloned	O
after	O
in	O
vivo	O
tumorigenic	O
assay	O
,	O
and	O
4	O
clones	O
were	O
analyzed	O
for	O
osteonectin	O
expression	O
by	O
Northern	O
blots	O
.	O

Two	O
of	O
them	O
were	O
selected	O
for	O
high	O
or	O
low	O
osteonectin	O
expression	O
and	O
tested	O
in	O
vivo	O
in	O
spontaneous	O
and	O
artificial	O
metastasis	O
assays	O
.	O

High	O
osteonectin	O
expression	O
was	O
correlated	O
with	O
high	O
lung	O
colonization	O
.	O

When	O
10	O
(	O
5	O
)	O
cells	O
were	O
injected	O
i	O
.	O
v	O
.	O
,	O
median	O
colony	O
value	O
was	O
55	O
and	O
20	O
in	O
higher	O
expressor	O
vs	O
.	O
lower	O
expressor	O
respectively	O
(	O
p	O
less	O
than	O
0	O
.	O
005	O
)	O
.	O

Spontaneous	O
metastasis	O
indicates	O
a	O
possible	O
reverse	O
correlation	O
.	O

Our	O
data	O
align	O
osteonectin	O
with	O
other	O
matrix	O
-	O
components	O
and	O
adhesion	O
molecules	O
in	O
affecting	O
potential	O
metastatic	O
spreading	O
of	O
transformed	O
cells	O
.	O

Early	O
post	O
-	O
mortem	O
metabolism	O
and	O
muscle	O
shortening	O
in	O
the	O
Pectoralis	O
major	O
muscle	O
of	O
broiler	O
chickens	O
.	O

Three	O
experiments	O
were	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
sodium	O
pentobarbital	O
(	O
SP	O
)	O
,	O
iodoacetate	O
(	O
IO	O
)	O
,	O
tubocurarine	O
(	O
TC	O
)	O
,	O
and	O
surgical	O
denervation	O
(	O
DN	O
)	O
on	O
early	O
rigor	O
development	O
in	O
broiler	O
breast	O
muscle	O
.	O

In	O
Experiment	O
1	O
,	O
birds	O
were	O
either	O
anesthetized	O
or	O
not	O
with	O
SP	O
before	O
receiving	O
an	O
injection	O
of	O
IO	O
or	O
TC	O
or	O
maintained	O
as	O
noninjected	O
controls	O
.	O

Experiment	O
2	O
was	O
identical	O
except	O
that	O
a	O
treatment	O
of	O
denervation	O
of	O
the	O
breast	O
muscle	O
was	O
added	O
.	O

Experiment	O
3	O
was	O
conducted	O
to	O
contrast	O
birds	O
at	O
1	O
day	O
(	O
DN1	O
)	O
and	O
3	O
days	O
(	O
DN3	O
)	O
denervation	O
prior	O
to	O
slaughter	O
to	O
nonoperated	O
controls	O
.	O

Measurements	O
of	O
muscle	O
lactate	O
,	O
ATP	O
,	O
R	O
value	O
(	O
ratio	O
of	O
inosine	O
to	O
adenine	O
nucleotides	O
)	O
,	O
pH	O
,	O
sarcomere	O
lengths	O
,	O
and	O
shear	O
were	O
used	O
to	O
evaluate	O
treatment	O
effects	O
.	O

Results	O
for	O
Experiment	O
1	O
showed	O
no	O
significant	O
differences	O
among	O
treatment	O
and	O
control	O
groups	O
for	O
ATP	O
and	O
lactate	O
contents	O
,	O
R	O
values	O
,	O
or	O
sarcomere	O
lengths	O
;	O
however	O
,	O
significantly	O
lower	O
pH	O
and	O
higher	O
shear	O
values	O
were	O
observed	O
for	O
control	O
birds	O
.	O

In	O
Experiment	O
2	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
among	O
the	O
treatment	O
groups	O
for	O
ATP	O
,	O
R	O
values	O
,	O
or	O
sarcomere	O
lengths	O
.	O

However	O
,	O
lactate	O
and	O
shear	O
values	O
were	O
significantly	O
lower	O
,	O
and	O
pH	O
higher	O
,	O
for	O
the	O
DN	O
and	O
SP	O
treated	O
birds	O
.	O

Experiment	O
3	O
resulted	O
in	O
lower	O
lactate	O
and	O
higher	O
pH	O
values	O
for	O
the	O
DN3	O
treatment	O
in	O
comparison	O
with	O
both	O
DN1	O
and	O
control	O
groups	O
.	O

Results	O
of	O
these	O
studies	O
indicate	O
that	O
the	O
use	O
of	O
SP	O
and	O
DN	O
can	O
be	O
used	O
to	O
alter	O
the	O
early	O
profiles	O
of	O
rigor	O
development	O
.	O

Effects	O
of	O
hypertension	O
and	O
sympathetic	O
denervation	O
on	O
cerebral	O
blood	O
flow	O
in	O
newborn	O
pigs	O
.	O

To	O
investigate	O
the	O
potential	O
role	O
of	O
sympathetic	O
nerves	O
in	O
preventing	O
pronounced	O
increases	O
in	O
cerebral	O
blood	O
flow	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
abrupt	O
hypertension	O
on	O
the	O
cerebral	O
circulation	O
of	O
newborn	O
pigs	O
with	O
intact	O
cerebral	O
sympathetic	O
innervation	O
and	O
after	O
cerebral	O
sympathetic	O
denervation	O
.	O

Epinephrine	O
infusion	O
was	O
used	O
to	O
induce	O
abrupt	O
increases	O
in	O
mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
arterial	O
pressure	O
(	O
innervated	O
pigs	O
,	O
62	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
to	O
115	O
+	O
/	O
-	O
3	O
mm	O
of	O
Hg	O
;	O
denervated	O
pigs	O
,	O
71	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
to	O
132	O
+	O
/	O
-	O
4	O
mm	O
of	O
Hg	O
)	O
that	O
remained	O
increased	O
for	O
the	O
3	O
minutes	O
of	O
the	O
study	O
.	O

Abrupt	O
hypertension	O
increased	O
blood	O
flow	O
to	O
all	O
brain	O
regions	O
.	O

In	O
denervated	O
pigs	O
,	O
the	O
increased	O
flow	O
to	O
the	O
cerebrum	O
was	O
prolonged	O
,	O
compared	O
with	O
that	O
in	O
pigs	O
with	O
intact	O
sympathetic	O
innervation	O
.	O

Differences	O
between	O
pigs	O
of	O
the	O
innervated	O
and	O
denervated	O
groups	O
were	O
not	O
apparent	O
,	O
with	O
respect	O
to	O
blood	O
flow	O
to	O
any	O
other	O
region	O
(	O
caudate	O
region	O
,	O
brain	O
stem	O
,	O
cerebellum	O
)	O
.	O

In	O
newborn	O
pigs	O
,	O
sympathetic	O
nerves	O
may	O
attenuate	O
hypertension	O
-	O
induced	O
increases	O
in	O
blood	O
flow	O
to	O
the	O
cerebrum	O
,	O
but	O
do	O
not	O
appear	O
to	O
affect	O
flow	O
to	O
the	O
rest	O
of	O
the	O
brain	O
.	O

[	O
Tumor	O
metastasis	O
and	O
the	O
fibrinolytic	O
system	O
]	O
.	O

Metastatic	O
spread	O
of	O
malignant	O
tumor	O
appears	O
to	O
correlate	O
with	O
activation	O
of	O
the	O
fibrolytic	O
system	O
.	O

The	O
role	O
of	O
fibrinolysis	O
in	O
growth	O
and	O
metastasis	O
was	O
examined	O
in	O
Lewis	O
lung	O
carcinoma	O
of	O
mice	O
.	O

The	O
inhibition	O
of	O
fibrinolysis	O
or	O
proteases	O
decreased	O
the	O
primary	O
tumor	O
growth	O
and	O
pulmonary	O
metastasis	O
,	O
whereas	O
the	O
activation	O
of	O
fibrinolysis	O
or	O
proteases	O
increased	O
the	O
number	O
of	O
metastatic	O
foci	O
in	O
the	O
lung	O
.	O

Electronmicroscopically	O
,	O
thrombus	O
formation	O
in	O
the	O
primary	O
site	O
prevented	O
tumor	O
invasion	O
and	O
metastasis	O
formation	O
.	O

Plasminogen	O
activator	O
(	O
PA	O
)	O
content	O
of	O
excised	O
tumors	O
was	O
determined	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
major	O
PA	O
was	O
found	O
to	O
be	O
urokinase	O
(	O
UK	O
)	O
type	O
.	O

Immunohistochemical	O
study	O
with	O
specific	O
antisera	O
was	O
done	O
.	O

When	O
tumor	O
cells	O
possessed	O
a	O
high	O
level	O
of	O
UK	O
,	O
laminin	O
and	O
type	O
IV	O
collagen	O
,	O
components	O
of	O
the	O
basement	O
membrane	O
,	O
disappeared	O
from	O
tumor	O
tissues	O
.	O

These	O
findings	O
suggest	O
that	O
PA	O
through	O
protease	O
cascade	O
plays	O
a	O
role	O
in	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Clinically	O
,	O
patients	O
with	O
advanced	O
cancer	O
are	O
usually	O
in	O
a	O
hypercoagulable	O
state	O
with	O
elevated	O
fibrinogen	O
,	O
and	O
fibrin	O
deposition	O
around	O
tumor	O
mass	O
is	O
a	O
serious	O
problem	O
in	O
cancer	O
chemotherapy	O
.	O

UK	O
infusion	O
prior	O
to	O
5	O
-	O
fluorouracil	O
increased	O
tissue	O
concentration	O
of	O
antitumor	O
agent	O
.	O

However	O
,	O
development	O
of	O
consumption	O
coagulopathy	O
characterized	O
by	O
progression	O
from	O
hypercoagulable	O
state	O
to	O
disseminated	O
intravascular	O
coagulation	O
has	O
also	O
been	O
found	O
in	O
several	O
cases	O
.	O

[	O
Intraepithelial	O
neoplasm	O
of	O
the	O
uterine	O
cervix	O
and	O
angiogenesis	O
:	O
morphologic	O
study	O
]	O

Thirty	O
uterine	O
cervix	O
specimens	O
sampled	O
following	O
conization	O
or	O
total	O
hysterectomy	O
were	O
studied	O
using	O
histology	O
,	O
histoenzymology	O
(	O
vessel	O
phosphatase	O
alkaline	O
activity	O
)	O
,	O
and	O
immunohistochemistry	O
(	O
demonstration	O
of	O
laminin	O
and	O
type	O
IV	O
collagen	O
in	O
epithelium	O
and	O
vessel	O
basement	O
membranes	O
)	O
.	O

Pathologic	O
conditions	O
included	O
dystrophia	O
,	O
moderate	O
dysplasia	O
,	O
severe	O
dysplasia	O
,	O
and	O
intraepithelial	O
carcinoma	O
.	O

Results	O
were	O
compared	O
to	O
findings	O
in	O
a	O
control	O
group	O
.	O

We	O
found	O
that	O
the	O
severity	O
of	O
vascular	O
abnormalities	O
correlated	O
positively	O
with	O
the	O
severity	O
of	O
histologic	O
epithelial	O
lesions	O
;	O
this	O
finding	O
is	O
consistent	O
with	O
colposcopic	O
results	O
.	O

Anarchic	O
angiogenesis	O
with	O
large	O
,	O
moniliform	O
,	O
tortuous	O
vessels	O
was	O
seen	O
in	O
severe	O
dysplasias	O
and	O
carcinomas	O
.	O

The	O
vascular	O
anomalies	O
seem	O
to	O
precede	O
the	O
development	O
of	O
histologic	O
lesions	O
in	O
some	O
instances	O
.	O

Histogenesis	O
of	O
the	O
abnormal	O
vessels	O
may	O
involve	O
production	O
of	O
an	O
angiogenic	O
factor	O
by	O
the	O
cancerized	O
epithelia	O
.	O

Glycolysis	O
and	O
glutaminolysis	O
in	O
perifused	O
Ehrlich	O
ascites	O
tumour	O
cells	O
.	O

A	O
perifusion	O
system	O
was	O
designed	O
in	O
order	O
to	O
study	O
glucose	O
and	O
glutamine	O
metabolism	O
by	O
freshly	O
harvested	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
steady	O
state	O
conditions	O
.	O

Cells	O
were	O
perifused	O
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
,	O
0	O
.	O
5	O
mM	O
glutamine	O
or	O
5	O
mM	O
glucose	O
and	O
0	O
.	O
5	O
mM	O
glutamine	O
.	O

The	O
results	O
in	O
steady	O
state	O
reveal	O
that	O
both	O
substrates	O
glucose	O
and	O
glutamine	O
are	O
continuously	O
wasted	O
by	O
tumour	O
cells	O
,	O
excreting	O
two	O
moles	O
of	O
lactate	O
per	O
mol	O
of	O
glucose	O
and	O
one	O
mol	O
of	O
glutamate	O
and	O
ammonia	O
per	O
mol	O
of	O
glutamine	O
consumed	O
into	O
the	O
medium	O
.	O

Glutamine	O
consumption	O
in	O
the	O
presence	O
of	O
glucose	O
was	O
higher	O
than	O
with	O
glutamine	O
alone	O
.	O

Invagination	O
of	O
the	O
otic	O
placode	O
:	O
normal	O
development	O
and	O
experimental	O
manipulation	O
.	O

The	O
inner	O
ear	O
forms	O
from	O
paired	O
ectodermal	O
primordia	O
that	O
lie	O
to	O
either	O
side	O
of	O
the	O
developing	O
hindbrain	O
.	O

Initially	O
each	O
primordium	O
forms	O
a	O
shallow	O
depression	O
in	O
the	O
ectodermal	O
surface	O
.	O

Invagination	O
to	O
form	O
an	O
otic	O
pit	O
coincides	O
with	O
the	O
formation	O
of	O
several	O
deep	O
folds	O
in	O
the	O
epithelial	O
surface	O
.	O

An	O
initial	O
fold	O
appears	O
parallel	O
to	O
the	O
embryonic	O
axis	O
and	O
at	O
the	O
junction	O
of	O
the	O
rhombencephalon	O
with	O
somitomeric	O
mesoderm	O
.	O

This	O
is	O
followed	O
by	O
formation	O
of	O
cranial	O
and	O
caudal	O
folds	O
perpendicular	O
to	O
the	O
axis	O
and	O
minor	O
folds	O
that	O
are	O
within	O
the	O
pit	O
formed	O
by	O
earlier	O
folding	O
.	O

The	O
central	O
region	O
of	O
the	O
otic	O
primordium	O
remains	O
in	O
close	O
apposition	O
to	O
the	O
lateral	O
surface	O
of	O
the	O
neural	O
tube	O
during	O
the	O
process	O
of	O
fold	O
formation	O
,	O
until	O
the	O
otic	O
pit	O
becomes	O
quite	O
deep	O
.	O

At	O
that	O
time	O
,	O
mesenchymal	O
cells	O
penetrate	O
between	O
the	O
two	O
layers	O
.	O

Experimental	O
analysis	O
of	O
invagination	O
supports	O
the	O
conclusion	O
that	O
otic	O
invagination	O
is	O
controlled	O
differently	O
from	O
that	O
of	O
similar	O
organ	O
primordia	O
,	O
such	O
as	O
the	O
eye	O
and	O
thyroid	O
.	O

Whereas	O
these	O
other	O
primordia	O
can	O
be	O
stimulated	O
to	O
undergo	O
normal	O
morphogenetic	O
shape	O
changes	O
precociously	O
by	O
treatments	O
that	O
presumably	O
activate	O
motile	O
processes	O
in	O
the	O
cytoskeleton	O
,	O
the	O
same	O
conditions	O
have	O
little	O
effect	O
on	O
the	O
otic	O
placode	O
.	O

Similarly	O
,	O
neither	O
inhibitors	O
of	O
calcium	O
transport	O
nor	O
inactivators	O
of	O
calmodulin	O
activity	O
prevent	O
otic	O
pit	O
formation	O
,	O
while	O
these	O
drugs	O
block	O
invagination	O
of	O
other	O
primordia	O
.	O

These	O
results	O
suggest	O
that	O
otic	O
invagination	O
may	O
be	O
caused	O
by	O
changes	O
in	O
the	O
surrounding	O
tissues	O
rather	O
than	O
by	O
an	O
activation	O
of	O
motility	O
within	O
the	O
primordium	O
.	O

Anaplastic	O
and	O
sarcomatoid	O
carcinoma	O
of	O
the	O
small	O
intestine	O
:	O
a	O
clinicopathologic	O
study	O
.	O

Carcinomas	O
involving	O
the	O
jejunum	O
and	O
ileum	O
are	O
rare	O
tumors	O
.	O

During	O
a	O
review	O
of	O
small	O
intestinal	O
neoplasms	O
,	O
six	O
primary	O
carcinomas	O
of	O
jejunum	O
or	O
ileum	O
with	O
an	O
anaplastic	O
and	O
sarcomatoid	O
histology	O
were	O
identified	O
.	O

At	O
presentation	O
,	O
three	O
of	O
the	O
patients	O
had	O
symptoms	O
related	O
to	O
metastatic	O
disease	O
and	O
three	O
had	O
symptoms	O
referable	O
to	O
the	O
local	O
tumor	O
.	O

The	O
tumors	O
were	O
large	O
(	O
greater	O
than	O
4	O
.	O
5	O
cm	O
in	O
diameter	O
)	O
,	O
usually	O
endophytic	O
masses	O
composed	O
of	O
large	O
cells	O
with	O
eosinophilic	O
cytoplasm	O
,	O
anaplastic	O
nuclei	O
,	O
and	O
prominent	O
nucleoli	O
.	O

In	O
many	O
areas	O
,	O
the	O
cells	O
had	O
a	O
spindled	O
configuration	O
.	O

Mucin	O
positivity	O
was	O
identified	O
in	O
all	O
six	O
cases	O
.	O

Electron	O
microscopic	O
findings	O
in	O
two	O
cases	O
were	O
indicative	O
of	O
epithelial	O
differentiation	O
.	O

The	O
tumors	O
behaved	O
aggressively	O
;	O
all	O
five	O
patients	O
for	O
whom	O
there	O
was	O
clinical	O
follow	O
-	O
up	O
died	O
of	O
metastases	O
within	O
40	O
months	O
.	O

The	O
six	O
anaplastic	O
and	O
sarcomatoid	O
carcinomas	O
were	O
compared	O
with	O
29	O
typical	O
adenocarcinomas	O
arising	O
in	O
the	O
jejunum	O
or	O
ileum	O
.	O

Only	O
two	O
of	O
the	O
latter	O
group	O
had	O
symptoms	O
referable	O
to	O
distant	O
metastases	O
at	O
presentation	O
.	O

These	O
tumors	O
also	O
tended	O
to	O
be	O
smaller	O
at	O
presentation	O
(	O
11	O
tumors	O
were	O
less	O
than	O
4	O
cm	O
in	O
greatest	O
dimension	O
)	O
.	O

Of	O
25	O
patients	O
with	O
typical	O
adenocarcinomas	O
who	O
had	O
acceptable	O
follow	O
-	O
up	O
,	O
18	O
(	O
72	O
%	O
)	O
died	O
of	O
disease	O
and	O
five	O
(	O
20	O
%	O
)	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
after	O
5	O
years	O
.	O

We	O
conclude	O
that	O
anaplastic	O
and	O
sarcomatoid	O
carcinoma	O
is	O
a	O
rare	O
variant	O
of	O
small	O
intestinal	O
carcinoma	O
with	O
an	O
aggressive	O
clinical	O
course	O
.	O

Time	O
course	O
of	O
transmitter	O
action	O
at	O
the	O
sympathetic	O
neuroeffector	O
junction	O
in	O
rodent	O
vascular	O
and	O
non	O
-	O
vascular	O
smooth	O
muscle	O
.	O

1	O
.	O

Transmitter	O
release	O
from	O
sympathetic	O
postganglionic	O
nerve	O
terminals	O
innervating	O
the	O
guinea	O
-	O
pig	O
and	O
mouse	O
vas	O
deferens	O
and	O
the	O
rat	O
tail	O
artery	O
has	O
been	O
studied	O
in	O
vitro	O
by	O
focal	O
extracellular	O
recording	O
with	O
particular	O
emphasis	O
on	O
the	O
time	O
course	O
of	O
transmitter	O
action	O
underlying	O
the	O
intracellular	O
potential	O
changes	O
.	O

2	O
.	O

In	O
the	O
absence	O
of	O
stimulation	O
,	O
spontaneous	O
excitatory	O
junction	O
currents	O
(	O
SEJCs	O
)	O
were	O
recorded	O
with	O
amplitudes	O
up	O
to	O
500	O
microV	O
and	O
durations	O
between	O
40	O
and	O
100	O
ms	O
.	O

SEJCs	O
were	O
unaffected	O
by	O
the	O
competitive	O
alpha	O
-	O
adrenoceptor	O
antagonist	O
prazosin	O
but	O
blocked	O
by	O
alpha	O
,	O
beta	O
-	O
methylene	O
ATP	O
which	O
desensitizes	O
P2	O
-	O
purinoceptors	O
.	O

3	O
.	O

During	O
trains	O
of	O
supramaximal	O
stimuli	O
at	O
0	O
.	O
1	O
-	O
4	O
Hz	O
stimulus	O
locked	O
excitatory	O
junction	O
currents	O
(	O
EJCs	O
)	O
were	O
evoked	O
intermittently	O
from	O
the	O
population	O
of	O
varicosities	O
located	O
under	O
the	O
suction	O
electrode	O
.	O

4	O
.	O

SEJCs	O
were	O
similar	O
in	O
amplitude	O
and	O
time	O
course	O
to	O
EJCs	O
evoked	O
by	O
low	O
-	O
frequency	O
stimulation	O
in	O
the	O
same	O
attachment	O
in	O
all	O
three	O
tissues	O
.	O

5	O
.	O

SEJCs	O
recorded	O
using	O
either	O
a	O
conventional	O
AC	O
amplifier	O
or	O
a	O
patch	O
clamp	O
amplifier	O
had	O
the	O
same	O
time	O
course	O
.	O

6	O
.	O

These	O
studies	O
show	O
that	O
the	O
time	O
course	O
of	O
the	O
current	O
underlying	O
the	O
excitatory	O
junction	O
potential	O
is	O
brief	O
and	O
essentially	O
the	O
same	O
in	O
three	O
different	O
tissues	O
.	O

The	O
prolonged	O
time	O
course	O
of	O
the	O
excitatory	O
junction	O
potential	O
in	O
different	O
tissues	O
can	O
be	O
accounted	O
for	O
by	O
the	O
passive	O
membrane	O
properties	O
.	O

Phase	O
II	O
trial	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
in	O
prostatic	O
carcinoma	O
:	O
comparison	O
with	O
other	O
hormonal	O
agents	O
.	O

Various	O
approaches	O
to	O
hormonal	O
treatment	O
of	O
prostate	O
carcinoma	O
are	O
discussed	O
.	O

Eighty	O
-	O
one	O
patients	O
with	O
prostatic	O
carcinoma	O
,	O
eight	O
with	O
stage	O
B	O
,	O
nine	O
with	O
stage	O
C	O
,	O
and	O
64	O
with	O
stage	O
D	O
disease	O
,	O
were	O
treated	O
subcutaneously	O
daily	O
for	O
3	O
months	O
with	O
the	O
LH	O
-	O
RH	O
agonist	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
Decapeptyl	O
)	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
remissions	O
according	O
to	O
WHO	O
recommendations	O
for	O
oncologic	O
trials	O
.	O

The	O
findings	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
other	O
hormonal	O
therapies	O
of	O
prostatic	O
carcinoma	O
according	O
to	O
the	O
statistical	O
method	O
of	O
""""	O
expected	O
response	O
rate	O
""""	O
as	O
adapted	O
by	O
Lee	O
and	O
Wesley	O
for	O
phase	O
II	O
trials	O
.	O

Treatment	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
greatly	O
reduced	O
serum	O
LH	O
and	O
testosterone	O
levels	O
without	O
raising	O
serum	O
prolactin	O
.	O

After	O
1	O
-	O
2	O
weeks	O
of	O
therapy	O
,	O
there	O
was	O
relief	O
of	O
subjective	O
symptoms	O
and	O
a	O
reversal	O
of	O
the	O
signs	O
of	O
prostatism	O
as	O
well	O
as	O
a	O
marked	O
decrease	O
in	O
bone	O
pain	O
.	O

At	O
90	O
days	O
52	O
patients	O
had	O
complete	O
relief	O
of	O
prostatism	O
and	O
21	O
had	O
only	O
mild	O
signs	O
and	O
symptoms	O
.	O

Seventy	O
patients	O
were	O
experiencing	O
no	O
bone	O
pain	O
and	O
an	O
additional	O
six	O
had	O
only	O
mild	O
pain	O
.	O

Prostatic	O
size	O
,	O
evaluated	O
by	O
rectal	O
examination	O
and	O
transabdominal	O
ultrasonography	O
,	O
reverted	O
to	O
normal	O
in	O
26	O
.	O
4	O
%	O
of	O
patients	O
(	O
complete	O
remission	O
)	O
and	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
in	O
an	O
additional	O
17	O
.	O
6	O
%	O
(	O
partial	O
remission	O
)	O
,	O
the	O
overall	O
rate	O
of	O
complete	O
plus	O
partial	O
regression	O
of	O
prostatic	O
enlargement	O
being	O
44	O
%	O
.	O

Scans	O
showed	O
a	O
major	O
improvement	O
of	O
bone	O
lesions	O
in	O
14	O
.	O
8	O
%	O
of	O
cases	O
.	O

This	O
response	O
increased	O
to	O
37	O
%	O
after	O
more	O
than	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O

Prostatic	O
acid	O
phosphatase	O
levels	O
were	O
decreased	O
by	O
more	O
than	O
50	O
%	O
in	O
61	O
%	O
of	O
the	O
patients	O
,	O
but	O
this	O
test	O
appears	O
to	O
be	O
a	O
less	O
valid	O
marker	O
than	O
the	O
lipid	O
-	O
associated	O
sialic	O
acid	O
(	O
LASA	O
)	O
.	O

The	O
increase	O
in	O
LASA	O
before	O
treatment	O
and	O
a	O
reduction	O
after	O
treatment	O
can	O
frequently	O
be	O
correlated	O
with	O
the	O
objective	O
volume	O
of	O
the	O
neoplasms	O
.	O

No	O
flare	O
-	O
up	O
of	O
the	O
disease	O
was	O
encountered	O
,	O
and	O
there	O
were	O
no	O
side	O
effects	O
except	O
for	O
impotence	O
.	O

Statistical	O
analyses	O
of	O
results	O
by	O
the	O
method	O
of	O
Lee	O
and	O
Wesley	O
indicated	O
that	O
the	O
incidence	O
of	O
complete	O
and	O
partial	O
regression	O
(	O
CR	O
and	O
PR	O
)	O
observed	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
was	O
not	O
significantly	O
different	O
from	O
that	O
recorded	O
in	O
previous	O
studies	O
for	O
another	O
LH	O
-	O
RH	O
analog	O
,	O
Buserelin	O
.	O

However	O
,	O
CR	O
and	O
PR	O
obtained	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
44	O
%	O
)	O
were	O
significantly	O
higher	O
than	O
with	O
subcapsular	O
orchiectomy	O
(	O
22	O
%	O
)	O
.	O

Hormonal	O
effects	O
and	O
some	O
other	O
actions	O
of	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
were	O
compared	O
and	O
contrasted	O
with	O
those	O
produced	O
by	O
castration	O
,	O
estrogens	O
,	O
antiandrogens	O
,	O
and	O
progestogens	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

On	O
the	O
mechanism	O
of	O
glycolysis	O
stimulation	O
by	O
neutral	O
detergents	O
in	O
3T3	B
and	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

Glycolysis	O
of	O
3T3	B
and	O
Ehrlich	O
ascites	O
tumor	O
cells	O
was	O
greatly	O
enhanced	O
by	O
Nonidet	O
P	O
-	O
40	O
or	O
Triton	O
X	O
-	O
100	O
at	O
about	O
100	O
micrograms	O
/	O
mg	O
cell	O
protein	O
.	O

This	O
enhanced	O
glycolysis	O
was	O
partly	O
sensitive	O
to	O
rutamycin	O
and	O
partly	O
sensitive	O
to	O
ouabain	O
,	O
suggesting	O
that	O
the	O
detergent	O
released	O
the	O
control	O
of	O
the	O
ATPase	O
of	O
the	O
mitochondria	O
and	O
of	O
the	O
plasma	O
membrane	O
Na	O
+	O
K	O
+	O
-	O
ATPase	O
.	O

Nonidet	O
P	O
-	O
40	O
had	O
no	O
effect	O
on	O
glycolysis	O
in	O
cell	O
-	O
free	O
extracts	O
from	O
Ehrlich	O
ascites	O
tumor	O
cells	O
to	O
which	O
soluble	O
mitochondrial	O
ATPase	O
was	O
added	O
.	O

Measuring	O
ouabain	O
-	O
sensitive	O
22Na	O
efflux	O
and	O
using	O
ouabain	O
-	O
sensitive	O
lactate	O
production	O
as	O
a	O
measure	O
of	O
ATP	O
hydrolysis	O
by	O
the	O
Na	O
+	O
K	O
+	O
pump	O
,	O
it	O
was	O
shown	O
that	O
Nonidet	O
P	O
-	O
40	O
greatly	O
decreased	O
the	O
efficiency	O
of	O
the	O
Na	O
+	O
K	O
+	O
pump	O
.	O

Quercetin	O
increased	O
the	O
efficiency	O
of	O
pumping	O
in	O
EAT	O
cells	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
the	O
detergent	O
.	O

Elevated	O
levels	O
of	O
diacylglycerol	O
and	O
decreased	O
phorbol	O
ester	O
sensitivity	O
in	O
ras	O
-	O
transformed	O
fibroblasts	O
.	O

Diacylglycerol	O
(	O
DG	O
)	O
plays	O
a	O
central	O
role	O
in	O
phospholipid	O
metabolism	O
and	O
is	O
an	O
endogenous	O
activator	O
of	O
protein	O
kinase	O
C	O
.	O

We	O
have	O
suggested	O
that	O
constitutive	O
activation	O
of	O
this	O
kinase	O
is	O
one	O
mechanism	O
by	O
which	O
oncogenes	O
transform	O
cells	O
.	O

The	O
ras	O
-	O
encoded	O
proteins	O
are	O
similar	O
to	O
regulatory	O
G	O
-	O
proteins	O
and	O
are	O
candidates	O
for	O
the	O
unknown	O
G	O
-	O
protein	O
that	O
modulates	O
phosphatidylinositol	O
(	O
PI	O
)	O
turnover	O
.	O

Differences	O
in	O
polyphosphoinositide	O
metabolism	O
have	O
been	O
reported	O
for	O
ras	O
-	O
transformed	O
cells	O
.	O

But	O
because	O
these	O
experiments	O
were	O
performed	O
on	O
confluent	O
cultures	O
of	O
established	O
cell	O
lines	O
,	O
the	O
differences	O
are	O
difficult	O
to	O
attribute	O
to	O
ras	O
transformation	O
.	O

Here	O
we	O
show	O
that	O
exponentially	O
growing	O
NIH	B
3T3	I
fibroblasts	O
recently	O
transformed	O
by	O
Ha	O
-	O
ras	O
or	O
Ki	O
-	O
ras	O
possess	O
elevated	O
DG	O
concentrations	O
without	O
significant	O
alterations	O
in	O
the	O
levels	O
of	O
other	O
polyphosphoinositide	O
metabolites	O
.	O

The	O
basal	O
phosphorylation	O
of	O
protein	O
kinase	O
C	O
substrate	O
of	O
relative	O
molecular	O
mass	O
(	O
Mr	O
)	O
80	O
,	O
000	O
(	O
80	O
K	O
)	O
is	O
significantly	O
increased	O
in	O
all	O
the	O
ras	O
-	O
transformed	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
however	O
,	O
further	O
phosphorylation	O
of	O
this	O
protein	O
on	O
addition	O
of	O
phorbol	O
ester	O
was	O
greatly	O
reduced	O
.	O

Ha	O
-	O
ras	O
cells	O
also	O
show	O
less	O
binding	O
of	O
phorbol	O
ester	O
than	O
control	O
cells	O
,	O
suggesting	O
that	O
elevation	O
of	O
DG	O
causes	O
partial	O
down	O
-	O
regulation	O
in	O
addition	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Epidermal	O
growth	O
factor	O
and	O
its	O
receptor	O
.	O

Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binds	O
with	O
high	O
affinity	O
and	O
specificity	O
to	O
a	O
single	O
site	O
on	O
the	O
external	O
domain	O
of	O
its	O
transmembrane	O
receptor	O
to	O
activate	O
the	O
tyrosine	O
protein	O
kinase	O
activity	O
of	O
its	O
cytoplasmic	O
portion	O
.	O

The	O
EGF	O
receptor	O
gene	O
is	O
amplified	O
and	O
over	O
-	O
expressed	O
in	O
several	O
human	O
tumors	O
,	O
suggesting	O
that	O
increased	O
concentrations	O
of	O
the	O
proto	O
-	O
oncogene	O
leads	O
to	O
constitutive	O
activity	O
similar	O
to	O
that	O
seen	O
with	O
oncogene	O
erb	O
B	O
.	O

Synthesis	O
and	O
degradation	O
of	O
the	O
EGF	O
receptor	O
are	O
regulated	O
,	O
in	O
addition	O
,	O
covalent	O
modification	O
by	O
phosphorylation	O
regulates	O
activity	O
of	O
the	O
receptor	O
protein	O
.	O

Intramolecular	O
self	O
-	O
phosphorylation	O
of	O
Tyr1173	O
removes	O
a	O
competitive	O
inhibitory	O
constraint	O
to	O
enhance	O
phosphorylation	O
of	O
substrates	O
.	O

Phosphorylation	O
of	O
Thr654	O
by	O
protein	O
kinase	O
C	O
decreases	O
high	O
affinity	O
EGF	O
binding	O
and	O
EGF	O
-	O
stimulated	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
providing	O
a	O
mechanism	O
for	O
heterologous	O
regulation	O
of	O
the	O
EGF	O
receptor	O
by	O
tumor	O
promoters	O
and	O
other	O
ligand	O
X	O
receptor	O
complexes	O
.	O

Extensive	O
regulation	O
contributes	O
to	O
normal	O
growth	O
control	O
,	O
abrogation	O
of	O
regulatory	O
controls	O
contributes	O
to	O
uncontrolled	O
growth	O
as	O
seen	O
with	O
erb	O
B	O
transformation	O
and	O
EGF	O
receptor	O
gene	O
amplification	O
in	O
human	O
tumors	O
.	O

Malate	O
-	O
citrate	O
cycle	O
during	O
glycolysis	O
and	O
glutaminolysis	O
in	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

The	O
malate	O
-	O
citrate	O
cycle	O
was	O
studied	O
during	O
aerobic	O
glycolysis	O
and	O
glutaminolysis	O
in	O
a	O
strain	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
which	O
showed	O
a	O
very	O
low	O
malate	O
-	O
aspartate	O
shuttle	O
system	O
activity	O
.	O

The	O
experimental	O
approach	O
includes	O
:	O
estimation	O
of	O
mitochondrial	O
NAD	O
[	O
P	O
]	O
+	O
-	O
dependent	O
malic	O
enzyme	O
activity	O
;	O
respiratory	O
activity	O
of	O
freshly	O
harvested	O
or	O
fasted	O
cells	O
,	O
and	O
of	O
isolated	O
mitochondria	O
;	O
and	O
determination	O
of	O
the	O
metabolites	O
involved	O
in	O
the	O
glycolytic	O
and	O
glutaminolytic	O
pathways	O
.	O

The	O
results	O
suggest	O
that	O
in	O
this	O
strain	O
,	O
the	O
malate	O
-	O
citrate	O
shuttle	O
is	O
not	O
an	O
effective	O
pathway	O
for	O
transferring	O
glycolytic	O
reducing	O
equivalents	O
from	O
cytosol	O
to	O
mitochondria	O
.	O

Less	O
than	O
15	O
%	O
of	O
the	O
glucose	O
uptake	O
was	O
affected	O
by	O
the	O
1	O
,	O
2	O
,	O
3	O
-	O
benzenetricarboxylate	O
inhibition	O
of	O
the	O
malate	O
-	O
citrate	O
shuttle	O
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
glucose	O
,	O
the	O
malate	O
-	O
citrate	O
cycle	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
glutaminolytic	O
process	O
.	O

The	O
present	O
work	O
supports	O
and	O
extends	O
the	O
finding	O
of	O
previous	O
studies	O
,	O
since	O
the	O
results	O
showed	O
that	O
the	O
glucose	O
metabolism	O
depressed	O
the	O
oxidative	O
processes	O
in	O
Ehrlich	O
ascites	O
tumor	O
mitochondria	O
,	O
not	O
only	O
alone	O
,	O
but	O
also	O
in	O
the	O
presence	O
of	O
glutamine	O
.	O

Interestingly	O
,	O
the	O
high	O
glutamine	O
uptake	O
was	O
maintained	O
in	O
the	O
presence	O
of	O
glucose	O
.	O

Differential	O
secretion	O
of	O
proteins	O
and	O
glycoproteins	O
by	O
livers	O
of	O
immature	O
and	O
adult	O
rats	O
.	O

Effect	O
of	O
antimicrotubule	O
drugs	O
.	O

This	O
study	O
was	O
initiated	O
to	O
re	O
-	O
examine	O
reported	O
differences	O
in	O
the	O
action	O
of	O
antimicrotubule	O
agents	O
on	O
plasma	O
protein	O
secretion	O
from	O
livers	O
of	O
immature	O
versus	O
adult	O
rats	O
.	O

The	O
aim	O
was	O
(	O
1	O
)	O
to	O
determine	O
the	O
composition	O
and	O
to	O
monitor	O
the	O
secretion	O
of	O
various	O
plasma	O
proteins	O
and	O
glycoproteins	O
from	O
liver	O
slices	O
labeled	O
in	O
vitro	O
with	O
specific	O
amino	O
acids	O
and	O
sugar	O
residues	O
,	O
and	O
(	O
2	O
)	O
to	O
correlate	O
observed	O
differences	O
in	O
secretion	O
of	O
these	O
proteins	O
with	O
structural	O
changes	O
in	O
the	O
hepatocytes	O
of	O
the	O
different	O
aged	O
animals	O
.	O

For	O
the	O
most	O
part	O
,	O
slices	O
of	O
liver	O
from	O
fetal	O
(	O
term	O
)	O
,	O
neonatal	O
(	O
4	O
-	O
to	O
5	O
days	O
old	O
)	O
,	O
and	O
adult	O
rats	O
(	O
70	O
days	O
old	O
)	O
were	O
incubated	O
with	O
radioactive	O
amino	O
acids	O
or	O
various	O
tritiated	O
sugars	O
specific	O
for	O
N	O
-	O
linked	O
core	O
oligosaccharide	O
and	O
/	O
or	O
N	O
-	O
linked	O
terminal	O
oligosaccharide	O
chains	O
.	O

Our	O
findings	O
indicate	O
that	O
liver	O
slices	O
of	O
fetal	O
and	O
neonatal	O
rats	O
are	O
efficient	O
in	O
synthesizing	O
plasma	O
proteins	O
including	O
fully	O
glycosylated	O
glycoproteins	O
.	O

The	O
secretion	O
of	O
glycosylated	O
and	O
nonglycosylated	O
proteins	O
believed	O
to	O
be	O
processed	O
through	O
Golgi	O
complexes	O
was	O
inhibited	O
to	O
the	O
same	O
extent	O
(	O
approximately	O
70	O
-	O
80	O
%	O
)	O
by	O
antimicrotubule	O
agents	O
,	O
regardless	O
of	O
the	O
age	O
of	O
the	O
host	O
animal	O
.	O

However	O
,	O
other	O
proteins	O
and	O
glycoproteins	O
secreted	O
by	O
livers	O
of	O
immature	O
rats	O
were	O
found	O
to	O
be	O
relatively	O
insensitive	O
(	O
i	O
.	O
e	O
.	O
inhibited	O
to	O
only	O
30	O
-	O
40	O
%	O
)	O
to	O
the	O
action	O
of	O
various	O
antimicrotubule	O
drugs	O
.	O

The	O
glycoproteins	O
were	O
found	O
to	O
lack	O
N	O
-	O
linked	O
terminal	O
sugars	O
(	O
although	O
the	O
glycoproteins	O
did	O
contain	O
N	O
-	O
linked	O
core	O
sugars	O
)	O
,	O
and	O
it	O
is	O
likely	O
that	O
the	O
drug	O
-	O
insensitive	O
proteins	O
bypassed	O
critical	O
glycosylating	O
sites	O
in	O
the	O
Golgi	O
compartment	O
prior	O
to	O
release	O
.	O

Overall	O
,	O
these	O
findings	O
support	O
earlier	O
data	O
showing	O
that	O
antimicrotubule	O
drugs	O
have	O
a	O
special	O
impact	O
on	O
Golgi	O
-	O
associated	O
events	O
in	O
liver	O
cells	O
.	O

To	O
what	O
extent	O
these	O
findings	O
are	O
related	O
to	O
the	O
action	O
of	O
microtubules	O
remains	O
to	O
be	O
seen	O
.	O

Multi	O
-	O
step	O
neoplastic	O
transformation	O
of	O
normal	O
human	O
fibroblasts	O
by	O
Co	O
-	O
60	O
gamma	O
rays	O
and	O
Ha	O
-	O
ras	O
oncogenes	O
.	O

As	O
reported	O
previously	O
(	O
Namba	O
et	O
al	O
.	O
,	O
1985	O
;	O
Namba	O
,	O
1985	O
)	O
,	O
normal	O
human	O
fibroblasts	O
were	O
transformed	O
into	O
immortal	O
cells	O
with	O
abnormal	O
karyotypes	O
by	O
Co	O
-	O
60	O
gamma	O
-	O
ray	O
irradiation	O
.	O

These	O
immortally	O
transformed	O
cells	O
(	O
KMST	B
-	I
6	I
)	O
showed	O
no	O
clonability	O
in	O
soft	O
agar	O
and	O
were	O
not	O
tumorigenic	O
.	O

However	O
,	O
by	O
treatment	O
with	O
Ha	O
-	O
ras	O
oncogenes	O
derived	O
from	O
a	O
human	O
lung	O
carcinoma	O
or	O
Harvey	O
murine	O
sarcoma	O
virus	O
,	O
the	O
KMST	B
-	I
6	I
cells	O
acquired	O
elevated	O
clonability	O
in	O
soft	O
agar	O
and	O
transplantability	O
in	O
nude	O
mice	O
.	O

All	O
the	O
tumors	O
produced	O
grew	O
progressively	O
without	O
showing	O
regression	O
and	O
killed	O
the	O
mice	O
.	O

The	O
tumors	O
were	O
also	O
serially	O
transplantable	O
into	O
other	O
mice	O
.	O

The	O
Ha	O
-	O
ras	O
oncogene	O
alone	O
did	O
not	O
convert	O
normal	O
human	O
fibroblasts	O
into	O
either	O
immortal	O
or	O
tumorigenic	O
cells	O
.	O

Our	O
current	O
data	O
suggest	O
that	O
gamma	O
rays	O
worked	O
as	O
an	O
initiator	O
of	O
carcinogenesis	O
in	O
normal	O
human	O
cells	O
,	O
giving	O
rise	O
to	O
chromosome	O
aberrations	O
and	O
immortality	O
,	O
and	O
the	O
Ha	O
-	O
ras	O
oncogene	O
played	O
a	O
role	O
in	O
the	O
progression	O
of	O
the	O
immortally	O
transformed	O
cell	O
population	O
to	O
a	O
neoplastic	O
one	O
showing	O
enhanced	O
colony	O
formation	O
in	O
soft	O
agar	O
and	O
tumorigenicity	O
in	O
nude	O
mice	O
.	O

N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
induced	O
transformation	O
of	O
rat	O
urothelial	O
cells	O
in	O
vitro	O
is	O
not	O
mediated	O
by	O
activation	O
of	O
ras	O
oncogenes	O
.	O

Adult	O
rat	O
urothelial	O
cells	O
were	O
transformed	O
in	O
vitro	O
following	O
treatment	O
with	O
a	O
single	O
dose	O
of	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
MNU	O
)	O
or	O
MNU	O
treatment	O
followed	O
by	O
promotion	O
with	O
sodium	O
saccharin	O
.	O

This	O
in	O
vitro	O
transformation	O
process	O
involves	O
multiple	O
steps	O
:	O
slow	O
-	O
growing	O
'	O
pre	O
-	O
neoplastic	O
'	O
epithelial	O
foci	O
are	O
induced	O
70	O
-	O
100	O
days	O
after	O
MNU	O
treatment	O
and	O
from	O
such	O
foci	O
rapidly	O
proliferating	O
immortal	O
cell	O
lines	O
were	O
established	O
,	O
some	O
of	O
which	O
became	O
tumorigenic	O
after	O
a	O
further	O
latent	O
period	O
.	O

A	O
series	O
of	O
epithelial	O
cell	O
lines	O
and	O
a	O
single	O
fibroblast	O
cell	O
line	O
established	O
in	O
this	O
way	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
transforming	O
genes	O
by	O
DNA	O
transfection	O
into	O
NIH3T3	B
cells	O
.	O

None	O
of	O
the	O
epithelial	O
cell	O
lines	O
induced	O
foci	O
in	O
a	O
focus	O
formation	O
assay	O
.	O

The	O
single	O
non	O
-	O
epithelial	O
line	O
induced	O
foci	O
and	O
was	O
found	O
to	O
contain	O
an	O
activated	O
c	O
-	O
Ki	O
-	O
ras	O
gene	O
with	O
a	O
G	O
-	O
-	O
-	O
-	O
A	O
transition	O
in	O
codon	O
12	O
.	O

To	O
assay	O
for	O
the	O
possible	O
presence	O
of	O
transforming	O
genes	O
which	O
were	O
not	O
active	O
in	O
a	O
focus	O
formation	O
assay	O
,	O
two	O
of	O
the	O
epithelial	O
lines	O
were	O
analysed	O
further	O
by	O
co	O
-	O
transfection	O
with	O
a	O
dominant	O
selectable	O
marker	O
,	O
followed	O
by	O
selection	O
and	O
inoculation	O
into	O
nude	O
mice	O
.	O

No	O
tumours	O
were	O
induced	O
within	O
the	O
latent	O
period	O
for	O
tumour	O
production	O
by	O
control	O
cells	O
transfected	O
with	O
NIH3T3	B
cell	O
DNA	O
(	O
40	O
-	O
60	O
days	O
)	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
cell	O
type	O
specificity	O
for	O
oncogene	O
activation	O
during	O
in	O
vitro	O
rat	O
bladder	O
transformation	O
initiated	O
by	O
a	O
single	O
carcinogen	O
and	O
that	O
ras	O
gene	O
activation	O
is	O
not	O
a	O
necessary	O
step	O
in	O
urothelial	O
transformation	O
in	O
vitro	O
.	O

The	O
posterior	O
tether	O
in	O
scoliosis	O
.	O

The	O
hypothesis	O
that	O
a	O
localized	O
lordosis	O
,	O
or	O
tethering	O
of	O
the	O
posterior	O
elements	O
of	O
the	O
spine	O
,	O
is	O
the	O
primary	O
cause	O
of	O
the	O
vertebral	O
rotation	O
in	O
idiopathic	O
scoliosis	O
was	O
investigated	O
in	O
anatomic	O
specimens	O
of	O
human	O
and	O
calf	O
spinal	O
columns	O
.	O

The	O
specimens	O
were	O
axially	O
loaded	O
with	O
and	O
without	O
a	O
posterior	O
tether	O
created	O
using	O
Zielke	O
instrumentation	O
.	O

Lateral	O
deflection	O
and	O
axial	O
rotation	O
were	O
monitored	O
roentgenographically	O
.	O

The	O
vertebrae	O
of	O
tethered	O
spines	O
showed	O
increased	O
rotation	O
in	O
the	O
direction	O
associated	O
with	O
idiopathic	O
scoliosis	O
.	O

The	O
spinous	O
processes	O
moved	O
toward	O
the	O
concavity	O
at	O
the	O
apex	O
of	O
the	O
induced	O
lateral	O
curve	O
.	O

Conversely	O
,	O
untethered	O
spines	O
either	O
exhibited	O
little	O
rotation	O
or	O
rotated	O
in	O
the	O
opposite	O
direction	O
;	O
the	O
spinous	O
processes	O
moved	O
toward	O
the	O
convexity	O
of	O
the	O
curve	O
.	O

Rotations	O
toward	O
the	O
convexity	O
occur	O
in	O
rotational	O
kyphosis	O
.	O

Thus	O
the	O
hypothesis	O
that	O
idiopathic	O
scoliosis	O
is	O
a	O
rotational	O
lordosis	O
is	O
substantiated	O
;	O
the	O
characteristic	O
rotation	O
can	O
be	O
explained	O
with	O
the	O
aid	O
of	O
a	O
geometric	O
model	O
.	O

Glutamine	O
and	O
glucose	O
as	O
energy	O
substrates	O
for	O
Ehrlich	O
ascites	O
tumour	O
cells	O
.	O

Energy	O
metabolism	O
of	O
freshly	O
harvested	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
the	O
presence	O
of	O
5	O
mM	O
glucose	O
and	O
/	O
or	O
0	O
.	O
5	O
mM	O
glutamine	O
was	O
studied	O
.	O

The	O
rate	O
of	O
oxygen	O
utilization	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
0	O
.	O
5	O
mM	O
glutamine	O
;	O
5	O
mM	O
glucose	O
induced	O
an	O
inhibition	O
of	O
respiration	O
.	O

In	O
the	O
presence	O
of	O
both	O
glucose	O
and	O
glutamine	O
,	O
the	O
Crabtree	O
effect	O
decreased	O
.	O

In	O
these	O
conditions	O
,	O
the	O
rates	O
of	O
oxygen	O
uptake	O
,	O
the	O
CO2	O
evolution	O
and	O
the	O
changes	O
in	O
the	O
redox	O
states	O
of	O
cytochromes	O
indicate	O
that	O
glucose	O
is	O
preferred	O
by	O
Ehrlich	O
ascites	O
tumour	O
cells	O
as	O
energy	O
substrate	O
.	O

Glucose	O
decreased	O
the	O
rate	O
of	O
glutamine	O
utilization	O
by	O
34	O
%	O
.	O

On	O
the	O
other	O
hand	O
,	O
glutaminolysis	O
did	O
not	O
inhibit	O
glycolysis	O
.	O

Sensitivity	O
analysis	O
of	O
the	O
influence	O
of	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risk	O
of	O
coal	O
-	O
fired	O
plants	O
.	O

A	O
sensitivity	O
analysis	O
was	O
undertaken	O
to	O
determine	O
the	O
influence	O
of	O
different	O
source	O
-	O
term	O
and	O
environmental	O
parameters	O
on	O
the	O
radiological	O
risks	O
from	O
a	O
coal	O
-	O
fired	O
plant	O
(	O
CFP	O
)	O
.	O

It	O
was	O
found	O
that	O
the	O
release	O
rate	O
of	O
radionuclides	O
and	O
the	O
effective	O
release	O
height	O
most	O
significantly	O
influence	O
radiological	O
risk	O
.	O

Site	O
characteristics	O
,	O
such	O
as	O
rain	O
scavenging	O
coefficients	O
and	O
food	O
acquirement	O
habits	O
,	O
have	O
a	O
lesser	O
influence	O
,	O
and	O
some	O
parameters	O
,	O
such	O
as	O
time	O
delay	O
before	O
ingestion	O
of	O
contaminated	O
food	O
,	O
have	O
practically	O
no	O
influence	O
on	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
.	O

The	O
contribution	O
to	O
radiation	O
risks	O
of	O
different	O
exposure	O
modes	O
(	O
i	O
.	O
e	O
.	O
inhalation	O
,	O
ingestion	O
and	O
contact	O
with	O
ground	O
surface	O
)	O
were	O
also	O
analyzed	O
,	O
as	O
well	O
as	O
of	O
specific	O
radionuclides	O
and	O
human	O
body	O
organs	O
.	O

Results	O
of	O
the	O
sensitivity	O
analysis	O
were	O
interpreted	O
in	O
terms	O
of	O
the	O
characteristics	O
of	O
the	O
fuel	O
,	O
facilities	O
and	O
site	O
of	O
a	O
CFP	O
.	O

It	O
is	O
concluded	O
that	O
by	O
proper	O
choice	O
of	O
coal	O
,	O
furnace	O
,	O
ash	O
filtration	O
and	O
stack	O
height	O
,	O
as	O
well	O
as	O
by	O
proper	O
siting	O
,	O
the	O
radiological	O
impact	O
of	O
a	O
CFP	O
can	O
be	O
drastically	O
reduced	O
.	O

Cigarette	O
smoking	O
and	O
alveolar	O
bone	O
height	O
in	O
subjects	O
with	O
a	O
high	O
standard	O
of	O
oral	O
hygiene	O
.	O

Smokers	O
and	O
non	O
-	O
smokers	O
were	O
compared	O
with	O
respect	O
to	O
alveolar	O
bone	O
height	O
.	O

The	O
study	O
covered	O
235	O
subjects	O
aged	O
21	O
-	O
60	O
years	O
,	O
72	O
of	O
whom	O
were	O
smokers	O
.	O

Oral	O
hygiene	O
status	O
and	O
dental	O
care	O
habits	O
were	O
above	O
average	O
and	O
of	O
equal	O
standard	O
in	O
both	O
groups	O
(	O
PlI	O
=	O
0	O
.	O
9	O
)	O
.	O

Alveolar	O
bone	O
height	O
was	O
assessed	O
on	O
radiographs	O
and	O
expressed	O
as	O
%	O
of	O
the	O
root	O
length	O
.	O

Alveolar	O
bone	O
height	O
was	O
significantly	O
reduced	O
in	O
smokers	O
as	O
compared	O
to	O
non	O
-	O
smokers	O
,	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
being	O
77	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
82	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
6	O
%	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Regression	O
analysis	O
suggested	O
that	O
periodontal	O
breakdown	O
judged	O
from	O
loss	O
of	O
alveolar	O
bone	O
over	O
time	O
was	O
more	O
accelerated	O
in	O
smokers	O
than	O
non	O
-	O
smokers	O
.	O

The	O
lower	O
bone	O
height	O
in	O
smokers	O
remained	O
when	O
age	O
and	O
oral	O
hygiene	O
were	O
allowed	O
for	O
.	O

It	O
is	O
concluded	O
that	O
smoking	O
is	O
a	O
risk	O
factor	O
for	O
periodontal	O
health	O
.	O

Growth	O
state	O
-	O
dependent	O
regulation	O
of	O
protein	O
kinase	O
C	O
in	O
normal	O
and	O
transformed	O
murine	O
cells	O
.	O

We	O
determined	O
whether	O
growth	O
state	O
can	O
influence	O
the	O
action	O
of	O
protein	O
kinase	O
C	O
by	O
measuring	O
protein	O
kinase	O
C	O
activity	O
in	O
growing	O
and	O
stationary	O
cultures	O
of	O
normal	O
and	O
transformed	O
cells	O
.	O

Two	O
approaches	O
were	O
used	O
to	O
measure	O
protein	O
kinase	O
C	O
:	O
assay	O
of	O
intact	O
cells	O
for	O
inhibition	O
of	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
binding	O
in	O
response	O
to	O
phorbol	O
dibutyrate	O
(	O
PDBu	O
)	O
;	O
and	O
assay	O
of	O
detergent	O
extracts	O
for	O
total	O
calcium	O
,	O
phospholipid	O
-	O
dependent	O
kinase	O
activity	O
.	O

In	O
extracts	O
of	O
growing	O
and	O
stationary	O
Swiss	B
3T3	I
cells	O
,	O
the	O
total	O
amount	O
of	O
protein	O
kinase	O
C	O
activity	O
was	O
similar	O
,	O
indicating	O
that	O
growth	O
state	O
does	O
not	O
alter	O
the	O
level	O
of	O
enzyme	O
in	O
the	O
cell	O
.	O

The	O
short	O
-	O
term	O
response	O
of	O
Swiss	B
3T3	I
cells	O
to	O
an	O
activator	O
of	O
protein	O
kinase	O
C	O
also	O
appeared	O
to	O
be	O
independent	O
of	O
growth	O
state	O
,	O
since	O
the	O
50	O
%	O
effective	O
dose	O
for	O
PDBu	O
inhibition	O
of	O
EGF	O
binding	O
to	O
its	O
receptor	O
was	O
approximately	O
7	O
nM	O
for	O
both	O
growth	O
conditions	O
.	O

In	O
contrast	O
,	O
the	O
response	O
of	O
cells	O
to	O
long	O
-	O
term	O
treatment	O
with	O
PDBu	O
was	O
significantly	O
different	O
depending	O
upon	O
the	O
initial	O
growth	O
state	O
of	O
the	O
cells	O
.	O

In	O
both	O
growth	O
states	O
,	O
PDBu	O
caused	O
loss	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
which	O
reflected	O
a	O
loss	O
in	O
protein	O
mass	O
as	O
determined	O
by	O
immunoblotting	O
with	O
antiserum	O
to	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
maximum	O
decrease	O
approached	O
100	O
%	O
in	O
stationary	O
cultures	O
versus	O
approximately	O
75	O
%	O
in	O
growing	O
cells	O
.	O

Protein	O
kinase	O
C	O
levels	O
in	O
several	O
transformed	O
cell	O
lines	O
were	O
subject	O
to	O
down	O
modulation	O
in	O
a	O
similar	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O

Further	O
,	O
the	O
inhibition	O
of	O
EGF	O
binding	O
by	O
tumor	O
promoters	O
following	O
long	O
-	O
term	O
treatment	O
of	O
Swiss	B
3T3	I
cells	O
with	O
PDBu	O
also	O
varied	O
with	O
growth	O
state	O
.	O

In	O
down	O
modulated	O
growing	O
cells	O
,	O
PDBu	O
caused	O
almost	O
complete	O
inhibition	O
of	O
EGF	O
binding	O
,	O
whereas	O
in	O
down	O
modulated	O
stationary	O
cells	O
,	O
minimal	O
inhibition	O
of	O
EGF	O
binding	O
by	O
PDBu	O
was	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
prolonged	O
treatment	O
with	O
tumor	O
promoters	O
alters	O
the	O
sensitivity	O
of	O
cells	O
to	O
activators	O
of	O
protein	O
kinase	O
C	O
in	O
a	O
growth	O
state	O
-	O
dependent	O
manner	O
.	O

Suppression	O
and	O
re	O
-	O
expression	O
of	O
transformed	O
phenotype	O
in	O
hybrids	O
of	O
HA	O
-	O
ras	O
-	O
1	O
-	O
transformed	O
rat	B
-	I
1	I
cells	O
and	O
early	O
-	O
passage	O
rat	O
embryonic	O
fibroblasts	O
.	O

Rat	B
-	I
1	I
cells	O
which	O
had	O
been	O
transformed	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
-	O
1	O
gene	O
from	O
human	O
EJ	B
bladder	O
carcinoma	O
cells	O
were	O
fused	O
with	O
diploid	O
embryonic	O
rat	O
fibroblasts	O
.	O

Four	O
selected	O
cell	O
hybrids	O
expressed	O
the	O
human	O
transforming	O
gene	O
product	O
p21	O
at	O
levels	O
of	O
10	O
to	O
30	O
%	O
compared	O
to	O
100	O
%	O
in	O
the	O
transformed	O
parental	O
cells	O
.	O

The	O
hybrid	O
cells	O
,	O
however	O
,	O
exhibited	O
normal	O
morphology	O
,	O
anchorage	O
requirement	O
for	O
proliferation	O
,	O
and	O
largely	O
extended	O
latency	O
periods	O
of	O
tumorigenicity	O
in	O
newborn	O
rats	O
.	O

Tumorigenic	O
hybrid	O
derivatives	O
contained	O
lower	O
numbers	O
of	O
chromosomes	O
than	O
the	O
tetraploid	O
parental	O
hybrids	O
.	O

DNA	O
of	O
the	O
non	O
-	O
tumorigenic	O
cell	O
hybrids	O
transformed	O
Rat	B
-	I
1	I
cells	O
to	O
anchorage	O
-	O
independent	O
proliferation	O
as	O
expected	O
for	O
the	O
transforming	O
human	O
Ha	O
-	O
ras	O
gene	O
present	O
in	O
the	O
donor	O
DNA	O
.	O

We	O
conclude	O
that	O
the	O
transforming	O
properties	O
of	O
the	O
activated	O
Ha	O
-	O
ras	O
gene	O
in	O
Rat	B
-	I
1	I
cells	O
can	O
be	O
suppressed	O
at	O
the	O
post	O
-	O
translational	O
level	O
by	O
the	O
presence	O
of	O
the	O
genome	O
from	O
diploid	O
embryonic	O
rat	O
fibroblasts	O
but	O
additional	O
controls	O
of	O
expression	O
of	O
the	O
transforming	O
gene	O
are	O
likely	O
to	O
exist	O
.	O

Normal	O
cells	O
contain	O
suppressor	O
gene	O
(	O
s	O
)	O
which	O
safeguard	O
these	O
cells	O
against	O
transformation	O
by	O
the	O
product	O
of	O
the	O
transforming	O
Ha	O
-	O
ras	O
-	O
1	O
oncogene	O
.	O

Antishock	O
trousers	O
:	O
a	O
collective	O
review	O
.	O

Antishock	O
trousers	O
have	O
become	O
an	O
integral	O
part	O
of	O
emergency	O
medical	O
care	O
for	O
many	O
traumatic	O
and	O
life	O
-	O
threatening	O
emergencies	O
.	O

This	O
article	O
represents	O
a	O
summary	O
of	O
the	O
current	O
state	O
of	O
knowledge	O
concerning	O
the	O
use	O
of	O
this	O
device	O
.	O

A	O
brief	O
history	O
of	O
the	O
development	O
of	O
antishock	O
garments	O
is	O
discussed	O
.	O

This	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
human	O
clinical	O
studies	O
and	O
results	O
of	O
clinical	O
research	O
on	O
hemodynamics	O
,	O
respiration	O
,	O
use	O
in	O
head	O
injury	O
,	O
and	O
effects	O
on	O
vascular	O
hemostasis	O
.	O

Indications	O
,	O
contraindications	O
,	O
complications	O
,	O
and	O
recommended	O
procedure	O
for	O
use	O
are	O
discussed	O
.	O

Based	O
on	O
randomized	O
prospective	O
studies	O
,	O
antishock	O
garments	O
have	O
not	O
,	O
as	O
yet	O
,	O
been	O
shown	O
to	O
improve	O
patient	O
morbidity	O
or	O
mortality	O
.	O

Proper	O
use	O
of	O
antishock	O
garments	O
requires	O
an	O
understanding	O
of	O
both	O
their	O
function	O
and	O
their	O
limitations	O
.	O

Measurement	O
of	O
serum	O
glycosylated	O
proteins	O
and	O
glycosylated	O
low	O
density	O
lipoprotein	O
fraction	O
in	O
diabetes	O
mellitus	O
.	O

A	O
simple	O
method	O
was	O
developed	O
for	O
estimating	O
serum	O
glycosylated	O
protein	O
levels	O
using	O
gel	O
filtration	O
with	O
Bio	O
-	O
Gel	O
P6	O
by	O
determining	O
the	O
protein	O
and	O
sugar	O
content	O
in	O
the	O
void	O
volume	O
fraction	O
.	O

The	O
glycosylated	O
protein	O
levels	O
(	O
GSP	O
)	O
correlated	O
well	O
with	O
fasting	O
blood	O
sugar	O
levels	O
and	O
glycosylated	O
albumin	O
level	O
(	O
G	O
-	O
ALB	O
)	O
determined	O
by	O
affinity	O
chromatography	O
with	O
Blue	O
Sepharose	O
CL6B	O
.	O

The	O
glycosylation	O
level	O
of	O
heparin	O
-	O
citrate	O
precipitable	O
fraction	O
of	O
serum	O
which	O
predominantly	O
contained	O
low	O
density	O
lipoprotein	O
(	O
G	O
-	O
LDL	O
)	O
also	O
correlated	O
well	O
with	O
GSP	O
and	O
LDL	O
-	O
cholesterol	O
levels	O
.	O

Significantly	O
different	O
values	O
were	O
obtained	O
for	O
GSP	O
,	O
G	O
-	O
ALB	O
,	O
and	O
G	O
-	O
LDL	O
between	O
normals	O
and	O
diabetics	O
.	O

Combined	O
aortic	O
,	O
mitral	O
and	O
tricuspid	O
surgery	O
:	O
results	O
in	O
78	O
patients	O
.	O

Between	O
1968	O
and	O
1984	O
,	O
78	O
patients	O
(	O
mean	O
age	O
43	O
,	O
range	O
14	O
to	O
65	O
years	O
)	O
underwent	O
combined	O
aortic	O
,	O
mitral	O
and	O
tricuspid	O
surgery	O
(	O
22	O
triple	O
valve	O
replacements	O
,	O
56	O
aortic	O
valve	O
replacements	O
with	O
tricuspid	O
conservative	O
surgery	O
and	O
mitral	O
valve	O
replacement	O
(	O
N	O
=	O
48	O
)	O
,	O
or	O
commissuroplasty	O
(	O
N	O
=	O
8	O
)	O
.	O

Pre	O
-	O
operative	O
consequences	O
of	O
valvular	O
disease	O
(	O
mainly	O
mixed	O
valve	O
disease	O
)	O
were	O
severe	O
as	O
assessed	O
by	O
functional	O
class	O
(	O
72	O
pts	O
in	O
III	O
or	O
IV	O
NYHA	O
)	O
,	O
cardiomegaly	O
(	O
CTR	O
:	O
62	O
+	O
/	O
-	O
6	O
%	O
)	O
,	O
increase	O
of	O
mean	O
pulmonary	O
arterial	O
and	O
wedge	O
pressures	O
(	O
respectively	O
30	O
+	O
/	O
-	O
12	O
and	O
19	O
+	O
/	O
-	O
6	O
mmHg	O
)	O
decrease	O
in	O
cardiac	O
index	O
(	O
2	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
5	O
l	O
min	O
-	O
1	O
m	O
-	O
2	O
)	O
,	O
LV	O
dilatation	O
(	O
LV	O
end	O
diastolic	O
volume	O
:	O
184	O
+	O
/	O
-	O
86	O
ml	O
m	O
-	O
2	O
)	O
and	O
impairment	O
of	O
LV	O
systolic	O
function	O
(	O
LV	O
ejection	O
fraction	O
:	O
50	O
+	O
/	O
-	O
12	O
%	O
)	O
.	O

Operative	O
mortality	O
rate	O
was	O
11	O
.	O
5	O
%	O
.	O

The	O
69	O
survivors	O
were	O
all	O
followed	O
up	O
,	O
for	O
a	O
mean	O
of	O
56	O
months	O
(	O
2	O
to	O
207	O
)	O
.	O

16	O
late	O
deaths	O
occurred	O
.	O

Actuarial	O
survival	O
rate	O
at	O
10	O
years	O
was	O
58	O
.	O
4	O
%	O
,	O
and	O
greatly	O
influenced	O
by	O
pre	O
-	O
operative	O
NYHA	O
class	O
.	O

Linearized	O
rates	O
of	O
thromboembolic	O
events	O
,	O
valve	O
thrombosis	O
and	O
haemorrhage	O
were	O
respectively	O
6	O
.	O
4	O
,	O
1	O
.	O
5	O
and	O
1	O
.	O
2	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
.	O

Those	O
of	O
infective	O
endocarditis	O
,	O
periprosthetic	O
leak	O
,	O
reoperation	O
and	O
valve	O
failure	O
were	O
0	O
.	O
6	O
,	O
3	O
.	O
3	O
and	O
4	O
.	O
9	O
%	O
pt	O
-	O
1	O
yr	O
-	O
1	O
respectively	O
.	O

At	O
9	O
years	O
,	O
42	O
%	O
of	O
the	O
patients	O
were	O
in	O
NYHA	O
class	O
I	O
or	O
II	O
and	O
free	O
from	O
complications	O
.	O

Torsade	O
de	O
pointes	O
during	O
loading	O
with	O
amiodarone	O
.	O

Torsade	O
de	O
pointes	O
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	O
therapy	O
.	O

Several	O
reports	O
have	O
emphasized	O
the	O
need	O
for	O
a	O
loading	O
dose	O
in	O
order	O
to	O
achieve	O
therapeutic	O
blood	O
levels	O
rapidly	O
.	O

We	O
report	O
a	O
case	O
of	O
torsade	O
de	O
pointes	O
following	O
a	O
single	O
oral	O
dose	O
of	O
amiodarone	O
(	O
1400	O
mg	O
or	O
30	O
mg	O
kg	O
-	O
1	O
)	O
administered	O
after	O
short	O
intravenous	O
loading	O
for	O
prevention	O
of	O
paroxysmal	O
atrial	O
flutter	O
.	O

Torsades	O
de	O
pointes	O
were	O
preceded	O
and	O
associated	O
with	O
marked	O
QT	O
prolongation	O
and	O
bradycardia	O
.	O

This	O
report	O
suggests	O
that	O
careful	O
monitoring	O
of	O
patients	O
undergoing	O
oral	O
amiodarone	O
loading	O
is	O
necessary	O
.	O

Conjunctival	O
hypoxia	O
in	O
diabetes	O
mellitus	O
.	O

A	O
frequently	O
cited	O
theory	O
for	O
the	O
pathogenesis	O
of	O
neovascularization	O
in	O
diabetic	O
retinopathy	O
is	O
that	O
retinal	O
hypoxia	O
and	O
/	O
or	O
ischemia	O
release	O
a	O
factor	O
which	O
stimulates	O
neovascularization	O
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
there	O
is	O
no	O
direct	O
in	O
vivo	O
evidence	O
in	O
the	O
human	O
proving	O
this	O
theory	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
diabetic	O
subjects	O
were	O
studied	O
to	O
see	O
whether	O
worsening	O
retinopathy	O
was	O
associated	O
with	O
changes	O
in	O
conjunctival	O
oxygen	O
tension	O
(	O
pO2	O
)	O
.	O

Diabetics	O
without	O
retinopathy	O
had	O
a	O
conjunctival	O
pO2	O
which	O
was	O
similar	O
to	O
an	O
age	O
-	O
matched	O
normal	O
population	O
.	O

Diabetics	O
with	O
only	O
background	O
retinopathy	O
had	O
a	O
significantly	O
lower	O
conjunctival	O
pO2	O
than	O
those	O
without	O
retinopathy	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Diabetics	O
with	O
proliferative	O
retinopathy	O
showed	O
a	O
conjunctival	O
pO2	O
that	O
was	O
significantly	O
lower	O
than	O
either	O
of	O
the	O
first	O
two	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
lowest	O
value	O
of	O
all	O
was	O
found	O
in	O
patients	O
with	O
rubeosis	O
iridis	O
.	O

Duration	O
of	O
diabetes	O
alone	O
did	O
not	O
correlate	O
significantly	O
to	O
conjunctival	O
pO2	O
.	O

These	O
findings	O
support	O
the	O
hypoxic	O
theory	O
of	O
diabetic	O
neovascular	O
retinopathy	O
.	O

Unsatisfactory	O
forehead	O
scar	O
following	O
face	O
lift	O
.	O

The	O
W	O
-	O
plasty	O
scar	O
revision	O
technique	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
repair	O
of	O
the	O
difficult	O
and	O
cosmetically	O
unsatisfactory	O
hairline	O
scar	O
following	O
the	O
ill	O
-	O
advised	O
face	O
lift	O
technique	O
that	O
excises	O
forehead	O
skin	O
.	O

Clinical	O
evaluation	O
of	O
radiotherapy	O
for	O
Graves	O
'	O
ophthalmopathy	O
.	O

Seventeen	O
patients	O
with	O
moderately	O
severe	O
ophthalmopathy	O
due	O
to	O
Graves	O
'	O
disease	O
were	O
treated	O
by	O
cobalt	O
or	O
supervoltage	O
radiotherapy	O
.	O

All	O
patients	O
complained	O
of	O
diplopia	O
.	O

The	O
mean	O
proptosis	O
value	O
was	O
21	O
.	O
4	O
mm	O
.	O

Three	O
patients	O
(	O
18	O
%	O
)	O
showed	O
good	O
response	O
,	O
7	O
(	O
41	O
%	O
)	O
moderate	O
and	O
7	O
minimal	O
or	O
no	O
response	O
.	O

Improvement	O
was	O
noted	O
mainly	O
in	O
soft	O
tissue	O
changes	O
and	O
diplopia	O
,	O
while	O
proptosis	O
decreased	O
in	O
only	O
5	O
patients	O
.	O

All	O
except	O
one	O
patient	O
who	O
had	O
marked	O
extraocular	O
muscle	O
involvement	O
revealed	O
by	O
computed	O
tomography	O
responded	O
to	O
treatment	O
.	O

These	O
data	O
indicate	O
that	O
radiotherapy	O
may	O
be	O
indicated	O
in	O
patients	O
with	O
progressive	O
ophthalmopathy	O
,	O
especially	O
in	O
those	O
who	O
are	O
associated	O
with	O
extraocular	O
muscle	O
enlargement	O
.	O

The	O
origin	O
of	O
yolk	O
-	O
DNA	O
in	O
Xenopus	O
laevis	O
.	O

Xenopus	O
laevis	O
serum	O
and	O
plasma	O
was	O
found	O
to	O
contain	O
an	O
average	O
of	O
25	O
microgram	O
DNA	O
/	O
ml	O
.	O

Isolated	O
X	O
.	O
laevis	O
oocytes	O
incubated	O
in	O
medium	O
containing	O
25	O
microgram	O
DNA	O
/	O
ml	O
labeled	O
with	O
either	O
125I	O
,	O
32P	O
or	O
14C	O
and	O
from	O
three	O
different	O
sources	O
(	O
bovine	O
,	O
E	O
.	O
coli	O
and	O
X	O
.	O
laevis	O
)	O
,	O
incorporated	O
the	O
label	O
at	O
an	O
average	O
rate	O
of	O
0	O
.	O
11	O
ng	O
.	O
mm	O
-	O
2	O
.	O
hr	O
-	O
1	O
.	O

Sucrose	O
gradient	O
fractionation	O
of	O
oocytes	O
revealed	O
that	O
40	O
-	O
75	O
%	O
of	O
the	O
acid	O
-	O
precipitable	O
label	O
incorporated	O
was	O
associated	O
with	O
the	O
yolk	O
platelets	O
.	O

Additional	O
incubations	O
of	O
oocytes	O
in	O
unlabeled	O
medium	O
demonstrated	O
that	O
the	O
DNA	O
incorporated	O
into	O
the	O
yolk	O
platelets	O
was	O
undergoing	O
turnover	O
;	O
only	O
20	O
%	O
of	O
the	O
yolk	O
-	O
associated	O
DNA	O
was	O
still	O
present	O
after	O
a	O
one	O
-	O
week	O
incubation	O
.	O

Our	O
data	O
suggest	O
that	O
yolk	O
-	O
DNA	O
arises	O
by	O
the	O
adventitious	O
uptake	O
of	O
DNA	O
present	O
in	O
the	O
maternal	O
serum	O
by	O
vitellogenic	O
oocytes	O
.	O

New	O
functions	O
of	O
epidermal	O
growth	O
factor	O
:	O
stimulation	O
of	O
capillary	O
endothelial	O
cell	O
migration	O
and	O
matrix	O
dependent	O
proliferation	O
.	O

The	O
proliferative	O
response	O
of	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
to	O
EGF	O
is	O
dependent	O
upon	O
attaching	O
the	O
cells	O
to	O
a	O
matrix	O
of	O
fibronectin	O
.	O

Bovine	O
capillary	O
endothelial	O
cells	O
are	O
also	O
stimulated	O
to	O
actively	O
migrate	O
when	O
exposed	O
to	O
EGF	O
in	O
vitro	O
.	O

These	O
activities	O
provide	O
an	O
explanation	O
for	O
the	O
angiogenic	O
properties	O
of	O
EGF	O
in	O
vivo	O
.	O

Capillary	O
cell	O
migration	O
and	O
proliferation	O
are	O
proposed	O
as	O
sensitive	O
quantifiable	O
bioassays	O
to	O
explore	O
the	O
functional	O
domains	O
of	O
the	O
EGF	O
molecule	O
.	O

Studies	O
on	O
the	O
inactivation	O
of	O
these	O
properties	O
of	O
EGF	O
by	O
specific	O
cleavage	O
of	O
the	O
molecule	O
with	O
CNBr	O
or	O
proteases	O
suggest	O
that	O
an	O
intact	O
loop	O
composed	O
in	O
part	O
by	O
amino	O
acid	O
residues	O
20	O
to	O
31	O
is	O
essential	O
for	O
at	O
least	O
some	O
functions	O
.	O

The	O
effect	O
of	O
aflatoxin	O
B1	O
on	O
the	O
utilization	O
of	O
serum	O
calcium	O
.	O

The	O
mathematical	O
analysis	O
for	O
plasma	O
disappearance	O
curve	O
of	O
aflatoxicosed	O
animals	O
,	O
subsequently	O
injected	O
with	O
45Ca	O
was	O
determined	O
.	O

The	O
analysis	O
showed	O
that	O
the	O
three	O
main	O
compartments	O
of	O
the	O
calcium	O
pool	O
(	O
plasma	O
,	O
bone	O
and	O
the	O
labile	O
calcium	O
pool	O
on	O
the	O
surface	O
of	O
bone	O
and	O
soft	O
tissues	O
)	O
had	O
been	O
affected	O
.	O

Specifically	O
,	O
the	O
fractional	O
rate	O
constant	O
for	O
migration	O
of	O
45Ca	O
from	O
plasma	O
pool	O
to	O
the	O
labile	O
pool	O
had	O
been	O
diminished	O
to	O
its	O
third	O
value	O
.	O

This	O
led	O
to	O
a	O
corresponding	O
reduction	O
in	O
the	O
calcium	O
content	O
of	O
the	O
bone	O
ash	O
.	O

The	O
probable	O
mechanism	O
by	O
which	O
aflatoxin	O
B1	O
affects	O
calcium	O
dynamics	O
may	O
be	O
interpreted	O
by	O
the	O
inhibitory	O
effect	O
of	O
aflatoxin	O
in	O
the	O
hydroxylation	O
mechanism	O
of	O
vitamin	O
D3	O
into	O
an	O
active	O
intermediate	O
.	O

During	O
aflatoxicosis	O
(	O
induction	O
of	O
15	O
days	O
)	O
the	O
animals	O
entered	O
a	O
state	O
of	O
calcium	O
deficiency	O
,	O
secondary	O
to	O
intestinal	O
absorption	O
inhibition	O
.	O

This	O
was	O
followed	O
by	O
bone	O
resorption	O
and	O
disturbance	O
of	O
the	O
fractional	O
removal	O
rate	O
constant	O
among	O
different	O
calcium	O
compartments	O
.	O

Low	O
-	O
level	O
X	O
-	O
radiation	O
effects	O
on	O
functional	O
vascular	O
changes	O
in	O
Syrian	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
hydrocarbon	O
carcinogenesis	O
.	O

Effects	O
of	O
repeated	O
low	O
-	O
level	O
X	O
radiation	O
on	O
functional	O
microvascular	O
changes	O
in	O
hamster	O
cheek	O
pouch	O
epithelium	O
during	O
and	O
following	O
carcinogenesis	O
by	O
7	O
,	O
12	O
-	O
dimethylbenz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
studied	O
.	O

Prior	O
studies	O
showed	O
enhancement	O
of	O
such	O
carcinogenesis	O
by	O
repeated	O
20	O
rad	O
head	O
and	O
neck	O
X	O
-	O
radiation	O
exposures	O
,	O
and	O
it	O
was	O
proposed	O
that	O
one	O
possible	O
mechanism	O
was	O
radiogenic	O
alteration	O
of	O
the	O
functional	O
microvasculature	O
in	O
a	O
manner	O
which	O
favored	O
subsequent	O
tumor	O
development	O
.	O

Hamsters	O
were	O
treated	O
with	O
either	O
radiation	O
,	O
DMBA	O
,	O
radiation	O
+	O
DMBA	O
,	O
or	O
no	O
treatment	O
.	O

Animals	O
were	O
sacrificed	O
at	O
3	O
-	O
week	O
intervals	O
from	O
0	O
to	O
39	O
weeks	O
after	O
treatments	O
began	O
.	O

Pouch	O
vascular	O
volume	O
and	O
permeability	O
changes	O
were	O
studied	O
by	O
fractional	O
distributions	O
of	O
radiotracers	O
and	O
were	O
analyzed	O
by	O
a	O
variety	O
of	O
statistical	O
methods	O
which	O
explored	O
the	O
vascular	O
parameters	O
,	O
treatment	O
types	O
,	O
elapsed	O
time	O
,	O
presence	O
of	O
the	O
carcinogen	O
,	O
and	O
histopathologic	O
changes	O
.	O

All	O
treatments	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
volume	O
with	O
time	O
,	O
while	O
only	O
DMBA	O
treatments	O
alone	O
resulted	O
in	O
significant	O
changes	O
in	O
vascular	O
permeability	O
with	O
time	O
.	O

Prior	O
to	O
the	O
appearances	O
of	O
frank	O
neoplasms	O
,	O
volumetric	O
changes	O
in	O
DMBA	O
only	O
and	O
radiation	O
only	O
groups	O
were	O
similar	O
,	O
while	O
volume	O
changes	O
in	O
DMBA	O
+	O
radiation	O
groups	O
increased	O
slowly	O
to	O
a	O
peak	O
later	O
than	O
in	O
other	O
groups	O
and	O
then	O
declined	O
steadily	O
to	O
levels	O
similar	O
to	O
the	O
radiation	O
only	O
group	O
.	O

As	O
in	O
prior	O
studies	O
,	O
there	O
were	O
significant	O
vascular	O
volume	O
differences	O
between	O
DMBA	O
and	O
DMBA	O
+	O
radiation	O
groups	O
of	O
tumor	O
-	O
bearing	O
cheek	O
pouches	O
.	O

DMBA	O
maxima	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
DMBA	O
+	O
radiation	O
.	O

Radiation	O
significantly	O
affected	O
DMBA	O
-	O
associated	O
vascular	O
volume	O
and	O
permeability	O
changes	O
during	O
carcinogenesis	O
.	O

Several	O
possible	O
explanations	O
for	O
the	O
relationship	O
of	O
these	O
changes	O
to	O
the	O
enhancement	O
of	O
DMBA	O
carcinogenesis	O
include	O
:	O
radiation	O
blocking	O
normal	O
capillary	O
proliferative	O
and	O
/	O
or	O
dilatory	O
responses	O
to	O
inflammation	O
secondary	O
to	O
neoplastic	O
changes	O
;	O
radiation	O
-	O
induced	O
focal	O
increases	O
in	O
the	O
pericapillary	O
connective	O
tissue	O
histohematic	O
barrier	O
,	O
stimulating	O
angiogenesis	O
but	O
reducing	O
nutrient	O
diffusion	O
;	O
radiation	O
exposures	O
sensitizing	O
vascular	O
endothelium	O
to	O
subsequent	O
angiogenic	O
stimulation	O
from	O
premalignant	O
tissues	O
;	O
DMBA	O
vascular	O
and	O
epithelial	O
effects	O
partially	O
or	O
completely	O
blocking	O
radiation	O
effects	O
on	O
epithelial	O
and	O
/	O
or	O
endothelial	O
cells	O
;	O
and	O
radiation	O
damage	O
to	O
vessel	O
walls	O
partially	O
or	O
fully	O
inhibiting	O
normal	O
physiologic	O
mechanisms	O
of	O
repairing	O
DMBA	O
damage	O
to	O
the	O
vessels	O
.	O

Immunoglobulins	O
associated	O
with	O
elevated	O
riboflavin	O
binding	O
by	O
plasma	O
from	O
cancer	O
patients	O
.	O

Plasma	O
from	O
182	O
patients	O
with	O
different	O
malignant	O
diseases	O
was	O
tested	O
for	O
riboflavin	O
binding	O
by	O
immunoglobulins	O
,	O
which	O
have	O
been	O
recently	O
identified	O
as	O
major	O
carriers	O
of	O
this	O
micronutrient	O
.	O

A	O
wide	O
range	O
of	O
binding	O
(	O
5	O
.	O
9	O
to	O
130	O
pmole	O
/	O
ml	O
plasma	O
)	O
was	O
observed	O
,	O
and	O
significant	O
elevations	O
were	O
found	O
for	O
patients	O
having	O
breast	O
cancer	O
(	O
21	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
melanoma	O
(	O
25	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
compared	O
to	O
controls	O
(	O
15	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
)	O
.	O

The	O
proteins	O
responsible	O
for	O
a	O
majority	O
of	O
the	O
higher	O
binding	O
were	O
identified	O
as	O
immunoglobulins	O
,	O
based	O
on	O
their	O
elution	O
from	O
gel	O
filtration	O
columns	O
and	O
the	O
removal	O
of	O
57	O
-	O
88	O
%	O
of	O
the	O
non	O
-	O
albumin	O
binding	O
by	O
treating	O
of	O
plasma	O
with	O
Protein	O
A	O
-	O
agarose	O
.	O

The	O
binding	O
was	O
only	O
weakly	O
related	O
to	O
the	O
total	O
concentration	O
of	O
immunoglobulins	O
(	O
r	O
=	O
0	O
.	O
11	O
by	O
linear	O
regression	O
analysis	O
)	O
,	O
however	O
,	O
and	O
is	O
apparently	O
due	O
to	O
a	O
subclass	O
that	O
is	O
elevated	O
in	O
some	O
types	O
of	O
cancer	O
.	O

Elevated	O
levels	O
of	O
these	O
immunoglobulins	O
may	O
contribute	O
to	O
the	O
lower	O
urinary	O
levels	O
and	O
clearance	O
of	O
riboflavin	O
in	O
cancer	O
.	O

Mast	O
cells	O
and	O
tumors	O
.	O

The	O
specific	O
enhancement	O
of	O
tumor	O
proliferation	O
in	O
vitro	O
.	O

Mast	O
cells	O
were	O
found	O
to	O
be	O
unique	O
among	O
the	O
peritoneal	O
leukocytes	O
by	O
virtue	O
of	O
their	O
capacity	O
to	O
enhance	O
profoundly	O
the	O
proliferation	O
of	O
a	O
variety	O
of	O
tumors	O
in	O
vitro	O
.	O

This	O
phenomenon	O
occurs	O
at	O
mast	O
cell	O
/	O
tumor	O
ratios	O
which	O
reflect	O
the	O
stoichiometry	O
of	O
host	O
cell	O
/	O
tumor	O
relationships	O
in	O
vivo	O
.	O

The	O
growth	O
factor	O
was	O
found	O
to	O
reside	O
in	O
mast	O
cell	O
granules	O
and	O
was	O
identified	O
as	O
heparin	O
by	O
sequential	O
purification	O
and	O
enzymatic	O
degradation	O
.	O

This	O
cellular	O
interaction	O
was	O
tumor	O
-	O
specific	O
,	O
although	O
isolated	O
granules	O
could	O
enhance	O
fibroblast	O
proliferation	O
.	O

The	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
previous	O
morphologic	O
studies	O
,	O
reports	O
of	O
in	O
vitro	O
mast	O
-	O
cell	O
-	O
mediated	O
tumor	O
cytotoxicity	O
,	O
and	O
the	O
role	O
of	O
mast	O
cells	O
in	O
angiogenesis	O
and	O
connective	O
tissue	O
proliferation	O
.	O

Management	O
of	O
the	O
tortuous	O
internal	O
carotid	O
artery	O
.	O

The	O
tortuous	O
internal	O
carotid	O
artery	O
as	O
the	O
basis	O
of	O
cerebral	O
vascular	O
insufficiency	O
is	O
a	O
controversial	O
entity	O
,	O
as	O
such	O
lesions	O
frequently	O
occur	O
without	O
neurologic	O
symptoms	O
.	O

However	O
,	O
some	O
tortuous	O
vessels	O
are	O
associated	O
with	O
significant	O
carotid	O
atherosclerotic	O
disease	O
requiring	O
a	O
specific	O
surgical	O
approach	O
.	O

This	O
formed	O
the	O
basis	O
of	O
our	O
report	O
.	O

Symptoms	O
of	O
cerebrovascular	O
insufficiency	O
in	O
association	O
with	O
a	O
tortuous	O
internal	O
carotid	O
artery	O
was	O
encountered	O
in	O
27	O
of	O
853	O
carotid	O
endarterectomies	O
over	O
a	O
22	O
year	O
period	O
.	O

Stenosis	O
of	O
hemodynamic	O
significance	O
was	O
noted	O
in	O
nine	O
patients	O
and	O
irregularities	O
or	O
ulceration	O
were	O
noted	O
in	O
the	O
rest	O
.	O

With	O
the	O
standard	O
technique	O
of	O
carotid	O
endarterectomy	O
,	O
removal	O
of	O
plaque	O
from	O
a	O
tortuous	O
vessel	O
leads	O
to	O
loss	O
of	O
the	O
stenting	O
effect	O
provided	O
by	O
the	O
plaque	O
such	O
that	O
angulation	O
occlusion	O
is	O
likely	O
to	O
occur	O
.	O

The	O
optimal	O
reconstruction	O
in	O
our	O
experience	O
is	O
eversion	O
endarterectomy	O
by	O
transection	O
and	O
lower	O
reimplantation	O
of	O
the	O
internal	O
carotid	O
artery	O
on	O
the	O
common	O
carotid	O
artery	O
.	O

Our	O
experience	O
with	O
17	O
such	O
procedures	O
in	O
15	O
patients	O
has	O
been	O
presented	O
.	O

Postpartum	O
rubella	O
immunization	O
:	O
association	O
with	O
development	O
of	O
prolonged	O
arthritis	O
,	O
neurological	O
sequelae	O
,	O
and	O
chronic	O
rubella	O
viremia	O
.	O

Six	O
women	O
developed	O
chronic	O
long	O
-	O
term	O
arthropathy	O
after	O
postpartum	O
immunization	O
against	O
rubella	O
.	O

All	O
individuals	O
developed	O
acute	O
polyarticular	O
arthritis	O
within	O
12	O
days	O
to	O
three	O
weeks	O
postimmunization	O
and	O
have	O
had	O
continuing	O
chronic	O
or	O
recurrent	O
arthralgia	O
or	O
arthritis	O
for	O
two	O
to	O
seven	O
years	O
after	O
vaccination	O
.	O

Acute	O
neurological	O
manifestations	O
,	O
consisting	O
of	O
carpal	O
tunnel	O
syndrome	O
or	O
multiple	O
paresthesiae	O
,	O
developed	O
postvaccination	O
in	O
three	O
women	O
.	O

Two	O
have	O
developed	O
continuing	O
active	O
or	O
chronic	O
recurrent	O
episodes	O
of	O
blurred	O
vision	O
,	O
paresthesiae	O
,	O
and	O
painful	O
limb	O
syndromes	O
together	O
with	O
recurrent	O
joint	O
symptoms	O
.	O

Chronic	O
rubella	O
viremia	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
MNC	O
)	O
populations	O
in	O
five	O
of	O
the	O
six	O
women	O
up	O
to	O
six	O
years	O
after	O
vaccination	O
.	O

In	O
addition	O
rubella	O
virus	O
was	O
isolated	O
from	O
breast	O
milk	O
MNCs	O
in	O
one	O
individual	O
at	O
nine	O
months	O
postvaccination	O
and	O
from	O
peripheral	O
blood	O
MNCs	O
in	O
two	O
of	O
four	O
breast	O
-	O
fed	O
infants	O
studied	O
at	O
12	O
-	O
18	O
months	O
of	O
age	O
.	O

Immune	O
responses	O
to	O
rubella	O
virus	O
studied	O
at	O
sequential	O
intervals	O
after	O
vaccination	O
correlated	O
with	O
development	O
of	O
rheumatologic	O
and	O
neurological	O
manifestations	O
.	O

Rapid	O
enzyme	O
analysis	O
of	O
amniotic	O
fluid	O
phospholipids	O
containing	O
choline	O
:	O
a	O
comparison	O
with	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
in	O
prenatal	O
assessment	O
of	O
fetal	O
lung	O
maturity	O
.	O

The	O
relation	O
between	O
the	O
choline	O
containing	O
surfactant	O
phospholipids	O
lecithin	O
and	O
sphingomyelin	O
in	O
amniotic	O
fluid	O
and	O
fetal	O
lung	O
maturity	O
is	O
well	O
established	O
.	O

An	O
enzymatic	O
method	O
that	O
had	O
been	O
automated	O
and	O
optimised	O
for	O
use	O
on	O
a	O
centrifugal	O
analyser	O
was	O
used	O
to	O
measure	O
the	O
total	O
choline	O
containing	O
phospholipids	O
in	O
amniotic	O
fluid	O
.	O

The	O
total	O
time	O
taken	O
for	O
this	O
assay	O
was	O
10	O
minutes	O
.	O

The	O
results	O
obtained	O
from	O
100	O
patient	O
samples	O
,	O
using	O
this	O
procedure	O
,	O
compared	O
favourably	O
with	O
the	O
results	O
obtained	O
by	O
the	O
thin	O
layer	O
chromatography	O
procedure	O
used	O
to	O
determine	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
(	O
r	O
=	O
0	O
.	O
93	O
)	O
.	O

A	O
clinical	O
study	O
of	O
60	O
patients	O
showed	O
that	O
this	O
assay	O
predicted	O
prenatal	O
respiratory	O
distress	O
syndrome	O
as	O
well	O
as	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratios	O
.	O

The	O
advantage	O
of	O
this	O
assay	O
over	O
existing	O
procedures	O
is	O
that	O
it	O
requires	O
minimum	O
preparation	O
of	O
the	O
specimen	O
and	O
no	O
extraction	O
,	O
is	O
quick	O
,	O
and	O
shows	O
a	O
high	O
degree	O
of	O
precision	O
.	O

[	O
Histophysiology	O
and	O
histopathology	O
of	O
the	O
adrenals	O
in	O
experimental	O
hypokinesia	O
]	O
.	O

In	O
experiments	O
on	O
male	O
rats	O
in	O
the	O
course	O
of	O
3	O
-	O
month	O
hypokinesia	O
phasic	O
changes	O
were	O
observed	O
in	O
the	O
relative	O
adrenal	O
gland	O
weight	O
,	O
in	O
the	O
volume	O
of	O
the	O
cell	O
nuclei	O
of	O
the	O
glomerular	O
,	O
fasicular	O
zones	O
and	O
the	O
medulla	O
,	O
in	O
the	O
activity	O
of	O
the	O
succinic	O
dehydrogenase	O
,	O
alkaline	O
and	O
acid	O
phosphatases	O
,	O
in	O
the	O
RNA	O
and	O
catecholamine	O
content	O
.	O

These	O
changes	O
are	O
associated	O
with	O
variations	O
in	O
the	O
secretion	O
and	O
biosynthesis	O
of	O
the	O
hormones	O
of	O
the	O
cortical	O
and	O
the	O
medullary	O
layer	O
of	O
the	O
adrenal	O
glands	O
during	O
the	O
hypokinetic	O
stress	O
development	O
.	O

Cardiac	O
gap	O
junction	O
configuration	O
after	O
an	O
uncoupling	O
treatment	O
as	O
a	O
function	O
of	O
time	O
.	O

Rabbit	O
ventricle	O
either	O
was	O
fixed	O
in	O
glutaraldehyde	O
without	O
injury	O
(	O
control	O
)	O
or	O
was	O
injured	O
before	O
fixation	O
,	O
presumably	O
causing	O
electrical	O
uncoupling	O
of	O
the	O
gap	O
junctions	O
.	O

All	O
tissue	O
was	O
then	O
processed	O
for	O
freeze	O
-	O
fracture	O
.	O

Replicas	O
of	O
control	O
gap	O
junctions	O
exhibited	O
irregular	O
packing	O
of	O
the	O
P	O
-	O
face	O
particles	O
and	O
E	O
-	O
face	O
pits	O
.	O

Average	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
was	O
10	O
.	O
5	O
nm	O
.	O

Tissue	O
fixed	O
1	O
-	O
5	O
min	O
after	O
injury	O
showed	O
clumping	O
of	O
gap	O
junctional	O
particles	O
and	O
pits	O
.	O

Within	O
the	O
clumps	O
,	O
the	O
particles	O
and	O
pits	O
were	O
hexagonally	O
packed	O
and	O
the	O
center	O
-	O
to	O
-	O
center	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O

In	O
tissue	O
fixed	O
15	O
-	O
30	O
min	O
after	O
injury	O
,	O
the	O
clumps	O
of	O
gap	O
junctional	O
particles	O
had	O
coalesced	O
into	O
a	O
homogeneous	O
structure	O
in	O
most	O
junctions	O
.	O

The	O
packing	O
of	O
the	O
particles	O
and	O
pits	O
was	O
hexagonal	O
and	O
the	O
spacing	O
of	O
the	O
particles	O
averaged	O
9	O
.	O
5	O
nm	O
.	O

A	O
few	O
pieces	O
of	O
rabbit	O
atrium	O
were	O
frozen	O
without	O
prior	O
fixation	O
or	O
cryoprotection	O
to	O
try	O
to	O
assess	O
the	O
effect	O
of	O
glutarldehyde	O
fixation	O
on	O
gap	O
junction	O
structure	O
.	O

In	O
this	O
tissue	O
the	O
gap	O
junctional	O
particles	O
were	O
irregularly	O
packed	O
and	O
their	O
spacing	O
averaged	O
10	O
.	O
0	O
nm	O
.	O

Absence	O
of	O
effect	O
of	O
prenatal	O
ethanol	O
on	O
adult	O
emotionality	O
and	O
ethanol	O
consumption	O
in	O
rats	O
.	O

Lower	O
peak	O
blood	O
ethanol	O
concentrations	O
after	O
1	O
and	O
2	O
g	O
of	O
ethanol	O
per	O
kg	O
were	O
found	O
in	O
pregnant	O
rats	O
than	O
in	O
virgin	O
females	O
.	O

No	O
significant	O
differences	O
in	O
adult	O
""""	O
emotionality	O
""""	O
or	O
ethanol	O
consumption	O
were	O
found	O
in	O
rats	O
exposed	O
to	O
prenatal	O
alcohol	O
and	O
in	O
pair	O
-	O
fed	O
and	O
untreated	O
controls	O
.	O

Tropical	O
splenomegaly	O
syndrome	O
in	O
Zambia	O
:	O
further	O
observations	O
and	O
effects	O
of	O
cycloguanil	O
and	O
proguanil	O
.	O

Nineteen	O
Zambian	O
patients	O
with	O
the	O
tropical	O
splenomegaly	O
syndrome	O
and	O
sinusoidal	O
lymphocytosis	O
on	O
liver	O
biopsy	O
were	O
studied	O
.	O

The	O
association	O
of	O
macrobulinaemia	O
with	O
the	O
tropical	O
splenomegaly	O
syndrome	O
has	O
again	O
been	O
confirmed	O
.	O

Sixteen	O
patients	O
were	O
treated	O
with	O
antimalarials	O
-	O
12	O
with	O
cycloguanil	O
pamoate	O
alone	O
,	O
3	O
with	O
cycloguanil	O
and	O
proguanil	O
,	O
and	O
1	O
with	O
proguanil	O
alone	O
.	O

Twelve	O
patients	O
were	O
observed	O
for	O
periods	O
of	O
sufficient	O
length	O
for	O
the	O
drug	O
effect	O
to	O
be	O
assessed	O
,	O
and	O
in	O
11	O
there	O
was	O
a	O
good	O
response	O
in	O
terms	O
of	O
decrease	O
in	O
spleen	O
size	O
.	O
Cycloguanil	O
pamoate	O
may	O
be	O
of	O
value	O
both	O
for	O
prophylaxis	O
and	O
treatment	O
in	O
areas	O
where	O
tropical	O
splenomegaly	O
syndrome	O
is	O
endemic	O
.	O

Regulation	O
of	O
glucosyl	O
-	O
and	O
fructosyltransferase	O
synthesis	O
by	O
continuous	O
cultures	O
of	O
Streptococcus	O
mutans	O
.	O

Streptococcus	O
mutans	O
strains	O
Ingbritt	O
,	O
and	O
its	O
derivative	O
B7	O
which	O
had	O
been	O
passaged	O
through	O
monkeys	O
,	O
have	O
been	O
used	O
to	O
investigate	O
how	O
the	O
synthesis	O
of	O
extracellular	O
glucosyl	O
-	O
and	O
fructosyltransferases	O
is	O
regulated	O
.	O

The	O
most	O
active	O
enzyme	O
from	O
carbon	O
-	O
limited	O
continuous	O
cultures	O
was	O
a	O
fructosyltransferase	O
;	O
enzymes	O
catalysing	O
the	O
formation	O
of	O
water	O
-	O
insoluble	O
glucans	O
from	O
sucrose	O
were	O
relatively	O
inactive	O
.	O

Dextransucrase	O
(	O
EC	O
2	O
.	O
4	O
.	O
1	O
.	O
5	O
)	O
,	O
which	O
catalyses	O
soluble	O
glucan	O
synthesis	O
,	O
was	O
most	O
active	O
in	O
the	O
supernatant	O
fluid	O
from	O
cultures	O
grown	O
with	O
excess	O
glucose	O
,	O
fructose	O
or	O
sucrose	O
,	O
but	O
full	O
activity	O
was	O
detected	O
only	O
when	O
the	O
enzyme	O
was	O
incubated	O
with	O
both	O
sucrose	O
and	O
dextran	O
.	O

Little	O
dextransucrase	O
activity	O
was	O
detected	O
in	O
carbon	O
-	O
limited	O
cultures	O
.	O

It	O
is	O
concluded	O
that	O
glucosyl	O
-	O
and	O
fructosyltransferases	O
are	O
constitutive	O
enzymes	O
in	O
that	O
they	O
are	O
synthesized	O
at	O
similar	O
rates	O
during	O
growth	O
with	O
an	O
excess	O
of	O
the	O
substrate	O
or	O
of	O
the	O
products	O
of	O
the	O
reactions	O
which	O
they	O
catalyse	O
.	O

Although	O
the	O
Ingbritt	O
strain	O
was	O
originally	O
isolated	O
from	O
a	O
carious	O
lesion	O
,	O
it	O
is	O
now	O
a	O
poor	O
source	O
of	O
glucosyltransferase	O
activity	O
.	O

Glucosyltransferases	O
were	O
extremely	O
active	O
in	O
cultures	O
of	O
a	O
recent	O
clinical	O
isolate	O
,	O
strain	O
3209	O
,	O
and	O
were	O
apparently	O
induced	O
during	O
growth	O
with	O
excess	O
glucose	O
.	O

Differences	O
between	O
the	O
arterial	O
and	O
the	O
venous	O
pathomorphology	O
in	O
Buerger	O
'	O
s	O
disease	O
.	O

Morphological	O
lesions	O
were	O
found	O
to	O
be	O
different	O
in	O
arteries	O
and	O
in	O
veins	O
,	O
in	O
9	O
cases	O
of	O
Buerger	O
'	O
s	O
disease	O
.	O

The	O
arterial	O
lesions	O
were	O
not	O
characteristic	O
and	O
consisted	O
of	O
non	O
-	O
specific	O
inflammation	O
,	O
thrombosis	O
and	O
obliteration	O
which	O
also	O
occur	O
in	O
many	O
other	O
disease	O
.	O

In	O
contrast	O
,	O
in	O
addition	O
to	O
wall	O
infiltration	O
and	O
thrombosis	O
,	O
the	O
veins	O
showed	O
microabscesses	O
and	O
giant	O
cell	O
granulomas	O
,	O
which	O
we	O
believe	O
to	O
be	O
absent	O
in	O
all	O
other	O
known	O
diseases	O
.	O

The	O
affected	O
venous	O
segment	O
exhibited	O
a	O
variety	O
of	O
lesions	O
.	O

In	O
the	O
earliest	O
period	O
,	O
the	O
morphological	O
aspect	O
of	O
inflammation	O
in	O
arteries	O
and	O
veins	O
was	O
fairly	O
similar	O
.	O

In	O
a	O
late	O
periods	O
,	O
that	O
is	O
those	O
of	O
vascular	O
obliteration	O
,	O
the	O
arteries	O
and	O
veins	O
did	O
not	O
show	O
any	O
distinguishing	O
morphological	O
differences	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
in	O
experimental	O
ocular	O
vasoproliferation	O
.	O

Scanning	O
electron	O
microscopy	O
of	O
vascular	O
casts	O
was	O
used	O
to	O
investigate	O
three	O
experimental	O
models	O
of	O
neovascularization	O
.	O

In	O
each	O
experimental	O
situation	O
,	O
the	O
casts	O
provided	O
a	O
valuable	O
three	O
dimensional	O
representation	O
of	O
the	O
newly	O
formed	O
blood	O
vessels	O
and	O
permitted	O
subclassification	O
of	O
the	O
vessels	O
within	O
normal	O
and	O
proliferating	O
vascular	O
networks	O
.	O

They	O
defined	O
also	O
the	O
predominant	O
origin	O
of	O
new	O
vessels	O
from	O
venules	O
and	O
capillaries	O
,	O
and	O
enabled	O
the	O
evolution	O
of	O
proliferating	O
vessels	O
into	O
arterioles	O
and	O
venules	O
to	O
be	O
documented	O
.	O

Although	O
vascular	O
casts	O
must	O
be	O
interpreted	O
with	O
caution	O
in	O
light	O
of	O
the	O
possibility	O
of	O
incomplete	O
filling	O
and	O
other	O
artifacts	O
,	O
they	O
are	O
a	O
valuable	O
tool	O
in	O
the	O
study	O
of	O
ocular	O
vasoproliferation	O
.	O

Identification	O
of	O
the	O
putative	O
transforming	O
protein	O
of	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
viruses	O
HTLV	O
-	O
I	O
and	O
HTLV	O
-	O
II	O
are	O
unique	O
among	O
the	O
transforming	O
retroviruses	O
of	O
vertebrates	O
in	O
their	O
ability	O
to	O
transform	O
human	O
T	O
cells	O
in	O
vitro	O
and	O
in	O
their	O
close	O
association	O
with	O
human	O
malignancies	O
(	O
T	O
-	O
cell	O
lymphomas	O
and	O
leukemia	O
)	O
.	O

Their	O
genomes	O
are	O
relatively	O
simple	O
,	O
containing	O
the	O
genes	O
gag	O
,	O
pol	O
,	O
env	O
,	O
and	O
a	O
3	O
'	O
region	O
termed	O
""""	O
X	O
.	O
""""	O
This	O
3	O
'	O
region	O
may	O
be	O
responsible	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
viruses	O
.	O

The	O
existence	O
of	O
proteins	O
encoded	O
by	O
the	O
3	O
'	O
region	O
has	O
been	O
postulated	O
on	O
the	O
basis	O
of	O
multiple	O
open	O
reading	O
frames	O
.	O

In	O
the	O
present	O
study	O
this	O
region	O
is	O
shown	O
to	O
contain	O
a	O
gene	O
encoding	O
a	O
protein	O
of	O
40	O
kilodaltons	O
in	O
HTLV	O
-	O
I	O
and	O
37	O
kilodaltons	O
in	O
HTLV	O
-	O
II	O
.	O

It	O
is	O
proposed	O
that	O
these	O
proteins	O
be	O
called	O
,	O
respectively	O
,	O
p40xI	O
and	O
p37xII	O
.	O

Participation	O
of	O
p53	O
cellular	O
tumour	O
antigen	O
in	O
transformation	O
of	O
normal	O
embryonic	O
cells	O
.	O

The	O
cellular	O
tumour	O
antigen	O
p53	O
is	O
found	O
at	O
elevated	O
levels	O
in	O
a	O
wide	O
variety	O
of	O
transformed	O
cells	O
(	O
for	O
reviews	O
see	O
refs	O
1	O
,	O
2	O
)	O
.	O

Very	O
little	O
is	O
yet	O
known	O
about	O
the	O
precise	O
relationship	O
of	O
p53	O
to	O
malignant	O
transformation	O
.	O

Although	O
the	O
increase	O
in	O
p53	O
levels	O
could	O
be	O
a	O
secondary	O
by	O
-	O
product	O
of	O
the	O
transformed	O
state	O
,	O
it	O
is	O
equally	O
possible	O
that	O
p53	O
is	O
actively	O
involved	O
in	O
altering	O
cellular	O
growth	O
properties	O
,	O
especially	O
as	O
it	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
normal	O
cell	O
proliferation	O
.	O

We	O
sought	O
to	O
test	O
whether	O
p53	O
could	O
behave	O
in	O
a	O
manner	O
similar	O
to	O
known	O
genes	O
in	O
a	O
biological	O
test	O
system	O
,	O
and	O
we	O
demonstrate	O
here	O
that	O
p53	O
can	O
cooperate	O
with	O
the	O
activated	O
Ha	O
-	O
ras	O
oncogene	O
to	O
transform	O
normal	O
embryonic	O
cells	O
.	O

The	O
resultant	O
foci	O
contain	O
cells	O
of	O
a	O
markedly	O
altered	O
morphology	O
which	O
produce	O
high	O
levels	O
of	O
p53	O
.	O

Cell	O
lines	O
established	O
from	O
such	O
foci	O
elicit	O
tumours	O
in	O
syngeneic	O
animals	O
.	O

Dynorphin	O
is	O
contained	O
within	O
hippocampal	O
mossy	O
fibers	O
:	O
immunochemical	O
alterations	O
after	O
kainic	O
acid	O
administration	O
and	O
colchicine	O
-	O
induced	O
neurotoxicity	O
.	O

Antisera	O
raised	O
against	O
synthetic	O
dynorphin	O
or	O
[	O
Leu5	O
]	O
enkephalin	O
demonstrate	O
immunostaining	O
in	O
hippocampal	O
mossy	O
fibers	O
and	O
in	O
dentate	O
granule	O
cells	O
.	O

However	O
,	O
dynorphin	O
immunoreactivity	O
(	O
ir	O
)	O
appears	O
to	O
be	O
denser	O
in	O
immunocytochemical	O
preparations	O
and	O
is	O
quantitatively	O
greater	O
by	O
radioimmunoassay	O
than	O
enkephalin	O
-	O
ir	O
.	O

Immunostaining	O
with	O
dynorphin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
dynorphin	O
-	O
17	O
whereas	O
immunostaining	O
with	O
enkephalin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
[	O
Leu5	O
]	O
enkephalin	O
,	O
dynorphin	O
-	O
17	O
,	O
dynorphin	O
-	O
(	O
1	O
-	O
13	O
)	O
,	O
or	O
alpha	O
-	O
neo	O
-	O
endorphin	O
.	O

Intrahippocampal	O
colchicine	O
injections	O
,	O
which	O
selectively	O
destroy	O
dentate	O
granule	O
cells	O
,	O
significantly	O
decrease	O
the	O
dynorphin	O
-	O
ir	O
and	O
enkephalin	O
-	O
ir	O
levels	O
in	O
rat	O
hippocampus	O
.	O

Intraventricularly	O
administered	O
kainic	O
acid	O
,	O
which	O
selectively	O
destroys	O
CA3	O
-	O
4	O
pyramidal	O
cells	O
,	O
results	O
in	O
an	O
increase	O
of	O
enkephalin	O
immunostaining	O
in	O
mossy	O
fibers	O
and	O
a	O
significant	O
increase	O
in	O
enkephalin	O
-	O
ir	O
by	O
radioimmunoassay	O
in	O
whole	O
hippocampus	O
.	O

The	O
enkephalin	O
-	O
ir	O
cells	O
and	O
fibers	O
in	O
entorhinal	O
/	O
perirhinal	O
cortex	O
,	O
which	O
innervate	O
rat	O
hippocampus	O
and	O
dentate	O
gyrus	O
,	O
do	O
not	O
contain	O
dynorphin	O
-	O
ir	O
.	O

Interaction	O
between	O
cellular	O
and	O
viral	O
genes	O
in	O
the	O
expression	O
of	O
the	O
RSV	O
-	O
induced	O
transformation	O
-	O
specific	O
cell	O
-	O
surface	O
antigen	O
VCSA	O
.	O

Transformation	O
of	O
BHK	B
hamster	O
fibroblasts	O
by	O
an	O
env	O
-	O
strain	O
of	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
leads	O
to	O
the	O
appearance	O
at	O
the	O
cell	O
surface	O
of	O
a	O
virus	O
-	O
induced	O
nonvirion	O
antigen	O
(	O
VCSA	O
)	O
,	O
specific	O
for	O
transformation	O
,	O
whose	O
expression	O
is	O
controlled	O
by	O
the	O
transforming	O
src	O
gene	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
a	O
rabbit	O
anti	O
-	O
VCSA	O
serum	O
lyses	O
specifically	O
,	O
in	O
the	O
presence	O
of	O
complement	O
,	O
51Cr	O
-	O
labelled	O
RSV	O
-	O
transformed	O
cells	O
from	O
different	O
animal	O
species	O
.	O

Now	O
,	O
by	O
competition	O
experiments	O
with	O
a	O
panel	O
of	O
different	O
unlabelled	O
cells	O
we	O
show	O
that	O
the	O
VCSA	O
expressed	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
is	O
a	O
complex	O
of	O
at	O
least	O
three	O
distinct	O
antigenic	O
specificities	O
:	O
(	O
1	O
)	O
one	O
expressed	O
on	O
all	O
RSV	O
-	O
transformed	O
fibroblasts	O
,	O
regardless	O
their	O
species	O
and	O
the	O
subgroup	O
or	O
strain	O
of	O
the	O
transforming	O
virus	O
;	O
(	O
2	O
)	O
one	O
cross	O
-	O
reacting	O
with	O
a	O
cell	O
-	O
surface	O
antigen	O
(	O
CSA	O
)	O
expressed	O
at	O
various	O
degrees	O
on	O
untransformed	O
avian	O
fibroblasts	O
,	O
but	O
not	O
on	O
mammalian	O
fibroblasts	O
;	O
(	O
3	O
)	O
one	O
species	O
-	O
specific	O
,	O
present	O
only	O
on	O
RSV	O
-	O
transformed	O
hamster	O
fibroblasts	O
.	O

It	O
is	O
concluded	O
that	O
VCSA	O
is	O
a	O
complex	O
of	O
several	O
antigenic	O
determinants	O
,	O
and	O
that	O
some	O
of	O
these	O
differ	O
in	O
different	O
cells	O
transformed	O
by	O
RSV	O
.	O

This	O
observation	O
indicates	O
that	O
VCSA	O
expression	O
at	O
the	O
cell	O
surface	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
the	O
viral	O
src	O
gene	O
product	O
pp60src	O
with	O
host	O
cell	O
gene	O
(	O
s	O
)	O
or	O
gene	O
product	O
(	O
s	O
)	O
,	O
rather	O
than	O
the	O
simple	O
expression	O
of	O
this	O
molecule	O
at	O
the	O
cell	O
surface	O
.	O

Angiogenesis	O
:	O
initiation	O
and	O
control	O
.	O

From	O
in	O
vivo	O
experiments	O
using	O
new	O
methods	O
such	O
as	O
the	O
rabbit	O
cornea	O
,	O
it	O
is	O
now	O
becoming	O
clear	O
that	O
the	O
growth	O
of	O
a	O
capillary	O
involves	O
an	O
ordered	O
sequence	O
of	O
events	O
that	O
includes	O
lysis	O
of	O
the	O
basement	O
membrane	O
of	O
a	O
parent	O
venule	O
,	O
directional	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
toward	O
the	O
angiogenic	O
stimulus	O
,	O
lumen	O
formation	O
,	O
development	O
of	O
branches	O
,	O
and	O
anastomosis	O
of	O
the	O
tip	O
of	O
one	O
tube	O
with	O
another	O
to	O
form	O
a	O
loop	O
.	O

It	O
is	O
also	O
clear	O
that	O
diffusible	O
angiogenic	O
stimuli	O
can	O
be	O
released	O
not	O
only	O
from	O
most	O
solid	O
tumors	O
,	O
but	O
also	O
from	O
at	O
least	O
three	O
non	O
-	O
neoplastic	O
cells	O
.	O

These	O
include	O
activated	O
macrophages	O
,	O
sensitized	O
lymphocytes	O
,	O
and	O
adipocytes	O
.	O

Other	O
normal	O
tissues	O
can	O
also	O
stimulate	O
angiogenesis	O
,	O
but	O
the	O
type	O
of	O
cell	O
giving	O
rise	O
to	O
the	O
angiogenic	O
stimulus	O
is	O
unknown	O
,	O
and	O
the	O
period	O
of	O
angiogenic	O
stimulation	O
is	O
brief	O
.	O

With	O
the	O
recent	O
ability	O
to	O
clone	O
capillary	O
endothelial	O
cells	O
and	O
to	O
carry	O
them	O
in	O
long	O
-	O
term	O
culture	O
,	O
it	O
has	O
been	O
possible	O
to	O
further	O
delineate	O
the	O
mechanism	O
of	O
capillary	O
growth	O
.	O

In	O
vitro	O
studies	O
have	O
shown	O
that	O
the	O
mast	O
cell	O
seems	O
to	O
behave	O
as	O
a	O
helper	O
cell	O
for	O
capillary	O
endothelial	O
cells	O
,	O
in	O
some	O
way	O
speeding	O
up	O
their	O
rate	O
of	O
directional	O
migration	O
.	O

At	O
this	O
writing	O
,	O
heparin	O
appears	O
to	O
be	O
the	O
principal	O
mast	O
cell	O
factor	O
responsible	O
for	O
this	O
effect	O
on	O
capillary	O
endothelial	O
cells	O
.	O

One	O
theoretical	O
possibility	O
is	O
that	O
mast	O
cells	O
may	O
prepare	O
the	O
matrix	O
,	O
perhaps	O
by	O
slow	O
release	O
of	O
heparin	O
,	O
so	O
that	O
capillary	O
sprouts	O
can	O
more	O
easily	O
move	O
through	O
it	O
toward	O
their	O
angiogenic	O
target	O
.	O

While	O
the	O
study	O
of	O
angiogenesis	O
as	O
a	O
phenomenon	O
is	O
still	O
in	O
an	O
early	O
phase	O
,	O
it	O
has	O
become	O
possible	O
,	O
by	O
using	O
a	O
combination	O
of	O
in	O
vitro	O
and	O
in	O
vivo	O
techniques	O
,	O
to	O
more	O
thoroughly	O
understand	O
the	O
initiation	O
and	O
control	O
of	O
capillary	O
growth	O
.	O

Role	O
of	O
interleukin	O
1	O
in	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
.	O

The	O
role	O
of	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
in	O
human	O
antigen	O
-	O
specific	O
T	O
cell	O
proliferation	O
was	O
examined	O
.	O

Nylon	O
wool	O
-	O
purified	O
T	O
cells	O
proliferated	O
in	O
the	O
presence	O
of	O
autologous	O
monocytes	O
(	O
Mo	O
.	O
)	O
pulsed	O
for	O
18	O
h	O
with	O
tetanus	O
toxoid	O
(	O
TT	O
)	O
antigen	O
(	O
Mo	O
.	O
TT	O
)	O
.	O

Irradiation	O
of	O
Mo	O
.	O
TT	O
with	O
ultraviolet	O
(	O
UV	O
)	O
light	O
(	O
72	O
J	O
/	O
m2	O
)	O
abolished	O
their	O
capacity	O
to	O
support	O
T	O
cell	O
proliferation	O
and	O
drastically	O
reduced	O
their	O
capacity	O
to	O
secrete	O
IL	O
1	O
after	O
stimulation	O
with	O
Staphylococcus	O
albus	O
.	O

The	O
defect	O
in	O
antigen	O
presentation	O
induced	O
by	O
UV	O
irradiation	O
of	O
Mo	O
.	O
TT	O
was	O
reversed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
the	O
addition	O
of	O
two	O
different	O
preparations	O
containing	O
human	O
interleukin	O
1	O
(	O
IL	O
1	O
)	O
.	O

The	O
first	O
preparation	O
consisted	O
of	O
supernatants	O
of	O
Mo	O
.	O
stimulated	O
with	O
Con	O
A	O
for	O
18	O
hr	O
and	O
in	O
which	O
Con	O
A	O
activity	O
was	O
blocked	O
by	O
alpha	O
-	O
D	O
-	O
methyl	O
-	O
mannoside	O
(	O
Mo	O
.	O
-	O
Con	O
A	O
-	O
Sup	O
)	O
.	O

The	O
second	O
preparation	O
consisted	O
of	O
human	O
IL	O
1	O
partially	O
purified	O
from	O
supernatants	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
stimulated	O
with	O
S	O
.	O
albus	O
.	O

This	O
IL	O
1	O
copurified	O
with	O
human	O
leukocyte	O
pyrogen	O
(	O
LP	O
)	O
and	O
was	O
termed	O
IL	O
1	O
/	O
LP	O
.	O

Both	O
IL	O
1	O
-	O
containing	O
preparations	O
enhanced	O
the	O
response	O
of	O
C57BL	O
/	O
6	O
mouse	O
thymocytes	O
to	O
phytohemagglutinin	O
.	O

A	O
rabbit	O
antibody	O
to	O
human	O
IL	O
1	O
/	O
LP	O
inhibited	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
proliferate	O
in	O
response	O
to	O
Mo	O
.	O
TT	O
and	O
inhibited	O
the	O
capacity	O
of	O
Mo	O
.	O
-	O
Con	O
A	O
-	O
Sup	O
to	O
reconstitute	O
the	O
T	O
cell	O
response	O
to	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
.	O

IL	O
1	O
/	O
LP	O
was	O
not	O
necessary	O
for	O
T	O
cells	O
to	O
recognize	O
the	O
immunogenic	O
moiety	O
presented	O
by	O
Mo	O
.	O
,	O
because	O
monolayers	O
of	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
were	O
equivalent	O
to	O
monolayers	O
of	O
unirradiated	O
MO	O
.	O
TT	O
in	O
their	O
capacity	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	O
cells	O
specifically	O
.	O

Furthermore	O
,	O
the	O
addition	O
of	O
rabbit	O
antibody	O
to	O
IL	O
1	O
/	O
LP	O
did	O
not	O
interfere	O
with	O
the	O
capacity	O
of	O
UV	O
-	O
irradiated	O
Mo	O
.	O
TT	O
to	O
adsorb	O
TT	O
-	O
reactive	O
T	O
cells	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
indicate	O
that	O
IL	O
1	O
is	O
involved	O
in	O
optimal	O
antigen	O
-	O
driven	O
proliferation	O
of	O
human	O
T	O
lymphocytes	O
.	O

Ca	O
+	O
+	O
distribution	O
after	O
Na	O
+	O
pump	O
inhibition	O
in	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
.	O

The	O
influence	O
of	O
inhibition	O
of	O
the	O
Na	O
+	O
pump	O
,	O
with	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
on	O
cellular	O
Ca	O
+	O
+	O
distribution	O
is	O
examined	O
using	O
the	O
on	O
-	O
line	O
scintillation	O
disk	O
technique	O
and	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
.	O

Under	O
control	O
conditions	O
,	O
La	O
+	O
+	O
+	O
displaced	O
78	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
13	O
%	O
(	O
SEM	O
)	O
of	O
the	O
total	O
cell	O
associated	O
45Ca	O
.	O

Application	O
of	O
1	O
mm	O
ouabain	O
or	O
reduction	O
of	O
[	O
K	O
+	O
]	O
o	O
to	O
0	O
.	O
5	O
mM	O
resulted	O
in	O
a	O
net	O
increase	O
of	O
10	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
and	O
13	O
.	O
8	O
+	O
/	O
-	O
2	O
%	O
,	O
respectively	O
,	O
in	O
total	O
cell	O
-	O
associated	O
Ca	O
+	O
+	O
.	O

Of	O
this	O
added	O
45Ca	O
,	O
75	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
7	O
%	O
and	O
78	O
.	O
4	O
+	O
/	O
-	O
2	O
.	O
1	O
%	O
,	O
respectively	O
remained	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
.	O

The	O
45Ca	O
-	O
binding	O
characteristics	O
of	O
isolated	O
sarcolemma	O
,	O
prepared	O
from	O
the	O
cultured	O
neonatal	O
rat	O
myocardial	O
cells	O
using	O
the	O
gas	O
dissection	O
technique	O
,	O
were	O
examined	O
.	O

When	O
treated	O
with	O
either	O
ouabain	O
or	O
low	O
[	O
K	O
+	O
]	O
o	O
solutions	O
,	O
sarcolemmal	O
45Ca	O
binding	O
did	O
not	O
change	O
.	O

This	O
result	O
indicates	O
that	O
functional	O
,	O
intact	O
tissue	O
is	O
necessary	O
to	O
observe	O
the	O
Ca	O
+	O
+	O
increase	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
verapamil	O
before	O
and	O
during	O
ouabain	O
exposure	O
failed	O
to	O
inhibit	O
the	O
ouabain	O
-	O
induced	O
increase	O
in	O
cell	O
-	O
associated	O
45Ca	O
.	O

The	O
evidence	O
indicates	O
that	O
inhibition	O
of	O
the	O
Na	O
+	O
-	O
pump	O
,	O
and	O
secondary	O
stimulation	O
of	O
Na	O
+	O
-	O
Ca	O
+	O
+	O
exchange	O
,	O
result	O
in	O
a	O
net	O
increase	O
of	O
11	O
-	O
15	O
%	O
in	O
cell	O
-	O
associated	O
Ca	O
+	O
+	O
,	O
78	O
%	O
of	O
which	O
remains	O
La	O
+	O
+	O
+	O
-	O
displaceable	O
and	O
is	O
,	O
therefore	O
,	O
localized	O
to	O
the	O
sarcolemma	O
-	O
glycocalyx	O
complex	O
.	O

Phosphorylation	O
-	O
induced	O
mobility	O
shift	O
in	O
phospholamban	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
.	O

Evidence	O
for	O
a	O
protein	O
structure	O
consisting	O
of	O
multiple	O
identical	O
phosphorylatable	O
subunits	O
.	O

Phosphorylation	O
of	O
purified	O
phospholamban	O
isolated	O
from	O
canine	O
cardiac	O
sarcoplasmic	O
reticulum	O
vesicles	O
decreased	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
protein	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
polyacrylamide	O
gels	O
.	O

Different	O
mobility	O
forms	O
of	O
phospholamban	O
in	O
SDS	O
gels	O
were	O
visualized	O
both	O
by	O
direct	O
protein	O
staining	O
and	O
by	O
autoradiography	O
.	O

Unphosphorylated	O
phospholamban	O
migrated	O
with	O
an	O
apparent	O
Mr	O
=	O
25	O
,	O
000	O
in	O
SDS	O
gels	O
;	O
maximal	O
phosphorylation	O
of	O
phospholamban	O
by	O
cAMP	O
-	O
or	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
increased	O
the	O
apparent	O
Mr	O
to	O
27	O
,	O
000	O
.	O

Partial	O
phosphorylation	O
of	O
phospholamban	O
by	O
either	O
protein	O
kinase	O
gave	O
intermediate	O
mobility	O
forms	O
of	O
molecular	O
weights	O
between	O
25	O
,	O
000	O
and	O
27	O
,	O
000	O
,	O
suggesting	O
that	O
more	O
than	O
one	O
phosphorylation	O
site	O
was	O
present	O
on	O
the	O
holoprotein	O
for	O
each	O
activity	O
.	O

Boiling	O
of	O
phospholamban	O
in	O
SDS	O
dissociated	O
the	O
holoprotein	O
into	O
an	O
apparently	O
homogeneous	O
class	O
of	O
low	O
molecular	O
weight	O
""""	O
monomers	O
.	O
""""	O
Only	O
two	O
mobility	O
forms	O
of	O
monomeric	O
phospholamban	O
were	O
observed	O
in	O
SDS	O
gels	O
after	O
phosphorylation	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
corresponding	O
to	O
9	O
-	O
kDa	O
dephospho	O
-	O
and	O
11	O
-	O
kDa	O
phosphoproteins	O
.	O

All	O
of	O
the	O
9	O
-	O
kDa	O
protein	O
could	O
be	O
phosphorylated	O
and	O
converted	O
into	O
the	O
11	O
-	O
kDa	O
mobility	O
form	O
,	O
suggesting	O
the	O
presence	O
of	O
only	O
one	O
site	O
of	O
phosphorylation	O
on	O
a	O
single	O
type	O
of	O
monomer	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O

Simultaneous	O
phosphorylation	O
of	O
monomeric	O
phospholamban	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
gave	O
an	O
additional	O
mobility	O
form	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
different	O
sites	O
of	O
phosphorylation	O
were	O
present	O
for	O
each	O
activity	O
on	O
each	O
monomer	O
.	O

Incomplete	O
dissociation	O
of	O
the	O
holoprotein	O
by	O
boiling	O
it	O
in	O
a	O
relatively	O
low	O
concentration	O
of	O
SDS	O
facilitated	O
the	O
detection	O
of	O
five	O
major	O
mobility	O
forms	O
of	O
the	O
protein	O
in	O
SDS	O
gels	O
,	O
and	O
the	O
mobilities	O
of	O
all	O
of	O
these	O
forms	O
were	O
decreased	O
by	O
phosphorylation	O
.	O

We	O
propose	O
that	O
the	O
high	O
molecular	O
weight	O
form	O
of	O
phospholamban	O
is	O
a	O
multimer	O
of	O
electrophoretically	O
indistinguishable	O
monomers	O
,	O
each	O
of	O
which	O
contains	O
a	O
different	O
phosphorylation	O
site	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activity	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
activity	O
.	O

Phosphorylation	O
of	O
phospholamban	O
at	O
multiple	O
sites	O
is	O
responsible	O
for	O
the	O
various	O
mobility	O
forms	O
of	O
the	O
holoprotein	O
detected	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
.	O

Protection	O
from	O
experimental	O
ocular	O
herpetic	O
keratitis	O
by	O
a	O
heat	O
-	O
killed	O
virus	O
vaccine	O
.	O

New	O
Zealand	O
white	O
rabbits	O
were	O
given	O
limbal	O
inoculations	O
of	O
a	O
heat	O
-	O
killed	O
suspension	O
of	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
in	O
a	O
lysate	O
of	O
human	O
embryonic	O
kidney	O
cells	O
.	O

At	O
intervals	O
of	O
four	O
to	O
14	O
days	O
,	O
the	O
animals	O
were	O
challenged	O
by	O
intrastromal	O
inoculation	O
with	O
10	O
,	O
000	O
plaque	O
-	O
forming	O
units	O
of	O
viable	O
HSV	O
.	O

Epithelial	O
keratitis	O
,	O
disciform	O
edema	O
,	O
and	O
necrotizing	O
keratitis	O
with	O
neovascularization	O
of	O
the	O
cornea	O
developed	O
in	O
control	O
animals	O
.	O

Epithelial	O
keratitis	O
and	O
corneal	O
edema	O
also	O
developed	O
in	O
the	O
immunized	O
animals	O
during	O
the	O
first	O
week	O
after	O
virus	O
challenge	O
,	O
but	O
these	O
symptoms	O
rapidly	O
resolved	O
during	O
the	O
following	O
weeks	O
.	O

The	O
absence	O
of	O
iritis	O
,	O
neovascularization	O
,	O
and	O
necrotizing	O
keratitis	O
in	O
the	O
corneas	O
of	O
the	O
immunized	O
animals	O
was	O
particularly	O
striking	O
.	O

Cells	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
release	O
transforming	O
growth	O
factors	O
.	O

Chicken	O
embryo	O
fibroblasts	O
and	O
hamster	O
BHK	B
cells	O
transformed	O
by	O
Rous	O
sarcoma	O
virus	O
(	O
RSV	O
)	O
release	O
in	O
their	O
culture	O
media	O
growth	O
factors	O
which	O
enhance	O
markedly	O
anchorage	O
-	O
independent	O
colony	O
formation	O
in	O
gelified	O
medium	O
,	O
at	O
the	O
restrictive	O
temperature	O
(	O
41	O
degrees	O
5	O
C	O
)	O
,	O
of	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
infected	O
by	O
RSV	O
mutants	O
with	O
a	O
ts	O
mutation	O
of	O
the	O
src	O
gene	O
.	O

This	O
action	O
is	O
not	O
observed	O
with	O
uninfected	O
CEF	O
,	O
and	O
,	O
therefore	O
,	O
appears	O
to	O
require	O
some	O
expression	O
of	O
the	O
viral	O
src	O
gene	O
in	O
the	O
target	O
cells	O
.	O

The	O
enhancing	O
factors	O
are	O
proteins	O
related	O
to	O
the	O
family	O
of	O
the	O
transforming	O
growth	O
factors	O
(	O
TGFs	O
)	O
by	O
their	O
molecular	O
weight	O
(	O
about	O
20	O
kd	O
)	O
,	O
their	O
heat	O
and	O
acid	O
resistance	O
,	O
and	O
their	O
sensitivity	O
to	O
dithiothreitol	O
.	O

They	O
do	O
not	O
compete	O
with	O
125I	O
EGF	O
for	O
binding	O
on	O
the	O
EGF	O
receptors	O
of	O
the	O
membrane	O
of	O
A431	B
cells	O
.	O

As	O
chicken	O
embryo	O
fibroblasts	O
are	O
devoid	O
of	O
EGF	O
receptors	O
,	O
their	O
activity	O
is	O
not	O
potentiated	O
by	O
EGF	O
.	O

The	O
genetics	O
of	O
transformation	O
by	O
SV	O
40	O
.	O

Experiments	O
using	O
the	O
tsA	O
58	O
allele	O
of	O
the	O
SV	O
40	O
-	O
A	O
gene	O
have	O
demonstrated	O
that	O
the	O
SV	O
40	O
large	O
T	O
-	O
antigen	O
is	O
strictly	O
required	O
both	O
for	O
immortalization	O
and	O
induction	O
anchorage	O
independence	O
of	O
cells	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
immortalized	O
phenotype	O
is	O
mediated	O
by	O
an	O
extra	O
cellular	O
factor	O
.	O

The	O
synthesis	O
and	O
/	O
or	O
the	O
excretion	O
of	O
this	O
factor	O
in	O
a	O
medium	O
is	O
controlled	O
by	O
the	O
A	O
gene	O
.	O

Effects	O
of	O
growth	O
temperature	O
,	O
47	O
-	O
megadalton	O
plasmid	O
,	O
and	O
calcium	O
deficiency	O
on	O
the	O
outer	O
membrane	O
protein	O
porin	O
and	O
lipopolysaccharide	O
composition	O
of	O
Yersinia	O
pestis	O
EV76	O
.	O

The	O
expression	O
of	O
several	O
virulence	O
determinants	O
of	O
Yersinia	O
pestis	O
is	O
known	O
to	O
be	O
dependent	O
on	O
the	O
in	O
vitro	O
growth	O
temperature	O
.	O

One	O
of	O
these	O
,	O
calcium	O
dependence	O
,	O
is	O
associated	O
with	O
the	O
presence	O
of	O
a	O
47	O
-	O
megadalton	O
plasmid	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
incubation	O
temperature	O
,	O
calcium	O
in	O
the	O
growth	O
medium	O
,	O
the	O
presence	O
of	O
the	O
47	O
-	O
megadalton	O
plasmid	O
on	O
the	O
outer	O
membrane	O
protein	O
,	O
and	O
the	O
lipopolysaccharide	O
composition	O
of	O
Y	O
.	O
pestis	O
EV76	O
.	O

When	O
cells	O
were	O
grown	O
at	O
37	O
degrees	O
C	O
as	O
opposed	O
to	O
26	O
degrees	O
C	O
,	O
a	O
change	O
in	O
lipopolysaccharide	O
composition	O
and	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
an	O
outer	O
membrane	O
protein	O
(	O
protein	O
E	O
)	O
were	O
observed	O
.	O

The	O
lipopolysaccharide	O
obtained	O
from	O
cells	O
incubated	O
at	O
37	O
degrees	O
C	O
had	O
a	O
lower	O
proportion	O
of	O
2	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
,	O
a	O
lower	O
phosphate	O
to	O
2	O
-	O
keto	O
-	O
3	O
-	O
deoxyoctanate	O
ratio	O
,	O
and	O
an	O
increased	O
gel	O
mobility	O
upon	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
when	O
compared	O
with	O
lipopolysaccharide	O
obtained	O
from	O
cells	O
grown	O
at	O
26	O
degrees	O
C	O
.	O

Because	O
of	O
its	O
growth	O
temperature	O
-	O
related	O
abundance	O
,	O
we	O
investigated	O
the	O
nature	O
of	O
protein	O
E	O
.	O

This	O
protein	O
had	O
physical	O
properties	O
similar	O
to	O
those	O
of	O
other	O
enterobacterial	O
porins	O
,	O
including	O
apparent	O
formation	O
of	O
an	O
oligomer	O
on	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
when	O
solubilized	O
at	O
low	O
temperature	O
,	O
acidic	O
isoelectric	O
point	O
,	O
and	O
strong	O
noncovalent	O
association	O
with	O
the	O
peptidoglycan	O
.	O

Protein	O
E	O
was	O
purified	O
and	O
shown	O
to	O
form	O
an	O
aqueous	O
channel	O
in	O
planar	O
lipid	O
membranes	O
with	O
a	O
conductance	O
of	O
1	O
.	O
1	O
nS	O
in	O
1	O
M	O
KCl	O
.	O

In	O
addition	O
to	O
growth	O
temperature	O
-	O
related	O
alterations	O
in	O
the	O
lipopolysaccharide	O
and	O
porin	O
components	O
of	O
the	O
outer	O
membrane	O
,	O
the	O
amount	O
of	O
three	O
spots	O
in	O
two	O
-	O
dimensional	O
polyacrylamide	O
gels	O
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
temperature	O
or	O
the	O
presence	O
of	O
calcium	O
during	O
growth	O
.	O

One	O
of	O
these	O
spots	O
was	O
shown	O
to	O
contain	O
residual	O
unmodified	O
portions	O
of	O
two	O
major	O
heat	O
-	O
modifiable	O
proteins	O
which	O
failed	O
to	O
shift	O
to	O
their	O
heat	O
-	O
modified	O
positions	O
on	O
gels	O
,	O
despite	O
solubilization	O
at	O
100	O
degrees	O
C	O
for	O
10	O
min	O
before	O
electrophoresis	O
.	O

The	O
other	O
two	O
spots	O
were	O
the	O
heat	O
-	O
modified	O
and	O
unmodified	O
forms	O
of	O
another	O
outer	O
membrane	O
protein	O
(	O
J	O
)	O
which	O
did	O
not	O
appear	O
in	O
the	O
isoelectric	O
focusing	O
gel	O
of	O
cells	O
grown	O
at	O
37	O
degrees	O
C	O
.	O

It	O
is	O
proposed	O
that	O
the	O
appearance	O
of	O
these	O
spots	O
in	O
two	O
-	O
dimensional	O
analyses	O
is	O
related	O
to	O
the	O
lipopolysaccharide	O
composition	O
of	O
the	O
cells	O
from	O
which	O
the	O
outer	O
membrane	O
is	O
derived	O
and	O
reflects	O
lipopolysaccharide	O
-	O
protein	O
interactions	O
or	O
calcium	O
-	O
protein	O
interactions	O
.	O

Protein	O
kinase	O
activities	O
in	O
immune	O
complexes	O
of	O
simian	O
virus	O
40	O
large	O
T	O
-	O
antigen	O
and	O
transformation	O
-	O
associated	O
cellular	O
p53	O
protein	O
.	O

Immune	O
complex	O
kinase	O
assays	O
in	O
the	O
simian	O
virus	O
40	O
system	O
were	O
performed	O
by	O
incubation	O
of	O
immunoprecipitates	O
containing	O
tumor	O
antigens	O
with	O
[	O
gamma	O
-	O
32P	O
]	O
ATP	O
,	O
followed	O
by	O
analysis	O
of	O
any	O
phosphoacceptor	O
proteins	O
.	O

These	O
assays	O
yielded	O
mainly	O
the	O
viral	O
large	O
T	O
-	O
antigen	O
and	O
,	O
in	O
particular	O
,	O
the	O
associated	O
cellular	O
p53	O
as	O
endogenous	O
substrates	O
.	O

The	O
nature	O
of	O
these	O
substrates	O
was	O
confirmed	O
by	O
proteolysis	O
techniques	O
.	O

Under	O
specific	O
conditions	O
,	O
casein	O
could	O
be	O
used	O
as	O
an	O
exogenous	O
substrate	O
as	O
well	O
.	O

The	O
kinase	O
reactions	O
showed	O
preference	O
for	O
ATP	O
and	O
MgCl2	O
instead	O
of	O
GTP	O
or	O
MnCl2	O
.	O

Both	O
phosphoserine	O
and	O
phosphothreonine	O
,	O
but	O
in	O
no	O
case	O
phosphotyrosine	O
,	O
were	O
detected	O
after	O
an	O
immune	O
complex	O
kinase	O
reaction	O
.	O

Apparently	O
,	O
several	O
in	O
vivo	O
phosphorylation	O
sites	O
were	O
recognized	O
in	O
vitro	O
in	O
both	O
large	O
T	O
-	O
antigen	O
and	O
p53	O
,	O
but	O
the	O
presence	O
of	O
some	O
artifactual	O
sites	O
could	O
not	O
be	O
completely	O
excluded	O
.	O

Although	O
contaminating	O
kinases	O
were	O
detectable	O
in	O
the	O
immune	O
complexes	O
,	O
at	O
least	O
the	O
p53	O
molecules	O
were	O
phosphorylated	O
in	O
vitro	O
in	O
a	O
more	O
specific	O
way	O
.	O

This	O
followed	O
from	O
several	O
characteristics	O
of	O
the	O
immune	O
complex	O
kinase	O
reactions	O
and	O
especially	O
from	O
the	O
strong	O
inhibition	O
of	O
p53	O
phosphorylation	O
by	O
two	O
anti	O
-	O
large	O
-	O
T	O
monoclonal	O
antibodies	O
.	O

It	O
was	O
shown	O
that	O
large	O
T	O
-	O
antigen	O
showed	O
associated	O
kinase	O
activity	O
,	O
although	O
none	O
of	O
our	O
results	O
could	O
unambiguously	O
demonstrate	O
an	O
intrinsic	O
kinase	O
activity	O
of	O
this	O
protein	O
.	O

Finally	O
,	O
anti	O
-	O
p53	O
monoclonal	O
antibodies	O
only	O
slightly	O
affected	O
in	O
vitro	O
phosphorylation	O
reactions	O
,	O
whereas	O
a	O
p53	O
molecule	O
from	O
a	O
simian	O
virus	O
40	O
-	O
free	O
,	O
chemically	O
transformed	O
human	O
cell	O
line	O
was	O
not	O
phosphorylated	O
in	O
vitro	O
under	O
any	O
condition	O
tested	O
.	O

Thus	O
,	O
it	O
is	O
highly	O
unlikely	O
that	O
the	O
p53	O
molecule	O
per	O
se	O
carries	O
intrinsic	O
or	O
even	O
associated	O
kinase	O
activities	O
.	O

Molecular	O
events	O
leading	O
to	O
enhanced	O
glucose	O
transport	O
in	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
cells	O
.	O

Transformation	O
by	O
Rous	O
sarcoma	O
virus	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
the	O
rate	O
at	O
which	O
the	O
transformed	O
cells	O
transport	O
glucose	O
across	O
the	O
cell	O
membrane	O
.	O

The	O
increased	O
transport	O
rate	O
is	O
a	O
consequence	O
of	O
an	O
increased	O
number	O
of	O
transporters	O
in	O
the	O
transformed	O
cells	O
.	O

Utilizing	O
antibody	O
raised	O
against	O
the	O
purified	O
human	O
erythrocyte	O
glucose	O
transporter	O
,	O
we	O
have	O
identified	O
the	O
glucose	O
transporter	O
as	O
a	O
membrane	O
glycoprotein	O
with	O
a	O
monomer	O
Mr	O
of	O
approximately	O
41	O
,	O
000	O
.	O

The	O
increased	O
rate	O
of	O
glucose	O
transport	O
is	O
dependent	O
on	O
the	O
activity	O
of	O
pp60src	O
,	O
the	O
transforming	O
protein	O
of	O
Rous	O
sarcoma	O
virus	O
.	O

This	O
protein	O
has	O
been	O
shown	O
to	O
be	O
a	O
protein	O
kinase	O
that	O
phosphorylates	O
on	O
tyrosine	O
residues	O
.	O

We	O
have	O
examined	O
the	O
tyrosine	O
phosphorylation	O
of	O
a	O
major	O
cellular	O
protein	O
of	O
Mr	O
36	O
,	O
000	O
in	O
cells	O
infected	O
with	O
a	O
panel	O
of	O
partially	O
transforming	O
mutants	O
of	O
Rous	O
sarcoma	O
virus	O
.	O

One	O
of	O
these	O
mutants	O
(	O
CU2	O
)	O
increases	O
the	O
rate	O
of	O
glucose	O
transport	O
only	O
slightly	O
and	O
does	O
not	O
render	O
the	O
infected	O
cells	O
fully	O
anchorage	O
independent	O
or	O
tumorigenic	O
(	O
although	O
other	O
transformation	O
parameters	O
are	O
fully	O
induced	O
)	O
.	O

Cells	O
infected	O
with	O
this	O
mutant	O
display	O
a	O
36	O
,	O
000	O
-	O
dalton	O
protein	O
that	O
is	O
phosphorylated	O
to	O
a	O
considerably	O
lesser	O
extent	O
than	O
cells	O
infected	O
with	O
wild	O
-	O
type	O
virus	O
.	O

Analyses	O
of	O
this	O
sort	O
may	O
help	O
to	O
identify	O
the	O
cellular	O
targets	O
of	O
pp60src	O
whose	O
phosphorylation	O
is	O
necessary	O
for	O
the	O
increased	O
glucose	O
transport	O
rate	O
.	O

Preliminary	O
evidence	O
for	O
a	O
pyridine	O
nucleotide	O
cycle	O
in	O
Bordetella	O
pertussis	O
.	O

Preliminary	O
evidence	O
that	O
Bordetella	O
pertussis	O
has	O
a	O
functional	O
pyridine	O
nucleotide	O
cycle	O
was	O
the	O
observation	O
that	O
[	O
14C	O
]	O
-	O
nicotinic	O
acid	O
was	O
rapidly	O
metabolized	O
during	O
its	O
uptake	O
by	O
the	O
bacteria	O
to	O
pyridine	O
nucleotides	O
and	O
nicotinamide	O
.	O

Nicotinamide	O
deamidase	O
activity	O
,	O
necessary	O
for	O
the	O
completion	O
of	O
the	O
cycle	O
by	O
conversion	O
of	O
nicotinamide	O
to	O
nicotinic	O
acid	O
,	O
was	O
found	O
in	O
a	O
soluble	O
extract	O
(	O
20	O
000	O
X	O
g	O
supernatant	O
)	O
of	O
B	O
.	O
pertussis	O
cell	O
lysates	O
.	O

Use	O
of	O
monoclonal	O
antibodies	O
to	O
investigate	O
a	O
possible	O
role	O
of	O
thyroglobulin	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
.	O

One	O
possible	O
mechanism	O
for	O
Graves	O
'	O
ophthalmopathy	O
is	O
that	O
the	O
progressive	O
orbital	O
inflammation	O
is	O
initiated	O
by	O
formation	O
of	O
thyroglobulin	O
(	O
Tg	O
)	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
at	O
sites	O
of	O
Tg	O
binding	O
to	O
extraocular	O
muscle	O
membranes	O
.	O

In	O
this	O
study	O
monoclonal	O
antibodies	O
(	O
MCAB	O
)	O
against	O
human	O
Tg	O
were	O
used	O
as	O
probes	O
(	O
1	O
)	O
to	O
identify	O
Tg	O
in	O
eye	O
muscle	O
membranes	O
prepared	O
from	O
normal	O
subjects	O
and	O
(	O
2	O
)	O
to	O
measure	O
binding	O
of	O
human	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
to	O
eye	O
muscle	O
membranes	O
.	O

Reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
Tg	O
,	O
thyroid	O
,	O
and	O
eye	O
muscle	O
membranes	O
was	O
determined	O
by	O
binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
monoclonal	O
antibody	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O

Seven	O
membrane	O
fractions	O
,	O
prepared	O
by	O
differential	O
sucrose	O
gradient	O
centrifugation	O
,	O
were	O
used	O
.	O

Whereas	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
MCAB	O
bound	O
to	O
all	O
thyroid	O
membrane	O
fractions	O
tested	O
,	O
no	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
bound	O
to	O
eye	O
muscle	O
membranes	O
.	O

Similarly	O
,	O
reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
eye	O
muscle	O
membranes	O
was	O
not	O
demonstrated	O
in	O
ELISA	O
or	O
immunofluorescence	O
tests	O
.	O

Although	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
bound	O
to	O
thyroid	O
membranes	O
,	O
such	O
complexes	O
did	O
not	O
bind	O
to	O
eye	O
muscle	O
membranes	O
.	O

Significant	O
binding	O
of	O
[	O
125I	O
]	O
human	O
Tg	O
to	O
eye	O
muscle	O
or	O
thyroid	O
membranes	O
was	O
not	O
demonstrated	O
for	O
any	O
membrane	O
preparation	O
.	O

On	O
the	O
other	O
hand	O
moderate	O
,	O
but	O
significant	O
,	O
binding	O
to	O
skeletal	O
muscle	O
was	O
shown	O
.	O

Similar	O
results	O
were	O
found	O
using	O
an	O
ELISA	O
.	O

Binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
-	O
Tg	O
complexes	O
of	O
[	O
125I	O
]	O
Tg	O
to	O
thyroid	O
and	O
eye	O
muscle	O
membranes	O
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
normal	O
human	O
serum	O
,	O
phosphate	O
ions	O
,	O
pH	O
,	O
or	O
incubation	O
temperature	O
,	O
conditions	O
claimed	O
by	O
others	O
to	O
be	O
critical	O
for	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complex	O
binding	O
.	O

Since	O
Tg	O
is	O
not	O
present	O
in	O
normal	O
human	O
eye	O
muscle	O
a	O
major	O
role	O
of	O
Tg	O
,	O
or	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
,	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
appears	O
to	O
have	O
been	O
excluded	O
by	O
these	O
findings	O
.	O

DNA	O
methylation	O
and	O
expression	O
of	O
HLA	O
-	O
DR	O
alpha	O
.	O

B	O
-	O
cell	O
lines	O
established	O
from	O
two	O
individuals	O
with	O
T	O
-	O
cell	O
acute	O
lymphocytic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
express	O
HLA	O
-	O
DR	O
antigens	O
,	O
whereas	O
the	O
isogenic	O
T	O
-	O
cells	O
do	O
not	O
.	O

The	O
lack	O
of	O
expression	O
correlates	O
with	O
a	O
lack	O
of	O
detectable	O
HLA	O
-	O
DR	O
mRNA	O
.	O

All	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
detected	O
by	O
a	O
cloned	O
DR	O
alpha	O
cDNA	O
probe	O
are	O
contained	O
in	O
a	O
BglII	O
fragment	O
which	O
varies	O
slightly	O
in	O
size	O
(	O
4	O
.	O
0	O
to	O
4	O
.	O
8	O
kilobases	O
)	O
from	O
one	O
individual	O
to	O
another	O
.	O

In	O
DNA	O
from	O
the	O
T	O
-	O
cells	O
not	O
expressing	O
DR	O
alpha	O
mRNA	O
,	O
all	O
of	O
the	O
potential	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
appeared	O
to	O
be	O
methylated	O
.	O

In	O
contrast	O
,	O
at	O
least	O
some	O
of	O
these	O
sites	O
were	O
not	O
methylated	O
in	O
DNA	O
from	O
the	O
B	O
-	O
cells	O
expressing	O
high	O
levels	O
of	O
DR	O
alpha	O
mRNA	O
.	O

Treatment	O
of	O
these	O
T	O
-	O
cells	O
with	O
5	O
-	O
azacytidine	O
resulted	O
in	O
the	O
induction	O
of	O
DR	O
surface	O
antigen	O
expression	O
,	O
the	O
appearance	O
of	O
DR	O
alpha	O
mRNA	O
,	O
and	O
the	O
partial	O
demethylation	O
of	O
the	O
DR	O
alpha	O
DNA	O
sequences	O
.	O

T	O
-	O
cell	O
lines	O
established	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
associated	O
T	O
-	O
cell	O
neoplasias	O
,	O
in	O
contrast	O
to	O
the	O
T	O
-	O
cell	O
acute	O
lymphocytic	O
leukemia	O
cell	O
lines	O
,	O
expressed	O
both	O
DR	O
antigens	O
and	O
DR	O
alpha	O
mRNA	O
;	O
the	O
HpaII	O
sites	O
within	O
the	O
BglII	O
fragment	O
of	O
DR	O
alpha	O
DNA	O
of	O
these	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
positive	O
T	O
-	O
cell	O
lines	O
were	O
in	O
all	O
cases	O
at	O
least	O
partially	O
unmethylated	O
.	O

Uncultured	O
peripheral	O
blood	O
T	O
-	O
cells	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
-	O
lymphoma	O
virus	O
-	O
infected	O
individuals	O
expressed	O
DR	O
antigens	O
at	O
a	O
low	O
level	O
,	O
and	O
the	O
DR	O
alpha	O
locus	O
was	O
partially	O
unmethylated	O
.	O

After	O
48	O
h	O
in	O
culture	O
,	O
DR	O
antigen	O
expression	O
was	O
substantially	O
increased	O
,	O
but	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
methylation	O
of	O
the	O
DR	O
alpha	O
locus	O
or	O
in	O
the	O
amount	O
of	O
DR	O
mRNA	O
which	O
was	O
present	O
.	O

This	O
suggests	O
that	O
expression	O
of	O
DR	O
antigens	O
also	O
can	O
be	O
modulated	O
post	O
-	O
transcriptionally	O
.	O

Oesophageal	O
candidiasis	O
and	O
croup	O
in	O
a	O
child	O
with	O
defective	O
neutrophil	O
motility	O
.	O

Severe	O
oesophageal	O
candidiasis	O
and	O
croup	O
due	O
to	O
involvement	O
of	O
the	O
larynx	O
developed	O
insidiously	O
in	O
a	O
girl	O
aged	O
20	O
months	O
.	O

There	O
had	O
been	O
delayed	O
separation	O
of	O
the	O
umbilical	O
cord	O
and	O
repeated	O
infections	O
associated	O
with	O
a	O
defect	O
of	O
neutrophil	O
motility	O
.	O

The	O
significance	O
of	O
the	O
early	O
clinical	O
features	O
was	O
not	O
fully	O
appreciated	O
and	O
the	O
diagnosis	O
considered	O
only	O
when	O
stricture	O
of	O
the	O
oesophagus	O
became	O
evident	O
.	O

She	O
was	O
treated	O
with	O
oral	O
ketoconazole	O
100	O
mg	O
daily	O
.	O

After	O
one	O
month	O
'	O
s	O
treatment	O
there	O
was	O
striking	O
radiological	O
improvement	O
apart	O
from	O
the	O
persistence	O
of	O
the	O
oesophageal	O
stricture	O
.	O

The	O
croup	O
resolved	O
completely	O
but	O
there	O
was	O
only	O
partial	O
relief	O
of	O
dysphagia	O
because	O
of	O
the	O
residual	O
stricture	O
.	O

We	O
would	O
emphasis	O
that	O
candidiasis	O
should	O
be	O
anticipated	O
and	O
treated	O
vigorously	O
in	O
children	O
with	O
such	O
a	O
defect	O
of	O
neutrophil	O
motility	O
.	O

Rapid	O
micromeasurement	O
of	O
lactate	O
in	O
whole	O
blood	O
.	O

A	O
new	O
lactate	O
sensor	O
makes	O
it	O
possible	O
to	O
measure	O
the	O
lactate	O
content	O
of	O
whole	O
blood	O
directly	O
in	O
less	O
than	O
1	O
min	O
,	O
using	O
only	O
a	O
10	O
-	O
microL	O
blood	O
sample	O
.	O

The	O
procedure	O
works	O
equally	O
well	O
with	O
plasma	O
,	O
serum	O
,	O
spinal	O
fluid	O
,	O
other	O
body	O
fluids	O
,	O
or	O
tissue	O
homogenates	O
.	O

The	O
instrument	O
is	O
calibrated	O
with	O
lactate	O
standards	O
between	O
0	O
and	O
15	O
mMol	O
/	O
L	O
.	O

The	O
sensor	O
,	O
a	O
polarographic	O
enzyme	O
electrode	O
,	O
gives	O
a	O
current	O
which	O
is	O
a	O
linear	O
function	O
of	O
the	O
lactate	O
concentration	O
.	O

There	O
is	O
no	O
interference	O
from	O
glucose	O
,	O
pyruvate	O
,	O
alcohol	O
,	O
ascorbate	O
,	O
anticoagulants	O
,	O
lidocaine	O
,	O
acetaminophen	O
,	O
or	O
other	O
drugs	O
and	O
metabolites	O
commonly	O
encountered	O
in	O
critically	O
ill	O
patients	O
.	O

The	O
lactate	O
sensor	O
is	O
composed	O
of	O
a	O
peroxide	O
sensor	O
and	O
an	O
enzyme	O
transducer	O
membrane	O
.	O

The	O
lactate	O
is	O
stoichiometrically	O
converted	O
to	O
pyruvate	O
and	O
hydrogen	O
peroxide	O
by	O
lactate	O
oxygen	O
oxidoreductase	O
derived	O
from	O
Pediococcus	O
species	O
.	O

The	O
oxygen	O
required	O
for	O
the	O
enzymatic	O
oxidation	O
is	O
supplied	O
via	O
an	O
air	O
-	O
permeable	O
silicone	O
elastomeric	O
membrane	O
used	O
for	O
stirring	O
.	O

Comparison	O
of	O
our	O
new	O
electroenzymatic	O
method	O
with	O
the	O
Boehringer	O
-	O
Mannheim	O
photoenzymatic	O
method	O
gives	O
correlations	O
of	O
0	O
.	O
997	O
for	O
both	O
whole	O
blood	O
and	O
plasma	O
.	O

The	O
effect	O
of	O
translocations	O
on	O
the	O
cellular	O
myc	O
gene	O
in	O
Burkitt	O
lymphomas	O
.	O

Chromosomal	O
translocations	O
are	O
found	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
Burkitt	O
lymphomas	O
.	O

Similar	O
translocations	O
are	O
found	O
in	O
mouse	O
plasmacytomas	O
and	O
both	O
diseases	O
involve	O
interchanges	O
between	O
one	O
of	O
the	O
immunoglobulin	O
loci	O
and	O
DNA	O
in	O
the	O
vicinity	O
of	O
the	O
myc	O
gene	O
.	O

The	O
structure	O
of	O
the	O
myc	O
gene	O
has	O
been	O
elucidated	O
from	O
studies	O
on	O
translocated	O
versions	O
of	O
the	O
gene	O
.	O

Activation	O
of	O
the	O
myc	O
gene	O
may	O
play	O
a	O
role	O
in	O
transformation	O
by	O
promoting	O
growth	O
of	O
the	O
cells	O
bearing	O
the	O
rearranged	O
chromosomes	O
.	O

Preparation	O
and	O
physicochemical	O
and	O
immunological	O
characterization	O
of	O
polysaccharide	O
-	O
outer	O
membrane	O
protein	O
complexes	O
of	O
Neisseria	O
meningitidis	O
.	O

A	O
crude	O
complex	O
containing	O
group	O
C	O
polysaccharide	O
,	O
outer	O
membrane	O
proteins	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
was	O
isolated	O
from	O
the	O
cell	O
-	O
free	O
culture	O
liquid	O
of	O
Neisseria	O
meningitidis	O
serogroup	O
C	O
,	O
serotype	O
2a	O
.	O

Group	O
C	O
polysaccharide	O
and	O
LPS	O
were	O
removed	O
from	O
this	O
complex	O
,	O
resulting	O
in	O
an	O
outer	O
membrane	O
complex	O
and	O
a	O
purified	O
complex	O
,	O
respectively	O
.	O

Analysis	O
by	O
electron	O
microscopy	O
showed	O
the	O
outer	O
membrane	O
origin	O
of	O
the	O
crude	O
complex	O
and	O
the	O
outer	O
membrane	O
complex	O
,	O
whereas	O
such	O
a	O
structure	O
was	O
absent	O
in	O
the	O
purified	O
complex	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
patterns	O
of	O
the	O
three	O
complexes	O
were	O
identical	O
.	O

Pyrolysis	O
-	O
mass	O
spectrometry	O
data	O
correlated	O
well	O
with	O
those	O
obtained	O
by	O
the	O
biochemical	O
assays	O
and	O
suggested	O
a	O
low	O
LPS	O
content	O
in	O
the	O
purified	O
complex	O
and	O
a	O
low	O
polysaccharide	O
content	O
in	O
the	O
outer	O
membrane	O
complex	O
.	O

The	O
purified	O
complex	O
was	O
shown	O
to	O
be	O
nonpyrogenic	O
and	O
could	O
be	O
prepared	O
with	O
the	O
same	O
yield	O
as	O
that	O
of	O
purified	O
polysaccharide	O
.	O

The	O
immunogenic	O
activities	O
of	O
the	O
complexes	O
were	O
studied	O
in	O
mice	O
.	O

The	O
antibodies	O
were	O
measured	O
by	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
and	O
the	O
bactericidal	O
antibody	O
assay	O
.	O

All	O
complexes	O
induced	O
immunoglobulin	O
G	O
antibodies	O
to	O
group	O
C	O
polysaccharide	O
as	O
well	O
as	O
to	O
the	O
serotype	O
antigen	O
,	O
although	O
the	O
removal	O
of	O
polysaccharide	O
and	O
LPS	O
resulted	O
in	O
a	O
reduction	O
of	O
the	O
immunogenic	O
activities	O
of	O
outer	O
membrane	O
complex	O
and	O
purified	O
complex	O
,	O
respectively	O
.	O

A	O
second	O
dose	O
of	O
all	O
complexes	O
produced	O
a	O
clear	O
booster	O
effect	O
of	O
both	O
antibody	O
responses	O
.	O

The	O
antibodies	O
were	O
bactericidal	O
.	O

[	O
Suppurated	O
acute	O
obstructive	O
cholangitis	O
.	O
Anatomoclinical	O
and	O
therapeutic	O
aspects	O
]	O
.	O

A	O
total	O
of	O
134	O
cases	O
are	O
discussed	O
,	O
with	O
suppurated	O
acute	O
obstructive	O
angiocholitis	O
,	O
that	O
underwent	O
surgical	O
treatment	O
over	O
a	O
period	O
of	O
10	O
years	O
,	O
representing	O
12	O
,	O
8	O
%	O
of	O
the	O
total	O
number	O
of	O
organic	O
obstructions	O
of	O
the	O
hepato	O
-	O
choledocus	O
.	O

From	O
the	O
standpoint	O
of	O
the	O
etiopathogenic	O
mechanisms	O
the	O
angiocholitis	O
was	O
determined	O
by	O
biliary	O
lithiasis	O
in	O
59	O
cases	O
,	O
by	O
sclerosis	O
of	O
the	O
Oddi	O
sphincter	O
in	O
5	O
cases	O
,	O
by	O
postoperative	O
cicatriceal	O
stenosis	O
of	O
the	O
main	O
biliary	O
pathway	O
in	O
2	O
cases	O
,	O
by	O
hepatic	O
hydatitosis	O
in	O
16	O
cases	O
,	O
by	O
Vater	O
ampuloma	O
in	O
10	O
cases	O
by	O
cancers	O
of	O
the	O
main	O
biliary	O
pathway	O
in	O
40	O
cases	O
and	O
by	O
the	O
congenital	O
cyst	O
of	O
the	O
choledocus	O
in	O
one	O
case	O
.	O

The	O
high	O
frequency	O
was	O
noted	O
,	O
of	O
the	O
severe	O
forms	O
of	O
ictero	O
-	O
uremigenic	O
angiocholitis	O
(	O
representing	O
68	O
cases	O
,	O
or	O
50	O
,	O
7	O
%	O
of	O
the	O
total	O
,	O
with	O
a	O
death	O
rate	O
of	O
34	O
%	O
)	O
.	O

Medico	O
-	O
surgical	O
treatment	O
should	O
be	O
performed	O
as	O
early	O
as	O
possible	O
,	O
and	O
it	O
must	O
be	O
intensive	O
,	O
complex	O
,	O
and	O
adapted	O
to	O
the	O
anatomo	O
-	O
clinical	O
forms	O
.	O

The	O
authors	O
performed	O
evacuation	O
choledocotomy	O
with	O
external	O
draining	O
in	O
22	O
cases	O
(	O
3	O
deaths	O
)	O
,	O
and	O
choledoco	O
-	O
duodenal	O
anastomosis	O
in	O
46	O
cases	O
(	O
10	O
deaths	O
)	O
,	O
choledoco	O
-	O
jejunostomia	O
in	O
3	O
cases	O
,	O
Oddi	O
sphincterotomia	O
in	O
12	O
cases	O
(	O
2	O
deaths	O
)	O
ampulectomia	O
in	O
5	O
cases	O
(	O
2	O
deaths	O
)	O
.	O

Peripheral	O
bilio	O
-	O
hepatodigestive	O
anastomoses	O
were	O
performed	O
in	O
40	O
cases	O
with	O
5	O
deaths	O
.	O

[	O
Reactive	O
states	O
among	O
psychopathic	O
personalities	O
of	O
different	O
clinical	O
groups	O
]	O
.	O

On	O
the	O
basis	O
of	O
a	O
clinical	O
follow	O
-	O
up	O
of	O
71	O
psychopaths	O
with	O
manifestations	O
of	O
reactive	O
psychosis	O
,	O
the	O
authors	O
established	O
the	O
clinico	O
-	O
typological	O
characteristics	O
of	O
both	O
groups	O
of	O
pathology	O
and	O
the	O
system	O
of	O
correlations	O
between	O
them	O
.	O

They	O
also	O
described	O
the	O
structure	O
of	O
the	O
psychopathic	O
and	O
psychogenic	O
syndromes	O
,	O
the	O
type	O
of	O
psychopathic	O
personality	O
reaction	O
and	O
the	O
form	O
of	O
psychogenic	O
responses	O
and	O
proved	O
statistically	O
their	O
close	O
interrelationship	O
.	O

Data	O
were	O
obtained	O
on	O
some	O
general	O
regularities	O
of	O
interrelations	O
of	O
reactive	O
psychoses	O
with	O
a	O
psychopathic	O
background	O
which	O
are	O
important	O
for	O
the	O
prognosis	O
,	O
prophylaxis	O
and	O
therapy	O
of	O
reactive	O
states	O
.	O

Hemostasis	O
and	O
mechanism	O
of	O
action	O
of	O
selective	O
antimetastatic	O
drugs	O
in	O
mice	O
bearing	O
Lewis	O
lung	O
carcinoma	O
.	O

The	O
selective	O
antimetastatic	O
agents	O
p	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
benzoic	O
acid	O
potassium	O
salt	O
(	O
DM	O
-	O
COOK	O
)	O
,	O
5	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
imidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
DTIC	O
)	O
and	O
(	O
+	O
/	O
-	O
)	O
1	O
,	O
2	O
-	O
di	O
(	O
3	O
,	O
5	O
-	O
dioxopiperazin	O
-	O
1	O
-	O
yl	O
)	O
propane	O
(	O
ICRF	O
-	O
159	O
)	O
have	O
been	O
shown	O
to	O
markedly	O
depress	O
the	O
formation	O
of	O
spontaneous	O
hematogenous	O
metastases	O
in	O
mice	O
bearing	O
s	O
.	O
c	O
.	O

Lewis	O
lung	O
carcinoma	O
,	O
with	O
a	O
mechanism	O
unrelated	O
to	O
cytotoxicity	O
for	O
tumor	O
cells	O
.	O

The	O
effects	O
on	O
hemostasis	O
of	O
DM	O
-	O
COOK	O
,	O
DTIC	O
and	O
ICRF	O
-	O
159	O
have	O
thus	O
been	O
examined	O
in	O
comparison	O
with	O
those	O
of	O
a	O
purely	O
cytotoxic	O
agent	O
,	O
cyclophosphamide	O
,	O
in	O
mice	O
bearing	O
i	O
.	O
m	O
.	O

Lewis	O
lung	O
carcinoma	O
.	O

The	O
parameters	O
considered	O
are	O
the	O
number	O
of	O
platelets	O
and	O
their	O
aggregability	O
,	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
,	O
plasma	O
fibrinogen	O
concentration	O
and	O
tumor	O
cell	O
procoagulant	O
activity	O
.	O

Slight	O
variations	O
are	O
caused	O
by	O
drug	O
treatment	O
in	O
tumor	O
-	O
bearing	O
mice	O
as	O
compared	O
with	O
untreated	O
tumor	O
-	O
bearing	O
controls	O
;	O
the	O
pattern	O
of	O
effects	O
of	O
the	O
selective	O
antimetastatic	O
agents	O
does	O
not	O
differ	O
from	O
that	O
of	O
the	O
reference	O
cytotoxic	O
compound	O
used	O
,	O
cyclophosphamide	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
effects	O
on	O
hemostasis	O
of	O
the	O
drugs	O
examined	O
can	O
contribute	O
only	O
marginally	O
to	O
their	O
antimetastatic	O
action	O
,	O
since	O
more	O
pronounced	O
effects	O
on	O
hemostasis	O
have	O
been	O
shown	O
to	O
be	O
required	O
to	O
significantly	O
affect	O
metastasis	O
formation	O
.	O

Purification	O
and	O
characterization	O
of	O
various	O
esterases	O
from	O
rat	O
liver	O
.	O

The	O
major	O
rat	O
liver	O
microsomal	O
esterases	O
acting	O
on	O
o	O
-	O
nitrophenylacetate	O
with	O
isoelectric	O
points	O
5	O
.	O
0	O
,	O
5	O
.	O
5	O
,	O
6	O
.	O
1	O
and	O
6	O
.	O
4	O
were	O
resolved	O
by	O
isoelectric	O
focusing	O
.	O

Molecular	O
weights	O
were	O
determined	O
by	O
sedimentation	O
analysis	O
in	O
isokinetic	O
gradients	O
of	O
sucrose	O
and	O
,	O
after	O
purification	O
,	O
in	O
sodium	O
dodecyl	O
sulphate	O
/	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Their	O
subunit	O
molecular	O
weights	O
were	O
between	O
57	O
000	O
and	O
60	O
000	O
.	O

They	O
behaved	O
as	O
monomers	O
except	O
the	O
pI	O
-	O
6	O
.	O
1	O
enzyme	O
which	O
behaved	O
as	O
a	O
trimer	O
.	O

Esterases	O
of	O
pI	O
5	O
.	O
0	O
,	O
pI	O
6	O
.	O
1	O
and	O
pI	O
6	O
.	O
4	O
behaved	O
like	O
glycoproteins	O
of	O
the	O
polymannose	O
type	O
in	O
the	O
presence	O
of	O
125I	O
-	O
labelled	O
concanavalin	O
A	O
.	O

Preparations	O
of	O
the	O
pI	O
-	O
5	O
.	O
0	O
enzyme	O
contained	O
two	O
esterases	O
of	O
highly	O
homologous	O
structure	O
.	O

Antibodies	O
directed	O
against	O
this	O
preparation	O
did	O
not	O
inhibit	O
but	O
precipitated	O
pI	O
-	O
5	O
.	O
0	O
esterase	O
activity	O
quantitatively	O
.	O

They	O
did	O
not	O
react	O
with	O
the	O
pI	O
-	O
6	O
.	O
1	O
and	O
pI	O
-	O
6	O
.	O
4	O
esterases	O
but	O
precipitated	O
several	O
nonimmunologically	O
related	O
esterases	O
.	O

Two	O
of	O
these	O
enzymes	O
were	O
inducible	O
by	O
phenobarbital	O
.	O

Total	O
activity	O
was	O
very	O
low	O
in	O
3	O
-	O
day	O
-	O
old	O
animals	O
.	O

Individual	O
esterase	O
activities	O
rose	O
at	O
different	O
rates	O
during	O
development	O
;	O
the	O
enzyme	O
focusing	O
near	O
pI	O
5	O
.	O
0	O
was	O
about	O
three	O
times	O
more	O
active	O
in	O
adult	O
females	O
than	O
in	O
males	O
.	O

All	O
microsomal	O
esterases	O
are	O
located	O
on	O
the	O
luminal	O
side	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Hippocampal	O
afterdischarge	O
interferes	O
with	O
storage	O
of	O
spatial	O
information	O
in	O
a	O
working	O
memory	O
test	O
.	O

In	O
an	O
attempt	O
to	O
impair	O
spatial	O
working	O
memory	O
by	O
reversible	O
functional	O
blockade	O
rather	O
than	O
by	O
irreversible	O
lesion	O
of	O
the	O
hippocampus	O
,	O
eight	O
male	O
hooded	O
rats	O
were	O
trained	O
to	O
asymptotic	O
performance	O
of	O
1	O
.	O
2	O
to	O
1	O
.	O
4	O
errors	O
per	O
trial	O
in	O
the	O
spatial	O
12	O
-	O
choice	O
apparatus	O
(	O
Bure	O
s	O
et	O
al	O
.	O
1982	O
)	O
,	O
formally	O
similar	O
to	O
the	O
radial	O
maze	O
.	O

The	O
rats	O
were	O
implanted	O
with	O
hippocampal	O
stimulating	O
and	O
recording	O
electrodes	O
,	O
which	O
were	O
used	O
for	O
eliciting	O
and	O
monitoring	O
hippocampal	O
afterdischarge	O
(	O
HAD	O
)	O
lasting	O
for	O
at	O
least	O
20	O
s	O
.	O

In	O
Experiment	O
1	O
,	O
HAD	O
elicited	O
1	O
or	O
10	O
min	O
before	O
testing	O
increased	O
the	O
incidence	O
of	O
errors	O
to	O
2	O
.	O
75	O
or	O
2	O
.	O
50	O
per	O
trial	O
,	O
respectively	O
,	O
but	O
the	O
performance	O
still	O
remained	O
above	O
chance	O
level	O
(	O
4	O
.	O
18	O
)	O
.	O

In	O
Experiment	O
2	O
,	O
interruption	O
of	O
the	O
trial	O
by	O
1	O
,	O
10	O
,	O
20	O
and	O
30	O
min	O
intervals	O
inserted	O
between	O
choices	O
6	O
and	O
7	O
increased	O
the	O
incidence	O
of	O
errors	O
in	O
choices	O
7	O
to	O
12	O
to	O
1	O
.	O
0	O
,	O
1	O
.	O
5	O
,	O
2	O
.	O
1	O
and	O
2	O
.	O
5	O
,	O
respectively	O
.	O

HAD	O
elicited	O
immediately	O
after	O
choice	O
6	O
increased	O
error	O
incidence	O
in	O
the	O
subsequent	O
6	O
choices	O
performed	O
after	O
1	O
-	O
min	O
or	O
10	O
-	O
min	O
intervals	O
to	O
3	O
.	O
1	O
or	O
2	O
.	O
75	O
,	O
respectively	O
,	O
i	O
.	O
e	O
.	O
to	O
the	O
chance	O
level	O
of	O
3	O
errors	O
in	O
6	O
choices	O
.	O

It	O
is	O
concluded	O
that	O
HAD	O
elicits	O
transient	O
shortening	O
of	O
the	O
memory	O
span	O
for	O
newly	O
acquired	O
spatial	O
information	O
(	O
anterograde	O
effect	O
)	O
and	O
erases	O
the	O
current	O
spatial	O
working	O
memory	O
record	O
(	O
retrograde	O
effect	O
)	O
.	O

Inhibition	O
by	O
N	O
-	O
(	O
phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
of	O
Ehrlich	O
ascites	O
tumour	O
growth	O
and	O
glucose	O
transport	O
.	O

N	O
-	O
(	O
Phosphonacetyl	O
)	O
-	O
L	O
-	O
aspartate	O
(	O
PALA	O
)	O
suppressed	O
the	O
growth	O
of	O
Ehrlich	O
ascites	O
tumour	O
cells	O
in	O
vivo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Simultaneously	O
as	O
the	O
growth	O
rate	O
decreased	O
,	O
the	O
cellular	O
uptake	O
of	O
glucose	O
and	O
the	O
density	O
of	O
a	O
class	O
of	O
glucose	O
-	O
reversible	O
binding	O
sites	O
for	O
cytochalasin	O
B	O
on	O
the	O
cell	O
surface	O
were	O
also	O
found	O
to	O
be	O
reduced	O
.	O

There	O
is	O
a	O
highly	O
significant	O
correlation	O
between	O
the	O
magnitude	O
of	O
changes	O
in	O
the	O
number	O
of	O
cytochalasin	O
B	O
binding	O
sites	O
and	O
the	O
magnitude	O
of	O
changes	O
in	O
glucose	O
uptake	O
.	O

The	O
physiological	O
significance	O
of	O
these	O
observations	O
are	O
discussed	O
.	O

[	O
In	O
vitro	O
studies	O
of	O
the	O
thyroid	O
gland	O
regulation	O
principles	O
and	O
their	O
evaluation	O
]	O
.	O

The	O
free	O
fractions	O
of	O
the	O
thyroid	O
hormone	O
further	O
the	O
metabolism	O
of	O
the	O
body	O
cells	O
and	O
regulate	O
the	O
synthesis	O
of	O
the	O
thyroid	O
hormone	O
.	O

Once	O
the	O
level	O
of	O
FT3	O
and	O
FT4	O
decreases	O
.	O

With	O
the	O
help	O
of	O
a	O
liberation	O
of	O
the	O
hormone	O
stimulating	O
the	O
thyroid	O
gland	O
from	O
the	O
anterior	O
lobe	O
of	O
the	O
pituitary	O
gland	O
the	O
lack	O
of	O
thyroid	O
hormone	O
is	O
corrected	O
.	O

The	O
synthesis	O
and	O
secretion	O
of	O
the	O
thyroid	O
gland	O
stimulating	O
hormone	O
is	O
induced	O
by	O
the	O
thyreotropin	O
releasing	O
hormone	O
which	O
is	O
given	O
by	O
the	O
hypothalamus	O
.	O

Moreover	O
,	O
the	O
organism	O
is	O
able	O
as	O
needed	O
to	O
carry	O
out	O
the	O
monodiodation	O
of	O
LT4	O
to	O
biologically	O
active	O
LT3	O
or	O
biologically	O
inactive	O
so	O
-	O
called	O
revers	O
T3	O
(	O
RT3	O
)	O
.	O

The	O
estimation	O
of	O
thyroid	O
gland	O
stimulating	O
hormone	O
before	O
and	O
30	O
minutes	O
after	O
intravenous	O
application	O
of	O
thyreotropin	O
releasing	O
hormone	O
has	O
its	O
main	O
importance	O
for	O
the	O
early	O
recognition	O
of	O
a	O
disturbance	O
of	O
the	O
regulating	O
circle	O
hypophysis	O
-	O
thyroid	O
gland	O
,	O
above	O
all	O
in	O
the	O
diagnosis	O
of	O
clinically	O
not	O
yet	O
manifest	O
clinical	O
pictures	O
,	O
such	O
as	O
the	O
latent	O
hypothyreosis	O
and	O
the	O
latent	O
hyperthyreosis	O
,	O
respectively	O
(	O
Basedow	O
hyperthyreosis	O
and	O
thyroidal	O
autonomy	O
)	O
.	O

According	O
to	O
the	O
questioning	O
the	O
estimations	O
of	O
the	O
levels	O
of	O
the	O
thyroid	O
hormones	O
and	O
of	O
the	O
thyroid	O
gland	O
stimulating	O
hormone	O
should	O
be	O
used	O
stepwise	O
.	O

Relationship	O
of	O
self	O
-	O
concept	O
during	O
late	O
pregnancy	O
to	O
neonatal	O
perception	O
and	O
parenting	O
profile	O
.	O

Thirty	O
-	O
one	O
gravidas	O
were	O
studied	O
to	O
examine	O
the	O
relationship	O
between	O
a	O
woman	O
'	O
s	O
feelings	O
about	O
herself	O
during	O
late	O
pregnancy	O
,	O
her	O
perception	O
of	O
her	O
newborn	O
,	O
and	O
her	O
profile	O
of	O
parenting	O
.	O

The	O
Tennessee	O
Self	O
-	O
Concept	O
Scale	O
was	O
completed	O
during	O
the	O
third	O
trimester	O
of	O
pregnancy	O
,	O
the	O
Neonatal	O
Perception	O
Inventory	O
I	O
at	O
one	O
-	O
to	O
-	O
two	O
days	O
postpartum	O
,	O
and	O
the	O
Neonatal	O
Perception	O
Inventory	O
II	O
and	O
the	O
Michigan	O
Screening	O
Profile	O
of	O
Parenting	O
at	O
four	O
-	O
to	O
-	O
six	O
weeks	O
postpartum	O
.	O

When	O
considered	O
separately	O
,	O
no	O
positive	O
significant	O
relationships	O
were	O
found	O
between	O
scores	O
on	O
these	O
variables	O
.	O

However	O
,	O
all	O
subjects	O
with	O
negative	O
scores	O
on	O
both	O
self	O
-	O
concept	O
and	O
neonatal	O
perception	O
had	O
negative	O
scores	O
on	O
at	O
least	O
two	O
subscales	O
of	O
the	O
parenting	O
profile	O
.	O

Differential	O
reactivity	O
of	O
the	O
functional	O
sulfhydryl	O
groups	O
of	O
cysteine	O
-	O
32	O
and	O
cysteine	O
-	O
35	O
present	O
in	O
the	O
reduced	O
form	O
of	O
thioredoxin	O
from	O
Escherichia	O
coli	O
.	O

Only	O
one	O
of	O
the	O
sulfhydryl	O
groups	O
from	O
Cys	O
-	O
32	O
and	O
Cys	O
-	O
35	O
in	O
the	O
active	O
center	O
of	O
native	O
Escherichia	O
coli	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
was	O
alkylated	O
by	O
excess	O
iodoacetic	O
acid	O
at	O
pH	O
values	O
below	O
8	O
.	O
0	O
.	O

Both	O
groups	O
reacted	O
in	O
the	O
protein	O
denatured	O
with	O
4	O
.	O
5	O
M	O
guanidine	O
hydrochloride	O
.	O

The	O
second	O
order	O
rate	O
of	O
alkylation	O
of	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
with	O
1	O
eq	O
of	O
iodoacetic	O
acid	O
was	O
pH	O
-	O
dependent	O
and	O
showed	O
independent	O
initial	O
reactions	O
of	O
one	O
thiolate	O
ion	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
and	O
a	O
second	O
with	O
a	O
pK	O
value	O
close	O
to	O
9	O
.	O
0	O
.	O

The	O
same	O
pH	O
dependence	O
was	O
observed	O
for	O
alkylation	O
with	O
iodoacetamide	O
but	O
the	O
apparent	O
rate	O
constant	O
,	O
107	O
M	O
-	O
1	O
S	O
-	O
1	O
at	O
pH	O
7	O
.	O
2	O
,	O
was	O
about	O
20	O
-	O
fold	O
higher	O
than	O
the	O
corresponding	O
rate	O
with	O
iodoacetate	O
.	O

The	O
sulfhydryl	O
group	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
was	O
shown	O
to	O
belong	O
to	O
Cys	O
-	O
32	O
by	O
labeling	O
thioredoxin	O
with	O
[	O
14C	O
]	O
iodoacetic	O
acid	O
followed	O
by	O
complete	O
alkylation	O
with	O
[	O
3H	O
]	O
iodoacetate	O
and	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptides	O
from	O
the	O
active	O
center	O
.	O

The	O
abnormally	O
low	O
pK	O
value	O
of	O
Cys	O
-	O
32	O
is	O
suggested	O
to	O
arise	O
by	O
electrostatic	O
influence	O
from	O
a	O
positive	O
charge	O
on	O
the	O
amino	O
group	O
of	O
Lys	O
-	O
36	O
.	O

A	O
mechanism	O
of	O
action	O
for	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
as	O
a	O
protein	O
disulfide	O
reductase	O
has	O
been	O
formulated	O
.	O

This	O
is	O
based	O
on	O
an	O
initial	O
nucleophilic	O
attack	O
by	O
the	O
thiolate	O
of	O
Cys	O
-	O
32	O
with	O
the	O
formation	O
of	O
an	O
unstable	O
transient	O
mixed	O
disulfide	O
involving	O
Cys	O
-	O
32	O
and	O
one	O
of	O
the	O
sulfurs	O
in	O
the	O
substrate	O
.	O

This	O
is	O
followed	O
by	O
a	O
conformational	O
change	O
and	O
a	O
nucleophilic	O
attack	O
of	O
Cys	O
-	O
35	O
to	O
give	O
the	O
14	O
-	O
membered	O
disulfide	O
ring	O
in	O
thioredoxin	O
-	O
S2	O
and	O
the	O
dithiol	O
of	O
the	O
substrate	O
.	O

Subretinal	O
neovascularization	O
following	O
rubella	O
retinopathy	O
.	O

A	O
17	O
-	O
year	O
-	O
old	O
girl	O
and	O
an	O
11	O
-	O
year	O
-	O
old	O
girl	O
with	O
rubella	O
retinopathy	O
had	O
decreased	O
vision	O
in	O
one	O
eye	O
secondary	O
to	O
subretinal	O
neovascularization	O
and	O
hemorrhage	O
.	O

In	O
both	O
cases	O
a	O
disciform	O
scar	O
with	O
permanent	O
decrease	O
in	O
central	O
vision	O
resulted	O
.	O

Verrucous	O
carcinoma	O
of	O
the	O
endometrium	O
-	O
-	O
a	O
unique	O
neoplasm	O
with	O
long	O
survival	O
.	O

A	O
case	O
of	O
verrucous	O
carcinoma	O
of	O
the	O
endometrium	O
with	O
long	O
survival	O
is	O
described	O
.	O

It	O
represents	O
the	O
first	O
of	O
its	O
type	O
to	O
be	O
recorded	O
in	O
this	O
site	O
.	O

The	O
literature	O
on	O
verrucous	O
carcinoma	O
and	O
on	O
other	O
cases	O
of	O
squamous	O
carcinoma	O
of	O
the	O
endometrium	O
is	O
briefly	O
reviewed	O
.	O

Effects	O
of	O
3	O
-	O
chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
on	O
nucleic	O
acid	O
,	O
protein	O
,	O
and	O
aerobic	O
and	O
anaerobic	O
metabolism	O
of	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

3	O
-	O
Chloromethylthiochromone	O
-	O
1	O
,	O
1	O
-	O
dioxide	O
was	O
observed	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
Ehrlich	O
ascites	O
carcinoma	O
growth	O
and	O
a	O
moderate	O
inhibitor	O
of	O
P	B
-	I
388	I
lymphocytic	O
leukemia	O
growth	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Preliminary	O
in	O
vitro	O
studies	O
showed	O
that	O
the	O
agents	O
significantly	O
inhibited	O
RNA	O
and	O
DNA	O
synthesis	O
in	O
Ehrlich	O
ascites	O
cells	O
.	O

In	O
vivo	O
studies	O
after	O
dosing	O
on	O
Days	O
6	O
,	O
7	O
,	O
and	O
8	O
demonstrated	O
the	O
same	O
reductions	O
in	O
nucleic	O
acid	O
synthesis	O
and	O
a	O
moderate	O
reduction	O
in	O
protein	O
synthesis	O
.	O

The	O
primary	O
site	O
of	O
nucleic	O
acid	O
synthesis	O
,	O
which	O
was	O
blocked	O
by	O
3	O
-	O
chloromethylthiochromone	O
,	O
was	O
at	O
orotidine	O
monophosphate	O
decarboxylase	O
in	O
the	O
primidine	O
pathway	O
.	O

Other	O
enzymes	O
,	O
in	O
anaerobic	O
and	O
aerobic	O
glycolysis	O
,	O
which	O
were	O
blocked	O
include	O
hexokinase	O
,	O
phosphofructokinase	O
,	O
succinic	O
and	O
alpha	O
-	O
ketoglutarate	O
dehydrogenases	O
,	O
as	O
well	O
as	O
States	O
3	O
and	O
4	O
of	O
oxidative	O
phosphorylation	O
.	O

Metabolic	O
alterations	O
in	O
a	O
noncachectic	O
animal	O
tumor	O
system	O
.	O

The	O
increased	O
energy	O
expended	O
by	O
the	O
host	O
to	O
synthesize	O
substrate	O
,	O
which	O
is	O
utilized	O
by	O
the	O
tumor	O
,	O
is	O
a	O
potential	O
cause	O
of	O
cancer	O
cachexia	O
.	O

In	O
vivo	O
glucose	O
and	O
alanine	O
kinetics	O
were	O
examined	O
by	O
tracer	O
methodology	O
in	O
a	O
sarcoma	O
-	O
bearing	O
rat	O
model	O
.	O

The	O
effects	O
of	O
3	O
-	O
mercaptopicolinic	O
acid	O
,	O
a	O
potent	O
inhibitor	O
of	O
gluconeogenesis	O
,	O
was	O
also	O
examined	O
on	O
this	O
model	O
.	O

Both	O
tumor	O
-	O
bearing	O
(	O
TB	O
)	O
and	O
nontumor	O
bearing	O
(	O
NTB	O
)	O
animals	O
were	O
gaining	O
weight	O
prior	O
to	O
study	O
and	O
the	O
tumors	O
were	O
relatively	O
small	O
.	O

The	O
TB	O
animals	O
had	O
significantly	O
lower	O
plasma	O
glucose	O
and	O
higher	O
blood	O
lactic	O
acid	O
levels	O
compared	O
with	O
NTB	O
animals	O
.	O

After	O
inhibition	O
of	O
gluconeogenesis	O
,	O
the	O
plasma	O
glucose	O
decreased	O
and	O
the	O
blood	O
lactate	O
increased	O
significantly	O
more	O
in	O
TB	O
than	O
NTB	O
animals	O
.	O

The	O
glucose	O
turnover	O
rate	O
was	O
significantly	O
greater	O
in	O
TB	O
compared	O
with	O
NTB	O
animals	O
,	O
as	O
was	O
the	O
rate	O
of	O
glucose	O
recycling	O
and	O
the	O
rate	O
of	O
gluconeogenesis	O
(	O
alanine	O
leads	O
to	O
glucose	O
)	O
,	O
both	O
energy	O
demanding	O
processes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
tumor	O
-	O
bearing	O
animal	O
,	O
even	O
prior	O
to	O
significant	O
cachexia	O
,	O
has	O
an	O
excess	O
demand	O
for	O
energy	O
,	O
the	O
provision	O
of	O
which	O
may	O
be	O
a	O
significant	O
factor	O
in	O
malignant	O
cachexia	O
.	O

[	O
Organization	O
of	O
pectoral	O
muscle	O
motor	O
neurons	O
in	O
the	O
rat	O
.	O
Contribution	O
to	O
the	O
study	O
of	O
the	O
axillary	O
arch	O
(	O
Achselbogen	O
)	O
]	O
.	O

In	O
spite	O
of	O
their	O
role	O
of	O
the	O
forelimb	O
activity	O
,	O
the	O
organization	O
of	O
the	O
mammalian	O
pectoral	O
muscles	O
remains	O
unclear	O
.	O

In	O
order	O
to	O
get	O
more	O
information	O
,	O
we	O
have	O
studied	O
,	O
qualitatively	O
and	O
quantitatively	O
,	O
the	O
motor	O
pools	O
of	O
the	O
various	O
pectoral	O
muscles	O
in	O
the	O
rat	O
(	O
musculus	O
pectoralis	O
major	O
,	O
musculus	O
pectoralis	O
minor	O
and	O
musculus	O
panniculus	O
carnosus	O
)	O
.	O

The	O
method	O
applied	O
was	O
the	O
retrograde	O
transport	O
of	O
horseradish	O
peroxidase	O
by	O
the	O
peripheral	O
nerves	O
supplying	O
the	O
various	O
muscles	O
.	O

The	O
results	O
provided	O
the	O
precise	O
localization	O
within	O
the	O
ventral	O
horn	O
of	O
the	O
motor	O
neurons	O
from	O
the	O
pectoral	O
muscles	O
which	O
were	O
all	O
in	O
the	O
most	O
ventral	O
part	O
of	O
the	O
gray	O
matter	O
.	O

Three	O
distinct	O
motor	O
pools	O
were	O
observed	O
,	O
which	O
confirms	O
the	O
functional	O
identity	O
of	O
each	O
muscle	O
.	O

The	O
motor	O
neurons	O
of	O
m	O
.	O
panniculus	O
carnosus	O
exhibited	O
some	O
particularities	O
.	O

They	O
were	O
4	O
times	O
more	O
numerous	O
than	O
those	O
from	O
m	O
.	O
pectoralis	O
major	O
,	O
they	O
occupied	O
the	O
whole	O
ventral	O
edge	O
of	O
the	O
ventral	O
horn	O
,	O
from	O
its	O
medial	O
part	O
to	O
its	O
lateral	O
tip	O
.	O

The	O
cell	O
size	O
was	O
different	O
from	O
that	O
of	O
the	O
other	O
muscles	O
.	O

These	O
results	O
were	O
discussed	O
,	O
according	O
to	O
the	O
role	O
of	O
this	O
muscle	O
,	O
which	O
links	O
the	O
forelimb	O
to	O
the	O
whole	O
trunk	O
.	O

In	O
mammals	O
,	O
m	O
.	O
panniculus	O
carnosus	O
constitutes	O
,	O
with	O
musculus	O
latissimus	O
dorsi	O
,	O
the	O
axillary	O
arch	O
(	O
Achselbogen	O
)	O
.	O

A	O
small	O
area	O
of	O
overlapping	O
between	O
the	O
motor	O
pools	O
of	O
these	O
two	O
muscles	O
was	O
observed	O
.	O

It	O
was	O
suggested	O
that	O
the	O
muscular	O
fibers	O
from	O
the	O
axillary	O
arch	O
were	O
innervated	O
by	O
the	O
same	O
,	O
well	O
-	O
defined	O
spinal	O
area	O
,	O
independent	O
of	O
the	O
muscle	O
from	O
which	O
they	O
originate	O
.	O

An	O
unusual	O
case	O
of	O
benign	O
mucous	O
membrane	O
pemphigoid	O
.	O

This	O
case	O
of	O
benign	O
mucous	O
membrane	O
pemphigoid	O
(	O
BMMP	O
)	O
is	O
unusual	O
in	O
that	O
blistering	O
,	O
scarring	O
lesions	O
were	O
confined	O
to	O
the	O
skin	O
for	O
15	O
years	O
before	O
mucous	O
membranes	O
were	O
involved	O
.	O

The	O
onset	O
of	O
this	O
disorder	O
at	O
the	O
age	O
of	O
38	O
is	O
also	O
unusual	O
.	O

Detailed	O
immunological	O
investigation	O
was	O
performed	O
on	O
this	O
patient	O
but	O
the	O
results	O
in	O
no	O
way	O
clarify	O
the	O
present	O
confusion	O
regarding	O
the	O
immunopathological	O
processes	O
in	O
BMMP	O
related	O
to	O
those	O
operative	O
in	O
bullous	O
pemphigoid	O
.	O

Mast	O
cell	O
heparin	O
stimulates	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
in	O
vitro	O
.	O

Migration	O
of	O
capillary	O
endothelial	O
cells	O
is	O
an	O
important	O
component	O
of	O
angiogenesis	O
in	O
vivo	O
.	O

Increased	O
numbers	O
of	O
mast	O
cells	O
have	O
been	O
associated	O
with	O
several	O
types	O
of	O
angiogenesis	O
.	O

We	O
have	O
used	O
a	O
quantitative	O
assay	O
in	O
vitro	O
to	O
demonstrate	O
that	O
mast	O
cells	O
release	O
a	O
factor	O
that	O
significantly	O
increases	O
bovine	O
capillary	O
endothelial	O
cell	O
migration	O
.	O

The	O
factor	O
is	O
present	O
in	O
medium	O
conditioned	O
by	O
mast	O
cells	O
as	O
well	O
as	O
lysates	O
of	O
mast	O
cells	O
.	O

The	O
stimulatory	O
effect	O
of	O
mast	O
cells	O
on	O
migration	O
is	O
specific	O
for	O
capillary	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
mast	O
cells	O
have	O
no	O
mitogenic	O
activity	O
for	O
capillary	O
endothelial	O
cells	O
.	O

Of	O
all	O
the	O
secretory	O
products	O
of	O
mast	O
cells	O
tested	O
,	O
only	O
heparin	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
in	O
vitro	O
.	O

Heparin	O
preparations	O
from	O
a	O
variety	O
of	O
sources	O
stimulated	O
capillary	O
endothelial	O
cell	O
migration	O
to	O
the	O
same	O
degree	O
but	O
did	O
not	O
stimulate	O
migration	O
of	O
several	O
other	O
cell	O
types	O
.	O

The	O
migration	O
activity	O
of	O
heparin	O
and	O
mast	O
cell	O
conditioned	O
medium	O
was	O
blocked	O
by	O
specific	O
antagonists	O
of	O
heparin	O
(	O
protamine	O
and	O
heparinase	O
)	O
,	O
but	O
not	O
by	O
chondroitinase	O
ABC	O
.	O

The	O
migration	O
activity	O
of	O
mast	O
cell	O
conditioned	O
medium	O
was	O
resistant	O
to	O
heat	O
(	O
100	O
degrees	O
C	O
)	O
and	O
incubation	O
with	O
proteolytic	O
enzymes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
mast	O
cells	O
in	O
angiogenesis	O
may	O
be	O
to	O
enhance	O
migration	O
of	O
the	O
endothelial	O
cells	O
of	O
growing	O
capillaries	O
.	O

The	O
inhibition	O
of	O
cultured	O
myoblast	O
differentiation	O
by	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
occurs	O
after	O
myogenin	O
expression	O
and	O
Rb	O
up	O
-	O
regulation	O
and	O
is	O
not	O
exerted	O
by	O
transformation	O
-	O
competent	O
cytoplasmic	O
mutants	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
by	O
which	O
the	O
simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SVLT	O
)	O
interferes	O
with	O
the	O
differentiation	O
of	O
C2	B
myoblasts	O
.	O

SVLT	O
mutants	O
,	O
defective	O
either	O
in	O
the	O
Rb	O
binding	O
site	O
,	O
near	O
the	O
N	O
-	O
terminal	O
end	O
,	O
in	O
a	O
region	O
that	O
affects	O
binding	O
to	O
p53	O
,	O
or	O
in	O
the	O
nuclear	O
transport	O
signal	O
,	O
were	O
also	O
employed	O
to	O
determine	O
whether	O
the	O
interference	O
was	O
especially	O
dependent	O
on	O
these	O
functional	O
domains	O
.	O

It	O
was	O
found	O
that	O
wild	O
-	O
type	O
(	O
wt	O
)	O
SVLT	O
strongly	O
inhibited	O
the	O
terminal	O
differentiation	O
of	O
mouse	O
C2	B
myoblasts	O
,	O
but	O
this	O
arrest	O
occurred	O
only	O
after	O
the	O
synthesis	O
of	O
myogenin	O
,	O
an	O
initial	O
step	O
in	O
biochemical	O
differentiation	O
.	O

Neither	O
the	O
synthesis	O
nor	O
some	O
basic	O
activities	O
of	O
MyoD	O
appeared	O
to	O
be	O
affected	O
by	O
wt	O
SVLT	O
.	O

In	O
these	O
transformants	O
,	O
mitogen	O
depletion	O
elicited	O
an	O
increase	O
in	O
the	O
Rb	O
level	O
comparable	O
to	O
that	O
in	O
normal	O
C2	B
cells	O
;	O
wt	O
SVLT	O
,	O
however	O
,	O
promoted	O
the	O
phosphorylation	O
of	O
a	O
large	O
part	O
of	O
the	O
induced	O
Rb	O
.	O

Mutations	O
affecting	O
nuclear	O
transport	O
were	O
far	O
more	O
critical	O
for	O
the	O
ability	O
to	O
interfere	O
with	O
myogenic	O
differentiation	O
than	O
were	O
those	O
affecting	O
the	O
transforming	O
potential	O
;	O
cytoplasmic	O
SVLT	O
expression	O
was	O
fully	O
compatible	O
with	O
the	O
terminal	O
differentiation	O
of	O
C2	B
cells	O
,	O
despite	O
enabling	O
them	O
to	O
grow	O
in	O
semisolid	O
medium	O
,	O
thus	O
showing	O
that	O
the	O
myogenesis	O
-	O
inhibiting	O
property	O
can	O
be	O
dissociated	O
from	O
transforming	O
competence	O
.	O

The	O
remaining	O
SVLT	O
mutants	O
presented	O
different	O
degrees	O
of	O
ability	O
to	O
inhibit	O
differentiation	O
(	O
as	O
shown	O
by	O
the	O
expression	O
of	O
tissue	O
-	O
specific	O
markers	O
in	O
transformants	O
)	O
.	O

The	O
inhibiting	O
mutants	O
,	O
including	O
the	O
Rb	O
binding	O
site	O
mutant	O
,	O
were	O
able	O
to	O
promote	O
a	O
higher	O
state	O
of	O
Rb	O
phosphorylation	O
than	O
that	O
observed	O
in	O
either	O
normal	O
cells	O
or	O
cytoplasmic	O
-	O
SVLT	O
transformants	O
.	O

A	O
transcript	O
from	O
the	O
long	O
terminal	O
repeats	O
of	O
a	O
murine	O
retrovirus	O
associated	O
with	O
trans	O
activation	O
of	O
cellular	O
genes	O
.	O

Infection	O
of	O
human	O
or	O
murine	O
cells	O
with	O
murine	O
leukemia	O
viruses	O
rapidly	O
increases	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
that	O
belong	O
to	O
the	O
immunoglobulin	O
superfamily	O
and	O
are	O
involved	O
in	O
T	O
-	O
lymphocyte	O
activation	O
,	O
including	O
the	O
class	O
I	O
major	O
histocompatibility	O
complex	O
antigens	O
.	O

We	O
have	O
reported	O
recently	O
that	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
encodes	O
a	O
trans	O
activator	O
which	O
induces	O
transcription	O
and	O
expression	O
of	O
class	O
I	O
major	O
histocompatibility	O
complex	O
genes	O
and	O
certain	O
cytokine	O
genes	O
.	O

The	O
portion	O
of	O
the	O
LTR	O
responsible	O
for	O
trans	O
activation	O
was	O
mapped	O
by	O
deletions	O
to	O
lie	O
within	O
the	O
U3	O
region	O
.	O

We	O
demonstrate	O
here	O
that	O
a	O
transcript	O
is	O
initiated	O
within	O
the	O
U3	O
region	O
and	O
that	O
its	O
presence	O
correlates	O
with	O
the	O
trans	O
-	O
activating	O
activity	O
.	O

Analysis	O
of	O
the	O
LTR	O
region	O
reveals	O
a	O
potential	O
internal	O
promoter	O
element	O
for	O
RNA	O
polymerase	O
III	O
transcription	O
within	O
the	O
U3	O
region	O
.	O

Studies	O
with	O
polymerase	O
inhibitors	O
suggest	O
that	O
this	O
LTR	O
transcript	O
,	O
designated	O
let	O
(	O
LTR	O
-	O
encoded	O
trans	O
activator	O
)	O
,	O
is	O
a	O
product	O
of	O
RNA	O
polymerase	O
III	O
.	O

The	O
mechanisms	O
whereby	O
RNA	O
leukemia	O
viruses	O
cause	O
lymphoid	O
neoplasia	O
after	O
a	O
long	O
latent	O
period	O
have	O
been	O
extensively	O
studied	O
but	O
are	O
only	O
partially	O
understood	O
.	O

The	O
region	O
of	O
the	O
LTR	O
identified	O
here	O
as	O
being	O
important	O
in	O
trans	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
be	O
a	O
critical	O
determinant	O
of	O
the	O
leukemogenicity	O
and	O
latency	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O

These	O
findings	O
suggest	O
a	O
novel	O
mechanism	O
of	O
retrovirus	O
-	O
induced	O
activation	O
of	O
cellular	O
gene	O
expression	O
,	O
potentially	O
contributing	O
to	O
leukemogenesis	O
.	O

Cancer	O
progression	O
and	O
p53	O
.	O

In	O
a	O
complex	O
organism	O
,	O
somatic	O
cells	O
are	O
under	O
intermittent	O
selection	O
pressure	O
for	O
the	O
emergence	O
of	O
mutants	O
that	O
can	O
survive	O
environmental	O
insults	O
and	O
that	O
can	O
grow	O
autonomously	O
despite	O
adverse	O
conditions	O
.	O

Repeated	O
rounds	O
of	O
mutation	O
,	O
selection	O
,	O
and	O
proliferation	O
may	O
lead	O
to	O
cancer	O
.	O

The	O
organism	O
prevents	O
malignant	O
transformation	O
by	O
assuring	O
accurate	O
DNA	O
repair	O
before	O
cell	O
division	O
,	O
by	O
forcing	O
the	O
death	O
of	O
cells	O
with	O
excessive	O
DNA	O
damage	O
,	O
and	O
by	O
placing	O
limits	O
on	O
the	O
replicative	O
lifespans	O
of	O
most	O
somatic	O
cells	O
.	O

The	O
p53	O
gene	O
is	O
a	O
""""	O
guardian	O
of	O
the	O
genome	O
""""	O
-	O
-	O
it	O
regulates	O
multiple	O
components	O
of	O
the	O
DNA	O
damage	O
control	O
response	O
and	O
promotes	O
cellular	O
senescence	O
.	O

Disabling	O
mutations	O
and	O
deletions	O
of	O
p53	O
occur	O
in	O
50	O
%	O
of	O
human	O
tumours	O
.	O

p53	O
-	O
deficient	O
cancers	O
are	O
often	O
unstable	O
,	O
aggressive	O
,	O
and	O
resistant	O
to	O
therapy	O
.	O

Anti	O
-	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
antibodies	O
inhibit	O
breast	O
cancer	O
cell	O
tumorigenicity	O
and	O
increase	O
mouse	O
spleen	O
natural	O
killer	O
cell	O
activity	O
.	O

Implications	O
for	O
a	O
possible	O
role	O
of	O
tumor	O
cell	O
/	O
host	O
TGF	O
-	O
beta	O
interactions	O
in	O
human	O
breast	O
cancer	O
progression	O
.	O

TGF	O
-	O
beta	O
effects	O
on	O
angiogenesis	O
,	O
stroma	O
formation	O
,	O
and	O
immune	O
function	O
suggest	O
its	O
possible	O
involvement	O
in	O
tumor	O
progression	O
.	O

This	O
hypothesis	O
was	O
tested	O
using	O
the	O
2G7	O
IgG2b	O
,	O
which	O
neutralizes	O
TGF	O
-	O
beta	O
1	O
,	O
-	O
beta	O
2	O
,	O
and	O
-	O
beta	O
3	O
,	O
and	O
the	O
MDA	B
-	I
231	I
human	O
breast	O
cancer	O
cell	O
line	O
.	O

Inoculation	O
of	O
these	O
cells	O
in	O
athymic	O
mice	O
decreases	O
mouse	O
spleen	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O

Intraperitoneal	O
injections	O
of	O
2G7	O
starting	O
1	O
d	O
after	O
intraperitoneal	O
inoculation	O
of	O
tumor	O
cells	O
suppressed	O
intraabdominal	O
tumor	O
and	O
lung	O
metastases	O
,	O
whereas	O
the	O
nonneutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
12H5	O
IgG2a	O
had	O
no	O
effect	O
.	O

2G7	O
transiently	O
inhibited	O
growth	O
of	O
established	O
MDA	B
-	I
231	I
subcutaneous	O
tumors	O
.	O

Histologically	O
,	O
both	O
2G7	O
-	O
treated	O
and	O
control	O
tumors	O
were	O
identical	O
.	O

Intraperitoneal	O
administration	O
of	O
2G7	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
mouse	O
spleen	O
NK	O
cell	O
activity	O
.	O

2G7	O
did	O
not	O
inhibit	O
MDA	B
-	I
231	I
primary	O
tumor	O
or	O
metastases	O
formation	O
,	O
nor	O
did	O
it	O
stimulate	O
NK	O
cell	O
-	O
mediated	O
cytotoxicity	O
in	O
beige	O
NK	O
-	O
deficient	O
nude	O
mice	O
.	O

Finally	O
,	O
serum	O
-	O
free	O
conditioned	O
medium	O
from	O
MDA	B
-	I
231	I
cells	O
inhibited	O
the	O
NK	O
cell	O
activity	O
of	O
human	O
blood	O
lymphocytes	O
.	O

This	O
inhibition	O
was	O
blocked	O
by	O
the	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
2G7	O
antibody	O
but	O
not	O
by	O
a	O
nonspecific	O
IgG2	O
.	O

These	O
data	O
support	O
a	O
possible	O
role	O
for	O
tumor	O
cell	O
TGF	O
-	O
beta	O
in	O
the	O
progression	O
of	O
mammary	O
carcinomas	O
by	O
suppressing	O
host	O
immune	O
surveillance	O
.	O

The	O
Met	O
proto	O
-	O
oncogene	O
mesenchymal	O
to	O
epithelial	O
cell	O
conversion	O
.	O

Coexpression	O
of	O
the	O
human	O
Met	O
receptor	O
and	O
its	O
ligand	O
,	O
hepatocyte	O
growth	O
factor	O
/	O
scatter	O
factor	O
(	O
HGF	O
/	O
SF	O
)	O
,	O
in	O
NIH	B
3T3	I
fibroblasts	O
causes	O
the	O
cells	O
to	O
become	O
tumorigenic	O
in	O
nude	O
mice	O
.	O

The	O
resultant	O
tumors	O
display	O
lumen	O
-	O
like	O
morphology	O
,	O
contain	O
carcinoma	O
-	O
like	O
focal	O
areas	O
with	O
intercellular	O
junctions	O
resembling	O
desmosomes	O
,	O
and	O
coexpress	O
epithelial	O
(	O
cytokeratin	O
)	O
and	O
mesenchymal	O
(	O
vimentin	O
)	O
cytoskeletal	O
markers	O
.	O

The	O
tumor	O
cells	O
also	O
display	O
enhanced	O
expression	O
of	O
desmosomal	O
and	O
tight	O
-	O
junction	O
proteins	O
.	O

The	O
apparent	O
mesenchymal	O
to	O
epithelial	O
conversion	O
of	O
the	O
tumor	O
cells	O
mimics	O
the	O
conversion	O
that	O
occurs	O
during	O
embryonic	O
kidney	O
development	O
,	O
suggesting	O
that	O
Met	O
-	O
HGF	O
/	O
SF	O
signaling	O
plays	O
a	O
role	O
in	O
this	O
process	O
as	O
well	O
as	O
in	O
tumors	O
that	O
express	O
both	O
epithelial	O
and	O
mesenchymal	O
markers	O
.	O

Additional	O
tests	O
of	O
interest	O
to	O
the	O
dermatologist	O
.	O

The	O
carcinoid	O
syndrome	O
and	O
its	O
clinical	O
manifestations	O
have	O
been	O
discussed	O
.	O

The	O
standard	O
laboratory	O
test	O
for	O
making	O
that	O
diagnosis	O
is	O
urinary	O
5	O
-	O
HIAA	O
levels	O
but	O
newer	O
,	O
more	O
sensitive	O
tests	O
may	O
also	O
be	O
available	O
.	O

Molecular	O
mediators	O
of	O
interactions	O
with	O
extracellular	O
matrix	O
components	O
in	O
metastasis	O
and	O
angiogenesis	O
.	O

Metastasis	O
and	O
tumor	O
angiogenesis	O
are	O
invasive	O
phenomena	O
and	O
share	O
many	O
common	O
properties	O
at	O
the	O
physiological	O
level	O
and	O
some	O
similarities	O
at	O
the	O
molecular	O
level	O
.	O

Each	O
consists	O
of	O
repetitive	O
cycles	O
of	O
interaction	O
with	O
adjacent	O
extracellular	O
matrix	O
components	O
by	O
mediating	O
cellular	O
adhesion	O
,	O
matrix	O
dissolution	O
,	O
and	O
cellular	O
motility	O
to	O
achieve	O
metastasis	O
of	O
cancer	O
cells	O
or	O
neovascularization	O
of	O
tumors	O
.	O

Molecular	O
factors	O
which	O
implement	O
this	O
triad	O
of	O
events	O
are	O
reviewed	O
,	O
as	O
are	O
several	O
signal	O
transduction	O
components	O
which	O
may	O
regulate	O
them	O
.	O

Some	O
potentially	O
promising	O
prognostic	O
,	O
diagnostic	O
,	O
and	O
therapeutic	O
modalities	O
for	O
tumor	O
angiogenesis	O
and	O
metastatic	O
disease	O
are	O
also	O
discussed	O
.	O

Enhanced	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
Stat3	O
-	O
related	O
protein	O
in	O
cells	O
transformed	O
by	O
the	O
Src	O
oncoprotein	O
.	O

Cytokines	O
and	O
growth	O
factors	O
induce	O
tyrosine	O
phosphorylation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
that	O
directly	O
activate	O
gene	O
expression	O
.	O

Cells	O
stably	O
transformed	O
by	O
the	O
Src	O
oncogene	O
tyrosine	O
kinase	O
were	O
examined	O
for	O
STAT	O
protein	O
activation	O
.	O

Assays	O
of	O
electrophoretic	O
mobility	O
,	O
DNA	O
-	O
binding	O
specificity	O
,	O
and	O
antigenicity	O
indicated	O
that	O
Stat3	O
or	O
a	O
closely	O
related	O
STAT	O
family	O
member	O
was	O
constitutively	O
activated	O
by	O
the	O
Src	O
oncoprotein	O
.	O

Induction	O
of	O
this	O
DNA	O
-	O
binding	O
activity	O
was	O
accompanied	O
by	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
correlated	O
with	O
Src	O
transformation	O
.	O

These	O
findings	O
demonstrate	O
that	O
Src	O
can	O
activate	O
STAT	O
signaling	O
pathways	O
and	O
raise	O
the	O
possibility	O
that	O
Stat3	O
contributes	O
to	O
oncogenesis	O
by	O
Src	O
.	O

Ultraviolet	O
B	O
irradiation	O
promotes	O
tumorigenic	O
and	O
metastatic	O
properties	O
in	O
primary	O
cutaneous	O
melanoma	O
via	O
induction	O
of	O
interleukin	O
8	O
.	O

UV	O
radiation	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
initiation	O
of	O
human	O
cutaneous	O
melanoma	O
,	O
but	O
its	O
role	O
in	O
the	O
development	O
of	O
malignant	O
melanoma	O
to	O
the	O
metastatic	O
state	O
is	O
not	O
very	O
well	O
defined	O
.	O

Although	O
previous	O
studies	O
have	O
concentrated	O
on	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
host	O
immune	O
response	O
,	O
the	O
effect	O
of	O
UV	O
-	O
B	O
on	O
the	O
tumor	O
cells	O
was	O
not	O
elucidated	O
.	O

Here	O
we	O
show	O
that	O
UV	O
-	O
B	O
can	O
induce	O
interleukin	O
8	O
(	O
IL	O
-	O
8	O
)	O
mRNA	O
and	O
protein	O
secretion	O
in	O
human	O
cutaneous	O
melanoma	O
with	O
negligible	O
expression	O
of	O
IL	O
-	O
8	O
.	O

UV	O
-	O
B	O
-	O
induced	O
IL	O
-	O
8	O
was	O
constitutively	O
expressed	O
60	O
days	O
after	O
irradiation	O
in	O
tumors	O
implanted	O
in	O
mice	O
.	O

Induction	O
of	O
IL	O
-	O
8	O
was	O
UV	O
-	O
B	O
dose	O
dependent	O
and	O
blocked	O
by	O
cyclohexamide	O
,	O
indicating	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
required	O
for	O
its	O
expression	O
.	O

The	O
UV	O
-	O
irradiated	O
cells	O
demonstrated	O
enhanced	O
tumorigenicity	O
and	O
metastatic	O
potential	O
in	O
nude	O
mice	O
.	O

The	O
increase	O
in	O
tumorigenicity	O
and	O
metastatic	O
ability	O
could	O
be	O
explained	O
by	O
the	O
increase	O
in	O
Mr	O
72	O
,	O
000	O
type	O
IV	O
collagenase	O
activity	O
and	O
angiogenesis	O
attributed	O
to	O
the	O
induction	O
of	O
IL	O
-	O
8	O
after	O
irradiation	O
.	O

The	O
acquisition	O
of	O
the	O
metastatic	O
phenotype	O
induced	O
by	O
UV	O
-	O
B	O
could	O
not	O
be	O
attributed	O
to	O
abnormalities	O
in	O
the	O
p53	O
or	O
MTS	O
-	O
1	O
(	O
p16INK4	O
)	O
genes	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
to	O
show	O
that	O
UV	O
-	O
B	O
can	O
increase	O
the	O
aggressiveness	O
of	O
human	O
cutaneous	O
melanoma	O
for	O
growth	O
and	O
metastasis	O
.	O

Suppressed	O
transformation	O
and	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
by	O
emodin	O
.	O

The	O
amplification	O
and	O
overexpression	O
of	O
the	O
HER	O
-	O
2	O
/	O
neu	O
proto	O
-	O
oncogene	O
,	O
which	O
encodes	O
the	O
tyrosine	O
kinase	O
receptor	O
p185neu	O
,	O
have	O
been	O
observed	O
frequently	O
in	O
tumors	O
from	O
human	O
breast	O
cancer	O
patients	O
and	O
are	O
correlated	O
with	O
poor	O
prognosis	O
.	O

To	O
explore	O
the	O
potential	O
of	O
chemotherapy	O
directed	O
at	O
the	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
we	O
have	O
found	O
that	O
emodin	O
(	O
3	O
-	O
methyl	O
-	O
1	O
,	O
6	O
,	O
8	O
-	O
trihydroxyanthraquinone	O
)	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
suppresses	O
autophosphorylation	O
and	O
transphosphorylation	O
activities	O
of	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
,	O
resulting	O
in	O
tyrosine	O
hypophosphorylation	O
of	O
p185neu	O
in	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
.	O

Emodin	O
,	O
at	O
a	O
40	O
-	O
microM	O
concentration	O
,	O
which	O
repressed	O
tyrosine	O
kinase	O
of	O
p185neu	O
,	O
efficiently	O
inhibited	O
both	O
anchorage	O
-	O
dependent	O
and	O
anchorage	O
-	O
independent	O
growth	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
inhibition	O
was	O
much	O
less	O
effective	O
for	O
those	O
cells	O
expressing	O
basal	O
levels	O
of	O
p185neu	O
under	O
the	O
same	O
conditions	O
.	O

Emodin	O
also	O
induced	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
breast	O
cancer	O
cells	O
by	O
exhibiting	O
a	O
morphological	O
maturation	O
property	O
of	O
large	O
lacy	O
nuclei	O
surrounded	O
by	O
sizable	O
flat	O
cytoplasm	O
and	O
by	O
showing	O
a	O
measurable	O
production	O
of	O
large	O
lipid	O
droplets	O
,	O
which	O
is	O
a	O
marker	O
of	O
mature	O
breast	O
cells	O
.	O

Therefore	O
,	O
our	O
results	O
indicate	O
that	O
emodin	O
inhibits	O
HER	O
-	O
2	O
/	O
neu	O
tyrosine	O
kinase	O
activity	O
and	O
preferentially	O
suppresses	O
growth	O
and	O
induces	O
differentiation	O
of	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	O
cells	O
.	O

These	O
results	O
may	O
have	O
chemotherapeutic	O
implications	O
for	O
using	O
emodin	O
to	O
target	O
HER	O
-	O
2	O
/	O
neu	O
-	O
overexpressing	O
cancer	O
cells	O
.	O

The	O
LHRH	O
pulse	O
generator	O
:	O
a	O
mediobasal	O
hypothalamic	O
location	O
.	O

The	O
location	O
and	O
mechanism	O
of	O
LHRH	O
pulse	O
generator	O
are	O
discussed	O
based	O
on	O
our	O
series	O
of	O
experiments	O
.	O

Suckling	O
stimulus	O
is	O
a	O
novel	O
stimulus	O
that	O
inhibits	O
LH	O
pulses	O
without	O
any	O
cooperation	O
from	O
ovarian	O
steroids	O
,	O
unlike	O
other	O
stimuli	O
such	O
as	O
stress	O
,	O
photoperiod	O
etc	O
.	O

It	O
is	O
directly	O
involved	O
in	O
suppressing	O
the	O
activity	O
of	O
the	O
LHRH	O
pulse	O
generator	O
.	O

The	O
information	O
from	O
teats	O
suckled	O
by	O
pups	O
or	O
babies	O
is	O
conveyed	O
dorsally	O
to	O
the	O
mediobasal	O
hypothalamus	O
(	O
MBH	O
)	O
,	O
where	O
the	O
LHRH	O
pulse	O
generator	O
may	O
be	O
located	O
.	O

Experiments	O
using	O
various	O
types	O
of	O
deafferentation	O
and	O
fetal	O
brain	O
tissue	O
transplantation	O
confirmed	O
that	O
the	O
LHRH	O
pulse	O
generator	O
is	O
located	O
in	O
the	O
MBH	O
and	O
suggested	O
that	O
LHRH	O
pulse	O
generator	O
consists	O
of	O
nonLHRH	O
neurons	O
.	O

Endogenous	O
excitatory	O
amino	O
acid	O
is	O
one	O
of	O
the	O
possible	O
neurotransmitters	O
that	O
regulate	O
LHRH	O
release	O
at	O
the	O
nerve	O
terminal	O
in	O
ME	O
.	O

Bicistronic	O
retroviral	O
vector	O
reveals	O
capacity	O
of	O
v	O
-	O
erbA	O
to	O
induce	O
erythroleukemia	O
and	O
to	O
co	O
-	O
operate	O
with	O
v	O
-	O
myb	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
can	O
induce	O
the	O
proliferation	O
of	O
avian	O
erythroid	O
cells	O
in	O
culture	O
.	O

To	O
study	O
the	O
combined	O
effects	O
of	O
v	O
-	O
erbA	O
and	O
v	O
-	O
myb	O
,	O
the	O
two	O
oncogenes	O
were	O
engineered	O
into	O
a	O
retrovirus	O
bicistronic	O
vector	O
with	O
an	O
internal	O
ribosomal	O
entry	O
site	O
(	O
IRES	O
)	O
or	O
into	O
a	O
vector	O
with	O
a	O
splice	O
acceptor	O
(	O
SPL	O
)	O
.	O

This	O
allowed	O
coexpression	O
of	O
the	O
two	O
proteins	O
and	O
a	O
comparison	O
with	O
the	O
same	O
vector	O
containing	O
either	O
v	O
-	O
erbA	O
or	O
v	O
-	O
myb	O
only	O
.	O

Both	O
the	O
erbA	O
IRES	O
and	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
constructs	O
transformed	O
erythroid	O
cells	O
after	O
infection	O
of	O
bone	O
marrow	O
or	O
blastoderm	O
cultures	O
.	O

The	O
erbA	O
/	O
myb	O
IRES	O
virus	O
exhibited	O
a	O
5	O
-	O
10	O
-	O
fold	O
higher	O
transformed	O
colony	O
forming	O
efficiency	O
than	O
the	O
erbA	O
IRES	O
virus	O
in	O
the	O
blastoderm	O
assay	O
.	O

Surprisingly	O
,	O
when	O
injected	O
into	O
chicken	O
embryos	O
in	O
the	O
presence	O
of	O
helper	O
virus	O
,	O
both	O
viruses	O
induced	O
an	O
erythroleukemia	O
in	O
about	O
half	O
of	O
the	O
animals	O
.	O

In	O
contrast	O
,	O
no	O
leukemia	O
was	O
observed	O
with	O
a	O
myb	O
IRES	O
virus	O
,	O
with	O
spliced	O
vectors	O
containing	O
v	O
-	O
erbA	O
alone	O
or	O
v	O
-	O
erbA	O
in	O
combination	O
with	O
v	O
-	O
myb	O
,	O
nor	O
with	O
erbA	O
IRES	O
and	O
erbA	O
/	O
myb	O
IRES	O
viruses	O
produced	O
in	O
the	O
absence	O
of	O
helper	O
virus	O
.	O

The	O
average	O
latency	O
of	O
leukemia	O
induction	O
was	O
shorter	O
for	O
the	O
erbA	O
/	O
myb	O
IRES	O
virus	O
(	O
3	O
.	O
5	O
weeks	O
)	O
than	O
for	O
the	O
erbA	O
IRES	O
virus	O
(	O
5	O
weeks	O
)	O
.	O

Nevertheless	O
,	O
for	O
both	O
viruses	O
the	O
leukemic	O
blasts	O
retained	O
full	O
factor	O
dependence	O
for	O
growth	O
.	O

These	O
results	O
show	O
that	O
v	O
-	O
erbA	O
is	O
capable	O
of	O
inducing	O
an	O
erythroleukemia	O
when	O
expressed	O
by	O
a	O
high	O
titer	O
bicistronic	O
retrovirus	O
under	O
conditions	O
of	O
virus	O
spreading	O
and	O
that	O
its	O
in	O
vitro	O
and	O
in	O
vivo	O
transforming	O
potential	O
can	O
be	O
enhanced	O
by	O
v	O
-	O
myb	O
.	O

Cancer	O
metastasis	O
:	O
negative	O
regulation	O
by	O
an	O
invasion	O
-	O
suppressor	O
complex	O
.	O

Invasion	O
is	O
the	O
hallmark	O
of	O
tumor	O
malignancy	O
.	O

We	O
situate	O
invasion	O
within	O
microecosystems	O
comprising	O
neoplastic	O
cells	O
as	O
well	O
as	O
host	O
cells	O
.	O

Modulation	O
of	O
invasion	O
within	O
such	O
systems	O
is	O
ascribed	O
to	O
balances	O
between	O
promoter	O
and	O
suppressor	O
pathways	O
.	O

The	O
E	O
-	O
cadherin	O
/	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
gamma	O
-	O
catenin	O
complex	O
has	O
an	O
invasion	O
-	O
suppressor	O
function	O
as	O
evidenced	O
by	O
transfections	O
either	O
with	O
sense	O
cDNA	O
encoding	O
these	O
molecules	O
or	O
with	O
antisense	O
cDNA	O
inhibiting	O
their	O
expression	O
.	O

Loss	O
of	O
heterozygosity	O
at	O
the	O
E	O
-	O
Cadherin	O
(	O
uvo	O
)	O
locus	O
has	O
been	O
reported	O
,	O
but	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
seem	O
to	O
be	O
rare	O
.	O

Downregulation	O
of	O
E	O
-	O
cadherin	O
occurred	O
at	O
the	O
level	O
of	O
transcription	O
or	O
of	O
mRNA	O
stability	O
.	O

Ex	O
vivo	O
cultures	O
from	O
invasive	O
tumors	O
or	O
metastases	O
produced	O
cells	O
that	O
were	O
homogeneously	O
E	O
-	O
cadherin	O
-	O
positive	O
and	O
noninvasive	O
in	O
vitro	O
.	O

These	O
observations	O
have	O
led	O
to	O
the	O
idea	O
that	O
factors	O
in	O
the	O
host	O
downmodulate	O
the	O
E	O
-	O
cadherin	O
complex	O
and	O
promote	O
invasion	O
most	O
probably	O
in	O
a	O
transient	O
way	O
.	O

VEGF165	O
expressed	O
by	O
a	O
replication	O
-	O
deficient	O
recombinant	O
adenovirus	O
vector	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
concept	O
that	O
localized	O
delivery	O
of	O
angiogenic	O
factors	O
via	O
virus	O
-	O
mediated	O
gene	O
transfer	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
ischemic	O
disorders	O
,	O
the	O
replication	O
-	O
deficient	O
adenovirus	O
(	O
Ad	O
)	O
vector	O
AdCMV	O
.	O
VEGF165	O
(	O
where	O
CMV	O
is	O
cytomegalovirus	O
and	O
VEGF	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
)	O
containing	O
the	O
cDNA	O
for	O
human	O
VEGF165	O
,	O
a	O
secreted	O
endothelial	O
cell	O
-	O
specific	O
angiogenic	O
growth	O
factor	O
,	O
was	O
constructed	O
.	O

Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
rat	O
aorta	O
smooth	O
muscle	O
cells	O
(	O
RASMCs	O
)	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
5	O
and	O
20	O
plaque	O
-	O
forming	O
units	O
[	O
pfu	O
]	O
per	O
cell	O
)	O
demonstrated	O
VEGF	O
mRNA	O
expression	O
and	O
protein	O
secretion	O
into	O
the	O
supernatant	O
.	O

Furthermore	O
,	O
the	O
conditioned	O
medium	O
from	O
these	O
cells	O
enhanced	O
vascular	O
permeability	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
neither	O
VEGF	O
mRNA	O
nor	O
secreted	O
protein	O
was	O
found	O
in	O
uninfected	O
HUVECs	O
or	O
RASMCs	O
or	O
in	O
cells	O
infected	O
with	O
the	O
control	O
vector	O
AdCMV	O
.	O
beta	O
gal	O
(	O
where	O
beta	O
gal	O
is	O
beta	O
-	O
galactosidase	O
)	O
.	O

Assessment	O
of	O
starved	O
HUVECs	O
at	O
14	O
days	O
demonstrated	O
sixfold	O
more	O
cells	O
for	O
AdCMV	O
.	O
VEGF165	O
-	O
infected	O
HUVECs	O
(	O
20	O
pfu	O
per	O
cell	O
)	O
than	O
for	O
either	O
infected	O
or	O
uninfected	O
control	O
cells	O
.	O

RASMC	O
proliferation	O
was	O
unaffected	O
by	O
infection	O
with	O
AdCMV	O
.	O
VEGF165	O
.	O

When	O
plated	O
in	O
2	O
%	O
serum	O
on	O
dishes	O
precoated	O
with	O
reconstituted	O
basement	O
membrane	O
(	O
Matrigel	O
)	O
,	O
HUVECs	O
infected	O
with	O
AdCMV	O
.	O
VEGF165	O
(	O
20	O
pfu	O
per	O
cell	O
)	O
differentiated	O
into	O
capillary	O
-	O
like	O
structures	O
.	O

Under	O
similar	O
conditions	O
,	O
both	O
uninfected	O
HUVECs	O
and	O
HUVECs	O
infected	O
with	O
AdCMV	O
.	O
beta	O
gal	O
did	O
not	O
differentiate	O
.	O

To	O
evaluate	O
the	O
ability	O
of	O
AdCMV	O
.	O
VEGF165	O
to	O
function	O
in	O
vivo	O
,	O
either	O
AdCMV	O
.	O

VEGF165	O
or	O
AdCMV	O
.	O
beta	O
gal	O
(	O
2	O
x	O
10	O
(	O
10	O
)	O
pfu	O
)	O
was	O
resuspended	O
in	O
0	O
.	O
5	O
mL	O
Matrigel	O
and	O
injected	O
subcutaneously	O
into	O
mice	O
.	O

Immunohistochemical	O
staining	O
demonstrated	O
VEGF	O
in	O
the	O
tissues	O
surrounding	O
the	O
Matrigel	O
plugs	O
containing	O
AdCMV	O
.	O
VEGF165	O
up	O
to	O
3	O
weeks	O
after	O
injection	O
,	O
whereas	O
no	O
VEGF	O
was	O
found	O
in	O
the	O
control	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Two	O
weeks	O
after	O
injection	O
,	O
there	O
was	O
histological	O
evidence	O
of	O
neovascularization	O
in	O
the	O
tissues	O
surrounding	O
the	O
Matrigel	O
containing	O
AdCMV	O
.	O
VEGF165	O
,	O
whereas	O
no	O
significant	O
angiogenesis	O
was	O
observed	O
in	O
response	O
to	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Furthermore	O
,	O
the	O
Matrigel	O
plugs	O
with	O
AdCMV	O
.	O
VEGF165	O
demonstrated	O
hemoglobin	O
content	O
fourfold	O
higher	O
than	O
the	O
plugs	O
with	O
AdCMV	O
.	O
beta	O
gal	O
.	O

Together	O
,	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
are	O
consistent	O
with	O
the	O
concept	O
that	O
Ad	O
vectors	O
may	O
provide	O
a	O
useful	O
strategy	O
for	O
efficient	O
local	O
delivery	O
of	O
VEGF165	O
in	O
the	O
treatment	O
of	O
ischemic	O
diseases	O
.	O

Identification	O
of	O
NAB1	O
,	O
a	O
repressor	O
of	O
NGFI	O
-	O
A	O
-	O
and	O
Krox20	O
-	O
mediated	O
transcription	O
.	O

NGFI	O
-	O
A	O
(	O
also	O
called	O
Egr1	O
,	O
Zif268	O
,	O
or	O
Krox24	O
)	O
and	O
the	O
closely	O
related	O
proteins	O
Krox20	O
,	O
NGFI	O
-	O
C	O
,	O
and	O
Egr3	O
are	O
zinc	O
-	O
finger	O
transcription	O
factors	O
encoded	O
by	O
immediate	O
-	O
early	O
genes	O
which	O
are	O
induced	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
stimuli	O
.	O

NGFI	O
-	O
A	O
has	O
been	O
implicated	O
in	O
cell	O
proliferation	O
,	O
macrophage	O
differentiation	O
,	O
synaptic	O
activation	O
,	O
and	O
long	O
-	O
term	O
potentiation	O
,	O
whereas	O
Krox20	O
is	O
critical	O
for	O
proper	O
hindbrain	O
segmentation	O
and	O
peripheral	O
nerve	O
myelination	O
.	O

In	O
previous	O
work	O
,	O
a	O
structure	O
/	O
function	O
analysis	O
of	O
NGFI	O
-	O
A	O
revealed	O
a	O
34	O
-	O
aa	O
inhibitory	O
domain	O
that	O
was	O
hypothesized	O
to	O
be	O
the	O
target	O
of	O
a	O
cellular	O
factor	O
that	O
represses	O
NGFI	O
-	O
A	O
transcriptional	O
activity	O
.	O

Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
clone	O
which	O
encodes	O
a	O
protein	O
that	O
interacts	O
with	O
this	O
inhibitory	O
domain	O
and	O
inhibits	O
the	O
ability	O
of	O
NGFI	O
-	O
A	O
to	O
activate	O
transcription	O
.	O

This	O
NGFI	O
-	O
A	O
-	O
binding	O
protein	O
,	O
NAB1	O
,	O
is	O
a	O
570	O
-	O
aa	O
nuclear	O
protein	O
that	O
bears	O
no	O
obvious	O
sequence	O
homology	O
to	O
known	O
proteins	O
.	O

NAB1	O
also	O
represses	O
Krox20	O
activity	O
,	O
but	O
it	O
does	O
not	O
influence	O
Egr3	O
or	O
NGFI	O
-	O
G	O
,	O
thus	O
providing	O
a	O
mechanism	O
for	O
the	O
differential	O
regulation	O
of	O
this	O
family	O
of	O
immediate	O
-	O
early	O
transcription	O
factors	O
.	O

Metastatic	O
NIH	B
3T3	I
x	O
LTA	B
cell	O
hybrids	O
express	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

We	O
previously	O
reported	O
that	O
the	O
murine	O
fibroblast	O
cell	O
line	O
LTA	B
is	O
tumorigenic	O
but	O
non	O
-	O
metastatic	O
,	O
and	O
is	O
non	O
-	O
responsive	O
to	O
a	O
transfected	O
H	O
-	O
ras	O
oncogene	O
.	O

In	O
contrast	O
,	O
NIH	B
3T3	I
cells	O
are	O
non	O
-	O
tumorigenic	O
but	O
are	O
ras	O
-	O
responsive	O
and	O
become	O
metastatic	O
when	O
transfected	O
with	O
ras	O
.	O

Somatic	O
cell	O
hybrids	O
between	O
LTA	B
and	O
NIH	B
3T3	I
cells	O
are	O
tumorigenic	O
,	O
metastatic	O
and	O
ras	O
-	O
responsive	O
.	O

Here	O
we	O
examined	O
expression	O
of	O
type	O
IV	O
collagenases	O
in	O
parental	O
LTA	B
and	O
NIH	B
3T3	I
cells	O
(	O
with	O
and	O
without	O
ras	O
)	O
and	O
four	O
metastatic	O
LTA	B
x	O
NIH	B
3T3	I
hybrids	O
(	O
also	O
with	O
and	O
without	O
ras	O
)	O
.	O

Parental	O
NIH	B
3T3	I
-	O
derived	O
cells	O
had	O
both	O
72	O
kDa	O
and	O
92	O
kDa	O
gelatinase	O
activities	O
,	O
and	O
LTA	B
-	O
derived	O
cells	O
had	O
either	O
aberrantly	O
sized	O
approximately	O
90	O
kDa	O
activity	O
alone	O
or	O
neither	O
enzyme	O
activity	O
.	O

All	O
four	O
metastatic	O
hybrids	O
expressed	O
60	O
-	O
72	O
kDa	O
gelatinase	O
activity	O
,	O
while	O
three	O
of	O
them	O
also	O
had	O
92	O
kDa	O
activity	O
and	O
one	O
had	O
only	O
minimal	O
92	O
kDa	O
activity	O
.	O

Thus	O
the	O
metastatic	O
phenotype	O
of	O
the	O
hybrids	O
was	O
associated	O
with	O
expression	O
of	O
72	O
kDa	O
gelatinase	O
.	O

Levels	O
of	O
RNA	O
for	O
tissue	O
inhibitors	O
of	O
metalloproteinases	O
(	O
TIMP	O
-	O
1	O
,	O
TIMP	O
-	O
2	O
)	O
were	O
relatively	O
constant	O
,	O
suggesting	O
independent	O
regulation	O
of	O
type	O
IV	O
collagenases	O
and	O
their	O
inhibitors	O
.	O

Southern	O
blotting	O
and	O
probing	O
with	O
PCR	O
-	O
synthesized	O
cDNA	O
fragments	O
of	O
the	O
mouse	O
72	O
kDa	O
type	O
IV	O
collagenase	O
gene	O
showed	O
that	O
this	O
gene	O
was	O
present	O
in	O
all	O
cells	O
although	O
the	O
structure	O
of	O
this	O
gene	O
in	O
one	O
of	O
the	O
three	O
LTA	B
cell	O
lines	O
differed	O
from	O
that	O
of	O
the	O
other	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
key	O
change	O
in	O
the	O
metastatic	O
hybrids	O
,	O
relative	O
to	O
non	O
-	O
metastatic	O
parental	O
LTA	B
cells	O
,	O
is	O
induction	O
of	O
expression	O
of	O
72	O
kDa	O
type	O
IV	O
collagenase	O
.	O

Central	O
nervous	O
system	O
infection	O
with	O
Eikenella	O
corrodens	O
:	O
report	O
of	O
two	O
cases	O
.	O

Two	O
cases	O
of	O
central	O
nervous	O
system	O
infections	O
from	O
which	O
E	O
.	O
corrodens	O
has	O
been	O
isolated	O
are	O
reported	O
.	O

The	O
portals	O
of	O
entry	O
,	O
clinical	O
course	O
,	O
and	O
antimicrobial	O
responses	O
conform	O
to	O
other	O
reports	O
in	O
the	O
literature	O
.	O

The	O
importance	O
of	O
obtaining	O
careful	O
anaerobic	O
cultures	O
is	O
emphasized	O
.	O

Neoplastic	O
progression	O
of	O
human	O
colorectal	O
cancer	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
stromelysin	O
-	O
3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
genes	O
.	O

The	O
interaction	O
of	O
neoplastic	O
cells	O
with	O
the	O
extracellular	O
matrix	O
is	O
a	O
critical	O
event	O
for	O
the	O
initiation	O
of	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
potential	O
implication	O
of	O
stromelysin	O
-	O
3	O
(	O
ST3	O
)	O
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
matrix	O
-	O
degrading	O
metalloproteinase	O
family	O
,	O
and	O
of	O
BM	O
-	O
40	O
/	O
SPARC	O
,	O
a	O
glycoprotein	O
associated	O
with	O
the	O
extracellular	O
matrix	O
,	O
during	O
the	O
progression	O
of	O
human	O
colorectal	O
cancers	O
.	O

We	O
analyzed	O
the	O
relative	O
abundance	O
of	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
by	O
Northern	O
blot	O
,	O
and	O
their	O
distribution	O
by	O
in	O
situ	O
hybridization	O
,	O
in	O
normal	O
mucosa	O
,	O
benign	O
adenomas	O
,	O
and	O
primary	O
colorectal	O
adenocarcinomas	O
and	O
their	O
liver	O
metastases	O
.	O

The	O
ST3	O
and	O
BM	O
-	O
40	O
/	O
SPARC	O
transcripts	O
were	O
overexpressed	O
in	O
primary	O
colorectal	O
cancers	O
and	O
their	O
liver	O
metastases	O
compared	O
to	O
non	O
-	O
neoplastic	O
mucosa	O
.	O

These	O
transcripts	O
were	O
localized	O
in	O
stromal	O
fibroblasts	O
adjacent	O
to	O
the	O
neoplastic	O
foci	O
.	O

Overexpression	O
of	O
ST3	O
correlated	O
with	O
the	O
progression	O
of	O
human	O
colorectal	O
tumors	O
toward	O
local	O
invasion	O
and	O
liver	O
metastasis	O
.	O

Induction	O
of	O
these	O
genes	O
also	O
occurred	O
in	O
diverticulitis	O
and	O
digestive	O
neoplasms	O
such	O
as	O
gastric	O
and	O
esophageal	O
carcinomas	O
.	O

Comparative	O
immunohistochemical	O
study	O
of	O
primary	O
and	O
metastatic	O
carcinomas	O
of	O
the	O
liver	O
.	O

Distinguishing	O
primary	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
from	O
metastatic	O
carcinomas	O
to	O
the	O
liver	O
is	O
often	O
difficult	O
,	O
if	O
not	O
impossible	O
,	O
particularly	O
in	O
needle	O
biopsy	O
and	O
fine	O
-	O
needle	O
aspiration	O
specimens	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
a	O
specific	O
immunohistochemical	O
profile	O
that	O
would	O
distinguish	O
HCC	O
from	O
metastatic	O
carcinomas	O
,	O
we	O
studied	O
56	O
HCCs	O
,	O
8	O
cholangiocarcinomas	O
,	O
and	O
24	O
metastatic	O
adenocarcinomas	O
with	O
monoclonal	O
antibodies	O
to	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
,	O
keratin	O
(	O
AE1	O
,	O
AE3	O
,	O
and	O
CAM5	O
.	O
2	O
)	O
,	O
Leu	O
-	O
M1	O
,	O
human	O
milk	O
fat	O
globule	O
(	O
HMFG	O
-	O
2	O
)	O
,	O
tumor	O
-	O
associated	O
glycoprotein	O
-	O
72	O
(	O
B72	O
.	O
3	O
)	O
,	O
epithelial	O
specific	O
membrane	O
antigen	O
(	O
Ber	O
-	O
EP4	O
)	O
,	O
and	O
BCA	O
-	O
225	O
(	O
CU	O
-	O
18	O
)	O
.	O

Both	O
monoclonal	O
and	O
polyclonal	O
(	O
mCEA	O
and	O
pCEA	O
)	O
antibodies	O
to	O
carcinoembryonic	O
antigen	O
also	O
were	O
used	O
.	O

Metastatic	O
adenocarcinomas	O
were	O
often	O
positive	O
for	O
CU	O
-	O
18	O
(	O
71	O
%	O
)	O
,	O
Leu	O
-	O
M1	O
(	O
75	O
%	O
)	O
,	O
B72	O
.	O
3	O
(	O
50	O
%	O
)	O
,	O
HMFG	O
-	O
2	O
(	O
67	O
%	O
)	O
,	O
Ber	O
-	O
EP4	O
(	O
83	O
%	O
)	O
and	O
mCEA	O
(	O
71	O
%	O
)	O
.	O

Using	O
these	O
antibodies	O
,	O
the	O
frequency	O
of	O
positivity	O
for	O
HCC	O
was	O
9	O
%	O
,	O
16	O
%	O
,	O
11	O
%	O
,	O
20	O
%	O
,	O
36	O
%	O
,	O
and	O
11	O
%	O
,	O
respectively	O
.	O

CU	O
-	O
18	O
was	O
the	O
only	O
monoclonal	O
antibody	O
in	O
which	O
there	O
was	O
a	O
significant	O
difference	O
in	O
positive	O
rates	O
between	O
HCC	O
and	O
metastatic	O
adenocarcinomas	O
.	O

Most	O
HCCs	O
(	O
71	O
%	O
)	O
revealed	O
a	O
bile	O
canalicular	O
staining	O
pattern	O
with	O
pCEA	O
.	O

Because	O
this	O
staining	O
pattern	O
was	O
absent	O
in	O
metastatic	O
carcinomas	O
,	O
pCEA	O
appears	O
to	O
be	O
useful	O
in	O
confirming	O
a	O
diagnosis	O
of	O
HCC	O
.	O

AE1	O
,	O
AE3	O
and	O
CAM5	O
.	O
2	O
antibodies	O
were	O
not	O
useful	O
in	O
distinguishing	O
HCC	O
from	O
metastatic	O
carcinomas	O
.	O

Each	O
cholangiocarcinoma	O
shared	O
a	O
staining	O
profile	O
similar	O
to	O
that	O
of	O
metastatic	O
carcinomas	O
.	O

Heparin	O
-	O
steroid	O
conjugates	O
:	O
new	O
angiogenesis	O
inhibitors	O
with	O
antitumor	O
activity	O
in	O
mice	O
.	O

Inhibitors	O
of	O
angiogenesis	O
hold	O
potential	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
where	O
the	O
disease	O
is	O
caused	O
or	O
maintained	O
by	O
the	O
inappropriate	O
growth	O
of	O
blood	O
vessels	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
novel	O
inhibitor	O
of	O
angiogenesis	O
was	O
synthesized	O
by	O
covalently	O
linking	O
a	O
nonanticoagulating	O
derivative	O
of	O
heparin	O
,	O
heparin	O
adipic	O
hydrazide	O
(	O
HAH	O
)	O
,	O
by	O
an	O
acid	O
-	O
labile	O
bond	O
to	O
the	O
antiangiogenic	O
steroid	O
,	O
cortisol	O
.	O

The	O
rationale	O
was	O
that	O
the	O
heparin	O
derivative	O
,	O
which	O
binds	O
to	O
sulfated	O
polyanion	O
receptors	O
on	O
endothelial	O
cells	O
,	O
should	O
concentrate	O
the	O
steroid	O
on	O
the	O
surface	O
of	O
vascular	O
endothelial	O
cells	O
.	O

Endocytosis	O
of	O
the	O
conjugate	O
and	O
decomposition	O
of	O
the	O
acid	O
-	O
labile	O
linkage	O
inside	O
lysosomes	O
and	O
other	O
acidic	O
intracellular	O
compartments	O
should	O
then	O
lead	O
to	O
release	O
of	O
the	O
cortisol	O
and	O
expression	O
of	O
its	O
antiproliferative	O
activity	O
.	O

Analysis	O
of	O
the	O
stability	O
of	O
HAH	O
-	O
cortisol	O
showed	O
that	O
it	O
was	O
stable	O
at	O
pH	O
7	O
.	O
4	O
and	O
broke	O
down	O
rapidly	O
(	O
t1	O
/	O
2	O
15	O
min	O
)	O
at	O
pH	O
4	O
.	O
8	O
at	O
37	O
degrees	O
C	O
.	O

Treatment	O
of	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
with	O
HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
5	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
suppressed	O
their	O
DNA	O
synthesis	O
by	O
50	O
%	O
and	O
inhibited	O
their	O
migration	O
into	O
wounded	O
areas	O
of	O
confluent	O
monolayers	O
.	O

HAH	O
-	O
cortisol	O
at	O
10	O
(	O
-	O
4	O
)	O
M	O
(	O
with	O
respect	O
to	O
cortisol	O
)	O
did	O
not	O
suppress	O
the	O
DNA	O
synthesis	O
of	O
Lewis	O
lung	O
carcinoma	O
cells	O
.	O

Daily	O
i	O
.	O
p	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
into	O
mice	O
bearing	O
s	O
.	O
c	O
.	O
sponge	O
implants	O
retarded	O
vascularization	O
of	O
the	O
sponge	O
,	O
and	O
injections	O
directly	O
into	O
the	O
sponge	O
abolished	O
vascularization	O
for	O
as	O
long	O
as	O
the	O
injections	O
were	O
continued	O
.	O

Daily	O
i	O
.	O
v	O
.	O
injections	O
of	O
HAH	O
-	O
cortisol	O
at	O
doses	O
causing	O
no	O
apparent	O
toxicity	O
retarded	O
the	O
growth	O
of	O
solid	O
s	O
.	O
c	O
.	O

Lewis	O
lung	O
carcinomas	O
in	O
mice	O
by	O
up	O
to	O
65	O
%	O
.	O

In	O
all	O
of	O
these	O
assays	O
,	O
equivalent	O
treatments	O
with	O
a	O
mixture	O
of	O
the	O
HAH	O
plus	O
cortisol	O
was	O
significantly	O
less	O
effective	O
.	O

The	O
antiproliferative	O
effect	O
of	O
HAH	O
-	O
cortisol	O
on	O
endothelial	O
cells	O
appeared	O
independent	O
of	O
the	O
glucocorticoid	O
activity	O
of	O
the	O
steroid	O
since	O
HAH	O
conjugated	O
to	O
5	O
beta	O
-	O
pregnane	O
-	O
3	O
alpha	O
,	O
17	O
alpha	O
,	O
21	O
-	O
triol	O
-	O
20	O
-	O
one	O
,	O
a	O
steroid	O
lacking	O
glucocorticoid	O
or	O
mineralocorticoid	O
activity	O
,	O
was	O
even	O
more	O
effective	O
at	O
inhibiting	O
DNA	O
synthesis	O
by	O
murine	O
pulmonary	O
capillary	O
endothelial	O
cells	O
than	O
was	O
HAH	O
-	O
cortisol	O
.	O

In	O
conclusion	O
,	O
HAH	O
-	O
cortisol	O
represents	O
the	O
prototype	O
of	O
a	O
new	O
class	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
angiogenic	O
diseases	O
.	O

Colorimetrical	O
rate	O
assay	O
for	O
urinary	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
activity	O
using	O
a	O
new	O
substrate	O
.	O

We	O
synthesized	O
a	O
new	O
substrate	O
glycyl	O
-	O
L	O
-	O
proline	O
3	O
,	O
5	O
-	O
dibromo	O
-	O
4	O
-	O
hydroxyanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
)	O
,	O
for	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
.	O

Its	O
hydrolysis	O
by	O
DPPIV	O
resulted	O
in	O
the	O
formation	O
of	O
a	O
chromophore	O
,	O
2	O
,	O
6	O
-	O
dibromophenol	O
-	O
indo	O
-	O
p	O
-	O
xylenol	O
,	O
and	O
its	O
maximal	O
absorption	O
wavelength	O
(	O
600	O
nm	O
)	O
was	O
longer	O
than	O
that	O
of	O
p	O
-	O
nitroaniline	O
(	O
415	O
nm	O
)	O
released	O
from	O
conventional	O
substrate	O
,	O
glycyl	O
-	O
L	O
-	O
proline	O
p	O
-	O
nitroanilide	O
(	O
Gly	O
-	O
Pro	O
-	O
pNA	O
)	O
.	O

We	O
also	O
established	O
the	O
rate	O
assay	O
for	O
urinary	O
DPPIV	O
activity	O
using	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O

The	O
optimum	O
pH	O
was	O
between	O
8	O
.	O
5	O
and	O
9	O
.	O
0	O
.	O

The	O
apparent	O
Km	O
was	O
1	O
.	O
1	O
mmol	O
/	O
1	O
.	O

The	O
detectable	O
range	O
was	O
2	O
.	O
5	O
-	O
350	O
U	O
/	O
l	O
.	O

No	O
changes	O
in	O
blank	O
values	O
occurred	O
throughout	O
the	O
enzyme	O
reaction	O
in	O
the	O
optimum	O
pH	O
.	O

Its	O
value	O
was	O
also	O
much	O
lower	O
than	O
Gly	O
-	O
Pro	O
-	O
pNA	O
.	O

CVs	O
for	O
within	O
-	O
run	O
and	O
between	O
-	O
run	O
were	O
1	O
.	O
1	O
%	O
(	O
n	O
=	O
10	O
)	O
and	O
3	O
.	O
0	O
%	O
(	O
n	O
=	O
10	O
)	O
,	O
respectively	O
.	O

Among	O
tested	O
peptidases	O
,	O
only	O
DPPIV	O
could	O
hydrolyze	O
Gly	O
-	O
Pro	O
-	O
DBAP	O
.	O

Among	O
the	O
protease	O
inhibitors	O
,	O
only	O
two	O
,	O
diprotin	O
-	O
A	O
and	O
phenylmethylsulfonyl	O
fluoride	O
(	O
PMSA	O
)	O
,	O
could	O
inhibit	O
DPPIV	O
activity	O
.	O

The	O
present	O
method	O
did	O
not	O
interfere	O
with	O
urinary	O
ingredients	O
such	O
as	O
hemoglobin	O
.	O

The	O
correlation	O
between	O
the	O
present	O
(	O
y	O
)	O
and	O
conventional	O
(	O
x	O
)	O
methods	O
is	O
presented	O
by	O
the	O
equation	O
y	O
=	O
1	O
.	O
121x	O
+	O
0	O
.	O
096	O
(	O
r	O
=	O
0	O
.	O
993	O
)	O
.	O

Thus	O
the	O
present	O
method	O
provides	O
practical	O
advantages	O
over	O
the	O
conventional	O
method	O
for	O
routine	O
laboratory	O
use	O
.	O

Primary	O
hyperparathyroidism	O
and	O
the	O
heart	O
:	O
cardiac	O
abnormalities	O
correlated	O
to	O
clinical	O
and	O
biochemical	O
data	O
.	O

Comparing	O
patients	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
to	O
a	O
normocalcemic	O
control	O
population	O
,	O
those	O
with	O
PHP	O
have	O
a	O
higher	O
incidence	O
of	O
cardiovascular	O
disease	O
and	O
cardiac	O
abnormalities	O
.	O

This	O
study	O
aimed	O
at	O
correlating	O
cardiac	O
findings	O
(	O
valvular	O
and	O
myocardial	O
calcification	O
,	O
myocardial	O
hypertrophy	O
)	O
with	O
clinical	O
data	O
(	O
age	O
,	O
sex	O
,	O
clinical	O
manifestation	O
,	O
nephrolithiasis	O
,	O
nephrocalcinosis	O
,	O
hypertension	O
,	O
skeletal	O
abnormalities	O
,	O
hypercalcemic	O
syndrome	O
)	O
and	O
biochemical	O
data	O
(	O
serum	O
calcium	O
,	O
serum	O
phosphate	O
,	O
serum	O
iPTH	O
level	O
,	O
serum	O
creatinine	O
)	O
.	O

A	O
group	O
of	O
132	O
consecutive	O
patients	O
with	O
surgically	O
verified	O
PHP	O
(	O
94	O
women	O
,	O
38	O
men	O
;	O
ages	O
15	O
-	O
86	O
,	O
mean	O
age	O
57	O
+	O
/	O
-	O
16	O
years	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

Blood	O
chemistry	O
,	O
clinical	O
presentation	O
,	O
radiography	O
,	O
and	O
echocardiography	O
were	O
carried	O
out	O
in	O
all	O
patients	O
for	O
univariate	O
and	O
multivariate	O
analyses	O
of	O
all	O
parameters	O
.	O

There	O
was	O
no	O
statistical	O
correlation	O
between	O
clinical	O
symptoms	O
,	O
biochemical	O
data	O
,	O
and	O
cardiac	O
calcific	O
alterations	O
.	O

Typical	O
skeletal	O
manifestations	O
(	O
osteolysis	O
/	O
subperiostal	O
resorption	O
)	O
and	O
valvular	O
calcifications	O
were	O
significantly	O
correlated	O
to	O
left	O
ventricular	O
hypertrophy	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

Cardiac	O
abnormalities	O
such	O
as	O
calcific	O
myocardial	O
deposits	O
or	O
mitral	O
and	O
aortic	O
valvular	O
calcifications	O
do	O
not	O
correlate	O
with	O
laboratory	O
findings	O
and	O
clinical	O
presentation	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

There	O
was	O
no	O
biochemical	O
or	O
clinical	O
variable	O
that	O
could	O
predict	O
the	O
frequency	O
or	O
severity	O
of	O
valvular	O
sclerosis	O
or	O
calcific	O
deposits	O
in	O
the	O
myocardium	O
.	O

However	O
,	O
PHP	O
-	O
related	O
skeletal	O
abnormalities	O
and	O
valvular	O
calcification	O
were	O
predicting	O
factors	O
for	O
left	O
ventricular	O
hypertrophy	O
,	O
a	O
reversible	O
cardiac	O
manifestation	O
of	O
PHP	O
.	O

Myocardial	O
hypertrophy	O
is	O
more	O
often	O
found	O
with	O
classic	O
symptomatic	O
PHP	O
with	O
osseous	O
abnormalities	O
.	O

Childhood	O
conscientiousness	O
and	O
longevity	O
:	O
health	O
behaviors	O
and	O
cause	O
of	O
death	O
.	O

Previous	O
research	O
showed	O
that	O
conscientiousness	O
(	O
social	O
dependability	O
)	O
in	O
childhood	O
predicted	O
longevity	O
in	O
an	O
archival	O
prospective	O
cohort	O
study	O
of	O
bright	O
children	O
first	O
studied	O
by	O
Terman	O
in	O
the	O
1920s	O
(	O
H	O
.	O
S	O
.	O
Friedman	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Possible	O
behavioral	O
mechanisms	O
for	O
this	O
robust	O
association	O
are	O
now	O
examined	O
by	O
gathering	O
cause	O
of	O
death	O
information	O
and	O
by	O
considering	O
the	O
possible	O
mediating	O
influences	O
of	O
drinking	O
alcohol	O
,	O
smoking	O
,	O
and	O
overeating	O
.	O

Survival	O
analyses	O
(	O
N	O
=	O
1	O
,	O
215	O
)	O
suggest	O
that	O
the	O
protective	O
effect	O
of	O
conscientiousness	O
is	O
not	O
primarily	O
due	O
to	O
accident	O
avoidance	O
and	O
can	O
not	O
be	O
mostly	O
explained	O
by	O
abstinence	O
from	O
unhealthy	O
substance	O
intake	O
.	O

Conscientiousness	O
may	O
have	O
more	O
wide	O
-	O
ranging	O
effects	O
on	O
health	O
-	O
relevant	O
activities	O
.	O

Selenoperoxidase	O
-	O
dependent	O
glutathione	O
cycle	O
activity	O
in	O
peroxide	O
-	O
challenged	O
leukemia	O
cells	O
.	O

Murine	O
leukemia	O
L1210	B
cells	O
rendered	O
deficient	O
in	O
glutathione	O
peroxidase	O
(	O
GPX	O
)	O
and	O
phospholipid	O
hydroperoxide	O
glutathione	O
peroxidase	O
(	O
PHGPX	O
)	O
by	O
Se	O
deprivation	O
(	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
)	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
tert	O
-	O
butyl	O
hydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
cytotoxicity	O
than	O
Se	O
-	O
replete	O
controls	O
(	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
)	O
.	O

Human	O
K562	B
cells	O
,	O
which	O
express	O
PHGPX	O
,	O
but	O
not	O
GPX	O
,	O
were	O
also	O
more	O
sensitive	O
to	O
t	O
-	O
BuOOH	O
in	O
the	O
Se	O
-	O
deficient	O
(	O
K	O
.	O
Se	O
(	O
-	O
)	O
)	O
than	O
Se	O
-	O
satisfied	O
(	O
K	O
.	O
Se	O
(	O
+	O
)	O
)	O
condition	O
.	O

In	O
examining	O
the	O
metabolic	O
basis	O
for	O
selenoperoxidase	O
-	O
dependent	O
resistance	O
,	O
we	O
found	O
that	O
glucose	O
-	O
replete	O
Se	O
(	O
-	O
)	O
cells	O
reduce	O
t	O
-	O
BuOOH	O
to	O
t	O
-	O
butanol	O
far	O
more	O
slowly	O
than	O
Se	O
(	O
+	O
)	O
cells	O
,	O
the	O
ratio	O
of	O
the	O
first	O
-	O
order	O
rate	O
constants	O
approximating	O
that	O
of	O
the	O
GPX	O
activities	O
(	O
L1210	B
cells	O
)	O
or	O
PHGPX	O
activities	O
(	O
K562	B
cells	O
)	O
.	O

Monitoring	O
peroxide	O
-	O
induced	O
changes	O
in	O
GSH	O
and	O
GSSG	O
gave	O
consistent	O
results	O
;	O
e	O
.	O
g	O
.	O
,	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
+	O
)	O
cells	O
exhibited	O
a	O
first	O
order	O
loss	O
of	O
GSH	O
that	O
was	O
substantially	O
faster	O
than	O
that	O
of	O
glucose	O
-	O
depleted	O
L	O
.	O
Se	O
(	O
-	O
)	O
cells	O
.	O

Under	O
the	O
conditions	O
used	O
,	O
peroxide	O
-	O
induced	O
conversion	O
of	O
GSH	O
to	O
GSSG	O
could	O
be	O
stoichiometrically	O
reversed	O
by	O
resupplying	O
D	O
-	O
glucose	O
,	O
indicating	O
that	O
no	O
significant	O
lysis	O
or	O
GSSG	O
efflux	O
and	O
/	O
or	O
interchange	O
had	O
taken	O
place	O
.	O

The	O
apparent	O
first	O
-	O
order	O
rate	O
constant	O
for	O
GSH	O
decay	O
increased	O
progressively	O
for	O
L1210	B
cells	O
expressing	O
a	O
range	O
of	O
GPX	O
activities	O
from	O
approximately	O
5	O
%	O
to	O
100	O
%	O
,	O
demonstrating	O
that	O
peroxide	O
detoxification	O
is	O
strictly	O
dependent	O
on	O
enzyme	O
content	O
.	O

The	O
initial	O
rate	O
of	O
14CO2	O
release	O
from	O
D	O
-	O
[	O
1	O
-	O
14C	O
]	O
glucose	O
supplied	O
in	O
the	O
medium	O
was	O
much	O
greater	O
for	O
L	O
.	O
Se	O
(	O
+	O
)	O
or	O
K	O
.	O
Se	O
(	O
+	O
)	O
cells	O
than	O
for	O
their	O
respective	O
Se	O
(	O
-	O
)	O
counterparts	O
,	O
consistent	O
with	O
greater	O
hexose	O
monophosphate	O
shunt	O
activity	O
in	O
the	O
former	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
selenoperoxidase	O
action	O
in	O
the	O
glutathione	O
cycle	O
as	O
a	O
means	O
by	O
which	O
tumor	O
cells	O
cope	O
with	O
hydroperoxide	O
stress	O
.	O

Differential	O
expression	O
and	O
mutation	O
of	O
NME	O
genes	O
in	O
autologous	O
cultured	O
human	O
melanoma	O
cells	O
with	O
different	O
metastatic	O
potentials	O
.	O

The	O
putative	O
metastasis	O
suppressor	O
genes	O
,	O
NME1	O
(	O
nm23	O
-	O
1	O
)	O
and	O
NME2	O
(	O
nm23	O
-	O
2	O
)	O
,	O
were	O
examined	O
in	O
a	O
model	O
system	O
we	O
developed	O
to	O
approximate	O
the	O
dissemination	O
of	O
melanoma	O
from	O
a	O
primary	O
skin	O
tumor	O
.	O

We	O
utilized	O
two	O
autologous	O
human	O
melanoma	O
cell	O
lines	O
,	O
IV	B
Cl	I
1	I
and	O
IV	B
Cl	I
3	I
,	O
which	O
displayed	O
qualitatively	O
different	O
metastatic	O
phenotypes	O
following	O
subdermal	O
inoculation	O
into	O
nude	O
mice	O
.	O

Highly	O
metastatic	O
IV	B
Cl	I
1	I
cells	O
expressed	O
approximately	O
5	O
fold	O
lower	O
levels	O
of	O
protein	O
encoded	O
by	O
NME	O
genes	O
than	O
non	O
-	O
metastatic	O
IV	B
Cl	I
3	I
cells	O
.	O

Similar	O
differences	O
in	O
NME	O
protein	O
levels	O
were	O
observed	O
in	O
tumors	O
induced	O
by	O
the	O
two	O
cell	O
lines	O
in	O
nude	O
mice	O
.	O

There	O
were	O
no	O
differences	O
in	O
NME	O
mRNA	O
levels	O
between	O
these	O
two	O
cell	O
lines	O
,	O
suggesting	O
that	O
expression	O
of	O
these	O
proteins	O
is	O
regulated	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
found	O
a	O
ser122	O
-	O
pro	O
mutation	O
in	O
the	O
NME2	O
gene	O
of	O
metastatic	O
IV	B
Cl	I
1	I
cells	O
.	O

A	O
similar	O
ser120	O
-	O
gly	O
mutation	O
in	O
NME1	O
has	O
been	O
found	O
in	O
human	O
neuroblastoma	O
,	O
suggesting	O
that	O
mutation	O
in	O
this	O
region	O
may	O
be	O
a	O
general	O
phenomenon	O
related	O
to	O
tumor	O
progression	O
.	O

These	O
mutations	O
may	O
have	O
functional	O
consequences	O
since	O
they	O
eliminate	O
potential	O
phosphorylation	O
sites	O
and	O
may	O
affect	O
the	O
tertiary	O
structure	O
of	O
mature	O
protein	O
complexes	O
.	O

Image	O
-	O
directed	O
and	O
color	O
Doppler	O
studies	O
of	O
gallbladder	O
tumors	O
.	O

Thirteen	O
cases	O
of	O
primary	O
adenocarcinoma	O
of	O
the	O
gallbladder	O
(	O
GB	O
)	O
,	O
1	O
of	O
malignant	O
fibrous	O
histocytoma	O
,	O
3	O
of	O
metastatic	O
adenocarcinoma	O
,	O
5	O
of	O
adenoma	O
,	O
5	O
of	O
polypus	O
,	O
2	O
of	O
xanthogranuloma	O
,	O
6	O
of	O
chronic	O
cholecystitis	O
,	O
4	O
of	O
acute	O
cholecystitis	O
,	O
and	O
8	O
of	O
subacute	O
cholecystitis	O
were	O
studied	O
by	O
image	O
-	O
directed	O
and	O
color	O
Doppler	O
ultrasonography	O
(	O
CDUS	O
)	O
.	O

All	O
of	O
the	O
14	O
cases	O
of	O
primary	O
GB	O
cancer	O
(	O
10	O
masses	O
,	O
4	O
thickening	O
wall	O
)	O
were	O
found	O
to	O
have	O
a	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signal	O
in	O
the	O
wall	O
of	O
the	O
GB	O
.	O

In	O
contrast	O
,	O
the	O
3	O
cases	O
of	O
metastatic	O
cancer	O
of	O
the	O
GB	O
had	O
no	O
blood	O
flow	O
signal	O
in	O
the	O
wall	O
of	O
the	O
GB	O
.	O

For	O
the	O
30	O
cases	O
of	O
benign	O
lesions	O
of	O
the	O
GB	O
,	O
only	O
in	O
12	O
cases	O
was	O
a	O
low	O
velocity	O
blood	O
flow	O
signal	O
found	O
.	O

Nine	O
of	O
10	O
cases	O
of	O
primary	O
GB	O
malignancy	O
were	O
found	O
to	O
have	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signals	O
in	O
the	O
tumor	O
masses	O
.	O

No	O
blood	O
flow	O
signal	O
was	O
observed	O
in	O
the	O
masses	O
of	O
13	O
cases	O
(	O
3	O
of	O
metastatic	O
adenocarcinoma	O
,	O
5	O
of	O
adenoma	O
,	O
5	O
of	O
polypus	O
)	O
.	O

An	O
abnormal	O
high	O
velocity	O
arterial	O
blood	O
flow	O
signal	O
observed	O
within	O
masses	O
in	O
the	O
GB	O
or	O
in	O
the	O
GB	O
wall	O
is	O
a	O
significant	O
feature	O
of	O
primary	O
GB	O
cancer	O
and	O
thus	O
helps	O
to	O
differentiate	O
primary	O
GB	O
cancer	O
from	O
metastatic	O
and	O
benign	O
lesions	O
of	O
the	O
GB	O
.	O

Differential	O
effects	O
of	O
carbachol	O
on	O
calcium	O
entry	O
and	O
release	O
in	O
CHO	B
cells	O
expressing	O
the	O
m3	O
muscarinic	O
receptor	O
.	O

Calcium	O
signalling	O
was	O
examined	O
in	O
CHO	B
-	I
k1	I
cells	O
that	O
stably	O
express	O
the	O
m3	O
subtype	O
of	O
the	O
muscarinic	O
receptor	O
.	O

The	O
calcium	O
indicator	O
Fura	O
-	O
2	O
was	O
retained	O
in	O
these	O
cells	O
only	O
in	O
the	O
presence	O
of	O
probenecid	O
(	O
1	O
mM	O
)	O
,	O
suggesting	O
that	O
Fura	O
-	O
2	O
efflux	O
was	O
mediated	O
by	O
an	O
organic	O
anion	O
transporter	O
.	O

The	O
addition	O
of	O
carbachol	O
(	O
CCh	O
)	O
to	O
Fura	O
-	O
2	O
loaded	O
cells	O
in	O
suspension	O
caused	O
a	O
rapid	O
transient	O
increase	O
in	O
intracellular	O
calcium	O
[	O
Ca	O
]	O
i	O
followed	O
by	O
a	O
smaller	O
sustained	O
plateau	O
phase	O
.	O

The	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
was	O
dose	O
-	O
dependent	O
with	O
a	O
threshold	O
response	O
of	O
89	O
+	O
/	O
-	O
18	O
nM	O
above	O
baseline	O
with	O
10	O
nM	O
CCh	O
and	O
a	O
maximum	O
stimulation	O
of	O
734	O
+	O
/	O
-	O
46	O
nM	O
with	O
10	O
microM	O
CCh	O
.	O

This	O
phase	O
was	O
accompanied	O
by	O
a	O
similar	O
dose	O
-	O
dependent	O
stimulation	O
of	O
total	O
inositol	O
phosphate	O
production	O
and	O
was	O
assumed	O
to	O
be	O
generated	O
by	O
release	O
from	O
intracellular	O
stores	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

The	O
sustained	O
increase	O
in	O
[	O
Ca	O
]	O
i	O
was	O
generated	O
by	O
entry	O
from	O
the	O
extracellular	O
bath	O
since	O
it	O
was	O
blocked	O
by	O
pretreatment	O
with	O
La3	O
+	O
(	O
1	O
microM	O
)	O
and	O
was	O
absent	O
when	O
bath	O
calcium	O
was	O
chelated	O
with	O
EGTA	O
.	O

This	O
phase	O
was	O
not	O
dependent	O
on	O
CCh	O
dose	O
,	O
and	O
a	O
stimulation	O
of	O
[	O
Ca	O
]	O
i	O
of	O
approximately	O
90	O
nM	O
above	O
baseline	O
was	O
observed	O
with	O
CCh	O
concentrations	O
between	O
50	O
nM	O
and	O
10	O
microM	O
.	O

With	O
this	O
dose	O
range	O
,	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
of	O
Fura	O
-	O
2	O
at	O
the	O
Ca	O
-	O
insensitive	O
excitation	O
wavelength	O
of	O
360	O
nm	O
was	O
likewise	O
maximally	O
stimulated	O
.	O

At	O
lower	O
CCh	O
concentrations	O
(	O
10	O
-	O
50	O
nM	O
)	O
,	O
it	O
was	O
clear	O
that	O
the	O
activation	O
of	O
Ca	O
entry	O
could	O
not	O
be	O
dissociated	O
from	O
a	O
threshold	O
release	O
of	O
Ca	O
from	O
intracellular	O
stores	O
.	O

The	O
phorbol	O
ester	O
PMA	O
,	O
which	O
uncouples	O
the	O
muscarinic	O
receptor	O
from	O
phospholipase	O
C	O
,	O
reduced	O
the	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
by	O
approximately	O
50	O
%	O
with	O
little	O
or	O
no	O
effect	O
on	O
Ca	O
entry	O
at	O
higher	O
CCh	O
levels	O
(	O
>	O
or	O
=	O
1	O
microM	O
)	O
.	O

At	O
lower	O
CCh	O
concentrations	O
(	O
<	O
or	O
=	O
100	O
nM	O
)	O
however	O
,	O
pretreatment	O
with	O
PMA	O
completely	O
blocked	O
all	O
Ca	O
mobilization	O
and	O
supports	O
the	O
contention	O
that	O
Ca	O
entry	O
is	O
coupled	O
to	O
Ca	O
release	O
from	O
stores	O
or	O
to	O
store	O
depletion	O
.	O

The	O
emptying	O
of	O
inositol	O
trisphosphate	O
-	O
sensitive	O
stores	O
with	O
thapsigargin	O
(	O
10	O
nM	O
)	O
stimulated	O
Ca	O
entry	O
and	O
also	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
.	O

Store	O
depletion	O
by	O
incubation	O
in	O
Ca	O
-	O
free	O
media	O
likewise	O
stimulated	O
Mn2	O
+	O
uptake	O
without	O
a	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
.	O

Our	O
data	O
are	O
therefore	O
consistent	O
with	O
a	O
'	O
capacitative	O
'	O
coupling	O
model	O
,	O
whereby	O
the	O
activation	O
of	O
the	O
plasma	O
membrane	O
receptor	O
leads	O
to	O
an	O
InsP3	O
-	O
induced	O
change	O
in	O
the	O
degree	O
of	O
filling	O
of	O
the	O
ER	O
Ca	O
pool	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Down	O
-	O
regulation	O
of	O
collagen	O
XII	O
in	O
transformed	O
mesenchymal	O
cells	O
.	O

Collagen	O
XII	O
is	O
a	O
complex	O
multidomain	O
protein	O
associated	O
with	O
the	O
surface	O
of	O
interstitial	O
collagen	O
fibrils	O
.	O

This	O
protein	O
is	O
produced	O
in	O
large	O
amounts	O
by	O
fibroblasts	O
cultivated	O
in	O
vitro	O
.	O

However	O
,	O
it	O
is	O
completely	O
absent	O
from	O
cells	O
transformed	O
by	O
the	O
oncogene	O
v	O
-	O
myc	O
or	O
v	O
-	O
src	O
and	O
from	O
cells	O
derived	O
from	O
a	O
methylcholanthrene	O
-	O
induced	O
fibrosarcoma	O
.	O

Since	O
all	O
these	O
cells	O
lack	O
any	O
mRNA	O
for	O
collagen	O
,	O
XII	O
,	O
it	O
seems	O
likely	O
that	O
the	O
synthesis	O
is	O
blocked	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
of	O
Rous	O
sarcoma	O
virus	O
demonstrated	O
that	O
a	O
single	O
oncogene	O
product	O
is	O
sufficient	O
to	O
inhibit	O
the	O
synthesis	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
collagen	O
XII	O
might	O
have	O
profound	O
effects	O
on	O
the	O
stability	O
of	O
the	O
extracellular	O
matrix	O
of	O
transformed	O
cells	O
.	O

Comparative	O
NMR	O
study	O
of	O
a	O
differentiated	O
rat	O
hepatoma	O
and	O
its	O
dedifferentiated	O
subclone	O
cultured	O
as	O
spheroids	O
and	O
as	O
implanted	O
tumors	O
.	O

H4IIEC3	B
(	O
H4	B
)	O
,	O
a	O
differentiated	O
rat	O
hepatoma	O
line	O
and	O
H5	B
,	O
its	O
dedifferentiated	O
subclone	O
,	O
were	O
investigated	O
as	O
proliferating	O
spheroids	O
and	O
as	O
implanted	O
subcutaneous	O
tumors	O
in	O
juvenile	O
rats	O
.	O

H4	B
cells	O
formed	O
tight	O
,	O
round	O
spheroids	O
whereas	O
H5	B
cells	O
formed	O
loose	O
,	O
grape	O
-	O
like	O
structures	O
.	O

31P	O
MR	O
spectra	O
showed	O
that	O
phosphocreatine	O
was	O
present	O
in	O
H5	B
spheroids	O
but	O
not	O
in	O
H4	B
spheroids	O
or	O
tumors	O
.	O

[	O
13C	O
]	O
Lactate	O
production	O
from	O
[	O
13C	O
]	O
glucose	O
,	O
with	O
no	O
detectable	O
uptake	O
of	O
[	O
13C	O
]	O
alanine	O
,	O
indicated	O
that	O
energy	O
production	O
in	O
H5	B
spheroids	O
was	O
primarily	O
via	O
glycolysis	O
.	O

No	O
[	O
13C	O
]	O
glucose	O
utilization	O
was	O
detected	O
in	O
H4	B
spheroids	O
,	O
but	O
uptake	O
of	O
alanine	O
and	O
accumulation	O
of	O
labeled	O
lactate	O
,	O
glutamate	O
and	O
glutamine	O
indicated	O
oxidation	O
via	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
.	O

Tumors	O
of	O
H4	B
cells	O
were	O
well	O
perfused	O
,	O
unlike	O
tumors	O
of	O
H5	B
cells	O
which	O
were	O
highly	O
necrotic	O
.	O

Following	O
i	O
.	O
v	O
.	O
infusion	O
with	O
[	O
13C	O
]	O
alanine	O
,	O
[	O
13C	O
]	O
lactate	O
and	O
glutamate	O
,	O
evidence	O
of	O
oxidation	O
via	O
the	O
TCA	O
cycle	O
,	O
were	O
observed	O
in	O
H4	B
tumors	O
.	O

Thus	O
the	O
results	O
obtained	O
by	O
31P	O
and	O
13C	O
MRS	O
correlated	O
with	O
the	O
differentiation	O
state	O
of	O
H4	B
and	O
H5	B
spheroids	O
and	O
tumors	O
.	O

Modulation	O
of	O
apoptosis	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
by	O
GM	O
-	O
CSF	O
.	O

Apoptosis	O
(	O
programmed	O
cell	O
death	O
)	O
regulates	O
cell	O
population	O
size	O
.	O

To	O
determine	O
the	O
mechanisms	O
whereby	O
hematopoietic	O
growth	O
factors	O
(	O
HGFs	O
)	O
modulate	O
apoptosis	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
,	O
we	O
evaluated	O
the	O
roles	O
of	O
protein	O
and	O
mRNA	O
synthesis	O
for	O
altering	O
apoptosis	O
in	O
growth	O
factor	O
-	O
stimulated	O
vs	O
.	O
quiescent	O
leukemic	O
TF1	B
cells	O
.	O

Lysates	O
of	O
cells	O
from	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
-	O
dependent	O
myeloid	O
leukemic	O
cell	O
line	O
TF1	B
were	O
separated	O
into	O
high	O
molecular	O
weight	O
(	O
HMW	O
)	O
pellets	O
of	O
intact	O
DNA	O
and	O
supernatants	O
of	O
fragmented	O
low	O
MW	O
(	O
LMW	O
)	O
DNA	O
,	O
and	O
the	O
DNA	O
purified	O
from	O
these	O
fractions	O
was	O
quantified	O
.	O

In	O
the	O
absence	O
of	O
both	O
GM	O
-	O
CSF	O
and	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
70	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
after	O
3	O
days	O
in	O
culture	O
,	O
with	O
a	O
characteristic	O
apoptotic	O
ladder	O
-	O
like	O
pattern	O
on	O
agarose	O
gel	O
electrophoresis	O
,	O
whereas	O
this	O
proportion	O
had	O
initially	O
been	O
<	O
5	O
%	O
.	O

In	O
contrast	O
,	O
less	O
than	O
5	O
%	O
of	O
the	O
DNA	O
was	O
fragmented	O
in	O
cells	O
incubated	O
with	O
GM	O
-	O
CSF	O
plus	O
FBS	O
or	O
GM	O
-	O
CSF	O
alone	O
.	O

Delayed	O
addition	O
of	O
GM	O
-	O
CSF	O
,	O
but	O
not	O
FBS	O
,	O
permitted	O
partial	O
rescue	O
of	O
the	O
cells	O
,	O
inhibiting	O
increasing	O
rates	O
of	O
accumulation	O
of	O
fragmented	O
DNA	O
.	O

When	O
the	O
macro	O
-	O
molecular	O
synthesis	O
inhibitor	O
cycloheximide	O
(	O
CHX	O
)	O
or	O
actinomycin	O
D	O
(	O
Act	O
D	O
)	O
was	O
present	O
for	O
26	O
hours	O
in	O
the	O
absence	O
of	O
GM	O
-	O
CSF	O
and	O
FBS	O
,	O
apoptosis	O
was	O
inhibited	O
.	O

In	O
contrast	O
,	O
in	O
the	O
presence	O
of	O
GM	O
-	O
CSF	O
or	O
FBS	O
,	O
apoptosis	O
was	O
enhanced	O
upon	O
addition	O
of	O
CHX	O
or	O
Act	O
D	O
.	O

The	O
latter	O
effect	O
persisted	O
even	O
with	O
the	O
late	O
addition	O
of	O
CHX	O
.	O

These	O
findings	O
indicate	O
that	O
disparate	O
mechanisms	O
of	O
enhancing	O
or	O
inhibiting	O
apoptosis	O
exist	O
in	O
myeloid	O
leukemic	O
cells	O
related	O
to	O
environmental	O
conditions	O
,	O
including	O
HGF	O
-	O
regulated	O
cellular	O
synthesis	O
of	O
distinct	O
proteins	O
and	O
mRNA	O
.	O

Effects	O
of	O
doxycycline	O
on	O
in	O
vitro	O
growth	O
,	O
migration	O
,	O
and	O
gelatinase	O
activity	O
of	O
breast	O
carcinoma	O
cells	O
.	O

Metastatic	O
disease	O
is	O
one	O
of	O
the	O
major	O
causes	O
of	O
death	O
from	O
cancer	O
in	O
human	O
beings	O
.	O

Several	O
enzyme	O
systems	O
have	O
been	O
implicated	O
in	O
the	O
metastatic	O
process	O
,	O
but	O
the	O
metalloproteinases	O
(	O
MPs	O
)	O
appear	O
to	O
be	O
the	O
major	O
group	O
involved	O
in	O
most	O
instances	O
of	O
neoplastic	O
invasion	O
.	O

Increased	O
MP	O
activity	O
has	O
been	O
correlated	O
with	O
the	O
metastatic	O
potential	O
of	O
many	O
cancers	O
,	O
including	O
breast	O
cancer	O
.	O

MPs	O
also	O
play	O
a	O
role	O
in	O
tumor	O
angiogenesis	O
.	O

Tetracyclines	O
are	O
antimicrobial	O
agents	O
that	O
can	O
suppress	O
MP	O
activity	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
gingiva	O
,	O
bone	O
,	O
and	O
cartilage	O
.	O

Several	O
reports	O
have	O
indicated	O
that	O
tetracyclines	O
can	O
suppress	O
tumor	O
MPs	O
as	O
well	O
.	O

A	O
synthetic	O
tetracycline	O
,	O
doxycycline	O
,	O
inhibits	O
migration	O
of	O
human	O
MDA	B
-	I
MB	I
-	I
435	I
breast	O
adenocarcinoma	O
cells	O
through	O
a	O
reconstituted	O
basement	O
membrane	O
(	O
Matrigel	O
)	O
,	O
an	O
assay	O
used	O
as	O
an	O
in	O
vitro	O
surrogate	O
for	O
the	O
in	O
vivo	O
process	O
of	O
tumor	O
invasion	O
through	O
basement	O
membranes	O
.	O

Additionally	O
,	O
doxycycline	O
diminishes	O
the	O
proliferation	O
of	O
this	O
breast	O
cancer	O
cell	O
line	O
and	O
also	O
decreases	O
its	O
gelatinolytic	O
activity	O
,	O
as	O
determined	O
by	O
gel	O
zymography	O
.	O

[	O
The	O
erbB	O
gene	O
family	O
:	O
significance	O
for	O
tumor	O
development	O
,	O
prognosis	O
and	O
new	O
therapeutic	O
modalities	O
]	O
.	O

RNA	O
and	O
DNA	O
viruses	O
can	O
be	O
transforming	O
and	O
tumourigenic	O
agents	O
.	O

The	O
transformation	O
is	O
a	O
consequence	O
of	O
the	O
ability	O
of	O
viruses	O
to	O
integrate	O
into	O
the	O
host	O
cell	O
'	O
s	O
DNA	O
and	O
to	O
produce	O
transforming	O
proteins	O
.	O

These	O
proteins	O
are	O
mainly	O
produced	O
by	O
specific	O
integral	O
parts	O
of	O
the	O
viral	O
genome	O
,	O
the	O
oncogenes	O
.	O

Comparison	O
between	O
RNA	O
/	O
DNA	O
sequence	O
of	O
viral	O
oncogenes	O
and	O
normal	O
human	O
genome	O
of	O
non	O
-	O
transformed	O
cells	O
revealed	O
high	O
sequence	O
similarities	O
in	O
specific	O
genomic	O
areas	O
,	O
which	O
were	O
named	O
cellular	O
proto	O
-	O
oncogens	O
.	O

They	O
are	O
important	O
components	O
of	O
the	O
growth	O
regulatory	O
pathways	O
in	O
normal	O
cells	O
.	O

The	O
accumulation	O
of	O
genetic	O
alterations	O
of	O
some	O
proto	O
-	O
oncogens	O
,	O
like	O
the	O
erbB	O
-	O
family	O
,	O
may	O
be	O
part	O
of	O
the	O
mechanism	O
,	O
by	O
which	O
malignant	O
cells	O
can	O
acquire	O
a	O
selective	O
growth	O
advantage	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
R	O
,	O
c	O
-	O
erbB1	O
)	O
,	O
Her	O
-	O
2	O
/	O
neu	O
(	O
c	O
-	O
erbB2	O
)	O
,	O
and	O
c	O
-	O
erbB3	O
are	O
members	O
of	O
the	O
erbB	O
-	O
family	O
.	O

The	O
detection	O
of	O
increased	O
abundance	O
of	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
proteins	O
in	O
human	O
tumours	O
can	O
provide	O
additional	O
information	O
on	O
the	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
for	O
patients	O
with	O
breast	O
,	O
ovarian	O
,	O
endometrial	O
or	O
cervical	O
cancer	O
.	O

Molecular	O
and	O
cell	O
-	O
physiological	O
analyses	O
have	O
improved	O
the	O
understanding	O
of	O
tumour	O
biology	O
and	O
provide	O
the	O
opportunity	O
for	O
new	O
therapeutic	O
approaches	O
.	O

Monoclonal	O
antibody	O
targeted	O
therapy	O
directed	O
against	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
,	O
the	O
use	O
of	O
anti	O
-	O
sense	O
oligonucleotides	O
and	O
oligodeoxynucleotides	O
,	O
and	O
the	O
application	O
of	O
tyrosine	O
kinase	O
and	O
protein	O
C	O
-	O
kinase	O
inhibitors	O
are	O
currently	O
being	O
investigated	O
.	O

Transforming	O
growth	O
factor	O
beta	O
1	O
promotes	O
spontaneous	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
.	O

The	O
neoplastic	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
by	O
various	O
means	O
has	O
consistently	O
been	O
associated	O
with	O
the	O
development	O
of	O
resistance	O
to	O
the	O
mito	O
-	O
inhibitory	O
effect	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
suggesting	O
that	O
such	O
phenotype	O
plays	O
a	O
mechanistic	O
role	O
during	O
the	O
transformation	O
of	O
these	O
cells	O
.	O

We	O
have	O
studied	O
the	O
induction	O
of	O
the	O
""""	O
TGF	O
-	O
beta	O
-	O
resistant	O
""""	O
phenotype	O
in	O
a	O
clonal	O
strain	O
of	O
early	O
passage	O
WB	B
-	I
F344	I
normal	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
,	O
the	O
proliferation	O
of	O
which	O
was	O
markedly	O
inhibited	O
by	O
TGF	O
-	O
beta	O
.	O

The	O
control	O
WB	O
cells	O
in	O
continuous	O
culture	O
slowly	O
developed	O
TGF	O
-	O
beta	O
resistance	O
.	O

However	O
,	O
when	O
the	O
same	O
cells	O
were	O
exposed	O
to	O
step	O
-	O
wise	O
increases	O
of	O
TGF	O
-	O
beta	O
concentration	O
in	O
their	O
culture	O
medium	O
,	O
the	O
development	O
of	O
TGF	O
-	O
beta	O
resistance	O
was	O
accelerated	O
.	O

Cells	O
which	O
had	O
been	O
grown	O
in	O
medium	O
containing	O
1	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
developed	O
colony	O
-	O
forming	O
capacity	O
in	O
soft	O
agar	O
containing	O
epidermal	O
growth	O
factor	O
.	O

Cells	O
which	O
were	O
grown	O
in	O
media	O
containing	O
5	O
and	O
10	O
ng	O
/	O
ml	O
TGF	O
-	O
beta	O
demonstrated	O
a	O
low	O
level	O
of	O
colony	O
-	O
forming	O
efficiency	O
in	O
soft	O
agar	O
medium	O
without	O
added	O
epidermal	O
growth	O
factor	O
and	O
tumorigenicity	O
in	O
isogeneic	O
rats	O
.	O

These	O
TGF	O
-	O
beta	O
-	O
resistant	O
cells	O
also	O
exhibited	O
progressively	O
increasing	O
levels	O
of	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
and	O
myc	O
mRNA	O
,	O
and	O
increased	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
Adriamycin	O
and	O
melphalan	O
.	O

The	O
latter	O
phenomenon	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
mdr	O
-	O
1	O
mRNA	O
expression	O
,	O
cellular	O
glutathione	O
level	O
,	O
and	O
glutathione	O
S	O
-	O
transferase	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
chronic	O
exposure	O
to	O
high	O
concentration	O
of	O
TGF	O
-	O
beta	O
promotes	O
the	O
spontaneous	O
neoplastic	O
transformation	O
of	O
cultured	O
rat	O
liver	O
epithelial	O
cells	O
,	O
and	O
that	O
this	O
process	O
may	O
represent	O
one	O
of	O
the	O
mechanisms	O
of	O
cellular	O
adaptation	O
for	O
induction	O
of	O
the	O
multidrug	O
-	O
resistant	O
phenotype	O
during	O
the	O
carcinogenesis	O
of	O
epithelial	O
cells	O
.	O

Human	O
cytomegalovirus	O
elevates	O
levels	O
of	O
the	O
cellular	O
protein	O
p53	O
in	O
infected	O
fibroblasts	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
like	O
other	O
DNA	O
tumor	O
viruses	O
,	O
induces	O
morphological	O
transformation	O
of	O
cells	O
in	O
vitro	O
and	O
stimulates	O
host	O
cell	O
macromolecular	O
synthesis	O
in	O
infected	O
cells	O
.	O

Since	O
other	O
DNA	O
tumor	O
viruses	O
,	O
such	O
as	O
simian	O
virus	O
40	O
and	O
adenovirus	O
,	O
have	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
cellular	O
protein	O
p53	O
,	O
we	O
investigated	O
whether	O
infection	O
of	O
cells	O
by	O
HCMV	O
would	O
modulate	O
cellular	O
p53	O
levels	O
.	O

Our	O
results	O
indicate	O
that	O
HCMV	O
elevates	O
cellular	O
p53	O
levels	O
on	O
the	O
order	O
of	O
10	O
-	O
to	O
20	O
-	O
fold	O
in	O
infected	O
fibroblasts	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
active	O
virus	O
and	O
was	O
prevented	O
by	O
neutralizing	O
antibody	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
was	O
determined	O
not	O
to	O
be	O
due	O
to	O
virus	O
-	O
receptor	O
interactions	O
or	O
HCMV	O
late	O
events	O
.	O

The	O
induction	O
of	O
elevated	O
p53	O
levels	O
commenced	O
at	O
immediate	O
-	O
early	O
times	O
of	O
the	O
HCMV	O
multiplication	O
cycle	O
(	O
6	O
h	O
postinfection	O
)	O
and	O
reached	O
maximal	O
levels	O
by	O
24	O
h	O
postinfection	O
,	O
before	O
most	O
of	O
the	O
HCMV	O
DNA	O
synthesis	O
was	O
initiated	O
.	O

HCMV	O
immediate	O
-	O
early	O
proteins	O
were	O
clearly	O
shown	O
to	O
be	O
responsible	O
for	O
elevating	O
p53	O
levels	O
in	O
infected	O
fibroblasts	O
;	O
expression	O
of	O
HCMV	O
immediate	O
-	O
early	O
region	O
1	O
and	O
2	O
proteins	O
resulted	O
in	O
elevation	O
of	O
p53	O
levels	O
in	O
transfected	O
human	O
fibroblasts	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
increased	O
p53	O
levels	O
caused	O
by	O
HCMV	O
in	O
infected	O
fibroblasts	O
.	O

Appetite	O
regulation	O
by	O
serotoninergic	O
mechanisms	O
and	O
effects	O
of	O
d	O
-	O
fenfluramine	O
.	O

In	O
this	O
literature	O
review	O
,	O
evidence	O
is	O
presented	O
for	O
the	O
theory	O
that	O
the	O
neurotransmitter	O
,	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
,	O
5HT	O
)	O
,	O
in	O
medial	O
hypothalamic	O
centres	O
is	O
an	O
important	O
regulator	O
for	O
appetite	O
and	O
for	O
the	O
selection	O
of	O
major	O
food	O
constituents	O
.	O

High	O
local	O
levels	O
of	O
5HT	O
cause	O
a	O
reduction	O
of	O
appetite	O
and	O
a	O
preference	O
for	O
protein	O
,	O
low	O
levels	O
the	O
opposite	O
.	O

The	O
main	O
antagonistic	O
system	O
is	O
noradrenergic	O
.	O

The	O
drug	O
d	O
-	O
fenfluramine	O
mimics	O
the	O
effects	O
of	O
5HT	O
by	O
releasing	O
5HT	O
from	O
serotoninergic	O
nerve	O
endings	O
and	O
inhibiting	O
its	O
neuronal	O
re	O
-	O
uptake	O
.	O

Further	O
experimental	O
data	O
prove	O
that	O
a	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
diet	O
promotes	O
uptake	O
of	O
serum	O
tryptophan	O
in	O
the	O
brain	O
and	O
its	O
conversion	O
into	O
5HT	O
.	O

Hence	O
,	O
this	O
serotoninergic	O
system	O
may	O
function	O
as	O
a	O
self	O
-	O
regulatory	O
mechanism	O
.	O

In	O
patients	O
with	O
decreased	O
peripheral	O
insulin	O
sensitivity	O
,	O
the	O
system	O
may	O
be	O
disturbed	O
,	O
causing	O
overconsumption	O
of	O
carbohydrates	O
.	O

This	O
is	O
sometimes	O
compulsive	O
(	O
""""	O
carbohydrate	O
craving	O
""""	O
)	O
.	O

It	O
may	O
be	O
presumed	O
that	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
in	O
addition	O
to	O
the	O
use	O
of	O
serotoninergic	O
drugs	O
,	O
successes	O
with	O
reducing	O
diets	O
may	O
be	O
enhanced	O
by	O
including	O
periods	O
of	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
intake	O
.	O

It	O
would	O
be	O
worthwhile	O
to	O
explore	O
whether	O
similar	O
alimentary	O
self	O
-	O
regulatory	O
mechanisms	O
of	O
neurotransmitter	O
function	O
exist	O
in	O
other	O
regulatory	O
systems	O
.	O

Comparison	O
of	O
image	O
(	O
CAS	O
200	O
)	O
and	O
flow	O
cytometry	O
determined	O
DNA	O
content	O
of	O
paraffin	O
-	O
embedded	O
Hodgkin	O
'	O
s	O
disease	O
tissue	O
.	O

To	O
assess	O
the	O
reliability	O
of	O
DNA	O
estimation	O
using	O
image	O
cytometry	O
,	O
deparaffinized	O
lymph	O
nodes	O
from	O
70	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
were	O
examined	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
with	O
those	O
from	O
flow	O
cytometry	O
.	O

Image	O
analysis	O
without	O
discriminating	O
between	O
the	O
various	O
cell	O
types	O
,	O
as	O
found	O
in	O
Hodgkin	O
'	O
s	O
disease	O
,	O
revealed	O
no	O
separate	O
aneuploid	O
peak	O
.	O

Selecting	O
on	O
morphologically	O
defined	O
nuclear	O
types	O
DNA	O
aneuploidy	O
was	O
detected	O
in	O
20	O
%	O
of	O
the	O
cases	O
(	O
14	O
/	O
70	O
)	O
.	O

The	O
aneuploid	O
populations	O
were	O
limited	O
to	O
the	O
population	O
of	O
nuclei	O
defined	O
as	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
-	O
like	O
or	O
medium	O
-	O
sized	O
lymphocytes	O
.	O

Benign	O
lymph	O
nodes	O
DNA	O
aneuploidy	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
controls	O
.	O

Comparison	O
of	O
DNA	O
histograms	O
obtained	O
by	O
image	O
and	O
flow	O
cytometry	O
showed	O
aneuploid	O
peaks	O
using	O
image	O
cytometry	O
in	O
4	O
of	O
30	O
diploid	O
and	O
10	O
of	O
40	O
aneuploid	O
flow	O
histograms	O
.	O

In	O
conclusion	O
,	O
image	O
analysis	O
using	O
the	O
CAS	O
200	O
system	O
as	O
compared	O
to	O
flow	O
cytometry	O
is	O
more	O
time	O
-	O
consuming	O
and	O
less	O
sensitive	O
to	O
assess	O
ploidy	O
status	O
,	O
although	O
it	O
may	O
provide	O
extra	O
information	O
in	O
some	O
selected	O
cases	O
.	O

Evidence	O
is	O
obtained	O
that	O
DNA	O
aneuploidy	O
in	O
Hodgkin	O
'	O
s	O
disease	O
is	O
preferentially	O
expressed	O
by	O
cells	O
with	O
the	O
RS	O
/	O
H	O
-	O
like	O
and	O
medium	O
-	O
sized	O
lymphocyte	O
morphology	O
.	O

Inhibition	O
of	O
calmodulin	O
-	O
dependent	O
myosin	O
light	O
-	O
chain	O
kinase	O
by	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
and	O
vasoactive	O
intestinal	O
peptide	O
.	O

In	O
view	O
of	O
the	O
ability	O
of	O
calmodulin	O
to	O
bind	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
and	O
growth	O
-	O
hormone	O
-	O
releasing	O
factor	O
(	O
GRF	O
)	O
with	O
high	O
affinity	O
[	O
Stallwood	O
,	O
Brugger	O
,	O
Baggenstoss	O
,	O
Stemmer	O
,	O
Shiraga	O
,	O
Landers	O
and	O
Paul	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
19617	O
-	O
19621	O
]	O
,	O
the	O
effects	O
of	O
these	O
neuropeptides	O
on	O
a	O
model	O
calmodulin	O
-	O
dependent	O
enzyme	O
,	O
myosin	O
light	O
-	O
chain	O
kinase	O
(	O
MLCK	O
)	O
,	O
were	O
studied	O
.	O

Both	O
peptides	O
were	O
potent	O
inhibitors	O
of	O
MLCK	O
activity	O
.	O

The	O
inhibition	O
of	O
enzyme	O
activity	O
by	O
VIP	O
and	O
GRF	O
was	O
progressively	O
overcome	O
with	O
increasing	O
calmodulin	O
concentrations	O
,	O
with	O
no	O
inhibition	O
observed	O
at	O
a	O
saturating	O
calmodulin	O
concentration	O
.	O

Nanomolar	O
concentrations	O
of	O
MLCK	O
blocked	O
the	O
formation	O
of	O
calmodulin	O
-	O
[	O
125I	O
-	O
Tyr10	O
]	O
VIP	O
complexes	O
.	O

These	O
data	O
provide	O
support	O
for	O
a	O
functional	O
role	O
of	O
VIP	O
and	O
GRF	O
binding	O
by	O
calmodulin	O
.	O

Cyclin	O
D1	O
/	O
bcl	O
-	O
1	O
cooperates	O
with	O
myc	O
genes	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
lymphoma	O
in	O
transgenic	O
mice	O
.	O

The	O
chromosomal	O
translocation	O
t	O
(	O
11	O
:	O
14	O
)	O
is	O
associated	O
with	O
human	O
lymphoid	O
neoplasia	O
affecting	O
centrocytic	O
B	O
-	O
cells	O
of	O
intermediate	O
differentiation	O
.	O

As	O
a	O
consequence	O
the	O
cyclin	O
D1	O
(	O
bcl	O
-	O
1	O
)	O
gene	O
is	O
juxtaposed	O
to	O
the	O
immunoglobulin	O
heavy	O
chain	O
enhancer	O
E	O
mu	O
.	O

To	O
show	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
is	O
causally	O
involved	O
in	O
the	O
generation	O
of	O
B	O
-	O
cell	O
neoplasia	O
we	O
have	O
generated	O
transgenic	O
mice	O
that	O
carry	O
a	O
cyclin	O
D1	O
gene	O
under	O
the	O
transcriptional	O
control	O
of	O
the	O
E	O
mu	O
element	O
.	O

E	O
mu	O
cyclin	O
D1	O
transgenic	O
mice	O
show	O
only	O
very	O
subtle	O
alterations	O
in	O
the	O
cycling	O
behaviour	O
of	O
B	O
-	O
cell	O
populations	O
in	O
the	O
bone	O
marrow	O
compared	O
with	O
normal	O
mice	O
and	O
do	O
not	O
develop	O
lymphoid	O
tumours	O
.	O

However	O
,	O
E	O
mu	O
-	O
directed	O
coexpression	O
of	O
cyclin	O
D1	O
and	O
N	O
-	O
MYC	O
or	O
L	O
-	O
MYC	O
in	O
double	O
transgenic	O
mice	O
reveals	O
a	O
strong	O
cooperative	O
effect	O
between	O
MYC	O
and	O
cyclin	O
D1	O
provoking	O
the	O
rapid	O
development	O
of	O
clonal	O
pre	O
-	O
B	O
and	O
B	O
-	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
crossing	O
of	O
cyclin	O
D1	O
transgenic	O
mice	O
with	O
E	O
mu	O
L	O
-	O
myc	O
transgenics	O
that	O
express	O
their	O
transgene	O
in	O
both	O
B	O
-	O
and	O
T	O
-	O
cells	O
but	O
predominantly	O
develop	O
T	O
-	O
cell	O
tumours	O
leads	O
in	O
double	O
transgenics	O
exclusively	O
to	O
B	O
-	O
cell	O
neoplasia	O
.	O

The	O
data	O
presented	O
here	O
demonstrate	O
that	O
transcriptional	O
activation	O
of	O
cyclin	O
D1	O
can	O
oncogenically	O
transform	O
B	O
-	O
cells	O
in	O
concert	O
with	O
a	O
myc	O
gene	O
.	O

They	O
establish	O
cyclin	O
D1	O
as	O
a	O
proto	O
-	O
oncogene	O
whose	O
activity	O
appears	O
to	O
depend	O
on	O
a	O
specific	O
cell	O
type	O
as	O
well	O
as	O
on	O
a	O
specific	O
cooperating	O
partner	O
and	O
link	O
disturbances	O
in	O
the	O
regulation	O
of	O
cell	O
cycle	O
progression	O
to	O
the	O
development	O
of	O
human	O
malignancies	O
.	O

Imaging	O
techniques	O
for	O
the	O
assessment	O
of	O
body	O
composition	O
.	O

Three	O
imaging	O
methods	O
,	O
ultrasound	O
imaging	O
(	O
UI	O
)	O
,	O
computer	O
-	O
assisted	O
axial	O
tomography	O
(	O
CAT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
are	O
widely	O
used	O
in	O
medicine	O
.	O

Their	O
application	O
to	O
the	O
assessment	O
of	O
body	O
composition	O
in	O
nutrition	O
research	O
is	O
still	O
being	O
explored	O
and	O
developed	O
.	O

Ultrasound	O
imaging	O
yields	O
poor	O
image	O
quality	O
but	O
,	O
because	O
it	O
is	O
cheap	O
and	O
safe	O
,	O
deserves	O
further	O
exploration	O
.	O

Both	O
CAT	O
and	O
MRI	O
can	O
produce	O
images	O
with	O
good	O
discrimination	O
among	O
bone	O
,	O
muscle	O
and	O
adipose	O
tissue	O
.	O

Movement	O
artifacts	O
tend	O
to	O
be	O
more	O
serious	O
in	O
MRI	O
than	O
in	O
CAT	O
due	O
to	O
the	O
longer	O
imaging	O
time	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
X	O
-	O
ray	O
exposure	O
in	O
CAT	O
is	O
likely	O
to	O
limit	O
its	O
use	O
in	O
human	O
nutrition	O
research	O
.	O

Repeated	O
measurements	O
of	O
tissue	O
volumes	O
by	O
CAT	O
and	O
MRI	O
give	O
similar	O
CV	O
.	O

In	O
both	O
CAT	O
and	O
MRI	O
,	O
intra	O
-	O
abdominal	O
adipose	O
tissue	O
presents	O
greater	O
problems	O
of	O
measurement	O
than	O
subcutaneous	O
adipose	O
tissue	O
.	O

Validation	O
studies	O
with	O
77	O
-	O
kg	O
pigs	O
of	O
MRI	O
,	O
using	O
13	O
slices	O
,	O
predicted	O
total	O
body	O
lipid	O
with	O
residual	O
standard	O
deviation	O
of	O
1	O
.	O
9	O
%	O
.	O

In	O
validating	O
any	O
of	O
these	O
methods	O
,	O
account	O
should	O
be	O
take	O
of	O
the	O
extent	O
to	O
which	O
the	O
information	O
they	O
give	O
can	O
augment	O
that	O
given	O
by	O
more	O
simple	O
measures	O
like	O
age	O
and	O
weight	O
.	O

[	O
Preliminary	O
results	O
of	O
observing	O
18	O
cases	O
of	O
retinoblastoma	O
carried	O
within	O
the	O
international	O
research	O
program	O
RICS	O
]	O
.	O

In	O
the	O
years	O
1988	O
-	O
1989	O
,	O
the	O
Ophthalmological	O
Clinic	O
in	O
Cracow	O
took	O
part	O
in	O
the	O
International	O
Research	O
Programme	O
on	O
Retinoblastoma	O
as	O
one	O
of	O
28	O
clinical	O
centres	O
in	O
14	O
countries	O
.	O

The	O
study	O
included	O
18	O
children	O
with	O
retinoblastoma	O
,	O
in	O
most	O
cases	O
in	O
the	O
advanced	O
stadium	O
of	O
the	O
disease	O
.	O

As	O
a	O
rule	O
,	O
the	O
eyes	O
filled	O
with	O
tumours	O
were	O
enucleated	O
,	O
and	O
the	O
less	O
advanced	O
cases	O
were	O
treated	O
with	O
combined	O
methods	O
applying	O
radiation	O
with	O
60Co	O
plaques	O
with	O
xenon	O
arc	O
photocoagulation	O
,	O
cryopexy	O
,	O
and	O
chemotherapy	O
.	O

In	O
18	O
treated	O
children	O
23	O
eyes	O
were	O
enucleated	O
(	O
in	O
5	O
children	O
both	O
eyes	O
,	O
in	O
6	O
children	O
with	O
bilateral	O
retinoblastoma	O
1	O
eye	O
,	O
and	O
7	O
eyes	O
in	O
all	O
unilateral	O
cases	O
)	O
.	O

Six	O
eyes	O
with	O
less	O
advanced	O
lesions	O
were	O
treated	O
with	O
combined	O
methods	O
.	O

One	O
child	O
died	O
because	O
of	O
metastases	O
to	O
the	O
brain	O
.	O

The	O
obtained	O
data	O
reveal	O
that	O
retinoblastoma	O
is	O
diagnosed	O
too	O
late	O
,	O
which	O
decreases	O
the	O
chance	O
of	O
cure	O
and	O
causes	O
great	O
danger	O
for	O
the	O
life	O
of	O
the	O
child	O
.	O

Identification	O
of	O
latency	O
-	O
associated	O
transcripts	O
that	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
of	O
Marek	O
'	O
s	O
disease	O
virus	O
.	O

Two	O
small	O
RNAs	O
(	O
0	O
.	O
9	O
and	O
0	O
.	O
75	O
kb	O
)	O
,	O
named	O
Marek	O
'	O
s	O
disease	O
virus	O
(	O
MDV	O
)	O
small	O
RNAs	O
(	O
MSRs	O
)	O
and	O
a	O
10	O
-	O
kb	O
RNA	O
,	O
all	O
of	O
which	O
map	O
antisense	O
to	O
the	O
MDV	O
ICP4	O
homolog	O
gene	O
,	O
have	O
been	O
readily	O
detected	O
in	O
MDCC	B
-	I
MSB1	I
MDV	O
-	O
transformed	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

These	O
RNAs	O
were	O
not	O
detectable	O
in	O
reticuloendotheliosis	O
virus	O
-	O
transformed	O
T	O
cells	O
.	O

When	O
MDV	O
was	O
reactivated	O
by	O
treatment	O
of	O
lymphoblastoid	O
cells	O
with	O
25	O
micrograms	O
of	O
iododeoxyuridine	O
per	O
ml	O
,	O
the	O
relative	O
levels	O
of	O
the	O
transcripts	O
decreased	O
.	O

These	O
RNAs	O
were	O
not	O
detected	O
by	O
Northern	O
(	O
RNA	O
)	O
hybridization	O
in	O
productively	O
infected	O
chicken	O
embryo	O
fibroblasts	O
48	O
h	O
postinfection	O
;	O
however	O
,	O
they	O
were	O
apparent	O
140	O
h	O
postinfection	O
.	O

By	O
using	O
Northern	O
hybridization	O
,	O
RNase	O
protection	O
assays	O
,	O
and	O
primer	O
extension	O
analysis	O
,	O
the	O
MSRs	O
were	O
determined	O
to	O
map	O
antisense	O
to	O
the	O
predicted	O
translational	O
start	O
site	O
of	O
the	O
ICP4	O
homolog	O
gene	O
.	O

The	O
conclusion	O
most	O
consistent	O
with	O
the	O
data	O
is	O
that	O
the	O
two	O
MSRs	O
are	O
overlapping	O
,	O
spliced	O
RNAs	O
.	O

Both	O
small	O
RNAs	O
contain	O
a	O
latency	O
promoter	O
binding	O
factor	O
consensus	O
recognition	O
sequence	O
located	O
toward	O
their	O
5	O
'	O
ends	O
as	O
well	O
as	O
two	O
potential	O
ICP4	O
recognition	O
consensus	O
sequences	O
,	O
one	O
in	O
each	O
orientation	O
.	O

The	O
region	O
contains	O
a	O
number	O
of	O
small	O
open	O
reading	O
frames	O
on	O
each	O
side	O
and	O
within	O
the	O
MSRs	O
.	O

Although	O
the	O
exact	O
endpoints	O
are	O
unknown	O
,	O
the	O
large	O
10	O
-	O
kb	O
species	O
spans	O
the	O
entire	O
ICP4	O
homolog	O
region	O
.	O

We	O
believe	O
that	O
this	O
group	O
of	O
RNAs	O
,	O
which	O
map	O
antisense	O
to	O
the	O
ICP4	O
homolog	O
gene	O
,	O
are	O
latency	O
-	O
associated	O
transcripts	O
of	O
MDV	O
.	O

Elevated	O
expression	O
of	O
the	O
junB	O
proto	O
-	O
oncogene	O
is	O
essential	O
for	O
v	O
-	O
fos	O
induced	O
transformation	O
of	O
Rat	B
-	I
1	I
cells	O
.	O

We	O
previously	O
described	O
the	O
isolation	O
of	O
non	O
-	O
tumorigenic	O
revertants	O
from	O
mutagenized	O
populations	O
of	O
v	O
-	O
fos	O
-	O
transformed	O
Rat	B
-	I
1	I
cells	O
(	O
Zarbl	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
examined	O
the	O
possibility	O
that	O
the	O
revertant	O
phenotype	O
resulted	O
from	O
mutations	O
that	O
altered	O
the	O
expression	O
or	O
activities	O
of	O
the	O
c	O
-	O
jun	O
or	O
junB	O
proto	O
-	O
oncogenes	O
.	O

The	O
results	O
demonstrated	O
that	O
levels	O
of	O
the	O
c	O
-	O
jun	O
mRNA	O
and	O
protein	O
were	O
unchanged	O
in	O
the	O
revertants	O
when	O
compared	O
to	O
the	O
transformed	O
parental	O
cells	O
,	O
and	O
ectopic	O
overexpression	O
of	O
c	O
-	O
jun	O
failed	O
to	O
retransform	O
the	O
revertants	O
.	O

Although	O
one	O
mutant	O
allele	O
was	O
detected	O
in	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
,	O
overexpression	O
of	O
this	O
mutant	O
allele	O
failed	O
to	O
inhibit	O
v	O
-	O
fos	O
induced	O
cell	O
transformation	O
.	O

Together	O
these	O
results	O
indicated	O
that	O
the	O
revertant	O
phenotype	O
did	O
not	O
result	O
from	O
altered	O
expression	O
or	O
mutations	O
in	O
the	O
c	O
-	O
jun	O
gene	O
.	O

In	O
contrast	O
to	O
the	O
results	O
obtained	O
with	O
c	O
-	O
jun	O
,	O
the	O
levels	O
of	O
junB	O
mRNA	O
and	O
protein	O
were	O
found	O
to	O
be	O
reduced	O
two	O
-	O
or	O
threefold	O
in	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
.	O

Ectopic	O
overexpression	O
of	O
junB	O
induced	O
transformation	O
of	O
revertant	O
EMS	B
-	I
1	I
-	I
19	I
,	O
but	O
failed	O
to	O
transform	O
Rat	B
-	I
1	I
cells	O
.	O

Moreover	O
,	O
about	O
10	O
%	O
of	O
v	O
-	O
fos	O
transformed	O
cells	O
transfected	O
with	O
vectors	O
that	O
express	O
antisense	O
junB	O
mRNA	O
acquired	O
a	O
non	O
-	O
transformed	O
phenotype	O
.	O

Together	O
these	O
results	O
indicate	O
that	O
expression	O
of	O
junB	O
above	O
a	O
threshold	O
level	O
is	O
essential	O
for	O
v	O
-	O
fos	O
-	O
induced	O
transformation	O
of	O
Rat	B
-	I
1	I
fibroblasts	O
.	O

Increased	O
expression	O
of	O
specific	O
protein	O
tyrosine	O
phosphatases	O
in	O
human	O
breast	O
epithelial	O
cells	O
neoplastically	O
transformed	O
by	O
the	O
neu	O
oncogene	O
.	O

Protein	O
tyrosine	O
phosphorylation	O
/	O
dephosphorylation	O
is	O
a	O
fundamental	O
mechanism	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
neoplastic	O
transformation	O
;	O
this	O
metabolic	O
process	O
is	O
modulated	O
by	O
the	O
opposing	O
activities	O
of	O
protein	O
tyrosine	O
kinases	O
and	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
.	O

While	O
the	O
role	O
of	O
protein	O
tyrosine	O
kinases	O
has	O
been	O
examined	O
extensively	O
in	O
human	O
breast	O
tumorigenesis	O
,	O
the	O
role	O
of	O
PTPases	O
in	O
this	O
process	O
is	O
virtually	O
unknown	O
.	O

To	O
address	O
this	O
issue	O
,	O
an	O
activated	O
neu	O
oncogene	O
was	O
introduced	O
into	O
an	O
immortalized	O
nontumorigenic	O
human	O
breast	O
epithelial	O
cell	O
line	O
(	O
184B5	B
)	O
.	O

This	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
P185neu	O
expression	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
progressively	O
growing	O
carcinomas	O
after	O
such	O
cells	O
were	O
inoculated	O
into	O
athymic	O
nude	O
mice	O
.	O

Importantly	O
,	O
a	O
striking	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
,	O
LAR	O
and	O
PTP1B	O
,	O
was	O
observed	O
in	O
3	O
independently	O
neu	O
transformed	O
cell	O
lines	O
and	O
their	O
derived	O
tumors	O
.	O

This	O
elevation	O
was	O
verified	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

TC	O
-	O
PTP	O
PTPase	O
expression	O
was	O
only	O
slightly	O
increased	O
in	O
these	O
neu	O
transformed	O
cells	O
,	O
and	O
no	O
expression	O
of	O
CD45	O
PTPase	O
was	O
observed	O
.	O

The	O
level	O
of	O
neu	O
expression	O
,	O
as	O
well	O
as	O
the	O
differential	O
expression	O
between	O
P185neu	O
and	O
LAR	O
/	O
PTP1B	O
,	O
directly	O
correlated	O
with	O
tumorigenicity	O
.	O

Furthermore	O
,	O
rat	O
mammary	O
carcinomas	O
with	O
elevated	O
neu	O
expression	O
(	O
neu	O
-	O
induced	O
)	O
also	O
had	O
sharply	O
elevated	O
LAR	O
-	O
PTPase	O
expression	O
when	O
compared	O
to	O
rat	O
mammary	O
carcinomas	O
with	O
little	O
or	O
no	O
neu	O
expression	O
(	O
7	O
,	O
12	O
-	O
dimethylbenzanthracene	O
induced	O
)	O
;	O
the	O
level	O
of	O
expression	O
of	O
LAR	O
PTPase	O
was	O
directly	O
correlated	O
with	O
the	O
level	O
of	O
neu	O
expression	O
.	O

Thus	O
,	O
our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
,	O
in	O
human	O
breast	O
carcinoma	O
cells	O
and	O
in	O
rat	O
mammary	O
carcinomas	O
that	O
have	O
an	O
induced	O
increase	O
in	O
neu	O
expression	O
,	O
a	O
consistent	O
and	O
substantial	O
increase	O
in	O
the	O
expression	O
of	O
specific	O
PTPases	O
occurs	O
.	O

The	O
relationship	O
between	O
P185neu	O
-	O
protein	O
tyrosine	O
kinase	O
expression	O
and	O
specific	O
PTPase	O
expression	O
may	O
play	O
a	O
critical	O
role	O
in	O
human	O
breast	O
tumorigenesis	O
.	O

Epilepsy	O
in	O
Down	O
syndrome	O
:	O
clinical	O
aspects	O
and	O
possible	O
mechanisms	O
.	O

Although	O
epilepsy	O
is	O
more	O
common	O
in	O
persons	O
with	O
trisomy	O
21	O
(	O
Down	O
syndrome	O
)	O
than	O
in	O
the	O
general	O
population	O
,	O
the	O
mechanisms	O
by	O
which	O
seizures	O
are	O
generated	O
in	O
this	O
population	O
have	O
received	O
little	O
attention	O
.	O

It	O
is	O
likely	O
that	O
this	O
increased	O
seizure	O
susceptibility	O
is	O
due	O
to	O
a	O
combination	O
of	O
medical	O
risk	O
factors	O
and	O
inherent	O
neurologic	O
abnormalities	O
characteristic	O
of	O
Down	O
syndrome	O
.	O

In	O
this	O
review	O
clinical	O
aspects	O
of	O
seizures	O
among	O
individuals	O
with	O
Down	O
syndrome	O
were	O
described	O
and	O
possible	O
mechanisms	O
by	O
which	O
the	O
trisomy	O
21	O
brain	O
may	O
generate	O
seizures	O
were	O
explored	O
.	O

In	O
vivo	O
effects	O
of	O
insulin	O
on	O
tumor	O
and	O
skeletal	O
muscle	O
glucose	O
metabolism	O
in	O
patients	O
with	O
lymphoma	O
.	O

BACKGROUND	O
:	O
The	O
anabolic	O
properties	O
of	O
insulin	O
have	O
been	O
suggested	O
for	O
use	O
to	O
reverse	O
malnutrition	O
associated	O
with	O
cancer	O
.	O

The	O
host	O
and	O
tumor	O
sensitivities	O
to	O
insulin	O
are	O
critical	O
for	O
such	O
treatments	O
,	O
which	O
aim	O
to	O
improve	O
patient	O
nutrition	O
.	O

The	O
authors	O
studied	O
insulin	O
effects	O
on	O
tumor	O
and	O
skeletal	O
muscle	O
metabolism	O
with	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
[	O
18F	O
]	O
FDG	O
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

METHODS	O
:	O
Six	O
patients	O
with	O
lymphoma	O
twice	O
underwent	O
[	O
18F	O
]	O
FDG	O
-	O
PET	O
imaging	O
:	O
once	O
after	O
fasting	O
overnight	O
and	O
once	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
.	O

The	O
dynamic	O
uptake	O
of	O
the	O
glucose	O
analogue	O
[	O
18F	O
]	O
FDG	O
was	O
measured	O
in	O
diseased	O
nodes	O
and	O
upper	O
arm	O
skeletal	O
muscle	O
in	O
both	O
metabolic	O
states	O
.	O

The	O
[	O
18F	O
]	O
FDG	O
uptake	O
in	O
muscle	O
and	O
the	O
whole	O
body	O
glucose	O
use	O
during	O
euglycemic	O
hyperinsulinemic	O
clamp	O
were	O
compared	O
with	O
those	O
of	O
weight	O
-	O
matched	O
healthy	O
subjects	O
studied	O
under	O
similar	O
circumstances	O
.	O

RESULTS	O
:	O
In	O
lymphomatous	O
tissue	O
,	O
[	O
18F	O
]	O
FDG	O
uptake	O
rates	O
were	O
similar	O
in	O
overnight	O
fasting	O
and	O
euglycemic	O
hyperinsulinemic	O
clamp	O
(	O
38	O
+	O
/	O
-	O
10	O
versus	O
41	O
+	O
/	O
-	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
not	O
significant	O
)	O
,	O
whereas	O
glucose	O
uptake	O
in	O
skeletal	O
muscle	O
was	O
increased	O
by	O
insulin	O
(	O
1	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
3	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

Both	O
basal	O
(	O
2	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
2	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
061	O
)	O
and	O
insulin	O
-	O
stimulated	O
(	O
8	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
9	O
mumol	O
/	O
100	O
g	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
055	O
)	O
skeletal	O
arm	O
muscle	O
glucose	O
uptake	O
rates	O
were	O
higher	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
.	O

Whole	O
body	O
glucose	O
use	O
was	O
55	O
%	O
lower	O
in	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
17	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
versus	O
38	O
+	O
/	O
-	O
3	O
mumol	O
/	O
kg	O
/	O
minute	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
consistent	O
with	O
insulin	O
resistance	O
in	O
cancer	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
that	O
insulin	O
does	O
not	O
induce	O
major	O
changes	O
in	O
glucose	O
uptake	O
of	O
lymphomatous	O
tissue	O
.	O

Although	O
insulin	O
sensitivity	O
of	O
skeletal	O
muscle	O
was	O
also	O
reduced	O
in	O
patients	O
with	O
lymphoma	O
,	O
the	O
net	O
insulin	O
effect	O
may	O
counteract	O
imbalance	O
between	O
glucose	O
uptake	O
of	O
tumor	O
and	O
muscle	O
,	O
offering	O
a	O
potential	O
means	O
to	O
circumvent	O
at	O
least	O
some	O
metabolic	O
abnormalities	O
found	O
in	O
cancer	O
.	O

Kinins	O
contribute	O
to	O
the	O
improvement	O
of	O
insulin	O
sensitivity	O
during	O
treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
.	O

Although	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
and	O
alpha	O
1	O
-	O
blockers	O
have	O
been	O
reported	O
to	O
improve	O
insulin	O
sensitivity	O
,	O
their	O
mechanisms	O
of	O
action	O
have	O
not	O
been	O
elucidated	O
.	O

To	O
investigate	O
the	O
role	O
of	O
kinins	O
in	O
insulin	O
sensitivity	O
,	O
we	O
treated	O
4	O
-	O
week	O
-	O
old	O
spontaneously	O
hypertensive	O
rats	O
with	O
either	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
(	O
enalapril	O
)	O
,	O
an	O
alpha	O
1	O
-	O
blocker	O
(	O
doxazosin	O
)	O
,	O
or	O
an	O
angiotensin	O
II	O
antagonist	O
(	O
losartan	O
)	O
for	O
3	O
weeks	O
.	O

A	O
control	O
group	O
received	O
no	O
drugs	O
.	O

In	O
addition	O
,	O
18	O
rats	O
treated	O
with	O
enalapril	O
or	O
doxazosin	O
received	O
a	O
simultaneous	O
administration	O
of	O
a	O
kinin	O
antagonist	O
(	O
Hoe	O
140	O
)	O
.	O

Glucose	O
clamp	O
testing	O
was	O
performed	O
in	O
each	O
group	O
.	O

Enalapril	O
(	O
128	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
and	O
doxazosin	O
(	O
132	O
+	O
/	O
-	O
2	O
mmHg	O
)	O
decreased	O
mean	O
blood	O
pressure	O
compared	O
with	O
control	O
levels	O
(	O
148	O
+	O
/	O
-	O
1	O
mmHg	O
)	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

The	O
glucose	O
requirement	O
for	O
the	O
clamp	O
test	O
during	O
the	O
administration	O
of	O
enalapril	O
(	O
25	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
or	O
doxazosin	O
(	O
28	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
7	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
(	O
19	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Although	O
Hoe	O
140	O
did	O
not	O
alter	O
the	O
glucose	O
requirement	O
of	O
doxazosin	O
(	O
27	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
5	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
,	O
it	O
decreased	O
that	O
of	O
enalapril	O
(	O
22	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
9	O
mg	O
/	O
kg	O
per	O
minute	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
without	O
affecting	O
the	O
changes	O
in	O
mean	O
blood	O
pressure	O
induced	O
by	O
enalapril	O
.	O

In	O
addition	O
,	O
losartan	O
decreased	O
mean	O
blood	O
pressure	O
but	O
did	O
not	O
affect	O
the	O
glucose	O
requirement	O
.	O

Thus	O
,	O
the	O
improvement	O
in	O
insulin	O
sensitivity	O
produced	O
by	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
is	O
mostly	O
dependent	O
on	O
kinins	O
but	O
not	O
on	O
angiotensin	O
II	O
antagonism	O
,	O
and	O
an	O
alpha	O
1	O
-	O
blocker	O
improves	O
insulin	O
sensitivity	O
irrespective	O
of	O
kinins	O
.	O

H	O
-	O
ras	O
mutations	O
in	O
human	O
pituitary	O
carcinoma	O
metastases	O
.	O

Molecular	O
mechanisms	O
of	O
pituitary	O
tumorigenesis	O
were	O
studied	O
using	O
Polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
with	O
DNA	O
sequencing	O
to	O
identify	O
potential	O
mutations	O
in	O
the	O
ras	O
protooncogenes	O
and	O
the	O
tumor	O
suppressor	O
gene	O
p53	O
in	O
invasive	O
pituitary	O
adenomas	O
and	O
carcinomas	O
.	O

Sequencing	O
of	O
exons	O
5	O
through	O
8	O
of	O
the	O
p53	O
gene	O
revealed	O
no	O
mutations	O
,	O
nor	O
were	O
mutations	O
detected	O
in	O
the	O
N	O
-	O
or	O
K	O
-	O
ras	O
protooncogenes	O
in	O
four	O
of	O
the	O
carcinomas	O
and	O
their	O
respective	O
metastatic	O
deposits	O
.	O

Point	O
mutations	O
of	O
H	O
-	O
ras	O
however	O
,	O
were	O
identified	O
in	O
three	O
distant	O
metastatic	O
pituitary	O
tumor	O
secondaries	O
,	O
but	O
not	O
in	O
their	O
respective	O
primary	O
pituitary	O
carcinomas	O
,	O
or	O
in	O
six	O
invasive	O
adenomas	O
.	O

Two	O
of	O
the	O
mutations	O
included	O
a	O
G	O
to	O
C	O
substitution	O
at	O
codon	O
12	O
,	O
and	O
a	O
G	O
to	O
A	O
substitution	O
at	O
codon	O
18	O
,	O
resulting	O
in	O
a	O
glycine	O
to	O
arginine	O
,	O
and	O
an	O
alanine	O
to	O
threonine	O
change	O
at	O
these	O
amino	O
acids	O
,	O
respectively	O
.	O

A	O
third	O
mutation	O
involved	O
a	O
single	O
base	O
pair	O
(	O
adenine	O
)	O
deletion	O
in	O
codon	O
3	O
of	O
H	O
-	O
ras	O
which	O
causes	O
a	O
frame	O
shift	O
,	O
resulting	O
in	O
a	O
termination	O
signal	O
at	O
codon	O
19	O
.	O

These	O
results	O
suggest	O
that	O
point	O
mutations	O
in	O
p53	O
and	O
ras	O
are	O
not	O
associated	O
with	O
pituitary	O
tumorigenesis	O
,	O
however	O
,	O
point	O
mutations	O
of	O
the	O
H	O
-	O
ras	O
gene	O
may	O
be	O
important	O
in	O
the	O
formation	O
and	O
or	O
growth	O
of	O
pituitary	O
metastases	O
.	O

This	O
observed	O
genomic	O
instability	O
will	O
be	O
of	O
value	O
in	O
predicting	O
the	O
potential	O
metastatic	O
behavior	O
of	O
these	O
aggressive	O
pituitary	O
tumors	O
.	O

Distribution	O
and	O
predictors	O
of	O
depressive	O
symptoms	O
in	O
osteoarthritis	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
the	O
prevalence	O
and	O
correlates	O
of	O
depressive	O
symptoms	O
in	O
a	O
sample	O
of	O
elderly	O
persons	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

METHODS	O
:	O

Secondary	O
analysis	O
of	O
cross	O
sectional	O
interview	O
data	O
from	O
108	O
community	O
living	O
persons	O
age	O
50	O
or	O
over	O
who	O
met	O
American	O
College	O
of	O
Rheumatology	O
clinical	O
criteria	O
for	O
OA	O
of	O
the	O
hip	O
and	O
/	O
or	O
knee	O
.	O

RESULTS	O
:	O

The	O
prevalence	O
of	O
substantial	O
depressive	O
symptomatology	O
appeared	O
to	O
be	O
no	O
greater	O
than	O
would	O
be	O
expected	O
in	O
the	O
general	O
population	O
for	O
this	O
age	O
group	O
.	O

However	O
,	O
persons	O
currently	O
under	O
a	O
physician	O
'	O
s	O
care	O
for	O
OA	O
were	O
significantly	O
more	O
depressed	O
than	O
those	O
not	O
under	O
care	O
,	O
and	O
,	O
with	O
the	O
exception	O
of	O
those	O
who	O
had	O
post	O
-	O
high	O
school	O
education	O
,	O
depression	O
was	O
a	O
better	O
predictor	O
of	O
being	O
under	O
care	O
than	O
OA	O
symptoms	O
.	O

The	O
direct	O
and	O
interactive	O
effects	O
of	O
3	O
variables	O
-	O
-	O
education	O
,	O
age	O
and	O
self	O
-	O
perceived	O
impact	O
of	O
the	O
OA	O
problem	O
-	O
-	O
were	O
found	O
to	O
explain	O
40	O
%	O
of	O
variance	O
in	O
depression	O
scores	O
in	O
the	O
total	O
sample	O
and	O
50	O
%	O
among	O
those	O
currently	O
receiving	O
care	O
.	O

Younger	O
and	O
less	O
educated	O
subjects	O
had	O
relatively	O
more	O
depressive	O
symptoms	O
and	O
,	O
furthermore	O
,	O
in	O
this	O
subgroup	O
the	O
correlation	O
between	O
OA	O
impact	O
and	O
depression	O
was	O
high	O
.	O

CONCLUSIONS	O
:	O

The	O
importance	O
of	O
assessing	O
depression	O
in	O
persons	O
who	O
seek	O
care	O
for	O
OA	O
is	O
supported	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
observed	O
relationship	O
between	O
education	O
and	O
arthritis	O
outcomes	O
could	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
depression	O
.	O

Methotrexate	O
osteopathy	O
in	O
rheumatic	O
disease	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
two	O
adults	O
with	O
stress	O
fractures	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
had	O
methotrexate	O
osteopathy	O
.	O

CASE	O
REPORTS	O
:	O

Two	O
adult	O
patients	O
developed	O
features	O
consistent	O
with	O
methotrexate	O
osteopathy	O
while	O
receiving	O
low	O
weekly	O
doses	O
of	O
methotrexate	O
.	O

METHODS	O
:	O

Iliac	O
crest	O
biopsy	O
samples	O
were	O
taken	O
and	O
bone	O
histomorphometry	O
carried	O
out	O
.	O

RESULTS	O
:	O

Symptoms	O
resolved	O
when	O
the	O
methotrexate	O
was	O
discontinued	O
.	O

Bone	O
histology	O
showed	O
changes	O
consistent	O
with	O
osteoblast	O
inhibition	O
by	O
methotrexate	O
.	O

CONCLUSIONS	O
:	O

When	O
given	O
in	O
low	O
doses	O
for	O
prolonged	O
periods	O
,	O
methotrexate	O
may	O
have	O
adverse	O
effects	O
on	O
bone	O
,	O
particularly	O
in	O
post	O
-	O
menopausal	O
women	O
.	O

Overexpression	O
of	O
Glut	O
-	O
1	O
glucose	O
transporter	O
in	O
human	O
breast	O
cancer	O
.	O

An	O
immunohistochemical	O
study	O
.	O

BACKGROUND	O
:	O
Breast	O
cancers	O
have	O
higher	O
than	O
normal	O
glucose	O
metabolism	O
,	O
but	O
the	O
mechanism	O
of	O
glucose	O
entry	O
into	O
these	O
tumors	O
is	O
not	O
well	O
understood	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
five	O
facilitative	O
glucose	O
transporters	O
,	O
Glut	O
-	O
1	O
(	O
erythrocyte	O
type	O
)	O
,	O
Glut	O
-	O
2	O
(	O
liver	O
type	O
)	O
,	O
Glut	O
-	O
3	O
(	O
brain	O
type	O
)	O
,	O
Glut	O
-	O
4	O
(	O
muscle	O
/	O
fat	O
type	O
)	O
,	O
and	O
Glut	O
-	O
5	O
(	O
small	O
intestine	O
type	O
)	O
,	O
was	O
studied	O
by	O
immunohistochemistry	O
of	O
paraffin	O
sections	O
from	O
12	O
primary	O
human	O
breast	O
cancers	O
and	O
8	O
lymph	O
node	O
metastases	O
from	O
2	O
patients	O
.	O

Rat	O
tissues	O
known	O
to	O
express	O
these	O
glucose	O
transporters	O
were	O
used	O
as	O
controls	O
.	O

RESULTS	O
:	O
All	O
the	O
primary	O
breast	O
cancers	O
and	O
the	O
lymph	O
node	O
metastases	O
were	O
positive	O
for	O
Glut	O
-	O
1	O
.	O

This	O
transporter	O
was	O
expressed	O
on	O
the	O
cell	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
of	O
the	O
tumor	O
cells	O
,	O
but	O
exhibited	O
marked	O
intratumoral	O
and	O
intertumoral	O
variability	O
in	O
the	O
proportions	O
of	O
positive	O
cells	O
and	O
the	O
intensity	O
of	O
staining	O
.	O

Staining	O
of	O
the	O
normal	O
mammary	O
epithelium	O
,	O
if	O
present	O
,	O
was	O
much	O
lower	O
than	O
observed	O
in	O
tumor	O
cells	O
from	O
the	O
same	O
patient	O
.	O

Glut	O
-	O
2	O
was	O
expressed	O
in	O
all	O
of	O
the	O
tumors	O
,	O
but	O
the	O
intensity	O
of	O
staining	O
was	O
not	O
consistently	O
stronger	O
than	O
that	O
seen	O
in	O
healthy	O
breast	O
.	O

Clusters	O
of	O
Glut	O
-	O
4	O
-	O
positive	O
granule	O
were	O
observed	O
in	O
cells	O
in	O
six	O
of	O
the	O
tumors	O
.	O

None	O
of	O
the	O
tumors	O
or	O
the	O
healthy	O
breast	O
in	O
the	O
tissues	O
studied	O
expressed	O
Glut	O
-	O
3	O
or	O
Glut	O
-	O
5	O
.	O

CONCLUSIONS	O
:	O
Higher	O
expression	O
of	O
the	O
glucose	O
transporter	O
Glut	O
-	O
1	O
by	O
breast	O
cancer	O
cells	O
compared	O
with	O
the	O
healthy	O
breast	O
tissue	O
is	O
common	O
.	O

Increased	O
glucose	O
transporter	O
protein	O
expression	O
may	O
contribute	O
to	O
the	O
increased	O
uptake	O
of	O
2	O
-	O
[	O
18F	O
]	O
-	O
fluoro	O
-	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
(	O
FDG	O
)	O
by	O
these	O
tumors	O
observed	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
imaging	O
.	O

Methodologies	O
for	O
measuring	O
carcinogen	O
adducts	O
in	O
humans	O
.	O

In	O
summary	O
,	O
although	O
some	O
of	O
the	O
more	O
optimistic	O
aspirations	O
for	O
human	O
biomonitoring	O
studies	O
envisaged	O
a	O
decade	O
ago	O
have	O
not	O
been	O
realized	O
thus	O
far	O
,	O
some	O
considerable	O
advances	O
have	O
been	O
made	O
.	O

The	O
examples	O
cited	O
above	O
indicate	O
that	O
the	O
feasibility	O
of	O
biomonitoring	O
has	O
been	O
clearly	O
established	O
.	O

In	O
addition	O
,	O
they	O
demonstrate	O
the	O
need	O
for	O
preliminary	O
biomarker	O
testing	O
and	O
validation	O
through	O
transitional	O
studies	O
prior	O
to	O
their	O
field	O
application	O
.	O

In	O
the	O
next	O
decade	O
of	O
research	O
into	O
carcinogen	O
adducts	O
in	O
humans	O
,	O
continued	O
improvements	O
in	O
the	O
reproducibility	O
and	O
specificity	O
of	O
assays	O
for	O
DNA	O
adducts	O
will	O
be	O
needed	O
.	O

Perhaps	O
the	O
increasing	O
use	O
of	O
hybrid	O
methodologies	O
to	O
concentrate	O
adducts	O
followed	O
by	O
specific	O
chemical	O
analyses	O
will	O
allow	O
such	O
adducts	O
to	O
be	O
monitored	O
more	O
precisely	O
.	O

Of	O
course	O
,	O
further	O
basic	O
research	O
into	O
the	O
mechanisms	O
of	O
carcinogenesis	O
will	O
allow	O
the	O
measurement	O
of	O
specific	O
novel	O
markers	O
which	O
are	O
more	O
closely	O
tied	O
to	O
the	O
disease	O
endpoint	O
than	O
adducts	O
.	O

The	O
development	O
of	O
new	O
assays	O
for	O
determining	O
metabolic	O
phenotypes	O
and	O
genotypes	O
relevant	O
to	O
carcinogenesis	O
should	O
improve	O
our	O
estimates	O
of	O
susceptibility	O
(	O
46	O
-	O
48	O
)	O
.	O

Such	O
new	O
approaches	O
along	O
with	O
the	O
sustained	O
improvement	O
of	O
current	O
assays	O
will	O
allow	O
molecular	O
approaches	O
to	O
continue	O
to	O
enrich	O
cancer	O
epidemiology	O
in	O
the	O
future	O
.	O

Effect	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
energy	O
metabolism	O
of	O
cancer	O
cells	O
.	O

The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
a	O
homologous	O
series	O
of	O
1	O
-	O
alkylpyrrolidine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	B
murine	O
leukemia	O
cells	O
.	O

The	O
effect	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumor	O
cells	O
incubated	O
in	O
vitro	O
was	O
investigated	O
.	O

1	O
-	O
Tetradecylpyrrolidine	O
N	O
-	O
oxide	O
(	O
TPNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	O
cells	O
in	O
an	O
ice	O
bath	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
to	O
the	O
same	O
extent	O
over	O
the	O
whole	O
concentration	O
range	O
.	O

After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
lower	O
.	O

The	O
decrease	O
in	O
ATP	O
level	O
might	O
be	O
explained	O
through	O
the	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	O
membrane	O
integrity	O
.	O

High	O
density	O
of	O
somatostatin	O
receptors	O
in	O
veins	O
surrounding	O
human	O
cancer	O
tissue	O
:	O
role	O
in	O
tumor	O
-	O
host	O
interaction	O
?	O

Somatostatin	O
receptors	O
were	O
detected	O
in	O
peritumoral	O
veins	O
of	O
various	O
human	O
cancer	O
tissue	O
specimens	O
.	O

Vascular	O
and	O
neoplastic	O
tissue	O
from	O
14	O
colonic	O
adenocarcinomas	O
,	O
13	O
carcinoids	O
,	O
6	O
renal	O
-	O
cell	O
carcinomas	O
and	O
7	O
malignant	O
lymphomas	O
were	O
analyzed	O
for	O
somatostatin	O
receptors	O
by	O
use	O
of	O
quantitative	O
receptor	O
autoradiography	O
.	O

In	O
colonic	O
carcinoma	O
specimens	O
,	O
the	O
peritumoral	O
vessels	O
expressed	O
a	O
high	O
density	O
of	O
somatostatin	O
receptors	O
,	O
whereas	O
the	O
neoplastic	O
tissue	O
itself	O
was	O
receptor	O
-	O
negative	O
in	O
many	O
cases	O
.	O

In	O
contrast	O
,	O
the	O
incidence	O
and	O
density	O
of	O
somatostatin	O
receptors	O
in	O
peritumoral	O
vessels	O
was	O
low	O
in	O
well	O
-	O
differentiated	O
gastrointestinal	O
and	O
bronchial	O
carcinoids	O
,	O
in	O
contrast	O
to	O
the	O
high	O
density	O
of	O
such	O
receptors	O
in	O
the	O
carcinoid	O
tumor	O
tissue	O
.	O

Autochthonous	O
vessels	O
surrounding	O
other	O
tumors	O
such	O
as	O
renal	O
-	O
cell	O
carcinomas	O
or	O
malignant	O
lymphomas	O
also	O
frequently	O
expressed	O
somatostatin	O
receptors	O
.	O

In	O
all	O
cases	O
,	O
the	O
somatostatin	O
receptors	O
were	O
localized	O
in	O
veins	O
,	O
particularly	O
in	O
the	O
smooth	O
-	O
muscle	O
cell	O
layer	O
.	O

They	O
exhibited	O
specific	O
and	O
high	O
-	O
affinity	O
binding	O
of	O
somatostatin	O
-	O
14	O
,	O
somatostatin	O
-	O
28	O
and	O
octreotide	O
,	O
suggesting	O
a	O
preferential	O
expression	O
of	O
the	O
SSTR2	O
receptor	O
subtype	O
.	O

Since	O
the	O
vessels	O
of	O
normal	O
non	O
-	O
neoplastic	O
human	O
tissues	O
,	O
e	O
.	O
g	O
.	O
of	O
intestine	O
or	O
lymphatic	O
organs	O
,	O
have	O
few	O
somatostatin	O
receptors	O
,	O
the	O
increased	O
somatostatin	O
receptor	O
expression	O
in	O
peritumoral	O
vessels	O
observed	O
in	O
this	O
study	O
may	O
be	O
linked	O
to	O
the	O
neoplastic	O
process	O
itself	O
.	O

The	O
results	O
suggest	O
that	O
somatostatin	O
and	O
somatostatin	O
receptors	O
may	O
play	O
a	O
regulatory	O
role	O
for	O
hemodynamic	O
tumor	O
-	O
host	O
interactions	O
,	O
possibly	O
involving	O
tumor	O
stroma	O
generation	O
,	O
tumor	O
environment	O
,	O
angiogenesis	O
and	O
,	O
particularly	O
,	O
vascular	O
drainage	O
of	O
poorly	O
differentiated	O
neoplasms	O
.	O

[	O
Treatment	O
of	O
the	O
diabetic	O
foot	O
by	O
hyperbaric	O
oxygen	O
]	O

Diabetic	O
foot	O
wounds	O
are	O
consequences	O
of	O
the	O
neuropathy	O
and	O
the	O
small	O
and	O
large	O
vessel	O
disease	O
that	O
complicate	O
diabetes	O
.	O

At	O
the	O
cellular	O
level	O
,	O
the	O
result	O
is	O
hypoxia	O
which	O
impairs	O
wound	O
healing	O
.	O

Hyperbaric	O
oxygenation	O
(	O
HBO	O
)	O
may	O
be	O
a	O
useful	O
adjuvant	O
to	O
wound	O
care	O
.	O

It	O
leads	O
to	O
enhanced	O
oxygenation	O
of	O
the	O
affected	O
tissues	O
,	O
has	O
an	O
antiseptic	O
effect	O
,	O
reduces	O
edema	O
,	O
and	O
accelerates	O
collagen	O
production	O
and	O
angiogenesis	O
,	O
thus	O
enhancing	O
tissue	O
repair	O
.	O

14	O
diabetics	O
with	O
chronic	O
nonhealing	O
wounds	O
which	O
did	O
not	O
respond	O
to	O
treatment	O
for	O
at	O
least	O
3	O
months	O
were	O
treated	O
by	O
HBO	O
.	O

All	O
had	O
palpable	O
pedal	O
pulses	O
.	O

Transcutaneous	O
measurements	O
of	O
tissue	O
pO2	O
showed	O
elevation	O
from	O
20	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
during	O
air	O
breathing	O
to	O
643	O
+	O
/	O
-	O
242	O
mm	O
Hg	O
while	O
breathing	O
pure	O
oxygen	O
at	O
2	O
.	O
5	O
ATA	O
.	O

They	O
were	O
treated	O
with	O
HBO	O
in	O
56	O
+	O
/	O
-	O
10	O
consecutive	O
HBO	O
sessions	O
.	O

In	O
11	O
there	O
was	O
complete	O
wound	O
healing	O
,	O
while	O
in	O
1	O
there	O
was	O
partial	O
response	O
,	O
in	O
1	O
minimal	O
response	O
,	O
and	O
in	O
1	O
a	O
transient	O
response	O
.	O

HBO	O
is	O
useful	O
in	O
chronic	O
nonhealing	O
wounds	O
of	O
the	O
diabetic	O
foot	O
and	O
of	O
the	O
diabetic	O
foot	O
with	O
impending	O
amputation	O
.	O

It	O
is	O
a	O
safe	O
mode	O
of	O
therapy	O
,	O
but	O
further	O
studies	O
are	O
required	O
to	O
establish	O
its	O
efficacy	O
and	O
to	O
ascertain	O
which	O
diabetic	O
patients	O
and	O
wounds	O
will	O
benefit	O
the	O
most	O
from	O
it	O
.	O

Chelation	O
treatment	O
of	O
neurological	O
Wilson	O
'	O
s	O
disease	O
.	O

The	O
results	O
of	O
chelation	O
treatment	O
of	O
137	O
patients	O
presenting	O
with	O
neurological	O
Wilson	O
'	O
s	O
disease	O
are	O
described	O
,	O
together	O
with	O
the	O
more	O
commonly	O
observed	O
toxic	O
reactions	O
to	O
the	O
various	O
drugs	O
employed	O
.	O

Fifty	O
-	O
seven	O
patients	O
made	O
an	O
excellent	O
response	O
to	O
treatment	O
and	O
became	O
symptom	O
free	O
.	O

Thirty	O
-	O
six	O
patients	O
made	O
a	O
good	O
recovery	O
,	O
but	O
were	O
left	O
with	O
some	O
minor	O
neurological	O
deficit	O
.	O

Twenty	O
-	O
four	O
patients	O
had	O
a	O
poor	O
response	O
:	O
although	O
the	O
disease	O
process	O
was	O
arrested	O
they	O
were	O
left	O
more	O
or	O
less	O
disabled	O
.	O

Twenty	O
patients	O
died	O
:	O
nine	O
had	O
little	O
or	O
no	O
treatment	O
,	O
but	O
11	O
died	O
despite	O
apparently	O
adequate	O
chelation	O
therapy	O
.	O

There	O
was	O
no	O
obvious	O
reason	O
for	O
this	O
failure	O
.	O

The	O
liver	O
copper	O
level	O
was	O
estimated	O
in	O
six	O
of	O
these	O
patients	O
:	O
it	O
was	O
still	O
significantly	O
elevated	O
in	O
only	O
one	O
,	O
but	O
in	O
all	O
four	O
in	O
whom	O
it	O
was	O
possible	O
to	O
make	O
the	O
determination	O
,	O
the	O
concentration	O
of	O
copper	O
in	O
the	O
basal	O
ganglia	O
was	O
in	O
excess	O
of	O
45	O
micrograms	O
/	O
g	O
wet	O
weight	O
.	O

It	O
was	O
not	O
apparent	O
why	O
adequate	O
therapy	O
failed	O
to	O
remove	O
copper	O
from	O
the	O
brains	O
of	O
these	O
patients	O
.	O

There	O
was	O
no	O
obvious	O
clinical	O
,	O
histological	O
or	O
biochemical	O
indicator	O
of	O
failure	O
to	O
respond	O
to	O
treatment	O
.	O

Initial	O
deterioration	O
before	O
improvement	O
was	O
seen	O
in	O
30	O
patients	O
:	O
the	O
prognosis	O
for	O
a	O
useful	O
recovery	O
was	O
not	O
necessarily	O
worse	O
than	O
that	O
in	O
patients	O
who	O
did	O
not	O
show	O
this	O
phenomenon	O
.	O

Transformation	O
-	O
associated	O
cytokine	O
9E3	O
/	O
CEF4	O
is	O
chemotactic	O
for	O
chicken	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

9E3	O
/	O
CEF4	O
,	O
which	O
is	O
released	O
from	O
transformed	O
chicken	O
embryo	O
fibroblasts	O
(	O
CEF	O
)	O
,	O
is	O
a	O
member	O
of	O
the	O
platelet	O
factor	O
4	O
family	O
of	O
inflammatory	O
proteins	O
and	O
may	O
be	O
the	O
avian	O
homolog	O
of	O
interleukin	O
-	O
8	O
.	O

Since	O
the	O
function	O
of	O
9E3	O
/	O
CEF4	O
is	O
unknown	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
protein	O
on	O
mitogenicity	O
and	O
chemotaxis	O
,	O
as	O
well	O
as	O
its	O
expression	O
,	O
in	O
fibroblasts	O
and	O
peripheral	O
blood	O
cells	O
.	O

9E3	O
/	O
CEF4	O
mRNA	O
was	O
expressed	O
in	O
chicken	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
its	O
expression	O
was	O
stimulated	O
by	O
incubation	O
of	O
the	O
monocytes	O
with	O
lipopolysaccharide	O
or	O
phorbol	O
myristic	O
acetate	O
.	O

Boyden	O
double	O
-	O
membrane	O
analysis	O
of	O
chemotaxis	O
showed	O
that	O
9E3	O
/	O
CEF4	O
was	O
chemotactic	O
for	O
chicken	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
as	O
well	O
as	O
for	O
heterophils	O
.	O

Untransformed	O
CEF	O
and	O
CEF	O
transformed	O
with	O
Rous	O
sarcoma	O
virus	O
also	O
migrated	O
to	O
9E3	O
/	O
CEF4	O
protein	O
,	O
as	O
measured	O
by	O
Boyden	O
single	O
-	O
membrane	O
analysis	O
.	O

9E3	O
/	O
CEF4	O
was	O
slightly	O
mitogenic	O
for	O
CEF	O
,	O
causing	O
a	O
doubling	O
of	O
[	O
3H	O
]	O
thymidine	O
uptake	O
when	O
added	O
to	O
serum	O
-	O
starved	O
CEF	O
.	O
9E3	O
/	O
CEF4	O
was	O
found	O
associated	O
not	O
only	O
with	O
the	O
cell	O
and	O
in	O
the	O
culture	O
medium	O
of	O
Rous	O
sarcoma	O
virus	O
-	O
transformed	O
CEF	O
but	O
also	O
with	O
the	O
extracellular	O
matrix	O
.	O

The	O
in	O
vivo	O
role	O
of	O
9E3	O
/	O
CEF4	O
may	O
be	O
involved	O
with	O
chemotaxis	O
and	O
metastasis	O
,	O
rather	O
than	O
with	O
direct	O
stimulation	O
of	O
mitogenicity	O
.	O

Lactotransferrin	O
binding	O
to	O
its	O
platelet	O
receptor	O
inhibits	O
platelet	O
aggregation	O
.	O

A	O
fluorescent	O
lactotransferrin	O
probe	O
was	O
prepared	O
by	O
coupling	O
5	O
-	O
(	O
(	O
[	O
2	O
-	O
(	O
carbhydrazino	O
)	O
methyl	O
]	O
-	O
thio	O
)	O
acetyl	O
)	O
amino	O
fluorescein	O
to	O
aldehyde	O
groups	O
that	O
were	O
produced	O
by	O
a	O
mild	O
periodic	O
-	O
acid	O
oxidation	O
of	O
the	O
glycan	O
moieties	O
of	O
lactotransferrin	O
.	O

In	O
this	O
manner	O
,	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
remains	O
active	O
in	O
contrast	O
to	O
the	O
binding	O
site	O
of	O
the	O
lactotransferrin	O
derivatized	O
with	O
fluorescein	O
isothiocyanate	O
.	O

The	O
fluorescent	O
probe	O
allowed	O
us	O
to	O
characterize	O
,	O
by	O
flow	O
cytometry	O
,	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
non	O
-	O
activated	O
human	O
platelets	O
.	O

The	O
putative	O
lactotransferrin	O
platelet	O
receptor	O
was	O
purified	O
and	O
its	O
immunological	O
and	O
physico	O
-	O
chemical	O
properties	O
were	O
found	O
to	O
be	O
very	O
similar	O
to	O
those	O
of	O
the	O
receptor	O
previously	O
isolated	O
from	O
activated	O
human	O
lymphocytes	O
.	O

Lactotransferrin	O
inhibits	O
ADP	O
-	O
induced	O
platelet	O
aggregation	O
at	O
concentrations	O
down	O
to	O
5	O
nM	O
,	O
which	O
can	O
be	O
reached	O
in	O
the	O
plasma	O
after	O
leukocyte	O
degranulation	O
.	O

Inhibition	O
of	O
platelet	O
aggregation	O
was	O
also	O
observed	O
with	O
the	O
N	O
-	O
terminal	O
fragment	O
of	O
lactotransferrin	O
(	O
residues	O
3	O
-	O
281	O
;	O
50	O
%	O
inhibition	O
=	O
2	O
microM	O
)	O
and	O
with	O
CFQWQRNMRKVRGPPVSC	O
synthetic	O
octodecapeptide	O
(	O
residues	O
20	O
-	O
37	O
;	O
50	O
%	O
inhibition	O
=	O
20	O
microM	O
)	O
corresponding	O
to	O
one	O
of	O
the	O
two	O
external	O
loops	O
(	O
residues	O
28	O
-	O
34	O
and	O
39	O
-	O
42	O
)	O
where	O
we	O
recently	O
located	O
the	O
receptor	O
-	O
binding	O
site	O
.	O

The	O
activity	O
(	O
50	O
%	O
inhibition	O
=	O
500	O
microM	O
)	O
of	O
the	O
tetrapeptide	O
KRDS	O
(	O
residues	O
39	O
-	O
42	O
)	O
,	O
which	O
has	O
already	O
been	O
described	O
,	O
was	O
at	O
least	O
25	O
-	O
times	O
and	O
16000	O
-	O
times	O
lower	O
than	O
the	O
activity	O
of	O
the	O
octodecapeptide	O
and	O
of	O
the	O
lactotransferrin	O
molecules	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
inhibition	O
was	O
demonstrated	O
to	O
be	O
mediated	O
by	O
a	O
mechanism	O
which	O
requires	O
the	O
binding	O
of	O
lactotransferrin	O
to	O
its	O
putative	O
receptor	O
and	O
not	O
to	O
platelet	O
glycoprotein	O
IIb	O
-	O
IIIa	O
.	O

Vitamins	O
regulate	O
gene	O
expression	O
and	O
induce	O
differentiation	O
and	O
growth	O
inhibition	O
in	O
cancer	O
cells	O
.	O

Their	O
relevance	O
in	O
cancer	O
prevention	O
.	O

Although	O
several	O
hypotheses	O
for	O
human	O
carcinogenesis	O
have	O
been	O
proposed	O
,	O
the	O
specific	O
genetic	O
changes	O
that	O
cause	O
normal	O
cells	O
to	O
become	O
cancer	O
cells	O
have	O
not	O
been	O
identified	O
.	O

In	O
spite	O
of	O
uncertainties	O
regarding	O
the	O
mechanisms	O
of	O
carcinogenesis	O
,	O
several	O
vitamins	O
such	O
as	O
beta	O
-	O
carotene	O
and	O
vitamins	O
A	O
,	O
C	O
,	O
and	O
E	O
,	O
which	O
can	O
reduce	O
the	O
risk	O
of	O
cancer	O
,	O
have	O
been	O
identified	O
,	O
using	O
animal	O
and	O
in	O
vitro	O
models	O
of	O
carcinogenesis	O
.	O

These	O
studies	O
have	O
led	O
to	O
a	O
hypothesis	O
that	O
the	O
supplemental	O
intake	O
of	O
these	O
vitamins	O
may	O
reduce	O
the	O
risk	O
of	O
cancer	O
.	O

This	O
hypothesis	O
in	O
humans	O
can	O
be	O
tested	O
only	O
by	O
intervention	O
trials	O
that	O
are	O
in	O
progress	O
.	O

Prospective	O
and	O
retrospective	O
case	O
-	O
controlled	O
experimental	O
designs	O
are	O
not	O
suitable	O
for	O
testing	O
the	O
above	O
hypothesis	O
.	O

The	O
fact	O
that	O
some	O
vitamins	O
induce	O
cell	O
differentiation	O
and	O
/	O
or	O
growth	O
inhibition	O
in	O
tumor	O
cells	O
in	O
culture	O
suggests	O
that	O
the	O
use	O
of	O
these	O
vitamins	O
in	O
cancer	O
prevention	O
has	O
a	O
cellular	O
basis	O
.	O

In	O
addition	O
to	O
having	O
a	O
direct	O
effect	O
on	O
tumor	O
cells	O
,	O
vitamins	O
such	O
as	O
alpha	O
-	O
tocopheryl	O
succinate	O
and	O
beta	O
-	O
carotene	O
enhance	O
the	O
effect	O
of	O
other	O
agents	O
that	O
induce	O
differentiation	O
in	O
tumor	O
cells	O
.	O

Some	O
vitamins	O
like	O
beta	O
-	O
carotene	O
,	O
retinoic	O
acid	O
,	O
alpha	O
-	O
tocopheryl	O
succinate	O
,	O
and	O
vitamin	O
D	O
also	O
regulate	O
the	O
expressions	O
of	O
certain	O
oncogenes	O
and	O
cellular	O
genes	O
.	O

These	O
are	O
exciting	O
new	O
functions	O
of	O
vitamins	O
that	O
nobody	O
could	O
have	O
predicted	O
only	O
a	O
few	O
years	O
ago	O
.	O

Increased	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
messenger	O
RNA	O
expression	O
and	O
absence	O
of	O
mutations	O
in	O
colon	O
carcinomas	O
of	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O

BACKGROUND	O
:	O
The	O
murine	O
nm23	O
gene	O
suppresses	O
the	O
metastatic	O
behavior	O
of	O
malignant	O
rodent	O
tumor	O
lines	O
,	O
and	O
reduced	O
nm23	O
expression	O
correlates	O
with	O
increased	O
likelihood	O
of	O
lymph	O
node	O
metastases	O
in	O
human	O
breast	O
cancers	O
.	O

More	O
recent	O
data	O
have	O
demonstrated	O
the	O
existence	O
of	O
two	O
human	O
nm23	O
gene	O
homologues	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
and	O
have	O
shown	O
that	O
deletion	O
of	O
nm23	O
-	O
H1	O
alleles	O
occurs	O
in	O
some	O
colon	O
carcinomas	O
associated	O
with	O
poor	O
prognosis	O
.	O

These	O
findings	O
suggest	O
that	O
nm23	O
-	O
H1	O
encodes	O
for	O
suppression	O
of	O
colon	O
carcinoma	O
metastasis	O
.	O

In	O
contrast	O
,	O
we	O
have	O
previously	O
reported	O
that	O
total	O
nm23	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
is	O
increased	O
to	O
similar	O
levels	O
in	O
colon	O
tumors	O
of	O
both	O
high	O
and	O
low	O
metastatic	O
potential	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
reconcile	O
our	O
previous	O
findings	O
with	O
the	O
recent	O
report	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
in	O
human	O
colon	O
cancers	O
associated	O
with	O
poor	O
prognosis	O
.	O

Our	O
purpose	O
was	O
to	O
examine	O
human	O
colon	O
cancers	O
for	O
inactivation	O
of	O
two	O
candidate	O
metastasis	O
suppressor	O
genes	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
,	O
either	O
by	O
mutation	O
or	O
by	O
loss	O
of	O
gene	O
transcription	O
.	O

METHODS	O
:	O
We	O
used	O
ribonuclease	O
protection	O
assays	O
to	O
analyze	O
human	O
colon	O
tumors	O
for	O
the	O
level	O
of	O
nm23	O
-	O
H1	O
(	O
43	O
samples	O
)	O
and	O
nm23	O
-	O
H2	O
(	O
41	O
samples	O
)	O
transcript	O
(	O
mRNA	O
)	O
expression	O
and	O
the	O
presence	O
of	O
mutations	O
that	O
could	O
inactivate	O
potential	O
suppressor	O
function	O
.	O

RESULTS	O
:	O
We	O
detected	O
only	O
wild	O
-	O
type	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
.	O

Expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
increased	O
in	O
33	O
of	O
41	O
colon	O
tumors	O
,	O
and	O
expression	O
of	O
nm23	O
-	O
H2	O
mRNA	O
was	O
elevated	O
in	O
28	O
of	O
41	O
colon	O
tumors	O
relative	O
to	O
that	O
in	O
matched	O
normal	O
mucosa	O
.	O

Increases	O
in	O
these	O
mRNA	O
levels	O
were	O
similar	O
in	O
tumors	O
of	O
both	O
low	O
and	O
high	O
metastatic	O
potential	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
,	O
despite	O
correlation	O
of	O
nm23	O
-	O
H1	O
allelic	O
deletions	O
with	O
colon	O
cancers	O
associated	O
with	O
poor	O
prognosis	O
,	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
alleles	O
do	O
not	O
directly	O
mediate	O
metastasis	O
suppression	O
in	O
colon	O
carcinoma	O
.	O

Our	O
results	O
leave	O
unexplained	O
the	O
observation	O
that	O
nm23	O
-	O
H1	O
allelic	O
deletion	O
correlates	O
with	O
metastatic	O
potential	O
of	O
colon	O
carcinomas	O
.	O

IMPLICATIONS	O
:	O
These	O
findings	O
also	O
contrast	O
with	O
the	O
demonstration	O
of	O
nm23	O
metastasis	O
suppressor	O
activity	O
in	O
murine	O
melanoma	O
and	O
with	O
the	O
correlation	O
of	O
loss	O
of	O
nm23	O
expression	O
in	O
breast	O
cancer	O
with	O
poor	O
prognosis	O
.	O

It	O
may	O
be	O
that	O
metastasis	O
suppression	O
by	O
the	O
nm23	O
gene	O
is	O
a	O
tissue	O
-	O
specific	O
phenomenon	O
.	O

E	O
mu	O
-	O
bcl	O
-	O
2	O
transgene	O
facilitates	O
spontaneous	O
transformation	O
of	O
early	O
pre	O
-	O
B	O
and	O
immunoglobulin	O
-	O
secreting	O
cells	O
but	O
not	O
T	O
cells	O
.	O

To	O
assess	O
the	O
lymphoid	O
tumorigenic	O
potential	O
of	O
bcl	O
-	O
2	O
,	O
mice	O
of	O
five	O
independent	O
strains	O
expressing	O
a	O
bcl	O
-	O
2	O
transgene	O
in	O
B	O
and	O
/	O
or	O
T	O
cells	O
were	O
monitored	O
for	O
disease	O
up	O
to	O
12	O
months	O
of	O
age	O
.	O

Lymphoma	O
prevalence	O
was	O
minimal	O
in	O
the	O
T	O
lineage	O
but	O
significant	O
,	O
although	O
low	O
(	O
3	O
-	O
15	O
%	O
)	O
,	O
in	O
the	O
B	O
lineage	O
.	O

The	O
principal	O
types	O
of	O
tumors	O
were	O
plasmacytomas	O
secreting	O
immunoglobulin	O
and	O
novel	O
lymphomas	O
that	O
expressed	O
markers	O
such	O
as	O
Sca	O
-	O
1	O
,	O
CD4	O
,	O
Thy	O
-	O
1	O
,	O
CD34	O
and	O
CD45	O
(	O
B220	O
)	O
,	O
consistent	O
with	O
an	O
origin	O
very	O
early	O
in	O
B	O
-	O
lymphoid	O
development	O
.	O

Rearrangement	O
of	O
the	O
c	O
-	O
myc	O
gene	O
was	O
common	O
in	O
the	O
plasmacytomas	O
,	O
implying	O
a	O
synergistic	O
role	O
for	O
myc	O
and	O
bcl	O
-	O
2	O
in	O
their	O
etiology	O
,	O
but	O
was	O
not	O
detected	O
in	O
the	O
lymphomas	O
.	O

Appearance	O
of	O
tumorous	O
phenotypes	O
in	O
goldfish	O
erythrophores	O
transfected	O
with	O
ras	O
,	O
src	O
,	O
and	O
myc	O
oncogenes	O
and	O
spontaneous	O
differentiation	O
of	O
the	O
transformants	O
in	O
vitro	O
.	O

When	O
goldfish	O
erythrophores	O
isolated	O
from	O
the	O
skin	O
by	O
tissue	O
digestion	O
and	O
centrifugation	O
in	O
a	O
Percoll	O
density	O
gradient	O
were	O
transfected	O
in	O
a	O
monolayer	O
-	O
culture	O
with	O
v	O
-	O
Ha	O
-	O
ras	O
or	O
v	O
-	O
src	O
oncogene	O
either	O
singly	O
or	O
in	O
combination	O
with	O
v	O
-	O
myc	O
by	O
means	O
of	O
calcium	O
phosphate	O
-	O
DNA	O
co	O
-	O
precipitation	O
,	O
there	O
appeared	O
a	O
certain	O
number	O
of	O
transformants	O
manifesting	O
a	O
chromatoblast	O
-	O
like	O
profile	O
and	O
tumorous	O
phenotypes	O
as	O
seen	O
in	O
the	O
capability	O
for	O
unlimited	O
growth	O
,	O
and	O
piling	O
-	O
up	O
in	O
a	O
monolayer	O
-	O
culture	O
or	O
colony	O
formation	O
in	O
semi	O
-	O
solid	O
soft	O
agar	O
.	O

After	O
successive	O
growth	O
in	O
vitro	O
for	O
longer	O
than	O
one	O
month	O
which	O
was	O
scarcely	O
observed	O
with	O
the	O
erythrophores	O
,	O
the	O
vast	O
majority	O
of	O
such	O
transformants	O
began	O
to	O
differentiate	O
into	O
erythrophores	O
and	O
ceased	O
proliferation	O
spontaneously	O
.	O

The	O
onset	O
of	O
their	O
differentiation	O
was	O
ascertained	O
by	O
the	O
deposition	O
of	O
marker	O
pteridine	O
pigments	O
.	O

None	O
of	O
the	O
transformants	O
differentiated	O
into	O
melanophores	O
or	O
iridophores	O
or	O
other	O
neural	O
crest	O
derivatives	O
as	O
seen	O
in	O
goldfish	O
erythrophoroma	O
cells	O
.	O

Little	O
difference	O
was	O
observed	O
in	O
their	O
transforming	O
efficiency	O
(	O
0	O
.	O
2	O
-	O
0	O
.	O
3	O
transformants	O
/	O
micrograms	O
DNA	O
)	O
between	O
the	O
combinations	O
of	O
oncogenes	O
applied	O
but	O
a	O
tendency	O
was	O
noted	O
that	O
cells	O
transfected	O
with	O
ras	O
or	O
src	O
in	O
combination	O
with	O
myc	O
developed	O
the	O
capacity	O
to	O
grow	O
for	O
a	O
longer	O
period	O
and	O
differentiated	O
at	O
a	O
later	O
stage	O
than	O
those	O
transfected	O
solely	O
with	O
ras	O
or	O
src	O
.	O

One	O
cell	O
line	O
(	O
ESM	B
-	I
1	I
)	O
derived	O
from	O
the	O
erythrophores	O
transfected	O
with	O
src	O
/	O
myc	O
grew	O
successively	O
over	O
nine	O
months	O
,	O
indicating	O
its	O
acquisition	O
of	O
immortality	O
.	O

The	O
expression	O
of	O
the	O
transfected	O
oncogenes	O
in	O
this	O
cell	O
line	O
was	O
examined	O
in	O
comparison	O
with	O
the	O
erythrophoroma	O
cells	O
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
.	O

[	O
Prehospital	O
service	O
in	O
Denmark	O
]	O
.	O

In	O
Denmark	O
,	O
emergency	O
ambulances	O
are	O
dispatched	O
by	O
41	O
centres	O
manned	O
either	O
by	O
trained	O
firemen	O
(	O
in	O
Copenhagen	O
)	O
or	O
policemen	O
(	O
outside	O
Copenhagen	O
)	O
.	O

In	O
1990	O
,	O
emergency	O
ambulance	O
calls	O
totalled	O
284	O
,	O
000	O
.	O

Utilisation	O
of	O
emergency	O
ambulance	O
services	O
increases	O
with	O
urbanisation	O
.	O

A	O
doctor	O
-	O
manned	O
ambulance	O
is	O
in	O
operation	O
in	O
Copenhagen	O
,	O
and	O
in	O
some	O
other	O
large	O
towns	O
anaesthesiology	O
and	O
intensive	O
care	O
teams	O
can	O
be	O
dispatched	O
from	O
hospital	O
to	O
give	O
on	O
-	O
the	O
-	O
spot	O
care	O
.	O

In	O
less	O
populated	O
areas	O
,	O
some	O
general	O
practitioners	O
give	O
advanced	O
life	O
-	O
support	O
.	O

Although	O
many	O
areas	O
are	O
serviced	O
by	O
ambulances	O
equipped	O
with	O
defibrillators	O
,	O
the	O
majority	O
of	O
patients	O
receive	O
only	O
basic	O
life	O
-	O
support	O
from	O
ambulance	O
personnel	O
.	O

New	O
initiatives	O
resulting	O
from	O
a	O
recent	O
report	O
by	O
a	O
commission	O
appointed	O
by	O
central	O
authorities	O
,	O
and	O
focused	O
on	O
prehospital	O
treatment	O
,	O
are	O
expected	O
to	O
improve	O
the	O
service	O
by	O
raising	O
the	O
level	O
of	O
training	O
given	O
to	O
ambulance	O
personnel	O
.	O

Tumorigenic	O
activity	O
of	O
rho	O
genes	O
from	O
Aplysia	O
californica	O
.	O

rho	O
genes	O
have	O
been	O
found	O
in	O
both	O
lower	O
and	O
higher	O
eucaryotes	O
.	O

They	O
code	O
for	O
proteins	O
of	O
21	O
kDa	O
,	O
highly	O
conserved	O
in	O
evolution	O
,	O
which	O
belong	O
to	O
the	O
superfamily	O
of	O
ras	O
GTPases	O
.	O

Among	O
the	O
members	O
of	O
this	O
superfamily	O
there	O
are	O
proteins	O
with	O
a	O
regulatory	O
function	O
,	O
such	O
as	O
ras	O
,	O
and	O
proteins	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
such	O
as	O
the	O
family	O
of	O
rab	O
proteins	O
.	O

We	O
have	O
investigated	O
the	O
putative	O
role	O
of	O
rho	O
proteins	O
from	O
Aplysia	O
californica	O
as	O
transforming	O
GTPases	O
utilizing	O
the	O
wild	O
-	O
type	O
and	O
a	O
Val	O
-	O
14	O
mutant	O
,	O
equivalent	O
to	O
the	O
oncogenic	O
Val	O
-	O
12	O
mutation	O
of	O
ras	O
genes	O
found	O
in	O
animal	O
and	O
human	O
tumors	O
.	O

Over	O
-	O
expression	O
of	O
either	O
rho	O
gene	O
was	O
sufficient	O
to	O
confer	O
anchorage	O
-	O
and	O
serum	O
-	O
independent	O
growth	O
.	O

Moreover	O
,	O
when	O
introduced	O
into	O
nude	O
mice	O
,	O
selected	O
clones	O
generated	O
from	O
either	O
gene	O
were	O
able	O
to	O
induce	O
tumors	O
,	O
although	O
those	O
carrying	O
the	O
mutated	O
version	O
were	O
more	O
efficient	O
.	O

Pathological	O
analysis	O
indicated	O
that	O
generated	O
tumors	O
corresponded	O
to	O
well	O
-	O
differentiated	O
fibrosarcomas	O
with	O
distinct	O
and	O
intersecting	O
bundles	O
and	O
spindle	O
cells	O
.	O

By	O
contrast	O
,	O
ras	O
-	O
induced	O
tumors	O
were	O
poorly	O
differentiated	O
fibrosarcomas	O
.	O

Thus	O
,	O
our	O
results	O
indicate	O
that	O
under	O
appropriate	O
conditions	O
rho	O
genes	O
function	O
as	O
oncogenes	O
and	O
may	O
have	O
a	O
role	O
in	O
the	O
regulation	O
of	O
proliferation	O
in	O
fibroblast	O
cells	O
.	O

Immune	O
consequences	O
of	O
burn	O
injury	O
.	O

The	O
purpose	O
of	O
the	O
immune	O
system	O
is	O
to	O
protect	O
cells	O
from	O
invasion	O
by	O
microorganisms	O
.	O

The	O
body	O
has	O
three	O
equally	O
important	O
interactive	O
immune	O
defense	O
systems	O
,	O
all	O
of	O
which	O
are	O
profoundly	O
disrupted	O
with	O
major	O
burn	O
injury	O
.	O

The	O
immune	O
response	O
to	O
burn	O
injury	O
is	O
immediate	O
,	O
prolonged	O
,	O
and	O
severe	O
.	O

The	O
end	O
result	O
in	O
individuals	O
surviving	O
burn	O
shock	O
is	O
immunosuppression	O
,	O
with	O
increased	O
susceptibility	O
to	O
potentially	O
fatal	O
systemic	O
burn	O
wound	O
or	O
pulmonary	O
sepsis	O
.	O

Nursing	O
actions	O
to	O
support	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
system	O
of	O
the	O
burned	O
patient	O
include	O
providing	O
nutritional	O
support	O
to	O
maintain	O
serum	O
protein	O
levels	O
at	O
optimal	O
levels	O
;	O
measures	O
to	O
decrease	O
edema	O
and	O
promote	O
angiogenesis	O
in	O
areas	O
of	O
partial	O
-	O
thickness	O
injury	O
;	O
meticulous	O
treatment	O
of	O
the	O
wound	O
to	O
prevent	O
infection	O
and	O
promote	O
healing	O
;	O
monitoring	O
of	O
antibiotic	O
use	O
;	O
conservative	O
use	O
of	O
invasive	O
techniques	O
,	O
including	O
intubation	O
and	O
vascular	O
access	O
devices	O
;	O
maintenance	O
of	O
fluid	O
and	O
electrolyte	O
balance	O
and	O
body	O
temperature	O
;	O
and	O
energy	O
conservation	O
measures	O
.	O

Autocrine	O
angiogenic	O
vascular	O
prosthesis	O
with	O
bone	O
marrow	O
transplantation	O
.	O

Synthetic	O
vascular	O
prostheses	O
are	O
foreign	O
bodies	O
,	O
so	O
that	O
blood	O
coagulation	O
can	O
occur	O
on	O
their	O
luminal	O
surfaces	O
,	O
causing	O
graft	O
occlusion	O
very	O
frequently	O
in	O
prostheses	O
of	O
small	O
diameter	O
.	O

A	O
vascular	O
prosthesis	O
needs	O
angiogenesis	O
for	O
endothelialization	O
of	O
the	O
luminal	O
surface	O
,	O
as	O
endothelial	O
cells	O
have	O
natural	O
and	O
permanent	O
antithrombogenic	O
properties	O
.	O

To	O
induce	O
capillary	O
growth	O
into	O
the	O
graft	O
,	O
we	O
developed	O
a	O
method	O
of	O
transplanting	O
bone	O
marrow	O
cells	O
,	O
which	O
are	O
primitive	O
,	O
strong	O
enough	O
to	O
survive	O
,	O
and	O
create	O
blood	O
cells	O
,	O
resulting	O
in	O
the	O
inducement	O
of	O
capillary	O
growth	O
.	O

In	O
an	O
animal	O
experiment	O
,	O
marrow	O
cells	O
were	O
infiltrated	O
into	O
the	O
walls	O
of	O
long	O
-	O
fibril	O
expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
.	O

The	O
grafts	O
were	O
implanted	O
in	O
the	O
abdominal	O
aortic	O
position	O
of	O
24	O
dogs	O
autologously	O
.	O

Marrow	O
cells	O
survived	O
and	O
continued	O
exogenous	O
hemopoiesis	O
for	O
up	O
to	O
six	O
months	O
and	O
were	O
immunohistochemically	O
reactive	O
to	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O

All	O
the	O
grafts	O
older	O
than	O
three	O
weeks	O
had	O
complete	O
endothelialization	O
and	O
maintained	O
their	O
patency	O
.	O

Twenty	O
grafts	O
without	O
bone	O
marrow	O
were	O
implanted	O
as	O
controls	O
.	O

Endothelialization	O
was	O
present	O
at	O
anastomotic	O
sites	O
,	O
but	O
other	O
areas	O
were	O
covered	O
with	O
fresh	O
thrombi	O
.	O

Four	O
out	O
of	O
seven	O
control	O
grafts	O
were	O
patent	O
with	O
endothelial	O
cell	O
lining	O
at	O
six	O
months	O
,	O
but	O
three	O
were	O
occluded	O
and	O
one	O
of	O
the	O
four	O
grafts	O
was	O
still	O
covered	O
with	O
a	O
thrombus	O
layer	O
.	O

Bone	O
marrow	O
with	O
its	O
unique	O
native	O
properties	O
produced	O
autocrine	O
angiogenicity	O
in	O
the	O
graft	O
.	O

Toward	O
a	O
theory	O
regarding	O
the	O
pathogenesis	O
of	O
the	O
systemic	O
inflammatory	O
response	O
syndrome	O
:	O
what	O
we	O
do	O
and	O
do	O
not	O
know	O
about	O
cytokine	O
regulation	O
.	O

OBJECTIVES	O
:	O

The	O
systemic	O
inflammatory	O
response	O
syndrome	O
(	O
SIRS	O
)	O
is	O
the	O
massive	O
inflammatory	O
reaction	O
resulting	O
from	O
systemic	O
mediator	O
release	O
that	O
may	O
lead	O
to	O
multiple	O
organ	O
dysfunction	O
.	O

The	O
objective	O
of	O
this	O
review	O
article	O
is	O
to	O
analyze	O
the	O
roles	O
of	O
cytokines	O
,	O
cytokine	O
production	O
,	O
and	O
the	O
relationship	O
of	O
cytokine	O
production	O
to	O
the	O
development	O
of	O
SIRS	O
.	O

DATA	O
SOURCES	O
:	O

Previous	O
research	O
and	O
clinical	O
studies	O
related	O
to	O
cytokines	O
and	O
their	O
relationship	O
to	O
SIRS	O
.	O

STUDY	O
SELECTION	O
:	O

From	O
the	O
studies	O
reviewed	O
,	O
three	O
critical	O
questions	O
are	O
addressed	O
.	O

First	O
,	O
what	O
is	O
the	O
definition	O
of	O
increased	O
cytokine	O
concentrations	O
?	O

Second	O
,	O
what	O
other	O
systemic	O
illnesses	O
besides	O
sepsis	O
can	O
alter	O
cytokine	O
concentrations	O
?	O

Third	O
,	O
what	O
are	O
the	O
right	O
cytokines	O
to	O
measure	O
?	O

DATA	O
SYNTHESIS	O
:	O

This	O
article	O
postulates	O
a	O
three	O
-	O
stage	O
development	O
of	O
SIRS	O
,	O
in	O
which	O
stage	O
1	O
is	O
a	O
local	O
production	O
of	O
cytokines	O
in	O
response	O
to	O
an	O
injury	O
or	O
infection	O
.	O

Stage	O
2	O
is	O
the	O
protective	O
release	O
of	O
a	O
small	O
amount	O
of	O
cytokines	O
into	O
the	O
body	O
'	O
s	O
circulation	O
.	O

Stage	O
3	O
is	O
the	O
massive	O
systemic	O
reaction	O
where	O
cytokines	O
turn	O
destructive	O
by	O
compromising	O
the	O
integrity	O
of	O
the	O
capillary	O
walls	O
and	O
flooding	O
end	O
organs	O
.	O

CONCLUSIONS	O
:	O

While	O
cytokines	O
are	O
generally	O
viewed	O
as	O
a	O
destructive	O
development	O
in	O
the	O
patient	O
that	O
generally	O
leads	O
to	O
multiple	O
organ	O
dysfunction	O
,	O
cytokines	O
also	O
protect	O
the	O
body	O
when	O
localized	O
.	O

It	O
will	O
be	O
necessary	O
to	O
study	O
the	O
positive	O
effects	O
of	O
cytokines	O
while	O
also	O
studying	O
their	O
role	O
in	O
causing	O
SIRS	O
.	O

It	O
will	O
also	O
be	O
important	O
to	O
investigate	O
the	O
relationship	O
between	O
cytokines	O
and	O
their	O
blockers	O
in	O
SIRS	O
.	O

Application	O
of	O
clonal	O
analysis	O
.	O

Differential	O
diagnosis	O
for	O
synchronous	O
primary	O
ovarian	O
and	O
endometrial	O
cancers	O
and	O
metastatic	O
cancer	O
.	O

Simultaneous	O
involvement	O
of	O
the	O
endometrium	O
and	O
the	O
ovary	O
by	O
carcinoma	O
is	O
a	O
familiar	O
problem	O
in	O
the	O
routine	O
practice	O
of	O
surgical	O
pathology	O
.	O

Such	O
cases	O
may	O
be	O
considered	O
either	O
examples	O
of	O
a	O
single	O
primary	O
carcinoma	O
with	O
metastasis	O
or	O
as	O
synchronous	O
primary	O
neoplasms	O
.	O

The	O
distinction	O
between	O
these	O
two	O
possibilities	O
is	O
made	O
based	O
on	O
clinicopathologic	O
observations	O
,	O
and	O
therefore	O
may	O
not	O
be	O
definitive	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
used	O
molecular	O
techniques	O
to	O
analyze	O
the	O
clonal	O
composition	O
of	O
five	O
cases	O
of	O
concurrent	O
adenocarcinomas	O
of	O
the	O
endometrium	O
and	O
ovary	O
that	O
were	O
clinicopathologically	O
diagnosed	O
as	O
synchronous	O
primary	O
tumors	O
.	O

Patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
,	O
mutations	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
mutations	O
or	O
allelic	O
loss	O
of	O
the	O
p53	O
gene	O
,	O
or	O
human	O
papillomavirus	O
detection	O
were	O
identical	O
in	O
both	O
endometrial	O
and	O
ovarian	O
lesions	O
in	O
three	O
of	O
the	O
cases	O
suggesting	O
that	O
those	O
three	O
cases	O
represented	O
single	O
primary	O
tumors	O
with	O
metastases	O
.	O

In	O
both	O
of	O
the	O
other	O
two	O
cases	O
,	O
the	O
patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
clearly	O
demonstrated	O
the	O
presence	O
of	O
independent	O
primary	O
tumors	O
.	O

The	O
application	O
of	O
molecular	O
technology	O
may	O
play	O
an	O
important	O
role	O
for	O
the	O
differential	O
diagnosis	O
between	O
synchronous	O
primary	O
carcinomas	O
and	O
a	O
single	O
carcinoma	O
with	O
metastasis	O
.	O

Pancreatic	O
somatostatin	O
-	O
secreting	O
gangliocytic	O
paraganglioma	O
with	O
lymph	O
node	O
metastases	O
.	O

Gangliocytic	O
paraganglioma	O
(	O
GPG	O
)	O
with	O
local	O
lymph	O
node	O
metastasis	O
was	O
found	O
in	O
the	O
pancreas	O
of	O
a	O
74	O
-	O
yr	O
-	O
old	O
female	O
who	O
presented	O
with	O
diarrhea	O
,	O
steatorrhea	O
,	O
vomiting	O
,	O
nausea	O
,	O
and	O
abdominal	O
pain	O
.	O

A	O
Whipple	O
procedure	O
led	O
to	O
a	O
complete	O
resolution	O
of	O
these	O
symptoms	O
and	O
a	O
return	O
of	O
an	O
elevated	O
stomatostatin	O
level	O
to	O
normal	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
GPG	O
in	O
this	O
location	O
and	O
the	O
first	O
endocrinologically	O
active	O
GPG	O
.	O

Molecular	O
biology	O
of	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O

Cervical	O
cancer	O
develops	O
from	O
well	O
-	O
defined	O
precursor	O
lesions	O
referred	O
to	O
as	O
either	O
cervical	O
intraepithelial	O
neoplasia	O
or	O
squamous	O
intraepithelial	O
lesions	O
.	O

It	O
is	O
now	O
known	O
that	O
specific	O
types	O
of	O
human	O
papillomaviruses	O
(	O
HPV	O
)	O
are	O
the	O
principal	O
etiologic	O
agents	O
for	O
both	O
cervical	O
cancer	O
and	O
its	O
precursors	O
.	O

The	O
high	O
-	O
oncogenic	O
-	O
risk	O
HPV	O
types	O
associated	O
with	O
invasive	O
cervical	O
cancer	O
produce	O
two	O
oncoproteins	O
,	O
designated	O
E6	O
and	O
E7	O
,	O
which	O
interact	O
with	O
endogenous	O
cell	O
cycle	O
regulatory	O
proteins	O
,	O
including	O
p53	O
and	O
Rb	O
.	O

The	O
interaction	O
of	O
virally	O
derived	O
and	O
endogenous	O
cellular	O
proteins	O
converges	O
in	O
deregulation	O
of	O
cell	O
cycle	O
progression	O
and	O
appears	O
to	O
be	O
critical	O
for	O
the	O
development	O
of	O
cervical	O
cancers	O
.	O

However	O
,	O
the	O
development	O
of	O
cervical	O
cancer	O
is	O
a	O
multistep	O
process	O
that	O
can	O
not	O
be	O
explained	O
simply	O
by	O
infection	O
with	O
specific	O
types	O
of	O
HPV	O
.	O

One	O
additional	O
event	O
that	O
appears	O
to	O
play	O
a	O
role	O
in	O
tumor	O
progression	O
is	O
integration	O
of	O
HPV	O
DNA	O
into	O
the	O
host	O
genome	O
.	O

Integration	O
of	O
HPV	O
DNA	O
frequently	O
disrupts	O
the	O
E2	O
open	O
reading	O
frames	O
,	O
resulting	O
in	O
overexpression	O
of	O
the	O
E6	O
and	O
E7	O
oncoproteins	O
and	O
possibly	O
causing	O
genomic	O
instability	O
.	O

Additional	O
cofactors	O
and	O
mutational	O
events	O
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
invasive	O
cervical	O
cancers	O
and	O
may	O
include	O
chromosomal	O
rearrangements	O
,	O
loss	O
of	O
constitutional	O
heterozygosity	O
,	O
and	O
proto	O
-	O
oncogene	O
activation	O
.	O

Cell	O
surface	O
binding	O
characteristics	O
correlate	O
with	O
consensus	O
type	O
I	O
interferon	O
enhanced	O
activity	O
.	O

The	O
binding	O
characteristics	O
of	O
a	O
genetically	O
engineered	O
consensus	O
interferon	O
with	O
unusually	O
high	O
biologic	O
activity	O
were	O
compared	O
to	O
the	O
characteristics	O
of	O
recombinant	O
interferon	O
-	O
alpha	O
2	O
.	O

Both	O
interferon	O
-	O
alpha	O
2	O
and	O
the	O
consensus	O
interferon	O
produced	O
typical	O
biphasic	O
Scatchard	O
plots	O
,	O
indicating	O
multiple	O
independent	O
binding	O
sites	O
.	O

The	O
consensus	O
interferon	O
,	O
which	O
exhibited	O
a	O
biologic	O
potency	O
more	O
than	O
10	O
-	O
fold	O
greater	O
than	O
all	O
other	O
type	O
I	O
interferons	O
,	O
also	O
exhibited	O
binding	O
site	O
affinities	O
greater	O
than	O
those	O
for	O
IFN	O
-	O
alpha	O
2b	O
.	O

In	O
addition	O
,	O
a	O
larger	O
number	O
of	O
high	O
,	O
and	O
low	O
-	O
affinity	O
cell	O
surface	O
sites	O
were	O
recognized	O
by	O
the	O
consensus	O
interferon	O
,	O
resulting	O
in	O
equivalent	O
numbers	O
of	O
sites	O
at	O
reduced	O
molar	O
concentrations	O
compared	O
to	O
IFN	O
-	O
a2b	O
.	O

Thus	O
,	O
at	O
any	O
given	O
biologic	O
activity	O
,	O
similar	O
numbers	O
of	O
sites	O
were	O
bound	O
by	O
the	O
consensus	O
interferon	O
and	O
IFN	O
-	O
alpha	O
2	O
,	O
despite	O
differences	O
in	O
their	O
molar	O
concentrations	O
.	O

No	O
differences	O
in	O
internalization	O
kinetics	O
were	O
identified	O
between	O
the	O
two	O
interferons	O
,	O
indicating	O
that	O
the	O
differences	O
in	O
cell	O
surface	O
binding	O
may	O
be	O
sufficient	O
to	O
produce	O
the	O
differences	O
in	O
biologic	O
activity	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
viral	O
background	O
plays	O
a	O
major	O
role	O
in	O
development	O
of	O
resistance	O
to	O
protease	O
inhibitors	O
.	O

The	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
benefit	O
of	O
combination	O
treatment	O
with	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
agents	O
prompted	O
us	O
to	O
examine	O
the	O
potential	O
of	O
resistance	O
development	O
when	O
two	O
protease	O
inhibitors	O
are	O
used	O
concurrently	O
.	O

Recombinant	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proteases	O
containing	O
combined	O
resistance	O
mutations	O
associated	O
with	O
BMS	O
-	O
186318	O
and	O
A	O
-	O
77003	O
(	O
or	O
saquinavir	O
)	O
were	O
either	O
inactive	O
or	O
had	O
impaired	O
enzyme	O
activity	O
.	O

Subsequent	O
construction	O
of	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proviral	O
clones	O
containing	O
the	O
same	O
mutations	O
yielded	O
viruses	O
that	O
were	O
severely	O
impaired	O
in	O
growth	O
or	O
nonviable	O
,	O
confirming	O
that	O
combination	O
therapy	O
may	O
be	O
advantageous	O
.	O

However	O
,	O
passage	O
of	O
BMS	O
-	O
186318	O
-	O
resistant	O
HIV	O
-	O
1	O
(	O
RF	O
)	O
in	O
the	O
presence	O
of	O
either	O
saquinavir	O
or	O
SC52151	O
,	O
which	O
represented	O
sequential	O
drug	O
treatment	O
,	O
produced	O
viable	O
viruses	O
resistant	O
to	O
both	O
BMS	O
-	O
186318	O
and	O
the	O
second	O
compound	O
.	O

The	O
predominant	O
breakthrough	O
virus	O
contained	O
the	O
G48V	O
/	O
A71	O
T	O
/	O
V82A	O
protease	O
mutations	O
.	O

The	O
clone	O
-	O
purified	O
RF	O
(	O
G48V	O
/	O
A71	O
T	O
/	O
V82A	O
)	O
virus	O
,	O
unlike	O
the	O
corresponding	O
defective	O
NL4	O
-	O
3	O
triple	O
mutant	O
,	O
grew	O
well	O
and	O
displayed	O
cross	O
-	O
resistance	O
to	O
four	O
distinct	O
protease	O
inhibitors	O
.	O

Chimeric	O
virus	O
and	O
in	O
vitro	O
mutagenesis	O
studies	O
indicated	O
that	O
the	O
RF	O
-	O
specific	O
protease	O
sequence	O
,	O
specifically	O
the	O
Ile	O
at	O
residue	O
10	O
,	O
enabled	O
the	O
NL4	O
-	O
3	O
strain	O
with	O
the	O
triple	O
mutant	O
to	O
grow	O
.	O

Our	O
results	O
clearly	O
indicate	O
that	O
viral	O
genetic	O
background	O
will	O
play	O
a	O
key	O
role	O
in	O
determining	O
whether	O
cross	O
-	O
resistance	O
variants	O
will	O
arise	O
.	O

The	O
effects	O
of	O
radiation	O
on	O
neovascularization	O
in	O
a	O
rat	O
model	O
.	O

It	O
is	O
thought	O
that	O
radiation	O
treatment	O
inhibits	O
neovascularization	O
of	O
recipient	O
and	O
/	O
or	O
graft	O
tissues	O
,	O
and	O
this	O
may	O
account	O
in	O
part	O
for	O
abnormalities	O
in	O
wound	O
healing	O
associated	O
with	O
radiation	O
therapy	O
.	O

We	O
have	O
examined	O
this	O
hypothesis	O
using	O
a	O
model	O
that	O
measures	O
the	O
neovascularization	O
of	O
an	O
implanted	O
foreign	O
material	O
.	O

Expanded	O
polytetrafluoroethylene	O
(	O
PTFE	O
)	O
sheets	O
were	O
implanted	O
adjacent	O
to	O
both	O
superficial	O
epigastric	O
vascular	O
pedicles	O
of	O
63	O
rats	O
distributed	O
into	O
7	O
groups	O
(	O
n	O
=	O
7	O
)	O
that	O
differed	O
with	O
respect	O
to	O
dose	O
and	O
timing	O
of	O
irradiation	O
.	O

Zero	O
to	O
10	O
daily	O
fractions	O
of	O
electron	O
-	O
beam	O
radiation	O
(	O
300	O
cGy	O
each	O
)	O
were	O
delivered	O
to	O
the	O
implant	O
in	O
the	O
right	O
groin	O
,	O
while	O
the	O
implant	O
in	O
the	O
left	O
groin	O
served	O
as	O
a	O
nonirradiated	O
internal	O
control	O
.	O

Unirradiated	O
animals	O
showed	O
equal	O
neovascularization	O
of	O
both	O
implants	O
.	O

Rats	O
that	O
were	O
irradiated	O
twice	O
(	O
single	O
fractions	O
at	O
0	O
and	O
24	O
hours	O
after	O
implantation	O
)	O
did	O
not	O
show	O
a	O
significant	O
decrease	O
in	O
the	O
neovascularization	O
of	O
the	O
irradiated	O
implant	O
compared	O
with	O
the	O
contralateral	O
control	O
implant	O
.	O

In	O
contrast	O
,	O
the	O
implants	O
that	O
were	O
irradiated	O
three	O
times	O
(	O
single	O
fractions	O
at	O
0	O
,	O
24	O
,	O
and	O
48	O
hours	O
after	O
implantation	O
)	O
demonstrated	O
significantly	O
diminished	O
(	O
greater	O
than	O
25	O
percent	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
neovascularization	O
beyond	O
day	O
7	O
,	O
whereas	O
implants	O
irradiated	O
only	O
at	O
48	O
hours	O
after	O
implantation	O
did	O
not	O
.	O

Interestingly	O
,	O
neovascularization	O
of	O
the	O
implants	O
irradiated	O
with	O
10	O
fractions	O
(	O
3000	O
cGy	O
)	O
was	O
not	O
significantly	O
decreased	O
compared	O
with	O
irradiation	O
with	O
three	O
fractions	O
(	O
900	O
cGy	O
)	O
.	O

Irradiation	O
delivered	O
before	O
implantation	O
(	O
900	O
cGy	O
)	O
inhibited	O
neovascularization	O
significantly	O
less	O
than	O
the	O
same	O
dose	O
administered	O
after	O
implantation	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
a	O
subclinical	O
cumulative	O
dose	O
of	O
900	O
cGy	O
is	O
the	O
threshold	O
for	O
impaired	O
tissue	O
revascularization	O
provided	O
that	O
treatment	O
is	O
delivered	O
immediately	O
after	O
implantation	O
over	O
a	O
48	O
-	O
hour	O
interval	O
.	O

Stimulation	O
of	O
endothelial	O
cell	O
migration	O
by	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
through	O
cooperative	O
mechanisms	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
osteopontin	O
,	O
and	O
thrombin	O
.	O

We	O
have	O
identified	O
several	O
mechanisms	O
by	O
which	O
the	O
angiogenic	O
cytokine	O
vascular	O
permeability	O
factor	O
/	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VPF	O
/	O
VEGF	O
)	O
likely	O
regulates	O
endothelial	O
cells	O
(	O
EC	O
)	O
migration	O
.	O

VPF	O
/	O
VEGF	O
induced	O
dermal	O
microvascular	O
EC	O
expression	O
of	O
mRNAs	O
encoding	O
the	O
alphav	O
and	O
beta3	O
integrin	O
subunits	O
resulting	O
in	O
increased	O
levels	O
of	O
the	O
alphavbeta3	O
heterodimer	O
at	O
the	O
cell	O
surface	O
,	O
and	O
VPF	O
/	O
VEGF	O
also	O
induced	O
mRNA	O
encoding	O
osteopontin	O
(	O
OPN	O
)	O
,	O
an	O
alphavbeta3	O
ligand	O
.	O

OPN	O
promoted	O
EC	O
migration	O
in	O
vitro	O
;	O
and	O
VPF	O
/	O
VEGF	O
induction	O
of	O
alphavbeta3	O
was	O
accompanied	O
by	O
increased	O
EC	O
migration	O
toward	O
OPN	O
.	O

Because	O
thrombin	O
cleavage	O
of	O
OPN	O
results	O
in	O
substantial	O
enhancement	O
of	O
OPN	O
'	O
s	O
adhesive	O
properties	O
,	O
and	O
because	O
VPF	O
/	O
VEGF	O
promotes	O
increased	O
microvascular	O
permeability	O
leading	O
to	O
activation	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
,	O
we	O
also	O
investigated	O
whether	O
VPF	O
/	O
VEGF	O
facilitates	O
thrombin	O
cleavage	O
of	O
OPN	O
in	O
vivo	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
co	O
-	O
injection	O
of	O
VPF	O
/	O
VEGF	O
together	O
with	O
OPN	O
resulted	O
in	O
rapid	O
cleavage	O
of	O
OPN	O
by	O
endogenous	O
thrombin	O
.	O

Furthermore	O
,	O
in	O
comparison	O
with	O
native	O
OPN	O
,	O
thrombin	O
-	O
cleaved	O
OPN	O
stimulated	O
a	O
greater	O
rate	O
of	O
EC	O
migration	O
in	O
vitro	O
,	O
which	O
was	O
additive	O
to	O
the	O
increased	O
migration	O
associated	O
with	O
induction	O
of	O
alpha	O
v	O
beta	O
3	O
.	O

Thus	O
,	O
these	O
data	O
demonstrate	O
cooperative	O
mechanisms	O
for	O
VPF	O
/	O
VEGF	O
regulation	O
of	O
EC	O
migration	O
involving	O
the	O
alphavbeta3	O
integrin	O
,	O
the	O
alphavbeta3	O
ligand	O
OPN	O
,	O
and	O
thrombin	O
cleavage	O
of	O
OPN	O
.	O

These	O
findings	O
also	O
illustrate	O
an	O
operational	O
link	O
between	O
VPF	O
/	O
VEGF	O
induction	O
of	O
EC	O
gene	O
expression	O
and	O
VPF	O
/	O
VEGF	O
enhancement	O
of	O
microvascular	O
permeability	O
,	O
suggesting	O
that	O
these	O
distinct	O
biological	O
activities	O
may	O
act	O
accordingly	O
to	O
stimulate	O
EC	O
migration	O
during	O
angiogenesis	O
.	O

Referral	O
bias	O
among	O
health	O
workers	O
in	O
studies	O
using	O
hospitalization	O
as	O
a	O
proxy	O
measure	O
of	O
the	O
underlying	O
incidence	O
rate	O
.	O

Contacts	O
with	O
health	O
services	O
like	O
hospitals	O
or	O
general	O
practitioners	O
are	O
usually	O
the	O
only	O
available	O
proxy	O
measure	O
of	O
incidence	O
of	O
disease	O
in	O
studies	O
based	O
on	O
secondary	O
data	O
and	O
differential	O
referrals	O
or	O
care	O
-	O
seeking	O
behavior	O
often	O
bias	O
such	O
proxy	O
measures	O
.	O

In	O
former	O
analyses	O
based	O
on	O
the	O
Occupational	O
Hospitalization	O
Register	O
in	O
Denmark	O
assisting	O
nurses	O
had	O
high	O
Standardized	O
Hospitalization	O
Ratios	O
for	O
many	O
diseases	O
.	O

It	O
was	O
,	O
however	O
,	O
suspected	O
that	O
it	O
fully	O
or	O
partly	O
was	O
due	O
to	O
a	O
referral	O
bias	O
or	O
self	O
-	O
selection	O
to	O
hospital	O
treatment	O
rather	O
than	O
exposures	O
to	O
occupational	O
hazards	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
referral	O
bias	O
hypothesis	O
by	O
comparing	O
hospitalization	O
and	O
mortality	O
data	O
for	O
health	O
workers	O
for	O
a	O
disease	O
category	O
with	O
a	O
high	O
mortality	O
.	O

Cohorts	O
of	O
all	O
gainfully	O
employed	O
20	O
-	O
to	O
59	O
-	O
year	O
-	O
old	O
Danes	O
were	O
formed	O
in	O
order	O
to	O
compare	O
Standardized	O
Mortality	O
Ratios	O
and	O
Standardized	O
Hospitalization	O
Ratios	O
of	O
ischemic	O
heart	O
disease	O
(	O
IHD	O
)	O
in	O
occupational	O
groups	O
.	O

The	O
follow	O
-	O
up	O
period	O
was	O
10	O
years	O
.	O

For	O
most	O
of	O
the	O
investigated	O
occupational	O
groups	O
a	O
similar	O
disease	O
pattern	O
was	O
found	O
whether	O
hospitalization	O
or	O
death	O
was	O
used	O
as	O
the	O
outcome	O
measure	O
.	O

In	O
""""	O
nurse	O
assistants	O
""""	O
a	O
statistically	O
significant	O
higher	O
risk	O
was	O
,	O
however	O
,	O
found	O
using	O
hospitalization	O
due	O
to	O
IHD	O
as	O
the	O
end	O
point	O
rather	O
than	O
mortality	O
.	O

Additional	O
analysis	O
did	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
finding	O
could	O
be	O
explained	O
by	O
differentiated	O
hospitalization	O
due	O
to	O
social	O
factors	O
.	O

The	O
true	O
incidence	O
rates	O
of	O
the	O
disease	O
need	O
not	O
be	O
equally	O
well	O
described	O
by	O
proxy	O
measures	O
such	O
as	O
hospitalization	O
diagnosis	O
or	O
death	O
diagnosis	O
in	O
all	O
occupational	O
groups	O
.	O

Differential	O
access	O
to	O
medical	O
treatment	O
in	O
some	O
groups	O
may	O
lead	O
to	O
bias	O
when	O
hospital	O
data	O
are	O
used	O
as	O
proxy	O
measures	O
for	O
the	O
underlying	O
incidence	O
rates	O
.	O

Prognostic	O
value	O
of	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Tumour	O
angiogenesis	O
is	O
an	O
important	O
factor	O
for	O
tumour	O
growth	O
and	O
metastasis	O
.	O

Although	O
some	O
recent	O
reports	O
suggest	O
that	O
microvessel	O
counts	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
are	O
related	O
to	O
a	O
poor	O
disease	O
outcome	O
,	O
the	O
results	O
were	O
not	O
conclusive	O
and	O
were	O
not	O
compared	O
with	O
other	O
molecular	O
prognostic	O
markers	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
vascular	O
grade	O
was	O
assessed	O
in	O
107	O
(	O
T1	O
,	O
2	O
-	O
N0	O
,	O
1	O
)	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
carcinomas	O
,	O
using	O
the	O
JC70	O
monoclonal	O
antibody	O
to	O
CD31	O
.	O

Three	O
vascular	O
grades	O
were	O
defined	O
with	O
appraisal	O
by	O
eye	O
and	O
by	O
Chalkley	O
counting	O
:	O
high	O
(	O
Chalkley	O
score	O
7	O
-	O
12	O
)	O
,	O
medium	O
(	O
5	O
-	O
6	O
)	O
,	O
and	O
low	O
(	O
2	O
-	O
4	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
eye	O
appraisal	O
and	O
Chalkley	O
counting	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

Vascular	O
grade	O
was	O
not	O
related	O
to	O
histology	O
,	O
grade	O
,	O
proliferation	O
index	O
(	O
Ki67	O
)	O
,	O
or	O
EGFR	O
or	O
p53	O
expression	O
.	O

Tumours	O
from	O
younger	O
patients	O
had	O
a	O
higher	O
grade	O
of	O
angiogenesis	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Apart	O
from	O
the	O
vascular	O
grade	O
,	O
none	O
of	O
the	O
other	O
factors	O
examined	O
was	O
statistically	O
related	O
to	O
lymph	O
node	O
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

A	O
univariate	O
analysis	O
of	O
survival	O
showed	O
that	O
vascular	O
grade	O
was	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
,	O
followed	O
by	O
N	O
-	O
stage	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
N	O
-	O
stage	O
and	O
vascular	O
grade	O
were	O
not	O
found	O
to	O
be	O
independent	O
prognostic	O
factors	O
,	O
since	O
they	O
were	O
strongly	O
related	O
to	O
each	O
other	O
.	O

Excluding	O
N	O
-	O
stage	O
,	O
vascular	O
grade	O
was	O
the	O
only	O
independent	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
showed	O
a	O
statistically	O
significant	O
worse	O
prognosis	O
for	O
patients	O
with	O
high	O
vascular	O
grade	O
,	O
but	O
no	O
difference	O
was	O
observed	O
between	O
low	O
and	O
medium	O
vascular	O
grade	O
.	O

These	O
data	O
suggest	O
that	O
angiogenesis	O
in	O
operable	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
a	O
major	O
prognostic	O
factor	O
for	O
survival	O
and	O
,	O
among	O
the	O
parameters	O
tested	O
,	O
is	O
the	O
only	O
factor	O
related	O
to	O
cancer	O
cell	O
migration	O
to	O
lymph	O
nodes	O
.	O

The	O
integration	O
of	O
vascular	O
grading	O
in	O
clinical	O
trials	O
on	O
adjuvant	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
could	O
substantially	O
contribute	O
in	O
defining	O
groups	O
of	O
operable	O
patients	O
who	O
might	O
benefit	O
from	O
cytotoxic	O
treatment	O
.	O

The	O
impact	O
of	O
multiskilling	O
on	O
quality	O
of	O
care	O
.	O

Hospital	O
finances	O
in	O
the	O
USA	O
are	O
in	O
a	O
crisis	O
.	O

While	O
profits	O
earned	O
from	O
the	O
healthcare	O
industry	O
appear	O
to	O
be	O
at	O
an	O
all	O
-	O
time	O
high	O
,	O
individual	O
hospitals	O
are	O
going	O
bankrupt	O
.	O

Hospitals	O
are	O
not	O
generating	O
sufficient	O
income	O
to	O
pay	O
their	O
expenses	O
given	O
how	O
they	O
have	O
traditionally	O
operated	O
.	O

Hence	O
,	O
we	O
are	O
witnessing	O
the	O
merger	O
and	O
consolidation	O
of	O
competitors	O
,	O
resulting	O
in	O
significantly	O
fewer	O
hospital	O
beds	O
in	O
certain	O
geographical	O
areas	O
.	O

In	O
addition	O
to	O
the	O
strategy	O
of	O
closing	O
hospital	O
beds	O
,	O
severe	O
budget	O
restrictions	O
are	O
impacting	O
upon	O
all	O
remaining	O
services	O
within	O
the	O
hospitals	O
.	O

Vitamin	O
E	O
inhibits	O
experimental	O
carcinogenesis	O
and	O
tumour	O
angiogenesis	O
.	O

In	O
an	O
experiment	O
in	O
which	O
vitamin	O
E	O
inhibited	O
carcinogenesis	O
,	O
it	O
was	O
found	O
that	O
tumour	O
angiogenesis	O
and	O
tumour	O
growth	O
-	O
factor	O
alpha	O
(	O
TGF	O
alpha	O
)	O
expression	O
were	O
also	O
inhibited	O
.	O

Forty	O
male	O
golden	O
hamsters	O
were	O
divided	O
into	O
four	O
equal	O
groups	O
.	O

Group	O
1	O
animals	O
had	O
the	O
left	O
buccal	O
pouches	O
painted	O
three	O
times	O
weekly	O
with	O
7	O
,	O
12	O
-	O
dimethylbenz	O
(	O
a	O
)	O
anthracene	O
(	O
DMBA	O
)	O
for	O
14	O
weeks	O
.	O

Group	O
2	O
animals	O
had	O
the	O
same	O
procedure	O
of	O
DMBA	O
applications	O
but	O
also	O
received	O
alpha	O
tocopherol	O
.	O

Groups	O
3	O
and	O
4	O
were	O
vitamin	O
E	O
and	O
untreated	O
controls	O
.	O

Angiogenesis	O
was	O
studied	O
with	O
factor	O
8	O
-	O
related	O
antigen	O
(	O
F8	O
-	O
RA	O
)	O
which	O
identifies	O
endothelial	O
cells	O
.	O

TGF	O
alpha	O
was	O
studied	O
with	O
the	O
appropriate	O
antibody	O
.	O

Staining	O
was	O
effected	O
by	O
the	O
standard	O
avidin	O
-	O
biotin	O
horseradish	O
peroxidase	O
system	O
.	O

Mean	O
tumour	O
volume	O
was	O
significantly	O
lower	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
compared	O
to	O
the	O
tumour	O
control	O
group	O
.	O

Angiogenesis	O
was	O
significantly	O
inhibited	O
in	O
the	O
DMBA	O
-	O
vitamin	O
E	O
group	O
and	O
TGF	O
alpha	O
expression	O
was	O
also	O
inhibited	O
.	O

It	O
is	O
suggested	O
that	O
inhibition	O
of	O
tumour	O
angiogenesis	O
by	O
vitamin	O
E	O
may	O
be	O
an	O
additional	O
mechanism	O
for	O
the	O
anticancer	O
action	O
of	O
vitamin	O
E	O
.	O

Acetaminophen	O
and	O
hepatic	O
dysfunction	O
in	O
infectious	O
mononucleosis	O
.	O

Two	O
family	O
members	O
developed	O
severe	O
hepatitic	O
dysfunction	O
in	O
association	O
with	O
infectious	O
mononucleosis	O
and	O
acetaminophen	O
administration	O
.	O

Since	O
severe	O
hepatitis	O
is	O
an	O
extremely	O
rare	O
complication	O
of	O
infectious	O
mononucleosis	O
,	O
we	O
postulate	O
that	O
the	O
hepatic	O
dysfunction	O
was	O
induced	O
by	O
acetaminophen	O
.	O

Syndecan	O
-	O
1	O
expression	O
in	O
mammary	O
epithelial	O
tumor	O
cells	O
is	O
E	O
-	O
cadherin	O
-	O
dependent	O
.	O

E	O
-	O
cadherin	O
is	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
cell	O
-	O
cell	O
adhesion	O
molecule	O
,	O
which	O
is	O
mainly	O
expressed	O
in	O
epithelial	O
cells	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
E	O
-	O
cadherin	O
has	O
an	O
important	O
role	O
as	O
an	O
invasion	O
suppressor	O
molecule	O
in	O
epithelial	O
tumor	O
cells	O
.	O

Syndecan	O
-	O
1	O
is	O
a	O
cell	O
surface	O
proteoglycan	O
that	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
cellular	O
functions	O
including	O
cell	O
-	O
cell	O
adhesion	O
,	O
cell	O
-	O
matrix	O
anchorage	O
and	O
growth	O
factor	O
presentation	O
for	O
signalling	O
receptors	O
.	O

Its	O
suppression	O
has	O
also	O
been	O
shown	O
to	O
be	O
associated	O
with	O
malignant	O
transformation	O
of	O
epithelial	O
cells	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
coordinated	O
regulation	O
of	O
cell	O
-	O
cell	O
and	O
cell	O
-	O
matrix	O
interactions	O
during	O
malignant	O
transformation	O
,	O
we	O
have	O
studied	O
the	O
expression	O
of	O
syndecan	O
-	O
1	O
in	O
malignant	O
mammary	O
tumor	O
cells	O
genetically	O
manipulated	O
for	O
E	O
-	O
cadherin	O
expression	O
.	O

In	O
invasive	O
NM	B
-	I
e	I
-	O
ras	O
-	O
MAC1	O
cells	O
,	O
where	O
E	O
-	O
cadherin	O
was	O
partially	O
downregulated	O
by	O
specific	O
antisense	O
RNA	O
,	O
syndecan	O
-	O
1	O
expression	O
was	O
suppressed	O
.	O

Furthermore	O
,	O
transfection	O
of	O
E	O
-	O
cadherin	O
cDNA	O
into	O
invasive	O
NM	B
-	I
f	I
-	O
ras	O
-	O
TD	O
cells	O
resulted	O
in	O
the	O
upregulation	O
of	O
syndecan	O
-	O
1	O
expression	O
in	O
association	O
with	O
decreased	O
invasiveness	O
.	O

In	O
both	O
cases	O
,	O
regulation	O
of	O
syndecan	O
-	O
1	O
occurred	O
post	O
-	O
transcriptionally	O
,	O
since	O
syndecan	O
-	O
1	O
mRNA	O
levels	O
remained	O
unchanged	O
.	O

Instead	O
,	O
a	O
translational	O
regulation	O
is	O
suggested	O
,	O
since	O
syndecan	O
-	O
1	O
core	O
protein	O
synthesis	O
was	O
E	O
-	O
cadherin	O
dependent	O
.	O

Another	O
cell	O
adhesion	O
protein	O
,	O
beta	O
1	O
-	O
integrin	O
was	O
not	O
affected	O
by	O
E	O
-	O
cadherin	O
expression	O
.	O

The	O
data	O
provide	O
an	O
example	O
of	O
coordinated	O
changes	O
in	O
the	O
expression	O
of	O
two	O
cell	O
adhesion	O
molecules	O
,	O
syndecan	O
-	O
1	O
and	O
E	O
-	O
cadherin	O
during	O
epithelial	O
cell	O
transformation	O
.	O

Curcumin	O
induces	O
apoptosis	O
in	O
immortalized	O
NIH	B
3T3	I
and	O
malignant	O
cancer	O
cell	O
lines	O
.	O

Curcumin	O
,	O
which	O
is	O
a	O
widely	O
used	O
dietary	O
pigment	O
and	O
spice	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
an	O
effective	O
inhibitor	O
of	O
tumor	O
promotion	O
in	O
mouse	O
skin	O
carcinogenesis	O
.	O

We	O
report	O
that	O
curcumin	O
induces	O
cell	O
shrinkage	O
,	O
chromatin	O
condensation	O
,	O
and	O
DNA	O
fragmentation	O
,	O
characteristics	O
of	O
apoptosis	O
,	O
in	O
immortalized	O
mouse	O
embryo	O
fibroblast	O
NIH	B
3T3	I
erb	O
B2	O
oncogene	O
-	O
transformed	O
NIH	B
3T3	I
,	O
mouse	O
sarcoma	O
S180	B
,	O
human	O
colon	O
cancer	O
cell	O
HT	B
-	I
29	I
,	O
human	O
kidney	O
cancer	O
cell	O
293	B
,	O
and	O
human	O
hepatocellular	O
carcinoma	O
Hep	B
G2	I
cells	O
,	O
but	O
not	O
in	O
primary	O
culture	O
of	O
mouse	O
embryonic	O
fibroblast	O
C3H	B
10T1	I
/	I
2	I
,	O
rat	O
embryonic	O
fibroblast	O
,	O
and	O
human	O
foreskin	O
fibroblast	O
cells	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Many	O
cellular	O
and	O
biochemical	O
effects	O
of	O
curcumin	O
in	O
mouse	O
fibroblast	O
cells	O
have	O
been	O
reported	O
,	O
such	O
as	O
inhibition	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
treatment	O
,	O
inhibition	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
,	O
and	O
inhibition	O
of	O
arachidonic	O
acid	O
(	O
AA	O
)	O
metabolism	O
.	O

Treatment	O
of	O
NIH	B
3T3	I
cells	O
with	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
,	O
and	O
the	O
AA	O
metabolism	O
inhibitor	O
quinacrine	O
induces	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
some	O
immortalized	O
and	O
transformed	O
cells	O
,	O
blocking	O
the	O
cellular	O
signal	O
transduction	O
might	O
trigger	O
the	O
induction	O
of	O
apoptosis	O
.	O

c	O
-	O
erb	O
B2	O
overexpression	O
decreases	O
the	O
benefit	O
of	O
adjuvant	O
tamoxifen	O
in	O
early	O
-	O
stage	O
breast	O
cancer	O
without	O
axillary	O
lymph	O
node	O
metastases	O
.	O

PURPOSE	O
:	O
We	O
studied	O
retrospectively	O
the	O
interaction	O
between	O
c	O
-	O
erbB2	O
overexpression	O
and	O
adjuvant	O
tomoxifen	O
in	O
node	O
-	O
negative	O
breast	O
cancer	O
patients	O
enrolled	O
in	O
the	O
Gruppo	O
Universitario	O
Napoletano	O
1	O
(	O
GUN	O
-	O
1	O
)	O
trial	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
c	O
-	O
erbB2	O
,	O
evaluated	O
by	O
immunohistochemistry	O
in	O
145	O
of	O
173	O
patients	O
randomly	O
assigned	O
to	O
2	O
-	O
year	O
adjuvant	O
tamoxifen	O
or	O
no	O
further	O
therapy	O
,	O
was	O
considered	O
overexpressed	O
if	O
greater	O
than	O
10	O
%	O
of	O
the	O
cells	O
showed	O
specific	O
membrane	O
staining	O
.	O

The	O
role	O
of	O
each	O
prognostic	O
variable	O
and	O
their	O
independent	O
effect	O
were	O
studied	O
using	O
the	O
Cox	O
model	O
.	O

Disease	O
-	O
free	O
(	O
DFS	O
)	O
and	O
overall	O
(	O
OAS	O
)	O
survival	O
curves	O
were	O
estimated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

RESULTS	O
:	O
As	O
of	O
November	O
30	O
,	O
1994	O
,	O
the	O
median	O
follow	O
-	O
up	O
period	O
was	O
12	O
years	O
.	O

c	O
-	O
erbB2	O
was	O
overexpressed	O
in	O
43	O
of	O
145	O
patients	O
(	O
29	O
.	O
7	O
%	O
)	O
,	O
which	O
directly	O
correlated	O
with	O
tumor	O
size	O
and	O
inversely	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
level	O
.	O

At	O
univariate	O
analysis	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
did	O
not	O
affect	O
either	O
DFS	O
or	O
OAS	O
;	O
tamoxifen	O
had	O
a	O
greater	O
effect	O
on	O
reducing	O
the	O
risk	O
of	O
recurrence	O
than	O
of	O
death	O
.	O

Addition	O
of	O
c	O
-	O
erbB2	O
to	O
a	O
multivariate	O
Cox	O
model	O
that	O
contained	O
menopausal	O
status	O
,	O
tumor	O
size	O
,	O
nuclear	O
grade	O
,	O
and	O
treatment	O
as	O
covariates	O
did	O
not	O
affect	O
the	O
significance	O
of	O
the	O
model	O
for	O
DSF	O
or	O
OAS	O
,	O
whereas	O
addition	O
of	O
the	O
first	O
-	O
order	O
interaction	O
between	O
c	O
-	O
erbB2	O
and	O
tamoxifen	O
was	O
statistically	O
significant	O
both	O
for	O
DFS	O
and	O
OAS	O
.	O

The	O
same	O
result	O
was	O
obtained	O
when	O
the	O
model	O
contained	O
ER	O
status	O
and	O
ER	O
-	O
tamoxifen	O
interaction	O
.	O

Indeed	O
,	O
adjuvant	O
tamoxifen	O
significantly	O
prolonged	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
negative	O
cases	O
,	O
whereas	O
it	O
had	O
no	O
effect	O
on	O
DFS	O
and	O
OAS	O
in	O
c	O
-	O
erbB2	O
-	O
positive	O
patients	O
.	O

CONCLUSION	O
:	O
In	O
early	O
-	O
stage	O
breast	O
cancer	O
patients	O
,	O
overexpression	O
of	O
c	O
-	O
erbB2	O
is	O
a	O
marker	O
of	O
lack	O
of	O
efficacy	O
of	O
adjuvant	O
tamoxifen	O
.	O

Gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
three	O
isoforms	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
stimulates	O
collateral	O
development	O
in	O
vivo	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
naturally	O
secreted	O
endothelial	O
cell	O
-	O
specific	O
mitogen	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
naked	O
DNA	O
encoding	O
for	O
VEGF	O
could	O
be	O
used	O
in	O
a	O
strategy	O
of	O
arterial	O
gene	O
therapy	O
to	O
stimulate	O
collateral	O
artery	O
development	O
.	O

Plasmid	O
DNA	O
encoding	O
each	O
of	O
the	O
three	O
principal	O
human	O
VEGF	O
isoforms	O
(	O
phVEGF121	O
,	O
phVEGF165	O
,	O
or	O
phVEGF189	O
)	O
was	O
applied	O
to	O
the	O
hydrogel	O
polymer	O
coating	O
of	O
an	O
angioplasty	O
balloon	O
and	O
delivered	O
percutaneously	O
to	O
one	O
iliac	O
artery	O
of	O
rabbits	O
with	O
operatively	O
induced	O
hindlimb	O
ischemia	O
.	O

Compared	O
with	O
control	O
animals	O
transfected	O
with	O
LacZ	O
,	O
site	O
-	O
specific	O
transfection	O
of	O
phVEGF	O
resulted	O
in	O
augmented	O
collateral	O
vessel	O
development	O
documented	O
by	O
serial	O
angiography	O
,	O
and	O
improvement	O
in	O
calf	O
blood	O
pressure	O
ratio	O
(	O
ischemic	O
to	O
normal	O
limb	O
)	O
,	O
resting	O
and	O
maximum	O
blood	O
flow	O
,	O
and	O
capillary	O
to	O
myocyte	O
ratio	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
phVEGF121	O
,	O
phVEGF165	O
,	O
and	O
phVEGF189	O
,	O
which	O
suggests	O
that	O
these	O
isoforms	O
are	O
biologically	O
equivalent	O
with	O
respect	O
to	O
in	O
vivo	O
angiogenesis	O
.	O

The	O
fact	O
that	O
viral	O
or	O
other	O
adjunctive	O
vectors	O
were	O
not	O
required	O
further	O
suggests	O
that	O
secreted	O
gene	O
products	O
may	O
have	O
potential	O
therapeutic	O
utility	O
even	O
when	O
the	O
number	O
of	O
successfully	O
transfected	O
cells	O
remains	O
low	O
.	O

Arterial	O
gene	O
transfer	O
of	O
naked	O
DNA	O
encoding	O
for	O
a	O
secreted	O
angiogenic	O
cytokine	O
,	O
thus	O
,	O
represents	O
a	O
potential	O
alternative	O
to	O
recombinant	O
protein	O
administration	O
for	O
stimulating	O
collateral	O
vessel	O
development	O
.	O

Metastasis	O
-	O
associated	O
5T4	O
antigen	O
disrupts	O
cell	O
-	O
cell	O
contacts	O
and	O
induces	O
cellular	O
motility	O
in	O
epithelial	O
cells	O
.	O

The	O
5T4	O
antigen	O
is	O
defined	O
by	O
a	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
specific	O
for	O
human	O
trophoblast	O
.	O

It	O
is	O
also	O
expressed	O
by	O
many	O
types	O
of	O
tumour	O
cell	O
and	O
has	O
been	O
associated	O
with	O
metastasis	O
and	O
poor	O
clinical	O
outcome	O
in	O
a	O
number	O
of	O
cancers	O
.	O

This	O
pattern	O
of	O
expression	O
is	O
consistent	O
with	O
a	O
mechanistic	O
involvement	O
of	O
5T4	O
molecules	O
in	O
the	O
spread	O
of	O
cancer	O
cells	O
.	O

The	O
5T4	O
antigen	O
is	O
a	O
transmembrane	O
glycoprotein	O
with	O
a	O
310	O
amino	O
acid	O
extracellular	O
domain	O
and	O
a	O
44	O
amino	O
acid	O
cytoplasmic	O
domain	O
.	O

Transfection	O
of	O
full	O
-	O
length	O
5T4	O
cDNA	O
into	O
epithelial	O
cells	O
alters	O
cell	O
-	O
cell	O
contacts	O
and	O
cellular	O
motility	O
.	O

Thus	O
,	O
in	O
5T4	O
-	O
transfected	O
CL	B
-	I
S1	I
murine	O
mammary	O
cells	O
,	O
5T4	O
expression	O
is	O
associated	O
with	O
dendritic	O
morphology	O
,	O
accompanied	O
by	O
abrogation	O
of	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
and	O
increased	O
motility	O
.	O

In	O
transfected	O
MDCK	O
canine	O
kidney	O
epithelial	O
cells	O
,	O
5T4	O
over	O
-	O
expression	O
also	O
results	O
in	O
increased	O
motility	O
,	O
but	O
disruption	O
of	O
cell	O
-	O
cell	O
contacts	O
,	O
either	O
by	O
culturing	O
cells	O
in	O
low	O
calcium	O
medium	O
or	O
by	O
addition	O
of	O
HGF	O
/	O
SF	O
,	O
is	O
needed	O
.	O

The	O
effects	O
of	O
5T4	O
expression	O
on	O
morphology	O
and	O
motility	O
are	O
separable	O
since	O
cells	O
transfected	O
with	O
a	O
truncated	O
form	O
of	O
5T4	O
cDNA	O
in	O
which	O
the	O
cytoplasmic	O
domain	O
is	O
deleted	O
reveal	O
that	O
the	O
latter	O
is	O
necessary	O
to	O
abrogate	O
actin	O
/	O
cadherin	O
-	O
containing	O
contacts	O
but	O
does	O
not	O
influence	O
the	O
effects	O
on	O
motility	O
.	O

Thus	O
,	O
5T4	O
molecules	O
can	O
deliver	O
signals	O
through	O
both	O
the	O
extracellular	O
and	O
intracellular	O
domains	O
,	O
and	O
the	O
resultant	O
effects	O
are	O
consistent	O
with	O
a	O
role	O
for	O
5T4	O
molecules	O
in	O
invasion	O
processes	O
.	O

Induction	O
of	O
p18INK4c	O
and	O
its	O
predominant	O
association	O
with	O
CDK4	O
and	O
CDK6	O
during	O
myogenic	O
differentiation	O
.	O

Terminal	O
cell	O
differentiation	O
involves	O
permanent	O
withdrawal	O
from	O
the	O
cell	O
division	O
cycle	O
.	O

The	O
inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
are	O
potential	O
molecules	O
functioning	O
to	O
couple	O
cell	O
cycle	O
arrest	O
and	O
cell	O
differentiation	O
.	O

In	O
murine	O
C2C12	B
myoblast	O
cells	O
,	O
G1	O
CDK	O
enzymes	O
(	O
CDK2	O
,	O
CDK4	O
,	O
and	O
CDK6	O
)	O
associate	O
with	O
four	O
CDK	O
inhibitors	O
:	O
p18INK4c	O
,	O
p19INK4d	O
,	O
p21	O
,	O
and	O
p27Kip1	O
.	O

During	O
induced	O
myogenesis	O
,	O
p21	O
and	O
its	O
associated	O
CDK	O
proteins	O
underwent	O
an	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
as	O
cells	O
became	O
terminally	O
differentiated	O
.	O

The	O
level	O
of	O
p27	O
protein	O
gradually	O
increased	O
,	O
but	O
the	O
amount	O
of	O
total	O
associated	O
CDK	O
proteins	O
remained	O
unchanged	O
.	O

p19	O
protein	O
decreased	O
gradually	O
during	O
differentiation	O
,	O
as	O
did	O
its	O
associated	O
CDK4	O
protein	O
.	O

In	O
contrast	O
,	O
p18	O
protein	O
increased	O
50	O
-	O
fold	O
,	O
from	O
negligible	O
levels	O
in	O
proliferating	O
myoblasts	O
to	O
clearly	O
detectable	O
levels	O
within	O
8	O
-	O
12	O
h	O
of	O
myogenic	O
induction	O
.	O

This	O
initial	O
rise	O
was	O
followed	O
by	O
a	O
precipitous	O
increase	O
between	O
12	O
and	O
24	O
h	O
postinduction	O
,	O
with	O
p18	O
protein	O
finally	O
accumulating	O
to	O
its	O
highest	O
level	O
in	O
terminally	O
differentiated	O
cells	O
.	O

Induction	O
of	O
p18	O
correlated	O
with	O
increased	O
and	O
sequential	O
complex	O
formation	O
-	O
-	O
first	O
increasing	O
association	O
with	O
CDK6	O
and	O
then	O
with	O
CDK4	O
over	O
the	O
course	O
of	O
myogenic	O
differentiation	O
.	O

All	O
of	O
the	O
CDK6	O
and	O
half	O
of	O
the	O
CDK4	O
were	O
complexed	O
with	O
p18	O
in	O
terminally	O
differentiated	O
C2C12	B
cells	O
as	O
well	O
as	O
in	O
adult	O
mouse	O
muscle	O
tissue	O
.	O

Finally	O
,	O
kinase	O
activity	O
of	O
CDK2	O
and	O
CDK4	O
decreases	O
as	O
C2C12	B
cells	O
differentiate	O
,	O
whereas	O
the	O
CDK6	O
kinase	O
activity	O
is	O
low	O
in	O
both	O
proliferating	O
myoblasts	O
and	O
differentiated	O
myotubes	O
.	O

Our	O
results	O
indicate	O
that	O
p18	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
and	O
/	O
or	O
maintaining	O
permanent	O
cell	O
cycle	O
arrest	O
associated	O
with	O
mature	O
muscle	O
formation	O
.	O

Defective	O
biliary	O
copper	O
excretion	O
in	O
Wilson	O
'	O
s	O
disease	O
:	O
the	O
role	O
of	O
caeruloplasmin	O
.	O

Previous	O
studies	O
have	O
failed	O
to	O
explain	O
the	O
link	O
between	O
copper	O
accumulation	O
and	O
abnormal	O
caeruloplasmin	O
expression	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
despite	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Wilson	O
'	O
s	O
disease	O
,	O
which	O
predicts	O
a	O
defective	O
copper	O
transport	O
protein	O
,	O
the	O
localization	O
of	O
this	O
putative	O
protein	O
and	O
its	O
relationship	O
to	O
the	O
pathway	O
involved	O
in	O
copper	O
excretion	O
and	O
to	O
caeruloplasmin	O
remain	O
unknown	O
.	O

We	O
now	O
present	O
evidence	O
that	O
caeruloplasmin	O
,	O
the	O
major	O
plasma	O
copper	O
-	O
carrying	O
protein	O
,	O
is	O
present	O
in	O
the	O
liver	O
in	O
Wilson	O
'	O
s	O
disease	O
,	O
and	O
thus	O
that	O
reduced	O
circulating	O
levels	O
of	O
the	O
protein	O
result	O
from	O
a	O
post	O
-	O
translational	O
defect	O
in	O
the	O
secretory	O
pathway	O
.	O

We	O
have	O
also	O
identified	O
a	O
novel	O
form	O
of	O
caeruloplasmin	O
,	O
molecular	O
weight	O
125	O
kD	O
,	O
which	O
we	O
propose	O
may	O
act	O
as	O
the	O
carrier	O
for	O
excretory	O
copper	O
into	O
bile	O
,	O
since	O
it	O
is	O
normally	O
present	O
in	O
both	O
liver	O
and	O
bile	O
,	O
although	O
largely	O
absent	O
from	O
serum	O
,	O
and	O
undetectable	O
in	O
bile	O
from	O
Wilson	O
'	O
s	O
disease	O
patients	O
.	O

The	O
presence	O
of	O
this	O
form	O
of	O
caeruloplasmin	O
in	O
Wilson	O
'	O
s	O
disease	O
liver	O
suggests	O
that	O
a	O
related	O
post	O
-	O
translational	O
defect	O
may	O
also	O
be	O
responsible	O
for	O
its	O
absence	O
from	O
bile	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O

This	O
study	O
thus	O
provides	O
the	O
first	O
plausible	O
explanation	O
of	O
a	O
link	O
between	O
the	O
defective	O
copper	O
excretion	O
and	O
the	O
reduced	O
plasma	O
caeruloplasmin	O
,	O
which	O
characterize	O
Wilson	O
'	O
s	O
disease	O
.	O

Functional	O
model	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
using	O
an	O
isolated	O
frog	O
semicircular	O
canal	O
.	O

Bull	O
frogs	O
posterior	O
semicircular	O
canals	O
(	O
psc	O
)	O
wee	O
used	O
to	O
simulate	O
the	O
condition	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
(	O
BPPV	O
)	O
.	O

The	O
psc	O
was	O
isolated	O
in	O
frog	O
Ringer	O
'	O
s	O
solution	O
,	O
and	O
the	O
saccular	O
otoconia	O
were	O
used	O
as	O
a	O
responsible	O
material	O
to	O
stimulate	O
the	O
cupula	O
.	O

When	O
the	O
otoconia	O
were	O
placed	O
on	O
the	O
cupular	O
surface	O
to	O
mimic	O
the	O
condition	O
of	O
cupulolithiasis	O
,	O
the	O
psc	O
ampullary	O
nerve	O
action	O
potentials	O
instantaneously	O
changed	O
according	O
to	O
the	O
direction	O
of	O
the	O
gravity	O
produced	O
by	O
otoconia	O
.	O

When	O
the	O
otoconia	O
were	O
dropped	O
into	O
the	O
canal	O
to	O
mimic	O
the	O
condition	O
of	O
moving	O
otoconia	O
in	O
the	O
canal	O
,	O
the	O
action	O
potentials	O
changed	O
together	O
with	O
the	O
otoconial	O
flow	O
after	O
a	O
latent	O
period	O
.	O

Both	O
cupulolithiasis	O
and	O
moving	O
otoconia	O
are	O
possibly	O
valid	O
mechanisms	O
of	O
BPPV	O
,	O
since	O
they	O
effectively	O
stimulate	O
the	O
cupula	O
.	O

However	O
,	O
moving	O
otoconia	O
with	O
a	O
latent	O
period	O
would	O
better	O
explain	O
clinical	O
features	O
of	O
BPPV	O
.	O

Do	O
we	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
?	O

Metaperception	O
is	O
a	O
person	O
'	O
s	O
perception	O
about	O
a	O
second	O
person	O
'	O
s	O
perception	O
of	O
a	O
third	O
person	O
.	O

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
examine	O
the	O
accuracy	O
of	O
metaperceptions	O
of	O
liking	O
.	O

A	O
related	O
question	O
concerns	O
whether	O
the	O
heuristics	O
of	O
balance	O
,	O
reciprocity	O
,	O
and	O
agreement	O
are	O
used	O
by	O
perceivers	O
when	O
forming	O
such	O
judgments	O
.	O

The	O
authors	O
present	O
analyses	O
from	O
5	O
diverse	O
research	O
studies	O
that	O
used	O
an	O
adaptation	O
of	O
the	O
social	O
relations	O
model	O
for	O
triads	O
(	O
C	O
.	O
F	O
.	O
Bond	O
,	O
E	O
.	O
M	O
.	O
Horn	O
,	O
&	O
D	O
.	O
A	O
.	O
Kenny	O
,	O
in	O
press	O
)	O
.	O

The	O
results	O
indicate	O
that	O
people	O
know	O
how	O
much	O
people	O
like	O
one	O
another	O
,	O
even	O
with	O
small	O
amounts	O
of	O
information	O
.	O

Although	O
there	O
is	O
evidence	O
for	O
the	O
use	O
of	O
heuristics	O
,	O
particularly	O
reciprocity	O
and	O
agreement	O
,	O
accuracy	O
is	O
sometimes	O
enhanced	O
by	O
using	O
these	O
heuristics	O
.	O

Genetic	O
heterogeneity	O
evidenced	O
by	O
low	O
incidence	O
of	O
KAL	O
-	O
1	O
gene	O
mutations	O
in	O
sporadic	O
cases	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
deficiency	O
.	O

Isolated	O
GnRH	O
deficiency	O
is	O
a	O
heritable	O
condition	O
characterized	O
by	O
a	O
functional	O
deficit	O
in	O
GnRH	O
secretion	O
.	O

Familial	O
cases	O
with	O
different	O
modes	O
of	O
inheritance	O
have	O
been	O
described	O
,	O
and	O
the	O
gene	O
responsible	O
for	O
the	O
X	O
-	O
linked	O
form	O
(	O
KAL	O
-	O
1	O
)	O
has	O
been	O
identified	O
.	O

However	O
,	O
sporadic	O
cases	O
with	O
no	O
documented	O
family	O
history	O
of	O
GnRH	O
deficiency	O
account	O
for	O
the	O
majority	O
of	O
the	O
affected	O
patients	O
.	O

For	O
this	O
reason	O
,	O
we	O
sought	O
to	O
determine	O
the	O
frequency	O
with	O
which	O
KAL	O
-	O
1	O
gene	O
mutations	O
occur	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
.	O

Only	O
1	O
of	O
21	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
was	O
found	O
to	O
bear	O
a	O
defect	O
in	O
the	O
KAL	O
-	O
1	O
gene	O
(	O
a	O
deletion	O
of	O
14	O
bases	O
starting	O
at	O
codon	O
464	O
)	O
.	O

Three	O
types	O
of	O
polymorphic	O
single	O
base	O
substitutions	O
with	O
no	O
apparent	O
correlation	O
with	O
GnRH	O
deficiency	O
were	O
also	O
detected	O
in	O
several	O
patients	O
.	O

In	O
each	O
of	O
3	O
different	O
patients	O
with	O
an	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
,	O
3	O
genetic	O
defects	O
,	O
2	O
point	O
mutations	O
and	O
a	O
small	O
intragenic	O
deletion	O
,	O
were	O
detected	O
.	O

These	O
defects	O
consist	O
of	O
a	O
single	O
base	O
mutation	O
introducing	O
a	O
stop	O
codon	O
at	O
position	O
328	O
,	O
a	O
single	O
base	O
mutation	O
resulting	O
in	O
a	O
phenylalanine	O
to	O
leucine	O
substitution	O
at	O
position	O
517	O
,	O
and	O
a	O
9	O
-	O
base	O
deletion	O
at	O
the	O
3	O
'	O
-	O
exon	O
-	O
intron	O
splice	O
site	O
of	O
exon	O
8	O
,	O
respectively	O
.	O

All	O
identified	O
genetic	O
defects	O
occur	O
within	O
the	O
fibronectin	O
type	O
III	O
repeats	O
of	O
the	O
predicted	O
protein	O
encoded	O
by	O
the	O
KAL	O
-	O
1	O
gene	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
indicates	O
that	O
the	O
incidence	O
of	O
genetic	O
defects	O
within	O
the	O
coding	O
region	O
of	O
the	O
KAL	O
-	O
1	O
gene	O
in	O
patients	O
with	O
sporadic	O
GnRH	O
deficiency	O
is	O
low	O
(	O
5	O
-	O
8	O
%	O
)	O
,	O
thus	O
supporting	O
the	O
idea	O
that	O
the	O
X	O
-	O
linked	O
form	O
of	O
inheritance	O
represents	O
the	O
least	O
common	O
form	O
of	O
the	O
disease	O
.	O

[	O
Considerations	O
regarding	O
two	O
cases	O
of	O
macromastia	O
(	O
author	O
'	O
s	O
transl	O
)	O
]	O
.	O

Two	O
cases	O
of	O
macromastia	O
have	O
been	O
shown	O
;	O
one	O
which	O
appeared	O
during	O
puberty	O
,	O
the	O
other	O
during	O
menopause	O
.	O

Histopathological	O
examination	O
has	O
demonstrated	O
for	O
the	O
both	O
cases	O
a	O
cystic	O
degeneracy	O
of	O
the	O
glandular	O
tissue	O
with	O
a	O
hyperplazia	O
and	O
hypertrophy	O
of	O
the	O
conjunctive	O
tissue	O
.	O

The	O
pathogeny	O
of	O
macromastia	O
is	O
being	O
discussed	O
and	O
it	O
is	O
demonstrated	O
both	O
the	O
role	O
of	O
hypophysis	O
hormones	O
(	O
prolactine	O
and	O
growth	O
hormone	O
)	O
and	O
of	O
ovarian	O
hormones	O
(	O
estrogens	O
)	O
.	O

The	O
treatment	O
was	O
surgical	O
for	O
the	O
both	O
cases	O
.	O

The	O
effect	O
of	O
early	O
diagnosis	O
and	O
treatment	O
in	O
cystic	O
fibrosis	O
:	O
a	O
seven	O
-	O
year	O
study	O
of	O
16	O
sibling	O
pairs	O
.	O

Data	O
on	O
16	O
sibling	O
pairs	O
with	O
cystic	O
fibrosis	O
were	O
analyzed	O
to	O
test	O
the	O
hypothesis	O
that	O
early	O
treatment	O
of	O
this	O
condition	O
improves	O
prognosis	O
.	O

Younger	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
before	O
1	O
year	O
of	O
age	O
,	O
usually	O
before	O
the	O
onset	O
of	O
pulmonary	O
disease	O
.	O

Older	O
siblings	O
'	O
conditions	O
were	O
diagnosed	O
after	O
1	O
year	O
of	O
age	O
and	O
after	O
the	O
onset	O
of	O
pulmonary	O
disease	O
.	O

Although	O
the	O
sibling	O
pairs	O
received	O
similar	O
treatment	O
,	O
comparison	O
at	O
7	O
years	O
of	O
age	O
showed	O
that	O
the	O
younger	O
siblings	O
had	O
significantly	O
better	O
chest	O
roentgenogram	O
scores	O
,	O
total	O
clinical	O
scores	O
,	O
residual	O
lung	O
volumes	O
,	O
and	O
ratios	O
of	O
residual	O
volume	O
to	O
total	O
lung	O
volume	O
.	O

Younger	O
siblings	O
also	O
required	O
fewer	O
hospital	O
admissions	O
to	O
control	O
their	O
lung	O
disease	O
.	O

The	O
results	O
suggest	O
that	O
,	O
in	O
general	O
,	O
early	O
initiation	O
of	O
therapy	O
is	O
beneficial	O
for	O
patients	O
with	O
cystic	O
fibrosis	O
.	O

Comparison	O
of	O
transformation	O
by	O
manganese	O
sulfate	O
and	O
5	O
-	O
azacytidine	O
in	O
Rat	B
6	I
cells	O
overexpressing	O
the	O
c	O
-	O
myc	O
oncogene	O
.	O

Rat	B
6	I
cells	O
are	O
not	O
transformed	O
by	O
treatment	O
with	O
the	O
well	O
-	O
known	O
carcinogens	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
BP	O
)	O
or	O
N	O
-	O
methyl	O
-	O
N	O
-	O
nitro	O
-	O
N	O
'	O
-	O
nitrosoguanidine	O
(	O
MNNG	O
)	O
.	O

Upon	O
retroviral	O
transduction	O
of	O
the	O
mouse	O
c	O
-	O
myc	O
gene	O
,	O
Rat	B
6	I
cells	O
showed	O
mildly	O
altered	O
morphology	O
and	O
formed	O
microcolonies	O
in	O
soft	O
agar	O
;	O
furthermore	O
,	O
they	O
could	O
be	O
transformed	O
by	O
BP	O
and	O
MNNG	O
to	O
form	O
large	O
colonies	O
in	O
agar	O
(	O
Hsiao	O
et	O
al	O
.	O
(	O
1992	O
)	O
Mol	O
.	O
Carcinogenesis	O
,	O
5	O
,	O
140	O
-	O
154	O
)	O
.	O

In	O
the	O
current	O
report	O
,	O
we	O
tested	O
the	O
sensitivity	O
of	O
the	O
c	O
-	O
myc	O
-	O
overexpressing	O
cells	O
(	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
)	O
to	O
two	O
additional	O
chemicals	O
:	O
5	O
-	O
azacytidine	O
and	O
MnSO4	O
.	O

These	O
chemicals	O
differ	O
from	O
the	O
direct	O
-	O
acting	O
mutagens	O
tested	O
previously	O
.	O

5	O
-	O
Azacytidine	O
,	O
a	O
potent	O
DNA	O
methylation	O
inhibitor	O
,	O
induced	O
growth	O
of	O
large	O
colonies	O
in	O
soft	O
agar	O
cultures	O
of	O
Rat	B
6	I
or	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
MnSO4	O
only	O
induced	O
transformation	O
in	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
,	O
but	O
not	O
the	O
parental	O
Rat	B
6	I
cells	O
.	O

Transformants	O
induced	O
by	O
5	O
-	O
azacytidine	O
lost	O
c	O
-	O
myc	O
-	O
induced	O
apoptotic	O
cell	O
death	O
,	O
whereas	O
MnSO4	O
-	O
induced	O
transformants	O
showed	O
a	O
higher	O
degree	O
of	O
apoptosis	O
than	O
the	O
parental	O
Rat	B
6	I
/	O
c	O
-	O
myc	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
MnSO4	O
co	O
-	O
operates	O
with	O
overexpressed	O
c	O
-	O
myc	O
in	O
inducing	O
transformation	O
,	O
while	O
5	O
-	O
azacytidine	O
transformation	O
is	O
independent	O
of	O
c	O
-	O
myc	O
overexpression	O
and	O
may	O
involve	O
alterations	O
in	O
the	O
regulation	O
of	O
apoptosis	O
.	O

Fas	O
-	O
signaling	O
and	O
effects	O
on	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
in	O
human	O
breast	O
epithelial	O
cells	O
.	O

Fas	O
-	O
mediated	O
cell	O
death	O
was	O
examined	O
in	O
MCF	B
-	I
10AT	I
preneoplastic	O
human	O
breast	O
epithelial	O
cells	O
.	O

Treatment	O
with	O
anti	O
-	O
Fas	O
for	O
48	O
h	O
induced	O
apoptosis	O
with	O
cells	O
exhibiting	O
typical	O
apoptotic	O
features	O
including	O
loss	O
of	O
cell	O
contact	O
,	O
condensation	O
of	O
chromatin	O
,	O
and	O
increased	O
staining	O
of	O
the	O
nuclear	O
membrane	O
.	O

DNA	O
fragmentation	O
occurred	O
in	O
response	O
to	O
anti	O
-	O
Fas	O
treatment	O
.	O

Anti	O
-	O
Fas	O
treatment	O
resulted	O
in	O
decreased	O
p53	O
protein	O
levels	O
,	O
while	O
bcl	O
-	O
2	O
and	O
bax	O
protein	O
levels	O
remained	O
unaffected	O
.	O

Cells	O
treated	O
with	O
anti	O
-	O
Fas	O
also	O
exhibited	O
increased	O
tyrosine	O
phosphorylation	O
of	O
the	O
c	O
-	O
met	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
.	O

Immunoprecipitation	O
experiments	O
demonstrated	O
that	O
Fas	O
associated	O
with	O
c	O
-	O
erbB2	O
and	O
c	O
-	O
met	O
in	O
untreated	O
cells	O
.	O

Treatment	O
with	O
anti	O
-	O
Fas	O
,	O
however	O
,	O
significantly	O
decreased	O
Fas	O
-	O
c	O
-	O
erbB2	O
and	O
Fas	O
-	O
c	O
-	O
met	O
association	O
.	O

Anti	O
-	O
Fas	O
treatment	O
of	O
these	O
cells	O
caused	O
a	O
significant	O
decrease	O
in	O
p120	O
-	O
GAP	O
levels	O
,	O
ERK	O
-	O
1	O
levels	O
,	O
and	O
phosphorylation	O
,	O
as	O
well	O
as	O
Grb2	O
-	O
Sosl	O
and	O
MEK	O
-	O
1	O
-	O
ERK	O
-	O
1	O
association	O
.	O

These	O
results	O
show	O
that	O
Fas	O
-	O
signaling	O
exerted	O
a	O
suppressive	O
effect	O
on	O
p53	O
levels	O
and	O
on	O
downstream	O
effectors	O
of	O
receptor	O
tyrosine	O
kinase	O
signal	O
transduction	O
,	O
thereby	O
ensuring	O
cell	O
death	O
.	O

Prevention	O
of	O
hepatic	O
tumor	O
metastases	O
in	O
rats	O
with	O
herpes	O
viral	O
vaccines	O
and	O
gamma	O
-	O
interferon	O
.	O

Previous	O
studies	O
showed	O
that	O
gammaIFN	O
decreases	O
metastatic	O
hepatic	O
tumor	O
growth	O
by	O
stimulating	O
Kupffer	O
cells	O
(	O
KC	O
)	O
.	O

The	O
present	O
studies	O
examine	O
whether	O
lymphocyte	O
stimulation	O
via	O
cells	O
engineered	O
to	O
secrete	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
decreases	O
hepatic	O
tumor	O
growth	O
,	O
and	O
whether	O
stimulation	O
of	O
both	O
macrophages	O
and	O
lymphocytes	O
is	O
more	O
effective	O
than	O
either	O
individually	O
.	O

Rats	O
were	O
immunized	O
with	O
irradiated	O
hepatoma	O
cells	O
transduced	O
by	O
herpes	O
viral	O
amplicon	O
vectors	O
containing	O
the	O
genes	O
for	O
GM	O
-	O
CSF	O
,	O
IL	O
-	O
2	O
or	O
LacZ	O
.	O

On	O
day	O
18	O
,	O
half	O
of	O
each	O
group	O
was	O
treated	O
with	O
5	O
x	O
10	O
(	O
4	O
)	O
U	O
gammaIFN	O
,	O
or	O
saline	O
intraperitoneally	O
for	O
3	O
d	O
.	O

On	O
day	O
21	O
,	O
all	O
rats	O
received	O
5	O
x	O
10	O
(	O
5	O
)	O
hepatoma	O
cells	O
intrasplenically	O
.	O

On	O
day	O
41	O
,	O
rats	O
were	O
killed	O
and	O
tumor	O
nodules	O
were	O
counted	O
.	O

Separate	O
rats	O
underwent	O
splenocyte	O
and	O
KC	O
harvest	O
for	O
assessment	O
of	O
lymphocyte	O
-	O
and	O
macrophage	O
-	O
mediated	O
tumor	O
cell	O
kill	O
in	O
vitro	O
.	O

GM	O
-	O
CSF	O
or	O
IL	O
-	O
2	O
vaccines	O
or	O
gammaIFN	O
decreased	O
tumor	O
nodules	O
significantly	O
(	O
GM	O
-	O
CSF	O
13	O
+	O
/	O
-	O
4	O
,	O
IL	O
-	O
2	O
14	O
+	O
/	O
-	O
6	O
vs	O
.	O
control	O
75	O
+	O
/	O
-	O
24	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Combination	O
therapy	O
was	O
more	O
effective	O
,	O
and	O
completely	O
eliminated	O
tumor	O
in	O
4	O
of	O
12	O
IFN	O
-	O
GM	O
-	O
CSF	O
and	O
8	O
of	O
11	O
IFN	O
-	O
IL	O
-	O
2	O
animals	O
.	O

Additional	O
rats	O
underwent	O
partial	O
hepatectomy	O
,	O
an	O
immunosuppressive	O
procedure	O
known	O
to	O
accelerate	O
the	O
growth	O
of	O
hepatic	O
tumor	O
,	O
following	O
tumor	O
challenge	O
.	O

Therapy	O
was	O
equally	O
effective	O
in	O
this	O
immunosuppressive	O
setting	O
.	O

Vaccination	O
is	O
associated	O
with	O
enhancement	O
of	O
splenocyte	O
-	O
mediated	O
tumoricidal	O
activity	O
,	O
whereas	O
the	O
effect	O
of	O
gammaIFN	O
is	O
mediated	O
by	O
KC	O
.	O

GM	O
-	O
CSF	O
and	O
IL	O
-	O
2	O
vaccine	O
therapy	O
and	O
pretreatment	O
with	O
gammaIFN	O
represent	O
effective	O
strategies	O
in	O
reducing	O
hepatic	O
tumor	O
.	O

Combination	O
therapy	O
targets	O
both	O
lymphocytes	O
and	O
macrophages	O
,	O
and	O
is	O
more	O
effective	O
in	O
reducing	O
tumor	O
than	O
either	O
therapy	O
alone	O
.	O

[	O
Effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
hematogenous	O
metastasis	O
of	O
cancer	O
]	O
.	O

The	O
experimental	O
studies	O
in	O
vitro	O
and	O
in	O
vivo	O
were	O
performed	O
to	O
investigate	O
the	O
effects	O
of	O
carcinostatic	O
agents	O
in	O
the	O
adhesion	O
of	O
cancer	O
cells	O
to	O
endothelial	O
cells	O
.	O

Certain	O
carcinostatic	O
agents	O
induce	O
the	O
expression	O
of	O
E	O
-	O
selectin	O
on	O
endothelial	O
cells	O
and	O
enhance	O
the	O
expression	O
of	O
carbohydrate	O
ligands	O
on	O
cancer	O
cells	O
.	O

Consequently	O
,	O
increased	O
adhesion	O
of	O
cancer	O
cells	O
to	O
endothelial	O
cells	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

In	O
the	O
trans	O
-	O
splenic	O
hepatic	O
metastasis	O
model	O
using	O
nude	O
mice	O
,	O
the	O
augmentation	O
of	O
cancer	O
metastasis	O
was	O
observed	O
by	O
the	O
treatment	O
of	O
carcinostatic	O
agents	O
.	O

From	O
the	O
above	O
,	O
we	O
concluded	O
that	O
carcinostatic	O
agents	O
may	O
increase	O
the	O
metastatic	O
ability	O
of	O
cancer	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

Procedural	O
memory	O
stimulation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
impact	O
of	O
a	O
training	O
programme	O
.	O

The	O
study	O
evaluates	O
the	O
efficacy	O
of	O
a	O
procedural	O
memory	O
stimulation	O
programme	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

Twenty	O
basic	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
have	O
been	O
selected	O
,	O
and	O
divided	O
into	O
two	O
groups	O
,	O
comparable	O
for	O
difficulty	O
.	O

Ten	O
normal	O
elderly	O
subjects	O
(	O
age	O
68	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
8	O
years	O
;	O
MMSE	O
score	O
:	O
28	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
9	O
;	O
education	O
:	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
were	O
asked	O
to	O
perform	O
the	O
two	O
groups	O
of	O
daily	O
activities	O
and	O
the	O
time	O
required	O
to	O
perform	O
the	O
tasks	O
of	O
each	O
group	O
was	O
recorded	O
and	O
used	O
as	O
a	O
reference	O
.	O

Ten	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
(	O
age	O
77	O
.	O
2	O
+	O
/	O
-	O
5	O
.	O
3	O
years	O
;	O
MMSE	O
score	O
:	O
19	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
;	O
education	O
:	O
7	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
7	O
years	O
)	O
without	O
major	O
behavioural	O
disturbances	O
constituted	O
the	O
experimental	O
group	O
.	O

Patients	O
were	O
evaluated	O
in	O
all	O
20	O
daily	O
activities	O
and	O
the	O
time	O
employed	O
was	O
recorded	O
at	O
baseline	O
and	O
after	O
a	O
3	O
-	O
week	O
training	O
(	O
1	O
h	O
/	O
d	O
,	O
5	O
d	O
/	O
week	O
)	O
period	O
.	O

Five	O
patients	O
were	O
trained	O
during	O
the	O
3	O
weeks	O
on	O
half	O
of	O
the	O
20	O
daily	O
activities	O
and	O
the	O
other	O
five	O
patients	O
were	O
trained	O
on	O
the	O
remainder	O
.	O

This	O
procedure	O
was	O
adopted	O
in	O
order	O
to	O
detect	O
separately	O
the	O
improvement	O
in	O
""""	O
trained	O
""""	O
and	O
""""	O
not	O
trained	O
""""	O
activities	O
,	O
allowing	O
to	O
control	O
better	O
the	O
effects	O
of	O
the	O
intervention	O
.	O

The	O
assessment	O
of	O
the	O
functional	O
impact	O
of	O
the	O
training	O
was	O
directly	O
measured	O
,	O
through	O
the	O
variation	O
of	O
time	O
employed	O
to	O
perform	O
tasks	O
before	O
and	O
after	O
training	O
.	O

After	O
3	O
weeks	O
of	O
training	O
a	O
significant	O
improvement	O
was	O
observed	O
for	O
the	O
trained	O
activities	O
,	O
from	O
3	O
.	O
6	O
to	O
1	O
.	O
9	O
standard	O
deviations	O
below	O
the	O
performance	O
of	O
the	O
normal	O
elderly	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

AD	O
patients	O
improved	O
also	O
in	O
not	O
-	O
trained	O
activities	O
from	O
3	O
.	O
5	O
to	O
2	O
.	O
7	O
standard	O
deviations	O
below	O
the	O
controls	O
'	O
performance	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
rehabilitation	O
of	O
activities	O
of	O
daily	O
living	O
through	O
developing	O
procedural	O
memory	O
strategies	O
may	O
be	O
effective	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
.	O

Regulation	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
transcriptional	O
repression	O
,	O
and	O
cell	O
transformation	O
by	O
phosphorylation	O
of	O
the	O
55	O
-	O
kilodalton	O
E1B	O
protein	O
of	O
human	O
adenovirus	O
type	O
5	O
.	O

The	O
adenovirus	O
type	O
5	O
55	O
-	O
kDa	O
E1B	O
protein	O
(	O
E1B	O
-	O
55kDa	O
)	O
cooperates	O
with	O
E1A	O
gene	O
products	O
to	O
induce	O
cell	O
transformation	O
.	O

E1A	O
proteins	O
stimulate	O
DNA	O
synthesis	O
and	O
cell	O
proliferation	O
;	O
however	O
,	O
they	O
also	O
cause	O
rapid	O
cell	O
death	O
by	O
p53	O
-	O
dependent	O
and	O
p53	O
-	O
independent	O
apoptosis	O
.	O

It	O
is	O
believed	O
that	O
the	O
role	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
in	O
transformation	O
is	O
to	O
protect	O
against	O
p53	O
-	O
dependent	O
apoptosis	O
by	O
binding	O
to	O
and	O
inactivating	O
p53	O
.	O

It	O
has	O
been	O
shown	O
previously	O
that	O
the	O
55	O
-	O
kDa	O
polypeptide	O
abrogates	O
p53	O
-	O
mediated	O
transactivation	O
and	O
that	O
mutants	O
defective	O
in	O
p53	O
binding	O
are	O
unable	O
to	O
cooperate	O
with	O
E1A	O
in	O
transformation	O
.	O

We	O
have	O
previously	O
mapped	O
phosphorylation	O
sites	O
near	O
the	O
carboxy	O
terminus	O
of	O
the	O
E1B	O
-	O
55kDa	O
protein	O
at	O
Ser	O
-	O
490	O
and	O
Ser	O
-	O
491	O
,	O
which	O
lie	O
within	O
casein	O
kinase	O
II	O
consensus	O
sequences	O
.	O

Conversion	O
of	O
these	O
sites	O
to	O
alanine	O
residues	O
greatly	O
reduced	O
transforming	O
activity	O
,	O
and	O
although	O
the	O
mutant	O
55	O
-	O
kDa	O
protein	O
was	O
found	O
to	O
interact	O
with	O
p53	O
at	O
normal	O
levels	O
,	O
it	O
was	O
somewhat	O
defective	O
for	O
suppression	O
of	O
p53	O
transactivation	O
activity	O
.	O

We	O
now	O
report	O
that	O
a	O
nearby	O
residue	O
,	O
Thr	O
-	O
495	O
,	O
also	O
appears	O
to	O
be	O
phosphorylated	O
.	O

We	O
demonstrate	O
directly	O
that	O
the	O
wild	O
-	O
type	O
55	O
-	O
kDa	O
protein	O
is	O
able	O
to	O
block	O
E1A	O
-	O
induced	O
p53	O
-	O
dependent	O
apoptosis	O
,	O
whereas	O
cells	O
infected	O
by	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
,	O
which	O
contains	O
alanine	O
residues	O
at	O
all	O
three	O
phosphorylation	O
sites	O
,	O
exhibited	O
extensive	O
DNA	O
fragmentation	O
and	O
classic	O
apoptotic	O
cell	O
death	O
.	O

The	O
E1B	O
-	O
55kDa	O
product	O
has	O
been	O
shown	O
to	O
exhibit	O
intrinsic	O
transcriptional	O
repression	O
activity	O
when	O
localized	O
to	O
promoters	O
,	O
such	O
as	O
by	O
fusion	O
with	O
the	O
GAL4	O
DNA	O
-	O
binding	O
domain	O
,	O
even	O
in	O
the	O
absence	O
of	O
p53	O
.	O

Such	O
repression	O
activity	O
was	O
totally	O
absent	O
with	O
mutant	O
pm490	O
/	O
1	O
/	O
5A	O
.	O

These	O
data	O
suggested	O
that	O
inhibition	O
of	O
p53	O
-	O
dependent	O
apoptosis	O
may	O
depend	O
on	O
the	O
transcriptional	O
repression	O
function	O
of	O
the	O
55	O
-	O
kDa	O
protein	O
,	O
which	O
appears	O
to	O
be	O
regulated	O
be	O
phosphorylation	O
at	O
the	O
carboxy	O
terminus	O
.	O

Non	O
-	O
invasive	O
grading	O
of	O
primary	O
brain	O
tumours	O
:	O
results	O
of	O
a	O
comparative	O
study	O
between	O
SPET	O
with	O
123I	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
and	O
PET	O
with	O
18F	O
-	O
deoxyglucose	O
.	O

Use	O
of	O
iodine	O
-	O
123	O
-	O
alpha	O
-	O
methyl	O
tyrosine	O
(	O
123I	O
-	O
IMT	O
)	O
allows	O
investigation	O
of	O
the	O
amino	O
acid	O
transport	O
rate	O
in	O
gliomas	O
.	O

It	O
was	O
the	O
aim	O
of	O
this	O
study	O
to	O
compare	O
the	O
value	O
of	O
measurement	O
of	O
glucose	O
metabolism	O
with	O
that	O
of	O
measurement	O
of	O
123I	O
-	O
IMT	O
uptake	O
for	O
the	O
non	O
-	O
invasive	O
grading	O
of	O
brain	O
tumours	O
.	O

The	O
study	O
population	O
comprised	O
23	O
patients	O
with	O
histopathologically	O
proven	O
primary	O
brain	O
tumours	O
;	O
14	O
had	O
high	O
-	O
grade	O
gliomas	O
,	O
and	O
nine	O
low	O
-	O
grade	O
brain	O
neoplasms	O
.	O

Glucose	O
metabolism	O
was	O
studied	O
using	O
an	O
ECAT	O
EXACT	O
47	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
camera	O
and	O
fluorine	O
-	O
18	O
fluorodeoxyglucose	O
(	O
18F	O
-	O
FDG	O
)	O
;	O
123I	O
-	O
IMT	O
uptake	O
was	O
measured	O
with	O
the	O
triple	O
-	O
headed	O
single	O
-	O
photon	O
emission	O
tomography	O
(	O
SPET	O
)	O
camera	O
,	O
MULTISPECT	O
3	O
.	O

18F	O
-	O
FDG	O
and	O
123I	O
-	O
IMT	O
uptake	O
was	O
quantified	O
as	O
ratios	O
between	O
the	O
uptake	O
by	O
the	O
tumour	O
and	O
contralateral	O
regions	O
of	O
reference	O
.	O

Glucose	O
metabolism	O
and	O
amino	O
acid	O
uptake	O
of	O
the	O
brain	O
tumours	O
correlated	O
significantly	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Assuming	O
discrimination	O
thresholds	O
between	O
high	O
-	O
grade	O
and	O
low	O
-	O
grade	O
tumours	O
of	O
0	O
.	O
8	O
for	O
18F	O
-	O
FDG	O
uptake	O
and	O
1	O
.	O
8	O
for	O
123I	O
-	O
IMT	O
uptake	O
,	O
the	O
accuracy	O
values	O
of	O
18F	O
-	O
FDG	O
PET	O
and	O
123I	O
-	O
IMT	O
SPET	O
for	O
differentiating	O
between	O
high	O
-	O
grade	O
and	O
low	O
-	O
grade	O
tumours	O
were	O
21	O
/	O
23	O
(	O
91	O
%	O
)	O
and	O
19	O
/	O
23	O
(	O
83	O
%	O
)	O
,	O
respectively	O
.	O

The	O
difference	O
in	O
diagnostic	O
performance	O
was	O
not	O
significant	O
on	O
receiver	O
operating	O
characteristic	O
analysis	O
(	O
P	O
>	O
0	O
.	O
4	O
)	O
.	O

It	O
is	O
concluded	O
that	O
there	O
is	O
no	O
major	O
difference	O
between	O
the	O
PET	O
investigation	O
of	O
glucose	O
metabolism	O
and	O
the	O
less	O
expensive	O
SPET	O
measurement	O
of	O
amino	O
acid	O
uptake	O
in	O
terms	O
of	O
their	O
accuracy	O
in	O
evaluating	O
the	O
malignancy	O
grade	O
of	O
primary	O
brain	O
tumours	O
.	O

This	O
encourages	O
the	O
performance	O
of	O
further	O
studies	O
to	O
analyse	O
the	O
potential	O
impact	O
of	O
123I	O
-	O
IMT	O
SPET	O
on	O
the	O
therapeutic	O
management	O
of	O
patients	O
with	O
brain	O
tumours	O
.	O

Some	O
findings	O
concerning	O
beliefs	O
about	O
alcoholism	O
.	O

The	O
beliefs	O
that	O
alcoholics	O
hold	O
about	O
alcoholism	O
and	O
themselves	O
,	O
and	O
the	O
beliefs	O
that	O
hospital	O
staff	O
and	O
other	O
personnel	O
hold	O
about	O
alcoholism	O
,	O
were	O
investigated	O
using	O
methods	O
derived	O
from	O
the	O
repertory	O
grid	O
,	O
with	O
anonymous	O
facial	O
photographs	O
as	O
elements	O
.	O

Data	O
are	O
presented	O
as	O
to	O
the	O
degree	O
of	O
association	O
of	O
various	O
characteristics	O
with	O
alcoholism	O
for	O
the	O
various	O
groups	O
.	O

Differences	O
between	O
groups	O
,	O
and	O
overall	O
changes	O
during	O
group	O
psychotherapy	O
for	O
patients	O
were	O
small	O
.	O

The	O
relative	O
contribution	O
of	O
personal	O
and	O
shared	O
aspects	O
of	O
belief	O
was	O
measured	O
.	O

It	O
was	O
found	O
that	O
the	O
agreement	O
between	O
groups	O
was	O
high	O
and	O
closely	O
similar	O
to	O
that	O
predictable	O
from	O
consistencies	O
within	O
groups	O
.	O

It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
very	O
general	O
stereotype	O
of	O
alcoholism	O
,	O
consistent	O
with	O
a	O
personality	O
disorder	O
concept	O
which	O
is	O
implicitly	O
held	O
even	O
in	O
the	O
face	O
of	O
nominal	O
acceptance	O
of	O
other	O
concepts	O
.	O

The	O
self	O
constructs	O
of	O
alcoholics	O
were	O
found	O
to	O
be	O
complex	O
.	O

In	O
a	O
small	O
follow	O
-	O
up	O
study	O
of	O
patients	O
,	O
there	O
was	O
found	O
to	O
be	O
a	O
relationship	O
of	O
poor	O
outcome	O
with	O
tightness	O
of	O
construing	O
for	O
key	O
constructs	O
after	O
psychotherapy	O
.	O

The	O
implications	O
of	O
the	O
findings	O
are	O
discussed	O
briefly	O
.	O

The	O
effects	O
of	O
oxidative	O
stress	O
on	O
in	O
vivo	O
brain	O
GSH	O
turnover	O
in	O
young	O
and	O
mature	O
mice	O
.	O

Glutathione	O
(	O
GSH	O
)	O
synthetase	O
activities	O
and	O
GSH	O
turnover	O
rates	O
were	O
examined	O
during	O
severe	O
oxidative	O
stress	O
in	O
the	O
mouse	O
brain	O
as	O
induced	O
by	O
t	O
-	O
butylhydroperoxide	O
(	O
t	O
-	O
BuOOH	O
)	O
.	O

Brain	O
GSH	O
synthetase	O
activities	O
in	O
8	O
-	O
mo	O
-	O
old	O
mice	O
in	O
the	O
cortex	O
,	O
striatum	O
,	O
thalamus	O
,	O
hippocampus	O
,	O
midbrain	O
,	O
and	O
cerebellum	O
were	O
found	O
to	O
increase	O
following	O
t	O
-	O
BuOOH	O
treatment	O
.	O

The	O
effect	O
of	O
GSH	O
synthesis	O
on	O
brain	O
GSH	O
turnover	O
rates	O
for	O
2	O
-	O
and	O
8	O
-	O
mo	O
-	O
old	O
mice	O
were	O
determined	O
after	O
intracerebroventricular	O
(	O
icv	O
)	O
injection	O
of	O
[	O
35S	O
]	O
cysteine	O
.	O

Rate	O
constants	O
for	O
GSH	O
turnover	O
were	O
determined	O
by	O
least	O
-	O
squares	O
iterative	O
minimization	O
from	O
the	O
specific	O
activity	O
data	O
from	O
20	O
min	O
to	O
108	O
h	O
after	O
[	O
35S	O
]	O
cysteine	O
administration	O
.	O

GSH	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
specific	O
activities	O
were	O
determined	O
after	O
separation	O
by	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
.	O

The	O
half	O
-	O
life	O
of	O
GSH	O
in	O
the	O
2	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
59	O
.	O
5	O
h	O
and	O
in	O
the	O
8	O
-	O
mo	O
-	O
old	O
mouse	O
was	O
79	O
.	O
1	O
h	O
.	O

In	O
summary	O
,	O
defense	O
mechanisms	O
against	O
oxidative	O
stress	O
in	O
the	O
brain	O
differ	O
with	O
age	O
.	O

Young	O
mice	O
can	O
increase	O
the	O
cellular	O
availability	O
of	O
GSH	O
,	O
whereas	O
mature	O
mice	O
can	O
increase	O
GSH	O
synthetase	O
activity	O
during	O
oxidative	O
stress	O
.	O

These	O
differences	O
make	O
mature	O
mice	O
more	O
susceptible	O
to	O
brain	O
oxidative	O
damage	O
.	O

Changes	O
in	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
levels	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Increased	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
levels	O
are	O
increased	O
in	O
a	O
number	O
of	O
malignancies	O
and	O
have	O
been	O
correlated	O
with	O
decreased	O
disease	O
-	O
free	O
interval	O
and	O
decreased	O
overall	O
survival	O
.	O

We	O
have	O
,	O
therefore	O
,	O
examined	O
components	O
of	O
this	O
plasminogen	O
activating	O
system	O
in	O
patients	O
with	O
Non	O
-	O
Small	O
Cell	O
Lung	O
Cancer	O
(	O
NSCLC	O
)	O
.	O

Levels	O
of	O
uPA	O
,	O
urokinase	O
-	O
plasminogen	O
activator	O
receptor	O
(	O
uPAR	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
were	O
measured	O
semiquantitatively	O
in	O
paraffin	O
sections	O
of	O
tumours	O
from	O
147	O
patients	O
with	O
NSCLC	O
.	O

Immunohistochemically	O
stained	O
sections	O
of	O
tumour	O
were	O
allocated	O
a	O
score	O
for	O
stain	O
intensity	O
and	O
results	O
correlated	O
to	O
:	O
survival	O
;	O
tumour	O
stage	O
(	O
T	O
)	O
;	O
nodal	O
stage	O
(	O
N	O
)	O
;	O
stage	O
grouping	O
(	O
I	O
to	O
IIIb	O
)	O
,	O
survival	O
status	O
and	O
sex	O
.	O

Increased	O
levels	O
of	O
PAI	O
-	O
1	O
were	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
X2	O
=	O
5	O
.	O
72	O
,	O
p	O
=	O
0	O
.	O
017	O
(	O
n	O
=	O
74	O
)	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
N	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
presence	O
of	O
nodal	O
metastases	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
,	O
stage	O
grouping	O
(	O
p	O
=	O
<	O
0	O
.	O
01	O
)	O
and	O
extent	O
of	O
disease	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
and	O
the	O
SCC	O
subgroup	O
,	O
but	O
not	O
adenocarcinoma	O
.	O

There	O
was	O
a	O
significant	O
positive	O
relationship	O
between	O
PAI	O
-	O
1	O
levels	O
and	O
T	O
-	O
stage	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
total	O
group	O
,	O
and	O
survival	O
status	O
(	O
p	O
=	O
<	O
0	O
.	O
05	O
)	O
in	O
the	O
SCC	O
subgroup	O
alone	O
.	O

uPA	O
and	O
uPAR	O
levels	O
were	O
not	O
significantly	O
associated	O
with	O
tumour	O
staging	O
or	O
survival	O
.	O

We	O
conclude	O
that	O
increased	O
PAI	O
-	O
1	O
antigen	O
levels	O
may	O
be	O
associated	O
with	O
a	O
decreased	O
survival	O
in	O
patients	O
with	O
SCC	O
.	O

Insulin	O
-	O
like	O
growth	O
factor	O
I	O
induces	O
tumor	O
hexokinase	O
RNA	O
expression	O
in	O
cancer	O
cells	O
.	O

Increased	O
glycolysis	O
is	O
a	O
characteristic	O
of	O
cancer	O
cells	O
.	O

Though	O
less	O
efficient	O
in	O
energy	O
production	O
,	O
it	O
ensures	O
continuous	O
supply	O
of	O
energy	O
and	O
phosphometabolites	O
for	O
biosynthesis	O
enabling	O
metastatic	O
and	O
less	O
vascularized	O
cancer	O
cells	O
to	O
proliferate	O
even	O
under	O
hypoxic	O
conditions	O
.	O

Since	O
hexokinase	O
is	O
the	O
first	O
rate	O
limiting	O
enzyme	O
in	O
the	O
glycolytic	O
pathway	O
,	O
elevated	O
levels	O
of	O
Type	O
II	O
like	O
hexokinase	O
in	O
tumors	O
are	O
of	O
great	O
significance	O
in	O
this	O
context	O
.	O

Under	O
normal	O
conditions	O
insulin	O
regulates	O
expression	O
of	O
hexokinase	O
Type	O
II	O
isoenzyme	O
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
muscle	O
.	O

On	O
the	O
other	O
hand	O
cancer	O
cells	O
overexpress	O
insulin	O
-	O
like	O
growth	O
factors	O
and	O
their	O
receptors	O
which	O
mimic	O
many	O
activities	O
of	O
insulin	O
.	O

This	O
prompted	O
us	O
to	O
examine	O
a	O
hypothesis	O
that	O
insulin	O
-	O
like	O
growth	O
factors	O
may	O
be	O
responsible	O
for	O
overexpression	O
of	O
tumor	O
hexokinase	O
.	O

Our	O
experiments	O
demonstrate	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
indeed	O
induces	O
hexokinase	O
gene	O
expression	O
in	O
a	O
concentration	O
and	O
time	O
dependent	O
manner	O
in	O
two	O
cancer	O
cell	O
lines	O
we	O
studied	O
.	O

The	O
Wilms	O
tumor	O
suppressor	O
gene	O
WT1	O
induces	O
G1	O
arrest	O
and	O
apoptosis	O
in	O
myeloblastic	O
leukemia	O
M1	B
cells	O
.	O

WT1	O
was	O
isolated	O
as	O
a	O
tumor	O
suppressor	O
gene	O
of	O
Wilms	O
tumor	O
.	O

However	O
,	O
high	O
expression	O
of	O
WT1	O
correlates	O
with	O
poor	O
prognosis	O
in	O
acute	O
leukemia	O
.	O

In	O
addition	O
suppression	O
of	O
WT1	O
expression	O
by	O
WT1	O
anti	O
-	O
sense	O
oligonucleotide	O
inhibits	O
proliferation	O
of	O
leukemia	O
cells	O
,	O
suggesting	O
that	O
WT1	O
is	O
important	O
for	O
their	O
proliferation	O
.	O

To	O
further	O
elucidate	O
the	O
biological	O
significance	O
of	O
WT1	O
in	O
leukemic	O
cell	O
growth	O
,	O
we	O
overexpressed	O
exogenous	O
WT1	O
in	O
murine	O
M1	B
myeloblastic	O
leukemia	O
cells	O
using	O
the	O
isopropyl	O
-	O
beta	O
-	O
D	O
-	O
thiogalactoside	O
(	O
IPTG	O
)	O
-	O
controlled	O
expression	O
system	O
.	O

We	O
found	O
that	O
induction	O
of	O
one	O
splicing	O
variant	O
of	O
WT1	O
[	O
WT1	O
-	O
17AA	O
(	O
+	O
)	O
-	O
KTS	O
(	O
-	O
)	O
]	O
in	O
M1	B
cells	O
induces	O
cell	O
cycle	O
arrest	O
and	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
WT1	O
is	O
different	O
depending	O
on	O
the	O
type	O
of	O
leukemia	O
cell	O
in	O
which	O
it	O
is	O
expressed	O
.	O

[	O
Expression	O
of	O
metastasis	O
suppressor	O
gene	O
nm23	O
in	O
human	O
hepatocellular	O
carcinoma	O
]	O
.	O

For	O
the	O
purpose	O
of	O
investigating	O
the	O
relationship	O
between	O
the	O
metastatic	O
potential	O
of	O
the	O
tumor	O
as	O
well	O
as	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
and	O
for	O
determing	O
the	O
location	O
of	O
the	O
positive	O
sites	O
in	O
the	O
cells	O
,	O
tumor	O
metastasis	O
suppressor	O
gene	O
nm23	O
-	O
H1	O
in	O
human	O
hepatocellular	O
carcinoma	O
(	O
and	O
the	O
nonneoplastic	O
area	O
surrounding	O
the	O
tumor	O
)	O
was	O
detected	O
by	O
in	O
situ	O
hybridization	O
using	O
digoxiginin	O
-	O
labeled	O
nm23	O
-	O
H1	O
antisense	O
complementary	O
RNA	O
probe	O
.	O

The	O
primary	O
results	O
indicated	O
(	O
i	O
)	O
positive	O
results	O
of	O
in	O
situ	O
hybridization	O
are	O
presence	O
of	O
granules	O
or	O
masses	O
in	O
the	O
cytoplasm	O
;	O
(	O
ii	O
)	O
the	O
less	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
,	O
the	O
higher	O
metastatic	O
rate	O
of	O
the	O
human	O
hepatocellular	O
carcinoma	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
(	O
iii	O
)	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
dose	O
not	O
correlate	O
with	O
some	O
other	O
factors	O
such	O
as	O
tumor	O
size	O
and	O
the	O
background	O
of	O
other	O
liver	O
diseases	O
.	O

Monitoring	O
the	O
efficiency	O
of	O
interferon	O
-	O
alpha	O
therapy	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
patients	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
.	O

Interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
induces	O
cytogenetic	O
responses	O
of	O
variable	O
degree	O
in	O
patients	O
with	O
CML	O
.	O

We	O
sought	O
to	O
establish	O
the	O
relationship	O
between	O
BCR	O
-	O
ABL	O
transcript	O
numbers	O
measured	O
by	O
competitive	O
two	O
-	O
step	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cytogenetic	O
status	O
in	O
CML	O
patients	O
treated	O
with	O
IFN	O
-	O
alpha	O
.	O

All	O
398	O
samples	O
from	O
163	O
patients	O
investigated	O
by	O
RT	O
-	O
PCR	O
were	O
positive	O
for	O
BCR	O
-	O
ABL	O
transcripts	O
.	O

In	O
order	O
to	O
standardize	O
results	O
for	O
variability	O
in	O
RNA	O
and	O
cDNA	O
quality	O
,	O
we	O
quantified	O
total	O
ABL	O
transcripts	O
in	O
each	O
sample	O
as	O
internal	O
control	O
.	O

The	O
BCR	O
-	O
ABL	O
/	O
ABL	O
ratios	O
correlated	O
with	O
the	O
cytogenetic	O
results	O
.	O

Quantitative	O
nested	O
PCR	O
allowed	O
the	O
detection	O
of	O
residual	O
BCR	O
-	O
ABL	O
transcripts	O
in	O
all	O
complete	O
cytogenetic	O
responders	O
on	O
IFN	O
-	O
alpha	O
.	O

We	O
conclude	O
that	O
competitive	O
PCR	O
with	O
internal	O
controls	O
is	O
a	O
reliable	O
method	O
for	O
monitoring	O
patients	O
on	O
IFN	O
-	O
alpha	O
and	O
reduces	O
the	O
need	O
for	O
repeated	O
marrow	O
investigations	O
.	O

Suppression	O
of	O
tumor	O
growth	O
by	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
mel	O
-	O
18	O
in	O
3Y1	B
cells	O
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
.	O

By	O
introducing	O
a	O
cDNA	O
library	O
derived	O
from	O
rat	O
embryonic	O
fibroblast	O
cells	O
,	O
we	O
isolated	O
several	O
morphologically	O
flat	O
revertants	O
of	O
rat	O
3Y1	B
cells	O
transformed	O
by	O
the	O
E6	O
and	O
E7	O
genes	O
of	O
human	O
papillomavirus	O
type	O
18	O
(	O
HPV18	O
)	O
.	O

From	O
one	O
of	O
the	O
revertants	O
,	O
we	O
recovered	O
a	O
0	O
.	O
2	O
-	O
kb	O
cDNA	O
,	O
N56	O
,	O
that	O
suppresses	O
the	O
tumor	O
growth	O
of	O
the	O
transformed	O
3Y1	B
cells	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
E6	O
and	O
E7	O
genes	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
cDNA	O
was	O
shown	O
to	O
be	O
identical	O
to	O
that	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
a	O
putative	O
mammalian	O
polycomb	O
group	O
gene	O
,	O
mel	O
-	O
18	O
.	O

[	O
Treatment	O
of	O
acute	O
liver	O
failure	O
in	O
children	O
]	O
.	O

Among	O
the	O
main	O
causes	O
of	O
acute	O
liver	O
failure	O
(	O
ALF	O
)	O
in	O
children	O
,	O
metabolic	O
diseases	O
(	O
especially	O
in	O
infants	O
)	O
,	O
viral	O
and	O
toxin	O
or	O
drug	O
induced	O
hepatitis	O
are	O
the	O
most	O
frequent	O
.	O

The	O
cause	O
remains	O
,	O
however	O
,	O
undetermined	O
in	O
about	O
30	O
%	O
of	O
the	O
cases	O
.	O

Management	O
must	O
be	O
conducted	O
in	O
a	O
pediatric	O
hepatology	O
unit	O
or	O
intensive	O
care	O
unit	O
in	O
relation	O
with	O
a	O
pediatric	O
transplant	O
team	O
in	O
order	O
:	O
1	O
)	O
to	O
perform	O
urgent	O
etiological	O
diagnosis	O
;	O
2	O
)	O
to	O
initiate	O
specific	O
therapy	O
and	O
symptomatic	O
treatment	O
;	O
3	O
)	O
to	O
evaluate	O
the	O
severity	O
and	O
prognosis	O
of	O
liver	O
disease	O
for	O
selection	O
of	O
children	O
for	O
emergency	O
liver	O
transplantation	O
;	O
4	O
)	O
to	O
evaluate	O
contraindications	O
to	O
liver	O
transplantation	O
.	O

The	O
overall	O
survival	O
of	O
post	O
-	O
emergency	O
liver	O
transplantation	O
for	O
ALF	O
in	O
children	O
averages	O
65	O
%	O
.	O

Blind	O
separation	O
of	O
auditory	O
event	O
-	O
related	O
brain	O
responses	O
into	O
independent	O
components	O
.	O

Averaged	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
data	O
recorded	O
from	O
the	O
human	O
scalp	O
reveal	O
electroencephalographic	O
(	O
EEG	O
)	O
activity	O
that	O
is	O
reliably	O
time	O
-	O
locked	O
and	O
phase	O
-	O
locked	O
to	O
experimental	O
events	O
.	O

We	O
report	O
here	O
the	O
application	O
of	O
a	O
method	O
based	O
on	O
information	O
theory	O
that	O
decomposes	O
one	O
or	O
more	O
ERPs	O
recorded	O
at	O
multiple	O
scalp	O
sensors	O
into	O
a	O
sum	O
of	O
components	O
with	O
fixed	O
scalp	O
distributions	O
and	O
sparsely	O
activated	O
,	O
maximally	O
independent	O
time	O
courses	O
.	O

Independent	O
component	O
analysis	O
(	O
ICA	O
)	O
decomposes	O
ERP	O
data	O
into	O
a	O
number	O
of	O
components	O
equal	O
to	O
the	O
number	O
of	O
sensors	O
.	O

The	O
derived	O
components	O
have	O
distinct	O
but	O
not	O
necessarily	O
orthogonal	O
scalp	O
projections	O
.	O

Unlike	O
dipole	O
-	O
fitting	O
methods	O
,	O
the	O
algorithm	O
does	O
not	O
model	O
the	O
locations	O
of	O
their	O
generators	O
in	O
the	O
head	O
.	O

Unlike	O
methods	O
that	O
remove	O
second	O
-	O
order	O
correlations	O
,	O
such	O
as	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
ICA	O
also	O
minimizes	O
higher	O
-	O
order	O
dependencies	O
.	O

Applied	O
to	O
detected	O
-	O
and	O
undetected	O
-	O
target	O
ERPs	O
from	O
an	O
auditory	O
vigilance	O
experiment	O
,	O
the	O
algorithm	O
derived	O
ten	O
components	O
that	O
decomposed	O
each	O
of	O
the	O
major	O
response	O
peaks	O
into	O
one	O
or	O
more	O
ICA	O
components	O
with	O
relatively	O
simple	O
scalp	O
distributions	O
.	O

Three	O
of	O
these	O
components	O
were	O
active	O
only	O
when	O
the	O
subject	O
detected	O
the	O
targets	O
,	O
three	O
other	O
components	O
only	O
when	O
the	O
target	O
went	O
undetected	O
,	O
and	O
one	O
in	O
both	O
cases	O
.	O

Three	O
additional	O
components	O
accounted	O
for	O
the	O
steady	O
-	O
state	O
brain	O
response	O
to	O
a	O
39	O
-	O
Hz	O
background	O
click	O
train	O
.	O

Major	O
features	O
of	O
the	O
decomposition	O
proved	O
robust	O
across	O
sessions	O
and	O
changes	O
in	O
sensor	O
number	O
and	O
placement	O
.	O

This	O
method	O
of	O
ERP	O
analysis	O
can	O
be	O
used	O
to	O
compare	O
responses	O
from	O
multiple	O
stimuli	O
,	O
task	O
conditions	O
,	O
and	O
subject	O
states	O
.	O

CD56	O
+	O
putative	O
natural	O
killer	O
cell	O
lymphomas	O
:	O
production	O
of	O
cytolytic	O
effectors	O
and	O
related	O
proteins	O
mediating	O
tumor	O
cell	O
apoptosis	O
?	O

Apoptosis	O
is	O
a	O
regulated	O
form	O
of	O
cell	O
death	O
that	O
may	O
be	O
triggered	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
or	O
cytotoxic	O
T	O
cells	O
,	O
which	O
effect	O
target	O
cell	O
lysis	O
by	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
through	O
complex	O
intracellular	O
signals	O
.	O

This	O
study	O
was	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
selective	O
expression	O
of	O
these	O
cytolytic	O
markers	O
in	O
the	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
and	O
whether	O
there	O
is	O
correlation	O
with	O
zonal	O
tumor	O
cell	O
death	O
in	O
these	O
tumors	O
.	O

Expression	O
of	O
the	O
cytolytic	O
effectors	O
perforin	O
,	O
granzyme	O
B9	O
,	O
and	O
the	O
granule	O
membrane	O
protein	O
TIA1	O
were	O
examined	O
in	O
24	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
,	O
18	O
postthymic	O
T	O
-	O
cell	O
lymphomas	O
(	O
one	O
case	O
CD8	O
+	O
CD56	O
+	O
and	O
three	O
anaplastic	O
large	O
cell	O
lymphomas	O
(	O
ALCL	O
)	O
,	O
three	O
T	O
-	O
lymphoblastic	O
lymphomas	O
,	O
and	O
20	O
B	O
-	O
cell	O
lymphomas	O
.	O

Nineteen	O
(	O
79	O
%	O
)	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
expressed	O
perforin	O
,	O
and	O
all	O
24	O
cases	O
expressed	O
granzyme	O
B9	O
and	O
TIA1	O
.	O

The	O
only	O
CD8	O
+	O
CD56	O
+	O
postthymic	O
T	O
-	O
cell	O
lymphoma	O
also	O
expressed	O
all	O
three	O
cytolytic	O
markers	O
,	O
two	O
CD8	O
-	O
ALCL	O
expressed	O
TIA1	O
;	O
other	O
postthymic	O
T	O
-	O
cell	O
,	O
T	O
-	O
lymphoblastic	O
,	O
and	O
B	O
-	O
cell	O
lymphomas	O
were	O
consistently	O
negative	O
.	O

There	O
was	O
strong	O
correlation	O
between	O
percentage	O
perforin	O
-	O
positive	O
cells	O
and	O
zonal	O
tumor	O
cell	O
death	O
.	O

Angioinvasion	O
,	O
in	O
contrast	O
,	O
was	O
present	O
only	O
in	O
a	O
proportion	O
(	O
37	O
%	O
)	O
of	O
these	O
lymphomas	O
despite	O
the	O
frequent	O
presence	O
of	O
zonal	O
tumor	O
cell	O
death	O
(	O
71	O
%	O
)	O
.	O

We	O
propose	O
that	O
cytolytic	O
effector	O
and	O
related	O
proteins	O
produced	O
by	O
putative	O
NK	O
and	O
some	O
CD8	O
+	O
CD56	O
+	O
postthymic	O
T	O
-	O
cell	O
lymphomas	O
,	O
probably	O
in	O
conjunction	O
with	O
other	O
mechanisms	O
,	O
may	O
effect	O
massive	O
tumor	O
cell	O
apoptosis	O
.	O

The	O
frequent	O
expression	O
of	O
cytolytic	O
effector	O
markers	O
in	O
the	O
CD2	O
+	O
surface	O
CD3	O
-	O
CD56	O
+	O
putative	O
NK	O
-	O
cell	O
lymphomas	O
lends	O
further	O
support	O
to	O
their	O
probable	O
NK	O
cell	O
origin	O
.	O

Calretinin	O
.	O

A	O
selective	O
marker	O
of	O
normal	O
and	O
neoplastic	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O

OBJECTIVE	O
:	O
To	O
document	O
that	O
a	O
polyclonal	O
antiserum	O
to	O
calretinin	O
,	O
a	O
29	O
-	O
kd	O
calcium	O
-	O
binding	O
protein	O
,	O
consistently	O
decorates	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
cytologic	O
preparations	O
.	O

STUDY	O
DESIGN	O
:	O
Thirty	O
-	O
three	O
archival	O
cytologic	O
specimens	O
from	O
eight	O
patients	O
with	O
histologically	O
confirmed	O
malignant	O
mesothelioma	O
and	O
13	O
from	O
patients	O
with	O
metastatic	O
serous	O
effusions	O
were	O
destained	O
and	O
then	O
immunostained	O
with	O
anticalretinin	O
antiserum	O
.	O

For	O
investigation	O
of	O
cell	O
suspensions	O
,	O
four	O
pleural	O
fluids	O
were	O
incubated	O
with	O
anticalretinin	O
antiserum	O
.	O

After	O
cytocentrifugation	O
the	O
specimens	O
were	O
stained	O
in	O
accordance	O
with	O
the	O
alkaline	O
phosphatase	O
anti	O
-	O
alkaline	O
phosphatase	O
(	O
APAAP	O
)	O
method	O
.	O

For	O
electron	O
microscopic	O
examination	O
the	O
cell	O
suspensions	O
were	O
then	O
incubated	O
with	O
gold	O
-	O
labeled	O
antirabbit	O
antibody	O
.	O

RESULTS	O
:	O
The	O
diagnostic	O
sensitivity	O
of	O
this	O
new	O
immunocytochemical	O
approach	O
reached	O
100	O
%	O
for	O
the	O
eight	O
malignant	O
mesotheliomas	O
investigated	O
.	O

Only	O
3	O
of	O
the	O
13	O
adenocarcinomas	O
metastatic	O
to	O
the	O
serous	O
membranes	O
included	O
in	O
this	O
study	O
were	O
weakly	O
reactive	O
,	O
accounting	O
for	O
81	O
%	O
specificity	O
.	O

Binding	O
of	O
anticalretinin	O
antiserum	O
to	O
living	O
mesothelial	O
cells	O
was	O
consistently	O
documented	O
in	O
all	O
four	O
cases	O
investigated	O
.	O

CONCLUSION	O
:	O
Calretinin	O
is	O
a	O
very	O
useful	O
marker	O
for	O
positive	O
identification	O
of	O
normal	O
and	O
tumor	O
mesothelial	O
cells	O
in	O
serous	O
effusions	O
.	O

[	O
Extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	O
aorta	O
to	O
the	O
supraceliac	O
abdominal	O
aorta	O
-	O
-	O
surgical	O
option	O
applied	O
to	O
reoperation	O
for	O
aortic	O
coarctation	O
or	O
interruption	O
]	O
.	O

The	O
optimal	O
approach	O
for	O
reoperation	O
following	O
repair	O
of	O
aortic	O
coarctation	O
(	O
CoA	O
)	O
or	O
interruption	O
(	O
IAA	O
)	O
remains	O
controversial	O
.	O

Four	O
patients	O
underwent	O
extra	O
-	O
anatomic	O
bypass	O
for	O
restenosis	O
after	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O

The	O
age	O
ranged	O
from	O
4	O
to	O
12	O
years	O
.	O

The	O
initial	O
repairs	O
for	O
two	O
CoA	O
,	O
one	O
type	O
A	O
-	O
IAA	O
,	O
and	O
one	O
type	O
B	O
-	O
IAA	O
consisted	O
of	O
two	O
grafting	O
,	O
one	O
subclavian	O
arterial	O
turning	O
-	O
down	O
aortoplasty	O
,	O
and	O
one	O
subclavian	O
flap	O
aortoplasty	O
.	O

All	O
of	O
them	O
underwent	O
during	O
infancy	O
.	O

Preoperative	O
right	O
arm	O
systolic	O
pressure	O
ranged	O
from	O
140	O
to	O
190	O
mmHg	O
ar	O
rest	O
.	O

Through	O
a	O
midline	O
sternotomy	O
and	O
an	O
upper	O
laparotmy	O
incision	O
,	O
an	O
extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	O
aorta	O
to	O
the	O
supraceliac	O
abdominal	O
aorta	O
was	O
employed	O
using	O
a	O
12	O
to	O
18	O
mm	O
tube	O
graft	O
.	O

All	O
patients	O
survived	O
surgeries	O
,	O
and	O
their	O
hypertension	O
markedly	O
improved	O
.	O

Our	O
experience	O
confirms	O
safety	O
and	O
effectiveness	O
of	O
this	O
option	O
in	O
selected	O
young	O
patients	O
with	O
re	O
-	O
stenosis	O
of	O
following	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O

Effect	O
of	O
a	O
mutation	O
in	O
the	O
anticodon	O
of	O
human	O
mitochondrial	O
tRNAPro	O
on	O
its	O
post	O
-	O
transcriptional	O
modification	O
pattern	O
.	O

Although	O
the	O
gene	O
sequences	O
of	O
all	O
22	O
tRNAs	O
encoded	O
in	O
the	O
human	O
mitochondrial	O
genome	O
are	O
known	O
,	O
little	O
information	O
exists	O
about	O
their	O
sequences	O
at	O
the	O
RNA	O
level	O
.	O

This	O
becomes	O
a	O
crucial	O
limitation	O
when	O
searching	O
for	O
a	O
molecular	O
understanding	O
of	O
the	O
growing	O
number	O
of	O
maternally	O
inherited	O
human	O
diseases	O
correlated	O
with	O
point	O
mutations	O
in	O
tRNA	O
genes	O
.	O

Here	O
we	O
describe	O
the	O
sequence	O
of	O
human	O
mt	O
-	O
tRNAPropurified	O
from	O
placenta	O
.	O

It	O
shows	O
absence	O
of	O
editing	O
events	O
in	O
this	O
tRNA	O
and	O
highlights	O
the	O
presence	O
of	O
eight	O
post	O
-	O
transcriptional	O
modifications	O
.	O

These	O
include	O
T54	O
,	O
never	O
found	O
so	O
far	O
in	O
an	O
animal	O
mt	O
-	O
tRNA	O
,	O
and	O
m1G37	O
,	O
a	O
modification	O
known	O
to	O
have	O
fundamental	O
functional	O
properties	O
in	O
a	O
number	O
of	O
canonical	O
tRNAs	O
.	O

Occurrence	O
of	O
m1G37	O
was	O
further	O
investigated	O
in	O
an	O
analysis	O
of	O
the	O
substrate	O
properties	O
of	O
in	O
vitro	O
transcripts	O
of	O
human	O
mt	O
-	O
tRNAProtowards	O
pure	O
Escherichia	O
coli	O
methylguanosine	O
transferase	O
.	O

This	O
enzyme	O
properly	O
methylates	O
G37	O
in	O
mt	O
-	O
tRNA	O
and	O
is	O
sensitive	O
to	O
the	O
presence	O
of	O
a	O
second	O
G	O
at	O
position	O
36	O
,	O
neighboring	O
the	O
target	O
nucleotide	O
for	O
methylation	O
.	O

Since	O
mutation	O
of	O
nt	O
36	O
was	O
shown	O
to	O
be	O
correlated	O
with	O
myopathy	O
,	O
the	O
potential	O
consequences	O
of	O
non	O
-	O
modification	O
or	O
under	O
-	O
modification	O
of	O
mt	O
-	O
tRNA	O
nucleotides	O
in	O
expression	O
of	O
the	O
particular	O
myopathy	O
and	O
of	O
mitochondrial	O
diseases	O
in	O
general	O
are	O
discussed	O
.	O

Prognostic	O
value	O
of	O
HLA	O
-	O
DR	O
expression	O
and	O
dendritic	O
cell	O
infiltration	O
in	O
gastric	O
cancer	O
.	O

We	O
attempted	O
to	O
correlate	O
the	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
DR	O
(	O
HLA	O
-	O
DR	O
)	O
and	O
tumor	O
infiltration	O
by	O
S	O
-	O
100	O
-	O
protein	O
-	O
positive	O
dendritic	O
cells	O
with	O
clinicopathologic	O
features	O
in	O
165	O
patients	O
with	O
gastric	O
cancer	O
.	O

The	O
expression	O
of	O
HLA	O
-	O
DR	O
was	O
correlated	O
with	O
the	O
histologic	O
type	O
.	O

Infiltration	O
of	O
dendritic	O
cells	O
correlated	O
negatively	O
with	O
distant	O
lymph	O
node	O
metastases	O
,	O
clinical	O
stage	O
,	O
and	O
peritoneal	O
invasion	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
expression	O
of	O
HLA	O
-	O
DR	O
and	O
infiltration	O
by	O
dendritic	O
cells	O
.	O

In	O
patients	O
with	O
resectable	O
gastric	O
cancer	O
,	O
the	O
grade	O
of	O
infiltrating	O
dendritic	O
cells	O
may	O
be	O
a	O
suitable	O
predictor	O
of	O
prognosis	O
.	O

Integrin	O
alphavbeta3	O
requirement	O
for	O
sustained	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activity	O
during	O
angiogenesis	O
.	O

Angiogenesis	O
depends	O
on	O
growth	O
factors	O
and	O
vascular	O
cell	O
adhesion	O
events	O
.	O

Integrins	O
and	O
growth	O
factors	O
are	O
capable	O
of	O
activating	O
the	O
ras	O
/	O
MAP	O
kinase	O
pathway	O
in	O
vitro	O
,	O
yet	O
how	O
these	O
signals	O
influence	O
endothelial	O
cells	O
during	O
angiogenesis	O
is	O
unknown	O
.	O

Upon	O
initiation	O
of	O
angiogenesis	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
on	O
the	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
,	O
endothelial	O
cell	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
(	O
ERK	O
)	O
activity	O
was	O
detected	O
as	O
early	O
as	O
5	O
min	O
yet	O
was	O
sustained	O
for	O
at	O
least	O
20	O
h	O
.	O

The	O
initial	O
wave	O
of	O
ERK	O
activity	O
(	O
5	O
-	O
120	O
min	O
)	O
was	O
refractory	O
to	O
integrin	O
antagonists	O
,	O
whereas	O
the	O
sustained	O
activity	O
(	O
4	O
-	O
20	O
h	O
)	O
depended	O
on	O
integrin	O
alphavbeta3	O
,	O
but	O
not	O
beta1	O
integrins	O
.	O

Inhibition	O
of	O
MAP	O
kinase	O
kinase	O
(	O
MEK	O
)	O
during	O
this	O
sustained	O
alphavbeta3	O
-	O
dependent	O
ERK	O
signal	O
blocked	O
the	O
formation	O
of	O
new	O
blood	O
vessels	O
while	O
not	O
influencing	O
preexisting	O
blood	O
vessels	O
on	O
the	O
CAM	O
.	O

Inhibition	O
of	O
MEK	O
also	O
blocked	O
growth	O
factor	O
induced	O
migration	O
but	O
not	O
adhesion	O
of	O
endothelial	O
cells	O
in	O
vitro	O
.	O

Therefore	O
,	O
angiogenesis	O
depends	O
on	O
sustained	O
ERK	O
activity	O
regulated	O
by	O
the	O
ligation	O
state	O
of	O
both	O
a	O
growth	O
factor	O
receptor	O
and	O
integrin	O
alphavbeta3	O
.	O

Conservative	O
treatment	O
of	O
endometriosis	O
:	O
the	O
effects	O
of	O
limited	O
surgery	O
and	O
hormonal	O
pseudopregnancy	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
limited	O
surgery	O
or	O
hormonal	O
pseudopregnancy	O
,	O
or	O
a	O
combination	O
of	O
these	O
two	O
,	O
upon	O
fertility	O
and	O
the	O
need	O
for	O
subsequent	O
surgery	O
with	O
respect	O
to	O
the	O
extent	O
of	O
the	O
disease	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
in	O
patients	O
with	O
endometriosis	O
externa	O
.	O

Of	O
the	O
61	O
patients	O
who	O
desired	O
to	O
enhance	O
or	O
preserve	O
reproductive	O
capacity	O
,	O
20	O
patients	O
became	O
pregnant	O
,	O
for	O
a	O
pregnancy	O
rate	O
of	O
33	O
%	O
.	O

The	O
pregnancy	O
rate	O
in	O
all	O
categories	O
,	O
that	O
is	O
,	O
those	O
patients	O
treated	O
with	O
pseudopregnancy	O
,	O
conservative	O
surgery	O
,	O
and	O
combined	O
pseudopregnancy	O
and	O
surgery	O
,	O
was	O
found	O
to	O
be	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
.	O

In	O
such	O
patients	O
,	O
conservative	O
surgery	O
alone	O
seemed	O
to	O
give	O
the	O
best	O
results	O
in	O
the	O
achievement	O
of	O
pregnancy	O
.	O

There	O
seemed	O
to	O
be	O
little	O
difference	O
between	O
pseudopregnancy	O
alone	O
and	O
conservative	O
surgery	O
in	O
regard	O
to	O
the	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
,	O
although	O
there	O
seemed	O
to	O
be	O
a	O
significantly	O
greater	O
chance	O
for	O
the	O
need	O
for	O
subsequent	O
surgery	O
in	O
patients	O
receiving	O
a	O
combination	O
of	O
the	O
two	O
forms	O
of	O
therapy	O
.	O

The	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
in	O
80	O
patients	O
increased	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
present	O
,	O
despite	O
the	O
form	O
of	O
therapy	O
used	O
.	O

Fifty	O
-	O
nine	O
other	O
patients	O
with	O
endometriosis	O
,	O
who	O
did	O
not	O
desire	O
to	O
preserve	O
fertility	O
and	O
presented	O
for	O
relief	O
of	O
other	O
symptoms	O
,	O
underwent	O
initial	O
""""	O
radical	O
""""	O
therapy	O
.	O

Forty	O
-	O
six	O
patients	O
underwent	O
complete	O
operation	O
,	O
including	O
removal	O
of	O
uterus	O
,	O
tubes	O
and	O
ovaries	O
,	O
and	O
none	O
required	O
subsequent	O
reoperation	O
.	O

Of	O
the	O
13	O
remaining	O
patients	O
,	O
who	O
underwent	O
incomplete	O
surgical	O
removal	O
,	O
leaving	O
one	O
or	O
both	O
ovaries	O
in	O
situ	O
,	O
11	O
required	O
subsequent	O
reoperation	O
for	O
recurrent	O
pelvic	O
endometriosis	O
.	O

Clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
in	O
a	O
patient	O
with	O
dopaminergic	O
psychosis	O
.	O

In	O
patients	O
with	O
Parkinson	O
'	O
disease	O
and	O
dopaminergic	O
psychosis	O
,	O
clozapine	O
treatment	O
is	O
recommended	O
as	O
the	O
drug	O
is	O
free	O
from	O
extrapyramidal	O
side	O
effects	O
and	O
does	O
not	O
worsen	O
motor	O
symptoms	O
of	O
the	O
underlying	O
disease	O
.	O

The	O
use	O
of	O
clozapine	O
,	O
however	O
,	O
is	O
limited	O
due	O
to	O
its	O
hematotoxic	O
side	O
effects	O
.	O

For	O
treatment	O
of	O
clozapine	O
-	O
induced	O
agranulocytosis	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factors	O
(	O
G	O
-	O
CSF	O
)	O
are	O
recommended	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
72	O
-	O
years	O
-	O
old	O
male	O
patient	O
with	O
clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
.	O

Neutropenia	O
was	O
successfully	O
treated	O
with	O
G	O
-	O
CSF	O
,	O
but	O
thrombopenia	O
persisted	O
and	O
resolved	O
spontaneously	O
after	O
14	O
days	O
.	O

Bone	O
marrow	O
toxicity	O
of	O
clozapine	O
is	O
not	O
restricted	O
to	O
white	O
cell	O
maturation	O
,	O
but	O
may	O
also	O
impair	O
thrombocytopoesis	O
.	O

Basic	O
fibroblast	O
growth	O
factor	O
:	O
a	O
missing	O
link	O
between	O
collagen	O
VII	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
in	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(	O
RDEB	O
)	O
have	O
deficiencies	O
of	O
collagen	O
type	O
VII	O
and	O
have	O
elevated	O
levels	O
of	O
fibroblast	O
collagenase	O
,	O
and	O
a	O
greatly	O
increased	O
risk	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
.	O

Patients	O
with	O
other	O
genetic	O
blistering	O
disorders	O
do	O
not	O
have	O
elevated	O
collagenase	O
or	O
an	O
increased	O
risk	O
of	O
squamous	O
cell	O
carcinoma	O
,	O
despite	O
chronic	O
wounding	O
.	O

The	O
connection	O
between	O
collagen	O
type	O
VII	O
deficiency	O
,	O
increased	O
collagenase	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
is	O
not	O
understood	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Urine	O
from	O
81	O
patients	O
with	O
RDEB	O
(	O
39	O
patients	O
)	O
,	O
junctional	O
epidermolysis	O
bullosa	O
(	O
JEB	O
;	O
12	O
patients	O
)	O
,	O
and	O
epidermolysis	O
bullosa	O
simplex	O
(	O
EBS	O
;	O
30	O
patients	O
)	O
,	O
as	O
well	O
as	O
unaffected	O
family	O
members	O
of	O
RDEB	O
patients	O
(	O
33	O
patients	O
)	O
,	O
was	O
tested	O
for	O
the	O
presence	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
using	O
a	O
sensitive	O
radioimmunoassay	O
.	O

These	O
patients	O
included	O
many	O
who	O
were	O
enrolled	O
in	O
the	O
Epidermolysis	O
Bullosa	O
Registry	O
and	O
others	O
who	O
were	O
referred	O
by	O
their	O
physicians	O
.	O

RESULTS	O
:	O
Fifty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
RDEB	O
had	O
elevated	O
levels	O
(	O
greater	O
than	O
5000	O
pg	O
/	O
g	O
)	O
of	O
urinary	O
bFGF	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
patients	O
with	O
JEB	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
clinically	O
unaffected	O
family	O
members	O
had	O
elevated	O
levels	O
of	O
bFGF	O
,	O
and	O
13	O
%	O
of	O
patients	O
with	O
EBS	O
had	O
elevated	O
levels	O
of	O
bFGF	O
.	O

The	O
frequency	O
of	O
elevated	O
bFGF	O
values	O
among	O
all	O
groups	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
and	O
the	O
levels	O
of	O
bFGF	O
in	O
RDEB	O
patients	O
were	O
significantly	O
elevated	O
compared	O
with	O
those	O
of	O
other	O
groups	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
found	O
that	O
patients	O
with	O
RDEB	O
have	O
elevated	O
levels	O
of	O
bFGF	O
,	O
which	O
may	O
contribute	O
to	O
increased	O
fibroblast	O
collagenase	O
and	O
the	O
development	O
of	O
squamous	O
cell	O
carcinoma	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
treatment	O
for	O
RDEB	O
,	O
namely	O
,	O
angiogenesis	O
inhibitors	O
,	O
which	O
may	O
antagonize	O
the	O
effects	O
of	O
bFGF	O
in	O
this	O
disorder	O
.	O

There	O
are	O
currently	O
no	O
other	O
means	O
of	O
treatment	O
for	O
this	O
disorder	O
,	O
which	O
has	O
a	O
high	O
morbidity	O
and	O
mortality	O
rate	O
.	O

Multiple	O
phosphotyrosine	O
phosphatase	O
mRNAs	O
are	O
expressed	O
in	O
the	O
human	O
lung	O
fibroblast	O
cell	O
line	O
WI	B
-	I
38	I
.	O

Protein	O
tyrosine	O
phosphatases	O
are	O
important	O
components	O
of	O
signal	O
transduction	O
pathways	O
.	O

The	O
authors	O
have	O
used	O
reverse	O
transcription	O
/	O
polymerase	O
chain	O
reactions	O
to	O
accomplish	O
a	O
comprehensive	O
examination	O
of	O
the	O
RNA	O
expression	O
for	O
58	O
distinct	O
mammalian	O
protein	O
tyrosine	O
and	O
dual	O
specificity	O
phosphatase	O
(	O
PTPase	O
)	O
and	O
PTPase	O
-	O
like	O
genes	O
in	O
the	O
normal	O
human	O
diploid	O
fibroblast	O
cell	O
line	O
WI	B
-	I
38	I
.	O

Thirty	O
-	O
seven	O
of	O
these	O
PTPase	O
genes	O
express	O
easily	O
measurable	O
RNA	O
,	O
and	O
four	O
simultaneously	O
express	O
the	O
RNA	O
for	O
two	O
or	O
more	O
isoforms	O
.	O

Messages	O
for	O
an	O
additional	O
eight	O
PTPase	O
genes	O
are	O
detectable	O
at	O
low	O
levels	O
.	O

Only	O
14	O
known	O
PTPase	O
genes	O
do	O
not	O
express	O
measurable	O
RNA	O
under	O
our	O
conditions	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
the	O
authors	O
also	O
assessed	O
the	O
PTPases	O
expressed	O
in	O
the	O
WI	B
-	I
38	I
cell	O
line	O
using	O
highly	O
degenerate	O
primers	O
to	O
conserved	O
motifs	O
found	O
in	O
the	O
classical	O
tyrosine	O
-	O
specific	O
PTPases	O
.	O

Only	O
eight	O
of	O
the	O
22	O
classic	O
tyrosine	O
-	O
specific	O
PTPases	O
detected	O
using	O
the	O
specific	O
primers	O
were	O
detected	O
using	O
these	O
degenerate	O
primers	O
.	O

Our	O
panel	O
of	O
specific	O
PTPase	O
primers	O
should	O
be	O
very	O
useful	O
for	O
semiquantitatively	O
assessing	O
the	O
repertoire	O
of	O
PTPases	O
expressed	O
by	O
cells	O
.	O

Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
nonsmall	O
cell	O
lung	O
carcinoma	O
:	O
undifferentiated	O
""""	O
lymphoepithelioma	O
-	O
like	O
""""	O
carcinoma	O
as	O
a	O
distinct	O
entity	O
with	O
better	O
prognosis	O
.	O

BACKGROUND	O
:	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
in	O
nonsmall	O
cell	O
lung	O
carcinoma	O
(	O
NSCLC	O
)	O
has	O
been	O
demonstrated	O
in	O
some	O
ethnic	O
groups	O
.	O

The	O
pathobiology	O
and	O
the	O
role	O
of	O
EBV	O
and	O
oncoprotein	O
expression	O
in	O
these	O
tumors	O
have	O
not	O
been	O
studied	O
extensively	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
investigated	O
EBV	O
-	O
encoded	O
RNA	O
-	O
1	O
(	O
EBER1	O
)	O
transcripts	O
by	O
in	O
situ	O
hybridization	O
and	O
the	O
expression	O
of	O
latent	O
membrane	O
protein	O
-	O
1	O
(	O
LMP	O
-	O
1	O
)	O
and	O
bcl	O
-	O
2	O
protein	O
by	O
immunohistochemistry	O
in	O
NSCLC	O
patients	O
from	O
Taiwan	O
,	O
where	O
nasopharyngeal	O
carcinoma	O
is	O
endemic	O
.	O

METHODS	O
:	O

A	O
total	O
of	O
127	O
cases	O
of	O
NSCLC	O
(	O
43	O
cases	O
of	O
squamous	O
cell	O
carcinoma	O
[	O
SCC	O
]	O
,	O
67	O
cases	O
of	O
adenocarcinoma	O
[	O
AD	O
]	O
,	O
12	O
cases	O
of	O
large	O
cell	O
carcinoma	O
[	O
LCC	O
]	O
,	O
and	O
5	O
cases	O
of	O
lymphoepithelioma	O
-	O
like	O
carcinoma	O
[	O
LE	O
]	O
)	O
were	O
included	O
.	O

A	O
sensitive	O
polymerase	O
chain	O
reaction	O
-	O
derived	O
,	O
digoxigenin	O
-	O
labeled	O
DNA	O
probe	O
for	O
in	O
situ	O
detection	O
of	O
EBER1	O
transcripts	O
was	O
performed	O
for	O
the	O
detection	O
of	O
EBV	O
.	O

Immunohistochemistry	O
using	O
the	O
avidin	O
-	O
biotin	O
-	O
immunoperoxidase	O
method	O
was	O
also	O
performed	O
to	O
evaluate	O
the	O
expression	O
of	O
bcl	O
-	O
2	O
and	O
LMP	O
-	O
1	O
.	O

RESULTS	O
:	O

EBER1	O
was	O
detected	O
in	O
11	O
of	O
the	O
127	O
NSCLC	O
cases	O
(	O
8	O
.	O
7	O
%	O
;	O
6	O
SCC	O
cases	O
and	O
5	O
LE	O
cases	O
)	O
.	O

All	O
5	O
LE	O
cases	O
were	O
EBV	O
-	O
positive	O
,	O
whereas	O
only	O
6	O
of	O
the	O
43	O
SCC	O
cases	O
(	O
14	O
%	O
)	O
,	O
0	O
of	O
67	O
AD	O
cases	O
,	O
and	O
12	O
LCC	O
cases	O
were	O
EBV	O
-	O
positive	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

All	O
five	O
LE	O
cases	O
showed	O
diffuse	O
,	O
strong	O
,	O
positive	O
staining	O
of	O
tumor	O
cells	O
;	O
five	O
of	O
the	O
six	O
SCC	O
cases	O
showed	O
diffuse	O
but	O
weak	O
staining	O
.	O

Among	O
the	O
nontumor	O
epithelial	O
cells	O
,	O
there	O
was	O
no	O
EBER1	O
staining	O
of	O
any	O
of	O
the	O
11	O
EBER1	O
-	O
positive	O
cases	O
.	O

The	O
mean	O
age	O
of	O
the	O
LE	O
patients	O
was	O
10	O
years	O
younger	O
than	O
that	O
of	O
the	O
patients	O
with	O
other	O
histological	O
types	O
.	O

All	O
5	O
LE	O
patients	O
were	O
nonsmokers	O
,	O
whereas	O
3	O
of	O
the	O
6	O
patients	O
with	O
EBER1	O
-	O
positive	O
SCC	O
(	O
50	O
%	O
)	O
were	O
smokers	O
.	O

EBER1	O
expression	O
did	O
not	O
correlate	O
with	O
the	O
2	O
-	O
year	O
survival	O
rate	O
of	O
overall	O
cases	O
,	O
but	O
all	O
5	O
LE	O
patients	O
were	O
alive	O
without	O
clinical	O
evidence	O
of	O
disease	O
at	O
last	O
follow	O
-	O
up	O
.	O

Gender	O
,	O
lymph	O
node	O
or	O
distant	O
metastasis	O
,	O
and	O
clinical	O
stage	O
were	O
not	O
found	O
to	O
have	O
any	O
correlation	O
with	O
EBER1	O
expression	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

All	O
LE	O
cases	O
had	O
bcl	O
-	O
2	O
oncoprotein	O
expression	O
(	O
100	O
%	O
)	O
.	O

This	O
frequency	O
was	O
significantly	O
different	O
from	O
other	O
histologic	O
types	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
LMP	O
-	O
1	O
detection	O
rate	O
was	O
low	O
and	O
demonstrated	O
no	O
correlation	O
with	O
bcl	O
-	O
2	O
expression	O
.	O

CONCLUSIONS	O
:	O

In	O
this	O
study	O
,	O
the	O
authors	O
found	O
that	O
the	O
primary	O
LE	O
of	O
the	O
lung	O
is	O
associated	O
with	O
young	O
age	O
,	O
a	O
history	O
of	O
not	O
smoking	O
,	O
high	O
bcl	O
-	O
2	O
immunoreactivity	O
,	O
and	O
better	O
survival	O
rate	O
.	O

These	O
characteristics	O
demonstrate	O
that	O
EBV	O
-	O
associated	O
LE	O
of	O
the	O
lung	O
is	O
a	O
unique	O
entity	O
.	O

The	O
findings	O
of	O
the	O
current	O
study	O
suggest	O
that	O
EBV	O
infection	O
may	O
play	O
a	O
different	O
role	O
in	O
the	O
tumorigenesis	O
of	O
primary	O
LE	O
of	O
the	O
lung	O
than	O
it	O
does	O
in	O
other	O
EBER1	O
-	O
positive	O
NSCLCs	O
.	O

Prophylactic	O
thyroidectomy	O
in	O
MEN	O
IIA	O
:	O
does	O
the	O
calcitonin	O
level	O
correlate	O
with	O
tumor	O
spread	O
?	O

BACKGROUND	O
:	O
The	O
fate	O
of	O
patients	O
with	O
multiple	O
endocrine	O
neoplasia	O
of	O
type	O
II	O
A	O
(	O
MEN	O
II	O
A	O
)	O
is	O
determined	O
by	O
medullary	O
thyroid	O
carcinoma	O
,	O
which	O
occurs	O
in	O
all	O
cases	O
.	O

This	O
has	O
led	O
to	O
the	O
therapeutic	O
concept	O
of	O
prophylactic	O
thyroidectomy	O
in	O
affected	O
family	O
members	O
with	O
the	O
goal	O
of	O
removing	O
the	O
thyroid	O
before	O
the	O
manifestation	O
of	O
carcinoma	O
.	O

We	O
investigated	O
a	O
prophylactically	O
thyroidectomized	O
MEN	O
II	O
A	O
population	O
to	O
determine	O
whether	O
the	O
highly	O
specific	O
and	O
sensitive	O
tumor	O
marker	O
calcitonin	O
correlates	O
with	O
tumor	O
spread	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Fifteen	O
patients	O
with	O
MEN	O
II	O
A	O
(	O
aged	O
4	O
-	O
24	O
years	O
)	O
who	O
had	O
undergone	O
prophylactic	O
thyroidectomy	O
since	O
1990	O
were	O
included	O
in	O
the	O
study	O
.	O

Baseline	O
and	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
were	O
preoperatively	O
determined	O
in	O
all	O
cases	O
.	O

The	O
indication	O
for	O
surgery	O
was	O
established	O
on	O
the	O
basis	O
of	O
pathologic	O
calcitonin	O
levels	O
in	O
the	O
first	O
seven	O
patients	O
and	O
on	O
the	O
basis	O
of	O
detected	O
RET	O
proto	O
-	O
oncogene	O
mutation	O
in	O
the	O
other	O
eight	O
patients	O
.	O

Bilateral	O
central	O
lymphadenectomy	O
was	O
performed	O
in	O
all	O
patients	O
in	O
addition	O
to	O
thyroidectomy	O
.	O

RESULTS	O
:	O
Histology	O
demonstrated	O
C	O
-	O
cell	O
hyperplasia	O
in	O
five	O
patients	O
(	O
aged	O
4	O
-	O
13	O
years	O
)	O
,	O
unilateral	O
medullary	O
microcarcinoma	O
in	O
six	O
(	O
aged	O
9	O
-	O
17	O
years	O
)	O
and	O
a	O
bilateral	O
medullary	O
microcarcinoma	O
in	O
three	O
cases	O
(	O
aged	O
17	O
-	O
24	O
years	O
)	O
.	O

One	O
9	O
-	O
year	O
-	O
old	O
boy	O
with	O
bilateral	O
microcarcinoma	O
already	O
had	O
a	O
lymph	O
node	O
metastasis	O
.	O

The	O
mean	O
baseline	O
calcitonin	O
level	O
correlated	O
with	O
the	O
histologic	O
findings	O
(	O
r	O
=	O
0	O
.	O
71	O
,	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
there	O
was	O
no	O
correlation	O
between	O
pentagastrin	O
-	O
stimulated	O
calcitonin	O
levels	O
and	O
histology	O
(	O
r	O
=	O
0	O
.	O
21	O
,	O
P	O
=	O
0	O
.	O
47	O
)	O
.	O

CONCLUSION	O
:	O
In	O
MEN	O
II	O
A	O
patients	O
undergoing	O
prophylactic	O
thyroidectomy	O
,	O
baseline	O
but	O
not	O
stimulated	O
calcitonin	O
levels	O
already	O
correlate	O
with	O
the	O
histologic	O
tumor	O
stage	O
at	O
the	O
stage	O
of	O
clinically	O
occult	O
C	O
-	O
cell	O
hyperplasia	O
or	O
medullary	O
microcarcinoma	O
.	O

However	O
,	O
biochemical	O
screening	O
can	O
not	O
reliably	O
discriminate	O
the	O
transition	O
from	O
C	O
-	O
cell	O
hyperplasia	O
to	O
invasive	O
microcarcinoma	O
.	O

Individuals	O
with	O
MEN	O
IIA	O
should	O
therefore	O
undergo	O
early	O
prophylactic	O
thyroidectomy	O
once	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
molecular	O
genetic	O
testing	O
.	O

Induction	O
of	O
Ets	O
-	O
1	O
in	O
endothelial	O
cells	O
during	O
reendothelialization	O
after	O
denuding	O
injury	O
.	O

Ets	O
-	O
1	O
,	O
a	O
transcription	O
factor	O
,	O
is	O
induced	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
during	O
angiogenesis	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Ets	O
-	O
1	O
during	O
reendothelialization	O
.	O

When	O
a	O
confluent	O
monolayer	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
line	O
,	O
ECV304	B
,	O
was	O
denuded	O
,	O
ECV304	B
at	O
the	O
wound	O
edge	O
expressed	O
Ets	O
-	O
1	O
.	O

An	O
immunohistochemical	O
analysis	O
revealed	O
that	O
Ets	O
-	O
1	O
accumulated	O
in	O
migrating	O
cells	O
at	O
the	O
wound	O
edge	O
and	O
returned	O
to	O
basal	O
level	O
when	O
reendothelialization	O
was	O
accomplished	O
.	O

This	O
induction	O
of	O
Ets	O
-	O
1	O
could	O
be	O
reproduced	O
in	O
in	O
vivo	O
denudation	O
of	O
rat	O
aortic	O
endothelium	O
by	O
a	O
balloon	O
catheter	O
.	O

The	O
induction	O
of	O
Ets	O
-	O
1	O
in	O
ECs	O
after	O
denudation	O
was	O
regulated	O
transcriptionally	O
,	O
and	O
humeral	O
factors	O
released	O
from	O
injured	O
ECs	O
might	O
not	O
be	O
responsible	O
.	O

Mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activities	O
were	O
investigated	O
to	O
explore	O
the	O
mechanism	O
of	O
this	O
induction	O
.	O

Although	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
1	O
(	O
JNK1	O
)	O
,	O
and	O
p38	O
were	O
activated	O
after	O
denudation	O
,	O
the	O
activation	O
of	O
ERK1	O
and	O
p38	O
was	O
more	O
rapid	O
and	O
prominent	O
.	O

PD98059	O
,	O
a	O
specific	O
MAPK	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
1	O
inhibitor	O
,	O
did	O
not	O
affect	O
the	O
induction	O
of	O
ets	O
-	O
1	O
mRNA	O
,	O
whereas	O
SB203580	O
,	O
a	O
specific	O
p38	O
inhibitor	O
,	O
almost	O
completely	O
abrogated	O
its	O
induction	O
.	O

These	O
results	O
indicate	O
that	O
Ets	O
-	O
1	O
is	O
induced	O
in	O
ECs	O
after	O
denudation	O
through	O
activation	O
of	O
p38	O
.	O

This	O
induction	O
of	O
Ets	O
-	O
1	O
may	O
be	O
relevant	O
for	O
reendothelialization	O
by	O
regulating	O
the	O
expression	O
of	O
certain	O
genes	O
.	O

SV40	O
Tag	O
transformation	O
of	O
the	O
normal	O
invasive	O
trophoblast	O
results	O
in	O
a	O
premalignant	O
phenotype	O
.	O

I	O
.	O

Mechanisms	O
responsible	O
for	O
hyperinvasiveness	O
and	O
resistance	O
to	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
.	O

Invasion	O
of	O
the	O
uterus	O
by	O
first	O
trimester	O
human	O
placental	O
extravillous	O
trophoblast	O
(	O
EVT	O
)	O
cells	O
depends	O
on	O
mechanisms	O
shared	O
by	O
malignant	O
cells	O
.	O

However	O
,	O
unlike	O
tumor	O
invasion	O
,	O
trophoblast	O
invasion	O
of	O
the	O
uterus	O
is	O
stringently	O
controlled	O
in	O
situ	O
by	O
local	O
molecules	O
such	O
as	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
beta	O
.	O

Since	O
EVT	O
cells	O
possess	O
active	O
invasion	O
-	O
associated	O
genes	O
but	O
are	O
nontumorigenic	O
,	O
our	O
objective	O
was	O
to	O
induce	O
premalignant	O
and	O
then	O
malignant	O
phenotype	O
into	O
a	O
normal	O
EVT	B
cell	O
line	O
in	O
order	O
to	O
identify	O
the	O
molecular	O
basis	O
of	O
tumor	O
progression	O
.	O

Simian	O
virus	O
40	O
large	O
T	O
antigen	O
(	O
SV40	O
Tag	O
)	O
was	O
introduced	O
into	O
a	O
normal	O
human	O
first	O
trimester	O
invasive	O
EVT	B
cell	O
line	O
,	O
HTR8	B
,	O
established	O
in	O
our	O
laboratory	O
.	O

Since	O
the	O
HTR8	B
line	O
has	O
a	O
limited	O
in	O
vitro	O
lifespan	O
of	O
12	O
-	O
15	O
passages	O
,	O
SV40	O
Tag	O
-	O
transformed	O
cells	O
were	O
selected	O
on	O
the	O
basis	O
of	O
extended	O
lifespan	O
.	O

A	O
long	O
-	O
lived	O
line	O
,	O
RSVT	B
-	I
2	I
,	O
was	O
produced	O
and	O
an	O
immortalized	O
subclone	O
,	O
RSVT2	B
/	I
C	I
,	O
was	O
further	O
derived	O
under	O
a	O
forced	O
crisis	O
regimen	O
.	O

We	O
examined	O
transformation	O
-	O
induced	O
alterations	O
in	O
proliferative	O
and	O
invasive	O
abilities	O
,	O
responses	O
to	O
the	O
invasion	O
and	O
proliferation	O
-	O
regulating	O
growth	O
factor	O
TGFbeta	O
and	O
changes	O
in	O
gene	O
expression	O
for	O
invasion	O
-	O
associated	O
enzymes	O
or	O
enzyme	O
inhibitors	O
.	O

RSVT	B
-	I
2	I
and	O
RSVT2	B
/	I
C	I
cell	O
lines	O
were	O
hyperproliferative	O
and	O
hyperinvasive	O
when	O
compared	O
with	O
the	O
parental	O
HTR8	B
cell	O
line	O
.	O

They	O
were	O
also	O
variably	O
resistant	O
to	O
the	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
invasive	O
signals	O
from	O
TGFbeta	O
.	O

Since	O
both	O
cell	O
lines	O
remained	O
non	O
-	O
tumorigenic	O
in	O
nude	O
mice	O
,	O
these	O
properties	O
indicate	O
that	O
they	O
attained	O
a	O
premalignant	O
phenotype	O
.	O

Both	O
cell	O
lines	O
showed	O
reduced	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteases	O
(	O
TIMP	O
)	O
-	O
1	O
,	O
while	O
TIMP	O
-	O
2	O
and	O
plasminogen	O
activator	O
inhibitor	O
(	O
PAI	O
)	O
-	O
I	O
expression	O
was	O
was	O
also	O
reduced	O
in	O
RSVT2	B
/	I
C	I
cells	O
,	O
thus	O
contributing	O
to	O
their	O
hyperinvasiveness	O
.	O

Their	O
resistance	O
to	O
the	O
anti	O
-	O
invasive	O
action	O
of	O
TGFbeta	O
was	O
explained	O
by	O
the	O
failure	O
of	O
TGFbeta	O
to	O
upregulate	O
TIMPs	O
and	O
PAI	O
-	O
I	O
,	O
in	O
contrast	O
to	O
the	O
TGFbeta	O
-	O
induced	O
upregulation	O
noted	O
in	O
parental	O
HTR8	B
cells	O
.	O

Antisocial	O
patients	O
:	O
a	O
comparison	O
of	O
those	O
with	O
and	O
those	O
without	O
childhood	O
conduct	O
disorder	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
persons	O
with	O
antisocial	O
personality	O
disorder	O
(	O
ASP	O
)	O
with	O
those	O
who	O
meet	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
fail	O
to	O
meet	O
the	O
criteria	O
for	O
childhood	O
conduct	O
disorder	O
.	O

Sociodemographic	O
data	O
,	O
medical	O
history	O
,	O
and	O
psychiatric	O
symptoms	O
exhibited	O
during	O
a	O
recent	O
hospital	O
admission	O
were	O
compared	O
in	O
the	O
two	O
groups	O
by	O
chart	O
review	O
.	O

The	O
two	O
groups	O
were	O
virtually	O
indistinguishable	O
,	O
except	O
that	O
patients	O
without	O
childhood	O
conduct	O
disorder	O
were	O
less	O
likely	O
to	O
smoke	O
or	O
consume	O
alcohol	O
,	O
were	O
less	O
likely	O
to	O
have	O
spent	O
time	O
in	O
a	O
training	O
school	O
/	O
boot	O
camp	O
as	O
a	O
child	O
or	O
adolescent	O
,	O
were	O
less	O
likely	O
to	O
have	O
been	O
admitted	O
for	O
a	O
recent	O
suicide	O
attempt	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
conned	O
others	O
.	O

We	O
conclude	O
that	O
persons	O
meeting	O
the	O
adult	O
criteria	O
for	O
ASP	O
but	O
not	O
the	O
childhood	O
conduct	O
disorder	O
criteria	O
essentially	O
suffer	O
the	O
same	O
disorder	O
as	O
those	O
who	O
meet	O
full	O
ASP	O
criteria	O
but	O
are	O
less	O
severely	O
affected	O
.	O

Acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
.	O

The	O
aminoacylase	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
was	O
identified	O
as	O
acylase	O
I	O
after	O
purification	O
by	O
column	O
chromatography	O
and	O
electrophoretic	O
analysis	O
.	O

Rat	O
kidney	O
cytosol	O
was	O
fractionated	O
by	O
ammonium	O
sulfate	O
precipitation	O
,	O
and	O
the	O
proteins	O
were	O
separated	O
by	O
ion	O
-	O
exchange	O
column	O
chromatography	O
,	O
gel	O
-	O
filtration	O
column	O
chromatography	O
,	O
and	O
hydrophobic	O
interaction	O
column	O
chromatography	O
.	O

Acylase	O
activity	O
with	O
NAC	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
methionine	O
(	O
NAM	O
)	O
,	O
a	O
known	O
substrate	O
for	O
acylase	O
I	O
,	O
as	O
substrates	O
coeluted	O
during	O
all	O
chromatographic	O
steps	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
that	O
the	O
protein	O
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
had	O
a	O
subunit	O
Mr	O
of	O
43	O
000	O
,	O
which	O
is	O
identical	O
with	O
the	O
Mr	O
of	O
acylase	O
I	O
from	O
porcine	O
kidney	O
and	O
bovine	O
liver	O
.	O

n	O
-	O
Butylmalonic	O
acid	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
acylase	O
I	O
and	O
inhibited	O
the	O
deacetylation	O
of	O
NAC	O
with	O
a	O
Ki	O
of	O
192	O
+	O
/	O
-	O
27	O
microM	O
.	O

These	O
results	O
show	O
that	O
acylase	O
I	O
catalyzes	O
the	O
deacetylation	O
of	O
NAC	O
.	O

The	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
a	O
range	O
of	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
,	O
their	O
carbon	O
and	O
oxygen	O
analogues	O
,	O
and	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
also	O
studied	O
with	O
porcine	O
kidney	O
acylase	O
I	O
.	O

The	O
specific	O
activity	O
of	O
the	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
these	O
substrates	O
was	O
related	O
to	O
their	O
calculated	O
molar	O
volumes	O
and	O
log	O
P	O
values	O
.	O

The	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
short	O
(	O
C0	O
-	O
C3	O
)	O
and	O
unbranched	O
S	O
-	O
alkyl	O
substituents	O
were	O
good	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
long	O
(	O
>	O
C3	O
)	O
and	O
branched	O
S	O
-	O
alkyl	O
substituents	O
were	O
poLr	O
acylase	O
I	O
substrates	O
.	O

The	O
carbon	O
and	O
oxygen	O
analogues	O
of	O
S	O
-	O
methyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
the	O
carbon	O
analogue	O
of	O
S	O
-	O
ethyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
were	O
poor	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
a	O
good	O
acylase	O
I	O
substrate	O
.	O

Expression	O
of	O
two	O
type	O
II	O
-	O
like	O
tumor	O
hexokinase	O
RNA	O
transcripts	O
in	O
cancer	O
cell	O
lines	O
.	O

To	O
maintain	O
an	O
elevated	O
glycolytic	O
rate	O
,	O
cancerous	O
or	O
proliferating	O
cells	O
alter	O
the	O
expression	O
pattern	O
of	O
rate	O
limiting	O
glycolytic	O
enzymes	O
.	O

Since	O
glucose	O
phosphorylation	O
is	O
the	O
first	O
step	O
in	O
glycolysis	O
,	O
hexokinase	O
(	O
HK	O
)	O
,	O
the	O
first	O
rate	O
limiting	O
glycolytic	O
enzyme	O
,	O
can	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
this	O
process	O
.	O

A	O
low	O
-	O
Km	O
,	O
mitochondrial	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
is	O
described	O
as	O
the	O
predominant	O
form	O
in	O
hepatomas	O
.	O

However	O
,	O
recent	O
identification	O
of	O
a	O
high	O
-	O
Km	O
glucose	O
phosphorylating	O
activity	O
in	O
a	O
range	O
of	O
cancer	O
cells	O
prompted	O
us	O
to	O
characterize	O
glucose	O
phosphorylating	O
enzymes	O
of	O
cancer	O
cells	O
at	O
the	O
molecular	O
level	O
.	O

Highly	O
sensitive	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
identifies	O
an	O
induction	O
and	O
overexpression	O
of	O
a	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
RNA	O
in	O
a	O
range	O
of	O
cancer	O
cell	O
lines	O
irrespective	O
of	O
tissue	O
origin	O
.	O

In	O
addition	O
,	O
we	O
report	O
here	O
the	O
identification	O
of	O
two	O
RNA	O
transcripts	O
of	O
type	O
II	O
-	O
like	O
tumor	O
HK	O
of	O
approximately	O
5	O
.	O
5	O
and	O
approximately	O
4	O
.	O
0	O
kb	O
in	O
these	O
cancer	O
cells	O
lines	O
,	O
including	O
muscle	O
-	O
derived	O
L6	B
myoblast	O
cells	O
.	O

Interestingly	O
,	O
under	O
normal	O
conditions	O
muscle	O
cells	O
express	O
only	O
a	O
approximately	O
5	O
.	O
5	O
-	O
kb	O
type	O
II	O
HK	O
RNA	O
transcript	O
.	O

A	O
significant	O
amount	O
of	O
type	O
I	O
HK	O
RNA	O
was	O
also	O
found	O
expressed	O
in	O
cancer	O
cell	O
lines	O
.	O

RNA	O
encoding	O
glucokinase	O
(	O
GK	O
)	O
,	O
the	O
high	O
-	O
Km	O
HK	O
isozyme	O
,	O
was	O
found	O
only	O
in	O
cancer	O
cells	O
originating	O
from	O
liver	O
and	O
pancreas	O
,	O
which	O
express	O
GK	O
under	O
normal	O
conditions	O
.	O

Homeobox	O
genes	O
in	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O

Homeobox	O
genes	O
have	O
a	O
strikingly	O
conserved	O
61	O
-	O
amino	O
acid	O
sequence	O
,	O
encoding	O
DNA	O
-	O
binding	O
domain	O
.	O

Some	O
homeobox	O
genes	O
,	O
located	O
in	O
four	O
clusters	O
are	O
designated	O
HOX	O
A	O
through	O
D	O
,	O
while	O
others	O
are	O
known	O
as	O
divergent	O
homeobox	O
genes	O
.	O

Many	O
researchers	O
have	O
demonstrated	O
that	O
hematopoietic	O
cells	O
express	O
many	O
homeobox	O
genes	O
.	O

Induced	O
over	O
-	O
and	O
under	O
-	O
expression	O
of	O
these	O
genes	O
has	O
been	O
used	O
to	O
demonstrate	O
their	O
affect	O
on	O
some	O
aspects	O
of	O
hematopoiesis	O
and	O
leukemogenesis	O
.	O

Recently	O
,	O
knock	O
-	O
out	O
mice	O
of	O
homeobox	O
genes	O
by	O
targeted	O
disruption	O
have	O
also	O
been	O
used	O
to	O
examine	O
their	O
hematological	O
effect	O
.	O

There	O
are	O
examples	O
of	O
the	O
aberrant	O
expression	O
of	O
a	O
homeobox	O
gene	O
causing	O
leukemias	O
in	O
humans	O
.	O

In	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
with	O
t	O
(	O
1	O
;	O
19	O
)	O
translocation	O
,	O
a	O
fusion	O
protein	O
is	O
created	O
between	O
E2A	O
and	O
a	O
homeobox	O
gene	O
PBX	O
.	O

In	O
T	O
-	O
cell	O
ALL	O
with	O
t	O
(	O
10	O
;	O
14	O
)	O
translocation	O
,	O
the	O
HOX	O
11	O
gene	O
is	O
deregulated	O
.	O

In	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
with	O
t	O
(	O
7	O
;	O
11	O
)	O
translocation	O
,	O
the	O
HOX	O
A9	O
gene	O
is	O
rearranged	O
.	O

In	O
this	O
review	O
article	O
,	O
many	O
functions	O
of	O
homeobox	O
genes	O
both	O
at	O
the	O
early	O
stem	O
cell	O
level	O
as	O
well	O
as	O
at	O
the	O
later	O
stages	O
of	O
hematopoietic	O
differentiation	O
,	O
and	O
the	O
leukemogenic	O
effect	O
of	O
altered	O
homeobox	O
genes	O
are	O
discussed	O
.	O

The	O
myoadipose	O
flap	O
:	O
a	O
new	O
composite	O
.	O

A	O
prefabricated	O
composite	O
fat	O
flap	O
consisting	O
of	O
muscle	O
woven	O
into	O
an	O
anatomically	O
distinct	O
fat	O
pad	O
was	O
studied	O
in	O
a	O
rabbit	O
model	O
.	O

In	O
17	O
rabbits	O
,	O
a	O
2	O
-	O
cm	O
strip	O
of	O
latissimus	O
dorsi	O
was	O
woven	O
into	O
the	O
parascapular	O
fat	O
pad	O
on	O
one	O
side	O
,	O
with	O
the	O
contralateral	O
fat	O
pad	O
serving	O
as	O
a	O
control	O
.	O

At	O
3	O
weeks	O
,	O
the	O
endogenous	O
blood	O
supply	O
of	O
both	O
the	O
control	O
and	O
the	O
experimental	O
fat	O
pads	O
was	O
isolated	O
and	O
ligated	O
,	O
and	O
the	O
composite	O
fat	O
/	O
muscle	O
flap	O
was	O
transferred	O
to	O
the	O
chest	O
wall	O
.	O

At	O
6	O
weeks	O
,	O
animals	O
were	O
killed	O
,	O
and	O
flaps	O
were	O
analyzed	O
for	O
length	O
,	O
width	O
,	O
and	O
weight	O
;	O
perfused	O
with	O
fluorescein	O
or	O
lead	O
oxide	O
;	O
and	O
examined	O
histologically	O
.	O

Significant	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
experimental	O
fat	O
pads	O
with	O
regard	O
to	O
weight	O
and	O
length	O
.	O

Experimental	O
flaps	O
were	O
found	O
to	O
be	O
perfused	O
fully	O
with	O
fluorescein	O
and	O
lead	O
oxide	O
;	O
control	O
fat	O
pads	O
were	O
found	O
not	O
to	O
be	O
perfused	O
.	O

The	O
lead	O
oxide	O
group	O
revealed	O
extensive	O
growth	O
of	O
blood	O
vessels	O
from	O
the	O
latissimus	O
graft	O
into	O
the	O
experimental	O
fat	O
pad	O
.	O

No	O
vessels	O
were	O
visualized	O
in	O
the	O
controls	O
.	O

Finally	O
,	O
sections	O
of	O
the	O
control	O
and	O
experimental	O
flaps	O
were	O
analyzed	O
histologically	O
.	O

A	O
preponderance	O
of	O
viable	O
fat	O
,	O
with	O
evidence	O
of	O
neovascularization	O
,	O
was	O
found	O
in	O
experimental	O
flaps	O
,	O
compared	O
with	O
the	O
necrotic	O
fat	O
that	O
characterized	O
the	O
controls	O
.	O

We	O
conclude	O
that	O
prefabrication	O
of	O
a	O
fat	O
flap	O
is	O
possible	O
and	O
may	O
have	O
extensive	O
application	O
in	O
various	O
areas	O
of	O
plastic	O
surgery	O
.	O

Store	O
-	O
operated	O
calcium	O
entry	O
promotes	O
shape	O
change	O
in	O
pulmonary	O
endothelial	O
cells	O
expressing	O
Trp1	O
.	O

Activation	O
of	O
Ca2	O
+	O
entry	O
is	O
known	O
to	O
produce	O
endothelial	O
cell	O
shape	O
change	O
,	O
leading	O
to	O
increased	O
permeability	O
,	O
leukocyte	O
migration	O
,	O
and	O
initiation	O
of	O
angiogenesis	O
in	O
conduit	O
-	O
vessel	O
endothelial	O
cells	O
.	O

The	O
mode	O
of	O
Ca2	O
+	O
entry	O
regulating	O
cell	O
shape	O
is	O
unknown	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	O
+	O
channels	O
(	O
SOCs	O
)	O
is	O
sufficient	O
to	O
promote	O
cell	O
shape	O
change	O
necessary	O
for	O
these	O
processes	O
.	O

SOC	O
activation	O
in	O
rat	O
pulmonary	O
arterial	O
endothelial	O
cells	O
increased	O
free	O
cytosolic	O
Ca2	O
+	O
that	O
was	O
dependent	O
on	O
a	O
membrane	O
current	O
having	O
a	O
net	O
inward	O
component	O
of	O
5	O
.	O
45	O
+	O
/	O
-	O
0	O
.	O
90	O
pA	O
/	O
pF	O
at	O
-	O
80	O
mV	O
.	O

Changes	O
in	O
endothelial	O
cell	O
shape	O
accompanied	O
SOC	O
activation	O
and	O
were	O
dependent	O
on	O
Ca2	O
+	O
entry	O
-	O
induced	O
reconfiguration	O
of	O
peripheral	O
(	O
cortical	O
)	O
filamentous	O
actin	O
(	O
F	O
-	O
actin	O
)	O
.	O

Because	O
the	O
identity	O
of	O
pulmonary	O
endothelial	O
SOCs	O
is	O
unknown	O
,	O
but	O
mammalian	O
homologues	O
of	O
the	O
Drosophila	O
melanogaster	O
transient	O
receptor	O
potential	O
(	O
trp	O
)	O
gene	O
have	O
been	O
proposed	O
to	O
form	O
Ca2	O
+	O
entry	O
channels	O
in	O
nonexcitable	O
cells	O
,	O
we	O
performed	O
RT	O
-	O
PCR	O
using	O
Trp	O
oligonucleotide	O
primers	O
in	O
both	O
rat	O
and	O
human	O
pulmonary	O
arterial	O
endothelial	O
cells	O
.	O

Both	O
cell	O
types	O
were	O
found	O
to	O
express	O
Trp1	O
,	O
but	O
neither	O
expressed	O
Trp3	O
nor	O
Trp6	O
.	O

Our	O
study	O
indicates	O
that	O
1	O
)	O
Ca2	O
+	O
entry	O
in	O
pulmonary	O
endothelial	O
cells	O
through	O
SOCs	O
produces	O
cell	O
shape	O
change	O
that	O
is	O
dependent	O
on	O
site	O
-	O
specific	O
rearrangement	O
of	O
the	O
microfilamentous	O
cytoskeleton	O
and	O
2	O
)	O
Trp1	O
may	O
be	O
a	O
component	O
of	O
pulmonary	O
endothelial	O
SOCs	O
.	O

Brainstem	O
auditory	O
-	O
evoked	O
potential	O
evaluation	O
in	O
children	O
with	O
meningitis	O
.	O

Brainstem	O
auditory	O
-	O
evoked	O
potential	O
(	O
BAEP	O
)	O
was	O
performed	O
on	O
101	O
children	O
with	O
meningitis	O
to	O
assess	O
the	O
incidence	O
of	O
hearing	O
impairment	O
.	O

Fifty	O
-	O
two	O
(	O
51	O
.	O
5	O
%	O
)	O
children	O
had	O
bacterial	O
meningitis	O
,	O
six	O
(	O
5	O
.	O
9	O
%	O
)	O
had	O
viral	O
meningitis	O
,	O
and	O
43	O
(	O
42	O
.	O
6	O
%	O
)	O
had	O
aseptic	O
meningitis	O
.	O

Fifty	O
-	O
one	O
(	O
50	O
.	O
5	O
%	O
)	O
patients	O
were	O
assessed	O
before	O
discharge	O
and	O
50	O
(	O
49	O
.	O
5	O
%	O
)	O
9	O
days	O
to	O
17	O
months	O
later	O
(	O
mean	O
=	O
4	O
months	O
)	O
.	O

BAEP	O
impairment	O
was	O
found	O
in	O
28	O
(	O
27	O
.	O
7	O
%	O
)	O
of	O
101	O
patients	O
;	O
24	O
had	O
sensorineural	O
and	O
four	O
had	O
conductive	O
type	O
of	O
hearing	O
loss	O
,	O
and	O
17	O
(	O
60	O
.	O
7	O
%	O
)	O
had	O
unilateral	O
and	O
11	O
(	O
39	O
.	O
3	O
%	O
)	O
had	O
bilateral	O
impairment	O
.	O

Hearing	O
threshold	O
was	O
elevated	O
in	O
22	O
(	O
21	O
.	O
8	O
%	O
)	O
patients	O
,	O
and	O
the	O
other	O
six	O
had	O
increased	O
latency	O
and	O
interpeak	O
latencies	O
with	O
normal	O
threshold	O
.	O

Frequency	O
of	O
BAEP	O
impairment	O
or	O
hearing	O
loss	O
associated	O
with	O
bacterial	O
meningitis	O
was	O
34	O
.	O
6	O
%	O
and	O
30	O
.	O
8	O
%	O
,	O
respectively	O
;	O
frequency	O
associated	O
with	O
aseptic	O
meningitis	O
was	O
20	O
.	O
9	O
%	O
and	O
13	O
.	O
9	O
%	O
,	O
respectively	O
.	O

One	O
child	O
with	O
viral	O
meningitis	O
(	O
coxsackie	O
virus	O
)	O
had	O
mild	O
BAEP	O
impairment	O
.	O

Most	O
of	O
the	O
BAEP	O
impairment	O
in	O
the	O
bacterial	O
meningitis	O
group	O
was	O
associated	O
with	O
H	O
.	O
influenzae	O
.	O

Prospective	O
BAEP	O
study	O
was	O
performed	O
in	O
20	O
patients	O
randomly	O
at	O
0	O
.	O
3	O
to	O
18	O
months	O
to	O
assess	O
hearing	O
status	O
after	O
antibiotic	O
treatment	O
,	O
10	O
with	O
normal	O
and	O
10	O
with	O
abnormal	O
BAEP	O
.	O

All	O
the	O
initially	O
normal	O
BAEP	O
patients	O
remained	O
normal	O
.	O

Of	O
the	O
10	O
patients	O
with	O
abnormal	O
BAEP	O
results	O
initially	O
,	O
four	O
returned	O
to	O
normal	O
,	O
two	O
improved	O
,	O
three	O
remained	O
unchanged	O
,	O
and	O
one	O
deteriorated	O
.	O

The	O
incidence	O
of	O
hearing	O
loss	O
after	O
bacterial	O
and	O
aseptic	O
meningitis	O
is	O
high	O
.	O

BAEP	O
is	O
useful	O
to	O
screen	O
for	O
possible	O
hearing	O
loss	O
in	O
children	O
with	O
meningitis	O
,	O
and	O
follow	O
-	O
up	O
BAEP	O
is	O
necessary	O
for	O
those	O
patients	O
with	O
initially	O
abnormal	O
BAEP	O
.	O

Hemispheric	O
control	O
of	O
motor	O
function	O
:	O
a	O
whole	O
brain	O
echo	O
planar	O
fMRI	O
study	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
whether	O
recruitment	O
of	O
the	O
ipsilateral	O
motor	O
cortex	O
during	O
non	O
-	O
dominant	O
motor	O
movement	O
reflects	O
left	O
hemispheric	O
control	O
of	O
motor	O
function	O
or	O
simply	O
the	O
greater	O
complexity	O
or	O
unfamiliarity	O
of	O
the	O
motor	O
task	O
.	O

BOLD	O
fMRI	O
was	O
performed	O
in	O
normal	O
right	O
-	O
handers	O
during	O
two	O
motor	O
tasks	O
:	O
(	O
1	O
)	O
sequential	O
finger	O
movements	O
(	O
SM	O
task	O
)	O
with	O
the	O
right	O
or	O
left	O
hand	O
;	O
and	O
(	O
2	O
)	O
random	O
finger	O
movements	O
(	O
RM	O
task	O
)	O
with	O
the	O
right	O
hand	O
.	O

In	O
all	O
subjects	O
,	O
activation	O
was	O
predominantly	O
in	O
the	O
contralateral	O
motor	O
areas	O
(	O
primary	O
sensorimotor	O
,	O
lateral	O
premotor	O
,	O
parietal	O
and	O
supplementary	O
motor	O
regions	O
)	O
and	O
ipsilateral	O
cerebellum	O
.	O

While	O
the	O
ipsilateral	O
motor	O
areas	O
were	O
also	O
activated	O
,	O
single	O
subject	O
analysis	O
revealed	O
these	O
areas	O
to	O
be	O
more	O
extensive	O
and	O
to	O
be	O
seen	O
in	O
more	O
subjects	O
during	O
the	O
non	O
-	O
dominant	O
hand	O
SM	O
task	O
and	O
dominant	O
hand	O
RM	O
task	O
than	O
during	O
the	O
more	O
familiar	O
dominant	O
hand	O
SM	O
task	O
.	O

Similarly	O
,	O
group	O
analysis	O
also	O
revealed	O
ipsilateral	O
activation	O
in	O
the	O
primary	O
sensorimotor	O
and	O
lateral	O
premotor	O
areas	O
,	O
but	O
only	O
during	O
the	O
non	O
-	O
dominant	O
SM	O
task	O
and	O
the	O
dominant	O
hand	O
RM	O
task	O
.	O

Non	O
-	O
dominant	O
hand	O
movements	O
,	O
perhaps	O
because	O
they	O
are	O
less	O
'	O
automatic	O
'	O
,	O
appear	O
to	O
require	O
more	O
cortical	O
activity	O
similar	O
to	O
complex	O
tasks	O
with	O
the	O
dominant	O
hand	O
,	O
and	O
result	O
in	O
greater	O
recruitment	O
of	O
ipsilateral	O
cortical	O
motor	O
areas	O
and	O
striatum	O
.	O

The	O
study	O
also	O
illustrates	O
how	O
potentially	O
meaningful	O
subtleties	O
seen	O
on	O
individual	O
maps	O
may	O
be	O
obscured	O
with	O
group	O
averaging	O
approaches	O
.	O

[	O
The	O
assessment	O
of	O
flow	O
velocity	O
in	O
carotid	O
and	O
intracranial	O
arteries	O
in	O
three	O
different	O
age	O
groups	O
]	O
.	O

In	O
this	O
report	O
we	O
assess	O
the	O
systolic	O
maximal	O
flow	O
velocity	O
in	O
carotid	O
and	O
intracranial	O
arteries	O
in	O
191	O
subjects	O
with	O
no	O
history	O
of	O
cerebral	O
vascular	O
disease	O
in	O
3	O
age	O
groups	O
:	O
20	O
-	O
40	O
years	O
(	O
1	O
group	O
)	O
,	O
41	O
-	O
60	O
years	O
(	O
2	O
group	O
)	O
,	O
and	O
above	O
60	O
years	O
(	O
3	O
group	O
)	O
.	O

The	O
subjects	O
were	O
assessed	O
using	O
Sonomed	O
Transcranial	O
Doppler	O
Spectrograph	O
according	O
to	O
generally	O
accepted	O
principles	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
establish	O
the	O
mean	O
value	O
of	O
maximal	O
flow	O
velocity	O
in	O
each	O
particular	O
artery	O
in	O
three	O
age	O
groups	O
,	O
and	O
to	O
observe	O
the	O
changes	O
in	O
this	O
parameter	O
with	O
age	O
.	O

The	O
results	O
were	O
analyzed	O
using	O
statistical	O
methods	O
and	O
a	O
significant	O
decrease	O
in	O
blood	O
flow	O
,	O
Vmax	O
,	O
was	O
found	O
in	O
all	O
investigated	O
arteries	O
.	O

A	O
mean	O
decrease	O
of	O
8	O
.	O
02	O
%	O
in	O
flow	O
velocity	O
Vmax	O
was	O
found	O
,	O
when	O
comparing	O
groups	O
2	O
and	O
1	O
,	O
and	O
difference	O
15	O
.	O
99	O
%	O
comparing	O
3	O
and	O
1	O
.	O

Lack	O
of	O
developmental	O
and	O
reproductive	O
toxicity	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
in	O
ring	O
-	O
necked	O
pheasants	O
.	O

Mono	O
-	O
ortho	O
PCBs	O
are	O
global	O
contaminants	O
of	O
wildlife	O
with	O
the	O
potential	O
to	O
produce	O
toxicity	O
by	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
-	O
mediated	O
mechanism	O
.	O

To	O
determine	O
the	O
potency	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
for	O
producing	O
reproductive	O
and	O
developmental	O
toxicity	O
,	O
adult	O
ring	O
-	O
necked	O
pheasant	O
hens	O
(	O
Phasianus	O
colchicus	O
)	O
were	O
orally	O
dosed	O
with	O
0	O
,	O
0	O
.	O
06	O
,	O
0	O
.	O
6	O
,	O
or	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
/	O
week	O
for	O
10	O
weeks	O
to	O
achieve	O
cumulative	O
doses	O
of	O
0	O
,	O
0	O
.	O
6	O
,	O
6	O
,	O
or	O
60	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
after	O
which	O
hens	O
were	O
bred	O
with	O
untreated	O
roosters	O
once	O
per	O
week	O
for	O
8	O
weeks	O
.	O

Except	O
at	O
week	O
6	O
of	O
the	O
egg	O
-	O
laying	O
period	O
when	O
cumulative	O
egg	O
production	O
in	O
the	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
group	O
was	O
greater	O
than	O
controls	O
,	O
fertilized	O
egg	O
production	O
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Embryo	O
mortality	O
and	O
chick	O
mortality	O
were	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

Total	O
body	O
and	O
heart	O
weights	O
of	O
all	O
chicks	O
1	O
day	O
posthatch	O
(	O
dph	O
)	O
were	O
not	O
different	O
between	O
groups	O
,	O
however	O
,	O
liver	O
weights	O
of	O
chicks	O
from	O
the	O
60	O
mg	O
/	O
kg	O
treatment	O
group	O
were	O
greater	O
than	O
controls	O
at	O
1	O
dph	O
.	O

The	O
first	O
chick	O
to	O
hatch	O
from	O
each	O
hen	O
was	O
reared	O
to	O
21	O
dph	O
and	O
among	O
these	O
birds	O
,	O
the	O
total	O
body	O
,	O
liver	O
,	O
and	O
heart	O
weights	O
were	O
not	O
different	O
between	O
groups	O
.	O

There	O
were	O
no	O
dose	O
-	O
related	O
malformations	O
of	O
the	O
beak	O
or	O
limbs	O
,	O
and	O
no	O
signs	O
of	O
subcutaneous	O
edema	O
,	O
ascites	O
,	O
or	O
pericardial	O
edema	O
in	O
chicks	O
at	O
1	O
or	O
21	O
dph	O
.	O

Hepatic	O
microsomal	O
monooxygenase	O
activities	O
[	O
ethoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
EROD	O
)	O
,	O
benzyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
BROD	O
)	O
,	O
and	O
methyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
MROD	O
)	O
]	O
were	O
significantly	O
elevated	O
in	O
chicks	O
at	O
1	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
105	O
dose	O
of	O
6	O
mg	O
/	O
kg	O
and	O
in	O
chicks	O
at	O
21	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
dose	O
of	O
60	O
mg	O
/	O
kg	O
.	O

These	O
results	O
indicate	O
that	O
a	O
cumulative	O
PCB	O
105	O
dose	O
up	O
to	O
60	O
mg	O
/	O
kg	O
hen	O
does	O
not	O
decrease	O
the	O
production	O
of	O
fertilized	O
eggs	O
or	O
increase	O
embryo	O
or	O
chick	O
mortality	O
in	O
ring	O
-	O
necked	O
pheasants	O
,	O
but	O
does	O
increase	O
chick	O
hepatic	O
monooxygenase	O
activity	O
.	O

Glucose	O
and	O
lactate	O
metabolism	O
in	O
C6	B
glioma	O
cells	O
:	O
evidence	O
for	O
the	O
preferential	O
utilization	O
of	O
lactate	O
for	O
cell	O
oxidative	O
metabolism	O
.	O

13C	O
and	O
1H	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(	O
NMR	O
)	O
was	O
used	O
to	O
investigate	O
the	O
metabolism	O
of	O
L	O
-	O
lactate	O
and	O
D	O
-	O
glucose	O
in	O
C6	B
glioma	O
cells	O
.	O

The	O
13C	O
enrichment	O
of	O
cell	O
metabolites	O
was	O
examined	O
after	O
a	O
4	O
-	O
h	O
incubation	O
in	O
media	O
containing	O
5	O
.	O
5	O
mM	O
glucose	O
and	O
11	O
mM	O
lactate	O
,	O
each	O
metabolite	O
being	O
alternatively	O
labelled	O
with	O
either	O
[	O
1	O
-	O
13C	O
]	O
D	O
-	O
glucose	O
or	O
[	O
3	O
-	O
13C	O
]	O
L	O
-	O
lactate	O
.	O

The	O
results	O
indicated	O
that	O
exogenous	O
lactate	O
was	O
the	O
major	O
substrate	O
for	O
oxidative	O
metabolism	O
.	O

They	O
were	O
consistent	O
with	O
the	O
concept	O
of	O
the	O
existence	O
of	O
2	O
pools	O
of	O
both	O
lactate	O
and	O
pyruvate	O
,	O
of	O
which	O
1	O
pool	O
was	O
closely	O
connected	O
with	O
exogenous	O
lactate	O
and	O
oxidative	O
metabolism	O
,	O
and	O
the	O
other	O
pool	O
was	O
closely	O
related	O
to	O
glycolysis	O
and	O
disconnected	O
from	O
oxidative	O
metabolism	O
.	O

The	O
molecular	O
basis	O
of	O
this	O
behaviour	O
could	O
be	O
related	O
to	O
different	O
locations	O
for	O
the	O
lactate	O
dehydrogenase	O
isoenzymes	O
,	O
as	O
suggested	O
by	O
their	O
immunohistochemical	O
labelling	O
.	O

Detection	O
of	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
the	O
pulsatility	O
of	O
a	O
continuous	O
flow	O
artificial	O
heart	O
:	O
in	O
vivo	O
evaluation	O
.	O

Our	O
novel	O
control	O
strategy	O
for	O
a	O
continuous	O
flow	O
artificial	O
heart	O
by	O
detecting	O
the	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
pump	O
pulsatility	O
was	O
evaluated	O
in	O
acute	O
animal	O
experiments	O
using	O
beagle	O
dogs	O
and	O
our	O
mixed	O
flow	O
pump	O
.	O

The	O
pump	O
was	O
installed	O
as	O
a	O
left	O
ventricular	O
(	O
LV	O
)	O
bypass	O
through	O
a	O
left	O
thoracotomy	O
.	O

To	O
change	O
LV	O
contractility	O
,	O
the	O
left	O
coronary	O
arteries	O
were	O
occluded	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
120	O
min	O
reperfusion	O
.	O

To	O
change	O
LV	O
end	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
,	O
dextran	O
solution	O
was	O
rapidly	O
infused	O
.	O

To	O
estimate	O
the	O
pump	O
pulsatility	O
without	O
any	O
specific	O
sensor	O
,	O
we	O
calculated	O
the	O
index	O
of	O
current	O
amplitude	O
(	O
ICA	O
)	O
,	O
which	O
was	O
obtained	O
from	O
the	O
amplitude	O
of	O
the	O
motor	O
current	O
waveform	O
divided	O
by	O
the	O
simultaneous	O
mean	O
value	O
.	O

To	O
investigate	O
the	O
basic	O
characteristics	O
of	O
the	O
ICA	O
,	O
the	O
pump	O
speed	O
was	O
changed	O
temporarily	O
from	O
2	O
,	O
300	O
rpm	O
to	O
5	O
,	O
000	O
rpm	O
.	O

In	O
92	O
%	O
of	O
all	O
measurements	O
,	O
the	O
ICA	O
plotted	O
against	O
the	O
pump	O
speed	O
had	O
a	O
peak	O
point	O
(	O
t	O
-	O
point	O
)	O
that	O
corresponded	O
highly	O
with	O
the	O
turning	O
point	O
from	O
partial	O
to	O
total	O
assistance	O
.	O

The	O
ICA	O
also	O
had	O
a	O
trough	O
(	O
s	O
-	O
point	O
)	O
that	O
corresponded	O
with	O
the	O
beginning	O
of	O
severe	O
sucking	O
in	O
most	O
cases	O
.	O

Only	O
preload	O
significantly	O
influenced	O
pump	O
flow	O
rate	O
at	O
the	O
t	O
-	O
point	O
from	O
among	O
preload	O
(	O
LVEDP	O
)	O
,	O
afterload	O
(	O
SAoP	O
)	O
,	O
and	O
contractility	O
(	O
max	O
LV	O
dP	O
/	O
dt	O
)	O
,	O
by	O
which	O
we	O
can	O
simulate	O
Starling	O
'	O
s	O
law	O
of	O
the	O
natural	O
heart	O
.	O

We	O
concluded	O
that	O
a	O
continuous	O
flow	O
artificial	O
heart	O
could	O
be	O
well	O
controlled	O
by	O
detecting	O
the	O
t	O
-	O
point	O
and	O
s	O
-	O
point	O
.	O

Tumors	O
of	O
the	O
retinal	O
pigment	O
epithelium	O
metastasize	O
to	O
inguinal	O
lymph	O
nodes	O
and	O
spleen	O
in	O
tyrosinase	O
-	O
related	O
protein	O
1	O
/	O
SV40	O
T	O
antigen	O
transgenic	O
mice	O
.	O

The	O
pigment	O
epithelium	O
of	O
the	O
retina	O
(	O
RPE	O
)	O
is	O
derived	O
from	O
the	O
optic	O
cup	O
and	O
is	O
essential	O
for	O
function	O
and	O
development	O
of	O
the	O
eye	O
.	O

We	O
produced	O
a	O
transgenic	O
mouse	O
line	O
that	O
expresses	O
simian	O
virus	O
(	O
SV40	O
)	O
transforming	O
sequences	O
under	O
control	O
of	O
the	O
1	O
.	O
4	O
kb	O
tyrosinase	O
-	O
related	O
protein	O
1	O
(	O
TRP	O
-	O
1	O
)	O
promoter	O
,	O
targeting	O
expression	O
of	O
T	O
antigen	O
(	O
Tag	O
)	O
to	O
the	O
RPE	O
.	O

In	O
transgenic	O
embryos	O
,	O
RPE	O
cells	O
proliferated	O
in	O
the	O
anterior	O
part	O
of	O
the	O
eye	O
and	O
near	O
the	O
optic	O
nerve	O
.	O

This	O
resulted	O
in	O
formation	O
of	O
tumors	O
,	O
which	O
were	O
pigmented	O
and	O
of	O
epithelial	O
origin	O
.	O

In	O
3	O
months	O
-	O
old	O
mice	O
,	O
pigmented	O
cells	O
were	O
detected	O
in	O
spleen	O
and	O
inguinal	O
lymph	O
nodes	O
.	O

In	O
spleen	O
,	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
and	O
SV40	O
Tag	O
were	O
expressed	O
and	O
tyrosinase	O
was	O
enzymatically	O
active	O
.	O

Pigmented	O
regions	O
were	O
positive	O
for	O
an	O
epithelial	O
marker	O
,	O
cytokeratin	O
.	O

Cell	O
lines	O
were	O
established	O
from	O
tumor	O
and	O
metastases	O
and	O
kept	O
in	O
culture	O
for	O
more	O
than	O
2	O
months	O
.	O

These	O
were	O
pigmented	O
,	O
and	O
maintained	O
expression	O
of	O
tyrosinase	O
,	O
TRP	O
-	O
1	O
,	O
cytokeratin	O
and	O
SV40	O
Tag	O
.	O

This	O
demonstrates	O
that	O
RPE	O
tumor	O
cells	O
metastasize	O
to	O
lymph	O
node	O
and	O
spleen	O
.	O

In	O
conclusion	O
,	O
the	O
metastasis	O
from	O
TRP	O
-	O
1	O
/	O
Tag	O
RPE	O
tumors	O
towards	O
spleen	O
and	O
lymph	O
nodes	O
serves	O
as	O
potential	O
tool	O
to	O
investigate	O
biology	O
and	O
metastasis	O
of	O
tumors	O
derived	O
from	O
the	O
pigment	O
epithelium	O
.	O

Glucagon	O
induces	O
suppression	O
of	O
ATP	O
-	O
sensitive	O
K	O
+	O
channel	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
pathway	O
in	O
mouse	O
pancreatic	O
beta	O
-	O
cells	O
.	O

Glucagon	O
is	O
known	O
to	O
increase	O
intracellular	O
cAMP	O
levels	O
and	O
enhance	O
glucose	O
-	O
induced	O
electrical	O
activity	O
and	O
insulin	O
secretion	O
in	O
pancreatic	O
beta	O
-	O
cell	O
perfused	O
with	O
Krebs	O
-	O
Ringer	O
bicarbonate	O
solution	O
.	O

The	O
present	O
experiments	O
were	O
aimed	O
at	O
evaluation	O
of	O
the	O
hypothesis	O
that	O
changes	O
in	O
beta	O
-	O
cells	O
ATP	O
-	O
sensitive	O
K	O
+	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channel	O
activity	O
are	O
involved	O
in	O
the	O
glucagon	O
-	O
induced	O
enhancement	O
of	O
electrical	O
activity	O
.	O

Channel	O
activity	O
was	O
recorded	O
using	O
the	O
cell	O
-	O
attached	O
configuration	O
of	O
the	O
patch	O
-	O
clamp	O
technique	O
.	O

Addition	O
of	O
glucagon	O
(	O
2	O
.	O
9	O
x	O
10	O
(	O
-	O
7	O
)	O
m	O
)	O
in	O
the	O
presence	O
of	O
11	O
.	O
1	O
mm	O
glucose	O
caused	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
followed	O
by	O
an	O
increase	O
in	O
the	O
frequency	O
of	O
biphasic	O
current	O
transients	O
(	O
action	O
currents	O
)	O
due	O
to	O
action	O
potential	O
generation	O
in	O
the	O
cell	O
.	O

Three	O
calmodulin	O
-	O
antagonists	O
(	O
W	O
-	O
7	O
,	O
chlorpromazine	O
,	O
and	O
trifluoperazine	O
)	O
restored	O
with	O
similar	O
efficacy	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
in	O
cells	O
being	O
exposed	O
to	O
glucagon	O
.	O

At	O
2	O
.	O
8	O
mm	O
glucose	O
,	O
glucagon	O
did	O
not	O
affect	O
K	O
(	O
ATP	O
)	O
channel	O
activity	O
until	O
Ca2	O
+	O
was	O
released	O
from	O
Nitr	O
-	O
5	O
by	O
flash	O
photolysis	O
,	O
at	O
which	O
point	O
channel	O
activity	O
was	O
transiently	O
suppressed	O
.	O

Similar	O
effects	O
were	O
seen	O
when	O
db	O
-	O
cAMP	O
was	O
used	O
instead	O
of	O
glucagon	O
.	O

These	O
results	O
support	O
the	O
view	O
that	O
glucagon	O
and	O
other	O
cAMP	O
-	O
generating	O
agonists	O
enhance	O
glucose	O
-	O
induced	O
beta	O
-	O
cell	O
electrical	O
activity	O
through	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
dependent	O
-	O
closure	O
of	O
K	O
(	O
ATP	O
)	O
channels	O
.	O

Requirement	O
of	O
estrogen	O
receptor	O
expression	O
and	O
function	O
for	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
-	O
mediated	O
NIH3T3	B
cell	O
transformation	O
.	O

We	O
investigated	O
the	O
biological	O
significance	O
of	O
estrogen	O
receptors	O
(	O
ERs	O
)	O
in	O
NIH3T3	B
cell	O
transformation	O
by	O
the	O
[	O
12Val	O
]	O
K	O
-	O
Ras	O
mutant	O
.	O

This	O
mutant	O
enhanced	O
the	O
steady	O
-	O
level	O
and	O
transcriptional	O
activity	O
of	O
ER	O
.	O

Coexpression	O
of	O
the	O
progesterone	O
receptor	O
with	O
mutant	O
K	O
-	O
Ras	O
led	O
to	O
suppression	O
of	O
tumorigenicity	O
and	O
inhibition	O
of	O
the	O
activation	O
of	O
ER	O
.	O

The	O
antisense	O
oligomers	O
complementary	O
to	O
the	O
ER	O
suppressed	O
proliferation	O
and	O
transformed	O
phenotypes	O
of	O
K12V	B
cells	O
.	O

These	O
observations	O
support	O
the	O
importance	O
of	O
ER	O
in	O
Ras	O
-	O
mediated	O
cell	O
transformation	O
.	O

Gene	O
therapy	O
for	O
gliomas	O
:	O
p53	O
and	O
E2F	O
-	O
1	O
proteins	O
and	O
the	O
target	O
of	O
apoptosis	O
.	O

Current	O
therapy	O
for	O
glioma	O
is	O
suboptimal	O
.	O

The	O
transfer	O
of	O
apoptosis	O
genes	O
to	O
tumors	O
constitutes	O
one	O
of	O
the	O
most	O
promising	O
strategies	O
for	O
cancer	O
gene	O
therapy	O
.	O

We	O
have	O
previously	O
shown	O
that	O
massive	O
apoptosis	O
occurs	O
when	O
wild	O
-	O
type	O
p53	O
or	O
E2F	O
-	O
1	O
expression	O
is	O
induced	O
in	O
glioma	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
action	O
and	O
the	O
efficiency	O
in	O
inducing	O
apoptosis	O
of	O
these	O
two	O
proteins	O
are	O
not	O
similar	O
.	O

Adenovirus	O
-	O
mediated	O
p53	O
gene	O
transfer	O
is	O
ineffective	O
in	O
causing	O
apoptosis	O
in	O
glioma	O
cells	O
that	O
retain	O
wild	O
-	O
type	O
p53	O
genotype	O
or	O
overexpress	O
the	O
p21	O
protein	O
.	O

The	O
p16	O
/	O
Rb	O
/	O
E2F	O
pathway	O
is	O
the	O
most	O
frequent	O
target	O
of	O
genetic	O
alterations	O
in	O
gliomas	O
,	O
and	O
therefore	O
constitutes	O
a	O
suitable	O
target	O
for	O
gene	O
therapy	O
strategies	O
.	O

However	O
,	O
the	O
transfer	O
of	O
either	O
the	O
p16	O
or	O
Rb	O
gene	O
to	O
glioma	O
cells	O
results	O
in	O
cytostatic	O
effect	O
.	O

The	O
E2F	O
-	O
1	O
protein	O
is	O
able	O
to	O
induce	O
generalized	O
apoptosis	O
in	O
gliomas	O
independently	O
of	O
the	O
p53	O
,	O
p16	O
or	O
Rb	O
status	O
.	O

In	O
addition	O
,	O
p21	O
-	O
or	O
p16	O
-	O
mediated	O
growth	O
arrest	O
did	O
not	O
protect	O
glioma	O
cells	O
from	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
.	O

The	O
apoptotic	O
molecule	O
bax	O
is	O
induced	O
in	O
p53	O
-	O
mediated	O
apoptosis	O
,	O
but	O
bax	O
is	O
not	O
induced	O
in	O
E2F	O
-	O
1	O
-	O
mediated	O
apoptosis	O
in	O
glioma	O
cells	O
.	O

Careful	O
selection	O
of	O
patients	O
may	O
be	O
necessary	O
before	O
designing	O
therapeutic	O
strategies	O
using	O
either	O
p53	O
or	O
E2F	O
-	O
1	O
as	O
a	O
therapeutic	O
tools	O
for	O
glioma	O
patients	O
.	O

Protective	O
function	O
of	O
von	O
Hippel	O
-	O
Lindau	O
protein	O
against	O
impaired	O
protein	O
processing	O
in	O
renal	O
carcinoma	O
cells	O
.	O

The	O
absence	O
of	O
functional	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	O
suppressor	O
gene	O
leads	O
to	O
the	O
development	O
of	O
neoplasias	O
characteristic	O
of	O
VHL	O
disease	O
,	O
including	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

Here	O
,	O
we	O
compared	O
the	O
sensitivity	O
of	O
RCC	O
cells	O
lacking	O
VHL	O
gene	O
function	O
with	O
that	O
of	O
RCC	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
VHL	O
gene	O
(	O
wtVHL	O
)	O
after	O
exposure	O
to	O
various	O
stresses	O
.	O

While	O
the	O
response	O
to	O
most	O
treatments	O
was	O
not	O
affected	O
by	O
the	O
VHL	O
gene	O
status	O
,	O
glucose	O
deprivation	O
was	O
found	O
to	O
be	O
much	O
more	O
cytotoxic	O
for	O
RCC	O
cells	O
lacking	O
VHL	O
gene	O
function	O
than	O
for	O
wtVHL	O
-	O
expressing	O
cells	O
.	O

The	O
heightened	O
sensitivity	O
of	O
VHL	O
-	O
deficient	O
cells	O
was	O
not	O
attributed	O
to	O
dissimilar	O
energy	O
requirements	O
or	O
to	O
differences	O
in	O
glucose	O
uptake	O
,	O
but	O
more	O
likely	O
reflects	O
a	O
lesser	O
ability	O
of	O
VHL	O
-	O
deficient	O
cells	O
to	O
handle	O
abnormally	O
processed	O
proteins	O
arising	O
from	O
impaired	O
glycosylation	O
.	O

In	O
support	O
of	O
this	O
hypothesis	O
,	O
other	O
treatments	O
which	O
act	O
through	O
different	O
mechanisms	O
to	O
interfere	O
with	O
protein	O
processing	O
(	O
i	O
.	O
e	O
.	O
,	O
tunicamycin	O
,	O
brefeldin	O
A	O
,	O
and	O
azetidine	O
)	O
were	O
also	O
found	O
to	O
be	O
much	O
more	O
toxic	O
for	O
VHL	O
-	O
deficient	O
cells	O
.	O

Furthermore	O
,	O
ubiquitination	O
of	O
cellular	O
proteins	O
was	O
elevated	O
in	O
VHL	O
-	O
deficient	O
cells	O
,	O
particularly	O
after	O
glucose	O
deprivation	O
,	O
supporting	O
a	O
role	O
for	O
the	O
VHL	O
gene	O
in	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
.	O

Accordingly	O
,	O
the	O
rate	O
of	O
elimination	O
of	O
abnormal	O
proteins	O
was	O
lower	O
in	O
cells	O
lacking	O
a	O
functional	O
VHL	O
gene	O
than	O
in	O
wtVHL	O
-	O
expressing	O
cells	O
.	O

Thus	O
,	O
pVHL	O
appears	O
to	O
participate	O
in	O
the	O
elimination	O
of	O
misprocessed	O
proteins	O
,	O
such	O
as	O
those	O
arising	O
in	O
the	O
cell	O
due	O
to	O
the	O
unavailability	O
of	O
glucose	O
or	O
to	O
other	O
stresses	O
.	O

Effect	O
of	O
U	O
-	O
995	O
,	O
a	O
potent	O
shark	O
cartilage	O
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
on	O
anti	O
-	O
angiogenesis	O
and	O
anti	O
-	O
tumor	O
activities	O
.	O

BACKGROUND	O
:	O
A	O
potent	O
angiogenesis	O
inhibitor	O
,	O
U	O
-	O
995	O
,	O
has	O
been	O
purified	O
from	O
the	O
cartilage	O
of	O
the	O
blue	O
shark	O
(	O
Prionace	O
glauca	O
)	O
.	O

U	O
-	O
995	O
is	O
composed	O
of	O
two	O
single	O
peptides	O
with	O
molecular	O
mass	O
of	O
10	O
and	O
14	O
kDa	O
,	O
respectively	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
U	O
-	O
995	O
was	O
designed	O
to	O
study	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
migration	O
and	O
proliferation	O
in	O
vitro	O
and	O
angiogenesis	O
induced	O
by	O
TNF	O
alpha	O
in	O
chicken	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
.	O

Furthermore	O
,	O
we	O
determined	O
the	O
ability	O
of	O
U	O
-	O
995	O
to	O
inhibiting	O
tumor	O
cell	O
growth	O
and	O
metastasis	O
.	O

RESULTS	O
:	O
U	O
-	O
995	O
(	O
15	O
and	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
inhibited	O
HUVEC	O
migration	O
and	O
,	O
at	O
15	O
-	O
50	O
micrograms	O
/	O
ml	O
produced	O
a	O
dose	O
-	O
dependent	O
decline	O
in	O
[	O
3H	O
]	O
-	O
thymidine	O
incorporation	O
.	O

30	O
and	O
50	O
micrograms	O
/	O
ml	O
of	O
U	O
-	O
995	O
,	O
when	O
added	O
to	O
TNF	O
alpha	O
-	O
induced	O
angiogenesis	O
caused	O
discontinuous	O
and	O
disrupted	O
blood	O
vessels	O
.	O

Moreover	O
,	O
U	O
-	O
995	O
(	O
30	O
micrograms	O
/	O
ml	O
)	O
markedly	O
prevented	O
collagenase	O
-	O
induced	O
collagenolysis	O
.	O

In	O
addition	O
,	O
when	O
200	O
micrograms	O
U	O
-	O
995	O
was	O
injected	O
i	O
.	O
p	O
.	O
into	O
mice	O
it	O
suppressed	O
sarcoma	B
-	I
180	I
cell	O
growth	O
and	O
B16	B
-	I
F10	I
mouse	O
melanoma	O
cell	O
metastasis	O
in	O
vivo	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
the	O
anti	O
-	O
angiogenic	O
effects	O
of	O
U	O
-	O
995	O
may	O
be	O
be	O
due	O
to	O
interference	O
with	O
the	O
proliferation	O
and	O
migration	O
of	O
HUVECs	O
as	O
well	O
as	O
inhibition	O
of	O
collagenolysis	O
,	O
thereby	O
leading	O
to	O
inhibition	O
of	O
both	O
angiogenesis	O
and	O
tumor	O
cell	O
growth	O
.	O

Potential	O
roles	O
for	O
focal	O
adhesion	O
kinase	O
in	O
development	O
.	O

Focal	O
adhesion	O
kinase	O
(	O
pp125FAK	O
or	O
FAK	O
)	O
is	O
a	O
protein	O
tyrosine	O
kinase	O
which	O
is	O
associated	O
with	O
intracellular	O
signalling	O
cascades	O
which	O
are	O
initiated	O
when	O
the	O
integrin	O
family	O
of	O
cell	O
adhesion	O
molecules	O
engage	O
extracellular	O
matrix	O
molecules	O
.	O

In	O
cultured	O
cells	O
,	O
this	O
molecule	O
is	O
physically	O
associated	O
with	O
focal	O
adhesions	O
,	O
which	O
are	O
well	O
-	O
defined	O
regions	O
of	O
intimate	O
cell	O
-	O
to	O
-	O
substratum	O
adhesion	O
.	O

In	O
this	O
location	O
,	O
it	O
interacts	O
with	O
other	O
proteins	O
of	O
the	O
focal	O
adhesion	O
to	O
activate	O
intracellular	O
signalling	O
events	O
associated	O
with	O
cell	O
adhesion	O
.	O

The	O
in	O
vitro	O
expression	O
of	O
FAK	O
and	O
its	O
level	O
of	O
phosphorylation	O
appear	O
to	O
be	O
related	O
to	O
several	O
physiological	O
phenomena	O
,	O
including	O
cell	O
spreading	O
,	O
cell	O
differentiation	O
,	O
cell	O
locomotion	O
and	O
cell	O
death	O
.	O

Because	O
these	O
phenomena	O
are	O
all	O
of	O
critical	O
importance	O
during	O
morphogenesis	O
,	O
and	O
because	O
FAK	O
is	O
expressed	O
in	O
embryonic	O
cells	O
,	O
evidence	O
has	O
been	O
accumulating	O
to	O
indicate	O
that	O
FAK	O
may	O
be	O
an	O
important	O
modulator	O
of	O
developmental	O
processes	O
.	O

In	O
this	O
review	O
,	O
this	O
evidence	O
is	O
surveyed	O
together	O
with	O
evidence	O
from	O
analogous	O
situations	O
,	O
such	O
as	O
tumour	O
cell	O
migration	O
and	O
invasiveness	O
.	O

Although	O
evidence	O
suggesting	O
a	O
role	O
for	O
FAK	O
in	O
morphogenesis	O
is	O
accumulating	O
,	O
current	O
uncertainties	O
regarding	O
its	O
cytoplasmic	O
location	O
and	O
its	O
molecular	O
interactions	O
in	O
vivo	O
make	O
it	O
difficult	O
to	O
reach	O
definitive	O
conclusions	O
regarding	O
the	O
significance	O
of	O
its	O
contributions	O
to	O
developmental	O
processes	O
.	O

Selective	O
inhibition	O
of	O
the	O
renal	O
dopamine	O
subtype	O
D1A	O
receptor	O
induces	O
antinatriuresis	O
in	O
conscious	O
rats	O
.	O

Both	O
dopamine	O
D1	O
-	O
like	O
(	O
D1A	O
and	O
D1B	O
)	O
and	O
D2	O
-	O
like	O
(	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
)	O
receptor	O
subfamilies	O
are	O
present	O
in	O
the	O
kidney	O
.	O

Blockade	O
of	O
the	O
intrarenal	O
D1	O
-	O
like	O
receptor	O
family	O
is	O
associated	O
with	O
natriuresis	O
and	O
diuresis	O
.	O

Because	O
the	O
D1A	O
and	O
D1B	O
receptor	O
subtypes	O
are	O
not	O
distinguishable	O
by	O
currently	O
available	O
dopaminergic	O
agents	O
,	O
their	O
functional	O
role	O
remains	O
undefined	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
selective	O
inhibition	O
of	O
the	O
renal	O
D1A	O
receptor	O
with	O
phosphorothioated	O
antisense	O
oligodeoxynucleotide	O
(	O
AS	O
-	O
ODN	O
)	O
was	O
investigated	O
in	O
conscious	O
uninephrectomized	O
rats	O
.	O

After	O
renal	O
interstitial	O
administration	O
of	O
Texas	O
red	O
-	O
labeled	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
,	O
intense	O
fluorescent	O
signal	O
was	O
localized	O
in	O
the	O
renal	O
tubular	O
epithelium	O
and	O
vasculature	O
.	O

In	O
rats	O
on	O
normal	O
salt	O
intake	O
,	O
AS	O
-	O
ODN	O
injected	O
interstitially	O
into	O
the	O
kidney	O
reduced	O
daily	O
urinary	O
sodium	O
excretion	O
(	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
04	O
versus	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
2	O
mEq	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
urine	O
output	O
(	O
16	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
versus	O
12	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
6	O
mL	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
rats	O
on	O
high	O
sodium	O
intake	O
,	O
continuous	O
renal	O
interstitial	O
administration	O
of	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
transiently	O
decreased	O
daily	O
urinary	O
sodium	O
excretion	O
(	O
5	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mEq	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
urine	O
output	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
5	O
versus	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
8	O
mL	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Neither	O
vehicle	O
nor	O
sense	O
oligodeoxynucleotide	O
had	O
significant	O
effects	O
.	O

Systolic	O
blood	O
pressure	O
remained	O
unchanged	O
.	O

The	O
renal	O
D1A	O
receptor	O
protein	O
was	O
significantly	O
decreased	O
by	O
35	O
%	O
and	O
46	O
%	O
at	O
the	O
end	O
of	O
the	O
study	O
in	O
AS	O
-	O
ODN	O
-	O
treated	O
rats	O
on	O
normal	O
and	O
high	O
salt	O
intake	O
,	O
respectively	O
,	O
whereas	O
the	O
D1B	O
receptor	O
and	O
beta	O
-	O
actin	O
were	O
not	O
affected	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
the	O
renal	O
D1A	O
receptor	O
subtype	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
sodium	O
excretion	O
.	O

Reactivity	O
of	O
lymphocytes	B
to	O
a	O
progesterone	O
receptor	O
-	O
specific	O
monoclonal	O
antibody	O
.	O

In	O
this	O
study	O
we	O
present	O
evidence	O
for	O
reactivity	O
of	O
pregnancy	O
lymphocytes	O
,	O
but	O
not	O
nonpregnancy	O
lymphocytes	O
,	O
with	O
the	O
progesterone	O
receptor	O
-	O
specific	O
monoclonal	O
antibody	O
mPRI	O
.	O

Using	O
an	O
avidin	O
-biotin	O
peroxidase	O
detection	O
system	O
,	O
we	O
found	O
a	O
nuclear	O
staining	O
in	O
14.6	O
+	O
/-	O
3.7	O
%	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
N	O
=	O
27	O
)	O
of	O
pregnancy	O
lymphocytes	O
,	O
while	O
only	O
0.47	O
+	O
/-	O
0.33	O
%	O
(	O
mean	O
+	O
/-	O
SEM	O
,	O
N	O
=	O
15	O
)	O
of	O
nonpregnancy	O
lymphocytes	O
reacted	O
with	O
the	O
antibody	O
.	O

To	O
characterize	O
the	O
receptor	O
-	O
bearing	O
subset	O
,	O
CD8	B
+	I
and	I
CD4	I
+	I
cells	I
were	O
depleted	O
by	O
complement	O
-	O
dependent	O
lysis	O
.	O

Depletion	O
of	O
CD8	B
+	I
cells	I
was	O
accompanied	O
by	O
62	O
+	O
/-	O
18	O
%	O
loss	O
of	O
progesterone	B
receptor	I
-	I
bearing	I
cells	I
,	O
while	O
depletion	O
of	O
CD4	B
+	I
cells	I
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
number	O
of	O
positively	O
staining	O
lymphocytes	B
.	O

In	O
nonpregnancy	B
lymphocytes	I
a	O
3-day	O
PHA	O
treatment	O
,	O
as	O
well	O
as	O
allogeneic	O
stimulation	O
,	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
receptor	O
-	O
containing	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
pregnancy	O
,	O
but	O
not	O
nonpregnancy	O
,	O
lymphocytes	B
contain	O
progesterone	O
binding	O
structures	O
,	O
and	O
that	O
these	O
are	O
inducible	O
by	O
mitogenic	O
or	O
alloantigenic	O
stimuli	O
.	O

Two	O
distinct	O
transcription	O
factors	O
that	O
bind	O
the	O
immunoglobulin	O
enhancer	O
microE5	O
/	O
kappa	O
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	O
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	O
and	O
ITF-2	O
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5	O
/	O
kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	O
and	O
ITF-2	O
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix	O
-	O
loop	O
-	O
helix	O
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	O
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	O
factors	O
.	O

Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	O
single	O
element	O
seems	O
absolutely	O
required	O
for	O
activity	O
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non	O
-	O
B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	O
factor	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
lymphoid	O
cells	O
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF	O
-	O
muE3	O
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	O
in	O
non	O
-	O
B	O
cells	O
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell	O
-	O
type	O
-	O
specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell	O
-	O
specific	O
factors	O
such	O
as	O
Oct-2A	O
and	O
Oct-2B	O
that	O
are	O
not	O
expressed	O
in	O
most	O
other	O
cell	O
types	O
:	O
(	O
b	O
)	O
ubiquitous	O
factors	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	O
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	O
apparently	O
unable	O
to	O
bind	O
to	O
the	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
in	O
non	O
-	O
B	O
cells	O
,	O
perhaps	O
due	O
to	O
a	O
non	O
-	O
permissive	O
chromatin	O
structure	O
of	O
the	O
Ig	O
heavy	O
chain	O
locus	O
.	O

Transcriptional	O
and	O
post	O
-	O
transcriptional	O
regulation	O
of	O
c	O
-	O
jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	B
myeloid	I
leukemic	I
cells	I
.	O

AP-1	O
,	O
the	O
polypeptide	O
product	O
of	O
c	O
-	O
jun	O
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c	O
-	O
jun	O
gene	O
expression	O
in	O
HL-60	B
cells	I
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c	O
-	O
jun	O
transcripts	O
were	O
detectable	O
in	O
untreated	B
HL-60	I
leukemic	I
cells	I
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c	O
-	O
jun	O
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	B
U-937	I
and	O
THP-1	B
monocytic	I
leukemia	I
cells	I
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	O
kinase	O
C	O
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c	O
-	O
jun	O
expression	O
.	O

TPA	O
treatment	O
of	O
HL-60	B
cells	I
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c	O
-	O
jun	O
transcripts	O
.	O

Run	O
-	O
on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c	O
-	O
jun	O
gene	O
transcription	O
in	O
untreated	B
HL-60	I
cells	I
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O

Treatment	O
of	O
HL-60	B
cells	I
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	O
effect	O
on	O
the	O
rates	O
of	O
c	O
-	O
jun	O
transcription	O
.	O

The	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
as	O
determined	O
by	O
treating	O
HL-60	B
cells	I
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
RNA	O
in	O
TPA	B
-	I
treated	I
HL-60	I
cells	I
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c	O
-	O
jun	O
RNA	O
observed	O
during	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
mechanisms	O
.	O

The	O
ubiquitous	O
octamer	O
-	O
binding	O
protein	O
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O

All	O
immunoglobulin	O
genes	O
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer	O
-	O
binding	O
proteins	O
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	O
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	O
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	B
pre	I
-	I
B	I
-	I
cell	I
lines	I
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	O
yet	O
still	O
express	O
high	O
levels	O
of	O
steady	O
-	O
state	O
immunoglobulin	O
heavy	O
-	O
chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	O
gene	O
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	O
made	O
from	O
one	O
of	O
these	O
pre	B
-	I
B	I
cells	I
or	O
from	O
HeLa	B
cells	I
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	O
gene	O
.	O

Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	O
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF-1	O
,	O
without	O
OTF-2	O
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
and	O
that	O
OTF-2	O
alone	O
is	O
not	O
responsible	O
for	O
the	O
B	O
-	O
cell	O
-	O
specific	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Perceived	O
social	O
support	O
and	O
tumor	O
estrogen	O
/	O
progesterone	O
receptor	O
status	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
breast	O
cancer	O
patients	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
prediction	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
in	O
61	O
Stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
,	O
between	O
the	O
ages	O
of	O
25	O
and	O
70	O
,	O
who	O
were	O
accrued	O
to	O
this	O
project	O
.	O

All	O
baseline	O
interview	O
and	O
testing	O
data	O
were	O
obtained	O
either	O
just	O
before	O
patients	O
were	O
discharged	O
from	O
the	O
hospital	O
,	O
or	O
at	O
their	O
first	O
outpatient	O
visit	O
,	O
within	O
two	O
weeks	O
of	O
discharge	O
.	O

A	O
major	O
interest	O
of	O
this	O
project	O
is	O
the	O
predictive	O
value	O
of	O
perceived	O
social	O
support	O
,	O
as	O
a	O
potential	O
`	O
`	O
stress	O
''	O
buffer	O
,	O
related	O
to	O
NK	O
activity	O
.	O

In	O
the	O
main	O
model	O
reported	O
here	O
,	O
we	O
found	O
that	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
could	O
be	O
explained	O
by	O
five	O
variables	O
.	O

Higher	O
NK	O
activity	O
could	O
be	O
predicted	O
by	O
the	O
perception	O
of	O
high	O
quality	O
emotional	O
support	O
from	O
a	O
spouse	O
or	O
intimate	O
other	O
,	O
perceived	O
social	O
support	O
from	O
the	O
patient	O
's	O
physician	O
,	O
estrogen	O
receptor	O
-negative	O
tumor	O
status	O
,	O
having	O
an	O
excisional	O
biopsy	O
as	O
surgical	O
treatment	O
,	O
and	O
actively	O
seeking	O
social	O
support	O
as	O
a	O
major	O
coping	O
strategy	O
(	O
R2	O
=	O
0.33	O
,	O
F	O
(	O
5	O
,	O
55	O
)	O
=	O
5.5	O
,	O
p	O
less	O
than	O
0.0004	O
)	O
.	O

Findings	O
are	O
discussed	O
in	O
terms	O
of	O
host	O
interaction	O
with	O
tumor	O
endocrine	O
status	O
,	O
and	O
the	O
role	O
that	O
social	O
support	O
might	O
play	O
in	O
modulating	O
such	O
activity	O
.	O

Constitutive	O
expression	O
of	O
HIV-1	O
tat	O
protein	O
in	O
human	B
Jurkat	I
T	I
cells	I
using	O
a	O
BK	O
virus	O
vector	O
.	O

The	O
production	O
and	O
characterization	O
of	O
Jurkat	B
cell	I
lines	I
that	O
constitutively	O
express	O
functional	O
human	O
immune	O
deficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
tat	O
protein	O
,	O
using	O
a	O
BK	O
virus	O
plasmid	O
expression	O
vector	O
and	O
HIV-1	O
tat	O
cDNA	O
,	O
is	O
described	O
.	O

An	O
increased	O
growth	O
rate	O
of	O
these	O
Jurkat	B
-	I
tat	I
cell	I
lines	I
as	O
compared	O
with	O
control	B
cell	I
lines	I
was	O
observed	O
.	O

Effects	O
of	O
aldosterone	O
on	O
intralymphocytic	O
sodium	O
and	O
potassium	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
vitro	O
binding	O
of	O
aldosterone	O
to	O
mineralocorticoid	O
receptors	O
on	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
and	O
its	O
effects	O
on	O
the	O
intracellular	O
sodium	O
and	O
potassium	O
concentrations	O
of	O
HML	O
have	O
already	O
been	O
described	O
.	O

In	O
the	O
present	O
paper	O
this	O
easily	O
accessible	O
human	O
cell	O
model	O
was	O
investigated	O
in	O
13	O
patients	O
with	O
essential	O
hypertension	O
.	O

In	O
only	O
four	O
patients	O
sodium	O
in	O
HML	O
without	O
incubation	O
was	O
elevated	O
compared	O
with	O
the	O
range	O
for	O
normal	O
persons	O
.	O

A	O
decrease	O
of	O
intracellular	O
sodium	O
or	O
potassium	O
occurred	O
during	O
incubation	O
without	O
aldosterone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
addition	O
of	O
1.4	O
nM	O
aldosterone	O
did	O
not	O
prevent	O
this	O
loss	O
of	O
electrolytes	O
as	O
observed	O
in	O
normal	O
persons	O
.	O

Plasma	O
renin	O
activity	O
and	O
aldosterone	O
were	O
not	O
correlated	O
with	O
the	O
electrolyte	O
response	O
and	O
were	O
within	O
the	O
normal	O
limits	O
.	O

The	O
number	O
of	O
mineralocorticoid	O
receptors	O
/cell	O
were	O
within	O
or	O
close	O
to	O
the	O
normal	O
range	O
(	O
n	O
=	O
9	O
)	O
.	O

The	O
independence	O
of	O
intracellular	O
electrolytes	O
from	O
aldosterone	O
despite	O
a	O
normal	O
number	O
of	O
mineralocorticoid	O
receptors	O
may	O
reflect	O
an	O
impairment	O
of	O
the	O
mineralocorticoid	O
effector	O
mechanism	O
in	O
the	O
HML	O
of	O
patients	O
with	O
essential	O
hypertension	O
.	O

Quantitative	O
immunohistochemical	O
analysis	O
of	O
mononuclear	O
infiltrates	O
in	O
breast	O
carcinomas	O
--	O
correlation	O
with	O
tumour	O
differentiation	O
.	O

Inflammatory	O
infiltrates	O
were	O
analysed	O
in	O
tissue	O
sections	O
of	O
76	O
breast	O
carcinomas	O
by	O
counting	O
the	O
percentage	O
of	O
macrophages	O
,	O
IgA+	O
and	O
IgG+	O
plasma	O
cells	O
,	O
T	O
cells	O
with	O
their	O
subpopulations	O
,	O
and	O
natural	O
killer	O
cells	O
,	O
and	O
by	O
measuring	O
postcapillary	O
venules	O
(	O
PCVs	O
,	O
found	O
in	O
12	O
cases	O
)	O
within	O
the	O
infiltrates	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
nuclear	O
grade	O
and	O
biochemically	O
determined	O
hormone	O
receptor	O
status	O
,	O
known	O
markers	O
of	O
tumour	O
differentiation	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
extent	O
of	O
inflammation	O
and	O
nuclear	O
grade	O
(	O
P	O
less	O
than	O
0.0001	O
)	O
,	O
and	O
an	O
inverse	O
correlation	O
between	O
inflammation	O
and	O
oestrogen	O
receptor	O
(	O
OR	O
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
as	O
well	O
as	O
inflammation	O
and	O
progesterone	O
receptor	O
(	O
PR	O
)	O
positivity	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
percentage	O
of	O
the	O
OKT8	B
+	I
suppressor	I
/	I
cytotoxic	I
T	I
cells	I
increased	O
when	O
the	O
inflammation	O
expanded	O
from	O
scanty	O
to	O
moderate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
diameter	O
of	O
the	O
PCVs	O
also	O
increased	O
with	O
increasing	O
inflammatory	O
infiltrate	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

In	O
addition	O
,	O
a	O
direct	O
correlation	O
exists	O
between	O
the	O
diameter	O
of	O
the	O
PCVs	O
and	O
both	O
the	O
percentage	O
of	O
the	O
OKT8	B
+	I
T	I
cells	I
(	O
P	O
less	O
than	O
0.04	O
)	O
and	O
the	O
Leu-7	O
+	O
natural	O
killer	O
cells	O
(	O
P	O
less	O
than	O
0.03	O
)	O
.	O

Mapping	O
of	O
B	O
-	O
cell	O
epitopes	O
of	O
the	O
human	O
hepatitis	O
B	O
virus	O
X	O
protein	O
.	O

The	O
immune	O
response	O
to	O
the	O
X	O
protein	O
of	O
human	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
was	O
studied	O
by	O
epitope	O
mapping	O
by	O
using	O
a	O
set	O
of	O
MS2-HBx	O
fusion	O
proteins	O
and	O
synthetic	O
peptides	O
.	O

Antibodies	O
in	O
sera	O
of	O
patients	O
with	O
acute	O
and	O
chronic	O
HBV	O
infection	O
showed	O
a	O
multispecific	O
immune	O
response	O
.	O

Each	O
serum	O
contained	O
antibodies	O
to	O
a	O
different	O
set	O
of	O
epitopes	O
,	O
which	O
taken	O
together	O
cover	O
most	O
of	O
the	O
HBx	O
sequence	O
.	O

Some	O
of	O
the	O
epitopes	O
were	O
detectable	O
only	O
by	O
immunoblotting	O
with	O
fusion	O
proteins	O
;	O
others	O
were	O
detectable	O
only	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
with	O
synthetic	O
peptides	O
.	O

The	O
carboxy	O
-	O
terminal	O
half	O
of	O
the	O
HBx	O
protein	O
was	O
preferentially	O
recognized	O
by	O
antibodies	O
from	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
contained	O
a	O
short	O
immunodominant	O
antigenic	O
region	O
with	O
at	O
least	O
two	O
major	O
nonoverlapping	O
epitopes	O
.	O

Anti-	O
HBx	O
antibody	O
titers	O
as	O
revealed	O
by	O
peptide	O
ELISAs	O
were	O
highest	O
and	O
most	O
frequent	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
and	O
usually	O
low	O
in	O
acutely	O
infected	O
patients	O
and	O
asymptomatic	O
carriers	O
.	O

The	O
data	O
demonstrate	O
a	O
remarkable	O
qualitative	O
and	O
quantitative	O
heterogeneity	O
of	O
the	O
humoral	O
HBx	O
immune	O
response	O
which	O
can	O
be	O
monitored	O
by	O
HBx	O
-specific	O
peptide	O
ELISAs	O
.	O

Such	O
tests	O
may	O
become	O
useful	O
diagnostic	O
tools	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
ORI1yt	O
enhancer	O
is	O
not	O
B	O
-	O
cell	O
specific	O
and	O
does	O
not	O
respond	O
synergistically	O
to	O
the	O
EBV	O
transcription	O
factors	O
R	O
and	O
Z	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
DR	O
promoter	O
is	O
located	O
upstream	O
of	O
the	O
PstI	O
repeats	O
,	O
and	O
in	O
addition	O
to	O
the	O
TATA	O
box	O
,	O
it	O
contains	O
an	O
upstream	O
region	O
(	O
positions	O
-69	O
to	O
-220	O
)	O
responsive	O
to	O
EB1	O
(	O
Z	O
)	O
(	O
the	O
BZLF1-encoded	O
transcription	O
factor	O
)	O
and	O
an	O
enhancer	O
with	O
two	O
functionally	O
distinct	O
domains	O
,	O
A	O
and	O
B	O
.	O

Domain	O
B	O
has	O
been	O
described	O
as	O
a	O
B	O
-	O
cell	O
-	O
specific	O
EB1-responsive	O
element	O
(	O
P.M.Lieberman	O
,	O
J.M.Hardwick	O
,	O
and	O
S.D.Hayward	O
,	O
J.Virol.63	O
:	O
3040	O
-	O
3050	O
,	O
1989	O
)	O
activated	O
synergistically	O
by	O
EB1	O
and	O
R	O
,	O
an	O
EBV	O
early	O
product	O
encoded	O
by	O
the	O
open	O
reading	O
frame	O
BRLF1	O
(	O
M.A.	O
Cox	O
,	O
J.Leahy	O
,	O
and	O
J.M.Hardwick	O
,	O
J.Virol.64	O
:	O
313	O
-	O
321	O
,	O
1990	O
)	O
.	O

We	O
show	O
here	O
that	O
domain	O
B	O
is	O
an	O
R	O
-	O
responsive	O
element	O
in	O
HeLa	B
cells	I
and	O
is	O
therefore	O
not	O
an	O
EB1-responsive	O
B	O
-	O
cell	O
-	O
specific	O
element	O
.	O

However	O
,	O
there	O
is	O
an	O
EB1-binding	O
site	O
(	O
ZRE	O
-	O
B	O
)	O
located	O
within	O
the	O
R	O
-	O
responsive	O
enhancer	O
region	O
.	O

ZRE	O
-	O
B	O
can	O
be	O
deleted	O
without	O
affecting	O
the	O
R	O
-	O
dependent	O
enhancer	O
activity	O
.	O

Moreover	O
,	O
there	O
is	O
no	O
cooperation	O
or	O
synergy	O
between	O
R	O
and	O
EB1	O
when	O
activating	O
the	O
B	O
domain	O
(	O
ZRE	O
-	O
B	O
plus	O
the	O
R	O
-	O
responsive	O
element	O
)	O
positioned	O
as	O
an	O
enhancer	O
.	O

ZRE	O
-	O
B	O
is	O
therefore	O
not	O
part	O
of	O
the	O
R-	O
inducible	O
enhancer	O
.	O

We	O
have	O
tested	O
several	O
subregions	O
of	O
the	O
DR	O
enhancer	O
B	O
domain	O
,	O
either	O
alone	O
or	O
in	O
combination	O
,	O
for	O
their	O
capacity	O
to	O
transmit	O
the	O
R	O
-	O
activating	O
signal	O
to	O
the	O
rabbit	O
beta	O
-	O
globin	O
promoter	O
.	O

We	O
found	O
that	O
the	O
R	O
-	O
responsive	O
element	O
is	O
composed	O
of	O
four	O
protoenhancers	O
that	O
span	O
the	O
whole	O
B	O
domain	O
.	O

These	O
protoenhancers	O
alone	O
are	O
weakly	O
or	O
not	O
responsive	O
to	O
R	O
.	O

One	O
of	O
the	O
protoenhancers	O
contains	O
the	O
overlapping	O
palindromes	O
5'-TTGTCCcgtGGACAAaTGTCC-3	O
'	O
.	O

However	O
,	O
one	O
palindrome	O
,	O
either	O
alone	O
or	O
duplicated	O
,	O
or	O
the	O
overlapping	O
palindromes	O
did	O
not	O
respond	O
to	O
R	O
.	O

Effects	O
of	O
mitogenic	O
agents	O
upon	O
glucocorticoid	O
action	O
in	O
human	O
tonsillar	O
T	O
-	O
lymphocytes	O
.	O

The	O
treatment	O
of	O
human	O
tonsillar	O
T	O
-	O
lymphocytes	O
with	O
4-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
resulted	O
in	O
about	O
two	O
fold	O
increase	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
number	O
,	O
without	O
any	O
significant	O
change	O
in	O
the	O
receptor	O
affinity	O
.	O

This	O
increase	O
disappeared	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Alone	O
,	O
PMA	O
and	O
calcium	O
ionophore	O
A23187	O
did	O
not	O
affect	O
,	O
but	O
together	O
stimulated	O
,	O
like	O
phytohaemagglutinin	O
(	O
PHA	O
)	O
,	O
leucine	O
and	O
,	O
in	O
particular	O
,	O
thymidine	O
incorporation	O
.	O

PMA	O
enhanced	O
slightly	O
the	O
stimulatory	O
effect	O
of	O
PHA	O
.	O

Alone	O
,	O
these	O
agents	O
failed	O
to	O
alter	O
the	O
suppressive	O
effect	O
of	O
dexamethasone	O
on	O
thymidine	O
and	O
leucine	O
incorporation	O
;	O
however	O
,	O
PMA	O
-	O
A23187	O
and	O
PMA	O
-PHA	O
combinations	O
appeared	O
to	O
antagonize	O
the	O
suppression	O
by	O
dexamethasone	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid	O
-	O
specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
gene	O
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	O
site	O
for	O
a	O
putative	O
additional	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
,	O
designated	O
NF	O
-	O
microB	O
,	O
in	O
the	O
murine	O
IgH	O
enhancer	O
.	O

We	O
demonstrate	O
that	O
the	O
NF	O
-	O
microB	O
-	O
binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	O
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
enhancer	O
in	O
cells	O
of	O
the	O
B	O
-	O
cell	O
lineage	O
but	O
not	O
in	O
nonlymphoid	O
cells	O
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70-base	O
-	O
pair	O
fragment	O
of	O
the	O
IgH	O
enhancer	O
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid	O
-	O
specific	O
protein	O
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid	O
-	O
specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O

Involvement	O
of	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	O
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
in	O
interleukin-1	B
(	I
IL-1	I
)	I
-responsive	I
cells	I
blocked	O
IL-1-induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	O
immunoglobulin	O
enhancer	O
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	O
affect	O
protein	O
kinase	O
C	O
-mediated	O
gene	O
transcription	O
,	O
suggesting	O
that	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinases	O
are	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
IL-1	O
in	O
a	O
number	O
of	O
responsive	O
cell	O
types	O
.	O

Increased	O
glucocorticoid	O
responsiveness	O
of	O
CD4	B
+	I
T	I
-	I
cell	I
clonal	I
lines	I
grown	O
in	O
serum	O
-	O
free	O
media	O
.	O

CEM	B
-	I
C7	I
,	O
a	O
human	B
leukemic	I
CD4	I
+	I
T	I
-	I
lymphocyte	I
cell	I
line	I
and	O
three	O
of	O
its	O
subclones	O
,	O
CEM-4R4	B
,	O
CEM-3R43	B
,	O
and	O
ICR-27	B
,	O
previously	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
5	O
to	O
10	O
%	O
fetal	O
bovine	O
serum	O
,	O
have	O
been	O
adapted	O
to	O
serum	O
-	O
free	O
media	O
.	O

The	O
best	O
medium	O
of	O
those	O
tested	O
was	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
micrograms	O
/	O
ml	O
each	O
transferrin	O
and	O
insulin	O
+	O
5	O
ng	O
/	O
ml	O
sodium	O
selenite	O
+	O
/-	O
0.1	O
%	O
bovine	O
serum	O
albumin	O
.	O

While	O
growing	O
either	O
with	O
or	O
without	O
albumin	O
,	O
the	O
several	O
clonal	B
lines	I
of	O
CEM	B
cells	O
displayed	O
growth	O
similar	O
to	O
serum	O
-	O
supplemented	O
cultures	O
.	O

Cell	O
proliferation	O
of	O
CEM	B
-	I
C7	I
cells	O
cultured	O
in	O
both	O
serum	O
-	O
free	O
media	O
has	O
been	O
sustained	O
for	O
3	O
mo	O
.	O

with	O
culture	O
doubling	O
times	O
of	O
about	O
25	O
h	O
for	O
both	O
serum	B
-	I
supplemented	I
and	I
serum	I
-	I
free	I
cultures	I
(	O
viability	O
greater	O
than	O
or	O
equal	O
to	O
90	O
%	O
)	O
.	O

Cell	O
morphology	O
remained	O
essentially	O
the	O
same	O
in	O
serum	O
-	O
free	O
or	O
serum	O
containing	O
media	O
.	O

The	O
expression	O
of	O
CD4	O
,	O
a	O
marker	O
for	O
T	O
-	O
derived	O
lymphoid	O
cells	O
,	O
was	O
not	O
significantly	O
different	O
in	O
serum	O
-	O
free	O
medium	O
.	O

When	O
grown	O
in	O
serum	O
-	O
free	O
medium	O
,	O
CEM	B
-	I
C7	I
cells	O
exhibited	O
increased	O
steroid	O
responsiveness	O
as	O
evidenced	O
by	O
increased	O
glucocorticoid	O
receptor	O
binding	O
sites	O
,	O
increased	O
induction	O
of	O
glutamine	O
synthetase	O
,	O
and	O
cell	O
lysis	O
at	O
lower	O
concentrations	O
of	O
steroid	O
.	O

Receptor	O
mutant	O
subclones	O
of	O
CEM	B
-	I
C7	I
,	O
which	O
are	O
proven	O
to	O
be	O
completely	O
unresponsive	O
to	O
micromolar	O
concentrations	O
of	O
dexamethasone	O
when	O
grown	O
in	O
serum	O
-	O
supplemented	O
medium	O
,	O
become	O
partially	O
sensitive	O
to	O
the	O
hormone	O
after	O
growth	O
in	O
defined	O
medium	O
.	O

The	O
increased	O
sensitivity	O
of	O
CEM	B
-	I
C7	I
cells	I
and	O
its	O
subclones	O
to	O
dexamethasone	O
in	O
serum	O
-	O
free	O
medium	O
returned	O
to	O
previous	O
levels	O
when	O
these	O
cells	O
were	O
recultured	O
in	O
serum	O
-	O
containing	O
medium	O
.	O

Our	O
results	O
suggest	O
that	O
substances	O
in	O
serum	O
influence	O
steroid	O
effects	O
on	O
these	O
cells	O
and	O
that	O
the	O
molecular	O
details	O
of	O
glucocorticoid	O
hormone	O
action	O
may	O
be	O
pursued	O
more	O
precisely	O
in	O
a	O
clearly	O
defined	O
culture	O
medium	O
.	O

Mononuclear	O
leukocyte	O
glucocorticoid	O
receptor	O
binding	O
characteristics	O
and	O
down	O
-	O
regulation	O
in	O
major	O
depression	O
.	O

Some	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
have	O
elevated	O
plasma	O
cortisol	O
concentrations	O
and	O
show	O
failure	O
to	O
suppress	O
cortisol	O
secretion	O
upon	O
administration	O
of	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
yet	O
they	O
do	O
not	O
have	O
Cushingoid	O
features	O
.	O

To	O
study	O
whether	O
this	O
represents	O
glucocorticoid	O
(	O
GC	O
)	O
resistance	O
,	O
[	O
3H	O
]	O
-DEX	O
-	O
binding	O
assays	O
were	O
used	O
to	O
measure	O
,	O
in	O
vitro	O
,	O
the	O
GC	O
receptor	O
affinity	O
(	O
1	O
/	O
Kd	O
)	O
and	O
number	O
(	O
Bmax	O
)	O
in	O
mononuclear	O
leukocytes	O
of	O
11	O
MDD	O
patients	O
and	O
15	O
control	O
subjects	O
.	O

No	O
receptor	O
abnormalities	O
were	O
detected	O
in	O
the	O
MDD	O
group	O
;	O
thus	O
any	O
cellular	O
defect	O
leading	O
to	O
a	O
lack	O
of	O
responsiveness	O
to	O
GC	O
in	O
the	O
MDD	O
patients	O
,	O
if	O
present	O
,	O
probably	O
lies	O
beyond	O
the	O
initial	O
receptor	O
binding	O
.	O

DEX	O
(	O
1.0	O
mg	O
orally	O
)	O
was	O
administered	O
to	O
study	O
in	O
vivo	O
GC	O
receptor	O
down	O
-	O
regulation	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
fewer	O
depressed	O
subjects	O
down	O
-	O
regulated	O
Bmax	O
after	O
DEX	O
.	O

By	O
paired	O
t	O
-	O
test	O
,	O
Bmax	O
decreased	O
significantly	O
in	O
the	O
control	O
group	O
but	O
not	O
in	O
the	O
depressed	O
group	O
.	O

Receptor	O
number	O
on	O
the	O
control	O
day	O
did	O
not	O
correlate	O
significantly	O
with	O
the	O
degree	O
of	O
receptor	O
down	O
-	O
regulation	O
,	O
severity	O
of	O
depression	O
or	O
cortisol	O
concentrations	O
across	O
all	O
the	O
subjects	O
.	O

These	O
results	O
do	O
not	O
lend	O
support	O
to	O
previous	O
reports	O
suggesting	O
that	O
GC	O
resistance	O
in	O
MDD	O
results	O
from	O
a	O
GC	O
receptor	O
-	O
binding	O
abnormality	O
,	O
and	O
they	O
emphasize	O
the	O
importance	O
of	O
considering	O
receptor	O
studies	O
in	O
the	O
context	O
of	O
GC	O
-	O
mediated	O
cell	O
processes	O
in	O
order	O
to	O
identify	O
the	O
exact	O
cellular	O
defect	O
(	O
s	O
)	O
leading	O
to	O
GC	O
resistance	O
.	O

Two	O
distinct	O
forms	O
of	O
active	O
transcription	O
factor	O
CREB	O
(	O
cAMP	O
response	O
element	O
binding	O
protein	O
)	O
.	O

Mammalian	O
cells	O
express	O
two	O
distinct	O
forms	O
of	O
transcription	O
factor	O
CREB	O
(	O
cAMP	O
response	O
element	O
binding	O
protein	O
)	O
that	O
are	O
apparently	O
the	O
products	O
of	O
alternative	O
splicing	O
of	O
the	O
CREB	O
gene	O
transcript	O
.	O

The	O
two	O
proteins	O
differ	O
by	O
a	O
14-amino	O
acid	O
serine	O
-	O
rich	O
insertion	O
present	O
in	O
one	O
of	O
the	O
CREB	O
isoforms	O
.	O

We	O
show	O
that	O
both	O
CREB	O
isoforms	O
are	O
expressed	O
in	O
many	O
cell	O
types	O
and	O
mammalian	O
species	O
.	O

Both	O
encode	O
proteins	O
that	O
bind	O
specifically	O
to	O
a	O
cAMP	O
response	O
element	O
in	O
vitro	O
.	O

As	O
expected	O
for	O
proteins	O
of	O
this	O
class	O
,	O
the	O
CREB	O
proteins	O
bind	O
DNA	O
as	O
dimers	O
.	O

Both	O
proteins	O
impart	O
cAMP	O
-	O
regulated	O
transcriptional	O
activity	O
to	O
a	O
heterologous	O
DNA	O
-	O
binding	O
domain	O
,	O
showing	O
that	O
cAMP	O
directly	O
modulates	O
the	O
transcriptional	O
stimulatory	O
activity	O
of	O
CREB	O
.	O

The	O
presence	O
of	O
multiple	O
CREB	O
isoforms	O
with	O
identical	O
DNA	O
-	O
binding	O
specificities	O
but	O
differences	O
in	O
the	O
presumed	O
regulatory	O
domain	O
raises	O
the	O
possibility	O
that	O
CREB	O
proteins	O
may	O
be	O
able	O
to	O
integrate	O
distinct	O
regulatory	O
signals	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

[	O
The	O
inhibitory	O
effect	O
of	O
hydrocortisone	O
on	O
the	O
chemotactic	O
migration	O
of	O
human	O
leukocytes	O
]	O

Random	O
migration	O
(	O
RM	O
)	O
and	O
chemotactic	O
migration	O
(	O
ChtM	O
)	O
of	O
human	O
leukocytes	O
to	O
yeast	O
activated	O
serum	O
were	O
studied	O
with	O
the	O
modified	O
Boyden	O
chamber	O
method	O
.	O

Both	O
RM	O
and	O
ChtM	O
showed	O
circadian	O
rhythm	O
.	O

Leukocytes	O
migrated	O
most	O
rapidly	O
at	O
night	O
.	O

The	O
difference	O
between	O
the	O
peak	O
(	O
0	O
:	O
00	O
)	O
and	O
trough	O
values	O
(	O
8	O
:	O
00	O
)	O
of	O
RM	O
and	O
ChtM	O
was	O
significant	O
statistically	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

ChtM	O
was	O
inhibited	O
by	O
hydrocortisone	O
(	O
F	O
)	O
of	O
physiological	O
concentration	O
(	O
10	O
(	O
-9	O
)	O
-10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
which	O
was	O
dose	O
-	O
dependent	O
and	O
completely	O
antagonized	O
by	O
the	O
competitive	O
antagonist	O
,	O
RU38486	O
.	O

The	O
inhibitory	O
effect	O
was	O
much	O
more	O
evident	O
with	O
higher	O
dose	O
(	O
more	O
than	O
10	O
(	O
-5	O
)	O
mol	O
/	O
L	O
)	O
and	O
it	O
was	O
also	O
reversed	O
by	O
RU38486	O
,	O
but	O
only	O
partially	O
.	O

It	O
is	O
suggested	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
may	O
be	O
a	O
physiological	O
regulator	O
of	O
the	O
activity	O
of	O
leukocytes	O
and	O
its	O
inhibitory	O
action	O
on	O
ChtM	O
may	O
be	O
involved	O
in	O
antiinflammatory	O
mechanisms	O
of	O
GC	O
of	O
pharmacological	O
doses	O
.	O

The	O
action	O
of	O
physiological	O
and	O
pharmacological	O
concentration	O
of	O
GC	O
may	O
be	O
mediated	O
by	O
low	O
affinity	O
specific	O
binding	O
sites	O
of	O
glucocorticoid	O
receptors	O
.	O

Tandem	O
AP-1-binding	O
sites	O
within	O
the	O
human	O
beta	O
-	O
globin	O
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	O
epsilon	O
-	O
globin	O
gene	O
within	O
the	O
dominant	O
control	O
or	O
locus	O
-	O
activating	O
region	O
.	O

This	O
enhancer	O
is	O
inducible	O
in	O
K562	B
human	I
erythroleukemia	I
cells	I
,	O
increasing	O
linked	O
gamma	O
-	O
globin	O
promoter	O
/luciferase	O
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	O
construct	O
.	O

The	O
enhancer	O
consists	O
of	O
tandem	O
AP-1-binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O

DNA	O
-	O
protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	O
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	O
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	O
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	O
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	O
and	O
fos	O
families	O
to	O
tandem	O
AP-1	O
consensus	O
sequences	O
.	O

Detection	O
in	O
non	O
-	O
erythroid	O
cells	O
of	O
a	O
factor	O
with	O
the	O
binding	O
characteristics	O
of	O
the	O
erythroid	O
cell	O
transcription	O
factor	O
EF1	O
.	O

The	O
erythroid	O
transcription	O
factor	O
erythroid	O
factor-1	O
(	O
EF1	O
)	O
plays	O
a	O
critical	O
role	O
in	O
the	O
transcription	O
of	O
erythroid	O
-	O
specific	O
genes	O
.	O

Here	O
we	O
report	O
the	O
presence	O
of	O
a	O
factor	O
with	O
the	O
mobility	O
and	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
characteristics	O
of	O
EF1	O
at	O
low	O
abundance	O
in	O
a	O
wide	O
variety	O
of	O
non	O
-	O
erythroid	O
cell	O
types	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
EF1	O
-like	O
activity	O
in	O
non	O
-	O
erythroid	O
cells	O
and	O
indicates	O
that	O
this	O
factor	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
expressed	O
in	O
such	O
cells	O
.	O

Interferon	O
affects	O
nuclear	O
proteins	O
in	O
cells	O
of	O
clinically	O
sensitive	O
chronic	O
myelogenous	O
leukemia	O
patients	O
.	O

Cytoplasmic	O
protein	O
extracts	O
from	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
cells	O
contained	O
an	O
activity	O
that	O
altered	O
the	O
electrophoretic	O
mobility	O
of	O
complexes	O
formed	O
between	O
nuclear	O
proteins	O
and	O
the	O
transcriptional	O
enhancers	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
genes	O
.	O

Exposure	O
of	O
CML	O
cells	O
to	O
IFN	O
-	O
alpha	O
diminished	O
the	O
effect	O
of	O
the	O
CML	O
cytoplasmic	O
proteins	O
on	O
these	O
nuclear	O
protein	O
-	O
DNA	O
complexes	O
.	O

The	O
presence	O
of	O
clinical	O
responsiveness	O
to	O
IFN	O
-	O
alpha	O
correlated	O
with	O
the	O
sensitivity	O
to	O
the	O
IFN	O
-induced	O
change	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
nuclear	O
protein	O
-	O
DNA	O
complexes	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
IFN	O
-	O
alpha	O
in	O
CML	O
may	O
be	O
linked	O
to	O
a	O
pathway	O
that	O
can	O
result	O
in	O
posttranslational	O
modification	O
of	O
nuclear	O
proteins	O
.	O

Two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
glucocorticoid	O
receptor	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
have	O
a	O
lytic	O
effect	O
in	O
leukemic	O
cells	O
via	O
interactions	O
with	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
.	O

Cortisol	O
and	O
various	O
synthetic	O
glucocorticoids	O
bind	O
to	O
the	O
GR	O
with	O
one	O
-	O
site	O
kinetics	O
.	O

Cortivazol	O
(	O
CVZ	O
)	O
is	O
a	O
unique	O
,	O
high	O
potency	O
synthetic	O
glucocorticoid	O
,	O
which	O
has	O
a	O
phenylpyrazol	O
fused	O
to	O
the	O
A	O
-	O
ring	O
of	O
the	O
steroid	O
nucleus	O
and	O
displays	O
binding	O
consistent	O
with	O
two	O
or	O
more	O
sites	O
in	O
the	O
cytosol	O
from	O
CEM	B
C7	I
cells	I
(	O
a	O
human	B
acute	I
lymphoblastic	I
T	I
-	I
cell	I
line	I
)	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
lower	O
affinity	O
class	O
of	O
sites	O
are	O
similar	O
in	O
affinity	O
and	O
site	O
molarity	O
to	O
those	O
recognized	O
by	O
dexamethasone	O
.	O

The	O
higher	O
affinity	O
sites	O
bind	O
CVZ	O
with	O
20-	O
to	O
50-fold	O
greater	O
affinity	O
,	O
consistent	O
with	O
CVZ	O
's	O
enhanced	O
biological	O
effects	O
.	O

In	O
mutant	O
leukemic	O
cells	O
resistant	O
to	O
the	O
lytic	O
effects	O
of	O
dexamethasone	O
,	O
CVZ	O
both	O
lyses	O
the	O
cells	O
and	O
recognizes	O
a	O
single	O
class	O
of	O
sites	O
similar	O
to	O
the	O
high	O
affinity	O
site	O
in	O
CEM	B
C7	I
cells	I
.	O

We	O
have	O
carried	O
out	O
experiments	O
to	O
define	O
the	O
nature	O
of	O
the	O
higher	O
affinity	O
CVZ	O
binding	O
site	O
.	O

We	O
now	O
show	O
that	O
:	O
1	O
)	O
CVZ	O
has	O
more	O
than	O
one	O
binding	O
site	O
in	O
a	O
second	O
,	O
independent	O
,	O
B	B
-	I
cell	I
line	I
,	O
IM-9	B
;	O
2	O
)	O
the	O
antiglucocorticoid	O
RU	O
38486	O
is	O
able	O
to	O
block	O
both	O
CVZ	O
's	O
higher	O
and	O
lower	O
affinity	O
sites	O
;	O
3	O
)	O
all	O
of	O
CVZ	O
's	O
binding	O
sites	O
are	O
on	O
a	O
protein	O
immunologically	O
indistinguishable	O
from	O
the	O
human	O
GR	O
;	O
and	O
4	O
)	O
freshly	O
isolated	O
clones	O
of	O
CVZ	O
-	O
resistant	O
cells	O
have	O
lost	O
all	O
binding	O
sites	O
for	O
CVZ	O
.	O

These	O
data	O
indicate	O
that	O
CVZ	O
is	O
recognizing	O
two	O
glucocorticoid	O
binding	O
sites	O
on	O
the	O
human	O
GR	O
or	O
a	O
protein	O
very	O
similar	O
to	O
it	O
.	O

Astrocytes	O
and	O
glioblastoma	O
cells	O
express	O
novel	O
octamer	O
-	O
DNA	O
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	O
and	O
B	O
cell	O
type	O
Oct-2	O
proteins	O
.	O

The	O
'	O
octamer	O
'	O
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	O
genes	O
in	O
B	O
-	O
lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer	O
-	O
binding	O
protein	O
Oct-2A	O
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B	O
-	O
cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	O
site	O
-dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	O
and	O
MHC	O
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer	O
-	O
binding	O
proteins	O
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	O
binding	O
proteins	O
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	B
glioblastoma	I
and	I
neuroblastoma	I
cell	I
lines	I
.	O

The	O
nervous	O
system	O
-	O
derived	O
(	O
N	O
-	O
Oct	O
)	O
proteins	O
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	O
and	O
Oct-2A	O
proteins	O
.	O

The	O
relationship	O
of	O
the	O
N	O
-	O
Oct	O
proteins	O
to	O
Oct-1	O
and	O
Oct-2A	O
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	O
and	O
Oct-2A	O
proteins	O
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N	O
-	O
Oct	O
-	O
factors	O
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	O
and	O
the	O
lymphoid	O
-	O
specific	O
Oct-2A	O
proteins	O
.	O

In	O
melanoma	O
cells	O
that	O
contain	O
the	O
N	O
-	O
Oct-3	O
factor	O
,	O
a	O
transfected	O
lymphocyte	O
-	O
specific	O
promoter	O
was	O
neither	O
activated	O
nor	O
was	O
it	O
repressed	O
upon	O
contransfection	O
with	O
an	O
Oct-2A	O
expression	O
vector	O
.	O

We	O
therefore	O
speculate	O
that	O
N	O
-	O
Oct-3	O
and	O
other	O
N	O
-	O
Oct	O
factors	O
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Circadian	O
rhythm	O
of	O
glucocorticoid	O
receptors	O
in	O
human	O
peripheral	O
leukocytes	O
and	O
their	O
reactivity	O
to	O
glucocorticoids	O
.	O

1	O
)	O
There	O
exists	O
a	O
CR	O
of	O
GR	O
in	O
human	O
leukocytes	O
,	O
PMN	O
,	O
and	O
monocytes	O
with	O
the	O
peak	O
values	O
from	O
0400	O
to	O
0800	O
hr	O
and	O
the	O
trough	O
values	O
between	O
2300	O
and	O
0000	O
hr	O
.	O

The	O
difference	O
between	O
them	O
was	O
significant	O
statistically	O
.	O

2	O
)	O
The	O
FI	O
of	O
the	O
chemotactic	O
migration	O
rate	O
of	O
PMN	O
by	O
cortisol	O
also	O
showed	O
diurnal	O
changes	O
which	O
were	O
synchronous	O
with	O
that	O
of	O
GR	O
.	O

This	O
indicates	O
that	O
the	O
CR	O
of	O
GR	O
may	O
be	O
of	O
functional	O
significance	O
.	O

3	O
)	O
In	O
Cushing	O
's	O
syndrome	O
,	O
the	O
CR	O
of	O
GR	O
was	O
normal	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
CR	O
of	O
plasma	O
cortisol	O
was	O
disturbed	O
.	O

This	O
indicates	O
the	O
independency	O
of	O
the	O
CR	O
of	O
GR	O
from	O
that	O
of	O
cortisol	O
.	O

4	O
)	O
In	O
apoplexy	O
caused	O
by	O
brain	O
ischemia	O
,	O
the	O
CR	O
of	O
GR	O
was	O
abolished	O
in	O
patients	O
with	O
basal	O
lesions	O
but	O
preserved	O
when	O
the	O
lesions	O
were	O
located	O
in	O
the	O
cerebral	O
cortex	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
main	O
`	O
`	O
circadian	O
pacemaker	O
''	O
of	O
GR	O
is	O
located	O
in	O
the	O
basal	O
brain	O
,	O
most	O
probably	O
in	O
the	O
suprachiasmatic	O
nuclei	O
as	O
has	O
been	O
suggested	O
for	O
rodents	O
.	O

Characterization	O
of	O
defensin	O
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	O
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	O
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP	O
/	O
phoQ	O
two	O
-	O
component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	O
defensins	O
NP-1	O
and	O
NP-2	O
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	O
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	O
[	O
membrane	O
sensor	O
kinase	O
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	O
.	O

The	O
predicted	O
periplasmic	O
domain	O
of	O
the	O
PhoQ	O
protein	O
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	O
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	O
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	O
are	O
polar	O
on	O
phoQ	O
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	O
protein	O
in	O
the	O
absence	O
of	O
PhoP	O
to	O
test	O
whether	O
resistance	O
to	O
defensin	O
requires	O
only	O
the	O
phoQ	O
gene	O
product	O
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	O
without	O
PhoP	O
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	O
.	O

This	O
implied	O
that	O
a	O
pag	O
(	O
phoP	O
-	O
activated	O
gene	O
)	O
product	O
is	O
responsible	O
for	O
defensin	O
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	O
NP-1	O
,	O
NP-5	O
,	O
and	O
HNP-1	O
to	O
activate	O
pag	O
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	O
effect	O
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP	O
-	O
PhoQ	O
regulon	O
because	O
mutations	O
in	O
pagC	O
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	O
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	O
activation	O
(	O
phenotype	O
PhoPc	O
)	O
,	O
had	O
no	O
effect	O
on	O
defensin	O
resistance	O
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP	O
-phoQ	O
two	O
-	O
component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	O
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O

Adherence	O
-	O
dependent	O
increase	O
in	O
human	O
monocyte	O
PDGF	O
(	O
B	O
)	O
mRNA	O
is	O
associated	O
with	O
increases	O
in	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
mRNA	O
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	O
growth	O
factors	O
such	O
as	O
platelet	O
-	O
derived	O
growth	O
factor	O
B	O
subunit	O
(	O
PDGF	O
[	O
B	O
]	O
)	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	O
increase	O
in	O
TGF	O
-	O
beta	O
mRNA	O
was	O
observed	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen	O
-	O
coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	O
(	O
B	O
)	O
mRNA	O
accumulation	O
.	O

The	O
increased	O
PDGF	O
(	O
B	O
)	O
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	O
of	O
the	O
early	O
growth	O
response	O
genes	O
c	O
-	O
fos	O
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c	O
-	O
jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6	O
-	O
24	O
h	O
)	O
.	O

The	O
increase	O
in	O
c	O
-	O
jun	O
and	O
EGR2	O
,	O
but	O
not	O
c	O
-	O
fos	O
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
increases	O
in	O
c	O
-	O
jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Cloning	O
of	O
a	O
mitogen	O
-	O
inducible	O
gene	O
encoding	O
a	O
kappa	O
B	O
DNA	O
-	O
binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	O
oncogene	O
and	O
to	O
cell	O
-	O
cycle	O
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen	O
-	O
inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino	O
-	O
terminal	O
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	O
rel	O
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O

The	O
carboxy	O
-	O
terminal	O
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell	O
-	O
cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	O
oncogene	O
bcl-3	O
and	O
in	O
the	O
ankyrin	O
protein	O
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA	O
-	O
binding	O
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Stimulation	O
of	O
a	O
human	B
T	I
-	I
cell	I
clone	I
with	O
anti	O
-	O
CD3	O
or	O
tumor	O
necrosis	O
factor	O
induces	O
NF	O
-	O
kappa	O
B	O
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer	O
-	O
dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	O
enhancer	O
-	O
binding	O
protein	O
NF	O
-	O
kappa	O
B	O
were	O
analyzed	O
in	O
two	O
human	O
T	B
-	I
cell	I
clones	I
stimulated	O
through	O
their	O
T	O
-	O
cell	O
receptor	O
complex	O
or	O
by	O
tumor	O
necrosis	O
factor	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF	O
-	O
kappa	O
B	O
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O

Interleukin	O
2	O
induced	O
proliferation	O
but	O
not	O
NF	O
-	O
kappa	O
B	O
translocation	O
or	O
LTR	O
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band	O
-	O
shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
is	O
not	O
sufficient	O
to	O
induce	O
HIV	O
enhancer	O
-dependent	O
transcription	O
in	O
cloned	B
T	I
cells	I
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B
T	I
-	I
cell	I
lines	I
and	O
indicates	O
that	O
normal	O
T	O
lymphocytes	O
differ	O
from	O
tumoral	O
T	O
cells	O
in	O
terms	O
of	O
requirements	O
for	O
HIV	O
LTR	O
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T	O
-	O
cell	O
activation	O
,	O
in	O
addition	O
to	O
NF	O
-	O
kappa	O
B	O
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
with	O
the	O
HIV	O
enhancer	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double	O
-	O
stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	O
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
proteins	O
was	O
achieved	O
with	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	O
transcription	O
factor	O
or	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF	O
-	O
kappa	O
B	O
-dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	B
transfected	I
B	I
cell	I
line	I
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	B
T	I
leukemia	I
cells	I
inhibited	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL-2	O
enhancer	O
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti	O
-	O
viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	O
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
NF	O
-	O
AT	O
and	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	O
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
to	O
quantitate	O
beta	O
-	O
galactosidase	O
(	O
beta	O
-	O
gal	O
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF	O
-	O
AT	O
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	O
gene	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	B
stably	I
transfected	I
Jurkat	I
T	I
cells	I
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta	O
-	O
gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	O
beta	O
-	O
gal	O
and	O
others	O
express	O
high	O
levels	O
.	O

This	O
expression	O
pattern	O
can	O
not	O
be	O
accounted	O
for	O
by	O
cell	O
-	O
cycle	O
position	O
or	O
heritable	O
variation	O
.	O

Further	O
results	O
,	O
in	O
which	O
beta	O
-	O
gal	O
activity	O
is	O
correlated	O
with	O
NF	O
-	O
AT	O
-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF	O
-	O
AT	O
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF	O
-	O
AT	O
concentration	O
-	O
dependent	O
assembly	O
of	O
transcription	O
complexes	O
at	O
the	O
promoter	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF	O
-	O
kappa	O
B	O
or	O
the	O
entire	O
interleukin-2	O
enhancer	O
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	O
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O

Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV-1	O
and	O
HIV-2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	O
kappa	O
B	O
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV-2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	O
or	O
HIV-2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	O
kappa	O
B	O
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	O
transcriptional	O
enhancer	O
.	O

Instead	O
of	O
NF	O
kappa	O
B	O
,	O
the	O
activator	O
protein	O
3	O
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O

In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	O
produced	O
by	O
T	O
lymphocytes	O
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	O
protein	O
,	O
cyclophilin	O
and	O
FKBP	O
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

Using	O
constructs	O
in	O
which	O
mRNA	O
production	O
controlled	O
by	O
a	O
specific	O
transcription	O
factor	O
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF	O
-	O
AT	O
,	O
NFIL2	O
A	O
,	O
NFIL2	O
B	O
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	O
kappa	O
B	O
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2	O
+	O
mobilization	O
.	O

However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2	O
+	O
mobilization	O
dependent	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2	O
+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	O
factors	O
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2	O
+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	O
factors	O
.	O

Lymphoid	O
specific	O
gene	O
expression	O
of	O
the	O
adenovirus	O
early	O
region	O
3	O
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
binding	O
motifs	O
.	O

A	O
primary	O
site	O
of	O
infection	O
by	O
human	O
adenoviruses	O
is	O
lymphoid	O
cells	O
.	O

However	O
,	O
analysis	O
of	O
the	O
viral	O
control	O
elements	O
and	O
the	O
cellular	O
factors	O
that	O
regulate	O
adenoviral	O
gene	O
expression	O
in	O
lymphocytes	O
has	O
not	O
been	O
reported	O
.	O

The	O
adenovirus	O
early	O
region	O
3	O
(	O
ES	O
)	O
gene	O
products	O
are	O
involved	O
in	O
the	O
maintenance	O
of	O
viral	O
persistence	O
by	O
complexing	O
with	O
the	O
class	O
I	O
MHC	O
antigens	O
,	O
thus	O
preventing	O
their	O
cell	O
surface	O
expression	O
with	O
a	O
resultant	O
decrease	O
in	O
host	O
immunologic	O
destruction	O
.	O

To	O
determine	O
whether	O
different	O
cellular	O
factors	O
were	O
involved	O
in	O
E3	O
regulation	O
in	O
lymphocytes	O
as	O
compared	O
with	O
HeLa	B
cells	I
,	O
both	O
DNA	O
binding	O
and	O
transfection	O
analysis	O
with	O
the	O
E3	O
promoter	O
in	O
both	O
cell	O
types	O
were	O
performed	O
.	O

These	O
studies	O
detected	O
two	O
novel	O
domains	O
referred	O
to	O
as	O
L1	O
and	O
L2	O
with	O
a	O
variety	O
of	O
lymphoid	O
but	O
not	O
HeLa	O
extracts	O
.	O

Each	O
of	O
these	O
domains	O
possessed	O
strong	O
homology	O
to	O
motifs	O
previously	O
found	O
to	O
bind	O
the	O
cellular	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Transfections	O
of	O
E3	O
constructs	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
revealed	O
that	O
mutagenesis	O
of	O
the	O
distal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L2	O
)	O
had	O
minimal	O
effects	O
on	O
promoter	O
expression	O
in	O
HeLa	B
cells	I
,	O
but	O
resulted	O
in	O
dramatic	O
decreases	O
in	O
expression	O
by	O
lymphoid	O
cells	O
.	O

In	O
contrast	O
,	O
mutagenesis	O
of	O
proximal	O
NF	O
-	O
kappa	O
B	O
motif	O
(	O
L1	O
)	O
had	O
minimal	O
effects	O
on	O
gene	O
expression	O
in	O
both	O
HeLa	B
cells	I
and	O
lymphoid	O
cells	O
but	O
resulted	O
in	O
a	O
small	O
,	O
but	O
reproducible	O
,	O
increase	O
in	O
gene	O
expression	O
in	O
lymphoid	O
cells	O
when	O
coupled	O
to	O
the	O
L2	O
mutation	O
.	O

Reversing	O
the	O
position	O
and	O
subsequent	O
mutagenesis	O
of	O
the	O
L1	O
and	O
L2	O
domains	O
indicated	O
that	O
the	O
primary	O
sequence	O
of	O
these	O
motifs	O
rather	O
than	O
their	O
position	O
in	O
the	O
E3	O
promoter	O
was	O
critical	O
for	O
regulating	O
gene	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Oncogene	O
amplification	O
correlates	O
with	O
dense	O
lymphocyte	O
infiltration	O
in	O
human	O
breast	O
cancers	O
:	O
a	O
role	O
for	O
hematopoietic	O
growth	O
factor	O
release	O
by	O
tumor	O
cells	O
?	O

One	O
hundred	O
six	O
primary	O
breast	O
cancer	O
samples	O
were	O
analysed	O
for	O
c	O
-	O
erbB2	O
,	O
int-2	O
,	O
and	O
c	O
-	O
myc	O
gene	O
amplification	O
.	O

Surgically	O
confirmed	O
nodal	O
involvement	O
was	O
observed	O
in	O
42	O
%	O
.	O

Level	O
of	O
gene	O
amplification	O
was	O
studied	O
by	O
Southern	O
and/or	O
slot	O
blot	O
techniques	O
.	O

Amplified	O
c	O
-	O
erbB2	O
gene	O
sequences	O
were	O
present	O
in	O
21.5	O
%	O
of	O
all	O
samples	O
.	O

Int-2	O
was	O
amplified	O
in	O
13.1	O
%	O
and	O
c	O
-	O
myc	O
was	O
amplified	O
in	O
10.3	O
%	O
.	O

In	O
a	O
non	O
-	O
parametric	O
test	O
(	O
Kruskal	O
-	O
Wallis	O
)	O
a	O
strong	O
negative	O
association	O
was	O
found	O
between	O
high	O
levels	O
of	O
c	O
-	O
erbB2	O
amplification	O
and	O
absence	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
(	O
P	O
=	O
.0009	O
)	O
or	O
progesterone	O
receptor	O
(	O
PR	O
)	O
(	O
P	O
=	O
.011	O
)	O
expression	O
.	O

No	O
correlations	O
were	O
found	O
between	O
all	O
or	O
high	O
levels	O
of	O
amplification	O
of	O
each	O
oncogene	O
separately	O
or	O
combined	O
with	O
T	O
,	O
N	O
,	O
grade	O
,	O
multifocality	O
of	O
tumor	O
,	O
or	O
associated	O
carcinoma	O
in	O
situ	O
.	O

There	O
was	O
a	O
trend	O
approaching	O
statistical	O
significance	O
for	O
patients	O
with	O
c	O
-	O
erbB2	O
amplifications	O
to	O
have	O
positive	O
lymph	O
nodes	O
at	O
surgery	O
(	O
P	O
=	O
0.09	O
)	O
.	O

A	O
somewhat	O
surprising	O
finding	O
however	O
was	O
a	O
very	O
strong	O
association	O
between	O
oncogene	O
amplification	O
and	O
dense	O
lymphocyte	O
infiltration	O
of	O
the	O
tumor	O
(	O
P	O
=	O
.05	O
)	O
.	O
This	O
correlation	O
is	O
even	O
stronger	O
when	O
only	O
high	O
levels	O
of	O
amplification	O
are	O
considered	O
,	O
either	O
for	O
each	O
oncogene	O
separately	O
(	O
P	O
=	O
.0048	O
)	O
or	O
in	O
combination	O
(	O
P	O
=	O
.0007	O
)	O
.	O

We	O
propose	O
that	O
malignant	O
cell	O
cytokine	O
production	O
may	O
help	O
explain	O
this	O
observation	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF	O
-	O
kappa	O
B	O
-like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	O
)	O
of	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	O
plus	O
two	O
p50s	O
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
is	O
mediated	O
by	O
NF	O
-	O
kappa	O
B	O
.	O

However	O
,	O
as	O
NF	O
-	O
kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
which	O
synergizes	O
with	O
NF	O
-	O
kappa	O
B	O
should	O
be	O
considered	O
.	O

Thyroid	O
hormone	O
receptors	O
form	O
distinct	O
nuclear	O
protein	O
-	O
dependent	O
and	O
independent	O
complexes	O
with	O
a	O
thyroid	O
hormone	O
response	O
element	O
.	O

We	O
have	O
examined	O
the	O
binding	O
of	O
nuclear	O
proteins	O
and	O
recombinant	O
thyroid	O
hormone	O
receptors	O
(	O
TRs	O
)	O
to	O
the	O
palindromic	O
thyroid	O
hormone	O
responsive	O
element	O
AGGTCATGACCT	O
(	O
TREp	O
)	O
using	O
a	O
gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Four	O
specific	O
protein	O
-	O
DNA	O
complexes	O
were	O
detected	O
after	O
incubation	O
of	O
nuclear	O
extracts	O
(	O
NE	O
)	O
from	O
T3-responsive	B
pituitary	I
(	I
GH3	I
)	I
cells	I
with	O
a	O
TREp	O
-	O
containing	O
DNA	O
fragment	O
.	O

This	O
was	O
compared	O
with	O
the	O
TREp	O
binding	O
of	O
reticulocyte	O
lysate	O
-	O
synthesized	O
TRs	O
.	O

TR	O
alpha	O
1	O
and	O
TR	O
beta	O
2	O
each	O
formed	O
a	O
single	O
major	O
TR	O
:	O
TREp	O
complex	O
which	O
comigrated	O
with	O
the	O
least	O
retarded	O
complex	O
formed	O
by	O
GH3	O
NE	O
,	O
while	O
TR	O
beta	O
1	O
formed	O
multiple	O
complexes	O
suggesting	O
that	O
it	O
can	O
bind	O
to	O
TREp	O
as	O
an	O
oligomer	O
.	O

Interestingly	O
,	O
coincubation	O
of	O
35S	O
-	O
TR	O
alpha	O
1	O
,	O
GH3	O
NE	O
,	O
and	O
unlabeled	O
TREp	O
resulted	O
in	O
not	O
only	O
the	O
35S	O
-	O
TR	O
:	O
TREp	O
complex	O
,	O
but	O
in	O
two	O
additional	O
more	O
greatly	O
retarded	O
complexes	O
containing	O
35S	O
-	O
TR	O
alpha	O
1	O
and	O
comigrating	O
with	O
those	O
formed	O
by	O
GH3	O
extract	O
alone	O
.	O

Incubation	O
of	O
each	O
of	O
the	O
TRs	O
with	O
NE	O
from	O
COS-7	B
cells	I
,	O
which	O
do	O
not	O
possess	O
sufficient	O
endogenous	O
TRs	O
to	O
mediate	O
T3-responses	O
,	O
resulted	O
in	O
formation	O
of	O
a	O
new	O
,	O
more	O
greatly	O
shifted	O
complex	O
.	O

A	O
similar	O
,	O
heat	O
labile	O
activity	O
which	O
altered	O
mobility	O
of	O
the	O
TR	O
:	O
TRE	O
complex	O
was	O
also	O
present	O
in	O
NE	O
from	O
T3-unresponsive	B
JEG-3	I
cells	I
.	O

At	O
high	O
concentration	O
of	O
NE	O
,	O
all	O
of	O
the	O
TR	O
bound	O
to	O
TREp	O
was	O
more	O
greatly	O
retarded	O
than	O
in	O
the	O
absence	O
of	O
NE	O
.	O

Truncation	O
of	O
TR	O
alpha	O
1	O
at	O
amino	O
acid	O
210	O
prevented	O
additional	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
NE	O
without	O
affecting	O
DNA	O
binding	O
,	O
suggesting	O
that	O
the	O
carboxyl	O
-	O
terminus	O
of	O
the	O
TRs	O
is	O
essential	O
for	O
interaction	O
with	O
nuclear	O
proteins	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF	O
-	O
kappa	O
B	O
element	O
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	B
T	I
cell	I
line	I
.	O

The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	O
LTR	O
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF	O
-	O
kappa	O
B	O
motif	O
.	O

These	O
changes	O
in	O
the	O
enhancer	O
element	O
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

Subcloning	O
of	O
the	O
variant	O
NF	O
-	O
kappa	O
B	O
segments	O
into	O
LTR	O
-	O
driven	O
CAT	O
expression	O
vectors	O
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative	O
/	O
cytopathic	O
capacity	O
.	O

Glucocorticoid	O
receptors	O
on	O
mononuclear	O
leukocytes	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Several	O
lines	O
of	O
evidence	O
suggest	O
disturbances	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
system	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

In	O
an	O
exploration	O
of	O
the	O
potential	O
role	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
in	O
AD	O
,	O
GR	O
density	O
and	O
affinity	O
were	O
assessed	O
on	O
mononuclear	O
leukocytes	O
of	O
12	O
AD	O
patients	O
and	O
12	O
healthy	O
controls	O
.	O

GR	O
binding	O
characteristics	O
did	O
not	O
differ	O
between	O
patients	O
and	O
controls	O
or	O
between	O
patients	O
subdivided	O
according	O
to	O
diagnosis	O
or	O
associated	O
clinical	O
features	O
.	O

These	O
data	O
suggest	O
that	O
the	O
abnormalities	O
of	O
the	O
HPA	O
system	O
in	O
AD	O
are	O
not	O
related	O
to	O
a	O
GR	O
deficiency	O
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	O
Thy-1	O
gene	O
promoter	O
.	O

The	O
Thy-1	O
gene	O
promoter	O
resembles	O
a	O
`	O
`	O
housekeeping	O
''	O
promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation	O
-	O
free	O
island	O
,	O
lacks	O
a	O
canonical	O
TATA	O
box	O
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	O
termini	O
of	O
the	O
mRNA	O
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	O
confer	O
any	O
tissue	O
specificity	O
and	O
is	O
active	O
only	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	O
promoter	O
and	O
show	O
that	O
the	O
dominant	O
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
Sp1	O
,	O
an	O
inverted	O
CCAAT	O
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O

DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	O
factors	O
to	O
these	O
elements	O
,	O
including	O
Sp1	O
and	O
CP1	O
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	O
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	O
factors	O
Sp1	O
and	O
CP1	O
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	O
sequences	O
.	O

Estrogen	O
receptor	O
concentration	O
and	O
social	O
factors	O
as	O
predictors	O
of	O
natural	O
killer	O
cell	O
activity	O
in	O
early	O
-	O
stage	O
breast	O
cancer	O
patients	O
.	O

Confirmation	O
of	O
a	O
model	O
.	O

Previous	O
work	O
of	O
ours	O
has	O
demonstrated	O
that	O
a	O
significant	O
amount	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
activity	O
variance	O
after	O
surgery	O
in	O
stage	O
I	O
and	O
II	O
breast	O
cancer	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
both	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
status	O
of	O
the	O
tumor	O
and	O
by	O
social	O
factors	O
,	O
namely	O
,	O
perceived	O
social	O
support	O
and	O
seeking	O
social	O
support	O
as	O
a	O
general	O
coping	O
strategy	O
.	O

As	O
considerable	O
evidence	O
has	O
accumulated	O
that	O
social	O
support	O
in	O
both	O
animal	O
and	O
human	O
populations	O
may	O
have	O
survival	O
value	O
,	O
we	O
sought	O
to	O
test	O
the	O
reliability	O
of	O
this	O
regression	O
model	O
,	O
using	O
coping	O
and	O
perceived	O
support	O
factor	O
values	O
obtained	O
at	O
3	O
months	O
after	O
surgery	O
to	O
account	O
for	O
concurrent	O
follow	O
-	O
up	O
NK	O
activity	O
in	O
this	O
serially	O
assessed	O
group	O
of	O
patients	O
.	O

It	O
was	O
found	O
that	O
the	O
most	O
significant	O
variable	O
predicting	O
NK	O
activity	O
at	O
follow	O
-	O
up	O
was	O
tumor	O
ER	O
concentration	O
,	O
with	O
higher	O
NK	O
activity	O
associated	O
with	O
ER	O
-status	O
.	O

In	O
addition	O
,	O
seeking	O
social	O
support	O
as	O
a	O
coping	O
strategy	O
,	O
as	O
well	O
as	O
the	O
perceived	O
quality	O
of	O
support	O
,	O
also	O
entered	O
the	O
model	O
to	O
account	O
for	O
a	O
significant	O
amount	O
of	O
NK	O
activity	O
variance	O
(	O
multivariate	O
F	O
=	O
5.25	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

If	O
,	O
as	O
the	O
literature	O
suggests	O
,	O
NK	O
activity	O
is	O
relevant	O
to	O
breast	O
cancer	O
control	O
,	O
and	O
since	O
ER	O
-tumors	O
have	O
a	O
worse	O
prognosis	O
,	O
we	O
suggest	O
here	O
that	O
perhaps	O
such	O
tumors	O
are	O
resistant	O
to	O
control	O
by	O
NK	O
cells	O
because	O
they	O
lack	O
the	O
ability	O
to	O
attract	O
an	O
accumulation	O
of	O
effector	O
cells	O
to	O
the	O
tumor	O
site	O
,	O
or	O
because	O
blocking	O
factors	O
at	O
the	O
site	O
of	O
the	O
tumor	O
prevent	O
local	O
tumor	O
control	O
at	O
the	O
site	O
of	O
action	O
.	O

The	O
finding	O
related	O
to	O
social	O
support	O
also	O
replicates	O
results	O
from	O
an	O
independent	O
sample	O
of	O
breast	O
cancer	O
patients	O
.	O

This	O
finding	O
,	O
taken	O
together	O
with	O
other	O
evidence	O
that	O
this	O
social	O
variable	O
is	O
associated	O
with	O
longer	O
survival	O
in	O
breast	O
cancer	O
populations	O
,	O
underscores	O
the	O
potential	O
importance	O
of	O
this	O
social	O
support	O
variable	O
.	O

Our	O
findings	O
also	O
suggest	O
one	O
possible	O
immunological	O
variable	O
involved	O
,	O
with	O
potential	O
clinical	O
significance	O
,	O
for	O
this	O
patient	O
population	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B	O
-	O
related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
tax	O
gene	O
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B	O
-	O
related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
and	O
the	O
beta	O
-	O
interferon	O
gene	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	O
constitutively	O
active	O
in	O
B	O
lymphocytes	O
,	O
suggesting	O
that	O
other	O
regulatory	O
mechanisms	O
must	O
play	O
a	O
role	O
in	O
determining	O
the	O
patterns	O
of	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B	O
-	O
related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	B
plasma	I
cells	I
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B	O
-	O
cell	O
-	O
derived	O
NF	O
-	O
kappa	O
B	O
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	O
2	O
receptor	O
or	O
T	O
-	O
cell	O
receptor	O
genes	O
in	O
S194	B
cells	I
.	O

However	O
,	O
in	O
either	O
EL-4	B
(	I
T	I
)	I
cells	I
or	O
S194	B
cells	I
,	O
both	O
lower	O
-	O
affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	O
gene	O
product	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF	O
-	O
kappa	O
B	O
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B	B
-	I
cell	I
line	I
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	O
receptor	O
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	O
cytosolic	O
glucocorticoid	O
receptors	O
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning	O
-	O
to	O
-	O
afternoon	O
decline	O
in	O
glucocorticoid	O
receptor	O
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O

The	O
number	O
of	O
glucocorticoid	O
receptors	O
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

No	O
group	O
differences	O
in	O
cortisol	O
levels	O
were	O
observed	O
,	O
nor	O
were	O
glucocorticoid	O
receptor	O
number	O
and	O
cortisol	O
levels	O
correlated	O
.	O

The	O
number	O
of	O
morning	O
glucocorticoid	O
receptors	O
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	O
glucocorticoid	O
receptors	O
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O

Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O

Sex	O
and	O
age	O
distribution	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
receptors	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
human	O
subjects	O
.	O

Specific	O
receptors	O
for	O
1	O
,	O
25	O
Dihydroxyvitamin	O
D3	O
have	O
been	O
described	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

We	O
have	O
tried	O
to	O
find	O
out	O
whether	O
these	O
receptors	O
could	O
show	O
any	O
difference	O
in	O
sex	O
or	O
age	O
distribution	O
.	O

Twenty	O
two	O
healthy	O
men	O
aged	O
21	O
-	O
66	O
yr	O
(	O
mean	O
+	O
/-	O
SD	O
41.0	O
+	O
/-	O
13.6	O
)	O
and	O
nineteen	O
healthy	O
women	O
aged	O
22	O
-	O
60	O
yr	O
(	O
38.9	O
+	O
/-	O
13.9	O
)	O
have	O
been	O
studied	O
.	O

The	O
mean	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
both	O
sexes	O
(	O
1.35	O
+	O
/-	O
0.70	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
males	O
,	O
1.13	O
+	O
/-	O
0.66	O
x	O
10	O
(	O
-10	O
)	O
M	O
in	O
females	O
)	O
,	O
but	O
the	O
concentration	O
of	O
binding	O
sites	O
(	O
Nmax	O
)	O
was	O
significantly	O
lower	O
in	O
females	O
(	O
2.32	O
+	O
/-	O
0.92	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
vs	O
4.43	O
+	O
/-	O
1.38	O
fmol	O
/	O
10	O
(	O
7	O
)	O
PBMC	O
in	O
males	O
;	O
p	O
=	O
0.0001	O
)	O
.	O

Neither	O
Kd	O
nor	O
Nmax	O
were	O
significantly	O
correlated	O
with	O
age	O
.	O

No	O
difference	O
was	O
found	O
between	O
pre	O
and	O
postmenopausal	O
women	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
elucidate	O
if	O
this	O
sex	O
difference	O
in	O
PBMC	O
receptors	O
for	O
1.25	O
Dihydroxyvitamin	O
D3	O
is	O
of	O
any	O
pathophysiological	O
relevance	O
.	O

Multiple	O
Oct2	O
isoforms	O
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

The	O
interaction	O
of	O
the	O
Oct2	O
transcription	O
factor	O
with	O
the	O
cognate	O
octamer	O
motif	O
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid	O
-	O
specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Ectopic	O
expression	O
of	O
cloned	O
Oct2	O
cDNA	O
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non	O
-	O
lymphoid	O
cells	O
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	O
cDNAs	O
encoding	O
mouse	O
Oct2	O
from	O
a	O
mature	B
B	I
-	I
cell	I
line	I
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	O
factor	O
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

All	O
the	O
isoforms	O
retain	O
the	O
previously	O
characterized	O
POU	O
-	O
domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	O
motif	O
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	O
are	O
present	O
within	O
the	O
same	O
B	O
-	O
cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	O
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	O
are	O
able	O
to	O
activate	O
an	O
octamer	O
containing	O
promoter	O
element	O
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	O
encodes	O
the	O
previously	O
described	O
lymphoid	O
-	O
specific	O
Oct2B	O
protein	O
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	O
motif	O
in	O
the	O
context	O
of	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
.	O

Murine	O
and	O
human	O
T	O
-	O
lymphocyte	O
GATA-3	O
factors	O
mediate	O
transcription	O
through	O
a	O
cis	O
-	O
regulatory	O
element	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O
these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	O
finger	O
DNA	O
-	O
binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	O
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	O
GATA-3	O
factors	O
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	B
and	I
murine	I
T	I
-	I
cell	I
lines	I
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue	O
-	O
specific	O
GATA	O
-	O
binding	O
site	O
identified	O
within	O
the	O
human	O
T	O
-	O
cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

We	O
infer	O
that	O
the	O
murine	O
and	O
human	O
GATA-3	O
proteins	O
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
regulation	O
.	O

A	O
novel	O
T	O
-	O
cell	O
trans	O
-	O
activator	O
that	O
recognizes	O
a	O
phorbol	O
ester	O
-	O
inducible	O
element	O
of	O
the	O
interleukin-2	O
promoter	O
.	O

The	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
promoter	O
is	O
recognized	O
by	O
several	O
cell	O
-	O
type	O
-	O
specific	O
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	O
production	O
and	O
T	O
-	O
cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein	O
-	O
DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
activator	O
TCF-1	O
(	O
for	O
T	O
-	O
Cell	O
Factor-1	O
)	O
,	O
which	O
recognizes	O
a	O
T	O
-	O
cell	O
-	O
specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL-2	O
promoter	O
.	O

Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	O
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	O
is	O
distinct	O
from	O
NF	O
kappa	O
B	O
.	O

However	O
,	O
like	O
NF	O
kappa	O
B	O
,	O
TCF-1	O
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T	O
-	O
cell	O
activators	O
.	O

[	O
Estrogen	O
receptor	O
content	O
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
]	O

ER	O
content	O
in	O
lymphocytes	O
of	O
peripheral	O
blood	O
from	O
27	O
SLE	O
patients	O
and	O
20	O
healthy	O
controls	O
were	O
determined	O
by	O
dextran	O
-	O
coated	O
charcoal	O
assay	O
.	O

ER	O
content	O
in	O
lymphocytes	O
of	O
each	O
sample	O
was	O
expressed	O
by	O
both	O
fmol	O
/	O
mg	O
of	O
lymphocyte	O
cytosolic	O
protein	O
and	O
fmol	O
/	O
micrograms	O
of	O
lymphocyte	O
DNA	O
.	O

The	O
results	O
showed	O
that	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
ER	O
content	O
of	O
lymphocytes	O
from	O
the	O
controls	O
and	O
that	O
from	O
patients	O
with	O
SLE	O
.	O

But	O
the	O
logarithmic	O
mean	O
of	O
ER	O
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
mg	O
of	O
cytosolic	O
protein	O
,	O
in	O
14	O
patients	O
with	O
active	O
SLE	O
(	O
0.9356	O
+	O
/-	O
0.31	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
13	O
patients	O
with	O
inactive	O
SLE	O
(	O
0.2979	O
+	O
/-	O
0.23	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
0.6204	O
+	O
/-	O
0.52	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
normal	O
upper	O
limit	O
of	O
ER	O
content	O
in	O
lymphocytes	O
,	O
expressed	O
by	O
fmol	O
/	O
micrograms	O
of	O
DNA	O
,	O
was	O
0.136	O
.	O

The	O
elevated	O
rate	O
of	O
ER	O
content	O
in	O
lymphocytes	O
in	O
14	O
active	O
SLE	O
(	O
92.9	O
%	O
)	O
was	O
also	O
higher	O
than	O
that	O
in	O
quieiescent	O
patients	O
(	O
23.1	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
and	O
in	O
the	O
controls	O
(	O
10	O
%	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
elevated	O
level	O
of	O
ER	O
content	O
was	O
found	O
to	O
be	O
related	O
to	O
the	O
positive	O
antidsDNA	O
antibody	O
and	O
hypocomplementemia	O
.	O

Cloning	O
of	O
murine	O
TCF-1	O
,	O
a	O
T	O
cell	O
-	O
specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3-epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O

CD3	O
-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	B
cell	I
lineage	I
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF-1	O
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte	O
-	O
specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	O
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF-1	O
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so	O
-	O
called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	O
TCF-1	O
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	O
were	O
not	O
previously	O
observed	O
in	O
human	O
TCF-1	O
.	O

Murine	O
and	O
human	O
TCF-1	O
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	O
TCF-1	O
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF-1	O
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	O
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence	O
-	O
specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	O
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF-1	O
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell	O
-	O
specific	O
element	O
in	O
the	O
T	O
cell	O
receptor	O
alpha	O
(	O
TCR	O
-	O
alpha	O
)	O
enhancer	O
.	O

The	O
T	O
lineage	O
-	O
specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR	O
-	O
alpha	O
and	O
CD3-epsilon	O
enhancers	O
imply	O
an	O
important	O
role	O
for	O
TCF-1	O
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF	O
-	O
kappa	O
B	O
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

However	O
,	O
the	O
U937	B
monocytic	I
cell	I
line	I
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	O
necrosis	O
factor	O
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
suppresses	O
human	O
B	O
lymphocyte	O
Ig	O
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
inhibits	O
B	O
cell	O
Ig	O
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	O
expression	O
.	O

The	O
addition	O
of	O
TGF	O
-	O
beta	O
to	O
human	B
B	I
lymphocyte	I
cultures	I
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	O
completely	O
inhibited	O
B	O
cell	O
Ig	O
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O

In	O
contrast	O
,	O
TGF	O
-	O
beta	O
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	O
cell	O
membrane	O
proteins	O
,	O
HLA	O
-	O
DR	O
and	O
CD20	O
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti	O
-	O
IgM	O
,	O
anti	O
-	O
kappa	O
,	O
and	O
anti	O
-	O
lambda	O
antibodies	O
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	O
L	O
chain	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	O
L	O
chain	O
and	O
microH	O
chain	O
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF	O
-	O
beta	O
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
.	O

Nuclear	O
run	O
-	O
on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	O
L	O
chain	O
.	O

The	O
effects	O
of	O
TGF	O
-	O
beta	O
on	O
two	O
transcriptional	O
regulatory	O
factors	O
,	O
Oct-2	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappa	O
B	O
,	O
known	O
to	O
be	O
important	O
in	O
Ig	O
gene	O
transcription	O
were	O
examined	O
.	O

Oct-2	O
mRNA	O
levels	O
and	O
both	O
Oct-2	O
and	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
nuclear	O
extracts	O
were	O
not	O
altered	O
by	O
treatment	O
with	O
TGF	O
-	O
beta	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	O
factor	O
AP-1	O
,	O
which	O
is	O
not	O
known	O
to	O
be	O
important	O
in	O
B	O
cell	O
Ig	O
production	O
,	O
were	O
reduced	O
by	O
TGF	O
-	O
beta	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF	O
-	O
beta	O
decreases	O
B	O
lymphocyte	O
Ig	O
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O

The	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
inhibits	O
Ig	O
chain	O
synthesis	O
is	O
unclear	O
although	O
it	O
does	O
not	O
involve	O
inhibition	O
of	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
or	O
Oct-2	O
to	O
their	O
respective	O
target	O
sequences	O
.	O

Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	O
receptor	O
messenger	O
ribonucleic	O
acid	O
in	O
wild	B
-	I
type	I
and	O
dexamethasone	B
-	I
resistant	I
human	I
leukemic	I
(	I
CEM	I
)	I
cells	I
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild	B
-	I
type	I
and	O
highly	O
dexamethasone	B
(	I
dex	I
)	I
-resistant	I
clones	I
of	O
the	O
human	B
leukemic	I
cell	I
line	I
CEM	I
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild	B
-	I
type	I
CEM	I
cells	I
but	O
not	O
in	O
a	O
dex	B
-	I
resistant	I
,	I
glucocorticoid	I
receptor	I
(	I
GR	I
)	I
-defective	I
clone	I
ICR-27	B
TK-3	I
,	O
dex	O
induces	O
GR	O
mRNA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex	B
-	I
resistant	I
cells	I
by	O
making	O
use	O
of	O
the	O
residual	O
GR	O
found	O
there	O
,	O
wild	O
-	O
type	O
and	O
dex	B
-	I
resistant	I
clones	I
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	O
mRNA	O
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	O
GR	O
mRNA	O
in	O
the	O
normal	B
CEM	I
-	I
C7	I
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex	B
-	I
resistant	I
clones	I
,	O
although	O
the	O
dex	B
-	I
resistant	I
clones	I
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	O
mRNA	O
induction	O
.	O

Increased	O
levels	O
of	O
GR	O
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	O
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex	B
-	I
resistant	I
cells	I
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	O
mRNA	O
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	B
and	I
dex	I
-	I
resistant	I
CEM	I
cells	I
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex	B
-	I
resistant	I
cells	I
is	O
defective	O
in	O
that	O
dex	B
-	I
resistant	I
clones	I
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	B
cells	I
for	O
lysis	O
of	O
the	O
cells	O
.	O

Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M	O
-	O
CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	O
and	O
fos	O
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c	O
-	O
jun	O
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units	O
/	O
ml	O
human	O
recombinant	O
M	O
-	O
CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c	O
-	O
jun	O
mRNA	O
levels	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M	O
-	O
CSF	O
regulates	O
c	O
-	O
jun	O
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half	O
-	O
life	O
of	O
c	O
-	O
jun	O
transcripts	O
.	O

M	O
-	O
CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun	O
-	O
B	O
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c	O
-	O
jun	O
.	O

We	O
further	O
demonstrate	O
that	O
M	O
-	O
CSF	O
increases	O
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c	O
-	O
fos	O
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos	O
-	O
B	O
gene	O
.	O

Moreover	O
,	O
M	O
-	O
CSF	O
-induced	O
expression	O
of	O
the	O
fos	O
-	O
related	O
gene	O
,	O
fra-1	O
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c	O
-	O
fos	O
and	O
fos	O
-	O
B	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M	O
-	O
CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun	O
/	O
fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

Contribution	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T	O
-	O
cell	O
types	O
.	O

Starting	O
with	O
a	O
replication	O
-	O
incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	O
all	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
binding	O
sites	O
present	O
in	O
the	O
native	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	O
for	O
their	O
capacity	O
to	O
produce	O
virus	O
progeny	O
following	O
transfection	O
-	O
cocultivation	O
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T	O
-	O
cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF	O
-	O
kappa	O
B	O
elements	O
(	O
and	O
no	O
Sp1	O
binding	O
sites	O
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	B
greater	O
than	O
H9	B
greater	O
than	O
CEM	B
greater	O
than	O
Jurkat	B
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second	O
-	O
site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T	O
-	O
cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	O
factors	O
present	O
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	O
receptor	O
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

The	O
number	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method	O
.	O
The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex	O
-	O
and	O
age	O
-	O
matched	O
healthy	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	O
in	O
leucocytes	O
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	O
were	O
1054	O
+	O
/-	O
254	O
sites	O
/	O
cell	O
)	O
.	O

It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O

Regulation	O
of	O
M	O
-	O
CSF	O
expression	O
by	O
M	O
-	O
CSF	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
and	O
transcription	O
factor	O
NF	O
kappa	O
B	O
.	O

Macrophage	O
-	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	O
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high	O
-	O
affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c	O
-	O
fms	O
protooncogene	O
.	O

The	O
detection	O
of	O
both	O
M	O
-	O
CSF	O
and	O
c	O
-	O
fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M	O
-	O
CSF	O
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M	O
-	O
CSF	O
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M	O
-	O
CSF	O
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M	O
-	O
CSF	O
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M	O
-	O
CSF	O
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M	O
-	O
CSF	O
.	O

We	O
show	O
that	O
M	O
-	O
CSF	O
activates	O
and	O
translocates	O
PKC	O
.	O

Inhibition	O
of	O
PKC	O
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M	O
-	O
CSF	O
by	O
M	O
-	O
CSF	O
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	O
was	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	O
kappa	O
B	O
protein	O
in	O
nuclear	O
extracts	O
of	O
M	B
-	I
CSF	I
-	I
induced	I
blood	I
monocytes	I
but	O
not	O
in	O
monocytes	O
exposed	O
to	O
medium	O
treatment	O
only	O
.	O

The	O
results	O
suggest	O
that	O
M	O
-	O
CSF	O
induction	O
of	O
M	O
-	O
CSF	O
involves	O
G	O
proteins	O
,	O
PKC	O
and	O
NF	O
kappa	O
B	O
.	O

Regulation	O
of	O
glucocorticoid	O
receptors	O
in	O
human	O
mononuclear	O
cells	O
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O

Glucocorticoid	O
receptors	O
(	O
GcR	O
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	O
mononulear	O
leukocytes	O
(	O
hMNL	O
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	O
ketoconazole	O
therapy	O
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
GcR	O
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	O
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down	O
-	O
regulatory	O
effect	O
.	O

Furthermore	O
,	O
GcR	O
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O

We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	O
in	O
intact	O
cells	O
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

The	O
results	O
suggested	O
that	O
GcR	O
in	O
hMNL	O
are	O
down	O
-	O
regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down	O
-	O
regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O

Finally	O
,	O
we	O
did	O
not	O
observed	O
either	O
up	O
-	O
regulation	O
or	O
antagonism	O
of	O
GcR	O
by	O
ketoconazole	O
treatment	O
,	O
at	O
the	O
time	O
that	O
cortisol	O
levels	O
of	O
patients	O
with	O
Cushing	O
's	O
disease	O
were	O
reduced	O
.	O

This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	O
of	O
target	O
cells	O
,	O
and	O
that	O
the	O
process	O
of	O
GcR	O
regulation	O
in	O
hMNL	O
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

USF	O
-	O
related	O
transcription	O
factor	O
,	O
HIV	O
-	O
TF1	O
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O

The	O
transcription	O
factor	O
HIV	O
-	O
TF1	O
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O

HIV	O
-	O
TF1	O
had	O
a	O
molecular	O
weight	O
of	O
39	O
,	O
000	O
.	O

Binding	O
of	O
HIV	O
-	O
TF1	O
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O

The	O
HIV	O
-	O
TF1-binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	O
stimulatory	O
factor	O
(	O
USF	O
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O

DNA	O
-	O
binding	O
properties	O
of	O
HIV	O
-	O
TF1	O
suggested	O
that	O
HIV	O
-	O
TF1	O
might	O
be	O
identical	O
or	O
related	O
to	O
USF	O
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV	O
-	O
TF1	O
by	O
phosphatase	O
greatly	O
reduced	O
its	O
DNA	O
-	O
binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV	O
-	O
TF1	O
was	O
essential	O
for	O
DNA	O
binding	O
.	O

The	O
disruption	O
of	O
HIV	O
-	O
TF1-binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV	O
-	O
TF1	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O

Induction	O
of	O
NF	O
-	O
kappa	O
B	O
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV	O
-	O
gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte	O
-	O
macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	B
cell	I
lines	I
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	B
cell	I
line	I
chronically	O
infected	O
with	O
HIV	O
,	O
NF	O
-	O
kappa	O
B	O
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	O
alpha	O
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	B
cell	I
lines	I
by	O
phorbol	O
esters	O
or	O
TNF	O
alpha	O
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans	O
-	O
activator	O
of	O
HTLV	O
-	O
I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
using	O
the	O
human	B
T	I
-	I
cell	I
lines	I
Jurkat	B
and	O
MOLT	B
4	I
,	O
which	O
are	O
negative	O
for	O
HTLV	O
-	O
I	O
,	O
and	O
MT-2	O
and	O
TL	O
-	O
Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV	O
-	O
I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
.	O

One	O
is	O
the	O
21-base	O
-	O
pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans	O
-	O
activation	O
by	O
the	O
HTLV	O
-	O
I	O
trans	O
-	O
activator	O
p40tax	O
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic	O
-	O
AMP	O
responsive	O
element	O
binding	O
factor	O
(	O
CREB	O
)	O
-like	O
factor	O
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	O
elements	O
is	O
involved	O
in	O
trans	O
-	O
activation	O
by	O
p40tax	O
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
nuclear	O
factor	O
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein	O
-	O
DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	O
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	O
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	O
.	O

However	O
,	O
the	O
C26	O
element	O
alone	O
,	O
even	O
when	O
repeated	O
,	O
could	O
not	O
be	O
activated	O
by	O
p40tax	O
,	O
unlike	O
other	O
NF	O
-	O
kappa	O
B	O
-	O
binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV	O
-	O
I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
factors	O
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
in	O
response	O
to	O
p40tax	O
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA	O
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O

Inhibition	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
(	O
AP-1	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
early	O
response	O
genes	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA	O
-	O
induced	O
increases	O
in	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNA	O
levels	O
in	O
U-937	B
leukemia	I
cells	I
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA	O
-	O
induced	O
increases	O
in	O
lamin	O
A	O
,	O
lamin	O
C	O
,	O
and	O
vimentin	O
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	O
effect	O
on	O
TPA	O
-	O
induced	O
activation	O
of	O
PKC	O
suggests	O
that	O
this	O
glucocorticoid	O
inhibits	O
signals	O
downstream	O
or	O
parallel	O
to	O
this	O
enzyme	O
.	O

Nuclear	O
run	O
-	O
on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
does	O
not	O
require	O
protein	O
synthesis	O
,	O
and	O
(	O
3	O
)	O
TPA	O
-	O
induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c	O
-	O
jun	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Increases	O
in	O
CAT	O
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA	B
-	I
treated	I
U-937	I
cells	I
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP-1	O
binding	O
site	O
.	O

This	O
induction	O
of	O
CAT	O
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	O
down	O
-	O
regulates	O
TPA	O
-	O
induced	O
transcription	O
of	O
the	O
c	O
-	O
jun	O
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	O
site	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor	O
-	O
induced	O
genes	O
with	O
almost	O
identical	O
zinc	O
-	O
finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS	O
-like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc	O
-	O
finger	O
sequences	O
of	O
the	O
type	O
Cys2-Xaa12-His2	O
.	O

This	O
zinc	O
-	O
finger	O
region	O
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	O
factors	O
pAT	O
225	O
/	O
EGR1	O
and	O
pAT	O
591	O
/	O
EGR2	O
.	O

Except	O
for	O
the	O
conserved	O
zinc	O
-	O
finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc	O
-	O
finger	O
-	O
encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	O
225	O
/	O
EGR1	O
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	O
representing	O
pAT	O
591	O
/	O
EGR2	O
was	O
not	O
expressed	O
in	O
these	O
cells	O
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

Regulation	O
of	O
interleukin-1	O
beta	O
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	O
beta	O
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	O
beta	O
mRNA	O
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide	O
-	O
induced	O
interleukin-1	O
beta	O
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate	O
-	O
induced	O
production	O
was	O
increased	O
3	O
-	O
10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	O
beta	O
mRNA	O
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA	O
-	O
induced	O
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate	O
-	O
induced	O
signal	O
(	O
prolonged	O
protein	O
kinase	O
C	O
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Elevated	O
glucocorticoid	O
receptor	O
concentrations	O
before	O
and	O
after	O
glucocorticoid	O
therapy	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
.	O

The	O
number	O
and	O
affinity	O
of	O
glucocorticoid	O
binding	O
sites	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
of	O
patients	O
with	O
atopic	O
dermatitis	O
(	O
AD	O
)	O
and	O
healthy	O
controls	O
were	O
determined	O
under	O
baseline	O
conditions	O
and	O
after	O
a	O
defined	O
oral	O
glucocorticoid	O
treatment	O
.	O

Patients	O
with	O
AD	O
(	O
n	O
=	O
15	O
)	O
exhibited	O
significantly	O
more	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
per	O
cell	O
than	O
the	O
control	O
group	O
(	O
n	O
=	O
22	O
)	O
,	O
while	O
the	O
GR	O
affinity	O
did	O
not	O
differ	O
.	O

Methylprednisolone	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
GR	O
sites	O
per	O
cell	O
in	O
the	O
steroid	O
-	O
treated	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
contrast	O
to	O
the	O
patients	O
.	O

The	O
dissociation	O
constant	O
was	O
not	O
affected	O
by	O
methylprednisolone	O
treatment	O
in	O
either	O
group	O
.	O

In	O
view	O
of	O
the	O
therapeutic	O
efficiency	O
of	O
glucocorticoids	O
in	O
AD	O
and	O
findings	O
of	O
abnormal	O
cAMP	O
and	O
cAMP	O
-	O
phosphodiesterase	O
activity	O
,	O
the	O
elevated	O
GR	O
concentrations	O
in	O
AD	O
lend	O
support	O
to	O
the	O
hypothesis	O
of	O
a	O
compensatory	O
GR	O
upregulation	O
due	O
to	O
an	O
insufficient	O
action	O
of	O
endogenous	O
cortisol	O
or	O
to	O
altered	O
cAMP	O
-	O
induced	O
GR	O
expression	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	B
cell	I
lines	I
U-937	B
and	O
HL-60	B
by	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c	O
-	O
jun	O
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP-1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP-1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c	O
-	O
jun	O
expression	O
,	O
the	O
generation	O
of	O
AP-1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

The	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin	B
-	I
activated	I
human	I
platelets	I
are	O
forms	O
of	O
the	O
estrogen	O
receptor	O
-	O
related	O
27-kDa	O
heat	O
shock	O
protein	O
.	O

Thrombin	O
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	O
proteins	O
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O

We	O
have	O
characterized	O
several	O
29-kDa	O
proteins	O
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	O
human	O
platelets	O
to	O
thrombin	O
.	O

A	O
murine	O
monoclonal	O
antibody	O
raised	O
to	O
an	O
unidentified	O
estrogen	O
receptor	O
-	O
related	O
29-kDa	O
protein	O
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	O
27-kDa	O
protein	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	O
unphosphorylated	O
form	O
to	O
the	O
29-kDa	O
phosphoprotein	O
species	O
.	O

Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	O
27-kDa	O
heat	O
shock	O
protein	O
(	O
HSP27	O
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O

The	O
29-kDa	O
proteins	O
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	O
by	O
immunoprecipitation	O
studies	O
.	O

Thus	O
,	O
the	O
`	O
`	O
estrogen	O
receptor	O
-	O
related	O
protein	O
''	O
is	O
HSP27	O
,	O
and	O
the	O
three	O
major	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin	O
-	O
activated	O
platelets	O
are	O
forms	O
of	O
HSP27	O
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	O
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	O
activation	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	O
nuclear	O
factor-1	O
alpha	O
(	O
HNF-1	O
alpha	O
)	O
is	O
a	O
homeodomain	O
-	O
containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	O
cofactor	O
of	O
HNF-1	O
alpha	O
(	O
DCoH	O
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	O
bind	O
to	O
DNA	O
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	O
alpha	O
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH	O
-	O
HNF-1	O
alpha	O
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF-1	O
alpha	O
,	O
did	O
not	O
change	O
the	O
DNA	O
binding	O
characteristics	O
of	O
HNF-1	O
alpha	O
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	O
did	O
not	O
confer	O
transcriptional	O
activation	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

These	O
results	O
indicate	O
that	O
DCoH	O
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	O
receptor	O
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O

Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life	O
-	O
threatening	O
hypokalemia	O
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	O
hypokalemia	O
.	O

All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20	O
-	O
30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O

Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1	O
-	O
1.5	O
mg	O
/	O
day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O

There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O

Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O

Glucocorticoid	O
receptors	O
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	O
abnormalities	O
were	O
found	O
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen	O
-	O
stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	B
breast	I
cancer	I
cell	I
lines	I
to	O
lysis	O
by	O
lymphokine	O
-	O
activated	O
killer	O
cells	O
.	O

The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O

Estrogen	B
receptor	I
positive	I
(	I
ER+	I
:	I
MCF-7	I
)	I
and	I
negative	I
(	I
ER-	I
:	I
MDA	I
-	I
MB-231	I
)	I
human	I
breast	I
cancer	I
cell	I
lines	I
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine	O
-	O
activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O

E2-stimulated	B
ER+	I
cells	I
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM	B
-	I
treated	I
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER-	B
cells	I
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	O
alter	O
from	O
control	O
their	O
susceptibility	O
to	O
this	O
immune	O
-	O
mediated	O
lysis	O
.	O

All	O
ER+	B
and	I
ER-	I
cells	I
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	O
cells	O
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	O
reactive	O
human	O
-	O
mouse	O
chimeric	O
monoclonal	O
antibody	O
(	O
ING-1	O
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell	O
-	O
mediated	O
lysis	O
of	O
control	B
,	I
E2-treated	I
,	I
and	I
TAM	I
-	I
treated	I
ER+	I
and	I
ER-	I
cells	I
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody	O
-	O
dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O

Glucocorticoid	O
receptor	O
and	O
inhibition	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

We	O
have	O
measured	O
the	O
glucocorticoid	O
receptor	O
concentration	O
in	O
mononuclear	O
and	O
polymorphonuclear	O
leukocytes	O
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	O
leukocytes	O
.	O

The	O
glucocorticoid	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
correlated	O
with	O
those	O
in	O
polymorphonuclear	O
leukocytes	O
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
and	O
glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
in	O
mononuclear	O
leukocytes	O
.	O

When	O
mononuclear	O
leukocytes	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo	O
-	O
cAMP	O
,	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
.	O

We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	O
leukocytes	O
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	O
receptor	O
.	O

Stimulation	O
of	O
interferon	O
beta	O
gene	O
transcription	O
in	O
vitro	O
by	O
purified	O
NF	O
-	O
kappa	O
B	O
and	O
a	O
novel	O
TH	O
protein	O
.	O

The	O
human	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	O
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
mediating	O
IFN	O
-	O
beta	O
induction	O
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	B
T	I
-	I
cells	I
and	O
from	O
IFN	B
primed	I
,	I
cycloheximide	I
/	I
polyinosinic	I
-	I
polycytidylic	I
acid	I
treated	I
HeLa	I
S3	I
cells	I
.	O

From	O
HeLa	B
cells	I
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T	O
-	O
cells	O
,	O
four	O
proteins	O
--	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43	O
-	O
47	O
kD	O
--	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	B
cells	I
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1	O
/	O
ISGF2	O
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	O
beta	O
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2	O
-	O
4-fold	O
increase	O
in	O
IFN	O
-	O
beta	O
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN	O
-	O
beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN	O
-	O
beta	O
transcription	O
.	O

Transcriptional	O
regulation	O
during	O
T	O
-	O
cell	O
development	O
:	O
the	O
alpha	O
TCR	O
gene	O
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T	O
-	O
cell	O
-	O
specific	O
gene	O
,	O
alpha	O
TCR	O
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T	O
-	O
cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T	O
-	O
cell	O
activation	O
,	O
are	O
described	O
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	O
the	O
clinical	O
signs	O
or	O
metabolic	O
consequences	O
of	O
hypercortisolism	O
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O

An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	O
receptor	O
characteristics	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	O
receptor	O
activation	O
.	O

Glucocorticoid	O
receptor	O
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
+	O
/-	O
9.4	O
fmol	O
/	O
million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	O
an	O
Addisonian	O
picture	O
(	O
group	O
2	O
;	O
6.05	O
+	O
/-	O
2.6	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age	O
-	O
matched	O
controls	O
(	O
3.15	O
+	O
/-	O
2.3	O
fmol	O
/	O
million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
affinity	O
of	O
glucocorticoid	O
receptors	O
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
+	O
/-	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
+	O
/-	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
+	O
/-	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose	O
-	O
dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O
the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	O
receptor	O
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	O
receptor	O
abnormality	O
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	O
glucocorticoid	O
receptors	O
on	O
lymphocytes	O
.	O

Resistance	O
to	O
glucocorticoids	O
implies	O
a	O
complex	O
change	O
in	O
immune	O
-	O
endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	O
syndrome	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	B
cells	I
represent	O
a	O
bipotential	B
myelomonoblastic	I
cell	I
population	I
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	O
on	O
the	O
cell	O
surface	O
,	O
PLB-985	B
cells	I
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB	B
-	I
IIIB	I
cells	I
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid	O
-	O
specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c	O
-	O
fms	O
proto	O
-	O
oncogene	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	B
.	O

However	O
,	O
in	O
PLB	B
-	I
IIIB	I
cells	I
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF	O
-	O
kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF	O
-	O
kappa	O
B	O
site	O
from	O
the	O
interferon	O
beta	O
(	O
IFN	O
-	O
beta	O
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	O
to	O
compete	O
for	O
these	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
proteins	O
.	O

Inducibility	O
of	O
endogenous	O
IFN	O
-	O
beta	O
and	O
IFN	O
-	O
alpha	O
RNA	O
was	O
also	O
increased	O
in	O
PLB	B
-	I
IIIB	I
cells	I
.	O

These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF	O
-	O
kappa	O
B	O
-mediated	O
gene	O
expression	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
in	O
mononuclear	O
leucocytes	O
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	O
different	O
between	O
the	O
two	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	O
(	O
preeclampsia	O
,	O
81	O
+	O
/-	O
44	O
receptors	O
/	O
cell	O
;	O
controls	O
,	O
306	O
+	O
/-	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
+	O
/-	O
7	O
mV	O
;	O
controls	O
,	O
12	O
+	O
/-	O
5	O
mV	O
)	O
.	O

In	O
six	O
cases	O
we	O
determined	O
MR	O
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O

MR	O
were	O
reduced	O
before	O
delivery	O
(	O
96	O
+	O
/-	O
27	O
receptors	O
/	O
cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
+	O
/-	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	O
,	O
242	O
+	O
/-	O
79	O
;	O
SPD	O
,	O
14.0	O
+	O
/-	O
4	O
mV	O
)	O
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	O
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	O
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O

An	O
11-base	O
-	O
pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	O
4	O
gene	O
confers	O
responsiveness	O
to	O
T	O
-	O
cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
4	O
gene	O
in	O
Jurkat	B
cells	I
.	O

The	O
human	O
IL-4	O
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis	O
-	O
acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O
no	O
additional	O
DNA	O
segments	O
with	O
enhancer	O
activity	O
were	O
identified	O
in	O
the	O
human	O
IL-4	O
gene	O
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-4	O
gene	O
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL-4	O
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base	O
-	O
substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
were	O
identified	O
by	O
DNA	O
-	O
mobility	O
-	O
shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	O
(	O
P	O
)	O
interaction	O
is	O
sequence	O
-	O
specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	O
expression	O
in	O
vivo	O
.	O

The	O
P	O
sequence	O
does	O
not	O
share	O
homology	O
with	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-2	O
gene	O
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	O
gene	O
share	O
high	O
homology	O
with	O
the	O
IL-2	O
gene	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	O
IL-2	O
and	O
IL-4	O
genes	O
.	O

[	O
Hormonal	O
interactions	O
and	O
glucocorticoid	O
receptors	O
in	O
patients	O
with	O
the	O
nephrotic	O
syndrome	O
]	O

As	O
many	O
as	O
27	O
children	O
aged	O
6	O
to	O
15	O
years	O
with	O
morphologically	O
verified	O
nephropathies	O
were	O
examined	O
.	O

Four	O
variants	O
of	O
changes	O
in	O
the	O
thyroid	O
status	O
,	O
characteristic	O
of	O
children	O
with	O
different	O
variants	O
of	O
nephrotic	O
syndrome	O
were	O
distinguished	O
:	O
1	O
)	O
biochemical	O
signs	O
of	O
primary	O
hypothyroidism	O
,	O
2	O
)	O
biochemical	O
signs	O
of	O
secondary	O
hypothyroidism	O
,	O
3	O
)	O
low	O
content	O
of	O
T3	O
,	O
4	O
)	O
dysfunction	O
of	O
the	O
hypophyseal	O
and	O
thyroid	O
system	O
.	O

It	O
is	O
shown	O
that	O
the	O
low	O
level	O
of	O
steroid	O
receptors	O
,	O
thyroid	O
hormones	O
that	O
the	O
low	O
level	O
of	O
steroid	O
receptors	O
,	O
thyroid	O
hormones	O
(	O
T3	O
and	O
T4	O
)	O
and	O
cortisol	O
is	O
typical	O
of	O
children	O
with	O
the	O
signs	O
of	O
renal	O
dysplasia	O
.	O

It	O
is	O
assumed	O
that	O
superaddition	O
under	O
such	O
conditions	O
of	O
immune	O
glomerulopathy	O
(	O
glomerulonephritis	O
and	O
nephrotic	O
syndrome	O
)	O
gives	O
rise	O
to	O
the	O
resistance	O
to	O
the	O
treatment	O
with	O
glucocorticoids	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

Hepatic	O
microsomes	O
and	O
isolated	O
hepatocytes	O
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	O
T3SO4	O
could	O
mimic	O
the	O
action	O
of	O
thyroid	O
hormone	O
in	O
vitro	O
.	O

T3SO4	O
had	O
no	O
thyromimetic	O
effect	O
on	O
the	O
activity	O
of	O
Ca	O
(	O
2	O
+	O
)	O
-ATPase	O
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10	O
,	O
000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
)	O
.	O

In	O
GH4C1	B
pituitary	I
cells	I
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	O
receptors	O
in	O
intact	B
cells	I
or	O
soluble	O
preparations	O
.	O

Thus	O
,	O
T3SO4	O
was	O
not	O
directly	O
thyromimetic	O
in	O
either	O
an	O
isolated	O
human	O
membrane	O
system	O
or	O
a	O
pituitary	O
cell	O
system	O
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O

Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	B
human	I
dermal	I
fibroblasts	I
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O

Human	O
fibroblasts	O
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p	O
-	O
nitrophenyl	O
sulfatase	O
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	O
microsomes	O
.	O

Propylthiouracil	O
(	O
50	O
mumol	O
/	O
L	O
)	O
did	O
not	O
affect	O
the	O
action	O
of	O
T3SO4	O
,	O
suggesting	O
that	O
deiodination	O
was	O
not	O
important	O
for	O
this	O
activity	O
of	O
T3SO4	O
.	O

Thus	O
,	O
it	O
appears	O
T3SO4	O
has	O
no	O
intrinsic	O
biological	O
activity	O
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	O
be	O
reactivated	O
by	O
desulfation	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
contains	O
Fos	O
and	O
Jun	O
.	O

The	O
nuclear	O
factor	O
NF	O
-	O
AT	O
(	O
ref	O
.	O
1	O
)	O
is	O
induced	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
-	O
cell	O
receptor	O
/	O
CD3	O
complex	O
,	O
and	O
is	O
required	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
induction	O
.	O

Although	O
NF	O
-	O
AT	O
has	O
not	O
been	O
cloned	O
or	O
purified	O
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2	O
-	O
7	O
)	O
.	O

NF	O
-	O
AT	O
induction	O
may	O
require	O
two	O
activation	O
-	O
dependent	O
events	O
:	O
the	O
CsA	O
-	O
sensitive	O
translocation	O
of	O
a	O
pre	O
-	O
existing	O
component	O
and	O
the	O
CsA	O
-	O
resistant	O
synthesis	O
of	O
a	O
nuclear	O
component	O
.	O

Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	O
component	O
of	O
NF	O
-	O
AT	O
is	O
the	O
transcription	O
factor	O
AP-1	O
.	O

We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF	O
-	O
AT	O
contains	O
Fos	O
and	O
Jun	O
proteins	O
.	O

Furthermore	O
,	O
we	O
identify	O
a	O
pre	O
-	O
existing	O
NF	O
-	O
AT	O
-	O
binding	O
factor	O
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
.	O

On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	O
that	O
activation	O
of	O
NF	O
-	O
AT	O
occurs	O
in	O
at	O
least	O
two	O
stages	O
:	O
a	O
CsA	O
-	O
sensitive	O
stage	O
involving	O
modification	O
and/or	O
translocation	O
of	O
the	O
pre	O
-	O
existing	O
NF	O
-	O
AT	O
complex	O
,	O
and	O
a	O
CsA	O
-	O
insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	O
or	O
Fos	O
/	O
Jun	O
proteins	O
to	O
the	O
pre	O
-	O
existing	O
complex	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	O
cells	O
.	O

They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	O
genes	O
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O
they	O
bind	O
endogenous	O
intracellular	O
receptors	O
,	O
the	O
immunophilins	O
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	O
phosphatase	O
,	O
calcineurin	O
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	O
dependent	O
on	O
NFAT-1	O
.	O

The	O
function	O
of	O
a	O
putative	O
NFAT-1	O
site	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
is	O
minimal	O
in	O
Jurkat	B
cells	I
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O

The	O
putative	O
NFAT-1	O
region	O
is	O
not	O
required	O
for	O
the	O
response	O
to	O
anti	O
-	O
CD3	O
or	O
to	O
mitogens	O
in	O
T	B
-	I
cell	I
,	O
B	B
-	I
cell	I
,	O
or	O
monocyte	B
/	I
macrophage	I
leukemia	I
lines	I
,	O
nor	O
is	O
it	O
a	O
cis	O
-	O
acting	O
negative	O
regulatory	O
element	O
.	O

Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl	B
-	I
methanesulfonate	I
-	I
treated	I
CEM	I
subclones	I
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
.	O

We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	B
subclones	I
that	O
express	O
CD4	O
receptors	O
and	O
bind	O
soluble	O
gp120	O
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O

Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activator	O
PMA	O
.	O

PMA	O
treatment	O
induced	O
CD3	O
and	O
CD25	O
(	O
IL-2R	O
)	O
receptors	O
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl	B
-	I
methanesulfonate	I
-	I
derived	I
subclones	I
,	O
but	O
not	O
on	O
these	O
two	O
mutants	O
.	O

Direct	O
assays	O
of	O
PKC	O
activity	O
were	O
conducted	O
.	O

Total	O
cellular	O
PKC	O
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O

PMA	O
-	O
induced	O
CD4	O
down	O
-	O
modulation	O
occurred	O
normally	O
.	O

In	O
addition	O
,	O
activation	O
of	O
c	O
-	O
raf	O
kinase	O
was	O
normal	O
.	O

Since	O
HIV-1	O
long	O
terminal	O
repeat	O
contains	O
two	O
functional	O
nuclear	O
factor	O
kB	O
(	O
NF	O
-	O
kB	O
)	O
regulatory	O
elements	O
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF	O
-	O
kB	O
binding	O
activity	O
by	O
different	O
assays	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
assays	O
using	O
the	O
HIV-1	O
(	O
-139	O
)	O
long	O
terminal	O
repeat	O
-	O
CAT	O
construct	O
showed	O
no	O
PMA	O
induction	O
of	O
CAT	O
activity	O
in	O
these	O
subclones	O
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O

Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
did	O
not	O
overcome	O
the	O
defect	O
in	O
these	O
subclones	O
.	O

Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P	O
-	O
probe	O
containing	O
the	O
HIV-1	O
NF	O
-	O
kB	O
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA	O
-	O
treated	O
cells	O
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	O
NF	O
-	O
kB	O
binding	O
proteins	O
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	O
type	O
CEM	O
and	O
a	O
control	O
subclone	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF	O
-	O
kB	O
binding	O
proteins	O
from	O
their	O
cytoplasmic	O
pools	O
.	O

Thus	O
,	O
reduced	O
levels	O
of	O
PKC	O
-induced	O
nuclear	O
NF	O
-	O
kB	O
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	O
affect	O
their	O
normal	O
cell	O
growth	O
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O

Cell	O
cycle	O
-	O
dependent	O
initiation	O
and	O
lineage	O
-	O
dependent	O
abrogation	O
of	O
GATA-1	O
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O

The	O
programmed	O
activation	O
/	O
repression	O
of	O
transcription	O
factors	O
in	O
early	O
hematopoietic	O
differentiation	O
has	O
not	O
yet	O
been	O
explored	O
.	O

The	O
DNA	O
-	O
binding	O
protein	O
GATA-1	O
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid	O
-	O
expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O

We	O
analyzed	O
GATA-1	O
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
`	O
`	O
pure	O
''	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte	O
-	O
macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA-1	O
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte	O
-	O
macrophage	O
lineage	O
.	O

These	O
results	O
suggest	O
a	O
microenvironment	O
-	O
directed	O
,	O
two	O
-	O
step	O
model	O
for	O
GATA-1	O
expression	O
in	O
differentiating	O
hematopoietic	O
progenitors	O
that	O
involves	O
(	O
i	O
)	O
cycle	O
-	O
dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage	O
-	O
dependent	O
maintenance	O
or	O
suppression	O
.	O

Hypothetically	O
,	O
on	O
/	O
off	O
switches	O
of	O
lineage	O
-	O
restricted	O
transactivators	O
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	O
progenitors	O
.	O

[	O
Age	O
-	O
related	O
changes	O
in	O
glucocorticoid	O
and	O
mineralocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O

The	O
mechanisms	O
of	O
hormone	O
-	O
receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O
the	O
number	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
binding	O
sites	O
grows	O
in	O
hypertensive	O
patients	O
.	O

Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid	O
-	O
age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O

NF	O
-	O
kappa	O
B	O
-dependent	O
induction	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
gene	O
promoter	O
underlies	O
self	O
-	O
perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
observed	O
in	O
U937	B
monocytic	I
cells	I
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	O
regulating	O
the	O
synthesis	O
of	O
the	O
p105	O
precursor	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
p50	O
subunit	O
was	O
enhanced	O
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	O
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF	O
-	O
kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	O
motif	O
,	O
by	O
bona	O
fide	O
p50	O
/	O
p65	O
heterodimers	O
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF	O
-	O
kappa	O
B	O
levels	O
were	O
increased	O
in	O
HIV	O
-	O
infected	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF	O
-	O
kappa	O
B	O
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF	O
-	O
kappa	O
B	O
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	O
dependent	O
on	O
PKC	O
isoenzymes	O
alpha	O
and	O
beta	O
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	B
cells	I
,	O
continuous	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p65	O
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF	O
-	O
kappa	O
B	O
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

This	O
HIV	O
-	O
mediated	O
mechanism	O
results	O
in	O
a	O
self	O
-	O
perpetuating	O
loop	O
of	O
NF	O
-	O
kappa	O
B	O
production	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
,	O
AP-1	O
and	O
a	O
marked	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
levels	O
.	O

In	O
contrast	O
,	O
no	O
effect	O
on	O
the	O
levels	O
of	O
the	O
octamer	O
binding	O
proteins	O
,	O
Oct-1	O
or	O
Oct-2	O
,	O
were	O
found	O
.	O

Since	O
both	O
AP-1	O
and	O
NF	O
-	O
kappa	O
B	O
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF	O
-	O
alpha	O
mRNA	O
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF	O
-	O
alpha	O
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF	O
-	O
alpha	O
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	O
and	O
NF	O
-	O
kappa	O
B	O
it	O
did	O
not	O
induce	O
either	O
B	O
cell	O
proliferation	O
or	O
immunoglobulin	O
secretion	O
.	O

Characterization	O
of	O
a	O
new	O
tissue	O
-	O
specific	O
transcription	O
factor	O
binding	O
to	O
the	O
simian	O
virus	O
40	O
enhancer	O
TC	O
-	O
II	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
element	O
.	O

We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	O
factor	O
,	O
NP	O
-	O
TCII	O
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	B
T	I
and	I
B	I
lymphocytes	I
but	O
is	O
not	O
found	O
in	O
nonhematopoietic	O
cells	O
.	O

This	O
factor	O
has	O
a	O
DNA	O
-	O
binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	O
proteins	O
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O

It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte	O
-	O
specific	O
DNA	O
-	O
binding	O
proteins	O
.	O

A	O
novel	O
B	O
cell	O
-	O
derived	O
coactivator	O
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer	O
-	O
binding	O
transcription	O
factors	O
.	O

A	O
novel	O
B	O
cell	O
-	O
restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer	O
/	O
Oct	O
-dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	B
cell	I
-derived	O
extracts	O
complemented	O
with	O
fractionated	O
B	O
cell	O
nuclear	O
proteins	O
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
OCA	O
-	O
B	O
)	O
.	O

OCA	O
-	O
B	O
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct-1	O
or	O
Oct-2	O
but	O
shows	O
no	O
significant	O
effect	O
on	O
the	O
octamer	O
/	O
Oct	O
-dependent	O
transcription	O
of	O
the	O
ubiquitously	O
expressed	O
histone	O
H2B	O
promoter	O
and	O
the	O
transcription	O
of	O
USF-	O
and	O
Sp1-regulated	O
promoters	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA	O
-	O
B	O
is	O
a	O
tissue-	O
,	O
promoter-	O
,	O
and	O
factor	O
-	O
specific	O
coactivator	O
and	O
that	O
OCA	O
-	O
B	O
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell	O
-	O
specific	O
activation	O
of	O
immunoglobulin	O
promoters	O
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	O
factors	O
and	O
OCA	O
-	O
B	O
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA	O
-	O
B	O
and	O
discuss	O
the	O
implications	O
of	O
OCA	O
-	O
B	O
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue	O
-	O
specific	O
promoters	O
.	O

A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	O
receptor	O
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	O
cells	O
and	O
expression	O
of	O
endothelial	O
-	O
leukocyte	O
adhesion	O
molecule	O
1	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	O
molecular	O
mechanisms	O
that	O
impart	O
their	O
efficacy	O
have	O
not	O
been	O
defined	O
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	O
leukocytes	O
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	O
molecules	O
for	O
leukocytes	O
[	O
e.g.	O
,	O
endothelial	O
-	O
leukocyte	O
adhesion	O
molecule	O
1	O
(	O
ELAM-1	O
)	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM-1	O
)	O
]	O
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	O
molecules	O
for	O
neutrophils	O
(	O
polymorphonuclear	O
leukocytes	O
)	O
.	O

Preincubation	O
of	O
endothelial	O
cells	O
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram	O
/	O
ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	O
leukocytes	O
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	O
cells	O
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	O
cells	O
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Moreover	O
,	O
the	O
steroid	O
receptor	O
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	O
its	O
inactive	O
metabolite	O
tetrahydrocortisol	O
(	O
10	O
microM	O
)	O
,	O
diminished	O
LPS	O
-	O
induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	O
receptors	O
[	O
human	O
glucocorticoid	O
receptors	O
(	O
hGRs	O
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	O
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	O
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	O
cells	O
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

Treatment	O
of	O
endothelial	O
cells	O
with	O
LPS	O
(	O
1	O
microgram	O
/	O
ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	O
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane	O
-	O
associated	O
ELAM-1	O
and	O
ICAM-1	O
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O

Dexamethasone	O
markedly	O
inhibited	O
LPS	O
-	O
stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	O
and	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4	O
-	O
9	O
)	O
;	O
inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4	O
-	O
6	O
)	O
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	O
tetrahydrocortisol	O
inhibited	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	O
adhesion	O
nor	O
expression	O
of	O
these	O
adhesion	O
molecules	O
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin	O
-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	O
receptor	O
is	O
a	O
hormone	O
-	O
dependent	O
regulator	O
of	O
transcription	O
.	O

Membrane	O
receptors	O
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O

Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	O
(	O
+	O
)	O
-H+	O
antiport	O
have	O
been	O
found	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

Binding	O
of	O
125I	O
-	O
labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	O
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O

This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	O
(	O
+	O
)	O
-H	O
(	O
+	O
)	O
-antiport	O
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O

Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O

Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

In	O
the	O
human	O
genome	O
,	O
the	O
erythroid	O
-	O
specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	O
the	O
transcription	O
of	O
the	O
downstream	O
beta	O
-	O
like	O
globin	O
genes	O
10	O
-	O
50	O
kilobases	O
away	O
.	O

The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	O
known	O
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
plasmids	O
.	O

In	O
erythroid	B
K562	I
cells	I
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	O
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O

In	O
nonerythroid	B
HL-60	I
cells	I
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	O
detectable	O
.	O

Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis	O
-	O
linked	O
CAT	O
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	O
structure	O
of	O
a	O
gene	O
domain	O
and	O
(	O
ii	O
)	O
deliver	O
enhancer	O
binding	O
proteins	O
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	O
site	O
.	O

Ablation	O
of	O
transplanted	O
HTLV	O
-	O
I	O
Tax	O
-	O
transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O

Mice	O
transgenic	O
for	O
the	O
human	O
T	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
Tax	O
gene	O
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF	O
-	O
kappa	O
B	O
-	O
inducible	O
early	O
genes	O
.	O

In	O
vitro	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture	B
-	I
adapted	I
Tax	I
-	I
transformed	I
fibroblasts	I
as	O
well	O
as	O
an	O
HTLV	B
-	I
I	I
-	I
transformed	I
human	I
lymphocyte	I
line	I
.	O

In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	O
itself	O
had	O
no	O
apparent	O
effect	O
on	O
cell	O
growth	O
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF	O
-	O
kappa	O
B	O
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

This	O
suggests	O
that	O
NF	O
-	O
kappa	O
B	O
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV	O
-	O
I	O
-	O
associated	O
disease	O
.	O

Targeted	O
degradation	O
of	O
c	O
-	O
Fos	O
,	O
but	O
not	O
v	O
-	O
Fos	O
,	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
signal	O
on	O
c	O
-	O
Jun	O
.	O

The	O
proto	O
-	O
oncogene	O
products	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
heterodimerize	O
through	O
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP-1	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c	O
-	O
Fos	O
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c	O
-	O
Fos	O
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	O
c	O
-	O
Jun	O
.	O

c	O
-	O
Jun	O
protein	O
isolated	O
from	O
phorbol	B
ester	I
-	I
induced	I
cells	I
did	O
not	O
target	O
c	O
-	O
Fos	O
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c	O
-	O
Fos	O
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O

v	O
-	O
Fos	O
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c	O
-	O
Fos	O
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c	O
-	O
Jun	O
.	O

Mutations	O
in	O
the	O
Pit-1	O
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit-1	O
is	O
a	O
pituitary	O
-	O
specific	O
transcription	O
factor	O
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	O
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU	O
-	O
specific	O
domain	O
,	O
and	O
POU	O
-	O
homeodomain	O
,	O
respectively	O
.	O

Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O

A	O
MEDLINE	O
search	O
of	O
the	O
English	O
-	O
language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'	O
immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O

Sixty	O
-	O
six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O

Forty	O
-	O
five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O

The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O

No	O
unifying	O
hypothesis	O
has	O
yet	O
emerged	O
explaining	O
this	O
collection	O
of	O
data	O
.	O

This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c	O
-	O
Fos	O
and	O
AP-1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	O
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5'-	O
(	O
N	O
-	O
ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c	O
-	O
Fos	O
and	O
Jun	O
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
both	O
c	O
-	O
Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c	O
-	O
Fos	O
)	O
or	O
decrease	O
(	O
Jun	O
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	O
binding	O
,	O
as	O
judged	O
by	O
gel	O
-	O
shift	O
assay	O
,	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear	O
-	O
cut	O
synergy	O
between	O
the	O
PKC	O
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	O
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	O
transcriptional	O
activity	O
in	O
a	O
T	B
-	I
leukemia	I
cell	I
line	I
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

The	O
use	O
of	O
interferon	B
-	I
gamma	I
-	I
treated	I
U937	I
cells	I
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
of	O
potential	O
clinical	O
significance	O
.	O

The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon	B
-	I
gamma	I
-	I
treated	I
U937	I
(	I
IFN	I
-	I
U937	I
)	I
cells	I
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
.	O

A	O
clone	O
of	O
U937	B
cells	I
was	O
selected	O
which	O
expressed	O
Fc	O
receptor	O
I	O
(	O
Fc	O
gamma	O
RI	O
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN	O
-	O
gamma	O
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin	O
-	O
enhanced	O
CL	O
.	O

The	O
CL	O
responses	O
of	O
IFN	B
-	I
U937	I
cells	I
and	O
peripheral	O
blood	O
human	O
monocytes	O
to	O
sensitized	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
were	O
then	O
compared	O
.	O

Assays	O
using	O
monocytes	O
or	O
IFN	B
-	I
U937	I
cells	I
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	O
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
IFN	B
-	I
U937	I
cells	I
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O

The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	O
and	O
IFN	B
-	I
U937	I
cells	I
to	O
respond	O
to	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O

In	O
addition	O
,	O
monocytes	O
and	O
IFN	B
-	I
U937	I
cells	I
both	O
responded	O
to	O
red	O
cells	O
sensitized	O
with	O
antibodies	O
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O

In	O
contrast	O
,	O
monocytes	O
and	O
IFN	B
-	I
U937	I
cells	I
responded	O
only	O
weakly	O
to	O
red	O
cells	O
sensitized	O
with	O
either	O
anti	O
-	O
D	O
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	O
titre	O
antibodies	O
with	O
specificities	O
not	O
normally	O
associated	O
with	O
significantly	O
reduced	O
red	O
cell	O
survival	O
.	O

Expression	O
of	O
tal-1	O
and	O
GATA	O
-	O
binding	O
proteins	O
during	O
human	O
hematopoiesis	O
.	O

Tal-1	O
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal-1	O
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
a	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
domain	O
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal-1	O
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	O
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal-1	O
1A	O
promoter	O
,	O
which	O
contains	O
two	O
consensus	O
GATA	O
-	O
binding	O
sites	O
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O

Because	O
the	O
GATA-1	O
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic	O
/	O
basophilic	O
lineages	O
,	O
we	O
studied	O
GATA-1	O
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
GATA-1	O
and	O
tal-1	O
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

In	O
immature	O
hematopoietic	O
cells	O
,	O
tal-1	O
and	O
GATA-1	O
genes	O
are	O
coexpressed	O
in	O
committed	O
progenitors	O
cells	O
(	O
CD34+	B
/	I
CD38	I
(	I
2	I
+	I
)	I
)	O
,	O
whereas	O
they	O
are	O
not	O
detectable	O
in	O
the	O
most	O
primitive	O
cells	O
(	O
CD34	B
(	I
2	I
+	I
)	I
/CD38-	I
)	O
.	O

In	O
contrast	O
,	O
GATA-2	O
is	O
strongly	O
expressed	O
in	O
both	O
most	O
primitive	O
and	O
committed	O
progenitors	O
cells	O
,	O
whereas	O
GATA-3	O
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	O
modulates	O
the	O
transcription	O
of	O
tal-1	O
during	O
the	O
differentiation	O
of	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
basosophilic	O
lineages	O
.	O

Interleukin-3	O
expression	O
by	O
activated	O
T	O
cells	O
involves	O
an	O
inducible	O
,	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
and	O
an	O
octamer	O
binding	O
protein	O
.	O

Interleukin-3	O
(	O
IL-3	O
)	O
is	O
exclusively	O
expressed	O
by	O
activated	O
T	O
and	O
natural	O
killer	O
cells	O
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage	O
-	O
specific	O
and	O
in	O
a	O
stimulation	O
-	O
dependent	O
manner	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	O
region	O
of	O
the	O
IL-3	O
promoter	O
.	O

This	O
region	O
binds	O
an	O
inducible	O
,	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
over	O
its	O
5	O
'	O
end	O
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	O
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

Over	O
its	O
3	O
'	O
end	O
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O

This	O
factor	O
is	O
Oct-1	O
or	O
an	O
immunologically	O
related	O
octamer	O
-	O
binding	O
protein	O
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	O
elements	O
.	O

These	O
characteristics	O
make	O
the	O
ACT-1	O
site	O
analogous	O
to	O
the	O
activating	O
ARRE-1	O
site	O
in	O
the	O
IL-2	O
promoter	O
.	O

Furthermore	O
,	O
and	O
despite	O
a	O
lack	O
of	O
sequence	O
homology	O
,	O
the	O
promoters	O
of	O
IL-3	O
and	O
IL-2	O
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	O
is	O
likely	O
to	O
be	O
important	O
for	O
the	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
these	O
genes	O
.	O

ras	O
protein	O
activity	O
is	O
essential	O
for	O
T	O
-	O
cell	O
antigen	O
receptor	O
signal	O
transduction	O
.	O

In	O
a	O
Jurkat	B
cell	I
model	I
of	O
T	O
-	O
cell	O
activation	O
an	O
interleukin-2	O
promoter	O
/	O
reporter	O
gene	O
construct	O
was	O
activated	O
by	O
antigen	O
receptor	O
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	O
interleukin-1	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	O
stimulation	O
but	O
did	O
not	O
replace	O
either	O
the	O
calcium	O
signal	O
or	O
interleukin-1	O
.	O

Activated	O
ras	O
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	O
stimulation	O
in	O
activation	O
of	O
the	O
T	O
-	O
cell	O
transcription	O
factor	O
NF	O
-	O
AT	O
.	O

A	O
dominant	O
inhibitory	O
ras	O
mutant	O
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	O
activity	O
is	O
required	O
for	O
antigen	O
receptor	O
signaling	O
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	O
blocked	O
both	O
activated	O
ras	O
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	O
upstream	O
of	O
PKC	O
.	O

Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid	O
-	O
specific	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
complex	O
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
complex	O
,	O
NF	O
-	O
AT	O
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	O
cells	O
and	O
is	O
assembled	O
from	O
a	O
pre	O
-	O
existing	O
,	O
T	O
cell	O
restricted	O
cytoplasmic	O
factor	O
and	O
an	O
inducible	O
ubiquitous	O
nuclear	O
component	O
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	O
receptor	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	O
factors	O
as	O
components	O
of	O
the	O
murine	O
NF	O
-	O
AT	O
complex	O
.	O

Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	O
NF	O
-	O
AT	O
contains	O
the	O
phorbol	O
ester	O
-	O
inducible	O
transcription	O
factor	O
AP1	O
(	O
Jun	O
/	O
Fos	O
)	O
.	O

We	O
further	O
characterize	O
which	O
AP1	O
family	O
members	O
can	O
assume	O
this	O
role	O
.	O

Antisera	O
to	O
Fos	O
inhibits	O
NF	O
-	O
AT	O
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	O
site	O
for	O
AP1	O
.	O

Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra-1	O
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF	O
-	O
AT	O
-directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O

Overexpression	O
of	O
cJun	O
or	O
JunD	O
,	O
but	O
not	O
JunB	O
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	O
that	O
many	O
but	O
not	O
all	O
Jun-	O
and	O
Fos	O
-	O
related	O
proteins	O
functionally	O
activate	O
NF	O
-	O
AT	O
-dependent	O
transcription	O
in	O
the	O
presence	O
of	O
the	O
cytoplasmic	O
component	O
.	O

NF	O
-	O
AT	O
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi	O
-	O
purified	O
AP1	O
proteins	O
mixed	O
with	O
cytosol	O
from	O
T	O
lymphocytes	O
.	O

Fos	O
proteins	O
are	O
not	O
needed	O
for	O
this	O
reconstitution	O
,	O
and	O
although	O
JunB	O
is	O
not	O
functional	O
,	O
it	O
can	O
participate	O
in	O
the	O
NF	O
-	O
AT	O
DNA	O
binding	O
complex	O
.	O

Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF	O
-	O
AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O

Expression	O
of	O
the	O
Tat	O
protein	O
of	O
HIV1	O
in	O
human	B
promonocytic	I
U937	I
cells	I
.	O

Numerous	O
studies	O
have	O
shown	O
that	O
,	O
upon	O
HIV1	O
infection	O
,	O
human	B
promonocytic	I
U937	I
cells	I
were	O
induced	O
to	O
differentiate	O
,	O
as	O
indicated	O
,	O
for	O
example	O
,	O
by	O
increased	O
expression	O
of	O
adhesion	O
molecules	O
.	O

One	O
of	O
the	O
viral	O
proteins	O
involved	O
in	O
this	O
process	O
might	O
be	O
the	O
Tat	O
protein	O
.	O

Indeed	O
,	O
this	O
viral	O
protein	O
,	O
which	O
is	O
essential	O
for	O
productive	O
infection	O
,	O
has	O
also	O
been	O
shown	O
to	O
display	O
growth	O
-	O
stimulating	O
properties	O
and	O
immunomodulatory	O
activities	O
.	O

In	O
order	O
to	O
apprehend	O
the	O
role	O
of	O
the	O
HIV1	O
tat	O
gene	O
in	O
inducing	O
the	O
differentiation	O
of	O
HIV1-infected	B
U937	I
cells	I
,	O
we	O
have	O
successfully	O
introduced	O
this	O
gene	O
into	O
U937	B
cells	I
by	O
infecting	O
them	O
with	O
retroviral	O
particles	O
transducing	O
tat	O
.	O

The	O
effect	O
of	O
the	O
Tat	O
protein	O
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c	O
-	O
fos	O
and	O
of	O
the	O
c	O
-	O
fms	O
proto	O
-	O
oncogenes	O
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	O
cells	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
in	O
these	O
cells	O
,	O
an	O
increase	O
in	O
the	O
transcription	O
of	O
these	O
two	O
proto	O
-	O
oncogenes	O
,	O
and	O
this	O
increase	O
was	O
amplified	O
after	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
.	O

No	O
such	O
increase	O
was	O
observed	O
in	O
control	O
U937	B
cells	I
.	O

These	O
results	O
indicate	O
that	O
,	O
among	O
HIV1	O
gene	O
products	O
,	O
the	O
Tat	O
protein	O
appears	O
to	O
trigger	O
monocytic	O
differentiation	O
,	O
and	O
suggests	O
that	O
this	O
viral	O
protein	O
directs	O
progenitors	O
of	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
towards	O
a	O
differentiation	O
stage	O
in	O
which	O
production	O
of	O
viral	O
antigens	O
and	O
virions	O
might	O
be	O
more	O
efficient	O
.	O

Stimulation	O
of	O
interleukin-1	O
alpha	O
and	O
interleukin-1	O
beta	O
production	O
in	O
human	O
monocytes	O
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
.	O

Protein	O
phosphatases	O
1	O
and	O
2A	O
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O

In	O
human	O
monocytes	O
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	O
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	O
beta	O
and	O
interleukin-1	O
alpha	O
.	O

The	O
increased	O
mRNA	O
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin-1	O
genes	O
.	O

Stimulation	O
of	O
interleukin-1	O
gene	O
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	O
factor	O
activities	O
,	O
including	O
those	O
of	O
AP-1	O
,	O
by	O
these	O
protein	O
phosphatase	O
inhibitors	O
.	O

Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	O
beta	O
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	O
beta	O
convertase	O
mRNA	O
accumulation	O
.	O

The	O
stimulation	O
of	O
interleukin-1	O
alpha	O
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	O
beta	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	O
interleukin-1	O
alpha	O
cytokine	O
was	O
increased	O
.	O

These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	O
monocytes	O
and	O
suggest	O
that	O
these	O
two	O
phosphatases	O
play	O
important	O
roles	O
in	O
regulating	O
interleukin-1	O
production	O
.	O

Transcription	O
factor	O
jun	O
-	O
B	O
is	O
target	O
of	O
autoreactive	O
T	O
-	O
cells	O
in	O
IDDM	O
.	O

Target	O
antigens	O
defined	O
by	O
autoantibodies	O
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	O
cell	O
antibodies	O
,	O
and	O
a	O
64	O
,	O
000-M	O
(	O
r	O
)	O
protein	O
recently	O
identified	O
as	O
glutamic	O
acid	O
decarboxylase	O
.	O

In	O
addition	O
,	O
some	O
IDDM	O
sera	O
that	O
contain	O
antibodies	O
to	O
glutamic	O
acid	O
decarboxylase	O
also	O
coprecipitate	O
a	O
38	O
,	O
000-M	O
(	O
r	O
)	O
protein	O
from	O
islets	O
.	O

This	O
study	O
used	O
a	O
high	O
titer	O
anti-38	O
,	O
000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	O
lambda	O
cDNA	O
expression	O
libraries	O
and	O
identified	O
human	O
islet	O
and	O
placental	B
clones	I
encoding	O
jun	O
-	O
B	O
,	O
the	O
nuclear	O
transcription	O
protein	O
,	O
of	O
predicted	O
38	O
,	O
000	O
M	O
(	O
r	O
)	O
.	O

Peripheral	O
blood	O
T	O
-	O
cells	O
exhibited	O
significant	O
proliferation	O
in	O
response	O
to	O
a	O
recombinant	O
fragment	O
of	O
jun	O
-	O
B	O
(	O
amino	O
acids	O
1	O
-	O
180	O
)	O
in	O
12	O
of	O
17	O
(	O
71	O
%	O
)	O
recent	O
-	O
onset	O
IDDM	O
subjects	O
,	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
ICA	O
-	O
positive	O
first	O
-	O
degree	O
relatives	O
of	O
IDDM	O
subjects	O
who	O
were	O
at	O
risk	O
,	O
3	O
of	O
12	O
(	O
25	O
%	O
)	O
other	O
autoimmune	O
disease	O
subjects	O
,	O
and	O
0	O
of	O
10	O
healthy	O
control	O
subjects	O
.	O

Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

Responses	O
to	O
jun	O
-	O
B	O
were	O
not	O
related	O
to	O
age	O
,	O
sex	O
,	O
or	O
human	O
leukocyte	O
antigen	O
status	O
.	O

Thus	O
,	O
autoreactive	O
T	O
-	O
cells	O
identify	O
a	O
novel	O
antigen	O
,	O
p38	O
jun	O
-	O
B	O
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

Induced	O
myeloid	O
differentiation	O
of	O
K562	B
cells	I
with	O
downregulation	O
of	O
erythroid	O
and	O
megakaryocytic	O
transcription	O
factors	O
:	O
a	O
novel	O
experimental	O
model	O
for	O
hemopoietic	O
lineage	O
restriction	O
.	O

The	O
human	B
erythroleukemia	I
cell	I
line	I
K562	I
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	B
cells	I
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O

This	O
was	O
accompanied	O
by	O
downregulation	O
of	O
two	O
transcription	O
factors	O
normally	O
expressed	O
in	O
erythroid	O
,	O
mast	O
and	O
megakaryocyte	O
lineages	O
.	O

Northern	O
analysis	O
demonstrated	O
coordinate	O
downregulation	O
of	O
alpha	O
globin	O
and	O
gamma	O
globin	O
in	O
addition	O
to	O
the	O
two	O
lineage	O
-	O
restricted	O
transcription	O
factors	O
,	O
SCL	O
and	O
GATA-1	O
.	O

Proliferation	O
of	O
the	O
K562	B
cells	I
was	O
also	O
suppressed	O
.	O

Clonal	O
assay	O
showed	O
that	O
the	O
suppression	O
was	O
irreversible	O
and	O
appeared	O
analogous	O
to	O
the	O
commitment	O
of	O
murine	B
erythroleukemia	I
(	I
MEL	I
)	I
cells	I
to	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
to	O
MEL	B
cells	I
,	O
however	O
,	O
K562	B
cells	I
acquired	O
a	O
macrophage	O
-	O
like	O
morphology	O
and	O
exhibited	O
a	O
complete	O
failure	O
to	O
generate	O
benzidine	B
-	I
positive	I
cells	I
.	O

Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	O
.	O

Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA	B
-	I
induced	I
cells	I
expressed	O
reduced	O
levels	O
of	O
glycophorin	O
A	O
,	O
CD5	O
,	O
CD7	O
and	O
CD11b	O
.	O

No	O
upregulation	O
of	O
megakaryocyte	O
or	O
lymphoid	O
markers	O
occurred	O
.	O

Thus	O
the	O
response	O
of	O
K562	B
cells	I
to	O
HMBA	O
may	O
provide	O
a	O
useful	O
experimental	O
system	O
for	O
studying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
downmodulation	O
of	O
lineage	O
-	O
restricted	O
transcription	O
factors	O
during	O
hemopoietic	O
lineage	O
commitment	O
.	O

A	O
protein	O
of	O
the	O
AP-1	O
family	O
is	O
a	O
component	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
is	O
a	O
transcriptional	O
activator	O
involved	O
in	O
the	O
induction	O
of	O
IL-2	O
gene	O
expression	O
.	O

The	O
response	O
element	O
for	O
NF	O
-	O
AT	O
is	O
a	O
sequence	O
localized	O
between	O
-285	O
/	O
-254	O
in	O
the	O
IL-2	O
regulatory	O
region	O
.	O

The	O
composition	O
of	O
NF	O
-	O
AT	O
protein	O
is	O
still	O
not	O
fully	O
elucidated	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	O
cells	O
,	O
an	O
AP-1	O
protein	O
is	O
a	O
component	O
of	O
the	O
NF	O
-	O
AT	O
protein	O
complex	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	O
site	O
to	O
compete	O
with	O
the	O
NF	O
-	O
AT	O
site	O
for	O
binding	O
to	O
NF	O
-	O
AT	O
and	O
by	O
the	O
capacity	O
of	O
immobilized	O
anti	O
-	O
Jun	O
and	O
anti	O
-	O
Fos	O
antibodies	O
to	O
deplete	O
NF	O
-	O
AT	O
-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O

There	O
was	O
no	O
detectable	O
binding	O
of	O
in	O
vitro	O
translated	O
Jun	O
/	O
Fos	O
heterodimer	O
(	O
AP-1	O
)	O
to	O
the	O
NF	O
-	O
AT	O
sequence	O
,	O
and	O
the	O
NF	O
-	O
AT	O
sequence	O
was	O
unable	O
to	O
inhibit	O
the	O
binding	O
of	O
Jun	O
/	O
Fos	O
to	O
the	O
AP-1	O
sequence	O
.	O

The	O
presence	O
of	O
an	O
AP-1	O
protein	O
in	O
the	O
NF	O
-	O
AT	O
protein	O
complex	O
may	O
regulate	O
NF	O
-	O
AT	O
-binding	O
activity	O
through	O
protein	O
-	O
protein	O
interaction	O
.	O

Human	B
CD3-CD16	I
+	I
natural	I
killer	I
cells	I
express	O
the	O
hGATA-3	O
T	O
cell	O
transcription	O
factor	O
and	O
an	O
unrearranged	O
2.3-kb	O
TcR	O
delta	O
transcript	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
delta	O
transcripts	O
expressed	O
by	O
CD3-CD16	B
+	I
cells	I
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA-3	O
T	O
cell	O
transcription	O
factor	O
and	O
the	O
recombination	O
-	O
activating	O
gene	O
(	O
RAG	O
)	O
-1	O
.	O

Multiple	O
TcR	O
delta	O
transcripts	O
deriving	O
from	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
were	O
detected	O
in	O
both	O
polyclonal	B
and	I
clonal	I
CD3-CD16	I
+	I
natural	I
killer	I
(	I
NK	I
)	I
cell	I
lines	I
.	O

Two	O
unrearranged	O
TcR	O
delta	O
transcripts	O
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	O
delta	O
mRNA	O
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	O
in	O
TcR	B
gamma	I
/	I
delta+	I
T	I
lymphocytes	I
.	O

Sequence	O
analysis	O
of	O
nine	O
different	O
2.3-kb	O
cDNA	O
clones	O
obtained	O
from	O
NK	O
-	O
derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
.	O

These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	O
bp	O
upstream	O
from	O
the	O
J	O
delta	O
1	O
segment	O
.	O

The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	O
delta	O
1	O
segment	O
corresponded	O
to	O
the	O
previously	O
reported	O
germ	O
-	O
line	O
sequence	O
.	O

The	O
J	O
delta	O
1	O
segment	O
was	O
correctly	O
spliced	O
to	O
C	O
delta	O
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	O
C	O
delta	O
exon	O
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3-kb	O
cDNA	O
.	O

The	O
expression	O
of	O
hGATA-3	O
,	O
a	O
T	O
cell	O
-	O
specific	O
factor	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	O
delta	O
locus	O
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	B
cell	I
population	I
and	O
clones	O
(	O
but	O
not	O
in	O
freshly	O
derived	O
cell	O
populations	O
)	O
.	O

All	O
NK	B
clones	I
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	O
mRNA	O
,	O
suggesting	O
that	O
hGATA-3	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	O
delta	O
gene	O
expression	O
in	O
NK	O
cells	O
.	O

Finally	O
,	O
no	O
transcription	O
of	O
the	O
RAG-1	O
gene	O
could	O
be	O
detected	O
in	O
all	O
NK	B
cell	I
lines	I
or	O
clones	O
analyzed	O
.	O

Hypertension	O
in	O
pregnancy	O
.	O

Pregnancy	O
-	O
induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy	O
-	O
corticosterone	O
(	O
18-OH	O
-	O
B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
count	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

The	O
MR	O
-	O
count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH	O
-	O
group	O
.	O

The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH	O
-	O
B	O
were	O
also	O
low	O
.	O

These	O
results	O
can	O
not	O
be	O
explained	O
by	O
receptor	O
down	O
-	O
regulation	O
due	O
to	O
higher	O
level	O
of	O
mineralocorticoids	O
of	O
the	O
zona	O
glomerulosa	O
.	O

Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	O
-status	O
.	O

The	O
first	O
results	O
of	O
continuous	O
blood	O
pressure	O
measurements	O
with	O
a	O
noninvasive	O
,	O
real	O
-	O
time	O
blood	O
pressure	O
monitor	O
(	O
Finapres	O
)	O
are	O
presented	O
.	O

The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O

We	O
also	O
report	O
on	O
the	O
first	O
experiences	O
with	O
Urapidil	O
in	O
the	O
treatment	O
of	O
hypertension	O
in	O
severe	O
preeclampsia	O
.	O

The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex	O
-	O
tachycardia	O
.	O

Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O

Aldosterone	O
-	O
specific	O
membrane	O
receptors	O
and	O
rapid	O
non	O
-	O
genomic	O
actions	O
of	O
mineralocorticoids	O
.	O

Functional	O
studies	O
in	O
extrarenal	O
,	O
non	O
-	O
epithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non	O
-	O
genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium	O
/	O
proton	O
exchanger	O
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1	O
-	O
2	O
min	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol	O
1	O
,	O
4	O
,	O
5-trisphosphate	O
/	O
calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane	O
related	O
rapid	O
responses	O
.	O

The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	O
lymphocytes	O
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor	O
-	O
effector	O
mechanisms	O
involved	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10	O
,	O
000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Activation	O
of	O
primary	O
human	O
T	O
-	O
lymphocytes	O
through	O
CD2	O
plus	O
CD28	O
adhesion	O
molecules	O
induces	O
long	O
-	O
term	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T	O
-	O
cells	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	O
2	O
(	O
IL-2	O
)	O
-dependent	O
activation	O
does	O
not	O
require	O
monocytes	O
or	O
accessory	O
cells	O
.	O

Long	O
-	O
lasting	O
IL-2	O
receptivity	O
is	O
associated	O
with	O
high	O
-	O
level	O
expression	O
of	O
the	O
inducible	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	O
of	O
IL-2R	O
alpha	O
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5'-regulatory	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL-2R	O
alpha	O
kappa	O
B	O
-	O
specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	O
+	O
CD28	O
activation	O
.	O

Resting	O
T	O
-	O
cell	O
nuclear	O
extracts	O
contained	O
KBF1	O
/	O
p50	O
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B	O
-	O
specific	O
complexes	O
were	O
identified	O
as	O
NF	O
-	O
kappa	O
B	O
p50-p65	O
heterodimer	O
and	O
putative	O
c	O
-	O
Rel	O
homodimer	O
or	O
c	O
-	O
Rel	O
-	O
p65	O
heterodimer	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	O
+	O
CD28	O
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
T	O
-	O
lymphocytes	O
,	O
also	O
inhibited	O
IL-2	O
secretion	O
,	O
IL-2R	O
alpha	O
cell	O
surface	O
expression	O
,	O
and	O
T	O
-	O
cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long	O
-	O
term	O
activation	O
of	O
human	O
primary	O
T	O
-	O
lymphocytes	O
via	O
CD2	O
+	O
CD28	O
.	O

Oxidoreductive	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

Involvement	O
of	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	O
.	O

We	O
have	O
investigated	O
an	O
oxidoreductive	O
regulatory	O
pathway	O
for	O
the	O
DNA	O
binding	O
activity	O
of	O
a	O
pleiotropic	O
cellular	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
has	O
been	O
investigated	O
by	O
using	O
NF	O
kappa	O
B	O
prepared	O
from	O
the	O
nucleus	O
and	O
the	O
cytosol	O
of	O
the	O
primary	O
human	O
T	O
lymphocytes	O
.	O

We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	O
(	O
Trx	O
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	O
kappa	O
B	O
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	O
kappa	O
B	O
-dependent	O
gene	O
expression	O
.	O

We	O
demonstrate	O
evidence	O
suggesting	O
that	O
redox	O
regulation	O
of	O
NF	O
kappa	O
B	O
by	O
Trx	O
might	O
be	O
exerted	O
at	O
a	O
step	O
after	O
dissociation	O
of	O
the	O
inhibitory	O
molecule	O
I	O
kappa	O
B	O
,	O
a	O
cytosolic	O
-	O
anchoring	O
protein	O
for	O
NF	O
kappa	O
B	O
.	O

To	O
examine	O
the	O
effect	O
of	O
Trx	O
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	O
acetyltransferase	O
-	O
expressing	O
plasmid	O
under	O
the	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
and	O
an	O
effector	O
plasmid	O
expressing	O
human	O
Trx	O
.	O

The	O
promoter	O
activity	O
from	O
HIV	O
long	O
terminal	O
repeat	O
was	O
greatly	O
augmented	O
by	O
co	O
-	O
transfecting	O
the	O
Trx	O
-	O
expressing	O
plasmid	O
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	O
kappa	O
B	O
-binding	O
sites	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
cysteine	O
residue	O
(	O
s	O
)	O
of	O
NF	O
kappa	O
B	O
might	O
be	O
involved	O
in	O
the	O
DNA	O
-	O
recognition	O
by	O
NF	O
kappa	O
B	O
and	O
that	O
the	O
redox	O
control	O
mechanism	O
mediated	O
by	O
Trx	O
might	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
NF	O
kappa	O
B	O
-mediated	O
gene	O
expression	O
.	O

These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O

Synergism	O
between	O
the	O
CD3	O
antigen-	O
and	O
CD2	O
antigen	O
-	O
derived	O
signals	O
.	O

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3	O
/	O
TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	O
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA	O
-	O
binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and/or	O
CD2	O
proteins	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and/or	O
sn-1	O
,	O
2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin-2	O
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen	O
-	O
derived	O
signals	O
and	O
CD2	O
antigen	O
-derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF	O
-	O
AT1	O
,	O
AP-1	O
,	O
and	O
NF	O
-	O
kB	O
sites	O
located	O
in	O
the	O
promoter	O
/	O
enhancer	O
region	O
of	O
the	O
IL-2	O
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA	O
-	O
binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen	O
-	O
dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

A	O
concatenated	O
form	O
of	O
Epstein	O
-	O
Barr	O
viral	O
DNA	O
in	O
lymphoblastoid	B
cell	I
lines	I
induced	O
by	O
transfection	O
with	O
BZLF1	O
.	O

The	O
replicative	O
form	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
DNA	O
was	O
studied	O
using	O
two	O
lymphoblastoid	B
cell	I
lines	I
,	O
X50	O
-	O
7	O
and	O
6F11	O
,	O
which	O
are	O
latently	O
infected	O
by	O
Epstein	O
-	O
Barr	O
virus	O
.	O

The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1	O
/	O
BZLF1	O
coding	O
region	O
of	O
the	O
P3HR-1	O
defective	O
genome	O
.	O

We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein	O
-	O
Barr	O
viral	O
DNA	O
in	O
the	O
lytic	B
cycle	I
-	I
induced	I
cells	I
.	O

Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
.	O

This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	O
DNA	O
or	O
concatameric	O
linear	O
DNA	O
.	O

Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	O
EBV	O
DNA	O
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O

We	O
propose	O
from	O
these	O
results	O
that	O
the	O
source	O
of	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
is	O
a	O
concatenated	O
linear	O
EBV	O
DNA	O
molecule	O
,	O
and	O
that	O
such	O
a	O
concatenated	O
molecule	O
most	O
likely	O
represents	O
a	O
replicative	O
form	O
of	O
EBV	O
DNA	O
in	O
productively	O
infected	O
cells	O
.	O

Induction	O
of	O
CD8	O
antigen	O
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	B
human	I
leukemic	I
cell	I
clone	I
.	O

The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	O
surface	O
antigens	O
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	B
cell	I
lines	I
,	O
CEM	B
C7	I
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	B
C1	I
(	O
r+	O
,	O
ly-	O
)	O
.	O

The	O
reactivity	O
of	O
murine	O
monoclonal	O
antibodies	O
,	O
anti	O
-	O
CD4-FITC	O
,	O
anti	O
-	O
CD8-FITC	O
,	O
anti	O
-	O
CD2-FITC	O
and	O
anti	O
-	O
calla	O
-	O
FITC	O
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O

The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin	B
-	I
activated	I
peripheral	I
blood	I
lymphocytes	I
.	O

Dexamethasone	O
treatment	O
of	O
a	O
human	B
leukemic	I
cell	I
clone	I
CEM	I
C7	I
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	O
antigen	O
CD8	O
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	O
T	O
-	O
lymphocytes	O
.	O

By	O
comparison	O
,	O
there	O
was	O
no	O
modification	O
of	O
the	O
expression	O
of	O
CD4	O
antigen	O
,	O
which	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
cells	O
.	O

After	O
two	O
days	O
of	O
treatment	O
with	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
dexamethasone	O
,	O
CEM	B
C7	I
cells	I
showed	O
a	O
two	O
-	O
fold	O
increase	O
in	O
suppressor	O
activity	O
compared	O
to	O
untreated	O
cells	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
regulation	O
by	O
glucocorticoids	O
of	O
either	O
the	O
CD8	O
or	O
CD4	O
antigens	O
in	O
the	O
leukemic	B
clone	I
CEM	I
C1	I
.	O

Furthermore	O
,	O
no	O
modification	O
of	O
the	O
suppressor	O
function	O
in	O
CEM	B
C1	I
cells	I
by	O
dexamethasone	O
was	O
observed	O
.	O

In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	O
antigen	O
expression	O
in	O
a	O
CD4	B
+	I
cells	I
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	B
receptor	I
positive	I
cell	I
population	I
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	O
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	O
,	O
IL3	O
,	O
IL4	O
,	O
and	O
IL5	O
,	O
which	O
encode	O
interleukins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	O
,	O
-3	O
,	O
-4	O
,	O
and	O
-5	O
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	O
lymphocytes	O
involved	O
a	O
trans	O
-	O
acting	O
factor	O
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	O
factors	O
from	O
the	O
patient	O
's	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	O
.	O

Nuclear	O
factor	O
NF	O
-	O
kB	O
,	O
activation	O
protein	O
1	O
(	O
AP-1	O
)	O
,	O
OCT-1	O
,	O
and	O
NF	O
-	O
IL-2B	O
binding	O
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	O
enhancer	O
and	O
to	O
an	O
NF	O
-	O
AT	O
-	O
like	O
response	O
element	O
present	O
in	O
the	O
IL4	O
enhancer	O
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF	O
-	O
AT	O
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	O
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O

CAT	O
expression	O
directed	O
by	O
the	O
IL2	O
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	O
gene	O
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	O
proximal	O
(	O
OCT-1p	O
)	O
-binding	O
site	O
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of	O
/	O
or	O
influencing	O
NF	O
-	O
AT	O
may	O
underlie	O
the	O
multiple	O
lymphokine	O
deficiency	O
in	O
this	O
patient	O
.	O

Expression	O
of	O
mRNA	O
for	O
the	O
GATA	O
-	O
binding	O
proteins	O
in	O
human	O
eosinophils	O
and	O
basophils	O
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O

The	O
expression	O
of	O
the	O
hematopoietic	O
transcription	O
factors	O
GATA-1	O
,	O
GATA-2	O
,	O
and	O
GATA-3	O
was	O
studied	O
in	O
eosinophils	O
and	O
basophils	O
.	O

Eosinophils	O
express	O
mRNA	O
for	O
GATA-1	O
,	O
GATA-2	O
,	O
and	O
GATA-3	O
.	O

Basophils	O
express	O
GATA-2	O
and	O
GATA-3	O
.	O

Treatment	O
of	O
HL-60	B
eosinophilic	I
sublines	I
with	O
either	O
interleukin-5	O
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA-1	O
mRNA	O
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil	O
-	O
specific	O
genes	O
,	O
whereas	O
levels	O
of	O
GATA-2	O
mRNA	O
remained	O
relatively	O
constant	O
.	O

The	O
presence	O
of	O
mRNA	O
for	O
these	O
proteins	O
in	O
eosinophils	O
and	O
basophils	O
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA	O
-	O
binding	O
proteins	O
.	O

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug	B
-	I
resistant	I
HL-60	I
cells	I
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester	O
-	O
induced	O
monocytic	O
differentiation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	B
HL-60	I
myeloid	I
leukemia	I
cells	I
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c	O
-	O
jun	O
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine	O
-	O
selected	O
,	O
multidrug	O
resistance	O
on	O
12-O	O
-	O
tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
HL-60	O
cell	O
differentiation	O
.	O

The	O
results	O
demonstrate	O
that	O
multidrug	B
-	I
resistant	I
HL-60	I
cells	I
,	O
designated	O
HL-60	O
/	O
vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c	O
-	O
jun	O
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
HL-60	B
/	I
vinc	I
cells	I
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatases	O
,	O
induces	O
c	O
-	O
jun	O
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c	O
-	O
fms	O
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL-60	B
/	I
vinc	I
revertant	I
(	O
HL-60	B
/	I
vinc	I
/	I
R	I
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL-60	B
/	I
vinc	I
/	I
R	I
cells	I
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	O
c	O
-	O
jun	O
expression	O
,	O
suggests	O
that	O
c	O
-	O
jun	O
induction	O
is	O
not	O
obligatory	O
for	O
monocytic	O
differentiation	O
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun	O
-	O
B	O
and	O
fra-1	O
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60	B
/	I
vinc	I
and	O
HL-60	B
/	I
vinc	I
/	I
R	I
cells	I
,	O
whereas	O
c	O
-	O
fos	O
expression	O
is	O
attenuated	O
in	O
the	O
HL-60	O
/	O
vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL-60	B
and	O
HL-60	B
/	I
vinc	I
/	I
R	I
cells	I
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL-60	B
/	I
vinc	I
cells	I
.	O

Activity	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c	O
-	O
Jun	O
Y	O
-	O
peptide	O
was	O
markedly	O
diminished	O
in	O
TPA	B
-	I
treated	I
HL-60	I
/	I
vinc	I
cells	I
,	O
but	O
not	O
in	O
response	O
to	O
okadaic	O
acid	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA	O
-	O
induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC	O
-mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun	O
/	O
fos	O
early	O
response	O
gene	O
expression	O
.	O

Differential	O
contribution	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
gene	O
products	O
and	O
cellular	O
factors	O
to	O
the	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
provirus	O
.	O

We	O
have	O
previously	O
reported	O
that	O
infection	O
with	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
activates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
provirus	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
HIV-1	O
provirus	O
correlated	O
with	O
the	O
activation	O
of	O
binding	O
of	O
55-	O
and	O
85-kDa	O
proteins	O
to	O
the	O
kappa	O
B	O
enhancer	O
and	O
binding	O
of	O
the	O
50-kDa	O
HLP-1	O
protein	O
to	O
the	O
LBP-1	O
sequences	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O

Further	O
examination	O
of	O
this	O
system	O
has	O
shown	O
that	O
the	O
inhibition	O
of	O
HSV-1	O
replication	O
by	O
the	O
antiviral	O
drug	O
acyclovir	O
does	O
not	O
inhibit	O
HSV-1-mediated	O
induction	O
of	O
HIV-1	O
provirus	O
.	O

Surprisingly	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
HLP-1	O
binding	O
activities	O
were	O
substantially	O
inhibited	O
in	O
acyclovir	B
-	I
treated	I
cells	I
.	O

In	O
the	O
transient	O
-	O
transfection	O
assay	O
,	O
ICP0	O
,	O
but	O
not	O
ICP4	O
,	O
activated	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
promoter	O
region	O
and	O
the	O
effect	O
of	O
ICP0	O
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
proteins	O
,	O
suggesting	O
that	O
induction	O
of	O
the	O
HIV-1	O
provirus	O
involves	O
cooperation	O
between	O
the	O
HSV-1-activated	O
cellular	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
virus	O
-	O
encoded	O
transactivator	O
,	O
ICP0	O
.	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
by	O
IL-2	O
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
protein	O
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
(	O
Mo	O
)	O
constitutively	O
display	O
the	O
beta	O
-	O
chain	O
of	O
the	O
receptor	O
for	O
IL-2	O
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	O
alpha	O
-	O
chain	O
is	O
not	O
constitutive	O
but	O
inducible	O
with	O
IL-2	O
.	O

Here	O
we	O
report	O
that	O
binding	O
of	O
human	O
IL-2	O
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	O
CSF	O
(	O
M	O
-	O
CSF	O
)	O
gene	O
in	O
Mo	O
resulting	O
in	O
accumulation	O
of	O
M	O
-	O
CSF	O
mRNA	O
and	O
subsequent	O
release	O
of	O
bioactive	O
M	O
-	O
CSF	O
protein	O
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL-2	O
induced	O
release	O
of	O
an	O
activity	O
-	O
stimulating	O
growth	O
of	O
monocyte	B
-	I
type	I
colonies	I
by	O
a	O
neutralizing	O
anti	O
-	O
M	O
-	O
CSF	O
antibody	O
.	O

Transcriptional	O
activation	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
by	O
IL-2	O
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M	O
-	O
CSF	O
gene	O
.	O

Moreover	O
,	O
using	O
a	O
heterologous	O
promoter	O
(	O
herpes	O
thymidine	O
kinase	O
)	O
construct	O
containing	O
the	O
NF	O
-	O
kappa	O
B	O
consensus	O
sequence	O
,	O
it	O
is	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
binding	O
by	O
an	O
IL-2-induced	O
monocyte	O
-	O
derived	O
nuclear	O
protein	O
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL-2	O
induces	O
gene	O
expression	O
of	O
M	O
-	O
CSF	O
in	O
human	O
blood	O
-	O
derived	O
Mo	O
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O

Cell	O
cycle	O
analysis	O
of	O
E2F	O
in	O
primary	O
human	O
T	O
cells	O
reveals	O
novel	O
E2F	O
complexes	O
and	O
biochemically	O
distinct	O
forms	O
of	O
free	O
E2F	O
.	O

The	O
transcription	O
factor	O
E2F	O
activates	O
the	O
expression	O
of	O
multiple	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c	O
-	O
myc	O
and	O
the	O
dihydrofolate	O
reductase	O
gene	O
.	O

Regulation	O
of	O
E2F	O
involves	O
its	O
interactions	O
with	O
other	O
cellular	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
protein	O
(	O
Rb	O
)	O
,	O
the	O
Rb	O
-	O
related	O
protein	O
p107	O
,	O
cyclin	O
A	O
,	O
and	O
cdk2	O
.	O

We	O
undertook	O
a	O
detailed	O
analysis	O
of	O
E2F	O
DNA	O
-	O
binding	O
activities	O
and	O
their	O
cell	O
cycle	O
behavior	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Three	O
E2F	O
DNA	O
-	O
binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	O
cells	O
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	O
complexes	O
.	O

One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb-	O
E2F	O
complex	O
.	O

The	O
most	O
prominent	O
E2F	O
activity	O
in	O
resting	O
T	O
cells	O
(	O
termed	O
complex	O
X	O
)	O
was	O
abundant	O
in	O
both	O
G0	O
and	O
G1	O
but	O
disappeared	O
as	O
cells	O
entered	O
S	O
phase	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
negatively	O
regulating	O
E2F	O
function	O
.	O

Complex	O
X	O
could	O
be	O
dissociated	O
by	O
adenovirus	O
E1A	O
with	O
a	O
requirement	O
for	O
an	O
intact	O
E1A	O
conserved	O
region	O
2	O
.	O

However	O
,	O
X	O
failed	O
to	O
react	O
with	O
a	O
variety	O
of	O
antibodies	O
against	O
Rb	O
or	O
p107	O
,	O
implicating	O
the	O
involvement	O
of	O
an	O
E1A	O
-	O
binding	O
protein	O
other	O
than	O
Rb	O
or	O
p107	O
.	O

In	O
addition	O
to	O
these	O
novel	O
E2F	O
complexes	O
,	O
three	O
distinct	O
forms	O
of	O
unbound	O
(	O
free	O
)	O
E2F	O
were	O
resolved	O
in	O
gel	O
shift	O
experiments	O
.	O

These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O

UV	O
cross	O
-	O
linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	O
DNA	O
-	O
binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S	O
-	O
phase	O
p107	O
complex	O
and	O
is	O
not	O
associated	O
with	O
Rb	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
E2F	O
consists	O
of	O
multiple	O
,	O
biochemically	O
distinct	O
DNA	O
-	O
binding	O
proteins	O
which	O
function	O
at	O
different	O
points	O
in	O
the	O
cell	O
cycle	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
block	O
CD11b	O
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL-60	B
granulocytes	I
.	O

NF	O
-	O
kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF	O
-	O
kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	B
and	I
stimulated	I
granulocytes	I
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	O
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	B
sulfoxide	I
-	I
differentiated	I
HL-60	I
leukemia	I
cells	I
stimulated	O
by	O
12-O	O
-	O
tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	O
integrin	O
expression	O
on	O
the	O
surface	O
of	O
treated	B
cells	I
.	O

Furthermore	O
,	O
the	O
p65	O
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	O
that	O
was	O
produced	O
by	O
formyl	O
-	O
met	O
-	O
leu	O
-	O
phe	O
and	O
TPA	O
.	O

However	O
,	O
the	O
p65	O
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	O
significant	O
effect	O
on	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
or	O
on	O
phagocytosis	O
by	O
these	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	O
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O

Exposure	O
of	O
certain	O
cell	O
types	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
an	O
inducible	O
transcription	O
factor	O
.	O

One	O
of	O
NF	O
-	O
kappa	O
B	O
's	O
unique	O
properties	O
is	O
its	O
posttranslational	O
activation	O
via	O
release	O
of	O
an	O
inhibitory	O
subunit	O
,	O
called	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
I	O
kappa	O
B	O
)	O
,	O
from	O
a	O
sequestered	O
cytoplasmic	O
form	O
.	O

This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O

Other	O
bacterial	O
toxins	O
,	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
)	O
,	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
T	O
cell	O
mitogens	O
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
activated	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
rapidly	O
taken	O
up	O
into	O
nuclei	O
,	O
initiates	O
transcription	O
from	O
immediate	O
early	O
genes	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Most	O
of	O
the	O
target	O
genes	O
for	O
NF	O
-	O
kappa	O
B	O
are	O
of	O
relevance	O
for	O
the	O
immune	O
response	O
and	O
can	O
be	O
grouped	O
into	O
those	O
encoding	O
cytokines	O
,	O
cell	O
surface	O
receptors	O
,	O
acute	O
phase	O
proteins	O
and	O
viral	O
genomes	O
,	O
such	O
as	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

We	O
will	O
discuss	O
recent	O
experimental	O
evidences	O
suggesting	O
that	O
LPS	O
might	O
share	O
a	O
pathway	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
with	O
other	O
inducers	O
of	O
the	O
factor	O
.	O

This	O
common	O
pathway	O
may	O
involve	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
as	O
messenger	O
molecules	O
.	O

Analysis	O
of	O
the	O
preexisting	O
and	O
nuclear	O
forms	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
3	O
is	O
an	O
inducible	O
DNA	O
-	O
binding	O
protein	O
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	O
gene	O
during	O
T	O
cell	O
activation	O
.	O

NF	O
-	O
AT	O
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	O
,	O
inducible	O
nuclear	O
component	O
that	O
we	O
have	O
identified	O
as	O
Fos	O
and	O
Jun	O
proteins	O
,	O
and	O
a	O
preexisting	O
,	O
T	O
cell	O
-	O
specific	O
component	O
(	O
NF	O
-	O
ATp	O
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

We	O
have	O
previously	O
shown	O
that	O
nuclear	O
extracts	O
from	O
activated	O
T	O
cells	O
form	O
two	O
inducible	O
NF	O
-	O
AT	O
complexes	O
with	O
an	O
oligonucleotide	O
corresponding	O
to	O
the	O
distal	O
NF	O
-	O
AT	O
site	O
of	O
the	O
murine	O
IL-2	O
promoter	O
,	O
although	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
form	O
a	O
single	O
complex	O
containing	O
NF	O
-	O
ATp	O
.	O

We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF	O
-	O
ATp	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF	O
-	O
AT	O
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O

Moreover	O
we	O
present	O
evidence	O
that	O
the	O
component	O
that	O
forms	O
the	O
faster	O
-	O
migrating	O
(	O
`	O
`	O
lower	O
''	O
)	O
nuclear	O
NF	O
-	O
AT	O
complex	O
is	O
derived	O
by	O
a	O
calcium	O
-	O
dependent	O
,	O
cyclosporin	O
-	O
sensitive	O
,	O
posttranslational	O
modification	O
of	O
NF	O
-	O
ATp	O
,	O
and	O
that	O
Fos	O
and	O
Jun	O
proteins	O
stabilize	O
its	O
interaction	O
with	O
DNA	O
.	O

The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
relating	O
the	O
two	O
nuclear	O
NF	O
-	O
AT	O
complexes	O
to	O
NF	O
-	O
ATp	O
.	O

The	O
impaired	O
transcription	O
factor	O
AP-1	O
DNA	O
binding	O
activity	O
in	O
lymphocytes	O
derived	O
from	O
subjects	O
with	O
some	O
symptoms	O
of	O
premature	O
aging	O
.	O

The	O
study	O
of	O
human	O
disorders	O
known	O
as	O
premature	O
aging	O
syndromes	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
cellular	O
senescence	O
.	O

The	O
main	O
feature	O
of	O
cellular	O
senescence	O
in	O
vitro	O
is	O
cessation	O
of	O
cell	O
proliferation	O
.	O

Down	O
syndrome	O
(	O
DS	O
)	O
and	O
neuronal	O
ceroid	O
-	O
lypofuscinosis	O
(	O
NCL	O
)	O
are	O
clinically	O
characterized	O
by	O
the	O
premature	O
onset	O
of	O
numerous	O
features	O
normally	O
associated	O
with	O
human	O
aging	O
.	O

Phytohemagglutinin	O
stimulated	O
lymphocytes	O
derived	O
from	O
DS	O
subjects	O
showed	O
a	O
statistically	O
significant	O
diminished	O
proliferation	O
capacity	O
in	O
comparison	O
with	O
lymphocytes	O
derived	O
from	O
NCL	O
and	O
healthy	O
individuals	O
.	O

We	O
demonstrated	O
,	O
by	O
applying	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
slightly	O
impaired	O
AP-1	O
DNA	O
binding	O
activity	O
in	O
NCL	O
lymphocytes	O
and	O
strong	O
in	O
DS	O
ones	O
.	O

Our	O
results	O
showed	O
that	O
the	O
same	O
molecular	O
mechanisms	O
of	O
proliferation	O
cessation	O
could	O
exist	O
in	O
fibroblasts	O
characterized	O
by	O
replicative	O
senescence	O
and	O
in	O
lymphocytes	O
derived	O
from	O
individuals	O
with	O
premature	O
aging	O
syndromes	O
(	O
Down	O

Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	O
factor	O
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O

Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	O
cells	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	O
effector	O
gene	O
products	O
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O

The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	O
helper	O
cell	O
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	O
.	O

We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	O
Factor	O
(	O
TF	O
)	O
gene	O
and	O
the	O
function	O
of	O
the	O
TF	O
protein	O
.	O

The	O
enhanced	O
initiation	O
of	O
transcription	O
of	O
the	O
TF	O
gene	O
appears	O
to	O
require	O
engagement	O
of	O
a	O
56	O
bp	O
LPS	O
Response	O
Element	O
,	O
an	O
enhancer	O
that	O
is	O
engaged	O
by	O
both	O
AP-1	O
type	O
heterodimeric	O
complexes	O
as	O
well	O
as	O
NF	O
kappa	O
B	O
like	O
heterodimeric	O
complexes	O
.	O

Dissociation	O
of	O
NF	O
kappa	O
B	O
from	O
Ig	O
kappa	O
B	O
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	O
T	O
cells	O
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	O
and	O
other	O
inflammatory	O
genes	O
.	O

Enhancement	O
of	O
expression	O
of	O
TF	O
is	O
observed	O
upon	O
adhesion	O
of	O
Mo	O
to	O
endothelial	O
cells	O
and	O
extracellular	O
matrix	O
proteins	O
,	O
as	O
well	O
as	O
upon	O
engagement	O
of	O
leukocyte	O
integrins	O
.	O

The	O
biological	O
effects	O
that	O
follow	O
from	O
expression	O
of	O
TF	O
by	O
vascular	O
cells	O
have	O
been	O
resolved	O
by	O
analysis	O
of	O
function	O
aided	O
by	O
the	O
use	O
of	O
recombinant	O
full	O
length	O
TF	O
and	O
truncated	O
surface	O
domain	O
of	O
TF	O
.	O

The	O
rules	O
of	O
assembly	O
of	O
the	O
cognate	O
ligands	O
of	O
TF	O
,	O
namely	O
the	O
zymogen	O
plasma	O
factors	O
VII	O
and	O
the	O
serine	O
protease	O
factor	O
VIIa	O
,	O
with	O
the	O
soluble	O
surface	O
domain	O
of	O
TF	O
in	O
free	O
solution	O
,	O
in	O
the	O
presence	O
of	O
phospholipid	O
surfaces	O
and	O
cell	O
surface	O
and	O
of	O
the	O
anchored	O
TF	O
molecule	O
have	O
been	O
described	O
.	O

It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	O
domain	O
of	O
TF	O
with	O
VIIa	O
to	O
form	O
the	O
binary	O
TF.VIIa	O
complex	O
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	O
domain	O
of	O
VIIa	O
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	O
substrate	O
.	O

This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	O
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	O
,	O
its	O
cognate	O
catalytic	O
cofactor	O
.	O

It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	O
complex	O
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	O
plasma	O
factor	O
X	O
to	O
the	O
serine	O
protease	O
Xa	O
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	O
complex	O
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	O
recognition	O
structure	O
.	O

It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	O
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	O
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV	O
-	O
I	O
tax	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	B
T	I
-	I
cell	I
lines	I
.	O

The	O
HTLV	O
-	O
I	O
transcriptional	O
activator	O
tax	O
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF	O
-	O
beta	O
)	O
gene	O
induction	O
.	O

Tax	B
-	I
expressing	I
cell	I
lines	I
produce	O
LT	O
biologic	O
activity	O
.	O

An	O
LT	O
promoter	O
(	O
LT-293	O
)	O
CAT	O
construct	O
that	O
contained	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT	B
-	I
producing	I
C81	I
-	I
66	I
-	I
45	I
cell	I
line	I
,	O
which	O
contains	O
defective	O
HTLV	O
-	O
I	O
but	O
expresses	O
tax	O
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT	O
-	O
kappa	O
B	O
construct	O
(	O
M1-CAT	O
)	O
was	O
inactive	O
in	O
C81	B
-	I
66	I
-	I
45	I
,	O
confirmed	O
the	O
importance	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
LT	O
gene	O
expression	O
.	O

Tax	O
was	O
transfected	O
into	O
HTLV	B
-	I
I	I
-	I
negative	I
human	I
T	I
-	I
cell	I
lines	I
.	O

Jurkat	B
T	I
cells	I
stably	O
expressing	O
tax	O
contained	O
elevated	O
levels	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT	O
-	O
kappa	O
B	O
site	O
.	O

Tax	O
co	O
-	O
transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	B
cells	I
maximally	O
activated	O
HTLV	O
-	O
I	O
-	O
LTR	O
-	O
CAT	O
and	O
kappa	O
B	O
-	O
fos	O
-	O
CAT	O
and	O
also	O
activated	O
LT-293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	B
T	I
cells	I
,	O
tax	O
induced	O
LT-293	O
activity	O
by	O
two-	O
to	O
four	O
-	O
fold	O
,	O
though	O
there	O
was	O
no	O
induction	O
of	O
M1-CAT	O
.	O

The	O
increase	O
in	O
LT-293	O
CAT	O
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV	O
-	O
I	O
tax	O
causes	O
low	O
-	O
level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	O
aldosterone	O
receptors	O
.	O

Results	O
in	O
two	O
affected	O
infants	O
.	O

We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O

Both	O
patients	O
presented	O
with	O
a	O
salt	O
-	O
losing	O
episode	O
simulating	O
adrenal	O
insufficiency	O
.	O

In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	O
receptors	O
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O

Aldosterone	O
receptors	O
were	O
normal	O
in	O
both	O
patients	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF	O
-	O
kappa	O
B2	O
p100	O
gene	O
product	O
:	O
implications	O
for	O
viral	O
latency	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	B
human	I
CD4	I
T	I
cells	I
.	O

HTLV	O
-	O
I	O
encodes	O
an	O
essential	O
40-kDa	O
protein	O
termed	O
Tax	O
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	O
genes	O
.	O

Tax	O
-mediated	O
transformation	O
of	O
T	O
cells	O
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	O
genes	O
that	O
normally	O
regulate	O
lymphocyte	O
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	O
factors	O
.	O

In	O
particular	O
,	O
Tax	O
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
and	O
CREB	O
/	O
ATF	O
families	O
,	O
as	O
well	O
as	O
the	O
cellular	O
factors	O
HEB-1	O
and	O
p67SRF	O
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV	O
-	O
I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV	O
-	O
I	O
Tax	O
can	O
physically	O
associate	O
with	O
p100	O
,	O
the	O
product	O
of	O
the	O
Rel	O
-	O
related	O
NF	O
-	O
kappa	O
B2	O
gene	O
,	O
both	O
in	O
transfected	B
cells	I
and	O
in	O
HTLV	B
-	I
I	I
-	I
infected	I
leukemic	I
T	I
-	I
cell	I
lines	I
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	O
with	O
p100	O
leads	O
to	O
the	O
inhibition	O
of	O
Tax	O
-induced	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeats	O
,	O
reflecting	O
p100	O
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	O
protein	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	O
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF	O
-	O
kappa	O
B	O
expression	O
does	O
not	O
associate	O
with	O
p100	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Effects	O
of	O
CD45	O
on	O
NF	O
-	O
kappa	O
B	O
.	O

Implications	O
for	O
replication	O
of	O
HIV-1	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	O
T	O
cells	O
through	O
the	O
TCR	O
.	O

However	O
,	O
anti-	O
CD45	O
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	O
and	O
HIV-1	O
further	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV-1	O
LTR	O
in	O
T	B
cell	I
lines	I
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	O
and	O
in	O
those	O
that	O
lacked	O
the	O
expression	O
of	O
CD45	O
on	O
their	O
surfaces	O
.	O

First	O
,	O
anti	O
-	O
CD45	O
antibodies	O
did	O
not	O
affect	O
basal	O
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	O
LTR	O
.	O

Second	O
,	O
T	O
cells	O
,	O
which	O
lack	O
CD45	O
and	O
can	O
not	O
signal	O
via	O
the	O
TCR	O
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF	O
-	O
kappa	O
B	O
complexes	O
in	O
the	O
nucleus	O
of	O
CD45	O
-T	O
cells	O
.	O

Additionally	O
,	O
infected	O
T	O
cells	O
displayed	O
lower	O
levels	O
of	O
CD45	O
on	O
their	O
surfaces	O
.	O

Thus	O
,	O
CD45	O
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	O
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	O
mRNA	O
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	O
and	O
IgD	O
in	O
the	O
human	B
B	I
cell	I
line	I
B104	I
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	B
B	I
lymphoma	I
cell	I
line	I
,	I
B104	I
,	O
expressed	O
surface	O
IgM	O
(	O
sIgM	O
)	O
and	O
surface	O
IgD	O
(	O
sIgD	O
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	O
and	O
sIgD	O
by	O
anti	O
-	O
IgM	O
antibody	O
(	O
Ab	O
)	O
and	O
anti	O
-	O
IgD	O
Ab	O
,	O
respectively	O
,	O
induced	O
Ca2	O
+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	O
-crosslinking	O
caused	O
B104	B
cell	I
death	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
accumulation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
the	O
hydrolysis	O
of	O
inositol	O
phosphates	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
and	O
the	O
induction	O
of	O
Egr-1	O
and	O
c	O
-	O
fos	O
mRNA	O
expression	O
by	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
to	O
examine	O
differences	O
in	O
the	O
signals	O
mediated	O
through	O
sIgM	O
and	O
sIgD	O
in	O
B104	B
cells	I
.	O

Both	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	O
activation	O
and	O
expression	O
of	O
Egr-1	O
and	O
c	O
-	O
fos	O
mRNA	O
,	O
although	O
sIgM	O
-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD	O
-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	O
than	O
of	O
sIgD	O
.	O

Egr-1	O
mRNA	O
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD	O
-	O
crosslinking	O
was	O
inhibited	O
by	O
H7	O
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	O
by	O
HA1004	O
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg	O
-	O
crosslinking	O
-	O
induced	O
Egr-1	O
mRNA	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg	O
-	O
crosslinking	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Phorbol	O
myristate	O
acetate	O
induced	O
Egr-1	O
mRNA	O
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
Egr-1	O
mRNA	O
activating	O
signals	O
through	O
sIgM	O
and	O
sIgD	O
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC	O
-	O
dependent	O
,	O
but	O
protein	O
kinase	O
A	O
-independent	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	B
cells	I
from	O
death	O
induced	O
by	O
anti	O
-	O
IgM	O
Ab	O
,	O
but	O
did	O
not	O
affect	O
the	O
expression	O
of	O
Egr-1	O
and	O
c	O
-	O
fos	O
mRNA	O
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	O
from	O
or	O
downstream	O
to	O
these	O
molecules	O
.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	O
and	O
sIgD	O
in	O
B104	B
cells	I
is	O
discussed	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	O
beta	O
and	O
interleukin-6	O
expression	O
in	O
human	O
monocytes	O
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	O
cytokine	O
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	O
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N	O
-	O
acetylglucosaminyl-1	O
,	O
6-anhydro	O
-	O
N	O
-	O
acetylmuramyl	O
-	O
L	O
-	O
alanyl	O
-	O
D-	O
isoglutamyl	O
-	O
m	O
-	O
diaminopimelyl	O
-	O
D	O
-	O
alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	O
transglycosylase	O
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	O
expression	O
in	O
human	O
monocytes	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	O
(	O
IL	O
)	O
-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
after	O
2	O
h	O
and	O
IL-1	O
beta	O
and	O
IL-6	O
protein	O
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	O
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
tyrosine	O
kinase	O
-	O
dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-6	O
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	O
beta	O
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra	O
-	O
induced	O
IL-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
could	O
be	O
enhanced	O
by	O
co	O
-	O
stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	O
beta	O
and	O
IL-6	O
expression	O
in	O
human	O
monocytes	O
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	O
during	O
sepsis	O
.	O

Characterization	O
of	O
NF	O
(	O
P	O
)	O
,	O
the	O
nuclear	O
factor	O
that	O
interacts	O
with	O
the	O
regulatory	O
P	O
sequence	O
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	O
interleukin-4	O
gene	O
:	O
relationship	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

The	O
P	O
sequence	O
of	O
the	O
human	O
interleukin-4	O
(	O
IL-4	O
)	O
gene	O
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	B
T	I
cells	I
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
.	O

We	O
examined	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF	O
-	O
kappa	O
B	O
and	O
NF	O
-	O
AT	O
.	O

NF	O
-	O
kappa	O
B	O
(	O
P65	O
or	O
P65	O
/	O
P50	O
heterodimer	O
)	O
bound	O
to	O
the	O
P	O
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	O
sequence	O
when	O
expression	O
plasmids	O
were	O
cotransfected	O
with	O
P	O
sequence	O
-	O
driven	O
reporter	O
plasmids	O
in	O
Jurkat	B
T	I
cells	I
.	O

In	O
EMSAs	O
,	O
NF	O
(	O
P	O
)	O
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	O
NF	O
-	O
AT	O
binding	O
site	O
but	O
not	O
by	O
the	O
unlabeled	O
AP1	O
binding	O
site	O
and	O
purified	O
NF	O
-	O
AT	O
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF	O
-	O
AT	O
were	O
similar	O
to	O
those	O
of	O
NF	O
(	O
P	O
)	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	O
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF	O
-	O
AT	O
has	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
whereas	O
NF	O
-	O
kappa	O
B	O
alone	O
can	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
crude	O
extracts	O
.	O

Unlike	O
NF	O
-	O
AT	O
,	O
NF	O
(	O
P	O
)	O
does	O
not	O
contain	O
AP1	O
as	O
its	O
DNA	O
binding	O
component	O
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
through	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	O
regulatory	O
proteins	O
such	O
as	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	O
response	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
increased	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	O
gene	O
construct	O
containing	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
binding	O
sites	O
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	O
kinase	O
inhibitors	O
and	O
the	O
dominant	O
negative	O
allele	O
of	O
c	O
-	O
Raf-1	O
(	O
Raf	O
301	O
)	O
inhibited	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
NF	O
-	O
kappa	O
B	O
binding	O
,	O
and	O
transactivation	O
of	O
kappa	O
B	O
reporter	O
constructs	O
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	O
kappa	O
B	O
alpha	O
with	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
we	O
immunoprecipitated	O
I	O
kappa	O
B	O
alpha	O
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	O
kappa	O
B	O
alpha	O
prevented	O
I	O
kappa	O
B	O
alpha	O
degradation	O
and	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF	O
-	O
kappa	O
B	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	O
necrosis	O
factor	O
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	O
kappa	O
B	O
alpha	O
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF	O
-	O
kappa	O
B	O
.	O

Androgen	O
binding	O
sites	O
in	O
peripheral	O
human	O
mononuclear	O
leukocytes	O
of	O
healthy	O
males	O
and	O
females	O
.	O

Androgen	O
binding	O
sites	O
have	O
been	O
identified	O
in	O
circulating	O
human	O
mononuclear	O
leukocytes	O
of	O
healthy	O
donors	O
of	O
both	O
sexes	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O

The	O
binding	O
sites	O
fulfil	O
the	O
required	O
criteria	O
for	O
specific	O
steroid	O
binding	O
sites	O
however	O
differ	O
somewhat	O
from	O
the	O
classic	O
androgen	O
receptors	O
from	O
genital	O
skin	O
fibroblast	O
:	O
in	O
fertile	O
adult	O
males	O
(	O
n	O
=	O
20	O
)	O
the	O
binding	O
sites	O
showed	O
(	O
1	O
)	O
a	O
high	O
affinity	O
for	O
testosterone	O
(	O
1.32	O
+	O
/-	O
0.49	O
nM	O
;	O
mean	O
+	O
/-	O
SD	O
)	O
,	O
(	O
2	O
)	O
a	O
saturable	O
capacity	O
(	O
184	O
+	O
/-	O
52	O
binding	O
sites	O
per	O
cell	O
;	O
mean	O
+	O
/-	O
SD	O
)	O
,	O
and	O
(	O
3	O
)	O
a	O
characteristic	O
competitive	O
binding	O
profile	O
for	O
other	O
steroid	O
hormones	O
(	O
relative	O
binding	O
affinities	O
:	O
testosterone	O
=	O
dihydrotestosterone	O
>	O
17	O
beta	O
-	O
estradiol	O
>	O
progesterone	O
,	O
whereas	O
aldosterone	O
,	O
17-hydroxy	O
-	O
progesterone	O
and	O
cortisol	O
did	O
not	O
compete	O
appreciably	O
)	O
.	O

Furthermore	O
the	O
number	O
of	O
binding	O
sites	O
determined	O
using	O
[	O
3H	O
]	O
dihydrotestosterone	O
,	O
[	O
3H	O
]	O
RU-1881	O
,	O
or	O
[	O
3H	O
]	O
testosterone	O
were	O
comparable	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
androgen	O
receptors	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
differ	O
from	O
those	O
in	O
genital	O
skin	O
fibroblasts	O
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
serum	O
testosterone	O
concentrations	O
and	O
androgen	O
binding	O
sites	O
.	O

In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	O
binding	O
sites	O
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O

The	O
presence	O
of	O
androgen	O
receptors	O
in	O
peripheral	O
mononuclear	O
leukocytes	O
provides	O
for	O
the	O
first	O
time	O
the	O
experimental	O
basis	O
for	O
an	O
hypothesis	O
of	O
direct	O
,	O
receptor	O
-	O
mediated	O
effects	O
of	O
androgens	O
on	O
mature	O
immunocompetent	O
cells	O
.	O

The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Comparative	O
mapping	O
of	O
SRY	O
in	O
the	O
great	O
apes	O
.	O

Cytogenetic	O
studies	O
of	O
the	O
primate	O
Y	O
chromosomes	O
have	O
suggested	O
that	O
extensive	O
rearrangements	O
have	O
occurred	O
during	O
evolution	O
of	O
the	O
great	O
apes	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O

pHU-14	O
,	O
a	O
probe	O
including	O
sequences	O
from	O
the	O
sex	O
determining	O
gene	O
SRY	O
,	O
hybridizes	O
close	O
to	O
the	O
early	O
replicating	O
pseudoautosomal	O
segment	O
in	O
a	O
telomeric	O
or	O
subtelomeric	O
position	O
of	O
the	O
Y	O
chromosomes	O
of	O
all	O
great	O
apes	O
.	O

The	O
low	O
copy	O
repeat	O
detected	O
by	O
the	O
probe	O
Fr35-II	O
is	O
obviously	O
included	O
in	O
Y	O
chromosomal	O
rearrangements	O
during	O
hominid	O
evolution	O
.	O

These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	O
region	O
and	O
the	O
testis	O
-	O
determining	O
region	O
.	O

The	O
rest	O
of	O
the	O
Y	O
chromosome	O
has	O
undergone	O
several	O
rearrangements	O
in	O
the	O
different	O
great	O
apes	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	B
neuroblastoma	I
cell	I
lines	I
.	O

The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
eukaryotic	O
transcription	O
factor	O
.	O

In	O
B	O
cells	O
and	O
macrophages	O
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF	O
-	O
kappa	O
B	O
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	B
cell	I
lines	I
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	O
cells	O
NF	O
-	O
kappa	O
B	O
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	O
alpha	O
treatment	O
.	O

The	O
TNF	O
alpha	O
-activated	O
NF	O
-	O
kappa	O
B	O
was	O
transcriptionally	O
functional	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
by	O
TNF	O
alpha	O
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH	B
-	I
SY5Y	I
neuroblastoma	I
cell	I
line	I
,	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
but	O
only	O
in	O
that	O
particular	O
cell	B
line	I
.	O

In	O
a	O
NGF	B
-	I
responsive	I
rat	I
pheochromocytoma	I
cell	I
line	I
,	O
PC12	B
,	O
PMA	O
activated	O
NF	O
-	O
kappa	O
B	O
,	O
whereas	O
NGF	O
did	O
not	O
.	O

In	O
other	O
neuroblastoma	B
cell	I
lines	I
,	O
such	O
as	O
SK	B
-	I
N	I
-	I
Be	I
(	I
2	I
)	I
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK	B
-	I
N	I
-	I
Be	I
(	I
2	I
)	I
cells	I
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	B
cell	I
line	I
and	O
that	O
the	O
low	O
PKC	O
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	O
protein	O
expression	O
.	O

NF	O
-	O
kappa	O
B	O
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	B
cell	I
lines	I
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	O
cell	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	O
alpha	O
proved	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	O
differentiation	O
.	O

Function	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
in	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
invariant	O
chain	O
promoter	O
is	O
dependent	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
different	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
subunits	O
.	O

The	O
promoter	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
class	O
II	O
-	O
associated	O
invariant	O
-	O
chain	O
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
located	O
at	O
-109	O
to	O
-118	O
(	O
Ii	O
kappa	O
B-1	O
)	O
and	O
-163	O
to	O
-172	O
(	O
Ii	O
kappa	O
B-2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
transcription	O
factors	O
.	O

Ii	O
kappa	O
B-1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B	B
-	I
cell	I
lines	I
and	O
in	O
the	O
Ii	B
-	I
expressing	I
T	I
-	I
cell	I
line	I
,	O
H9	B
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	B
and	I
glia	I
cell	I
lines	I
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	O
B-1	O
in	O
cell	B
lines	I
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA	O
-	O
binding	O
complexes	O
that	O
contain	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	O
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	O
kappa	O
B-2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	B
-	I
cell	I
lines	I
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	B
T	I
cells	I
,	O
myelomonocytic	B
,	I
and	I
glial	I
cell	I
lines	I
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	B
T	I
-	I
cell	I
line	I
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	O
and	O
p52	O
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
binding	O
sites	O
.	O

Positive	O
regulators	O
of	O
the	O
lineage	O
-	O
specific	O
transcription	O
factor	O
GATA-1	O
in	O
differentiating	O
erythroid	O
cells	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
GATA-1	O
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
and	O
mast	O
cell	O
lineages	O
.	O

GATA-1	O
binds	O
to	O
WGATAR	O
consensus	O
motifs	O
in	O
the	O
regulatory	O
regions	O
of	O
virtually	O
all	O
erythroid	O
cell	O
-	O
specific	O
genes	O
.	O

Analyses	O
with	O
cultured	B
cells	I
and	O
cell	O
-	O
free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	O
is	O
involved	O
in	O
control	O
of	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	O
element	O
in	O
the	O
distal	O
promoter	O
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	O
transcription	O
.	O

To	O
examine	O
whether	O
GATA-1	O
expression	O
involves	O
additional	O
regulatory	O
factors	O
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	O
factors	O
to	O
activate	O
the	O
GATA-1	O
gene	O
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	O
and	O
mature	O
erythroid	O
cells	O
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	O
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	O
cells	O
.	O

Nuclei	O
from	O
GATA-1	B
-mutant	I
embryonic	I
stem	I
cells	I
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	O
genes	O
in	O
erythroid	O
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	O
is	O
not	O
required	O
for	O
globin	O
gene	O
activation	O
following	O
cell	O
fusion	O
.	O

Effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
.	O

The	O
transcription	O
factor	O
AP-1	O
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	O
factors	O
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O	O
-	O
tetradecanoyl	O
-	O
phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP-1	O
complex	O
consists	O
of	O
distinct	O
protein	O
heterodimers	O
encoded	O
by	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	O
factors	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	O
kinase	O
C	O
leading	O
to	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
.	O

To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha	O
-	O
lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
human	B
Jurkat	I
T	I
cells	I
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha	O
-	O
lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c	O
-	O
fos	O
mRNA	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
lymphoblastoid	O
cells	O
by	O
low	O
-	O
dose	O
ionizing	O
radiation	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
a	O
pleiotropic	O
transcription	O
factor	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2	O
-	O
50	O
Gy	O
results	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	B
KG-1	I
myeloid	I
leukemia	I
cells	I
and	O
human	O
B	O
-	O
lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25	O
-	O
2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
EBV	B
-	I
transformed	I
244B	I
human	I
lymphoblastoid	I
cells	I
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy	O
/	O
min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

Time	O
-	O
course	O
studies	O
revealed	O
a	O
biphasic	O
time	O
-	O
dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O

The	O
expression	O
of	O
the	O
p50	O
and	O
p65	O
NF	O
-	O
kappa	O
B	O
subunits	O
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

Calcineurin	O
potentiates	O
activation	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
gene	O
in	O
T	O
cells	O
:	O
involvement	O
of	O
the	O
conserved	O
lymphokine	O
element	O
0	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
interleukin-2	O
(	O
IL-2	O
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	B
T	I
cell	I
leukemia	I
Jurkat	I
cells	I
.	O

The	O
expression	O
of	O
GM	O
-	O
CSF	O
and	O
IL-2	O
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	O
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
phosphatase	O
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	O
promoter	O
through	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	O
for	O
CN	O
A	O
(	O
catalytic	O
)	O
and	O
CN	O
B	O
(	O
regulatory	O
)	O
subunits	O
also	O
augments	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	O
A	O
subunit	O
,	O
which	O
lacks	O
the	O
auto	O
-	O
inhibitory	O
and	O
calmodulin	O
-	O
binding	O
domains	O
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	O
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM	O
-	O
CSF	O
and	O
IL-2	O
.	O

By	O
multimerizing	O
the	O
regulatory	O
elements	O
of	O
the	O
GM	O
-	O
CSF	O
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	O
sites	O
for	O
the	O
CN	O
action	O
is	O
the	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
located	O
at	O
positions	O
between	O
-54	O
and	O
-40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	O
sequence	O
has	O
an	O
AP1-binding	O
site	O
and	O
is	O
associated	O
with	O
an	O
NF	O
-	O
AT	O
-	O
like	O
factor	O
,	O
termed	O
NF	O
-	O
CLE0	O
gamma	O
.	O

NF-	O
CLE0	O
gamma	O
binding	O
is	O
induced	O
by	O
PMA	O
/	O
A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	O
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM	O
-	O
CSF	O
and	O
IL-2	O
genes	O
and	O
that	O
the	O
CLE0	O
sequence	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
in	O
the	O
IL-2	O
promoter	O
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	O
matrix	O
protein	O
tenascin	O
.	O

Tenascin	O
(	O
TN	O
)	O
is	O
an	O
extracellular	O
matrix	O
protein	O
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	O
inhibits	O
proliferation	O
of	O
human	O
T	O
cells	O
in	O
response	O
to	O
alpha	O
CD3	O
Ab	O
co	O
-	O
immobilized	O
with	O
the	O
extracellular	O
matrix	O
protein	O
fibronectin	O
(	O
FN	O
)	O
.	O

TN	O
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	O
CD3	O
/	O
IL-2	O
or	O
by	O
phorbol	O
ester	O
/	O
IL-2	O
,	O
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL-2R	O
.	O

The	O
presence	O
of	O
TN	O
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	O
CD3	O
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF	O
-	O
AT1	O
transcription	O
factor	O
complexes	O
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	O
as	O
a	O
natural	O
antagonist	O
to	O
FN	O
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	O
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O

Central	O
nervous	O
system	O
-	O
derived	O
cells	O
express	O
a	O
kappa	O
B	O
-	O
binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	O
-independent	O
transactivation	O
by	O
Tat	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	O
terminal	O
repeat	O
-directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	O
with	O
the	O
unusual	O
transcription	O
element	O
TAR	O
,	O
astrocytic	O
glial	O
cells	O
support	O
TAR	O
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
by	O
Tat	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	O
activation	O
is	O
mediated	O
by	O
the	O
viral	O
enhancer	O
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	O
lymphocytes	O
.	O

Tat	O
transactivation	O
mediated	O
by	O
the	O
kappa	O
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	O
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	O
B	O
-	O
specific	O
binding	O
factors	O
present	O
in	O
human	O
glial	O
astrocytes	O
that	O
differ	O
from	O
prototypical	O
NF	O
-	O
kappa	O
B	O
.	O

The	O
novel	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	O
affinity	O
column	O
,	O
while	O
prototypical	O
NF	O
-	O
kappa	O
B	O
from	O
Jurkat	B
T	I
cells	I
is	O
not	O
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte	O
-	O
derived	O
kappa	O
B	O
-	O
binding	O
factors	O
activate	O
transcription	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	O
B	O
domain	O
.	O

Moreover	O
,	O
TAR	O
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor	O
-	O
dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B	O
-	O
binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	O
nervous	O
system	O
-	O
enriched	O
kappa	O
B	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

Human	O
interleukin-13	O
activates	O
the	O
interleukin-4-dependent	O
transcription	O
factor	O
NF	O
-	O
IL4	O
sharing	O
a	O
DNA	O
binding	O
motif	O
with	O
an	O
interferon	O
-	O
gamma	O
-	O
induced	O
nuclear	O
binding	O
factor	O
.	O

The	O
effects	O
of	O
interleukin-13	O
(	O
IL-13	O
)	O
and	O
interleukin-4	O
(	O
IL-4	O
)	O
on	O
cellular	O
functions	O
were	O
shown	O
to	O
be	O
quite	O
similar	O
.	O

We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	O
lymphocytes	O
both	O
IL-4	O
and	O
IL-13	O
activate	O
the	O
same	O
recently	O
identified	O
transcription	O
factor	O
NF	O
-	O
IL4	O
which	O
binds	O
to	O
the	O
specific	O
responsive	O
element	O
IL-4RE	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
a	O
nuclear	O
factor	O
activated	O
by	O
interferon	O
-	O
gamma	O
also	O
interacts	O
with	O
the	O
IL-4RE	O
.	O

It	O
differs	O
from	O
NF	O
-	O
IL4	O
in	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
complex	O
with	O
DNA	O
,	O
in	O
its	O
DNA	O
-	O
binding	O
specificity	O
and	O
in	O
the	O
proteins	O
interacting	O
with	O
the	O
DNA	O
sequence	O
.	O

Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	O
.	O

JNK	O
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	O
lymphocytes	O
.	O

T	O
lymphocyte	O
activation	O
and	O
interleukin-2	O
(	O
IL-2	O
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2	O
+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
and	O
the	O
CD28	O
auxiliary	O
receptor	O
.	O

We	O
investigated	O
how	O
these	O
stimuli	O
affect	O
mitogen	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O

Full	O
activation	O
of	O
the	O
MAP	O
kinases	O
that	O
phosphorylate	O
the	O
Jun	O
activation	O
domain	O
,	O
JNK1	O
and	O
JNK2	O
,	O
required	O
costimulation	O
of	O
T	O
cells	O
with	O
either	O
TPA	O
and	O
Ca2	O
+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	O
and	O
CD28	O
.	O

Alone	O
,	O
each	O
stimulus	O
resulted	O
in	O
little	O
or	O
no	O
activation	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	O
induction	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
JNK	O
,	O
and	O
a	O
competitive	O
inhibitor	O
of	O
Jun	O
phosphorylation	O
by	O
JNK	O
inhibited	O
IL-2	O
promoter	O
activation	O
.	O

By	O
contrast	O
,	O
the	O
MAP	O
kinases	O
ERK1	O
and	O
ERK2	O
were	O
fully	O
activated	O
by	O
TPA	O
or	O
TCR	O
stimulation	O
and	O
were	O
not	O
affected	O
by	O
Ca2	O
+	O
,	O
CD28	O
,	O
or	O
CsA	O
.	O

Hence	O
,	O
integration	O
of	O
signals	O
that	O
lead	O
to	O
T	O
cell	O
activation	O
occurs	O
at	O
the	O
level	O
of	O
JNK	O
activation	O
.	O

Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	O
cell	O
proliferation	O
and	O
interleukin-2	O
receptor	O
(	O
IL-2R	O
)	O
generation	O
were	O
studied	O
.	O

Dexamethasone	O
inhibited	O
IL-2	O
-induced	O
T	O
cell	O
proliferation	O
by	O
30	O
%	O
-88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL-2R	O
alpha	O
(	O
Tac	O
,	O
p55	O
,	O
CD25	O
)	O
and	O
beta	O
(	O
p75	O
)	O
genes	O
in	O
activated	O
T	O
cells	O
was	O
examined	O
next	O
.	O

In	O
T	O
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	O
(	O
PHA	O
-	O
p	O
)	O
and	O
4	O
beta	O
-	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL-2R	O
alpha	O
and	O
a	O
30	O
%	O
reduction	O
in	O
IL-2R	O
beta	O
membrane	O
expression	O
compared	O
to	O
T	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Inhibition	O
of	O
membrane	O
IL-2R	O
alpha	O
and	O
IL-2R	O
beta	O
expression	O
by	O
10	O
(	O
-6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	O
human	O
IL-2	O
(	O
rhIL-2	O
)	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	O
alpha	O
and	O
in	O
IL-2R	O
beta	O
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen	O
-	O
stimulated	O
T	O
cells	O
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL-2R	O
alpha	O
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL-2R	O
beta	O
gene	O
was	O
unaffected	O
by	O
DM	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	O
alpha	O
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
stimulates	O
IL-2R	O
alpha	O
gene	O
expression	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-6	O
)	O
M	O
DM	O
increased	O
T	O
cell	O
p50	O
NF	O
-	O
kappa	O
B	O
mRNA	O
levels	O
by	O
four	O
-	O
fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

Further	O
,	O
the	O
level	O
of	O
nuclear	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
NF	O
-	O
kappa	O
B	O
sites	O
in	O
activated	O
T	O
cells	O
increased	O
in	O
response	O
to	O
DM	O
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	O
cell	O
membrane	O
expression	O
of	O
IL-2R	O
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	O
phagocytes	O
by	O
leukemia	O
inhibitory	O
factor	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	O
inhibitory	O
factor	O
(	O
LIF	O
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	O
phagocytes	O
(	O
MNP	O
)	O
.	O

LIF	O
induced	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
p24	O
antigen	O
production	O
in	O
the	O
chronically	B
infected	I
promonocytic	I
cell	I
line	I
U1	I
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	O
effects	O
were	O
similar	O
to	O
interleukin	O
1	O
(	O
IL-1	O
)	O
,	O
IL-6	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	O
effects	O
,	O
levels	O
of	O
HIV	O
mRNA	O
,	O
activation	O
of	O
the	O
DNA	O
binding	O
protein	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kB	O
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	O
were	O
analyzed	O
.	O

LIF	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
HIV	O
mRNA	O
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O

The	O
DNA	O
binding	O
protein	O
NF	O
-	O
kB	O
is	O
a	O
central	O
mediator	O
in	O
cytokine	O
activation	O
of	O
HIV	O
transcription	O
.	O

NF	O
-	O
kB	O
levels	O
were	O
higher	O
in	O
unstimulated	B
U1	I
cells	I
as	O
compared	O
to	O
the	O
parent	B
cell	I
line	I
U937	B
.	O

In	O
both	O
cell	O
lines	O
LIF	O
increased	O
NF	O
-	O
kB	O
activity	O
.	O

Induction	O
of	O
NF	O
-	O
kB	O
and	O
HIV	O
replication	O
by	O
cytokines	O
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
oxygen	O
radical	O
scavenger	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
,	O
inhibited	O
LIF	O
-induced	O
HIV	O
replication	O
.	O

LIF	O
induces	O
the	O
production	O
of	O
other	O
cytokines	O
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	O
to	O
IL-1	O
,	O
TNF	O
,	O
or	O
IL-6	O
.	O

These	O
results	O
identify	O
LIF	O
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Tat	O
upregulates	O
interleukin-2	O
secretion	O
in	O
activated	O
T	O
cells	O
.	O

Dysregulation	O
of	O
cytokines	O
secreted	O
by	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
Tat	O
on	O
interleukin-2	O
(	O
IL-2	O
)	O
expression	O
,	O
we	O
used	O
IL-2	O
promoter	O
-	O
chloramphenicol	O
acetyltransferase	O
constructs	O
and	O
IL-2-secreting	B
Jurkat	I
T	I
cells	I
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV-1	O
Tat	O
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
in	O
Jurkat	B
T	I
cells	I
stimulated	O
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL-2	O
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	B
T	I
cells	I
and	O
primary	B
T	I
cells	I
stimulated	O
by	O
extracellular	O
HIV-1	O
Tat	O
protein	O
.	O

Analysis	O
of	O
mRNA	O
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	O
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
site	O
at	O
positions	O
-206	O
to	O
-195	O
of	O
the	O
IL-2	O
promoter	O
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	O
effect	O
.	O

The	O
Tat	O
-mediated	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or	O
-	O
unlike	O
the	O
analogous	O
effect	O
of	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	O
-by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL-2	O
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	O
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T	O
-	O
helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

Gene	O
for	O
a	O
tissue	O
-	O
specific	O
transcriptional	O
activator	O
(	O
EBF	O
or	O
Olf-1	O
)	O
,	O
expressed	O
in	O
early	O
B	O
lymphocytes	O
,	O
adipocytes	O
,	O
and	O
olfactory	O
neurons	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
5	O
,	O
band	O
q34	O
,	O
and	O
proximal	O
mouse	O
chromosome	O
11	O
.	O

Murine	O
B	O
lymphocytes	O
,	O
adipocytes	O
,	O
and	O
olfactory	O
neurons	O
contain	O
a	O
DNA	O
-	O
binding	O
protein	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	O
encoding	O
tissue	O
-	O
specific	O
components	O
of	O
signal	O
transduction	O
.	O

Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B	O
-	O
cell	O
factor	O
(	O
EBF	O
)	O
,	O
from	O
murine	O
B	O
lymphocytes	O
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	O
,	O
from	O
olfactory	O
neuronal	O
cells	O
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O

As	O
a	O
first	O
step	O
towards	O
identifying	O
a	O
human	O
genetic	O
disorder	O
or	O
mouse	O
mutation	O
for	O
which	O
EBF	O
could	O
be	O
a	O
candidate	O
gene	O
,	O
we	O
have	O
chromosomally	O
mapped	O
the	O
corresponding	O
locus	O
in	O
both	O
species	O
.	O

By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	O
cDNA	O
probe	O
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	O
genomic	O
clones	O
,	O
and	O
analysis	O
of	O
recombinant	B
inbred	I
mouse	I
strains	I
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	O
homologous	O
sequences	O
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	O
q34	O
,	O
and	O
on	O
proximal	O
mouse	O
Chr	O
11	O
,	O
in	O
an	O
evolutionarily	O
conserved	O
region	O
.	O

Effects	O
of	O
prostaglandin	O
E2	O
on	O
Th0-type	B
human	I
T	I
cell	I
clones	I
:	O
modulation	O
of	O
functions	O
of	O
nuclear	O
proteins	O
involved	O
in	O
cytokine	O
production	O
.	O

The	O
effects	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
on	O
cytokine	O
production	O
and	O
proliferation	O
of	O
the	O
CD4	B
+	I
human	I
helper	I
T	I
cell	I
clone	I
SP	I
-	I
B21	I
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
,	O
PGE2	O
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	O
examined	O
.	O

Addition	O
of	O
rIL-2	O
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	O
and	O
IL-5	O
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	O
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	O
enhanced	O
the	O
production	O
of	O
IL-4	O
and	O
IL-5	O
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	O
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL-4	O
and	O
IL-5	O
are	O
regulated	O
differently	O
from	O
other	O
cytokines	O
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p50	O
)	O
homodimer	O
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	O
B	O
sequence	O
in	O
unstimulated	O
SP	O
-	O
B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA	O
/	O
A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/p65	O
)	O
heterodimer	O
with	O
the	O
kappa	O
B	O
sequence	O
was	O
induced	O
.	O

Interestingly	O
,	O
PGE2	O
or	O
di	O
-	O
butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p65	O
)	O
heterodimer	O
to	O
the	O
kappa	O
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
mAb	O
but	O
not	O
with	O
PMA	O
/	O
A23187	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	O
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	O
is	O
selective	O
.	O

PGE2	O
enhanced	O
the	O
complex	O
formation	O
with	O
NF	O
-	O
AT	O
,	O
AP-1	O
and	O
CLE0	O
sequences	O
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti	O
-	O
CD3	O
mAb	O
or	O
PMA	O
/	O
A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	O
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF	O
-	O
kappa	O
B	O
but	O
not	O
for	O
NF	O
-	O
AT	O
,	O
AP-1	O
or	O
CLE0	O
binding	O
protein	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	O
2	O
(	O
IL-2	O
)	O
is	O
an	O
important	O
lymphokine	O
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL-2	O
gene	O
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4	O
+	O
T	O
cells	O
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis	O
-	O
acting	O
regulatory	O
sites	O
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	O
gene	O
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis	O
-	O
acting	O
regulatory	O
sites	O
in	O
the	O
context	O
of	O
the	O
native	O
IL-2	O
enhancer	O
and	O
promoter	O
sequence	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	O
(	O
-276	O
to	O
-261	O
)	O
,	O
the	O
distal	O
octamer	O
(	O
-256	O
to	O
-248	O
)	O
and	O
the	O
proximal	O
octamer	O
(	O
-75	O
to	O
-66	O
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	O
gene	O
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	O
gene	O
expression	O
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	O
gene	O
expression	O
in	O
different	O
T	B
leukemia	I
cell	I
lines	I
:	O
the	O
distal	O
purine	O
box	O
(	O
-291	O
to	O
-277	O
)	O
and	O
the	O
proximal	O
purine	O
box	O
sites	O
(	O
-145	O
to	O
-128	O
)	O
.	O

Finally	O
,	O
the	O
AP-1	O
(	O
-186	O
to	O
-176	O
)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-206	O
to	O
-195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	B
cells	I
.	O

The	O
AP-1	O
site	O
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	O
B	O
site	O
responded	O
to	O
IL-1	O
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis	O
-	O
acting	O
regulatory	O
sites	O
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	O
cells	O
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Tat	O
-	O
binding	O
protein	O
7	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
protease	O
.	O

Subunit	O
6	O
(	O
S6	O
)	O
,	O
an	O
integral	O
component	O
of	O
the	O
26S	O
protease	O
from	O
human	O
erythrocytes	O
,	O
has	O
been	O
studied	O
by	O
SDS	O
-	O
PAGE	O
,	O
peptide	O
mapping	O
and	O
sequence	O
analysis	O
.	O

S6	O
was	O
cleaved	O
with	O
CNBr	O
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O

A	O
comparison	O
with	O
known	O
proteins	O
in	O
Genbank	O
revealed	O
that	O
all	O
three	O
S6	O
peptides	O
match	O
the	O
predicted	O
sequence	O
of	O
TBP7	O
,	O
Tat	O
-	O
binding	O
protein	O
7	O
.	O

Based	O
on	O
peptide	O
matches	O
covering	O
more	O
than	O
10	O
%	O
of	O
the	O
TBP7	O
sequence	O
,	O
and	O
the	O
fact	O
that	O
the	O
migration	O
of	O
S6	O
on	O
SDS	O
-	O
PAGE	O
is	O
consistent	O
with	O
the	O
estimated	O
molecular	O
mass	O
for	O
TBP7	O
,	O
we	O
conclude	O
that	O
subunit	O
6	O
of	O
the	O
26S	O
protease	O
is	O
TBP7	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	O
to	O
undergo	O
X	O
inactivation	O
.	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X	O
/	O
46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	O
locus	O
on	O
their	O
tiny	O
ring	O
X	O
chromosomes	O
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O

As	O
XIST	O
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	O
chromosome	O
in	O
female	O
somatic	O
cells	O
and	O
spermatogonia	O
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	O
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	O
chromosomes	O
lacking	O
XIST	O
expression	O
(	O
XISTE-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
two	O
tiny	O
ring	O
X	O
chromosomes	O
studied	O
with	O
an	O
antibody	O
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	O
H4	O
marking	O
transcribed	O
chromatin	O
domains	O
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE-	O
ring	O
chromosomes	O
to	O
determine	O
whether	O
genes	O
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	O
X	O
are	O
expressed	O
from	O
these	O
chromosomes	O
.	O

Analyses	O
of	O
hybrid	B
cells	I
show	O
that	O
TIMP	O
,	O
ZXDA	O
,	O
and	O
ZXDB	O
loci	O
on	O
the	O
proximal	O
short	O
arm	O
,	O
and	O
AR	O
and	O
PHKA1	O
loci	O
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	O
from	O
the	O
tiny	O
ring	O
X	O
chromosome	O
lacking	O
XIST	O
DNA	O
.	O

Studies	O
of	O
the	O
ring	O
chromosome	O
that	O
has	O
XIST	O
DNA	O
but	O
does	O
not	O
transcribe	O
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

An	O
interleukin-4-induced	O
transcription	O
factor	O
:	O
IL-4	O
Stat	O
.	O

Interleukin-4	O
(	O
IL-4	O
)	O
is	O
an	O
immunomodulatory	O
cytokine	O
secreted	O
by	O
activated	O
T	O
lymphocytes	O
,	O
basophils	O
,	O
and	O
mast	O
cells	O
.	O

It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	O
helper	O
(	O
Th	O
)	O
cell	O
subsets	O
,	O
favoring	O
expansion	O
of	O
the	O
Th2	O
lineage	O
relative	O
to	O
Th1	O
.	O

Imbalance	O
of	O
these	O
T	O
lymphocyte	O
subsets	O
has	O
been	O
implicated	O
in	O
immunological	O
diseases	O
including	O
allergy	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
disease	O
.	O

IL-4	O
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine	O
-	O
phosphorylated	O
DNA	O
binding	O
protein	O
.	O

This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
family	O
of	O
DNA	O
binding	O
proteins	O
,	O
hereby	O
designated	O
IL-4	O
Stat	O
.	O

Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine	O
-	O
containing	O
peptides	O
derived	O
from	O
the	O
intracellular	O
domain	O
of	O
the	O
IL-4	O
receptor	O
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	O
and	O
transcription	O
factor	O
during	O
the	O
IL-4	O
Stat	O
activation	O
cycle	O
.	O

Such	O
observations	O
indicate	O
that	O
IL-4	O
Stat	O
has	O
the	O
same	O
functional	O
domain	O
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
human	O
GATA3	O
gene	O
.	O

GATA3	O
,	O
a	O
member	O
of	O
the	O
GATA	O
family	O
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T	O
-	O
lymphocyte	O
lineage	O
,	O
is	O
thought	O
to	O
participate	O
in	O
T	O
-	O
cell	O
receptor	O
gene	O
activation	O
through	O
binding	O
to	O
enhancers	O
.	O

To	O
understand	O
GATA3	O
gene	O
regulation	O
,	O
we	O
cloned	O
the	O
human	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	O
GATA3	O
gene	O
.	O

We	O
show	O
that	O
the	O
human	O
GATA3	O
gene	O
contains	O
six	O
exons	O
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	O
GATA3	O
zinc	O
fingers	O
are	O
encoded	O
by	O
two	O
separate	O
exons	O
highly	O
conserved	O
with	O
those	O
of	O
GATA1	O
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	O
and	O
mouse	O
GATA3	O
transcription	O
units	O
start	O
at	O
a	O
major	O
initiation	O
site	O
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	O
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	O
of	O
housekeeping	O
genes	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	O
fragment	O
containing	O
the	O
human	O
GATA3	O
transcription	O
unit	O
,	O
3	O
kb	O
upstream	O
from	O
the	O
initiation	O
site	O
and	O
4	O
kb	O
downstream	O
from	O
the	O
polyadenylation	O
site	O
,	O
displays	O
T	O
-	O
cell	O
specificity	O
.	O

T	O
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T	O
-	O
cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	O
cells	O
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif	O
-	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	O
patient	O
T	O
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	O
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	O
to	O
kappa	O
B	O
/	O
Rel	O
family	O
proteins	O
,	O
the	O
kappa	O
B	O
-	O
binding	O
activity	O
constitutively	O
expressed	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF	O
-	O
kappa	O
B1	O
(	O
p50	O
)	O
subunit	O
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	O
,	O
a	O
member	O
of	O
the	O
Rel	O
homology	O
family	O
which	O
is	O
part	O
of	O
the	O
normal	O
NF	O
-	O
kappa	O
B	O
complex	O
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	O
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	O
cells	O
.	O

The	O
altered	O
kappa	O
B	O
-	O
binding	O
activity	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

In	O
vivo	O
modification	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
DRA	O
promoter	O
occupancy	O
mediated	O
by	O
the	O
AIR-1	O
trans	O
-	O
activator	O
.	O

RJ	B
2.2.5	I
is	O
a	O
human	B
B	I
cell	I
mutant	I
derived	O
from	O
the	O
Burkitt	B
lymphoma	I
Raji	I
cell	I
which	O
is	O
defective	O
in	O
the	O
AIR-1	O
locus	O
function	O
.	O

This	O
locus	O
encodes	O
a	O
transcriptional	O
trans	O
-	O
activator	O
required	O
for	O
the	O
constitutive	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
,	O
by	O
in	O
vivo	O
DNase	O
I	O
footprinting	O
,	O
that	O
the	O
AIR-1	O
locus	O
defect	O
correlates	O
with	O
changes	O
in	O
the	O
DRA	O
promoter	O
occupancy	O
.	O

Interestingly	O
,	O
reexpression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
RJ	B
2.2.5	I
x	I
mouse	I
spleen	I
cell	I
hybrids	I
is	O
associated	O
with	O
partial	O
reversion	O
of	O
DRA	O
promoter	O
occupancy	O
to	O
the	O
Raji	O
pattern	O
.	O

DRA	O
promoter	O
occupancy	O
in	O
other	O
class	B
II	I
-	I
negative	I
B	I
cell	I
lines	I
,	O
derived	O
from	O
patients	O
with	O
bare	O
lymphocyte	O
syndrome	O
,	O
is	O
drastically	O
different	O
from	O
the	O
one	O
observed	O
in	O
RJ	B
2.2.5	I
and	O
Raji	B
cells	I
.	O

Moreover	O
,	O
the	O
use	O
of	O
the	O
DNase	O
I	O
as	O
an	O
in	O
vivo	O
footprinting	O
agent	O
reveals	O
that	O
the	O
patients	B
'	I
cell	I
lines	I
do	O
not	O
display	O
a	O
completely	O
`	O
`	O
bare	O
promoter	O
`	O
`	O
as	O
previously	O
reported	O
using	O
dimethyl	O
sulfate	O
as	O
the	O
footprinting	O
agent	O
.	O

Thus	O
,	O
the	O
use	O
of	O
DNase	O
I	O
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR-1	O
locus	O
defect	O
with	O
class	O
II	O
promoter	O
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	B
class	I
II	I
-	I
negative	I
cells	I
.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O

Androgen	O
receptor	O
mRNA	O
was	O
translated	O
in	O
vitro	O
,	O
and	O
androgen-	O
and	O
antiandrogen	O
-	O
bound	O
receptor	O
complexes	O
were	O
studied	O
using	O
limited	O
proteolytic	O
digestion	O
by	O
trypsin	O
.	O

Partial	O
proteolysis	O
of	O
androgen	O
-	O
bound	O
receptor	O
protein	O
resulted	O
in	O
a	O
29-kDa	O
proteolysis	O
-	O
resisting	O
fragment	O
,	O
whereas	O
antiandrogen	O
binding	O
stabilised	O
a	O
35-kDa	O
fragment	O
.	O

Both	O
fragments	O
contain	O
the	O
entire	O
ligand	O
binding	O
domain	O
,	O
and	O
the	O
35-kDa	O
fragment	O
extended	O
into	O
the	O
hinge	O
region	O
of	O
the	O
receptor	O
.	O

Several	O
antiandrogens	O
show	O
agonistic	O
properties	O
for	O
a	O
mutated	O
androgen	O
receptor	O
(	O
LNCaP	B
cell	I
variant	I
)	O
;	O
trypsin	O
digestion	O
of	O
antiandrogen	O
-	O
bound	O
mutated	O
receptor	O
also	O
resulted	O
in	O
a	O
29-kDa	O
fragment	O
.	O

Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	O
hormone	O
receptors	O
.	O

Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	O
region	O
and	O
C	O
-	O
terminus	O
of	O
the	O
androgen	O
receptor	O
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
ligand	O
binding	O
domain	O
of	O
their	O
respective	O
receptors	O
to	O
protease	O
.	O

Differences	O
in	O
conformation	O
of	O
the	O
hinge	O
region	O
distinguish	O
androgen	O
-	O
bound	O
from	O
antiandrogen	O
-	O
bound	O
receptor	O
complexes	O
,	O
which	O
represents	O
an	O
important	O
feature	O
of	O
antiandrogen	O
action	O
.	O

[	O
An	O
overexpression	O
of	O
retinoic	O
acid	O
receptor	O
alpha	O
blocks	O
myeloid	O
cell	O
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	O
receptors	O
(	O
RARs	O
)	O
.	O

RARs	O
are	O
members	O
of	O
the	O
steroid	O
/	O
thyroid	O
hormone	O
receptor	O
superfamily	O
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA	O
-	O
binding	O
and	O
RA	O
(	O
ligand	O
)	O
-binding	O
domains	O
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	O
,	O
predominantly	O
RAR	O
alpha	O
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
progenitors	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	O
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	O
alpha	O
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
)	O
into	O
murine	O
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	O
resistant	O
marker	O
(	O
Neo	O
(	O
r	O
)	O
)	O
cultured	O
on	O
the	O
stroma	B
cell	I
line	I
(	O
PA6-neo	B
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	O
cells	O
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	O
alpha	O
exhibited	O
promyelocytic	O
morphology	O
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	O
cells	O
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
.	O

RAR	O
alpha	O
infected	O
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	O
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	B
colony	I
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	O
alpha	O
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	O
cell	O
differentiation	O
and	O
RAR	O
alpha	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	O
genes	O
for	O
differentiation	O
of	O
normal	O
bone	O
marrow	O
cells	O
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	O
activation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
is	O
expressed	O
rapidly	O
by	O
human	O
monocytes	O
exposed	O
to	O
bacterial	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
and	O
other	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
protease	O
inhibitors	O
N	O
alpha	O
-	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
proteins	O
by	O
preventing	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
expression	O
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	B
THP-1	I
cells	I
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
protein	O
,	O
TF	O
mRNA	O
and	O
TF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
encoding	O
the	O
transcription	O
factor	O
,	O
Egr-1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
prevented	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
.	O

C	O
/	O
EBP	O
beta	O
regulation	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
.	O

Activated	O
macrophages	O
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	O
and	O
proteinases	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
is	O
particularly	O
important	O
in	O
this	O
process	O
because	O
of	O
its	O
ability	O
to	O
regulate	O
other	O
inflammatory	O
mediators	O
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
the	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
TNF	O
alpha	O
is	O
not	O
known	O
.	O

We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	O
alpha	O
is	O
regulated	O
by	O
the	O
transcription	O
factor	O
C	O
/	O
EBP	O
beta	O
(	O
NF	O
-	O
IL6	O
)	O
.	O

C	O
/	O
EBP	O
beta	O
activated	O
the	O
TNF	O
alpha	O
gene	O
promoter	O
in	O
cotransfection	O
assays	O
and	O
bound	O
to	O
it	O
at	O
a	O
site	O
which	O
failed	O
to	O
bind	O
the	O
closely	O
related	O
protein	O
C	O
/	O
EBP	O
alpha	O
.	O

Finally	O
,	O
a	O
dominant	O
-	O
negative	O
version	O
of	O
C	O
/	O
EBP	O
beta	O
blocked	O
TNF	O
alpha	O
promoter	O
activation	O
in	O
myeloid	O
cells	O
.	O

Our	O
results	O
implicate	O
C	O
/	O
EBP	O
beta	O
as	O
an	O
important	O
regulator	O
of	O
TNF	O
alpha	O
by	O
myelomonocytic	O
cells	O
.	O

Simultaneous	O
activation	O
of	O
Ig	O
and	O
Oct-2	O
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	O
class	O
II	O
expression	O
by	O
IL-6	O
.	O

Terminal	O
differentiation	O
of	O
B	O
cells	O
to	O
plasma	O
cells	O
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	O
and	O
extinction	O
of	O
MHC	O
class	O
II	O
expression	O
on	O
the	O
cell	O
surface	O
.	O

We	O
show	O
that	O
IL-6	O
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	O
in	O
clonal	B
human	I
B	I
cell	I
lines	I
and	O
newly	O
isolated	O
polyclonal	O
B	O
lymphocytes	O
in	O
vitro	O
.	O

The	O
IL-6-induced	B
cells	I
resemble	O
plasma	O
cells	O
in	O
ultrastructure	O
and	O
in	O
reduced	O
expression	O
of	O
surface	O
MHC	O
class	O
II	O
.	O

Enhanced	O
Ig	O
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	O
genes	O
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	O
encoding	O
the	O
secreted	O
form	O
of	O
Ig	O
heavy	O
chain	O
.	O

It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL-6	O
stimulation	O
is	O
prolonged	O
.	O

Coordinate	O
with	O
temporal	O
changes	O
in	O
Ig	O
synthesis	O
,	O
the	O
DNA	O
-	O
binding	O
activity	O
and	O
the	O
synthesis	O
of	O
the	O
B	O
cell	O
-	O
enriched	O
transcription	O
factor	O
Oct-2	O
are	O
regulated	O
.	O

Thus	O
,	O
differentiation	O
of	O
B	O
cells	O
with	O
IL-6	O
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	O
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	O
octamer	O
motif	O
of	O
the	O
interleukin	O
2	O
enhancer	O
by	O
AP-1	O
,	O
Oct-2	O
,	O
and	O
retinoic	O
acid	O
receptor	O
.	O

The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O	O
-	O
tetradecanoyl	O
-	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2	O
+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	O
to	O
-66-bp	O
octamer	O
motif	O
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
,	O
which	O
encodes	O
a	O
major	O
T	O
lymphocyte	O
growth	O
factor	O
.	O

The	O
IL-2	O
octamer	O
motif	O
is	O
a	O
composite	O
cis	O
-	O
element	O
which	O
binds	O
Oct-1	O
and	O
Oct-2	O
as	O
well	O
as	O
a	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-inducible	O
nuclear	O
factor	O
,	O
previously	O
termed	O
octamer	O
-	O
associated	O
protein	O
(	O
OAP40	O
)	O
.	O

We	O
show	O
here	O
that	O
Oct-2	O
,	O
despite	O
the	O
presence	O
of	O
an	O
active	O
transcriptional	O
activation	O
domain	O
,	O
requires	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
signals	O
to	O
strongly	O
transactivate	O
the	O
IL-2	O
octamer	O
motif	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
Oct-2	O
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

The	O
presence	O
of	O
an	O
intact	O
COOH	O
-	O
terminal	O
domain	O
of	O
Oct-2	O
contributes	O
to	O
both	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA	O
-	O
mediated	O
repression	O
.	O

We	O
also	O
show	O
that	O
both	O
Fos	O
and	O
Jun	O
components	O
of	O
the	O
AP-1	O
factors	O
participate	O
in	O
the	O
OAP40	O
complex	O
.	O

Furthermore	O
,	O
transfected	O
c	O
-	O
jun	O
,	O
jun	O
-	O
B	O
,	O
jun	O
-	O
D	O
,	O
c	O
-	O
fos	O
,	O
or	O
Fos	O
-	O
B	O
expression	O
vectors	O
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2	O
+	O
and	O
cooperate	O
with	O
Oct-2	O
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP	O
/	O
octamer	O
cis	O
-	O
element	O
.	O

Mutations	O
of	O
the	O
genuine	O
octamer	O
-	O
binding	O
site	O
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	O
and	O
Oct-2	O
and	O
the	O
TPA	O
/	O
Ca	O
(	O
2	O
+	O
)	O
-induced	O
transactivation	O
of	O
the	O
OAP	O
/	O
octamer	O
motif	O
.	O

OAP	O
confers	O
to	O
Oct-2	O
responsivity	O
to	O
both	O
TPA	O
/	O
Ca2	O
+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1	O
/	O
OAP	O
-	O
binding	O
site	O
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	O
in	O
response	O
to	O
TPA	O
and	O
Ca2	O
+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O

Furthermore	O
,	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	O
/OAP	O
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	O
-dependent	O
cis	O
-	O
regulatory	O
function	O
of	O
this	O
AP-1	O
element	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA	O
/	O
calcium	O
-	O
activated	O
AP-1	O
/OAP	O
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL-2	O
octamer	O
motif	O
,	O
through	O
synergism	O
with	O
Oct-2	O
and	O
antagonism	O
by	O
RAR	O
.	O

Inhibition	O
of	O
rat	O
splenocyte	O
proliferation	O
with	O
methylprednisolone	O
:	O
in	O
vivo	O
effect	O
of	O
liposomal	O
formulation	O
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	O
cells	O
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Liposomes	O
do	O
not	O
alter	O
the	O
suppressive	O
action	O
of	O
MPL	O
when	O
placed	O
in	O
lymphocyte	B
culture	I
.	O

Rat	O
splenocytes	O
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O

In	O
vivo	O
studies	O
in	O
rats	O
utilized	O
2	O
mg	O
/	O
kg	O
IV	O
bolus	O
doses	O
of	O
liposomal	O
MPL	O
compared	O
to	O
drug	O
in	O
solution	O
.	O

Animals	O
were	O
sacrificed	O
at	O
various	O
times	O
post	O
-	O
dosing	O
until	O
120	O
h	O
,	O
spleen	O
was	O
excised	O
and	O
,	O
after	O
incubation	O
of	O
lymphocytes	O
with	O
PHA	O
,	O
splenocyte	O
blastogenic	O
responses	O
were	O
assessed	O
by	O
measuring	O
cellular	O
incorporation	O
of	O
3H	O
-	O
thymidine	O
.	O

The	O
suppressive	O
effect	O
of	O
liposomal	O
MPL	O
in	O
comparison	O
with	O
free	O
drug	O
was	O
significantly	O
prolonged	O
(	O
>	O
120	O
h	O
vs	O
<	O
18	O
h	O
)	O
.	O

Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	O
as	O
an	O
input	O
function	O
.	O

A	O
nonlinear	O
relationship	O
was	O
found	O
between	O
suppression	O
of	O
splenocyte	O
proliferation	O
and	O
the	O
concentration	O
of	O
bound	O
glucocorticoid	O
receptors	O
in	O
spleen	O
.	O

Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O

The	O
suppression	O
of	O
endogenous	O
corticosterone	O
in	O
plasma	O
for	O
both	O
treatments	O
was	O
similar	O
with	O
values	O
from	O
L	O
-	O
MPL	O
rats	O
returning	O
to	O
baseline	O
after	O
24	O
h	O
.	O

These	O
results	O
demonstrate	O
enhanced	O
efficacy	O
of	O
local	O
immunosuppression	O
by	O
targeting	O
spleen	O
with	O
liposomal	O
MPL	O
.	O

Steel	O
factor	O
affects	O
SCL	O
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	O
factor	O
is	O
one	O
of	O
the	O
growth	O
factors	O
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
and	O
SCL	O
,	O
also	O
known	O
as	O
Tcl-5	O
or	O
Tal-1	O
,	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	O
peripheral	O
blood	O
burst	O
-	O
forming	O
unit	O
-	O
erythroid	O
(	O
BFU	O
-	O
E	O
)	O
and	O
the	O
effects	O
of	O
Steel	O
factor	O
on	O
SCL	O
expression	O
in	O
proliferating	O
erythroid	O
cells	O
.	O

BFU	B
-	I
E	I
-	I
derived	I
colonies	I
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	O
protein	O
levels	O
in	O
BFU	B
-	I
E	I
-	I
derived	I
cells	I
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	O
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	O
mRNA	O
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	O
protein	O
observed	O
.	O

The	O
role	O
of	O
SCL	O
in	O
Steel	O
factor	O
-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU	B
-	I
E	I
-	I
derived	I
colonies	I
cultured	O
with	O
Steel	O
factor	O
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	O
precursors	O
cultured	O
with	O
Steel	O
factor	O
,	O
SCL	O
protein	O
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	O
in	O
SCL	O
protein	O
levels	O
in	O
early	O
erythroid	O
precursors	O
stimulated	O
with	O
Steel	O
factor	O
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	O
factor	O
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	O
mRNA	O
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	O
factor	O
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	O
protein	O
observed	O
in	O
response	O
to	O
Steel	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	O
cells	O
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	O
(	O
TRX	O
)	O
.	O

As	O
the	O
protein	O
tyrosine	O
kinase	O
activities	O
p56lck	O
and	O
p59fyn	O
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O

These	O
redox	O
-	O
regulated	O
enzymes	O
trigger	O
signal	O
cascades	O
for	O
NF	O
kappa	O
B	O
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
,	O
from	O
CD4	O
and	O
CD8	O
molecules	O
,	O
and	O
from	O
the	O
IL-2	O
receptor	O
beta	O
-	O
chain	O
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
IL-2	O
-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well	O
-	O
known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV	O
-	O
infected	O
patients	O
and	O
SIV	O
-	O
infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

Cross	O
-	O
linking	O
CD40	O
on	O
B	O
cells	O
rapidly	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
.	O

The	O
B	O
cell	O
-	O
associated	O
surface	O
molecule	O
CD40	O
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross	O
-	O
linking	O
CD40	O
on	O
B	O
cells	O
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL-6	O
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	O
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	O
cross	O
-	O
linking	O
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
like	O
transcription	O
factors	O
are	O
activated	O
after	O
cross	O
-	O
linking	O
CD40	O
on	O
resting	O
human	O
tonsillar	O
B	O
cells	O
and	O
on	O
B	B
cell	I
lines	I
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase	O
-	O
dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	O
,	O
p65	O
(	O
RelA	O
)	O
,	O
c	O
-	O
Rel	O
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross	O
-	O
linking	O
CD40	O
supports	O
NF	O
-	O
kappa	O
B	O
-dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	O
signaling	O
and	O
suggest	O
that	O
the	O
CD40	O
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	O
cell	O
-	O
associated	O
genes	O
with	O
NF	O
-	O
kappa	O
B	O
consensus	O
sites	O
.	O

One	O
gene	O
,	O
two	O
transcripts	O
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	O
La	O
/	O
SS	O
-	O
B	O
from	O
a	O
cDNA	O
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	O
library	O
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	O
autoantigen	O
La	O
/	O
SS	O
-	O
B	O
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	O
mRNA	O
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	O
mRNA	O
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	O
1	O
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	O
5'-end	O
is	O
a	O
part	O
of	O
the	O
intron	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	O
promoter	O
site	O
,	O
which	O
exists	O
within	O
the	O
intron	O
downstream	O
of	O
the	O
exon	O
1	O
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	O
La	O
mRNA	O
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	O
factor	O
binding	O
sites	O
,	O
including	O
a	O
NF	O
-	O
kappa	O
B	O
element	O
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	O
autoantigen	O
La	O
/	O
SS	O
-	O
B	O
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

DNA	O
-	O
binding	O
studies	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA-2	O
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	O
membrane	O
protein	O
gene	O
promoter	O
-	O
binding	O
proteins	O
in	O
EBNA-2-positive	B
cell	I
lines	I
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA-2	O
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O

EBNA-2	O
trans	O
-	O
activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	O
,	O
c	O
-	O
fgr	O
,	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
and	O
terminal	O
protein	O
1	O
(	O
TP1	O
)	O
.	O

Trans	O
-	O
activation	O
of	O
the	O
TP1	O
promoter	O
and	O
of	O
the	O
BamHI	O
C	O
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein	O
-	O
protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	O
type	O
A	O
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA-2	O
is	O
able	O
to	O
trans	O
-	O
activate	O
the	O
expression	O
of	O
the	O
LMP	O
gene	O
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
LMP	O
promoter	O
through	O
which	O
EBNA-2	O
mediates	O
trans	O
-	O
activation	O
.	O

To	O
determine	O
whether	O
EBNA-2	O
also	O
trans	O
-	O
activates	O
the	O
LMP	O
promoter	O
by	O
protein	O
-	O
protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	O
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein	O
-	O
binding	O
region	O
on	O
the	O
LMP	O
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	O
with	O
the	O
DNA	O
via	O
protein	O
-	O
protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA-2	O
-positive	O
and	O
EBNA-2	O
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	O
to	O
the	O
TP1	O
promoter	O
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	O
promoter	O
-	O
binding	O
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	O
cell	O
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	B
cells	I
might	O
indeed	O
contain	O
specific	O
complexes	O
bound	O
to	O
the	O
LMP	O
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Separation	O
of	O
oxidant	O
-	O
initiated	O
and	O
redox	O
-	O
regulated	O
steps	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli	O
-	O
specific	O
pathways	O
through	O
which	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

We	O
distinguish	O
the	O
stimuli	O
-	O
specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
only	O
one	O
of	O
two	O
human	B
T	I
-	I
cell	I
lines	I
(	O
Wurzburg	B
but	O
not	O
Jurkat	B
)	O
,	O
whereas	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox	O
-	O
regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
Jurkat	B
cells	I
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF	O
-	O
kappa	O
B	O
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	O
-stimulated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	O
,	O
and	O
overexpressed	O
EGFR	O
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available	O
.	O

We	O
initiated	O
this	O
study	O
to	O
determine	O
1	O
)	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
breast	O
tissue	O
abnormalities	O
in	O
a	O
group	O
of	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
,	O
and	O
2	O
)	O
if	O
the	O
prevalence	O
of	O
biomarker	O
abnormalities	O
is	O
greater	O
in	O
high	O
risk	O
than	O
in	O
low	O
risk	O
women	O
.	O

Eligible	O
high	O
risk	O
women	O
were	O
those	O
with	O
a	O
first	O
degree	O
relative	O
with	O
breast	O
cancer	O
,	O
prior	O
breast	O
cancer	O
,	O
or	O
precancerous	O
mastopathy	O
.	O

Low	O
risk	O
women	O
were	O
those	O
without	O
these	O
or	O
other	O
major	O
identifiable	O
risk	O
factors	O
.	O

Ductal	O
cells	O
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O

Biomarkers	O
included	O
DNA	O
ploidy	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
,	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	O
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	O
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O

The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	O
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	O
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	O
and	O
the	O
small	O
number	O
of	O
controls	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

Influence	O
of	O
age	O
on	O
the	O
production	O
of	O
Fos	O
and	O
Jun	O
by	O
influenza	O
virus	O
-	O
exposed	O
T	O
cells	O
.	O

This	O
study	O
investigated	O
age	O
-	O
related	O
T	O
cell	O
responses	O
after	O
in	O
vitro	O
exposure	O
to	O
influenza	O
A	O
virus	O
.	O

Mononuclear	O
leukocytes	O
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham	O
-	O
exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O

Immunofluorescent	O
staining	O
and	O
flow	O
cytometric	O
analysis	O
were	O
then	O
used	O
to	O
detect	O
T	O
cells	O
producing	O
the	O
transcriptional	O
regulating	O
proteins	O
Fos	O
and	O
Jun	O
.	O

Fewer	O
virus	O
-	O
exposed	O
cells	O
from	O
elderly	O
donors	O
stained	O
for	O
Fos	O
and	O
Jun	O
at	O
each	O
data	O
point	O
compared	O
with	O
cells	O
from	O
young	O
donors	O
.	O

Flow	O
cytometric	O
analysis	O
also	O
showed	O
that	O
at	O
72	O
h	O
of	O
virus	O
exposure	O
fewer	O
T	O
cells	O
from	O
the	O
elderly	O
produced	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
magnitude	O
of	O
the	O
Fos	O
and	O
Jun	O
and	O
IFN	O
-	O
gamma	O
responses	O
.	O

Thus	O
,	O
failure	O
of	O
virus	O
-	O
exposed	O
T	O
cells	O
to	O
produce	O
Fos	O
and	O
Jun	O
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O

[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	O
leukocytes	O
in	O
asthmatic	O
subjects	O
]	O

The	O
number	O
of	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
in	O
peripheral	O
leukocytes	O
was	O
determined	O
by	O
radioligand	O
-	O
binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O

The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	O
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	O
and	O
the	O
course	O
of	O
asthma	O
.	O

Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	O
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	O
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	O
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O

Identification	O
of	O
the	O
promoter	O
region	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
containing	O
a	O
novel	O
enhancer	O
-	O
like	O
element	O
.	O

The	O
single	O
promoter	O
region	O
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol	O
.	O
65	O
(	O
1991	O
)	O
3131	O
-	O
3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	O
T	O
-	O
cells	O
was	O
analysed	O
via	O
CAT	O
assays	O
.	O

A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near	O
-	O
perfect	O
direct	O
repeats	O
(	O
DR	O
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	O
insert	O
was	O
proven	O
to	O
be	O
the	O
main	O
transcription	O
-	O
activation	O
element	O
,	O
with	O
enhancer	O
-	O
like	O
characteristics	O
.	O

PCR	O
studies	O
revealed	O
that	O
CAV	O
isolates	O
from	O
across	O
the	O
world	O
all	O
contained	O
this	O
promoter	O
sequence	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
individual	O
DR	O
units	O
,	O
as	O
well	O
as	O
the	O
12-bp	O
insert	O
,	O
can	O
bind	O
to	O
nuclear	O
factors	O
of	O
chicken	O
T	O
-	O
cells	O
.	O

Competition	O
assays	O
revealed	O
that	O
the	O
DR	O
units	O
bound	O
to	O
factors	O
other	O
than	O
the	O
12-bp	O
insert	O
.	O

A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	O
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	O
insert	O
.	O

Purified	O
human	O
SP1	O
was	O
shown	O
to	O
have	O
very	O
strong	O
affinity	O
for	O
the	O
12-bp	O
insert	O
.	O

T	O
-	O
cell	O
functional	O
regions	O
of	O
the	O
human	O
IL-3	O
proximal	O
promoter	O
.	O

The	O
human	O
interleukin-3	O
(	O
IL-3	O
)	O
gene	O
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	O
cells	O
.	O

Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	B
T	I
cells	I
with	O
phytohemaglutinin	O
(	O
PHA	O
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	O
gene	O
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	O
gene	O
5	O
'	O
and	O
3	O
'	O
flanking	O
sequences	O
.	O

Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-3	O
gene	O
.	O

The	O
promoter	O
region	O
between	O
-173	O
and	O
-60	O
contained	O
the	O
strongest	O
activating	O
elements	O
.	O

The	O
transcription	O
factor	O
AP-1	O
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	O
CK-1	O
/	O
CK-2	O
elements	O
that	O
are	O
present	O
in	O
many	O
cytokine	O
genes	O
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/PHA	O
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	O
stem	O
cells	O
and	O
extrathymic	O
T	O
-	O
cell	O
development	O
.	O

We	O
here	O
summarize	O
evidence	O
that	O
thymic	O
atrophy	O
induced	O
by	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
(	O
TCDD	O
)	O
can	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
damage	O
to	O
extrathymic	O
T	O
-	O
cell	O
precursors	O
in	O
bone	O
marrow	O
and	O
fetal	O
liver	O
.	O

This	O
atrophy	O
induction	O
does	O
not	O
involve	O
apoptotic	O
mechanisms	O
in	O
thymocytes	O
affected	O
by	O
the	O
bcl-2	O
proto	O
-	O
oncogene	O
.	O

TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	O
)	O
and	O
not	O
through	O
effects	O
on	O
the	O
estrogen	O
receptor	O
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T	O
-	O
cell	O
differentiation	O
in	O
the	O
liver	O
.	O

These	O
extrathymic	O
T	O
-	O
cell	O
populations	O
include	O
cells	O
expressing	O
elevated	O
levels	O
of	O
V	O
beta	O
T	O
-	O
cell	O
receptors	O
that	O
are	O
normally	O
deleted	O
in	O
thymic	O
development	O
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	O
transcription	O
induced	O
by	O
interleukin-6	O
in	O
the	O
B	B
cell	I
hybridoma	I
7TD1	I
.	O

We	O
have	O
measured	O
the	O
level	O
of	O
junB	O
mRNA	O
in	O
the	O
B	B
hybridoma	I
cell	I
line	I
7TD1	I
,	O
under	O
interleukin-6	O
(	O
IL-6	O
)	O
stimulation	O
.	O

IL-6	O
increases	O
junB	O
mRNA	O
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early	O
-	O
induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	O
mRNA	O
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	O
factors	O
,	O
including	O
IL-6	O
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	O
mRNA	O
,	O
IL-6	O
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	O
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL-6	O
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	O
mRNA	O
and	O
JunB	O
protein	O
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	O
transcription	O
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	O
-induced	O
junB	O
transcription	O
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early	O
-	O
induced	O
burst	O
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	O
mRNA	O
peak	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	O
mRNA	O
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	B
cells	I
,	O
IL-6	O
controls	O
junB	O
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

Association	O
of	O
alterations	O
in	O
NF	O
-	O
kappa	O
B	O
moieties	O
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	O
encoded	O
and	O
cellular	O
proteins	O
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV-1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	B
cell	I
line	I
U1	I
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
moieties	O
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross	O
-	O
linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	O
NF	O
-	O
kappa	O
B	O
moieties	O
and	O
possibly	O
p50	O
homodimers	O
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50-p56	O
heterodimer	O
of	O
NF	O
-	O
kappa	O
B	O
that	O
is	O
the	O
predominant	O
NF	O
-	O
kappa	O
B	O
species	O
in	O
most	O
T	O
lymphocytic	O
and	O
monocytic	O
cells	O
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	B
cells	I
.	O

This	O
pattern	O
of	O
NF	O
-	O
kappa	O
B	O
-	O
related	O
moieties	O
differs	O
from	O
the	O
latently	B
infected	I
T	I
lymphocytic	I
cell	I
line	I
ACH-2	I
,	O
and	O
from	O
the	O
U937	B
monocytic	I
line	I
,	O
the	O
parental	B
cell	I
line	I
of	O
the	O
U1	B
cellular	I
clone	I
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

Alteration	O
of	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membrane	O
by	O
glucocorticoids	O
and	O
the	O
influence	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
.	O

High	O
-	O
dose	O
pulse	O
glucocorticoid	O
therapy	O
has	O
been	O
used	O
successfully	O
in	O
the	O
clinic	O
in	O
severe	O
pathological	O
conditions	O
for	O
about	O
20	O
years	O
.	O

The	O
mode	O
of	O
glucocorticoid	O
action	O
after	O
administration	O
of	O
such	O
megadoses	O
is	O
inexplicable	O
up	O
to	O
now	O
.	O

It	O
is	O
supposed	O
that	O
some	O
effects	O
may	O
be	O
due	O
to	O
membrane	O
alterations	O
.	O

In	O
the	O
present	O
in	O
-	O
vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady	O
-	O
state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O

Dexamethasone	O
was	O
found	O
to	O
induce	O
a	O
significant	O
decrease	O
in	O
membrane	O
structural	O
order	O
at	O
concentrations	O
of	O
about	O
10	O
(	O
-6	O
)	O
M	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

We	O
found	O
a	O
correlation	O
between	O
the	O
uptake	O
of	O
dexamethasone	O
by	O
the	O
ghost	O
membranes	O
and	O
the	O
decrease	O
in	O
the	O
structural	O
order	O
.	O

The	O
other	O
glucocorticoids	O
tested	O
,	O
methylprednisolone	O
and	O
corticosterone	O
,	O
were	O
also	O
effective	O
at	O
concentrations	O
of	O
10	O
(	O
-5	O
)	O
M	O
or	O
greater	O
.	O

We	O
observed	O
no	O
change	O
in	O
membrane	O
structural	O
order	O
with	O
RU	O
486	O
up	O
to	O
a	O
concentration	O
of	O
10	O
(	O
-4	O
)	O
M	O
.	O

However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O

Thus	O
,	O
the	O
glucocorticoid	O
-	O
induced	O
membrane	O
perturbation	O
,	O
the	O
possibility	O
to	O
inhibit	O
it	O
by	O
RU	O
486	O
,	O
and	O
the	O
inactivity	O
of	O
the	O
structurally	O
related	O
progesterone	O
,	O
refer	O
to	O
relatively	O
specific	O
binding	O
sites	O
for	O
the	O
glucocorticoids	O
in	O
the	O
membrane	O
of	O
erythrocyte	O
ghosts	O
.	O

Glucocorticoid	O
-	O
induced	O
apoptosis	O
of	O
human	O
leukemic	O
cells	O
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	O
receptor	O
.	O

However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	O
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so	O
-	O
called	O
'	O
lysis	O
genes	O
'	O
by	O
the	O
activated	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation	O
-	O
deficient	O
glucocorticoid	O
receptor	O
mutant	O
is	O
as	O
effective	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
in	O
repression	O
of	O
AP-1	O
activity	O
,	O
inhibition	O
of	O
interleukin-2	O
production	O
,	O
inhibition	O
of	O
c	O
-	O
myc	O
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	O
acid	O
receptor	O
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	O
factors	O
required	O
for	O
cell	O
survival	O
.	O

HIV-1	O
Tat	O
potentiates	O
TNF	O
-induced	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
Tat	O
protein	O
amplifies	O
the	O
activity	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

In	O
HeLa	B
cells	I
stably	O
transfected	O
with	O
the	O
HIV-1	O
tat	O
gene	O
(	O
HeLa	B
-	I
tat	I
cells	I
)	O
,	O
expression	O
of	O
the	O
Tat	O
protein	O
enhanced	O
both	O
TNF	O
-induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
TNF	O
-mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	O
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	B
cells	I
treated	O
with	O
soluble	O
Tat	O
protein	O
.	O

TNF	O
-mediated	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	O
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	O
cells	O
and	O
HeLa	B
cells	I
HIV-1	O
Tat	O
suppressed	O
the	O
expression	O
of	O
Mn	O
-	O
dependent	O
superoxide	O
dismutase	O
(	O
Mn	O
-	O
SOD	O
)	O
,	O
a	O
mitochondrial	O
enzyme	O
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn	O
-	O
SOD	O
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	O
.	O

Decreased	O
Mn	O
-	O
SOD	O
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	O
protein	O
(	O
Tat1	O
-	O
72	O
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
no	O
longer	O
affected	O
Mn	O
-	O
SOD	O
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	O
-mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
HIV-1	O
Tat	O
is	O
required	O
to	O
suppress	O
Mn	O
-	O
SOD	O
expression	O
and	O
to	O
induce	O
pro	O
-	O
oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Expression	O
of	O
the	O
Runt	O
domain	O
-	O
encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	O
cells	O
during	O
thymic	O
development	O
.	O

The	O
PEBP2	O
alpha	O
A	O
and	O
PEBP2	O
alpha	O
B	O
genes	O
encode	O
the	O
DNA	O
-	O
binding	O
subunit	O
of	O
a	O
murine	O
transcription	O
factor	O
,	O
PEBP2	O
,	O
which	O
is	O
implicated	O
as	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcriptional	O
regulator	O
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	O
domain	O
.	O

PEBP2	O
alpha	O
B	O
is	O
the	O
murine	O
counterpart	O
of	O
human	O
AML1	O
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	O
;	O
21	O
and	O
3	O
;	O
21	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	O
alpha	O
A	O
and	O
mouse	O
AML1	O
/	O
PEBP2	O
alpha	O
B	O
were	O
detected	O
in	O
T	O
lymphocytes	O
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week	O
-	O
old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4-	O
CD8-	O
,	O
CD4	O
+	O
CD8	O
+	O
,	O
CD4	O
+	O
CD8-	O
,	O
and	O
CD4-	O
CD8	O
+	O
cell	O
populations	O
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	O
cells	O
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Transcripts	O
of	O
mouse	O
AML1	O
/	O
PEBP2	O
alpha	O
B	O
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	O
marrow	O
cells	O
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1	O
/	O
PEBP2	O
alpha	O
B	O
expression	O
in	O
hematopoietic	O
cells	O
other	O
than	O
those	O
of	O
T	O
-	O
cell	O
lineage	O
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	O
factor	O
binding	O
to	O
DNA	O
.	O

The	O
interaction	O
of	O
the	O
transcription	O
factors	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
and	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
with	O
DNA	O
and	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
was	O
analyzed	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF	O
-	O
alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	O
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	O
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	O
response	O
element	O
binding	O
and	O
a	O
concomitant	O
40	O
-	O
50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	O
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	O
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	O
factors	O
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	O
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine	O
-	O
stimulated	O
transcription	O
factors	O
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Control	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
proteolysis	O
by	O
site	O
-	O
specific	O
,	O
signal	O
-	O
induced	O
phosphorylation	O
.	O

I	O
kappa	O
B	O
-	O
alpha	O
inhibits	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	O
kappa	O
B	O
-	O
alpha	O
.	O

This	O
liberates	O
NF	O
-	O
kappa	O
B	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	O
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
correlates	O
with	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal	O
-	O
induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

HIV-1	O
Nef	O
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	O
cells	O
depending	O
on	O
its	O
intracellular	O
localization	O
.	O

Nef	O
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	O
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	O
CD8-Nef	O
protein	O
in	O
Jurkat	B
cells	I
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	O
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	O
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
.	O

Activated	O
Jurkat	B
cells	I
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	O
genes	O
expressing	O
truncated	O
Nefs	O
survived	O
,	O
which	O
rendered	O
Nef	O
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	O
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	O
and	O
suggest	O
a	O
role	O
for	O
its	O
N	O
-	O
terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	O
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	O
receptors	O
(	O
RARs	O
)	O
in	O
T	B
-	I
lymphoid	I
and	I
monocytoid	I
cell	I
lines	I
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all	O
-	O
trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T	B
-	I
lymphoid	I
(	O
H9	B
,	I
CEM	I
)	O
and	O
monocytoid	B
(	I
U937	I
,	I
THP-1	I
)	I
cell	I
lines	I
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	O
levels	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
,	O
receptor	O
for	O
all	O
-	O
trans	O
RA	O
)	O
and	O
the	O
human	O
retinoid	O
-	O
X	O
receptor	O
alpha	O
(	O
hRXR	O
alpha	O
receptor	O
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all	O
-	O
trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	B
IIIB	I
-	I
infected	I
monocytoid	I
cells	I
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co	O
-	O
stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T	B
-	I
cell	I
lines	I
.	O

HIV	O
production	O
by	O
PMA	B
-	I
stimulated	I
T	I
-	I
cell	I
lines	I
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all	O
-	O
trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	O
RAR	O
alpha	O
was	O
expressed	O
in	O
H9	B
,	O
U937	B
and	O
THP-1	B
cells	I
,	O
but	O
almost	O
undetectable	O
in	O
CEM	B
cells	I
.	O

Human	O
RXR	O
alpha	O
was	O
significantly	O
expressed	O
in	O
U937	B
and	I
THP-1	I
cells	I
,	O
weakly	O
expressed	O
in	O
H9	B
cells	I
and	O
not	O
detectable	O
in	O
CEM	B
cells	I
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	O
alpha	O
expression	O
increased	O
in	O
H9	B
and	O
U937	B
cells	I
but	O
not	O
in	O
CEM	B
cells	I
.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B
and	O
CEM	B
cells	I
,	O
and	O
elevated	O
in	O
U937	B
cells	I
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell	O
-	O
type	O
-	O
dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	O
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Identification	O
of	O
human	O
TR2	O
orphan	O
receptor	O
response	O
element	O
in	O
the	O
transcriptional	O
initiation	O
site	O
of	O
the	O
simian	O
virus	O
40	O
major	O
late	O
promoter	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	O
response	O
element	O
(	O
TR2RE	O
-	O
SV40	O
)	O
for	O
the	O
TR2	O
orphan	O
receptor	O
,	O
a	O
member	O
of	O
the	O
steroid	O
-	O
thyroid	O
hormone	O
receptor	O
superfamily	O
,	O
has	O
been	O
identified	O
in	O
the	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
+	O
55	O
region	O
(	O
nucleotide	O
numbers	O
368	O
-	O
389	O
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	O
orphan	O
receptor	O
with	O
a	O
molecular	O
mass	O
of	O
67	O
kilodaltons	O
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA	O
-	O
swap	O
experiments	O
using	O
chloramphenicol	O
acetyl	O
-	O
transferase	O
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	O
early	O
promoter	O
via	O
the	O
interaction	O
between	O
this	O
TR2RE	O
-	O
SV40	O
and	O
the	O
chimeric	O
receptor	O
AR	O
/	O
TR2	O
/	O
AR	O
with	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
TR2	O
orphan	O
receptor	O
flanked	O
by	O
the	O
N	O
-	O
terminal	O
and	O
androgen	O
-	O
binding	O
domains	O
of	O
the	O
androgen	O
receptor	O
.	O

In	O
addition	O
,	O
this	O
TR2RE	O
-	O
SV40	O
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	O
early	O
and	O
late	O
promoters	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE	O
-	O
SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	O
response	O
element	O
for	O
the	O
TR2	O
orphan	O
receptor	O
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	O
gene	O
in	O
B	O
-	O
lymphocytes	O
]	O

Since	O
most	O
B	B
cell	I
clones	I
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	O
,	O
a	O
typical	O
T	O
cell	O
cytokine	O
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	O
promoter	O
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NF	O
-	O
kB	O
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	B
clones	I
tested	O
.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	O
cells	O
of	O
the	O
Jurkat	B
line	I
.	O

The	O
NFATd	O
element	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NFAT-1	O
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	B
clone	I
and	O
not	O
at	O
all	O
in	O
another	O
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL-2	O
promoter	O
activity	O
in	O
different	O
cells	O
.	O

Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold	O
-	O
air	O
exposures	O
.	O

Repeated	O
cold	O
-	O
air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

To	O
study	O
the	O
response	O
of	O
the	O
nuclear	O
T3	O
receptor	O
(	O
NT3R	O
)	O
in	O
this	O
condition	O
,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
.	O

In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice	O
/	O
d	O
,	O
30	O
min	O
/	O
exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

The	O
T3-subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3	O
+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms	O
/	O
d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
.	O

Mononuclear	O
leukocytes	O
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	O
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between	O
-	O
subject	O
variability	O
.	O

In	O
the	O
T3	O
+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O

The	O
log10Kd	O
increased	O
0.304	O
+	O
/-	O
0.139	O
(	O
p	O
<	O
0.04	O
)	O
and	O
the	O
log10MBC	O
increased	O
0.49	O
+	O
/-	O
0.10	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
T3	O
+	O
subjects	O
compared	O
to	O
baseline	O
.	O

This	O
change	O
in	O
MBC	O
represents	O
a	O
311	O
%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo	O
-	O
treated	O
subjects	O
.	O

The	O
T3	O
-group	O
showed	O
no	O
change	O
in	O
MBC	O
over	O
the	O
study	O
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	O
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

Nitric	O
oxide	O
-	O
stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	O
.	O

The	O
protooncogene	O
p21ras	O
,	O
a	O
monomeric	O
G	O
protein	O
family	O
member	O
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	O
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP	O
-	O
bound	O
p21ras	O
.	O

In	O
vitro	O
studies	O
using	O
pure	O
recombinant	O
p21ras	O
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	O
in	O
association	O
with	O
GDP	O
/	O
GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S	O
-	O
nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	O
is	O
essential	O
for	O
NO	O
-	O
induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	O
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	O
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	O
nucleotide	O
exchange	O
factors	O
.	O

Functional	O
characterization	O
of	O
novel	O
IL-2	O
transcriptional	O
inhibitors	O
.	O

IL-2	O
-mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT-1	O
transcriptional	O
complex	O
on	O
the	O
IL-2	O
promoter	O
is	O
essential	O
for	O
IL-2	O
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	O
regulatory	O
element	O
linked	O
to	O
a	O
lac	O
-	O
Z	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	O
-1-mediated	O
beta	O
-	O
galactosidase	O
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta	O
-	O
galactosidase	O
mRNA	O
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	O
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B
line	I
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B
lac	I
-	I
Z	I
transfectants	I
,	O
and	O
in	O
human	O
lymphocytes	O
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	O
.	O

WIN	O
53071	O
inhibited	O
IL-2	O
production	O
induced	O
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium	O
-	O
independent	O
anti	O
-	O
CD28	O
Ab	O
and	O
PMA	O
-	O
induced	O
IL-2	O
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT-1	O
transcriptional	O
complex	O
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	O
-1-mediated	O
transcription	O
.	O

cDNA	O
cloning	O
of	O
a	O
NGFI	O
-	O
B	O
/	O
nur77-related	O
transcription	O
factor	O
from	O
an	O
apoptotic	B
human	I
T	I
cell	I
line	I
.	O

A	O
human	B
T	I
lymphoid	I
cell	I
line	I
,	O
PEER	B
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	O
,	O
TINUR	O
,	O
was	O
cloned	O
from	O
apoptotic	B
PEER	I
cells	I
.	O

The	O
expression	O
of	O
the	O
TINUR	O
gene	O
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross	O
-	O
linking	O
of	O
the	O
T	O
cell	O
Ag	O
receptor	O
complex	O
.	O

TINUR	O
belongs	O
to	O
the	O
NGFI	O
-	O
B	O
/	O
nur77	O
family	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
and	O
is	O
an	O
orphan	O
receptor	O
.	O

TINUR	O
binds	O
to	O
the	O
same	O
DNA	O
sequence	O
as	O
NGFI	O
-	O
B	O
/	O
nur77	O
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI	O
-	O
B	O
/	O
nur77	O
family	O
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Platelet	O
-	O
activating	O
factor	O
stimulates	O
transcription	O
of	O
the	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
in	O
monocytes	O
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
with	O
up	O
-	O
regulation	O
of	O
the	O
transcript	O
for	O
heparin	O
-	O
binding	O
epidermal	O
growth	O
factor	O
-	O
like	O
growth	O
factor	O
(	O
HB	O
-	O
EGF	O
)	O
,	O
a	O
potent	O
mitogen	O
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
function	O
of	O
PAF	O
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	O
-induced	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	O
surface	O
PAF	O
receptors	O
,	O
as	O
two	O
PAF	O
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	O
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	O
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
markedly	O
reduced	O
PAF	O
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up	O
-	O
regulation	O
of	O
HB	O
-	O
EGF	O
mRNA	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	O
in	O
HB	O
-	O
EGF	O
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Identification	O
and	O
purification	O
of	O
human	O
Stat	O
proteins	O
activated	O
in	O
response	O
to	O
interleukin-2	O
.	O

A	O
key	O
cytokine	O
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	O
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL-2	O
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL-2	O
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	O
lymphocytes	O
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	O
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	O
factors	O
induced	O
in	O
response	O
to	O
IL-2	O
.	O

Human	O
peripheral	O
blood	O
lymphocytes	O
were	O
observed	O
to	O
contain	O
several	O
IL-2	O
-inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B
human	I
lymphocyte	I
line	I
,	O
termed	O
YT	B
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	O
component	O
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin	O
-	O
induced	O
transcription	O
factor	O
first	O
identified	O
in	O
sheep	O
mammary	O
gland	O
tissue	O
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	O
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	O
during	O
the	O
immune	O
response	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B
prostatic	I
cancer	I
LNCaP	I
cells	I
as	O
induced	O
by	O
T	O
lymphocyte	O
-	O
conditioned	O
medium	O
.	O

Human	B
prostatic	I
epithelial	I
cells	I
from	O
an	O
androgen	B
-	I
dependent	I
LNCaP	I
cell	I
line	I
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B
(	I
PHA	I
)	I
-stimulated	I
lymphocytes	I
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth	O
-	O
modulating	O
effect	O
was	O
dose	O
-	O
dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	O
receptor	O
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	O
cell	O
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	O
and	O
intracellular	O
proteins	O
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	O
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	O
8	O
and	O
18	O
,	O
associated	O
with	O
differentiated	O
cell	O
types	O
of	O
prostate	O
epithelia	O
,	O
and	O
neuron	O
-	O
specific	O
enolase	O
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	O
cells	O
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	O
cells	O
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	O
modulator	O
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	O
,	O
TNF	O
,	O
and	O
some	O
commonly	O
known	O
lymphokines	O
.	O

The	O
interaction	O
between	O
lymphoid	O
and	O
prostatic	O
cells	O
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

Mouse	O
interleukin-2	O
receptor	O
alpha	O
gene	O
expression	O
.	O

Interleukin-1	O
and	O
interleukin-2	O
control	O
transcription	O
via	O
distinct	O
cis	O
-	O
acting	O
elements	O
.	O

We	O
have	O
shown	O
that	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
IL-2	O
control	O
IL-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
transcription	O
in	O
CD4-CD8-	B
murine	I
T	I
lymphocyte	I
precursors	I
.	O

Here	O
we	O
map	O
the	O
cis	O
-	O
acting	O
elements	O
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	O
IL-2R	O
alpha	O
gene	O
using	O
a	O
thymic	B
lymphoma	I
-	I
derived	I
hybridoma	I
(	O
PC60	B
)	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
to	O
stimulation	O
by	O
IL-1	O
+	O
IL-2	O
is	O
biphasic	O
.	O

IL-1	O
induces	O
a	O
rapid	O
,	O
protein	O
synthesis	O
-	O
independent	O
appearance	O
of	O
IL-2R	O
alpha	O
mRNA	O
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	O
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	O
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	O
alpha	O
transcripts	O
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter	O
-	O
proximal	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
contribute	O
to	O
IL-1	O
responsiveness	O
,	O
most	O
importantly	O
an	O
NF	O
-	O
kappa	O
B	O
site	O
conserved	O
in	O
the	O
human	O
and	O
mouse	O
gene	O
.	O

IL-2	O
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	O
segment	O
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	O
enhancer	O
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	O
I	O
hypersensitive	O
in	O
normal	O
T	O
cells	O
in	O
which	O
IL-2R	O
alpha	O
expression	O
has	O
been	O
induced	O
.	O

IL-2	O
responsiveness	O
requires	O
three	O
distinct	O
elements	O
within	O
the	O
enhancer	O
.	O

Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	O
proteins	O
.	O

Neutrophils	O
and	O
monocytes	O
express	O
high	O
levels	O
of	O
PU.1	O
(	O
Spi-1	O
)	O
but	O
not	O
Spi	O
-	O
B	O
.	O

PU.1	O
(	O
the	O
Spi-1	O
oncogene	O
)	O
and	O
Spi	O
-	O
B	O
are	O
closely	O
related	O
members	O
of	O
the	O
ets	O
transcription	O
factor	O
family	O
,	O
sharing	O
similar	O
DNA	O
binding	O
specificities	O
mediated	O
by	O
similar	O
DNA	O
binding	O
domains	O
.	O

PU.1	O
and	O
Spi	O
-	O
B	O
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	O
and	O
B	O
cells	O
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	O
and	O
macrophages	O
or	O
to	O
neutrophils	O
has	O
not	O
been	O
extensively	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
PU.1	O
mRNA	O
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B
purified	I
CD34	I
+	I
cells	I
and	O
murine	B
multipotential	I
FDCP	I
-	I
mix	I
A4	I
cells	I
,	O
suggesting	O
that	O
PU.1	O
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	O
progenitor	O
cells	O
.	O

PU.1	O
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	B
cell	I
lines	I
U937	B
and	O
HL-60	B
to	O
monocytic	O
and	O
neutrophilic	O
cells	O
.	O

PU.1	O
is	O
expressed	O
at	O
highest	O
levels	O
in	O
mature	O
human	O
monocytes	O
and	O
human	O
peripheral	O
blood	O
neutrophils	O
.	O

In	O
contrast	O
to	O
PU.1	O
,	O
significant	O
levels	O
of	O
Spi	O
-	O
B	O
mRNA	O
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B	B
-	I
cell	I
lines	I
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	B
cell	I
lines	I
,	O
neutrophils	O
,	O
or	O
macrophages	O
.	O

In	O
vitro	O
translated	O
Spi	O
-	O
B	O
protein	O
can	O
bind	O
to	O
PU.1	O
binding	O
sites	O
in	O
myeloid	O
promoters	O
and	O
transactivate	O
these	O
promoters	O
in	O
nonmyeloid	O
cells	O
.	O

Therefore	O
,	O
although	O
PU.1	O
and	O
Spi	O
-	O
B	O
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi	O
-	O
B	O
in	O
myeloid	O
cells	O
makes	O
it	O
unlikely	O
that	O
Spi	O
-	O
B	O
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
PU.1	O
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	O
and	O
macrophages	O
but	O
also	O
in	O
neutrophils	O
,	O
indicating	O
that	O
PU.1	O
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	O
myeloid	O
lineages	O
.	O

Differential	O
induction	O
of	O
the	O
NF	O
-	O
AT	O
complex	O
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T	O
-	O
cell	O
anergy	O
.	O

Stimulation	O
of	O
human	B
CD4	I
+	I
T	I
-	I
cell	I
clones	I
through	O
the	O
T	O
-	O
cell	O
receptor	O
(	O
TcR	O
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long	O
-	O
lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	O
cells	O
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	O
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	O
and	O
CD25	O
receptors	O
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	O
T	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
transcription	O
of	O
the	O
IL-2	O
gene	O
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL-2	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	O
factors	O
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	O
cells	O
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T	O
-	O
cell	O
-	O
specific	O
expression	O
of	O
the	O
IL-2	O
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	O
genes	O
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF-1	O
site	O
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	O
,	O
activated	O
,	O
and	O
anergized	O
cells	O
.	O

The	O
inducible	O
factors	O
NK	O
-	O
kappa	O
B	O
,	O
beta	O
E2	O
,	O
CD28RC	O
,	O
and	O
AP-1	O
are	O
not	O
expressed	O
in	O
resting	O
cells	O
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
T	O
cells	O
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF	O
-	O
AT	O
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	O
factors	O
that	O
regulates	O
IL-2	O
gene	O
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Erythropoietin	O
stimulates	O
transcription	O
of	O
the	O
TAL1	O
/	O
SCL	O
gene	O
and	O
phosphorylation	O
of	O
its	O
protein	O
products	O
.	O

Activation	O
of	O
the	O
TAL1	O
(	O
or	O
SCL	O
)	O
gene	O
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	O
products	O
of	O
this	O
gene	O
contain	O
the	O
basic	O
-	O
helix	O
-	O
loop	O
-	O
helix	O
motif	O
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
canonical	O
DNA	O
sequence	O
CANNTG	O
as	O
protein	O
heterodimers	O
.	O

TAL1	O
expression	O
by	O
erythroid	O
cells	O
in	O
vivo	O
and	O
in	O
chemical	B
-	I
induced	I
erythroleukemia	I
cell	I
lines	I
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	O
hormone	O
erythropoietin	O
(	O
Epo	O
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	O
gene	O
and	O
its	O
protein	O
products	O
were	O
affected	O
by	O
Epo	O
in	O
splenic	O
erythroblasts	O
from	O
mice	O
infected	O
with	O
an	O
anemia	O
-	O
inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	O
elicited	O
a	O
rapid	O
,	O
dose	O
-	O
related	O
increase	O
in	O
TAL1	O
mRNA	O
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	O
.	O

An	O
Epo	O
-inducible	O
TAL1	O
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	O
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	O
-induced	O
phosphorylation	O
of	O
nuclear	O
TAL1	O
protein	O
.	O

These	O
results	O
indicate	O
that	O
Epo	O
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	O
locus	O
in	O
Friend	B
virus	I
-	I
induced	I
erythroblasts	I
and	O
establish	O
a	O
link	O
between	O
Epo	O
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
differentiation	O
of	O
diverse	O
cell	O
lineages	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	O
protein	O
.	O

The	O
IE2	O
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	O
)	O
dramatically	O
suppressed	O
this	O
IE2	O
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	O
,	O
Rb	O
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	O
specifically	O
interacts	O
with	O
IE2	O
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein	O
-	O
affinity	O
chromatography	O
that	O
Rb	O
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	O
.	O

Our	O
results	O
suggest	O
that	O
Rb	O
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Epstein	O
-	O
Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	O
and	O
its	O
repressor	O
RAZ	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	O
genome	O
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	O
ZLF-1	O
gene	O
product	O
,	O
ZEBRA	O
,	O
by	O
RT	O
-	O
PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	O
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	O
locus	O
and	O
the	O
adjacent	O
BRLF-1	O
locus	O
,	O
was	O
detected	O
by	O
RT	O
-	O
PCR	O
.	O

ZEBRA	O
protein	O
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	O
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	O
than	O
from	O
the	O
Cp	O
/	O
Wp	O
promoter	O
which	O
is	O
used	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

Transcripts	O
encoding	O
gp350	O
/	O
220	O
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	O
or	O
EBER-1	O
loci	O
in	O
infected	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	O
of	O
Sp1	O
phosphorylation	O
and	O
NF	O
-	O
kappa	O
B	O
-	O
independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer	O
-	O
dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR	O
-	O
driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	O
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	O
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	O
,	O
phorbol	O
ester	O
,	O
or	O
PHA	O
and	O
interleukin	O
2	O
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	O
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	O
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	O
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine	O
-	O
threonine	O
phosphatase	O
PP2A	O
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	O
,	O
and	O
Sp1	O
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF	O
-	O
kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

GM	O
-	O
CSF	O
and	O
IL-2	O
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3	O
kb	O
upstream	O
to	O
respond	O
to	O
TCR	O
-like	O
signals	O
.	O

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	O
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK-1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM	O
-	O
CSF	O
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	O
transactivator	O
protein	O
,	O
tax	O
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM	O
-	O
CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	O
the	O
GM	O
-	O
CSF	O
promoter	O
through	O
the	O
CK-1	O
/CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor	O
-	O
kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF	O
-	O
kappa	O
B	O
are	O
required	O
for	O
tax	O
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK-1	O
/CD28RE	O
of	O
GM	O
-	O
CSF	O
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	O
CD28RE	O
and	O
the	O
IL-3	O
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM	O
-	O
CSF	O
and	O
IL-2	O
respond	O
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

A	O
Myc	O
-	O
associated	O
zinc	O
finger	O
protein	O
binding	O
site	O
is	O
one	O
of	O
four	O
important	O
functional	O
regions	O
in	O
the	O
CD4	O
promoter	O
.	O

The	O
CD4	O
promoter	O
plays	O
an	O
important	O
role	O
in	O
the	O
developmental	O
control	O
of	O
CD4	O
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	O
promoter	O
has	O
four	O
factor	O
binding	O
sites	O
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O

Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	O
factors	O
bind	O
to	O
these	O
independent	O
sites	O
.	O

We	O
determined	O
that	O
an	O
initiator	O
-	O
like	O
sequence	O
present	O
at	O
the	O
cap	O
site	O
and	O
an	O
Ets	O
consensus	O
sequence	O
are	O
required	O
for	O
full	O
promoter	O
function	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
Myc	O
-	O
associated	O
zinc	O
finger	O
protein	O
(	O
MAZ	O
)	O
appears	O
to	O
be	O
the	O
predominant	O
factor	O
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O

This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	O
G3AG4AG3	O
motif	O
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	O
promoter	O
of	O
the	O
c	O
-	O
myc	O
gene	O
.	O

We	O
therefore	O
believe	O
that	O
the	O
MAZ	O
transcription	O
factor	O
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	O
gene	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	O
gene	O
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
have	O
tumor	O
-	O
specific	O
rearrangements	O
of	O
the	O
TAL1	O
gene	O
.	O

Although	O
TAL1	O
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	O
lymphocytes	O
,	O
TAL1	O
gene	O
products	O
are	O
readily	O
detected	O
in	O
leukemic	O
cells	O
that	O
harbor	O
a	O
rearranged	O
TAL1	O
allele	O
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	O
promotes	O
the	O
development	O
of	O
T	O
-	O
ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	O
is	O
expressed	O
in	O
the	O
leukemic	O
cells	O
of	O
most	O
patients	O
with	O
T	O
-	O
ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	O
gene	O
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	O
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	O
transcription	O
in	O
primary	O
T	O
-	O
ALL	O
cells	O
.	O

Monoallelic	O
expression	O
of	O
TAL1	O
was	O
observed	O
in	O
the	O
leukemic	O
cells	O
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	O
gene	O
rearrangement	O
.	O

In	O
the	O
leukemic	O
cells	O
of	O
patients	O
without	O
detectable	O
TAL1	O
rearrangements	O
,	O
TAL1	O
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	O
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis	O
-	O
acting	O
regulatory	O
sequences	O
(	O
affecting	O
expression	O
of	O
a	O
single	O
TAL1	O
allele	O
)	O
or	O
changes	O
in	O
trans	O
-	O
acting	O
factors	O
that	O
control	O
TAL1	O
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	O
alleles	O
)	O
.	O

Hematopoietic	O
lineage	O
commitment	O
:	O
role	O
of	O
transcription	O
factors	O
.	O

This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	O
factors	O
in	O
hematopoietic	O
lineage	O
commitment	O
.	O

A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	O
factors	O
important	O
in	O
specifying	O
hematopoietic	O
cell	O
types	O
.	O

Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	O
stem	O
cells	O
in	O
the	O
analysis	O
of	O
hematopoietic	O
gene	O
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	O
factors	O
in	O
hematopoiesis	O
.	O

Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	O
factors	O
in	O
the	O
commitment	O
to	O
erythroid	O
,	O
myeloid	O
and	O
lymphoid	O
cell	O
types	O
is	O
summarized	O
.	O

E1A	O
gene	O
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	O
cells	O
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	O
cells	O
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	O
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	O
expression	O
in	O
human	O
cells	O
.	O

Only	O
stably	O
transfected	B
target	I
cells	I
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	O
proteins	O
in	O
Ad	B
-	I
infected	I
targets	I
.	O

The	O
inability	O
of	O
E1A	O
gene	O
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	O
cells	O
or	O
by	O
viral	O
gene	O
effects	O
on	O
class	O
I	O
MHC	O
antigen	O
expression	O
on	O
target	O
cells	O
.	O

This	O
differential	O
effect	O
of	O
E1A	O
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	O
cells	O
suggests	O
that	O
human	O
NK	O
cells	O
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A	B
-	I
immortalized	I
cells	I
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	O
infected	O
cells	O
in	O
the	O
human	O
host	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	O
epitopes	O
.	O

The	O
CD4	O
coreceptor	O
interacts	O
with	O
non	O
-	O
polymorphic	O
regions	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
on	O
antigen	O
-	O
presenting	O
cells	O
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	O
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
which	O
recognize	O
different	O
CD4	O
epitopes	O
.	O

We	O
demonstrate	O
that	O
CD4	O
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF	O
-	O
AT	O
transcription	O
factor	O
which	O
is	O
required	O
for	O
interleukin-2	O
gene	O
expression	O
.	O

Whereas	O
different	O
anti	O
-	O
CD4	O
mAb	O
or	O
HIV-1	O
gp120	O
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
phosphorylation	O
of	O
the	O
Shc	O
adaptor	O
protein	O
,	O
which	O
mediates	O
signals	O
to	O
Ras	O
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF	O
-	O
AT	O
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF	O
-	O
AT	O
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	O
on	O
the	O
CD4	O
coreceptor	O
involved	O
in	O
activation	O
of	O
the	O
Ras	O
/	O
protein	O
kinase	O
C	O
and	O
calcium	O
pathways	O
.	O

A	O
functional	O
T	O
-	O
cell	O
receptor	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	O
activity	O
.	O

Stimulation	O
of	O
the	O
T	O
-	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	O
kinases	O
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	O
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O

It	O
contains	O
a	O
number	O
of	O
structural	O
motifs	O
,	O
including	O
Src	O
homology	O
2	O
,	O
Src	O
homology	O
3	O
,	O
and	O
pleckstrin	O
homology	O
domains	O
and	O
a	O
putative	O
guanine	O
nucleotide	O
exchange	O
domain	O
.	O

The	O
role	O
of	O
p95vav	O
in	O
TCR	O
-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	O
alone	O
in	O
Jurkat	O
T	O
cells	O
leads	O
to	O
activation	O
of	O
the	O
nuclear	O
factors	O
,	O
including	O
NFAT	O
,	O
involved	O
in	O
interleukin-2	O
expression	O
.	O

Furthermore	O
,	O
p95vav	O
synergizes	O
with	O
TCR	O
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	O
activation	O
by	O
a	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
is	O
not	O
modulated	O
by	O
p95vav	O
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	O
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	O
67	O
amino	O
acids	O
of	O
p95vav	O
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B
3T3	I
cells	I
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	O
-induced	O
NFAT	O
activation	O
is	O
not	O
mimicked	O
by	O
Ras	O
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	O
and	O
Raf	O
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	O
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	O
.	O

To	O
further	O
dissect	O
p95vav	O
involvement	O
in	O
TCR	O
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	B
mutants	I
deficient	O
in	O
TCR	O
signaling	O
function	O
or	O
TCR	O
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	O
to	O
function	O
.	O

However	O
,	O
overexpression	O
of	O
p95vav	O
does	O
not	O
appear	O
to	O
influence	O
TCR	O
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	O
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	O
signaling	O
cascade	O
.	O

Lipopolysaccharide	O
-	O
induced	O
E	O
-	O
selectin	O
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal	O
/	O
permeability	O
-	O
increasing	O
protein	O
.	O

Endothelial	O
cells	O
stimulated	O
by	O
LPS	O
express	O
E	O
-	O
selectin	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	O
adhesion	O
during	O
inflammation	O
.	O

E	O
-	O
selectin	O
is	O
induced	O
within	O
1	O
-	O
2	O
h	O
,	O
peaks	O
at	O
4	O
-	O
6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	O
,	O
a	O
recombinant	O
N	O
-	O
terminal	O
fragment	O
of	O
human	O
bactericidal	O
/	O
permeability	O
-	O
increasing	O
protein	O
(	O
BPI	O
)	O
,	O
inhibited	O
LPS	O
-	O
induced	O
E	O
-	O
selectin	O
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	O
also	O
affected	O
LPS	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF	O
-	O
kappa	O
B	O
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	O
resulted	O
in	O
marked	O
reduction	O
of	O
NF	O
-	O
kappa	O
B	O
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	O
acts	O
to	O
reverse	O
LPS	O
-	O
mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on	O
-	O
going	O
LPS	O
signal	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
phosphatase	O
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
at	O
phosphatase	O
2A	O
-	O
sensitive	O
sites	O
.	O

Activation	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine	O
/	O
threonine	O
phosphatases	O
in	O
the	O
regulation	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	O
T	O
cells	O
with	O
low	O
concentrations	O
(	O
approximately	O
1	O
-	O
5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	O
phosphatase	O
type	O
1	O
(	O
PP-1	O
)	O
and	O
type	O
2A	O
(	O
PP-2A	O
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA.p50	O
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	O
I	O
kappa	O
B	O
alpha	O
from	O
calyculin	B
A	I
-	I
treated	I
cells	I
,	O
but	O
not	O
that	O
from	O
TNF	B
-	I
alpha	I
-	I
stimulated	I
cells	I
,	O
is	O
sensitive	O
to	O
PP-2A	O
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
induced	O
by	O
the	O
two	O
different	O
NF	O
-	O
kappa	O
B	O
inducers	O
.	O

However	O
,	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
by	O
both	O
TNF	O
-	O
alpha	O
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

We	O
further	O
demonstrate	O
that	O
TNF	O
-	O
alpha-	O
and	O
calyculin	O
A	O
-	O
induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
mediated	O
through	O
both	O
the	O
TNF	O
-	O
alpha	O
-inducible	O
and	O
the	O
PP-2A	O
-	O
opposing	O
kinases	O
,	O
may	O
serve	O
to	O
target	O
I	O
kappa	O
B	O
alpha	O
for	O
proteasome	O
-mediated	O
degradation	O
.	O

IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	O
and	O
Jak1	O
and	O
the	O
differential	O
assembly	O
of	O
STAT1	O
alpha	O
and	O
STAT3	O
complexes	O
in	O
human	O
T	O
cells	O
and	O
monocytes	O
.	O

IL-10	O
affects	O
monocytes	O
and	O
T	O
cells	O
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte	O
-	O
mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	O
and	O
T	O
cells	O
IL-10	O
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
,	O
STAT1	O
alpha	O
and	O
STAT3	O
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	O
and	O
heterodimers	O
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	O
express	O
a	O
novel	O
IL-10-stimulated	O
STAT	O
protein	O
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	O
kDa	O
that	O
is	O
recognized	O
by	O
the	O
anti	O
-	O
STAT3	O
Ab	O
but	O
is	O
not	O
observed	O
in	O
T	O
cells	O
.	O

IL-10	O
treatment	O
of	O
both	O
T	O
cells	O
and	O
monocytes	O
results	O
in	O
the	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	O
and	O
Jak1	O
,	O
but	O
not	O
Jak2	O
or	O
Jak3	O
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	O
in	O
cells	O
such	O
as	O
monocytes	O
and	O
T	O
cells	O
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	O
protein	O
pairs	O
.	O

Characterization	O
of	O
5	O
'	O
end	O
of	O
human	O
thromboxane	O
receptor	O
gene	O
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	O
kinase	O
C	O
--	O
responsive	O
elements	O
regulating	O
expression	O
in	O
platelets	O
.	O

Platelet	O
thromboxane	O
receptors	O
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	O
receptors	O
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	O
genomic	O
DNA	O
clones	O
containing	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
.	O

The	O
exon	O
-	O
intron	O
structure	O
of	O
the	O
5	O
'	O
portion	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	O
uterine	O
thromboxane	O
receptor	O
cDNA	O
that	O
extended	O
the	O
mRNA	O
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	O
placental	O
cDNA	O
.	O

A	O
major	O
transcription	O
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
and	O
380	O
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	O
initiation	O
site	O
.	O

The	O
thromboxane	O
receptor	O
gene	O
has	O
neither	O
a	O
TATA	O
nor	O
a	O
CAAT	O
consensus	O
site	O
.	O

Promoter	O
function	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	O
receptor	O
gene	O
promoter	O
/	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
chimera	O
plasmids	O
into	O
platelet	O
-	O
like	O
K562	B
cells	I
.	O

Thromboxane	O
receptor	O
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	O
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5	O
'	O
deletion	O
constructs	O
in	O
transfected	O
K562	B
cells	I
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester	O
-	O
responsive	O
motifs	O
in	O
the	O
thromboxane	O
receptor	O
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	O
protein-2	O
(	O
AP-2	O
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
and	O
demonstrate	O
that	O
thromboxane	O
receptor	O
gene	O
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	O
kinase	O
C	O
via	O
induction	O
of	O
an	O
AP-2-like	O
nuclear	O
factor	O
binding	O
to	O
upstream	O
promoter	O
elements	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	O
thromboxane	O
receptors	O
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	O
receptor	O
gene	O
transcription	O
in	O
platelet	O
-	O
progenitor	O
cells	O
.	O

HIV-1	O
envelope	O
glycoproteins	O
induce	O
activation	O
of	O
activated	O
protein-1	O
in	O
CD4	O
+	O
T	O
cells	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	O
positive	O
T	O
cells	O
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B
positive	I
T	I
cell	I
lines	I
and	O
purified	O
T	O
cells	O
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
,	O
gp	O
160	O
,	O
can	O
induce	O
activation	O
of	O
transcription	O
factor	O
,	O
activated	O
protein-1	O
(	O
AP-1	O
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	O
molecule	O
,	O
since	O
treatment	O
of	O
gp160	O
with	O
soluble	O
CD4-IgG	O
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B
negative	I
T	I
cell	I
lines	I
fail	O
to	O
be	O
stimulated	O
with	O
gp160	O
.	O

Immunoprecipitation	O
of	O
the	O
gp	O
160	O
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	O
antibodies	O
to	O
Fos	O
and	O
Jun	O
proteins	O
indicates	O
that	O
AP-1	O
complex	O
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160-induced	O
AP-1	O
complex	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis	O
-	O
independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	O
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	O
cells	O
:	O
pre	O
-	O
treatment	O
of	O
CD4	O
+	O
T	O
cells	O
with	O
gp160	O
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti	O
-	O
CD3	O
-induced	O
interleukin-2	O
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	O
were	O
seen	O
with	O
anti	O
-	O
CD4	O
mAb	O
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	O
by	O
gp160	O
in	O
CD4	O
positive	O
T	O
cells	O
could	O
result	O
in	O
up	O
-	O
regulation	O
of	O
cytokines	O
containing	O
AP-1	O
sites	O
,	O
e.g	O
.	O
interleukin-3	O
and	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
and	O
concurrently	O
lead	O
to	O
T	O
cell	O
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	O
secretion	O
.	O

Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	O
and	O
tat	O
mutations	O
in	O
primary	O
and	O
long	O
-	O
term	O
human	O
lymphoid	O
cells	O
.	O

Tat	O
is	O
an	O
essential	O
regulatory	O
protein	O
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	O
gene	O
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	O
releases	O
an	O
elongation	O
block	O
to	O
the	O
transcription	O
of	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
when	O
Tat	O
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	O
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	O
mutants	O
,	O
including	O
two	O
stop	O
codon	O
mutants	O
and	O
one	O
deletion	O
mutant	O
using	O
replication	O
-	O
competent	O
HIV-1	O
constructs	O
carrying	O
wild	O
-	O
type	O
or	O
mutant	O
LTRs	O
with	O
modifications	O
in	O
the	O
NF	O
-	O
kappa	O
B	O
and/or	O
Sp1	O
binding	O
sites	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild	O
-	O
type	O
LTRs	O
can	O
replicate	O
in	O
HeLa	B
cells	I
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	B
cells	I
can	O
infect	O
primary	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	O
mutants	O
containing	O
wild	O
-	O
type	O
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR	O
-	O
modified	O
Tat	O
mutants	O
.	O

Large	O
amounts	O
of	O
viral	O
RNA	O
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	O
mutants	O
that	O
contain	O
modified	O
LTRs	O
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR	O
-	O
modified	O
tat	O
mutants	O
was	O
restricted	O
to	O
some	O
lymphoid	B
cell	I
lines	I
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	O
block	O
,	O
Tat	O
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full	O
-	O
length	O
HIV	O
transcripts	O
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	O
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild	O
-	O
type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	O
-virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	O
function	O
are	O
discussed	O
.	O

Expression	O
of	O
erythroid	O
-	O
specific	O
genes	O
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	O
cells	O
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	O
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid	O
-	O
specific	O
mRNAs	O
encoding	O
gamma	O
-	O
globin	O
and	O
erythroid	O
delta	O
-	O
aminolevulinate	O
synthase	O
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	O
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	O
encoding	O
GATA-1	O
and	O
GATA-2	O
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	O
blasts	O
and	O
TMD	O
blasts	O
correspond	O
to	O
the	O
erythroid	O
/	O
megakaryocytic	O
bipotential	O
progenitor	O
cells	O
.	O

Relationship	O
between	O
Rap1	O
protein	O
phosphorylation	O
and	O
regulation	O
of	O
Ca2	O
+	O
transport	O
in	O
platelets	O
:	O
a	O
new	O
approach	O
.	O

Although	O
the	O
interrelationship	O
between	O
the	O
two	O
messengers	O
Ca2	O
+	O
and	O
cyclic	O
AMP	O
in	O
platelet	O
function	O
is	O
well	O
documented	O
,	O
its	O
mechanism	O
of	O
action	O
still	O
remains	O
to	O
be	O
established	O
.	O

We	O
investigated	O
here	O
the	O
question	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca	O
(	O
2	O
+	O
)	O
-ATPases	O
by	O
cyclic	O
AMP	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	O
protein	O
using	O
a	O
pathological	O
model	O
.	O

We	O
first	O
found	O
experimental	O
conditions	O
where	O
Ca	O
(	O
2	O
+	O
)	O
-transport	O
by	O
platelet	O
membrane	O
vesicles	O
appeared	O
to	O
be	O
dependent	O
on	O
the	O
phosphorylation	O
of	O
the	O
Rap1	O
protein	O
.	O

Then	O
,	O
we	O
studied	O
platelets	O
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
for	O
their	O
expression	O
of	O
the	O
potential	O
97	O
kDa	O
Ca	O
(	O
2	O
+	O
)	O
-ATPase	O
target	O
of	O
regulation	O
through	O
the	O
Rap1	O
protein	O
as	O
well	O
as	O
the	O
phosphorylation	O
of	O
the	O
Rap1	O
protein	O
using	O
the	O
catalytic	O
subunit	O
of	O
the	O
cyclic	O
AMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
C.	O
Sub	O
.	O
)	O
.	O

In	O
the	O
first	O
patients	O
studied	O
,	O
we	O
found	O
no	O
significant	O
modification	O
in	O
the	O
expression	O
of	O
the	O
97	O
kDa	O
Ca	O
(	O
2	O
+	O
)	O
-ATPase	O
by	O
Western	O
blotting	O
using	O
the	O
PL	O
/	O
IM	O
430	O
monoclonal	O
antibody	O
which	O
specifically	O
recognized	O
this	O
isoform	O
.	O

In	O
contrast	O
,	O
the	O
Rap1	O
protein	O
was	O
differentially	O
phosphorylated	O
when	O
using	O
15	O
micrograms	O
/	O
ml	O
of	O
the	O
C.	O
Sub	O
.	O

These	O
results	O
allowed	O
us	O
to	O
use	O
these	O
pathological	O
platelets	O
to	O
study	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
Rap1	O
protein	O
and	O
the	O
regulation	O
of	O
Ca2	O
+	O
transport	O
by	O
selecting	O
a	O
patient	O
with	O
severe	O
heart	O
failure	O
.	O

We	O
could	O
show	O
a	O
decrease	O
in	O
the	O
expression	O
as	O
well	O
as	O
in	O
the	O
phosphorylation	O
of	O
Rap1	O
protein	O
and	O
demonstrate	O
a	O
lower	O
effect	O
of	O
C.	O
Sub	O
.	O
on	O
Ca2	O
+	O
transport	O
.	O

Finally	O
,	O
by	O
studying	O
a	O
further	O
series	O
of	O
patients	O
,	O
we	O
could	O
confirm	O
that	O
the	O
decrease	O
in	O
Rap1	O
protein	O
expression	O
in	O
heart	O
failure	O
,	O
whatever	O
its	O
extent	O
,	O
was	O
variable	O
,	O
and	O
could	O
strictly	O
correlate	O
the	O
expression	O
of	O
Rap1	O
protein	O
with	O
the	O
stimulatory	O
effect	O
of	O
C.	O
Sub	O
.	O
on	O
Ca2	O
+	O
transport	O
.	O

Besides	O
the	O
evidence	O
for	O
regulation	O
of	O
the	O
expression	O
of	O
the	O
Rap1	O
protein	O
in	O
platelets	O
from	O
patients	O
with	O
heart	O
failure	O
,	O
these	O
findings	O
constitute	O
a	O
new	O
approach	O
in	O
favour	O
of	O
the	O
regulation	O
of	O
platelet	O
Ca2	O
+	O
transport	O
through	O
the	O
phosphorylation	O
of	O
the	O
Rap1	O
protein	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	O
tyrosine	O
kinases	O
in	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
tax	O
protein	O
or	O
virus	B
-	I
transformed	I
cells	I
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	O
encoded	O
protein	O
tax	O
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	O
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	O
transforms	O
mouse	O
fibroblasts	O
but	O
not	O
thymocytes	O
,	O
despite	O
comparable	O
levels	O
of	O
tax	O
expression	O
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	O
protein	O
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	O
transformed	B
fibroblast	I
B	I
line	I
and	O
in	O
HTLV-1	B
transformed	I
human	I
lymphoid	I
lines	I
,	O
but	O
not	O
in	O
thymocytes	O
from	O
Thy	O
-	O
tax	O
transgenic	O
mice	O
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	O
kinase	O
specific	O
antibodies	O
,	O
identified	O
p130	O
as	O
Jak2	O
in	O
the	O
tax	O
transformed	O
mouse	B
fibroblastic	I
cell	I
line	I
and	O
Jak3	O
in	O
HTLV-1	B
transformed	I
human	I
T	I
cell	I
lines	I
.	O

Phosphorylation	O
of	O
Jak2	O
in	O
tax	B
transformed	I
cells	I
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb	B
/	I
c3T3	I
cells	I
using	O
a	O
supernatant	O
from	O
the	O
B	B
line	I
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	O
neutralizing	O
antibodies	O
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	O
kinases	O
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	O
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Disruption	O
of	O
a	O
GATA	O
motif	O
in	O
the	O
Duffy	O
gene	O
promoter	O
abolishes	O
erythroid	O
gene	O
expression	O
in	O
Duffy	O
-	O
negative	O
individuals	O
.	O

The	O
mRNA	O
for	O
the	O
Duffy	O
blood	O
group	O
antigen	O
,	O
the	O
erythrocyte	O
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	O
receptor	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	O
antigen	O
/	O
chemokine	O
receptor	O
gene	O
(	O
DARC	O
)	O
is	O
composed	O
of	O
a	O
single	O
exon	O
and	O
that	O
most	O
Duffy	O
-	O
negative	O
blacks	O
carry	O
a	O
silent	O
FY*B	O
allele	O
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	O
cells	O
by	O
disrupting	O
a	O
binding	O
site	O
for	O
the	O
GATA1	O
erythroid	O
transcription	O
factor	O
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid	O
-	O
specific	O
repression	O
of	O
the	O
DARC	O
gene	O
in	O
Duffy	O
-	O
negative	O
individuals	O
.	O

Interleukin-2	O
promoter	O
activity	O
in	O
Epstein	B
-	I
Barr	I
virus	I
-	I
transformed	I
B	I
lymphocytes	I
is	O
controlled	O
by	O
nuclear	O
factor	O
-	O
chi	O
B	O
.	O

The	O
regulation	O
of	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	O
lymphocytes	O
,	O
the	O
predominant	O
producers	O
of	O
IL-2	O
.	O

However	O
,	O
B	O
cells	O
can	O
also	O
synthesize	O
IL-2	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	O
promoter	O
activity	O
in	O
Epstein	B
-	I
Barr	I
virus	I
(	I
EBV	I
)	I
-transformed	I
B	I
cell	I
clones	I
which	O
are	O
capable	O
of	O
secreting	O
IL-2	O
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2	O
+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	O
constructs	O
with	O
multiples	O
of	O
transcription	O
factor	O
binding	O
sites	O
from	O
the	O
IL-2	O
promoter	O
[	O
distal	O
nuclear	O
factor	O
(	O
NF	O
)	O
-AT	O
,	O
proximal	O
NF	O
-	O
AT	O
,	O
AP-1	O
/	O
Octamer	O
(	O
UPS	O
)	O
or	O
NF	O
-	O
chi	O
B	O
(	O
TCEd	O
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV	B
-	I
transformed	I
B	I
clones	I
,	O
the	O
chi	O
B	O
site	O
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF	O
-	O
AT	O
binding	O
sites	O
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	B
T	I
cells	I
.	O

An	O
IL-2	O
promoter	O
bearing	O
a	O
defective	O
NF	O
-	O
chi	O
B	O
site	O
was	O
completely	O
inactive	O
in	O
EBV	B
-	I
transformed	I
B	I
cells	I
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	B
T	I
cells	I
.	O

In	O
seven	O
EBV	B
-	I
B	I
cell	I
clones	I
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	O
,	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	O
secretion	O
.	O

Similarly	O
,	O
a	O
human	O
immunodeficiency	O
virus	O
promoter	O
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	O
B	O
factors	O
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B
producing	I
EBV	I
-	I
B	I
cells	I
,	O
but	O
inactive	O
in	O
the	O
non	B
-	I
IL-2-producing	I
cells	I
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV	B
-	I
B	I
cells	I
and	O
the	O
IL-2	O
NF	O
-	O
chi	O
B	O
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	O
B	O
complexes	O
in	O
IL-2-secreting	B
cells	I
consisting	O
mainly	O
of	O
heterodimeric	O
p50	O
/	O
p65	O
complexes	O
.	O

A	O
weaker	O
chi	O
B	O
complex	O
formation	O
and	O
faster	O
-	O
migrating	O
complexes	O
were	O
detected	O
in	O
non	B
-	I
IL-2-secreting	I
cells	I
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	O
NF	O
-	O
chi	O
B	O
site	O
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
EBV	B
-	I
transformed	I
B	I
cells	I
,	O
whereas	O
other	O
transcription	O
factors	O
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	O
expression	O
in	O
these	O
cells	O
.	O

A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	O
site	O
for	O
the	O
zinc	O
finger	O
proteins	O
Sp1	O
and	O
EGR-1	O
.	O

Activation	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	O
factors	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL-2	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	O
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	O
and	O
the	O
inducible	O
early	O
growth	O
response	O
protein	O
EGR-1	O
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	O
IL-2	O
,	O
only	O
Sp1	O
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	B
IL-2	I
secreting	I
cells	I
the	O
inducible	O
EGR-1	O
protein	O
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	B
T	I
cells	I
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	O
for	O
IL-2	O
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL-2	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	O
site	O
for	O
IL-2	O
promoter	O
activity	O
.	O

Direct	O
demonstration	O
of	O
NFATp	O
dephosphorylation	O
and	O
nuclear	O
localization	O
in	O
activated	B
HT-2	I
cells	I
using	O
a	O
specific	O
NFATp	O
polyclonal	O
antibody	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
transcription	O
of	O
a	O
number	O
of	O
cytokine	O
genes	O
,	O
and	O
NFAT	O
DNA	O
binding	O
activity	O
is	O
stimulated	O
following	O
T	O
cell	O
activation	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
suggested	O
that	O
NFAT	O
is	O
a	O
substrate	O
for	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	O
phosphatase	O
.	O

Using	O
a	O
polyclonal	O
antibody	O
to	O
murine	O
NFATp	O
,	O
Western	O
blot	O
analysis	O
of	O
various	O
mouse	O
tissues	O
demonstrated	O
that	O
the	O
110	O
-	O
130-kDa	O
NFATp	O
protein	O
was	O
highly	O
expressed	O
in	O
thymus	O
and	O
spleen	O
.	O

Treatment	O
of	O
immunoprecipitated	O
NFATp	O
from	O
untreated	O
HT-2	B
cells	I
with	O
calcineurin	O
resulted	O
in	O
the	O
dephosphorylation	O
of	O
NFATp	O
,	O
demonstrating	O
that	O
NFATp	O
is	O
an	O
in	O
vitro	O
substrate	O
for	O
calcineurin	O
.	O

NFATp	O
immunoprecipitated	O
from	O
32P	B
-	I
labeled	I
HT-2	I
cells	I
migrated	O
as	O
an	O
approximately	O
120-kDa	O
protein	O
that	O
was	O
localized	O
to	O
the	O
cytosol	O
of	O
the	O
cells	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
ionomycin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
molecular	O
weight	O
of	O
NFATp	O
and	O
a	O
loss	O
of	O
32P	O
,	O
consistent	O
with	O
NFATp	O
dephosphorylation	O
.	O

The	O
dephosphorylation	O
of	O
NFATp	O
was	O
accompanied	O
by	O
localization	O
of	O
the	O
protein	O
to	O
the	O
nuclear	O
fraction	O
.	O

Both	O
of	O
these	O
events	O
were	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
FK506	O
,	O
a	O
calcineurin	O
inhibitor	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
NFATp	O
is	O
a	O
calcineurin	O
substrate	O
in	O
cells	O
.	O

Temperature	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
glucocorticoid	O
receptor	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocyte	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	O
receptor	O
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	O
receptors	O
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
leucocytes	O
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25	O
-	O
79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	O
receptors	O
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	O
receptor	O
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	O
receptor	O
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	O
receptor	O
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	O
receptor	O
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	O
receptor	O
number	O
and	O
affinity	O
.	O

N-	O
and	O
C	O
-	O
terminal	O
sequences	O
control	O
degradation	O
of	O
MAD3	O
/	O
I	O
kappa	O
B	O
alpha	O
in	O
response	O
to	O
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
inhibitory	O
protein	O
MAD3	O
/	O
I	O
kappa	O
B	O
alpha	O
in	O
response	O
to	O
extracellular	O
stimulation	O
is	O
a	O
prerequisite	O
step	O
in	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
human	O
I	O
kappa	O
B	O
alpha	O
protein	O
in	O
stable	O
transfectants	O
of	O
mouse	B
70Z	I
/	I
3	I
cells	I
shows	O
that	O
,	O
as	O
for	O
the	O
endogenous	O
murine	O
protein	O
,	O
exogenous	O
I	O
kappa	O
B	O
alpha	O
is	O
degraded	O
in	O
response	O
to	O
inducers	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
,	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
lipopolysaccharide	O
.	O

In	O
addition	O
,	O
pretreatment	O
of	O
the	O
cells	O
with	O
the	O
proteasome	O
inhibitor	O
N	O
-	O
Ac	O
-	O
Leu	O
-	O
Leu	O
-	O
norleucinal	O
inhibits	O
this	O
ligand	O
-	O
induced	O
degradation	O
and	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
,	O
stabilizes	O
a	O
hyperphosphorylated	O
form	O
of	O
the	O
human	O
I	O
kappa	O
B	O
alpha	O
protein	O
.	O

By	O
expressing	O
mutant	O
forms	O
of	O
the	O
human	O
protein	O
in	O
this	O
cell	B
line	I
,	O
we	O
have	O
been	O
able	O
to	O
delineate	O
the	O
sequences	O
responsible	O
for	O
both	O
the	O
ligand	O
-	O
induced	O
phosphorylation	O
and	O
the	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Our	O
results	O
show	O
that	O
deletion	O
of	O
the	O
C	O
terminus	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
molecule	O
up	O
to	O
amino	O
acid	O
279	O
abolishes	O
constitutive	O
but	O
not	O
ligand	O
-	O
inducible	O
phosphorylation	O
and	O
inhibits	O
ligand	O
-	O
inducible	O
degradation	O
.	O

Further	O
analysis	O
reveals	O
that	O
the	O
inducible	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
maps	O
to	O
two	O
serines	O
in	O
the	O
N	O
terminus	O
of	O
the	O
protein	O
(	O
residues	O
32	O
and	O
36	O
)	O
and	O
that	O
the	O
mutation	O
of	O
either	O
residue	O
is	O
sufficient	O
to	O
abolish	O
ligand	O
-	O
induced	O
degradation	O
,	O
whereas	O
both	O
residues	O
must	O
be	O
mutated	O
to	O
abolish	O
inducible	O
phosphorylation	O
of	O
the	O
protein	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
human	O
TCF-1	O
gene	O
encodes	O
a	O
nuclear	O
DNA	O
-	O
binding	O
protein	O
uniquely	O
expressed	O
in	O
normal	B
and	I
neoplastic	I
T	I
-	I
lineage	I
lymphocytes	I
.	O

The	O
TCF-1	O
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
affinity	O
for	O
a	O
sequence	O
motif	O
occurring	O
in	O
a	O
number	O
of	O
T	O
-	O
cell	O
enhancers	O
.	O

TCF-1	O
mRNA	O
was	O
originally	O
found	O
to	O
be	O
expressed	O
in	O
a	O
T	O
cell	O
-	O
specific	O
fashion	O
within	O
a	O
set	O
of	O
human	B
and	I
mouse	I
cell	I
lines	I
.	O

In	O
contrast	O
,	O
expression	O
reportedly	O
occurs	O
in	O
multiple	O
nonlymphoid	O
tissues	O
during	O
murine	O
embryogenesis	O
.	O

We	O
have	O
now	O
raised	O
a	O
monoclonal	O
antibody	O
to	O
document	O
expression	O
and	O
biochemistry	O
of	O
the	O
human	O
TCF-1	O
protein	O
.	O

As	O
expected	O
,	O
the	O
TCF-1	O
protein	O
was	O
detectable	O
only	O
in	O
cell	B
lines	I
of	I
T	I
lineage	I
.	O

Its	O
expression	O
was	O
always	O
restricted	O
to	O
the	O
nucleus	O
.	O

Immunohistochemistry	O
on	O
a	O
panel	O
of	O
human	O
tissues	O
revealed	O
that	O
the	O
TCF-1	O
protein	O
was	O
found	O
exclusively	O
in	O
thymocytes	O
and	O
in	O
CD3	B
+	I
T	I
cells	I
in	O
peripheral	O
lymphoid	O
tissues	O
.	O

Western	O
blotting	O
yielded	O
a	O
set	O
of	O
bands	O
ranging	O
from	O
25	O
kD	O
to	O
55	O
kD	O
,	O
resulting	O
from	O
extensive	O
alternative	O
splicing	O
.	O

The	O
TCF-1	O
protein	O
was	O
detectable	O
in	O
all	O
samples	O
of	O
a	O
set	O
of	O
22	O
T	O
-	O
cell	O
malignancies	O
of	O
various	O
stages	O
of	O
maturation	O
,	O
but	O
was	O
absent	O
from	O
a	O
large	O
number	O
of	O
other	O
hematologic	O
neoplasms	O
.	O

These	O
observations	O
imply	O
a	O
T	O
cell	O
-	O
specific	O
function	O
for	O
TCF-1	O
,	O
a	O
notion	O
corroborated	O
by	O
recent	O
observations	O
on	O
Tcf-1	O
knock	O
-	O
out	O
mice	O
.	O

In	O
addition	O
,	O
these	O
results	O
indicate	O
that	O
nuclear	O
TCF-1	O
expression	O
can	O
serve	O
as	O
a	O
pan	O
-	O
T	O
-	O
lineage	O
marker	O
in	O
the	O
diagnosis	O
of	O
lymphoid	O
malignancies	O
.	O

Constitutive	O
overexpression	O
of	O
the	O
L	O
-	O
selectin	O
gene	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
that	O
can	O
be	O
transactivated	O
by	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax	O
.	O

L	O
-	O
selectin	O
is	O
an	O
adhesion	O
molecule	O
of	O
the	O
selectin	O
family	O
that	O
mediates	O
the	O
initial	O
step	O
of	O
leukocyte	O
adhesion	O
to	O
vascular	O
endothelium	O
.	O

Upon	O
cellular	O
activation	O
,	O
expression	O
of	O
the	O
L	O
-	O
selectin	O
gene	O
is	O
downregulated	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
leukemic	O
cell	O
infiltration	O
into	O
organs	O
,	O
we	O
studied	O
the	O
expression	O
and	O
regulation	O
of	O
L	O
-	O
selectin	O
mRNA	O
in	O
fresh	O
leukemic	O
cells	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
patients	O
and	O
investigated	O
the	O
response	O
of	O
the	O
L	O
-	O
selectin	O
promoter	O
to	O
human	O
T	O
-	O
cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	O
,	O
which	O
is	O
a	O
viral	O
transcriptional	O
transactivator	O
.	O

Flow	O
cytometry	O
showed	O
that	O
L	O
-	O
selectin	O
was	O
expressed	O
on	O
fresh	O
ATL	B
cells	I
along	O
with	O
other	O
activation	O
antigens	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
ATL	B
cells	I
overexpressed	O
that	O
L	O
-	O
selectin	O
mRNA	O
and	O
that	O
the	O
level	O
was	O
aberrantly	O
upregulated	O
after	O
PMA	O
stimulation	O
.	O

Studies	O
using	O
in	O
situ	O
hybridization	O
showed	O
expression	O
of	O
the	O
L	O
-	O
selectin	O
mRNA	O
in	O
the	O
infiltrating	O
leukemic	O
cells	O
in	O
the	O
liver	O
of	O
two	O
ATL	O
patients	O
.	O

Intravenous	O
injection	O
of	O
a	O
rat	B
T	I
-	I
cell	I
line	I
that	O
overexpresses	O
L	O
-	O
selectin	O
showed	O
increased	O
organ	O
infiltration	O
.	O

The	O
induction	O
of	O
Tax	O
expression	O
in	O
JPX9	B
cells	I
resulted	O
in	O
about	O
a	O
twofold	O
increase	O
in	O
the	O
mRNA	O
expression	O
levels	O
compared	O
with	O
the	O
basal	O
level	O
.	O

Chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
assay	O
after	O
transient	O
cotransfection	O
showed	O
about	O
a	O
fivefold	O
transactivation	O
of	O
the	O
L	O
-	O
selectin	O
promoter	O
by	O
Tax	O
.	O

The	O
serum	O
level	O
of	O
the	O
shed	O
form	O
of	O
L	O
-	O
selectin	O
was	O
significantly	O
increased	O
in	O
ATL	O
patients	O
(	O
mean	O
+	O
/-	O
SD	O
,	O
4	O
,	O
215.4	O
+	O
/-	O
4	O
,	O
111	O
ng	O
/	O
mL	O
)	O
compared	O
with	O
those	O
of	O
asymptomatic	O
carriers	O
and	O
healthy	O
blood	O
donors	O
(	O
mean	O
+	O
/-	O
SD	O
,	O
1	O
,	O
148.0	O
+	O
/-	O
269.0	O
ng	O
/	O
mL	O
and	O
991.9	O
+	O
/-	O
224	O
ng	O
/	O
mL	O
,	O
respectively	O
)	O
.	O

These	O
results	O
indicated	O
that	O
ATL	B
cells	I
constitutively	O
overexpress	O
the	O
L	O
-	O
selectin	O
gene	O
that	O
can	O
be	O
transactivated	O
by	O
HTLV-1	O
Tax	O
.	O

The	O
overexpression	O
of	O
L	O
-	O
selectin	O
,	O
as	O
well	O
as	O
of	O
inflammatory	O
cytokines	O
,	O
by	O
ATL	B
cells	I
may	O
provide	O
a	O
basis	O
for	O
ATL	B
cells	I
to	O
attach	O
the	O
vascular	O
endothelium	O
,	O
leading	O
to	O
transmigration	O
and	O
organ	O
infitration	O
.	O

Tissue	O
-	O
specific	O
regulation	O
of	O
the	O
rabbit	O
15-lipoxygenase	O
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O

The	O
15-lipoxygenase	O
(	O
lox	O
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15-lox	O
gene	O
contains	O
sequences	O
which	O
down	O
-	O
regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non	B
-	I
erythroid	I
cell	I
lines	I
but	O
not	O
in	O
two	O
erythroid	B
cell	I
lines	I
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'	O
silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non-	O
erythroid	O
cells	O
but	O
not	O
in	O
erythroid	O
cells	O
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue	O
-	O
specific	O
down	O
-	O
regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	O
promoter	O
fragment	O
.	O

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O

Mutually	O
exclusive	O
interaction	O
of	O
a	O
novel	O
matrix	O
attachment	O
region	O
binding	O
protein	O
and	O
the	O
NF	O
-	O
muNR	O
enhancer	O
repressor	O
.	O

Implications	O
for	O
regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
expression	O
.	O

The	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
intronic	O
enhancer	O
stimulates	O
transcription	O
from	O
functional	O
promoters	O
in	O
B	O
lymphocytes	O
but	O
not	O
other	O
cell	O
types	O
.	O

The	O
observation	O
that	O
binding	O
sites	O
for	O
the	O
nuclear	O
factor	O
-	O
mu	O
negative	O
regulator	O
(	O
NF	O
-	O
muNR	O
)	O
enhancer	O
repressor	O
overlap	O
nuclear	O
matrix	O
attachment	O
regions	O
(	O
MARs	O
)	O
in	O
this	O
enhancer	O
has	O
lead	O
to	O
the	O
hypothesis	O
that	O
the	O
cell	O
type	O
specificity	O
of	O
the	O
enhancer	O
might	O
be	O
controlled	O
by	O
regulating	O
nuclear	O
matrix	O
attachment	O
(	O
Scheuermann	O
,	O
R.	O
H.	O
,	O
and	O
Chen	O
,	O
U.	O
(	O
1989	O
)	O
Genes	O
&	O
Dev	O
.	O
3	O
,	O
1255	O
-	O
1266	O
)	O
.	O

To	O
understand	O
the	O
role	O
of	O
MARs	O
in	O
IgH	O
enhancer	O
regulation	O
,	O
we	O
have	O
identified	O
a	O
novel	O
MAR	O
-	O
binding	O
protein	O
,	O
MAR	O
-	O
BP1	O
,	O
from	O
soluble	O
nuclear	O
matrix	O
preparations	O
based	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
MARs	O
associated	O
with	O
the	O
IgH	O
enhancer	O
.	O

Purified	O
MAR	O
-	O
BP1	O
migrates	O
as	O
a	O
33-kDa	O
protein	O
,	O
and	O
it	O
can	O
be	O
found	O
in	O
nuclear	O
matrix	O
preparations	O
from	O
a	O
number	O
of	O
different	O
types	O
of	O
lymphoid	B
cell	I
lines	I
.	O

Although	O
specific	O
binding	O
sites	O
have	O
been	O
difficult	O
to	O
localize	O
by	O
chemical	O
or	O
enzymatic	O
footprinting	O
procedures	O
,	O
NF	O
-	O
muNR	O
binding	O
sites	O
are	O
critical	O
for	O
efficient	O
MAR	O
-	O
BP1	O
binding	O
.	O

Indeed	O
,	O
binding	O
of	O
the	O
IgH	O
enhancer	O
to	O
either	O
intact	O
nuclear	O
matrix	O
preparations	O
or	O
to	O
MAR	O
-	O
BP1	O
is	O
mutually	O
exclusive	O
to	O
NF	O
-	O
muNR	O
binding	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
model	O
for	O
cell	O
-	O
type	O
specific	O
regulation	O
in	O
which	O
binding	O
of	O
the	O
NF	O
-	O
muNR	O
repressor	O
to	O
the	O
IgH	O
enhancer	O
prevents	O
nuclear	O
matrix	O
attachment	O
in	O
inappropriate	O
cells	O
by	O
interfering	O
with	O
MAR	O
-	O
BP1	O
/enhancer	O
interaction	O
.	O

Identification	O
of	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
within	O
the	O
promoter	O
of	O
the	O
platelet	O
glycoprotein	O
Ib	O
alpha	O
gene	O
.	O

Platelet	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
-	O
IX	O
-	O
V	O
is	O
a	O
multisubunit	O
adhesion	O
receptor	O
that	O
supports	O
platelet	O
attachment	O
to	O
thrombogenic	O
surfaces	O
at	O
sites	O
of	O
vascular	O
injury	O
.	O

The	O
congenital	O
absence	O
of	O
the	O
receptor	O
results	O
in	O
a	O
bleeding	O
disorder	O
associated	O
with	O
`	O
`	O
giant	O
''	O
platelets	O
,	O
a	O
condition	O
linking	O
the	O
expression	O
of	O
the	O
complex	O
to	O
platelet	O
morphogenesis	O
.	O

To	O
understand	O
better	O
the	O
expression	O
of	O
the	O
GP	O
Ib	O
-	O
IX	O
-	O
V	O
complex	O
,	O
studies	O
were	O
undertaken	O
to	O
define	O
the	O
essential	O
genetic	O
elements	O
supporting	O
the	O
expression	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
complex	O
(	O
GP	O
Ib	O
alpha	O
)	O
.	O

GP	O
Ib	O
alpha	O
promoter	O
activity	O
was	O
evaluated	O
by	O
transfection	O
of	O
human	O
erythroleukemia	O
cells	O
with	O
reporter	O
plasmids	O
coding	O
for	O
the	O
enzyme	O
,	O
luciferase	O
.	O

Studies	O
were	O
initiated	O
with	O
a	O
fragment	O
extending	O
2	O
,	O
738	O
nucleotides	O
5	O
'	O
to	O
the	O
transcription	O
start	O
site	O
and	O
lead	O
to	O
the	O
identification	O
of	O
253	O
nucleotides	O
retaining	O
full	O
promoter	O
activity	O
in	O
human	O
erythroleukemia	O
cells	O
.	O

In	O
cells	O
of	O
nonhematopoietic	O
lineage	O
,	O
human	O
endothelial	O
and	O
HeLa	O
cells	O
,	O
the	O
GP	O
Ib	O
alpha	O
promoter	O
activity	O
was	O
no	O
greater	O
than	O
background	O
levels	O
obtained	O
with	O
promoterless	O
constructs	O
.	O

Gel	O
shift	O
assays	O
and	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
defined	O
essential	O
GATA	O
and	O
Ets	O
binding	O
motifs	O
93	O
and	O
150	O
nucleotides	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
,	O
a	O
finding	O
which	O
further	O
substantiates	O
these	O
elements	O
as	O
important	O
determinants	O
of	O
megakaryocytic	O
gene	O
expression	O
.	O

The	O
results	O
define	O
essential	O
cis	O
-	O
acting	O
elements	O
responsible	O
for	O
the	O
expression	O
of	O
GP	O
Ib	O
alpha	O
and	O
provide	O
insights	O
into	O
molecular	O
events	O
coinciding	O
with	O
the	O
release	O
of	O
normal	O
platelets	O
into	O
the	O
bloodstream	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
through	O
induction	O
of	O
I	O
kappa	O
B	O
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	O
and	O
of	O
several	O
cell	O
surface	O
molecules	O
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear	O
.	O
Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
in	O
mice	O
and	O
cultured	B
cells	I
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
inactive	O
cytoplasmic	O
complexes	O
.	O

Because	O
NF	O
-	O
kappa	O
B	O
activates	O
many	O
immunoregulatory	O
genes	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

The	O
murine	O
BCL6	O
gene	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

The	O
chromosomal	O
translocation	O
involving	O
3q27	O
is	O
often	O
detected	O
in	O
human	O
B	O
-	O
cell	O
lymphomas	O
,	O
especially	O
diffuse	O
lymphomas	O
with	O
a	O
large	O
-	O
cell	O
component	O
.	O

The	O
BCL6	O
gene	O
has	O
been	O
isolated	O
from	O
the	O
chromosomal	O
breakpoint	O
in	O
these	O
lymphomas	O
.	O

Here	O
we	O
cloned	O
the	O
murine	O
BCL6	O
(	O
mBCL6	O
)	O
cDNA	O
from	O
the	O
muscle	O
cDNA	O
library	O
using	O
the	O
human	O
BCL6	O
(	O
hBCL6	O
)	O
cDNA	O
as	O
a	O
probe	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
was	O
95	O
%	O
identical	O
to	O
that	O
of	O
hBCL6	O
.	O

It	O
contains	O
six	O
repeats	O
of	O
the	O
Kruppel	O
-	O
like	O
zinc	O
-	O
finger	O
motif	O
that	O
are	O
completely	O
identical	O
to	O
those	O
of	O
hBCL6	O
,	O
indicating	O
that	O
the	O
BCL6	O
gene	O
is	O
well	O
conserved	O
between	O
humans	O
and	O
mice	O
.	O

Expression	O
of	O
the	O
mBCL6	O
gene	O
was	O
ubiquitously	O
detected	O
in	O
adult	O
mouse	O
tissues	O
including	O
lymphatic	O
organs	O
.	O

Furthermore	O
,	O
it	O
was	O
induced	O
in	O
lymphocytes	O
activated	O
with	O
phorbol	O
ester	O
and	O
Ca2	O
+	O
ionophore	O
within	O
30	O
min	O
after	O
stimulation	O
.	O

This	O
induction	O
was	O
not	O
inhibited	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
.	O

These	O
results	O
suggest	O
that	O
BCL6	O
plays	O
a	O
role	O
in	O
activated	O
lymphocytes	O
as	O
an	O
immediate	O
early	O
gene	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activity	O
,	O
and	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	O
cytokines	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water	O
-	O
soluble	O
emulsion	O
of	O
alpha	O
-	O
tocopherol	O
.	O

Alpha	O
-	O
tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF	O
-	O
kappa	O
B	O
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte	O
/	O
macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF	O
-	O
kappa	O
B	O
binding	O
and	O
an	O
increase	O
in	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
messenger	O
RNA	O
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha	O
-	O
tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF	O
-	O
kappa	O
B	O
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF	O
-	O
kappa	O
B	O
expression	O
caused	O
by	O
free	O
radical	O
production	O
/	O
oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	O
cytokine	O
synthesis	O
.	O

Triggering	O
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b	O
/	O
CD18	O
)	O
induces	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p65	O
)	O
in	O
human	O
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV	O
-	O
infected	O
monocytic	O
cells	O
.	O

Monocyte	O
/	O
macrophages	O
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	O
such	O
as	O
TNF	O
-	O
alpha	O
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF	O
-	O
alpha	O
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA	O
-	O
binding	O
heterodimer	O
NF	O
-	O
kappa	O
B	O
(	O
p50	O
/	O
p65	O
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV	O
-	O
long	O
terminal	O
repeat	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b	O
/	O
CD18	O
)	O
enhances	O
viral	O
replication	O
in	O
HIV	B
-	I
infected	I
human	I
monocytic	I
cells	I
.	O

Monocytic	B
cell	I
lines	I
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragments	O
of	O
monoclonal	O
anti	O
-	O
CR1	O
or	O
anti	O
-	O
CR3	O
Abs	O
or	O
with	O
C3	O
fragments	O
.	O

Stimulation	O
of	O
CR1	O
or	O
CR3	O
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell	O
-	O
associated	O
and	O
released	O
p24	O
Ag	O
in	O
cell	B
cultures	I
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	B
cultures	I
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	O
or	O
CR3	O
induces	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	O
/	O
p65	O
in	O
infected	O
cells	O
.	O

Translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	O
/	O
p65	O
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	O
or	O
CR3	O
of	O
uninfected	O
peripheral	O
blood	O
monocytes	O
from	O
HIV	O
-	O
seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF	O
-	O
alpha	O
.	O

TNF	O
-	O
alpha	O
did	O
not	O
mediate	O
the	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
p50	O
/	O
p65	O
induced	O
by	O
triggering	O
of	O
complement	O
receptors	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	O
monocytes	O
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement	O
-	O
opsonized	O
particles	O
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	O
receptor	O
-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
.	O

BCL-6	O
and	O
the	O
molecular	O
pathogenesis	O
of	O
B	O
-	O
cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	O
gene	O
product	O
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	O
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL-6	O
in	O
normal	O
and	O
neoplastic	O
B	O
-	O
cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL-6	O
under	O
heterologous	O
promoters	O
or	O
lacking	O
BCL-6	O
function	O
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	O
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long	O
-	O
term	O
disease	O
-	O
free	O
survival	O
(	O
Schneider	O
et	O
al.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL-6	O
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL-6	O
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	O
clone	O
with	O
sensitive	O
PCR	O
-	O
based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al.	O
1993	O
)	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	O
glucocorticoid	O
receptor	O
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95	B
-	I
8	I
lymphoid	I
cells	I
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95	O
-	O
8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0.01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	B
lymphoid	I
cell	I
line	I
(	O
HL	B
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	O
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150	O
-	O
200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	O
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95	O
-	O
8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95	O
-	O
8	O
cells	O
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	O
receptor	O
.	O

Initiation	O
binding	O
repressor	O
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:	O
735	O
]	O

Initiation	O
binding	O
repressor	O
[	O
corrected	O
]	O
(	O
IBR	O
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	O
have	O
IBR	O
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	O
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	O
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	O
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	O
and	O
IBF	O
.	O

IBR	O
is	O
a	O
503-amino	O
-	O
acid	O
-	O
long	O
acidic	O
protein	O
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF-1	O
/	O
alpha	O
-	O
Pal	O
factor	O
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	O
and	O
erected	O
wing	O
gene	O
product	O
(	O
EWG	O
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	O
and	O
IBF	O
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR	O
/	O
F	O
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA	O
-	O
binding	O
species	O
.	O

The	O
evolutionarily	O
conserved	O
N	O
-	O
terminal	O
half	O
of	O
IBR	O
/	O
F	O
harbors	O
the	O
DNA	O
-	O
binding	O
/	O
dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high	O
-	O
affinity	O
IBR	O
/	O
F	O
binding	O
sites	O
and	O
that	O
the	O
direct	O
-	O
repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth	O
-	O
related	O
metabolism	O
.	O

Correlation	O
of	O
differentiation	O
-	O
inducing	O
activity	O
of	O
retinoids	O
on	O
human	B
leukemia	I
cell	I
lines	I
HL-60	B
and	O
NB4	B
.	O

Retinoids	O
,	O
including	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
,	O
its	O
isomers	O
,	O
and	O
fifty	O
synthetic	O
retinoids	O
(	O
retinobenzoic	O
acids	O
)	O
,	O
were	O
tested	O
for	O
differentiation	O
-	O
inducing	O
activity	O
on	O
human	B
leukemia	I
cell	I
lines	I
HL-60	B
and	O
NB4	B
.	O

A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation	O
-	O
inducing	O
activity	O
towards	O
HL-60	B
cells	I
and	O
that	O
towards	O
NB4	B
cells	I
was	O
found	O
.	O

Staphylococcal	O
enterotoxins	O
modulate	O
interleukin	O
2	O
receptor	O
expression	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	O
protein	O
-	O
tyrosine	O
kinase	O
3	O
(	O
Jak3	O
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
proteins	O
)	O
.	O

Staphylococcal	O
enterotoxins	O
(	O
SE	O
)	O
stimulate	O
T	O
cells	O
expressing	O
the	O
appropriate	O
variable	O
region	O
beta	O
chain	O
of	O
(	O
V	O
beta	O
)	O
T	O
-	O
cell	O
receptors	O
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	O
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	O
cells	O
.	O

In	O
addition	O
,	O
SE	O
can	O
induce	O
an	O
interleukin-2	O
(	O
IL-2	O
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here	O
,	O
we	O
show	O
that	O
SE	O
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
beta	O
and	O
gamma	O
chains	O
(	O
IL-2R	O
beta	O
and	O
IL-2R	O
gamma	O
)	O
in	O
human	B
antigen	I
-	I
specific	I
CD4	I
+	I
T	I
-	I
cell	I
lines	I
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	O
and	O
SEB	O
,	O
the	O
expression	O
of	O
IL-2R	O
beta	O
was	O
down	O
-	O
regulated	O
,	O
IL-2R	O
gamma	O
was	O
slightly	O
up	O
-	O
regulated	O
,	O
while	O
IL-2R	O
alpha	O
remained	O
largely	O
unaffected	O
.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	O
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	O
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	O
protein	O
-	O
tyrosine	O
kinase	O
3	O
(	O
Jak3	O
)	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
called	O
Stat3	O
and	O
Stat5	O
.	O

In	O
parallel	O
experiments	O
,	O
IL-2	O
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	O
,	O
the	O
expression	O
of	O
IL-2R	O
beta	O
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	O
alpha	O
and	O
IL2R	O
gamma	O
was	O
further	O
up	O
-	O
regulated	O
,	O
and	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	O
and	O
Stat	O
proteins	O
was	O
partly	O
normalized	O
.	O

Yet	O
,	O
IL-2	O
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	O
/Stat	O
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	O
stimulation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	O
can	O
modulate	O
IL-2R	O
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak	O
/	O
Stat	O
pathway	O
in	O
CD4	B
+	I
T	I
-	I
cell	I
lines	I
.	O

IFN	O
-	O
gamma	O
priming	O
of	O
monocytes	O
enhances	O
LPS	O
-	O
induced	O
TNF	O
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	O
expression	O
in	O
monocytes	O
/	O
macrophages	O
by	O
bacterial	O
endotoxin	O
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	O
monocytes	O
.	O

Priming	O
by	O
IFN	O
-	O
gamma	O
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	O
mRNA	O
accumulation	O
.	O

IFN	O
-	O
gamma	O
pre	O
-	O
treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN	O
-	O
gamma	O
or	O
GM	O
-	O
CSF	O
,	O
but	O
not	O
M	O
-	O
CSF	O
.	O

Primed	O
monocytes	O
transcribed	O
TNF	O
mRNA	O
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	O
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	O
factor	O
-	O
kappa	O
B	O
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	O
NF	O
-	O
kappa	O
B	O
oligonucleotide	O
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	O
mRNA	O
induced	O
in	O
primed	B
cells	I
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B
cells	I
(	O
T1	O
/	O
2	O
increased	O
6	O
-	O
8-fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	O
stability	O
,	O
the	O
duration	O
of	O
mRNA	O
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	O
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H-89	O
.	O

H-89	O
substantially	O
suppressed	O
LPS	O
-	O
induced	O
TNF	O
mRNA	O
accumulation	O
in	O
unprimed	B
cells	I
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B
monocytes	I
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Prolactin	O
and	O
interleukin-2	O
receptors	O
in	O
T	O
lymphocytes	O
signal	O
through	O
a	O
MGF	O
-	O
STAT5-like	O
transcription	O
factor	O
.	O

The	O
cell	O
surface	O
receptors	O
for	O
PRL	O
and	O
interleukin-2	O
(	O
IL-2	O
)	O
are	O
structurally	O
distinct	O
,	O
but	O
share	O
regulatory	O
tasks	O
in	O
T	O
lymphocytes	O
.	O

They	O
can	O
stimulate	O
proliferation	O
and	O
activate	O
transcription	O
of	O
over	O
-	O
lapping	O
sets	O
of	O
genes	O
of	O
T	O
cells	O
.	O

PRL	O
and	O
IL-2	O
receptor	O
activation	O
are	O
both	O
linked	O
to	O
the	O
Jak	O
/	O
Stat	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
pathway	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
PRL	O
and	O
IL-2	O
to	O
activate	O
Stat	O
proteins	O
in	O
different	O
T	B
cell	I
lines	I
.	O

The	O
DNA	O
binding	O
specificities	O
,	O
the	O
reactivities	O
toward	O
Stat	O
-	O
specific	O
antisera	O
,	O
and	O
the	O
mol	O
wt	O
of	O
IL-2	O
-and	O
PRL	O
-	O
induced	O
DNA	O
-	O
binding	O
proteins	O
in	O
Nb2	B
and	I
C196	I
T	I
cell	I
lines	I
were	O
investigated	O
.	O

A	O
comparison	O
with	O
the	O
Stat	O
proteins	O
induced	O
by	O
interferon	O
-	O
gamma	O
,	O
PRL	O
,	O
and	O
IL-6	O
in	O
T47D	B
mammary	I
tumor	I
cells	I
was	O
made	O
.	O

We	O
found	O
that	O
these	O
parameters	O
were	O
indistinguishable	O
for	O
one	O
of	O
the	O
PRL-	O
and	O
IL-2-induced	O
factors	O
.	O

A	O
transcription	O
factor	O
closely	O
related	O
to	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
is	O
rapidly	O
activated	O
upon	O
interaction	O
of	O
IL-2	O
and	O
PRL	O
with	O
their	O
respective	O
receptors	O
.	O

Activation	O
of	O
a	O
second	O
protein	O
related	O
to	O
Stat1	O
was	O
also	O
observed	O
.	O

Our	O
results	O
emphasize	O
the	O
role	O
of	O
PRL	O
as	O
a	O
regulator	O
of	O
the	O
immune	O
response	O
and	O
indicate	O
that	O
the	O
Stat	O
factors	O
mammary	O
gland	O
factor	O
-	O
Stat5	O
and	O
Stat1	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
T	O
cell	O
development	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide	O
-	O
induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	O
Factor	O
VII	O
/	O
VIIa	O
to	O
the	O
tissue	O
factor	O
(	O
TF	O
)	O
receptor	O
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	O
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	O
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	O
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	B
THP-1	I
cells	I
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS	O
-	O
induced	O
proteolytic	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	O
inhibit	O
LPS	O
induction	O
of	O
the	O
TF	O
gene	O
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c	O
-	O
fos	O
in	O
B	B
and	I
T	I
cell	I
lines	I
:	O
implication	O
for	O
c	O
-	O
fos	O
control	O
via	O
surface	O
immunoglobulin	O
and	O
T	O
cell	O
antigen	O
receptors	O
.	O

Expression	O
of	O
the	O
protooncogene	O
c	O
-	O
fos	O
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	O
C	O
,	O
cAMP	O
,	O
and	O
calcium	O
.	O

Kinase	O
C	O
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
which	O
interacts	O
with	O
the	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	O
(	O
cAMP	O
regulatory	O
element	O
binding	O
protein	O
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	O
kinase	O
A	O
or	O
calmodulin	O
-	O
regulated	O
kinase	O
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	B
's	I
lymphoma	I
cells	I
(	O
Ramos	B
and	O
Daudi	B
)	O
as	O
well	O
as	O
a	O
T	B
lymphocytic	I
cell	I
line	I
(	O
Jurkat	B
)	O
.	O

We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c	O
-	O
fos	O
induction	O
.	O

However	O
,	O
kinase	O
C	O
activation	O
(	O
PMA	O
stimulation	O
)	O
combined	O
with	O
either	O
cAMP	O
(	O
forskolin	O
plus	O
MIX	O
)	O
or	O
calcium	O
stimulation	O
(	O
ionophore	O
)	O
leads	O
to	O
greatly	O
enhanced	O
c	O
-	O
fos	O
induction	O
.	O

By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c	O
-	O
fos	O
induction	O
.	O

Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium	O
-	O
mediated	O
activation	O
of	O
c	O
-	O
fos	O
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

The	O
main	O
difference	O
between	O
Ramos	B
(	O
B	O
cells	O
)	O
and	O
Jurkat	B
(	O
T	O
cells	O
)	O
in	O
the	O
regulation	O
of	O
c	O
-	O
fos	O
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	B
and	O
is	O
without	O
effect	O
in	O
Ramos	B
.	O

Analysis	O
of	O
AP-1	O
activity	O
using	O
gel	O
mobility	O
shift	O
assays	O
confirms	O
that	O
the	O
requirements	O
for	O
synergy	O
in	O
c	O
-	O
fos	O
mRNA	O
induction	O
are	O
paralleled	O
by	O
requirements	O
for	O
synergy	O
in	O
induction	O
of	O
AP-1	O
activity	O
.	O

Signaling	O
in	O
B	O
cells	O
due	O
to	O
anti	O
-	O
Ig	O
stimulation	O
involves	O
both	O
kinase	O
C	O
activation	O
and	O
release	O
of	O
intracellular	O
calcium	O
,	O
and	O
results	O
in	O
c	O
-	O
fos	O
mRNA	O
induction	O
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	O
C	O
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c	O
-	O
fos	O
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c	O
-	O
fos	O
well	O
.	O

That	O
synergy	O
of	O
signaling	O
pathways	O
is	O
relevant	O
for	O
the	O
anti	O
-	O
Ig	O
induction	O
of	O
c	O
-	O
fos	O
is	O
supported	O
by	O
the	O
fact	O
that	O
cAMP	O
-	O
inducing	O
agents	O
and	O
okadaic	O
acid	O
further	O
enhance	O
anti	O
-	O
Ig	O
induction	O
of	O
c	O
-	O
fos	O
.	O

These	O
results	O
suggest	O
that	O
cell	O
-	O
specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c	O
-	O
fos	O
induction	O
and	O
may	O
be	O
relevant	O
for	O
c	O
-	O
fos	O
control	O
through	O
B	O
and	O
T	O
cell	O
antigen	O
receptors	O
.	O

Anti	O
-	O
immunoglobulin	O
M	O
activates	O
nuclear	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
in	O
human	O
B	O
lymphocytes	O
.	O

We	O
and	O
others	O
have	O
previously	O
shown	O
that	O
the	O
nuclear	O
protein	O
,	O
Ets-1	O
,	O
is	O
phosphorylated	O
in	O
a	O
calcium	O
-	O
dependent	O
manner	O
after	O
ligation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
M	O
on	O
B	O
lymphocytes	O
.	O

As	O
this	O
phosphorylation	O
was	O
independent	O
of	O
protein	O
kinase	O
C	O
activity	O
,	O
we	O
tested	O
whether	O
a	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
(	O
CaM	O
kinase	O
)	O
might	O
phosphorylate	O
the	O
Ets-1	O
protein	O
after	O
elevation	O
of	O
intracellular	O
free	O
calcium	O
concentrations	O
.	O

The	O
dephosphorylated	O
form	O
of	O
Ets-1	O
has	O
been	O
shown	O
to	O
bind	O
to	O
chromatin	O
,	O
suggesting	O
that	O
the	O
operative	O
kinase	O
should	O
be	O
detectable	O
in	O
the	O
nucleus	O
.	O

We	O
prepared	O
nuclear	O
extracts	O
from	O
two	O
human	B
B	I
cell	I
lines	I
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
levels	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
the	O
Ets-1	O
protein	O
.	O

Activity	O
of	O
the	O
CaM	O
kinases	O
was	O
determined	O
using	O
a	O
synthetic	O
peptide	O
substrate	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
inhibitor	O
specific	O
for	O
the	O
CaM	O
kinase	O
family	O
,	O
KN-62	O
.	O

Stimulation	O
of	O
cells	O
with	O
anti	O
-	O
IgM	O
led	O
to	O
increased	O
activity	O
of	O
a	O
nuclear	O
kinase	O
that	O
could	O
phosphorylate	O
the	O
peptide	O
,	O
and	O
this	O
activity	O
was	O
reduced	O
by	O
10	O
microM	O
KN-62	O
.	O

Kinase	O
activity	O
was	O
reduced	O
in	O
lysates	O
preadsorbed	O
using	O
an	O
antibody	O
specific	O
for	O
CaM	O
kinase	O
II	O
.	O

Two	O
-	O
dimensional	O
phosphopeptide	O
maps	O
of	O
the	O
Ets-1	O
protein	O
from	O
cells	O
incubated	O
with	O
ionomycin	O
or	O
anti	O
-	O
IgM	O
contained	O
two	O
unique	O
phosphopeptides	O
that	O
were	O
absent	O
in	O
untreated	O
cells	O
.	O

Incubation	O
of	O
isolated	O
Ets-1	O
protein	O
with	O
purified	O
CaM	O
kinase	O
II	O
produced	O
phosphorylation	O
of	O
peptides	O
that	O
migrated	O
identically	O
to	O
those	O
found	O
in	O
cells	O
incubated	O
with	O
either	O
anti	O
-	O
IgM	O
or	O
ionomycin	O
.	O

These	O
data	O
suggest	O
a	O
model	O
of	O
signal	O
transduction	O
by	O
the	O
antigen	O
receptor	O
on	O
B	O
lymphocytes	O
in	O
which	O
increased	O
intracellular	O
free	O
calcium	O
can	O
rapidly	O
activate	O
nuclear	O
CaM	O
kinase	O
II	O
,	O
potentially	O
resulting	O
in	O
phosphorylation	O
and	O
regulation	O
of	O
DNA	O
-	O
binding	O
proteins	O
.	O

Cross	O
-	O
linking	O
of	O
Fc	O
gamma	O
receptors	O
activates	O
HIV-1	O
long	O
terminal	O
repeat	O
-driven	O
transcription	O
in	O
human	O
monocytes	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	O
immune	O
complexes	O
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross	O
-	O
linking	O
of	O
Fc	O
gamma	O
RI	O
or	O
Fc	O
gamma	O
RII	O
by	O
adherent	O
human	O
IgG	O
or	O
by	O
specific	O
anti	O
-	O
Fc	O
gamma	O
R	O
mAb	O
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	B
monocytic	I
cell	I
line	I
BF24	B
and	O
increased	O
HIV	O
RNA	O
expression	O
in	O
monocytes	O
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

In	O
THP-1	B
cells	I
,	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
induced	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O
Anti	O
-	O
TNF	O
-	O
alpha	O
antibody	O
but	O
not	O
anti	O
-	O
IL-1	O
beta	O
antibody	O
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-	O
LTR	O
-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
Fc	O
gamma	O
R	O
cross	O
-	O
linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	O
gamma	O
R	O
can	O
mediate	O
a	O
TNF	O
-	O
alpha	O
-dependent	O
induction	O
of	O
HIV-1	O
gene	O
transcription	O
and	O
suggest	O
that	O
immune	O
complexes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	O
.	O

E2F-1	O
blocks	O
terminal	O
differentiation	O
and	O
causes	O
proliferation	O
in	O
transgenic	O
megakaryocytes	O
.	O

The	O
transcription	O
factor	O
E2F-1	O
plays	O
a	O
central	O
role	O
in	O
the	O
cell	O
cycle	O
through	O
its	O
ability	O
to	O
activate	O
genes	O
involved	O
in	O
cell	O
division	O
.	O

E2F-1	O
activity	O
is	O
regulated	O
by	O
a	O
number	O
of	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
,	O
cyclin	O
-	O
dependent	O
kinases	O
,	O
and	O
their	O
inhibitors	O
,	O
proteins	O
that	O
have	O
been	O
implicated	O
in	O
the	O
control	O
of	O
certain	O
developmental	O
processes	O
.	O

To	O
investigate	O
a	O
potential	O
role	O
of	O
E2F-1	O
in	O
differentiation	O
,	O
we	O
assayed	O
the	O
ability	O
of	O
megakaryocytes	O
to	O
form	O
platelets	O
in	O
an	O
in	O
vivo	O
transgenic	O
model	O
.	O

E2F-1	O
expression	O
in	O
megakaryocytes	O
blocked	O
differentiation	O
during	O
maturation	O
,	O
resulting	O
in	O
severe	O
thrombocytopenia	O
.	O

Ultrastructural	O
analysis	O
of	O
megakaryocytes	O
revealed	O
abnormal	O
development	O
characterized	O
by	O
hyperdemarcation	O
of	O
cytoplasmic	O
membranes	O
and	O
reduced	O
numbers	O
of	O
alpha	O
granules	O
.	O

Administration	O
of	O
megakaryocyte	O
growth	O
and	O
development	O
factor	O
or	O
interleukin	O
6	O
could	O
not	O
overcome	O
the	O
differentiation	O
block	O
.	O

Additionally	O
,	O
E2F-1	O
caused	O
massive	O
megakaryocyte	O
accumulation	O
in	O
both	O
normal	O
and	O
ectopic	O
sites	O
,	O
first	O
evident	O
in	O
E15	O
embryonic	O
liver	O
.	O

Furthermore	O
,	O
significant	O
apoptosis	O
was	O
observed	O
in	O
transgenic	O
megakaryocytes	O
.	O

These	O
data	O
indicate	O
that	O
E2F-1	O
can	O
prevent	O
terminal	O
differentiation	O
,	O
probably	O
through	O
its	O
cell	O
cycle	O
-	O
stimulatory	O
activity	O
.	O

Identification	O
of	O
an	O
ionomycin	O
/	O
cyclosporin	O
A	O
-	O
responsive	O
element	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
enhancer	O
.	O

Activation	O
through	O
the	O
Ca2+	O
/	O
calcineurin	O
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	O
genes	O
.	O

The	O
conserved	O
cis	O
-	O
acting	O
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	O
factors	O
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2	O
+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non	O
-	O
cytokine	O
gene	O
,	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
(	O
TCRG	O
)	O
enhancer	O
.	O

Results	O
from	O
site	O
-	O
directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin	O
-	O
induced	O
activation	O
of	O
the	O
TCRG	O
enhancer	O
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	O
mRNA	O
levels	O
,	O
but	O
not	O
mRNA	O
levels	O
for	O
T	O
cell	O
receptor	O
alpha	O
and	O
-beta	O
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Thrombopoietin	O
induces	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
Stat5	O
in	O
human	O
blood	O
platelets	O
.	O

Thrombopoietin	O
is	O
known	O
to	O
be	O
essential	O
for	O
megakaryocytopoiesis	O
and	O
thrombopoiesis	O
.	O

Recently	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
thrombopoietin	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
Jak2	O
and	O
other	O
proteins	O
in	O
human	O
platelets	O
and	O
BaF3	B
cells	I
,	O
genetically	O
engineered	O
to	O
express	O
c	O
-	O
Mpl	O
,	O
a	O
receptor	O
for	O
thrombopoietin	O
.	O

The	O
Jak	O
family	O
of	O
tyrosine	O
kinases	O
are	O
known	O
to	O
mediate	O
some	O
of	O
the	O
effects	O
of	O
cytokines	O
or	O
hematopoietic	O
growth	O
factors	O
by	O
recruitment	O
and	O
tyrosine	O
phosphorylation	O
of	O
a	O
variety	O
of	O
Stat	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Hence	O
,	O
we	O
have	O
investigated	O
whether	O
Stat	O
proteins	O
are	O
present	O
in	O
platelets	O
and	O
,	O
if	O
so	O
,	O
whether	O
they	O
become	O
tyrosine	O
phosphorylated	O
in	O
response	O
to	O
thrombopoietin	O
.	O

We	O
immunologically	O
identified	O
Stat1	O
,	O
Stat2	O
,	O
Stat3	O
,	O
and	O
Stat5	O
in	O
human	O
platelet	O
lysates	O
.	O

Thrombopoietin	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
Stat5	O
in	O
these	O
cells	O
.	O

Thrombopoietin	O
also	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Stat3	O
and	O
Stat5	O
in	O
FDCP-2	B
cells	I
genetically	O
engineered	O
to	O
constitutively	O
express	O
human	O
c	O
-	O
Mpl	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
that	O
Stat3	O
and	O
Stat5	O
may	O
be	O
involved	O
in	O
signal	O
transduction	O
after	O
ligand	O
binding	O
to	O
c	O
-	O
Mpl	O
and	O
that	O
this	O
event	O
may	O
have	O
a	O
role	O
in	O
megakaryopoiesis	O
/	O
thrombopoiesis	O
or	O
possibly	O
a	O
mature	O
platelet	O
function	O
such	O
as	O
aggregation	O
.	O

Inhibition	O
of	O
lipopolysaccharide	O
-	O
induced	O
monocyte	O
interleukin-1	O
receptor	O
antagonist	O
synthesis	O
by	O
cortisol	O
:	O
involvement	O
of	O
the	O
mineralocorticoid	O
receptor	O
.	O

Glucocorticoids	O
,	O
as	O
a	O
part	O
of	O
their	O
physiological	O
role	O
in	O
the	O
control	O
of	O
inflammatory	O
and	O
immune	O
processes	O
,	O
suppress	O
the	O
expression	O
of	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
other	O
cytokines	O
.	O

Human	O
monocyte	O
IL-1	O
receptor	O
antagonist	O
(	O
IL-1ra	O
)	O
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
expression	O
and	O
protein	O
secretion	O
are	O
inhibited	O
by	O
dexamethasone	O
.	O

We	O
have	O
now	O
further	O
studied	O
the	O
regulation	O
of	O
IL-1ra	O
by	O
the	O
major	O
physiological	O
human	O
glucocorticoid	O
,	O
cortisol	O
.	O

We	O
found	O
that	O
cortisol	O
incubation	O
induced	O
a	O
decrease	O
in	O
IL-1ra	O
mRNA	O
expression	O
and	O
a	O
significant	O
inhibition	O
of	O
IL-1ra	O
protein	O
secretion	O
in	O
cell	O
cultures	O
of	O
human	O
peripheral	O
monocytes	O
stimulated	O
with	O
the	O
bacterial	O
endotoxin	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Oral	O
administration	O
of	O
276	O
mumol	O
cortisol	O
to	O
normal	O
subjects	O
also	O
decreased	O
LPS	O
-	O
induced	O
IL-1ra	O
synthesis	O
in	O
cultured	B
monocytes	I
.	O

By	O
coincubating	O
the	O
monocytes	O
with	O
either	O
the	O
mineralocorticoid	O
antagonist	O
spironolactone	O
or	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
38486	O
,	O
the	O
in	O
vitro	O
cortisol	O
-	O
induced	O
inhibition	O
of	O
LPS	O
-	O
stimulated	O
IL-1ra	O
secretion	O
was	O
partially	O
reversed	O
.	O

The	O
mineralocorticoid	O
aldosterone	O
exerted	O
a	O
significant	O
decrease	O
in	O
LPS	O
-	O
induced	O
monocyte	O
IL-1ra	O
secretion	O
in	O
vitro	O
,	O
which	O
was	O
blocked	O
by	O
coincubation	O
with	O
spironolactone	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
mineralocorticoid	O
receptor	O
mRNA	O
in	O
human	O
monocytes	O
was	O
observed	O
by	O
PCR	O
of	O
reversed	O
transcribed	O
RNA	O
.	O

Our	O
results	O
further	O
indicate	O
that	O
corticosteroids	O
physiologically	O
control	O
the	O
IL-1	O
/	O
IL-1ra	O
system	O
during	O
inflammatory	O
or	O
immune	O
processes	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
a	O
glucocorticoid	O
receptor	O
-mediated	O
effect	O
,	O
the	O
mineralocorticoid	O
receptor	O
is	O
involved	O
in	O
the	O
inhibition	O
of	O
monocyte	O
IL-1ra	O
secretion	O
by	O
cortisol	O
.	O

HIV	O
glycoprotein	O
120	O
enhances	O
intercellular	O
adhesion	O
molecule-1	O
gene	O
expression	O
in	O
glial	O
cells	O
.	O

Involvement	O
of	O
Janus	O
kinase	O
/signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
and	O
protein	O
kinase	O
C	O
signaling	O
pathways	O
.	O

It	O
is	O
well	O
established	O
that	O
the	O
two	O
major	O
glial	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
astrocytes	O
and	O
microglia	O
,	O
are	O
key	O
participants	O
in	O
mediating	O
the	O
neurologic	O
dysfunction	O
associated	O
with	O
HIV	O
infection	O
of	O
the	O
CNS	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
the	O
major	O
envelope	O
glycoprotein	O
of	O
HIV	O
,	O
glycoprotein	O
120	O
(	O
gp120	O
)	O
,	O
to	O
regulate	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
expression	O
in	O
glial	O
cells	O
,	O
because	O
ICAM-1	O
is	O
important	O
in	O
mediating	O
immune	O
responsiveness	O
in	O
the	O
CNS	O
,	O
facilitating	O
entry	O
of	O
HIV	O
-	O
infected	O
cells	O
into	O
the	O
CNS	O
,	O
and	O
promoting	O
syncytia	O
formation	O
.	O

Our	O
results	O
indicate	O
that	O
gp120	O
enhances	O
ICAM-1	O
gene	O
expression	O
in	O
primary	O
rat	O
astrocytes	O
,	O
primary	O
human	O
astrocytes	O
,	O
a	O
human	B
astroglioma	I
cell	I
line	I
CRT	I
,	O
and	O
primary	O
rat	O
microglia	O
.	O

The	O
signal	O
transduction	O
events	O
involved	O
in	O
gp120	O
-mediated	O
enhancement	O
of	O
ICAM-1	O
appear	O
to	O
involve	O
activation	O
of	O
both	O
protein	O
kinase	O
C	O
and	O
tyrosine	O
kinase	O
,	O
because	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
and	O
tyrosine	O
kinase	O
abrogate	O
gp120	O
-mediated	O
ICAM-1	O
expression	O
in	O
both	O
astrocytes	O
and	O
microglia	O
.	O

Moreover	O
,	O
gp120	O
induces	O
tyrosine	O
phosphorylation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT-1	O
alpha	O
)	O
as	O
well	O
as	O
the	O
Janus	O
kinase	O
(	O
JAK2	O
)	O
in	O
glial	O
cells	O
.	O

We	O
also	O
demonstrate	O
that	O
gp120	O
-mediated	O
ICAM-1	O
expression	O
has	O
functional	O
significance	O
,	O
as	O
it	O
enhances	O
the	O
ability	O
of	O
monocytic	O
cells	O
to	O
bind	O
to	O
gp120-stimulated	O
human	O
astrocytes	O
in	O
an	O
ICAM-1	O
/beta	O
2	O
integrin	O
-dependent	O
fashion	O
.	O

These	O
results	O
provide	O
new	O
insights	O
into	O
how	O
gp120	O
can	O
influence	O
the	O
involvement	O
of	O
glial	O
cells	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
dementia	O
complex	O
.	O

Aspirin	O
-	O
like	O
drugs	O
can	O
protect	O
human	O
T	O
lymphocytes	O
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
reductase	O
-dependent	O
mechanism	O
.	O

Benzene	O
toxicity	O
towards	O
lymphocytes	O
is	O
thought	O
to	O
be	O
mediated	O
by	O
metabolites	O
of	O
benzene	O
including	O
benzoquinone	O
(	O
BQ	O
)	O
.	O

NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
reductase	O
(	O
QR	O
)	O
is	O
known	O
to	O
protect	O
against	O
BQ	O
toxicity	O
.	O

The	O
expression	O
of	O
the	O
QR	O
gene	O
is	O
regulated	O
by	O
the	O
transcription	O
factor	O
AP-1	O
.	O

We	O
had	O
previously	O
found	O
that	O
aspirin	O
-	O
like	O
drugs	O
(	O
ALD	O
)	O
induce	O
AP-1	O
in	O
human	O
T	O
lymphocytes	O
.	O

It	O
was	O
therefore	O
hypothesized	O
that	O
ALD	O
would	O
protect	O
lymphocytes	O
against	O
BQ	O
toxicity	O
by	O
inducing	O
QR	O
.	O

Molt-4	B
cells	I
(	O
M4	B
)	O
,	O
a	O
human	B
T	I
lymphocyte	I
cell	I
line	I
,	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
two	O
ALD	O
,	O
flurbiprofen	O
and	O
sodium	O
diclofenac	O
,	O
and	O
then	O
exposed	O
to	O
BQ	O
.	O

Toxicity	O
was	O
measured	O
by	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
e.g.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ	O
-	O
treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O

ALDs	O
induced	O
QR	O
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O

The	O
protective	O
effect	O
of	O
ALD	O
was	O
significantly	O
reduced	O
by	O
dicoumarol	O
,	O
a	O
QR	O
-specific	O
inhibitor	O
.	O

Since	O
human	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
do	O
not	O
metabolize	O
arachidonic	O
acid	O
,	O
our	O
data	O
suggest	O
that	O
ALD	O
can	O
protect	O
human	O
T	O
lymphocytes	O
against	O
a	O
metabolite	O
of	O
benzene	O
by	O
induction	O
of	O
QR	O
activity	O
.	O

Translocation	O
breakpoints	O
in	O
three	O
patients	O
with	O
campomelic	O
dysplasia	O
and	O
autosomal	O
sex	O
reversal	O
map	O
more	O
than	O
130	O
kb	O
from	O
SOX9	O
.	O

Campomelic	O
dysplasia	O
(	O
CMPD1	O
)	O
and	O
autosomal	O
XY	O
sex	O
reversal	O
(	O
SRA1	O
)	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
SRY	O
-	O
related	O
gene	O
SOX9	O
on	O
17q	O
.	O

Unexpectedly	O
,	O
the	O
17q	O
breakpoints	O
in	O
four	O
CMPD1	O
translocation	O
cases	O
previously	O
analyzed	O
by	O
us	O
and	O
others	O
map	O
50	O
kb	O
or	O
more	O
from	O
SOX9	O
.	O

Here	O
,	O
we	O
present	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
data	O
from	O
a	O
new	O
CMPD1	O
/	O
SRA1	O
patient	O
with	O
t	O
(	O
6	O
;	O
17	O
)	O
(	O
q14	O
;	O
q24	O
)	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
has	O
shown	O
that	O
the	O
17q	O
breakpoint	O
in	O
this	O
case	O
maps	O
to	O
the	O
same	O
region	O
as	O
the	O
breakpoints	O
in	O
the	O
other	O
translocation	O
cases	O
,	O
at	O
least	O
130	O
kb	O
from	O
SOX9	O
.	O

Likewise	O
,	O
the	O
breakpoints	O
in	O
two	O
of	O
the	O
previously	O
described	O
cases	O
also	O
map	O
more	O
than	O
130	O
kb	O
and	O
,	O
as	O
shown	O
by	O
pulsed	O
field	O
gel	O
electrophoresis	O
analysis	O
,	O
at	O
most	O
400	O
kb	O
or	O
690	O
kb	O
from	O
SOX9	O
.	O

By	O
using	O
a	O
SOX9	O
coding	O
sequence	O
polymorphism	O
,	O
expression	O
of	O
both	O
SOX9	O
alleles	O
has	O
been	O
demonstrated	O
by	O
the	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
in	O
lymphoblastoid	O
cells	O
from	O
one	O
of	O
the	O
translocation	O
cases	O
.	O

GATA	O
transcription	O
factors	O
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	O
and	O
megakaryocytes	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	O
transcription	O
factors	O
in	O
murine	O
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

Specific	O
bright	O
foci	O
of	O
GATA-1	O
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	O
cells	O
and	O
primary	O
murine	O
erythroblasts	O
and	O
megakaryocytes	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	O
represent	O
sites	O
of	O
active	O
transcription	O
or	O
binding	O
of	O
GATA-1	O
to	O
consensus	O
sites	O
in	O
the	O
beta	O
-	O
globin	O
loci	O
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA-1	O
foci	O
seen	O
by	O
immunofluorescence	O
.	O

The	O
GATA-1	O
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	O
co	O
-	O
localization	O
with	O
nuclear	O
antigens	O
involved	O
in	O
RNA	O
processing	O
or	O
other	O
ubiquitous	O
(	O
Spl	O
,	O
c	O
-	O
Jun	O
and	O
TBP	O
)	O
or	O
haemopoietic	O
(	O
NF	O
-	O
E2	O
)	O
transcription	O
factors	O
.	O

Interestingly	O
,	O
GATA-2	O
and	O
GATA-3	O
proteins	O
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co	O
-	O
expressing	O
GATA-1	O
and	O
-2	O
or	O
GATA-1	O
and	O
-3	O
gene	O
products	O
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	O
transcription	O
factors	O
and	O
suggests	O
a	O
protein	O
-	O
protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	O
zinc	O
finger	O
domain	O
.	O

Activation	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
in	O
bacterial	O
lipopolysaccharide	O
-	O
stimulated	O
macrophages	O
.	O

Activation	O
of	O
macrophages	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
transcription	O
of	O
genes	O
that	O
encode	O
for	O
proinflammatory	O
regulators	O
of	O
the	O
immune	O
response	O
.	O

Previous	O
work	O
has	O
suggested	O
that	O
activation	O
of	O
the	O
transcription	O
factor	O
activator	O
protein	O
1	O
(	O
AP-1	O
)	O
is	O
one	O
LPS	O
-	O
induced	O
event	O
that	O
mediates	O
this	O
response	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
we	O
found	O
that	O
LPS	O
stimulated	O
AP-1	O
-mediated	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
in	O
the	O
murine	B
macrophage	I
cell	I
line	I
RAW	I
264.7	I
.	O

As	O
AP-1	O
activity	O
is	O
regulated	O
in	O
part	O
by	O
activation	O
of	O
the	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
which	O
phosphorylates	O
and	O
subsequently	O
increases	O
the	O
transcriptional	O
activity	O
of	O
c	O
-	O
Jun	O
,	O
we	O
examined	O
whether	O
LPS	O
treatment	O
of	O
macrophages	O
resulted	O
in	O
activation	O
of	O
this	O
kinase	O
.	O

LPS	O
treatment	O
of	O
RAW	B
264.7	I
cells	I
,	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
,	O
and	O
the	O
human	B
monocyte	I
cell	I
line	I
THP-1	I
resulted	O
in	O
rapid	O
activation	O
of	O
the	O
p46	O
and	O
p54	O
isoforms	O
of	O
JNK	O
.	O

Treatment	O
with	O
wild	O
-	O
type	O
and	O
rough	O
mutant	O
forms	O
of	O
LPS	O
and	O
synthetic	O
lipid	O
A	O
resulted	O
in	O
JNK	O
activation	O
,	O
while	O
pretreatment	O
with	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
A	O
inhibited	O
this	O
response	O
.	O

Binding	O
of	O
LPS-	O
LPS	O
binding	O
protein	O
(	O
LBP	O
)	O
complexes	O
to	O
CD14	O
,	O
a	O
surface	O
receptor	O
that	O
mediates	O
many	O
LPS	O
responses	O
,	O
was	O
found	O
to	O
be	O
crucial	O
,	O
as	O
pretreatment	O
of	O
THP-1	B
cells	I
with	O
the	O
monoclonal	O
antibody	O
60b	O
,	O
which	O
blocks	O
this	O
binding	O
,	O
inhibited	O
JNK	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
LPS	O
activation	O
of	O
JNK	O
in	O
monocyte	O
/	O
macrophage	O
cells	O
is	O
a	O
CD14-	O
and	O
protein	O
tyrosine	O
phosphorylation	O
-	O
dependent	O
event	O
that	O
may	O
mediate	O
the	O
early	O
activation	O
of	O
AP-1	O
in	O
regulating	O
LPS	O
-	O
triggered	O
gene	O
induction	O
.	O

IL-13	O
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	O
Janus	O
kinase	O
in	O
human	B
colon	I
carcinoma	I
cell	I
lines	I
:	O
similarities	O
between	O
IL-4	O
and	O
IL-13	O
signaling	O
.	O

We	O
have	O
recently	O
reported	O
that	O
IL-13R	O
may	O
share	O
a	O
component	O
with	O
IL-4R	O
.	O
Here	O
we	O
report	O
that	O
both	O
IL-4	O
and	O
IL-13	O
share	O
signaling	O
events	O
in	O
human	B
colon	I
carcinoma	I
cell	I
lines	I
(	O
HT-29	B
and	O
WiDr	B
)	O
.	O

IL-13	O
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	O
family	O
of	O
kinases	O
(	O
JAKs	O
)	O
.	O

We	O
show	O
that	O
JAK2	O
kinase	O
is	O
rapidly	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
IL-13	O
.	O

Within	O
1	O
min	O
of	O
activation	O
,	O
JAK2	O
was	O
phosphorylated	O
,	O
and	O
peaked	O
in	O
10	O
min	O
.	O

In	O
addition	O
,	O
IL-13	O
phosphorylated	O
insulin	O
response	O
substrate-1	O
,	O
IL-4R	O
p140	O
,	O
JAK1	O
,	O
and	O
Tyk2	O
,	O
but	O
not	O
JAK3	O
kinase	O
.	O

IL-4	O
also	O
stimulated	O
all	O
three	O
kinases	O
and	O
substrates	O
,	O
but	O
unlike	O
in	O
immune	O
cells	O
,	O
IL-4	O
did	O
not	O
involve	O
JAK3	O
activation	O
for	O
its	O
signaling	O
in	O
colon	B
cancer	I
cell	I
lines	I
.	O

Furthermore	O
,	O
JAK2	O
associated	O
with	O
the	O
IL-4R	O
p140	O
before	O
and	O
after	O
stimulation	O
with	O
IL-13	O
.	O

Both	O
IL-13	O
and	O
IL-4	O
induced	O
phosphorylation	O
of	O
IL-4	O
STAT	O
(	O
STAT6	O
)	O
but	O
not	O
STAT1	O
,	O
STAT3	O
,	O
or	O
STAT5	O
.	O

125I	O
-	O
IL-13	O
did	O
not	O
bind	O
to	O
colon	B
cancer	I
cell	I
lines	I
,	O
but	O
unlabeled	O
IL-13	O
competed	O
for	O
the	O
binding	O
of	O
125I	O
-	O
IL-4	O
.	O

Our	O
data	O
suggest	O
that	O
IL-13	O
utilizes	O
IL-4R	O
and	O
its	O
signaling	O
pathway	O
,	O
and	O
JAK2	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
IL-4R	O
and	O
IL-13R	O
in	O
colon	O
cancer	O
cells	O
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
elements	O
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF	O
-	O
kappaB	O
and/or	O
Sp1	O
binding	O
elements	O
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	O
the	O
NF	O
-	O
kappaB	O
and	O
four	O
Spl	O
binding	O
elements	O
,	O
replicated	O
with	O
wild	O
-	O
type	O
kinetics	O
and	O
to	O
a	O
wild	O
-	O
type	O
level	O
in	O
peripheral	B
blood	I
mononuclear	I
cell	I
cultures	I
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	B
cells	I
(	O
2x	O
NFKappaB	O
>	O
or	O
=	O
SlVmac239	O
approximately	O
deltaNFkappaB	O
approximately	O
deltaSpl234	O
approximately	O
substNFkappaB	O
approximately	O
substSpl2	O
approximately	O
substSp23	O
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	B
cells	I
(	O
SIVmac239	O
>	O
substSp34	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSp1	O
>	O
substSpl234	O
)	O
.	O

Reversions	O
or	O
additional	O
mutations	O
were	O
not	O
detected	O
in	O
the	O
U3	O
and	O
R	O
regions	O
of	O
proviral	O
DNA	O
from	O
CEMxl74	B
cells	I
infected	O
with	O
the	O
SIVmac239	O
mutants	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage	O
-	O
competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
CEMx174	B
cultures	I
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	O
approximately	O
substNFkappaB	O
>	O
deltaNFkappaB	O
>	O
deltaNFkappaB	O
deltaSpl234	O
approximately	O
deltaNFkappaBdeltaSpl	O
>	O
deltaSpl234	O
approximately	O
substSpl2	O
>	O
substSp23	O
approximately	O
substSp34	O
approximately	O
substSpl234	O
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	O
binding	O
sites	O
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	B
macrophage	I
cultures	I
.	O

Analysis	O
of	O
long	O
terminal	O
repeat	O
-driven	O
secreted	O
alkaline	O
phosphatase	O
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	O
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	O
region	O
just	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
sites	O
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	O
.	O

In	O
addition	O
,	O
the	O
SIV	O
TATA	O
box	O
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF	O
-	O
kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer	O
/	O
promoter	O
region	O
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto	O
-	O
differentiating	O
effects	O
on	O
acute	B
promyelocytic	I
leukemia	I
cells	I
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	B
cells	I
express	O
PML	O
-	O
RAR	O
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	O
acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
alpha	O
)	O
derived	O
from	O
the	O
leukemia	O
-	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	O
alpha	O
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	B
,	O
an	O
APL	B
-	I
derived	I
cell	I
line	I
,	O
and	O
in	O
freshly	O
isolated	O
APL	O
blasts	O
.	O

After	O
treatment	O
of	O
APL	B
cells	I
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	O
alkaline	O
phosphatase	O
,	O
CD11b	O
,	O
CD33	O
,	O
and	O
G	O
-	O
CSF	O
receptor	O
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	O
effective	O
as	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
these	O
differentiation	O
markers	O
in	O
the	O
HL-60	B
cell	I
line	I
and	O
in	O
freshly	O
isolated	O
granulocytes	O
obtained	O
from	O
the	O
peripheral	O
blood	O
of	O
chronic	O
myelogenous	O
leukemia	O
patients	O
during	O
the	O
stable	O
phase	O
of	O
the	O
disease	O
.	O

In	O
NB4	B
cells	I
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	O
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta-	O
or	O
RAR	O
gamma	O
-	O
specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML	O
-	O
RAR	O
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS-7	B
cells	I
transiently	O
transfected	O
with	O
PML	O
-	O
RAR	O
and	O
the	O
normal	O
RAR	O
alpha	O
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML	O
-	O
RAR	O
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	O
acid	O
-	O
responsive	O
element	O
-	O
containing	O
promoters	O
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	O
alpha	O
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto	O
-	O
differentiating	O
potential	O
of	O
AM580	O
in	O
PML	O
-	O
RAR	O
-	O
containing	O
leukemic	O
cells	O
.	O

An	O
element	O
upstream	O
from	O
the	O
human	O
delta	O
-	O
globin	O
-	O
encoding	O
gene	O
specifically	O
enhances	O
beta	O
-	O
globin	O
reporter	O
gene	O
expression	O
in	O
murine	O
erythroleukemia	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA	O
-	O
binding	O
factor	O
specific	O
to	O
adult	O
hematopoietic	O
cells	O
(	O
polypryrimidine	O
-	O
binding	O
factor	O
,	O
PYBF	O
)	O
binds	O
to	O
a	O
pyrimidine	O
-	O
rich	O
region	O
1	O
kb	O
upstream	O
from	O
the	O
human	O
delta	O
-	O
globin	O
-	O
encoding	O
gene	O
(	O
HBD	O
)	O
.	O

The	O
developmental	O
stage	O
-	O
specificity	O
of	O
PYBF	O
and	O
the	O
location	O
of	O
its	O
binding	O
site	O
between	O
the	O
fetal	O
and	O
adult	O
beta	O
-	O
globin	O
(	O
HBB	O
)	O
-like	O
genes	O
suggest	O
that	O
PBYF	O
and	O
its	O
binding	O
site	O
may	O
function	O
in	O
fetal	O
-	O
to	O
-	O
adult	O
globin	O
gene	O
switching	O
.	O

Here	O
,	O
we	O
describe	O
the	O
effect	O
of	O
383-bp	O
(	O
delta383	O
)	O
and	O
99-bp	O
(	O
delta99	O
)	O
sequences	O
containing	O
the	O
PYBF	O
-	O
binding	O
site	O
on	O
transcription	O
from	O
various	O
globin	O
and	O
non	O
-	O
globin	O
promoters	O
,	O
using	O
a	O
transient	O
assay	O
with	O
the	O
cat	O
reporter	O
gene	O
in	O
murine	B
erythroleukemia	I
(	I
MEL	I
)	I
cells	I
,	O
a	O
cell	O
line	O
with	O
abundant	O
PYBF	O
activity	O
.	O

We	O
show	O
that	O
both	O
delta383	O
and	O
delta99	O
specifically	O
enhance	O
expression	O
of	O
cat	O
for	O
plasmids	O
containing	O
a	O
human	O
adult	O
globin	O
(	O
HBB	O
)	O
promoter	O
,	O
whereas	O
expression	O
of	O
similar	O
constructs	O
using	O
human	O
fetal	O
(	O
A	O
gamma-	O
)	O
globin	O
(	O
HBG1	O
)	O
or	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
promoters	O
is	O
not	O
enhanced	O
.	O

The	O
results	O
suggest	O
that	O
PYBF	O
and	O
the	O
pyrimidine	O
-	O
rich	O
region	O
upstream	O
from	O
HBD	O
can	O
specifically	O
enhance	O
HBB	O
transcription	O
in	O
adult	O
erythroid	O
cells	O
.	O

cAMP	O
inducibility	O
of	O
transcriptional	O
repressor	O
ICER	O
in	O
developing	O
and	O
mature	O
human	O
T	O
lymphocytes	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jul	O
23	O
;	O
93	O
(	O
15	O
)	O
:	O
8154	O
]	O

Stimulation	O
of	O
the	O
cAMP	O
-	O
dependent	O
signaling	O
pathway	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
and	O
effector	O
functions	O
of	O
T	O
cells	O
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
form	O
high	O
intracellular	O
levels	O
of	O
cAMP	O
is	O
acquired	O
during	O
development	O
in	O
the	O
human	O
thymus	O
and	O
is	O
retained	O
by	O
the	O
majority	O
of	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
elevated	O
cAMP	O
levels	O
in	O
T	O
cells	O
correlate	O
with	O
the	O
expression	O
of	O
the	O
potent	O
transcriptional	O
repressor	O
ICER	O
(	O
inducible	O
cAMP	O
early	O
repressor	O
)	O
previously	O
described	O
in	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
axis	O
.	O

Further	O
,	O
in	O
transcriptional	O
assays	O
in	O
vivo	O
,	O
ICER	O
inhibits	O
calcineurin	O
-mediated	O
expression	O
of	O
the	O
interleukin	O
2	O
promoter	O
as	O
well	O
as	O
Tax	O
-mediated	O
transactivation	O
of	O
the	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
promoter	O
.	O

Thus	O
,	O
the	O
induction	O
of	O
ICER	O
in	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
cAMP	O
-	O
induced	O
quiescence	O
and	O
the	O
persistent	O
latency	O
of	O
HTLV	O
-	O
I	O
.	O

Second	O
messenger	O
up	O
-	O
regulation	O
of	O
androgen	O
receptor	O
gene	O
transcription	O
is	O
absent	O
in	O
androgen	B
insensitive	I
human	I
prostatic	I
carcinoma	I
cell	I
lines	I
,	O
PC-3	B
and	O
DU-145	B
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-508	O
to	O
-501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo	O
-	O
cAMP	O
,	O
AR	O
mRNA	O
was	O
upregulated	O
in	O
LNCaP	B
but	O
not	O
in	O
either	O
PC-3	B
or	O
DU-145	B
cell	I
lines	I
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR	O
-	O
CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	O
.	O

The	O
ability	O
to	O
regulate	O
AR	O
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	B
and	I
DU-145	I
cell	I
lines	I
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

Involvement	O
of	O
intracellular	O
Ca2	O
+	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
human	B
Jurkat	I
T	I
cells	I
and	O
its	O
subclone	O
Wurzburg	B
cells	I
oxidant	O
challenge	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
by	O
mobilizing	O
Ca2	O
+	O
from	O
intracellular	O
stores	O
.	O

In	O
Jurkat	B
cells	I
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	B
cells	I
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

H2O2-induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
Wurzburg	B
cells	I
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
extracellular	O
EGTA	O
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

In	O
Jurkat	B
cells	I
that	O
are	O
not	O
sensitive	O
to	O
H2O2-induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
H2O2	O
potentiated	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

NF	O
-	O
kappaB	O
regulatory	O
effect	O
of	O
alpha	O
-	O
lipoate	O
and	O
N	O
-	O
acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2	O
+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2	O
+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
new	O
variant	O
translocation	O
in	O
acute	O
promyelocytic	O
leukaemia	O
:	O
molecular	O
characterization	O
and	O
clinical	O
correlation	O
.	O

Translocation	O
t	O
(	O
15	O
;	O
17	O
)	O
(	O
q22	O
;	O
q21	O
)	O
is	O
an	O
acquired	O
clonal	O
cytogenetic	O
change	O
present	O
in	O
almost	O
all	O
cases	O
of	O
acute	O
promelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

The	O
molecular	O
genetic	O
basis	O
of	O
the	O
translocation	O
supports	O
its	O
integral	O
role	O
in	O
pathogenesis	O
.	O

We	O
describe	O
a	O
patient	O
with	O
APL	O
in	O
whom	O
the	O
leukaemic	O
clone	O
was	O
characterized	O
by	O
a	O
true	O
variant	O
of	O
the	O
classical	O
t	O
(	O
15	O
;	O
17	O
)	O
.	O

The	O
patient	O
whose	O
disease	O
had	O
numerous	O
atypical	O
clinical	O
features	O
,	O
had	O
t	O
(	O
11	O
;	O
17	O
)	O
(	O
q13	O
;	O
121	O
)	O
.	O

The	O
chromosome	O
17	O
breakpoint	O
was	O
localized	O
to	O
intron	O
2	O
of	O
RARA	O
by	O
Southern	O
blotting	O
,	O
and	O
there	O
was	O
no	O
evidence	O
at	O
the	O
molecular	O
level	O
for	O
rearrangement	O
at	O
PML	O
locus	O
.	O

These	O
data	O
,	O
along	O
with	O
previous	O
reports	O
of	O
rare	O
variant	O
translocations	O
in	O
APL	O
,	O
indicate	O
that	O
while	O
dysregulation	O
of	O
RARA	O
by	O
gene	O
fusion	O
may	O
be	O
essential	O
for	O
the	O
APL	O
phenotype	O
,	O
the	O
particular	O
fusion	O
partner	O
may	O
determine	O
clinicopathological	O
aspects	O
,	O
including	O
presentation	O
,	O
response	O
to	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
and	O
prognosis	O
.	O

This	O
heterogeneity	O
suggests	O
that	O
the	O
variant	O
fusion	O
partners	O
of	O
RARA	O
in	O
APL	O
encode	O
factors	O
with	O
properties	O
both	O
common	O
to	O
and	O
distinct	O
from	O
those	O
of	O
PML	O
.	O

Investigation	O
of	O
these	O
factors	O
promises	O
to	O
shed	O
light	O
on	O
the	O
complex	O
development	O
pathways	O
involved	O
in	O
the	O
regulation	O
of	O
haematopoiesis	O
.	O

The	O
role	O
of	O
p16	O
in	O
the	O
E2F	O
-	O
dependent	O
thymidine	O
kinase	O
regulation	O
.	O

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	O
,	O
the	O
inhibitor	O
of	O
cyclin	O
-	O
dependent	O
-	O
kinase-4	O
and	O
6	O
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
by	O
cyclin	O
-	O
dependent	O
kinases	O
4	O
and	O
6	O
prevents	O
its	O
interaction	O
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	O
kinase	O
.	O

Although	O
a	O
role	O
of	O
p16	O
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F	O
-mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	O
kinase	O
in	O
phytohemagglutinin	B
-	I
stimulated	I
normal	I
human	I
lymphocytes	I
and	O
in	O
the	O
p16-negative	B
human	I
acute	I
lymphoblastic	I
leukemia	I
cell	I
lines	I
,	O
MOLT-4	B
and	O
CEM	B
.	O

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT-4	B
and	I
CEM	I
cells	I
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	O
kinase	O
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	O
kinase	O
mRNA	O
expression	O
.	O

Transient	O
expression	O
of	O
p16	O
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	O
effect	O
on	O
the	O
cell	O
growth	O
of	O
MOLT-4	B
and	I
CEM	I
cells	I
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	O
protein	O
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	B
cell	I
lines	I
transient	O
overexpression	O
of	O
p16	O
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	O
kinase	O
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	O
protein	O
and	O
decrease	O
of	O
free	O
E2F	O
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	O
kinase	O
promoter	O
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	O
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	O
protein	O
.	O

Expression	O
of	O
A	O
-	O
myb	O
,	O
but	O
not	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
,	O
is	O
restricted	O
to	O
Burkitt	O
's	O
lymphoma	O
,	O
sIg+	O
B	O
-	O
acute	O
lymphoblastic	O
leukemia	O
,	O
and	O
a	O
subset	O
of	O
chronic	O
lymphocytic	O
leukemias	O
.	O

The	O
A	O
-	O
myb	O
gene	O
encodes	O
a	O
transcription	O
factor	O
that	O
is	O
related	O
both	O
functionally	O
and	O
structurally	O
to	O
the	O
v	O
-	O
myb	O
oncogene	O
.	O

Following	O
our	O
observations	O
that	O
A	O
-	O
myb	O
is	O
expressed	O
in	O
a	O
restricted	O
subset	O
of	O
normal	O
mature	O
human	O
B	O
lymphocytes	O
,	O
with	O
the	O
phenotype	O
CD38	O
+	O
,	O
CD39-	O
,	O
slgM-	O
,	O
we	O
have	O
now	O
investigated	O
the	O
pattern	O
of	O
A	O
-	O
myb	O
expression	O
in	O
neoplastic	O
B	O
cells	O
representating	O
the	O
whole	O
spectrum	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
compared	O
it	O
to	O
that	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
.	O

In	O
a	O
panel	O
of	O
32	O
B	B
-	I
cell	I
lines	I
,	O
A	O
-	O
myb	O
was	O
very	O
strongly	O
expressed	O
in	O
most	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
but	O
weak	O
or	O
negative	O
in	O
2	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
4	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
6	O
Epstein	B
-	I
Barr	I
virus	I
-	I
immortalized	I
lymphoblastoid	I
cell	I
lines	I
,	O
and	O
6	O
myeloma	B
lines	I
.	O

Protein	O
expression	O
paralleled	O
that	O
of	O
the	O
RNA	O
.	O

We	O
have	O
also	O
investigated	O
A	O
-	O
myb	O
expression	O
in	O
49	O
fresh	O
cases	O
of	O
B	O
leukemias	O
.	O

Among	O
24	O
ALL	O
,	O
6	O
were	O
of	O
the	O
null	O
and	O
11	O
of	O
the	O
common	O
type	O
and	O
all	O
these	O
were	O
negative	O
for	O
A	O
-	O
myb	O
expression	O
;	O
on	O
the	O
other	O
hand	O
,	O
all	O
7	O
B	O
-	O
ALL	O
cases	O
(	O
slg+	O
)	O
,	O
as	O
well	O
as	O
one	O
fresh	O
BL	O
case	O
with	O
bone	O
marrow	O
infiltration	O
,	O
expressed	O
A	O
-	O
myb	O
.	O

A	O
-	O
myb	O
was	O
undetectable	O
in	O
4	O
prolymphocytic	O
leukemias	O
(	O
PLL	O
)	O
but	O
was	O
strongly	O
expressed	O
in	O
5	O
/	O
20	O
(	O
25	O
%	O
)	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
samples	O
.	O

In	O
the	O
latter	O
A	O
-	O
myb	O
did	O
not	O
correlate	O
with	O
phenotype	O
or	O
clinical	O
stage	O
.	O

Finally	O
,	O
we	O
have	O
studied	O
the	O
progression	O
of	O
one	O
case	O
of	O
CLL	O
into	O
Richter	O
's	O
syndrome	O
and	O
have	O
found	O
that	O
the	O
Richter	B
's	I
cells	I
expressed	O
about	O
25-fold	O
less	O
A	O
-	O
myb	O
RNA	O
than	O
the	O
CLL	B
cells	I
from	O
the	O
same	O
patient	O
.	O
The	O
pattern	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
was	O
clearly	O
distinct	O
from	O
that	O
of	O
A	O
-	O
myb	O
.	O

C	O
-	O
myb	O
and	O
B	O
-	O
myb	O
were	O
expressed	O
in	O
all	O
neoplastic	O
groups	O
,	O
except	O
in	O
CLL	B
cells	I
.	O

Thus	O
,	O
A	O
-	O
myb	O
expression	O
,	O
unlike	O
that	O
of	O
c	O
-	O
myb	O
and	O
B	O
-	O
myb	O
,	O
is	O
restricted	O
to	O
a	O
subset	O
of	O
B	O
-	O
cell	O
neoplasias	O
(	O
in	O
particular	O
BL	O
and	O
slg+B	O
-	O
ALL	O
)	O
representative	O
of	O
a	O
specific	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
.	O

This	O
expression	O
may	O
in	O
part	O
reflect	O
expression	O
of	O
A	O
-	O
myb	O
by	O
the	O
normal	O
germinal	O
center	O
B	O
cells	O
that	O
are	O
the	O
normal	O
counterpart	O
of	O
these	O
transformed	B
B	I
cells	I
.	O

The	O
data	O
presented	O
strongly	O
support	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
B	O
-	O
cell	O
differentiation	O
and	O
perhaps	O
in	O
B	O
-	O
cell	O
transformation	O
in	O
some	O
neoplasias	O
.	O

C	O
-	O
terminal	O
activating	O
and	O
inhibitory	O
domains	O
determine	O
the	O
transactivation	O
potential	O
of	O
BSAP	O
(	O
Pax-5	O
)	O
,	O
Pax-2	O
and	O
Pax-8	O
.	O

Pax-5	O
encodes	O
the	O
transcription	O
factor	O
BSAP	O
which	O
plays	O
an	O
essential	O
role	O
in	O
early	O
B	O
cell	O
development	O
and	O
midbrain	O
patterning	O
.	O

In	O
this	O
study	O
we	O
have	O
analysed	O
the	O
structural	O
requirements	O
for	O
transcriptional	O
activation	O
by	O
BSAP	O
.	O

In	O
vitro	O
mutagenesis	O
and	O
transient	O
transfection	O
experiments	O
indicate	O
that	O
the	O
C	O
-	O
terminal	O
serine	O
/	O
threonine	O
/	O
proline	O
-	O
rich	O
region	O
of	O
BSAP	O
contains	O
a	O
potent	O
transactivation	O
domain	O
of	O
55	O
amino	O
acids	O
which	O
is	O
active	O
from	O
promoter	O
and	O
enhancer	O
positions	O
.	O

This	O
transactivation	O
domain	O
was	O
found	O
to	O
be	O
inactivated	O
by	O
a	O
naturally	O
occurring	O
frameshift	O
mutation	O
in	O
one	O
PAX-5	O
allele	O
of	O
the	O
acute	B
lymphoblastic	I
leukemia	I
cell	I
line	I
REH	I
.	O

The	O
function	O
of	O
the	O
transactivation	O
domain	O
is	O
negatively	O
regulated	O
by	O
adjacent	O
sequences	O
from	O
the	O
extreme	O
C	O
-	O
terminus	O
.	O

The	O
activating	O
and	O
inhibitory	O
domains	O
function	O
together	O
as	O
an	O
independent	O
regulatory	O
module	O
in	O
different	O
cell	O
types	O
as	O
shown	O
by	O
fusion	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
.	O

The	O
same	O
arrangement	O
of	O
positively	O
and	O
negatively	O
acting	O
sequences	O
has	O
been	O
conserved	O
in	O
the	O
mammalian	O
Pax-2	O
and	O
Pax-8	O
,	O
the	O
zebrafish	O
Pax	O
-	O
b	O
as	O
well	O
as	O
the	O
sea	O
urchin	O
Pax-258	O
proteins	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
transcriptional	O
competence	O
of	O
a	O
subfamily	O
of	O
Pax	O
proteins	O
is	O
determined	O
by	O
a	O
C	O
-	O
terminal	O
regulatory	O
module	O
composed	O
of	O
activating	O
and	O
inhibitory	O
sequences	O
.	O

Putative	O
steroid	O
binding	O
domain	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
,	O
expressed	O
in	O
E.	O
coli	O
in	O
the	O
presence	O
of	O
heat	O
shock	O
proteins	O
shows	O
typical	O
native	O
receptor	O
characteristics	O
.	O

Domain	O
E	O
,	O
considered	O
as	O
the	O
putative	O
hormone	O
binding	O
domain	O
(	O
HBD	O
)	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
(	O
hMR	O
)	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
a	O
fusion	O
protein	O
with	O
either	O
maltose	O
binding	O
protein	O
(	O
MBP	O
)	O
or	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
.	O

These	O
bacterially	O
-	O
produced	O
MR	O
constructs	O
had	O
no	O
steroid	O
binding	O
activity	O
per	O
se	O
.	O

In	O
fact	O
,	O
heat	O
shock	O
protein	O
association	O
(	O
hsp	O
)	O
is	O
required	O
for	O
high	O
affinity	O
ligand	O
-	O
binding	O
of	O
the	O
MR	O
.	O

After	O
incubation	O
of	O
purified	O
MBP-	O
or	O
GST	O
-	O
HBD	O
with	O
rabbit	O
reticulocyte	O
lysate	O
,	O
known	O
to	O
be	O
rich	O
in	O
heat	O
shock	O
proteins	O
,	O
we	O
obtained	O
saturable	O
binding	O
of	O
[	O
3H	O
]	O
aldosterone	O
.	O

The	O
Kd	O
value	O
for	O
aldosterone	O
was	O
0.3	O
nM	O
and	O
the	O
Bmax	O
=	O
32	O
pmol	O
/	O
mg	O
.	O

Hormone	O
binding	O
specificity	O
was	O
assessed	O
by	O
competition	O
studies	O
with	O
various	O
steroid	O
ligands	O
.	O

Sucrose	O
gradient	O
assays	O
performed	O
with	O
[	O
3H	O
]	O
aldosterone	O
-	O
MBP	O
-	O
HBD	O
revealed	O
complex	O
sedimenting	O
at	O
8.3S	O
and	O
4.9S	O
with	O
[	O
3H	O
]	O
progesterone	O
-	O
MBP	O
-	O
HBD	O
.	O

Western	O
-	O
blot	O
analysis	O
of	O
the	O
sedimentation	O
peak	O
showed	O
the	O
concomitant	O
presence	O
of	O
MBP	O
-	O
HBD	O
by	O
a	O
monoclonal	O
anti	O
-	O
MBP	O
antibody	O
,	O
and	O
hsp90	O
by	O
a	O
monoclonal	O
anti	O
-	O
hsp	O
antibody	O
.	O

Moreover	O
,	O
following	O
incubation	O
with	O
the	O
anti	O
-	O
rabbit	O
hsp90	O
monoclonal	O
antibody	O
the	O
sedimenting	O
gradient	O
showed	O
a	O
10.4S	O
sedimenting	O
complex	O
.	O

These	O
analyses	O
demonstrated	O
that	O
the	O
[	O
3H	O
]	O
aldosterone-	O
MBP	O
-	O
HBD	O
complex	O
is	O
at	O
least	O
associated	O
with	O
hsp90	O
in	O
reticulocyte	O
lysate	O
and	O
that	O
the	O
HBD	O
of	O
hMR	O
is	O
sufficient	O
to	O
bind	O
hsp90	O
.	O

Deletions	O
of	O
a	O
relatively	O
short	O
amino-	O
(	O
729	O
-	O
766	O
)	O
or	O
carboxy-	O
terminal	O
(	O
940	O
-	O
984	O
)	O
region	O
of	O
the	O
HBD	O
fragment	O
eliminated	O
all	O
steroid	O
-	O
binding	O
properties	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
the	O
integrity	O
of	O
domain	O
E	O
is	O
necessary	O
and	O
sufficient	O
to	O
bind	O
steroid	O
ligands	O
,	O
agonists	O
or	O
antagonists	O
,	O
with	O
characteristics	O
similar	O
to	O
the	O
entire	O
native	O
MR	O
.	O

CNI-1493	O
inhibits	O
monocyte	O
/	O
macrophage	O
tumor	O
necrosis	O
factor	O
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI-1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	O
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Bloom	O
,	O
O.	O
,	O
Meistrell	O
,	O
M.	O
,	O
Zimmerman	O
,	O
G.A.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Donnelley	O
,	O
T.	O
,	O
Bucala	O
,	O
R.	O
,	O
Sherry	O
,	O
B.	O
,	O
Manogue	O
,	O
K.R.	O
,	O
Tortolani	O
,	O
A.J.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
K.J.	O
(	O
1995	O
)	O
Mol	O
.	O
Med.1	O
,	O
254	O
-	O
266	O
,	O
and	O
Bianchi	O
,	O
M.	O
,	O
Bloom	O
,	O
O.	O
,	O
Raabe	O
,	O
T.	O
,	O
Cohen	O
,	O
P.	O
S.	O
,	O
Chesney	O
,	O
J.	O
,	O
Sherry	O
,	O
B.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Zhang	O
,	O
X.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
J.	O
(	O
1996	O
)	O
J.Exp	O
.	O
Med	O
.	O
,	O
in	O
press	O
]	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	O
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	O
translation	O
efficiency	O
.	O

CNI-1493	O
blocked	O
neither	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
increases	O
in	O
the	O
expression	O
of	O
TNF	O
mRNA	O
nor	O
the	O
translocation	O
of	O
nuclear	O
factor	O
NF	O
-	O
kappa	O
B	O
to	O
the	O
nucleus	O
in	O
macrophages	O
activated	O
by	O
15	O
min	O
of	O
LPS	O
stimulation	O
,	O
indicating	O
that	O
CNI-1493	O
does	O
not	O
interfere	O
with	O
early	O
NF	O
-	O
kappa	O
B	O
-mediated	O
transcriptional	O
regulation	O
of	O
TNF	O
.	O

However	O
,	O
synthesis	O
of	O
the	O
26-kDa	O
membrane	O
form	O
of	O
TNF	O
was	O
effectively	O
blocked	O
by	O
CNI-1493	O
.	O

Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	O
is	O
given	O
by	O
experiments	O
using	O
chloram	O
-	O
phenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
constructs	O
containing	O
elements	O
of	O
the	O
TNF	O
gene	O
that	O
are	O
involved	O
in	O
TNF	O
translational	O
regulation	O
.	O

Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
TNF	O
gene	O
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI-1493	O
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	O
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	O
)	O
-oestrogen	O
receptor	O
fusion	O
proteins	O
complement	O
the	O
EBNA2-deficient	O
Epstein	O
-	O
Barr	O
virus	O
strain	O
P3HR1	O
in	O
transformation	O
of	O
primary	O
B	O
cells	O
but	O
suppress	O
growth	O
of	O
human	B
B	I
cell	I
lymphoma	I
lines	I
.	O

To	O
develop	O
a	O
transformation	O
system	O
with	O
a	O
conditional	O
Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	O
)	O
gene	O
,	O
we	O
fused	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
oestrogen	O
receptor	O
to	O
the	O
N	O
or	O
C	O
terminus	O
of	O
EBNA2	O
.	O

In	O
promoter	O
transactivation	O
as	O
well	O
as	O
primary	O
B	O
cell	O
transformation	O
assays	O
these	O
chimeric	O
EBNA2	O
proteins	O
are	O
able	O
to	O
substitute	O
for	O
wild	O
-	O
type	O
EBNA2	O
in	O
the	O
presence	O
of	O
oestrogen	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
this	O
transformation	O
is	O
the	O
result	O
of	O
double	O
infection	O
of	O
a	O
cell	O
with	O
two	O
virions	O
,	O
the	O
P3HR1	O
virus	O
genome	O
and	O
a	O
mini	O
-	O
EBV	O
plasmid	O
carrying	O
the	O
chimeric	O
EBNA2	O
gene	O
.	O

Unexpectedly	O
,	O
expression	O
of	O
the	O
same	O
EBNA2	O
-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
established	B
human	I
B	I
cell	I
lymphoma	I
lines	I
resulted	O
in	O
growth	O
retardation	O
or	O
growth	O
arrest	O
upon	O
the	O
addition	O
of	O
oestrogen	O
.	O

By	O
titrating	O
the	O
oestrogen	O
concentration	O
in	O
these	O
stably	B
transfected	I
cells	I
,	O
the	O
growth	O
retarding	O
and	O
the	O
transactivating	O
function	O
of	O
the	O
chimeric	O
proteins	O
could	O
not	O
be	O
dissociated	O
.	O

We	O
propose	O
that	O
growth	O
inhibition	O
of	O
established	O
B	B
cell	I
lymphoma	I
lines	I
is	O
a	O
novel	O
function	O
of	O
EBNA2	O
which	O
has	O
not	O
been	O
detected	O
in	O
the	O
absence	O
of	O
an	O
inducible	O
system	O
.	O

It	O
remains	O
open	O
whether	O
the	O
growth	O
retarding	O
property	O
of	O
the	O
EBNA2-oestrogen	O
receptor	O
fusion	O
protein	O
in	O
B	B
cell	I
lymphoma	I
lines	I
is	O
due	O
to	O
unphysiologically	O
high	O
expression	O
of	O
the	O
chimeric	O
protein	O
or	O
to	O
interference	O
with	O
a	O
cellular	O
programme	O
driving	O
proliferation	O
in	O
these	O
cell	B
lines	I
.	O

Lymphoid	O
cell	O
resistance	O
to	O
glucocorticoids	O
in	O
HIV	O
infection	O
.	O

In	O
humans	O
infected	O
with	O
the	O
HIV-1	O
virus	O
there	O
may	O
be	O
a	O
disproportionate	O
severity	O
of	O
signs	O
and	O
symptoms	O
of	O
illness	O
compared	O
to	O
the	O
fraction	O
of	O
CD4	B
+	I
infected	I
T	I
-	I
lymphoid	I
cells	I
.	O

In	O
part	O
,	O
this	O
may	O
be	O
due	O
to	O
altered	O
intercellular	O
signalling	O
systems	O
and	O
intracellular	O
signal	O
transduction	O
.	O

Glucocorticoids	O
are	O
well	O
known	O
for	O
their	O
effects	O
on	O
the	O
vitality	O
and	O
function	O
of	O
lymphoid	O
cells	O
.	O

Patients	O
with	O
HIV	O
infections	O
often	O
show	O
elevated	O
circulating	O
levels	O
of	O
cortisol	O
,	O
suggesting	O
some	O
misfunction	O
in	O
the	O
regulatory	O
systems	O
that	O
maintain	O
the	O
levels	O
of	O
this	O
critical	O
hormone	O
.	O

At	O
the	O
cellular	O
level	O
,	O
it	O
is	O
known	O
that	O
both	O
acute	O
HIV	O
infection	O
and	O
glucocorticoids	O
can	O
cause	O
apoptotic	O
cell	O
death	O
in	O
thymic	O
lymphocytes	O
.	O

However	O
,	O
chronically	O
HIV	O
-	O
infected	O
cells	O
appear	O
to	O
be	O
resistant	O
to	O
glucocorticoid	O
-	O
evoked	O
cell	O
death	O
.	O

Glucocorticoid	O
receptor	O
-ligand	O
binding	O
studies	O
on	O
patients	O
'	O
cells	O
have	O
shown	O
reduced	O
affinity	O
between	O
the	O
receptor	O
binding	O
sites	O
and	O
test	O
steroids	O
.	O

In	O
vitro	O
,	O
chronically	B
HIV	I
-	I
infected	I
cells	I
of	O
the	O
lymphoid	B
CEM	I
line	I
displayed	O
resistance	O
to	O
glucocorticoid	O
-	O
induced	O
apoptosis	O
.	O

These	O
cells	O
showed	O
reduced	O
numbers	O
of	O
binding	O
sites	O
with	O
little	O
alteration	O
in	O
apparent	O
affinity	O
between	O
ligand	O
and	O
receptor	O
.	O

Thus	O
it	O
appears	O
that	O
there	O
may	O
often	O
be	O
malfunction	O
of	O
the	O
normal	O
glucocorticoid	O
response	O
in	O
HIV	O
-	O
infected	O
cells	O
probably	O
due	O
to	O
altered	O
interactions	O
between	O
the	O
glucocorticoid	O
receptor	O
and	O
its	O
hormone	O
.	O

Such	O
alterations	O
may	O
have	O
clinical	O
consequences	O
,	O
including	O
the	O
possibility	O
of	O
a	O
relatively	O
longer	O
life	O
span	O
of	O
infected	O
CD4	O
+	O
T	O
-	O
lymphocytes	O
,	O
as	O
well	O
as	O
systemic	O
effects	O
of	O
chronically	O
elevated	O
cortisol	O
level	O
.	O

A	O
novel	O
interferon	O
regulatory	O
factor	O
family	O
transcription	O
factor	O
,	O
ICSAT	O
/	O
Pip	O
/	O
LSIRF	O
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon	O
-	O
regulated	O
genes	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
cDNA	O
clone	O
encoding	O
interferon	O
(	O
IFN	O
)	O
consensus	O
sequence	O
-	O
binding	O
protein	O
in	O
adult	B
T	I
-	I
cell	I
leukemia	I
cell	I
line	I
or	O
activated	O
T	O
cells	O
(	O
ICSAT	O
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip	O
/	O
LSIRF	O
.	O

ICSAT	O
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	O
,	O
a	O
member	O
of	O
the	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
proteins	O
that	O
binds	O
to	O
interferon	O
consensus	O
sequences	O
(	O
ICSs	O
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN	O
-	O
regulated	O
genes	O
.	O

Among	O
T	B
-	I
cell	I
lines	I
investigated	O
,	O
ICSAT	O
was	O
abundantly	O
expressed	O
in	O
human	B
T	I
-	I
cell	I
leukemia	I
virus	I
type	I
1	I
(	I
HTLV-1	I
)	I
-infected	I
T	I
cells	I
.	O

When	O
the	O
HTLV-1	O
tax	O
gene	O
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate	O
-	O
A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	O
expression	O
was	O
induced	O
in	O
Jurkat	B
cells	I
which	O
otherwise	O
do	O
not	O
express	O
ICSAT	O
.	O

When	O
the	O
binding	O
of	O
ICSAT	O
to	O
four	O
different	O
ICSs	O
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	O
were	O
determined	O
.	O

To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	O
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	B
embryonal	I
carcinoma	I
cell	I
line	I
N	I
-	I
Tera2	I
.	O

ICSAT	O
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	O
stimulation	O
or	O
by	O
IRF-1	O
cotransfection	O
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF-2	O
or	O
ICSBP	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	O
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	O
or	O
ICSBP	O
in	O
some	O
IFN	O
-	O
responsive	O
reporter	O
constructs	O
.	O

These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
`	O
`	O
differential	O
repression	O
''	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	O
proteins	O
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN	O
-	O
responsive	O
genes	O
.	O

Mapping	O
of	O
the	O
transcriptional	O
repression	O
domain	O
of	O
the	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
oct-2A	O
.	O

The	O
lymphoid	O
-	O
specific	O
transcription	O
factor	O
Oct-2a	O
is	O
implicated	O
in	O
B	O
cell	O
-	O
specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure	O
/	O
function	O
analysis	O
of	O
various	O
Oct-2a	O
effector	O
regions	O
in	O
the	O
context	O
of	O
the	O
GAL4	O
DNA	O
-	O
binding	O
domain	O
revealed	O
that	O
Oct-2a	O
contains	O
two	O
functionally	O
different	O
activation	O
domains	O
at	O
the	O
N	O
and	O
the	O
C	O
termini	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	O
cell	O
-	O
specific	O
coactivators	O
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	O
domain	O
located	O
within	O
the	O
N	O
terminus	O
of	O
Oct-2a	O
(	O
amino	O
acids	O
2	O
-	O
99	O
)	O
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Oct-2a	O
to	O
determine	O
the	O
minimal	O
repression	O
domain	O
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	O
present	O
in	O
the	O
reporter	O
plasmid	O
as	O
well	O
as	O
on	O
the	O
cell	B
line	I
tested	O
.	O

The	O
possibility	O
that	O
Oct-2a	O
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	O
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O

To	O
characterize	O
the	O
protein	O
-	O
DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF	O
-	O
E2	O
(	O
or	O
AP-1	O
)	O
and	O
GATA-1	O
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
genes	O
are	O
expressed	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma-	O
and	O
the	O
beta	O
-	O
globin	O
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta	O
-	O
globin	O
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein	O
-	O
DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma-	O
and	O
beta	O
-	O
globin	O
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta	O
-	O
globin	O
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
.	O

Tissue	O
-	O
specific	O
activity	O
of	O
the	O
gammac	O
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	O
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA	O
-	O
binding	O
protein	O
.	O

The	O
gammac	O
chain	O
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	O
receptors	O
(	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
IL-4	O
,	O
IL-7	O
,	O
IL-9	O
,	O
and	O
IL-15	O
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	O
lineages	O
.	O

A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	O
gammac	O
promoter	O
and	O
define	O
the	O
minimal	O
tissue	O
-	O
specific	O
promoter	O
region	O
,	O
progressive	O
5'-deletion	O
constructs	O
of	O
a	O
segment	O
extending	O
1053	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
types	O
.	O

The	O
-1053	O
/	O
+34	O
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	O
binding	O
sites	O
conserved	O
in	O
the	O
murine	O
gammac	O
promoter	O
gene	O
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	O
binding	O
site	O
was	O
found	O
to	O
bind	O
Ets	O
family	O
proteins	O
,	O
principally	O
GA	O
-	O
binding	O
protein	O
and	O
Elf-1	O
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	O
and	O
-beta	O
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	O
promoter	O
,	O
GA	O
-	O
binding	O
protein	O
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	O
expression	O
is	O
not	O
restricted	O
to	O
the	O
hematopoietic	O
lineage	O
,	O
its	O
interaction	O
with	O
other	O
specific	O
factors	O
may	O
contribute	O
to	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
gammac	O
gene	O
.	O

Binding	O
and	O
cooperative	O
interactions	O
between	O
two	O
B	O
cell	O
-	O
specific	O
transcriptional	O
coactivators	O
.	O

The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
and	O
B	O
cell	O
octamer	O
-	O
binding	O
protein	O
1	O
/	O
octamer	O
-	O
binding	O
factor	O
1	O
/	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
Bob1	O
/	O
OBF-1	O
/	O
OCA	O
-	O
B	O
)	O
represent	O
two	O
B	O
cell	O
-	O
specific	O
transcriptional	O
coactivators	O
.	O

CIITA	O
and	O
Bob1	O
interact	O
with	O
proteins	O
that	O
bind	O
to	O
conserved	O
upstream	O
sequences	O
in	O
promoters	O
of	O
class	O
II	O
major	O
histocompatibility	O
genes	O
and	O
octamer	O
-	O
binding	O
transcription	O
factors	O
Oct-1	O
and	O
Oct-2	O
,	O
respectively	O
.	O

Both	O
CIITA	O
and	O
Bob1	O
increase	O
the	O
expression	O
from	O
the	O
DRA	O
promoter	O
,	O
which	O
is	O
a	O
prototypic	O
class	O
II	O
promoter	O
.	O

Moreover	O
,	O
in	O
the	O
presence	O
of	O
CIITA	O
,	O
interactions	O
between	O
class	O
II	O
promoters	O
and	O
Bob1	O
are	O
independent	O
of	O
the	O
octamer	O
-	O
binding	O
site	O
.	O

Using	O
in	O
vivo	O
and	O
in	O
vitro	O
binding	O
assays	O
,	O
we	O
confirm	O
that	O
Bob1	O
binds	O
to	O
CIITA	O
.	O

Thus	O
,	O
CIITA	O
not	O
only	O
activates	O
the	O
expression	O
of	O
class	O
II	O
genes	O
but	O
recruits	O
another	O
B	O
cell	O
-	O
specific	O
coactivator	O
to	O
increase	O
transcriptional	O
activity	O
of	O
class	O
II	O
promoters	O
in	O
B	O
cells	O
.	O

Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
are	O
stronger	O
in	O
neonatal	O
than	O
adult	O
T	O
lymphocytes	O
.	O

The	O
molecular	O
background	O
of	O
the	O
defects	O
in	O
the	O
immune	O
reactivity	O
of	O
human	O
neonates	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

As	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
has	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
transcription	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
the	O
authors	O
have	O
analysed	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
umbilical	O
cord	O
T	O
lymphocytes	O
.	O

The	O
activity	O
was	O
tested	O
by	O
quantitating	O
the	O
nuclear	O
proteins	O
binding	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	O
kappa	O
B	O
binding	O
sequence	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
.	O

The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate	O
/	O
calcium	O
ionophore	O
A23187	O
(	O
PDBu	O
/	O
iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
neonatal	O
than	O
adult	O
T	O
cells	O
.	O

This	O
higher	O
NF	O
-	O
kappa	O
B	O
activity	O
was	O
restricted	O
to	O
the	O
CD4	O
+	O
T	O
-	O
cell	O
subset	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	O
directed	O
against	O
the	O
major	O
components	O
of	O
NF	O
-	O
kappa	O
B	O
the	O
p50	O
and	O
RelA	O
(	O
p65	O
)	O
proteins	O
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
similar	O
in	O
neonatal	O
and	O
adult	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
neonatal	O
T	O
cells	O
are	O
exposed	O
to	O
oxidative	O
stress	O
-	O
inducing	O
signals	O
during	O
delivery	O
and/or	O
are	O
inherently	O
more	O
sensitive	O
to	O
NF	O
-	O
kappa	O
B	O
activating	O
signals	O
than	O
adult	O
T	O
cells	O
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	O
isotypes	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	B
U937	I
cells	I
.	O

Constitutive	O
expression	O
of	O
IFN	O
-	O
alpha5	O
and	O
IFN	O
-	O
beta	O
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	O
mRNA	O
by	O
reverse	O
transcriptase	O
-polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	O
product	O
.	O

The	O
activated	O
form	O
of	O
the	O
interferon	O
-	O
induced	O
transcription	O
factor	O
complex	O
ISGF3	O
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	B
cells	I
.	O

Culture	O
supernatants	O
from	O
uninduced	B
U937	I
cells	I
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	O
cloned	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
,	O
indicating	O
the	O
presence	O
of	O
endogenous	O
IFN	O
activity	O
equivalent	O
to	O
approximately	O
0.3	O
to	O
0.5	O
IU	O
/	O
mL	O
.	O

This	O
endogenous	O
IFN	O
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	O
histocompatibility	O
class	O
I	O
genes	O
in	O
lymphoid	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
IFN	O
-	O
alpha5	O
and	O
IFN	O
-	O
beta	O
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

Activation	O
protein	O
1	O
-dependent	O
transcriptional	O
activation	O
of	O
interleukin	O
2	O
gene	O
by	O
Ca2+	O
/	O
calmodulin	O
kinase	O
type	O
IV	O
/	O
Gr	O
.	O

The	O
Ca2+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
(	O
CaMK	O
)	O
type	O
IV	O
/	O
Gr	O
is	O
selectively	O
expressed	O
in	O
T	O
lymphocytes	O
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	O
engagement	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV	O
/	O
Gr	O
induces	O
the	O
transcription	O
factor	O
activation	O
protein	O
1	O
(	O
AP-1	O
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	O
cell	O
mitogens	O
and	O
with	O
the	O
p21ras	O
oncoprotein	O
.	O

CaMKIV	O
/	O
Gr	O
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c	O
-	O
fos	O
but	O
is	O
independent	O
of	O
p21ras	O
or	O
calcineurin	O
.	O

AP-1	O
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
transcriptional	O
complex	O
,	O
which	O
is	O
required	O
for	O
interleukin	O
2	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

We	O
demonstrate	O
that	O
CaMKIV	O
/	O
Gr	O
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	O
to	O
direct	O
transcription	O
from	O
NFAT	O
sites	O
in	O
non-	O
T	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV	O
/	O
Gr	O
as	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

IL-10	O
inhibits	O
nuclear	O
factor	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3-stimulated	B
human	I
peripheral	I
T	I
lymphocytes	I
.	O

IL-10	O
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti	O
-	O
CD3	O
mAb	O
OKT3	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	O
that	O
produced	O
by	O
PMA	O
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA	O
-	O
protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
protein	O
family	O
,	O
the	O
p50	O
/	O
p65	O
(	O
Rel	O
A	O
)	O
heterodimeric	O
form	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL-10	O
concentration	O
of	O
20	O
U	O
/	O
ml	O
.	O

IL-10	O
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL-10	O
are	O
able	O
so	O
inhibit	O
NF	O
-	O
kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O

Soluble	O
factors	O
do	O
not	O
appear	O
to	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
inhibition	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
up	O
-	O
regulation	O
of	O
CD80	O
Ag	O
,	O
found	O
on	O
monocytes	O
obtained	O
from	O
PBMC	O
incubated	O
with	O
OKT3	O
,	O
is	O
not	O
detected	O
after	O
addition	O
of	O
IL-10	O
,	O
and	O
the	O
anti	O
-	O
CD28	O
mAb	O
CLB	O
-	O
CD28	O
/	O
1	O
restores	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
IL-10-inhibited	B
lymphocytes	I
.	O

Therefore	O
,	O
the	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down	O
-	O
regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	O
,	O
produced	O
by	O
IL-10	O
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL-10	O
can	O
inhibit	O
the	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
nuclear	O
activity	O
in	O
CD3-stimulated	B
T	I
lymphocytes	I
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B	O
-	O
driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Effects	O
of	O
IL-10	O
and	O
IL-4	O
on	O
LPS	O
-	O
induced	O
transcription	O
factors	O
(	O
AP-1	O
,	O
NF	O
-	O
IL6	O
and	O
NF	O
-	O
kappa	O
B	O
)	O
which	O
are	O
involved	O
in	O
IL-6	O
regulation	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
,	O
like	O
IL-4	O
,	O
is	O
known	O
to	O
inhibit	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

We	O
showed	O
that	O
both	O
IL-10	O
and	O
IL-4	O
inhibit	O
LPS	O
-	O
induced	O
IL-6	O
mRNA	O
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL-6	O
gene	O
.	O

The	O
strong	O
inhibition	O
of	O
the	O
IL-6	O
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL-10	O
and	O
IL-4	O
on	O
the	O
expression	O
of	O
transcription	O
factors	O
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL-10	O
and	O
IL-4	O
affected	O
the	O
expression	O
of	O
transcription	O
factors	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL-6	O
transcription	O
rate	O
,	O
namely	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
nuclear	O
factor	O
IL-6	O
(	O
NF	O
-	O
IL6	O
)	O
,	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	O
and	O
IL-4	O
inhibited	O
LPS	O
-	O
induced	O
AP-1	O
binding	O
activity	O
.	O

The	O
inhibiting	O
effect	O
of	O
IL-4	O
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL-10	O
.	O

Downregulation	O
of	O
LPS	O
-	O
induced	O
AP-1	O
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	O
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP-1	O
complex	O
,	O
namely	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Binding	O
activity	O
of	O
NF	O
-	O
IL6	O
was	O
also	O
strongly	O
inhibited	O
by	O
IL-4	O
whereas	O
IL-10	O
showed	O
no	O
effect	O
.	O

NF	O
-	O
IL6	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
IL-10	O
or	O
IL-4	O
,	O
suggesting	O
that	O
IL-4	O
affects	O
binding	O
activity	O
of	O
preexisting	O
NF	O
-	O
IL6	O
.	O

Neither	O
IL-10	O
nor	O
IL-4	O
inhibited	O
LPS	O
-	O
induced	O
NF	O
-	O
kappa	O
B	O
binding	O
activity	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	O
and	O
p105	O
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	O
of	O
these	O
components	O
of	O
the	O
NF	O
-	O
kappa	O
B	O
transcription	O
factor	O
were	O
not	O
affected	O
by	O
IL-10	O
or	O
IL-4	O
.	O

Furthermore	O
,	O
neither	O
IL-10	O
nor	O
IL-4	O
showed	O
any	O
effect	O
on	O
I	O
-	O
kappa	O
B	O
mRNA	O
expression	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Thus	O
,	O
IL-10	O
and	O
IL-4	O
similarly	O
affect	O
IL-6	O
expression	O
.	O

However	O
,	O
for	O
IL-4	O
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP-1	O
and	O
NF	O
-	O
IL6	O
binding	O
activity	O
whereas	O
IL-10	O
only	O
inhibited	O
AP-1	O
binding	O
activity	O
.	O

Inhibition	O
of	O
T	O
lymphocyte	O
activation	O
by	O
cAMP	O
is	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
two	O
parallel	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathways	O
,	O
the	O
extracellular	O
signal	O
-	O
related	O
kinase	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
.	O

The	O
induction	O
of	O
T	O
cell	O
proliferation	O
requires	O
signals	O
from	O
the	O
TCR	O
and	O
a	O
co	O
-	O
receptor	O
molecule	O
,	O
such	O
as	O
CD28	O
,	O
that	O
activate	O
parallel	O
and	O
partially	O
cross	O
-	O
reactive	O
signaling	O
pathways	O
.	O

These	O
pathways	O
are	O
disrupted	O
by	O
agonists	O
that	O
utilize	O
adenylate	O
cyclase	O
and	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

We	O
found	O
that	O
the	O
adenylate	O
cyclase	O
activator	O
,	O
forskolin	O
,	O
inhibits	O
anti	O
-	O
CD3	O
-induced	O
shift	O
in	O
Lck	O
electrophoretic	O
mobility	O
,	O
suggesting	O
an	O
intervention	O
at	O
the	O
TCR	O
-coupled	O
phosphoinositide	O
turnover	O
that	O
precedes	O
the	O
activation	O
of	O
PKC	O
.	O

The	O
shift	O
of	O
Lck	O
following	O
direct	O
PKC	O
activation	O
by	O
12-O	O
-	O
tetradecanoyl	O
phorbol	O
13-acetate	O
,	O
which	O
bypasses	O
early	O
receptor	O
-	O
triggered	O
biochemical	O
events	O
,	O
is	O
insensitive	O
to	O
forskolin	O
.	O

Nevertheless	O
,	O
forskolin	O
also	O
inhibits	O
PKC	O
downstream	O
events	O
,	O
such	O
as	O
c	O
-	O
jun	O
expression	O
,	O
which	O
is	O
critical	O
for	O
the	O
activation	O
process	O
of	O
T	O
cells	O
.	O

To	O
further	O
analyze	O
potential	O
cross	O
points	O
between	O
positively	O
and	O
negatively	O
regulating	O
signaling	O
pathways	O
in	O
T	O
cells	O
,	O
we	O
tested	O
the	O
effects	O
of	O
activators	O
of	O
the	O
adenylate	O
cyclase	O
or	O
PKA	O
on	O
two	O
parallel	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathways	O
mediated	O
by	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
.	O

Using	O
a	O
PKC	O
-specific	O
inhibitor	O
,	O
GF109203X	O
,	O
or	O
PKC	B
-	I
depleted	I
T	I
cells	I
,	O
we	O
found	O
that	O
a	O
large	O
part	O
of	O
the	O
anti	O
-	O
CD3	O
-induced	O
ERK	O
activation	O
is	O
PKC	O
dependent	O
.	O

Both	O
PKC-	O
dependent	O
and	O
-independent	O
activation	O
of	O
ERK	O
were	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
or	O
a	O
cell	O
-	O
permeable	O
cAMP	O
analogue	O
,	O
dbcAMP	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
12-O	O
-	O
tetradecanoyl	O
phorbol	O
13-acetate	O
and	O
ionomycin	O
,	O
which	O
synergized	O
to	O
fully	O
activate	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
was	O
also	O
sensitive	O
to	O
inhibition	O
by	O
forskolin	O
.	O

Our	O
results	O
suggest	O
that	O
PKA	O
inhibits	O
T	O
cell	O
activation	O
by	O
interfering	O
with	O
multiple	O
events	O
along	O
the	O
two	O
signaling	O
pathways	O
operating	O
downstream	O
of	O
the	O
TCR	O
and	O
the	O
CD28	O
co	O
-	O
receptor	O
molecules	O
.	O

oriP	O
is	O
essential	O
for	O
EBNA	O
gene	O
promoter	O
activity	O
in	O
Epstein	B
-	I
Barr	I
virus	I
-	I
immortalized	I
lymphoblastoid	I
cell	I
lines	I
.	O

During	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	O
nuclear	O
antigens	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Upon	O
infection	O
,	O
Wp	O
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
for	O
the	O
duration	O
of	O
latency	O
.	O

In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	O
gene	O
promoters	O
in	O
established	O
in	B
vitro	I
immortalized	I
lymphoblastoid	I
cell	I
lines	I
(	O
LCLs	B
)	O
.	O

It	O
was	O
determined	O
that	O
oriP	O
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	O
or	O
Wp	O
in	O
LCLs	B
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	B
's	I
lymphoma	I
cell	I
lines	I
.	O

Deletion	O
of	O
the	O
EBNA2-dependent	O
enhancer	O
located	O
upstream	O
of	O
Cp	O
resulted	O
in	O
a	O
ca	O
.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	O
activity	O
in	O
the	O
LCLs	B
assayed	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	O
,	O
including	O
the	O
EBNA2-dependent	O
enhancer	O
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	O
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	O
boxes	O
,	O
a	O
proximal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-61	O
to	O
-65	O
and	O
a	O
distal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-253	O
to	O
-257	O
,	O
upstream	O
of	O
Cp	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
these	O
cis	O
elements	O
demonstrated	O
that	O
Cp	O
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	O
box	O
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	O
CCAAT	O
box	O
apparent	O
only	O
when	O
the	O
proximal	O
CCAAT	O
box	O
was	O
deleted	O
or	O
mutated	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca	O
.	O
bp	O
-850	O
upstream	O
of	O
Cp	O
did	O
not	O
result	O
in	O
a	O
significant	O
loss	O
in	O
activity	O
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	O
activity	O
resulted	O
in	O
induction	O
of	O
Wp	O
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	O
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	O
.	O

The	O
identification	O
of	O
oriP	O
and	O
the	O
EBNA2-dependent	O
enhancer	O
as	O
the	O
major	O
positive	O
cis	O
elements	O
involved	O
in	O
regulating	O
Cp	O
activity	O
in	O
LCL	B
suggests	O
that	O
EBNA	O
gene	O
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	O
1	O
and	O
EBNA	O
2	O
.	O

Protein	O
-	O
tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	O
1beta	O
and	O
NFkappaB	O
activation	O
,	O
but	O
not	O
NFkappaB	O
nuclear	O
translocation	O
.	O

In	O
human	O
monocytes	O
,	O
interleukin	O
1beta	O
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	O
1beta	O
gene	O
.	O

Expression	O
of	O
interleukin	O
1beta	O
and	O
other	O
cytokines	O
,	O
such	O
as	O
interleukin	O
6	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NFkappaB	O
.	O

Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide	O
-	O
induced	O
tyrosine	O
kinase	O
activation	O
is	O
not	O
required	O
for	O
NFkappaB	O
nuclear	O
translocation	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
NFkappaB	O
translocated	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
was	O
active	O
in	O
stimulating	O
transcription	O
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro	B
-	I
monocytic	I
cell	I
line	I
,	O
THP-1	B
,	O
the	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
interleukin	O
1beta	O
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activation	O
.	O

Tyrosine	O
kinases	O
are	O
not	O
required	O
for	O
lipopolysaccharide	O
-	O
mediated	O
nuclear	O
translocation	O
of	O
NFkappaB	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	O
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	O
;	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
AP-1	O
-dependent	O
transcription	O
is	O
enhanced	O
.	O

These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
inflammatory	O
mediators	O
requires	O
tyrosine	O
kinase	O
activity	O
,	O
tyrosine	O
kinase	O
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

LYSP100	O
-associated	O
nuclear	O
domains	O
(	O
LANDs	O
)	O
:	O
description	O
of	O
a	O
new	O
class	O
of	O
subnuclear	O
structures	O
and	O
their	O
relationship	O
to	O
PML	O
nuclear	O
bodies	O
.	O

The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
gene	O
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML	O
-	O
RAR	O
alpha	O
fusion	O
oncoprotein	O
.	O

The	O
PML	O
gene	O
product	O
has	O
been	O
localized	O
to	O
subnuclear	B
dot	I
-	I
like	I
structures	I
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid	O
-	O
restricted	O
gene	O
,	O
LYSP100	O
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	O
.	O

In	O
addition	O
to	O
SP100	O
homology	O
regions	O
,	O
one	O
LYSP100	O
cDNA	O
isoform	O
contains	O
a	O
bromodomain	O
and	O
a	O
PHD	O
/	O
TTC	O
domain	O
,	O
which	O
are	O
present	O
in	O
a	O
variety	O
of	O
transcriptional	O
regulatory	O
proteins	O
.	O

By	O
immunofluorescence	O
,	O
LYSP100	O
was	O
localized	O
to	O
nuclear	O
dots	O
that	O
were	O
surprisingly	O
largely	O
nonoverlapping	O
with	O
PML	O
NBs	O
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	O
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	O
and	O
SP100	O
.	O

We	O
term	O
the	O
LYSP100	O
structures	O
`	O
`	O
LANDs	O
,	O
''	O
for	O
LYSP100	O
-associated	O
nuclear	O
domains	O
.	O

Although	O
LYSP100	O
is	O
expressed	O
only	O
in	O
lymphoid	O
cells	O
,	O
LANDs	O
could	O
be	O
visualized	O
in	O
HeLa	B
cells	I
by	O
transfection	O
of	O
a	O
LYSP100	O
cDNA	O
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron	O
-	O
dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

LANDs	O
were	O
most	O
often	O
found	O
in	O
the	O
nucleoplasm	O
,	O
but	O
were	O
also	O
found	O
at	O
the	O
nuclear	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
these	O
structures	O
may	O
traffic	O
between	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
.	O

By	O
double	O
-	O
immunogold	O
labeling	O
of	O
PML	O
and	O
LYSP100	O
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	O
and	O
LYSP100	O
.	O

Thus	O
,	O
PML	O
is	O
localized	O
to	O
a	O
second	O
subnuclear	O
domain	O
that	O
is	O
morphologically	O
and	O
biochemically	O
distinct	O
from	O
PML	O
NBs	O
.	O

[	O
NGFI	O
-	O
B	O
/	O
nur77	O
family	O
involved	O
in	O
T	O
-	O
cell	O
apoptosis	O
]	O

NGFI	O
-	O
B	O
/	O
nur77	O
is	O
a	O
member	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
.	O

NGFI	O
-	O
B	O
/	O
nur77	O
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI	O
-	O
B	O
/	O
nur77	O
family	O
consists	O
of	O
three	O
subtypes	O
,	O
named	O
nur77	O
alpha	O
,	O
nur77	O
beta	O
,	O
nur77	O
gamma	O
.	O

We	O
cloned	O
human	O
nur77	O
beta	O
cDNA	O
,	O
called	O
TINUR	O
.	O

Although	O
NGFI	O
-	O
B	O
/	O
nur77	O
is	O
essential	O
for	O
TCR	O
-	O
mediated	O
apoptosis	O
in	O
T	O
-	O
cell	O
hybridomas	O
,	O
the	O
reports	O
on	O
nur77	O
knock	O
-	O
out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI	O
-	O
B	O
/	O
nur77	O
family	O
.	O

NGFI	O
-	O
B	O
/	O
nur77	O
binds	O
to	O
the	O
response	O
element	O
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
.	O

Assuming	O
that	O
9-cis	O
-	O
retinoic	O
acid	O
(	O
9-cis	O
-	O
RA	O
)	O
inhibits	O
TCR	O
-	O
mediated	O
apoptosis	O
,	O
nur77	O
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis	O
-	O
RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	O
in	O
the	O
presence	O
of	O
9-cis	O
-	O
RA	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein	O
-	O
Barr	O
virus	O
gene	O
expression	O
in	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	O
cells	O
.	O

Although	O
case	O
-	O
oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	O
epithelial	O
cells	O
is	O
/	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV	O
-	O
positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV	O
-	O
positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
1	O
mRNA	O
,	O
but	O
not	O
EBNA2	O
mRNA	O
.	O

The	O
EBNA	O
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	O
promoters	O
,	O
Qp	O
:	O
by	O
contrast	O
,	O
both	O
Cp	O
and	O
Wp	O
were	O
silent	O
,	O
thus	O
resulting	O
in	O
the	O
lack	O
of	O
EBNA2	O
mRNA	O
.	O

Latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
2A	O
mRNA	O
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O
however	O
,	O
neither	O
LMP1	O
nor	O
LMP2B	O
mRNA	O
was	O
detected	O
in	O
any	O
of	O
the	O
tumours	O
tested	O
.	O

Transcripts	O
from	O
the	O
BamHI	O
-	O
A	O
region	O
of	O
the	O
viral	O
genome	O
were	O
detectable	O
in	O
all	O
cases	O
.	O

BZLF1	O
mRNA	O
and	O
the	O
product	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
for	O
EBV	O
replication	O
,	O
was	O
not	O
expressed	O
in	O
any	O
of	O
them	O
,	O
thereby	O
suggesting	O
that	O
the	O
tumour	O
cells	O
carried	O
EBV	O
genomes	O
in	O
a	O
tightly	O
latent	O
form	O
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	O
carcinoma	O
cells	O
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'	O
latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'	O
latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

The	O
role	O
of	O
early	O
growth	O
response	O
gene	O
1	O
(	O
egr-1	O
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

The	O
induction	O
of	O
immediate	O
early	O
genes	O
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	O
factor	O
products	O
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function	O
-	O
related	O
genes	O
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	O
early	O
gene	O
,	O
egr-1	O
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
the	O
egr-1	O
promoter	O
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	O
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	O
cell	O
precursors	O
has	O
been	O
recently	O
elaborated	O
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc	O
-	O
finger	O
transcription	O
factor	O
encoded	O
by	O
egr-1	O
include	O
the	O
interleukin-2	O
,	O
CD44	O
,	O
ICAM-1	O
,	O
and	O
tumor	O
necrosis	O
factor	O
genes	O
.	O

The	O
role	O
of	O
egr-1	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O

Absence	O
of	O
T	O
-	O
cell-	O
and	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factors	O
TCF-1	O
,	O
GATA-3	O
,	O
and	O
BSAP	O
in	O
Hodgkin	B
's	I
Reed	I
-	I
Sternberg	I
cells	I
.	O

Based	O
on	O
the	O
presence	O
of	O
T	O
cell	O
receptor	O
-	O
beta	O
(	O
TcR	O
-	O
beta	O
)	O
gene	O
rearrangements	O
in	O
L428	B
and	I
HDLM-1	I
cells	I
,	O
the	O
expression	O
of	O
CD2	O
in	O
HDLM-1	B
cells	I
,	O
and	O
the	O
presence	O
of	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
gene	O
rearrangement	O
in	O
KM	B
-	I
H2	I
cells	I
,	O
some	O
researchers	O
have	O
concluded	O
that	O
these	O
long	B
-	I
term	I
cell	I
lines	I
derived	O
from	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
are	O
lymphoid	O
in	O
nature	O
.	O

The	O
information	O
obtained	O
from	O
these	O
cell	B
lines	I
has	O
also	O
been	O
used	O
in	O
arguments	O
for	O
a	O
lymphoid	O
origin	O
of	O
H	B
-	I
RS	I
cells	I
in	O
tissue	O
despite	O
the	O
frequent	O
absence	O
of	O
lymphoid	O
markers	O
and	O
Ig	O
/	O
TcR	O
gene	O
rearrangements	O
in	O
these	O
cells	O
.	O

We	O
questioned	O
whether	O
one	O
can	O
use	O
the	O
limited	O
expression	O
of	O
lymphoid	O
markers	O
or	O
the	O
limited	O
gene	O
rearrangement	O
to	O
conclude	O
that	O
H	B
-	I
RS	I
cells	I
have	O
a	O
lymphoid	O
origin	O
,	O
because	O
these	O
markers	O
may	O
be	O
aberrant	O
in	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
two	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factors	O
(	O
TCF-1	O
and	O
GATA-3	O
)	O
and	O
one	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
(	O
BSAP	O
)	O
in	O
cultured	B
H	I
-	I
RS	I
cells	I
by	O
using	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
this	O
assay	O
for	O
determination	O
of	O
cell	B
lineage	I
have	O
been	O
established	O
in	O
a	O
large	O
number	O
of	O
cultured	B
human	I
and	I
murine	I
cell	I
lines	I
.	O

All	O
three	O
types	O
of	O
H	B
-	I
RS	I
cell	I
lines	I
were	O
consistently	O
negative	O
for	O
BSAP	O
,	O
TCF-1	O
,	O
and	O
GATA-3	O
.	O

The	O
absence	O
of	O
GATA-3	O
was	O
confirmed	O
in	O
H	B
-	I
RS	I
cells	I
in	O
tissues	O
by	O
an	O
in	O
situ	O
hybridization	O
technique	O
.	O

Virtually	O
all	O
B	B
-	I
cell	I
lines	I
,	O
with	O
the	O
exception	O
of	O
some	O
myeloma	B
cell	I
lines	I
,	O
are	O
positive	O
for	O
BSAP	O
,	O
which	O
is	O
the	O
transcription	O
factor	O
for	O
promoters	O
for	O
several	O
B	O
-	O
cell	O
markers	O
,	O
including	O
VpreB1	O
,	O
lambda	O
5	O
,	O
CD19	O
,	O
and	O
CD20	O
.	O

All	O
T	B
-	I
cell	I
lines	I
tested	O
were	O
positive	O
for	O
TCF-1	O
and	O
GATA-3	O
,	O
which	O
are	O
the	O
transcription	O
factors	O
for	O
promoters	O
for	O
several	O
T	O
-	O
cell	O
-	O
restricted	O
markers	O
,	O
including	O
CD2	O
,	O
CD3	O
,	O
TcR	O
,	O
and	O
lck	O
.	O

The	O
absence	O
of	O
BSAP	O
,	O
TCF-1	O
,	O
and	O
GATA-3	O
clearly	O
indicates	O
an	O
underlying	O
difference	O
between	O
H	B
-	I
RS	I
cells	I
and	O
lymphoid	O
cells	O
.	O

Translocation	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
of	O
B	O
-	O
cell	O
type	O
with	O
BCL6	O
rearrangement	O
.	O

We	O
report	O
a	O
65-year	O
-	O
old	O
woman	O
with	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
carrying	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
and	O
BCL6	O
rearrangement	O
in	O
the	O
affected	O
cells	O
.	O

She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	O
cells	O
at	O
presentation	O
.	O

Histological	O
diagnosis	O
was	O
`	O
`	O
malignant	O
lymphoma	O
,	O
diffuse	O
,	O
large	O
cell	O
''	O
type	O
according	O
to	O
an	O
International	O
Working	O
Formulation	O
.	O

Chromosome	O
analysis	O
revealed	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
,	O
which	O
is	O
a	O
new	O
variant	O
translocation	O
of	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q32	O
)	O
.	O

Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	O
,	O
JH	O
,	O
and	O
TCR	O
beta	O
but	O
not	O
of	O
TCR	O
delta	O
.	O

Cosmid	O
probe	O
of	O
BCL6	O
hybridized	O
to	O
14q11	O
and	O
3q27	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Although	O
the	O
band	O
14q11	O
is	O
a	O
locus	O
of	O
T	O
-	O
cell	O
receptor	O
alpha-	O
and	O
delta	O
-	O
chains	O
(	O
TCR	O
alpha	O
/	O
delta	O
)	O
,	O
lymphoma	O
cells	O
expressed	O
B	O
-	O
cell	O
,	O
IgGk	O
phenotype	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
novel	O
proto	O
-	O
oncogene	O
in	O
the	O
vicinity	O
of	O
TCR	O
alpha	O
/	O
delta	O
is	O
involved	O
in	O
this	O
translocation	O
.	O

Quantitation	O
of	O
beta	O
1	O
triiodothyronine	O
receptor	O
mRNA	O
in	O
human	O
tissues	O
by	O
competitive	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O

Thyroid	O
hormones	O
act	O
by	O
binding	O
to	O
nuclear	O
receptor	O
proteins	O
,	O
the	O
thyroid	O
hormone	O
receptors	O
(	O
TR	O
)	O
alpha	O
and	O
beta	O
.	O

Data	O
from	O
cell	O
culture	O
and	O
animal	O
studies	O
indicate	O
that	O
TR	O
expression	O
may	O
be	O
regulated	O
to	O
modulate	O
target	O
organ	O
responsiveness	O
to	O
thyroid	O
hormone	O
.	O

To	O
investigate	O
whether	O
such	O
adaptive	O
changes	O
in	O
TR	O
expression	O
occur	O
in	O
humans	O
,	O
we	O
determined	O
the	O
mRNA	O
levels	O
of	O
the	O
hTR	O
beta	O
1	O
in	O
various	O
thyroid	O
states	O
.	O

Patients	O
with	O
overt	O
hypo	O
-or	O
hyperthyroidism	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
determined	O
by	O
quantitative	O
competitive	O
reverse	O
transcription	O
PCR	O
.	O

For	O
comparison	O
,	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
determined	O
in	O
lymphocytes	O
and	O
normal	O
thyroid	O
tissue	O
of	O
euthyroid	O
patients	O
.	O

Human	O
TR	O
beta	O
1	O
mRNA	O
levels	O
in	O
lymphocytes	O
were	O
1.8	O
+	O
/-	O
0.4	O
,	O
1.9	O
+	O
/-	O
0.5	O
,	O
1.1	O
+	O
/-	O
0.4	O
10	O
(	O
-18	O
)	O
mol	O
/	O
microgram	O
RNA	O
in	O
hypo-	O
,	O
eu	O
-and	O
hyperthyroid	O
patients	O
,	O
respectively	O
,	O
corresponding	O
to	O
an	O
estimated	O
0.5	O
-2	O
molecules	O
per	O
cell	O
.	O

Although	O
the	O
mean	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
40	O
%	O
lower	O
in	O
hyperthyroid	O
than	O
in	O
euthyroid	O
subjects	O
,	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Similar	O
levels	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
were	O
detected	O
in	O
thyroid	O
gland	O
from	O
euthyroid	O
patients	O
.	O

In	O
summary	O
,	O
we	O
developed	O
an	O
assay	O
for	O
the	O
quantitative	O
determination	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
in	O
small	O
human	O
tissue	O
samples	O
,	O
containing	O
as	O
little	O
as	O
50	O
ng	O
of	O
total	O
RNA	O
.	O

Absolute	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
are	O
very	O
low	O
with	O
an	O
estimated	O
one	O
molecule	O
of	O
mRNA	O
being	O
present	O
in	O
a	O
mononuclear	O
blood	O
cell	O
or	O
thyrocyte	O
.	O

No	O
up	O
-	O
regulation	O
of	O
hTR	O
beta	O
1	O
was	O
seen	O
in	O
hypothyroid	O
relative	O
to	O
euthyroid	O
patients	O
.	O

However	O
,	O
there	O
is	O
a	O
non	O
-	O
significant	O
trend	O
towards	O
a	O
down	O
-	O
regulation	O
of	O
hTR	O
beta	O
1	O
mRNA	O
levels	O
in	O
hyperthyroid	O
patients	O
.	O

Calcineurin	O
mutants	O
render	O
T	O
lymphocytes	O
resistant	O
to	O
cyclosporin	O
A	O
.	O

The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O

CsA	O
and	O
FK506	O
associate	O
with	O
intracellular	O
binding	O
proteins	O
(	O
i.e.	O
,	O
CsA	O
with	O
cyclophilin	O
A	O
and	O
FK506	O
with	O
FKBP12	O
)	O
to	O
form	O
protein	O
/	O
drug	O
complexes	O
that	O
suppress	O
the	O
immune	O
system	O
by	O
preventing	O
activation	O
of	O
T	O
cells	O
in	O
response	O
to	O
antigen	O
presentation	O
.	O

The	O
common	O
target	O
of	O
CsA	O
and	O
FK506	O
is	O
calcineurin	O
,	O
a	O
Ca2+	O
/	O
calmodulin	O
-	O
regulated	O
,	O
serine	O
/	O
threonine	O
-	O
specific	O
protein	O
phosphatase	O
that	O
regulates	O
the	O
nuclear	O
import	O
of	O
a	O
transcription	O
factor	O
,	O
NF	O
-	O
AT	O
,	O
required	O
for	O
expression	O
of	O
T	O
cell	O
activation	O
genes	O
.	O

In	O
previous	O
studies	O
,	O
we	O
identified	O
calcineurin	O
mutations	O
that	O
block	O
binding	O
by	O
the	O
cyclophilin	O
A	O
/	O
CsA	O
or	O
FKBP12	O
/	O
FK506	O
complexes	O
and	O
thereby	O
render	O
yeast	O
cells	O
resistant	O
to	O
the	O
antifungal	O
effects	O
of	O
CsA	O
or	O
FK506	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	O
render	O
the	O
T	O
cell	O
receptor	O
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	B
Jurkat	I
T	I
cells	I
.	O

Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	O
X	O
-	O
ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	O
is	O
the	O
only	O
CsA	O
-	O
sensitive	O
component	O
limiting	O
signaling	O
from	O
the	O
T	O
cell	O
receptor	O
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O

Characterization	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
gene	O
promoter	O
.	O

MNDA	O
(	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
)	O
is	O
an	O
interferon	O
alpha	O
regulated	O
nuclear	O
protein	O
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O

To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage	O
-	O
specific	O
and	O
interferon	O
-	O
regulated	O
expression	O
,	O
the	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Two	O
interferon	O
-	O
stimulated	O
response	O
elements	O
(	O
ISRE	O
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	O
as	O
a	O
TATA	O
-	O
less	O
interferon	O
-	O
regulated	O
gene	O
.	O

Other	O
DNA	O
elements	O
present	O
include	O
a	O
cluster	O
of	O
Myb	O
sites	O
,	O
several	O
Ets	O
,	O
an	O
Ets	O
related	O
PU.1	O
site	O
and	O
an	O
Sp1	O
site	O
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	O
start	O
sites	O
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	O
expression	O
.	O

The	O
5	O
'	O
flanking	O
sequence	O
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	O
alpha	O
.	O

The	O
findings	O
indicate	O
that	O
MNDA	O
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	O
cell	O
specific	O
genes	O
and	O
genes	O
up	O
-	O
regulated	O
by	O
interferon	O
alpha	O
.	O

Abnormality	O
of	O
Oct-1	O
DNA	O
binding	O
in	O
T	O
cells	O
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O

Primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O

To	O
understand	O
the	O
diminished	O
T	O
cell	O
response	O
to	O
activation	O
signals	O
,	O
we	O
measured	O
nucleoprotein	O
DNA	O
-	O
binding	O
activities	O
regulating	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Peripheral	O
blood	O
lymphocytes	O
from	O
9	O
/	O
19	O
SS	O
patients	O
were	O
found	O
to	O
be	O
defective	O
in	O
their	O
ability	O
to	O
bind	O
an	O
october	O
sequence	O
(	O
Oct-1	O
)	O
.	O

This	O
Oct-1	O
-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O

This	O
abnormality	O
was	O
not	O
seen	O
in	O
resting	O
T	O
cells	O
nor	O
T	O
cells	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
or	O
SS	O
accompanied	O
by	O
RA	O
.	O

The	O
SS	O
Oct-1	O
DNA	O
-	O
binding	O
abnormality	O
correlated	O
significantly	O
with	O
an	O
inability	O
of	O
cells	O
to	O
exit	O
the	O
Gzero	O
/	O
G1	O
cell	O
cycle	O
phase	O
when	O
stimulated	O
in	O
vitro	O
.	O

Importantly	O
,	O
nucleoprotein	O
extracts	O
showing	O
decreased	O
DNA	O
-	O
binding	O
activity	O
had	O
normal	O
amounts	O
of	O
Oct-1	O
proteins	O
as	O
determined	O
by	O
immunoprecipitation	O
,	O
implying	O
a	O
functional	O
defect	O
in	O
the	O
Oct-1	O
protein	O
.	O

Moreover	O
,	O
defective	O
DNA	O
binding	O
was	O
corrected	O
by	O
treatment	O
with	O
acid	O
phosphatase	O
.	O

Severe	O
combined	O
immunodeficiency	O
due	O
to	O
defective	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
in	O
T	O
lymphocytes	O
of	O
two	O
male	O
siblings	O
.	O

Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
and	O
alloreactive	B
T	I
cell	I
lines	I
of	O
two	O
male	O
infants	O
born	O
to	O
consanguinous	O
parents	O
and	O
presenting	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
showed	O
a	O
pronounced	O
deficiency	O
in	O
T	O
cell	O
activation	O
.	O

Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	O
cells	O
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	O
(	O
IL-2	O
)	O
.	O

Furthermore	O
both	O
childrens	O
'	O
T	O
cells	O
were	O
unable	O
to	O
produce	O
the	O
cytokines	O
IL-2	O
,	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
,	O
IL-4	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

This	O
multiple	O
cytokine	O
production	O
deficiency	O
could	O
not	O
be	O
restored	O
by	O
IL-2	O
or	O
co	O
-	O
stimulatory	O
signals	O
provided	O
by	O
antigen	O
-	O
presenting	O
cells	O
(	O
APC	O
)	O
.	O

Moreover	O
,	O
mRNA	O
for	O
IL-2	O
and	O
IFN	O
-	O
gamma	O
could	O
not	O
be	O
detected	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
activation	O
-	O
dependent	O
cell	O
surface	O
markers	O
CD25	O
and	O
CD69	O
was	O
within	O
normal	O
limits	O
.	O

To	O
determine	O
whether	O
the	O
functional	O
defect	O
of	O
the	O
patients	O
'	O
T	O
cells	O
was	O
due	O
to	O
the	O
absence	O
or	O
abnormal	O
binding	O
of	O
transcription	O
factors	O
involved	O
in	O
cytokine	O
gene	O
expression	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
used	O
to	O
examine	O
the	O
DNA	O
binding	O
of	O
AP-1	O
,	O
Oct	O
,	O
CREB	O
,	O
SP1	O
,	O
NF	O
-	O
kappa	O
B	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
their	O
respective	O
response	O
elements	O
in	O
the	O
promoter	O
of	O
the	O
IL-2	O
gene	O
.	O

Whereas	O
AP-1	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
Oct	O
,	O
CREB	O
and	O
SP1	O
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF	O
-	O
AT	O
to	O
its	O
IL-2	O
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF	O
-	O
AT	O
/DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	O
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O

Regulation	O
of	O
sialoadhesin	O
expression	O
on	O
rat	O
macrophages	O
.	O

Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
gamma	O
,	O
IL-4	O
,	O
and	O
lipopolysaccharide	O
.	O

Sialoadhesin	O
is	O
a	O
macrophage	O
-	O
restricted	O
member	O
of	O
the	O
Ig	O
superfamily	O
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	O
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	O
expression	O
on	O
freshly	O
isolated	O
rat	O
macrophages	O
and	O
the	O
rat	B
macrophage	I
cell	I
line	I
R2	I
.	O

The	O
cytokines	O
IFN	O
-	O
beta	O
,	O
IFN	O
-	O
gamma	O
,	O
IL-4	O
,	O
and	O
LPS	O
,	O
although	O
unable	O
to	O
induce	O
sialoadhesin	O
expression	O
by	O
themselves	O
,	O
were	O
able	O
to	O
enhance	O
GC	O
-	O
mediated	O
induction	O
of	O
sialoadhesin	O
.	O

Sialoadhesin	O
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines	O
/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC	O
-	O
dependent	O
enhancement	O
of	O
sialoadhesin	O
expression	O
,	O
with	O
IFN	O
-	O
beta	O
and	O
IL-4	O
being	O
more	O
potent	O
than	O
IFN	O
-	O
gamma	O
and	O
LPS	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN	O
-	O
gamma	O
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN	O
-	O
beta	O
and	O
IL-4	O
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

The	O
regulation	O
of	O
sialoadhesin	O
expression	O
was	O
mediated	O
by	O
the	O
GC	O
receptor	O
,	O
and	O
not	O
by	O
mineralocorticoid	O
receptor	O
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	O
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	O
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	O
expression	O
on	O
rat	O
macrophages	O
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN	O
-	O
beta	O
,	O
T	O
cell	O
-	O
derived	O
cytokines	O
,	O
or	O
LPS	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	O
and	O
ATF-2	O
/	O
JUN	O
.	O

The	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	O
its	O
antigen	O
receptor	O
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	O
of	O
TNF	O
-	O
alpha	O
gene	O
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	O
family	O
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	O
bind	O
to	O
the	O
TNF	O
-	O
alpha	O
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF-2	O
and	O
Jun	O
proteins	O
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O

Here	O
,	O
using	O
the	O
murine	B
B	I
-	I
cell	I
lymphoma	I
cell	I
line	I
A20	B
,	O
we	O
show	O
that	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
.	O

In	O
A20	B
B	I
cells	I
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
not	O
regulated	O
by	O
NFATp	O
bound	O
to	O
the	O
kappa	O
3	O
element	O
.	O

Instead	O
,	O
ATF-2	O
and	O
Jun	O
proteins	O
bind	O
to	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
and	O
NFATp	O
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-76	O
nucleotides	O
relative	O
to	O
the	O
TNF	O
-	O
alpha	O
transcription	O
start	O
site	O
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium	O
-	O
mediated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
TNF	O
-	O
alpha	O
in	O
both	O
A20	B
B	I
cells	I
and	O
Ar-5	B
cells	I
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	O
footprinting	O
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	O
demonstrated	O
that	O
the	O
-76	O
site	O
binds	O
to	O
NFATp	O
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp	O
-	O
binding	O
sites	O
in	O
the	O
proximal	O
TNF	O
-	O
alpha	O
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Induction	O
of	O
bcl-2	O
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B	O
-	O
cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	O
of	O
bcl-2	O
mRNA	O
and	O
protein	O
increase	O
with	O
cross	O
-	O
linking	O
of	O
surface	O
immunoglobulin	O
.	O

We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	O
expression	O
in	O
B	O
cells	O
in	O
the	O
5'-flanking	O
region	O
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	O
and	O
a	O
downstream	O
regulatory	O
region	O
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross	O
-	O
linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	O
site	O
that	O
result	O
in	O
loss	O
of	O
CREB	O
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient	O
-	O
transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	O
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	O
cells	O
.	O

Treatment	O
of	O
the	O
mature	B
B	I
-	I
cell	I
line	I
BAL-17	I
with	O
either	O
anti	O
-	O
immunoglobulin	O
M	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl-2	O
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	O
site	O
.	O

Treatment	O
of	O
the	O
more	O
immature	B
B	I
-	I
cell	I
line	I
,	O
Ramos	B
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium	O
-	O
dependent	O
apoptosis	O
.	O

bcl-2	O
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	O
site	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	O
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	O
kinase	O
C	O
rather	O
than	O
by	O
protein	O
kinase	O
A	O
.	O

Although	O
the	O
CRE	O
site	O
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl-2	O
expression	O
requires	O
participation	O
of	O
the	O
upstream	O
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	O
alters	O
its	O
interaction	O
with	O
the	O
upstream	O
regulatory	O
element	O
.	O

The	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl-2	O
expression	O
during	O
the	O
activation	O
of	O
mature	O
B	O
cells	O
and	O
during	O
the	O
rescue	O
of	O
immature	O
B	O
cells	O
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	O
site	O
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	O
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	O
kinase	O
C	O
is	O
involved	O
.	O

Interleukin-6	O
promotes	O
multiple	O
myeloma	O
cell	O
growth	O
via	O
phosphorylation	O
of	O
retinoblastoma	O
protein	O
.	O

Interleukin-6	O
(	O
IL-6	O
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	B
myeloma	I
(	I
MM	I
)	I
cells	I
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

Abnormalities	O
of	O
retinoblastoma	O
protein	O
(	O
pRB	O
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM	B
-	I
derived	I
cell	I
lines	I
.	O

Because	O
dephosphorylated	O
(	O
activated	O
)	O
pRB	O
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	O
(	O
inactivated	O
)	O
pRB	O
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	O
in	O
IL-6	O
-mediated	O
MM	O
cell	O
growth	O
.	O

Both	O
phosphorylated	O
and	O
dephosphorylated	O
pRB	O
were	O
expressed	O
in	O
all	O
serum	O
-	O
starved	O
MM	O
patient	O
cells	O
and	O
MM	B
-	I
derived	I
cell	I
lines	I
,	O
but	O
pRB	O
was	O
predominantly	O
in	O
its	O
phosphorylated	O
form	O
.	O

In	O
MM	B
cells	I
that	O
proliferated	O
in	O
response	O
to	O
IL-6	O
,	O
exogenous	O
IL-6	O
downregulated	O
dephosphorylated	O
pRB	O
and	O
decreased	O
dephosphorylated	O
pRB	O
-	O
E2F	O
complexes	O
.	O

Importantly	O
,	O
culture	O
of	O
MM	B
cells	I
with	O
RB	O
antisense	O
,	O
but	O
not	O
RB	O
sense	O
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	O
secretion	O
and	O
proliferation	O
in	O
MM	B
cells	I
;	O
however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti	O
-	O
IL-6	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
.	O

In	O
contrast	O
to	O
MM	B
cells	I
,	O
normal	O
splenic	O
B	O
cells	O
express	O
dephosphorylated	O
pRB	O
.	O

Although	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	O
and	O
proliferation	O
of	O
B	O
cells	O
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	O
to	O
CD40L	O
-treated	O
B	O
cells	O
does	O
not	O
alter	O
either	O
pRB	O
or	O
proliferation	O
,	O
as	O
observed	O
in	O
MM	B
cells	I
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	O
pRB	O
is	O
constitutively	O
expressed	O
in	O
MM	B
cells	I
and	O
that	O
IL-6	O
further	O
shifts	O
pRB	O
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	O
pRB	O
due	O
to	O
reduced	O
dephosphorylated	O
pRB	O
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	O
secretion	O
by	O
MM	B
cells	I
and	O
related	O
IL-6	O
-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

E3	O
,	O
a	O
hematopoietic	O
-	O
specific	O
transcript	O
directly	O
regulated	O
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	O
library	O
constructed	O
from	O
the	O
murine	O
RA	B
-	I
inducible	I
MPRO	I
promyelocyte	I
cell	I
line	I
to	O
identify	O
immediate	O
-	O
early	O
genes	O
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O

E3	O
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate	O
-	O
early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	O
transcripts	O
were	O
RA	O
-	O
inducible	O
in	O
HL60	B
cells	I
,	O
but	O
not	O
in	O
an	O
RA	B
-	I
resistant	I
subclone	I
,	O
HL60R	B
,	O
that	O
harbors	O
a	O
mutated	O
RAR	O
alpha	O
gene	O
.	O

However	O
,	O
when	O
HL60R	B
cells	I
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	O
alpha	O
gene	O
,	O
RA	O
induced	O
a	O
10-fold	O
increase	O
in	O
E3	O
mRNA	O
levels	O
.	O

E3	O
transcripts	O
are	O
present	O
in	O
the	O
myeloid	O
,	O
B	O
-	O
lymphoid	O
,	O
and	O
erythroid	O
lineages	O
,	O
absent	O
in	O
nonhematopoietic	O
cells	O
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	O
cells	O
.	O

The	O
murine	O
E3	O
promoter	O
harbors	O
a	O
single	O
bipartite	O
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O

These	O
results	O
indicate	O
that	O
E3	O
is	O
a	O
hematopoietic	O
-	O
specific	O
gene	O
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	O
alpha	O
during	O
myelopoiesis	O
.	O

DNA	O
-	O
binding	O
phosphoproteins	O
induced	O
after	O
T	O
cell	O
activation	O
:	O
effects	O
of	O
cyclosporin	O
A	O
.	O

To	O
define	O
novel	O
proteins	O
involved	O
in	O
the	O
early	O
transcriptional	O
response	O
during	O
the	O
activation	O
of	O
human	O
T	O
lymphocytes	O
,	O
we	O
used	O
a	O
high	O
-	O
resolution	O
,	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
system	O
to	O
identify	O
nuclear	O
,	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
binding	O
proteins	O
exhibiting	O
rapid	O
changes	O
in	O
phosphorylation	O
following	O
cell	O
stimulation	O
.	O

We	O
identified	O
18	O
nuclear	O
proteins	O
whose	O
phosphorylation	O
level	O
changed	O
more	O
than	O
5-fold	O
upon	O
activation	O
.	O

Of	O
these	O
,	O
11	O
were	O
found	O
to	O
possess	O
DNA	O
-	O
binding	O
properties	O
.	O

The	O
11	O
phosphoproteins	O
with	O
DNA	O
-	O
binding	O
activity	O
,	O
along	O
with	O
4	O
others	O
,	O
were	O
analyzed	O
further	O
.	O

Phosphoamino	O
acid	O
analysis	O
revealed	O
several	O
sets	O
of	O
proteins	O
with	O
different	O
phosphorylated	O
residues	O
Kinetic	O
analysis	O
of	O
the	O
phosphorylation	O
of	O
the	O
selected	O
proteins	O
was	O
performed	O
and	O
revealed	O
a	O
complex	O
group	O
of	O
transient	O
and	O
sustained	O
responses	O
to	O
cell	O
activation	O
.	O

Finally	O
,	O
the	O
activation	O
-	O
induced	O
changes	O
in	O
one	O
set	O
of	O
phosphoproteins	O
were	O
dramatically	O
inhibited	O
by	O
cyclosporin	O
A	O
.	O

We	O
suggest	O
that	O
these	O
phosphoproteins	O
may	O
be	O
directly	O
involved	O
in	O
regulating	O
the	O
transcriptional	O
response	O
to	O
cellular	O
activation	O
by	O
external	O
stimuli	O
.	O

Transcriptional	O
control	O
of	O
steroid	O
-	O
regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O

Early	O
studies	O
in	O
murine	O
T	B
cell	I
lines	I
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
N	O
-	O
terminal	O
domain	O
are	O
required	O
for	O
glucocorticoid	O
-	O
mediated	O
apoptosis	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	B
T	I
cell	I
lines	I
have	O
suggested	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
is	O
not	O
necessary	O
for	O
steroid	O
-	O
regulated	O
apoptosis	O
and	O
that	O
GR	O
-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	O
N	O
-	O
terminal	O
transactivation	O
domain	O
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	O
,	O
GR	O
variants	O
,	O
and	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
into	O
receptor	B
-	I
negative	I
S49	I
murine	I
thymoma	I
cells	I
.	O

GR	O
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate	O
-	O
limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR	O
-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
LTR	O
reporter	O
gene	O
was	O
observed	O
.	O

Analysis	O
of	O
GR	O
chimeric	O
receptors	O
containing	O
the	O
potent	O
VP16	O
and	O
E1A	O
viral	O
transactivation	O
domains	O
in	O
place	O
of	O
the	O
GR	O
N	O
terminus	O
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	O
can	O
initiate	O
apoptosis	O
in	O
S49	B
cells	I
after	O
treatment	O
with	O
5	O
alpha	O
-	O
dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid	O
-	O
regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte	O
-	O
specific	O
gene	O
called	O
GIG18	O
.	O

We	O
found	O
that	O
GIG18	O
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	O
and	O
GR	O
,	O
demonstrating	O
that	O
AR	O
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	B
cells	I
and	O
,	O
moreover	O
,	O
that	O
GIG18	O
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid	O
-	O
treated	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR	O
-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

Suppression	O
of	O
c	O
-	O
jun	O
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	O
respiratory	O
burst	O
during	O
phorbol	O
ester	O
-	O
induced	O
differentiation	O
of	O
U937	B
human	I
monoblastic	I
cells	I
.	O

We	O
studied	O
the	O
role	O
of	O
the	O
immediate	O
early	O
gene	O
c	O
-	O
jun	O
in	O
cell	O
proliferation	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
differentiation	O
in	O
U937	B
human	I
monoblastic	I
cells	I
,	O
using	O
c	O
-	O
jun	O
-specific	O
antisense	O
(	O
AS	O
)	O
phosphorothioate	O
oligonucleotides	O
.	O

In	O
selecting	O
the	O
most	O
specific	O
and	O
potent	O
oligonucleotide	O
sequence	O
,	O
we	O
performed	O
extensive	O
analyses	O
for	O
the	O
binding	O
specificity	O
between	O
all	O
candidates	O
of	O
c	O
-	O
jun	O
AS	O
oligonucleotides	O
and	O
the	O
whole	O
sequences	O
in	O
GenBank	O
database	O
,	O
using	O
a	O
computer	O
program	O
.	O

Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
between	O
2	O
and	O
10	O
microM	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
10	O
microM	O
of	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
reduced	O
c	O
-	O
jun	O
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

More	O
importantly	O
,	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
showed	O
distinct	O
effects	O
on	O
two	O
markers	O
of	O
PMA	O
-	O
induced	O
differentiation	O
;	O
the	O
C	O
-	O
JUN	O
AS	O
oligonucleotides	O
inhibited	O
cell	O
adhesion	O
,	O
whereas	O
they	O
did	O
not	O
affect	O
another	O
marker	O
of	O
differentiation	O
,	O
respiratory	O
burst	O
(	O
measured	O
by	O
nitro	O
blue	O
tetrazolium	O
reduction	O
assay	O
)	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c	O
-	O
jun	O
in	O
both	O
cell	O
proliferation	O
and	O
PMA	O
-	O
induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA	O
-	O
induced	O
respiratory	O
burst	O
in	O
U937	B
cells	I
.	O

Human	O
TAFII	O
105	O
is	O
a	O
cell	O
type	O
-	O
specific	O
TFIID	O
subunit	O
related	O
to	O
hTAFII130	O
.	O

We	O
previously	O
characterized	O
Drosophila	O
and	O
human	O
TAF	O
subunits	O
that	O
make	O
up	O
the	O
core	O
TFIID	O
complex	O
found	O
in	O
all	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	O
of	O
105	O
kDa	O
not	O
found	O
associated	O
with	O
TFIID	O
isolated	O
from	O
other	O
cell	O
types	O
.	O

The	O
cDNA	O
encoding	O
hTAFII105	O
reveals	O
a	O
highly	O
conserved	O
C	O
-	O
terminal	O
domain	O
shared	O
by	O
hTAFII130	O
and	O
oTAFII110	O
,	O
while	O
the	O
N	O
-	O
terminal	O
coactivator	O
domain	O
has	O
diverged	O
significantly	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	O
mRNA	O
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	O
.	O

Transient	O
overexpression	O
of	O
hTAFII105	O
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	O
cells	O
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	O
is	O
a	O
cell	O
type	O
-	O
specific	O
subunit	O
of	O
TFIID	O
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	O
cells	O
.	O

Regulation	O
of	O
interferon	O
-	O
gamma	O
gene	O
expression	O
.	O

Interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
,	O
also	O
known	O
as	O
type	O
II	O
interferon	O
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

IFN	O
-	O
gamma	O
mRNA	O
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
.	O

The	O
IFN	O
-	O
gamma	O
mRNA	O
is	O
induced	O
/	O
inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O

In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	O
binding	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
IFN	O
-	O
gamma	O
gene	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

Inorganic	O
lead	O
activates	O
NF	O
-	O
kappa	O
B	O
in	O
primary	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O

Inorganic	O
lead	O
(	O
Pb	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
that	O
produces	O
a	O
variety	O
of	O
effects	O
on	O
humoral	O
and	O
cell	O
mediated	O
immune	O
responses	O
.	O

The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O

Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV	O
-	O
LTR	O
activation	O
.	O

We	O
demonstrate	O
that	O
Pb	O
at	O
physiologically	O
relevant	O
concentrations	O
activates	O
NF	O
-	O
kappa	O
B	O
in	O
primary	O
human	O
CD4	O
+	O
T	O
lymphocytes	O
.	O

Pb	O
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
is	O
blocked	O
by	O
antibodies	O
for	O
p65	O
and	O
p50	O
subunits	O
but	O
not	O
cRel	O
,	O
indicating	O
that	O
the	O
p65	O
:	O
p50	O
heterodimer	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
is	O
involved	O
.	O

Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	B
CD4	I
+	I
T	I
cells	I
transfected	O
with	O
an	O
NF	O
-	O
kappa	O
B	O
dependent	O
reporter	O
gene	O
construct	O
.	O

Pb	O
did	O
not	O
activate	O
NF	O
-	O
kappa	O
B	O
in	O
4	O
different	O
T	B
cell	I
lines	I
,	O
suggesting	O
that	O
lymphoid	O
cell	O
lines	O
may	O
not	O
be	O
reliable	O
surrogates	O
for	O
the	O
study	O
of	O
transcriptional	O
activation	O
in	O
human	O
T	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
NF	O
-	O
kappa	O
B	O
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb	O
-	O
induced	O
immunotoxicity	O
.	O

Detection	O
of	O
intracellular	O
signal	O
transduction	O
molecules	O
in	O
PBMC	O
from	O
rhesus	O
macaques	O
and	O
sooty	O
mangabeys	O
.	O

One	O
of	O
the	O
manifestations	O
of	O
human	O
HIV-1	O
and	O
nonhuman	O
primate	O
SIV	O
infection	O
that	O
lead	O
to	O
disease	O
is	O
reasoned	O
to	O
be	O
secondary	O
to	O
generalized	O
T	O
-	O
cell	O
dysfunction	O
.	O

The	O
molecular	O
mechanisms	O
associated	O
with	O
the	O
T	O
-	O
cell	O
dysfunction	O
remain	O
to	O
be	O
elucidated	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
sought	O
to	O
utilize	O
the	O
nonhuman	O
primate	O
model	O
to	O
study	O
intracellular	O
signaling	O
events	O
in	O
cells	O
from	O
disease	O
-	O
susceptible	O
rhesus	O
macaques	O
and	O
disease	O
-	O
resistant	O
sooty	O
mangabeys	O
.	O

Because	O
relatively	O
little	O
is	O
known	O
about	O
these	O
events	O
in	O
nonhuman	O
primates	O
,	O
our	O
laboratory	O
defined	O
optimal	O
conditions	O
,	O
reagents	O
,	O
and	O
assays	O
for	O
the	O
study	O
of	O
signal	O
transduction	O
events	O
in	O
cells	O
from	O
nonhuman	O
primates	O
.	O

The	O
protein	O
phosphorylation	O
patterns	O
in	O
the	O
two	O
monkeys	O
exhibited	O
quantitative	O
,	O
qualitative	O
,	O
and	O
kinetic	O
differences	O
.	O

Antibodies	O
to	O
Stat6	O
detected	O
a	O
unique	O
band	O
in	O
macaque	O
cell	O
lysates	O
.	O

This	O
band	O
is	O
markedly	O
decreased	O
human	O
cell	O
lysates	O
and	O
never	O
seen	O
in	O
mangabey	O
cell	O
lysates	O
.	O

Detection	O
of	O
various	O
other	O
intracellular	O
signaling	O
proteins	O
is	O
also	O
described	O
.	O

Isolation	O
and	O
characterization	O
of	O
murine	O
fra-1	O
:	O
induction	O
mediated	O
by	O
CD40	O
and	O
surface	O
Ig	O
is	O
protein	O
kinase	O
C	O
dependent	O
.	O

The	O
murine	O
fra-1	O
gene	O
,	O
encoding	O
Fos	O
-	O
related	O
Ag	O
1	O
,	O
was	O
isolated	O
from	O
a	O
splenic	O
cDNA	O
library	O
and	O
sequenced	O
.	O

Murine	O
fra-1	O
was	O
highly	O
homologous	O
to	O
rat	O
and	O
human	O
fra-1	O
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	O
sequence	O
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
assay	O
for	O
gene	O
expression	O
.	O

B	O
lymphocyte	O
stimulation	O
via	O
both	O
CD40	O
and	O
surface	O
Ig	O
(	O
sIg	O
)	O
receptors	O
substantially	O
induced	O
fra-1	O
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
dependent	O
.	O

This	O
contrasts	O
with	O
induction	O
of	O
c	O
-	O
fos	O
by	O
both	O
CD40	O
and	O
sIg	O
,	O
which	O
is	O
PKC	O
independent	O
and	O
indicates	O
that	O
CD40	O
is	O
capable	O
of	O
signaling	O
through	O
PKC	O
or	O
a	O
closely	O
related	O
kinase	O
.	O

Induction	O
of	O
fra-1	O
following	O
engagement	O
of	O
CD40	O
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	O
-dependent	O
linkage	O
between	O
CD40	O
and	O
fra-1	O
is	O
direct	O
.	O

CD40	O
-mediated	O
fra-1	O
induction	O
did	O
require	O
tyrosine	O
kinase	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
CD40	O
,	O
like	O
sIg	O
,	O
may	O
employ	O
PKC	O
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	O
cell	O
receptors	O
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC	O
-	O
dependent	O
and	O
PKC	O
-	O
independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	O
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
3	O
binding	O
sites	O
in	O
the	O
human	O
and	O
simian	O
Epstein	O
-	O
Barr	O
virus	O
oncogene	O
LMP1	O
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B	O
-	O
lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus	O
-	O
induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation	O
-	O
associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
homologs	O
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy	O
-	O
terminal	O
cytoplasmic	O
domain	O
essential	O
for	O
B	O
-	O
cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	O
EBV	O
LMP1s	O
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	O
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	O
(	O
kappa	O
)	O
B	O
activity	O
in	O
human	O
cells	O
,	O
to	O
bind	O
the	O
tumor	O
necrosis	O
factor	O
-	O
associated	O
factor	O
3	O
(	O
TRAF3	O
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
genes	O
,	O
such	O
as	O
ICAM1	O
,	O
in	O
human	O
B	O
lymphocytes	O
.	O

Multiple	O
TRAF3	O
binding	O
sites	O
containing	O
a	O
PXQXT	O
/	O
S	O
core	O
sequence	O
can	O
be	O
identified	O
in	O
the	O
simian	O
EBV	O
LMP1s	O
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT	O
/	O
S	O
-	O
containing	O
sequence	O
is	O
also	O
present	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	O
,	O
and	O
binds	O
TRAF3	O
in	O
vitro	O
.	O

The	O
last	O
13	O
amino	O
acids	O
containing	O
a	O
PXQXT	O
/	O
S	O
sequence	O
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	O
but	O
do	O
not	O
bind	O
TRAF3	O
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	O
.	O

The	O
conserved	O
TRAF3	O
binding	O
sites	O
in	O
LMP1	O
and	O
the	O
CD30	O
Hodgkin	O
's	O
disease	O
marker	O
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	O
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Interferons	O
induce	O
normal	O
and	O
aberrant	O
retinoic	O
-	O
acid	O
receptors	O
type	O
alpha	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O
potentiation	O
of	O
the	O
induction	O
of	O
retinoid	O
-	O
dependent	O
differentiation	O
markers	O
.	O

Treatment	O
of	O
the	O
acute	B
promyelocytic	I
(	I
APL	I
)	I
cell	I
line	I
NB4	B
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic	O
-	O
acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
(	O
alpha	O
)	O
)	O
and	O
the	O
leukemia	O
-	O
specific	O
retinoic	O
acid	O
receptor	O
PML	O
-	O
RAR	O
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	O
(	O
alpha	O
)	O
and	O
PML	O
-	O
RAR	O
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Up	O
-	O
regulation	O
of	O
RAR	O
(	O
alpha	O
)	O
and	O
PML	O
-	O
RAR	O
gene	O
expression	O
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
,	O
i.e.	O
,	O
granulocyte	O
-	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
mRNA	O
and	O
leukocyte	O
alkaline	O
phosphatase	O
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	O
have	O
any	O
effects	O
on	O
the	O
retinoid	O
-	O
dependent	O
regulation	O
of	O
the	O
myeloid	O
surface	O
markers	O
CD11b	O
and	O
CD33	O
.	O

The	O
IFN	O
-dependent	O
increase	O
in	O
RAR	O
(	O
alpha	O
)	O
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid	O
-	O
dependent	O
granulocytic	O
markers	O
expression	O
may	O
be	O
a	O
characteristic	O
of	O
PML	B
-	I
RAR	I
positive	I
cells	I
,	O
since	O
the	O
phenomena	O
are	O
not	O
observed	O
in	O
HL-60	B
promyelocytes	I
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	B
cells	I
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti	O
-	O
proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto	O
-	O
differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

Silencing	O
of	O
human	O
fetal	O
globin	O
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	O
beta	O
-	O
globin	O
gene	O
activator	O
protein	O
EKLF	O
.	O

Globin	O
genes	O
are	O
subject	O
to	O
tissue	O
-	O
specific	O
and	O
developmental	O
stage	O
-	O
specific	O
regulation	O
.	O

A	O
switch	O
from	O
human	O
fetal	O
(	O
gamma	O
)	O
-to	O
adult	O
(	O
beta	O
)	O
-globin	O
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	O
Kruppel	O
-	O
like	O
factor	O
(	O
EKLF	O
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high	O
-	O
affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O

To	O
examine	O
the	O
role	O
of	O
EKLF	O
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma	O
-	O
globin	O
gene	O
we	O
interbred	O
EKLF	O
heterozygotes	O
(	O
+	O
/-	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta	O
-	O
globin	O
yeast	O
artificial	O
chromosome	O
transgene	O
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	O
,	O
while	O
human	O
beta	O
-	O
globin	O
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma	O
-	O
globin	O
transcripts	O
are	O
elevated	O
approximately	O
5-fold	O
.	O

Impaired	O
silencing	O
of	O
gamma	O
-	O
globin	O
expression	O
identifies	O
EKLF	O
as	O
the	O
first	O
transcription	O
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma	O
-	O
globin	O
to	O
beta	O
-	O
globin	O
switch	O
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	O
mediates	O
an	O
adult	O
stage	O
-	O
specific	O
interaction	O
between	O
the	O
beta	O
-	O
globin	O
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma	O
-	O
globin	O
gene	O
.	O

Modulatory	O
effects	O
of	O
glucocorticoids	O
and	O
catecholamines	O
on	O
human	O
interleukin	O
-12	O
and	O
interleukin	O
-10	O
production	O
:	O
clinical	O
implications	O
.	O

Interleukin-12	O
(	O
IL-12	O
)	O
is	O
a	O
key	O
inducer	O
of	O
differentiation	O
of	O
uncommitted	O
T	O
helper	O
(	O
TH	O
)	O
cells	O
toward	O
the	O
TH1	O
phenotype	O
,	O
which	O
regulates	O
cellular	O
immunity	O
,	O
whereas	O
IL-10	O
inhibits	O
TH1	O
functions	O
and	O
potentiates	O
TH2-regulated	O
responses	O
(	O
i.e.	O
,	O
humoral	O
immunity	O
)	O
.	O

To	O
examine	O
the	O
potential	O
effects	O
of	O
stress	O
on	O
TH1	O
/	O
TH2	O
balance	O
,	O
we	O
studied	O
the	O
ability	O
of	O
three	O
prototype	O
stress	O
hormones	O
-	O
dexamethasone	O
(	O
a	O
synthetic	O
glucocorticoid	O
)	O
and	O
the	O
catecholamines	O
norepinephrine	O
and	O
epinephrine	O
-	O
to	O
alter	O
the	O
production	O
of	O
IL-12	O
(	O
p70	O
)	O
and	O
IL-10	O
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
human	O
whole	O
blood	O
.	O

Dexamethasone	O
inhibited	O
LPS	O
-	O
induced	O
bioactive	O
IL-12	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations	O
;	O
it	O
had	O
no	O
effect	O
on	O
IL-10	O
secretion	O
.	O

The	O
glucocorticoid	O
-	O
induced	O
reduction	O
of	O
IL-12	O
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid	O
-	O
receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

Norepinephrine	O
and	O
epinephrine	O
also	O
suppressed	O
IL-12	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
and	O
at	O
physiological	O
concentrations	O
;	O
both	O
catecholamines	O
,	O
however	O
,	O
dose	O
-	O
dependently	O
increased	O
the	O
production	O
of	O
IL-10	O
.	O

The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL-12	O
or	O
IL-10	O
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta	O
-	O
adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta	O
-	O
adrenergic	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1	O
/	O
TH2	O
balance	O
via	O
the	O
peripheral	O
end	O
-	O
effectors	O
of	O
the	O
stress	O
system	O
.	O

Thus	O
,	O
stress	O
may	O
cause	O
a	O
selective	O
suppression	O
of	O
TH1	O
functions	O
and	O
a	O
shift	O
toward	O
a	O
TH2	O
cytokine	O
pattern	O
rather	O
than	O
generalized	O
TH	O
suppression	O
.	O

The	O
TH1-to	O
-	O
TH2	O
shift	O
may	O
be	O
responsible	O
for	O
the	O
stress	O
-	O
induced	O
susceptibility	O
of	O
the	O
organism	O
to	O
certain	O
infections	O
.	O

Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O

Characterization	O
of	O
a	O
CD43	O
/	O
leukosialin	O
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
lymphoblastoid	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
J393	O
induces	O
apoptosis	O
in	O
Jurkat	B
T	I
-	I
cells	I
.	O

NH2	O
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	O
surface	O
antigen	O
for	O
mAb	O
J393	O
as	O
CD43	O
/	O
leukosialin	O
,	O
the	O
major	O
sialoglycoprotein	O
of	O
leukocytes	O
.	O

While	O
Jurkat	B
cells	I
co	O
-	O
expressed	O
two	O
discrete	O
cell	O
-	O
surface	O
isoforms	O
of	O
CD43	O
,	O
recognized	O
by	O
mAb	O
J393	O
and	O
mAb	O
G10	O
-	O
2	O
,	O
respectively	O
,	O
only	O
J393	O
/	O
CD43	O
signaled	O
apoptosis	O
.	O

J393	O
/	O
CD43	O
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O	O
-	O
linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10	O
-	O
2	O
/	O
CD43	O
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	O
J393	O
killed	O
25	O
-	O
50	O
%	O
of	O
the	O
cell	B
population	I
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	O
complex	O
or	O
the	O
integrins	O
CD18	O
and	O
CD29	O
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	B
cells	I
with	O
mAb	O
J393	O
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	O
receptor	O
costimulation	O
.	O

Tyrosine	O
kinase	O
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393	O
/	O
CD43	O
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	O
phosphatase	O
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium	O
-	O
IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393	O
/	O
CD43	O
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	O
regulatory	O
protein	O
NF	O
-	O
kappaB	O
and	O
proteins	O
binding	O
the	O
interferon	O
-	O
inducible	O
regulatory	O
element	O
.	O

Since	O
peripheral	O
blood	O
T	O
-	O
lymphocytes	O
express	O
cryptic	O
epitopes	O
for	O
mAb	O
J393	O
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	O
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T	O
-	O
cell	O
lineages	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte	O
-	O
specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	O
protein	O
designated	O
Sp140	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
Sp140	O
was	O
similar	O
to	O
Sp100	O
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O

The	O
carboxyl	O
portion	O
of	O
Sp140	O
contained	O
a	O
zinc	O
-	O
finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	O
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	O
mRNA	O
in	O
myeloid	B
precursor	I
cell	I
lines	I
HL60	B
and	O
NB4	B
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	O
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	B
and	O
NB4	B
cells	I
.	O

The	O
location	O
of	O
Sp140	O
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Interferon	O
augments	O
PML	O
and	O
PML	O
/	O
RAR	O
alpha	O
expression	O
in	O
normal	O
myeloid	O
and	O
acute	O
promyelocytic	O
cells	O
and	O
cooperates	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid	B
-	I
resistant	I
promyelocytic	I
cell	I
line	I
.	O

The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
gene	O
(	O
RAR	O
alpha	O
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

PML	O
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	O
cells	O
.	O

PML	O
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	O
I	O
and	O
II	O
interferons	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	O
cells	O
and	O
precursors	O
by	O
activating	O
PML	O
-dependent	O
pathways	O
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	O
cells	O
,	O
alone	O
or	O
in	O
combination	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML	O
/	O
RAR	O
alpha	O
fusion	O
transcript	O
that	O
results	O
from	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
is	O
induced	O
by	O
interferon	O
.	O

We	O
report	O
here	O
that	O
PML	O
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	O
monocytes	O
,	O
lymphocytes	O
,	O
and	O
polymorphonucleate	O
cells	O
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	O
;	O
that	O
PML	O
and	O
PML	O
/	O
RAR	O
alpha	O
expression	O
is	O
augmented	O
by	O
interferon	O
in	O
the	O
NB4	B
APL	I
cell	I
line	I
,	O
which	O
carries	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
in	O
APL	O
blasts	O
from	O
patients	O
;	O
that	O
interferon	O
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	O
cells	O
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	B
cells	I
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	O
gamma	O
,	O
but	O
not	O
alpha	O
or	O
beta	O
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	B
cells	I
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

T	O
cell	O
response	O
to	O
Epstein	O
-	O
Barr	O
virus	O
transactivators	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Implication	O
of	O
viruses	O
such	O
as	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O

Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	O
cells	O
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	O
transactivators	O
(	O
BZLF1	O
and	O
BMLF1	O
)	O
in	O
a	O
major	O
histocompatibility	O
complex	O
-restricted	O
fashion	O
.	O

Responses	O
to	O
these	O
EBV	O
antigens	O
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	O
transactivating	O
factors	O
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
,	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
c	O
-	O
Rel	O
,	O
and	O
RelB	O
,	O
constitute	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	O
knockout	O
mice	O
have	O
no	O
dendritic	O
cells	O
(	O
DC	O
)	O
.	O

An	O
overexpression	O
of	O
p50	O
has	O
been	O
described	O
in	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

A	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
has	O
been	O
reported	O
in	O
mature	O
macrophages	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
were	O
key	O
nuclear	O
factors	O
in	O
functions	O
of	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	O
and	O
c	O
-	O
Rel	O
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	O
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	O
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68	B
+	I
cells	I
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA	B
-	I
DR+	I
cells	I
with	O
an	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	O
and	O
RelB	O
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	B
and	O
CD68	B
+	I
cells	I
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	O
was	O
found	O
only	O
in	O
CD68-	B
and	I
CD1a-	I
cells	I
.	O

Cells	O
with	O
nuclear	O
p50	O
were	O
negative	O
for	O
the	O
CD38	O
,	O
CD20	O
and	O
CD2	O
markers	O
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	O
,	O
p52	O
and	O
RelB	O
are	O
restricted	O
to	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	O
in	O
GC	O
,	O
and	O
DC	O
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	O
macrophages	O
from	O
GC	O
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	O
and	O
RelB	O
,	O
whereas	O
macrophages	O
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	O
cells	O
,	O
do	O
have	O
both	O
nuclear	O
p52	O
and	O
RelB	O
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	O
and	O
RelB	O
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	B
,	O
CD68	B
+	I
or	O
both	O
,	O
cells	O
APC	O
,	O
whereas	O
p50	O
is	O
restricted	O
to	O
CD1a-	O
and	O
CD68-	O
APC	O
.	O

The	O
different	O
patterns	O
of	O
p50	O
,	O
p52	O
and	O
RelB	O
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
-	O
encoded	O
dUTPase	O
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	O
against	O
the	O
enzyme	O
.	O

The	O
gene	O
encoding	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-specific	O
dUTPase	O
was	O
amplified	O
from	O
virus	O
DNA	O
by	O
PCR	O
.	O

The	O
active	O
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
insect	O
cells	O
as	O
a	O
non	O
-	O
fusion	O
protein	O
.	O

The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	O
react	O
with	O
other	O
dNTPs	O
or	O
NTPs	O
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O

MAbs	O
against	O
the	O
dUTPase	O
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O	B
-	I
tetradecanoyl	I
-	I
phorbol-13-acetate	I
(	I
TPA	I
)	I
-stimulated	I
B	I
cells	I
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O

The	O
protein	O
was	O
found	O
in	O
untreated	O
cells	O
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	O
early	O
transactivator	O
BZLF1	O
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O

We	O
demonstrated	O
that	O
the	O
virus	O
dUTPase	O
isolated	O
from	O
EBV	O
-	O
infected	O
cells	O
is	O
a	O
phosphoprotein	O
.	O

The	O
protein	O
expressed	O
in	O
insect	O
cells	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	O
antibodies	O
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O

While	O
the	O
sera	O
of	O
EBV	O
-	O
negative	O
individuals	O
(	O
0	O
/	O
3	O
)	O
or	O
healthy	O
carriers	O
(	O
0	O
/	O
33	O
)	O
did	O
not	O
contain	O
detectable	O
levels	O
of	O
antibodies	O
,	O
patients	O
with	O
mononucleosis	O
(	O
5	O
/	O
18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2	O
/	O
7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7	O
/	O
20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5	O
/	O
24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O

Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
elements	O
in	O
human	O
T	O
lymphocytes	O
.	O

Prostaglandins	O
of	O
the	O
E	O
series	O
are	O
immunomodulatory	O
agents	O
which	O
exert	O
inhibitory	O
as	O
well	O
as	O
stimulatory	O
effects	O
on	O
a	O
variety	O
of	O
immune	O
responses	O
.	O

Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factors	O
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP	O
-	O
regulated	O
genes	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
demonstrated	O
that	O
a	O
short	O
treatment	O
of	O
human	O
T	O
lymphocytes	O
with	O
PGE2	O
induces	O
specific	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
,	O
but	O
not	O
AP-1	O
,	O
DNA	O
elements	O
.	O

Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O

This	O
activity	O
seems	O
to	O
be	O
due	O
to	O
increased	O
cAMP	O
levels	O
because	O
forskolin	O
and	O
IBMX	O
mimic	O
the	O
effects	O
of	O
PGE2	O
.	O

More	O
interestingly	O
,	O
transfection	O
experiments	O
with	O
CRE	O
-	O
CAT	O
plasmide	O
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE	O
-	O
containing	O
promoter	O
.	O

These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O

Tissue	O
and	O
cell	O
-	O
type	O
specific	O
expression	O
of	O
the	O
tuberous	O
sclerosis	O
gene	O
,	O
TSC2	O
,	O
in	O
human	O
tissues	O
.	O

TSC2	O
is	O
a	O
gene	O
on	O
chromosome	O
16p13.3	O
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	O
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin	O
-	O
labeled	O
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	O
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy	O
-	O
derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	O
messenger	O
RNA	O
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	O
cells	O
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	O
neurons	O
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	O
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	O
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	O
,	O
with	O
central	O
nervous	O
system	O
pyramidal	O
cells	O
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory	O
/	O
transport	O
functions	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	O
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor	O
/	O
growth	O
suppressor	O
.	O

Elf-1	O
and	O
Stat5	O
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin-2	O
receptor	O
alpha	O
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL-2R	O
alpha	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	O
2	O
(	O
IL-2	O
)	O
stimulates	O
IL-2R	O
alpha	O
.	O

transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high	O
-	O
affinity	O
receptor	O
.	O

IL-2R	O
alpha	O
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	O
regulatory	O
regions	O
,	O
PRRI	O
and	O
PRRII	O
.	O

PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-276	O
and	O
-244	O
,	O
which	O
contains	O
NF	O
-	O
kappaB	O
and	O
SRE	O
/	O
CArG	O
motifs	O
.	O

PRRII	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
,	O
which	O
binds	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Ets	O
protein	O
Elf-1	O
and	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
proteins	O
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	O
.	O

To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL-2-responsive	O
element	O
(	O
mIL-2rE	O
)	O
.	O

This	O
putative	O
human	O
IL-2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL-2	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd	O
/	O
EBSd	O
)	O
.	O

These	O
are	O
essential	O
for	O
IL-2	O
inducibility	O
of	O
PRRIII	O
/	O
CAT	O
reporter	O
constructs	O
.	O

IL-2	O
induced	O
the	O
binding	O
of	O
Stat5a	O
and	O
b	O
proteins	O
to	O
the	O
human	O
GASd	O
element	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	O
alpha	O
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd	O
/	O
EBSd	O
element	O
in	O
IL-2R	O
alpha	O
regulation	O
and	O
suggest	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Elf-1	O
factor	O
can	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
.	O

Association	O
of	O
TRAF1	O
,	O
TRAF2	O
,	O
and	O
TRAF3	O
with	O
an	O
Epstein	O
-	O
Barr	O
virus	O
LMP1	O
domain	O
important	O
for	O
B	O
-	O
lymphocyte	O
transformation	O
:	O
role	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
appears	O
to	O
be	O
a	O
constitutively	O
activated	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	O
carboxyl	O
terminus	O
(	O
CT	O
)	O
with	O
TNFR	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
.	O

We	O
now	O
show	O
that	O
in	O
EBV	B
-	I
transformed	I
B	I
lymphocytes	I
most	O
of	O
TRAF1	O
or	O
TRAF3	O
and	O
5	O
%	O
of	O
TRAF2	O
are	O
associated	O
with	O
LMP1	O
and	O
that	O
most	O
of	O
LMP1	O
is	O
associated	O
with	O
TRAF1	O
or	O
TRAF3	O
.	O

TRAF1	O
,	O
TRAF2	O
,	O
and	O
TRAF3	O
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	O
CT	O
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B	O
-	O
lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O

Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	O
binding	O
sequences	O
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	O
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT	O
/	O
S	O
is	O
a	O
core	O
TRAF	O
binding	O
motif	O
.	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
core	O
TRAF	O
binding	O
motif	O
on	O
TRAF	O
binding	O
and	O
NF	O
-	O
kappaB	O
activation	O
genetically	O
link	O
the	O
TRAFs	O
to	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

NF	O
-	O
kappaB	O
activation	O
by	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	O
/TRAF2	O
heteroaggregates	O
since	O
TRAF1	O
is	O
unique	O
among	O
the	O
TRAFs	O
in	O
coactivating	O
NF	O
-	O
kappaB	O
with	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
,	O
a	O
TRAF2	O
dominant	O
-	O
negative	O
mutant	O
can	O
block	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	O
-	O
kappaB	O
activation	O
as	O
well	O
as	O
TRAF1	O
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	O
is	O
associated	O
with	O
TRAF1	O
in	O
EBV	O
-	O
transformed	O
B	O
cells	O
.	O

TRAF3	O
is	O
a	O
negative	O
modulator	O
of	O
LMP1	O
(	O
1	O
-	O
231	O
)	O
-mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

Surprisingly	O
,	O
TRAF1	O
,	O
-2	O
,	O
or	O
-3	O
does	O
not	O
interact	O
with	O
the	O
terminal	O
LMP1	O
CT	O
aa	O
333	O
to	O
386	O
which	O
can	O
independently	O
mediate	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
constitutive	O
association	O
of	O
TRAFs	O
with	O
LMP1	O
through	O
the	O
aa	O
187	O
to	O
231	O
domain	O
which	O
is	O
important	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
primary	O
B	O
-	O
lymphocyte	O
growth	O
transformation	O
implicates	O
TRAF	O
aggregation	O
in	O
LMP1	O
signaling	O
.	O

CD40	O
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti	O
-	O
IgM	O
stimulation	O
of	O
primary	O
B	O
lymphocytes	O
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	O
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel	O
/	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
factors	O
in	O
primary	O
murine	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	O
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	O
ligands	O
expressed	O
on	O
L	O
cells	O
led	O
to	O
strong	O
activation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
controlled	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
primary	O
B	O
lymphocytes	O
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	O
proteins	O
after	O
CD40	O
induction	O
of	O
primary	O
B	O
cells	O
showed	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
accumulation	O
of	O
RelB	O
and	O
,	O
less	O
pronounced	O
,	O
of	O
c	O
-	O
Rel	O
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	O
and	O
c	O
-	O
Rel	O
,	O
whereas	O
nuclear	O
c	O
-	O
Rel	O
,	O
but	O
not	O
RelB	O
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	O
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	O
RNA	O
and	O
protein	O
.	O

S107	B
plasmacytoma	I
cells	I
,	O
which	O
express	O
CD40	O
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50	O
/	O
p65-NF	O
-	O
kappaB	O
,	O
do	O
not	O
express	O
RelB	O
after	O
CD40	O
stimulation	O
.	O

In	O
S107	B
cells	I
stably	O
transfected	O
with	O
relB	O
genes	O
,	O
stimulation	O
of	O
nuclear	O
RelB	O
translocation	O
by	O
CD40	O
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	O
signaling	O
pathways	O
exerts	O
a	O
long	O
-	O
lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	O
.	O

Since	O
LPS	O
and	O
anti	O
-	O
IgM	O
were	O
unable	O
to	O
activate	O
RelB	O
,	O
CD40	O
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and/or	O
differentiation	O
of	O
B	O
lymphocytes	O
.	O

[	O
Cortisone	O
-	O
resistant	O
bronchial	O
asthma	O
]	O

There	O
is	O
general	O
agreement	O
on	O
the	O
inflammatory	O
pathogenesis	O
of	O
bronchial	O
asthma	O
:	O
an	O
accumulation	O
of	O
activated	O
eosinophils	O
,	O
degranulated	O
mast	O
cells	O
,	O
T	O
lymphocytes	O
and	O
in	O
very	O
severe	O
forms	O
,	O
granulocytes	O
has	O
constantly	O
been	O
found	O
in	O
the	O
bronchial	O
mucosa	O
.	O

In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	O
lymphocytes	O
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	O
subset	O
able	O
to	O
produce	O
IL-4	O
and	O
IL-5	O
.	O

Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease	O
,	O
their	O
anti	O
-	O
inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O

Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid	O
-	O
resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O

This	O
review	O
analyzes	O
various	O
molecular	O
alterations	O
responsible	O
for	O
the	O
deficient	O
response	O
to	O
corticosteroid	O
treatment	O
observed	O
in	O
steroid	O
-	O
resistant	O
bronchial	O
asthmatic	O
subjects	O
.	O

New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O

The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon	O
-	O
gamma	O
promoter	O
mediates	O
selective	O
expression	O
in	O
T	O
cells	O
.	O

Interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
is	O
produced	O
by	O
natural	O
killer	O
cells	O
and	O
certain	O
subsets	O
of	O
T	O
cells	O
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

Within	O
the	O
region	O
between	O
-108	O
and	O
-40	O
base	O
pairs	O
of	O
the	O
IFN	O
-	O
gamma	O
promoter	O
are	O
two	O
conserved	O
and	O
essential	O
regulatory	O
elements	O
,	O
which	O
confer	O
activation	O
-	O
specific	O
expression	O
in	O
T	O
cells	O
.	O

This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	O
elements	O
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB	O
/	O
ATF	O
,	O
AP-1	O
,	O
and	O
octamer	O
families	O
of	O
transcription	O
factors	O
.	O

Jun	O
is	O
essential	O
for	O
activation	O
-	O
induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	O
.	O

In	O
contrast	O
,	O
CREB	O
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O

The	O
CpG	O
dinucleotide	O
in	O
this	O
element	O
is	O
selectively	O
methylated	O
in	O
Th2	O
T	O
cells	O
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN	O
-	O
gamma	O
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	O
factor	O
binding	O
.	O

As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	O
factors	O
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN	O
-	O
gamma	O
expression	O
.	O

HIV-1	O
LTR	O
activity	O
in	O
human	B
CD40-activated	I
B	I
lymphocytes	I
is	O
dependent	O
on	O
NF	O
-	O
kappaB	O
.	O

CD40-stimulated	B
human	I
B	I
lymphocytes	I
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	O
factors	O
involved	O
in	O
activation	O
of	O
the	O
HIV-1	O
LTR	O
,	O
which	O
contains	O
the	O
transcriptional	O
control	O
elements	O
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	O
region	O
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
binding	O
site	O
was	O
essential	O
for	O
HIV-1	O
LTR	O
activity	O
in	O
CD40-stimulated	B
B	I
lymphocytes	I
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF	O
-	O
kappaB	O
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	O
,	O
p65	O
,	O
and	O
c	O
-	O
Rel	O
NF	O
-	O
kappaB	O
subunits	O
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	B
B	I
cells	I
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	O
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF	O
-	O
kappaB	O
.	O

Lymphocytes	O
from	O
CML	O
patients	O
lack	O
a	O
47	O
kDa	O
factor	O
having	O
affinity	O
for	O
a	O
genomic	O
sterol	O
regulatory	O
sequence	O
.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Since	O
the	O
human	O
genomic	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha	O
-	O
interferon	O
therapy	O
.	O

Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	O
receptor	O
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
protein	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

Glucocorticoid	O
-	O
mediated	O
inhibition	O
of	O
RANTES	O
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O

The	O
chemokine	O
RANTES	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O

We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	O
mRNA	O
expression	O
dose	O
dependently	O
in	O
anti	B
-	I
CD3	I
activated	I
Hut-78	I
T	I
cells	I
and	O
human	O
PBMCs	O
.	O

Inhibition	O
of	O
RANTES	O
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	O
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	O
receptor	O
.	O

The	O
down	O
-	O
regulation	O
of	O
RANTES	O
expression	O
by	O
glucocorticoids	O
in	O
T	O
cells	O
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti	O
-	O
inflammatory	O
properties	O
.	O

A	O
novel	O
SP-1	O
site	O
in	O
the	O
human	O
interleukin-1	O
beta	O
promoter	O
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
in	O
non	O
-	O
monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	O
IL-1beta	O
promoter	O
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43-mer	O
oligonucleotide	O
derived	O
from	O
the	O
functionally	O
identified	O
cis	O
-	O
acting	O
element	O
revealed	O
specific	O
complexes	O
.	O

By	O
competition	O
analysis	O
with	O
transcription	O
factor	O
consensus	O
sequence	O
oligonucleotides	O
and	O
by	O
immunosupershift	O
,	O
transcription	O
factor	O
SP-1	O
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
this	O
regulatory	O
element	O
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP-1	O
consensus	O
sequence	O
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	O
motif	O
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low	O
-	O
mobility	O
complexes	O
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL-1beta	O
(	O
-170	O
/	O
+108	O
)	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
depended	O
on	O
the	O
SP-1	O
site	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
so	O
-	O
far	O
-	O
unrecognized	O
SP-1	O
site	O
in	O
the	O
human	O
IL-1beta	O
promoter	O
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	O
.	O

Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

Prolonged	O
poor	O
glycemic	O
control	O
in	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	O
secretion	O
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so	O
-	O
called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT	O
-	O
T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D	O
-	O
ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O

The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	O
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta	O
-	O
actin	O
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D	O
-	O
ribose	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	O
mRNA	O
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation	O
-	O
induced	O
cells	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
an	O
insulin	O
gene	O
transcription	O
factor	O
,	O
PDX-1	O
/	O
IPF1	O
/	O
STF-1	O
.	O

These	O
effects	O
of	O
D	O
-	O
ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N	O
-	O
acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Ras	O
-dependent	O
,	O
Ca2	O
+	O
-stimulated	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
by	O
a	O
constitutively	O
active	O
Cbl	O
mutant	O
in	O
T	O
cells	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
stimulation	O
induces	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
,	O
including	O
Cbl	O
,	O
a	O
protooncogene	O
product	O
whose	O
function	O
remains	O
unclear	O
.	O

As	O
a	O
first	O
step	O
toward	O
elucidating	O
the	O
function	O
of	O
Cbl	O
in	O
TCR	O
-initiated	O
signaling	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
wild	O
-	O
type	O
Cbl	O
or	O
a	O
transforming	O
Cbl	O
mutant	O
(	O
70Z	O
/	O
3	O
)	O
to	O
induce	O
transcriptional	O
activation	O
of	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
element	O
derived	O
from	O
the	O
interleukin	O
2	O
(	O
IL2	O
)	O
promoter	O
in	O
transiently	O
cotransfected	O
Jurkat	B
-	I
TAg	I
T	I
cells	I
.	O

70Z	O
/	O
3	O
,	O
but	O
not	O
Cbl	O
,	O
caused	O
NFAT	O
activation	O
which	O
was	O
significantly	O
enhanced	O
by	O
stimulation	O
with	O
calcium	O
ionophore	O
,	O
and	O
was	O
drastically	O
reduced	O
by	O
cyclosporin	O
A	O
pretreatment	O
.	O

A	O
point	O
mutation	O
of	O
a	O
potential	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3-K	O
)	O
binding	O
site	O
(	O
Y731EAM	O
to	O
Y731EAC	O
)	O
in	O
70Z	O
/	O
3	O
disrupted	O
the	O
association	O
of	O
PI3-K	O
with	O
70Z	O
/	O
3	O
,	O
but	O
did	O
not	O
reduce	O
the	O
induction	O
of	O
NFAT	O
activity	O
,	O
suggesting	O
that	O
the	O
interaction	O
between	O
Cbl	O
and	O
PI3-K	O
is	O
not	O
required	O
in	O
the	O
70Z	O
/	O
3	O
-mediated	O
induction	O
of	O
NFAT	O
.	O

Additional	O
mapping	O
studies	O
indicated	O
that	O
defined	O
deletions	O
of	O
C	O
-	O
terminal	O
70Z	O
/	O
3	O
sequences	O
affected	O
to	O
a	O
variable	O
degree	O
its	O
ability	O
to	O
stimulate	O
NFAT	O
activity	O
.	O

Strikingly	O
,	O
deletion	O
of	O
346	O
C	O
-	O
terminal	O
residues	O
augmented	O
this	O
activity	O
,	O
whereas	O
removal	O
of	O
20	O
additional	O
residues	O
abolished	O
it	O
.	O

Coexpression	O
of	O
dominant	O
negative	O
Ras	O
abrogated	O
the	O
basal	O
or	O
ionomycin	O
-	O
stimulated	O
,	O
70Z	O
/	O
3	O
-mediated	O
NFAT	O
activation	O
,	O
suggesting	O
a	O
functional	O
Ras	O
is	O
required	O
for	O
this	O
activation	O
.	O

These	O
results	O
implicate	O
Cbl	O
in	O
Ras	O
-dependent	O
signaling	O
pathways	O
which	O
lead	O
to	O
NFAT	O
activation	O
.	O

A	O
novel	O
transcription	O
factor	O
regulates	O
expression	O
of	O
the	O
vacuolar	O
H+-ATPase	O
B2	O
subunit	O
through	O
AP-2	O
sites	O
during	O
monocytic	O
differentiation	O
.	O

During	O
monocyte	O
-	O
to	O
-	O
macrophage	O
differentiation	O
,	O
the	O
cellular	O
content	O
of	O
vacuolar	O
H+-ATPase	O
(	O
V	O
-	O
ATPase	O
)	O
increases	O
more	O
than	O
4-fold	O
.	O

We	O
have	O
shown	O
previously	O
that	O
amplified	O
expression	O
of	O
the	O
B2	O
subunit	O
of	O
the	O
V	O
-	O
ATPase	O
occurs	O
solely	O
by	O
increased	O
transcription	O
,	O
and	O
that	O
the	O
5'-untranslated	O
region	O
of	O
the	O
B2	O
gene	O
,	O
containing	O
multiple	O
consensus	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-2	O
and	O
Sp1	O
,	O
is	O
required	O
for	O
this	O
expression	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
AP-2	O
binding	O
sequences	O
are	O
essential	O
for	O
increased	O
transcription	O
from	O
the	O
B2	O
promoter	O
during	O
monocyte	O
-	O
macrophage	O
differentiation	O
and	O
that	O
AP-2	O
,	O
expressed	O
exogenously	O
in	O
THP-1	B
and	O
other	O
cells	O
,	O
activates	O
transcription	O
from	O
the	O
B2	O
promoter	O
.	O

In	O
mobility	O
shift	O
assays	O
,	O
a	O
nuclear	O
factor	O
from	O
THP-1	B
and	O
U-937	B
cells	I
was	O
identified	O
that	O
binds	O
to	O
several	O
AP-2	O
response	O
elements	O
within	O
the	O
B2	O
promoter	O
,	O
but	O
does	O
not	O
react	O
with	O
AP-2	O
antibodies	O
,	O
and	O
has	O
a	O
DNA	O
sequence	O
binding	O
affinity	O
profile	O
that	O
differs	O
from	O
AP-2	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
novel	O
AP-2-like	O
transcription	O
factor	O
is	O
responsible	O
for	O
V	O
-	O
ATPase	O
B	O
subunit	O
amplification	O
during	O
monocyte	O
differentiation	O
.	O

Elf-2	O
,	O
a	O
rhombotin-2	O
binding	O
ets	O
transcription	O
factor	O
:	O
discovery	O
and	O
potential	O
role	O
in	O
T	O
cell	O
leukemia	O
.	O

Rhombotin-2	O
(	O
RBTN-2	O
)	O
is	O
a	O
proto	O
-	O
oncogene	O
only	O
in	O
the	O
context	O
of	O
T	O
lymphocytes	O
.	O

We	O
postulated	O
that	O
the	O
oncogenic	O
effect	O
of	O
RBTN-2	O
in	O
T	O
cells	O
is	O
likely	O
mediated	O
by	O
binding	O
protein	O
(	O
s	O
)	O
with	O
T	O
cell	O
-	O
specific	O
expression	O
.	O

By	O
screening	O
a	O
T	O
cell	O
cDNA	O
library	O
,	O
we	O
identified	O
a	O
novel	O
ets	O
transcription	O
factor	O
that	O
binds	O
RBTN-2	O
.	O

This	O
protein	O
was	O
named	O
elf-2	O
because	O
its	O
DNA	O
-	O
binding	O
domain	O
is	O
virtually	O
identical	O
to	O
that	O
of	O
ets	O
family	O
member	O
elf-1	O
.	O

Northern	O
analyses	O
showed	O
similar	O
levels	O
of	O
two	O
elf-2	O
transcripts	O
(	O
3.5	O
kb	O
and	O
3.8	O
kb	O
)	O
in	O
all	O
tissues	O
except	O
thymus	O
.	O

Thymocytes	O
expressed	O
four-	O
to	O
10-fold	O
greater	O
amounts	O
of	O
the	O
3.5	O
kb	O
transcript	O
than	O
other	O
tissues	O
.	O

Sequence	O
analyses	O
of	O
cDNA	O
clones	O
indicated	O
that	O
these	O
transcripts	O
encode	O
proteins	O
differing	O
only	O
at	O
their	O
amino	O
termini	O
,	O
and	O
likely	O
represent	O
alternatively	O
spliced	O
isoforms	O
.	O

These	O
isoforms	O
(	O
elf-2a	O
and	O
elf-2b	O
)	O
contain	O
identical	O
RBTN-2	O
binding	O
regions	O
and	O
DNA	O
-	O
binding	O
domains	O
.	O

Elf-2b	O
lacks	O
a	O
putative	O
transactivation	O
domain	O
.	O

The	O
expression	O
patterns	O
suggest	O
that	O
RBTN-2	O
normally	O
interacts	O
equally	O
with	O
elf-2a	O
and	O
elf-2b	O
.	O

In	O
contrast	O
,	O
when	O
RBTN-2	O
is	O
inappropriately	O
expressed	O
in	O
T	O
cells	O
,	O
RBTN-2	O
would	O
interact	O
predominantly	O
with	O
elf-2b	O
;	O
this	O
interaction	O
may	O
lead	O
to	O
T	O
cell	O
proliferation	O
.	O

V3	O
loop	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	O
2	O
-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:	O
633	O
]	O

We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	O
region	O
of	O
the	O
HTLV	O
-	O
III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2	O
-driven	O
T	O
cell	O
proliferation	O
.	O

V3-BH10	O
,	O
which	O
consists	O
of	O
42	O
amino	O
acids	O
and	O
has	O
a	O
loop	O
structure	O
,	O
suppressed	O
IL-2	O
-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	B
cells	I
[	O
Kit225	B
,	O
ED-40515	B
(	I
+	I
)	I
,	O
KT-3	B
,	O
7-day	B
PHA	I
-	I
blasts	I
,	O
and	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	O
suppress	O
the	O
cell	O
growth	O
of	O
IL-2-independent	B
cell	I
lines	I
(	O
Hut102	B
,	O
Molt-4	B
,	O
and	O
Jurkat	B
)	O
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2	O
-driven	O
cell	O
growth	O
of	O
CD8-positive	O
lymphocytes	O
purified	O
from	O
7-day	O
PHA	O
-	O
blasts	O
,	O
indicating	O
that	O
CD4	O
molecules	O
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

The	O
treatment	O
with	O
anti	O
-	O
V3	O
loop	O
monoclonal	O
antibody	O
(	O
902	O
antibody	O
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3-BH10	O
.	O

In	O
addition	O
,	O
V3-BH10	O
generated	O
the	O
arrest	O
of	O
Kit225	B
cells	I
and	O
also	O
purified	B
CD8-positive	I
lymphocytes	I
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	O
.	O

Neither	O
chromatin	O
condensation	O
nor	O
DNA	O
fragmentation	O
was	O
detected	O
in	O
Kit225	B
cells	I
cultured	O
with	O
V3-BH10	O
and	O
IL-2	O
.	O

V3-BH10	O
neither	O
blocked	O
radiolabeled	O
IL-2	O
binding	O
to	O
IL-2	O
receptors	O
nor	O
affected	O
tyrosyl	O
phosphorylation	O
of	O
several	O
cellular	O
proteins	O
(	O
p120	O
,	O
p98	O
,	O
p96	O
,	O
p54	O
,	O
and	O
p38	O
)	O
,	O
which	O
is	O
immediately	O
induced	O
by	O
IL-2	O
stimulation	O
.	O

However	O
,	O
V3-BH10	O
enhanced	O
IL-2	O
-induced	O
mRNA	O
expression	O
of	O
c	O
-	O
fos	O
but	O
not	O
c	O
-	O
myc	O
or	O
junB	O
.	O

Thus	O
,	O
the	O
binding	O
of	O
V3	O
loop	O
of	O
gp120	O
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	O
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2	O
-induced	O
T	O
cell	O
growth	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE	O
-	O
I	O
enhancer	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
in	O
different	O
T	O
cell	O
subsets	O
.	O

The	O
immunomodulatory	O
cytokine	O
IL-4	O
affects	O
cells	O
of	O
most	O
hemopoietic	O
lineages	O
.	O

IL-4	O
is	O
secreted	O
by	O
activated	O
Th2	O
but	O
not	O
Th1	O
cells	O
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	O
Th	O
cells	O
toward	O
the	O
Th2	O
phenotype	O
.	O

We	O
have	O
previously	O
identified	O
an	O
enhancer	O
element	O
,	O
PRE	O
-	O
I	O
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
IL-4	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
factors	O
binding	O
to	O
the	O
PRE	O
-	O
I	O
site	O
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	O
promoter	O
of	O
Th1	O
and	O
Th2	O
cells	O
.	O

We	O
show	O
that	O
PRE	O
-	O
I	O
interacts	O
with	O
PMA	O
-and	O
PMA	O
/	O
ionomycin	O
-	O
inducible	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
nuclear	O
factors	O
.	O

Using	O
anti	O
-	O
C	O
/	O
EBPbeta	O
(	O
NF	O
-	O
IL6	O
)	O
,	O
anti	O
-	O
C	O
/	O
EBPdelta	O
(	O
NF	O
-	O
IL6beta	O
)	O
,	O
anti	O
-	O
NF	O
-	O
ATc	O
,	O
anti	O
-	O
NF	O
-	O
ATp	O
,	O
anti	O
-	O
Fos	O
,	O
and	O
anti	O
-	O
Jun	O
Abs	O
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE	O
-	O
I	O
binding	O
factor	O
POS-1	O
is	O
composed	O
of	O
different	O
transcription	O
factors	O
in	O
different	O
Th	O
cell	O
subsets	O
.	O

In	O
the	O
IL-4-producing	B
Th0-like	I
human	I
Jurkat	I
and	O
mouse	B
EL-4	I
cells	I
,	O
POS-1	O
(	O
designated	O
POS-1a	O
)	O
contains	O
NF	O
-	O
IL6beta	O
and	O
Jun	O
.	O

In	O
the	O
mouse	B
Th2	I
D10	I
cells	I
and	O
in	O
the	O
human	B
Th2	I
clones	I
,	O
POS-1	O
(	O
designated	O
POS-1b	O
)	O
contains	O
NF	O
-	O
IL6beta	O
,	O
Jun	O
,	O
and	O
NF	O
-	O
ATc	O
/	O
p	O
.	O

In	O
contrast	O
,	O
POS-1	O
was	O
not	O
found	O
in	O
nuclear	O
extracts	O
of	O
human	B
Th1	I
clones	I
.	O

These	O
findings	O
suggest	O
that	O
PRE	O
-	O
I	O
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	O
gene	O
expression	O
levels	O
.	O

Induction	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
by	O
low	O
-	O
density	O
lipoprotein	O
.	O

Low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
is	O
a	O
well	O
-	O
established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	O
is	O
increased	O
recruitment	O
of	O
monocytes	O
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O

The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	O
lipoprotein	O
,	O
LDL	O
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O
Human	O
LDL	O
induces	O
the	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	O
promoter	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti	O
-	O
VCAM	O
antibodies	O
.	O

After	O
a	O
2-day	O
incubation	O
in	O
LDL	O
,	O
the	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative	O
-	O
stress	O
sensor	O
for	O
VCAM	O
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP-1	O
and	O
GATA	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	O
.	O

Thus	O
,	O
a	O
component	O
of	O
LDL	O
-enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	O
is	O
attributed	O
to	O
VCAM-1	O
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP-1	O
and	O
GATA	O
.	O

These	O
data	O
identify	O
LDL	O
as	O
a	O
VCAM	O
-inducer	O
possibly	O
distinct	O
from	O
cytokines	O
and	O
endotoxin	O
.	O

The	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	O
adhesion	O
molecules	O
CD62E	O
,	O
CD11b	O
/	O
CD18	O
and	O
CD106	O
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	O
and	O
5-lipoxygenase	O
has	O
been	O
shown	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
,	O
CD54	O
)	O
/MAC-1	O
(	O
CD11b	O
/	O
CD18	O
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	O
cells	O
to	O
IL-1	O
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	O
molecules	O
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65	O
/	O
p50	O
subunit	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b	O
/	O
CD18	O
on	O
monocytic	B
HL60	I
cells	I
,	O
and	O
endothelial	O
adhesion	O
molecule-1	O
(	O
CD62E	O
)	O
and	O
vascular	O
adhesion	O
molecule-1	O
(	O
CD106	O
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Expression	O
of	O
other	O
adhesion	O
molecules	O
such	O
as	O
lymphocyte	O
function	O
associated	O
-	O
antigen-1	O
(	O
CD11a	O
/	O
CD18	O
)	O
and	O
CD54	O
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF	O
-	O
kappa	O
B	O
regulated	O
chemokine	O
,	O
IL-8	O
,	O
a	O
known	O
inducer	O
of	O
CD11b	O
/	O
CD18	O
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b	O
/	O
CD18	O
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL-8	O
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	O
molecules	O
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Rapid	O
Ca2	O
+	O
-mediated	O
activation	O
of	O
Rap1	O
in	O
human	O
platelets	O
.	O

Rap1	O
is	O
a	O
small	O
,	O
Ras	O
-	O
like	O
GTPase	O
whose	O
function	O
and	O
regulation	O
are	O
still	O
largely	O
unknown	O
.	O

We	O
have	O
developed	O
a	O
novel	O
assay	O
to	O
monitor	O
the	O
active	O
,	O
GTP	O
-	O
bound	O
form	O
of	O
Rap1	O
based	O
on	O
the	O
differential	O
affinity	O
of	O
Rap1GTP	O
and	O
Rap1GDP	O
for	O
the	O
Rap	O
binding	O
domain	O
of	O
RalGDS	O
(	O
RBD	O
)	O
.	O

Stimulation	O
of	O
blood	O
platelets	O
with	O
alpha	O
-	O
thrombin	O
or	O
other	O
platelet	O
activators	O
caused	O
a	O
rapid	O
and	O
strong	O
induction	O
of	O
Rap1	O
that	O
associated	O
with	O
RBD	O
in	O
vitro	O
.	O

Binding	O
to	O
RBD	O
increased	O
from	O
undetectable	O
levels	O
in	O
resting	O
platelets	O
to	O
>	O
50	O
%	O
of	O
total	O
Rap1	O
within	O
30	O
s	O
after	O
stimulation	O
.	O

An	O
increase	O
in	O
the	O
intracellular	O
Ca2	O
+	O
concentration	O
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
Rap1	O
activation	O
since	O
it	O
was	O
induced	O
by	O
agents	O
that	O
increase	O
intracellular	O
Ca2	O
+	O
and	O
inhibited	O
by	O
a	O
Ca2	O
+	O
-chelating	O
agent	O
.	O

Neither	O
inhibition	O
of	O
translocation	O
of	O
Rap1	O
to	O
the	O
cytoskeleton	O
nor	O
inhibition	O
of	O
platelet	O
aggregation	O
affected	O
thrombin	O
-induced	O
activation	O
of	O
Rap1	O
.	O

In	O
contrast	O
,	O
prostaglandin	O
I2	O
(	O
PGI2	O
)	O
,	O
a	O
strong	O
negative	O
regulator	O
of	O
platelet	O
function	O
,	O
inhibited	O
agonist	O
-	O
induced	O
as	O
well	O
as	O
Ca2	O
+	O
-induced	O
activation	O
of	O
Rap1	O
.	O

From	O
our	O
results	O
,	O
we	O
conclude	O
that	O
Rap1	O
activation	O
in	O
platelets	O
is	O
an	O
important	O
common	O
event	O
in	O
early	O
agonist	O
-	O
induced	O
signalling	O
,	O
and	O
that	O
this	O
activation	O
is	O
mediated	O
by	O
an	O
increased	O
intracellular	O
Ca2	O
+	O
concentration	O

Characterization	O
of	O
a	O
mutant	B
cell	I
line	I
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
multiple	O
stimuli	O
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	O
kappaB	O
,	O
NF	O
-	O
kappaB	O
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	O
kappaB	O
is	O
proteolyzed	O
and	O
NF	O
-	O
kappaB	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	O
kappaB	O
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70	B
/	I
Z3-derived	I
1.3E2	I
murine	I
pre	I
-	I
B	I
cell	I
line	I
,	O
that	O
does	O
not	O
activate	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
several	O
stimuli	O
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	O
,	O
or	O
double	O
-	O
stranded	O
RNA	O
,	O
I	O
kappaB	O
alpha	O
is	O
not	O
degraded	O
,	O
as	O
a	O
result	O
of	O
an	O
absence	O
of	O
induced	O
phosphorylation	O
on	O
serines	O
32	O
and	O
36	O
.	O

Neither	O
a	O
mutation	O
in	O
I	O
kappaB	O
alpha	O
nor	O
a	O
mutation	O
in	O
p50	O
or	O
relA	O
,	O
the	O
two	O
major	O
subunits	O
of	O
NF	O
-	O
kappaB	O
in	O
this	O
cell	O
line	O
,	O
accounts	O
for	O
this	O
phosphorylation	O
defect	O
.	O

As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	O
kappaB	O
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	B
cells	I
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC	O
-	O
insensitive	O
pathways	O
,	O
induce	O
I	O
kappaB	O
alpha	O
degradation	O
in	O
1.3E2	B
.	O

Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	B
does	O
not	O
reveal	O
any	O
difference	O
from	O
wild	B
-	I
type	I
70Z	I
/	I
3	I
.	O

We	O
also	O
report	O
that	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-derived	O
Tax	O
trans	O
-	O
activator	O
induces	O
NF	O
-	O
kappaB	O
activity	O
in	O
1.3E2	B
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	O
other	O
I	O
kappaB	O
molecules	O
,	O
I	O
kappaB	O
beta	O
and	O
the	O
recently	O
identified	O
I	O
kappaB	O
epsilon	O
,	O
are	O
not	O
degraded	O
in	O
the	O
1.3E2	B
cell	O
line	O
following	O
stimulation	O
.	O

Our	O
results	O
demonstrate	O
that	O
1.3E2	B
is	O
a	O
cellular	O
transduction	O
mutant	O
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF	O
-	O
kappaB	O
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	O
kappaB	O
alpha	O
,	O
I	O
kappaB	O
beta	O
,	O
and	O
I	O
kappaB	O
epsilon	O
degradation	O
.	O

Transcription	O
mediated	O
by	O
NFAT	O
is	O
highly	O
inducible	O
in	O
effector	O
CD4	O
+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
but	O
not	O
in	O
Th1	O
cells	O
.	O

Transcriptional	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	O
genes	O
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	O
2	O
(	O
IL-2	O
)	O
and	O
IL-4	O
,	O
among	O
others	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4	O
+	O
T	O
helper	O
(	O
pTh	O
)	O
cells	O
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	O
cells	O
(	O
eTh1	O
and	O
eTh2	O
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	O
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

eTh2	O
cells	O
are	O
the	O
major	O
source	O
of	O
IL-4	O
,	O
while	O
gamma	O
interferon	O
is	O
produced	O
by	O
eTh1	O
cells	O
.	O

Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	O
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	O
cells	O
into	O
either	O
eTh1	O
or	O
eTh2	O
cells	O
to	O
mediate	O
the	O
expression	O
of	O
IL-2	O
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O

However	O
,	O
although	O
NFAT	O
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	O
complexes	O
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high	O
-	O
level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	O
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O

In	O
contrast	O
to	O
activated	O
pTh	O
cells	O
,	O
neither	O
eTh1	O
nor	O
eTh2	O
cells	O
produced	O
significant	O
IL-2	O
upon	O
stimulation	O
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	O
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL-4	O
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
activated	O
NFAT	O
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	O
cells	O
and	O
that	O
the	O
failure	O
of	O
eTh1	O
cells	O
to	O
produce	O
IL-4	O
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high	O
-	O
level	O
transcription	O
of	O
the	O
IL-4	O
gene	O
by	O
NFAT	O
.	O

Regulation	O
of	O
NFAT	O
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	O
or	O
eTh2	O
.	O

Constitutive	O
expression	O
of	O
p50	O
homodimer	O
in	O
freshly	O
isolated	O
human	O
monocytes	O
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	O
and	O
mature	O
macrophages	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O

We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF	O
-	O
kappaB	O
with	O
monocyte	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	O
inactive	O
p50	O
homodimer	O
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50	O
/	O
p65	O
and	O
p50	O
/	O
RelB	O
heterodimers	O
.	O

As	O
in	O
MDMs	O
,	O
AMs	O
constitutively	O
expressed	O
p50	O
/	O
p65	O
and	O
p50	O
/	O
RelB	O
although	O
at	O
lower	O
levels	O
.	O

HIV	O
infection	O
of	O
fresh	O
monocytes	O
failed	O
to	O
induce	O
p50	O
/	O
p65	O
as	O
seen	O
in	O
MDMs	O
.	O

The	O
replacement	O
of	O
p50	O
homodimers	O
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	O
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

The	O
change	O
in	O
NF	O
-	O
kappaB	O
components	O
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV	O
-	O
infected	O
individuals	O
.	O

NF	O
-	O
kappa	O
B	O
-independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	O
infected	O
T	O
lymphocytic	O
cells	O
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	O
cytokine	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

To	O
assess	O
whether	O
this	O
inhibition	O
was	O
mediated	O
via	O
modulation	O
of	O
the	O
cellular	O
transcription	O
factor	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
ascorbate	O
,	O
N	O
-	O
acetylcysteine	O
(	O
NAC	O
)	O
,	O
or	O
zidovudine	O
(	O
AZT	O
)	O
.	O

Pretreatment	O
of	O
ACH-2	B
T	I
cells	I
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF	O
-	O
alpha	O
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

In	O
contrast	O
,	O
neither	O
ascorbate	O
nor	O
AZT	O
affected	O
NF	O
-	O
kappa	O
B	O
activity	O
under	O
all	O
three	O
induction	O
conditions	O
in	O
the	O
ACH-2	B
cell	I
line	I
.	O

Ascorbate	O
and	O
AZT	O
also	O
had	O
no	O
effect	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
following	O
TNF	O
-	O
alpha-	O
or	O
PMA	O
-	O
induced	O
stimulation	O
of	O
U1	O
promonocytic	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF	O
-	O
kappa	O
B	O
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

c	O
-	O
Rel	O
is	O
a	O
target	O
of	O
pentoxifylline	O
-	O
mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell	O
-	O
dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

We	O
found	O
that	O
in	O
T	O
cells	O
,	O
anti	O
-	O
CD3-induced	O
c	O
-	O
Rel	O
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF	O
-	O
kappaB	O
family	O
members	O
was	O
not	O
significantly	O
affected	O
.	O

However	O
,	O
induction	O
of	O
NF	O
-	O
AT	O
,	O
which	O
has	O
the	O
same	O
signaling	O
requirements	O
as	O
c	O
-	O
Rel	O
induction	O
,	O
was	O
not	O
inhibited	O
by	O
PF	O
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	O
factors	O
,	O
IL-2	O
mRNA	O
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	O
(	O
alpha	O
)	O
chain	O
mRNA	O
induction	O
was	O
not	O
affected	O
.	O

These	O
observations	O
implicated	O
c	O
-	O
Rel	O
as	O
an	O
IL-2	O
promoter	O
factor	O
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O

In	O
contrast	O
with	O
the	O
observation	O
in	O
T	O
cells	O
,	O
c	O
-	O
Rel	O
induction	O
was	O
not	O
blocked	O
by	O
PF	O
in	O
B	O
cells	O
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

Regulation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Role	O
of	O
AP-1	O
,	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
,	O
and	O
Sp1	O
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide	O
-	O
induced	O
expression	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
expression	O
by	O
peripheral	O
blood	O
monocytes	O
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	O
gene	O
transcription	O
in	O
monocytes	O
.	O

The	O
human	O
TF	O
promoter	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-1	O
,	O
c	O
-	O
Rel	O
/	O
p65	O
,	O
Egr-1	O
,	O
and	O
Sp1	O
.	O

NF	O
-	O
kappa	O
B	O
/	O
Rel	O
proteins	O
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP-1	O
and	O
Sp1	O
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
uninduced	O
and	O
LPS	O
-	O
induced	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	O
sites	O
mediated	O
basal	O
expression	O
in	O
uninduced	O
cells	O
.	O

The	O
two	O
AP-1	O
sites	O
bound	O
c	O
-	O
Fos	O
/	O
c	O
-	O
Jun	O
heterodimers	O
in	O
both	O
unstimulated	O
and	O
LPS	O
-	O
stimulated	O
cells	O
.	O

Maximal	O
LPS	O
induction	O
of	O
the	O
TF	O
promoter	O
required	O
the	O
two	O
AP-1	O
sites	O
and	O
the	O
kappa	O
B	O
site	O
within	O
the	O
LPS	O
response	O
element	O
.	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	O
AP-1	O
site	O
and	O
the	O
kappa	O
B	O
site	O
abolished	O
LPS	O
induction	O
.	O

Replacement	O
of	O
the	O
two	O
AP-1	O
sites	O
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	O
LPS	O
induction	O
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP-1	O
sites	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	O
response	O
element	O
in	O
Drosophila	B
Schneider	I
cells	I
by	O
coexpression	O
of	O
c	O
-	O
Fos	O
,	O
c	O
-	O
Jun	O
,	O
c	O
-	O
Rel	O
,	O
and	O
p65	O
or	O
c	O
-	O
Jun	O
and	O
p65	O
required	O
the	O
transactivation	O
domains	O
of	O
c	O
-	O
Jun	O
and	O
p65	O
.	O

These	O
data	O
indicated	O
that	O
c	O
-	O
Fos	O
/c	O
-	O
Jun	O
,	O
c	O
-	O
Rel	O
/p65	O
,	O
and	O
Sp1	O
regulate	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
.	O

Differentiation	O
of	O
U-937	B
promonocytic	I
cells	I
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U-937	B
human	I
promonocytic	I
leukemia	I
cells	I
of	O
two	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O

One	O
hour	O
pulse	O
-	O
treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	O
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	O
effects	O
were	O
not	O
observed	O
upon	O
pulse	O
-	O
treatment	O
with	O
6	O
microM	O
ICRF-193	O
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane	O
-	O
bound	O
enzyme	O
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane	O
-	O
bound	O
and	O
cytosolic	O
enzyme	O
.	O

By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation	O
-	O
inducing	O
concentrations	O
,	O
both	O
topoisomerase	O
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	O
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide	O
-	O
treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF	O
-	O
kappa	O
(	O
B	O
)	O
and	O
EGR-1	O
transcription	O
factors	O
was	O
little	O
affected	O
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-	O
topoisomerase	O
drugs	O
.	O

Selective	O
expression	O
of	O
an	O
interleukin-12	O
receptor	O
component	O
by	O
human	O
T	O
helper	O
1	O
cells	O
.	O

Interleukin-12	O
(	O
IL-12	O
)	O
,	O
a	O
heterodimeric	O
cytokine	O
produced	O
by	O
activated	O
monocytes	O
and	O
dendritic	O
cells	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
interferon	O
(	O
IFN	O
)	O
-gamma	O
production	O
and	O
in	O
the	O
generation	O
of	O
IFN	O
-	O
gamma	O
-	O
producing	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
IL-12	O
receptor	O
(	O
IL-12R	O
)	O
beta	O
2	O
subunit	O
,	O
a	O
recently	O
cloned	O
binding	O
and	O
signal	O
transducing	O
component	O
of	O
the	O
IL-12R	O
,	O
is	O
expressed	O
on	O
human	B
Th1	I
but	I
not	I
Th2	I
clones	I
and	O
is	O
induced	O
during	O
differentiation	O
of	O
human	O
naive	O
cells	O
along	O
the	O
Th1	O
but	O
not	O
the	O
Th2	O
pathway	O
.	O

IL-12	O
and	O
type	O
I	O
but	O
not	O
type	O
II	O
interferons	O
induce	O
expression	O
of	O
the	O
IL-12R	O
beta	O
2	O
chain	O
during	O
in	O
vitro	O
T	O
cell	O
differentiation	O
after	O
antigen	O
receptor	O
triggering	O
.	O

The	O
selective	O
expression	O
and	O
regulation	O
of	O
the	O
IL-12R	O
beta	O
2	O
subunit	O
may	O
help	O
to	O
understand	O
the	O
basis	O
of	O
Th1	O
/	O
Th2	O
differentiation	O
and	O
may	O
provide	O
therapeutic	O
options	O
for	O
altering	O
the	O
Th1	O
/	O
Th2	O
balance	O
in	O
several	O
immuno	O
-	O
pathological	O
conditions	O
such	O
as	O
autoimmune	O
diseases	O
and	O
allergies	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
in	O
lipopolysaccharide	B
-	I
stimulated	I
U937	I
cells	I
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte	O
/	O
macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
cytokines	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
LPS	O
in	O
a	O
promonocytic	B
cell	I
line	I
(	O
U937	B
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB	O
-	O
alpha	O
inhibitor	O
hydrolysis	O
.	O

No	O
degradation	O
of	O
p105	O
and	O
p100	O
inhibitors	O
was	O
observed	O
under	O
these	O
conditions	O
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	B
cells	I
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF	O
-	O
kappaB	O
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	O
A2	O
and	O
5-lipoxygenase	O
are	O
also	O
involved	O
.	O

However	O
,	O
the	O
NF	O
-	O
kappaB	O
activation	O
pathway	O
involving	O
the	O
acidic	O
sphingomyelinase	O
of	O
the	O
endolysosomial	O
membrane	O
did	O
not	O
seem	O
to	O
participate	O
in	O
the	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
in	O
U937	B
cells	I
.	O

Detection	O
of	O
adenovirus	O
DNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

Adenovirus	O
can	O
establish	O
persistent	O
infections	O
which	O
may	O
reactivate	O
and	O
cause	O
disease	O
in	O
immunocompromised	O
hosts	O
.	O

Lymphocytes	O
have	O
been	O
postulated	O
to	O
serve	O
as	O
a	O
site	O
of	O
adenoviral	O
persistence	O
based	O
upon	O
the	O
ability	O
to	O
isolate	O
adenovirus	O
from	O
tonsils	O
and	O
to	O
detect	O
adenovirus	O
DNA	O
by	O
Southern	O
blot	O
hybridization	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
a	O
more	O
sensitive	O
and	O
specific	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
was	O
developed	O
to	O
detect	O
adenovirus	O
DNA	O
.	O

Two	O
sets	O
of	O
nested	O
primers	O
were	O
designed	O
to	O
conserved	O
sequences	O
in	O
the	O
adenovirus	O
E1A	O
and	O
hexon	O
genes	O
.	O

The	O
E1A	O
and	O
hexon	O
primers	O
amplified	O
DNA	O
from	O
representative	O
adenoviral	O
serotypes	O
in	O
all	O
six	O
adenoviral	O
groups	O
(	O
A	O
-	O
F	O
)	O
.	O

Both	O
primers	O
detected	O
a	O
single	O
copy	O
of	O
the	O
adenovirus	O
type	O
2	O
genome	O
but	O
were	O
less	O
sensitive	O
for	O
the	O
group	O
B	O
type	O
35	O
.	O

None	O
of	O
33	O
PBMC	O
specimens	O
from	O
healthy	O
adults	O
and	O
only	O
one	O
of	O
40	O
pediatric	O
samples	O
was	O
positive	O
(	O
at	O
a	O
low	O
level	O
)	O
for	O
adenovirus	O
DNA	O
by	O
nested	O
PCR	O
assay	O
.	O

In	O
comparison	O
,	O
PBMC	O
from	O
two	O
children	O
with	O
fatal	O
adenoviral	O
infection	O
were	O
both	O
strongly	O
positive	O
for	O
adenovirus	O
DNA	O
.	O

It	O
is	O
concluded	O
that	O
,	O
in	O
contrast	O
to	O
a	O
previous	O
study	O
,	O
PBMC	O
are	O
not	O
a	O
common	O
site	O
of	O
persistent	O
group	O
C	O
adenoviral	O
infection	O
.	O

In	O
addition	O
,	O
assay	O
of	O
PBMC	O
by	O
the	O
adenovirus	O
-	O
specific	O
PCR	O
may	O
help	O
detect	O
early	O
invasive	O
disease	O
and	O
warrants	O
further	O
evaluation	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
MEF2C	O
by	O
the	O
MAP	O
kinase	O
p38	O
in	O
inflammation	O
.	O

For	O
cells	O
of	O
the	O
innate	O
immune	O
system	O
to	O
mount	O
a	O
host	O
defence	O
response	O
to	O
infection	O
,	O
they	O
must	O
recognize	O
products	O
of	O
microbial	O
pathogens	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
the	O
endotoxin	O
secreted	O
by	O
Gram	O
-	O
negative	O
bacteria	O
.	O

These	O
cellular	O
responses	O
require	O
intracellular	O
signalling	O
pathways	O
,	O
such	O
as	O
the	O
four	O
MAP	O
kinase	O
(	O
MAPK	O
)	O
pathways	O
.	O

In	O
mammalian	O
cells	O
the	O
MAPK	O
p38	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
responses	O
during	O
infection	O
through	O
its	O
effects	O
on	O
the	O
expression	O
of	O
proinflammatory	O
molecules	O
.	O

One	O
means	O
of	O
understanding	O
the	O
role	O
of	O
p38	O
in	O
these	O
responses	O
is	O
to	O
identify	O
proteins	O
with	O
functions	O
regulated	O
by	O
p38	O
-catalysed	O
phosphorylation	O
.	O

Here	O
we	O
demonstrate	O
a	O
link	O
between	O
the	O
p38	O
pathway	O
and	O
a	O
member	O
of	O
the	O
myocyte	O
-	O
enhancer	O
factor	O
2	O
(	O
MEF2	O
)	O
group	O
of	O
transcription	O
factors	O
.	O

We	O
found	O
that	O
in	O
monocytic	O
cells	O
,	O
LPS	O
increases	O
the	O
transactivation	O
activity	O
of	O
MEF2C	O
through	O
p38	O
-catalysed	O
phosphorylation	O
.	O

One	O
consequence	O
of	O
MEF2C	O
activation	O
is	O
increased	O
c	O
-	O
jun	O
gene	O
transcription	O
.	O

Our	O
results	O
show	O
that	O
p38	O
may	O
influence	O
host	O
defence	O
and	O
inflammation	O
by	O
maintaining	O
the	O
balance	O
of	O
c	O
-	O
Jun	O
protein	O
consumed	O
during	O
infection	O
.	O

Signal	O
transducer	O
and	O
activator	O
of	O
transcription-3	O
(	O
STAT3	O
)	O
is	O
constitutively	O
activated	O
in	O
normal	O
,	O
self	O
-	O
renewing	O
B-1	O
cells	O
but	O
only	O
inducibly	O
expressed	O
in	O
conventional	O
B	O
lymphocytes	O
[	O
see	O
comments	O
]	O

Cytokine	O
and	O
growth	O
factor	O
receptor	O
engagement	O
leads	O
to	O
the	O
rapid	O
phosphorylation	O
and	O
activation	O
of	O
latent	O
,	O
cytosolic	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
,	O
which	O
then	O
translocate	O
to	O
the	O
nucleus	O
where	O
they	O
regulate	O
transcriptional	O
events	O
from	O
specific	O
promoter	O
sequences	O
.	O

STAT3	O
expression	O
in	O
particular	O
has	O
been	O
associated	O
with	O
Abl	O
,	O
Src	O
,	O
and	O
HTLV-1	O
transformation	O
of	O
normal	O
cells	O
.	O

B-1	O
lymphocytes	O
are	O
self	O
-	O
renewing	O
,	O
CD5	O
+	O
B	O
cells	O
that	O
display	O
a	O
propensity	O
for	O
malignant	O
transformation	O
and	O
are	O
the	O
normal	O
counterpart	O
to	O
human	O
chronic	O
lymphocytic	O
leukemias	O
.	O

Further	O
,	O
B-1	O
cells	O
are	O
characterized	O
by	O
aberrant	O
intracellular	O
signaling	O
,	O
including	O
hyperresponsiveness	O
to	O
phorbol	O
ester	O
PKC	O
agonists	O
.	O

Here	O
we	O
demonstrate	O
that	O
B-1	O
lymphocytes	O
constitutively	O
express	O
nuclear	O
activated	O
STAT3	O
,	O
which	O
is	O
not	O
expressed	O
by	O
unmanipulated	O
conventional	O
(	O
B-2	O
)	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
STAT3	O
activation	O
is	O
induced	O
in	O
B-2	O
cells	O
after	O
antigen	O
receptor	O
engagement	O
in	O
a	O
delayed	O
fashion	O
(	O
after	O
3	O
h	O
)	O
.	O

Induction	O
of	O
STAT3	O
is	O
inhibited	O
by	O
both	O
the	O
serine	O
/	O
threonine	O
protein	O
kinase	O
inhibitor	O
H-7	O
and	O
the	O
immunosuppressive	O
drug	O
rapamycin	O
and	O
requires	O
de	O
novo	O
protein	O
synthesis	O
,	O
demonstrating	O
novel	O
coupling	O
between	O
sIg	O
and	O
STAT	O
proteins	O
that	O
differs	O
from	O
the	O
classical	O
paradigm	O
for	O
STAT	O
induction	O
by	O
cytokine	O
receptors	O
.	O

The	O
inability	O
of	O
prolonged	O
stimulation	O
of	O
conventional	O
B-2	O
cells	O
with	O
anti	O
-	O
Ig	O
,	O
a	O
treatment	O
sufficient	O
to	O
induce	O
CD5	O
expression	O
,	O
to	O
result	O
in	O
sustained	O
STAT3	O
activation	O
suggests	O
that	O
STAT3	O
is	O
a	O
specific	O
nuclear	O
marker	O
for	O
B-1	O
cells	O
.	O

Thus	O
,	O
STAT3	O
may	O
play	O
a	O
role	O
in	O
B	O
cell	O
antigen	O
-	O
specific	O
signaling	O
responses	O
,	O
and	O
its	O
constitutive	O
activation	O
is	O
associated	O
with	O
a	O
normal	O
cell	O
population	O
exhibiting	O
intrinsic	O
proliferative	O
behavior	O
.	O

Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
involved	O
in	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
influence	O
of	O
the	O
anti	O
-	O
allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF	O
-	O
kappa	O
B	O
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O

Azeptin	O
dose	O
-	O
dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HF	O
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O
Generation	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interleukin	O
1-beta	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin-6	O
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
-	O
treated	O
PBL	O
and	O
human	O
monocytes	O
(	O
HM	O
)	O
was	O
decreased	O
to	O
approximately	O
1	O
/	O
3	O
to	O
2	O
/	O
3	O
of	O
the	O
control	O
levels	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	O
generation	O
,	O
each	O
cytokine	O
mRNA	O
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	O
nitric	O
oxide	O
synthase	O
-mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	O
by	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
PBL	O
,	O
HM	O
and	O
HF	O
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	O
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

The	O
T	O
cell	O
activation	O
factor	O
NF	O
-	O
ATc	O
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

We	O
report	O
that	O
certain	O
NF	O
-	O
AT	O
(	O
Rel	O
)	O
family	O
members	O
productively	O
bind	O
the	O
kappaB	O
regulatory	O
elements	O
,	O
synergize	O
with	O
NF	O
-	O
kappaB	O
and	O
Tat	O
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	O
cells	O
.	O

These	O
results	O
link	O
regulatory	O
factors	O
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O

Differentiation	O
of	O
T	O
-	O
helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	O
family	O
of	O
transcription	O
factors	O
.	O

Interleukin-4	O
(	O
IL-4	O
)	O
and	O
interleukin-12	O
(	O
IL-12	O
)	O
control	O
the	O
differentiation	O
of	O
T	O
-	O
helper	O
cells	O
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	O
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T	O
-	O
lymphocytes	O
.	O

Cytokine	O
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	O
domain	O
of	O
the	O
corresponding	O
cytokine	O
receptor	O
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	O
sites	O
for	O
latent	O
,	O
cytoplasmic	O
transcription	O
factors	O
known	O
as	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
proteins	O
.	O

Receptor	O
/	O
Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
of	O
the	O
corresponding	O
Stat	O
protein	O
.	O

Although	O
Stat	O
binding	O
to	O
the	O
intracellular	O
domain	O
of	O
the	O
cytokine	O
receptor	O
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	O
protein	O
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
phosphotyrosine	O
.	O

Specific	O
docking	O
sites	O
within	O
individual	O
cytokine	O
receptors	O
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	O
proteins	O
.	O

The	O
direct	O
coupling	O
between	O
cytokine	O
receptor	O
and	O
transcription	O
factor	O
helps	O
to	O
explain	O
how	O
different	O
cytokines	O
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Cytokine	O
signal	O
networks	O
and	O
a	O
new	O
era	O
in	O
biomedical	O
research	O
.	O

Elucidation	O
of	O
the	O
biochemical	O
nature	O
of	O
the	O
signal	O
transduction	O
pathway	O
that	O
regulate	O
transcription	O
and	O
replication	O
is	O
the	O
focus	O
of	O
attention	O
in	O
molecular	O
biology	O
.	O

This	O
research	O
may	O
make	O
feasible	O
manipulation	O
of	O
growth	O
and	O
differentiation	O
of	O
mammalian	O
cells	O
,	O
which	O
in	O
turn	O
would	O
have	O
profound	O
implication	O
in	O
biomedical	O
research	O
on	O
cell	O
and	O
gene	O
therapy	O
,	O
and	O
development	O
of	O
pharmaceutical	O
products	O
.	O

Cytokines	O
control	O
growth	O
,	O
differentiation	O
,	O
death	O
,	O
and	O
function	O
of	O
cells	O
of	O
lymphocytic	O
,	O
hemopoietic	O
systems	O
,	O
and	O
together	O
with	O
nerve	O
cells	O
provide	O
a	O
pertinent	O
model	O
to	O
study	O
intercellular	O
communications	O
and	O
intercellular	O
signal	O
networks	O
.	O

This	O
review	O
outlines	O
general	O
features	O
of	O
signal	O
transduction	O
and	O
several	O
aspects	O
of	O
cytokine	O
networks	O
are	O
discussed	O
with	O
emphasis	O
on	O
:	O
transcriptional	O
regulation	O
of	O
Th1	O
and	O
Th2-specific	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
the	O
roles	O
of	O
cytokines	O
and	O
their	O
receptors	O
in	O
growth	O
and	O
differentiation	O
of	O
hemopoietic	O
cells	O
,	O
and	O
the	O
manipulation	O
of	O
cytokine	O
networks	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
potently	O
up	O
-	O
regulates	O
the	O
promoter	O
activity	O
of	O
RANTES	O
,	O
a	O
chemokine	O
that	O
blocks	O
HIV	O
infection	O
.	O

The	O
complex	O
network	O
of	O
cytokines	O
that	O
are	O
involved	O
in	O
inflammatory	O
and	O
immunoregulatory	O
responses	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

RANTES	O
(	O
regulated	O
upon	O
activation	O
,	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
)	O
is	O
a	O
cytokine	O
that	O
belongs	O
to	O
the	O
beta	O
-	O
chemokine	O
family	O
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+	O
/	O
CD45RO	O
T	O
cells	O
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8	O
+	O
and	O
CD4	O
+	O
T	O
cells	O
as	O
well	O
as	O
monocytes	O
/	O
macrophages	O
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage	O
-	O
tropic	O
strains	O
of	O
HIV	O
in	O
CD4	O
+	O
T	O
cells	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	O
expression	O
,	O
the	O
RANTES	O
promoter	O
region	O
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel	O
-	O
mobility	O
shift	O
assays	O
.	O

We	O
demonstrate	O
that	O
:	O
1	O
)	O
RANTES	O
promoter	O
activity	O
is	O
up	O
-	O
regulated	O
by	O
PMA	O
plus	O
ionomycin	O
,	O
coexpression	O
of	O
the	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
,	O
the	O
proinflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
and	O
IL-1	O
beta	O
,	O
and	O
the	O
CD28	O
costimulatory	O
pathway	O
;	O
2	O
)	O
the	O
RANTES	O
promoter	O
region	O
contains	O
four	O
NF	O
-	O
kappa	O
B	O
binding	O
sites	O
at	O
positions	O
-30	O
,	O
-44	O
,	O
-213	O
,	O
and	O
-579	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
;	O
3	O
)	O
one	O
site	O
(	O
-213	O
)	O
is	O
an	O
NF	O
-	O
AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
binding	O
site	O
that	O
also	O
has	O
weak	O
affinity	O
to	O
NF	O
-	O
kappa	O
B	O
,	O
and	O
the	O
most	O
distal	O
site	O
(	O
-579	O
)	O
also	O
serves	O
as	O
a	O
CD28-responsive	O
element	O
;	O
and	O
4	O
)	O
mutation	O
on	O
any	O
of	O
those	O
NF	O
-	O
kappa	O
B	O
sites	O
or	O
coexpression	O
of	O
I	O
kappa	O
B	O
alpha	O
(	O
cytoplasmic	O
inhibitor	O
of	O
NF	O
-	O
kappa	O
B	O
)	O
markedly	O
reduced	O
the	O
promoter	O
activity	O
.	O

Thus	O
,	O
NF	O
-	O
kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
HIV	O
expression	O
,	O
is	O
also	O
involved	O
in	O
the	O
expression	O
of	O
RANTES	O
,	O
a	O
chemokine	O
that	O
blocks	O
infection	O
by	O
macrophage	O
-	O
tropic	O
strains	O
of	O
HIV	O
.	O

The	O
Pax-5	O
gene	O
is	O
alternatively	O
spliced	O
during	O
B	O
-	O
cell	O
development	O
.	O

The	O
transcription	O
factor	O
Pax-5	O
is	O
expressed	O
during	O
the	O
early	O
stages	O
of	O
B	O
-	O
cell	O
differentiation	O
and	O
influences	O
the	O
expression	O
of	O
several	O
B	O
-	O
cell	O
-	O
specific	O
genes	O
.	O

In	O
addition	O
to	O
the	O
existing	O
isoform	O
(	O
Pax-5	O
,	O
which	O
we	O
have	O
named	O
Pax-5a	O
)	O
,	O
we	O
have	O
isolated	O
three	O
new	O
isoforms	O
,	O
Pax-5b	O
,	O
Pax-5d	O
,	O
and	O
Pax-5e	O
,	O
from	O
murine	O
spleen	O
and	O
B	B
-	I
lymphoid	I
cell	I
lines	I
using	O
library	O
screenings	O
and	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O

Isoforms	O
Pax-5b	O
and	O
Pax-5e	O
have	O
spliced	O
out	O
their	O
second	O
exon	O
,	O
resulting	O
in	O
proteins	O
with	O
only	O
a	O
partial	O
DNA	O
-	O
binding	O
domain	O
.	O

Isoforms	O
Pax-5d	O
and	O
Pax-5e	O
have	O
deleted	O
the	O
3'-region	O
,	O
which	O
encodes	O
the	O
transactivating	O
domain	O
,	O
and	O
replaced	O
it	O
with	O
a	O
novel	O
sequence	O
.	O

The	O
existence	O
of	O
alternative	O
Pax-5	O
transcripts	O
was	O
confirmed	O
using	O
RNase	O
protection	O
assays	O
.	O

Furthermore	O
,	O
Pax-5a	O
and	O
Pax-5b	O
proteins	O
were	O
detected	O
using	O
Western	O
blot	O
analysis	O
.	O

Pax-5a	O
was	O
detectable	O
in	O
pro-	B
,	I
pre-	I
,	I
and	I
mature	I
B	I
-	I
cell	I
lines	I
,	O
but	O
not	O
in	O
two	O
plasmacytomas	O
;	O
Pax-5b	O
was	O
shown	O
to	O
be	O
present	O
at	O
low	O
levels	O
in	O
mature	B
B	I
-	I
cell	I
lines	I
and	O
,	O
unexpectedly	O
,	O
in	O
one	O
plasma	O
cell	O
line	O
,	O
but	O
not	O
in	O
pro	B
-	I
B	I
-	I
cell	I
or	I
T	I
-	I
cell	I
lines	I
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
in	O
vitro	O
translated	O
Pax-5a	O
and	O
Pax-5d	O
,	O
but	O
not	O
Pax-5b	O
or	O
Pax-5e	O
,	O
could	O
interact	O
with	O
a	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
-	O
binding	O
site	O
on	O
the	O
blk	O
promoter	O
.	O

Using	O
this	O
assay	O
,	O
we	O
also	O
showed	O
that	O
Pax-5d	O
was	O
present	O
in	O
nuclear	O
extracts	O
of	O
some	O
(	O
but	O
not	O
all	O
)	O
B	B
-	I
lymphoid	I
lines	I
and	O
interacts	O
with	O
the	O
B	O
-	O
cell	O
-	O
specific	O
activator	O
protein	O
-	O
binding	O
site	O
.	O

The	O
pattern	O
of	O
differential	O
expression	O
of	O
alternatively	O
spliced	O
Pax-5	O
isoforms	O
suggests	O
that	O
they	O
may	O
be	O
important	O
regulators	O
of	O
transcription	O
during	O
B	O
-	O
cell	O
maturation	O
.	O

Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O

Biological	O
markers	O
of	O
ovulation	O
,	O
after	O
a	O
great	O
in	O
the	O
past	O
,	O
have	O
been	O
fallen	O
into	O
disuse	O
for	O
the	O
large	O
diffusion	O
of	O
biochemical	O
and	O
biophysical	O
ones	O
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	O
tissues	O
.	O

To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	O
Factor	O
IV	O
(	O
as	O
indicator	O
of	O
Platelet	O
Aggregation	O
)	O
,	O
Type	O
II	O
estrogenic	O
receptors	O
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation	O
.	O

33	O
of	O
them	O
had	O
ovulation	O
and	O
9	O
developed	O
a	O
LUF	O
syndrome	O
,	O
constituting	O
two	O
biological	O
models	O
of	O
an	O
opposite	O
situation	O
for	O
the	O
three	O
markers	O
observed	O
.	O

All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	O
Factor	O
IV	O
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O

c	O
-	O
Jun	O
and	O
GST	O
-	O
pi	O
expression	O
in	O
human	O
plasma	O
cells	O
.	O

Bone	O
marrow	O
samples	O
from	O
33	O
patients	O
affected	O
by	O
MM	O
and	O
MGUS	O
,	O
and	O
8	O
patients	O
not	O
affected	O
by	O
lymphoproliferative	O
diseases	O
were	O
studied	O
for	O
expression	O
of	O
c	O
-	O
Jun	O
(	O
a	O
component	O
of	O
the	O
transcription	O
factor	O
AP-1	O
)	O
and	O
glutathione	O
-	O
S	O
-	O
transferase	O
pi	O
(	O
GST	O
-	O
pi	O
)	O
using	O
immunocytochemical	O
methods	O
.	O

A	O
high	O
and	O
frequent	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
found	O
both	O
in	O
MM	O
and	O
MGUS	O
patients	O
(	O
31	O
/	O
33	O
patients	O
positive	O
for	O
c	O
-	O
Jun	O
and	O
29	O
/	O
33	O
patients	O
positive	O
for	O
GST	O
-	O
pi	O
)	O
and	O
in	O
controls	O
not	O
affected	O
by	O
monoclonal	O
gammopathy	O
(	O
7	O
/	O
8	O
patients	O
positive	O
for	O
both	O
c	O
-	O
Jun	O
and	O
GST	O
-	O
pi	O
)	O
.	O

No	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
c	B
-	I
Jun-	I
and	I
GST	I
-	I
pi	I
-	I
positive	I
plasma	I
cells	I
.	O

The	O
expression	O
of	O
these	O
two	O
proteins	O
was	O
not	O
related	O
to	O
clinical	O
or	O
laboratory	O
data	O
.	O

Our	O
results	O
seem	O
to	O
confirm	O
a	O
possible	O
role	O
of	O
the	O
transcriptional	O
complex	O
AP-1	O
in	O
activating	O
GST	O
-	O
pi	O
promoter	O
in	O
human	O
plasma	O
cells	O
.	O

High	O
levels	O
of	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
E2F	O
in	O
adult	O
T	O
-	O
cell	O
leukemia	O
and	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
infected	O
cells	O
:	O
possible	O
enhancement	O
of	O
DNA	O
-	O
binding	O
of	O
E2F	O
by	O
the	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
I	O
transactivating	O
protein	O
,	O
Tax	O
.	O

Transcription	O
factor	O
E2F	O
binds	O
to	O
cellular	O
promoters	O
of	O
certain	O
growth-	O
and	O
cell	O
cycle	O
-	O
controlling	O
genes	O
and	O
forms	O
distinct	O
heteromeric	O
complexes	O
with	O
other	O
nuclear	O
proteins	O
.	O

It	O
has	O
therefore	O
been	O
proposed	O
that	O
E2F	O
is	O
involved	O
in	O
cellular	O
proliferation	O
control	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
show	O
here	O
by	O
mobility	O
-	O
shift	O
assay	O
that	O
E2F	O
-	O
containing	O
DNA	O
-	O
binding	O
complexes	O
were	O
detected	O
in	O
HTLV	B
-	I
I	I
-	I
infected	I
T	I
-	I
cell	I
lines	I
and	O
leukemic	O
cells	O
obtained	O
from	O
ATL	O
patients	O
but	O
not	O
in	O
an	O
uninfected	B
T	I
-	I
cell	I
line	I
,	O
Jurkat	B
,	O
and	O
normal	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

The	O
Tax	O
protein	O
,	O
encoded	O
by	O
HTLV	O
-	O
I	O
,	O
is	O
a	O
potent	O
transcription	O
activator	O
of	O
viral	O
and	O
several	O
cellular	O
genes	O
.	O

We	O
demonstrate	O
that	O
expression	O
of	O
Tax	O
can	O
induce	O
the	O
E2F	O
-	O
containing	O
DNA	O
-	O
binding	O
complexes	O
in	O
Jurkat	B
T	I
cells	I
.	O

Thus	O
,	O
Tax	O
,	O
through	O
enhancement	O
of	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
E2F	O
,	O
may	O
be	O
capable	O
of	O
regulating	O
cellular	O
gene	O
expression	O
implicated	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
T	O
cells	O
in	O
ATL	O
.	O

This	O
activity	O
may	O
be	O
relevant	O
to	O
the	O
mechanisms	O
whereby	O
HTLV	O
-	O
I	O
which	O
does	O
not	O
contain	O
oncogenes	O
induces	O
neoplasia	O
.	O

Reconstitution	O
of	O
T	O
cell	O
antigen	O
receptor	O
-	O
induced	O
Erk2	O
kinase	O
activation	O
in	O
Lck	B
-	I
negative	I
JCaM1	I
cells	I
by	O
Syk	O
.	O

The	O
two	O
related	O
protein	O
-	O
tyrosine	O
kinases	O
Syk	O
and	O
Zap	O
are	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
upon	O
crosslinking	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
activation	O
of	O
Syk	O
is	O
less	O
dependent	O
on	O
the	O
Src	O
family	O
kinase	O
Lck	O
than	O
the	O
activation	O
of	O
Zap	O
.	O

Here	O
we	O
report	O
that	O
overexpression	O
of	O
Syk	O
in	O
the	O
Lck	B
-	I
negative	I
JCaM1	I
cells	I
enabled	O
the	O
T	O
cell	O
antigen	O
receptor	O
/	O
CD3	O
complex	O
to	O
induce	O
a	O
normal	O
activation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
and	O
expression	O
of	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
reporter	O
construct	O
.	O

In	O
contrast	O
,	O
Zap	O
and	O
other	O
protein	O
-	O
tyrosine	O
kinases	O
were	O
unable	O
to	O
reconstitute	O
these	O
signaling	O
pathways	O
when	O
expressed	O
at	O
the	O
same	O
levels	O
.	O

In	O
parallel	O
,	O
Syk	O
was	O
phosphorylated	O
on	O
tyrosine	O
,	O
while	O
Zap	O
was	O
not	O
.	O

The	O
Syk	O
-mediated	O
T	O
cell	O
antigen	O
receptor	O
-induced	O
MAPK	O
activation	O
was	O
detectable	O
within	O
1	O
min	O
of	O
receptor	O
stimulation	O
and	O
peaked	O
at	O
3	O
-	O
5	O
min	O
.	O

The	O
capacity	O
of	O
Syk	O
to	O
reconstitute	O
the	O
MAPK	O
response	O
required	O
the	O
catalytic	O
activity	O
of	O
Syk	O
,	O
an	O
intact	O
autophosphorylation	O
site	O
(	O
Y518	O
and	O
Y519	O
)	O
,	O
both	O
Src	O
homology	O
2	O
domains	O
and	O
it	O
was	O
blocked	O
by	O
the	O
inhibitory	O
N17-mutated	O
dominant	O
-	O
negative	O
Ras	O
construct	O
.	O

A	O
Y341	O
--	O
>	O
F	O
mutant	O
of	O
Syk	O
,	O
which	O
is	O
deficient	O
in	O
its	O
interaction	O
with	O
phospholipase	O
Cy1	O
and	O
Vav	O
,	O
was	O
less	O
efficient	O
than	O
wild	O
-	O
type	O
Syk	O
.	O

Our	O
results	O
suggest	O
that	O
Syk	O
,	O
in	O
contrast	O
to	O
Zap	O
,	O
can	O
transduce	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
independently	O
of	O
Lck	O
.	O

Retinoic	O
acid	O
-	O
induced	O
modulation	O
of	O
IL-2	O
mRNA	O
production	O
and	O
IL-2	O
receptor	O
expression	O
on	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune	O
-	O
modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	O
(	O
Ig	O
)	O
response	O
.	O

Investigating	O
cytokines	O
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	O
production	O
is	O
augmented	O
by	O
RA	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	O
mRNA	O
,	O
another	O
important	O
cytokine	O
for	O
B	O
cell	O
immunoglobulin	O
production	O
,	O
the	O
expression	O
of	O
IL-2	O
receptors	O
on	O
T	O
cells	O
,	O
and	O
the	O
RA	O
nuclear	O
receptors	O
.	O

METHODS	O
:	O
Purified	O
T	O
cells	O
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent	O
/	O
media	O
control	O
for	O
0	O
,	O
6	O
-	O
8	O
,	O
and	O
24	O
h	O
.	O

Total	O
mRNA	O
was	O
extracted	O
from	O
T	O
cells	O
,	O
and	O
using	O
RT	O
-	O
PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	O
and	O
RA	O
receptors	O
(	O
RAR	O
)	O
-	O
alpha	O
,	O
beta	O
,	O
gamma	O
mRNA	O
were	O
determined	O
.	O

The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL-2	O
mRNA	O
production	O
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL-2R	O
-	O
alpha	O
expression	O
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR	O
-	O
alpha	O
.	O

Thus	O
,	O
IL-2	O
may	O
be	O
another	O
important	O
cytokine	O
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

The	O
tumour	O
associated	O
cell	O
surface	O
antigen	O
A6H	O
is	O
costimulatory	O
for	O
human	O
CD4	O
+	O
but	O
not	O
CD8	O
+	O
T	O
cells	O
.	O

The	O
A6H	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
recognizes	O
a	O
120	O
,	O
000	O
-	O
140	O
,	O
000	O
MW	O
antigen	O
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85	O
-	O
90	O
%	O
of	O
human	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cells	O
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

The	O
binding	O
of	O
the	O
A6H	O
mAb	O
induced	O
a	O
costimulatory	O
signal	O
in	O
anti	B
-	I
CD3	I
activated	I
T	I
cells	I
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	O
costimulated	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
in	O
purified	O
CD4	O
+	O
T	O
cells	O
.	O

Unexpectedly	O
,	O
the	O
CD8	O
+	O
T	O
-	O
cell	O
subpopulation	O
failed	O
to	O
respond	O
.	O

CD4	O
+	O
T	O
cells	O
costimulated	O
with	O
the	O
A6H	O
mAb	O
upregulated	O
CD80	O
,	O
CD86	O
,	O
CD71	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
R	O
alpha	O
,	O
IL-2R	O
beta	O
and	O
IL-2R	O
gamma	O
,	O
while	O
no	O
corresponding	O
up	O
-	O
regulation	O
of	O
these	O
cell	O
surface	O
molecules	O
was	O
seen	O
in	O
CD8	O
+	O
T	O
cells	O
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	O
mAb	O
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	O
factors	O
OCT-1	O
,	O
AP-1	O
and	O
NF	O
-	O
kappa	O
B	O
which	O
are	O
known	O
to	O
be	O
transcriptional	O
regulators	O
of	O
several	O
cytokine	O
and	O
cytokine	O
receptor	O
genes	O
,	O
including	O
the	O
IL-2	O
and	O
IL-2R	O
genes	O
.	O

Co	O
-	O
ligation	O
of	O
the	O
A6H	O
antigen	O
and	O
the	O
CD3	O
complex	O
induced	O
expression	O
of	O
the	O
transcription	O
factor	O
AP-1	O
in	O
CD4	O
+	O
T	O
cells	O
,	O
whereas	O
no	O
increase	O
in	O
NF	O
-	O
kappa	O
B	O
and	O
octamer	O
-	O
binding	O
(	O
Oct	O
)	O
proteins	O
was	O
seen	O
compared	O
to	O
T	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD3	O
alone	O
.	O

Furthermore	O
,	O
no	O
induction	O
of	O
AP-1	O
was	O
seen	O
in	O
A6H	O
costimulated	O
CD8	O
+	O
T	O
cells	O
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8	O
+	O
T	O
-	O
cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	O
ligation	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	O
molecule	O
or	O
distinct	O
regulation	O
of	O
the	O
A6H	O
transduced	O
AP-1	O
activation	O
pathway	O
may	O
exist	O
in	O
CD4	O
+	O
and	O
CD8	O
+	O
T	O
cell	O
subpopulations	O
.	O

Inhibitor	O
(	O
IK	O
)	O
of	O
IFN	O
-	O
gamma	O
induced	O
HLA	O
class	O
II	O
antigens	O
expression	O
also	O
inhibits	O
HLA	O
class	O
II	O
constitutive	O
expression	O
in	O
the	O
human	B
Raji	I
B	I
cell	I
line	I
.	O

The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
antigens	O
is	O
constitutive	O
in	O
professional	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	O
APCs	O
(	O
e.g	O
.	O
fibroblasts	O
)	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	O
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN	O
-	O
gamma	O
induction	O
of	O
MHC	O
class	O
II	O
antigens	O
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	O
in	O
MHC	O
class	O
II	O
expression	O
since	O
over	O
-	O
expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	O
class	O
II	O
mRNA	O
expression	O
.	O

The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN	O
-	O
gamma	O
induced	O
MHC	O
class	O
II	O
expressions	O
.	O

Examination	O
of	O
CIITA	O
mRNA	O
in	O
IK	O
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	O
mRNA	O
transcription	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	O
protein	O
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	O
class	O
II	O
antigens	O
and	O
that	O
inhibition	O
induced	O
by	O
IK	O
is	O
upstream	O
of	O
CIITA	O
in	O
this	O
regulatory	O
pathway	O
.	O

CD40	O
is	O
a	O
functional	O
activation	O
antigen	O
and	O
B7-independent	O
T	O
cell	O
costimulatory	O
molecule	O
on	O
normal	O
human	O
lung	O
fibroblasts	O
.	O

CD40	O
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	O
marrow	O
-	O
derived	O
cells	O
.	O

Recently	O
,	O
CD40	O
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	O
in	O
fibroblasts	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	O
expressed	O
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O

Communication	O
between	O
resident	O
tissue	O
fibroblasts	O
and	O
T	O
cells	O
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O

Signaling	O
through	O
CD40	O
with	O
soluble	O
CD40	O
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	O
IL-6	O
and	O
IL-8	O
.	O

IFN	B
-	I
gamma	I
-	I
primed	I
lung	I
fibroblasts	I
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	O
,	O
but	O
not	O
the	O
well	O
-	O
studied	O
costimulatory	O
molecules	O
B7	O
-	O
1	O
and	O
B7	O
-	O
2	O
.	O

Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	O
fibroblasts	O
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40	O
/CD40L	O
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O

HLA	O
-	O
DMA	O
and	O
HLA	O
-	O
DMB	O
gene	O
expression	O
functions	O
through	O
the	O
conserved	O
S	O
-	O
X	O
-	O
Y	O
region	O
.	O

The	O
MHC	O
class	O
II	O
homologous	O
proteins	O
HLA	O
-	O
DMA	O
and	O
HLA	O
-	O
DMB	O
function	O
in	O
the	O
loading	O
of	O
peptides	O
onto	O
class	O
II	O
molecules	O
.	O

Like	O
the	O
class	O
II	O
genes	O
,	O
the	O
HLA	O
-	O
DM	O
genes	O
contain	O
upstream	O
regulatory	O
sequences	O
similar	O
to	O
the	O
S	O
-	O
X	O
-	O
Y	O
regulatory	O
region	O
as	O
well	O
as	O
additional	O
putative	O
regulatory	O
sites	O
.	O

To	O
determine	O
whether	O
the	O
DM	O
genes	O
are	O
regulated	O
in	O
a	O
similar	O
manner	O
as	O
class	O
II	O
genes	O
,	O
a	O
series	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
was	O
performed	O
.	O

Deletion	O
analysis	O
showed	O
that	O
expression	O
from	O
the	O
DM	O
promoters	O
is	O
dependent	O
on	O
the	O
conserved	O
S	O
-	O
X	O
-	O
Y	O
region	O
.	O

The	O
class	O
II	O
-	O
specific	O
transcription	O
factors	O
RFX	O
and	O
CIITA	O
are	O
also	O
required	O
for	O
expression	O
,	O
as	O
cell	O
lines	O
deficient	O
in	O
these	O
factors	O
failed	O
to	O
allow	O
transcription	O
from	O
the	O
DM	O
promoters	O
.	O

In	O
addition	O
,	O
in	O
vivo	O
footprint	O
analysis	O
showed	O
the	O
putative	O
X	O
and	O
Y	O
boxes	O
to	O
be	O
occupied	O
by	O
transcription	O
factors	O
in	O
wild	O
-	O
type	O
B	O
cells	O
,	O
but	O
not	O
in	O
RFX	B
-	I
deficient	I
B	I
cells	I
.	O

In	O
astrocytes	O
,	O
IFN	O
-	O
gamma	O
treatment	O
induced	O
increased	O
occupancy	O
of	O
these	O
sites	O
.	O

None	O
of	O
the	O
other	O
putative	O
regulatory	O
sites	O
was	O
occupied	O
in	O
vivo	O
,	O
indicating	O
that	O
they	O
may	O
not	O
be	O
functional	O
.	O

Finally	O
,	O
gel	O
shift	O
analysis	O
showed	O
synergistic	O
complex	O
formation	O
between	O
proteins	O
that	O
bind	O
to	O
the	O
putative	O
X	O
boxes	O
of	O
the	O
DM	O
genes	O
,	O
as	O
is	O
found	O
for	O
the	O
DRA	O
gene	O
.	O

Therefore	O
,	O
the	O
DM	O
genes	O
share	O
a	O
common	O
mechanism	O
of	O
regulation	O
with	O
the	O
class	O
II	O
genes	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
between	O
alpha	O
and	O
delta	O
gene	O
segments	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
alpha	O
/	O
delta	O
locus	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
alpha	O
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O

An	O
enhancer	O
-	O
blocking	O
element	O
(	O
BEAD-1	O
,	O
for	O
blocking	O
element	O
alpha	O
/	O
delta	O
1	O
)	O
was	O
localized	O
to	O
a	O
2.0-kb	O
region	O
3	O
'	O
of	O
TCR	O
delta	O
gene	O
segments	O
and	O
5	O
'	O
of	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
within	O
this	O
locus	O
.	O

BEAD-1	O
blocked	O
the	O
ability	O
of	O
the	O
TCR	O
delta	O
enhancer	O
(	O
Edelta	O
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin	O
-	O
integrated	O
construct	O
.	O

We	O
propose	O
that	O
BEAD-1	O
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	O
alpha	O
/	O
delta	O
locus	O
into	O
distinct	O
regulatory	O
domains	O
controlled	O
by	O
Edelta	O
and	O
the	O
TCR	O
alpha	O
enhancer	O
,	O
and	O
that	O
it	O
prevents	O
Edelta	O
from	O
opening	O
the	O
chromatin	O
of	O
the	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O

Acute	O
leukemia	O
with	O
promyelocytic	O
features	O
in	O
PML	O
/	O
RARalpha	O
transgenic	O
mice	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
associated	O
with	O
reciprocal	O
chromosomal	O
translocations	O
involving	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RARalpha	O
)	O
locus	O
on	O
chromosome	O
17	O
.	O

In	O
the	O
majority	O
of	O
cases	O
,	O
RARalpha	O
translocates	O
and	O
fuses	O
with	O
the	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
gene	O
located	O
on	O
chromosome	O
15	O
.	O

The	O
resulting	O
fusion	O
genes	O
encode	O
the	O
two	O
structurally	O
unique	O
PML	O
/	O
RARalpha	O
and	O
RARalpha	O
/	O
PML	O
fusion	O
proteins	O
as	O
well	O
as	O
aberrant	O
PML	O
gene	O
products	O
,	O
the	O
respective	O
pathogenetic	O
roles	O
of	O
which	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
the	O
PML	O
/	O
RARalpha	O
fusion	O
protein	O
is	O
specifically	O
expressed	O
in	O
the	O
myeloid	O
-	O
promyelocytic	O
lineage	O
.	O

During	O
their	O
first	O
year	O
of	O
life	O
,	O
all	O
the	O
PML	O
/	O
RARalpha	O
transgenic	O
mice	O
have	O
an	O
abnormal	O
hematopoiesis	O
that	O
can	O
best	O
be	O
described	O
as	O
a	O
myeloproliferative	O
disorder	O
.	O

Between	O
12	O
and	O
14	O
months	O
of	O
age	O
,	O
10	O
%	O
of	O
them	O
develop	O
a	O
form	O
of	O
acute	O
leukemia	O
with	O
a	O
differentiation	O
block	O
at	O
the	O
promyelocytic	O
stage	O
that	O
closely	O
mimics	O
human	O
APL	O
even	O
in	O
its	O
response	O
to	O
retinoic	O
acid	O
.	O

Our	O
results	O
are	O
conclusive	O
in	O
vivo	O
evidence	O
that	O
PML	O
/	O
RARalpha	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
APL	O
.	O

Plasma	O
sialyltransferase	O
levels	O
in	O
psychiatric	O
disorders	O
as	O
a	O
possible	O
indicator	O
of	O
HPA	O
axis	O
function	O
.	O

A	O
dysfunction	O
in	O
the	O
regulation	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
possibly	O
attributed	O
to	O
a	O
change	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
functionality	O
,	O
has	O
been	O
implicated	O
in	O
depression	O
.	O

We	O
have	O
measured	O
both	O
lymphocyte	O
GR	O
receptor	O
binding	O
parameters	O
and	O
plasma	O
sialyltransferase	O
activity	O
,	O
as	O
a	O
biochemical	O
marker	O
of	O
GR	O
function	O
,	O
in	O
two	O
groups	O
of	O
patients	O
suffering	O
from	O
depression	O
or	O
schizophrenia	O
and	O
in	O
a	O
group	O
of	O
age-	O
and	O
sex	O
-	O
matched	O
controls	O
.	O

While	O
there	O
was	O
a	O
significant	O
increase	O
in	O
plasma	O
cortisol	O
levels	O
in	O
the	O
depressed	O
group	O
,	O
there	O
were	O
no	O
changes	O
in	O
the	O
lymphocyte	O
GR	O
binding	O
parameters	O
(	O
K	O
(	O
m	O
)	O
and	O
Bmax	O
)	O
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
sialyltransferase	O
:	O
cortisol	O
ratio	O
in	O
the	O
depressed	O
group	O
suggesting	O
an	O
inability	O
of	O
the	O
raised	O
cortisol	O
levels	O
to	O
induce	O
enzyme	O
expression	O
and	O
this	O
ratio	O
may	O
provide	O
a	O
useful	O
biochemical	O
marker	O
of	O
cortisol	O
receptor	O
function	O
.	O

Although	O
there	O
was	O
an	O
increase	O
in	O
the	O
plasma	O
activity	O
of	O
the	O
alpha	O
2	O
,	O
6	O
sialyltransferase	O
isozyme	O
in	O
the	O
schizophrenic	O
group	O
,	O
no	O
other	O
changes	O
were	O
determined	O
.	O

Therefore	O
,	O
while	O
the	O
total	O
plasma	O
sialyltransferase	O
:	O
cortisol	O
ratio	O
reflects	O
HPA	O
axis	O
function	O
,	O
alterations	O
in	O
specific	O
isozyme	O
activity	O
may	O
also	O
be	O
associated	O
with	O
other	O
CNS	O
disease	O
states	O
.	O

Involvement	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
hormone	O
-	O
binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	O
receptor	O
(	O
hMR	O
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone	O
-	O
binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729-Lys984	O
of	O
hMR	O
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	O
forms	O
,	O
as	O
well	O
as	O
the	O
hetero	O
-	O
oligomeric	O
MR	O
form	O
and	O
the	O
transformed	O
MR	O
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	O
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	O
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75	O
-	O
80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid	O
-	O
MR	O
complex	O
and	O
the	O
antibody	O
-	O
MR	O
complex	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat	O
-	O
shock	O
protein	O
hsp90	O
,	O
had	O
been	O
cross	O
-	O
linked	O
with	O
the	O
hMR	O
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	O
of	O
steroid	O
binding	O
of	O
HBD	O
mutants	O
with	O
the	O
Thr729-Leu765	O
sequence	O
deleted	O
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem	O
.	O
Mol	O
.	O
Biol.57	O
,	O
43	O
-	O
50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
Thr729-Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
differentially	O
modulates	O
tumor	O
necrosis	O
factor	O
alpha	O
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti	O
-	O
HLA	O
-	O
DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
by	O
the	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
cells	O
Ri	B
-	I
I	I
,	O
Ci	B
-	I
I	I
,	O
and	O
Sc	B
-	I
I	I
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B	O
-	O
cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	B
lymphoma	I
cell	I
Raji	I
;	O
in	O
contrast	O
,	O
it	O
did	O
not	O
induce	O
TNF	O
-	O
alpha	O
release	O
by	O
the	O
pre	O
-	O
B	O
leukemia	O
cells	O
Nalm-6	B
and	O
BV173	B
.	O

TNF	O
-	O
alpha	O
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF	O
-	O
alpha	O
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O

Secreted	O
TNF	O
-	O
alpha	O
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
and	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF	O
-	O
alpha	O
-	O
neutralizing	O
antibodies	O
did	O
not	O
upregulate	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
.	O

In	O
contrast	O
,	O
released	O
TNF	O
-	O
alpha	O
was	O
not	O
responsible	O
for	O
the	O
homotypic	O
aggregation	O
of	O
Ri	B
-	I
I	I
,	O
Ci	B
-	I
I	I
,	O
Sc	B
-	I
I	I
,	O
and	O
Raji	B
cells	I
induced	O
by	O
mAb	O
L243	O
,	O
and	O
it	O
did	O
not	O
affect	O
the	O
proliferation	O
of	O
B	O
cells	O
investigated	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF	O
-	O
alpha	O
after	O
triggering	O
of	O
HLA	O
-	O
DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	O
of	O
released	O
TNF	O
-	O
alpha	O
seem	O
to	O
correlate	O
with	O
the	O
stage	O
of	O
B	O
-	O
cell	O
maturation	O
but	O
do	O
not	O
correlate	O
with	O
the	O
amounts	O
of	O
cell	O
surface	O
HLA	O
-	O
DR	O
antigens	O
;	O
(	O
c	O
)	O
secreted	O
TNF	O
-	O
alpha	O
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF	O
-	O
alpha	O
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Immediate	O
early	O
and	O
early	O
lytic	O
cycle	O
proteins	O
are	O
frequent	O
targets	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
-	O
induced	O
cytotoxic	O
T	O
cell	O
response	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
,	O
a	O
human	O
gamma	O
-	O
herpesvirus	O
,	O
can	O
establish	O
both	O
nonproductive	O
(	O
latent	O
)	O
and	O
productive	O
(	O
lytic	O
)	O
infections	O
.	O

Although	O
the	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
latently	O
infected	O
cells	O
is	O
well	O
characterized	O
,	O
very	O
little	O
is	O
known	O
about	O
T	O
cell	O
controls	O
over	O
lytic	O
infection	O
;	O
this	O
imbalance	O
in	O
our	O
understanding	O
belies	O
the	O
importance	O
of	O
virus	O
-	O
replicative	O
lesions	O
in	O
several	O
aspects	O
of	O
EBV	O
disease	O
pathogenesis	O
.	O

The	O
present	O
work	O
shows	O
that	O
the	O
primary	O
CD8	O
+	O
CTL	O
response	O
to	O
EBV	O
in	O
infectious	O
mononucleosis	O
patients	O
contains	O
multiple	O
lytic	O
antigen	O
-	O
specific	O
reactivities	O
at	O
levels	O
at	O
least	O
as	O
high	O
as	O
those	O
seen	O
against	O
latent	O
antigens	O
;	O
similar	O
reactivities	O
are	O
also	O
detectable	O
in	O
CTL	O
memory	O
.	O

Clonal	O
analysis	O
revealed	O
individual	O
responses	O
to	O
the	O
two	O
immediate	O
early	O
proteins	O
BZLF1	O
and	O
BRLF1	O
,	O
and	O
to	O
three	O
(	O
BMLF1	O
,	O
BMRF1	O
,	O
and	O
BALF2	O
)	O
of	O
the	O
six	O
early	O
proteins	O
tested	O
.	O

In	O
several	O
cases	O
,	O
the	O
peptide	O
epitope	O
and	O
HLA	O
-	O
restricting	O
determinant	O
recognized	O
by	O
these	O
CTLs	O
has	O
been	O
defined	O
,	O
one	O
unusual	O
feature	O
being	O
the	O
number	O
of	O
responses	O
restricted	O
through	O
HLA	O
-	O
C	O
alleles	O
.	O

The	O
work	O
strongly	O
suggests	O
that	O
EBV	O
-	O
replicative	O
lesions	O
are	O
subject	O
to	O
direct	O
CTL	O
control	O
in	O
vivo	O
and	O
that	O
immediate	O
early	O
and	O
early	O
proteins	O
are	O
frequently	O
the	O
immunodominant	O
targets	O
.	O

This	O
contrasts	O
with	O
findings	O
in	O
alpha-	O
and	O
beta-	O
herpesvirus	O
systems	O
(	O
herpes	O
simplex	O
,	O
cytomegalovirus	O
)	O
where	O
viral	O
interference	O
with	O
the	O
antigen	O
-	O
processing	O
pathway	O
during	O
lytic	O
infection	O
renders	O
immediate	O
early	O
and	O
early	O
proteins	O
much	O
less	O
immunogenic	O
.	O

The	O
unique	O
capacity	O
of	O
gamma	O
-	O
herpesvirus	O
to	O
amplify	O
the	O
viral	O
load	O
in	O
vivo	O
through	O
a	O
latent	O
growth	O
-	O
transforming	O
infection	O
may	O
have	O
rendered	O
these	O
agents	O
less	O
dependent	O
upon	O
viral	O
replication	O
as	O
a	O
means	O
of	O
successfully	O
colonizing	O
their	O
hosts	O
.	O

Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
natural	O
killer	O
cells	O
.	O

The	O
role	O
of	O
cellular	O
redox	O
status	O
in	O
both	O
cytotoxic	O
activity	O
and	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
was	O
investigated	O
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	O
cells	O
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
or	O
long	B
-	I
term	I
cultured	I
NK	I
clones	I
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
transcription	O
factors	O
measured	O
by	O
gel	O
retardation	O
.	O

Pretreatment	O
of	O
NK	O
cells	O
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
but	O
the	O
AP-1	O
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O

The	O
inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
by	O
PDTC	O
paralleled	O
with	O
an	O
inhibition	O
of	O
spontaneous	O
cytotoxicity	O
mediated	O
by	O
NK	O
cells	O
.	O

Moreover	O
,	O
the	O
inhibitors	O
of	O
serine	O
proteases	O
,	O
N	O
-	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
and	O
N	O
-	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
phenylalanine	O
chloromethyl	O
ketone	O
,	O
also	O
blocked	O
the	O
cytolytic	O
activity	O
of	O
NK	O
cells	O
against	O
the	O
sensitive	O
target	O
K562	B
.	O

In	O
contrast	O
,	O
NK	O
activity	O
was	O
not	O
affected	O
by	O
pretreatment	O
of	O
the	O
effector	O
cells	O
with	O
the	O
proteasome	O
inhibitor	O
N	O
-	O
acetyl	O
-	O
leu	O
-	O
leu	O
-	O
norleucinal	O
which	O
selectively	O
inhibits	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	O
cells	O
involved	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	O
cells	O
.	O

Homodimerization	O
of	O
the	O
human	O
interleukin	O
4	O
receptor	O
alpha	O
chain	O
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	O
of	O
the	O
interleukin	O
2	O
receptor	O
gamma	O
chain	O
.	O

The	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
-4	O
and	O
IL-13	O
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL-4	O
receptor	O
(	O
IL-4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4-binding	O
IL-4Ralpha	O
chain	O
,	O
which	O
is	O
shared	O
with	O
the	O
IL-13R	O
,	O
and	O
the	O
IL-2Rgamma	O
(	O
gammac	O
)	O
chain	O
,	O
which	O
is	O
shared	O
with	O
IL-7R	O
,	O
IL-9R	O
,	O
and	O
IL-15R	O
.	O

IL-4	O
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	O
chain	O
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL-4	O
in	O
B	O
cells	O
that	O
lack	O
the	O
gammac	O
chain	O
may	O
involve	O
signaling	O
via	O
the	O
IL-13R	O
.	O

Alternatively	O
,	O
the	O
IL-4Ralpha	O
chain	O
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand	O
-	O
induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	O
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL-4Ralpha	O
induces	O
Janus	O
kinase	O
1	O
(	O
Jak1	O
)	O
activation	O
,	O
STAT6	O
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	B
B	I
cell	I
line	I
BJAB	I
.	O

Disruption	O
of	O
the	O
Jak1-binding	O
proline	O
-	O
rich	O
Box1	O
region	O
of	O
IL-4Ralpha	O
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	O
CD8alpha	O
/	O
IL-4Ralpha	O
receptor	O
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	O
chain	O
is	O
sufficient	O
to	O
transduce	O
Jak1	O
-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	O
alpha	O
.	O

A	O
role	O
in	O
thymic	O
maturation	O
for	O
factors	O
of	O
the	O
NF	O
-	O
kappaB	O
family	O
has	O
long	O
been	O
suspected	O
,	O
but	O
not	O
yet	O
proven	O
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte	O
-	O
specific	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	O
alpha	O
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double	B
-	I
positive	I
cells	I
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose	O
-	O
dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor	O
-	O
bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	O
delta	O
epsilon	O
gamma	O
and	O
TCR	O
zeta	O
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	O
zeta	O
chain	O
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	O
kinase	O
p56	O
(	O
lck	O
)	O
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	O
of	O
p65	O
translocation	O
to	O
the	O
nucleus	O
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta	O
-	O
chain	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	O
cytokines	O
(	O
IL-2	O
and	O
IFN	O
-	O
gamma	O
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	O
zeta	O
chain	O
and	O
p56	O
(	O
lck	O
)	O
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta	O
-	O
chain	O
.	O

Characterization	O
of	O
interleukin-10	O
receptor	O
expression	O
on	O
B	B
-	I
cell	I
chronic	I
lymphocytic	I
leukemia	I
cells	I
.	O

B	B
-	I
cell	I
chronic	I
lymphocytic	I
leukemia	I
(	I
B	I
-	I
CLL	I
)	I
cells	I
accumulate	O
in	O
vivo	O
in	O
the	O
G0	O
/	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
their	O
malignant	O
expansion	O
is	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
delay	O
in	O
cell	O
death	O
.	O

However	O
,	O
the	O
cellular	O
or	O
molecular	O
factors	O
responsible	O
for	O
a	O
delay	O
in	O
B	O
-	O
CLL	O
cell	O
death	O
are	O
unknown	O
.	O

B	O
-	O
CLL	O
cells	O
do	O
express	O
receptors	O
for	O
interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
and	O
IFN	O
-	O
gamma	O
,	O
and	O
activation	O
of	O
both	O
has	O
been	O
shown	O
to	O
promote	O
B	O
-	O
CLL	O
survival	O
in	O
vitro	O
by	O
preventing	O
apoptosis	O
.	O

The	O
interleukin-10	O
(	O
IL-10	O
)	O
receptor	O
is	O
another	O
member	O
of	O
the	O
IFN	O
receptor	O
family	O
,	O
but	O
its	O
ligand	O
,	O
IL-10	O
,	O
has	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
B	B
-	I
CLL	I
cells	I
.	O

In	O
the	O
current	O
study	O
,	O
we	O
undertook	O
a	O
biochemical	O
analysis	O
of	O
IL-10	O
receptor	O
expression	O
on	O
freshly	O
isolated	O
B	B
-	I
CLL	I
cells	I
and	O
characterized	O
the	O
functional	O
responsiveness	O
of	O
IL-10	O
binding	O
to	O
its	O
constitutively	O
expressed	O
receptor	O
.	O

We	O
show	O
that	O
B	B
-	I
CLL	I
cells	I
bind	O
IL-10	O
with	O
significant	O
specificity	O
and	O
express	O
between	O
47	O
and	O
127	O
IL-10	O
receptor	O
sites	O
per	O
cell	O
,	O
with	O
a	O
dissociation	O
constant	O
in	O
the	O
range	O
of	O
168	O
to	O
426	O
x	O
10	O
(	O
-12	O
)	O
mol	O
/	O
L	O
.	O

Ligand	O
binding	O
and	O
activation	O
of	O
the	O
IL-10	O
receptor	O
expressed	O
on	O
B	B
-	I
CLL	I
cells	I
results	O
in	O
the	O
phosphorylation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
and	O
STAT3	O
proteins	O
.	O

This	O
pattern	O
of	O
STAT	O
protein	O
phosphorylation	O
is	O
identical	O
to	O
IL-10	O
receptor	O
activation	O
on	O
normal	O
cells	O
and	O
similar	O
to	O
IFN	O
-	O
alpha	O
(	O
STAT1	O
and	O
STAT3	O
)	O
and	O
IFN	O
-	O
gamma	O
(	O
STAT1	O
)	O
receptor	O
activation	O
in	O
CLL	B
.	O

Further	O
,	O
in	O
consecutive	O
samples	O
of	O
fresh	O
blood	O
obtained	O
from	O
patients	O
with	O
B	B
-	I
CLL	I
cells	I
,	O
the	O
addition	O
of	O
IL-10	O
inhibited	O
B	B
-	I
CLL	I
proliferation	O
,	O
enhanced	O
B	B
-	I
CLL	I
differentiation	O
,	O
but	O
did	O
not	O
induce	O
apoptosis	O
.	O

Indeed	O
,	O
IL-10	O
,	O
like	O
IFN	O
-	O
gamma	O
,	O
was	O
able	O
to	O
significantly	O
reduce	O
the	O
amount	O
of	O
B	O
-	O
CLL	O
cell	O
death	O
caused	O
by	O
hydrocortisone	O
-	O
induced	O
apoptosis	O
.	O

We	O
conclude	O
that	O
cytokines	O
,	O
which	O
signal	O
through	O
the	O
interferon	O
family	O
of	O
receptors	O
,	O
have	O
comparable	O
functional	O
effects	O
on	O
B	B
-	I
CLL	I
cells	I
.	O

Tap	O
:	O
a	O
novel	O
cellular	O
protein	O
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	O
aggregation	O
.	O

Tip	O
of	O
herpesvirus	O
saimiri	O
associates	O
with	O
Lck	O
and	O
down	O
-	O
regulates	O
Lck	O
-mediated	O
activation	O
.	O

We	O
identified	O
a	O
novel	O
cellular	O
Tip	O
-	O
associated	O
protein	O
(	O
Tap	O
)	O
by	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
.	O

Tap	O
associated	O
with	O
Tip	O
following	O
transient	O
expression	O
in	O
COS-1	B
cells	I
and	O
stable	O
expression	O
in	O
human	B
Jurkat	I
-	I
T	I
cells	I
.	O

Expression	O
of	O
Tip	O
and	O
Tap	O
in	O
Jurkat	B
-	I
T	I
cells	I
induced	O
dramatic	O
cell	O
aggregation	O
.	O

Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up	O
-	O
regulated	O
surface	O
expression	O
of	O
adhesion	O
molecules	O
including	O
integrin	O
alpha	O
,	O
L	O
-	O
selectin	O
,	O
ICAM-3	O
,	O
and	O
H	O
-	O
CAM	O
.	O

Furthermore	O
,	O
NF	O
-	O
kappaB	O
transcriptional	O
factor	O
of	O
aggregated	O
cells	O
had	O
approximately	O
40-fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	O
cells	O
.	O

Thus	O
,	O
Tap	O
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	O
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

CCAAT	O
/	O
enhancer	O
binding	O
protein	O
epsilon	O
is	O
preferentially	O
up	O
-	O
regulated	O
during	O
granulocytic	O
differentiation	O
and	O
its	O
functional	O
versatility	O
is	O
determined	O
by	O
alternative	O
use	O
of	O
promoters	O
and	O
differential	O
splicing	O
.	O

CCAAT	O
/	O
enhancer	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
epsilon	O
is	O
a	O
recently	O
cloned	O
member	O
of	O
the	O
C	O
/	O
EBP	O
family	O
of	O
transcription	O
factors	O
and	O
is	O
expressed	O
exclusively	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
.	O

The	O
human	O
C	O
/	O
EBPepsilon	O
gene	O
is	O
transcribed	O
by	O
two	O
alternative	O
promoters	O
,	O
Palpha	O
and	O
Pbeta	O
.	O

A	O
combination	O
of	O
differential	O
splicing	O
and	O
alternative	O
use	O
of	O
promoters	O
generates	O
four	O
mRNA	O
isoforms	O
,	O
of	O
2.6	O
kb	O
and	O
1.3	O
-	O
1.5	O
kb	O
in	O
size	O
.	O

These	O
transcripts	O
can	O
encode	O
three	O
proteins	O
of	O
calculated	O
molecular	O
mass	O
32.2	O
kDa	O
,	O
27.8	O
kDa	O
,	O
and	O
14.3	O
kDa	O
.	O

Accordingly	O
,	O
Western	O
blots	O
with	O
antibodies	O
specific	O
for	O
the	O
DNA	O
-	O
binding	O
domain	O
,	O
that	O
is	O
common	O
to	O
all	O
forms	O
,	O
identify	O
multiple	O
proteins	O
.	O

C	O
/	O
EBPepsilon	O
mRNA	O
was	O
greatly	O
induced	O
during	O
in	O
vitro	O
granulocytic	O
differentiation	O
of	O
human	O
primary	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
HL60	B
promyelocytic	I
leukemia	I
cells	I
for	O
24	O
hr	O
induced	O
C	O
/	O
EBPepsilon	O
mRNA	O
levels	O
by	O
4-fold	O
,	O
while	O
prolonged	O
treatment	O
gradually	O
reduced	O
mRNA	O
expression	O
to	O
pretreatment	O
levels	O
.	O

Transient	O
transfection	O
experiments	O
with	O
expression	O
vectors	O
for	O
two	O
of	O
the	O
isoforms	O
demonstrated	O
that	O
the	O
32.2-kDa	O
protein	O
is	O
an	O
activator	O
of	O
transcription	O
of	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
promoter	O
,	O
while	O
the	O
14.3-kDa	O
protein	O
is	O
not	O
.	O

Thus	O
,	O
C	O
/	O
EBPepsilon	O
is	O
regulated	O
in	O
a	O
complex	O
fashion	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
myeloid	O
differentiation	O
.	O

Overexpression	O
of	O
HSF2-beta	O
inhibits	O
hemin	O
-induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	B
cells	I
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	O
shock	O
genes	O
in	O
hemin	O
-	O
treated	O
K562	B
cells	I
undergoing	O
erythroid	O
differentiation	O
.	O

Previous	O
studies	O
revealed	O
that	O
HSF2	O
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2-alpha	O
and	O
HSF2-beta	O
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2-alpha	O
and	O
HSF2-beta	O
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	O
and	O
whether	O
the	O
HSF2	O
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2-alpha	O
and	O
HSF2-beta	O
.	O

We	O
show	O
that	O
in	O
parental	O
K562	B
cells	I
,	O
the	O
HSF2-alpha	O
isoform	O
is	O
predominantly	O
expressed	O
and	O
HSF2	O
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2-beta	O
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	O
HSF2-alpha	O
,	O
the	O
hemin	O
-	O
induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	O
shock	O
genes	O
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2-alpha	O
results	O
in	O
an	O
enhanced	O
hemin	O
response	O
.	O

Furthermore	O
,	O
the	O
hemin	O
-induced	O
accumulation	O
of	O
globin	O
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	O
in	O
cells	O
overexpressing	O
HSF2-beta	O
.	O

We	O
suggest	O
that	O
HSF2-beta	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	O
activity	O
during	O
hemin	O
-	O
mediated	O
erythroid	O
differentiation	O
of	O
K562	B
cells	I
.	O

Glucocorticoid	O
-	O
mediated	O
repression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
arteritis	O
-	O
SCID	O
chimeras	O
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large	O
-	O
sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self	O
-	O
sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	B
artery	I
-	I
SCID	I
chimeras	I
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	O
,	O
IL-1beta	O
,	O
and	O
IL-6	O
mRNA	O
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	O
synthase	O
.	O

In	O
contrast	O
,	O
synthesis	O
of	O
IFN	O
-	O
gamma	O
mRNA	O
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF	O
-	O
beta1	O
was	O
unaffected	O
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	O
gene	O
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	O
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose	O
-	O
response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB	O
-mediated	O
cytokine	O
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	O
cell	O
products	O
IL-2	O
and	O
IFN	O
-	O
gamma	O
,	O
whereas	O
the	O
activation	O
of	O
tissue	O
-	O
infiltrating	O
macrophages	O
was	O
only	O
partially	O
affected	O
.	O

IL-1beta	O
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF	O
-	O
beta1	O
mRNA	O
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
persistence	O
of	O
TGF	O
-	O
beta1-transcribing	O
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Concomitant	O
downregulation	O
of	O
IgH	O
3	O
'	O
enhancer	O
activity	O
and	O
c	O
-	O
myc	O
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c	O
-	O
myc	O
.	O

Regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
expression	O
is	O
controlled	O
by	O
a	O
B	O
cell	O
-	O
specific	O
promoter	O
,	O
intronic	O
enhancer	O
and	O
additional	O
B	O
cell	O
-	O
specific	O
enhancer	O
elements	O
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	O
locus	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell	O
-	O
specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c	O
-	O
myc	O
oncogene	O
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	O
locus	O
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	O
gene	O
class	O
switch	O
recombination	O
.	O

We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
.	O

When	O
mouse	B
MPC11	I
plasmacytoma	I
cells	I
,	O
in	O
which	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	O
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	B
plasmacytoma	I
x	I
fibroblast	I
environment	I
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
transcriptionally	O
inactive	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	O
of	O
several	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
,	O
essential	O
for	O
IgH	O
3	O
'	O
enhancer	O
activity	O
,	O
is	O
lacking	O
,	O
which	O
may	O
explain	O
3	O
'	O
enhancer	O
inactivity	O
,	O
although	O
the	O
binding	O
of	O
repressors	O
can	O
not	O
be	O
excluded	O
.	O

Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c	O
-	O
myc	O
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	B
cells	I
carrying	O
the	O
t	O
(	O
12	O
;	O
15	O
)	O
translocation	O
,	O
is	O
down	O
-	O
regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	O
.	O

Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	O
factors	O
that	O
control	O
the	O
cell	O
-	O
specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	O
.	O

Construction	O
and	O
biological	O
characterization	O
of	O
an	O
interleukin-12	O
fusion	O
protein	O
(	O
Flexi-12	O
)	O
:	O
delivery	O
to	O
acute	O
myeloid	O
leukemic	O
blasts	O
using	O
adeno	O
-	O
associated	O
virus	O
.	O

Interleukin-12	O
(	O
IL-12	O
)	O
is	O
a	O
cytokine	O
that	O
exhibits	O
pleiotropic	O
effects	O
on	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
and	O
has	O
been	O
shown	O
to	O
have	O
promise	O
for	O
the	O
immunotherapy	O
of	O
cancer	O
.	O

The	O
combination	O
of	O
the	O
immune	O
costimulatory	O
molecule	O
B7.1	O
and	O
IL-12	O
has	O
been	O
shown	O
to	O
be	O
synergistic	O
for	O
T	O
cell	O
activation	O
.	O

By	O
transfecting	O
tumor	O
cells	O
with	O
both	O
IL-12	O
and	O
B7.1	O
cDNAs	O
,	O
it	O
may	O
be	O
possible	O
to	O
use	O
these	O
modified	O
targets	O
as	O
vaccines	O
.	O

A	O
major	O
obstacle	O
in	O
designing	O
a	O
vector	O
to	O
deliver	O
these	O
genes	O
results	O
from	O
the	O
structure	O
of	O
IL-12	O
.	O

Functional	O
IL-12	O
is	O
a	O
heterodimer	O
composed	O
of	O
two	O
distinct	O
subunits	O
that	O
are	O
encoded	O
by	O
separate	O
genes	O
on	O
different	O
chromosomes	O
.	O

Production	O
of	O
functional	O
IL-12	O
requires	O
the	O
coordinated	O
expression	O
of	O
both	O
genes	O
.	O

This	O
presents	O
several	O
problems	O
in	O
vectors	O
,	O
particularly	O
those	O
in	O
which	O
additional	O
genes	O
,	O
either	O
a	O
co	O
-	O
stimulatory	O
gene	O
or	O
a	O
selectable	O
marker	O
,	O
are	O
inserted	O
.	O

Therefore	O
,	O
we	O
have	O
constructed	O
a	O
single	O
cDNA	O
that	O
encodes	O
a	O
single	O
-	O
chain	O
protein	O
,	O
called	O
Flexi-12	O
,	O
which	O
retains	O
all	O
of	O
the	O
biological	O
characteristics	O
of	O
recombinant	O
IL-12	O
(	O
rIL-12	O
)	O
.	O

The	O
monomeric	O
polypeptide	O
Flexi-12	O
is	O
able	O
to	O
induce	O
the	O
proliferation	O
of	O
phytohemagglutinin	B
(	I
PHA	I
)	I
blasts	I
,	O
induce	O
PHA	B
blasts	I
to	O
secrete	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
additionally	O
,	O
by	O
preincubation	O
,	O
enhance	O
the	O
killing	O
of	O
K562	O
targets	O
by	O
PBLs	O
.	O

These	O
phenomena	O
are	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
comparable	O
to	O
that	O
seen	O
with	O
rIL-12	O
.	O

We	O
have	O
also	O
shown	O
that	O
tyrosine	O
phosphorylation	O
of	O
the	O
STAT	O
4	O
transcription	O
factor	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
unique	O
to	O
the	O
IL-12	O
signaling	O
pathway	O
,	O
occurs	O
with	O
Flexi-12	O
at	O
levels	O
similar	O
to	O
those	O
seen	O
with	O
rIL-12	O
.	O

We	O
have	O
packaged	O
Flexi-12	O
into	O
a	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)	O
and	O
used	O
this	O
vector	O
to	O
infect	O
acute	O
myeloid	O
leukemic	O
(	O
AML	O
)	O
blasts	O
.	O

Infected	O
AML	O
blasts	O
produced	O
between	O
2	O
and	O
6	O
ng	O
of	O
IL-12	O
/	O
10	O
(	O
6	O
)	O
cells	O
per	O
ml	O
per	O
48	O
hr	O
.	O

These	O
studies	O
also	O
confirm	O
that	O
AAV	O
is	O
an	O
efficient	O
delivery	O
vehicle	O
for	O
cytokines	O
to	O
leukemic	O
cells	O
.	O

Direct	O
analysis	O
of	O
these	O
modified	O
cells	O
acting	O
as	O
tumor	O
vaccines	O
is	O
underway	O
.	O

ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
synergistically	O
transactivate	O
the	O
human	O
GM	O
-	O
CSF	O
promoter	O
.	O

Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
is	O
one	O
such	O
cytokine	O
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis	O
-	O
acting	O
elements	O
with	O
NFkappaB	O
,	O
AP1	O
and	O
ETS	O
-	O
like	O
binding	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

ETS1	O
is	O
a	O
transcription	O
factor	O
of	O
the	O
ETS	O
family	O
that	O
is	O
expressed	O
in	O
T	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	O
can	O
transactivate	O
GM	O
-	O
CSF	O
in	O
Jurkat	B
T	I
cells	I
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	O
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	B
cells	I
,	O
may	O
act	O
in	O
concert	O
with	O
PMA	O
/	O
ionomycin	O
inducible	O
factors	O
.	O

Here	O
we	O
show	O
that	O
ETS1	O
can	O
transactivate	O
a	O
GM	O
-	O
CSF	O
reporter	O
construct	O
in	O
unstimulated	O
Jurkat	B
cells	I
,	O
providing	O
that	O
either	O
NFkappaB	O
or	O
AP1	O
transcription	O
factors	O
are	O
supplied	O
by	O
co	O
-	O
transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	O
and	O
AP1	O
is	O
induced	O
following	O
PMA	O
/	O
ionomycin	O
treatment	O
of	O
T	O
cells	O
.	O

Transactivation	O
by	O
ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	O
,	O
and	O
inducible	O
NFkappaB	O
and	O
AP1	O
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	O
complex	O
in	O
activated	O
T	O
cells	O
.	O

Relief	O
of	O
cyclin	O
A	O
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	O
primary	O
T	O
lymphocytes	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
.	O

Cyclin	O
A	O
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein	O
-	O
DNA	O
interactions	O
at	O
the	O
Cyclin	O
A	O
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	O
antibodies	O
directed	O
at	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	O
of	O
accessory	O
cells	O
.	O

Cyclin	O
A	O
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	O
CD2	O
+	O
CD28	O
whereas	O
stimulation	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
was	O
not	O
effective	O
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
sites	O
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	O
binding	O
sites	O
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	O
and	O
NF	O
-	O
Y	O
proteins	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	O
CD2	O
+	O
anti	O
CD28	O
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	O
CD2	O
+	O
anti	O
CD28	O
failed	O
to	O
do	O
so	O
after	O
cells	O
entered	O
a	O
proliferative	O
state	O
.	O

Thrombin	O
generation	O
by	O
apoptotic	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Thrombin	O
activation	O
requires	O
assembly	O
of	O
a	O
prothrombinase	O
complex	O
of	O
activated	O
coagulation	O
factors	O
on	O
an	O
anionic	O
phospholipid	O
surface	O
,	O
classically	O
provided	O
by	O
activated	O
platelets	O
.	O

We	O
have	O
previously	O
shown	O
that	O
anionic	O
phosphatidylserine	O
is	O
exposed	O
by	O
rat	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
undergoing	O
apoptosis	O
after	O
serum	O
withdrawal	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
chromogenic	O
assay	O
,	O
we	O
have	O
shown	O
thrombin	O
generation	O
by	O
apoptotic	O
VSMCs	O
expressing	O
c	O
-	O
myc	O
(	O
VSMC	B
-	I
myc	I
)	O
with	O
an	O
area	O
under	O
the	O
thrombin	O
-generation	O
curve	O
(	O
AUC	O
)	O
of	O
305	O
+	O
/-	O
17	O
nmol	O
x	O
min	O
/	O
L	O
and	O
a	O
peak	O
thrombin	O
(	O
PT	O
)	O
of	O
154	O
+	O
/-	O
9	O
nmol	O
/	O
L	O
.	O

The	O
thrombin	O
-generating	O
potential	O
of	O
the	O
apoptotic	B
VSMC	I
-	I
myc	I
cells	I
was	O
greater	O
than	O
that	O
of	O
unactivated	O
platelets	O
(	O
P	O
=	O
.003	O
for	O
AUC	O
;	O
P	O
=	O
.0002	O
for	O
PT	O
)	O
and	O
similar	O
to	O
calcium	O
-	O
ionophore	O
activated	O
platelets	O
(	O
AUC	O
of	O
332	O
+	O
/-	O
15	O
nmol	O
x	O
min	O
/	O
L	O
,	O
P	O
=	O
.3	O
;	O
PT	O
of	O
172	O
+	O
/-	O
8	O
nmol	O
/	O
L	O
,	O
P	O
=	O
.2	O
)	O
.	O

Thrombin	O
activation	O
was	O
also	O
seen	O
with	O
apoptotic	O
human	O
VSMCs	O
(	O
AUC	O
of	O
211	O
+	O
/-	O
8	O
nmol	O
x	O
min	O
/	O
L	O
;	O
PT	O
of	O
103	O
+	O
/-	O
4	O
nmol	O
/	O
L	O
)	O
and	O
was	O
inhibited	O
by	O
annexin	O
V	O
(	O
P	O
<	O
.0001	O
for	O
AUC	O
and	O
PT	O
)	O
.	O

VSMC	B
-	I
myc	I
cells	I
maintained	O
in	O
serum	O
generated	O
less	O
thrombin	O
than	O
after	O
serum	O
withdrawal	O
(	O
P	O
=	O
.0002	O
for	O
AUC	O
and	O
PT	O
)	O
.	O

VSMCs	O
derived	O
from	O
human	O
coronary	O
atherosclerotic	O
plaques	O
that	O
apoptose	O
even	O
in	O
serum	O
also	O
generated	O
thrombin	O
(	O
AUC	O
of	O
260	O
+	O
/-	O
2	O
nmol	O
x	O
min	O
/	O
L	O
;	O
PT	O
of	O
128	O
+	O
/-	O
4	O
nmol	O
/	O
L	O
)	O
.	O

We	O
conclude	O
that	O
apoptotic	O
VSMCs	O
possess	O
a	O
significant	O
thrombin	O
-generating	O
capacity	O
secondary	O
to	O
phosphatidylserine	O
exposure	O
.	O

Apoptotic	O
cells	O
within	O
atherosclerotic	O
plaques	O
may	O
allow	O
local	O
thrombin	O
activation	O
,	O
thereby	O
contributing	O
to	O
disease	O
progression	O
.	O

Interleukin-10	O
inhibits	O
interferon	O
-	O
gamma	O
-	O
induced	O
intercellular	O
adhesion	O
molecule-1	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
is	O
a	O
potent	O
monocyte	O
regulatory	O
cytokine	O
that	O
inhibits	O
gene	O
expression	O
of	O
proinflammatory	O
mediators	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
IL-10	O
downregulates	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
on	O
the	O
cell	O
surface	O
of	O
normal	O
human	O
monocytes	O
activated	O
with	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
.	O

IL-10	O
inhibition	O
of	O
IFN	O
-	O
gamma	O
-induced	O
ICAM-1	O
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti	O
-	O
IL-10	O
antibody	O
but	O
not	O
by	O
an	O
isotype	O
-	O
matched	O
control	O
antibody	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
IL-10	O
reduced	O
the	O
accumulation	O
of	O
ICAM-1	O
mRNA	O
in	O
IFN	B
-	I
gamma	I
-	I
stimulated	I
monocytes	I
.	O

IL-10	O
inhibition	O
of	O
ICAM-1	O
steady	O
-	O
state	O
mRNA	O
was	O
detected	O
at	O
3	O
hours	O
and	O
remained	O
at	O
24	O
hours	O
.	O

Nuclear	O
run	O
-	O
on	O
transcription	O
assays	O
showed	O
that	O
IL-10	O
inhibited	O
the	O
rate	O
of	O
IFN	O
-	O
gamma	O
-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	O
did	O
not	O
alter	O
the	O
half	O
-	O
life	O
of	O
IFN	O
-	O
gamma	O
-	O
induced	O
ICAM-1	O
message	O
.	O

Thus	O
,	O
IL-10	O
inhibits	O
IFN	O
-	O
gamma	O
-induced	O
ICAM-1	O
expression	O
in	O
monocytes	O
primarily	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Activation	O
of	O
IFN	O
-	O
gamma	O
-	O
responsive	O
genes	O
requires	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcriptional	O
factor	O
STAT-1alpha	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-1alpha	O
)	O
.	O

However	O
,	O
IL-10	O
did	O
not	O
affect	O
IFN	O
-	O
gamma	O
-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT-1alpha	O
or	O
alter	O
STAT-1alpha	O
binding	O
to	O
the	O
IFN	O
-	O
gamma	O
response	O
element	O
(	O
IRE	O
)	O
in	O
the	O
ICAM-1	O
promoter	O
.	O

Instead	O
,	O
IL-10	O
prevented	O
IFN	O
-	O
gamma	O
-induced	O
binding	O
activity	O
at	O
the	O
NF	O
-	O
kappaB	O
site	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-responsive	O
NF	O
-	O
kappaB	O
/	O
C	O
-	O
EBP	O
composite	O
element	O
in	O
the	O
ICAM-1	O
promoter	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	O
inhibits	O
IFN	O
-	O
gamma	O
-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF	O
-	O
kappaB	O
.	O

Comparison	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
and	O
Stat6	O
in	O
lymphoid	O
cells	O
and	O
mammary	O
epithelial	O
cells	O
.	O

Stat	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
and	O
Jak	O
(	O
Janus	O
kinases	O
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	O
and	O
epithelial	O
cells	O
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	O
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

Upon	O
ligand	O
binding	O
and	O
cytokine	O
receptor	O
dimerization	O
,	O
Stat	O
proteins	O
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	O
kinases	O
.	O

Activated	O
Stat	O
proteins	O
form	O
homo-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O

Stat5	O
and	O
Stat6	O
are	O
transcription	O
factors	O
active	O
in	O
mammary	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O

Prolactin	O
activates	O
Stat5	O
,	O
and	O
interleukin-4	O
(	O
IL-4	O
)	O
activates	O
Stat6	O
.	O

Both	O
cytokines	O
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

We	O
investigated	O
the	O
transactivation	O
potential	O
of	O
Stat6	O
and	O
found	O
that	O
it	O
is	O
not	O
restricted	O
to	O
lymphocytes	O
.	O

IL-4	O
-dependent	O
activation	O
of	O
Stat6	O
was	O
also	O
observed	O
in	O
HC11	B
mammary	I
epithelial	I
cells	I
.	O

In	O
these	O
cells	O
,	O
Stat6	O
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta	O
-	O
casein	O
gene	O
promoter	O
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	B
cells	I
.	O

The	O
glucocorticoid	O
receptor	O
was	O
able	O
to	O
further	O
enhance	O
IL-4	O
-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	O
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl	O
-	O
terminal	O
region	O
of	O
Stat6	O
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
.	O

The	O
potencies	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
,	O
Stat6	O
,	O
and	O
viral	O
protein	O
VP16	O
were	O
compared	O
.	O

Stat6	O
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10-fold	O
stronger	O
than	O
that	O
of	O
Stat5	O
.	O

In	O
pre	O
-	O
B	O
cells	O
(	O
Ba	O
/	O
F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
was	O
IL-4	O
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood	O
-	O
derived	O
monocytes	O
and	O
macrophages	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	O
monocytes	O
and	O
monocyte	O
-	O
derived	O
macrophages	O
with	O
regard	O
to	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
IL-1	O
beta	O
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	O
being	O
internalized	O
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O

No	O
virus	O
replication	O
and	O
no	O
transcription	O
of	O
the	O
Ad2	O
early	O
genes	O
was	O
observed	O
in	O
either	O
of	O
the	O
cells	O
.	O

Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	O
levels	O
for	O
TNF	O
-	O
alpha	O
and	O
IL-1	O
beta	O
in	O
both	O
monocytes	O
and	O
in	O
macrophages	O
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

The	O
production	O
of	O
both	O
cytokines	O
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	O
.	O

In	O
macrophages	O
,	O
a	O
slight	O
enhancement	O
of	O
TNF	O
-	O
alpha	O
production	O
was	O
seen	O
,	O
whereas	O
IL-1	O
beta	O
was	O
not	O
detected	O
.	O

The	O
data	O
indicate	O
that	O
cellular	O
genes	O
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	O
gene	O
products	O
could	O
be	O
detected	O
.	O

Activation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
beta	O
-	O
amyloid	O
peptides	O
and	O
interferon	O
-	O
gamma	O
in	O
murine	O
microglia	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid	O
-	O
beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	O
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
in	O
the	O
N9	B
murine	I
microglial	I
cell	I
line	I
.	O

Co	O
-	O
stimulation	O
of	O
microglia	O
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
and	O
100	O
U	O
/	O
ml	O
IFN	O
gamma	O
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF	O
-	O
kappa	O
B	O
complex	O
contains	O
both	O
RelA	O
and	O
p50	O
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF	O
-	O
kappa	O
B	O
/Rel	O
proteins	O
,	O
RelA	O
and	O
p50	O
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
plus	O
IFN	O
gamma	O
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25	O
-	O
35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF	O
-	O
kappa	O
B	O
activation	O
,	O
both	O
in	O
the	O
N9	B
microglial	I
cell	I
line	I
and	O
in	O
rat	B
primary	I
microglia	I
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF	O
-	O
kappa	O
B	O
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF	O
-	O
kappa	O
B	O
DNA	O
-	O
binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA	O
/	O
p50	O
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	O
B	O
-	O
dependent	O
genes	O
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	O
gamma	O
,	O
or	O
by	O
LPS	O
.	O

Interferons	O
up	O
-	O
regulate	O
STAT1	O
,	O
STAT2	O
,	O
and	O
IRF	O
family	O
transcription	O
factor	O
gene	O
expression	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
macrophages	O
.	O

IFN	O
signaling	O
is	O
mediated	O
by	O
binding	O
of	O
IFNs	O
to	O
their	O
receptors	O
and	O
subsequent	O
activation	O
of	O
Janus	O
tyrosine	O
kinase	O
(	O
JAK	O
)	O
-	O
STAT	O
signaling	O
pathway	O
.	O

Stimulation	O
of	O
cells	O
with	O
IFN	O
-	O
alpha	O
leads	O
to	O
the	O
assembly	O
of	O
IFN	O
-	O
stimulated	O
gene	O
factor	O
3	O
transcription	O
factor	O
complex	O
formed	O
by	O
STAT1	O
,	O
STAT2	O
,	O
and	O
p48	O
protein	O
.	O

IFN	O
-	O
gamma	O
signaling	O
is	O
mediated	O
by	O
homodimeric	O
STAT1	O
protein	O
.	O

Although	O
these	O
signaling	O
molecules	O
are	O
expressed	O
constitutively	O
,	O
there	O
is	O
also	O
evidence	O
of	O
transcriptional	O
regulation	O
by	O
IFNs	O
.	O

We	O
have	O
characterized	O
the	O
expression	O
of	O
STAT	O
and	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
transcription	O
factors	O
in	O
primary	O
human	O
blood	O
mononuclear	O
cells	O
and	O
macrophages	O
in	O
response	O
to	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
stimulation	O
.	O

We	O
show	O
that	O
IFN	O
-	O
alpha	O
and	O
IFN	O
-	O
gamma	O
rapidly	O
and	O
efficiently	O
enhanced	O
STAT1	O
,	O
STAT2	O
,	O
p48	O
,	O
and	O
IRF-1	O
gene	O
expression	O
.	O

IFN	O
-	O
gamma	O
induced	O
IRF-1	O
gene	O
expression	O
more	O
strongly	O
than	O
IFN	O
-	O
alpha	O
.	O

Stimulation	O
experiments	O
in	O
the	O
presence	O
of	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
,	O
suggested	O
that	O
these	O
genes	O
were	O
activated	O
directly	O
by	O
IFNs	O
.	O

IRF-2	O
gene	O
was	O
apparently	O
only	O
weakly	O
responsive	O
to	O
IFNs	O
in	O
these	O
cells	O
.	O

When	O
macrophages	O
were	O
pretreated	O
with	O
low	O
doses	O
of	O
IFN	O
-	O
gamma	O
and	O
then	O
stimulated	O
with	O
IFN	O
-	O
alpha	O
,	O
clearly	O
enhanced	O
formation	O
of	O
specific	O
transcription	O
factor	O
complexes	O
was	O
detected	O
.	O

This	O
suggests	O
that	O
higher	O
intracellular	O
levels	O
of	O
STAT1	O
,	O
STAT2	O
,	O
and	O
p48	O
protein	O
may	O
result	O
in	O
enhanced	O
signal	O
transduction	O
for	O
cytokines	O
utilizing	O
these	O
transcription	O
factors	O
.	O

Cytokines	O
:	O
shared	O
receptors	O
,	O
distinct	O
functions	O
.	O

That	O
the	O
signal	O
transduction	O
pathways	O
used	O
by	O
the	O
cytokines	O
IL-2	O
and	O
IL-15	O
are	O
identical	O
would	O
suggest	O
that	O
these	O
cytokines	O
have	O
redundant	O
roles	O
in	O
lymphoid	O
development	O
;	O
instead	O
,	O
IL-2	O
is	O
the	O
guardian	O
of	O
thymus	O
-	O
derived	O
T	O
-	O
cell	O
homeostasis	O
,	O
while	O
interleukin-15	O
promotes	O
extrathymic	O
development	O
of	O
T	O
and	O
NK	O
cells	O
.	O

In	O
vivo	O
footprinting	O
and	O
mutational	O
analysis	O
of	O
the	O
proximal	O
CD19	O
promoter	O
reveal	O
important	O
roles	O
for	O
an	O
SP1	O
/	O
Egr-1	O
binding	O
site	O
and	O
a	O
novel	O
site	O
termed	O
the	O
PyG	O
box	O
.	O

CD19	O
expression	O
begins	O
at	O
the	O
pro	O
-	O
B	O
cell	O
stage	O
of	O
B	O
cell	O
development	O
.	O

As	O
such	O
it	O
serves	O
as	O
a	O
good	O
prototype	O
for	O
B	O
cell	O
-	O
specific	O
genes	O
whose	O
expression	O
begins	O
shortly	O
after	O
lineage	O
commitment	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
CD19	O
gene	O
expression	O
,	O
we	O
isolated	O
and	O
functionally	O
characterized	O
the	O
CD19	O
promoter	O
using	O
in	O
vivo	O
footprinting	O
,	O
gel	O
shift	O
assays	O
,	O
and	O
transfection	O
studies	O
.	O

Reporter	O
constructs	O
spanning	O
portions	O
of	O
the	O
promoter	O
identified	O
a	O
region	O
between	O
-85	O
and	O
-200	O
that	O
produced	O
high	O
levels	O
of	O
reporter	O
gene	O
activity	O
in	O
lymphoid	O
cells	O
.	O

In	O
vivo	O
footprinting	O
identified	O
protected	O
regions	O
over	O
the	O
known	O
high	O
affinity	O
B	O
cell	O
lineage	O
-	O
specific	O
activator	O
protein	O
(	O
BSAP	O
)	O
site	O
,	O
the	O
low	O
affinity	O
BSAP	O
site	O
,	O
a	O
SP1	O
/	O
Egr-1	O
site	O
termed	O
the	O
CD19	O
GC	O
box	O
,	O
and	O
two	O
novel	O
sites	O
named	O
the	O
AT	O
box	O
and	O
PyG	O
box	O
.	O

Phorbol	O
ester	O
treatment	O
of	O
a	O
pre	B
-	I
B	I
cell	I
line	I
up	O
-	O
regulated	O
CD19	O
expression	O
,	O
induced	O
Egr-1	O
,	O
and	O
enhanced	O
the	O
footprint	O
over	O
the	O
GC	O
box	O
.	O

Gel	O
shift	O
assays	O
demonstrated	O
SP1	O
and	O
Egr-1	O
binding	O
to	O
the	O
CD19	O
GC	O
box	O
,	O
while	O
unknown	O
nuclear	O
proteins	O
bound	O
the	O
PyG	O
and	O
AT	O
boxes	O
.	O

Mutations	O
in	O
the	O
AT	O
box	O
or	O
in	O
the	O
BSAP	O
sites	O
did	O
not	O
affect	O
CD19	O
reporter	O
construct	O
activity	O
,	O
while	O
a	O
mutation	O
of	O
the	O
GC	O
box	O
reduced	O
it	O
modestly	O
,	O
and	O
a	O
PyG	O
box	O
mutation	O
reduced	O
it	O
dramatically	O
.	O

BSAP	O
failed	O
to	O
trans	O
-	O
activate	O
CD19	O
promoter	O
constructs	O
in	O
B	O
cells	O
or	O
non	O
-	O
B	O
cells	O
,	O
suggesting	O
that	O
cis	O
elements	O
such	O
as	O
the	O
PyG	O
and	O
GC	O
boxes	O
are	O
also	O
necessary	O
for	O
high	O
level	O
CD19	O
promoter	O
expression	O
.	O

A	O
human	O
homologue	O
of	O
the	O
Drosophila	O
Toll	O
protein	O
signals	O
activation	O
of	O
adaptive	O
immunity	O
[	O
see	O
comments	O
]	O

Induction	O
of	O
the	O
adaptive	O
immune	O
response	O
depends	O
on	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
and	O
cytokines	O
by	O
antigen	O
-	O
presenting	O
cells	O
.	O

The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O

It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non	O
-	O
clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O

We	O
report	O
here	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
toll	O
protein	O
(	O
Toll	O
)	O
which	O
has	O
been	O
shown	O
to	O
induce	O
the	O
innate	O
immune	O
response	O
in	O
adult	O
Drosophila	O
.	O

Like	O
Drosophila	O
Toll	O
,	O
human	O
Toll	O
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
consisting	O
of	O
a	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
homologous	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
-1	O
receptor	O
.	O

Both	O
Drosophila	O
Toll	O
and	O
the	O
IL-1	O
receptor	O
are	O
known	O
to	O
signal	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
.	O

We	O
show	O
that	O
a	O
constitutively	O
active	O
mutant	O
of	O
human	O
Toll	O
transfected	O
into	O
human	O
cell	O
lines	O
can	O
induce	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
controlled	O
genes	O
for	O
the	O
inflammatory	O
cytokines	O
IL-1	O
,	O
IL-6	O
and	O
IL-8	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
co	O
-	O
stimulatory	O
molecule	O
B7.1	O
,	O
which	O
is	O
required	O
for	O
the	O
activation	O
of	O
naive	O
T	O
cells	O
.	O

Bcl-2	O
protein	O
inhibits	O
bufalin	O
-	O
induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
in	O
human	B
leukemia	I
U937	I
cells	I
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	B
leukemia	I
U937	I
cells	I
by	O
anomalous	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	O
,	O
Raf-1	O
,	O
and	O
MAPK	O
kinase-1	O
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl-2	O
in	O
U937	B
cells	I
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	B
cells	I
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	O
protein	O
.	O

No	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
activation	O
of	O
MAPK	O
kinase-1	O
that	O
is	O
induced	O
by	O
bufalin	O
in	O
wild	O
-	O
type	O
or	O
Bcl-2-overexpressed	O
U937	O
cells	O
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	O
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl-2	O
.	O

Bufalin	O
treatment	O
activated	O
activator	O
protein-1	O
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2	O
-overexpressed	O
U937	B
cells	I
.	O

These	O
results	O
indicate	O
that	O
Bcl-2	O
acts	O
downstream	O
of	O
MAPK	O
kinase-1	O
but	O
upstream	O
of	O
MAPK	O
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	O
protein-1	O
may	O
be	O
down	O
-	O
regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	O
activity	O
by	O
Bcl-2	O
.	O

A	O
shortened	O
life	O
span	O
of	O
EKLF-	O
/	O
-	O
adult	O
erythrocytes	O
,	O
due	O
to	O
a	O
deficiency	O
of	O
beta	O
-	O
globin	O
chains	O
,	O
is	O
ameliorated	O
by	O
human	O
gamma	O
-	O
globin	O
chains	O
.	O

Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	O
alleles	O
in	O
murine	B
embryonic	I
stem	I
(	I
ES	I
)	I
cells	I
were	O
inactivated	O
.	O

These	O
EKLF-	B
/	I
-	I
ES	I
cells	I
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

However	O
,	O
the	O
EKLF-	B
/	I
-	I
colonies	I
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	O
erythrocytes	O
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	O
globin	O
genes	O
were	O
appropriately	O
regulated	O
,	O
with	O
the	O
exception	O
of	O
beta	O
h1-globin	O
,	O
which	O
continued	O
to	O
be	O
expressed	O
at	O
a	O
very	O
low	O
level	O
.	O

The	O
ratio	O
of	O
adult	O
beta	O
-	O
globin	O
/	O
alpha	O
-	O
globin	O
mRNA	O
in	O
the	O
mutant	B
ES	I
cells	I
was	O
1	O
/	O
15	O
of	O
that	O
in	O
wild	O
-	O
type	O
ES	O
cells	O
.	O

When	O
the	O
EKLF-	B
/	I
-	I
cells	I
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	O
contribute	O
at	O
a	O
detectable	O
level	O
to	O
the	O
mature	O
erythrocyte	O
compartment	O
of	O
the	O
chimeric	O
animals	O
,	O
based	O
on	O
analysis	O
of	O
glucose	O
phosphate	O
isomerase-1	O
(	O
GPI-1	O
)	O
isozymes	O
and	O
hemoglobins	O
that	O
distinguish	O
ES	O
cell	O
-	O
derived	O
erythrocytes	O
from	O
host	O
blastocyst	O
-	O
derived	O
erythrocytes	O
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	O
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

This	O
indicated	O
that	O
the	O
EKLF-	B
/	I
-	I
erythrocytes	I
in	O
adult	O
animals	O
must	O
be	O
short	O
-	O
lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta-	O
versus	O
alpha	O
-	O
globin	O
chains	O
,	O
leading	O
to	O
the	O
precipitation	O
of	O
excess	O
alpha	O
-	O
globin	O
chains	O
to	O
form	O
Heinz	O
bodies	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-	B
/	I
-	I
ES	I
cells	I
of	O
a	O
human	O
LCR	O
/	O
gamma	O
-	O
globin	O
gene	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	O
cell	O
-	O
derived	O
reticulocytes	O
as	O
well	O
as	O
mature	O
erythrocytes	O
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
leukocyte	O
-	O
specific	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
.	O

The	O
leukocyte	O
-	O
specific	O
,	O
cytoskeleton	O
-	O
binding	O
pp52	O
(	O
LSP-1	O
,	O
WP-34	O
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	O
and	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
macrophages	O
.	O

We	O
previously	O
detected	O
a	O
tissue	O
-	O
specific	O
promoter	O
preceding	O
the	O
exon	O
encoding	O
the	O
N	O
terminus	O
of	O
the	O
pp52	O
leukocyte	O
protein	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	O
promoter	O
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	O
'	O
terminus	O
of	O
pp52	O
mRNA	O
,	O
tandem	O
pairs	O
of	O
Ets	O
and	O
SP1	O
motifs	O
,	O
and	O
a	O
lone	O
C	O
/	O
EBP	O
motif	O
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	O
with	O
these	O
motifs	O
in	O
B	O
cells	O
vs	O
T	O
cells	O
.	O

The	O
Ets	O
motifs	O
are	O
preferentially	O
bound	O
by	O
PU-1	O
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	O
family	O
member	O
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
C	O
/	O
EBP	O
motif	O
is	O
bound	O
by	O
Ig	O
/	O
EBP-1	O
in	O
pre	O
-	O
B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	O
factor	O
-	O
IL-6beta	O
or	O
a	O
nuclear	O
factor	O
-	O
IL-6beta	O
-	O
Ig	O
/	O
EBP-1	O
heterodimer	O
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig	O
/	O
EBP-1	O
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	O
.	O

These	O
findings	O
reveal	O
the	O
features	O
controlling	O
the	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	O
of	O
this	O
promoter	O
in	O
other	O
leukocyte	O
lineages	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	O
neutrophils	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA	O
-	O
binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF	O
-	O
kappa	O
B	O
heterodimer	O
,	O
p50	O
/	O
RelA	O
,	O
is	O
induced	O
in	O
phagocytosing	O
neutrophils	O
.	O

Under	O
these	O
conditions	O
,	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10	O
-	O
15	O
min	O
,	O
and	O
returning	O
to	O
near	O
-	O
basal	O
levels	O
by	O
30	O
min	O
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	O
kappa	O
B	O
-	O
alpha	O
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	O
kappa	O
B	O
-alpha	O
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	O
B	O
-	O
responsive	O
genes	O
is	O
enhanced	O
in	O
phagocytosing	O
neutrophils	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF	O
-	O
kappa	O
B	O
activation	O
in	O
human	O
neutrophils	O
.	O

alpha	O
-	O
Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
by	O
suppressing	O
NF	O
-	O
kappa	O
B	O
mobilization	O
.	O

The	O
adherence	O
of	O
monocytes	O
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha	O
-	O
tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine	B
-	I
stimulated	I
human	I
umbilical	I
vein	I
endothelial	I
cells	I
(	O
HUVEC	B
)	O
.	O

Endothelial	O
cells	O
were	O
treated	O
with	O
TCP	O
,	O
alpha	O
-	O
tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha	O
-	O
tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
;	O
10	O
U	O
/	O
ml	O
,	O
6	O
h	O
)	O
.	O

Cytokine	O
-	O
stimulated	O
cell	O
surface	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
,	O
CD106	O
)	O
and	O
E	O
-	O
selectin	O
(	O
ELAM-1	O
,	O
CD62E	O
)	O
,	O
but	O
not	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
,	O
CD54	O
)	O
,	O
was	O
time-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
by	O
TCP	O
succinate	O
but	O
not	O
by	O
TCP	O
or	O
TCP	O
acetate	O
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF	O
-	O
induced	O
VCAM-1	O
and	O
E	O
-	O
selectin	O
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
+	O
/-	O
28	O
to	O
12	O
+	O
/-	O
4	O
channels	O
and	O
from	O
225	O
+	O
/-	O
38	O
to	O
79	O
+	O
/-	O
21	O
channels	O
,	O
respectively	O
.	O

Succinate	O
alone	O
had	O
no	O
effect	O
.	O

Decreased	O
adhesion	O
molecule	O
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	O
TCP	O
(	O
200	O
microM	O
,	O
72	O
h	O
)	O
,	O
reduced	O
U-937	B
cell	I
adhesion	O
to	O
TNF	B
-	I
alpha	I
-	I
stimulated	I
(	I
10	I
U	I
/	I
ml	I
,	I
6	I
h	I
)	I
HUVEC	I
by	O
30	O
%	O
(	O
P	O
<	O
0.025	O
)	O
and	O
to	O
IL-1	B
beta	I
-	I
stimulated	I
HUVEC	I
by	O
56	O
%	O
(	O
P	O
<	O
0.010	O
)	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
of	O
HUVEC	B
nuclear	O
proteins	O
revealed	O
a	O
decrease	O
in	O
TNF	O
-	O
alpha	O
-	O
stimulated	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	B
with	O
TCP	O
succinate	O
but	O
not	O
with	O
TCP	O
,	O
TCP	O
acetate	O
,	O
or	O
succinate	O
alone	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine	O
-	O
stimulated	O
endothelial	O
cells	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O

Sp3	O
mediates	O
transcriptional	O
activation	O
of	O
the	O
leukocyte	O
integrin	O
genes	O
CD11C	O
and	O
CD11B	O
and	O
cooperates	O
with	O
c	O
-	O
Jun	O
to	O
activate	O
CD11C	O
.	O

The	O
leukocyte	O
integrin	O
genes	O
CD11c	O
and	O
CD11b	O
are	O
expressed	O
predominately	O
in	O
myelomonocytic	O
cells	O
.	O

In	O
previous	O
experiments	O
,	O
the	O
-70	O
to	O
-65	O
and	O
-121	O
to	O
-103	O
regions	O
of	O
the	O
CD11c	O
promoter	O
and	O
the	O
-66	O
to	O
-59	O
region	O
of	O
the	O
CD11b	O
promoter	O
were	O
shown	O
to	O
be	O
essential	O
for	O
Sp1-	O
mediated	O
activation	O
of	O
these	O
genes	O
.	O

In	O
vivo	O
genomic	O
footprinting	O
had	O
also	O
revealed	O
cell	O
-	O
specific	O
binding	O
of	O
protein	O
,	O
presumably	O
Sp1	O
,	O
to	O
these	O
regions	O
.	O

In	O
this	O
study	O
,	O
electrophoretic	O
mobility	O
shift	O
analysis	O
showed	O
that	O
the	O
Sp1-related	O
factor	O
,	O
Sp3	O
,	O
also	O
binds	O
at	O
or	O
near	O
these	O
same	O
regions	O
.	O

Cotransfection	O
of	O
Sp3	O
along	O
with	O
CD11c	O
promoter	O
-	O
luciferase	O
constructs	O
into	O
Sp	B
-	I
deficient	I
Drosophila	I
Schneider	I
2	I
cells	I
showed	O
that	O
Sp3	O
could	O
activate	O
the	O
CD11c	O
promoter	O
.	O

Deletion	O
of	O
both	O
the	O
-70	O
to	O
-65	O
and	O
-121	O
to	O
-103	O
regions	O
of	O
the	O
CD11c	O
promoter	O
resulted	O
in	O
the	O
loss	O
of	O
activation	O
by	O
Sp3	O
.	O

Both	O
sites	O
showed	O
activation	O
by	O
Sp3	O
;	O
however	O
,	O
the	O
-70	O
to	O
-65	O
region	O
was	O
more	O
responsive	O
to	O
Sp3	O
than	O
to	O
Sp1	O
.	O

Similar	O
transfection	O
analysis	O
of	O
the	O
-66	O
to	O
-59	O
region	O
of	O
the	O
CD11b	O
promoter	O
showed	O
Sp3	O
-dependent	O
expression	O
.	O

Further	O
,	O
cotransfection	O
analysis	O
in	O
Drosophila	B
cells	I
showed	O
that	O
Sp3	O
,	O
as	O
was	O
previously	O
shown	O
for	O
Sp1	O
,	O
also	O
synergizes	O
with	O
c	O
-	O
Jun	O
to	O
activate	O
CD11c	O
.	O

Antisense	O
experiments	O
that	O
knocked	O
out	O
endogenous	O
Sp3	O
expression	O
in	O
the	O
myelomocytic	B
cell	I
line	I
,	O
HL60	B
,	O
revealed	O
that	O
Sp3	O
participates	O
in	O
activation	O
of	O
the	O
CD11c	O
and	O
CD11b	O
promoters	O
in	O
vivo	O
.	O

Vitamin	O
D	O
receptor	O
:	O
no	O
evidence	O
for	O
allele	O
-	O
specific	O
mRNA	O
stability	O
in	O
cells	O
which	O
are	O
heterozygous	O
for	O
the	O
Taq	O
I	O
restriction	O
enzyme	O
polymorphism	O
.	O

Allelic	O
variations	O
of	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
gene	O
have	O
been	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
prostate	O
cancer	O
in	O
men	O
and	O
osteoporosis	O
in	O
postmenopausal	O
women	O
.	O

Three	O
RFLPs	O
(	O
TaqI	O
,	O
ApaI	O
,	O
BsmI	O
)	O
define	O
two	O
common	O
haplotypes	O
:	O
BAt	O
and	O
baT	O
.	O

None	O
of	O
these	O
polymorphisms	O
change	O
the	O
translated	O
protein	O
.	O

Since	O
sequence	O
variations	O
in	O
the	O
3	O
'	O
UTR	O
of	O
VDR	O
have	O
been	O
linked	O
to	O
the	O
different	O
haplotypes	O
,	O
investigators	O
have	O
proposed	O
that	O
the	O
stability	O
of	O
VDR	O
mRNA	O
is	O
influenced	O
by	O
allelic	O
variations	O
.	O

Indirect	O
evidence	O
suggested	O
that	O
allele	O
T	O
is	O
less	O
stable	O
than	O
allele	O
t	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
RT	O
-	O
PCR	O
based	O
approach	O
to	O
compare	O
the	O
stability	O
of	O
the	O
big	O
T	O
and	O
small	O
t	O
allele	O
in	O
normal	O
heterozygous	O
lymphocytes	O
and	O
the	O
heterozygous	B
cell	I
lines	I
NB4	B
(	O
myeloid	O
leukemia	O
)	O
and	O
PC-3	B
and	O
DU	B
145	I
(	O
prostate	O
cancers	O
)	O
.	O

In	O
all	O
three	O
cases	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
stability	O
.	O

Interestingly	O
,	O
we	O
consistently	O
observed	O
30	O
%	O
less	O
RT	O
-	O
PCR	O
product	O
derived	O
from	O
the	O
small	O
t	O
allele	O
mRNA	O
in	O
steady	O
state	O
,	O
a	O
finding	O
which	O
also	O
speaks	O
against	O
a	O
higher	O
stability	O
of	O
the	O
small	O
t	O
allele	O
mRNA	O
.	O

These	O
results	O
indicate	O
a	O
variation	O
in	O
transcriptional	O
regulation	O
rather	O
than	O
mRNA	O
stability	O
between	O
the	O
alleles	O
.	O

We	O
hypothesize	O
that	O
an	O
unknown	O
gene	O
or	O
genes	O
in	O
linkage	O
with	O
the	O
polymorphisms	O
is	O
(	O
are	O
)	O
responsible	O
for	O
the	O
relationship	O
between	O
risk	O
of	O
prostate	O
cancer	O
and	O
VDR	O
polymorphisms	O
.	O

The	O
role	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
proteins	O
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Rel	O
/	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
consists	O
of	O
multiple	O
polypeptide	O
subunits	O
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein	O
-	O
protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
activity	O
is	O
not	O
surprising	O
since	O
this	O
transcription	O
factor	O
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Thus	O
,	O
it	O
is	O
not	O
unexpected	O
that	O
this	O
versatile	O
cellular	O
homeostatic	O
switch	O
would	O
be	O
affected	O
by	O
a	O
variety	O
of	O
viral	O
pathogens	O
,	O
which	O
have	O
evolved	O
mechanisms	O
to	O
utilize	O
various	O
aspects	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
activity	O
to	O
facilitate	O
their	O
replication	O
,	O
cell	O
survival	O
and	O
possibly	O
evasion	O
of	O
immune	O
responses	O
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
and	O
the	O
role	O
of	O
Rel	O
/	O
NF	O
-	O
kappa	O
B	O
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Mutations	O
in	O
the	O
TSC2	O
gene	O
:	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Mutations	O
in	O
the	O
TSC2	O
gene	O
on	O
chromosome	O
16p13.3	O
are	O
responsible	O
for	O
approximately	O
50	O
%	O
of	O
familial	O
tuberous	O
sclerosis	O
(	O
TSC	O
)	O
.	O

The	O
gene	O
has	O
41	O
small	O
exons	O
spanning	O
45	O
kb	O
of	O
genomic	O
DNA	O
and	O
encoding	O
a	O
5.5	O
kb	O
mRNA	O
.	O

Large	O
germline	O
deletions	O
of	O
TSC2	O
occur	O
in	O
<	O
5	O
%	O
of	O
cases	O
,	O
and	O
a	O
number	O
of	O
small	O
intragenic	O
mutations	O
have	O
been	O
described	O
.	O

We	O
analysed	O
mRNA	O
from	O
18	O
unrelated	O
cases	O
of	O
TSC	O
for	O
TSC2	O
mutations	O
using	O
the	O
protein	O
truncation	O
test	O
(	O
PTT	O
)	O
.	O

Three	O
cases	O
were	O
predicted	O
to	O
be	O
TSC2	O
mutations	O
on	O
the	O
basis	O
of	O
linkage	O
analysis	O
or	O
because	O
a	O
hamartoma	O
from	O
the	O
patient	O
showed	O
loss	O
of	O
heterozygosity	O
for	O
16p13.3	O
markers	O
.	O

Three	O
overlapping	O
PCR	O
products	O
,	O
covering	O
the	O
complete	O
coding	O
sequence	O
of	O
mRNA	O
,	O
were	O
generated	O
from	O
lymphoblastoid	B
cell	I
lines	I
,	O
translated	O
into	O
35S	O
-	O
methionine	O
labelled	O
protein	O
,	O
and	O
analysed	O
by	O
SDS	O
-	O
PAGE	O
.	O

PCR	O
products	O
showing	O
PTT	O
shifts	O
were	O
directly	O
sequenced	O
,	O
and	O
mutations	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
where	O
possible	O
.	O

Six	O
PTT	O
shifts	O
were	O
identified	O
.	O

Five	O
of	O
these	O
were	O
caused	O
by	O
mutations	O
predicted	O
to	O
produce	O
a	O
truncated	O
protein	O
:	O
(	O
i	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
32	O
bp	O
deletion	O
in	O
exon	O
11	O
,	O
and	O
a	O
mutant	O
mRNA	O
without	O
exon	O
11	O
was	O
produced	O
;	O
the	O
normal	O
exon	O
10	O
was	O
also	O
spliced	O
out	O
;	O
(	O
ii	O
)	O
a	O
sporadic	O
case	O
had	O
a	O
1	O
bp	O
deletion	O
in	O
exon	O
12	O
(	O
1634delT	O
)	O
;	O
(	O
iii	O
)	O
a	O
TSC2-linked	O
mother	O
and	O
daughter	O
pair	O
had	O
a	O
G	O
--	O
>	O
T	O
transversion	O
in	O
exon	O
23	O
(	O
G2715	O
T	O
)	O
introducing	O
a	O
cryptic	O
splice	O
site	O
causing	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	O
23	O
;	O
(	O
iv	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
2	O
bp	O
deletion	O
in	O
exon	O
36	O
;	O
(	O
v	O
)	O
a	O
sporadic	O
case	O
showed	O
a	O
1	O
bp	O
insertion	O
disrupting	O
the	O
donor	O
splice	O
site	O
of	O
exon	O
37	O
(	O
5007	O
+	O
2insA	O
)	O
,	O
resulting	O
in	O
the	O
use	O
of	O
an	O
upstream	O
exonic	O
cryptic	O
splice	O
site	O
to	O
cause	O
a	O
29	O
bp	O
truncation	O
of	O
mRNA	O
from	O
exon	O
37	O
.	O

In	O
one	O
case	O
,	O
the	O
PTT	O
shift	O
was	O
explained	O
by	O
in	O
-	O
frame	O
splicing	O
out	O
of	O
exon	O
10	O
,	O
in	O
the	O
presence	O
of	O
a	O
normal	O
exon	O
10	O
genomic	O
sequence	O
.	O

Alternative	O
splicing	O
of	O
exon	O
10	O
of	O
the	O
TSC2	O
gene	O
may	O
be	O
a	O
normal	O
variant	O
.	O

Three	O
3rd	O
base	O
substitution	O
polymorphisms	O
were	O
also	O
detected	O
during	O
direct	O
sequencing	O
of	O
PCR	O
products	O
.	O

Confirmed	O
mutations	O
were	O
identified	O
in	O
28	O
%	O
of	O
the	O
families	O
studied	O
and	O
on	O
the	O
assumption	O
that	O
half	O
of	O
the	O
sporadic	O
cases	O
should	O
have	O
TSC2	O
mutations	O
,	O
a	O
crude	O
estimate	O
of	O
the	O
detection	O
rate	O
would	O
be	O
60	O
%	O
.	O

This	O
compares	O
favourably	O
with	O
other	O
screening	O
methods	O
used	O
for	O
TSC2	O
,	O
notably	O
SSCP	O
,	O
and	O
since	O
PTT	O
involves	O
much	O
less	O
work	O
it	O
may	O
be	O
the	O
method	O
of	O
choice	O
.	O

Selection	O
of	O
down	O
-	O
regulated	O
sequences	O
along	O
the	O
monocytic	O
differentiation	O
of	O
leukemic	B
HL60	I
cells	I
.	O

In	O
order	O
to	O
dissect	O
the	O
molecular	O
mechanisms	O
of	O
monocytic	O
differentiation	O
we	O
have	O
developed	O
a	O
subtractive	O
hybridisation	O
method	O
based	O
on	O
a	O
simplified	O
'	O
representational	O
difference	O
analysis	O
'	O
.	O

We	O
have	O
selected	O
16	O
sequences	O
and	O
confirmed	O
their	O
down	O
-	O
regulation	O
along	O
the	O
TPA	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
HL60	B
cells	I
.	O

Among	O
these	O
sequences	O
we	O
have	O
identified	O
the	O
alpha	O
-	O
tubulin	O
,	O
the	O
TaxREB	O
protein	O
and	O
two	O
ribosomal	O
protein	O
sequences	O
which	O
had	O
not	O
been	O
previously	O
described	O
as	O
differentially	O
expressed	O
.	O

These	O
results	O
add	O
to	O
our	O
knowledge	O
about	O
the	O
molecules	O
implicated	O
along	O
the	O
monocytic	O
differentiation	O
and	O
growth	O
arrest	O
of	O
leukemic	O
cells	O
and	O
provide	O
a	O
first	O
step	O
in	O
the	O
study	O
of	O
their	O
respective	O
roles	O
.	O

Activation	O
of	O
a	O
novel	O
gene	O
in	O
3q21	O
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
in	O
leukemia	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
,	O
GR6	O
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	O
,	O
that	O
is	O
normally	O
expressed	O
in	O
early	O
fetal	O
development	O
but	O
not	O
in	O
adult	O
peripheral	O
blood	O
.	O

GR6	O
is	O
activated	O
in	O
the	O
UCSD	B
-	I
AML1	I
cell	I
line	I
and	O
in	O
a	O
leukemic	B
sample	I
,	O
both	O
of	O
which	O
carry	O
a	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
.	O

In	O
UCSD	B
-	I
AML1	I
,	O
we	O
have	O
also	O
identified	O
fusion	O
transcripts	O
between	O
the	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
(	O
EVI1	O
)	O
gene	O
in	O
3q26	O
and	O
GR6	O
and	O
between	O
EVI1	O
and	O
Ribophorin	O
I	O
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	O
in	O
3q21	O
.	O

All	O
fusions	O
splice	O
the	O
5	O
'	O
ends	O
of	O
the	O
3q21	O
genes	O
into	O
exon	O
2	O
of	O
the	O
EVI1	O
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	O
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	O
(	O
3	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
12	O
)	O
,	O
in	O
which	O
acute	O
myelogenous	O
leukemia	O
1-EVI1	O
fusions	O
and	O
ETV6-EVI1	O
fusions	O
,	O
respectively	O
,	O
occur	O
.	O

The	O
Ribophorin	O
I	O
-	O
EVI1	O
fusion	O
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	O
(	O
3	O
;	O
3	O
)	O
.	O

Four	O
P	O
-	O
like	O
elements	O
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	O
IL-4	O
gene	O
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein-1	O
family	O
proteins	O
.	O

We	O
previously	O
identified	O
the	O
P	O
sequence	O
as	O
a	O
critical	O
regulatory	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

In	O
the	O
mouse	O
IL-4	O
promoter	O
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	O
sequence	O
designated	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
P	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P	O
-	O
like	O
elements	O
and	O
their	O
binding	O
factors	O
in	O
the	O
native	O
promoter	O
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Transfection	O
of	O
EL-4	B
cells	I
with	O
the	O
IL-4	O
promoter	O
-	O
reporter	O
constructs	O
carrying	O
mutated	O
P	O
-	O
like	O
elements	O
showed	O
that	O
four	O
P	O
-	O
like	O
elements	O
,	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
but	O
not	O
P3	O
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-4	O
promoter	O
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	O
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	O
or	O
P2	O
proved	O
to	O
contain	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
proteins	O
as	O
major	O
components	O
.	O

Activator	O
protein	O
(	O
AP	O
)	O
-1	O
family	O
proteins	O
interacted	O
with	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
.	O

NFAT	O
/	O
AP-1	O
complex	O
formed	O
only	O
with	O
P	O
and	O
P2	O
.	O

Cross	O
-	O
competition	O
assays	O
among	O
the	O
P	O
-	O
like	O
elements	O
revealed	O
element	O
-	O
specific	O
and	O
common	O
complexes	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	O
element	O
linked	O
to	O
the	O
SV40	O
promoter	O
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	O
.	O
It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P	O
-	O
like	O
element	O
-	O
binding	O
complexes	O
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

Negative	O
regulation	O
by	O
HLA	O
-	O
DO	O
of	O
MHC	O
class	O
II	O
-restricted	O
antigen	O
processing	O
.	O

HLA	O
-	O
DM	O
is	O
a	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
-	O
like	O
molecule	O
that	O
facilitates	O
antigen	O
processing	O
by	O
catalyzing	O
the	O
exchange	O
of	O
invariant	O
chain	O
-	O
derived	O
peptides	O
(	O
CLIP	O
)	O
from	O
class	O
II	O
molecules	O
for	O
antigenic	O
peptides	O
.	O

HLA	O
-	O
DO	O
is	O
a	O
second	O
class	O
II	O
-	O
like	O
molecule	O
that	O
physically	O
associates	O
with	O
HLA	O
-	O
DM	O
in	O
B	O
cells	O
.	O

HLA	O
-	O
DO	O
was	O
shown	O
to	O
block	O
HLA	O
-	O
DM	O
function	O
.	O

Purified	O
HLA	O
-	O
DM	O
-	O
DO	O
complexes	O
could	O
not	O
promote	O
peptide	O
exchange	O
in	O
vitro	O
.	O

Expression	O
of	O
HLA	O
-	O
DO	O
in	O
a	O
class	B
II+	I
and	I
DM+	I
,	I
DO-	I
human	I
T	I
cell	I
line	I
caused	O
the	O
accumulation	O
of	O
class	O
II	O
-	O
CLIP	O
complexes	O
,	O
indicating	O
that	O
HLA	O
-	O
DO	O
blocked	O
DM	O
function	O
in	O
vivo	O
and	O
suggesting	O
that	O
HLA	O
-	O
DO	O
is	O
an	O
important	O
modulator	O
of	O
class	O
II	O
-	O
restricted	O
antigen	O
processing	O
.	O

Dual	O
effects	O
of	O
LPS	O
antibodies	O
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS	O
-	O
induced	O
proinflammatory	O
functions	O
.	O

Human	O
phagocytes	O
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	O
CD14	O
(	O
mCD14	O
)	O
,	O
a	O
proinflammatory	O
LPS	O
receptor	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti	O
-	O
LPS	O
Abs	O
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	O
.	O

Ab	O
-	O
associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC	O
-	O
LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	B
CD14-transfected	I
Chinese	I
hamster	I
ovary	I
fibroblasts	I
(	O
CHO	B
-	I
CD14	I
cells	I
)	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

LPS	O
core-	O
and	O
O	O
-	O
side	O
chain	O
-	O
specific	O
mAbs	O
inhibited	O
mCD14	O
-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

O	O
-	O
side	O
chain	O
-	O
specific	O
mAb	O
concurrently	O
enhanced	O
complement	O
-	O
dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	O
receptor-1	O
(	O
CR1	O
)	O
and	O
uptake	O
by	O
CHO	B
-	I
CD14	I
cells	I
involving	O
another	O
heat	O
-	O
labile	O
serum	O
factor	O
(	O
s	O
)	O
and	O
cell	O
-	O
associated	O
recognition	O
molecule	O
(	O
s	O
)	O
.	O

Core	O
-	O
specific	O
mAb	O
inhibited	O
mCD14	O
-mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-	O
mCD14	O
-mediated	O
LPS	O
uptake	O
.	O

The	O
modulation	O
by	O
anti	O
-	O
LPS	O
mAbs	O
of	O
mCD14	O
-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS	O
-	O
induced	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
translocation	O
and	O
TNF	O
-	O
alpha	O
secretion	O
in	O
CHO	B
-	I
CD14	I
cells	I
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-	O
mCD14	O
-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

LPS	O
-	O
specific	O
Abs	O
thus	O
mediate	O
anti	O
-	O
inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	O
and	O
augmenting	O
uptake	O
through	O
CR1	O
or	O
other	O
cell	O
receptors	O
.	O

Human	O
neutrophils	O
express	O
GH	O
-	O
N	O
gene	O
transcripts	O
and	O
the	O
pituitary	O
transcription	O
factor	O
Pit-1b	O
.	O

Since	O
GH	O
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	O
in	O
granulocyte	O
subsets	O
.	O

By	O
immunocytochemistry	O
,	O
25	O
+	O
/-	O
7	O
%	O
of	O
the	O
human	O
neutrophils	O
were	O
shown	O
to	O
express	O
immunoreactive	O
GH	O
,	O
whereas	O
eosinophils	O
were	O
negative	O
.	O

Reversed	O
transcription	O
(	O
RT	O
)	O
-PCR	O
analysis	O
demonstrated	O
GH	O
mRNA	O
in	O
neutrophils	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	O
the	O
GH	O
-	O
N	O
gene	O
but	O
not	O
the	O
GH	O
-	O
V	O
gene	O
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	O
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	O
transcription	O
factor	O
Pit-1	O
,	O
designated	O
Pit-1b	O
.	O

Analysis	O
of	O
myeloid	O
-	O
associated	O
genes	O
in	O
human	O
hematopoietic	O
progenitor	O
cells	O
.	O

The	O
distribution	O
of	O
myeloid	O
lineage	O
-	O
associated	O
cytokine	O
receptors	O
and	O
lysosomal	O
proteins	O
was	O
analyzed	O
in	O
human	B
CD34	I
+	I
cord	I
blood	I
cell	I
(	I
CB	I
)	I
subsets	I
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse	O
-	O
transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

The	O
highly	O
specific	O
granulomonocyte	O
-	O
associated	O
lysosomal	O
proteins	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
lysozyme	O
(	O
LZ	O
)	O
,	O
as	O
well	O
as	O
the	O
transcription	O
factor	O
PU.1	O
,	O
were	O
already	O
detectable	O
in	O
the	O
most	O
immature	O
CD34+Thy-1	B
+	I
subset	I
.	O

Messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
for	O
the	O
granulocyte	O
-	O
colony	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
receptor	O
,	O
granulocyte	O
-	O
macrophage	O
(	O
GM	O
)	O
-CSF	O
receptor	O
alpha	O
subunit	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptors	O
I	O
(	O
p55	O
)	O
and	O
II	O
(	O
p75	O
)	O
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c	O
-	O
kit	O
and	O
flt-3	O
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
monocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
receptor	O
was	O
largely	O
absent	O
at	O
this	O
stage	O
and	O
in	O
the	O
CD34+Thy-1-CD45RA-	B
subsets	I
.	O

The	O
M	O
-	O
CSF	O
receptor	O
was	O
first	O
detectable	O
in	O
the	O
myeloid	B
-	I
committed	I
CD34+Thy	I
-	I
l	I
-	I
CD45RA+	I
subset	I
.	O

All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O

Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	B
CD34+Thy-1	I
+	I
single	I
cells	I
.	O

Low	O
proliferative	O
capacity	O
was	O
observed	O
after	O
1	O
week	O
in	O
culture	O
in	O
the	O
presence	O
of	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
+	O
Flt-3	O
ligand	O
(	O
FL	O
)	O
+	O
G	O
-	O
CSF	O
.	O

Addition	O
of	O
GM	O
-	O
CSF	O
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	B
CD34+Thy-1	I
+	I
cells	I
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
+	O
/-	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF	O
-	O
alpha	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
myeloid	O
-	O
associated	O
growth	O
factor	O
receptor	O
transcripts	O
in	O
CD34	B
+	I
CB	I
subsets	I
does	O
not	O
discriminate	O
the	O
various	O
stages	O
of	O
differentiation	O
,	O
with	O
the	O
exception	O
of	O
the	O
M	O
-	O
CSF	O
receptor	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
TNF	O
-	O
alpha	O
is	O
a	O
potent	O
costimulatory	O
factor	O
of	O
the	O
very	O
immature	B
CD34+Thy-1	I
+	I
CB	I
subset	I
.	O

Dominant	O
cytotoxic	O
T	O
lymphocyte	O
response	O
to	O
the	O
immediate	O
-	O
early	O
trans	O
-	O
activator	O
protein	O
,	O
BZLF1	O
,	O
in	O
persistent	O
type	O
A	O
or	O
B	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
.	O

Five	O
healthy	O
human	O
leukocyte	O
antigen	O
-	O
B8	O
(	O
HLA	O
-	O
B8	O
)	O
-positive	O
virus	O
carriers	O
were	O
studied	O
to	O
investigate	O
the	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
response	O
to	O
an	O
HLA	O
-	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
immediate	O
-	O
early	O
trans	O
-	O
activator	O
protein	O
,	O
BZLF1	O
.	O

Of	O
the	O
5	O
virus	O
carriers	O
,	O
4	O
were	O
infected	O
with	O
type	O
A	O
and	O
1	O
with	O
type	O
B	O
EBV	O
.	O

Using	O
limiting	O
-	O
dilution	O
analysis	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
,	O
a	O
high	O
RAKFKQLLQ	O
-	O
specific	O
CTL	O
precursor	O
frequency	O
was	O
demonstrated	O
after	O
specific	O
peptide	O
or	O
autologous	O
lymphoblastoid	O
cell	O
line	O
stimulation	O
in	O
both	O
type	O
A	O
and	O
type	O
B	O
EBV	O
carriers	O
.	O

The	O
RAKFKQLLQ	O
-	O
specific	O
CTL	O
precursor	O
frequencies	O
in	O
all	O
5	O
persons	O
were	O
at	O
least	O
as	O
dominant	O
as	O
those	O
observed	O
with	O
two	O
other	O
EBV	O
-	O
associated	O
,	O
HLA	O
-	O
B8-restricted	O
latent	O
epitopes	O
,	O
FLRGRAYGL	O
and	O
QAKWRLQTL	O
.	O

These	O
findings	O
show	O
that	O
healthy	O
virus	O
carriers	O
maintain	O
a	O
high	O
frequency	O
of	O
BZLF1-specific	O
memory	O
T	O
cells	O
,	O
potentially	O
to	O
control	O
virus	O
spread	O
from	O
lytically	O
infected	O
cells	O
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester	O
-	O
inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin-2	O
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	O
kinase	O
C	O
activity	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
PKC	O
-mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	O
rat	O
peritoneal	O
neutrophils	O
and	O
human	B
Jurkat	I
T	I
cells	I
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30	O
-	O
50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	O
activator	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC	O
-independent	O
mechanism	O
.	O

The	O
NH2Cl	B
-	I
treated	I
neutrophils	I
showed	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
PMA	O
-	O
induced	O
phosphorylation	O
of	O
a	O
47-kDa	O
protein	O
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	O
factor	O
of	O
NADPH	O
oxidase	O
,	O
p47	O
(	O
phox	O
)	O
.	O

Jurkat	B
T	I
cells	I
pretreated	O
with	O
NH2Cl	O
(	O
20	O
-	O
70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin-2	O
receptor	O
alpha	O
chain	O
following	O
PMA	O
stimulation	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
nuclear	O
transcription	O
factor-	O
kappaB	O
activation	O
,	O
also	O
without	O
loss	O
of	O
cell	O
viability	O
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC	O
-mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	O
activity	O
.	O

Epstein	O
-	O
Barr	O
virus	O
EBNA3C	O
represses	O
Cp	O
,	O
the	O
major	O
promoter	O
for	O
EBNA	O
expression	O
,	O
but	O
has	O
no	O
effect	O
on	O
the	O
promoter	O
of	O
the	O
cell	O
gene	O
CD21	O
.	O

EBNA3C	O
is	O
a	O
potent	O
repressor	O
of	O
transcription	O
when	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
DNA	O
binding	O
domain	O
(	O
DBD	O
)	O
of	O
GALA	O
.	O

A	O
survey	O
of	O
promoters	O
has	O
revealed	O
that	O
the	O
wild	O
-	O
type	O
,	O
unfused	O
EBNA3C	O
can	O
specifically	O
repress	O
expression	O
from	O
reporter	O
plasmids	O
containing	O
the	O
Epstein	O
-	O
Barr	O
virus	O
Cp	O
latency	O
-	O
associated	O
promoter	O
.	O

Repression	O
of	O
Cp	O
activity	O
required	O
amino	O
acids	O
207	O
to	O
368	O
,	O
which	O
encompasses	O
a	O
region	O
resembling	O
a	O
basic	O
DBD	O
adjacent	O
to	O
a	O
leucine	O
zipper	O
DNA	O
binding	O
motif	O
and	O
a	O
site	O
which	O
binds	O
to	O
the	O
cellular	O
factor	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
.	O

However	O
,	O
amino	O
acids	O
207	O
to	O
368	O
are	O
dispensable	O
when	O
the	O
protein	O
is	O
bound	O
to	O
DNA	O
as	O
a	O
fusion	O
with	O
the	O
GAL4	O
DBD	O
,	O
thus	O
implicating	O
this	O
region	O
in	O
DNA	O
binding	O
.	O

Mutation	O
of	O
the	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
binding	O
site	O
in	O
EBNA3C	O
abrogated	O
repression	O
,	O
strongly	O
suggesting	O
that	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
is	O
necessary	O
for	O
targeting	O
the	O
viral	O
protein	O
to	O
Cp	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
mutation	O
of	O
the	O
EBNA2	O
response	O
element	O
(	O
a	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
binding	O
site	O
)	O
in	O
Cp	O
also	O
prevented	O
significant	O
repression	O
.	O

In	O
addition	O
,	O
amino	O
acids	O
346	O
to	O
543	O
,	O
which	O
were	O
previously	O
defined	O
as	O
important	O
for	O
the	O
repressor	O
activity	O
of	O
the	O
GAL4-EBNA3C	O
fusion	O
proteins	O
,	O
also	O
appear	O
to	O
be	O
necessary	O
for	O
the	O
repression	O
of	O
Cp	O
.	O

Since	O
repression	O
by	O
these	O
fusions	O
was	O
not	O
observed	O
in	O
all	O
cell	O
types	O
,	O
it	O
seems	O
likely	O
that	O
EBNA3C	O
either	O
depends	O
on	O
a	O
corepressor	O
which	O
may	O
interact	O
with	O
amino	O
acids	O
346	O
to	O
543	O
or	O
is	O
modified	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
in	O
order	O
to	O
repress	O
.	O

These	O
data	O
are	O
consistent	O
with	O
EBNA3C	O
contributing	O
to	O
the	O
regulation	O
of	O
EBNA	O
expression	O
in	O
latently	O
infected	O
B	O
cells	O
through	O
CBF1	O
/	O
RBP	O
-	O
Jkappa	O
and	O
another	O
factor	O
,	O
but	O
this	O
need	O
not	O
directly	O
involve	O
EBNA2	O
.	O

Finally	O
,	O
although	O
it	O
has	O
been	O
reported	O
that	O
EBNA3C	O
can	O
upregulate	O
CD21	O
in	O
some	O
B	O
cells	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
effect	O
of	O
EBNA3C	O
on	O
reporter	O
plasmids	O
which	O
contain	O
the	O
CD21	O
promoter	O
.	O

Late	O
gene	O
expression	O
from	O
the	O
Epstein	O
-	O
Barr	O
virus	O
BcLF1	O
and	O
BFRF3	O
promoters	O
does	O
not	O
require	O
DNA	O
replication	O
in	O
cis	O
.	O

Late	O
gene	O
expression	O
follows	O
and	O
is	O
dependent	O
upon	O
lytic	O
replication	O
of	O
the	O
viral	O
genome	O
.	O

Although	O
experimental	O
evidence	O
is	O
lacking	O
,	O
lytic	O
viral	O
DNA	O
replication	O
is	O
believed	O
to	O
remove	O
modifications	O
or	O
binding	O
factors	O
from	O
the	O
genome	O
which	O
serve	O
to	O
repress	O
late	O
gene	O
expression	O
during	O
latency	O
or	O
the	O
early	O
lytic	O
cycle	O
.	O

We	O
have	O
developed	O
a	O
reporter	O
assay	O
to	O
begin	O
characterizing	O
the	O
mechanisms	O
that	O
regulate	O
late	O
gene	O
expression	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
model	O
system	O
,	O
the	O
activities	O
of	O
late	O
promoter	O
-	O
reporter	O
fusions	O
are	O
measured	O
following	O
transient	O
transfection	O
into	O
tissue	B
culture	I
cells	I
expressing	O
EBV	O
during	O
different	O
stages	O
of	O
the	O
lytic	O
cycle	O
.	O

This	O
system	O
faithfully	O
recapitulates	O
late	O
expression	O
patterns	O
from	O
the	O
endogenous	O
virus	O
,	O
implicating	O
specific	O
cis	O
-	O
active	O
sequences	O
in	O
the	O
control	O
of	O
late	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
these	O
promoters	O
respond	O
only	O
indirectly	O
to	O
the	O
viral	O
immediate	O
-	O
early	O
transactivator	O
,	O
ZEBRA	O
.	O

This	O
indirect	O
response	O
is	O
mediated	O
by	O
other	O
viral	O
or	O
virally	O
induced	O
activities	O
downstream	O
of	O
ZEBRA	O
in	O
the	O
lytic	O
cascade	O
.	O

In	O
this	O
system	O
,	O
late	O
gene	O
expression	O
is	O
sensitive	O
to	O
inhibitors	O
of	O
the	O
viral	O
DNA	O
polymerase	O
such	O
as	O
phosphonoacetic	O
acid	O
,	O
although	O
the	O
reporters	O
lack	O
a	O
eukaryotic	O
origin	O
of	O
replication	O
and	O
are	O
not	O
replicated	O
under	O
the	O
assay	O
conditions	O
.	O

Thus	O
,	O
replication	O
of	O
the	O
transcriptional	O
template	O
is	O
not	O
a	O
prerequisite	O
for	O
expression	O
with	O
late	O
kinetics	O
,	O
a	O
finding	O
inconsistent	O
with	O
the	O
current	O
models	O
which	O
posit	O
a	O
cis	O
-	O
active	O
relationship	O
between	O
lytic	O
EBV	O
DNA	O
replication	O
and	O
late	O
gene	O
expression	O
.	O

Rather	O
,	O
analysis	O
of	O
this	O
system	O
has	O
revealed	O
a	O
trans	O
relationship	O
between	O
late	O
gene	O
expression	O
and	O
viral	O
DNA	O
replication	O
and	O
highlights	O
the	O
indirect	O
and	O
complex	O
link	O
between	O
these	O
two	O
events	O
.	O

Purification	O
and	O
characterization	O
of	O
the	O
human	O
SR	O
31747A	O
-	O
binding	O
protein	O
.	O

A	O
nuclear	O
membrane	O
protein	O
related	O
to	O
yeast	O
sterol	O
isomerase	O
.	O

SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	O
and	O
mouse	O
lymphocytes	O
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	O
31747A	O
-	O
binding	O
protein	O
(	O
SR	O
-	O
BP	O
)	O
.	O

Purified	O
SR	O
-	O
BP	O
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
as	O
a	O
Mr	O
28	O
,	O
000	O
protein	O
.	O

Cloning	O
of	O
the	O
cDNA	O
encoding	O
human	O
SR	O
-	O
BP	O
shows	O
an	O
open	O
reading	O
frame	O
for	O
a	O
223-amino	O
acid	O
protein	O
,	O
which	O
is	O
homologous	O
to	O
the	O
recently	O
cloned	O
sigma	O
1	O
receptor	O
.	O

Interestingly	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
be	O
related	O
to	O
fungal	O
C8-C7	O
sterol	O
isomerase	O
,	O
encoded	O
by	O
the	O
ERG2	O
gene	O
.	O

The	O
ERG2	O
gene	O
product	O
has	O
been	O
identified	O
recently	O
as	O
the	O
molecular	O
target	O
of	O
SR	O
31747A	O
that	O
mediates	O
antiproliferative	O
effects	O
of	O
the	O
drug	O
in	O
yeast	O
.	O

Northern	O
blot	O
analysis	O
of	O
SR	O
-	O
BP	O
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	O
kilobases	O
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O

Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	O
monoclonal	O
antibody	O
raised	O
against	O
SR	O
-	O
BP	O
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O

When	O
studying	O
the	O
binding	O
of	O
SR	O
31747A	O
on	O
membranes	O
from	O
yeast	O
expressing	O
SR	O
-	O
BP	O
,	O
we	O
found	O
a	O
pharmacological	O
profile	O
of	O
sigma	O
1	O
receptors	O
;	O
binding	O
was	O
displaced	O
by	O
(	O
+	O
)	O
-pentazocine	O
,	O
haloperidol	O
,	O
and	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
,	O
with	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
being	O
a	O
more	O
potent	O
competitor	O
than	O
(	O
-	O
)	O
-SKF	O
10	O
,	O
047	O
.	O

Scatchard	O
plot	O
analysis	O
revealed	O
Kd	O
values	O
of	O
7.1	O
nM	O
and	O
0.15	O
nM	O
for	O
(	O
+	O
)	O
-pentazocine	O
and	O
SR	O
31747A	O
,	O
respectively	O
,	O
indicating	O
an	O
affinity	O
of	O
SR	O
-	O
BP	O
50-fold	O
higher	O
for	O
SR	O
31747A	O
than	O
for	O
pentazocine	O
.	O

Additionally	O
,	O
we	O
showed	O
that	O
pentazocine	O
,	O
a	O
competitive	O
inhibitor	O
of	O
SR	O
31747A	O
binding	O
,	O
also	O
prevents	O
the	O
immunosuppressive	O
effect	O
of	O
SR	O
31747A	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR	O
-	O
BP	O
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O

Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
several	O
inducers	O
.	O

Double	O
-	O
stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	B
lymphocytic	I
cell	I
line	I
(	O
CEM	B
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF	O
-	O
kappa	O
B	O
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	O
involve	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
.	O

Since	O
these	O
latter	O
compounds	O
were	O
known	O
to	O
activate	O
NF	O
-	O
kappa	O
B	O
translocation	O
in	O
a	O
redox	O
-	O
sensitive	O
way	O
,	O
we	O
have	O
demonstrated	O
that	O
NF	O
-	O
kappa	O
B	O
activation	O
by	O
PMA	O
was	O
resistant	O
to	O
antioxidant	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
and	O
sensitive	O
to	O
kinase	O
inhibitors	O
staurosporine	O
and	O
H7	O
while	O
activation	O
by	O
H2O2	O
or	O
TNF	O
-	O
alpha	O
were	O
not	O
.	O

Association	O
of	O
glucocorticoid	O
insensitivity	O
with	O
increased	O
expression	O
of	O
glucocorticoid	O
receptor	O
beta	O
.	O

In	O
many	O
chronic	O
inflammatory	O
disorders	O
,	O
glucocorticoid	O
(	O
GC	O
)	O
insensitivity	O
is	O
a	O
challenging	O
clinical	O
problem	O
associated	O
with	O
life	O
-	O
threatening	O
disease	O
progression	O
.	O

The	O
molecular	O
basis	O
of	O
GC	O
insensitivity	O
,	O
however	O
,	O
is	O
unknown	O
.	O

Alternative	O
splicing	O
of	O
the	O
GC	O
receptor	O
(	O
R	O
)	O
pre	O
-	O
messenger	O
RNA	O
generates	O
a	O
second	O
GCR	O
,	O
termed	O
GCR	O
-	O
beta	O
,	O
which	O
does	O
not	O
bind	O
GCs	O
but	O
antagonizes	O
the	O
transactivating	O
activity	O
of	O
the	O
classic	O
GCR	O
,	O
termed	O
GCR	O
-	O
alpha	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
demonstrate	O
that	O
GC	O
-	O
insensitive	O
asthma	O
is	O
associated	O
with	O
a	O
significantly	O
higher	O
number	O
of	O
GCR	O
-	O
beta	O
-	O
immunoreactive	O
cells	O
in	O
peripheral	O
blood	O
than	O
GC	O
-	O
sensitive	O
asthmatics	O
or	O
normal	O
controls	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
patients	O
with	O
GC	O
-	O
insensitive	O
asthma	O
have	O
cytokine	O
-	O
induced	O
abnormalities	O
in	O
the	O
DNA	O
binding	O
capability	O
of	O
the	O
GCR	O
.	O

These	O
abnormalities	O
can	O
be	O
reproduced	O
by	O
transfection	O
of	O
cell	B
lines	I
with	O
the	O
GCR	O
-	O
beta	O
gene	O
resulting	O
in	O
significant	O
reduction	O
of	O
their	O
GCR	O
-	O
alpha	O
DNA	O
binding	O
capacity	O
.	O

We	O
conclude	O
that	O
increased	O
expression	O
of	O
GCR	O
-	O
beta	O
is	O
cytokine	O
inducible	O
and	O
may	O
account	O
for	O
GC	O
insensitivity	O
in	O
this	O
common	O
inflammatory	O
condition	O
.	O

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor	O
-	O
kappa	O
B	O
by	O
oxidized	O
low	O
-	O
density	O
lipoprotein	O
.	O

Nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
/Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF	O
-	O
kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF	O
-	O
kappa	O
B	O
system	O
in	O
human	O
THP-1	B
monocytic	I
cells	I
as	O
well	O
as	O
adherent	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
short	O
-	O
term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50	O
/	O
p65	O
containing	O
NF	O
-	O
kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL-8	O
.	O

This	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O

The	O
oxLDL	O
-induced	O
NF	O
-	O
kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long	O
-	O
term	O
treatment	O
with	O
oxLDL	O
prevented	O
the	O
lipopolysaccharide	O
-	O
induced	O
depletion	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
the	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin-1	O
beta	O
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF	O
-	O
kappa	O
B	O
/	O
Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans	O
-	O
activator	O
constructs	O
lacking	O
the	O
N	O
-	O
terminal	O
domain	O
.	O

The	O
class	O
II	O
trans	O
-	O
activator	O
(	O
CIITA	O
)	O
is	O
a	O
bi-	O
or	O
multi	O
-	O
functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N	O
-	O
terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	B
cells	I
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN	O
-	O
gamma	O
and	O
marked	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA	O
-	O
DRA	O
mRNA	O
synthesis	O
.	O

Inhibition	O
of	O
proliferation	O
and	O
apoptosis	O
of	O
human	O
and	O
rat	O
T	O
lymphocytes	O
by	O
curcumin	O
,	O
a	O
curry	O
pigment	O
.	O

Curcumin	O
(	O
diferuoylmethane	O
)	O
,	O
the	O
yellow	O
pigment	O
in	O
the	O
rhizome	O
of	O
tumeric	O
(	O
Curcuma	O
longa	O
)	O
,	O
an	O
ingredient	O
of	O
curry	O
spice	O
,	O
is	O
known	O
to	O
exhibit	O
a	O
variety	O
of	O
pharmacological	O
effects	O
including	O
antitumor	O
,	O
antiinflammatory	O
,	O
and	O
antiinfectious	O
activities	O
.	O

Although	O
its	O
precise	O
mode	O
of	O
action	O
remains	O
elusive	O
,	O
curcumin	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
activity	O
of	O
the	O
AP-1	O
transcription	O
factor	O
in	O
cells	O
stimulated	O
to	O
proliferate	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
that	O
curcumin	O
(	O
50	O
microM	O
)	O
inhibited	O
proliferation	O
of	O
rat	O
thymocytes	O
stimulated	O
with	O
concanavalin	O
A	O
(	O
Con	O
A	O
)	O
as	O
well	O
as	O
that	O
of	O
human	O
Jurkat	O
lymphoblastoid	O
cells	O
in	O
the	O
logarithmic	O
growth	O
phase	O
.	O

The	O
pigment	O
also	O
inhibited	O
apoptosis	O
in	O
dexamethasone	B
-	I
treated	I
rat	I
thymocytes	I
and	O
in	O
UV	B
-	I
irradiated	I
Jurkat	I
cells	I
as	O
judged	O
by	O
DNA	O
ladder	O
formation	O
,	O
cellular	O
morphological	O
changes	O
,	O
and	O
flow	O
cytometry	O
analysis	O
.	O

The	O
inhibition	O
of	O
apoptosis	O
by	O
curcumin	O
in	O
rat	O
thymocytes	O
was	O
accompanied	O
by	O
partial	O
suppression	O
of	O
AP-1	O
activity	O
.	O

Complete	O
suppression	O
of	O
AP-1	O
activity	O
was	O
observed	O
in	O
Con	B
A	I
-	I
treated	I
,	I
proliferating	I
thymocytes	I
.	O

The	O
capacity	O
of	O
curcumin	O
to	O
inhibit	O
both	O
cell	O
growth	O
and	O
death	O
strongly	O
implies	O
that	O
these	O
two	O
biological	O
processes	O
share	O
a	O
common	O
pathway	O
at	O
some	O
point	O
and	O
that	O
curcumin	O
affects	O
a	O
common	O
step	O
,	O
presumably	O
involving	O
a	O
modulation	O
of	O
the	O
AP-1	O
transcription	O
factor	O
.	O

Regulation	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
and	O
its	O
inhibitor	O
I	O
kappa	O
B	O
-	O
alpha	O
/	O
MAD-3	O
in	O
monocytes	O
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

Blood	O
monocytes	O
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
TNF	O
-	O
alpha	O
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL-2R	O
.	O

Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV-1	O
in	O
vitro	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	O
to	O
production	O
of	O
cytokines	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	O
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O

We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
,	O
the	O
major	O
cytoplasmic	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
kappa	O
B	O
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
with	O
tuberculosis	O
.	O

In	O
contrast	O
,	O
I	O
kappa	O
B	O
-	O
alpha	O
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O

Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF	O
-	O
kappa	O
B	O
was	O
activated	O
in	O
monocytes	O
from	O
tuberculous	O
patients	O
.	O

The	O
expression	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF	O
-	O
kappa	O
B	O
,	O
was	O
up	O
-	O
regulated	O
in	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
,	O
but	O
not	O
in	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
or	O
those	O
with	O
nontuberculous	O
lung	O
diseases	O
.	O

By	O
contrast	O
,	O
the	O
expression	O
of	O
other	O
adherence	O
-	O
associated	O
early	O
genes	O
,	O
such	O
as	O
IL-8	O
and	O
IL-1	O
beta	O
,	O
was	O
not	O
up	O
-	O
regulated	O
in	O
PBMC	O
of	O
tuberculous	O
patients	O
.	O

Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	O
,	O
purified	O
protein	O
derivative	O
,	O
induced	O
the	O
degradation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
and	O
the	O
expression	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
mRNA	O
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
monocytes	O
.	O

Analysis	O
of	O
interactions	O
between	O
huGATA-3	O
transcription	O
factor	O
and	O
three	O
GATA	O
regulatory	O
elements	O
of	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
by	O
surface	O
plasmon	O
resonance	O
.	O

Relative	O
affinities	O
of	O
transcriptional	O
regulatory	O
elements	O
for	O
their	O
respective	O
factor	O
have	O
been	O
essentially	O
studied	O
by	O
bandshift	O
analysis	O
.	O

Here	O
we	O
report	O
a	O
real	O
-	O
time	O
study	O
of	O
factor	O
/	O
DNA	O
interactions	O
using	O
a	O
surface	O
plasmon	O
resonance	O
approach	O
and	O
further	O
characterization	O
of	O
recovered	O
proteins	O
involved	O
in	O
this	O
interaction	O
.	O

For	O
this	O
purpose	O
,	O
human	O
GATA-3	O
,	O
either	O
recombinant	O
or	O
in	O
nuclear	O
extracts	O
,	O
and	O
three	O
natural	O
GATA	O
elements	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
sites	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
were	O
chosen	O
,	O
in	O
which	O
only	O
site	O
2	O
is	O
a	O
noncanonical	O
GATA	O
site	O
.	O

Direct	O
analysis	O
of	O
sensorgrams	O
,	O
with	O
recombinant	O
huGATA-3	O
,	O
allowed	O
the	O
comparison	O
of	O
association	O
and	O
dissociation	O
profiles	O
of	O
the	O
three	O
DNA	O
regions	O
and	O
their	O
ranking	O
according	O
to	O
their	O
relative	O
affinities	O
.	O

This	O
result	O
,	O
confirmed	O
by	O
competitions	O
with	O
each	O
GATA	O
site	O
,	O
demonstrated	O
the	O
higher	O
relative	O
affinity	O
(	O
at	O
least	O
sevenfold	O
)	O
of	O
site	O
3	O
.	O

Interactions	O
between	O
the	O
canonical	O
and	O
unique	O
GATA	O
site	O
3	O
and	O
nuclear	O
extracts	O
were	O
also	O
studied	O
in	O
real	O
time	O
and	O
provided	O
information	O
on	O
its	O
association	O
and	O
dissociation	O
rates	O
for	O
native	O
huGATA-3	O
.	O

Finally	O
,	O
recovered	O
protein	O
was	O
identified	O
as	O
genuine	O
huGATA-3	O
by	O
SDS	O
-	O
PAGE	O
,	O
Western	O
blotting	O
,	O
and	O
bandshift	O
assays	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

TNFalpha	O
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV-1	O
LTR	O
transcription	O
via	O
downstream	O
TRE	O
-	O
like	O
cAMP	O
response	O
elements	O
.	O

Activating	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP-1	O
and	O
CREB	O
/	O
ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP	O
-	O
responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV-1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	O
.	O

Ctx	O
combined	O
with	O
TNFalpha	O
or	O
IL-1beta	O
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	O
antigen	O
production	O
in	O
U1	B
promonocytic	I
cells	I
.	O

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR	O
-mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	O
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL-1beta	O
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	O
and	O
IL-1beta	O
cooperate	O
differently	O
with	O
the	O
cAMP	O
/PKA	O
activation	O
pathway	O
to	O
induce	O
HIV-1	O
expression	O
in	O
U1	B
cells	I
.	O

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1	O
-dependent	O
transcription	O
.	O

TNFalpha	O
as	O
well	O
as	O
IL-1beta	O
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP-1	O
-mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE	O
-	O
like	O
cAMP	O
-	O
responsive	O
DSE	O
sites	O
within	O
the	O
5'-untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	O
and	O
the	O
cAMP	O
/PKA	O
pathway	O
.	O

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
can	O
not	O
bind	O
CREB	O
/	O
ATF	O
homodimers	O
,	O
we	O
propose	O
a	O
mechanism	O
in	O
which	O
the	O
HIV-1	O
DSE	O
bind	O
heterodimers	O
composed	O
of	O
both	O
AP-1	O
and	O
CREB	O
/	O
ATF	O
proteins	O
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	O
human	O
myeloid	O
-	O
selective	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
gene	O
(	O
C	O
/	O
EBP	O
epsilon	O
)	O
.	O

Human	O
C	O
/	O
EBP	O
epsilon	O
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

Our	O
studies	O
showed	O
that	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
were	O
markedly	O
increased	O
in	O
NB4	B
cells	I
(	O
promyelocytic	B
leukemia	I
line	I
)	O
,	O
because	O
they	O
were	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
(	O
9-cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

Accumulation	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	B
cells	I
to	O
9-cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
mol	O
/	O
L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5.1-fold	O
.	O

Dose	O
-	O
response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol	O
/	O
L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

NB4	B
cells	I
pulse	O
-	O
exposed	O
(	O
30	O
minutes	O
)	O
to	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	O
effect	O
on	O
base	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
and	O
did	O
not	O
induce	O
differentiation	O
.	O

Macrophage	O
-	O
differentiation	O
of	O
NB4	B
reduced	O
levels	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
.	O

Nuclear	O
run	O
-	O
off	O
assays	O
and	O
half	O
-	O
life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
by	O
9-cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O

Furthermore	O
,	O
this	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
accumulation	O
did	O
not	O
require	O
synthesis	O
of	O
new	O
protein	O
factors	O
because	O
9-cis	O
RA	O
induced	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
accumulation	O
in	O
the	O
absence	O
of	O
new	O
protein	O
synthesis	O
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C	O
/	O
EBP	O
epsilon	O
protein	O
in	O
NB4	B
cells	I
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C	O
/	O
EBP	O
epsilon	O
in	O
9-cis	O
RA	O
-	O
mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO	O
-	O
induced	O
differentiation	O
of	O
HL-60	B
cells	I
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
levels	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	B
promyelocytes	I
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

This	O
induction	O
of	O
C	O
/	O
EBP	O
epsilon	O
mRNA	O
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	O
of	O
synthesis	O
of	O
additional	O
protein	O
factors	O
.	O

We	O
suspect	O
that	O
the	O
C	O
/	O
EBP	O
epsilon	O
promoter	O
/	O
enhancer	O
contains	O
a	O
retinoic	O
acid	O
-	O
response	O
element	O
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

Paternal	O
expression	O
of	O
WT1	O
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	O
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele	O
-	O
specific	O
expression	O
of	O
WT1	O
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	B
lines	I
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	O
was	O
also	O
shown	O
in	O
non	O
-	O
cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele	O
-	O
specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	O
and	O
H19	O
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	O
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele	O
-	O
specific	O
regulatory	O
system	O
of	O
WT1	O
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual	O
-	O
specific	O
modifier	O
.	O

Repression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
through	O
the	O
novel	O
cooperation	O
of	O
human	O
factors	O
YY1	O
and	O
LSF	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Virol	O
1998	O
Feb	O
;	O
72	O
(	O
2	O
)	O
:	O
1709	O
]	O

A	O
subpopulation	O
of	O
stably	O
infected	O
CD4	O
+	O
cells	O
capable	O
of	O
producing	O
virus	O
upon	O
stimulation	O
has	O
been	O
identified	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-positive	O
individuals	O
(	O
T	O
.-	O
W.Chun	O
,	O
D.Finzi	O
,	O
J.Margolick	O
,	O
K.Chadwick	O
,	O
D.Schwartz	O
,	O
and	O
R.F.Siliciano	O
,	O
Nat	O
.	O
Med.1	O
:	O
1284	O
-	O
1290	O
,	O
1995	O
)	O
.	O

Few	O
host	O
factors	O
that	O
directly	O
limit	O
HIV-1	O
transcription	O
and	O
could	O
support	O
this	O
state	O
of	O
nonproductive	O
HIV-1	O
infection	O
have	O
been	O
described	O
.	O

YY1	O
,	O
a	O
widely	O
distributed	O
human	O
transcription	O
factor	O
,	O
is	O
known	O
to	O
inhibit	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
transcription	O
and	O
virus	O
production	O
.	O

LSF	O
(	O
also	O
known	O
as	O
LBP-1	O
,	O
UBP	O
,	O
and	O
CP-2	O
)	O
has	O
been	O
shown	O
to	O
repress	O
LTR	O
transcription	O
in	O
vitro	O
,	O
but	O
transient	O
expression	O
of	O
LSF	O
has	O
no	O
effect	O
on	O
LTR	O
activity	O
in	O
vivo	O
.	O

We	O
report	O
that	O
both	O
YY1	O
and	O
LSF	O
participate	O
in	O
the	O
formation	O
of	O
a	O
complex	O
that	O
recognizes	O
the	O
initiation	O
region	O
of	O
the	O
HIV-1	O
LTR	O
.	O

Further	O
,	O
we	O
have	O
found	O
that	O
these	O
factors	O
cooperate	O
in	O
the	O
repression	O
of	O
LTR	O
expression	O
and	O
viral	O
replication	O
.	O

This	O
cooperative	O
function	O
may	O
account	O
for	O
the	O
divergent	O
effects	O
of	O
LSF	O
previously	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
cooperation	O
of	O
two	O
general	O
cellular	O
transcription	O
factors	O
may	O
allow	O
for	O
the	O
selective	O
downregulation	O
of	O
HIV	O
transcription	O
.	O

Through	O
this	O
mechanism	O
of	O
gene	O
regulation	O
,	O
YY1	O
and	O
LSF	O
could	O
contribute	O
to	O
the	O
establishment	O
and	O
maintenance	O
of	O
a	O
population	O
of	O
cells	O
stably	O
but	O
nonproductively	O
infected	O
with	O
HIV-1	O
.	O

Ras	O
-	O
related	O
GTP	O
-	O
binding	O
proteins	O
and	O
leukocyte	O
signal	O
transduction	O
.	O

Many	O
aspects	O
of	O
leukocyte	O
function	O
are	O
regulated	O
by	O
both	O
heterotrimeric	O
and	O
Ras	O
-	O
related	O
GTP	O
-	O
binding	O
proteins	O
,	O
but	O
there	O
is	O
little	O
definite	O
information	O
about	O
their	O
roles	O
in	O
the	O
specialized	O
processes	O
utilized	O
by	O
leukocytes	O
for	O
cell	O
killing	O
.	O

Recent	O
progress	O
in	O
understanding	O
the	O
regulation	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
by	O
the	O
Rac	O
GTP	O
-	O
binding	O
proteins	O
provides	O
a	O
basis	O
for	O
defining	O
the	O
operational	O
characteristics	O
of	O
one	O
such	O
phagocyte	O
system	O
.	O

It	O
is	O
clear	O
from	O
various	O
studies	O
that	O
the	O
activity	O
of	O
the	O
NADPH	O
oxidase	O
can	O
be	O
modulated	O
through	O
the	O
regulation	O
of	O
the	O
GTP	O
-	O
GDP	O
state	O
of	O
Rac	O
.	O

Proteins	O
exist	O
in	O
leukocytes	O
able	O
to	O
modify	O
GTP	O
-	O
binding	O
protein	O
function	O
in	O
this	O
manner	O
,	O
and	O
their	O
activity	O
may	O
be	O
regulated	O
by	O
signals	O
generated	O
on	O
phagocyte	O
stimulation	O
.	O

Proteins	O
of	O
the	O
Ras	O
superfamily	O
are	O
likely	O
to	O
be	O
involved	O
in	O
a	O
variety	O
of	O
normal	O
phagocyte	O
functions	O
through	O
their	O
ability	O
to	O
modulate	O
the	O
assembly	O
of	O
actin	O
filaments	O
,	O
direct	O
vesicle	O
trafficking	O
and	O
fusion	O
,	O
and	O
so	O
forth	O
.	O

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	B
cells	I
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non	O
-	O
B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	B
cells	I
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	B
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell	O
-	O
encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell	O
-	O
specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell	O
-	O
expressed	O
genes	O
that	O
are	O
not	O
dependent	O
on	O
cell	O
-	O
specific	O
controls	O
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	O
of	O
transcription	O
factors	O
that	O
are	O
essential	O
for	O
Ig	O
gene	O
transcription	O
.	O

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct-2	O
,	O
OBF-1	O
,	O
PU.1	O
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF	O
-	O
kappa	O
B	O
,	O
E47	O
)	O
.	O

By	O
isolating	O
Daudi	B
x	I
HeLa	I
heterokaryons	I
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell	O
-	O
specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct-2	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	B
cells	I
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell	O
-	O
expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	B
phenotype	I
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	O
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
group	O
of	O
transcription	O
factors	O
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	O
cells	O
.	O

NFAT	O
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

This	O
process	O
requires	O
calcium	O
-	O
dependent	O
dephosphorylation	O
of	O
NFAT	O
caused	O
by	O
the	O
phosphatase	O
calcineurin	O
.	O

The	O
c	O
-	O
Jun	O
amino	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
phosphorylates	O
NFAT4	O
on	O
two	O
sites	O
.	O

Mutational	O
removal	O
of	O
the	O
JNK	O
phosphorylation	O
sites	O
caused	O
constitutive	O
nuclear	O
localization	O
of	O
NFAT4	O
.	O

In	O
contrast	O
,	O
JNK	O
activation	O
in	O
calcineurin	B
-	I
stimulated	I
cells	I
caused	O
nuclear	O
exclusion	O
of	O
NFAT4	O
.	O

These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	O
of	O
NFAT4	O
promoted	O
by	O
calcineurin	O
is	O
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

Pathogenesis	O
.	O

There	O
are	O
many	O
hypotheses	O
concerning	O
the	O
pathogenesis	O
of	O
endometriosis	O
,	O
though	O
no	O
single	O
theory	O
can	O
explain	O
all	O
cases	O
.	O

It	O
is	O
likely	O
that	O
several	O
mechanisms	O
are	O
involved	O
.	O

Early	O
studies	O
concentrated	O
on	O
the	O
histogenesis	O
of	O
the	O
endometriotic	O
lesion	O
.	O

Recent	O
evidence	O
has	O
implicated	O
components	O
of	O
the	O
immune	O
system	O
in	O
the	O
pathogenesis	O
of	O
endometriosis	O
.	O

This	O
review	O
considers	O
the	O
evidence	O
for	O
different	O
theories	O
of	O
the	O
histogenesis	O
of	O
endometriosis	O
and	O
discusses	O
possible	O
immune	O
factors	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
disease	O
.	O

Phosphatidylinositol	O
3-kinase	O
couples	O
the	O
interleukin-2	O
receptor	O
to	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
.	O

Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin-2	O
(	O
IL-2	O
)	O
in	O
T	O
cells	O
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O

Phosphatidyl	O
inositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
is	O
activated	O
by	O
IL-2	O
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3	O
K	O
are	O
not	O
known	O
.	O

Here	O
we	O
identify	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
as	O
an	O
IL-2	O
target	O
in	O
T	O
lymphocytes	O
and	O
PI3	O
K	O
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

We	O
eliminate	O
both	O
Stat5	O
and	O
Raf	O
/MEK	O
pathways	O
from	O
E2F	O
regulation	O
.	O

Protein	O
kinase	O
B	O
(	O
PKB	O
)	O
is	O
activated	O
by	O
IL-2	O
via	O
PI3	O
K	O
.	O

The	O
expression	O
of	O
an	O
active	O
PKB	O
is	O
sufficient	O
to	O
induce	O
E2F	O
activity	O
.	O

Inhibition	O
of	O
PI3	O
K	O
inhibits	O
phosphorylation	O
of	O
Rb	O
,	O
induction	O
of	O
cyclin	O
D3	O
,	O
and	O
degradation	O
of	O
p27kip1	O
.	O

These	O
results	O
establish	O
a	O
crucial	O
PI3	O
K	O
/	O
PKB	O
-mediated	O
link	O
between	O
the	O
IL-2	O
teceptor	O
and	O
the	O
cell	O
cycle	O
machinery	O
.	O

Molecular	O
mechanisms	O
of	O
anoxia	O
/	O
reoxygenation	O
-	O
induced	O
neutrophil	O
adherence	O
to	O
cultured	B
endothelial	I
cells	I
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	B
umbilical	I
vein	I
endothelial	I
cells	I
(	O
HUVECs	B
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	B
HUVECs	I
to	O
human	O
neutrophils	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia	O
/	O
reoxygenation	O
(	O
A	O
/	O
R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	B
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Oxypurinol	O
and	O
catalase	O
inhibited	O
phase-1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	O
oxidase	O
and	O
H2O2	O
.	O

In	O
comparison	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O

Anti	O
-	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
and	O
anti	O
-	O
P	O
-	O
selectin	O
antibodies	O
(	O
monoclonal	O
antibodies	O
[	O
mAbs	O
]	O
)	O
attenuated	O
phase-1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	O
for	O
constitutively	O
expressed	O
ICAM-1	O
and	O
enhanced	O
surface	O
expression	O
of	O
preformed	O
P	O
-	O
selectin	O
.	O

Phase-2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti	O
-	O
E	O
-	O
selectin	O
mAb	O
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
containing	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
or	O
activator	O
protein-1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Surface	O
expression	O
of	O
ICAM-1	O
,	O
P	O
-	O
selectin	O
,	O
and	O
E	O
-	O
selectin	O
on	O
HUVECs	B
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A	O
/	O
R	O
elicits	O
a	O
two	O
-	O
phase	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein-1	O
triggers	O
AP-1	O
activity	O
via	O
the	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
cascade	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein-1	O
(	O
LMP-1	O
)	O
is	O
an	O
integral	O
membrane	O
protein	O
which	O
transforms	O
fibroblasts	O
and	O
is	O
essential	O
for	O
EBV	O
-	O
mediated	O
B	O
-	O
cell	O
immortalization	O
.	O

LMP-1	O
has	O
been	O
shown	O
to	O
trigger	O
cellular	O
NF	O
-	O
kappa	O
B	O
activity	O
which	O
,	O
however	O
,	O
can	O
not	O
fully	O
explain	O
the	O
oncogenic	O
potential	O
of	O
LMP-1	O
.	O

Here	O
we	O
show	O
that	O
LMP-1	O
induces	O
the	O
activity	O
of	O
the	O
AP-1	O
transcription	O
factor	O
,	O
a	O
dimer	O
of	O
Jun	O
/	O
Jun	O
or	O
Jun	O
/	O
Fos	O
proteins	O
.	O

LMP-1	O
effects	O
on	O
AP-1	O
are	O
mediated	O
through	O
activation	O
of	O
the	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
cascade	O
,	O
but	O
not	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
Erk	O
)	O
pathway	O
.	O

Consequently	O
,	O
LMP-1	O
triggers	O
the	O
activity	O
of	O
the	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
transactivation	O
domain	O
which	O
is	O
known	O
to	O
be	O
activated	O
upon	O
JNK	O
-mediated	O
phosphorylation	O
.	O

Deletion	O
analysis	O
indicates	O
that	O
the	O
55	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
the	O
LMP-1	O
molecule	O
,	O
but	O
not	O
its	O
TRAF	O
interaction	O
domain	O
,	O
are	O
essential	O
for	O
AP-1	O
activation	O
.	O

JNK	O
-mediated	O
transcriptional	O
activation	O
of	O
AP-1	O
is	O
the	O
direct	O
output	O
of	O
LMP	O
-1-triggered	O
signaling	O
,	O
as	O
shown	O
by	O
an	O
inducible	O
LMP-1	O
mutant	O
.	O

Using	O
a	O
tetracycline	O
-	O
regulated	O
LMP-1	O
allele	O
,	O
we	O
demonstrate	O
that	O
JNK	O
is	O
also	O
an	O
effector	O
of	O
non	O
-	O
cytotoxic	O
LMP-1	O
signaling	O
in	O
B	O
cells	O
,	O
the	O
physiological	O
target	O
cells	O
of	O
EBV	O
.	O

In	O
summary	O
,	O
our	O
data	O
reveal	O
a	O
novel	O
effector	O
of	O
LMP-1	O
,	O
the	O
SEK	O
/	O
JNK	O
/	O
c	O
-	O
Jun	O
/	O
AP-1	O
pathway	O
,	O
which	O
contributes	O
to	O
our	O
understanding	O
of	O
the	O
immortalizing	O
and	O
transforming	O
potential	O
of	O
LMP-1	O
.	O

c	O
-	O
Rel	O
and	O
p65	O
subunits	O
bind	O
to	O
an	O
upstream	O
NF	O
-	O
kappaB	O
site	O
in	O
human	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	B
cells	I
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF	O
-	O
kappaB	O
like	O
site	O
in	O
the	O
5637	B
non	I
-	I
lymphoid	I
cell	I
line	I
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM	O
-	O
CSF	O
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM	O
-	O
CSF	O
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	O
binding	O
complex	O
of	O
NF	O
-	O
kappaB	O
subunits	O
(	O
c	O
-	O
Rel	O
and	O
p65	O
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV	O
-	O
LTR	O
-	O
kappaB	O
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c	O
-	O
Rel	O
and	O
p50	O
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	B
T	I
-	I
lymphoid	I
HTLV	I
-	I
II	I
infected	I
cells	I
.	O

Selection	O
of	O
a	O
diverse	O
TCR	O
repertoire	O
in	O
response	O
to	O
an	O
Epstein	O
-	O
Barr	O
virus	O
-	O
encoded	O
transactivator	O
protein	O
BZLF1	O
by	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocytes	O
during	O
primary	O
and	O
persistent	O
infection	O
.	O

We	O
investigated	O
the	O
CD8	O
+	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
repertoire	O
to	O
an	O
HLA	O
B8-restricted	O
peptide	O
,	O
RAKFKQLLQ	O
,	O
located	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
immediate	O
-	O
early	O
protein	O
,	O
BZLF1	O
.	O

Repertoire	O
selection	O
was	O
monitored	O
by	O
determining	O
the	O
TCR	O
beta	O
chain	O
sequences	O
of	O
RAKFKQLLQ	B
-	I
specific	I
CTL	I
established	O
from	O
primary	O
infected	O
and	O
healthy	O
virus	O
carriers	O
.	O

PCR	O
analysis	O
of	O
spontaneous	B
EBV	I
-	I
transformed	I
lymphoblastoid	I
cell	I
lines	I
(	O
LCL	B
)	O
from	O
three	O
individuals	O
with	O
primary	O
infection	O
showed	O
that	O
two	O
were	O
infected	O
with	O
type	O
A	O
and	O
one	O
with	O
type	O
B	O
EBV	O
.	O

Polyclonal	B
and	I
clonal	I
CTL	I
that	O
were	O
generated	O
by	O
stimulating	O
peripheral	O
blood	O
mononuclear	O
cells	O
with	O
an	O
HLA	B
B8	I
+	I
homozygous	I
LCL	I
lysed	I
T	I
cell	I
blasts	I
pulsed	O
with	O
the	O
peptide	O
,	O
RAKFKQLLQ	O
;	O
lysis	O
of	O
certain	O
HLA	O
B8	O
+	O
LCL	O
targets	O
was	O
associated	O
with	O
the	O
abundance	O
of	O
BZLF1	O
transcripts	O
.	O

TCR	O
beta	O
analysis	O
showed	O
that	O
while	O
there	O
was	O
loop	O
length	O
restriction	O
in	O
the	O
putative	O
peptide	O
contact	O
site	O
of	O
all	O
responding	O
beta	O
chains	O
,	O
diverse	O
and	O
unique	B
(	I
non	I
-	I
recurrent	I
)	I
TCR	I
beta	I
clonotypes	I
were	O
selected	O
in	O
individuals	O
during	O
primary	O
infection	O
and	O
continued	O
to	O
emerge	O
after	O
long	O
-	O
term	O
virus	O
exposure	O
.	O

TCR	O
-contact	O
site	O
heterogeneity	O
was	O
excluded	O
as	O
the	O
selective	O
force	O
in	O
diversity	O
generation	O
since	O
the	O
epitope	O
-	O
encoded	O
sequences	O
were	O
found	O
to	O
be	O
identical	O
within	O
endogenous	O
virus	O
isolates	O
.	O

In	O
this	O
first	O
study	O
of	O
TCR	O
repertoire	O
selection	O
for	O
an	O
EBV	O
lytic	O
antigen	O
,	O
a	O
BZLF1	O
-reactive	O
component	O
of	O
diverse	O
clonotypes	O
was	O
identified	O
in	O
primary	O
type	O
A	O
or	O
type	O
B	O
EBV	O
infection	O
which	O
was	O
sustained	O
in	O
the	O
EBV	O
-	O
specific	O
memory	O
response	O
throughout	O
life	O
-	O
long	O
infection	O
.	O

This	O
diversity	O
selection	O
is	O
likely	O
to	O
play	O
a	O
critical	O
role	O
in	O
maintaining	O
a	O
balanced	O
viral	O
load	O
throughout	O
EBV	O
persistence	O
.	O

Constitutive	O
expression	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
NF	O
kappa	O
B	O
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
with	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	O
production	O
when	O
stimulated	O
either	O
via	O
their	O
T	O
-	O
cell	O
antigen	O
receptors	O
or	O
lectins	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal	O
/	O
neonatal	O
T	O
-	O
cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	O
regulatory	O
elements	O
required	O
for	O
T	O
-	O
cell	O
activation	O
.	O

We	O
used	O
reverse	O
transcriptase	O
-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	O
factors	O
implicated	O
in	O
T	O
-	O
cell	O
activation	O
:	O
c	O
-	O
jun	O
,	O
c	O
-	O
fos	O
,	O
and	O
NF	O
kappa	O
B	O
(	O
p50	O
subunit	O
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti	O
-	O
CD3	O
monoclonal	O
antibodies	O
resulted	O
in	O
up	O
-	O
regulation	O
of	O
both	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	O
of	O
IL-2	O
by	O
anti	B
-	I
CD3-stimulated	I
cord	I
blood	I
mononuclear	I
cells	I
was	O
still	O
blunted	O
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	O
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	O
blood	O
cells	O
.	O

Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
IL-2	O
promoter	O
are	O
currently	O
under	O
investigation	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL-5	O
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen	B
-	I
specific	I
human	I
helper	I
T	I
cells	I
.	O

BACKGROUND	O
:	O
Cytokines	O
produced	O
by	O
helper	O
T	O
cells	O
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	O
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	O
,	O
by	O
CD4	O
+	O
T	O
lymphocytes	O
in	O
patients	O
with	O
asthma	O
.	O

METHODS	O
:	O
Allergen	B
-	I
specific	I
T	I
cell	I
clones	I
and	O
T	B
cell	I
hybridomas	I
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL-5	O
production	O
by	O
CD4	O
+	O
T	O
cells	O
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	O
IL-5	O
after	O
incubation	O
with	O
mite	O
allergen	O
,	O
suggesting	O
that	O
mite	O
-	O
specific	O
helper	O
T	O
cells	O
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O

A	O
human	O
IL-5	O
promoter	O
/	O
enhancer	O
luciferase	O
gene	O
construct	O
transfected	O
into	O
IL-5-producing	B
T	I
cell	I
clones	I
was	O
clearly	O
transcribed	O
after	O
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL-5	O
gene	O
segment	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	O
to	O
respond	O
to	O
activating	O
signals	O
in	O
human	O
helper	O
T	O
cells	O
.	O

The	O
same	O
gene	O
segment	O
was	O
not	O
transcribed	O
in	O
IL-5-nonproducing	B
T	I
cell	I
clones	I
,	O
suggesting	O
that	O
human	O
T	O
cell	O
IL-5	O
synthesis	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

Experiments	O
with	O
T	B
cell	I
hybridomas	I
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	O
transcription	O
factor	O
may	O
be	O
essential	O
for	O
human	O
IL-5	O
gene	O
transcription	O
.	O

CONCLUSION	O
:	O
Enhanced	O
IL-5	O
production	O
by	O
helper	O
T	O
cells	O
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O

Elucidation	O
of	O
IL-5	O
-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Regulation	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
must	O
be	O
released	O
from	O
cytoplasmic	O
inhibitory	O
molecules	O
(	O
I	O
kappa	O
Bs	O
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	O
genes	O
.	O

Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	O
nuclear	O
NF	O
-	O
kappa	O
B	O
in	O
some	O
cell	O
-	O
types	O
and	O
of	O
sustained	O
nuclear	O
NF	O
-	O
kappa	O
B	O
activity	O
after	O
stimulation	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
mature	O
B	O
cells	O
.	O

We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
in	O
mature	O
B	O
cells	O
and	O
HeLa	B
cells	I
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	O
cells	O
although	O
I	O
kappa	O
B	O
beta	O
is	O
considerably	O
more	O
stable	O
than	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
half	O
-	O
life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	B
cells	I
.	O

In	O
contrast	O
,	O
all	O
other	O
NF	O
-	O
kappa	O
B	O
/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell	O
-	O
types	O
.	O

The	O
elevated	O
turnover	O
of	O
endogenous	O
I	O
kappa	O
B	O
alpha	O
in	O
Namalwa	O
cells	O
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non	O
-	O
B	O
cells	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

TNF	O
-	O
alpha	O
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	O
kappa	O
B	O
beta	O
pools	O
.	O

I	O
kappa	O
B	O
alpha	O
is	O
efficiently	O
resynthesized	O
whereas	O
I	O
kappa	O
B	O
beta	O
levels	O
stay	O
low	O
for	O
a	O
prolonged	O
time	O
.	O

NF	O
-	O
kappa	O
B	O
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF	O
-	O
alpha	O
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	O
NF	O
-	O
kappa	O
B	O
.	O

A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	O
is	O
inhibited	O
and	O
new	O
I	O
kappa	O
B	O
alpha	O
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O

There	O
is	O
no	O
significant	O
difference	O
in	O
the	O
turnover	O
of	O
pre-	O
and	O
post	O
-	O
inductive	O
I	O
kappa	O
B	O
alpha	O
.	O

These	O
observations	O
suggest	O
that	O
resynthesis	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Control	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
by	O
the	O
I	O
kappa	O
B	O
beta	O
inhibitor	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappa	O
B	O
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	O
kappa	O
B	O
inhibitors	O
.	O

In	O
mammalian	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
proteins	O
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF	O
-	O
kappa	O
B	O
through	O
their	O
association	O
with	O
the	O
p65	O
or	O
c	O
-	O
Rel	O
subunits	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF	O
-	O
kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
epsilon	O
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29.1	B
T	I
cell	I
hybridoma	I
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
are	O
equally	O
associated	O
with	O
p65	O
and	O
that	O
I	O
kappa	O
B	O
beta	O
is	O
degraded	O
in	O
response	O
to	O
TNF	O
alpha	O
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	O
form	O
.	O

The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	O
kappa	O
B	O
beta	O
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal	O
-	O
induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O

NF	O
-	O
kappa	O
B	O
/	O
Rel	O
family	O
members	O
regulating	O
the	O
ICAM-1	O
promoter	O
in	O
monocytic	B
THP-1	I
cells	I
.	O

A	O
kappa	O
B	O
-	O
site	O
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
gene	O
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM-1	O
expression	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
glucocorticoids	O
.	O

We	O
now	O
report	O
on	O
the	O
transcription	O
factors	O
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	O
sequence	O
.	O

In	O
vitro	O
,	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
appeared	O
to	O
bind	O
RelA	O
and	O
c	O
-	O
Rel	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
NF	O
-	O
kappa	O
B1	O
,	O
but	O
weakly	O
NF	O
-	O
kappa	O
B1	O
homodimers	O
.	O

In	O
addition	O
,	O
both	O
RelA	O
and	O
c	O
-	O
Rel	O
,	O
but	O
not	O
NF	O
-	O
kappa	O
B1	O
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	O
kappa	O
B	O
-	O
reporter	O
construct	O
.	O

In	O
monocytic	B
THP-1	I
cells	I
TNF	O
-	O
alpha	O
induced	O
two	O
nuclear	O
complexes	O
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF	O
-	O
kappa	O
B1	O
and	O
RelA	O
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	O
kappa	O
B	O
site	O
in	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

The	O
second	O
complex	O
contained	O
RelA	O
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM-1	O
kappa	O
B	O
than	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

The	O
glucocorticoid	O
receptor	O
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	O
homodimer	O
and	O
the	O
NF	O
-	O
kappa	O
B1	O
/	O
RelA	O
heterodimer	O
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	O
homodimers	O
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF	O
-	O
alpha	O
-induced	O
ICAM-1	O
transcription	O
in	O
monocytic	O
cells	O
.	O

The	O
winged	O
-	O
helix	O
transcription	O
factor	O
Trident	O
is	O
expressed	O
in	O
actively	O
dividing	O
lymphocytes	O
.	O

We	O
recently	O
identified	O
the	O
winged	O
-	O
helix	O
transcription	O
factor	O
Trident	O
and	O
described	O
its	O
expression	O
pattern	O
in	O
synchronized	O
fibroblasts	O
.	O

We	O
have	O
now	O
studied	O
Trident	O
expression	O
in	O
cell	B
lines	I
,	O
differentiating	O
thymocytes	O
and	O
in	O
lymphocytes	O
derived	O
from	O
peripheral	O
blood	O
.	O

During	O
T	O
cell	O
differentiation	O
,	O
expression	O
peaked	O
in	O
the	O
actively	O
dividing	O
immature	O
single	O
positive	O
cells	O
.	O

In	O
peripheral	O
blood	O
lymphocytes	O
,	O
expression	O
of	O
Trident	O
mRNA	O
was	O
absent	O
,	O
but	O
could	O
be	O
induced	O
upon	O
stimulation	O
with	O
mitogens	O
in	O
vitro	O
.	O

These	O
observations	O
imply	O
a	O
function	O
for	O
Trident	O
in	O
dividing	O
lymphocytes	O
.	O

Glucocorticoid	O
receptors	O
,	O
fibromyalgia	O
and	O
low	O
back	O
pain	O
.	O

Recently	O
,	O
fibromyalgia	O
(	O
FMS	O
)	O
was	O
shown	O
to	O
be	O
a	O
disorder	O
associated	O
with	O
an	O
altered	O
functioning	O
of	O
the	O
stress	O
response	O
system	O
.	O

FMS	O
patients	O
display	O
a	O
hyperreactive	O
pituitary	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
release	O
in	O
response	O
to	O
corticotropin	O
-	O
releasing	O
hormone	O
(	O
CRH	O
)	O
and	O
to	O
insulin	O
-	O
induced	O
hypoglycemia	O
.	O

We	O
suggested	O
that	O
negative	O
feedback	O
of	O
cortisol	O
could	O
be	O
deranged	O
.	O

Therefore	O
we	O
investigated	O
the	O
properties	O
and	O
function	O
of	O
the	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
FMS	O
patients	O
and	O
compared	O
the	O
results	O
with	O
those	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
(	O
LBP	O
a	O
localized	O
pain	O
condition	O
)	O
.	O

Forty	O
primary	O
FMS	O
patients	O
(	O
F	O
:	O
M	O
=	O
36	O
:	O
4	O
)	O
,	O
28	O
LBP	O
patients	O
(	O
25	O
:	O
3	O
)	O
and	O
14	O
(	O
12	O
:	O
2	O
)	O
healthy	O
,	O
sedentary	O
control	O
persons	O
were	O
recruited	O
for	O
the	O
study	O
.	O

Urinary	O
free	O
cortisol	O
excretion	O
in	O
FMS	O
and	O
LBP	O
patients	O
was	O
lower	O
compared	O
to	O
controls	O
.	O

Only	O
FMS	O
patients	O
displayed	O
lower	O
CBG	O
and	O
basal	O
serum	O
cortisol	O
concentrations	O
when	O
compared	O
to	O
controls	O
.	O

However	O
,	O
plasma	O
free	O
cortisol	O
concentrations	O
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
GR	O
per	O
cell	O
among	O
the	O
three	O
groups	O
(	O
FMS	O
:	O
6498	O
+	O
/-	O
252	O
,	O
LBP	O
:	O
6625	O
+	O
/-	O
284	O
,	O
controls	O
:	O
6576	O
+	O
/-	O
304	O
)	O
,	O
but	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
the	O
FMS	O
(	O
14.5	O
+	O
/-	O
0.9	O
nmol	O
/	O
l	O
)	O
and	O
LBP	O
(	O
14.7	O
+	O
/-	O
1.3	O
nmol	O
/	O
l	O
)	O
subjects	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
controls	O
(	O
10.9	O
+	O
/-	O
0.8	O
nmol	O
/	O
l	O
)	O
(	O
p	O
<	O
.05	O
)	O
.	O

The	O
maximal	O
stimulation	O
of	O
the	O
lymphocytes	O
,	O
as	O
measured	O
by	O
the	O
maximal	O
thymidine	O
incorporation	O
(	O
in	O
the	O
absence	O
of	O
cortisol	O
)	O
in	O
the	O
FMS	O
group	O
was	O
approximately	O
1.5	O
times	O
higher	O
(	O
p	O
<	O
.05	O
)	O
than	O
in	O
the	O
control	O
or	O
LBP	O
group	O
.	O

The	O
ED50	O
(	O
the	O
cortisol	O
concentration	O
giving	O
50	O
%	O
inhibition	O
of	O
the	O
thymidine	O
incorporation	O
)	O
,	O
however	O
,	O
was	O
identical	O
in	O
all	O
three	O
groups	O
.	O

We	O
conclude	O
that	O
FMS	O
patients	O
have	O
a	O
mild	O
hypocortisolemia	O
,	O
increased	O
cortisol	O
feedback	O
resistance	O
in	O
combination	O
probably	O
with	O
a	O
reduced	O
CRH	O
synthesis	O
or	O
release	O
in	O
the	O
hypothalamus	O
.	O

The	O
role	O
of	O
the	O
GR	O
and	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
in	O
the	O
CRH	O
regulation	O
in	O
the	O
FMS	O
patients	O
remains	O
to	O
be	O
solved	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	O
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	B
Th	I
cell	I
lines	I
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL-2	O
in	O
Th1	O
cells	O
and	O
by	O
IL-4	O
in	O
Th2	O
cells	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	O
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	O
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX	O
-	O
mediated	O
IkappaBalpha	O
induction	O
was	O
completely	O
inhibited	O
by	O
IL-2	O
,	O
but	O
not	O
IL-4	O
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	O
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX	O
-	O
induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up-	O
or	O
down	O
-	O
regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	O
of	O
IkappaBalpha	O
expression	O
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Endothelial	O
production	O
of	O
MCP-1	O
:	O
modulation	O
by	O
heparin	O
and	O
consequences	O
for	O
mononuclear	O
cell	O
activation	O
.	O

Heparin	O
is	O
a	O
polyanionic	O
glycosaminoglycan	O
(	O
GAG	O
)	O
that	O
can	O
bind	O
with	O
high	O
affinity	O
to	O
a	O
range	O
of	O
cytokines	O
including	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
and	O
members	O
of	O
the	O
chemokine	O
superfamily	O
.	O

This	O
GAG	O
also	O
possesses	O
immunomodulatory	O
activity	O
in	O
vivo	O
and	O
can	O
antagonize	O
the	O
capacity	O
of	O
IFN	O
-	O
gamma	O
to	O
induce	O
class	O
II	O
MHC	O
antigen	O
expression	O
,	O
and	O
to	O
up	O
-	O
regulate	O
intercellular	O
adhesion	O
molecule-1	O
,	O
by	O
cultured	B
endothelial	I
cells	I
.	O

Previous	O
studies	O
have	O
shown	O
that	O
binding	O
to	O
cell	O
-	O
surface	O
heparan	O
sulphate	O
is	O
essential	O
for	O
optimal	O
activity	O
of	O
IFN	O
-	O
gamma	O
and	O
that	O
free	O
heparin	O
competitively	O
inhibits	O
this	O
sequestration	O
process	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
immunosuppressive	O
activity	O
of	O
heparin	O
by	O
investigation	O
of	O
potential	O
antagonism	O
of	O
the	O
production	O
and	O
function	O
of	O
monocyte	O
chemotactic	O
peptide-1	O
(	O
MCP-1	O
)	O
,	O
a	O
chemokine	O
important	O
for	O
mononuclear	O
leucocyte	O
recruitment	O
across	O
vascular	O
endothelium	O
.	O

It	O
was	O
found	O
that	O
mixture	O
of	O
heparin	O
with	O
IFN	O
-	O
gamma	O
inhibited	O
up	O
-	O
regulation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
protein	O
,	O
STAT-1	O
produced	O
normally	O
by	O
treatment	O
of	O
endothelial	O
cells	O
with	O
IFN	O
-	O
gamma	O
.	O

An	O
inhibition	O
of	O
MCP-1	O
production	O
was	O
observed	O
that	O
was	O
specifically	O
caused	O
by	O
mixture	O
of	O
IFN	O
-	O
gamma	O
with	O
heparin	O
-	O
like	O
,	O
and	O
therefore	O
cytokine	O
-	O
binding	O
,	O
GAGs	O
.	O

It	O
was	O
also	O
shown	O
that	O
mixture	O
of	O
heparin	O
-	O
like	O
GAGs	O
with	O
MCP-1	O
inhibited	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
phosphatidylinositol	O
3-kinase	O
which	O
is	O
normally	O
produced	O
by	O
treatment	O
of	O
mononuclear	O
leucocytes	O
with	O
this	O
chemokine	O
.	O

Blockade	O
of	O
this	O
intracellular	O
signalling	O
event	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
normal	O
transendothelial	O
migration	O
response	O
towards	O
MCP-1	O
.	O

Results	O
from	O
this	O
study	O
indicate	O
that	O
soluble	O
,	O
heparin	O
-	O
like	O
GAGs	O
can	O
block	O
IFN	O
-	O
gamma	O
-dependent	O
up	O
-	O
regulation	O
of	O
MCP-1	O
production	O
by	O
cultured	B
endothelial	I
cells	I
,	O
and	O
can	O
also	O
antagonize	O
the	O
leucocyte	O
-	O
activating	O
and	O
migration	O
-	O
promoting	O
properties	O
of	O
pre	O
-	O
existing	O
MCP-1	O
.	O

These	O
activities	O
may	O
contribute	O
to	O
the	O
immunomodulatory	O
properties	O
of	O
heparin	O
.	O

Regulation	O
of	O
the	O
human	O
interleukin-2	O
gene	O
by	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
are	O
largely	O
due	O
to	O
transcriptional	O
inhibition	O
of	O
immunologically	O
relevant	O
genes	O
,	O
such	O
as	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
.	O

These	O
effects	O
are	O
mediated	O
by	O
the	O
intracellular	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
.	O

In	O
humans	O
,	O
alternative	O
splicing	O
of	O
the	O
GR	O
precursor	O
mRNA	O
gives	O
rise	O
to	O
two	O
receptor	O
isoforms	O
,	O
termed	O
GRalpha	O
and	O
GRbeta	O
.	O

We	O
previously	O
demonstrated	O
that	O
GRbeta	O
could	O
antagonize	O
GRalpha	O
-mediated	O
transactivation	O
of	O
a	O
glucocorticoid	O
-	O
responsive	O
element	O
(	O
GRE	O
)	O
-driven	O
reporter	O
gene	O
in	O
COS-7	B
cells	I
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
analyze	O
the	O
roles	O
of	O
the	O
two	O
GR	O
isoforms	O
on	O
glucocorticoid	O
-	O
mediated	O
transrepression	O
of	O
the	O
IL-2	O
gene	O
.	O

Using	O
a	O
recently	O
developed	O
transfection	O
technique	O
,	O
we	O
demonstrate	O
that	O
in	O
primary	O
human	O
lymphocytes	O
,	O
stimulation	O
of	O
a	O
548	O
bp	O
IL-2	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
by	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
is	O
reversed	O
by	O
dexamethasone	O
to	O
a	O
similar	O
extent	O
as	O
in	O
Jurkat	O
T	O
lymphoma	O
cells	O
transfected	O
with	O
a	O
GRalpha	O
expression	O
vector	O
.	O

Transfection	O
of	O
a	O
GRbeta	O
expression	O
vector	O
alone	O
did	O
not	O
result	O
in	O
IL-2	O
promoter	O
repression	O
in	O
response	O
to	O
glucocorticoids	O
.	O

Furthermore	O
,	O
GRbeta	O
did	O
not	O
antagonize	O
the	O
repressive	O
effects	O
of	O
GRalpha	O
on	O
IL-2	O
promoter	O
activity	O
.	O

Surprisingly	O
,	O
overexpression	O
of	O
GRbeta	O
in	O
Jurkat	B
cells	I
did	O
not	O
cause	O
significant	O
inhibition	O
of	O
GRalpha	O
-induced	O
transactivation	O
of	O
a	O
GRE	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
either	O
.	O

We	O
conclude	O
that	O
the	O
transrepressive	O
effect	O
of	O
glucocorticoids	O
on	O
IL-2	O
gene	O
transcription	O
is	O
exclusively	O
mediated	O
by	O
GRalpha	O
.	O

GRbeta	O
can	O
neither	O
antagonize	O
GRalpha	O
-mediated	O
transactivation	O
nor	O
transrepression	O
in	O
Jurkat	B
cells	I
,	O
indicating	O
a	O
cell	O
type	O
-	O
specific	O
pattern	O
of	O
GRbeta	O
-mediated	O
antiglucocorticoid	O
activity	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappaB	O
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	O
cells	O
.	O

Death	O
-	O
inducing	O
ligands	O
(	O
DILs	O
)	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
-dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O

We	O
demonstrate	O
here	O
that	O
TRAIL	O
(	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
)	O
,	O
a	O
recently	O
identified	O
DIL	O
,	O
also	O
activates	O
NFkappaB	O
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	O
.	O

NFkappaB	O
activity	O
is	O
independent	O
from	O
FADD	O
,	O
caspases	O
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	O
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	O
,	O
CD95	O
,	O
TNFalpha	O
,	O
or	O
doxorubicin	O
,	O
NFkappaB	O
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	O
inhibitor	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
leucinyl	O
-	O
L	O
-	O
norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	O
IkappaBalpha	O
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	B
lines	I
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	O
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	O
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	O
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

MLL	O
and	O
CALM	O
are	O
fused	O
to	O
AF10	O
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
with	O
translocation	O
t	O
(	O
10	O
;	O
11	O
)	O
:	O
both	O
rearrangements	O
are	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

The	O
translocation	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p13	O
;	O
q14	O
)	O
has	O
been	O
observed	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
as	O
well	O
as	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

A	O
recent	O
study	O
showed	O
a	O
MLL	O
/	O
AF10	O
fusion	O
in	O
all	O
cases	O
of	O
AML	O
with	O
t	O
(	O
10	O
;	O
11	O
)	O
and	O
various	O
breakpoints	O
on	O
chromosome	O
11	O
ranging	O
from	O
q13	O
to	O
q23	O
.	O

We	O
recently	O
cloned	O
CALM	O
(	O
Clathrin	O
Assembly	O
Lymphoid	O
Myeloid	O
leukemia	O
gene	O
)	O
,	O
the	O
fusion	O
partner	O
of	O
AF10	O
at	O
11q14	O
in	O
the	O
monocytic	B
cell	I
line	I
U937	I
.	O

To	O
further	O
define	O
the	O
role	O
of	O
these	O
genes	O
in	O
acute	O
leukemias	O
,	O
10	O
cases	O
(	O
9	O
AML	O
and	O
1	O
ALL	O
)	O
with	O
cytogenetically	O
proven	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p12	O
-	O
14	O
;	O
q13	O
-	O
21	O
)	O
and	O
well	O
-	O
characterized	O
morphology	O
,	O
immunophenotype	O
,	O
and	O
clinical	O
course	O
were	O
analyzed	O
.	O

Interphase	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
was	O
performed	O
with	O
2	O
YACs	O
flanking	O
the	O
CALM	O
region	O
,	O
a	O
YAC	O
contig	O
of	O
the	O
MLL	O
region	O
,	O
and	O
a	O
YAC	O
spanning	O
the	O
AF10	O
breakpoint	O
.	O

Rearrangement	O
of	O
at	O
least	O
one	O
of	O
these	O
genes	O
was	O
detected	O
in	O
all	O
cases	O
with	O
balanced	O
t	O
(	O
10	O
;	O
11	O
)	O
.	O

In	O
4	O
cases	O
,	O
including	O
3	O
AML	O
with	O
immature	O
morphology	O
(	O
1	O
AML	O
-	O
M0	O
and	O
2	O
AML	O
-	O
M1	O
)	O
and	O
1	O
ALL	O
,	O
the	O
signals	O
of	O
the	O
CALM	O
YACS	O
were	O
separated	O
in	O
interphase	O
cells	O
,	O
indicating	O
a	O
translocation	O
breakpoint	O
within	O
the	O
CALM	O
region	O
.	O

MLL	O
was	O
rearranged	O
in	O
3	O
AML	O
with	O
myelomonocytic	O
differentiation	O
(	O
2	O
AML	O
-	O
M2	O
and	O
1	O
AML	O
-	O
M5	O
)	O
,	O
including	O
1	O
secondary	O
AML	O
.	O

In	O
all	O
3	O
cases	O
,	O
a	O
characteristic	O
immunophenotype	O
was	O
identified	O
(	O
CD4	O
+	O
,	O
CD13	O
-	O
,	O
CD33	O
+	O
,	O
CD65s+	O
)	O
.	O

AF-10	O
was	O
involved	O
in	O
5	O
of	O
6	O
evaluable	O
cases	O
,	O
including	O
1	O
case	O
without	O
detectable	O
CALM	O
or	O
MLL	O
rearrangement	O
.	O

In	O
2	O
complex	O
translocations	O
,	O
none	O
of	O
the	O
three	O
genes	O
was	O
rearranged	O
.	O

All	O
cases	O
had	O
a	O
remarkably	O
poor	O
prognosis	O
,	O
with	O
a	O
mean	O
survival	O
of	O
9.6	O
+	O
/-	O
6.6	O
months	O
.	O

For	O
the	O
7	O
AML	O
cases	O
that	O
were	O
uniformly	O
treated	O
according	O
to	O
the	O
AMLCG86	O
/	O
92	O
protocols	O
,	O
disease	O
-	O
free	O
and	O
overall	O
survival	O
was	O
significantly	O
worse	O
than	O
for	O
the	O
overall	O
study	O
group	O
(	O
P	O
=	O
.03	O
and	O
P	O
=	O
.01	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
the	O
t	O
(	O
10	O
;	O
11	O
)	O
(	O
p13	O
;	O
q14	O
)	O
indicates	O
CALM	O
and	O
MLL	O
rearrangements	O
in	O
morphologically	O
distinct	O
subsets	O
of	O
acute	O
leukemia	O
and	O
may	O
be	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

Loss-	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
reveal	O
an	O
important	O
role	O
of	O
BSAP	O
(	O
Pax-5	O
)	O
at	O
the	O
start	O
and	O
end	O
of	O
B	O
cell	O
differentiation	O
.	O

Pax-5	O
codes	O
for	O
the	O
transcription	O
factor	O
BSAP	O
which	O
is	O
expressed	O
throughout	O
B	O
cell	O
development	O
except	O
in	O
terminally	O
differentiated	O
plasma	O
cells	O
.	O

Gene	O
targeting	O
experiments	O
in	O
the	O
mouse	O
revealed	O
a	O
differential	O
dependency	O
of	O
fetal	O
and	O
adult	O
B	O
-	O
lymphopoiesis	O
on	O
this	O
transcription	O
factor	O
.	O

BSAP	O
is	O
required	O
for	O
B	O
-	O
lineage	O
commitment	O
in	O
the	O
fetal	O
liver	O
and	O
for	O
progression	O
beyond	O
an	O
early	O
pro	O
-	O
B	O
cell	O
stage	O
in	O
adult	O
bone	O
marrow	O
.	O

The	O
characterization	O
of	O
Pax-5-deficient	O
pro	O
-	O
B	O
cells	O
demonstrated	O
an	O
important	O
role	O
of	O
BSAP	O
in	O
the	O
regulation	O
of	O
the	O
CD19	O
,	O
mb-1	O
(	O
Ig	O
alpha	O
)	O
and	O
N	O
-	O
myc	O
genes	O
as	O
well	O
as	O
in	O
the	O
developmental	O
pathway	O
controlling	O
VH	O
-	O
to	O
-	O
DHJH	O
recombination	O
at	O
the	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
locus	O
.	O

The	O
human	O
PAX-5	O
gene	O
was	O
recently	O
shown	O
to	O
participate	O
together	O
with	O
the	O
IgH	O
locus	O
in	O
the	O
chromosomal	O
translocation	O
t	O
(	O
9	O
;	O
14	O
)	O
(	O
p13	O
;	O
q32	O
)	O
.	O

This	O
translocation	O
is	O
characteristic	O
of	O
a	O
small	O
subset	O
of	O
non	O
-	O
Hodgkin	O
lymphomas	O
exhibiting	O
plasmacytoid	O
differentiation	O
.	O

The	O
translocated	O
PAX-5	O
gene	O
is	O
deregulated	O
by	O
the	O
insertion	O
of	O
IgH	O
regulatory	O
elements	O
into	O
its	O
5	O
'	O
region	O
,	O
which	O
may	O
contribute	O
to	O
tumorigenesis	O
by	O
interfering	O
with	O
the	O
shut	O
-	O
down	O
of	O
PAX-5	O
transcription	O
and	O
thus	O
with	O
the	O
completion	O
of	O
plasma	O
cell	O
differentiation	O

The	O
role	O
of	O
E	O
-	O
proteins	O
in	O
B-	O
and	O
T	O
-	O
lymphocyte	O
development	O
.	O

Department	O
of	O
lymphocytes	O
from	O
hematopoietic	O
stem	O
cells	O
is	O
controlled	O
,	O
in	O
part	O
,	O
by	O
the	O
activity	O
of	O
transcriptional	O
regulatory	O
proteins	O
.	O

In	O
particular	O
,	O
one	O
class	O
of	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
,	O
termed	O
E	O
-	O
proteins	O
,	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
B	O
-	O
cell	O
development	O
.	O

Recent	O
analysis	O
of	O
gene	O
-	O
targeted	O
mice	O
has	O
allowed	O
a	O
direct	O
assessment	O
of	O
the	O
functional	O
roles	O
of	O
several	O
E	O
-	O
protein	O
family	O
members	O
in	O
hematopoiesis	O
.	O

In	O
this	O
review	O
we	O
describe	O
the	O
defects	O
in	O
B-	O
and	O
T-	O
lymphocyte	O
development	O
in	O
mice	O
carrying	O
targeted	O
mutations	O
in	O
the	O
E	O
-	O
protein	O
genes	O
and	O
discuss	O
our	O
current	O
understanding	O
of	O
the	O
role	O
of	O
these	O
proteins	O
in	O
lymphoid	O
development	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	O
receptors	O
.	O

The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	O
receptors	O
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O

Ligand	O
binding	O
to	O
the	O
ligand	O
binding	O
domain	O
of	O
these	O
receptors	O
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	O
.	O

In	O
vitro	O
labeled	O
receptors	O
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	O
digestion	O
.	O

Proteolysis	O
products	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
quantified	O
.	O

The	O
amount	O
of	O
trypsin	O
-resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Using	O
the	O
wild	O
-	O
type	O
or	O
mutated	O
human	O
retinoic	O
acid	O
receptor	O
alpha	O
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	O
retinoic	O
X	O
receptor	O
alpha	O
,	O
glucocorticoid	O
receptor	O
,	O
and	O
progesterone	O
receptor	O
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Minimal	O
residual	O
disease	O
in	O
acute	O
myelogenous	O
leukemia	O
with	O
PML	O
/	O
RAR	O
alpha	O
or	O
AML1	O
/	O
ETO	O
mRNA	O
and	O
phenotypic	O
analysis	O
of	O
possible	O
T	O
and	O
natural	O
killer	O
cells	O
in	O
bone	O
marrow	O
.	O

Here	O
we	O
studied	O
minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
who	O
have	O
PML	O
/	O
RAR	O
alpha	O
or	O
AML1	O
/	O
ETO	O
as	O
well	O
as	O
the	O
phenotypic	O
analysis	O
of	O
lymphocyte	O
subsets	O
involved	O
in	O
antitumor	O
immunity	O
.	O

Eight	O
patients	O
in	O
long	O
-	O
term	O
(	O
LT	O
;	O
3	O
to	O
15	O
years	O
)	O
and	O
15	O
patients	O
in	O
short	O
-	O
term	O
(	O
ST	O
;	O
up	O
to	O
3	O
years	O
)	O
remission	O
were	O
studied	O
.	O

Using	O
the	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
)	O
assay	O
,	O
the	O
limit	O
of	O
detection	O
was	O
10	O
(	O
-5	O
)	O
to	O
10	O
(	O
-6	O
)	O
for	O
PML	O
/	O
RAR	O
alpha	O
transcript	O
and	O
10	O
(	O
-4	O
)	O
to	O
10	O
(	O
-5	O
)	O
for	O
the	O
AML1	O
/	O
ETO	O
transcript	O
.	O

Simultaneously	O
,	O
T	O
lymphocyte	O
subsets	O
and	O
NK	O
cells	O
from	O
the	O
peripheral	O
blood	O
(	O
PB	O
)	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
were	O
investigated	O
by	O
flow	O
cytometric	O
analysis	O
.	O

Four	O
of	O
the	O
eight	O
patients	O
in	O
LT	O
and	O
7	O
of	O
the	O
15	O
patients	O
in	O
ST	O
remission	O
were	O
MRD	O
-	O
positive	O
.	O

Although	O
all	O
MRD	O
-	O
positive	O
patients	O
in	O
LT	O
remission	O
are	O
still	O
until	O
now	O
event	O
-	O
free	O
,	O
3	O
of	O
the	O
7	O
MRD	O
-	O
positive	O
(	O
MRD+	O
)	O
patients	O
in	O
ST	O
remission	O
soon	O
relapsed	O
.	O

The	O
total	O
populations	O
of	O
CD4	O
+	O
,	O
CD8	O
+	O
and	O
CD56	O
+	O
[	O
possible	O
T	O
-	O
cell	O
and	O
natural	O
killer	O
(	O
T	O
/	O
NK	O
)	O
populations	O
]	O
in	O
the	O
BM	O
of	O
ST	O
patients	O
and	O
MRD+	O
/	O
LT	O
patients	O
were	O
significantly	O
(	O
p	O
<	O
.01	O
)	O
low	O
.	O

The	O
CD8	O
+	O
CD28	O
+	O
population	O
showed	O
the	O
same	O
tendency	O
(	O
p	O
<	O
.01-.02	O
)	O
.	O

The	O
T	O
/	O
NK	O
subsets	O
in	O
the	O
BM	O
of	O
MRD	O
-	O
negative	O
(	O
MRD-	O
)	O
LT	O
(	O
MRD-	O
/	O
LT	O
)	O
patients	O
showed	O
similar	O
numbers	O
of	O
cells	O
as	O
normal	O
volunteers	O
.	O

Basically	O
,	O
the	O
total	O
percentage	O
of	O
the	O
CD4	O
+	O
,	O
CD8	O
+	O
and	O
CD56	O
+	O
cell	O
populations	O
in	O
the	O
BM	O
was	O
increased	O
and	O
in	O
the	O
following	O
order	O
:	O
MRD-	O
/	O
LT	O
patients	O
,	O
normal	O
volunteers	O
,	O
MRD+	O
/	O
LT	O
patients	O
and	O
MRD+	O
or	O
-	O
/	O
ST	O
patients	O
.	O

The	O
percentages	O
of	O
the	O
T	O
/	O
NK	O
-	O
cell	O
subsets	O
in	O
the	O
PB	O
were	O
not	O
significantly	O
different	O
among	O
these	O
groups	O
.	O

Thus	O
,	O
the	O
difference	O
of	O
the	O
possible	O
T	O
/	O
NK	O
-	O
cell	O
phenotype	O
in	O
the	O
BM	O
may	O
strongly	O
influence	O
clinical	O
and	O
molecular	O
remission	O
.	O

These	O
results	O
still	O
remain	O
to	O
be	O
confirmed	O
by	O
further	O
studies	O
of	O
the	O
functional	O
anti	O
-	O
tumor	O
immunity	O
of	O
T	O
/	O
NK	O
cells	O
of	O
AML	O
in	O
remission	O
.	O

Ro	O
09	O
-	O
2210	O
exhibits	O
potent	O
anti	O
-	O
proliferative	O
effects	O
on	O
activated	O
T	O
cells	O
by	O
selectively	O
blocking	O
MKK	O
activity	O
.	O

By	O
using	O
high	O
throughput	O
screening	O
of	O
microbial	O
broths	O
,	O
we	O
have	O
identified	O
a	O
compound	O
,	O
designated	O
Ro	O
09	O
-	O
2210	O
,	O
which	O
is	O
able	O
to	O
block	O
anti	O
-	O
CD3	O
induced	O
peripheral	O
blood	O
T	O
cell	O
activation	O
with	O
an	O
IC50	O
=	O
40	O
nM	O
.	O

Ro	O
09	O
-	O
2210	O
was	O
also	O
able	O
to	O
block	O
antigen	O
-	O
induced	O
IL-2	O
secretion	O
with	O
an	O
IC50	O
=	O
30	O
nM	O
,	O
but	O
was	O
considerably	O
less	O
potent	O
at	O
blocking	O
Ca2	O
+	O
flux	O
stimulated	O
by	O
anti	O
-	O
CD3	O
treatment	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
action	O
of	O
Ro	O
09	O
-	O
2210	O
,	O
we	O
set	O
up	O
a	O
transient	O
expression	O
system	O
in	O
Jurkat	B
T	I
cells	I
using	O
a	O
variety	O
of	O
reporter	O
gene	O
constructs	O
and	O
showed	O
effective	O
inhibition	O
of	O
phorbol	O
ester	O
/	O
ionomycin	O
-	O
induced	O
NF	O
-	O
AT	O
activation	O
and	O
anti	O
-	O
CD3	O
induced	O
NF	O
-	O
AT	O
with	O
IC50	O
=	O
7.7	O
and	O
10	O
nM	O
,	O
respectively	O
.	O

Ro	O
09	O
-	O
2210	O
was	O
also	O
able	O
to	O
inhibit	O
phorbol	O
ester	O
/	O
ionomycin	O
-	O
induced	O
activation	O
of	O
AP1	O
with	O
IC50	O
=	O
<	O
10	O
nM	O
.	O

We	O
further	O
showed	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
unable	O
to	O
inhibit	O
c	O
-	O
jun	O
induced	O
expression	O
of	O
AP1-dependent	O
reporter	O
constructs	O
(	O
IC50	O
>	O
500	O
nM	O
)	O
,	O
but	O
was	O
able	O
to	O
potently	O
inhibit	O
ras	O
-	O
induced	O
AP1	O
activation	O
(	O
IC50	O
=	O
20	O
nM	O
)	O
.	O

This	O
suggested	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
inhibiting	O
an	O
activator	O
of	O
AP-1	O
which	O
was	O
upstream	O
of	O
c	O
-	O
jun	O
and	O
downstream	O
of	O
ras	O
signaling	O
.	O

To	O
investigate	O
further	O
,	O
we	O
then	O
purified	O
a	O
number	O
of	O
different	O
kinases	O
,	O
including	O
PKC	O
,	O
PhK	O
,	O
ZAP-70	O
,	O
ERK	O
,	O
and	O
MEK	O
1	O
(	O
a	O
MKK	O
)	O
,	O
and	O
showed	O
that	O
Ro	O
09	O
-	O
2210	O
was	O
a	O
selective	O
inhibitor	O
of	O
MEK1	O
in	O
vitro	O
(	O
IC50	O
=	O
59	O
nM	O
)	O
.	O

Role	O
of	O
GATA-1	O
in	O
proliferation	O
and	O
differentiation	O
of	O
definitive	O
erythroid	O
and	O
megakaryocytic	O
cells	O
in	O
vivo	O
.	O

To	O
elucidate	O
the	O
contributions	O
of	O
GATA-1	O
to	O
definitive	O
hematopoiesis	O
in	O
vivo	O
,	O
we	O
have	O
examined	O
adult	O
mice	O
that	O
were	O
rendered	O
genetically	O
defective	O
in	O
GATA-1	O
synthesis	O
(	O
Takahashi	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
12611	O
,	O
1997	O
)	O
.	O

Because	O
the	O
GATA-1	O
gene	O
is	O
located	O
on	O
the	O
X	O
chromosome	O
,	O
which	O
is	O
randomly	O
inactivated	O
in	O
every	O
cell	O
,	O
heterozygous	O
females	O
can	O
bear	O
either	O
an	O
active	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
referred	O
to	O
as	O
GATA-1.05	O
)	O
GATA-1	O
allele	O
,	O
consequently	O
leading	O
to	O
variable	O
anemic	O
severity	O
.	O

These	O
heterozygous	O
mutant	O
mice	O
usually	O
developed	O
normally	O
,	O
but	O
they	O
began	O
to	O
die	O
after	O
5	O
months	O
.	O

These	O
affected	O
animals	O
displayed	O
marked	O
splenomegaly	O
,	O
anemia	O
,	O
and	O
thrombocytopenia	O
.	O

Proerythroblasts	O
and	O
megakaryocytes	O
massively	O
accumulated	O
in	O
the	O
spleens	O
of	O
the	O
heterozygotes	O
,	O
and	O
we	O
showed	O
that	O
the	O
neomycin	O
resistance	O
gene	O
(	O
which	O
is	O
the	O
positive	O
selection	O
marker	O
in	O
ES	O
cells	O
)	O
was	O
expressed	O
profusely	O
in	O
the	O
abnormally	O
abundant	O
cells	O
generated	O
in	O
the	O
GATA-1.05	O
mutant	O
females	O
.	O

We	O
also	O
observed	O
hematopoiesis	O
outside	O
of	O
the	O
bone	O
marrow	O
in	O
the	O
affected	O
mutant	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
a	O
small	O
number	O
of	O
GATA-1.05	B
mutant	I
hematopoietic	I
progenitor	I
cells	I
begin	O
to	O
proliferate	O
vigorously	O
during	O
early	O
adulthood	O
,	O
but	O
because	O
the	O
cells	O
are	O
unable	O
to	O
terminally	O
differentiate	O
,	O
this	O
leads	O
to	O
progenitor	O
proliferation	O
in	O
the	O
spleen	O
and	O
consequently	O
death	O
.	O

Thus	O
,	O
GATA-1	O
plays	O
important	O
in	O
vivo	O
roles	O
for	O
directing	O
definitive	O
hematopoietic	O
progenitors	O
to	O
differentiate	O
along	O
both	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

The	O
GATA-1	O
heterozygous	O
mutant	O
mouse	O
shows	O
a	O
phenotype	O
that	O
is	O
analogous	O
to	O
human	O
myelodysplastic	O
syndrome	O
and	O
thus	O
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
this	O
disorder	O
.	O

A	O
novel	O
function	O
of	O
Stat1	O
and	O
Stat3	O
proteins	O
in	O
erythropoietin	O
-induced	O
erythroid	O
differentiation	O
of	O
a	O
human	B
leukemia	I
cell	I
line	I
.	O

We	O
recently	O
determined	O
that	O
erythropoietin	O
(	O
EPO	O
)	O
activates	O
3	O
members	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
,	O
Stat1alpha	O
,	O
Stat3	O
,	O
and	O
Stat5	O
,	O
in	O
the	O
human	B
EPO	I
-	I
dependent	I
cell	I
lines	I
,	O
UT-7	B
and	O
UT-7	B
/	I
EPO	I
(	O
Kirito	O
et	O
al	O
,	O
J	O
Biol	O
Chem	O
272	O
:	O
16507	O
,	O
1997	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
Stat1alpha	O
,	O
but	O
not	O
Stat3	O
,	O
is	O
involved	O
in	O
EPO	O
-induced	O
cellular	O
proliferation	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
Stat1alpha	O
and	O
Stat3	O
in	O
EPO	O
-induced	O
erythroid	O
differentiation	O
.	O

UT-7	B
/	I
GM	I
was	O
used	O
as	O
a	O
model	O
system	O
,	O
because	O
this	O
cell	O
line	O
can	O
differentiate	O
into	O
erythroid	O
-	O
lineage	O
cells	O
with	O
EPO	O
treatment	O
(	O
Komatsu	O
et	O
al	O
,	O
Blood	O
89	O
:	O
4021	O
,	O
1997	O
)	O
.	O

We	O
found	O
that	O
EPO	O
did	O
not	O
activate	O
Stat1alpha	O
or	O
Stat3	O
in	O
UT-7	B
/	I
GM	I
cells	I
.	O

Transfection	O
experiments	O
showed	O
that	O
both	O
Stat1alpha	O
and	O
Stat3	O
inhibited	O
the	O
induction	O
by	O
EPO	O
of	O
gamma	O
-	O
globin	O
and	O
erythroid	O
-	O
specific	O
5-aminolevulinate	O
synthetase	O
transcripts	O
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
percentage	O
of	O
hemoglobin	O
-	O
positive	O
cells	O
.	O

Dominant	O
negative	O
forms	O
of	O
Stat1alpha	O
or	O
Stat3	O
promoted	O
the	O
EPO	O
-induced	O
erythroid	O
differentiation	O
of	O
UT-7	B
/	I
GM	I
cells	I
,	O
even	O
in	O
the	O
presence	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
although	O
this	O
cytokine	O
never	O
induced	O
erythroid	O
differentiation	O
of	O
the	O
parent	B
UT-7	I
/	I
GM	I
cells	I
with	O
or	O
without	O
EPO	O
.	O

A	O
cell	O
cycle	O
analysis	O
showed	O
that	O
the	O
constitutive	O
activation	O
of	O
Stat1alpha	O
,	O
but	O
not	O
Stat3	O
,	O
shortened	O
the	O
period	O
of	O
G0	O
/	O
G1	O
prolongation	O
caused	O
by	O
EPO	O
stimulation	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
Stat1alpha	O
and	O
Stat3	O
act	O
as	O
negative	O
regulators	O
in	O
EPO	O
-induced	O
erythroid	O
differentiation	O
.	O

Specifically	O
,	O
Stat1alpha	O
may	O
activate	O
a	O
cell	O
cycle	O
-	O
associated	O
gene	O
(	O
s	O
)	O
,	O
leading	O
to	O
the	O
entry	O
of	O
cells	O
into	O
the	O
cell	O
cycle	O
.	O

DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	O
ligand	O
and	O
subsequent	O
apoptosis	O
in	O
T	O
lymphocytes	O
via	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
.	O

Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O

We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
is	O
crucially	O
involved	O
in	O
FasL	O
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O

A	O
nondegradable	O
mutant	O
of	O
I	O
kappa	O
B	O
blocked	O
both	O
FasL	O
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	O
Fas	O
ligation	O
.	O

These	O
stimuli	O
also	O
induced	O
the	O
stress	O
-	O
activated	O
kinase	O
pathway	O
(	O
SAPK	O
/	O
JNK	O
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O

A	O
1.2	O
kb	O
FasL	O
promoter	O
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	O
Rel	O
or	O
Fos	O
/	O
Jun	O
.	O

Mutations	O
in	O
the	O
relevant	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
binding	O
sites	O
eliminated	O
these	O
responses	O
.	O

Thus	O
,	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP-1	O
contributes	O
to	O
stress	O
-	O
induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	O
.	O

Uncoupling	O
of	O
nonreceptor	O
tyrosine	O
kinases	O
from	O
PLC	O
-	O
gamma1	O
in	O
an	O
SLP-76-deficient	O
T	O
cell	O
.	O

Activation	O
of	O
nonreceptor	O
protein	O
tyrosine	O
kinases	O
(	O
PTKs	O
)	O
is	O
essential	O
for	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
responsiveness	O
;	O
however	O
,	O
the	O
function	O
of	O
individual	O
PTK	O
substrates	O
is	O
often	O
uncertain	O
.	O

A	O
mutant	B
T	I
cell	I
line	I
was	O
isolated	O
that	O
lacked	O
expression	O
of	O
SLP-76	O
(	O
SH2	O
domain	O
-	O
containing	O
leukocyte	O
protein	O
of	O
76	O
kilodaltons	O
)	O
,	O
a	O
hematopoietically	O
expressed	O
adaptor	O
protein	O
and	O
PTK	O
substrate	O
.	O

SLP-76	O
was	O
not	O
required	O
for	O
TCR	O
-induced	O
tyrosine	O
phosphorylation	O
of	O
most	O
proteins	O
,	O
but	O
was	O
required	O
for	O
optimal	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
phospholipase	O
C	O
-	O
gamma1	O
(	O
PLC	O
-	O
gamma1	O
)	O
,	O
as	O
well	O
as	O
Ras	O
pathway	O
activation	O
.	O

TCR	O
-inducible	O
gene	O
expression	O
was	O
dependent	O
on	O
SLP-76	O
.	O

Thus	O
,	O
coupling	O
of	O
TCR	O
-	O
regulated	O
PTKs	O
to	O
downstream	O
signaling	O
pathways	O
requires	O
SLP-76	O
.	O

Fibrinogen	O
activates	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
in	O
mononuclear	O
phagocytes	O
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcription	O
factors	O
.	O

U937	B
cells	I
differentiated	O
with	O
PMA	O
in	O
nonadherent	B
culture	I
were	O
shown	O
to	O
express	O
two	O
fibrinogen	O
-	O
binding	O
integrins	O
,	O
predominately	O
CD11b	O
/	O
CD18	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c	O
/	O
CD18	O
.	O

Cells	O
stimulated	O
with	O
fibrinogen	O
(	O
10	O
-	O
100	O
microg	O
/	O
ml	O
)	O
/Mn2	O
+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

NF	O
-	O
kappa	O
B	O
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up	O
-	O
regulated	O
by	O
fibrinogen	O
.	O

Fibrinogen	O
also	O
caused	O
activation	O
of	O
AP-1	O
,	O
but	O
not	O
SP1	O
or	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
factors	O
.	O

Blocking	O
mAbs	O
against	O
CD18	O
and	O
CD11b	O
abrogated	O
fibrinogen	O
-induced	O
NF	O
-	O
kappa	O
B	O
activation	O
.	O

To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	B
cells	I
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	O
enhancer	O
(	O
bearing	O
two	O
NF	O
-	O
kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
.	O

Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen	O
/Mn2	O
+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	O
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	O
activity	O
induced	O
by	O
PMA	O
alone	O
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen	O
-	O
derived	O
proteins	O
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b	O
/	O
CD18	O
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	O
regulatory	O
factors	O
,	O
including	O
NF	O
-	O
kappa	O
B	O
.	O

Recognition	O
of	O
herpes	O
simplex	O
virus	O
type	O
2	O
tegument	O
proteins	O
by	O
CD4	O
T	O
cells	O
infiltrating	O
human	O
genital	O
herpes	O
lesions	O
.	O

The	O
local	O
cellular	O
immune	O
response	O
to	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
is	O
important	O
in	O
the	O
control	O
of	O
recurrent	O
HSV	O
infection	O
.	O

The	O
antiviral	O
functions	O
of	O
infiltrating	O
CD4-bearing	O
T	O
cells	O
may	O
include	O
cytotoxicity	O
,	O
inhibition	O
of	O
viral	O
growth	O
,	O
lymphokine	O
secretion	O
,	O
and	O
support	O
of	O
humoral	O
and	O
CD8	O
responses	O
.	O

The	O
antigens	O
recognized	O
by	O
many	O
HSV	O
-	O
specific	O
CD4	O
T	O
cells	O
localizing	O
to	O
genital	O
HSV-2	O
lesions	O
are	O
unknown	O
.	O

T	O
cells	O
recognizing	O
antigens	O
encoded	O
within	O
map	O
units	O
0.67	O
to	O
0.73	O
of	O
HSV	O
DNA	O
are	O
frequently	O
recovered	O
from	O
herpetic	O
lesions	O
.	O

Expression	O
cloning	O
with	O
this	O
region	O
of	O
DNA	O
now	O
shows	O
that	O
tegument	O
protein	O
VP22	O
and	O
the	O
viral	O
dUTPase	O
,	O
encoded	O
by	O
genes	O
UL49	O
and	O
UL50	O
,	O
respectively	O
,	O
are	O
T	O
-	O
cell	O
antigens	O
.	O

Separate	O
epitopes	O
in	O
VP22	O
were	O
defined	O
for	O
T	B
-	I
cell	I
clones	I
from	O
each	O
of	O
three	O
patients	O
.	O

Reactivity	O
with	O
the	O
tegument	O
protein	O
encoded	O
by	O
UL21	O
was	O
identified	O
for	O
an	O
additional	O
patient	O
.	O

Three	O
new	O
epitopes	O
were	O
identified	O
in	O
VP16	O
,	O
a	O
tegument	O
protein	O
associated	O
with	O
VP22	O
.	O

Some	O
tegument	B
-	I
specific	I
CD4	I
T	I
-	I
cell	I
clones	I
exhibited	O
cytotoxic	O
activity	O
against	O
HSV	O
-	O
infected	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
herpes	O
simplex	O
tegument	O
proteins	O
are	O
processed	O
for	O
antigen	O
presentation	O
in	O
vivo	O
and	O
are	O
possible	O
candidate	O
compounds	O
for	O
herpes	O
simplex	O
vaccines	O
.	O

A	O
CD28	O
-associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	O
gene	O
transcription	O
and	O
T	O
cell	O
proliferation	O
without	O
TCR	O
engagement	O
.	O

Stimulation	O
of	O
resting	O
human	O
T	O
cells	O
with	O
the	O
CD28-specific	O
mAb	O
BW	O
828	O
induces	O
proliferation	O
and	O
cytokine	O
synthesis	O
without	O
further	O
requirement	O
for	O
TCR	O
coengagement	O
.	O

This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	O
signal	O
1	O
(	O
TCR	O
signal	O
)	O
can	O
activate	O
T	O
cells	O
.	O

To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	O
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	O
cells	O
by	O
the	O
stimulatory	O
mAb	O
BW	O
828	O
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	O
CD28	O
mAb	O
9.3	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
BW	O
828	O
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2	O
+	O
,	O
but	O
did	O
not	O
lead	O
to	O
detectable	O
activation	O
of	O
the	O
protein	O
kinases	O
p56	O
(	O
lck	O
)	O
and	O
c	O
-	O
Raf-1	O
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factors	O
NF	O
-	O
kappa	O
B	O
,	O
NF	O
-	O
AT	O
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	O
response	O
element	O
of	O
the	O
IL-2	O
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
mAb	O
9.3	O
increased	O
the	O
level	O
of	O
intracellular	O
Ca2	O
+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	O
(	O
lck	O
)	O
and	O
c	O
-	O
Raf-1	O
,	O
but	O
was	O
unable	O
to	O
induce	O
the	O
binding	O
of	O
transcription	O
factors	O
to	O
the	O
IL-2	O
promoter	O
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	O
828	O
and	O
9.3	O
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	O
(	O
lck	O
)	O
activation	O
,	O
association	O
of	O
phosphatidylinositol	O
3-kinase	O
with	O
CD28	O
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	O
changes	O
with	O
activation	O
.	O

These	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
through	O
CD28	O
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O

Retinoic	O
acid	O
inhibits	O
CD40	O
+	O
interleukin-4	O
-mediated	O
IgE	O
production	O
in	O
vitro	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti	O
-	O
CD40	O
+	O
interleukin-4	O
(	O
IL-4	O
)	O
-mediated	O
B	O
-	O
cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol	O
/	O
L	O
RA	O
was	O
studied	O
in	O
anti	O
-	O
CD40	O
(	O
1	O
microgram	O
/	O
mL	O
)	O
+	O
IL-4	O
(	O
5	O
ng	O
/	O
mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
B	O
cells	O
in	O
healthy	O
donors	O
.	O

Anti	O
-	O
CD40	O
+	O
IL-4	O
-mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
+	O
/-	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
+	O
/-	O
4.4	O
%	O
in	O
B	O
cells	O
by	O
all	O
-	O
trans	O
RA	O
,	O
and	O
58	O
%	O
+	O
/-	O
6.7	O
%	O
and	O
51	O
%	O
+	O
/-	O
4.7	O
%	O
,	O
respectively	O
by	O
13-cis	O
RA	O
.	O

IgE	O
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-14	O
)	O
mol	O
/	O
L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
for	O
PBMC	O
.	O

Maximal	O
inhibition	O
of	O
IgE	O
production	O
for	O
B	O
cells	O
was	O
at	O
10	O
(	O
-8	O
)	O
mol	O
/	O
L	O
for	O
all	O
-	O
trans	O
RA	O
(	O
94	O
%	O
+	O
/-	O
1.8	O
%	O
)	O
and	O
96	O
%	O
+	O
/-	O
3.2	O
%	O
for	O
13-cis	O
RA	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	O
synthesis	O
(	O
10	O
(	O
-10	O
)	O
mol	O
/	O
L	O
)	O
affected	O
neither	O
B	O
-	O
cell	O
proliferation	O
nor	O
the	O
production	O
of	O
IgA	O
,	O
IgG	O
,	O
and	O
IgM	O
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	O
production	O
shows	O
that	O
epsilon	O
germline	O
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
was	O
not	O
enhanced	O
in	O
the	O
presence	O
of	O
RA	O
.	O

To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	O
receptors	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
,	O
the	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
was	O
examined	O
by	O
reverse	O
transcriptase	O
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

The	O
data	O
show	O
that	O
unstimulated	O
human	O
peripheral	O
B	O
cells	O
express	O
mRNA	O
of	O
the	O
RA	O
receptor	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose	O
-	O
dependent	O
inhibition	O
of	O
IgE	O
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	O
receptor	O
with	O
high	O
specificity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	O
production	O
of	O
anti	B
-	I
CD40	I
+	I
IL-4-stimulated	I
B	I
cells	I
in	O
vitro	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

CIITA	O
B	O
-	O
cell	O
-	O
specific	O
promoter	O
suppression	O
in	O
MHC	B
class	I
II	I
-	I
silenced	I
cell	I
hybrids	I
.	O

In	O
this	O
study	O
,	O
various	O
sets	O
of	O
somatic	B
cell	I
hybrids	I
,	O
generated	O
by	O
the	O
fusion	O
of	O
epithelial	B
cell	I
lines	I
with	O
B	B
-	I
lymphoblastoid	I
cell	I
lines	I
,	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
antigens	O
.	O

We	O
first	O
demonstrate	O
,	O
in	O
human	B
and	I
mouse	I
intraspecies	I
hybrids	I
,	O
the	O
coordinate	O
suppression	O
of	O
MHC	O
class	O
II	O
,	O
Ii	O
(	O
invariant	O
chain	O
)	O
and	O
HLA	O
-	O
DM	O
gene	O
transcription	O
,	O
and	O
the	O
release	O
of	O
the	O
silencing	O
by	O
the	O
addition	O
of	O
interferon	O
gamma	O
.	O

Using	O
interspecies	O
hybrids	O
,	O
the	O
segregation	O
of	O
human	O
chromosomes	O
allowed	O
us	O
to	O
establish	O
that	O
MHC	O
class	O
II	O
extinction	O
is	O
linked	O
to	O
the	O
presence	O
in	O
the	O
hybrids	O
of	O
the	O
chromosomes	O
from	O
the	O
epithelial	O
fusion	O
partner	O
.	O

Moreover	O
,	O
our	O
data	O
provide	O
evidence	O
that	O
the	O
expression	O
pattern	O
of	O
MHC	O
class	O
II	O
mRNA	O
is	O
correlated	O
with	O
that	O
of	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
,	O
suggesting	O
that	O
CIITA	O
is	O
the	O
actual	O
target	O
of	O
the	O
silencing	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
suppression	O
phenomenon	O
we	O
performed	O
luciferase	O
assays	O
which	O
show	O
that	O
silencing	O
affects	O
the	O
activity	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
promoter	O
of	O
CIITA	O
.	O

These	O
results	O
therefore	O
demonstrate	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
silencing	O
in	O
somatic	B
cell	I
hybrids	I
is	O
due	O
to	O
an	O
active	O
suppression	O
of	O
one	O
of	O
the	O
promoters	O
of	O
the	O
CIITA	O
gene	O
,	O
mediated	O
by	O
the	O
epithelial	O
cell	O
fusion	O
partner	O
.	O

Regulation	O
of	O
the	O
vitellogenin	O
gene	O
B1	O
promoter	O
after	O
transfer	O
into	O
hepatocytes	O
in	O
primary	O
cultures	O
.	O

The	O
estrogen	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
regulation	O
of	O
the	O
Xenopus	O
laevis	O
vitellogenin	O
gene	O
B1	O
promoter	O
has	O
been	O
studied	O
by	O
lipid	O
-	O
mediated	O
DNA	O
transfer	O
into	O
Xenopus	O
hepatocytes	O
in	O
primary	O
culture	O
.	O

Hepatocytes	O
achieve	O
an	O
efficient	O
hormonal	O
control	O
of	O
this	O
promoter	O
through	O
a	O
functional	O
interaction	O
between	O
the	O
estrogen	O
responsive	O
elements	O
and	O
a	O
promoter	O
proximal	O
region	O
upstream	O
of	O
the	O
TATA	O
box	O
,	O
which	O
is	O
characterized	O
by	O
a	O
high	O
density	O
of	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
CTF	O
/	O
NF-1	O
,	O
C	O
/	O
EBP	O
and	O
HNF3	O
.	O

DNA	O
accessibility	O
to	O
restriction	O
enzymes	O
within	O
the	O
chromosomal	O
copy	O
of	O
the	O
vitellogenin	O
gene	O
B1	O
promoter	O
shows	O
that	O
the	O
estrogen	O
responsive	O
unit	O
and	O
the	O
promoter	O
proximal	O
region	O
are	O
sensitive	O
to	O
digestion	O
in	O
uninduced	O
and	O
estrogen	O
-	O
induced	O
hepatocytes	O
but	O
not	O
in	O
erythrocyte	O
nuclei	O
.	O

Together	O
,	O
these	O
findings	O
support	O
the	O
notion	O
that	O
chromatin	O
configuration	O
as	O
well	O
as	O
the	O
interplay	O
of	O
promoter	O
elements	O
mediate	O
proper	O
hormone	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
B1	O
vitellogenin	O
gene	O
.	O

Peripheral	O
T	O
lymphocytes	O
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	O
signaling	O
molecules	O
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

In	O
6	O
of	O
14	O
patients	O
,	O
T	O
lymphocytes	O
displayed	O
an	O
impaired	O
ability	O
to	O
translocate	O
NFeB	O
p65	O
(	O
Rel	O
-	O
A	O
)	O
following	O
activation	O
by	O
anti	O
-	O
CD3	O
and	O
IL-2	O
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel	O
-	O
A	O
protein	O
.	O

We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	O
molecules	O
T	O
-	O
cell	O
receptor	O
(	O
TCR	O
)	O
-zeta	O
,	O
ZAP-70	O
and	O
p56lck	O
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
molecules	O
.	O

T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	O
phosphatase	O
,	O
map	O
kinase	O
phosphatase-1	O
(	O
MKP-1	O
)	O
.	O

MKP-1	O
inactivates	O
MAP	O
kinase	O
and	O
therefore	O
may	O
interfere	O
with	O
the	O
activation	O
of	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
.	O

Abnormalities	O
of	O
I	O
or	O
more	O
signaling	O
molecules	O
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	O
cells	O
that	O
exhibited	O
all	O
5	O
defects	O
.	O

Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	O
molecule	O
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T	O
-	O
cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O

Finally	O
,	O
despite	O
impaired	O
Rel	O
-	O
A	O
translocation	O
,	O
T	O
cells	O
were	O
capable	O
of	O
transcribing	O
IL-2	O
.	O

Impairments	O
in	O
the	O
translocation	O
of	O
Rel	O
-	O
B	O
and	O
c	O
-	O
Rel	O
further	O
suggest	O
that	O
the	O
NFKB	O
family	O
members	O
Rel	O
-	O
A	O
,	O
Rel	O
-	O
B	O
and	O
c	O
-	O
Rel	O
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL-2	O
in	O
the	O
peripheral	O
T	O
lymphocytes	O
of	O
patients	O
with	O
breast	O
cancer	O
.	O

Activation	O
of	O
E2F	O
-mediated	O
transcription	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
protein	O
in	O
a	O
p16	B
(	I
INK4A	I
)	I
-negative	I
T	I
-	I
cell	I
line	I
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV	O
-	O
I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	O
protein	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

This	O
40-kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	O
suppressor	O
p16	O
(	O
INK4A	O
)	O
.	O

Consequently	O
,	O
Tax	O
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	O
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	O
can	O
also	O
activate	O
E2F	O
-mediated	O
transcription	O
independently	O
of	O
p16	O
(	O
INK4A	O
)	O
.	O

Indeed	O
,	O
when	O
Tax	O
is	O
coexpressed	O
with	O
the	O
E2F-1	O
transcription	O
factor	O
in	O
CEM	B
T	I
-	I
cells	I
,	O
which	O
lack	O
expression	O
of	O
p16	O
(	O
INK4A	O
)	O
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	O
-dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F	O
-	O
binding	O
sites	O
.	O

In	O
addition	O
,	O
Tax	O
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F-1	O
gene	O
itself	O
.	O

Using	O
Tax	O
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	O
-or	O
NF	O
-	O
kappaB	O
-	O
dependent	O
promoters	O
and	O
different	O
5	O
'	O
truncation	O
mutants	O
of	O
the	O
E2F-1	O
promoter	O
,	O
we	O
show	O
that	O
the	O
Tax	O
-dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	O
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F-1	O
promoter	O
.	O

Calcineurin	O
and	O
the	O
biological	O
effect	O
of	O
cyclosporine	O
and	O
tacrolimus	O
.	O

The	O
mechanism	O
of	O
the	O
immunosuppressive	O
effect	O
of	O
CyA	O
and	O
FK	O
506	O
can	O
be	O
monitored	O
in	O
vivo	O
in	O
humans	O
.	O

The	O
picture	O
emerging	O
is	O
of	O
a	O
close	O
relationship	O
between	O
drug	O
concentrations	O
and	O
CN	O
inhibition	O
.	O

But	O
many	O
puzzles	O
of	O
the	O
drugs	O
remain	O
.	O

What	O
is	O
the	O
role	O
of	O
CyA	O
in	O
the	O
activation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
particularly	O
in	O
relationship	O
to	O
nephrotoxicity	O
and	O
fibrogenesis	O
?	O

How	O
important	O
are	O
the	O
anti	O
-	O
inflammatory	O
(	O
non	O
T	O
)	O
effects	O
of	O
CyA	O
,	O
and	O
which	O
cells	O
do	O
they	O
operate	O
in	O
?	O

Are	O
there	O
effects	O
of	O
CyA	O
and	O
FK	O
506	O
all	O
attributable	O
to	O
CN	O
inhibition	O
,	O
and	O
how	O
much	O
of	O
them	O
are	O
mediated	O
through	O
the	O
NFATC	O
family	O
of	O
transcription	O
factors	O
?	O

Finally	O
,	O
it	O
would	O
be	O
useful	O
to	O
know	O
what	O
the	O
inhibitory	O
effects	O
of	O
CyA	O
are	O
on	O
tolerance	O
and	O
negative	O
regulatory	O
events	O
.	O

p130	O
,	O
p107	O
,	O
and	O
pRb	O
are	O
differentially	O
regulated	O
in	O
proliferating	O
cells	O
and	O
during	O
cell	O
cycle	O
arrest	O
by	O
alpha	O
-	O
interferon	O
.	O

We	O
have	O
determined	O
how	O
the	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
family	O
(	O
pRb	O
,	O
p107	O
,	O
and	O
p130	O
)	O
is	O
governed	O
in	O
individual	O
cell	O
cycle	O
phases	O
of	O
Daudi	B
B	I
-	I
cells	I
during	O
cell	O
cycle	O
exit	O
triggered	O
by	O
alpha	O
-	O
interferon	O
(	O
alpha	O
-	O
IFN	O
)	O
.	O

alpha	O
-	O
IFN	O
causes	O
dephosphorylation	O
of	O
pRb	O
and	O
loss	O
of	O
p130	O
phosphorylated	O
Form	O
3	O
.	O

However	O
,	O
the	O
change	O
in	O
p130	O
phosphorylation	O
in	O
response	O
to	O
alpha	O
-	O
IFN	O
occurs	O
before	O
dephosphorylation	O
of	O
pRb	O
is	O
complete	O
because	O
loss	O
of	O
p130	O
Form	O
3	O
occurs	O
throughout	O
the	O
cell	O
cycle	O
prior	O
to	O
complete	O
arrest	O
in	O
G1	O
,	O
whereas	O
pRb	O
is	O
dephosphorylated	O
only	O
in	O
G1	O
.	O

In	O
contrast	O
,	O
p107	O
is	O
dephosphorylated	O
and	O
is	O
then	O
depleted	O
from	O
cells	O
as	O
they	O
exit	O
the	O
cell	O
cycle	O
.	O

p130	O
,	O
predominantly	O
in	O
Form	O
1	O
,	O
and	O
hypophosphorylated	O
pRb	O
bind	O
an	O
E2F	O
DNA	O
binding	O
site	O
;	O
p130	O
complexes	O
E2F-4	O
,	O
whereas	O
pRb	O
binds	O
both	O
E2F-4	O
and	O
E2F-1	O
.	O

The	O
phosphorylated	O
forms	O
of	O
E2F-4	O
that	O
bind	O
to	O
the	O
E2F	O
DNA	O
site	O
are	O
different	O
from	O
hyperphosphorylated	O
E2F-4	O
,	O
which	O
predominates	O
in	O
primary	O
hemopoietic	O
cells	O
in	O
G0	O
.	O

We	O
conclude	O
that	O
although	O
cell	O
cycle	O
arrest	O
induced	O
by	O
alpha	O
-	O
IFN	O
may	O
be	O
mediated	O
in	O
part	O
by	O
formation	O
of	O
a	O
complex	O
containing	O
p130	O
and	O
E2F-4	O
,	O
alpha	O
-	O
IFN	O
does	O
not	O
induce	O
hyperphosphorylation	O
of	O
E2F-4	O
,	O
which	O
characterizes	O
primary	O
hemopoietic	O
cells	O
in	O
G0	O
.	O

A	O
p56lck	O
-independent	O
pathway	O
of	O
CD2	O
signaling	O
involves	O
Jun	O
kinase	O
.	O

The	O
p56	O
Src	O
family	O
non	O
-	O
receptor	O
tyrosine	O
kinase	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
T	O
lymphocyte	O
differentiation	O
and	O
activation	O
.	O

Hence	O
in	O
the	O
absence	O
of	O
p56	O
,	O
T	O
cell	O
receptor	O
triggered	O
activation	O
does	O
not	O
occur	O
.	O

We	O
now	O
provide	O
evidence	O
for	O
a	O
CD2	O
-based	O
signaling	O
pathway	O
which	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
T	O
cell	O
receptor	O
,	O
is	O
independent	O
of	O
p56	O
.	O

CD2	O
-mediated	O
interleukin-2	O
production	O
occurs	O
via	O
activation	O
of	O
Jun	O
kinase	O
in	O
cell	O
lines	O
lacking	O
p56	O
.	O

Jun	O
kinase	O
then	O
facilitates	O
the	O
binding	O
of	O
c	O
-	O
Jun	O
/	O
c	O
-	O
Fos	O
heterodimers	O
to	O
the	O
AP-1	O
consensus	O
site	O
and	O
the	O
subsequent	O
transcriptional	O
activity	O
of	O
the	O
interleukin-2	O
promoter	O
.	O

These	O
data	O
elucidate	O
differences	O
between	O
TCR	O
and	O
CD2	O
signaling	O
pathways	O
in	O
the	O
same	O
T	O
cells	O
.	O

Establishment	O
and	O
characterization	O
of	O
EBV	B
-	I
positive	I
and	I
EBV	I
-	I
negative	I
primary	I
effusion	I
lymphoma	I
cell	I
lines	I
harbouring	O
human	O
herpesvirus	O
type-8	O
.	O

In	O
this	O
study	O
we	O
report	O
on	O
the	O
establishment	O
and	O
characterization	O
of	O
two	O
novel	O
lymphoma	B
cell	I
lines	I
(	O
CRO	B
-	I
AP	I
/	I
3	I
and	O
CRO	B
-	I
AP	I
/	I
5	I
)	O
which	O
carry	O
infection	O
by	O
human	O
herpesvirus	O
type-8	O
(	O
HHV-8	O
)	O
and	O
have	O
derived	O
from	O
AIDS	O
-	O
related	O
primary	O
effusion	O
lymphoma	O
(	O
PEL	B
)	O
.	O

These	O
two	O
cell	B
lines	I
are	O
representative	O
of	O
different	O
virologic	O
subtypes	O
of	O
PEL	B
,	O
i.e	O
.	O
HHV-8+	B
/	I
EBV-	I
PEL	I
in	O
the	O
case	O
of	O
CRO	B
-	I
AP	I
/	I
3	I
and	I
HHV-8+	I
/	I
EBV+	I
PEL	I
in	O
the	O
case	O
of	O
CRO	B
-	I
AP	I
/	I
5	I
.	O

Consistent	O
with	O
the	O
diagnosis	O
of	O
PEL	B
,	O
both	O
CRO	B
-	I
AP	I
/	I
3	I
and	O
CRO	B
-	I
AP	I
/	I
5	I
expressed	O
indeterminate	O
(	O
i.e.	O
non	O
-	O
B	O
,	O
non	O
-	O
T	O
)	O
phenotypes	O
although	O
immunogenotypic	O
studies	O
documented	O
their	O
B	O
-	O
cell	O
origin	O
.	O

Both	O
cell	B
lines	I
are	O
devoid	O
of	O
genetic	O
lesions	O
of	O
c	O
-	O
MYC	O
,	O
BCL-2	O
and	O
p53	O
as	O
well	O
as	O
gross	O
rearrangements	O
of	O
BCL-6	O
.	O

Detailed	O
histogenetic	O
characterization	O
of	O
these	O
novel	O
PEL	B
cell	I
lines	I
suggests	O
that	O
PEL	B
may	O
derive	O
from	O
a	O
post	B
-	I
germinal	I
centre	I
B	I
cell	I
which	O
has	O
undergone	O
pre	O
-	O
terminal	O
differentiation	O
.	O

The	O
CRO	B
-	I
AP	I
/	I
3	I
and	O
CRO	B
-	I
AP	I
/	I
5	I
cell	I
lines	I
may	O
provide	O
a	O
valuable	O
model	O
for	O
clarifying	O
the	O
pathogenesis	O
of	O
PEL	B
.	O

In	O
particular	O
,	O
these	O
cell	B
lines	I
may	O
help	O
understand	O
the	O
relative	O
contribution	O
of	O
HHV-8	O
and	O
EBV	O
to	O
PEL	O
growth	O
and	O
development	O
and	O
may	O
facilitate	O
the	O
identification	O
of	O
recurrent	O
cytogenetic	O
abnormalities	O
highlighting	O
putative	O
novel	O
cancer	O
related	O
loci	O
relevant	O
to	O
PEL	B
.	O

Phosphatidylinositides	O
bind	O
to	O
plasma	O
membrane	O
CD14	O
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	O
(	O
membrane	O
CD14	O
)	O
,	O
a	O
cell	O
-	O
surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host	O
-	O
derived	O
mCD14	O
ligands	O
are	O
poorly	O
defined	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4-phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	O
.	O

Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	O
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O

LPS	O
-	O
binding	O
protein	O
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	O
both	O
PS	O
-and	O
PtdIns-	O
mCD14	O
binding	O
.	O

PtdIns	O
binding	O
to	O
mCD14	O
can	O
be	O
blocked	O
by	O
anti	O
-	O
CD14	O
monoclonal	O
antibodies	O
that	O
inhibit	O
LPS	O
-mCD14	O
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS	O
-mCD14	O
binding	O
and	O
LPS	O
-	O
induced	O
responses	O
in	O
monocytes	O
.	O

Serum	O
-	O
equilibrated	O
PtdIns	O
also	O
binds	O
to	O
mCD14-expressing	O
cells	O
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	O
ligands	O
in	O
vivo	O
.	O

Low	O
CD3+CD28-induced	O
interleukin-2	O
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	O
T	O
cells	O
.	O

The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	O
interleukin-2	O
(	O
IL-2	O
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O

We	O
analysed	O
IL-2	O
production	O
in	O
purified	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor	O
-	O
mediated	O
anti	O
-	O
CD3	O
/anti	O
-	O
CD3	O
+	O
anti	O
-	O
CD28	O
stimulation	O
.	O

PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL-2	O
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate	O
-	O
bound	O
anti	O
-	O
CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
the	O
IL-2	O
secretion	O
by	O
neonatal	O
cells	O
was	O
undetectable	O
and	O
adult	O
cells	O
produced	O
low	O
amounts	O
of	O
IL-2	O
(	O
mean	O
331	O
+	O
/-	O
86	O
pg	O
/	O
ml	O
)	O
.	O

The	O
addition	O
of	O
anti	O
-	O
CD28	O
mAb	O
to	O
anti	B
-	I
CD3-stimulated	I
cells	I
markedly	O
increased	O
IL-2	O
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	O
in	O
neonatal	O
T	O
cells	O
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	O
T	O
cells	O
(	O
respective	O
mean	O
values	O
:	O
385	O
+	O
/-	O
109	O
pg	O
/	O
ml	O
and	O
4494	O
+	O
/-	O
1199	O
pg	O
/	O
ml	O
)	O
.	O

As	O
NF	O
-	O
kappa	O
B	O
is	O
a	O
critical	O
transcription	O
factor	O
in	O
the	O
control	O
of	O
IL-2	O
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI	O
-	O
reactive	O
fluorochrome	O
DCFH	O
-	O
DA	O
and	O
flow	O
cytometry	O
.	O

In	O
neonatal	O
T	O
cells	O
NF	O
-	O
kappa	O
B	O
activation	O
and	O
ROI	O
formation	O
after	O
anti	O
-	O
CD3	O
stimulation	O
were	O
low	O
compared	O
with	O
adult	O
T	O
cells	O
and	O
,	O
although	O
addition	O
of	O
anti	O
-	O
CD28	O
mAb	O
increased	O
induction	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
ROI	O
formation	O
,	O
levels	O
similar	O
to	O
those	O
of	O
adults	O
were	O
not	O
achieved	O
.	O

After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL-2	O
secretion	O
.	O

Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	O
production	O
by	O
neonatal	O
T	O
cells	O
is	O
specific	O
for	O
anti	O
-	O
CD3	O
and	O
anti	O
-	O
CD3	O
+	O
anti	O
-	O
CD28	O
-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI	O
-NF	O
-	O
kappa	O
B	O
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O

The	O
AD1	O
and	O
AD2	O
transactivation	O
domains	O
of	O
E2A	O
are	O
essential	O
for	O
the	O
antiapoptotic	O
activity	O
of	O
the	O
chimeric	O
oncoprotein	O
E2A	O
-	O
HLF	O
.	O

The	O
chimeric	O
oncoprotein	O
E2A	O
-	O
HLF	O
,	O
generated	O
by	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
chromosomal	O
translocation	O
in	O
pro	O
-	O
B	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
,	O
incorporates	O
the	O
transactivation	O
domains	O
of	O
E2A	O
and	O
the	O
basic	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
DNA	O
-	O
binding	O
and	O
protein	O
dimerization	O
domain	O
of	O
HLF	O
(	O
hepatic	O
leukemic	O
factor	O
)	O
.	O

The	O
ability	O
of	O
E2A	O
-	O
HLF	O
to	O
prolong	O
the	O
survival	O
of	O
interleukin-3	B
(	I
IL-3	I
)	I
-dependent	I
murine	I
pro	I
-	I
B	I
cells	I
after	O
IL-3	O
withdrawal	O
suggests	O
that	O
it	O
disrupts	O
signaling	O
pathways	O
normally	O
responsible	O
for	O
cell	O
suicide	O
,	O
allowing	O
the	O
cells	O
to	O
accumulate	O
as	O
transformed	O
lymphoblasts	O
.	O

To	O
determine	O
the	O
structural	O
motifs	O
that	O
contribute	O
to	O
this	O
antiapoptotic	O
effect	O
,	O
we	O
constructed	O
a	O
panel	O
of	O
E2A	O
-	O
HLF	O
mutants	O
and	O
programmed	O
their	O
expression	O
in	O
IL-3-dependent	B
murine	I
pro	I
-	I
B	I
cells	I
(	O
FL5.12	B
line	I
)	O
,	O
using	O
a	O
zinc	O
-	O
inducible	O
vector	O
.	O

Neither	O
the	O
E12	O
nor	O
the	O
E47	O
product	O
of	O
the	O
E2A	O
gene	O
nor	O
the	O
wild	O
-	O
type	O
HLF	O
protein	O
was	O
able	O
to	O
protect	O
the	O
cells	O
from	O
apoptosis	O
induced	O
by	O
IL-3	O
deprivation	O
.	O

Surprisingly	O
,	O
different	O
combinations	O
of	O
disabling	O
mutations	O
within	O
the	O
HLF	O
bZIP	O
domain	O
had	O
little	O
effect	O
on	O
the	O
antiapoptotic	O
property	O
of	O
the	O
chimeric	O
protein	O
,	O
so	O
long	O
as	O
the	O
amino	O
-	O
terminal	O
portion	O
of	O
E2A	O
remained	O
intact	O
.	O

In	O
the	O
context	O
of	O
a	O
bZIP	O
domain	O
defective	O
in	O
DNA	O
binding	O
,	O
mutants	O
retaining	O
either	O
of	O
the	O
two	O
transactivation	O
domains	O
of	O
E2A	O
were	O
able	O
to	O
extend	O
cell	O
survival	O
after	O
growth	O
factor	O
deprivation	O
.	O

Thus	O
,	O
the	O
block	O
of	O
apoptosis	O
imposed	O
by	O
E2A	O
-	O
HLF	O
in	O
pro	O
-	O
B	O
lymphocytes	O
depends	O
critically	O
on	O
the	O
transactivating	O
regions	O
of	O
E2A	O
.	O

Since	O
neither	O
DNA	O
binding	O
nor	O
protein	O
dimerization	O
through	O
the	O
bZIP	O
domain	O
of	O
HLF	O
is	O
required	O
for	O
this	O
effect	O
,	O
we	O
propose	O
mechanisms	O
whereby	O
protein	O
-	O
protein	O
interactions	O
with	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
E2A	O
allow	O
the	O
chimera	O
to	O
act	O
as	O
a	O
transcriptional	O
cofactor	O
to	O
alter	O
the	O
expression	O
of	O
genes	O
regulating	O
the	O
apoptotic	O
machinery	O
in	O
pro	O
-	O
B	O
cells	O
.	O

Altered	O
DNA	O
-	O
binding	O
specificity	O
mutants	O
of	O
EKLF	O
and	O
Sp1	O
show	O
that	O
EKLF	O
is	O
an	O
activator	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
in	O
vivo	O
.	O

The	O
locus	O
control	O
region	O
of	O
the	O
beta	O
-	O
globin	O
cluster	O
contains	O
five	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
5'HS1	O
-	O
5	O
)	O
required	O
for	O
locus	O
activation	O
.	O

5'HS3	O
contains	O
six	O
G	O
-	O
rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	O
fingers	O
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	O
factor	O
Sp1	O
,	O
interact	O
with	O
these	O
motifs	O
.	O

Because	O
point	O
mutagenesis	O
can	O
not	O
distinguish	O
between	O
family	O
members	O
,	O
it	O
is	O
not	O
known	O
which	O
protein	O
activates	O
5'HS3	O
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	O
fingers	O
of	O
Sp1	O
and	O
EKLF	O
.	O

Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	O
is	O
a	O
direct	O
activator	O
of	O
5'HS3	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
FY*B	O
allele	O
of	O
the	O
Duffy	O
chemokine	O
receptor	O
gene	O
is	O
associated	O
with	O
an	O
altered	O
erythrocyte	O
phenotype	O
.	O

The	O
Duffy	O
blood	O
group	O
system	O
is	O
of	O
clinical	O
and	O
biological	O
significance	O
.	O

Antibodies	O
to	O
Duffy	O
antigens	O
are	O
responsible	O
for	O
some	O
cases	O
of	O
transfusion	O
incompatibility	O
and	O
newborn	O
hemolytic	O
disease	O
.	O

The	O
Duffy	O
protein	O
is	O
a	O
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
erythrocyte	O
-	O
binding	O
protein	O
and	O
is	O
also	O
a	O
receptor	O
for	O
various	O
chemokines	O
(	O
thus	O
renamed	O
Duffy	O
Antigen	O
Receptor	O
for	O
Chemokines	O
[	O
DARC	O
]	O
)	O
.	O

The	O
two	O
Duffy	O
polymorphic	O
antigens	O
,	O
Fya	O
and	O
Fyb	O
(	O
coded	O
by	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
)	O
,	O
are	O
present	O
on	O
erythrocyte	O
membranes	O
.	O

The	O
Fy	O
(	O
a	O
-	O
b-	O
)	O
phenotype	O
is	O
the	O
predominant	O
one	O
in	O
populations	O
of	O
black	O
people	O
and	O
also	O
occurs	O
in	O
other	O
populations	O
,	O
including	O
some	O
non	O
-	O
Ashkenazi	O
Jewish	O
groups	O
.	O

The	O
Fy	O
(	O
a	O
-	O
b-	O
)	O
phenotype	O
has	O
been	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
FY*B	O
promoter	O
at	O
the	O
GATA	O
box	O
that	O
abolishes	O
the	O
expression	O
of	O
erythrocyte	O
Duffy	O
protein	O
.	O

We	O
describe	O
here	O
a	O
novel	O
mutation	O
,	O
present	O
in	O
the	O
FY*B	O
coding	O
sequence	O
(	O
271C	O
--	O
>	O
T	O
)	O
,	O
that	O
is	O
associated	O
with	O
some	O
Fy	O
(	O
b-	O
)	O
phenotypes	O
among	O
non	O
-	O
Ashkenazi	O
Jews	O
and	O
among	O
Brazilian	O
blacks	O
.	O

The	O
mutation	O
is	O
present	O
in	O
Fy	O
(	O
b-	O
)	O
individuals	O
,	O
who	O
have	O
wild	O
-	O
type	O
FY*B	O
GATA	O
and	O
carry	O
the	O
previously	O
described	O
304	O
G	O
--	O
>	O
A	O
substitution	O
.	O

The	O
271C	O
--	O
>	O
T	O
and	O
304	O
G	O
--	O
>	O
A	O
can	O
be	O
identified	O
by	O
restriction	O
enzyme	O
-	O
generated	O
restriction	O
fragment	O
length	O
polymorphisms	O
.	O

The	O
271C	O
--	O
>	O
T	O
substitution	O
represents	O
a	O
considerable	O
change	O
in	O
chemical	O
nature	O
(	O
Arg91	O
--	O
>	O
Cys	O
)	O
,	O
one	O
which	O
may	O
affect	O
the	O
antigenic	O
determinants	O
of	O
DARC	O
,	O
and	O
thus	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
mutation	O
may	O
have	O
implications	O
for	O
some	O
physiological	O
roles	O
of	O
DARC	O
and	O
be	O
of	O
interest	O
in	O
malaria	O
research	O
and	O
in	O
studies	O
of	O
population	O
genetics	O
.	O

BCL-6	O
mutations	O
in	O
normal	O
germinal	O
center	O
B	O
cells	O
:	O
evidence	O
of	O
somatic	O
hypermutation	O
acting	O
outside	O
Ig	O
loci	O
.	O

The	O
molecular	O
mechanism	O
involved	O
in	O
the	O
process	O
of	O
antigen	O
-	O
driven	O
somatic	O
hypermutation	O
of	O
Ig	O
genes	O
is	O
unknown	O
,	O
but	O
it	O
is	O
commonly	O
believed	O
that	O
this	O
mechanism	O
is	O
restricted	O
to	O
the	O
Ig	O
loci	O
.	O

B	O
cell	O
lymphomas	O
commonly	O
display	O
multiple	O
somatic	O
mutations	O
clustering	O
in	O
the	O
5'-regulatory	O
region	O
of	O
BCL-6	O
,	O
a	O
proto	O
-	O
oncogene	O
encoding	O
for	O
a	O
POZ	O
/	O
Zinc	O
finger	O
transcriptional	O
repressor	O
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
cells	O
and	O
required	O
for	O
GC	O
formation	O
.	O

To	O
determine	O
whether	O
BCL-6	O
mutations	O
represent	O
a	O
tumor	O
-	O
associated	O
phenomenon	O
or	O
reflect	O
a	O
physiologic	O
mechanism	O
,	O
we	O
screened	O
single	O
human	O
tonsillar	O
GC	O
B	O
cells	O
for	O
mutations	O
occurring	O
in	O
the	O
BCL-6	O
5'-noncoding	O
region	O
and	O
in	O
the	O
Ig	O
variable	O
heavy	O
chain	O
sequences	O
.	O

Thirty	O
percent	O
of	O
GC	O
B	O
cells	O
,	O
but	O
not	O
naive	O
B	O
cells	O
,	O
displayed	O
mutations	O
in	O
the	O
742	O
bp	O
region	O
analyzed	O
within	O
the	O
first	O
intron	O
of	O
BCL-6	O
(	O
overall	O
frequency	O
:	O
5	O
x	O
10	O
(	O
-4	O
)	O
/bp	O
)	O
.	O

Accordingly	O
,	O
an	O
expanded	O
survey	O
in	O
lymphoid	O
malignancies	O
showed	O
that	O
BCL-6	O
mutations	O
are	O
restricted	O
to	O
B	O
cell	O
tumors	O
displaying	O
GC	O
or	O
post	O
-	O
GC	O
phenotype	O
and	O
carrying	O
mutated	O
Ig	O
variable	O
heavy	O
chain	O
sequences	O
.	O

These	O
results	O
indicate	O
that	O
the	O
somatic	O
hypermutation	O
mechanism	O
active	O
in	O
GC	O
B	O
cells	O
physiologically	O
targets	O
non	O
-	O
Ig	O
sequences	O
.	O

Transcription	O
factor	O
activation	O
in	O
lymphokine	O
activated	O
killer	O
cells	O
and	O
lymphocytes	O
from	O
patients	O
receiving	O
IL-2	O
immunotherapy	O
.	O

Administration	O
of	O
the	O
cytokine	O
interleukin-2	O
(	O
IL-2	O
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP-1	O
,	O
Sp1	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL-2	O
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel	O
-	O
shift	O
assay	O
.	O

An	O
in	O
vitro	O
surrogate	O
of	O
IL-2	O
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
healthy	O
individuals	O
in	O
IL-2	O
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine	O
-activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O

One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O

Prior	O
to	O
in	O
vivo	O
IL-2	O
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	O
factors	O
in	O
PBMC	O
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	O
from	O
healthy	O
individuals	O
.	O

Over	O
a	O
3-week	O
course	O
of	O
IL-2	O
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	O
patterns	O
of	O
AP-1	O
,	O
Sp1	O
,	O
and	O
NF	O
-	O
kappaB	O
proteins	O
changed	O
to	O
resemble	O
those	O
seen	O
in	O
PBMC	O
activated	O
by	O
IL-2	O
in	O
vitro	O
.	O

However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2	O
-treated	O
patients	O
did	O
not	O
have	O
low	O
-	O
level	O
constitutive	O
expression	O
of	O
STAT	O
binding	O
factors	O
as	O
did	O
LAK	O
cells	O
.	O

When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL-2	O
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	O
induction	O
patterns	O
were	O
noted	O
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	O
cells	O
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	O
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	O
a	O
precise	O
congruence	O
between	O
PBMC	O
activated	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
IL-2	O
.	O

Position	O
effect	O
of	O
translocations	O
involving	O
the	O
inactive	O
X	O
chromosome	O
:	O
physical	O
linkage	O
to	O
XIC	O
/	O
XIST	O
does	O
not	O
lead	O
to	O
long	O
-	O
range	O
de	O
novo	O
inactivation	O
in	O
human	O
differentiated	O
cells	O
.	O

Given	O
the	O
reported	O
long	O
-	O
range	O
cis	O
-	O
inactivating	O
effect	O
of	O
the	O
XIST	O
gene	O
in	O
early	O
embryonic	O
development	O
and	O
the	O
lack	O
of	O
requirement	O
of	O
X	O
-	O
chromosome	O
-	O
specific	O
elements	O
for	O
propagating	O
the	O
inactive	O
state	O
,	O
there	O
exists	O
the	O
possibility	O
of	O
cis	O
inactivation	O
of	O
autosomal	O
material	O
after	O
de	O
novo	O
translocation	O
to	O
an	O
inactive	O
X	O
chromosome	O
(	O
Xi	O
)	O
in	O
differentiated	O
cells	O
.	O

We	O
have	O
analyzed	O
de	O
novo	O
radiation	O
-	O
induced	O
translocations	O
between	O
the	O
Xi	O
and	O
autosomes	O
to	O
study	O
the	O
maintenance	O
and	O
spreading	O
of	O
X	O
-	O
chromosome	O
inactivation	O
(	O
X	O
inactivation	O
)	O
in	O
relation	O
to	O
the	O
position	O
of	O
the	O
X	O
-	O
inactivation	O
center	O
(	O
XIC	O
)	O
/XIST	O
in	O
differentiated	O
cells	O
.	O

Autosome	O
/	O
Xi	O
translocations	O
were	O
detected	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

The	O
activation	O
status	O
of	O
the	O
chromosomes	O
involved	O
in	O
the	O
translocation	O
was	O
determined	O
by	O
simultaneous	O
immunocytogenetic	O
studies	O
using	O
antibodies	O
against	O
either	O
BrdU	O
incorporated	O
at	O
late	O
S	O
phase	O
or	O
acetylated	O
histone	O
H4	O
.	O

The	O
position	O
of	O
XIC	O
/	O
XIST	O
in	O
the	O
reciprocal	O
products	O
of	O
the	O
translocation	O
was	O
determined	O
by	O
XIST	O
-	O
specific	O
FISH	O
and	O
computer	O
enhancement	O
.	O

In	O
other	O
experiments	O
,	O
the	O
Xq13	O
region	O
carrying	O
XIC	O
/	O
XIST	O
was	O
localized	O
by	O
computer	O
enhancement	O
of	O
the	O
DAPI	O
banding	O
pattern	O
.	O

Our	O
study	O
in	O
differentiated	O
cells	O
provides	O
a	O
visual	O
demonstration	O
that	O
physical	O
separation	O
from	O
XIC	O
/	O
XIST	O
does	O
not	O
result	O
in	O
reactivation	O
of	O
inactive	O
X	O
-	O
chromosome	O
material	O
and	O
that	O
X	O
inactivation	O
is	O
not	O
spread	O
to	O
the	O
translocated	O
autosomes	O
irrespective	O
of	O
the	O
position	O
of	O
XIC	O
/	O
XIST	O
.	O

This	O
observation	O
suggests	O
that	O
physical	O
linkage	O
to	O
XIC	O
/	O
XIST	O
does	O
not	O
lead	O
to	O
de	O
novo	O
inactivation	O
of	O
autosomal	O
material	O
.	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
chain	O
/	O
CD25	O
promoter	O
is	O
a	O
target	O
for	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
expression	O
of	O
the	O
murine	O
interleukin	O
(	O
IL	O
)	O
-2	O
receptor	O
alpha	O
chain	O
/	O
CD25	O
is	O
strongly	O
induced	O
at	O
the	O
transcriptional	O
level	O
after	O
T	O
cell	O
activation	O
.	O

We	O
show	O
here	O
that	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NF	O
-	O
AT	O
)	O
factors	O
are	O
involved	O
in	O
the	O
control	O
of	O
CD25	O
promoter	O
induction	O
in	O
T	O
cells	O
.	O

NF	O
-	O
ATp	O
and	O
NF	O
-	O
ATc	O
bind	O
to	O
two	O
sites	O
around	O
positions	O
-585	O
and	O
-650	O
located	O
upstream	O
of	O
the	O
proximal	O
CD25	O
promoter	O
.	O

Immediately	O
3	O
'	O
from	O
these	O
NF	O
-	O
AT	O
motifs	O
,	O
nonconsensus	O
sites	O
are	O
located	O
for	O
the	O
binding	O
of	O
AP-1-like	O
factors	O
.	O

Mutations	O
of	O
sites	O
that	O
suppress	O
NF	O
-	O
AT	O
binding	O
impair	O
the	O
induction	O
and	O
strong	O
NF	O
-	O
ATp	O
-mediated	O
transactivation	O
of	O
the	O
CD25	O
promoter	O
in	O
T	O
cells	O
.	O

In	O
T	O
lymphocytes	O
from	O
NF	O
-	O
ATp	O
-deficient	O
mice	O
,	O
the	O
expression	O
of	O
CD25	O
is	O
severely	O
impaired	O
,	O
leading	O
to	O
a	O
delayed	O
IL-2	O
receptor	O
expression	O
after	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
/	O
CD3	O
stimulation	O
.	O

Our	O
data	O
indicate	O
an	O
important	O
role	O
for	O
NF	O
-	O
AT	O
in	O
the	O
faithful	O
expression	O
of	O
high	O
affinity	O
IL-2	O
receptors	O
and	O
a	O
close	O
link	O
between	O
the	O
TCR	O
-mediated	O
induction	O
of	O
IL-2	O
and	O
IL-2	O
receptor	O
alpha	O
chain	O
promoters	O
,	O
both	O
of	O
which	O
are	O
regulated	O
by	O
NF	O
-	O
AT	O
factors	O
.	O

Analysis	O
of	O
cytokine	O
signaling	O
in	O
patients	O
with	O
extrinsic	O
asthma	O
and	O
hyperimmunoglobulin	O
E	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
class	O
switching	O
to	O
IgE	O
by	O
cytokines	O
is	O
mediated	O
by	O
STAT	O
transcription	O
factors	O
.	O

The	O
induction	O
of	O
IgE	O
by	O
IL-4	O
and	O
IL-13	O
occurs	O
through	O
the	O
activation	O
of	O
the	O
intracellular	O
signal	O
-	O
transducing	O
protein	O
Stat6	O
,	O
whereas	O
the	O
inhibition	O
of	O
IgE	O
class	O
switching	O
by	O
interferon	O
-	O
y	O
(	O
IFN	O
-	O
gamma	O
)	O
occurs	O
through	O
the	O
activation	O
of	O
Statl	O
.	O

OBJECTIVE	O
:	O
We	O
hypothesized	O
that	O
in	O
extrinsic	O
asthma	O
or	O
in	O
cases	O
of	O
markedly	O
elevated	O
IgE	O
(	O
ie	O
,	O
hyperimmunoglobulin	O
E	O
[	O
HIE	O
]	O
)	O
increased	O
levels	O
of	O
IgE	O
may	O
be	O
associated	O
with	O
alterations	O
in	O
the	O
cytokine	O
levels	O
or	O
the	O
activation	O
of	O
Stat6	O
.	O

METHODS	O
:	O
PBMCs	O
and	O
sera	O
from	O
8	O
patients	O
with	O
extrinsic	O
asthma	O
(	O
mean	O
IgE	O
,	O
285+	O
/	O
-100	O
IU	O
/	O
mL	O
)	O
,	O
3	O
patients	O
with	O
HIE	O
(	O
mean	O
IgE	O
,	O
7050+	O
/	O
-1122	O
IU	O
/	O
mL	O
)	O
,	O
and	O
14	O
nonatopic	O
control	O
subjects	O
(	O
mean	O
IgE	O
,	O
112+	O
/	O
-28	O
IU	O
/	O
mL	O
)	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
mean	O
IL-4	O
level	O
detected	O
by	O
ELISA	O
was	O
much	O
greater	O
in	O
patients	O
with	O
HIE	O
than	O
control	O
subjects	O
(	O
88.6+	O
/	O
-11.5	O
pg	O
/	O
mL	O
vs	O
11.5+	O
/	O
-7.1	O
pg	O
/	O
mL	O
,	O
P	O
=	O
.005	O
)	O
,	O
and	O
increased	O
IL-4	O
levels	O
among	O
patients	O
with	O
both	O
asthma	O
and	O
HIE	O
correlated	O
with	O
the	O
increased	O
IgE	O
levels	O
.	O

In	O
contrast	O
,	O
IL-13	O
levels	O
were	O
not	O
elevated	O
.	O

Levels	O
of	O
Stat6	O
protein	O
present	O
in	O
PBMCs	O
did	O
not	O
differ	O
in	O
the	O
patients	O
and	O
control	O
subjects	O
.	O

Examination	O
of	O
Stat6	O
DNA	O
-	O
binding	O
activity	O
demonstrated	O
no	O
activation	O
of	O
IL-4	O
signaling	O
in	O
patients	O
with	O
either	O
HIE	O
or	O
acute	O
asthma	O
.	O

Interestingly	O
,	O
evidence	O
for	O
the	O
presence	O
of	O
B	O
cells	O
that	O
have	O
already	O
switched	O
to	O
IgE	O
was	O
seen	O
in	O
PBMCs	O
of	O
several	O
patients	O
with	O
asthma	O
or	O
HIE	O
.	O

CONCLUSION	O
:	O
These	O
results	O
indicate	O
that	O
(	O
1	O
)	O
IgE	O
production	O
in	O
asthma	O
and	O
HIE	O
usually	O
is	O
associated	O
with	O
elevated	O
levels	O
of	O
IL-4	O
,	O
but	O
not	O
IL-13	O
,	O
in	O
the	O
peripheral	O
blood	O
;	O
(	O
2	O
)	O
the	O
increased	O
sera	O
IL-4	O
levels	O
in	O
asthma	O
and	O
HIE	O
are	O
not	O
sufficient	O
to	O
induce	O
Stat6	O
activation	O
in	O
PBMCs	O
;	O
and	O
(	O
3	O
)	O
evidence	O
of	O
switch	O
recombination	O
to	O
epsilon	O
may	O
be	O
detected	O
in	O
isolated	O
cases	O
of	O
elevated	O
IgE	O
.	O

This	O
implies	O
that	O
high	O
levels	O
of	O
IgE	O
in	O
these	O
patients	O
either	O
results	O
from	O
B	O
cells	O
that	O
have	O
already	O
undergone	O
class	O
switching	O
,	O
from	O
Ig	O
class	O
switching	O
that	O
is	O
localized	O
to	O
target	O
tissues	O
,	O
or	O
both	O
.	O

GATA-3	O
-dependent	O
enhancer	O
activity	O
in	O
IL-4	O
gene	O
regulation	O
.	O

Previously	O
,	O
we	O
analyzed	O
the	O
proximal	O
IL-4	O
promoter	O
in	O
directing	O
Th2-specific	O
activity	O
.	O

An	O
800-base	O
pair	O
proximal	O
promoter	O
conferred	O
some	O
Th2-selective	O
expression	O
in	O
transgenic	O
mice	O
.	O

However	O
,	O
this	O
region	O
directed	O
extremely	O
low	O
reporter	O
mRNA	O
levels	O
relative	O
to	O
endogenous	O
IL-4	O
mRNA	O
,	O
suggesting	O
that	O
full	O
gene	O
activity	O
requires	O
additional	O
enhancer	O
elements	O
.	O

Here	O
,	O
we	O
analyzed	O
large	O
genomic	O
IL-4	O
regions	O
for	O
enhancer	O
activity	O
and	O
interaction	O
with	O
transcription	O
factors	O
.	O

The	O
proximal	O
IL-4	O
promoter	O
is	O
only	O
moderately	O
augmented	O
by	O
GATA-3	O
,	O
but	O
certain	O
genomic	O
regions	O
significantly	O
enhanced	O
GATA-3	O
promoter	O
transactivation	O
.	O

Some	O
enhancing	O
regions	O
contained	O
consensus	O
,	O
GATA	O
sites	O
that	O
bound	O
Th2-specific	O
complexes	O
.	O

However	O
,	O
retroviral	O
transduction	O
of	O
GATA-3	O
into	O
developing	O
T	O
cells	O
induced	O
IL-5	O
to	O
full	O
Th2	O
levels	O
,	O
but	O
only	O
partially	O
restored	O
IL-4	O
production	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
GATA-3	O
is	O
permissive	O
,	O
but	O
not	O
sufficient	O
,	O
for	O
full	O
IL-4	O
enhancement	O
and	O
may	O
act	O
through	O
GATA	O
elements	O
surrounding	O
the	O
IL-13	O
/	O
IL-4	O
gene	O
locus	O
.	O

Downstream	O
activation	O
of	O
a	O
TATA	O
-	O
less	O
promoter	O
by	O
Oct-2	O
,	O
Bob1	O
,	O
and	O
NF	O
-	O
kappaB	O
directs	O
expression	O
of	O
the	O
homing	O
receptor	O
BLR1	O
to	O
mature	O
B	O
cells	O
.	O

The	O
chemokine	O
receptor	O
,	O
BLR1	O
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O

In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA	O
-	O
less	O
blr1	O
core	O
promoter	O
that	O
confer	O
cell	O
type-	O
and	O
differentiation	O
-	O
specific	O
expression	O
in	O
the	O
B	O
cells	O
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	O
promoter	O
region	O
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	O
start	O
site	O
)	O
,	O
a	O
NF	O
-	O
kappaB	O
motif	O
(	O
+	O
44	O
)	O
,	O
and	O
a	O
noncanonical	O
octamer	O
motif	O
(	O
+	O
157	O
)	O
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene	O
-	O
targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	O
,	O
Bob1	O
,	O
or	O
both	O
NF	O
-	O
kappaB	O
subunits	O
p50	O
and	O
p52	O
.	O

In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	O
of	O
BLR1	O
was	O
reduced	O
or	O
absent	O
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52	O
/	O
NF	O
-	O
kappaB	O
,	O
BLR1	O
expression	O
was	O
unaffected	O
.	O

Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	O
is	O
a	O
target	O
gene	O
for	O
Oct-2	O
,	O
Bob1	O
,	O
and	O
members	O
of	O
the	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	O
for	O
these	O
factors	O
.	O

c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
in	O
activated	O
cord	O
and	O
adult	O
lymphocytes	O
:	O
an	O
analysis	O
by	O
Northern	O
hybridization	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
To	O
further	O
analyze	O
the	O
neonatal	O
immune	O
response	O
to	O
an	O
antigenic	O
challenge	O
such	O
as	O
blood	O
transfusion	O
,	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
were	O
analyzed	O
in	O
twelve	O
in	O
-	O
vitro	O
-	O
stimulated	O
normal	O
cord	O
blood	O
and	O
ten	O
in	O
-	O
vitro	O
-	O
stimulated	O
normal	O
adult	O
peripheral	O
blood	O
lymphocyte	O
samples	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Lymphocyte	O
samples	O
were	O
stimulated	O
by	O
either	O
the	O
mitogen	O
phytohemagglutinin	O
(	O
PHA	O
)	O
or	O
the	O
monoclonal	O
antibody	O
alphaCD3	O
.	O

Proliferation	O
rate	O
and	O
Northern	O
blot	O
hybridization	O
were	O
employed	O
.	O

RESULTS	O
:	O
Cord	O
lymphocytes	O
revealed	O
a	O
greater	O
proliferation	O
rate	O
with	O
PHA	O
and	O
alphaCD3	O
than	O
adult	O
lymphocytes	O
(	O
p	O
=	O
0.0081	O
and	O
0.0023	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
Northern	O
blot	O
analysis	O
of	O
cord	O
and	O
adult	O
samples	O
revealed	O
similar	O
maximal	O
increases	O
in	O
c	O
-	O
fos	O
(	O
99+	O
/	O
-15	O
and	O
126+	O
/	O
-11	O
%	O
,	O
p	O
=	O
0.0126	O
)	O
and	O
c	O
-	O
jun	O
(	O
123+	O
/	O
-9	O
and	O
185+	O
/	O
-38	O
%	O
,	O
p	O
=	O
0.0291	O
)	O
mRNA	O
expression	O
,	O
respectively	O
,	O
as	O
early	O
as	O
15	O
min	O
post-	O
alphaCD3	O
stimulation	O
.	O

Adult	O
lymphocytes	O
showed	O
an	O
equivalent	O
increase	O
in	O
mRNA	O
expression	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
(	O
140+	O
/	O
-25	O
and	O
155+	O
/	O
-31	O
%	O
)	O
at	O
30	O
min	O
post-	O
PHA	O
stimulation	O
,	O
while	O
cord	O
lymphocyte	O
maximum	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
expression	O
(	O
82+	O
/	O
-6	O
and	O
142+	O
/	O
-12	O
%	O
)	O
occurred	O
at	O
15	O
min	O
post-	O
PHA	O
stimulation	O
(	O
c	O
-	O
fos	O
,	O
p	O
=	O
0.0354	O
;	O
c	O
-	O
jun	O
,	O
p	O
=	O
0.0112	O
)	O
.	O

CONCLUSION	O
:	O
Although	O
cord	O
lymphocyte	O
proliferation	O
rates	O
were	O
significantly	O
greater	O
than	O
those	O
of	O
adult	O
lymphocytes	O
following	O
stimulation	O
,	O
lymphocyte	O
activation	O
,	O
as	O
analyzed	O
by	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
mRNA	O
expression	O
,	O
appears	O
similar	O
in	O
both	O
cord	O
and	O
adult	O
samples	O
.	O

We	O
conclude	O
that	O
cord	O
lymphocyte	O
activation	O
exhibits	O
an	O
adult	O
-	O
type	O
profile	O
.	O

Identification	O
of	O
transcription	O
factors	O
expressed	O
during	O
ATRA	O
-	O
induced	O
neutrophil	O
differentiation	O
of	O
HL60	B
cells	I
.	O

A	O
recent	O
clinical	O
therapeutic	O
initiative	O
has	O
been	O
the	O
use	O
of	O
chemical	O
agents	O
which	O
induce	O
the	O
leukaemic	O
cells	O
to	O
overcome	O
their	O
block	O
in	O
differentiation	O
.	O

In	O
order	O
to	O
understand	O
this	O
block	O
the	O
cascade	O
of	O
molecular	O
events	O
needs	O
to	O
be	O
characterized	O
.	O

Haemopoietic	O
differentiation	O
is	O
ultimately	O
controlled	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
which	O
is	O
mediated	O
by	O
an	O
array	O
of	O
transcription	O
factors	O
.	O

Many	O
transcription	O
factors	O
contain	O
similar	O
structural	O
protein	O
sequences	O
,	O
and	O
we	O
have	O
used	O
an	O
RT	O
-	O
PCR	O
-	O
based	O
approach	O
to	O
isolate	O
sequences	O
,	O
from	O
transcription	O
factor	O
gene	O
families	O
which	O
share	O
similar	O
domains	O
.	O

Degenerate	O
primers	O
corresponding	O
to	O
the	O
TFIIIA	O
zinc	O
-	O
finger	O
consensus	O
amino	O
acid	O
sequences	O
and	O
to	O
the	O
POU	O
-	O
homeodomain	O
and	O
POU	O
-	O
specific	O
domain	O
were	O
used	O
to	O
amplify	O
genes	O
on	O
the	O
basis	O
that	O
they	O
contained	O
similarities	O
in	O
structural	O
motifs	O
shared	O
within	O
these	O
families	O
of	O
transcription	O
factors	O
.	O

A	O
serum	B
-	I
independent	I
HL60	I
cell	I
line	I
was	O
induced	O
towards	O
the	O
neutrophil	O
lineage	O
by	O
treatment	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
24	O
h	O
.	O

CD38	O
+	O
cells	O
committed	O
towards	O
this	O
lineage	O
were	O
enriched	O
and	O
a	O
population	O
of	O
these	O
cells	O
treated	O
with	O
dihydroxyvitamin	O
D3	O
to	O
induce	O
neutrophil	O
maturation	O
.	O

RNA	O
extracted	O
from	O
uninduced	O
,	O
ATRA	B
-	I
induced	I
CD38	I
+	I
cells	I
,	O
and	O
vitamin	B
D3	I
treated	I
maturing	I
cell	I
cultures	I
were	O
amplified	O
using	O
the	O
degenerate	O
primers	O
.	O

PCR	O
fragments	O
were	O
cloned	O
,	O
sequenced	O
,	O
clustered	O
into	O
homologous	O
groups	O
,	O
and	O
the	O
group	O
sequences	O
searched	O
on	O
the	O
GenBank	O
database	O
.	O

The	O
Oct	O
1	O
transcription	O
factor	O
,	O
and	O
a	O
very	O
close	O
homologue	O
,	O
KIAA0144	O
,	O
was	O
identified	O
using	O
the	O
POU	O
family	O
primers	O
.	O

The	O
zinc	O
-	O
finger	O
primers	O
identified	O
three	O
zinc	O
-	O
finger	O
genes	O
.	O

The	O
pattern	O
of	O
gene	O
expression	O
was	O
suggested	O
from	O
the	O
number	O
of	O
clones	O
in	O
each	O
group	O
at	O
neutrophil	O
commitment	O
and	O
maturation	O
.	O

The	O
differential	O
expression	O
of	O
the	O
genes	O
in	O
the	O
zinc	O
finger	O
and	O
POU	O
families	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
cascade	O
of	O
gene	O
expression	O
which	O
occurs	O
following	O
ATRA	O
-	O
induced	O
differentiation	O
.	O

Inhibition	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
in	O
human	O
cells	O
by	O
synthetic	O
DNA	O
-	O
binding	O
ligands	O
[	O
see	O
comments	O
]	O

Sequence	O
-	O
specific	O
DNA	O
-	O
binding	O
small	O
molecules	O
that	O
can	O
permeate	O
human	O
cells	O
potentially	O
could	O
regulate	O
transcription	O
of	O
specific	O
genes	O
.	O

Multiple	O
cellular	O
DNA	O
-	O
binding	O
transcription	O
factors	O
are	O
required	O
by	O
HIV	O
type	O
1	O
for	O
RNA	O
synthesis	O
.	O

Two	O
pyrrole	O
-	O
imidazole	O
polyamides	O
were	O
designed	O
to	O
bind	O
DNA	O
sequences	O
immediately	O
adjacent	O
to	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
Ets-1	O
,	O
lymphoid	O
-	O
enhancer	O
binding	O
factor	O
1	O
,	O
and	O
TATA	O
-	O
box	O
binding	O
protein	O
.	O

These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA	O
-	O
binding	O
of	O
each	O
transcription	O
factor	O
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell	O
-	O
free	O
assays	O
.	O

When	O
used	O
in	O
combination	O
,	O
the	O
polyamides	O
inhibit	O
virus	O
replication	O
by	O
>	O
99	O
%	O
in	O
isolated	O
human	O
peripheral	O
blood	O
lymphocytes	O
,	O
with	O
no	O
detectable	O
cell	O
toxicity	O
.	O

The	O
ability	O
of	O
small	O
molecules	O
to	O
target	O
predetermined	O
DNA	O
sequences	O
located	O
within	O
RNA	O
polymerase	O
II	O
promoters	O
suggests	O
a	O
general	O
approach	O
for	O
regulation	O
of	O
gene	O
expression	O
,	O
as	O
well	O
as	O
a	O
mechanism	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
.	O

Signalling	O
into	O
the	O
T	O
-	O
cell	O
nucleus	O
:	O
NFAT	O
regulation	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
plays	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
the	O
rapid	O
calcineurin	O
-dependent	O
translocation	O
of	O
NFAT	O
transcription	O
factors	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

This	O
translocation	O
process	O
coupled	O
to	O
the	O
subsequent	O
active	O
maintenance	O
of	O
NFAT	O
in	O
the	O
nucleus	O
compartment	O
is	O
critical	O
for	O
the	O
induction	O
of	O
expression	O
of	O
several	O
genes	O
encoding	O
cytokines	O
and	O
membrane	O
proteins	O
that	O
modulate	O
immune	O
responses	O
.	O

The	O
molecular	O
cloning	O
of	O
the	O
NFAT	O
family	O
of	O
transcription	O
factors	O
has	O
facilitated	O
rapid	O
progress	O
in	O
the	O
understanding	O
of	O
the	O
signalling	O
mechanisms	O
that	O
control	O
the	O
activity	O
of	O
NFAT	O
.	O

IL-7	O
reconstitutes	O
multiple	O
aspects	O
of	O
v	O
-	O
Abl	O
-mediated	O
signaling	O
.	O

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v	O
-	O
Abl	O
is	O
currently	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	O
and	O
IL-7	O
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	O
protein	O
kinase	O
(	O
JAK	O
)	O
1	O
,	O
JAK3	O
,	O
STAT5	O
,	O
and	O
STAT6	O
,	O
in	O
pre	O
-	O
B	O
cells	O
transformed	O
by	O
v	O
-	O
Abl	O
.	O

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v	O
-	O
Abl	O
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL-4	O
and	O
IL-7	O
on	O
pre	O
-	O
B	O
cells	O
transformed	O
with	O
a	O
temperature	O
-	O
sensitive	O
v	O
-	O
Abl	O
mutant	O
were	O
examined	O
.	O

Whereas	O
IL-4	O
had	O
little	O
or	O
no	O
effect	O
,	O
IL-7	O
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v	O
-	O
Abl	O
kinase	O
inactivation	O
.	O

IL-7	O
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c	O
-	O
Myc	O
,	O
Bcl-2	O
,	O
and	O
Bcl	O
-	O
xL	O
that	O
occur	O
upon	O
loss	O
of	O
v	O
-	O
Abl	O
kinase	O
activity	O
.	O

IL-7	O
did	O
not	O
maintain	O
v	O
-	O
Abl	O
-mediated	O
differentiation	O
arrest	O
of	O
the	O
pre	O
-	O
B	O
cells	O
,	O
as	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL-7	O
.	O

These	O
results	O
identify	O
a	O
potential	O
role	O
for	O
IL-7	O
signaling	O
pathways	O
in	O
transformation	O
by	O
v	O
-	O
Abl	O
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL-4	O
and	O
IL-7	O
signaling	O
can	O
not	O
substitute	O
for	O
an	O
active	O
v	O
-	O
Abl	O
kinase	O
in	O
transformed	O
pre	O
-	O
B	O
cells	O
.	O

Detection	O
of	O
oestrogen	O
receptor	O
variants	O
in	O
endometrium	O
,	O
myometrium	O
,	O
leiomyoma	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
:	O
comparison	O
to	O
variants	O
present	O
in	O
breast	O
cancer	O
.	O

Oestradiol	O
has	O
mitogenic	O
and	O
regulatory	O
effects	O
on	O
various	O
organs	O
and	O
cells	O
,	O
mediated	O
mainly	O
by	O
its	O
nuclear	O
receptor	O
(	O
ER	O
)	O
.	O

The	O
presence	O
of	O
aberrant	O
ER	O
forms	O
in	O
Oestrogen	O
-	O
dependent	O
tumours	O
has	O
been	O
discussed	O
in	O
correlation	O
with	O
tumour	O
progression	O
.	O

ER	O
variants	O
,	O
generated	O
by	O
alternative	O
splicing	O
,	O
have	O
been	O
detected	O
in	O
human	O
breast	O
cancer	O
,	O
but	O
also	O
in	O
normal	O
mammary	O
glands	O
,	O
therefore	O
their	O
role	O
in	O
tumorigenesis	O
has	O
been	O
questioned	O
.	O

We	O
have	O
investigated	O
,	O
by	O
the	O
use	O
of	O
the	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
amplification	O
technique	O
,	O
the	O
possible	O
existence	O
of	O
ER	O
variants	O
in	O
other	O
normal	O
oestrogen	O
target	O
organs	O
and	O
cells	O
,	O
such	O
as	O
uterus	O
(	O
myometrium	O
and	O
endometrium	O
)	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
in	O
a	O
benign	O
uterus	O
tumour	O
(	O
leiomyoma	O
)	O
.	O

We	O
have	O
detected	O
variant	O
ER	O
in	O
these	O
samples	O
and	O
have	O
compared	O
the	O
variant	O
profile	O
to	O
that	O
observed	O
in	O
breast	O
cancer	O
.	O

All	O
tissues	O
and	O
cells	O
studied	O
expressed	O
both	O
wild	O
-	O
type	O
ER	O
and	O
variant	O
species	O
.	O

Variant	O
forms	O
encompassed	O
ER	O
with	O
deletions	O
of	O
exons	O
2	O
,	O
5	O
and	O
7	O
.	O

Variants	O
with	O
exon	O
5	O
deleted	O
were	O
detected	O
only	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
in	O
breast	O
cancer	O
.	O

Variants	O
with	O
exons	O
2	O
and	O
7	O
deleted	O
were	O
present	O
in	O
all	O
specimens	O
tested	O
.	O

These	O
results	O
corroborate	O
previous	O
findings	O
that	O
the	O
presence	O
of	O
ER	O
variants	O
is	O
not	O
a	O
characteristic	O
of	O
breast	O
cancer	O
.	O

The	O
physiological	O
significance	O
and	O
possible	O
clinical	O
relevance	O
of	O
the	O
variant	O
ER	O
forms	O
remain	O
to	O
be	O
elucidated	O
.	O

Transcription	O
factor	O
NF	O
-	O
kappaB	O
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O

The	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
family	O
of	O
transcription	O
factors	O
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

This	O
review	O
discusses	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
family	O
in	O
general	O
and	O
the	O
association	O
of	O
NF	O
-	O
kappaB	O
activation	O
with	O
cellular	O
/	O
molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O

Lack	O
of	O
T	O
-	O
cell	O
-	O
mediated	O
recognition	O
of	O
the	O
fusion	O
region	O
of	O
the	O
pml	O
/	O
RAR	O
-	O
alpha	O
hybrid	O
protein	O
by	O
lymphocytes	O
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml	O
/	O
RAR	O
-	O
alpha	O
protein	O
,	O
expressed	O
by	O
acute	B
promyelocytic	I
leukemia	I
(	I
APL	I
)	I
cells	I
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B
T	I
cells	I
in	O
a	O
HLA	O
class	O
II	O
DR11-restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml	O
/	O
RAR	O
-	O
alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	O
DR11	O
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	O
blood	O
lymphocytes	O
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1	O
/	O
25	O
,	O
a	O
25-mer	O
pml	O
/	O
RAR	O
-	O
alpha	O
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

We	O
then	O
generated	O
new	O
donor	O
anti	B
-	I
pml	I
/	I
RAR	I
-	I
alpha	I
CD4	I
(	I
+	I
)	I
T	I
-	I
cell	I
clones	I
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1	O
/	O
25	O
.	O

One	O
clone	O
(	O
C3	B
/	I
5	I
,	I
CD3	I
(	I
+	I
)	I
,	I
CD4	I
(	I
+	I
)	I
,	I
CD8	I
(	I
-	I
)	I
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Clone	B
C3	I
/	I
5	I
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
)	O
production	O
when	O
challenged	O
with	O
autologous	B
lymphoblastic	I
cell	I
lines	I
pulsed	O
with	O
peptide	O
BCR1	O
/	O
25	O
.	O

C3	B
/	I
5	I
cells	I
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide	B
-	I
pulsed	I
lymphoblastic	I
cell	I
lines	I
and	O
peripheral	O
blood	O
lymphocytes	O
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O

APL	O
blasts	O
,	O
available	O
only	O
from	O
patients	O
F.R.	O
and	O
P.G.	O
,	O
were	O
not	O
lysed	O
by	O
C3	B
/	I
5	I
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1	O
/	O
25	O
.	O

Incubation	O
of	O
APL	B
cells	I
with	O
IFN	O
-	O
gamma	O
failed	O
to	O
induce	O
HLA	O
class	O
II	O
molecules	O
and	O
recognition	O
by	O
the	O
C3	B
/	I
5	I
clone	I
.	O

Since	O
APL	B
cells	I
do	O
not	O
express	O
HLA	O
class	O
II	O
molecules	O
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1	O
/	O
9	O
)	O
would	O
generate	O
a	O
CD8	O
/HLA	O
class	O
I	O
-restricted	O
response	O
.	O

No	O
peptide	B
-	I
specific	I
T	I
-	I
cell	I
line	I
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O

TAL1	O
and	O
LIM	O
-	O
only	O
proteins	O
synergistically	O
induce	O
retinaldehyde	O
dehydrogenase	O
2	O
expression	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	O
and	O
the	O
LIM	O
-	O
only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	O
and	O
LMO	O
are	O
highly	O
synergistic	O
in	O
T	O
-	O
cell	O
tumorigenesis	O
in	O
double	O
-	O
transgenic	O
mice	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	O
and	O
LMO	O
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	O
dehydrogenase	O
2	O
(	O
RALDH2	O
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T	B
-	I
ALL	I
cell	I
lines	I
that	O
coexpressed	O
TAL1	O
and	O
LMO	O
.	O

Exogenously	O
transfected	O
TAL1	O
and	O
LMO	O
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	O
expression	O
in	O
a	O
T	B
-	I
ALL	I
cell	I
line	I
,	O
HPB	B
-	I
ALL	I
,	O
not	O
expressing	O
endogeneous	O
TAL1	O
or	O
LMO	O
.	O

The	O
RALDH2	O
transcripts	O
in	O
T	O
-	O
ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	O
intron	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	O
binds	O
to	O
this	O
site	O
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	O
potentiated	O
the	O
induction	O
of	O
RALDH2	O
by	O
TAL1	O
and	O
LMO	O
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
TAL1	O
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	O
in	O
the	O
presence	O
of	O
LMO	O
and	O
GATA3	O
.	O

Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	O
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
in	O
T	O
-	O
ALL	O
.	O

In	O
this	O
case	O
,	O
TAL1	O
and	O
LMO	O
act	O
as	O
cofactors	O
for	O
GATA3	O
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	O

Thrombopoietin	O
and	O
its	O
receptor	O
.	O

Thrombopoietin	O
(	O
TPO	O
)	O
,	O
the	O
primary	O
physiological	O
regulator	O
of	O
platelet	O
production	O
,	O
was	O
initially	O
thought	O
to	O
be	O
a	O
lineage	O
-	O
specific	O
factor	O
acting	O
predominantly	O
on	O
megakaryocytopoiesis	O
.	O

Detailed	O
studies	O
establish	O
that	O
this	O
cytokine	O
mediates	O
biological	O
effects	O
on	O
a	O
broad	O
spectrum	O
of	O
hematopoietic	O
progenitor	O
cells	O
,	O
including	O
stem	O
cells	O
.	O

TPO	O
is	O
a	O
hormone	O
constitutively	O
produced	O
mainly	O
by	O
the	O
liver	O
and	O
kidney	O
.	O

Plasma	O
TPO	O
levels	O
are	O
regulated	O
by	O
the	O
platelet	O
and	O
megakaryocyte	O
mass	O
through	O
Mpl	O
receptor	O
binding	O
,	O
internalization	O
and	O
degradation	O
.	O

The	O
Mpl	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	O
receptor	O
superfamily	O
lacking	O
intrinsic	O
kinase	O
activity	O
.	O

Upon	O
ligand	O
-	O
induced	O
Mpl	O
homodimerization	O
,	O
the	O
major	O
signaling	O
events	O
for	O
proliferation	O
are	O
mediated	O
through	O
the	O
JAK2	O
/STAT5	O
pathway	O
,	O
while	O
differentiation	O
might	O
occur	O
through	O
a	O
prolonged	O
activation	O
of	O
the	O
MAPK	O
pathway	O
.	O

Preclinical	O
and	O
clinical	O
studies	O
demonstrate	O
the	O
potential	O
use	O
of	O
TPO	O
in	O
a	O
variety	O
of	O
contexts	O
,	O
but	O
it	O
is	O
too	O
early	O
to	O
evaluate	O
its	O
benefit	O
in	O
reducing	O
platelet	O
transfusion	O
.	O

Differential	O
activation	O
of	O
functionally	O
distinct	O
STAT5	O
proteins	O
by	O
IL-5	O
and	O
GM	O
-	O
CSF	O
during	O
eosinophil	O
and	O
neutrophil	O
differentiation	O
from	O
human	B
CD34	I
+	I
hematopoietic	I
stem	I
cells	I
.	O

Interleukin-5	O
(	O
IL-5	O
)	O
and	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
are	O
important	O
cytokines	O
for	O
the	O
proliferation	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
myeloid	O
lineages	O
.	O

The	O
JAK	O
/STAT	O
pathway	O
is	O
one	O
of	O
the	O
signaling	O
pathways	O
implicated	O
in	O
mediating	O
biological	O
responses	O
induced	O
by	O
these	O
cytokines	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
these	O
cytokines	O
predominantly	O
activate	O
an	O
80	O
kDa	O
STAT5	O
isoform	O
in	O
mature	O
granulocytes	O
.	O

To	O
better	O
understand	O
the	O
role	O
of	O
STAT	O
proteins	O
during	O
growth	O
and	O
differentiation	O
of	O
granulocytes	O
,	O
we	O
evaluated	O
differentiation	O
of	O
human	B
CD34	I
+	I
hematopoietic	I
stem	I
cells	I
ex	O
vivo	O
toward	O
eosinophils	O
and	O
neutrophils	O
.	O

Bandshift	O
experiments	O
showed	O
that	O
in	O
an	O
early	O
stage	O
of	O
both	O
differentiation	O
pathways	O
(	O
14	O
days	O
)	O
,	O
the	O
94	O
kDa	O
STAT5B	O
protein	O
was	O
activated	O
by	O
both	O
IL-5	O
(	O
eosinophil	O
lineage	O
)	O
and	O
GM	O
-	O
CSF	O
(	O
neutrophil	O
lineage	O
)	O
.	O

However	O
,	O
during	O
maturation	O
of	O
both	O
lineages	O
(	O
days	O
21	O
and	O
28	O
)	O
,	O
increased	O
expression	O
of	O
a	O
functionally	O
distinct	O
80	O
kDa	O
STAT5	O
isoform	O
was	O
observed	O
,	O
resulting	O
in	O
heterodimer	O
DNA	O
-	O
binding	O
complexes	O
containing	O
both	O
the	O
94	O
and	O
80	O
kDa	O
STAT5	O
proteins	O
.	O

The	O
finding	O
that	O
functionally	O
distinct	O
isoforms	O
of	O
STAT5	O
are	O
activated	O
during	O
the	O
early	O
and	O
late	O
differentiation	O
stages	O
of	O
granulocytes	O
suggests	O
that	O
they	O
might	O
be	O
involved	O
in	O
regulating	O
different	O
biological	O
functions	O
in	O
these	O
cells	O
.	O

Tpl-2	O
induces	O
IL-2	O
expression	O
in	O
T	B
-	I
cell	I
lines	I
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	O
and	O
NF	O
-	O
kappaB	O
.	O

The	O
Tpl-2	O
kinase	O
activates	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
and	O
induces	O
IL-2	O
expression	O
in	O
T	B
-	I
cell	I
lines	I
.	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	O
is	O
inhibited	O
by	O
mutant	O
signaling	O
molecules	O
that	O
inhibit	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
or	O
the	O
calcineurin	O
/NFAT	O
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	O
molecules	O
that	O
activate	O
these	O
pathways	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	O
and	O
the	O
calcineurin	O
/NFAT	O
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	O
.	O

The	O
activation	O
of	O
both	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	O
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL-2	O
promoter	O
whose	O
activation	O
by	O
Tpl-2	O
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
MEK1S218	O
/	O
222A	O
and	O
the	O
MEK1	O
/	O
MEK2	O
inhibitor	O
PD098059	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	O
is	O
MAPK	O
-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	O
by	O
Tpl-2	O
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	O
and	O
MEK2	O
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	O
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK	O
-dependent	O
.	O

Experiments	O
in	O
COS-1	B
and	O
EL-4	B
cells	I
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	O
is	O
NF	O
-	O
kappaB	O
.	O

While	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT	O
-	O
driven	O
minimal	O
promoter	O
by	O
Tpl-2	O
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
NFAT	O
delta418	O
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	O
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2	O
-mediated	O
NFAT	O
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin	O
-	O
dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	O
or	O
Bcl	O
-	O
X	O
(	O
L	O
)	O
.	O

Conserved	O
elements	O
containing	O
NF	O
-	O
E2	O
and	O
tandem	O
GATA	O
binding	O
sites	O
are	O
required	O
for	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
reorganization	O
within	O
the	O
human	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
.	O

Proper	O
expression	O
of	O
the	O
genes	O
of	O
the	O
human	O
beta	O
-	O
globin	O
gene	O
locus	O
requires	O
the	O
associated	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
.	O

Structurally	O
,	O
the	O
LCR	O
is	O
defined	O
by	O
the	O
presence	O
of	O
four	O
domains	O
of	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
.	O

These	O
domains	O
,	O
which	O
have	O
been	O
characterized	O
as	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
HSs	O
)	O
,	O
comprise	O
the	O
active	O
elements	O
of	O
the	O
LCR	O
.	O

The	O
major	O
focus	O
of	O
this	O
research	O
is	O
to	O
define	O
the	O
cis	O
-acting	O
elements	O
which	O
are	O
required	O
for	O
the	O
formation	O
of	O
these	O
domains	O
of	O
unique	O
chromatin	O
structure	O
.	O

Our	O
previous	O
investigations	O
on	O
the	O
formation	O
of	O
LCR	O
HS4	O
demonstrated	O
that	O
NF	O
-	O
E2	O
and	O
tandem	O
,	O
inverted	O
GATA	O
binding	O
sites	O
are	O
required	O
for	O
the	O
formation	O
of	O
the	O
native	O
HS	O
.	O

Similarly	O
arranged	O
NF	O
-	O
E2	O
and	O
tandem	O
GATA	O
sites	O
are	O
present	O
within	O
the	O
core	O
regions	O
of	O
the	O
other	O
human	O
LCR	O
HSs	O
and	O
are	O
evolutionarily	O
conserved	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
of	O
human	O
HSs	O
2	O
and	O
3	O
we	O
have	O
tested	O
the	O
hypothesis	O
that	O
these	O
NF	O
-	O
E2	O
and	O
GATA	O
sites	O
are	O
common	O
requirements	O
for	O
the	O
formation	O
of	O
all	O
LCR	O
HSs	O
.	O

We	O
find	O
that	O
mutation	O
of	O
these	O
elements	O
,	O
and	O
particularly	O
the	O
GATA	O
elements	O
,	O
results	O
in	O
a	O
decrease	O
or	O
complete	O
loss	O
of	O
DNase	O
I	O
hypersensitivity	O
.	O

These	O
data	O
imply	O
the	O
presence	O
of	O
common	O
structural	O
elements	O
within	O
the	O
core	O
of	O
each	O
LCR	O
HS	O
which	O
are	O
required	O
for	O
erythroid	O
-	O
specific	O
chromatin	O
structure	O
reorganization	O
.	O

Adaptor	O
function	O
for	O
the	O
Syk	O
kinases	O
-	O
interacting	O
protein	O
3BP2	O
in	O
IL-2	O
gene	O
activation	O
.	O

Syk	O
-	O
family	O
tyrosine	O
kinases	O
are	O
essential	O
for	O
lymphocyte	O
development	O
and	O
activation	O
.	O

Using	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
Syk	O
kinases	O
-	O
interacting	O
proteins	O
(	O
SKIPs	O
)	O
,	O
we	O
isolated	O
3BP2	O
,	O
an	O
Abl	O
SH3-interacting	O
protein	O
of	O
unknown	O
function	O
.	O

3BP2	O
was	O
selectively	O
expressed	O
in	O
hematopoietic	O
/	O
lymphoid	O
tissues	O
and	O
bound	O
via	O
its	O
SH2	O
domain	O
activated	O
Syk	O
-	O
family	O
kinases	O
in	O
mammalian	O
cells	O
,	O
including	O
in	O
antigen	O
receptor	O
-	O
stimulated	O
T	O
cells	O
.	O

In	O
addition	O
to	O
Zap-70	O
,	O
the	O
3BP2	O
SH2	O
domain	O
associated	O
in	O
vitro	O
with	O
LAT	O
,	O
Grb2	O
,	O
PLCgamma1	O
,	O
and	O
Cbl	O
from	O
activated	O
T	O
cell	O
lysates	O
.	O

Transient	O
3BP2	O
overexpression	O
induced	O
transcriptional	O
activation	O
of	O
the	O
IL-2	O
promoter	O
and	O
its	O
NFAT	O
or	O
AP-1	O
elements	O
.	O

This	O
activity	O
was	O
dependent	O
on	O
the	O
SH2	O
and	O
pleckstrin	O
-	O
homology	O
domains	O
of	O
3BP2	O
,	O
and	O
required	O
functional	O
Syk	O
kinases	O
,	O
Ras	O
,	O
and	O
calcineurin	O
.	O

Thus	O
,	O
3BP2	O
is	O
an	O
important	O
adaptor	O
that	O
may	O
couple	O
activated	O
Zap-70	O
/	O
Syk	O
to	O
a	O
LAT	O
-	O
containing	O
signaling	O
complex	O
involved	O
in	O
TCR	O
-	O
mediated	O
gene	O
transcription	O
.	O

Activation	O
of	O
human	O
macrophages	O
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

Positive	O
-	O
pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	O
cells	O
can	O
be	O
submitted	O
to	O
a	O
prolonged	B
cyclic	I
pressure	I
-	I
stretching	I
strain	I
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O

The	O
lung	O
macrophage	O
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
the	O
chemokines	O
interleukin	O
(	O
IL	O
)	O
-8	O
and	O
-6	O
,	O
and	O
matrix	O
metalloproteinase-9	O
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O

These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	O
alveolar	O
macrophages	O
,	O
monocyte	O
-	O
derived	O
macrophages	O
,	O
and	O
promonocytic	B
THP-1	I
cells	I
.	O

Nuclear	O
factor	O
-	O
kappaB	O
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O

Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	O
endotoxin	O
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O

Dexamethasone	O
prevented	O
IL-8	O
and	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
secretion	O
in	O
ventilated	O
macrophages	O
.	O

Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL-8	O
secretion	O
by	O
alveolar	O
type	O
II	O
-	O
like	O
cells	O
.	O

Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	O
cells	O
,	O
bronchial	O
cells	O
,	O
and	O
fibroblasts	O
failed	O
to	O
produce	O
IL-8	O
in	O
response	O
to	O
a	O
prolonged	O
cyclic	O
pressure	O
-	O
stretching	O
load	O
.	O

This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress	O
-	O
induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O

Constitutive	O
association	O
of	O
JAK1	O
and	O
STAT5	O
in	O
pro	O
-	O
B	O
cells	O
is	O
dissolved	O
by	O
interleukin-4	O
-induced	O
tyrosine	O
phosphorylation	O
of	O
both	O
proteins	O
.	O

The	O
bipartite	O
human	O
interleukin-4	O
(	O
IL-4	O
)	O
receptor	O
was	O
functionally	O
expressed	O
in	O
murine	O
pro	O
-	O
B	O
cells	O
and	O
activated	O
by	O
human	O
IL-4	O
to	O
evoke	O
intracellular	O
signaling	O
.	O

Mutual	O
association	O
of	O
signal	O
transducing	O
proteins	O
within	O
the	O
receptor	O
complex	O
was	O
then	O
studied	O
in	O
dependence	O
of	O
ligand	O
stimulation	O
.	O

Besides	O
ligand	O
-	O
induced	O
receptor	O
heterodimerization	O
and	O
contacts	O
of	O
the	O
two	O
IL-4	O
receptor	O
subunits	O
alpha	O
and	O
gamma	O
with	O
Janus	O
kinases	O
JAK1	O
and	O
JAK3	O
a	O
prominent	O
constitutive	O
binding	O
between	O
JAK1	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
STAT5	O
was	O
detected	O
.	O

Since	O
both	O
these	O
proteins	O
become	O
phosphorylated	O
in	O
response	O
to	O
IL-4	O
receptor	O
stimulation	O
,	O
the	O
influence	O
of	O
tyrosine	O
phosphorylation	O
on	O
their	O
mutual	O
contact	O
was	O
analyzed	O
.	O

Association	O
of	O
JAK1	O
and	O
STAT5	O
was	O
found	O
to	O
occur	O
exclusively	O
between	O
unphosphorylated	O
proteins	O
.	O

Interleukin-10	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
promoter	O
polymorphisms	O
in	O
allergies	O
and	O
asthma	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	O
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O

These	O
cytokines	O
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL-10	O
and	O
TGF	O
-	O
beta	O
gene	O
promoters	O
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O

DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single	O
-	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL-10	O
gene	O
and	O
four	O
in	O
the	O
TGF	O
-	O
beta	O
gene	O
promoters	O
(	O
3	O
in	O
TGF	O
-	O
beta1	O
and	O
1	O
in	O
TGF	O
-	O
beta2	O
)	O
.	O

The	O
IL-10	O
gene	O
polymorphism	O
was	O
a	O
C	O
-	O
to	O
-	O
A	O
exchange	O
571	O
base	O
pairs	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
and	O
was	O
present	O
between	O
consensus	O
binding	O
sequences	O
for	O
Sp1	O
and	O
elevated	O
total	O
serum	O
.	O

This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	O
serum	O
IgE	O
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0.009	O
)	O
.	O

The	O
base	O
exchange	O
at	O
-509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF	O
-	O
beta	O
promoter	O
also	O
linked	O
to	O
elevated	O
total	O
IgE	O
(	O
p	O
<	O
0.01	O
)	O
.	O

This	O
polymorphism	O
represented	O
a	O
C	O
-	O
to	O
-	O
T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	O
consensus	O
sequence	O
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

Isolation	O
and	O
utilization	O
of	O
human	O
dendritic	O
cells	O
from	O
peripheral	O
blood	O
to	O
assay	O
an	O
in	O
vitro	O
primary	O
immune	O
response	O
to	O
varicella	O
-	O
zoster	O
virus	O
peptides	O
.	O

A	O
human	O
dendritic	O
cell	O
-	O
based	O
assay	O
used	O
to	O
monitor	O
a	O
T	O
cell	O
proliferation	O
response	O
to	O
viral	O
peptides	O
in	O
vitro	O
is	O
described	O
.	O

Dendritic	O
cells	O
and	O
autologous	O
CD4	O
+	O
T	O
cells	O
were	O
isolated	O
from	O
peripheral	O
blood	O
by	O
a	O
series	O
of	O
density	O
-	O
gradient	O
centrifugations	O
or	O
magnetic	O
bead	O
separations	O
(	O
or	O
both	O
)	O
.	O

Peptides	O
corresponding	O
to	O
residues	O
of	O
the	O
immediate	O
early	O
protein	O
,	O
IE62	O
,	O
of	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)	O
were	O
used	O
as	O
stimulating	O
antigens	O
,	O
and	O
persons	O
with	O
no	O
history	O
of	O
varicella	O
and	O
no	O
humoral	O
or	O
cellular	O
immunity	O
to	O
VZV	O
served	O
as	O
naive	O
donors	O
for	O
the	O
assays	O
.	O

Three	O
VZV	O
-	O
susceptible	O
donors	O
were	O
tested	O
,	O
and	O
all	O
demonstrated	O
an	O
in	O
vitro	O
response	O
to	O
multiple	O
VZV	O
peptides	O
.	O

This	O
assay	O
has	O
potential	O
as	O
a	O
screen	O
to	O
establish	O
the	O
immunogenicity	O
of	O
viral	O
antigens	O
in	O
vitro	O
using	O
T	O
cells	O
from	O
naive	O
donors	O
.	O

The	O
modulation	O
of	O
glucocorticoid	O
receptor	O
content	O
by	O
3-O	O
-	O
methyl	O
-	O
D	O
-	O
glucose	O
transport	O
in	O
human	O
mononuclear	O
leukocyte	O
in	O
obesity	O
.	O

Glucocorticoid	O
receptors	O
(	O
GR	O
)	O
and	O
3-O	O
-	O
methyl	O
-	O
D	O
glucose	O
(	O
3-O	O
-	O
MG	O
)	O
transport	O
were	O
determined	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
from	O
11	O
abdominal	O
obese	O
subjects	O
,	O
10	O
pituitary	O
-	O
dependent	O
Cushing	O
's	O
syndrome	O
(	O
Cushing	O
's	O
disease	O
)	O
and	O
10	O
healthy	O
controls	O
.	O

Using	O
a	O
whole	O
-	O
cell	O
competitive	O
binding	O
assay	O
and	O
3H	O
-	O
dexamethasone	O
as	O
tracer	O
,	O
MNL	O
of	O
abdominal	O
obese	O
subjects	O
were	O
found	O
to	O
have	O
4855	O
+	O
/-	O
1389	O
sites	O
/	O
cell	O
which	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
than	O
controls	O
(	O
6234	O
+	O
/-	O
1568	O
sites	O
/	O
cell	O
)	O
,	O
although	O
no	O
significant	O
difference	O
was	O
found	O
in	O
the	O
mean	O
serum	O
cortisol	O
level	O
.	O

Their	O
mean	O
Kd	O
(	O
affinity	O
)	O
was	O
also	O
significantly	O
lower	O
than	O
that	O
found	O
in	O
the	O
healthy	O
controls	O
(	O
obese	O
Kd	O
:	O
2.92	O
+	O
/-	O
0.84	O
nmol	O
/	O
l	O
,	O
control	O
Kd	O
:	O
4.55	O
+	O
/-	O
0.67	O
nM	O
,	O
p	O
<	O
0.05	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
receptor	O
characteristics	O
in	O
Cushing	O
's	O
disease	O
patients	O
were	O
within	O
the	O
normal	O
range	O
.	O

At	O
the	O
same	O
time	O
,	O
3-O	O
-	O
MG	O
transport	O
was	O
determined	O
in	O
the	O
same	O
subjects	O
.	O

In	O
Cushing	O
's	O
disease	O
,	O
3-O	O
-	O
MG	O
transport	O
was	O
within	O
the	O
normal	O
range	O
,	O
whereas	O
in	O
abdominal	O
obesity	O
this	O
value	O
was	O
significantly	O
lower	O
than	O
the	O
healthy	O
controls	O
(	O
abdominal	O
obese	O
:	O
31.90	O
+	O
/-	O
8.20	O
;	O
control	O
:	O
46.26	O
+	O
/-	O
12.91	O
fmol	O
/	O
10	O
(	O
6	O
)	O
cell	O
,	O
min	O
,	O
p	O
<	O
0.05	O
)	O
.	O

We	O
also	O
found	O
a	O
positive	O
correlation	O
between	O
3-O	O
-	O
MG	O
transport	O
and	O
GR	O
binding	O
capacity	O
in	O
abdominal	O
subjects	O
(	O
r	O
=	O
0.89	O
,	O
p	O
<	O
0.001	O
)	O
,	O
however	O
we	O
did	O
not	O
find	O
such	O
a	O
correlation	O
in	O
Cushing	O
's	O
disease	O
(	O
r	O
=	O
0.60	O
,	O
p	O
>	O
0.05	O
)	O
.	O

These	O
results	O
indicated	O
that	O
,	O
in	O
abdominal	O
obesity	O
,	O
the	O
GR	O
binding	O
capacity	O
in	O
MNL	O
is	O
influenced	O
by	O
the	O
changes	O
in	O
glucose	O
transport	O
.	O

Down	O
-	O
regulation	O
of	O
human	O
granzyme	O
B	O
expression	O
by	O
glucocorticoids	O
.	O

Dexamethasone	O
inhibits	O
binding	O
to	O
the	O
Ikaros	O
and	O
AP-1	O
regulatory	O
elements	O
of	O
the	O
granzyme	O
B	O
promoter	O
.	O

The	O
serine	O
protease	O
granzyme	O
B	O
is	O
an	O
essential	O
component	O
of	O
the	O
granule	O
exocytosis	O
pathway	O
,	O
a	O
major	O
apoptotic	O
mechanism	O
used	O
by	O
cytotoxic	O
T	O
lymphocytes	O
and	O
natural	O
killer	O
cells	O
to	O
induce	O
target	O
cell	O
apoptosis	O
.	O

Granzyme	O
B	O
gene	O
transcription	O
is	O
induced	O
in	O
activated	O
lymphocytes	O
upon	O
antigenic	O
stimulation	O
,	O
and	O
several	O
regulatory	O
regions	O
including	O
CBF	O
,	O
AP-1	O
,	O
and	O
Ikaros	O
binding	O
sites	O
have	O
been	O
shown	O
to	O
be	O
essential	O
in	O
the	O
control	O
of	O
granzyme	O
B	O
promoter	O
activation	O
.	O

Dexamethasone	O
,	O
a	O
glucocorticoid	O
that	O
is	O
widely	O
used	O
as	O
an	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
agent	O
,	O
inhibits	O
granzyme	O
B	O
mRNA	O
transcript	O
in	O
phytohemagglutinin	O
-	O
activated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Transfection	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
-148	O
to	O
+	O
60	O
region	O
of	O
the	O
human	O
granzyme	O
B	O
promoter	O
demonstrated	O
that	O
this	O
region	O
was	O
the	O
target	O
for	O
dexamethasone	O
repression	O
.	O

Mutation	O
of	O
Ikaros	O
or	O
AP-1	O
binding	O
sites	O
in	O
the	O
context	O
of	O
the	O
granzyme	O
B	O
promoter	O
demonstrated	O
that	O
both	O
sites	O
participate	O
in	O
dexamethasone	O
-	O
mediated	O
inhibition	O
of	O
the	O
granzyme	O
B	O
promoter	O
activity	O
.	O

Electromobility	O
shift	O
assay	O
revealed	O
that	O
dexamethasone	O
abolished	O
the	O
binding	O
of	O
nuclear	O
transcription	O
factors	O
to	O
the	O
Ikaros	O
binding	O
site	O
and	O
reduced	O
AP-1	O
binding	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
dexamethasone	O
is	O
able	O
to	O
abrogate	O
the	O
transcriptional	O
activity	O
of	O
the	O
human	O
granzyme	O
B	O
gene	O
promoter	O
by	O
inhibiting	O
the	O
binding	O
of	O
nuclear	O
factors	O
at	O
the	O
AP-1	O
and	O
Ikaros	O
sites	O
.	O

CD27	O
/CD70	O
interaction	O
augments	O
IgE	O
secretion	O
by	O
promoting	O
the	O
differentiation	O
of	O
memory	O
B	O
cells	O
into	O
plasma	O
cells	O
.	O

The	O
induction	O
of	O
IgE	O
switching	O
in	O
B	O
cells	O
requires	O
several	O
signals	O
given	O
by	O
cytokines	O
and	O
cell	O
contact	O
-	O
delivered	O
signals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
CD27	O
/CD70	O
interaction	O
in	O
B	O
cell	O
IgE	O
synthesis	O
.	O

The	O
addition	O
of	O
CD27	O
ligand	O
(	O
CD70	O
)	O
transfectants	O
to	O
B	B
cell	I
cultures	I
increased	O
the	O
IgE	O
synthesis	O
synergistically	O
in	O
the	O
presence	O
of	O
IL-4	O
plus	O
anti	O
-	O
CD40	O
mAb	O
(	O
anti	O
-	O
CD40	O
)	O
.	O

The	O
effect	O
of	O
CD70	B
transfectants	I
was	O
dose	O
dependent	O
and	O
was	O
completely	O
blocked	O
by	O
anti	O
-	O
CD70	O
mAb	O
.	O

CD27	O
+	O
B	O
cells	O
had	O
the	O
ability	O
to	O
produce	O
IgE	O
,	O
which	O
was	O
increased	O
by	O
contact	O
with	O
CD70	O
transfectants	O
,	O
whereas	O
CD27-	O
B	O
cells	O
did	O
not	O
produce	O
IgE	O
.	O

CD27	O
/CD70	O
interaction	O
enhanced	O
B	O
cell	O
proliferation	O
in	O
the	O
presence	O
of	O
IL-4	O
or	O
IL-4	O
plus	O
anti	O
-	O
CD40	O
.	O

The	O
augmentation	O
of	O
B	O
cell	O
proliferation	O
by	O
CD70	O
transfectants	O
was	O
apparent	O
in	O
CD27	O
+	O
B	O
cells	O
,	O
but	O
was	O
mild	O
in	O
CD27-	O
B	O
cells	O
.	O

The	O
helper	O
activity	O
for	O
IgE	O
synthesis	O
by	O
the	O
CD27	O
/CD70	O
interaction	O
did	O
not	O
contribute	O
to	O
the	O
enhancement	O
of	O
germline	O
epsilon	O
transcripts	O
.	O

Flow	O
cytometric	O
and	O
morphological	O
analyses	O
demonstrated	O
that	O
the	O
addition	O
of	O
CD70	O
transfectants	O
to	O
B	B
cell	I
cultures	I
remarkably	O
promoted	O
differentiation	O
into	O
plasma	O
cells	O
in	O
the	O
presence	O
of	O
IL-4	O
and	O
CD40	O
signaling	O
.	O

Finally	O
,	O
CD27	O
cross	O
-	O
linking	O
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
positive	O
regulatory	O
domain	O
I	O
-	O
binding	O
factor-1	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
signaling	O
via	O
CD27	O
on	O
B	O
cells	O
induces	O
IgE	O
synthesis	O
,	O
in	O
cooperation	O
with	O
IL-4	O
and	O
CD40	O
signaling	O
,	O
by	O
promoting	O
the	O
generation	O
of	O
plasma	O
cells	O
through	O
up	O
-	O
regulation	O
of	O
positive	O
regulatory	O
domain	O
I	O
-	O
binding	O
factor-1	O
.	O

The	O
B29	O
(	O
immunoglobulin	O
beta	O
-	O
chain	O
)	O
gene	O
is	O
a	O
genetic	O
target	O
for	O
early	O
B	O
-	O
cell	O
factor	O
.	O

Early	O
B	O
-	O
cell	O
factor	O
(	O
EBF	O
)	O
is	O
a	O
transcription	O
factor	O
suggested	O
as	O
essential	O
for	O
early	O
B	O
-	O
lymphocyte	O
development	O
by	O
findings	O
in	O
mice	O
where	O
the	O
coding	O
gene	O
has	O
been	O
inactivated	O
by	O
homologous	O
disruption	O
.	O

This	O
makes	O
the	O
identification	O
of	O
genetic	O
targets	O
for	O
this	O
transcription	O
factor	O
pertinent	O
for	O
the	O
understanding	O
of	O
early	O
B	O
-	O
cell	O
development	O
.	O

The	O
lack	O
of	O
B29	O
transcripts	O
,	O
coding	O
for	O
the	O
beta	O
subunit	O
of	O
the	O
B	O
-	O
cell	O
receptor	O
complex	O
,	O
in	O
pro	O
-	O
B	O
cells	O
from	O
EBF	O
-deficient	O
mice	O
suggested	O
that	O
B29	O
might	O
be	O
a	O
genetic	O
target	O
for	O
EBF	O
.	O

We	O
here	O
present	O
data	O
suggesting	O
that	O
EBF	O
interacts	O
with	O
three	O
independent	O
sites	O
within	O
the	O
mouse	O
B29	O
promoter	O
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
EBF	O
in	O
HeLa	B
cells	I
activated	O
a	O
B29	O
promoter	O
-	O
controlled	O
reporter	O
construct	O
13-fold	O
and	O
induced	O
a	O
low	O
level	O
of	O
expression	O
from	O
the	O
endogenous	O
B29	O
gene	O
.	O

Finally	O
,	O
mutations	O
in	O
the	O
EBF	O
binding	O
sites	O
diminished	O
B29	O
promoter	O
activity	O
in	O
pre	O
-	O
B	O
cells	O
while	O
the	O
same	O
mutations	O
did	O
not	O
have	O
as	O
striking	O
an	O
effect	O
on	O
the	O
promoter	O
function	O
in	O
B	B
-	I
cell	I
lines	I
of	O
later	O
differentiation	O
stages	O
.	O

These	O
data	O
suggest	O
that	O
the	O
B29	O
gene	O
is	O
a	O
genetic	O
target	O
for	O
EBF	O
in	O
early	O
B	O
-	O
cell	O
development	O
.	O

Effect	O
of	O
environmental	O
estrogens	O
on	O
IL-1beta	O
promoter	O
activity	O
in	O
a	O
macrophage	B
cell	I
line	I
.	O

Environmental	O
estrogens	O
or	O
estrogen	O
disrupters	O
have	O
recently	O
received	O
a	O
great	O
deal	O
of	O
attention	O
because	O
of	O
their	O
potential	O
health	O
impact	O
on	O
reproductive	O
tissues	O
.	O

Few	O
,	O
if	O
any	O
,	O
studies	O
have	O
been	O
made	O
on	O
the	O
impact	O
of	O
these	O
compounds	O
on	O
the	O
immune	O
system	O
.	O

We	O
sought	O
to	O
determine	O
the	O
activities	O
of	O
various	O
environmental	O
estrogens	O
on	O
the	O
modulation	O
of	O
the	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
gene	O
in	O
a	O
model	B
monocytic	I
cell	I
line	I
,	O
hER	B
+	I
IL-1beta	I
-	I
CAT+	I
.	O

This	O
cell	O
line	O
stably	O
transfected	O
with	O
the	O
human	O
estrogen	O
receptor	O
,	O
and	O
an	O
IL-1beta	O
promoter	O
construct	O
fused	O
to	O
the	O
CAT	O
reporter	O
gene	O
allows	O
us	O
to	O
monitor	O
the	O
effect	O
of	O
estrogenic	O
compounds	O
on	O
IL-1beta	O
promoter	O
activity	O
.	O

17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
markedly	O
enhanced	O
lipopolysaccharide	O
-	O
(	O
LPS	O
)	O
induced	O
IL-1beta	O
promoter	O
-driven	O
CAT	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
mycotoxins	O
alpha	O
-	O
zearalenol	O
and	O
zearalenone	O
both	O
exhibited	O
full	O
agonist	O
activity	O
,	O
but	O
at	O
lower	O
potencies	O
,	O
with	O
EC50	O
values	O
of	O
1.8	O
and	O
54	O
nM	O
,	O
respectively	O
,	O
compared	O
with	O
E2	O
at	O
0.5	O
nM	O
.	O

In	O
addition	O
,	O
genistein	O
was	O
a	O
very	O
low	O
-	O
potency	O
agonist	O
,	O
having	O
an	O
EC50	O
of	O
1.5	O
microM	O
.	O

Similar	O
to	O
the	O
E2	O
response	O
,	O
the	O
slope	O
factors	O
for	O
alpha	O
-	O
zearalenol	O
,	O
zearalenone	O
,	O
and	O
genistein	O
were	O
close	O
to	O
3.0	O
,	O
suggesting	O
positive	O
cooperativity	O
in	O
the	O
estrogenic	O
response	O
.	O

The	O
activity	O
of	O
the	O
mycotoxins	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
estrogen	O
receptor	O
,	O
since	O
both	O
the	O
antiestrogens	O
H1285	O
and	O
ICI	O
182	O
,	O
780	O
effectively	O
inhibited	O
their	O
agonist	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Representative	O
environmental	O
estrogenic	O
compounds	O
both	O
from	O
plant	O
and	O
industrial	O
sources	O
were	O
also	O
tested	O
.	O

Unlike	O
the	O
mycoestrogens	O
,	O
none	O
of	O
the	O
compounds	O
,	O
with	O
the	O
exception	O
of	O
genistein	O
,	O
synergized	O
with	O
LPS	O
to	O
enhance	O
IL-1beta	O
promoter	O
activity	O
.	O

When	O
tested	O
for	O
antiestrogenic	O
activity	O
,	O
the	O
industrial	O
compound	O
4-octylphenol	O
was	O
able	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
;	O
however	O
,	O
the	O
response	O
was	O
three	O
orders	O
of	O
magnitude	O
less	O
potent	O
than	O
H	O
1285	O
.	O

Naringenin	O
,	O
a	O
plant	O
flavonoid	O
,	O
showed	O
little	O
or	O
no	O
ability	O
to	O
antagonize	O
the	O
response	O
to	O
E2	O
.	O

Overall	O
,	O
the	O
results	O
show	O
that	O
some	O
environmental	O
estrogens	O
that	O
display	O
agonist	O
activity	O
in	O
reproductive	O
tissue	O
also	O
have	O
an	O
effect	O
on	O
IL-1	O
gene	O
expression	O
in	O
hemopoietic	O
-	O
derived	O
tissue	O
.	O

X	O
-	O
rays	O
-	O
induced	O
secretion	O
of	O
cellular	O
factor	O
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV-1	O
promoter	O
transcription	O
in	O
various	O
non	B
-	I
irradiated	I
transfected	I
cell	I
lines	I
.	O

Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-	O
1	O
)	O
replication	O
or	O
reporter	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
extracellular	O
factor	O
(	O
s	O
)	O
released	O
by	O
X	B
-	I
ray	I
-	I
treated	I
human	I
colonic	I
carcinoma	I
cell	I
line	I
(	O
HT29	B
)	O
might	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
in	O
non	B
-	I
irradiated	I
HT29	I
cells	I
.	O

In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	B
transfected	I
cell	I
lines	I
,	O
X	O
-	O
ray	O
irradiation	O
up	O
-	O
regulates	O
HIV-1	O
LTR	O
transcription	O
through	O
the	O
kappaB	O
regulatory	O
elements	O
.	O

A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non	O
-	O
irradiated	O
cells	O
of	O
either	O
X	B
-	I
ray	I
-	I
treated	I
cells	I
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	B
cultures	I
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

In	O
addition	O
,	O
X	O
-	O
ray	O
activation	O
of	O
HIV-1	O
LTR	O
in	O
transiently	O
or	O
stably	O
transfected	O
cell	B
lines	I
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	O
factors	O
,	O
suramin	O
.	O

The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS	O
-	O
related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O

Transcription	O
factor	O
binding	O
to	O
the	O
core	O
promoter	O
of	O
the	O
human	O
monoamine	O
oxidase	O
B	O
gene	O
in	O
the	O
cerebral	O
cortex	O
and	O
in	O
blood	O
cells	O
.	O

Many	O
studies	O
show	O
that	O
monoamine	O
oxidase	O
B	O
in	O
blood	O
cells	O
is	O
a	O
biological	O
marker	O
for	O
personality	O
characteristics	O
such	O
as	O
sensation	O
seeking	O
.	O

The	O
mechanism	O
underlying	O
this	O
association	O
is	O
so	O
far	O
not	O
explored	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
performed	O
electrophoretic	O
mobility	O
-	O
shift	O
assays	O
to	O
investigate	O
the	O
pattern	O
of	O
protein	O
binding	O
to	O
a	O
150	O
bp	O
fragment	O
of	O
the	O
proximal	O
5'-flanking	O
region	O
of	O
the	O
human	O
monoamine	O
oxidase	O
B	O
gene	O
.	O

We	O
compared	O
the	O
pattern	O
using	O
nuclear	O
extracts	O
from	O
human	O
brain	O
and	O
lymphocytes	O
.	O

Interestingly	O
,	O
a	O
correlation	O
was	O
observed	O
between	O
monoamine	O
oxidase	O
B	O
enzyme	O
activity	O
in	O
blood	O
cells	O
(	O
platelets	O
)	O
and	O
the	O
binding	O
pattern	O
of	O
two	O
uncharacterized	O
transcription	O
factors	O
.	O

These	O
data	O
are	O
well	O
in	O
line	O
with	O
the	O
long	O
-	O
standing	O
notion	O
that	O
interindividual	O
differences	O
in	O
platelet	O
monoamine	O
oxidase	O
may	O
represent	O
differences	O
in	O
expression	O
of	O
the	O
enzyme	O
rather	O
than	O
genotypic	O
variation	O
.	O

Regulation	O
of	O
fas	O
-	O
ligand	O
expression	O
during	O
activation	O
-	O
induced	O
cell	O
death	O
in	O
T	O
lymphocytes	O
via	O
nuclear	O
factor	O
kappaB	O
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	O
factors	O
important	O
for	O
cytokine	O
gene	O
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
lymphocytes	O
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	O
genes	O
expressed	O
in	O
activated	O
lymphocytes	O
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation	O
-	O
induced	O
FasL	O
expression	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
a	O
T	B
cell	I
hybridoma	I
leads	O
to	O
decreased	O
FasL	O
expression	O
and	O
apoptosis	O
upon	O
T	O
cell	O
receptor	O
stimulation	O
.	O

We	O
identified	O
the	O
NF	O
-	O
kappaB	O
site	O
in	O
the	O
FasL	O
promoter	O
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Co	O
-	O
expression	O
of	O
p65	O
(	O
Rel	O
A	O
)	O
with	O
the	O
FasL	O
promoter	O
enhanced	O
its	O
activity	O
,	O
and	O
co	O
-	O
expression	O
of	O
IkappaB	O
dramatically	O
inhibited	O
the	O
inducible	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
the	O
transcription	O
factor	O
AP-1	O
is	O
not	O
required	O
for	O
activation	O
-	O
induced	O
FasL	O
promoter	O
activity	O
.	O

These	O
results	O
define	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
mediating	O
FasL	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

Characterisation	O
of	O
regulatory	O
sequences	O
at	O
the	O
Epstein	O
-	O
Barr	O
virus	O
BamHI	O
W	O
promoter	O
.	O

Epstein	O
-	O
Barr	O
virus	O
,	O
a	O
human	O
gammaherpesvirus	O
,	O
possesses	O
a	O
unique	O
set	O
of	O
latent	O
genes	O
whose	O
constitutive	O
expression	O
in	O
B	O
cells	O
leads	O
to	O
cell	O
growth	O
transformation	O
.	O

The	O
initiation	O
of	O
this	O
growth	O
transforming	O
infection	O
depends	O
on	O
a	O
viral	O
promoter	O
in	O
BamHI	O
W	O
(	O
Wp	O
)	O
whose	O
regulation	O
is	O
poorly	O
understood	O
.	O

Using	O
Wp	O
reporter	O
constructs	O
in	O
in	O
vitro	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
Wp	O
was	O
11-	O
to	O
190-fold	O
more	O
active	O
in	O
B	B
cell	I
than	O
in	O
non	B
-	I
B	I
cell	I
lines	I
and	O
that	O
three	O
regions	O
of	O
the	O
promoter	O
(	O
termed	O
UAS1	O
,	O
UAS2	O
,	O
and	O
UAS3	O
)	O
contributed	O
to	O
transcriptional	O
activation	O
.	O

The	O
upstream	O
regions	O
UAS3	O
(	O
-1168	O
to	O
-440	O
)	O
and	O
UAS2	O
(	O
-352	O
to	O
-264	O
)	O
both	O
functioned	O
in	O
a	O
cell	O
lineage	O
-	O
independent	O
manner	O
and	O
were	O
together	O
responsible	O
for	O
the	O
bulk	O
of	O
Wp	O
activity	O
in	O
non	O
-	O
B	O
cells	O
;	O
mutational	O
analysis	O
indicated	O
the	O
importance	O
of	O
a	O
YY1	O
binding	O
site	O
in	O
UAS2	O
in	O
that	O
context	O
.	O

By	O
contrast	O
,	O
UAS1	O
(	O
-140	O
to	O
-87	O
)	O
was	O
B	O
cell	O
specific	O
and	O
was	O
the	O
key	O
determinant	O
of	O
the	O
promoter	O
's	O
increased	O
activity	O
in	O
B	B
cell	I
lines	I
.	O

Mutational	O
analysis	O
of	O
UAS1	O
sequences	O
combined	O
with	O
in	O
vitro	O
bandshift	O
assays	O
revealed	O
the	O
presence	O
of	O
three	O
binding	O
sites	O
for	O
cellular	O
factors	O
in	O
this	O
region	O
.	O

When	O
mutations	O
that	O
abolished	O
factor	O
binding	O
in	O
bandshift	O
assays	O
were	O
introduced	O
into	O
a	O
Wp	O
reporter	O
construct	O
,	O
the	O
loss	O
of	O
any	O
one	O
of	O
the	O
three	O
UAS1	O
binding	O
sites	O
was	O
sufficient	O
to	O
reduce	O
promoter	O
activity	O
by	O
10-	O
to	O
30-fold	O
in	O
B	O
cells	O
.	O

From	O
sequence	O
analysis	O
,	O
two	O
of	O
these	O
appear	O
to	O
be	O
novel	O
transcription	O
factor	O
binding	O
sites	O
,	O
whereas	O
the	O
third	O
was	O
identified	O
as	O
a	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
.	O

Our	O
data	O
indicate	O
that	O
this	O
CRE	O
interacts	O
with	O
CREB	O
and	O
ATF1	O
proteins	O
present	O
in	O
B	O
cell	O
nuclear	O
extracts	O
and	O
that	O
this	O
interaction	O
is	O
important	O
for	O
Wp	O
activity	O
.	O

Direct	O
suppression	O
of	O
Stat1	O
function	O
during	O
adenoviral	O
infection	O
.	O

The	O
action	O
of	O
adenoviral	O
E1A	O
oncoprotein	O
on	O
host	O
immune	O
-	O
response	O
genes	O
has	O
been	O
attributed	O
to	O
interaction	O
with	O
p300	O
/	O
CBP	O
-	O
type	O
transcriptional	O
coactivators	O
in	O
competition	O
with	O
endogenous	O
transcription	O
factors	O
such	O
as	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
.	O

However	O
,	O
we	O
show	O
that	O
mutant	O
forms	O
of	O
E1A	O
that	O
no	O
longer	O
bind	O
p300	O
/	O
CBP	O
can	O
still	O
interact	O
directly	O
with	O
Stat1	O
(	O
via	O
E1A	O
N	O
-	O
terminal	O
and	O
Stat1	O
C	O
-	O
terminal	O
residues	O
)	O
and	O
block	O
IFNgamma	O
-	O
driven	O
,	O
Stat1	O
-dependent	O
gene	O
activation	O
and	O
consequent	O
function	O
during	O
early	O
-	O
phase	O
infection	O
in	O
the	O
natural	O
host	O
cell	O
.	O

The	O
results	O
provide	O
a	O
distinct	O
and	O
more	O
specific	O
mechanism	O
for	O
E1A	O
-mediated	O
immune	O
suppression	O
and	O
an	O
alternative	O
model	O
of	O
IFNgamma	O
-driven	O
enhanceosome	O
formation	O
that	O
may	O
allow	O
for	O
other	O
adaptors	O
(	O
in	O
addition	O
to	O
p300	O
/	O
CBP	O
)	O
to	O
link	O
Stat1	O
to	O
the	O
basal	O
transcription	O
complex	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
tax	O
protein	O
abrogates	O
interleukin-2	O
dependence	O
in	O
a	O
mouse	B
T	I
-	I
cell	I
line	I
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Tax	O
,	O
the	O
viral	O
protein	O
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	O
T	O
cells	O
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	O
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin-2	B
(	I
IL-2	I
)	I
-dependent	I
T	I
-	I
cell	I
line	I
CTLL-2	B
.	O

Stable	O
expression	O
of	O
Tax	O
in	O
CTLL-2	B
transformed	O
cell	O
growth	O
from	O
being	O
IL-2	O
dependent	O
to	O
IL-2	O
independent	O
.	O

Tax	O
stimulated	O
transcription	O
through	O
NF	O
-	O
kappaB	O
and	O
the	O
cyclic	O
AMP	O
-	O
responsive	O
element	O
-	O
like	O
sequence	O
in	O
the	O
HTLV-1	O
promoter	O
.	O

The	O
finding	O
of	O
Tax	O
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF	O
-	O
kappaB	O
pathway	O
was	O
essential	O
for	O
IL-2	O
-independent	O
growth	O
of	O
CTLL-2	O
cells	O
while	O
the	O
CRE	O
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation	O
-	O
related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL-2	O
/	O
Tax	O
.	O

Our	O
results	O
show	O
that	O
Tax	O
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	O
plays	O
a	O
crucial	O
role	O
in	O
IL-2	O
-independent	O
T	O
-	O
cell	O
transformation	O
induced	O
by	O
HTLV-1	O
,	O
in	O
addition	O
to	O
its	O
well	O
-	O
known	O
IL-2	O
-dependent	O
cell	O
transformation	O
.	O

Mice	O
lacking	O
the	O
transcription	O
factor	O
CIITA	O
--	O
a	O
second	O
look	O
.	O

We	O
have	O
generated	O
a	O
second	O
line	O
of	O
mice	O
lacking	O
a	O
transcription	O
factor	O
thought	O
to	O
be	O
a	O
critical	O
regulator	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
,	O
CIITA	O
(	O
for	O
class	O
II	O
transactivator	O
)	O
.	O

Our	O
and	O
the	O
previously	O
published	O
lines	O
differ	O
in	O
the	O
deletion	O
that	O
was	O
engineered	O
and	O
by	O
the	O
fact	O
that	O
we	O
removed	O
the	O
neomycin	O
-	O
resistance	O
promoter	O
and	O
structural	O
gene	O
via	O
the	O
cre	O
-	O
loxP	O
recombination	O
system	O
.	O

Characterization	O
of	O
our	O
line	O
led	O
to	O
two	O
new	O
findings	O
.	O

First	O
,	O
a	O
substantial	O
number	O
of	O
cells	O
can	O
express	O
class	O
II	O
molecules	O
in	O
the	O
absence	O
of	O
CIITA	O
,	O
albeit	O
at	O
5-fold	O
reduced	O
levels	O
,	O
most	O
notably	O
dendritic	O
cells	O
in	O
s.c	O
.	O
lymph	O
nodes	O
;	O
therefore	O
,	O
the	O
CIITA	O
gene	O
can	O
not	O
be	O
an	O
absolute	O
'	O
master	O
gene	O
'	O
controlling	O
the	O
expression	O
of	O
class	O
II	O
molecules	O
,	O
as	O
had	O
been	O
thought	O
.	O

Second	O
,	O
in	O
contrast	O
to	O
recent	O
results	O
on	O
human	B
cell	I
lines	I
,	O
CIITA	O
is	O
not	O
critically	O
involved	O
in	O
the	O
IFN	O
-	O
gamma	O
-induced	O
up	O
-	O
regulation	O
of	O
MHC	O
class	O
I	O
genes	O
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

We	O
compared	O
U-937	B
cell	I
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
human	O
umbilical	O
venous	O
(	O
HUVECs	O
)	O
and	O
arterial	O
(	O
HUAECs	O
)	O
endothelial	O
cells	O
exposed	O
to	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interleukin-1	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

TNF	O
and	O
LPS	O
stimulated	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-1	O
surface	O
expression	O
and	O
adhesion	O
of	O
U-937	B
monocyte	I
-	I
like	I
cells	I
to	O
HUVECs	O
but	O
not	O
to	O
HUAECs	O
.	O

Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	O
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM-1	O
mediated	O
.	O

Interleukin-1	O
stimulated	O
U-937	B
cell	I
adhesion	O
to	O
and	O
VCAM-1	O
surface	O
expression	O
in	O
both	O
HUVECs	O
and	O
HUAECs	O
.	O

Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG-132	O
blocked	O
TNF	O
-and	O
LPS	O
-	O
stimulated	O
U-937	B
cell	I
adhesion	O
to	O
HUVECs	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF	O
-and	O
LPS	O
-	O
stimulated	O
increases	O
in	O
HUVEC	O
surface	O
VCAM-1	O
.	O

TNF	O
increased	O
VCAM-1	O
protein	O
and	O
mRNA	O
in	O
HUVECs	O
that	O
was	O
blocked	O
by	O
pyrrolidinedithiocarbamate	O
.	O

However	O
,	O
neither	O
TNF	O
or	O
LPS	O
stimulated	O
VCAM-1	O
expression	O
in	O
HUAECs	O
.	O

TNF	O
stimulated	O
expression	O
of	O
both	O
intercellular	O
adhesion	O
molecule-1	O
and	O
E	O
-	O
selectin	O
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	O
adhesion	O
molecule-1	O
was	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	O
difference	O
in	O
the	O
pattern	O
of	O
TNF	O
-stimulated	O
nuclear	O
factor	O
-	O
kappaB	O
activation	O
between	O
HUVECs	O
and	O
HUAECs	O
.	O

These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	O
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	O
to	O
upregulate	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
VCAM-1	O
.	O

Tissue	O
factor	O
expression	O
of	O
human	O
monocytes	O
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O

The	O
expression	O
of	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
promoted	O
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol	O
/	O
L	O
)	O
dose	O
-	O
dependently	O
reduced	O
TF	O
activity	O
in	O
human	O
monocytes	O
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	O
affect	O
LPS	O
-	O
induced	O
TF	O
activity	O
of	O
human	O
monocytes	O
.	O

TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	O
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

LysoPC	O
inhibited	O
the	O
TF	O
activity	O
of	O
Mono	B
Mac-6	I
cells	I
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O

LPS	O
binding	O
to	O
plasma	O
membrane	O
receptors	O
and	O
internalization	O
of	O
LPS	O
into	O
monocytes	O
were	O
not	O
affected	O
by	O
lysoPC	O
.	O

In	O
contrast	O
,	O
LPS	O
-	O
mediated	O
nuclear	O
binding	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
/	O
Rel	O
to	O
a	O
TF	O
-	O
specific	O
kappaB	O
site	O
was	O
inhibited	O
by	O
lysoPC	O
.	O

Induction	O
of	O
TF	O
mRNA	O
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Inhibition	O
of	O
adenylyl	O
cyclase	O
by	O
pretreatment	O
with	O
2'-deoxy-3'-adenosine	O
monophosphate	O
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS	O
-	O
mediated	O
TF	O
expression	O
of	O
human	O
monocytes	O
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF	O
-	O
kappaB	O
by	O
70	O
kDa	O
heat	O
shock	O
protein	O
.	O

The	O
70	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp70	O
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	O
protein	O
involved	O
in	O
chaperoning	O
proteins	O
to	O
various	O
cellular	O
organelles	O
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	O
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
fashion	O
.	O

We	O
exploited	O
this	O
ability	O
of	O
Hsp70	O
to	O
deliver	O
NF	O
-	O
kappaB	O
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C	O
-	O
terminal	O
Hsp70	O
peptide	O
and	O
the	O
p50	O
subunit	O
of	O
NF	O
-	O
kappaB	O
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	O
expression	O
and	O
TNFalpha	O
production	O
.	O

We	O
therefore	O
propose	O
that	O
Hsp70	O
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O

CD2	O
signalling	O
induces	O
phosphorylation	O
of	O
CREB	O
in	O
primary	O
lymphocytes	O
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
,	O
and	O
bind	O
transcription	O
factors	O
of	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
/activating	O
transcription	O
factor-1	O
(	O
ATF-1	O
)	O
family	O
.	O

We	O
have	O
used	O
a	O
human	O
T	O
-	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	O
promoter	O
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	O
CD3	O
receptor	O
cross	O
-	O
linking	O
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	O
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	O
and	O
CD3	O
receptor	O
-mediated	O
signalling	O
in	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

CD2	O
,	O
but	O
not	O
CD3	O
,	O
cross	O
-	O
linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O

CD2	O
cross	O
-	O
linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	O
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

Consistent	O
with	O
post	O
-	O
translational	O
regulation	O
,	O
no	O
change	O
in	O
total	O
level	O
of	O
CREB	O
protein	O
was	O
observed	O
.	O

Phosphorylation	O
of	O
CREB	O
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp	O
-	O
cAMP-	O
sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
and	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
CD2	O
and	O
CD3	O
cross	O
-	O
linking	O
increased	O
binding	O
of	O
nuclear	O
proteins	O
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB	O
/	O
ATF-1	O
family	O
of	O
transcription	O
factors	O
by	O
the	O
CD2	O
signalling	O
pathway	O
and	O
suggest	O
CD2	O
receptor	O
modulation	O
of	O
CRE	O
-mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
)	O
.	O

Protective	O
effects	O
of	O
notch-1	O
on	O
TCR	O
-induced	O
apoptosis	O
.	O

The	O
Notch	O
receptor	O
protein	O
was	O
originally	O
identified	O
in	O
Drosophila	O
and	O
is	O
known	O
to	O
mediate	O
cell	O
to	O
cell	O
communication	O
and	O
influence	O
cell	O
fate	O
decisions	O
.	O

Members	O
of	O
this	O
family	O
have	O
been	O
isolated	O
from	O
invertebrates	O
as	O
well	O
as	O
vertebrates	O
.	O

We	O
isolated	O
mouse	O
Notch-1	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
with	O
Nur77	O
,	O
which	O
is	O
a	O
protein	O
that	O
has	O
been	O
shown	O
previously	O
to	O
be	O
required	O
for	O
apoptosis	O
in	O
T	B
cell	I
lines	I
.	O

The	O
data	O
presented	O
below	O
indicate	O
that	O
Notch-1	O
expression	O
provides	O
significant	O
protection	O
to	O
T	B
cell	I
lines	I
from	O
TCR	O
-mediated	O
apoptosis	O
.	O

These	O
data	O
demonstrate	O
a	O
new	O
antiapoptotic	O
role	O
for	O
Notch-1	O
,	O
providing	O
evidence	O
that	O
,	O
in	O
addition	O
to	O
regulating	O
cell	O
fate	O
decisions	O
,	O
Notch-1	O
can	O
play	O
a	O
critical	O
role	O
in	O
controlling	O
levels	O
of	O
cell	O
death	O
in	O
T	O
cells	O
.	O

Requirement	O
of	O
GATA-1	O
and	O
p45	O
NF	O
-	O
E2	O
expression	O
in	O
butyric	O
acid	O
-	O
induced	O
erythroid	O
differentiation	O
.	O

Butyric	O
acid	O
(	O
BA	O
)	O
is	O
known	O
to	O
induce	O
overexpression	O
of	O
fetal	O
hemoglobin	O
and	O
then	O
erythroid	O
differentiation	O
.	O

Therefore	O
,	O
BA	O
is	O
currently	O
under	O
clinical	O
investigation	O
as	O
a	O
potential	O
therapy	O
for	O
the	O
treatment	O
of	O
sickle	O
cell	O
disease	O
and	O
cancer	O
.	O

Nevertheless	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
BA	O
-	O
induced	O
differentiation	O
remain	O
largely	O
unknown	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
BA	O
-	O
induced	O
overexpression	O
of	O
erythroid	O
genes	O
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
suggesting	O
the	O
involvement	O
of	O
erythroid	O
transcription	O
factors	O
.	O

Here	O
,	O
we	O
intend	O
to	O
demonstrate	O
the	O
requirement	O
of	O
GATA-1	O
and	O
NF	O
-	O
E2	O
transcription	O
factors	O
in	O
the	O
BA	O
-	O
induced	O
erythroid	O
differentiation	O
of	O
human	B
leukemic	I
K562	I
cells	I
.	O

Time	O
-	O
course	O
experiments	O
showed	O
that	O
nuclear	O
levels	O
of	O
GATA-1	O
and	O
p45	O
NF	O
-	O
E2	O
proteins	O
increased	O
during	O
BA	O
treatment	O
.	O

Moreover	O
,	O
antisense	O
oligodeoxynucleotides	O
targeting	O
either	O
GATA-1	O
or	O
p45	O
NF	O
-	O
E2	O
proteins	O
inhibited	O
both	O
protein	O
expression	O
and	O
BA	O
-	O
induced	O
differentiation	O
.	O

In	O
contrast	O
,	O
BA	O
-	O
induced	O
cell	O
growth	O
inhibition	O
was	O
not	O
affected	O
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
the	O
requirement	O
of	O
GATA-1	O
and	O
NF	O
-	O
E2	O
in	O
BA	O
-	O
induced	O
differentiation	O
process	O
.	O

Comparison	O
of	O
HTLV	O
-	O
I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB	O
/	O
ATF-1	O
/	O
CREM	O
family	O
members	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
Jurkat	B
T	I
cells	I
.	O

HTLV	O
-	O
I	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
/	O
lymphoma	O
and	O
is	O
associated	O
with	O
tropical	O
spastic	O
paraparesis	O
/	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
.	O

Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV	O
-	O
I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O

Low	O
levels	O
of	O
viral	O
transcription	O
(	O
basal	O
transcription	O
)	O
occur	O
before	O
expression	O
of	O
the	O
virally	O
encoded	O
Tax	O
protein	O
(	O
Tax	O
-mediated	O
transcription	O
)	O
.	O

Members	O
of	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element	O
binding	O
(	O
CREB	O
)	O
/activating	O
transcription	O
factor	O
1	O
(	O
ATF-1	O
)	O
family	O
of	O
transcription	O
factors	O
bind	O
three	O
21-bp	O
repeats	O
(	O
Tax	O
-	O
responsive	O
element-1	O
,	O
or	O
TRE-1	O
)	O
within	O
the	O
viral	O
promoter	O
and	O
are	O
important	O
for	O
basal	O
and	O
Tax	O
-	O
mediated	O
transcription	O
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
Jurkat	B
cells	I
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	O
factors	O
with	O
TRE-1	O
.	O

We	O
demonstrate	O
that	O
amounts	O
of	O
transcriptionally	O
active	O
phosphorylated	O
CREB	O
protein	O
(	O
P	O
-	O
CREB	O
)	O
differ	O
between	O
activated	O
PBMC	O
and	O
Jurkat	B
cells	I
.	O

Following	O
stimulation	O
,	O
P	O
-	O
CREB	O
levels	O
remain	O
elevated	O
in	O
PBMC	O
for	O
up	O
to	O
24	O
hours	O
whereas	O
CREB	O
is	O
dephosphorylated	O
in	O
Jurkat	B
cells	I
within	O
4	O
hours	O
following	O
stimulation	O
.	O

The	O
differences	O
in	O
P	O
-	O
CREB	O
levels	O
between	O
PBMC	O
and	O
Jurkat	B
cells	I
were	O
directly	O
correlated	O
with	O
basal	O
transcription	O
of	O
HTLV	O
-	O
I	O
in	O
the	O
two	O
cell	O
types	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O

These	O
data	O
demonstrate	O
that	O
PBMC	O
differentially	O
regulate	O
basal	O
HTLV	O
-	O
I	O
transcription	O
compared	O
with	O
Jurkat	B
T	I
cells	I
,	O
and	O
this	O
differential	O
regulation	O
is	O
due	O
,	O
in	O
part	O
to	O
differential	O
phosphorylation	O
and	O
binding	O
of	O
CREB	O
/	O
ATF-1	O
to	O
TRE-1	O
in	O
the	O
HTLV	O
-	O
I	O
promoter	O
.	O

We	O
demonstrate	O
the	O
utility	O
of	O
using	O
primary	O
lymphocyte	O
models	O
to	O
study	O
HTLV	O
-	O
I	O
transcription	O
in	O
the	O
context	O
of	O
cell	O
signaling	O
and	O
suggest	O
that	O
activated	O
PBMC	O
maintain	O
elevated	O
levels	O
of	O
P	O
-	O
CREB	O
,	O
which	O
promote	O
basal	O
HTLV	O
-	O
I	O
transcription	O
and	O
enhance	O
viral	O
persistence	O
in	O
vivo	O
.	O

Heterogeneity	O
of	O
clonal	O
development	O
in	O
chronic	O
myeloproliferative	O
disorders	O
.	O

Recent	O
reports	O
have	O
suggested	O
a	O
previously	O
unexpected	O
variability	O
in	O
the	O
expression	O
of	O
the	O
dominant	B
neoplastic	I
clone	I
in	O
myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
.	O

We	O
evaluated	O
49	O
female	O
patients	O
with	O
MPD	O
and	O
informative	O
at	O
the	O
X	O
-	O
linked	O
androgen	O
receptor	O
(	O
AR	O
)	O
locus	O
to	O
establish	O
the	O
X	O
chromosome	O
inactivation	O
pattern	O
of	O
hemopoietic	O
cells	O
.	O

Whereas	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
the	O
granulocytes	O
(	O
PMN	O
)	O
were	O
uniformly	O
of	O
monoclonal	O
origin	O
,	O
a	O
striking	O
heterogeneity	O
of	O
clonal	O
development	O
was	O
found	O
in	O
PMN	O
from	O
patients	O
with	O
other	O
MPD	O
,	O
with	O
up	O
to	O
50	O
%	O
of	O
them	O
expressing	O
a	O
polyclonal	O
pattern	O
of	O
X	O
inactivation	O
.	O

NF	O
-	O
kappaB	O
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue	O
-	O
damaging	O
granulocytes	O
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non	O
-	O
phlogistic	O
manner	O
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	O
neutrophils	O
and	O
eosinophils	O
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration	O
-	O
dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	O
by	O
its	O
inactive	O
analog	O
methylthiogliotoxin	O
.	O

This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD	O
-	O
fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF	O
-	O
kappaB	O
,	O
SN-50	O
;	O
other	O
NF	O
-	O
kappaB	O
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG-132	O
.	O

Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2	O
-	O
6	O
h	O
)	O
pro	O
-	O
apoptotic	O
effects	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
in	O
neutrophils	O
and	O
unmasked	O
the	O
ability	O
of	O
TNF	O
-	O
alpha	O
to	O
induce	O
eosinophil	O
apoptosis	O
.	O

In	O
neutrophils	O
,	O
TNF	O
-	O
alpha	O
caused	O
a	O
gliotoxin	O
-	O
inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF	O
-	O
kappaB	O
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF	O
-	O
alpha	O
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12	O
-	O
24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF	O
-	O
alpha	O
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	O
pro	O
-	O
apoptotic	O
effect	O
,	O
suggesting	O
that	O
NF	O
-	O
kappaB	O
may	O
regulate	O
the	O
production	O
of	O
protein	O
(	O
s	O
)	O
which	O
protect	O
neutrophils	O
from	O
the	O
cytotoxic	O
effects	O
of	O
TNF	O
-	O
alpha	O
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	O
.	O

Tuberculosis	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
in	O
Africans	O
and	O
variation	O
in	O
the	O
vitamin	O
D	O
receptor	O
gene	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1	O
,	O
25	O
dihydroxyvitamin	O
D3	O
,	O
is	O
an	O
important	O
immunoregulatory	O
hormone	O
[	O
1	O
]	O
.	O

Its	O
effects	O
are	O
exerted	O
by	O
interaction	O
with	O
the	O
vitamin	O
D	O
receptor	O
,	O
which	O
is	O
present	O
on	O
human	O
monocytes	O
and	O
activated	O
T	O
and	O
B	O
lymphocytes	O
.	O

Variation	O
in	O
the	O
vitamin	O
D	O
receptor	O
gene	O
was	O
typed	O
in	O
2015	O
subjects	O
from	O
large	O
case	O
-	O
control	O
studies	O
of	O
three	O
major	O
infectious	O
diseases	O
:	O
tuberculosis	O
,	O
malaria	O
,	O
and	O
hepatitis	O
B	O
virus	O
.	O

Homozygotes	O
for	O
a	O
polymorphism	O
at	O
codon	O
352	O
(	O
genotype	O
tt	O
)	O
were	O
significantly	O
underrepresented	O
among	O
those	O
with	O
tuberculosis	O
(	O
chi2=6.22	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
and	O
persistent	O
hepatitis	O
B	O
infection	O
(	O
chi2=6.25	O
,	O
1	O
df	O
,	O
P=.01	O
)	O
but	O
not	O
in	O
subjects	O
with	O
clinical	O
malaria	O
compared	O
with	O
the	O
other	O
genotypes	O
.	O

Therefore	O
,	O
this	O
genetic	O
variant	O
,	O
which	O
predisposes	O
to	O
low	O
bone	O
mineral	O
density	O
in	O
many	O
populations	O
,	O
may	O
confer	O
resistance	O
to	O
certain	O
infectious	O
diseases	O
.	O

Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	O
variant	O
of	O
the	O
human	O
IL-4	O
receptor	O
alpha	O
-	O
chain	O
in	O
IgE	O
synthesis	O
.	O

Two	O
variants	O
of	O
the	O
IL-4R	O
alpha	O
-	O
chain	O
(	O
IL-4Ralpha	O
)	O
gene	O
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O

To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	O
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	O
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	O
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	O
.	O

The	O
substitution	O
of	O
Ile	O
for	O
Val	O
augmented	O
STAT6	O
activation	O
,	O
proliferation	O
,	O
and	O
transcription	O
activity	O
of	O
the	O
Iepsilon	O
promoter	O
by	O
IL-4	O
,	O
whereas	O
that	O
of	O
Arg	O
for	O
Gln	O
did	O
not	O
change	O
these	O
IL-4	O
signals	O
.	O

Arg551	O
was	O
not	O
associated	O
with	O
atopic	O
asthma	O
in	O
the	O
Japanese	O
population	O
.	O

CD23	O
expression	O
and	O
IgE	O
synthesis	O
by	O
IL-4	O
were	O
augmented	O
in	O
Ile50-bearing	B
PBMC	I
,	O
compared	O
with	O
those	O
bearing	O
Val50	O
.	O

Taken	O
together	O
,	O
substitution	O
of	O
Arg551	O
does	O
not	O
enhance	O
the	O
IL-4	O
signal	O
for	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
whereas	O
the	O
substitution	O
of	O
Ile50	O
contributes	O
to	O
enhancement	O
of	O
IgE	O
synthesis	O
.	O

Evidence	O
for	O
repression	O
of	O
IL-2	O
gene	O
activation	O
in	O
anergic	O
T	O
cells	O
.	O

The	O
induction	O
of	O
clonal	O
anergy	O
in	O
a	O
T	O
cell	O
inhibits	O
IL-2	O
secretion	O
because	O
of	O
the	O
development	O
of	O
a	O
proximal	O
signal	O
transduction	O
defect	O
.	O

Fusion	O
of	O
anergic	O
murine	O
T	O
cells	O
to	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
and	O
formation	O
of	O
heterokaryons	B
failed	O
to	O
result	O
in	O
a	O
complementation	O
of	O
this	O
signaling	O
defect	O
and	O
restoration	O
of	O
murine	O
IL-2	O
mRNA	O
inducibility	O
.	O

Instead	O
,	O
signal	O
transduction	O
to	O
the	O
human	O
IL-2	O
gene	O
became	O
disrupted	O
.	O

Heterokaryons	B
formed	O
by	O
the	O
fusion	O
of	O
anergic	O
murine	O
T	O
cells	O
to	O
normal	O
murine	O
T	O
cells	O
also	O
failed	O
to	O
accumulate	O
intracellular	O
IL-2	O
protein	O
in	O
response	O
to	O
stimulation	O
either	O
with	O
the	O
combination	O
of	O
CD3	O
and	O
CD28	O
mAbs	O
or	O
with	O
ionomycin	O
plus	O
a	O
protein	O
kinase	O
C	O
-activating	O
phorbol	O
ester	O
.	O

The	O
results	O
argue	O
against	O
a	O
loss	O
-	O
of	O
-	O
function	O
signaling	O
defect	O
as	O
the	O
sole	O
basis	O
for	O
clonal	O
anergy	O
induction	O
and	O
document	O
the	O
presence	O
of	O
a	O
dominant	O
-	O
acting	O
repressor	O
molecule	O
that	O
inhibits	O
signal	O
transduction	O
to	O
the	O
IL-2	O
gene	O
within	O
viable	O
anergic	O
T	O
cells	O
.	O

Fas	O
ligand	O
induction	O
in	O
human	O
NK	O
cells	O
is	O
regulated	O
by	O
redox	O
through	O
a	O
calcineurin	O
-	O
nuclear	O
factors	O
of	O
activated	O
T	O
cell	O
-	O
dependent	O
pathway	O
.	O

Fas	O
ligand	O
(	O
FasL	O
)	O
on	O
cytotoxic	O
lymphocytes	O
is	O
important	O
for	O
mediating	O
apoptosis	O
of	O
activated	O
lymphocytes	O
and	O
other	O
target	O
cells	O
.	O

We	O
have	O
reported	O
that	O
NK	O
cell	O
functions	O
,	O
such	O
as	O
proliferation	O
,	O
cell	O
death	O
,	O
and	O
killing	O
activity	O
,	O
are	O
subject	O
to	O
regulation	O
by	O
cellular	O
redox	O
status	O
.	O

Here	O
,	O
we	O
report	O
that	O
expression	O
of	O
FasL	O
protein	O
and	O
mRNA	O
in	O
activated	O
NK	O
cells	O
is	O
also	O
regulated	O
by	O
redox	O
.	O

Ligation	O
of	O
CD16	O
on	O
IL-2-preactivated	O
NK	O
cells	O
resulted	O
in	O
reduction	O
of	O
intracellular	O
peroxide	O
level	O
as	O
well	O
as	O
induction	O
of	O
FasL	O
expression	O
.	O

This	O
CD16	O
-induced	O
FasL	O
expression	O
was	O
suppressed	O
by	O
oxidative	O
stress	O
,	O
including	O
thiol	O
deprivation	O
or	O
treatment	O
with	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

Addition	O
of	O
thiol	O
-	O
reducing	O
compounds	O
,	O
such	O
as	O
L	O
-	O
cystine	O
,	O
2-ME	O
,	O
or	O
N	O
-	O
acetyl	O
cysteine	O
,	O
restored	O
FasL	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
CD16	O
stimulation	O
requires	O
cellular	O
reducing	O
status	O
for	O
FasL	O
induction	O
in	O
NK	O
cells	O
.	O

Because	O
FasL	O
gene	O
activation	O
following	O
CD16	O
cross	O
-	O
linking	O
is	O
regulated	O
by	O
the	O
NF	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
we	O
examined	O
the	O
effect	O
of	O
oxidative	O
stresses	O
on	O
NFAT	O
activation	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
that	O
both	O
thiol	O
insufficiency	O
and	O
H2O2	O
treatment	O
suppressed	O
DNA	O
-	O
binding	O
activity	O
of	O
NFAT	O
and	O
that	O
addition	O
of	O
thiol	O
-	O
reducing	O
compounds	O
reversed	O
or	O
even	O
enhanced	O
it	O
.	O

Furthermore	O
,	O
these	O
oxidative	O
stresses	O
inhibited	O
activity	O
of	O
calcineurin	O
,	O
a	O
serine	O
/	O
threonine	O
phosphatase	O
that	O
regulates	O
NFAT	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
suppression	O
of	O
calcineurin	O
and	O
NFAT	O
activation	O
is	O
a	O
mechanism	O
by	O
which	O
oxidative	O
stress	O
inhibits	O
FasL	O
induction	O
in	O
activated	O
NK	O
cells	O
and	O
further	O
support	O
the	O
hypothesis	O
that	O
thiol	O
-	O
reducing	O
compounds	O
might	O
be	O
required	O
for	O
maintenance	O
of	O
optimal	O
NK	O
functions	O
under	O
physiologic	O
oxidative	O
conditions	O
.	O

Glucocorticoid	O
resistance	O
in	O
the	O
squirrel	O
monkey	O
is	O
associated	O
with	O
overexpression	O
of	O
the	O
immunophilin	O
FKBP51	O
.	O

Squirrel	O
monkeys	O
are	O
neotropical	O
primates	O
that	O
have	O
high	O
circulating	O
cortisol	O
to	O
compensate	O
for	O
expression	O
of	O
glucocorticoid	O
receptors	O
(	O
GRs	O
)	O
with	O
reduced	O
affinity	O
.	O

The	O
low	O
binding	O
affinity	O
of	O
squirrel	O
monkey	O
GR	O
does	O
not	O
result	O
from	O
substitutions	O
in	O
the	O
receptor	O
,	O
because	O
squirrel	O
monkey	O
GR	O
expressed	O
in	O
vitro	O
exhibits	O
high	O
affinity	O
.	O

Rather	O
,	O
squirrel	O
monkeys	O
express	O
a	O
soluble	O
factor	O
that	O
,	O
in	O
mixing	O
studies	O
of	O
cytosol	O
from	O
squirrel	O
monkey	O
lymphocytes	O
(	O
SML	O
)	O
and	O
mouse	O
L929	O
cells	O
,	O
reduced	O
GR	O
binding	O
affinity	O
by	O
11-fold	O
.	O

In	O
an	O
effort	O
to	O
identify	O
this	O
factor	O
,	O
the	O
cellular	O
levels	O
of	O
components	O
of	O
the	O
GR	O
heterocomplex	O
in	O
SML	O
and	O
human	O
lymphocytes	O
(	O
HL	O
)	O
were	O
compared	O
.	O

The	O
immunophilin	O
FKBP51	O
was	O
13-fold	O
higher	O
in	O
SML	O
than	O
in	O
HL	O
cytosol	O
;	O
FKBP52	O
in	O
SML	O
was	O
42	O
%	O
of	O
that	O
in	O
HL	O
cytosol	O
.	O

A	O
role	O
for	O
changes	O
in	O
immunophilins	O
,	O
causing	O
glucocorticoid	O
resistance	O
in	O
neotropical	O
primates	O
,	O
is	O
supported	O
by	O
the	O
following	O
:	O
the	O
changes	O
in	O
FKBP51	O
and	O
FKBP52	O
were	O
observed	O
in	O
cells	O
from	O
other	O
neotropical	O
primates	O
with	O
glucocorticoid	O
resistance	O
;	O
the	O
elevated	O
level	O
of	O
FKBP51	O
was	O
reflected	O
in	O
an	O
abundance	O
of	O
FKBP51	O
in	O
heat	O
shock	O
protein	O
90	O
complexes	O
in	O
SML	O
;	O
when	O
cytosols	O
of	O
SML	O
and	O
L929	B
cells	I
were	O
mixed	O
,	O
the	O
decrease	O
in	O
GR	O
binding	O
was	O
associated	O
with	O
incorporation	O
of	O
FKBP51	O
into	O
GR	O
heterocomplexes	O
;	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
was	O
reproduced	O
with	O
cytosol	O
from	O
COS	B
cells	I
expressing	O
squirrel	O
monkey	O
FKBP51	O
;	O
and	O
both	O
the	O
effect	O
of	O
SML	O
cytosol	O
on	O
GR	O
binding	O
and	O
the	O
incorporation	O
of	O
FKBP51	O
into	O
GR	O
heterocomplexes	O
were	O
blocked	O
by	O
FK506	O
.	O

Regulation	O
of	O
GR	O
binding	O
by	O
FKBP51	O
represents	O
a	O
previously	O
unrecognized	O
mechanism	O
for	O
regulating	O
glucocorticoid	O
sensitivity	O
.	O

Osteoclast	O
markers	O
accumulate	O
on	O
cells	O
developing	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
precursors	O
.	O

Recent	O
studies	O
show	O
that	O
human	O
osteoclasts	O
develop	O
in	O
vitro	O
from	O
hematopoietic	O
cells	O
;	O
however	O
,	O
special	O
cultures	O
conditions	O
and/or	O
cytokine	O
mobilized	O
peripheral	O
blood	O
are	O
apparently	O
required	O
.	O

Here	O
,	O
we	O
report	O
that	O
cells	O
expressing	O
osteoclast	O
markers	O
differentiate	O
from	O
precursors	O
present	O
in	O
nonmobilized	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
,	O
without	O
the	O
addition	O
of	O
stromal	O
cells	O
,	O
growth	O
factors	O
,	O
cytokines	O
or	O
steroids	O
;	O
and	O
characterize	O
their	O
phenotype	O
.	O

Three	O
days	O
after	O
establishing	O
high	O
-	O
density	O
PBMC	O
cultures	O
(	O
1.5	O
x	O
10	O
(	O
6	O
)	O
cells	O
/	O
cm2	O
)	O
,	O
in	O
serum	O
-	O
containing	O
medium	O
,	O
small	O
adherent	B
colonies	I
of	O
tartrate	B
resistant	I
acid	I
phosphatase	I
positive	I
(	I
TRAP+	I
)	I
cells	I
emerge	O
,	O
amidst	O
massive	O
monocyte	O
cell	O
death	O
.	O

These	O
adherent	O
cells	O
have	O
an	O
eccentrically	O
placed	O
,	O
round	O
nucleus	O
,	O
and	O
express	O
low	O
levels	O
of	O
TRAP	O
and	O
sodium	O
fluoride	O
-	O
resistant-	O
alpha	O
-	O
naphthyl	O
-	O
acetate	O
-	O
esterase	O
(	O
NaF	O
-	O
R	O
-	O
NSE	O
)	O
.	O

Over	O
the	O
next	O
week	O
,	O
this	O
cell	O
population	O
accumulates	O
phenotypic	O
markers	O
of	O
osteoclasts	O
(	O
vitronectin	O
receptor	O
[	O
VR	O
]	O
,	O
calcitonin	O
receptor	O
,	O
TRAP	O
,	O
cathepsin	O
K	O
protein	O
,	O
and	O
mRNA	O
)	O
with	O
increased	O
nuclearity	O
,	O
covering	O
the	O
entire	O
surface	O
by	O
15	O
days	O
.	O

When	O
cultured	O
on	O
bone	O
,	O
VR+	B
,	I
TRAP+	I
cells	I
of	O
low	O
multinuclearity	O
appear	O
and	O
cover	O
up	O
to	O
50	O
%	O
of	O
the	O
surface	O
.	O

Resorption	O
lacunae	O
can	O
be	O
observed	O
by	O
day	O
22	O
.	O

Although	O
these	O
pits	O
are	O
not	O
nearly	O
as	O
numerous	O
as	O
the	O
cells	O
of	O
preosteoclast	O
phenotype	O
,	O
they	O
do	O
represent	O
the	O
activity	O
of	O
a	O
subset	O
of	O
osteoclast	O
-	O
like	O
cells	O
that	O
has	O
achieved	O
osteoclastic	O
maturity	O
under	O
these	O
culture	O
conditions	O
.	O

Transcripts	O
for	O
osteoprotegerin	O
ligand	O
(	O
OPGL	O
)	O
,	O
an	O
osteoclast	O
differentiation	O
factor	O
(	O
also	O
known	O
as	O
RANKL	O
and	O
TRANCE	O
)	O
are	O
expressed	O
,	O
likely	O
by	O
adherent	O
cells	O
.	O

Thus	O
,	O
an	O
adherent	O
population	O
of	O
cells	O
,	O
with	O
preosteoclast	O
/	O
osteoclast	O
phenotypic	O
properties	O
,	O
arises	O
selectively	O
under	O
simple	O
culture	O
conditions	O
from	O
normal	O
PBMC	O
.	O

Further	O
characterization	O
of	O
these	O
cells	O
should	O
identify	O
factors	O
involved	O
in	O
the	O
growth	O
,	O
terminal	O
differentiation	O
and	O
activation	O
of	O
osteoclasts	O
.	O

Interleukin-10	O
inhibits	O
expression	O
of	O
both	O
interferon	O
alpha-	O
and	O
interferon	O
gamma-	O
induced	O
genes	O
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
helps	O
maintain	O
polarized	O
T	O
-	O
helper	O
cells	O
in	O
a	O
T	O
-	O
helper	O
lymphocyte	O
2	O
(	O
Th2	O
)	O
phenotype	O
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	O
cells	O
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	O
gamma	O
(	O
IFNgamma	O
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	O
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Because	O
monocytes	O
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed	O
-	O
type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	O
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha	O
-	O
induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL-10	O
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	O
or	O
IFNalpha	O
.	O

IL-10	O
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN	O
-	O
induced	O
genes	O
,	O
such	O
as	O
IP-10	O
,	O
ISG54	O
,	O
and	O
intercellular	O
adhesion	O
molecule-1	O
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	O
to	O
suppress	O
IFN	O
-induced	O
assembly	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
to	O
specific	O
promoter	O
motifs	O
on	O
IFNalpha-	O
and	O
IFNgamma	O
-	O
inducible	O
genes	O
.	O

This	O
was	O
accomplished	O
by	O
preventing	O
the	O
IFN	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
a	O
component	O
of	O
both	O
IFNalpha-	O
and	O
IFNgamma	O
-	O
induced	O
DNA	O
binding	O
complexes	O
.	O

Therefore	O
,	O
IL-10	O
can	O
directly	O
inhibit	O
STAT	O
-	O
dependent	O
early	O
response	O
gene	O
expression	O
induced	O
by	O
both	O
IFNalpha	O
and	O
IFNgamma	O
in	O
monocytes	O
by	O
suppressing	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	O
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
(	O
SOCS3	O
)	O
.	O

T	O
-	O
cell	O
expression	O
of	O
the	O
human	O
GATA-3	O
gene	O
is	O
regulated	O
by	O
a	O
non	O
-	O
lineage	O
-	O
specific	O
silencer	O
.	O

The	O
GATA-3	O
transcription	O
factor	O
is	O
required	O
for	O
development	O
of	O
the	O
T	B
-	I
cell	I
lineage	I
and	O
Th2	O
cytokine	O
gene	O
expression	O
in	O
CD4	O
T	O
-	O
cells	O
.	O

We	O
have	O
mapped	O
the	O
DNase	O
-	O
I	O
-	O
hypersensitive	O
(	O
HS	O
)	O
regions	O
of	O
the	O
human	O
GATA-3	O
gene	O
in	O
T	O
-	O
cells	O
and	O
non	O
-	O
T	O
-	O
cells	O
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O

HS	O
I	O
-	O
III	O
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	O
initiation	O
site	O
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non	O
-	O
hematopoietic	O
cells	O
,	O
whereas	O
HS	O
IV	O
-	O
VII	O
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	O
start	O
site	O
,	O
were	O
exclusively	O
observed	O
in	O
T	O
-	O
cells	O
.	O

Among	O
these	O
hypersensitive	O
sites	O
,	O
two	O
transcriptional	O
control	O
elements	O
were	O
found	O
,	O
one	O
in	O
the	O
first	O
intron	O
of	O
the	O
GATA-3	O
gene	O
and	O
the	O
other	O
between	O
8.3	O
and	O
5.9	O
kilobases	O
5	O
'	O
from	O
the	O
GATA-3	O
transcriptional	O
initiation	O
site	O
.	O

The	O
first	O
intron	O
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
and	O
with	O
no	O
cell	O
-	O
type	O
specificity	O
.	O

The	O
upstream	O
regulatory	O
element	O
could	O
confer	O
T	O
-	O
cell	O
specificity	O
to	O
the	O
GATA-3	O
promoter	O
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707-base	O
pair	O
silencer	O
that	O
drastically	O
inhibited	O
GATA-3	O
promoter	O
activity	O
in	O
non	O
-	O
T	O
-	O
cells	O
.	O

Two	O
CAGGTG	O
E	O
-	O
boxes	O
,	O
located	O
at	O
the	O
5'-	O
and	O
3'-ends	O
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O

The	O
3'-CAGGTG	O
E	O
-	O
box	O
could	O
bind	O
USF	O
proteins	O
,	O
the	O
ubiquitous	O
repressor	O
ZEB	O
,	O
or	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
proteins	O
E2A	O
and	O
HEB	O
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	O
and	O
E2A	O
/	O
HEB	O
proteins	O
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

Binding	O
of	O
c	O
-	O
Rel	O
to	O
STAT5	O
target	O
sequences	O
in	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
.	O

The	O
type	O
I	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
(	O
HTLV	O
-	O
I	O
)	O
induces	O
abnormal	O
growth	O
and	O
subsequent	O
transformation	O
of	O
T	O
cells	O
,	O
which	O
is	O
associated	O
with	O
the	O
development	O
of	O
an	O
acute	O
T	O
-	O
cell	O
malignancy	O
termed	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

A	O
characteristic	O
of	O
HTLV	O
-	O
I	O
-	O
transformed	O
T	O
cells	O
is	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
appears	O
to	O
be	O
essential	O
for	O
the	O
growth	O
of	O
these	O
transformed	O
cells	O
.	O

Although	O
NF	O
-	O
kappaB	O
/	O
Rel	O
factors	O
are	O
known	O
to	O
induce	O
the	O
expression	O
of	O
T	O
-	O
cell	O
growth	O
factor	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
it	O
is	O
unclear	O
how	O
they	O
participate	O
in	O
the	O
IL-2	O
-independent	O
growth	O
of	O
HTLV	B
-	I
I	I
-	I
transformed	I
cells	I
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
certain	O
NF	O
-	O
kappaB	O
/	O
Rel	O
members	O
,	O
predominantly	O
c	O
-	O
Rel	O
,	O
interact	O
with	O
enhancer	O
sequences	O
for	O
STAT5	O
,	O
a	O
key	O
transcription	O
factor	O
mediating	O
IL-2	O
-induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Reporter	O
gene	O
assays	O
reveal	O
that	O
the	O
binding	O
of	O
c	O
-	O
Rel	O
to	O
the	O
STAT5	O
site	O
present	O
in	O
the	O
Fc	O
gammaR1	O
gene	O
leads	O
to	O
potent	O
transactivation	O
of	O
this	O
enhancer	O
.	O

Binding	O
of	O
c	O
-	O
Rel	O
to	O
the	O
Fc	O
gammaR1	O
STAT	O
site	O
also	O
occurs	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
immortalized	O
with	O
HTLV	O
-	O
I	O
in	O
vitro	O
and	O
is	O
correlated	O
with	O
enhanced	O
levels	O
of	O
proliferation	O
of	O
these	O
cells	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
NF	O
-	O
kappaB	O
/	O
Rel	O
may	O
participate	O
in	O
the	O
growth	O
control	O
of	O
HTLV	B
-	I
I	I
-	I
transformed	I
T	I
cells	I
by	O
regulating	O
genes	O
driven	O
by	O
both	O
kappaB	O
and	O
certain	O
STAT	O
enhancers	O
.	O

AML	O
and	O
Ets	O
proteins	O
regulate	O
the	O
I	O
alpha1	O
germ	O
-	O
line	O
promoter	O
.	O

The	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
class	O
switch	O
recombination	O
of	O
B	O
lymphocytes	O
preferentially	O
targets	O
unrearranged	O
IgH	O
genes	O
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O

Transcription	O
of	O
the	O
germ	O
-	O
line	O
IgH	O
genes	O
is	O
controlled	O
by	O
intervening	O
(	O
I	O
)	O
regions	O
upstream	O
of	O
their	O
switch	O
regions	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	O
germ	O
-	O
line	O
C	O
alpha1	O
gene	O
for	O
IgA1	O
and	O
mediates	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-beta1	O
responsiveness	O
of	O
this	O
locus	O
.	O

Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML	O
/	O
PEBP2	O
/	O
CBF	O
family	O
of	O
transcription	O
factors	O
and	O
that	O
AML	O
and	O
Ets	O
proteins	O
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF	O
-	O
beta	O
-	O
inducible	O
promoter	O
activity	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF	O
-	O
beta	O
regulates	O
IgA	O
production	O
.	O

High	O
frequency	O
of	O
germ	O
-	O
line	O
BRCA2	O
mutations	O
among	O
Hungarian	O
male	O
breast	O
cancer	O
patients	O
without	O
family	O
history	O
.	O

To	O
determine	O
the	O
contribution	O
of	O
BRCA1	O
and	O
BRCA2	O
mutations	O
to	O
the	O
pathogenesis	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
,	O
the	O
country	O
with	O
the	O
highest	O
male	O
breast	O
cancer	O
mortality	O
rates	O
in	O
continental	O
Europe	O
,	O
a	O
series	O
of	O
18	O
male	O
breast	O
cancer	O
patients	O
and	O
three	O
patients	O
with	O
gynecomastia	O
was	O
analyzed	O
for	O
germ	O
-	O
line	O
mutations	O
in	O
both	O
BRCA1	O
and	O
BRCA2	O
.	O

Although	O
no	O
germ	O
-	O
line	O
BRCA1	O
mutation	O
was	O
observed	O
,	O
6	O
of	O
the	O
18	O
male	O
breast	O
cancer	O
cases	O
(	O
33	O
%	O
)	O
carried	O
truncating	O
mutations	O
in	O
the	O
BRCA2	O
gene	O
.	O

Unexpectedly	O
,	O
none	O
of	O
them	O
reported	O
a	O
family	O
history	O
for	O
breast	O
/	O
ovarian	O
cancer	O
.	O

Four	O
of	O
six	O
truncating	O
mutations	O
were	O
novel	O
,	O
and	O
two	O
mutations	O
were	O
recurrent	O
.	O

Four	O
patients	O
(	O
22	O
%	O
)	O
had	O
a	O
family	O
history	O
of	O
breast	O
/	O
ovarian	O
cancer	O
in	O
at	O
least	O
one	O
first-	O
or	O
second	O
-	O
degree	O
relative	O
;	O
however	O
,	O
no	O
BRCA2	O
mutation	O
was	O
identified	O
among	O
them	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
either	O
of	O
the	O
genes	O
in	O
the	O
gynecomastias	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
strong	O
genetic	O
component	O
of	O
male	O
breast	O
cancer	O
in	O
Hungary	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF	O
-	O
kappaB	O
inhibition	O
.	O

N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL-4	O
and	O
granulocyte	O
-	O
macrophage	O
CSF	O
.	O

We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS	O
-	O
induced	O
activity	O
of	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down	O
-	O
regulate	O
the	O
production	O
of	O
cytokines	O
by	O
DC	O
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA	O
-	O
DR	O
,	O
CD86	O
(	O
B7	O
-	O
2	O
)	O
,	O
and	O
CD40	O
molecules	O
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	O
engagement	O
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	O
due	O
to	O
nonspecific	O
toxicity	O
as	O
neither	O
the	O
viability	O
of	O
DC	O
nor	O
their	O
mannose	O
receptor	O
-	O
mediated	O
endocytosis	O
were	O
modified	O
by	O
NAC	O
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	O
T	O
cells	O
and	O
allogeneic	O
DC	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	O
could	O
be	O
attributed	O
to	O
a	O
defect	O
of	O
DC	O
as	O
APC	O
-	O
independent	O
T	O
cell	O
responses	O
were	O
not	O
inhibited	O
by	O
NAC	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O

NF	O
-	O
ATc	O
isoforms	O
are	O
differentially	O
expressed	O
and	O
regulated	O
in	O
murine	O
T	O
and	O
mast	O
cells	O
.	O

NF	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
denotes	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
regulate	O
the	O
activation	O
-	O
dependent	O
expression	O
of	O
many	O
immunologically	O
important	O
proteins	O
.	O

At	O
least	O
four	O
distinct	O
genes	O
encode	O
the	O
various	O
family	O
members	O
,	O
and	O
several	O
isoforms	O
of	O
these	O
have	O
been	O
identified	O
as	O
well	O
.	O

The	O
overlapping	O
expression	O
patterns	O
and	O
similar	O
in	O
vitro	O
binding	O
and	O
trans	O
-	O
activation	O
activities	O
on	O
various	O
promoter	O
elements	O
of	O
NF	O
-	O
AT	O
-	O
regulated	O
genes	O
suggest	O
some	O
redundancy	O
in	O
the	O
function	O
of	O
these	O
proteins	O
.	O

However	O
,	O
the	O
phenotypic	O
analysis	O
of	O
NF	O
-	O
AT	O
-deficient	O
mice	O
supports	O
the	O
idea	O
that	O
there	O
are	O
tissue-	O
and	O
gene-	O
specific	O
functions	O
as	O
well	O
.	O

In	O
this	O
study	O
we	O
have	O
characterized	O
the	O
expression	O
of	O
NF	O
-	O
AT	O
cDNAs	O
in	O
murine	O
mast	O
cells	O
.	O

The	O
majority	O
of	O
clones	O
identified	O
correspond	O
to	O
two	O
NF	O
-	O
ATc	O
isoforms	O
that	O
differ	O
only	O
in	O
their	O
amino	O
-	O
terminal	O
sequence	O
.	O

Despite	O
minimal	O
discrepancies	O
in	O
the	O
coding	O
region	O
,	O
there	O
are	O
striking	O
tissue-	O
and	O
cell	O
type	O
-	O
specific	O
differences	O
in	O
isoform	O
expression	O
patterns	O
.	O

Detection	O
of	O
NF-ATc.alpha	O
mRNA	O
is	O
strictly	O
dependent	O
on	O
cell	O
activation	O
signals	O
in	O
both	O
T	B
and	I
mast	I
cell	I
lines	I
.	O

In	O
contrast	O
,	O
the	O
beta	O
isoform	O
is	O
expressed	O
at	O
very	O
low	O
constitutive	O
levels	O
in	O
both	O
cell	O
types	O
but	O
is	O
only	O
up	O
-	O
regulated	O
in	O
response	O
to	O
mast	O
cell	O
activation	O
signals	O
delivered	O
through	O
the	O
FcepsilonRI	O
or	O
via	O
calcium	O
ionophores	O
.	O

These	O
results	O
demonstrate	O
another	O
level	O
of	O
regulation	O
within	O
the	O
NF	O
-	O
AT	O
family	O
that	O
can	O
contribute	O
to	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O

Detection	O
of	O
intracellular	O
phosphorylated	O
STAT-1	O
by	O
flow	O
cytometry	O
.	O

We	O
have	O
applied	O
flow	O
cytometry	O
to	O
the	O
investigation	O
of	O
interferon	O
-	O
gamma	O
activation	O
of	O
human	O
monocytes	O
.	O

This	O
approach	O
uses	O
monoclonal	O
antibodies	O
that	O
distinguish	O
between	O
the	O
native	O
and	O
phosphorylated	O
forms	O
of	O
STAT-1	O
.	O

It	O
enables	O
rapid	O
and	O
quantitative	O
assessment	O
of	O
STAT-1	O
phosphorylation	O
on	O
a	O
discrete	O
cell	O
basis	O
and	O
is	O
both	O
more	O
sensitive	O
and	O
less	O
time	O
consuming	O
than	O
immunoblotting	O
.	O

Furthermore	O
,	O
it	O
allows	O
for	O
discrimination	O
between	O
a	O
mixture	O
of	O
cells	O
that	O
differ	O
in	O
their	O
response	O
to	O
interferon	O
-	O
gamma	O
.	O

This	O
approach	O
should	O
allow	O
for	O
the	O
evaluation	O
of	O
different	O
intracellular	O
signaling	O
pathways	O
using	O
a	O
combination	O
of	O
monoclonal	O
reagents	O
that	O
are	O
specific	O
for	O
native	O
and	O
activation	O
modified	O
proteins	O
.	O

Application	O
of	O
this	O
form	O
of	O
testing	O
should	O
prove	O
valuable	O
in	O
screening	O
for	O
signaling	O
defects	O
in	O
selected	O
patients	O
with	O
recurrent	O
infections	O
.	O

In	O
addition	O
,	O
this	O
technique	O
should	O
permit	O
dissection	O
of	O
a	O
full	O
range	O
of	O
cellular	O
signaling	O
pathways	O
at	O
the	O
protein	O
level	O
.	O

Lineage	O
-	O
specific	O
activation	O
of	O
STAT3	O
by	O
interferon	O
-	O
gamma	O
in	O
human	O
neutrophils	O
.	O

Binding	O
of	O
interferon	O
-	O
gamma	O
(	O
IFN	O
-	O
gamma	O
)	O
to	O
its	O
heterodimeric	O
receptor	O
induces	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
JAK1	O
and	O
JAK2	O
followed	O
by	O
tyrosine	O
phosphorylation	O
of	O
STAT1alpha	O
.	O

Selective	O
activation	O
of	O
STAT1alpha	O
at	O
the	O
IFN	O
-	O
gamma	O
receptor	O
is	O
achieved	O
by	O
specific	O
interaction	O
between	O
a	O
cytosolic	O
tyrosine	O
motif	O
including	O
Y440	O
in	O
the	O
IFN	O
-	O
gamma	O
receptor	O
alpha	O
-	O
chain	O
and	O
the	O
SH2	O
domain	O
of	O
STAT1alpha	O
.	O

We	O
demonstrate	O
that	O
,	O
in	O
addition	O
to	O
STAT1alpha	O
,	O
STAT3	O
is	O
also	O
activated	O
by	O
IFN	O
-	O
gamma	O
in	O
human	O
neutrophils	O
.	O

The	O
activation	O
of	O
STAT3	O
was	O
not	O
found	O
in	O
human	O
eosinophils	O
,	O
monocytes	O
,	O
and	O
HL-60	B
cells	I
,	O
although	O
the	O
STAT3	O
protein	O
was	O
expressed	O
in	O
these	O
cells	O
.	O

The	O
cell	O
type	O
-	O
specific	O
activation	O
of	O
STAT3	O
by	O
IFN	O
-	O
gamma	O
was	O
also	O
observed	O
in	O
neutrophils	O
that	O
are	O
differentiated	O
in	O
vitro	O
from	O
human	O
CD34	O
+	O
hematopoietic	O
stem	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
single	O
cytokine	O
receptor	O
can	O
activate	O
different	O
STAT	O
family	O
members	O
in	O
a	O
cell	O
-	O
specific	O
manner	O
,	O
which	O
might	O
result	O
in	O
cell	O
-	O
specific	O
gene	O
transcription	O
.	O

Molecular	O
mechanisms	O
of	O
neutrophil	O
-	O
endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
and	O
transcriptional	O
regulation	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG	O
/	O
GSH	O
-	O
induced	O
adhesion	O
response	O
.	O

Treatment	O
of	O
human	B
umbilical	I
vein	I
endothelial	I
cell	I
(	I
HUVEC	I
)	I
monolayers	I
for	O
6	O
hours	O
with	O
0.2	O
mmol	O
/	O
L	O
diamide	O
and	O
1	O
mmol	O
/	O
L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	O
cell	O
toxicity	O
.	O

These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia	O
/	O
reoxygenation	O
.	O

Diamide	O
plus	O
BSO	O
-	O
induced	O
thiol	O
/	O
disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	B
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

N	O
-	O
Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	O
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	O
with	O
the	O
GSSG	O
/	O
GSH	O
ratio	O
,	O
whereas	O
phase	O
2	O
neutrophil	O
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG	O
/	O
GSH	O
ratio	O
but	O
not	O
with	O
GSH	O
levels	O
.	O

Intercellular	O
adhesion	O
molecule-1	O
and	O
P	O
-	O
selectin	O
-	O
specific	O
monoclonal	O
antibodies	O
attenuated	O
the	O
increased	O
neutrophil	O
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti	O
-	O
E	O
-	O
selectin	O
monoclonal	O
antibody	O
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds	O
-	O
oligonucleotides	O
that	O
contained	O
nuclear	O
factor	O
-	O
kappaB	O
or	O
activator	O
protein-1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
,	O
P	O
-	O
selectin	O
,	O
and	O
E	O
-	O
selectin	O
on	O
HUVECs	B
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG	O
/	O
GSH	O
cause	O
transcription	O
-	O
independent	O
and	O
transcription	O
-	O
dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
,	O
which	O
leads	O
to	O
a	O
2-phase	O
neutrophil	O
-endothelial	O
adhesion	O
response	O
.	O

T	O
helper	O
differentiation	O
proceeds	O
through	O
Stat1-dependent	O
,	O
Stat4-dependent	O
and	O
Stat4-independent	O
phases	O
.	O

Much	O
of	O
our	O
focus	O
in	O
understanding	O
Th1	O
/	O
Th2	O
development	O
has	O
been	O
on	O
the	O
signals	O
delivered	O
by	O
IL-12	O
and	O
IL-4	O
as	O
final	O
determinants	O
of	O
terminal	O
T	O
cell	O
differentiation	O
.	O

Because	O
extinction	O
of	O
IL-12	O
signaling	O
in	O
early	O
Th2	O
development	O
could	O
potentially	O
be	O
important	O
in	O
imprinting	O
a	O
more	O
permanent	O
Th2	O
phenotype	O
on	O
a	O
population	O
of	O
T	O
cells	O
,	O
we	O
have	O
also	O
examined	O
various	O
parameters	O
regulating	O
the	O
IL-12	O
signaling	O
pathway	O
.	O

Whereas	O
IL-4	O
appears	O
to	O
repress	O
functional	O
IL-12	O
signaling	O
through	O
inhibition	O
of	O
IL-12R	O
beta	O
2	O
expression	O
,	O
IFN	O
-	O
gamma	O
in	O
the	O
mouse	O
,	O
and	O
IFN	O
-	O
alpha	O
in	O
the	O
human	O
appear	O
to	O
induce	O
IL-12R	O
beta	O
2	O
expression	O
and	O
promote	O
IL-12	O
responsiveness	O
.	O

We	O
propose	O
that	O
Th1	O
development	O
can	O
be	O
considered	O
in	O
two	O
stages	O
,	O
capacitance	O
and	O
development	O
.	O

Capacitance	O
would	O
simply	O
involve	O
expression	O
of	O
IL-12R	O
beta	O
1	O
and	O
beta	O
2	O
subunits	O
,	O
regulated	O
by	O
TCR	O
,	O
IL-4	O
and	O
IFNs	O
.	O

The	O
second	O
stage	O
,	O
development	O
,	O
we	O
propose	O
is	O
the	O
true	O
IL-12	O
induced	O
developmental	O
stage	O
,	O
involving	O
expression	O
of	O
Stat4	O
inducible	O
proteins	O
.	O

In	O
the	O
human	O
,	O
this	O
may	O
also	O
occur	O
via	O
IFN	O
-	O
alpha	O
,	O
which	O
is	O
able	O
to	O
activate	O
Stat4	O
.	O

It	O
is	O
perhaps	O
possible	O
that	O
all	O
of	O
Stat4	O
actions	O
on	O
Th1	O
development	O
may	O
be	O
exert	O
directly	O
by	O
Stat4	O
at	O
the	O
IFN	O
-	O
gamma	O
gene	O
,	O
however	O
we	O
suggest	O
that	O
,	O
more	O
likely	O
,	O
Stat4	O
may	O
act	O
to	O
induce	O
Th1	O
development	O
through	O
the	O
induction	O
of	O
other	O
non	O
-	O
cytokine	O
genes	O
,	O
whose	O
stable	O
expression	O
maintains	O
the	O
transcriptional	O
state	O
of	O
a	O
Th1	O
cell	O
.	O

The	O
relationship	O
between	O
Ca2	O
+	O
-ATPase	O
and	O
freely	O
exchangeable	O
Ca2	O
+	O
in	O
the	O
dense	O
tubules	O
:	O
a	O
study	O
in	O
platelets	O
from	O
women	O
.	O

The	O
main	O
aims	O
of	O
this	O
work	O
were	O
to	O
examine	O
in	O
women	O
:	O
the	O
relationship	O
between	O
the	O
freely	O
exchangeable	O
Ca2	O
+	O
(	O
FECa2	O
+	O
)	O
in	O
the	O
dense	O
tubules	O
and	O
the	O
activity	O
of	O
the	O
sarco	O
(	O
endo	O
)	O
plasmic	O
reticulum	O
(	O
SER	O
)	O
Ca2	O
+	O
-ATPase	O
(	O
SERCA	O
)	O
in	O
platelets	O
,	O
and	O
the	O
relationship	O
of	O
these	O
parameters	O
with	O
blood	O
pressure	O
and	O
serum	O
lipoproteins	O
.	O

Platelets	O
from	O
14	O
white	O
and	O
13	O
black	O
women	O
in	O
good	O
health	O
were	O
studied	O
.	O

The	O
FECa2	O
+	O
was	O
measured	O
as	O
the	O
ionomycin	O
-	O
evoked	O
Ca2	O
+	O
release	O
(	O
in	O
the	O
presence	O
of	O
thapsigargin	O
)	O
in	O
Ca2	O
+	O
-free	O
medium	O
.	O

SERCA	O
activity	O
was	O
measured	O
as	O
the	O
thapsigargin	O
sensitive	O
,	O
Ca2	O
+	O
dependent	O
and	O
ouabain	O
resistant	O
,	O
ATP	O
hydrolyses	O
in	O
platelet	O
membranes	O
.	O

Relative	O
expressions	O
of	O
SERCA	O
2	O
and	O
3	O
isoforms	O
and	O
Ras	O
-	O
related	O
protein	O
(	O
Rap	O
)	O
1	O
in	O
platelet	O
membranes	O
were	O
determined	O
by	O
Western	O
immunoblots	O
.	O

Highly	O
significant	O
correlations	O
were	O
observed	O
for	O
FECa2	O
+	O
in	O
the	O
dense	O
tubules	O
with	O
:	O
1	O
)	O
the	O
maximal	O
reaction	O
velocity	O
(	O
Vmax	O
)	O
of	O
the	O
SERCA	O
(	O
r	O
=	O
0.592	O
,	O
P	O
=	O
.0014	O
)	O
,	O
and	O
2	O
)	O
Rapl	O
(	O
r	O
=	O
0.551	O
,	O
P	O
=	O
.0035	O
)	O
.	O

In	O
addition	O
,	O
negative	O
correlations	O
were	O
observed	O
between	O
FECa2	O
+	O
in	O
the	O
dense	O
tubules	O
and	O
age	O
.	O

No	O
correlations	O
were	O
observed	O
for	O
these	O
variables	O
with	O
blood	O
pressure	O
or	O
serum	O
lipoproteins	O
.	O

We	O
conclude	O
the	O
FECa2	O
+	O
and	O
the	O
Vmax	O
of	O
the	O
SERCA	O
are	O
reliable	O
indicators	O
of	O
Ca2	O
+	O
load	O
in	O
platelets	O
from	O
women	O
.	O

However	O
,	O
in	O
women	O
,	O
unlike	O
previous	O
observations	O
in	O
men	O
,	O
these	O
platelet	O
parameters	O
are	O
not	O
correlated	O
with	O
blood	O
pressure	O
and	O
serum	O
lipoproteins	O
.	O

Apoptosis	B
-	I
resistant	I
T	I
cells	I
have	O
a	O
deficiency	O
in	O
NF	O
-	O
kappaB	O
-mediated	O
induction	O
of	O
Fas	O
ligand	O
transcription	O
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4	O
+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	B
Jurkat	I
cells	I
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	O
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL-2	O
and	O
IFN	O
-	O
gamma	O
)	O
production	O
is	O
normal	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	O
and	O
a	O
consensus	O
NF	O
-	O
kappaB-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	O
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF	O
-	O
kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
the	O
regulation	O
of	O
FasL	O
expression	O
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	O
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF	O
-	O
kappaB	O
deprivation	O
.	O

NF	O
-	O
kappaB	O
regulates	O
Fas	O
/	O
APO-1	O
/	O
CD95-	O
and	O
TCR-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF	O
-	O
kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas	O
/	O
APO-1	O
/	O
CD95	O
-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	O
of	O
Jurkat	B
cells	I
with	O
the	O
NF	O
-	O
kappaB	O
subunits	O
p50	O
and	O
p65	O
confers	O
resistance	O
against	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	B
cell	I
hybridoma	I
more	O
susceptible	O
to	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	O
and	O
p65	O
provided	O
considerable	O
protection	O
from	O
TCR	O
-	O
mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas	O
-mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O

Concanavalin	O
A	O
-	O
activated	O
cycling	B
T	I
cell	I
blasts	I
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF	O
-	O
kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti	O
-	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF	O
-	O
kappaB	O
protects	O
against	O
Fas	O
-mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

Constitutive	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
primary	O
adult	O
T	O
-	O
cell	O
leukemia	O
cells	O
.	O

Human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	O
protein	O
Tax	O
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV	O
-	O
I	O
.	O

However	O
,	O
the	O
HTLV	O
-	O
I	O
genes	O
including	O
Tax	O
are	O
not	O
expressed	O
significantly	O
in	O
primary	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF	O
-	O
kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV	B
-	I
I	I
-	I
infected	I
T	I
-	I
cell	I
lines	I
,	O
display	O
constitutive	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	O
(	O
an	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
)	O
.	O

Whereas	O
the	O
NF	O
-	O
kappaB	O
binding	O
activity	O
in	O
Tax	B
-	I
expressing	I
T	I
-	I
cell	I
lines	I
consisted	O
mostly	O
of	O
p50	O
/	O
c	O
-	O
Rel	O
,	O
fresh	O
ATL	O
samples	O
contained	O
p50	O
/	O
p50	O
and	O
p50	O
/	O
p65	O
heterodimers	O
.	O

One	O
T	B
-	I
cell	I
line	I
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL	O
-	O
Om1	O
,	O
displayed	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	O
,	O
despite	O
the	O
lack	O
of	O
detectable	O
Tax	O
expression	O
.	O

Interestingly	O
,	O
the	O
NF	O
-	O
kappaB	O
in	O
TL	O
-	O
Om1	O
consists	O
of	O
p50	O
/	O
p50	O
and	O
p50	O
/	O
p65	O
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
a	O
Tax	O
-independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF	O
-	O
kappaB	O
subunit	O
activation	O
.	O

Differential	O
regulation	O
of	O
4E	O
-	O
BP1	O
and	O
4E	O
-	O
BP2	O
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL-60	B
promyelocytic	I
leukemia	I
cell	I
line	I
and	O
the	O
U-937	B
monoblastic	I
cell	I
line	I
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E	O
-	O
BP1	O
and	O
4E	O
-	O
BP2	O
.	O

Induction	O
of	O
HL-60	B
and	O
U-937	B
cell	O
differentiation	O
into	O
monocytes	O
/	O
macrophages	O
by	O
IFN	O
-	O
gamma	O
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E	O
-	O
BP1	O
.	O

Dephosphorylation	O
of	O
4E	O
-	O
BP1	O
was	O
also	O
observed	O
when	O
U-937	B
cells	I
were	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
/	O
macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL-60	B
cells	I
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E	O
-	O
BP1	O
amount	O
without	O
affecting	O
its	O
phosphorylation	O
and	O
strongly	O
increases	O
4E	O
-	O
BP2	O
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic	O
/	O
macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Characterization	O
of	O
expression	O
of	O
the	O
gene	O
for	O
human	O
pterin	O
carbinolamine	O
dehydratase	O
/	O
dimerization	O
cofactor	O
of	O
HNF1	O
.	O

Pterin	O
carbinolamine	O
dehydratase	O
/	O
dimerization	O
cofactor	O
of	O
HNF1	O
(	O
PCD	O
/	O
DCoH	O
)	O
is	O
a	O
dual	O
-	O
function	O
protein	O
.	O

In	O
the	O
cytoplasm	O
it	O
acts	O
as	O
a	O
dehydratase	O
in	O
the	O
regeneration	O
of	O
tetrahydrobiopterin	O
,	O
the	O
cofactor	O
for	O
aromatic	O
amino	O
acid	O
hydroxylases	O
.	O

In	O
the	O
nucleus	O
,	O
it	O
functions	O
as	O
a	O
dimerization	O
cofactor	O
of	O
HNF1	O
and	O
increases	O
the	O
transcriptional	O
activity	O
of	O
HNF1	O
.	O

To	O
deepen	O
our	O
understanding	O
of	O
this	O
protein	O
,	O
we	O
characterized	O
its	O
expression	O
in	O
human	O
tissues	O
and	O
cells	O
.	O

Human	O
PCD	O
/	O
DCoH	O
was	O
present	O
predominantly	O
in	O
liver	O
and	O
kidney	O
,	O
with	O
significant	O
amounts	O
in	O
testis	O
and	O
ovary	O
,	O
trace	O
amounts	O
in	O
lung	O
,	O
and	O
undetectable	O
levels	O
in	O
whole	O
brain	O
,	O
heart	O
,	O
and	O
spleen	O
.	O

It	O
was	O
expressed	O
in	O
all	O
of	O
the	O
cells	O
that	O
were	O
examined	O
.	O

Importantly	O
,	O
it	O
was	O
also	O
present	O
in	O
the	O
nucleus	O
of	O
HeLa	B
cells	I
,	O
which	O
lack	O
HNF1	O
,	O
and	O
in	O
the	O
cytoplasm	O
of	O
fibroblasts	O
that	O
have	O
little	O
or	O
no	O
tetrahydrobiopterin	O
.	O

The	O
expression	O
of	O
human	O
PCD	O
/	O
DCoH	O
in	O
the	O
liver	O
and	O
nonhepatic	O
cells	O
was	O
compared	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

Although	O
the	O
mRNA	O
level	O
in	O
liver	O
was	O
only	O
fourfold	O
higher	O
than	O
that	O
in	O
keratinocytes	O
and	O
fibroblasts	O
,	O
the	O
hepatic	O
PCD	O
/	O
DCoH	O
protein	O
level	O
was	O
20-fold	O
higher	O
than	O
that	O
in	O
normal	O
human	O
epidermal	O
keratinocytes	O
and	O
dermal	O
fibroblasts	O
.	O

Cloning	O
of	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
human	O
keratinocyte	O
PCD	O
/	O
DCoH	O
revealed	O
that	O
it	O
has	O
53	O
bp	O
more	O
of	O
GC	O
-	O
rich	O
5	O
'	O
untranslated	O
sequence	O
than	O
the	O
published	O
liver	O
PCD	O
/	O
DCoH	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
analysis	O
showed	O
that	O
the	O
longer	O
5	O
'	O
UTR	O
resulted	O
in	O
about	O
a	O
35	O
%	O
decrease	O
in	O
translation	O
efficiency	O
.	O

These	O
data	O
show	O
that	O
human	O
PCD	O
/	O
DCoH	O
is	O
not	O
only	O
present	O
in	O
cells	O
where	O
tetrahydrobiopterin	O
is	O
synthesized	O
or	O
HNF1	O
is	O
present	O
but	O
is	O
a	O
widely	O
distributed	O
protein	O
.	O

Its	O
differential	O
expression	O
in	O
different	O
tissues	O
and	O
cells	O
is	O
regulated	O
not	O
only	O
at	O
the	O
transcriptional	O
level	O
but	O
also	O
at	O
the	O
translational	O
level	O
.	O

Jeg-3	O
human	O
choriocarcinoma	O
-	O
induced	O
immunosuppression	O
:	O
downregulation	O
of	O
interleukin-2	O
,	O
interleukin-2	O
receptor	O
alpha	O
-	O
chain	O
,	O
and	O
its	O
Jak	O
/	O
Stat	O
signaling	O
pathway	O
.	O

PROBLEM	O
:	O
The	O
mechanisms	O
of	O
the	O
immunosuppressive	O
and	O
immunosuppression	O
-	O
inducing	O
capacities	O
of	O
Jeg-3	B
human	I
choriocarcinoma	I
cell	I
line	I
supernatants	O
(	O
HCSs	O
)	O
are	O
not	O
yet	O
completely	O
understood	O
.	O

The	O
influence	O
on	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
IL-4	O
and	O
interferon	O
(	O
IFN	O
)	O
-gamma	O
production	O
;	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
alpha	O
-	O
,	O
beta	O
-	O
,	O
and	O
gamma	O
-	O
chain	O
;	O
and	O
the	O
signaling	O
pathway	O
molecules	O
Janus	O
kinase	O
(	O
Jak	O
)	O
1	O
,	O
Jak3	O
,	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
should	O
be	O
investigated	O
.	O

METHOD	O
OF	O
STUDY	O
:	O
For	O
assessment	O
of	O
IL	O
production	O
,	O
whole	O
peripheral	O
venous	O
blood	O
from	O
healthy	O
donors	O
was	O
stimulated	O
with	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
.	O

Secretion	O
of	O
ILs	O
was	O
blocked	O
with	O
monensine	O
.	O

Intracellular	O
ILs	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

For	O
IL-2R	O
and	O
signaling	O
pathway	O
molecule	O
analysis	O
,	O
peripheral	O
blood	O
lymphocytes	O
were	O
stimulated	O
with	O
phytohemagglutinin	O
(	O
PHA	O
)	O
.	O

IL-2R	O
chains	O
were	O
measured	O
by	O
flow	O
cytometry	O
,	O
and	O
Jaks	O
/	O
Stats	O
by	O
sodium	O
dodecyl	O
sulfate	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Phorbol	O
-	O
myristate	O
-	O
acetate	O
and	O
ionomycine	O
strongly	O
increase	O
the	O
percent	O
-	O
age	O
of	O
IL-2	B
+	I
cells	I
;	O
an	O
additional	O
50	O
%	O
HCSs	O
significantly	O
suppresses	O
the	O
percentage	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

IFN	O
-	O
gamma	O
production	O
is	O
strongly	O
decreased	O
by	O
HCSs	O
in	O
some	O
cases	O
,	O
but	O
not	O
in	O
others	O
.	O

PHA	O
stimulates	O
IL-2R	O
alpha-	O
,	O
beta-	O
,	O
and	O
gamma	O
-	O
chain	O
expression	O
and	O
their	O
signaling	O
pathway	O
molecules	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
.	O

50	O
%	O
HCS	O
downregulates	O
the	O
alpha	O
-	O
chain	O
and	O
slightly	O
upregulates	O
the	O
beta	O
-	O
chain	O
.	O

Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
is	O
suppressed	O
approximately	O
to	O
,	O
or	O
below	O
the	O
level	O
of	O
unstimulated	O
cells	O
.	O

CONCLUSIONS	O
:	O
HCS	O
forcefully	O
blocks	O
the	O
production	O
of	O
IL-2	O
;	O
the	O
IL-2R	O
alpha	O
-	O
chain	O
;	O
and	O
Jak1	O
,	O
Jak3	O
,	O
Stat1	O
,	O
Stat3	O
,	O
and	O
Stat5	O
expression	O
.	O

The	O
observed	O
phenomena	O
might	O
be	O
caused	O
by	O
downregulation	O
of	O
an	O
IL-2R	O
regulation	O
gene	O
,	O
and	O
might	O
play	O
a	O
key	O
role	O
in	O
the	O
expansion	O
of	O
choriocarcinoma	O
,	O
and	O
possibly	O
in	O
the	O
survival	O
of	O
the	O
fetal	O
allograft	O
.	O

[	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
by	O
glucocorticoids	O
:	O
between	O
physiology	O
and	O
pharmacology	O
]	O

Glucocorticoids	O
are	O
physiological	O
molecules	O
that	O
are	O
also	O
extensively	O
used	O
in	O
clinics	O
as	O
anti	O
-	O
inflammatory	O
,	O
immunosuppressive	O
or	O
anti	O
-	O
tumoral	O
agents	O
.	O

Glucocorticoids	O
can	O
induce	O
apoptosis	O
on	O
normal	O
lymphoid	O
cells	O
and	O
play	O
a	O
key	O
role	O
in	O
the	O
physiology	O
of	O
thymic	O
selection	O
.	O

In	O
clinics	O
these	O
molecules	O
are	O
also	O
used	O
for	O
their	O
potencies	O
in	O
inducing	O
apoptosis	O
of	O
malignant	O
lymphoid	O
cells	O
.	O

Glucocorticoids	O
are	O
mediating	O
their	O
effects	O
after	O
binding	O
to	O
an	O
intracellular	O
receptor	O
belonging	O
to	O
the	O
steroid	O
receptor	O
superfamily	O
:	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
.	O

Once	O
activated	O
,	O
the	O
GR	O
,	O
can	O
mediate	O
his	O
effects	O
through	O
direct	O
binding	O
on	O
the	O
DNA	O
or	O
via	O
protein	O
/	O
protein	O
interactions	O
with	O
transcription	O
factors	O
.	O

Depending	O
on	O
the	O
type	O
of	O
lymphocytes	O
,	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
glucocorticoids	O
fall	O
roughly	O
in	O
two	O
categories	O
:	O
induction	O
of	O
`	O
`	O
death	O
genes	O
''	O
by	O
the	O
activated	O
GR	O
(	O
I	O
kappa	O
B	O
,	O
c	O
-	O
jun	O
)	O
or	O
repression	O
of	O
survival	O
factors	O
(	O
AP-1	O
,	O
c	O
-	O
Myc	O
)	O
.	O

In	O
the	O
case	O
of	O
thymic	O
selection	O
the	O
mechanism	O
is	O
more	O
subtle	O
depending	O
on	O
the	O
mutual	O
repression	O
of	O
Nur77	O
and	O
GR	O
.	O

A	O
human	O
IFNGR1	O
small	O
deletion	O
hotspot	O
associated	O
with	O
dominant	O
susceptibility	O
to	O
mycobacterial	O
infection	O
[	O
see	O
comments	O
]	O

The	O
immunogenetic	O
basis	O
of	O
severe	O
infections	O
caused	O
by	O
bacille	O
Calmette	O
-	O
Guerin	O
vaccine	O
and	O
environmental	O
mycobacteria	O
in	O
humans	O
remains	O
largely	O
unknown	O
.	O

We	O
describe	O
18	O
patients	O
from	O
several	O
generations	O
of	O
12	O
unrelated	O
families	O
who	O
were	O
heterozygous	O
for	O
1	O
to	O
5	O
overlapping	O
IFNGR1	O
frameshift	O
small	O
deletions	O
and	O
a	O
wild	O
-	O
type	O
IFNGR1	O
allele	O
.	O

There	O
were	O
12	O
independent	O
mutation	O
events	O
at	O
a	O
single	O
mutation	O
site	O
,	O
defining	O
a	O
small	O
deletion	O
hotspot	O
.	O

Neighbouring	O
sequence	O
analysis	O
favours	O
a	O
small	O
deletion	O
model	O
of	O
slipped	O
mispairing	O
events	O
during	O
replication	O
.	O

The	O
mutant	O
alleles	O
encode	O
cell	O
-	O
surface	O
IFNgamma	O
receptors	O
that	O
lack	O
the	O
intra	O
-	O
cytoplasmic	O
domain	O
,	O
which	O
,	O
through	O
a	O
combination	O
of	O
impaired	O
recycling	O
,	O
abrogated	O
signalling	O
and	O
normal	O
binding	O
to	O
IFNgamma	O
exert	O
a	O
dominant	O
-	O
negative	O
effect	O
.	O

We	O
thus	O
report	O
a	O
hotspot	O
for	O
human	O
IFNGR1	O
small	O
deletions	O
that	O
confer	O
dominant	O
susceptibility	O
to	O
infections	O
caused	O
by	O
poorly	O
virulent	O
mycobacteria	O
.	O

Erythroid	O
gene	O
expression	O
is	O
differentially	O
regulated	O
by	O
erythropoietin	O
,	O
haemin	O
and	O
delta	O
-	O
aminolaevulinic	O
acid	O
in	O
UT-7	B
cells	I
.	O

Erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
later	O
stages	O
of	O
erythropoiesis	O
,	O
acting	O
to	O
promote	O
cell	O
survival	O
and	O
proliferation	O
,	O
but	O
its	O
role	O
in	O
differentiation	O
remains	O
to	O
be	O
defined	O
.	O

The	O
UT-7	B
cell	I
line	I
exhibits	O
both	O
erythroid	O
and	O
megakaryocytic	O
characteristics	O
and	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
pathway	O
by	O
Epo	O
or	O
the	O
megakaryocytic	O
pathway	O
by	O
phorbol	O
myristic	O
acetate	O
.	O

We	O
have	O
compared	O
the	O
effects	O
of	O
Epo	O
and	O
the	O
chemical	O
inducers	O
,	O
delta	O
-	O
aminolaevulinic	O
acid	O
(	O
delta	O
-	O
ALA	O
)	O
and	O
haemin	O
on	O
the	O
differentiation	O
capacity	O
of	O
UT-7	B
cells	I
.	O

Epo	O
alone	O
promoted	O
relatively	O
early	O
events	O
in	O
erythroid	O
maturation	O
,	O
without	O
significant	O
changes	O
in	O
haemoglobin	O
production	O
or	O
morphology	O
.	O

GATA-2	O
and	O
c	O
-	O
myb	O
were	O
down	O
-	O
regulated	O
by	O
Epo	O
,	O
and	O
GATA-2	O
was	O
further	O
down	O
-	O
modulated	O
by	O
the	O
inducers	O
.	O

Conversely	O
,	O
SCL	O
expression	O
was	O
up	O
-	O
regulated	O
by	O
Epo	O
and	O
further	O
increased	O
by	O
haemin	O
and	O
delta	O
-	O
ALA	O
.	O

Epo	O
caused	O
an	O
increase	O
in	O
the	O
proportion	O
of	O
cells	O
expressing	O
cell	O
surface	O
glycophorin	O
A	O
(	O
GPA	O
)	O
and	O
up	O
-	O
regulated	O
beta-	O
and	O
gamma	O
-	O
globin	O
by	O
several	O
fold	O
.	O

Both	O
haemin	O
and	O
delta	O
-	O
ALA	O
caused	O
a	O
de	O
novo	O
increase	O
in	O
alpha	O
-	O
globin	O
expression	O
as	O
well	O
as	O
enhancing	O
Epo	O
-induced	O
beta	O
-	O
globin	O
expression	O
,	O
leading	O
to	O
a	O
marked	O
increase	O
in	O
haemoglobin	O
production	O
.	O

These	O
results	O
suggest	O
that	O
haemoglobin	O
production	O
in	O
UT-7	B
cells	I
is	O
limited	O
by	O
a	O
deficiency	O
of	O
erythroid	O
-	O
specific	O
aminolaevulinic	O
acid	O
synthase	O
(	O
ALAS	O
-	O
E	O
)	O
activity	O
or	O
globin	O
synthesis	O
as	O
a	O
consequence	O
of	O
their	O
immaturity	O
as	O
a	O
multipotential	B
cell	I
line	I
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	O
phosphatase	O
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	O
activation	O
in	O
T	O
lymphocytes	O
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB	O
-	O
alpha	O
phosphorylation	O
and	O
degradation	O
.	O

Nuclear	O
Factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF	O
-	O
alpha	O
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65	O
-	O
50	O
heterodimer	O
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	O
induction	O
in	O
TNF	O
-	O
alpha	O
treated	O
T	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
PAO	O
-	O
sensitive	O
phosphatase	O
in	O
the	O
activation	O
of	O
the	O
NFkappaB	O
via	O
this	O
pathway	O
in	O
human	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	O
influence	O
the	O
sensitivity	O
of	O
this	O
phosphatase	O
.	O

Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	O
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	O
to	O
degrade	O
IkappaB	O
-	O
alpha	O
in	O
cytosols	O
of	O
TNF	O
-	O
treated	O
T	O
cells	O
pretreated	O
with	O
PAO	O
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB	O
-	O
alpha	O
and	O
not	O
due	O
to	O
its	O
inhibitory	O
effect	O
on	O
proteasomal	O
degradation	O
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB	O
-	O
alpha	O
,	O
induced	O
by	O
TNF	O
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	O
,	O
independent	O
of	O
age	O
.	O

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factors	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
1	O
,	O
2	O
,	O
or	O
3	O
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT	O
/	O
S	O
in	O
STP	O
-	O
A11	O
as	O
critical	O
for	O
TRAF	O
association	O
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP	O
-	O
C488	O
is	O
critical	O
for	O
TRAF	O
association	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP	O
-	O
C488	O
induced	O
NF	O
-	O
kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	O
.	O

The	O
HVS	O
STP	O
-	O
C488	O
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T	O
-	O
lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild	O
-	O
type	O
phenotype	O
for	O
marmoset	O
T	O
-	O
lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP	O
-	O
C488	O
P10	O
--	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat-1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	O
dominant	O
-	O
negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	O
in	O
STP	O
-	O
C488	O
-mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP-1	O
expression	O
in	O
the	O
NKL	B
human	I
NK	I
cell	I
line	I
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	B
NKL	I
cell	I
line	I
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	O
early	O
activator	O
protein	O
(	O
AP	O
)	O
-1	O
transcription	O
factor	O
genes	O
such	O
as	O
JunB	O
,	O
FosB	O
and	O
c	O
-	O
Fos	O
.	O

In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	O
-	O
Fos	O
heterodimers	O
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	O
between	O
immunoglobulin	O
-	O
like	O
transcript-2	O
/	O
leukocyte	O
Ig	O
-	O
like	O
receptor	O
1	O
on	O
NKL	O
cells	O
and	O
HLA	O
-	O
B27	O
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	O
of	O
JunB	O
,	O
FosB	O
,	O
and	O
c	O
-	O
Fos	O
transcription	O
,	O
as	O
well	O
as	O
an	O
absence	O
of	O
their	O
DNA	O
-	O
binding	O
activity	O
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell	O
-	O
mediated	O
lysis	O
,	O
AP-1	O
transcription	O
factor	O
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	O
cell	O
inhibitory	O
receptors	O
for	O
MHC	O
class	O
I	O
molecules	O
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP-1	O
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	O
monocytes	O
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	O
genes	O
(	O
IL-1beta	O
,	O
A20	O
,	O
NF	O
-	O
kappaB	O
-	O
p105	O
/	O
p50	O
,	O
and	O
IkappaBalpha	O
)	O
in	O
unactivated	O
monocytes	O
and	O
that	O
neutralizing	O
Abs	O
to	O
the	O
major	O
HCMV	O
glycoproteins	O
,	O
gB	O
(	O
UL55	O
)	O
and	O
gH	O
(	O
UL75	O
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up	O
-	O
regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	O
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	O
protein	O
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF	O
-	O
kappaB	O
sites	O
in	O
their	O
promoter	O
regions	O
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up	O
-	O
regulation	O
of	O
nuclear	O
NF	O
-	O
kappaB	O
levels	O
.	O

These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF	O
-	O
kappaB	O
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O

Changes	O
in	O
IkappaBalpha	O
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF	O
-	O
kappaB	O
translocation	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	O
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	O
production	O
and	O
that	O
it	O
was	O
rapidly	O
up	O
-	O
regulated	O
following	O
infection	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory	O
-	O
type	O
conditions	O
.	O

Extracellular	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
,	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
and	O
c	O
-	O
Jun	O
are	O
involved	O
in	O
NF	O
-	O
kappa	O
B	O
-dependent	O
IL-6	O
expression	O
in	O
human	O
monocytes	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
family	O
members	O
extracellular	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
c-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
in	O
mediating	O
IL-6	O
gene	O
expression	O
in	O
human	O
monocytes	O
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF	O
-	O
kappa	O
B	O
activity	O
.	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL-6	O
protein	O
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1	O
/	O
2	O
and	O
JNK	O
proteins	O
.	O

The	O
ERK	O
pathway	O
-	O
specific	O
inhibitor	O
PD98059	O
inhibited	O
IL-6	O
secretion	O
from	O
monocytes	O
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf-1	O
or	O
JNK1	O
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B	O
-	O
dependent	O
IL-6	O
promoter	O
activity	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1	O
/	O
MEK1	O
/	O
ERK1	O
/	O
2	O
pathway	O
did	O
not	O
affect	O
the	O
DNA	O
binding	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappa	O
B	O
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF	O
-	O
kappa	O
B	O
-mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL-6	O
promoter	O
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c	O
-	O
Jun	O
protein	O
.	O

We	O
conclude	O
that	O
okadaic	O
acid	O
-	O
induced	O
IL-6	O
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1	O
/	O
2	O
and	O
JNK	O
pathway	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
transcriptional	O
capacity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	O
pathway	O
may	O
regulate	O
NF	O
-	O
kappa	O
B	O
-mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c	O
-	O
Jun	O
.	O

Suppressive	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
human	O
endothelial	O
cell	O
activation	O
and	O
induction	O
of	O
heat	O
shock	O
proteins	O
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	O
shock	O
protein	O
60	O
(	O
Hsp60	O
)	O
.	O

The	O
interactions	O
of	O
Hsp60-specific	B
T	I
cells	I
with	O
arterial	O
endothelial	O
cells	O
(	O
EC	O
)	O
require	O
expression	O
of	O
both	O
Hsp60	O
and	O
certain	O
adhesion	O
molecules	O
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	O
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti	O
-	O
inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	O
,	O
respectively	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	O
molecules	O
,	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
MCP-1	O
)	O
,	O
and	O
Hsp60	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
and	O
heat	O
shock	O
factor-1	O
(	O
HSF-1	O
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

RESULTS	O
:	O
With	O
the	O
exception	O
of	O
indomethacin	O
,	O
the	O
used	O
immunosuppressive	O
and	O
anti	O
-	O
inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	O
virus	O
antigen	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	O
suppress	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-induced	O
adhesion	O
molecule	O
expression	O
on	O
HUVECs	O
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
in	O
EC	O
.	O

All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	O
6	O
hr	O
after	O
application	O
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	O
CyA	O
,	O
induced	O
Hsp70	O
expression	O
in	O
HUVECs	O
that	O
correlated	O
with	O
induction	O
of	O
HSF-1	O
activity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	O
indomethacin	O
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell	O
-	O
mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	O
molecule	O
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	O
in	O
HUVECs	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti	O
-	O
atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	O
T	O
cells	O
to	O
stressed	O
EC	O
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis	O
-	O
promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	O
of	O
Hsp60	O
expression	O
and	O
its	O
inability	O
to	O
down	O
-	O
regulate	O
adhesion	O
molecule	O
expression	O
on	O
EC	O
;	O
and	O
(	O
3	O
)	O
that	O
down	O
-	O
regulation	O
of	O
MCP-1	O
expression	O
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	O
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	O
.	O

Retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
agonist	O
-	O
induced	O
activation	O
of	O
dominant	O
-	O
negative	O
RXR	O
-retinoic	O
acid	O
receptor	O
alpha403	O
heterodimers	O
is	O
developmentally	O
regulated	O
during	O
myeloid	O
differentiation	O
.	O

The	O
multiple	O
biologic	O
activities	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
mediated	O
through	O
RAR	O
and	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
nuclear	O
receptors	O
that	O
interact	O
with	O
specific	O
DNA	O
target	O
sequences	O
as	O
heterodimers	O
(	O
RXR	O
-	O
RAR	O
)	O
or	O
homodimers	O
(	O
RXR	O
-	O
RXR	O
)	O
.	O

RA	O
receptor	O
activation	O
appears	O
critical	O
to	O
regulating	O
important	O
aspects	O
of	O
hematopoiesis	O
,	O
since	O
transducing	O
a	O
COOH	O
-	O
terminally	O
truncated	O
RARalpha	O
exhibiting	O
dominant	O
-	O
negative	O
activity	O
(	O
RARalpha403	O
)	O
into	O
normal	O
mouse	O
bone	O
marrow	O
generates	O
hematopoietic	B
growth	I
factor	I
-	I
dependent	I
cell	I
lines	I
frozen	O
at	O
the	O
multipotent	O
progenitor	O
(	O
EML	O
)	O
or	O
committed	O
promyelocyte	O
(	O
MPRO	O
)	O
stages	O
.	O

Nevertheless	O
,	O
relatively	O
high	O
,	O
pharmacological	O
concentrations	O
of	O
RA	O
(	O
1	O
to	O
10	O
&	O
mgr	O
;	O
M	O
)	O
overcome	O
these	O
differentiation	O
blocks	O
and	O
induce	O
terminal	O
granulocytic	O
differentiation	O
of	O
the	O
MPRO	O
promyelocytes	O
while	O
potentiating	O
interleukin-3	O
(	O
IL-3	O
)	O
-induced	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
/	O
monocyte	O
lineage	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
utilized	O
RXR	O
-and	O
RAR	O
-specific	O
agonists	O
and	O
antagonists	O
to	O
determine	O
how	O
RA	O
overcomes	O
the	O
dominant	O
-	O
negative	O
activity	O
of	O
the	O
truncated	O
RARalpha	O
in	O
these	O
different	O
myeloid	O
developmental	O
stages	O
.	O

Unexpectedly	O
,	O
we	O
observed	O
that	O
an	O
RXR	O
-specific	O
,	O
rather	O
than	O
an	O
RAR	O
-specific	O
,	O
agonist	O
induces	O
terminal	O
granulocytic	O
differentiation	O
of	O
MPRO	O
promyelocytes	O
,	O
and	O
this	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
DNA	O
response	O
elements	O
corresponding	O
to	O
RAR	O
-	O
RXR	O
heterodimers	O
rather	O
than	O
RXR	O
-	O
RXR	O
homodimers	O
.	O

This	O
RXR	O
agonist	O
activity	O
is	O
blocked	O
by	O
RAR	O
-specific	O
antagonists	O
,	O
suggesting	O
extensive	O
cross	O
-	O
talk	O
between	O
the	O
partners	O
of	O
the	O
RXR	O
-RARalpha403	O
heterodimer	O
.	O

In	O
contrast	O
,	O
in	O
the	O
more	O
immature	O
,	O
multipotent	O
EML	O
cells	O
we	O
observed	O
that	O
this	O
RXR	O
-specific	O
agonist	O
is	O
inactive	O
either	O
in	O
potentiating	O
IL-3	O
-mediated	O
commitment	O
of	O
EML	O
cells	O
to	O
the	O
granulocyte	O
lineage	O
or	O
in	O
transactivating	O
RAR	O
-	O
RXR	O
response	O
elements	O
.	O

RA	O
-triggered	O
GALdbd-	O
RARalpha	O
hybrid	O
activity	O
in	O
these	O
cells	O
indicates	O
that	O
the	O
multipotent	O
EML	O
cells	O
harbor	O
substantial	O
nuclear	O
hormone	O
receptor	O
coactivator	O
activity	O
.	O

However	O
,	O
the	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitor	O
trichostatin	O
A	O
readily	O
activates	O
an	O
RXR	O
-	O
RAR	O
reporter	O
construct	O
in	O
the	O
multipotent	O
EML	O
cells	O
but	O
not	O
in	O
the	O
committed	O
MPRO	O
promyelocytes	O
,	O
indicating	O
that	O
differences	O
in	O
HDAC	O
-	O
containing	O
repressor	O
complexes	O
in	O
these	O
two	O
closely	O
related	O
but	O
distinct	O
hematopoietic	O
lineages	O
might	O
account	O
for	O
the	O
differential	O
activation	O
of	O
the	O
RXR	O
-	O
RARalpha403	O
heterodimers	O
that	O
we	O
observed	O
at	O
these	O
different	O
stages	O
of	O
myeloid	O
development	O
.	O

Retinoic	O
acid	O
induces	O
apoptosis	O
of	O
human	O
CD34	O
+	O
hematopoietic	O
progenitor	O
cells	O
:	O
involvement	O
of	O
retinoic	O
acid	O
receptors	O
and	O
retinoid	O
X	O
receptors	O
depends	O
on	O
lineage	O
commitment	O
of	O
the	O
hematopoietic	O
progenitor	O
cells	O
.	O

Retinoids	O
are	O
bifunctional	O
regulators	O
of	O
growth	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
.	O

In	O
this	O
study	O
we	O
explored	O
the	O
effects	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
on	O
apoptosis	O
of	O
human	O
CD34	O
+	O
hematopoietic	O
progenitor	O
cells	O
isolated	O
from	O
normal	O
bone	O
marrow	O
.	O

RA	O
(	O
100	O
nM	O
)	O
induced	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
dead	O
cells	O
from	O
24	O
%	O
to	O
44	O
%	O
at	O
day	O
6	O
(	O
p	O
<	O
0.05	O
,	O
n	O
=	O
6	O
)	O
as	O
compared	O
to	O
control	O
cells	O
cultured	O
in	O
medium	O
alone	O
.	O

The	O
effect	O
was	O
dose	O
dependent	O
and	O
appeared	O
relatively	O
late	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
day	O
4	O
onward	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
was	O
demonstrated	O
as	O
the	O
mode	O
of	O
cell	O
death	O
by	O
using	O
the	O
TUNEL	O
assay	O
,	O
which	O
detects	O
single	O
strand	O
nicks	O
in	O
DNA	O
,	O
or	O
by	O
the	O
Nicoletti	O
technique	O
demonstrating	O
a	O
subdiploid	O
population	O
by	O
DNA	O
staining	O
.	O

RA	O
previously	O
was	O
found	O
to	O
inhibit	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
--	O
and	O
not	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
--	O
stimulated	O
proliferation	O
of	O
CD34	O
+	O
cells	O
.	O

However	O
,	O
we	O
found	O
that	O
RA	O
opposed	O
anti	O
-	O
apoptotic	O
effects	O
of	O
G	O
-	O
CSF	O
and	O
GM	O
-	O
CSF	O
on	O
CD34	O
+	O
cells	O
(	O
G	O
-	O
CSF	O
:	O
8	O
%	O
dead	O
cells	O
at	O
day	O
6	O
;	O
G	O
-	O
CSF	O
+	O
RA	O
:	O
20	O
%	O
;	O
GM	O
-	O
CSF	O
:	O
12	O
%	O
;	O
GM	O
-	O
CSF	O
+	O
RA	O
:	O
27	O
%	O
)	O
.	O

Moreover	O
,	O
RA	O
induced	O
apoptosis	O
of	O
CD34	O
+	O
cells	O
and	O
CD34+CD71	O
+	O
cells	O
stimulated	O
with	O
erythropoietin	O
.	O

To	O
explore	O
the	O
receptor	O
signaling	O
pathways	O
involved	O
in	O
RA	O
-	O
induced	O
apoptosis	O
,	O
we	O
used	O
selective	O
ligands	O
for	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
;	O
RO13	O
-	O
7410	O
)	O
and	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
;	O
RO	O
25	O
-	O
6603	O
)	O
.	O

We	O
found	O
that	O
RARs	O
were	O
involved	O
in	O
RA	O
-	O
mediated	O
apoptosis	O
of	O
myeloid	O
progenitor	O
cells	O
,	O
whereas	O
RARs	O
as	O
well	O
as	O
RXRs	O
were	O
involved	O
in	O
RA	O
-	O
mediated	O
apoptosis	O
of	O
erythroid	O
progenitor	O
cells	O
.	O

Dicarba	O
-	O
closo	O
-	O
dodecaboranes	O
as	O
a	O
pharmacophore	O
.	O

Retinoidal	O
antagonists	O
and	O
potential	O
agonists	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
the	O
first	O
dicarba	O
-	O
closo	O
-	O
dodecaborane	O
(	O
carborane	O
)	O
derivatives	O
of	O
retinoids	O
are	O
described	O
.	O

Their	O
retinoidal	O
activity	O
were	O
examined	O
in	O
terms	O
of	O
the	O
differentiation	O
-	O
inducing	O
ability	O
toward	O
human	B
promyelocytic	I
leukemia	I
HL-60	I
cells	I
.	O

High	O
retinoidal	O
activity	O
(	O
agonist	O
or	O
antagonist	O
for	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
requires	O
a	O
carboxylic	O
acid	O
moiety	O
and	O
an	O
appropriate	O
hydrophobic	O
group	O
located	O
at	O
a	O
suitable	O
position	O
on	O
the	O
molecule	O
.	O

The	O
4-carboranyl	O
-	O
substituted	O
compounds	O
(	O
7	O
,	O
11	O
)	O
showed	O
antagonistic	O
activity	O
but	O
no	O
agonistic	O
activity	O
even	O
in	O
the	O
presence	O
of	O
the	O
potent	O
synergist	O
HX630	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3-carboranyl	O
-	O
substituted	O
compounds	O
(	O
8	O
,	O
12	O
)	O
showed	O
potential	O
agonistic	O
activity	O
,	O
but	O
no	O
antagonistic	O
activity	O
.	O

The	O
results	O
indicates	O
that	O
carboranes	O
are	O
applicable	O
as	O
the	O
hydrophobic	O
moiety	O
of	O
biologically	O
active	O
molecules	O
.	O

Expression	O
of	O
E2A	O
-	O
HLF	O
chimeric	O
protein	O
induced	O
T	O
-	O
cell	O
apoptosis	O
,	O
B	O
-	O
cell	O
maturation	O
arrest	O
,	O
and	O
development	O
of	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
E2A	O
-	O
HLF	O
fusion	O
gene	O
,	O
generated	O
by	O
t	O
(	O
17	O
;	O
19	O
)	O
(	O
q22	O
;	O
p13	O
)	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
encodes	O
a	O
chimeric	O
transcription	O
factor	O
in	O
which	O
the	O
trans	O
-	O
activating	O
domains	O
of	O
E2A	O
are	O
fused	O
to	O
the	O
DNA-	O
binding	O
and	O
dimerization	O
domains	O
of	O
hepatic	O
leukemic	O
factor	O
(	O
HLF	O
)	O
.	O

To	O
investigate	O
its	O
biological	O
role	O
,	O
we	O
generated	O
transgenic	O
mice	O
expressing	O
E2A	O
-	O
HLF	O
using	O
Ig	O
enhancer	O
and	O
promoter	O
,	O
which	O
direct	O
transgene	O
expression	O
in	O
cells	O
committed	O
to	O
the	O
lymphoid	O
lineage	O
.	O

The	O
transgenic	O
mice	O
exhibited	O
abnormal	O
development	O
in	O
the	O
thymus	O
and	O
spleen	O
and	O
were	O
susceptible	O
to	O
infection	O
.	O

The	O
thymus	O
contained	O
small	O
numbers	O
of	O
thymocytes	O
,	O
and	O
TUNEL	O
staining	O
showed	O
that	O
higher	O
population	O
of	O
thymocytes	O
were	O
undergoing	O
apoptosis	O
.	O

The	O
spleen	O
exhibited	O
a	O
marked	O
reduction	O
in	O
splenic	O
lymphocytes	O
and	O
the	O
flow	O
cytometric	O
analyses	O
and	O
the	O
in	O
vitro	O
colony	O
formation	O
assays	O
showed	O
that	O
the	O
B	O
-	O
cell	O
maturation	O
was	O
blocked	O
at	O
a	O
very	O
early	O
developmental	O
stage	O
.	O

These	O
findings	O
indicated	O
that	O
the	O
expression	O
of	O
E2A	O
-	O
HLF	O
induced	O
T	O
-	O
cell	O
apoptosis	O
and	O
B	O
-	O
cell	O
maturation	O
arrest	O
in	O
vivo	O
and	O
that	O
the	O
susceptibility	O
of	O
the	O
transgenic	O
mice	O
to	O
infection	O
was	O
due	O
to	O
immunodeficiency	O
.	O

Moreover	O
,	O
several	O
transgenic	O
mice	O
developed	O
acute	O
leukemia	O
,	O
classified	O
as	O
T	O
-	O
ALL	O
based	O
on	O
the	O
surface	O
marker	O
analysis	O
and	O
DNA	O
rearrangements	O
,	O
suggesting	O
that	O
an	O
additional	O
event	O
is	O
required	O
for	O
malignant	O
transformation	O
of	O
lymphoid	O
cells	O
expressing	O
E2A	O
-	O
HLF	O
.	O

Our	O
findings	O
provide	O
insight	O
into	O
the	O
biological	O
function	O
of	O
E2A	O
-	O
HLF	O
in	O
lymphoid	O
development	O
and	O
also	O
its	O
role	O
in	O
leukemogenesis	O
.	O

Leukocyte	O
populations	O
,	O
hormone	O
receptors	O
and	O
apoptosis	O
in	O
eutopic	O
and	O
ectopic	O
first	O
trimester	O
human	O
pregnancies	O
.	O

The	O
implantation	O
of	O
trophoblast	O
cells	O
at	O
extrauterine	O
sites	O
still	O
results	O
in	O
decidualization	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
decidualization	O
at	O
eutopic	O
and	O
ectopic	O
implantation	O
sites	O
.	O

Tissues	O
from	O
women	O
undergoing	O
elective	O
termination	O
of	O
uterine	O
pregnancy	O
and	O
from	O
women	O
with	O
ectopic	O
pregnancy	O
were	O
used	O
to	O
detect	O
the	O
presence	O
of	O
cells	O
important	O
for	O
the	O
maintenance	O
of	O
pregnancy	O
,	O
such	O
as	O
BCL-2	O
+	O
,	O
CD56	O
+	O
,	O
CD3	O
+	O
,	O
CD8	O
+	O
and	O
CD68	O
+	O
cells	O
,	O
and	O
the	O
presence	O
of	O
oestrogen	O
(	O
ER	O
)	O
and	O
progesterone	O
receptors	O
(	O
PR	O
)	O
by	O
immunohistochemistry	O
.	O

In	O
-	O
situ	O
detection	O
of	O
fragmented	O
DNA	O
was	O
performed	O
to	O
identify	O
apoptotic	O
cells	O
.	O

The	O
percentage	O
of	O
CD3	O
+	O
cells	O
among	O
all	O
immunocompetent	O
cells	O
in	O
the	O
tubal	O
epithelium	O
was	O
46.6	O
%	O
(	O
39.9	O
%	O
of	O
CD3	O
+	O
were	O
also	O
CD8	O
+	O
)	O
;	O
the	O
other	O
53.4	O
%	O
were	O
CD68	O
+	O
cells	O
.	O

CD56	O
+	O
cells	O
were	O
undetectable	O
in	O
ectopic	O
decidua	O
at	O
the	O
feto	O
-	O
maternal	O
interface	O
in	O
ectopic	O
tissue	O
.	O

In	O
uterine	O
decidua	O
,	O
we	O
found	O
29.9	O
%	O
CD3	O
+	O
cells	O
(	O
2.2	O
%	O
of	O
CD3	O
+	O
were	O
CD8	O
+	O
)	O
,	O
51.6	O
%	O
CD56	O
+	O
cells	O
and	O
18.5	O
%	O
CD68	O
+	O
cells	O
.	O

The	O
ratio	O
of	O
BCL2	O
+	O
to	O
CD3	O
+	O
cells	O
in	O
ectopic	O
pregnancy	O
was	O
0.41	O
.	O

In	O
uterine	O
pregnancy	O
,	O
the	O
ratio	O
of	O
BCL-2	O
to	O
CD3	O
was	O
0.44	O
and	O
0.39	O
for	O
CD56	O
.	O

Tissues	O
from	O
both	O
ectopic	O
and	O
uterine	O
pregnancies	O
were	O
positive	O
for	O
PR	O
.	O

Fewer	O
apoptotic	O
cell	O
bodies	O
were	O
present	O
in	O
ectopic	O
pregnancy	O
.	O

The	O
use	O
of	O
tissue	O
obtained	O
from	O
ectopic	O
pregnancy	O
may	O
become	O
an	O
excellent	O
model	O
to	O
identify	O
the	O
mechanism	O
of	O
trophoblast	O
invasion	O
in	O
eutopic	O
pregnancies	O
.	O

Differential	O
inhibition	O
of	O
Smad6	O
and	O
Smad7	O
on	O
bone	O
morphogenetic	O
protein-	O
and	O
activin	O
-	O
mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
B	O
cells	O
.	O

Smad6	O
and	O
Smad7	O
prevent	O
ligand	O
-	O
induced	O
activation	O
of	O
signal	O
-	O
transducing	O
Smad	O
proteins	O
in	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
family	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
Smad6	O
and	O
Smad7	O
are	O
human	O
bone	O
morphogenetic	O
protein-2	O
(	O
hBMP-2	O
)	O
-inducible	O
antagonists	O
of	O
hBMP-2	O
-induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
mouse	B
B	I
cell	I
hybridoma	I
HS-72	B
cells	I
.	O

Moreover	O
,	O
we	O
confirmed	O
that	O
the	O
ectopic	O
expressions	O
of	O
Smad6	O
and	O
Smad7	O
inhibited	O
the	O
hBMP-2	O
-induced	O
Smad1	O
/	O
Smad5	O
phosphorylation	O
.	O

We	O
previously	O
reported	O
that	O
Smad7	O
is	O
an	O
activin	O
A	O
-	O
inducible	O
antagonist	O
of	O
activin	O
A	O
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
HS-72	B
cells	I
.	O

Interestingly	O
,	O
although	O
mRNA	O
expression	O
of	O
Smad6	O
was	O
induced	O
by	O
activin	O
A	O
in	O
HS-72	B
cells	I
,	O
Smad6	O
showed	O
no	O
antagonistic	O
effect	O
on	O
activin	O
A	O
-	O
induced	O
growth	O
arrest	O
and	O
apoptosis	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
Smad7	O
,	O
but	O
not	O
Smad6	O
,	O
inhibited	O
the	O
activin	O
A	O
-	O
induced	O
Smad2	O
phosphorylation	O
in	O
HS-72	B
cells	I
.	O

Thus	O
,	O
Smad6	O
and	O
Smad7	O
exhibit	O
differential	O
inhibitory	O
effects	O
in	O
bone	O
morphogenetic	O
protein-2-	O
and	O
activin	O
A	O
-	O
mediated	O
signaling	O
in	O
B	O
lineage	O
cells	O
.	O

Regulation	O
of	O
Fas	O
ligand	O
expression	O
and	O
cell	O
death	O
by	O
apoptosis	O
-	O
linked	O
gene	O
4	O
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas	O
/Fas	O
ligand	O
(	O
FasL	O
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell	O
-	O
receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	O
cell	O
-	O
receptor	O
-	O
induced	O
FasL	O
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
ALG-4	O
induced	O
transcription	O
of	O
FasL	O
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG-4	O
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	O
expression	O
.	O

Fas	O
/	O
FasL	O
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	O
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
transduced	B
hematopoietic	I
stem	I
cells	I
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	O
modified	O
hematopoietic	O
stem	O
cells	O
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	O
viral	O
enhancer	O
in	O
the	O
U3	O
region	O
of	O
the	O
3	O
'	O
LTR	O
is	O
replaced	O
by	O
an	O
autoregulatory	O
enhancer	O
of	O
the	O
erythroid	O
-	O
specific	O
GATA-1	O
transcription	O
factor	O
gene	O
.	O

The	O
replaced	O
enhancer	O
is	O
propagated	O
to	O
the	O
5	O
'	O
LTR	O
upon	O
integration	O
into	O
the	O
target	O
cell	O
genome	O
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	B
hematopoietic	I
cell	I
lines	I
,	O
cord	O
blood	O
-	O
derived	O
CD34	O
(	O
+	O
)	O
stem	O
/	O
progenitor	O
cells	O
,	O
and	O
murine	B
bone	I
marrow	I
repopulating	I
stem	I
cells	I
.	O

The	O
expression	O
of	O
appropriate	O
reporter	O
genes	O
(	O
triangle	O
upLNGFR	O
,	O
EGFP	O
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	B
stem	I
cells	I
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA-1	O
autoregulatory	O
enhancer	O
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR	O
-	O
driven	O
proviral	O
transcription	O
unit	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
both	O
human	O
progenitors	O
and	O
mouse	B
-	I
repopulating	I
stem	I
cells	I
.	O

Packaging	O
of	O
viral	O
particles	O
,	O
integration	O
into	O
the	O
target	O
genome	O
,	O
and	O
stability	O
of	O
the	O
integrated	O
provirus	O
are	O
not	O
affected	O
by	O
the	O
LTR	O
modification	O
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	O
transgene	O
to	O
a	O
specific	O
progeny	O
of	O
transduced	B
hematopoietic	I
stem	I
cells	I
.	O

An	O
essential	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
survival	O
.	O

The	O
transcription	O
factor	O
,	O
NF	O
-	O
kappaB	O
,	O
is	O
important	O
for	O
T	O
-	O
cell	O
activation	O
,	O
B	O
-	O
cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
has	O
not	O
been	O
described	O
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
express	O
NF	O
-	O
kappaB	O
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	O
,	O
eg	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
interleukin-3	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
may	O
be	O
required	O
for	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Unicellular	B
-	I
unilineage	I
erythropoietic	I
cultures	I
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	O
of	O
lineage	O
specificity	O
and	O
developmental	O
stage	O
homogeneity	O
of	O
progenitor	O
/	O
precursor	O
cells	O
growing	O
in	O
culture	O
.	O

We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	O
hematopoietic	O
progenitor	O
cells	O
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	O
factor	O
(	O
GF	O
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate	O
/	O
mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	O
divisions	O
are	O
virtually	O
absent	O
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	O
erythropoietic	O
potential	O
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single	O
-	O
cell	O
reverse	O
transcriptase	O
-polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	O
,	O
markers	O
of	O
differentiation	O
,	O
and	O
transcription	O
factors	O
(	O
EKLF	O
,	O
GATA-1	O
,	O
GATA-2	O
,	O
p45	O
NF	O
-	O
E2	O
,	O
PU.1	O
,	O
and	O
SCL	O
/	O
Tal1	O
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Freshly	O
isolated	O
CD34	O
(	O
+	O
)	O
cells	O
expressed	O
CD34	O
,	O
c	O
-	O
kit	O
,	O
PU.1	O
,	O
and	O
GATA-2	O
but	O
did	O
not	O
express	O
CD36	O
,	O
erythropoietin	O
receptor	O
(	O
EpoR	O
)	O
,	O
SCL	O
/	O
Tal1	O
,	O
EKLF	O
,	O
NF	O
-	O
E2	O
,	O
GATA-1	O
,	O
or	O
glyocophorin	O
A	O
(	O
GPA	O
)	O
.	O

In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	O
of	O
CD36	O
,	O
Tal1	O
,	O
EKLF	O
,	O
NF	O
-	O
E2	O
,	O
and	O
GATA-1	O
that	O
preceeded	O
expression	O
of	O
EpoR	O
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	O
was	O
upregulated	O
,	O
whereas	O
CD34	O
,	O
c	O
-	O
kit	O
,	O
PU.1	O
,	O
and	O
GATA-2	O
were	O
barely	O
or	O
not	O
detected	O
.	O

In	O
addition	O
,	O
competitive	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
assay	O
CD34	O
mRNA	O
transcripts	O
in	O
sibling	B
CD34	I
(	I
+	I
)	I
CD38	I
(	I
-	I
)	I
cells	I
differentiating	O
in	O
unilineage	B
erythroid	I
cultures	I
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	O
mRNA	O
from	O
progenitor	O
cells	O
through	O
their	O
differentiating	B
erythroid	I
progeny	I
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single	O
-	O
cell	O
RT	O
-	O
PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	O
progenitors	O
/	O
precursors	O
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Bacterial	O
peptidoglycan	O
induces	O
CD14	O
-dependent	O
activation	O
of	O
transcription	O
factors	O
CREB	O
/	O
ATF	O
and	O
AP-1	O
.	O

Peptidoglycan	O
(	O
PGN	O
)	O
,	O
the	O
major	O
cell	O
wall	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
,	O
induces	O
secretion	O
of	O
cytokines	O
in	O
macrophages	O
through	O
CD14	O
,	O
the	O
pattern	O
recognition	O
receptor	O
that	O
binds	O
lipopolysaccharide	O
and	O
other	O
microbial	O
products	O
.	O

To	O
begin	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
regulate	O
the	O
transcription	O
of	O
cytokine	O
genes	O
,	O
we	O
wanted	O
to	O
determine	O
which	O
transcription	O
factors	O
are	O
activated	O
by	O
PGN	O
in	O
mouse	B
RAW264.7	I
and	O
human	B
THP-1	I
macrophage	I
cells	I
.	O

Our	O
results	O
demonstrated	O
that	O
:	O
(	O
i	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
the	O
transcription	O
factors	O
ATF-1	O
and	O
CREB	O
;	O
(	O
ii	O
)	O
ATF-1	O
and	O
CREB	O
bound	O
DNA	O
as	O
a	O
dimer	O
and	O
induced	O
transcriptional	O
activation	O
of	O
a	O
CRE	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
CREB	O
and	O
ATF-1	O
;	O
(	O
iii	O
)	O
PGN	O
induced	O
phosphorylation	O
of	O
c	O
-	O
Jun	O
,	O
protein	O
synthesis	O
of	O
JunB	O
and	O
c	O
-	O
Fos	O
,	O
and	O
transcriptional	O
activation	O
of	O
the	O
AP-1	O
reporter	O
plasmid	O
,	O
which	O
was	O
inhibited	O
by	O
dominant	O
negative	O
c	O
-	O
Fos	O
;	O
and	O
(	O
iv	O
)	O
PGN	O
-	O
induced	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP-1	O
was	O
mediated	O
through	O
CD14	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
activation	O
of	O
CREB	O
/	O
ATF	O
and	O
AP-1	O
transcription	O
factors	O
by	O
PGN	O
or	O
by	O
any	O
other	O
component	O
of	O
Gram	O
-	O
positive	O
bacteria	O
.	O

c	O
-	O
Myc	O
and	O
E1A	O
induced	O
cellular	O
sensitivity	O
to	O
activated	O
NK	O
cells	O
involves	O
cytotoxic	O
granules	O
as	O
death	O
effectors	O
.	O

The	O
contact	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
with	O
foreign	O
cells	O
and	O
with	O
certain	O
virus	O
-	O
infected	O
or	O
tumor	O
cells	O
triggers	O
the	O
cytolytic	O
machinery	O
of	O
NK	O
cells	O
.	O

This	O
triggering	O
leads	O
to	O
exocytosis	O
of	O
the	O
cytotoxic	O
NK	O
cell	O
granules	O
.	O

The	O
oncoproteins	O
c	O
-	O
Myc	O
and	O
E1A	O
render	O
cells	O
vulnerable	O
to	O
NK	O
cell	O
mediated	O
cytolysis	O
yet	O
the	O
mechanisms	O
of	O
sensitization	O
are	O
not	O
well	O
understood	O
.	O

In	O
a	O
model	O
where	O
foreign	O
cells	O
(	O
rat	O
fibroblasts	O
)	O
were	O
cocultured	O
with	O
human	O
IL-2	O
activated	O
NK	O
cells	O
,	O
we	O
observed	O
that	O
NK	O
cells	O
were	O
capable	O
of	O
efficiently	O
killing	O
their	O
targets	O
only	O
if	O
the	O
cells	O
overexpressed	O
the	O
oncogene	O
c	O
-	O
Myc	O
or	O
E1A	O
.	O

Both	O
the	O
parental	O
and	O
the	O
oncogene	O
expressing	O
fibroblasts	O
similarly	O
triggered	O
phosphoinositide	O
hydrolysis	O
in	O
the	O
bound	O
NK	O
cells	O
,	O
demonstrating	O
that	O
NK	O
cells	O
were	O
cytolytically	O
activated	O
in	O
contact	O
with	O
both	O
resistant	O
parental	O
and	O
oncogene	O
expressing	O
sensitive	O
target	O
fibroblasts	O
.	O

The	O
cell	O
death	O
was	O
independent	O
of	O
wild	O
-	O
type	O
p53	O
and	O
was	O
not	O
inhibited	O
by	O
an	O
anti	O
-	O
apoptotic	O
protein	O
EIB19	O
K	O
.	O

These	O
results	O
provided	O
evidence	O
that	O
c	O
-	O
Myc	O
and	O
E1A	O
activated	O
the	O
NK	O
cell	O
induced	O
cytolysis	O
at	O
a	O
post	O
-	O
triggering	O
stage	O
of	O
NK	O
cell	O
-	O
target	O
cell	O
interaction	O
.	O

In	O
consistence	O
,	O
the	O
c	O
-	O
Myc	O
and	O
E1A	O
overexpressing	O
fibroblasts	O
were	O
more	O
sensitive	O
to	O
the	O
cytolytic	O
effects	O
of	O
isolated	O
NK	O
cell	O
-	O
derived	O
granules	O
than	O
parental	O
cells	O
.	O

The	O
data	O
indicate	O
that	O
oncogenes	O
activate	O
the	O
cytotoxicity	O
of	O
NK	O
cell	O
granules	O
.	O

This	O
mechanism	O
can	O
have	O
a	O
role	O
in	O
directing	O
the	O
cytolytic	O
action	O
of	O
NK	O
cells	O
towards	O
the	O
virus	O
-	O
infected	O
and	O
cancer	O
cells	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL-10	O
on	O
cytokine	O
production	O
.	O

IL-10	O
is	O
a	O
well	O
-	O
known	O
immunosuppressive	O
and/or	O
anti	O
-	O
inflammatory	O
cytokine	O
.	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL-10	B
primed	I
leukocytes	I
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	O
human	O
IL-10	O
had	O
an	O
enhanced	O
capacity	O
to	O
produce	O
TNF	O
in	O
response	O
to	O
LPS	O
.	O

In	O
addition	O
to	O
TNF	O
,	O
LPS	O
-	O
induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O

When	O
isolated	O
PBMC	O
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	O
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	O
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	O
,	O
an	O
enhanced	O
release	O
of	O
TNF	O
was	O
observed	O
.	O

This	O
was	O
not	O
the	O
case	O
when	O
PBMC	O
were	O
pre	O
-	O
cultured	O
in	O
plastic	O
multidishes	O
in	O
the	O
presence	O
of	O
IL-10	O
.	O

TNF	O
mRNA	O
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre	O
-	O
treatment	O
of	O
PBMC	O
with	O
IL-10	O
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
when	O
cells	O
were	O
pre	O
-	O
cultured	O
with	O
IL-10	O
on	O
Teflon	O
.	O

Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL-10	O
pre	O
-	O
treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	O
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	O
,	O
independently	O
of	O
the	O
pre	O
-	O
culture	O
conditions	O
of	O
the	O
PBMC	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10	O
-induced	O
up	O
-	O
regulation	O
of	O
cytokine	O
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	O
cells	O
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	O
on	O
Teflon	O
.	O

In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	O
effect	O
on	O
the	O
IL-10	O
-induced	O
modulation	O
of	O
some	O
monocyte	O
surface	O
markers	O
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	O
element	O
upstream	O
of	O
the	O
GATA-1	O
gene	O
.	O

The	O
lineage	O
-	O
restricted	O
transcription	O
factor	O
GATA-1	O
is	O
required	O
for	O
differentiation	O
of	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis	O
-	O
acting	O
regulatory	O
element	O
,	O
HS	O
I	O
,	O
associated	O
with	O
a	O
hematopoietic	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
,	O
which	O
lies	O
approx	O
.	O

3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	O
hematopoietic	O
-	O
specific	O
GATA-1	O
IE	O
promoter	O
.	O

HS	O
I	O
directs	O
high	O
-	O
level	O
expression	O
of	O
reporter	O
GATA-1	O
/	O
lacZ	O
genes	O
to	O
primitive	O
and	O
definitive	O
erythroid	O
cells	O
and	O
megakaryocytes	O
in	O
transgenic	O
mice	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
HS	O
I	O
between	O
human	O
and	O
mouse	O
shows	O
approx	O
.	O

63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	O
base	O
pairs	O
(	O
86	O
%	O
identity	O
)	O
.	O

This	O
core	O
contains	O
a	O
GATA	O
site	O
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E	O
-	O
box	O
motif	O
.	O

The	O
composite	O
motif	O
binds	O
a	O
multi	O
-	O
protein	O
hematopoietic	O
-	O
specific	O
transcription	O
factor	O
complex	O
which	O
includes	O
GATA-1	O
,	O
SCL	O
/	O
tal-1	O
,	O
E2A	O
,	O
Lmo2	O
and	O
Ldb-1	O
.	O

Point	O
mutations	O
of	O
the	O
GATA	O
site	O
abolishes	O
HS	O
I	O
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E	O
-	O
box	O
motif	O
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O

Strict	O
dependence	O
of	O
HS	O
I	O
activity	O
on	O
a	O
GATA	O
site	O
implies	O
that	O
assembly	O
of	O
a	O
protein	O
complex	O
containing	O
a	O
GATA	O
-	O
factor	O
,	O
presumably	O
GATA-1	O
or	O
GATA-2	O
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O

Further	O
dissection	O
of	O
the	O
317	O
base	O
pair	O
region	O
demonstrates	O
that	O
,	O
whereas	O
all	O
317	O
base	O
pairs	O
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	O
,	O
only	O
the	O
5	O
'	O
62	O
base	O
pairs	O
are	O
needed	O
for	O
erythroid	O
-	O
specific	O
reporter	O
expression	O
.	O

These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	O
I	O
element	O
.	O

SLP-76	O
and	O
Vav	O
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin-2	O
promoter	O
activity	O
.	O

SLP-76	O
and	O
Vav	O
,	O
two	O
hematopoietic	O
cell	O
specific	O
molecules	O
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	O
T	O
cell	O
antigen	O
receptor	O
stimulation	O
,	O
SLP-76	O
and	O
Vav	O
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	O
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	O
.	O

Furthermore	O
,	O
SLP-76	O
and	O
Vav	O
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
activity	O
in	O
T	B
cells	I
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	O
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	O
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP-76	O
and	O
Vav	O
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL-2	O
promoter	O
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL-2	O
gene	O
expression	O
.	O

Overexpression	O
of	O
SLP-76	O
in	O
the	O
Jurkat	B
T	I
cell	I
line	I
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP-1	O
transcription	O
factors	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	O
leads	O
to	O
enhanced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
activity	O
without	O
affecting	O
AP-1	O
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	O
,	O
but	O
not	O
SLP-76	O
,	O
augments	O
CD28-induced	O
IL-2	O
promoter	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP-76	O
and	O
Vav	O
in	O
regulating	O
IL-2	O
gene	O
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

CD28	O
costimulation	O
augments	O
IL-2	O
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	O
enhancing	O
IL-2	O
gene	O
transactivation	O
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	O
propria	O
(	O
LP	O
)	O
T	O
cells	O
are	O
different	O
from	O
peripheral	O
T	O
cells	O
.	O

LP	O
T	O
cells	O
exhibit	O
enhanced	O
IL-2	O
secretion	O
when	O
activated	O
through	O
the	O
CD2	O
pathway	O
.	O

Coligation	O
of	O
CD28	O
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL-2	O
secretion	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	O
augmentation	O
of	O
TCR	O
-mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	O
promoter	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	O
costimulation	O
of	O
IL-2	O
production	O
in	O
LP	O
mononuclear	O
cells	O
(	O
LPMC	O
)	O
.	O

LPMC	O
exhibited	O
increased	O
IL-2	O
production	O
in	O
response	O
to	O
CD28	O
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	O
alone	O
.	O

IL-2	O
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	O
mRNA	O
,	O
resulting	O
from	O
enhanced	O
IL-2	O
mRNA	O
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	O
,	O
EMSA	O
revealed	O
that	O
CD28	O
coligation	O
of	O
CD2-activated	O
LPMC	O
does	O
not	O
result	O
in	O
increased	O
binding	O
of	O
trans	O
-	O
factors	O
to	O
the	O
CD28RE	O
,	O
nor	O
did	O
Western	O
blots	O
detect	O
changes	O
in	O
I	O
-	O
kappaBalpha	O
or	O
I	O
-	O
kappaBbeta	O
levels	O
following	O
CD28	O
coligation	O
.	O

Furthermore	O
,	O
CD28	O
coligation	O
fails	O
to	O
enhance	O
IL-2	O
promoter	O
-	O
reporter	O
or	O
RE	O
/	O
AP	O
construct	O
expression	O
in	O
CD2-activated	O
LPMC	O
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	O
cosignaling	O
and	O
regulation	O
of	O
IL-2	O
secretion	O
in	O
LP	O
T	O
cells	O
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	O
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	O
repertoire	O
found	O
in	O
the	O
mucosa	O
.	O

Repression	O
by	O
Ikaros	O
and	O
Aiolos	O
is	O
mediated	O
through	O
histone	O
deacetylase	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
lineage	O
-	O
determining	O
factors	O
Ikaros	O
and	O
Aiolos	O
can	O
function	O
as	O
strong	O
transcriptional	O
repressors	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	O
domains	O
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	O
proteins	O
correlates	O
with	O
hypo	O
-	O
acetylation	O
of	O
core	O
histones	O
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	O
deacetylase	O
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	O
and	O
its	O
repression	O
domains	O
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	O
family	O
of	O
co	O
-	O
repressors	O
which	O
bind	O
to	O
histone	O
deacetylases	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	O
and	O
Mi-2-HDAC	O
,	O
we	O
propose	O
that	O
Ikaros	O
family	O
members	O
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	O
deacetylase	O
complexes	O
to	O
specific	O
promoters	O
.	O

Development	O
and	O
maturation	O
of	O
secondary	O
lymphoid	O
tissues	O
.	O

The	O
secondary	O
lymphoid	O
tissues	O
are	O
located	O
at	O
strategic	O
sites	O
where	O
foreign	O
antigens	O
can	O
be	O
efficiently	O
brought	O
together	O
with	O
immune	O
system	O
regulatory	O
and	O
effector	O
cells	O
.	O

The	O
organized	O
structure	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
is	O
thought	O
to	O
enhance	O
the	O
sensitivity	O
of	O
antigen	O
recognition	O
and	O
to	O
support	O
proper	O
regulation	O
of	O
the	O
activation	O
and	O
maturation	O
of	O
the	O
antigen	O
-	O
responsive	O
lymphoid	O
cells	O
.	O

Although	O
a	O
substantial	O
amount	O
is	O
known	O
about	O
the	O
cellular	O
elements	O
that	O
compose	O
the	O
lymphoid	O
and	O
nonlymphoid	O
components	O
of	O
the	O
secondary	O
lymphoid	O
tissues	O
,	O
information	O
concerning	O
the	O
signals	O
that	O
control	O
the	O
development	O
of	O
the	O
tissues	O
and	O
that	O
maintain	O
the	O
organized	O
tissue	O
microenvironment	O
remain	O
undefined	O
.	O

Studies	O
over	O
the	O
past	O
few	O
years	O
have	O
identified	O
lymphotoxin	O
as	O
a	O
critical	O
signaling	O
molecule	O
not	O
only	O
for	O
the	O
organogenesis	O
of	O
secondary	O
lymphoid	O
tissues	O
but	O
for	O
the	O
maintenance	O
of	O
aspects	O
of	O
their	O
microarchitecture	O
as	O
well	O
.	O

Additional	O
signaling	O
molecules	O
that	O
contribute	O
to	O
the	O
formation	O
of	O
normal	O
lymphoid	O
tissue	O
structure	O
are	O
being	O
identified	O
at	O
an	O
accelerating	O
pace	O
.	O

Analyses	O
of	O
mouse	O
strains	O
with	O
congenital	O
defects	O
in	O
different	O
aspects	O
of	O
secondary	O
lymphoid	O
tissue	O
development	O
are	O
beginning	O
to	O
clarify	O
the	O
role	O
of	O
these	O
tissues	O
in	O
immune	O
responses	O
and	O
host	O
defense	O
.	O

This	O
review	O
focuses	O
on	O
studies	O
defining	O
recently	O
identified	O
crucial	O
signals	O
for	O
the	O
biogenesis	O
of	O
secondary	O
lymphoid	O
organs	O
and	O
for	O
the	O
maintenance	O
of	O
their	O
proper	O
microarchitecture	O
.	O

It	O
also	O
discusses	O
new	O
insights	O
into	O
how	O
the	O
structure	O
of	O
these	O
tissues	O
supports	O
effective	O
immune	O
responses	O
.	O

Selection	O
of	O
the	O
T	O
cell	O
repertoire	O
.	O

Advances	O
in	O
gene	O
technology	O
have	O
allowed	O
the	O
manipulation	O
of	O
molecular	O
interactions	O
that	O
shape	O
the	O
T	O
cell	O
repertoire	O
.	O

Although	O
recognized	O
as	O
fundamental	O
aspects	O
of	O
T	O
lymphocyte	O
development	O
,	O
only	O
recently	O
have	O
the	O
mechanisms	O
governing	O
positive	O
and	O
negative	O
selection	O
been	O
examined	O
at	O
a	O
molecular	O
level	O
.	O

Positive	O
selection	O
refers	O
to	O
the	O
active	O
process	O
of	O
rescuing	O
MHC	O
-	O
restricted	O
thymocytes	O
from	O
programmed	O
cell	O
death	O
.	O

Negative	O
selection	O
refers	O
to	O
the	O
deletion	O
or	O
inactivation	O
of	O
potentially	O
autoreactive	O
thymocytes	O
.	O

This	O
review	O
focuses	O
on	O
interactions	O
during	O
thymocyte	O
maturation	O
that	O
define	O
the	O
T	O
cell	O
repertoire	O
,	O
with	O
an	O
emphasis	O
placed	O
on	O
current	O
literature	O
within	O
this	O
field	O
.	O

Multiple	O
NF	O
-	O
ATc	O
isoforms	O
with	O
individual	O
transcriptional	O
properties	O
are	O
synthesized	O
in	O
T	O
lymphocytes	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
ATc	O
that	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
embryonic	O
cardiac	O
cells	O
is	O
expressed	O
in	O
three	O
prominent	O
isoforms	O
.	O

This	O
is	O
due	O
to	O
alternative	O
splice	O
/	O
polyadenylation	O
events	O
that	O
lead	O
to	O
the	O
predominant	O
synthesis	O
of	O
two	O
long	O
isoforms	O
in	O
naive	O
T	O
cells	O
and	O
a	O
shorter	O
NF	O
-	O
ATc	O
isoform	O
in	O
effector	O
T	O
cells	O
.	O

Whereas	O
the	O
previously	O
described	O
isoform	O
NF	O
-	O
ATc	O
/	O
A	O
contains	O
a	O
relatively	O
short	O
C	O
terminus	O
,	O
the	O
longer	O
isoforms	O
,	O
B	O
and	O
C	O
,	O
span	O
extra	O
C	O
-	O
terminal	O
peptides	O
of	O
128	O
and	O
246	O
aa	O
,	O
respectively	O
.	O

We	O
show	O
here	O
that	O
in	O
addition	O
to	O
the	O
strong	O
N	O
-	O
terminal	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
A	O
,	O
which	O
is	O
common	O
to	O
all	O
three	O
NF	O
-	O
ATc	O
isoforms	O
,	O
NF	O
-	O
ATc	O
/	O
C	O
contains	O
a	O
second	O
trans	O
-	O
activation	O
domain	O
,	O
TAD	O
-	O
B	O
,	O
in	O
its	O
C	O
-	O
terminal	O
peptide	O
.	O

Various	O
stimuli	O
of	O
T	O
cells	O
that	O
induce	O
the	O
activity	O
of	O
TAD	O
-	O
A	O
also	O
enhance	O
the	O
activity	O
of	O
TAD	O
-	O
B	O
,	O
but	O
,	O
unlike	O
TAD	O
-	O
A	O
,	O
TAD	O
-	O
B	O
remains	O
unphosphorylated	O
by	O
protein	O
from	O
12-O	B
-	I
tetradecanoyl	I
12-phorbol	I
13-acetate	I
-	I
stimulated	I
T	I
cells	I
.	O

The	O
shorter	O
C	O
-	O
terminal	O
peptide	O
of	O
isoform	O
NF	O
-	O
ATc	O
/	O
B	O
exerts	O
a	O
suppressive	O
transcriptional	O
effect	O
.	O

These	O
properties	O
of	O
NF	O
-	O
ATc	O
/	O
B	O
and	O
-C	O
might	O
be	O
of	O
importance	O
for	O
gene	O
regulation	O
in	O
naive	O
T	O
lymphocytes	O
in	O
which	O
NF	O
-	O
ATc	O
/	O
B	O
and	O
-C	O
are	O
predominantly	O
synthesized	O
.	O

Effects	O
of	O
diesel	O
organic	O
extracts	O
on	O
chemokine	O
production	O
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

BACKGROUND	O
:	O
Polyaromatic	O
hydrocarbons	O
(	O
PAHs	O
)	O
associated	O
with	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
are	O
found	O
in	O
the	O
atmospheric	O
urban	O
pollution	O
.	O

Such	O
compounds	O
have	O
been	O
shown	O
to	O
favor	O
IgE	O
production	O
,	O
bronchial	O
hyperresponsiveness	O
,	O
and	O
airway	O
inflammation	O
.	O

Chemokines	O
are	O
a	O
group	O
of	O
chemotactic	O
cytokines	O
involved	O
in	O
the	O
recruitment	O
of	O
inflammatory	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
effect	O
of	O
DEP	O
-	O
PAHs	O
on	O
the	O
release	O
and	O
mRNA	O
expression	O
of	O
IL-8	O
,	O
MCP-1	O
,	O
and	O
RANTES	O
by	O
PBMCs	O
obtained	O
from	O
healthy	O
subjects	O
.	O

METHODS	O
:	O
Protein	O
production	O
in	O
supernatants	O
was	O
assessed	O
by	O
ELISA	O
,	O
and	O
mRNA	O
expression	O
was	O
evaluated	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

RESULTS	O
:	O
Secretion	O
of	O
IL-8	O
and	O
RANTES	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
increasing	O
concentrations	O
of	O
DEP	O
-	O
PAHs	O
(	O
range	O
,	O
0.5	O
ng	O
to	O
50	O
ng	O
/	O
mL	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
release	O
of	O
MCP-1	O
was	O
significantly	O
inhibited	O
,	O
also	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Messenger	O
RNA	O
production	O
coding	O
for	O
IL-8	O
,	O
RANTES	O
,	O
and	O
MCP-1	O
showed	O
parallel	O
variations	O
to	O
the	O
production	O
of	O
the	O
correspondent	O
proteins	O
.	O

Effects	O
of	O
DEP	O
-	O
PAHs	O
became	O
significant	O
at	O
7	O
hours	O
and	O
up	O
to	O
48	O
hours	O
time	O
culture	O
for	O
MCP-1	O
,	O
and	O
up	O
to	O
24	O
hours	O
time	O
culture	O
for	O
IL-8	O
and	O
RANTES	O
.	O

Moreover	O
,	O
supernatants	O
from	O
DEP	O
-	O
PAH	O
-	O
activated	O
cells	O
,	O
compared	O
with	O
those	O
of	O
controls	O
,	O
exhibited	O
a	O
significantly	O
enhanced	O
chemotactic	O
activity	O
for	O
neutrophils	O
and	O
eosinophils	O
,	O
which	O
was	O
significantly	O
inhibited	O
by	O
pretreatment	O
with	O
anti	O
-	O
IL-8	O
and	O
anti	O
-	O
RANTES	O
neutralizing	O
antibodies	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
chemokine	O
pathways	O
are	O
modulated	O
by	O
DEP	O
-	O
PAHs	O
at	O
the	O
transcriptional	O
level	O
,	O
reinforcing	O
the	O
idea	O
that	O
the	O
development	O
of	O
inflammatory	O
reactions	O
might	O
be	O
affected	O
by	O
diesel	O
exhaust	O
emission	O
.	O

Binding	O
of	O
YY1	O
and	O
Oct1	O
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	O
in	O
human	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
IL-5	O
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL-5	O
is	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL-5	O
(	O
hIL-5	O
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	O
transcription	O
in	O
T	O
cells	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	O
I	O
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL-5	O
promoter	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	O
of	O
hIL-5	O
promoter	O
activity	O
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	O
and	O
BR4	O
located	O
at	O
positions	O
-102	O
to	O
-73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL-5	O
expression	O
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	O
regulatory	O
element	O
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	O
promoter	O
,	O
which	O
binds	O
Oct1	O
,	O
octamer	O
-	O
like	O
,	O
and	O
YY1	O
nuclear	O
factors	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	O
hIL-5	O
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	O
,	O
YY1	O
,	O
and	O
octamer	O
-	O
like	O
factors	O
binding	O
to	O
the	O
-90	O
/	O
-79	O
sequence	O
within	O
the	O
proximal	O
IL-5	O
promoter	O
are	O
involved	O
in	O
suppression	O
of	O
IL-5	O
transcription	O
in	O
T	O
cells	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live	O
-	O
HIV-1	O
by	O
gain	O
of	O
a	O
proteolysis	O
-	O
resistant	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
(	O
IkappaB	O
-	O
alphaS32	O
/	O
36A	O
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live	O
-	O
attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss	O
-	O
of	O
-	O
function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	O
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication	O
-	O
competent	O
,	O
HIV-1	O
/	O
SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss	O
-	O
of	O
-	O
function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss	O
-	O
of	O
-	O
function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	O
genome	O
.	O

Here	O
,	O
we	O
propose	O
gain	O
-	O
of	O
-	O
function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss	O
-	O
of	O
-	O
function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O

We	O
have	O
constructed	O
an	O
HIV-1	O
genome	O
carrying	O
the	O
cDNA	O
of	O
a	O
proteolysis	O
-	O
resistant	O
nuclear	O
factor	O
-	O
kappaB	O
inhibitor	O
(	O
IkappaB	O
-	O
alphaS32	O
/	O
36A	O
)	O
in	O
the	O
nef	O
region	O
.	O

HIV-1	O
expressing	O
IkappaB	O
-	O
alphaS32	O
/	O
36A	O
down	O
-	O
regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	B
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB	O
-	O
alphaS32	O
/	O
36A	O
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open	O
-	O
reading	O
frames	O
embedded	O
into	O
HIV	O
/	O
SIV	O
genome	O
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB	O
-	O
alphaS32	O
/	O
36A	O
offers	O
proof	O
-	O
of	O
-	O
principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain	O
-	O
of	O
-	O
function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live	O
-	O
attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

CBP	O
/	O
p300	O
integrates	O
Raf	O
/	O
Rac	O
-signaling	O
pathways	O
in	O
the	O
transcriptional	O
induction	O
of	O
NF	O
-	O
ATc	O
during	O
T	O
cell	O
activation	O
.	O

NF	O
-	O
ATc	O
,	O
an	O
inducibly	O
expressed	O
transcription	O
factor	O
,	O
controls	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
and	O
cardiomyocytes	O
.	O

We	O
show	O
here	O
that	O
the	O
transcriptional	O
co	O
-	O
activators	O
CBP	O
/	O
p300	O
bind	O
to	O
and	O
control	O
the	O
activity	O
of	O
the	O
inducible	O
N	O
-	O
terminal	O
transactivation	O
domain	O
of	O
NF	O
-	O
ATc	O
,	O
TAD	O
-	O
A	O
.	O

Similar	O
to	O
the	O
N	O
terminal	O
transactivation	O
domain	O
of	O
c	O
-	O
Jun	O
,	O
TAD	O
-	O
A	O
is	O
inducibly	O
phosphorylated	O
,	O
but	O
this	O
phosphorylation	O
is	O
dispensable	O
for	O
the	O
interaction	O
with	O
CBP	O
/	O
p300	O
.	O

Constitutive	O
active	O
versions	O
of	O
c	O
-	O
Raf	O
and	O
Rac	O
synergistically	O
enhance	O
the	O
CBP	O
/	O
p300	O
-mediated	O
increase	O
of	O
TAD	O
-	O
A	O
activity	O
,	O
indicating	O
the	O
important	O
role	O
CBP	O
/	O
p300	O
plays	O
in	O
the	O
integration	O
of	O
T	O
cell	O
activation	O
signals	O
.	O

Since	O
a	O
mutation	O
of	O
CBP	O
abolishing	O
HAT	O
activity	O
is	O
almost	O
as	O
active	O
as	O
wild	O
-	O
type	O
CBP	O
in	O
T	O
cells	O
,	O
functions	O
of	O
CBP	O
/	O
p300	O
other	O
than	O
histone	O
acetylation	O
appear	O
to	O
control	O
the	O
NF	O
-	O
AT	O
-dependent	O
transcription	O
in	O
T	O
cells	O
.	O

Expression	O
and	O
role	O
of	O
PML	O
gene	O
in	O
normal	O
adult	O
hematopoiesis	O
:	O
functional	O
interaction	O
between	O
PML	O
and	O
Rb	O
proteins	O
in	O
erythropoiesis	O
.	O

The	O
expression	O
of	O
the	O
PML	O
gene	O
was	O
investigated	O
in	O
purified	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
induced	O
to	O
unilineage	O
erythroid	O
or	O
granulocytic	O
differentiation	O
.	O

PML	O
mRNA	O
and	O
protein	O
,	O
while	O
barely	O
detectable	O
in	O
quiescent	O
HPCs	O
,	O
are	O
consistently	O
induced	O
by	O
growth	O
factor	O
stimulation	O
through	O
the	O
erythroid	O
or	O
granulocytic	O
lineage	O
.	O

Thereafter	O
,	O
PML	O
is	O
downmodulated	O
in	O
late	O
granulocytic	O
maturation	O
,	O
whereas	O
it	O
is	O
sustainably	O
expressed	O
through	O
the	O
erythroid	O
pathway	O
.	O

In	O
functional	O
studies	O
,	O
PML	O
expression	O
was	O
inhibited	O
by	O
addition	O
of	O
antisense	O
oligomers	O
targeting	O
PML	O
mRNA	O
(	O
alpha	O
-	O
PML	O
)	O
.	O

Interestingly	O
,	O
early	O
treatment	O
(	O
day	O
0	O
HPCs	O
)	O
with	O
alpha	O
-	O
PML	O
reduced	O
the	O
number	O
of	O
both	O
erythroid	B
and	I
granulocytic	I
colonies	I
,	O
whereas	O
late	O
treatment	O
(	O
day	O
5	O
culture	O
)	O
reduced	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
,	O
clonogenesis	O
.	O

These	O
findings	O
suggest	O
that	O
PML	O
is	O
required	O
for	O
early	O
hematopoiesis	O
and	O
erythroid	O
,	O
but	O
not	O
granulocytic	O
maturation	O
.	O

The	O
pattern	O
of	O
PML	O
expression	O
in	O
normal	O
hematopoiesis	O
mimics	O
that	O
of	O
retinoblastoma	O
pRb	O
105	O
.	O

Combined	O
treatment	O
of	O
HPCs	O
with	O
alpha	O
-	O
PML	O
and	O
alpha	O
-	O
Rb	O
oligomers	O
inhibited	O
both	O
PML	O
and	O
Rb	O
protein	O
expression	O
and	O
completely	O
blocked	O
erythroid	O
colony	O
development	O
.	O

Furthermore	O
,	O
PML	O
and	O
pRb	O
105	O
were	O
co	O
-	O
immunoprecipitated	O
in	O
cellular	O
lysates	O
derived	O
from	O
erythroid	O
precursors	O
indicating	O
that	O
this	O
functional	O
interaction	O
may	O
have	O
a	O
biochemical	O
basis	O
.	O

These	O
results	O
suggest	O
a	O
key	O
functional	O
role	O
of	O
PML	O
in	O
early	O
hematopoiesis	O
and	O
late	O
erythropoiesis	O
:	O
the	O
latter	O
phenomenon	O
may	O
be	O
related	O
to	O
the	O
molecular	O
and	O
functional	O
interaction	O
of	O
PML	O
with	O
pRb	O
105	O
.	O

p70	O
(	O
s6k	O
)	O
integrates	O
phosphatidylinositol	O
3-kinase	O
and	O
rapamycin	O
-	O
regulated	O
signals	O
for	O
E2F	O
regulation	O
in	O
T	O
lymphocytes	O
.	O

In	O
T	O
lymphocytes	O
,	O
the	O
hematopoietic	O
cytokine	O
interleukin-2	O
(	O
IL-2	O
)	O
uses	O
phosphatidylinositol	O
3-kinase	O
(	O
PI	O
3-kinase	O
)	O
-induced	O
signaling	O
pathways	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
,	O
a	O
critical	O
cell	O
cycle	O
checkpoint	O
.	O

PI	O
3-kinase	O
also	O
regulates	O
the	O
activity	O
of	O
p70	O
(	O
s6k	O
)	O
,	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
kinase	O
,	O
a	O
response	O
that	O
is	O
abrogated	O
by	O
the	O
macrolide	O
rapamycin	O
.	O

This	O
immunosuppressive	O
drug	O
is	O
known	O
to	O
prevent	O
T	O
-	O
cell	O
proliferation	O
,	O
but	O
the	O
precise	O
point	O
at	O
which	O
rapamycin	O
regulates	O
T	O
-	O
cell	O
cycle	O
progression	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
rapamycin	O
on	O
,	O
and	O
the	O
role	O
of	O
p70	O
(	O
s6k	O
)	O
in	O
,	O
IL-2	O
and	O
PI	O
3-kinase	O
activation	O
of	O
E2Fs	O
have	O
not	O
been	O
characterized	O
.	O

Our	O
present	O
results	O
show	O
that	O
IL-2	O
-and	O
PI	O
3-kinase	O
-induced	O
pathways	O
for	O
the	O
regulation	O
of	O
E2F	O
transcriptional	O
activity	O
include	O
both	O
rapamycin	O
-	O
resistant	O
and	O
rapamycin	O
-	O
sensitive	O
components	O
.	O

Expression	O
of	O
a	O
rapamycin	O
-	O
resistant	O
mutant	O
of	O
p70	O
(	O
s6k	O
)	O
in	O
T	O
cells	O
could	O
restore	O
rapamycin	O
-	O
suppressed	O
E2F	O
responses	O
.	O

Thus	O
,	O
the	O
rapamycin	O
-	O
controlled	O
processes	O
involved	O
in	O
E2F	O
regulation	O
appear	O
to	O
be	O
mediated	O
by	O
p70	O
(	O
s6k	O
)	O
.	O

However	O
,	O
the	O
rapamycin	O
-	O
resistant	O
p70	O
(	O
s6k	O
)	O
could	O
not	O
rescue	O
rapamycin	O
inhibition	O
of	O
T	O
-	O
cell	O
cycle	O
entry	O
,	O
consistent	O
with	O
the	O
involvement	O
of	O
additional	O
,	O
rapamycin	O
-	O
sensitive	O
pathways	O
in	O
the	O
control	O
of	O
T	O
-	O
cell	O
cycle	O
progression	O
.	O

The	O
present	O
results	O
thus	O
show	O
that	O
p70	O
(	O
s6k	O
)	O
is	O
able	O
to	O
regulate	O
E2F	O
transcriptional	O
activity	O
and	O
provide	O
direct	O
evidence	O
for	O
the	O
first	O
time	O
for	O
a	O
link	O
between	O
IL-2	O
receptors	O
,	O
PI	O
3-kinase	O
,	O
and	O
p70	O
(	O
s6k	O
)	O
that	O
regulates	O
a	O
crucial	O
G1	O
checkpoint	O
in	O
T	O
lymphocytes	O
.	O

Signal	O
transduction	O
pathways	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
cytokines	O
and	O
mediators	O
:	O
comparative	O
study	O
with	O
normal	O
human	O
neutrophils	O
or	O
transformed	B
cells	I
and	O
the	O
putative	O
roles	O
in	O
functionality	O
and	O
cell	O
biology	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
interleukin	O
(	O
IL	O
)	O
-3	O
induced	O
tyrosine	O
phosphorylation	O
of	O
92-kDa	O
protein	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
identified	O
this	O
92-kDa	O
protein	O
as	O
STAT5	O
,	O
but	O
not	O
as	O
STATs1	O
,	O
3	O
,	O
and	O
6	O
nor	O
c	O
-	O
fes	O
and	O
vav	O
protooncogene	O
products	O
,	O
and	O
demonstrated	O
its	O
translocation	O
to	O
the	O
nucleus	O
,	O
enhancement	O
of	O
specific	O
DNA	O
binding	O
capacity	O
,	O
and	O
potentiation	O
of	O
trancriptional	O
activity	O
by	O
GM	O
-	O
CSF	O
.	O

N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
FMLP	O
)	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
induced	O
tyrosine	O
phosphorylation	O
of	O
42-	O
and	O
44-kDa	O
proteins	O
,	O
which	O
were	O
identified	O
as	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
,	O
in	O
human	O
monocytes	O
.	O

In	O
marked	O
contrast	O
to	O
neutrophils	O
and	O
MO7e	O
cells	O
,	O
GM	O
-	O
CSF	O
did	O
not	O
induce	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
ERK	O
in	O
monocytes	O
.	O

Among	O
upstream	O
signaling	O
molecules	O
of	O
ERK	O
,	O
Shc	O
was	O
constitutively	O
associated	O
with	O
Grb2	O
and	O
was	O
not	O
tyrosine	O
-	O
phosphorylated	O
by	O
GM	O
-	O
CSF	O
and	O
FMLP	O
,	O
and	O
Sos1	O
and	O
c	O
-	O
Raf-1	O
were	O
not	O
phosphorylated	O
by	O
GM	O
-	O
CSF	O
,	O
IL-3	O
,	O
TNF	O
,	O
and	O
FMLP	O
in	O
monocytes	O
,	O
whereas	O
all	O
these	O
signaling	O
molecules	O
were	O
affected	O
and/or	O
utilized	O
by	O
GM	O
-	O
CSF	O
in	O
MO7e	O
cells	O
.	O

In	O
contrast	O
to	O
neutrophils	O
,	O
p38	O
was	O
constitutively	O
phosphorylated	O
and	O
agonist	O
-	O
dependent	O
phosphorylation	O
and	O
activation	O
was	O
not	O
detected	O
in	O
human	O
monocytes	O
.	O

Superoxide	O
release	O
stimulated	O
by	O
FMLP	O
was	O
inhibited	O
partially	O
by	O
PD98059	O
or	O
SB203580	O
,	O
a	O
specific	O
inhibitor	O
of	O
ERK	O
or	O
p38	O
pathway	O
,	O
and	O
was	O
almost	O
completely	O
inhibited	O
by	O
the	O
combination	O
of	O
both	O
inhibitors	O
,	O
whereas	O
PMA	O
-	O
induced	O
superoxide	O
release	O
was	O
resistant	O
to	O
these	O
two	O
inhibitors	O
in	O
monocytes	O
.	O

PD98059	O
inhibited	O
GM	O
-	O
CSF	O
-dependent	O
proliferation	O
of	O
MO7e	O
cells	O
.	O

Present	O
results	O
indicate	O
trancriptional	O
roles	O
of	O
STAT5	O
and	O
functional	O
roles	O
of	O
ERK	O
and/or	O
p38	O
in	O
normal	O
human	O
monocytes	O
stimulated	O
by	O
physiological	O
receptor	O
-	O
mediated	O
agonists	O
GM	O
-	O
CSF	O
and	O
FMLP	O
.	O

Possible	O
roles	O
of	O
ERK	O
in	O
proliferation	O
of	O
transformed	B
cells	I
were	O
also	O
suggested	O
.	O

PPARalpha	O
activators	O
inhibit	O
cytokine	O
-	O
induced	O
vascular	O
cell	O
adhesion	O
molecule-1	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
family	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	O
expression	O
in	O
human	O
ECs	O
and	O
their	O
regulation	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	O
carotid	O
artery	O
ECs	O
express	O
PPARalpha	O
.	O

Pretreatment	O
of	O
cultured	O
human	O
ECs	O
with	O
the	O
PPARalpha	O
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF	O
-	O
alpha	O
-	O
induced	O
VCAM-1	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
,	O
an	O
effect	O
not	O
seen	O
with	O
PPARgamma	O
activators	O
.	O

Both	O
PPARalpha	O
activators	O
decreased	O
cytokine	O
-	O
induced	O
VCAM-1	O
mRNA	O
expression	O
without	O
altering	O
its	O
mRNA	O
half	O
-	O
life	O
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM-1	O
promoter	O
constructs	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	O
transcription	O
in	O
part	O
by	O
inhibiting	O
NF	O
-	O
kappaB	O
.	O

Finally	O
,	O
PPARalpha	O
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	B
cells	I
to	O
cultured	O
human	O
ECs	O
.	O

CONCLUSIONS	O
:	O
Human	O
ECs	O
express	O
PPARalpha	O
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	O
gene	O
expression	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid	O
-	O
lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	O
.	O

Genetic	O
evidence	O
for	O
an	O
additional	O
factor	O
required	O
for	O
erythropoietin	O
-induced	O
signal	O
transduction	O
.	O

Erythropoietin	O
(	O
EPO	O
)	O
and	O
its	O
receptor	O
(	O
EPOR	O
)	O
are	O
required	O
for	O
the	O
development	O
of	O
mature	O
erythrocytes	O
.	O

After	O
binding	O
of	O
ligand	O
,	O
the	O
EPOR	O
activates	O
a	O
variety	O
of	O
signaling	O
pathways	O
that	O
ultimately	O
control	O
cellular	O
proliferation	O
,	O
survival	O
,	O
and	O
specific	O
gene	O
expression	O
.	O

Although	O
erythroid	O
progenitors	O
appear	O
to	O
be	O
the	O
principal	O
EPO	O
-	O
responsive	O
cell	O
type	O
in	O
vivo	O
due	O
to	O
the	O
restricted	O
expression	O
of	O
the	O
EPOR	O
,	O
many	O
growth	B
factor	I
-	I
dependent	I
cell	I
lines	I
expressing	O
the	O
EPOR	O
can	O
respond	O
to	O
EPO	O
by	O
activating	O
many	O
or	O
all	O
of	O
these	O
pathways	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
a	O
cellular	O
context	O
(	O
the	O
interleukin-2	B
[	I
IL-2	I
]	I
-dependent	I
HT-2	I
line	I
)	O
in	O
which	O
the	O
EPO	O
stimulation	O
of	O
the	O
EPOR	O
fails	O
to	O
support	O
cellular	O
proliferation	O
,	O
STAT-5	O
induction	O
,	O
or	O
MAPK	O
activation	O
,	O
despite	O
efficient	O
phosphorylation	O
of	O
the	O
EPOR	O
and	O
JAK2	O
and	O
inhibition	O
of	O
apoptosis	O
after	O
withdrawal	O
of	O
IL-2	O
.	O

Interestingly	O
,	O
when	O
we	O
fused	O
HT-2	B
cells	I
expressing	O
the	O
EPOR	O
with	O
Ba	B
/	I
F3	I
cells	I
in	O
a	O
complementation	O
assay	O
,	O
the	O
resulting	O
hybridomas	B
proliferated	O
and	O
potently	O
activated	O
STAT-5	O
and	O
MAPK	O
in	O
response	O
to	O
EPO	O
.	O

These	O
data	O
indicate	O
that	O
an	O
unidentified	O
cellular	O
factor	O
is	O
needed	O
to	O
mediate	O
signaling	O
by	O
the	O
EPOR	O
.	O

Moreover	O
,	O
Ba	B
/	I
F3	I
cells	I
apparently	O
express	O
this	O
factor	O
(	O
s	O
)	O
and	O
somatic	O
fusions	O
can	O
,	O
therefore	O
,	O
confer	O
EPO	O
-responsiveness	O
to	O
HT-2	B
cells	I
that	O
lack	O
this	O
factor	O
.	O

NF	O
-	O
kappaB	O
functions	O
as	O
both	O
a	O
proapoptotic	O
and	O
antiapoptotic	O
regulatory	O
factor	O
within	O
a	O
single	O
cell	O
type	O
.	O

Recently	O
NF	O
-	O
kappaB	O
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O

In	O
T	B
cell	I
hybridomas	I
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
using	O
a	O
dominant	O
negative	O
IkappaBalpha	O
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	O
Ligand	O
(	O
FasL	O
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
inhibits	O
the	O
P	O
/	O
I	O
mediated	O
induction	O
of	O
FasL	O
mRNA	O
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF	O
-	O
kappaB	O
as	O
a	O
proapoptotic	O
factor	O
in	O
this	O
context	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF	O
-	O
kappaB	O
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

We	O
conclude	O
that	O
NF	O
-	O
kappaB	O
is	O
a	O
context	O
-	O
dependent	O
apoptosis	O
regulator	O
.	O

Our	O
data	O
suggests	O
that	O
NF	O
-	O
kappaB	O
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	O
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	O
peripheral	O
T	O
cells	O
.	O

Functional	O
B	O
-	O
cell	O
response	O
in	O
intrahepatic	O
lymphoid	O
follicles	O
in	O
chronic	O
hepatitis	O
C	O
.	O

Intrahepatic	O
lymphoid	O
follicle	O
(	O
ILF	O
)	O
formation	O
is	O
one	O
of	O
the	O
most	O
characteristic	O
and	O
commonly	O
observed	O
histological	O
features	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
whether	O
follicles	O
in	O
the	O
liver	O
belong	O
to	O
functional	O
lymphoid	O
tissues	O
,	O
where	O
B	O
cells	O
are	O
activated	O
,	O
differentiated	O
,	O
and	O
proliferated	O
,	O
or	O
if	O
the	O
lymphocytes	O
are	O
merely	O
infiltrated	O
after	O
recruitment	O
from	O
the	O
secondary	O
lymphoid	O
organs	O
.	O

To	O
ascertain	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
expression	O
of	O
markers	O
for	O
B	O
-	O
cell	O
activation	O
,	O
differentiation	O
,	O
and	O
proliferation	O
in	O
ILFs	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
using	O
surgically	O
resected	O
specimens	O
,	O
and	O
compared	O
them	O
with	O
specimens	O
of	O
perihepatic	O
lymph	O
nodes	O
by	O
an	O
immunohistochemical	O
technique	O
.	O

Germinal	O
center	O
(	O
GC	O
)	O
formation	O
in	O
the	O
ILFs	O
was	O
frequently	O
found	O
in	O
HCV	O
-	O
positive	O
cases	O
.	O

The	O
distribution	O
of	O
immunoglobulin	O
M	O
(	O
IgM	O
)	O
-	O
,	O
IgD-	O
,	O
and	O
IgG	O
-	O
positive	O
cells	O
and	O
the	O
expression	O
patterns	O
of	O
Ki-67	O
,	O
CD23	O
,	O
or	O
bcl-2	O
and	O
bcl-6	O
gene	O
products	O
in	O
the	O
follicles	O
with	O
GC	O
formation	O
in	O
the	O
liver	O
of	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
were	O
similar	O
to	O
those	O
of	O
lymph	O
nodes	O
,	O
indicating	O
that	O
B	O
cells	O
are	O
activated	O
,	O
proliferated	O
,	O
and	O
differentiated	O
in	O
the	O
ILFs	O
with	O
GC	O
formation	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

Oligoclonal	O
expansion	O
of	O
B	O
cells	O
in	O
the	O
livers	O
with	O
ILFs	O
was	O
confirmed	O
by	O
an	O
analysis	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
rearrangement	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
ILFs	O
with	O
GC	O
formation	O
,	O
which	O
are	O
frequently	O
found	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
may	O
functionally	O
be	O
the	O
same	O
as	O
those	O
found	O
in	O
lymph	O
nodes	O
with	O
respect	O
to	O
B	O
-	O
cell	O
expansion	O
and	O
maturation	O
.	O

Cutting	O
edge	O
:	O
expression	O
of	O
the	O
NF	O
of	O
activated	O
T	O
cells	O
in	O
eosinophils	O
:	O
regulation	O
by	O
IL-4	O
and	O
IL-5	O
.	O

We	O
report	O
that	O
NF	O
-	O
AT1	O
and	O
NF	O
-	O
AT4	O
are	O
expressed	O
cytoplasmically	O
in	O
resting	O
eosinophils	O
,	O
whereas	O
NF	O
-	O
AT2	O
and	O
NF	O
-	O
AT3	O
have	O
not	O
been	O
seen	O
.	O

Likewise	O
,	O
NF	O
-	O
AT1	O
mRNA	O
and	O
NF	O
-	O
AT4	O
mRNA	O
have	O
been	O
detected	O
in	O
resting	O
eosinophils	O
,	O
and	O
their	O
levels	O
can	O
be	O
significantly	O
up	O
-	O
regulated	O
by	O
the	O
Th2-associated	O
cytokines	O
IL-4	O
and	O
IL-5	O
.	O

There	O
is	O
no	O
detectable	O
NF	O
-	O
AT	O
protein	O
expression	O
in	O
the	O
nuclei	O
of	O
resting	O
eosinophils	O
.	O

However	O
NF	O
-	O
ATs	O
appear	O
in	O
the	O
nuclei	O
of	O
IL-4-	B
,	I
IL-5-	I
,	I
or	I
ionomycin	I
-	I
stimulated	I
eosinophils	I
.	O

Only	O
NF	O
-	O
AT1	O
and	O
NF	O
-	O
AT4	O
,	O
but	O
not	O
NF	O
-	O
AT2	O
and	O
NF	O
-	O
AT3	O
,	O
have	O
translocated	O
into	O
the	O
nuclei	O
in	O
IL-4-	B
or	I
IL-5-stimulated	I
eosinophils	I
.	O

These	O
findings	O
delineate	O
a	O
novel	O
pathway	O
in	O
the	O
cytokine	O
network	O
in	O
which	O
Th2	B
lymphocytes	I
`	O
`	O
control	O
''	O
eosinophils	O
via	O
the	O
release	O
of	O
IL-4	O
and	O
IL-5	O
,	O
and	O
activation	O
of	O
NF	O
-	O
AT	O
in	O
eosinophils	O
.	O

The	O
findings	O
also	O
suggest	O
that	O
a	O
later	O
feedback	O
`	O
`	O
talking	O
''	O
may	O
exist	O
between	O
eosinophils	O
and	O
Th2	B
lymphocytes	I
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase	O
-	O
dependent	O
apoptosis	O
without	O
detectable	O
activation	O
of	O
caspase-1	O
and	O
-3	O
.	O

NF	O
-	O
kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF	O
-	O
kappa	O
B	O
activity	O
with	O
cell	O
-	O
permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF	O
-	O
kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
and	O
partially	O
blocked	O
by	O
Ac	O
-	O
DEVD	O
-	O
fmk	O
,	O
suggesting	O
that	O
SN50-mediated	O
apoptosis	O
is	O
caspase	O
-dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF	O
-	O
kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetrakis	O
[	O
2-pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	O
ligand	O
(	O
CD95	O
)	O
,	O
was	O
observed	O
in	O
the	O
absence	O
of	O
active	O
death	O
effector	O
proteases	O
caspase-1	O
-like	O
(	O
IL-1	O
converting	O
enzyme	O
)	O
,	O
caspase-3	O
-like	O
(	O
CPP32	O
/	O
Yama	O
/	O
apopain	O
)	O
,	O
and	O
caspase-6	O
-like	O
and	O
without	O
cleavage	O
of	O
caspase-3	O
substrates	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
and	O
DNA	O
fragmentation	O
factor-45	O
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF	O
-	O
kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50-induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF	O
-	O
kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O

Clonality	O
analysis	O
using	O
X	O
-	O
chromosome	O
inactivation	O
at	O
the	O
human	O
androgen	O
receptor	O
gene	O
(	O
Humara	O
)	O
.	O

Evaluation	O
of	O
large	O
cohorts	O
of	O
patients	O
with	O
chronic	O
myeloproliferative	O
diseases	O
,	O
secondary	O
neutrophilia	O
,	O
and	O
reactive	O
thrombocytosis	O
.	O

Chronic	O
myeloproliferative	O
diseases	O
(	O
MPDs	O
)	O
are	O
not	O
associated	O
with	O
consistent	O
cytogenetic	O
or	O
molecular	O
abnormalities	O
.	O

Demonstration	O
of	O
clonal	O
cell	O
growth	O
by	O
analysis	O
of	O
X	O
-	O
chromosome	O
inactivation	O
(	O
XCI	O
)	O
patterns	O
in	O
females	O
provides	O
a	O
promising	O
tool	O
for	O
diagnosis	O
.	O

However	O
,	O
this	O
technique	O
can	O
be	O
complicated	O
by	O
excessive	O
lyonization	O
of	O
normal	O
cells	O
mimicking	O
clonal	O
cell	O
growth	O
:	O
We	O
analyzed	O
XCI	O
patterns	O
at	O
the	O
human	O
androgen	O
receptor	O
(	O
HUMARA	O
)	O
locus	O
in	O
146	O
healthy	O
females	O
,	O
65	O
women	O
with	O
secondary	O
neutrophilia	O
,	O
31	O
women	O
with	O
reactive	O
thrombocytosis	O
,	O
and	O
86	O
women	O
with	O
chronic	O
MPDs	O
.	O

A	O
skewed	O
XCI	O
pattern	O
with	O
greater	O
than	O
75	O
%	O
amplification	O
of	O
1	O
allele	O
(	O
allele	O
ratio	O
>	O
3	O
:	O
1	O
)	O
was	O
found	O
in	O
22	O
(	O
9.1	O
%	O
)	O
of	O
242	O
control	O
subjects	O
.	O

The	O
incidence	O
of	O
skewing	O
was	O
statistically	O
significantly	O
lower	O
in	O
women	O
younger	O
than	O
30	O
years	O
(	O
2	O
/	O
73	O
)	O
compared	O
with	O
women	O
older	O
than	O
60	O
years	O
(	O
10	O
/	O
53	O
)	O
.	O

Of	O
86	O
patients	O
with	O
a	O
chronic	O
MPD	O
,	O
71	O
(	O
82	O
%	O
)	O
exhibited	O
an	O
allele	O
ratio	O
greater	O
than	O
3	O
:	O
1	O
,	O
whereas	O
only	O
10	O
(	O
12	O
%	O
)	O
of	O
86	O
age	O
-	O
matched	O
control	O
subjects	O
showed	O
a	O
skewed	O
XCI	O
pattern	O
.	O

Although	O
statistical	O
evaluation	O
of	O
the	O
data	O
showed	O
a	O
significant	O
difference	O
between	O
patients	O
with	O
a	O
chronic	O
MPD	O
and	O
control	O
subjects	O
,	O
proof	O
of	O
clonality	O
in	O
individual	O
,	O
especially	O
elderly	O
,	O
patients	O
is	O
difficult	O
.	O

The	O
glucocorticoid	O
receptor	O
cooperates	O
with	O
the	O
erythropoietin	O
receptor	O
and	O
c	O
-	O
Kit	O
to	O
enhance	O
and	O
sustain	O
proliferation	O
of	O
erythroid	O
progenitors	O
in	O
vitro	O
.	O

Although	O
erythropoietin	O
(	O
Epo	O
)	O
is	O
essential	O
for	O
the	O
production	O
of	O
mature	O
red	O
blood	O
cells	O
,	O
the	O
cooperation	O
with	O
other	O
factors	O
is	O
required	O
for	O
a	O
proper	O
balance	O
between	O
progenitor	O
proliferation	O
and	O
differentiation	O
.	O

In	O
avian	O
erythroid	O
progenitors	O
,	O
steroid	O
hormones	O
cooperate	O
with	O
tyrosine	O
kinase	O
receptors	O
to	O
induce	O
renewal	O
of	O
erythroid	O
progenitors	O
.	O

We	O
examined	O
the	O
role	O
of	O
corticosteroids	O
in	O
the	O
in	O
vitro	O
expansion	O
of	O
primary	O
human	O
erythroid	O
cells	O
in	O
liquid	O
cultures	O
and	O
colony	O
assays	O
.	O

Dexamethasone	O
(	O
Dex	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
hormone	O
,	O
cooperated	O
with	O
Epo	O
and	O
stem	O
cell	O
factor	O
to	O
induce	O
erythroid	O
progenitors	O
to	O
undergo	O
15	O
to	O
22	O
cell	O
divisions	O
,	O
corresponding	O
to	O
a	O
10	O
(	O
5	O
)	O
-	O
to	O
10	O
(	O
6	O
)	O
-fold	O
amplification	O
of	O
erythroid	O
cells	O
.	O

Dex	O
acted	O
directly	O
on	O
erythroid	O
progenitors	O
and	O
maintained	O
the	O
colony	O
-	O
forming	O
capacity	O
of	O
the	O
progenitor	O
cells	O
expanded	O
in	O
liquid	B
cultures	I
.	O

The	O
hormone	O
delayed	O
terminal	O
differentiation	O
into	O
erythrocytes	O
,	O
which	O
was	O
assayed	O
by	O
morphology	O
,	O
hemoglobin	O
accumulation	O
,	O
and	O
the	O
expression	O
of	O
genes	O
characteristic	O
for	O
immature	O
cells	O
.	O

Sustained	O
proliferation	O
of	O
erythroid	O
progenitors	O
could	O
be	O
induced	O
equally	O
well	O
from	O
purified	B
erythroid	I
burst	I
-	I
forming	I
units	I
(	O
BFU	B
-	I
E	I
)	O
,	O
from	O
CD34	O
(	O
+	O
)	O
blast	O
cells	O
,	O
and	O
from	O
bone	O
marrow	O
depleted	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

Monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti	O
-	O
endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	B
umbilical	I
vein	I
endothelial	I
cells	I
(	O
HUVEC	B
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein	O
-	O
Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	B
EC	I
(	O
HUVEC	B
)	O
and	O
microvascular	B
EC	I
(	O
human	B
bone	I
marrow	I
EC	I
immortalized	I
by	I
SV40	I
)	O
antigens	O
was	O
detected	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG	O
-	O
AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	B
EC	I
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	B
cell	I
line	I
(	O
U937	B
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E	O
-	O
selectin	O
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA	B
-	I
treated	I
EC	I
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF	O
-	O
kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	B
.	O

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	B
EC	I
,	O
but	O
none	O
had	O
significant	O
antimicrovascular	O
EC	O
activity	O
.	O

The	O
mAECA	O
,	O
but	O
not	O
normal	O
human	O
IgG	O
,	O
had	O
anti	O
-	O
human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	O
activated	B
EC	I
,	O
manifested	O
by	O
increased	O
IL-6	O
and	O
vWF	O
secretion	O
.	O

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factor	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF	O
-	O
kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

Clonality	O
analysis	O
of	O
granulocytes	O
and	O
T	O
lymphocytes	O
in	O
healthy	O
females	O
by	O
the	O
PCR	O
-	O
based	O
HUMARA	O
method	O
.	O

Clonality	O
analysis	O
utilizing	O
X	O
-	O
chromosome	O
inactivation	O
has	O
been	O
used	O
in	O
the	O
study	O
of	O
various	O
diseases	O
,	O
including	O
hematological	O
malignancies	O
.	O

The	O
human	O
androgen	O
receptor	O
gene	O
(	O
HUMARA	O
)	O
assay	O
is	O
the	O
newest	O
of	O
such	O
methods	O
,	O
and	O
the	O
majority	O
of	O
the	O
female	O
population	O
can	O
be	O
assessed	O
by	O
this	O
relatively	O
simple	O
procedure	O
.	O

One	O
problem	O
in	O
using	O
these	O
clonality	O
analysis	O
methods	O
,	O
however	O
,	O
is	O
that	O
there	O
may	O
be	O
significant	O
variation	O
in	O
Lyonization	O
in	O
blood	O
cells	O
in	O
normal	O
individuals	O
.	O

To	O
determine	O
the	O
diversity	O
in	O
X	O
-	O
chromosome	O
methylation	O
patterns	O
,	O
which	O
reflect	O
Lyonization	O
,	O
assessed	O
by	O
the	O
HUMARA	O
assay	O
in	O
the	O
supposedly	O
normal	O
population	O
,	O
we	O
analyzed	O
granulocytes	O
and	O
T	B
cells	I
from	O
97	O
relatively	O
young	O
(	O
18-	O
to	O
35-year	O
-	O
old	O
)	O
healthy	O
female	O
volunteers	O
.	O

We	O
found	O
that	O
the	O
methylation	O
patterns	O
in	O
the	O
two	O
HUMARA	O
alleles	O
were	O
distributed	O
even	O
more	O
widely	O
,	O
both	O
in	O
granuloctyes	O
and	O
in	O
T	B
cells	I
,	O
than	O
previously	O
reported	O
with	O
other	O
methods	O
.	O

We	O
also	O
found	O
that	O
the	O
deviation	O
of	O
methylation	O
in	O
granulocytes	O
and	O
T	B
cells	I
was	O
well	O
correlated	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
appropriate	O
controls	O
from	O
the	O
same	O
individuals	O
,	O
such	O
as	O
T	B
cells	I
in	O
the	O
case	O
of	O
stem	O
cell	O
disorders	O
,	O
should	O
always	O
be	O
employed	O
to	O
conclusively	O
determine	O
whether	O
certain	O
cells	O
of	O
hematopoietic	O
origin	O
are	O
clonal	O
.	O

Regulatory	O
effects	O
of	O
interleukin-11	O
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin-11	O
(	O
IL-11	O
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL-11	O
mRNA	O
and	O
protein	O
were	O
both	O
up	O
-	O
regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL-11	O
substantially	O
reduced	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
IL-11	O
were	O
associated	O
with	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM-1	O
.	O

It	O
is	O
interesting	O
that	O
IL-11	O
did	O
not	O
affect	O
BAL	O
fluid	O
content	O
of	O
the	O
CXC	O
chemokines	O
,	O
macrophage	O
inflammatory	O
protein-2	O
(	O
MIP-2	O
)	O
and	O
cytokine	O
-	O
inducible	O
neutrophil	O
chemoattractant	O
(	O
CINC	O
)	O
;	O
the	O
presence	O
of	O
IL-11	O
did	O
not	O
affect	O
these	O
chemokines	O
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	O
.	O

These	O
data	O
indicate	O
that	O
IL-11	O
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti	O
-	O
inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
diminished	O
production	O
of	O
TNF	O
-	O
alpha	O
,	O
and	O
reduced	O
up	O
-	O
regulation	O
of	O
lung	O
vascular	O
ICAM-1	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	O
membrane	O
protein	O
1	O
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
proteins	O
TRADD	O
and	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	O
induce	O
apoptosis	O
or	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

A	O
site	O
in	O
the	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
that	O
constitutively	O
associates	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
-associated	O
death	O
domain	O
protein	O
TRADD	O
to	O
mediate	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long	O
-	O
term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	O
signaling	O
through	O
TRADD	O
differs	O
from	O
TNFR1	O
signaling	O
through	O
TRADD	O
.	O

LMP1	O
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF	O
-	O
kappaB	O
or	O
synergize	O
with	O
TRADD	O
in	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	O
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	O
does	O
not	O
require	O
TRADD	O
residues	O
294	O
to	O
312	O
for	O
NF	O
-	O
kappaB	O
activation	O
,	O
while	O
TNFR1	O
requires	O
TRADD	O
residues	O
296	O
to	O
302	O
.	O

LMP1	O
is	O
partially	O
blocked	O
for	O
NF	O
-	O
kappaB	O
activation	O
by	O
a	O
TRADD	O
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	O
,	O
LMP1	O
can	O
interact	O
directly	O
with	O
receptor	O
-	O
interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV	B
-	I
transformed	I
lymphoblastoid	I
cell	I
lines	I
.	O

Surprisingly	O
,	O
LMP1	O
does	O
not	O
require	O
RIP	O
for	O
NF	O
-	O
kappaB	O
activation	O
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	O
or	O
RIP	O
,	O
LMP1	O
does	O
not	O
induce	O
apoptosis	O
in	O
EBV	B
-	I
negative	I
Burkitt	I
lymphoma	I
or	I
human	I
embryonic	I
kidney	I
293	I
cells	I
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	O
,	O
TRADD	O
,	O
and	O
RIP	O
participate	O
in	O
B	O
-	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	O
(	O
IL-2	O
,	O
IL-6	O
,	O
TNF	O
-	O
alpha	O
,	O
IL-10	O
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF	O
-	O
kB	O
DNA	O
binding	O
activity	O
by	O
activated	B
Jurkat	I
cell	I
line	I
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kB	O
in	O
Jurkat	B
cells	I
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	O
with	O
the	O
same	O
intensity	O
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF	O
-	O
kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue	O
-	O
specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O

Extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
-dependent	O
and	O
ERK	O
-	O
independent	O
pathways	O
target	O
STAT3	O
on	O
serine-727	O
in	O
human	O
neutrophils	O
stimulated	O
by	O
chemotactic	O
factors	O
and	O
cytokines	O
.	O

STAT3	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
)	O
is	O
a	O
latent	O
transcription	O
factor	O
that	O
is	O
activated	O
by	O
tyrosine	O
phosphorylation	O
(	O
Tyr-705	O
)	O
in	O
cells	O
stimulated	O
with	O
cytokines	O
or	O
growth	O
factors	O
.	O

Recent	O
studies	O
suggest	O
that	O
one	O
or	O
more	O
cytoplasmic	O
serine	O
kinases	O
also	O
phosphorylate	O
STAT3	O
and	O
are	O
necessary	O
for	O
maximal	O
gene	O
activation	O
.	O

Here	O
we	O
demonstrate	O
,	O
with	O
a	O
site	O
-	O
specific	O
antibody	O
,	O
that	O
STAT3	O
is	O
phosphorylated	O
on	O
Ser-727	O
in	O
human	O
neutrophils	O
stimulated	O
with	O
chemotactic	O
factors	O
(	O
N	O
-	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
and	O
complement	O
C5a	O
)	O
,	O
cytokines	O
[	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
and	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
]	O
,	O
or	O
a	O
protein	O
kinase	O
C	O
activator	O
(	O
PMA	O
)	O
.	O

(	O
2-Amino-3'-methoxyphenyl	O
)	O
oxanaphthalen-4-one	O
(	O
PD	O
98059	O
)	O
,	O
an	O
inhibitor	O
of	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
activation	O
,	O
blocked	O
the	O
serine	O
phosphorylation	O
of	O
STAT3	O
induced	O
by	O
chemotactic	O
factors	O
or	O
PMA	O
.	O

The	O
drug	O
was	O
less	O
effective	O
on	O
cytokines	O
:	O
it	O
virtually	O
abolished	O
the	O
response	O
to	O
GM	O
-	O
CSF	O
that	O
occurred	O
5	O
min	O
after	O
stimulation	O
but	O
only	O
partly	O
decreased	O
those	O
at	O
15	O
-	O
30	O
min	O
and	O
did	O
not	O
appreciably	O
alter	O
responses	O
to	O
G	O
-	O
CSF	O
regardless	O
of	O
incubation	O
time	O
.	O

1-	O
(	O
5-Isoquinolinylsulphonyl	O
)	O
-2-methylpiperazine	O
dihydrochloride	O
(	O
H7	O
)	O
,	O
an	O
inhibitor	O
of	O
a	O
putative	O
STAT3	O
serine	O
kinase	O
,	O
and	O
4-	O
(	O
4-fluorophenyl	O
)	O
-2-	O
(	O
4-methylsulphinylphenyl	O
)	O
-5-	O
(	O
4-pyridyl	O
)	O
1H	O
-	O
imidazole	O
(	O
SB	O
203580	O
)	O
,	O
an	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
,	O
did	O
not	O
dampen	O
any	O
of	O
these	O
serine	O
phosphorylation	O
responses	O
.	O

We	O
propose	O
that	O
neutrophils	O
use	O
both	O
ERK	O
-	O
dependent	O
and	O
ERK	O
-	O
independent	O
pathways	O
to	O
phosphorylate	O
Ser-727	O
on	O
STAT3	O
.	O

The	O
former	O
pathway	O
is	O
recruited	O
by	O
all	O
ERK	O
-activating	O
stimuli	O
,	O
whereas	O
the	O
latter	O
pathway	O
uses	O
an	O
undefined	O
serine	O
kinase	O
and	O
is	O
recruited	O
selectively	O
by	O
cytokines	O
.	O

Activation	O
of	O
STAT5	O
by	O
IL-4	O
relies	O
on	O
Janus	O
kinase	O
function	O
but	O
not	O
on	O
receptor	O
tyrosine	O
phosphorylation	O
,	O
and	O
can	O
contribute	O
to	O
both	O
cell	O
proliferation	O
and	O
gene	O
regulation	O
.	O

We	O
have	O
investigated	O
mechanisms	O
and	O
consequences	O
of	O
STAT5	O
activation	O
through	O
the	O
human	O
IL-4	O
receptor	O
(	O
IL-4R	O
)	O
.	O

By	O
functionally	O
expressing	O
receptor	O
mutants	O
in	O
the	O
murine	B
pro	I
-	I
B	I
cell	I
line	I
Ba	B
/	I
F3	I
,	O
we	O
could	O
show	O
that	O
phosphorylated	O
tyrosine	O
residues	O
within	O
the	O
IL-4R	O
alpha	O
chain	O
are	O
dispensable	O
for	O
IL-4	O
-induced	O
STAT5	O
activity	O
.	O

However	O
,	O
disruption	O
of	O
a	O
membrane	O
-	O
proximal	O
proline	O
-	O
rich	O
sequence	O
motif	O
(	O
'	O
box1	O
'	O
)	O
in	O
either	O
subunit	O
of	O
the	O
bipartite	O
IL-4R	O
abolished	O
not	O
only	O
ligand	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Janus	O
kinases	O
JAK1	O
and	O
JAK3	O
,	O
but	O
also	O
IL-4	O
-triggered	O
activation	O
of	O
STAT5	O
and	O
concomitant	O
cell	O
proliferation	O
.	O

A	O
dominant	O
-	O
negative	O
version	O
of	O
STAT5b	O
,	O
but	O
not	O
of	O
STAT5a	O
,	O
interfered	O
with	O
IL-4	O
-induced	O
DNA	O
synthesis	O
in	O
Ba	B
/	I
F3	I
cells	I
,	O
suggesting	O
an	O
involvement	O
of	O
STAT5b	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
through	O
IL-4R	O
.	O

Reporter	O
gene	O
experiments	O
finally	O
showed	O
that	O
transcription	O
from	O
promoters	O
of	O
STAT5	O
target	O
genes	O
can	O
be	O
specifically	O
induced	O
by	O
challenging	O
cells	O
with	O
IL-4	O
,	O
and	O
that	O
both	O
STAT5a	O
and	O
STAT5b	O
can	O
contribute	O
to	O
IL-4	O
-triggered	O
transcriptional	O
control	O
.	O

MHC	O
-	O
peptide	O
ligand	O
interactions	O
establish	O
a	O
functional	O
threshold	O
for	O
antigen	O
-	O
specific	O
T	O
cell	O
recognition	O
.	O

Antigen	O
-	O
specific	O
T	O
cell	O
recognition	O
is	O
dependent	O
on	O
the	O
functional	O
density	O
of	O
the	O
TCR	O
-ligand	O
,	O
which	O
consists	O
of	O
specific	O
MHC	O
molecules	O
and	O
a	O
specifically	O
bound	O
peptide	O
.	O

We	O
have	O
examined	O
the	O
influence	O
of	O
the	O
affinity	O
and	O
concentration	O
of	O
exogenous	O
peptide	O
and	O
the	O
density	O
of	O
specific	O
MHC	O
molecules	O
on	O
the	O
proliferation	O
of	O
a	O
CD4	B
+	I
,	I
DQA1	I
*	I
0501	I
/	I
DQB1	I
*	I
0201	I
(	I
DQ2.1	I
)	I
-restricted	I
,	I
HSV-2-specific	I
T	I
cell	I
clone	I
.	O

Using	O
antigen	O
peptide	O
analogs	O
with	O
different	O
mutations	O
of	O
known	O
DQ2-anchor	O
residues	O
,	O
T	O
cell	O
response	O
was	O
reduced	O
in	O
an	O
peptide	O
-	O
affinity	O
and	O
-	O
concentration	O
specific	O
manner	O
.	O

The	O
decrease	O
using	O
weaker	O
binding	O
peptides	O
was	O
gradual	O
as	O
stimulation	O
with	O
a	O
peptide	O
with	O
intermediate	O
affinity	O
yielded	O
intermediate	O
T	O
cell	O
proliferation	O
and	O
the	O
poorest	O
binding	O
peptide	O
induced	O
an	O
even	O
weaker	O
T	O
cell	O
response	O
.	O

MHC	O
class	O
II	O
density	O
on	O
the	O
APC	O
was	O
modified	O
using	O
DQ2	B
homo	I
-and	I
heterozygous	I
B	I
-	I
LCLs	I
as	O
APCs	O
,	O
however	O
this	O
variation	O
of	O
MHC	O
concentration	O
had	O
no	O
effect	O
on	O
T	O
cell	O
proliferation	O
.	O

We	O
interpret	O
this	O
as	O
a	O
reflection	O
of	O
a	O
low	O
threshold	O
for	O
activation	O
of	O
the	O
T	B
cell	I
clone	I
,	O
in	O
which	O
peptide-	O
MHC	O
avidity	O
is	O
the	O
over	O
-	O
riding	O
determinant	O
of	O
the	O
strength	O
of	O
ligand	O
signal	O
.	O

PPARgamma	O
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
gene	O
in	O
human	O
monocytes	O
.	O

The	O
peroxisome	O
-	O
proliferator	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
of	O
ligand	O
activated	O
transcription	O
factors	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti	O
-	O
diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O

PPARgamma	O
induces	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
(	O
aP2	O
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	O
differentiation	O
.	O

PPARgamma	O
is	O
also	O
expressed	O
in	O
hematopoietic	O
cells	O
and	O
is	O
up	O
-	O
regulated	O
in	O
activated	O
monocytes	O
/	O
macrophages	O
.	O

Activation	O
of	O
PPARgamma	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	O
to	O
foam	O
cells	O
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time-	O
and	O
dose	O
-	O
dependent	O
increases	O
in	O
aP2	O
mRNA	O
in	O
both	O
primary	O
human	O
monocytes	O
and	O
the	O
monocytic	B
cell	I
line	I
,	O
THP-1	B
.	O

These	O
data	O
suggest	O
that	O
PPARgamma	O
activation	O
may	O
play	O
a	O
role	O
in	O
monocyte	O
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well	O
-	O
characterized	O
role	O
in	O
adipocytes	O
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	O
lipoproteins	O
through	O
toll	O
-	O
like	O
receptors	O
.	O

The	O
generation	O
of	O
cell	O
-	O
mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	O
(	O
IL-12	O
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	O
production	O
by	O
macrophages	O
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	O
lipoproteins	O
are	O
potent	O
stimulators	O
of	O
IL-12	O
production	O
by	O
human	O
macrophages	O
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll	O
-	O
like	O
receptors	O
(	O
TLRs	O
)	O
.	O

Several	O
lipoproteins	O
stimulated	O
TLR	O
-	O
dependent	O
transcription	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O

Activation	O
of	O
TLRs	O
by	O
microbial	O
lipoproteins	O
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	O
mammary	O
epithelial	O
cells	O
and	O
breast	O
cancers	O
.	O

cDNA	O
microarrays	O
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	O
mammary	O
epithelial	O
cells	O
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

Clusters	O
of	O
coexpressed	O
genes	O
identified	O
through	O
manipulations	O
of	O
mammary	O
epithelial	O
cells	O
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O

Clusters	O
of	O
genes	O
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	O
cells	O
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN	O
-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

Clusters	O
of	O
genes	O
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

Cutting	O
edge	O
:	O
TCR	O
stimulation	O
by	O
antibody	O
and	O
bacterial	O
superantigen	O
induces	O
Stat3	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Recent	O
data	O
show	O
that	O
TCR	O
/	O
CD3	O
stimulation	O
induces	O
activation	O
of	O
Stat5	O
in	O
murine	O
T	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
Staphylococcal	O
enterotoxin	O
(	O
SE	O
)	O
induce	O
a	O
rapid	O
,	O
gradually	O
accumulating	O
,	O
long	O
-	O
lasting	O
tyrosine	O
,	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	O
(	O
but	O
not	O
Stat5	O
)	O
in	O
allogen	B
-	I
specific	I
human	I
CD4	I
+	I
T	I
cell	I
lines	I
.	O

In	O
contrast	O
,	O
IL-2	O
induces	O
a	O
rapid	O
and	O
transient	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	O
.	O

Compared	O
with	O
IL-2	O
,	O
CD3	O
ligation	O
induces	O
a	O
delayed	O
Stat3	O
binding	O
to	O
oligonucleotide	O
probes	O
from	O
the	O
ICAM-1	O
and	O
IL-2R	O
alpha	O
promoter	O
.	O

CD3	O
-mediated	O
activation	O
of	O
Stat3	O
is	O
almost	O
completely	O
inhibited	O
by	O
a	O
Src	O
kinase	O
inhibitor	O
(	O
PP1	O
)	O
,	O
whereas	O
IL-2	O
-induced	O
Stat3	O
activation	O
is	O
unaffected	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
CD3	O
ligation	O
by	O
mAb	O
and	O
SE	O
triggers	O
a	O
rapid	O
,	O
PP1	O
-sensitive	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
Stat3	O
in	O
human	O
CD4	O
+	O
T	O
cells	O
.	O

Moreover	O
,	O
we	O
provide	O
evidence	O
that	O
TCR	O
/	O
CD3	O
and	O
IL-2	O
induce	O
Stat3	O
activation	O
via	O
distinct	O
signaling	O
pathways	O
.	O

[	O
Hormonal	O
metabolic	O
status	O
in	O
breast	O
cancer	O
patients	O
after	O
conservative	O
surgery	O
:	O
comparison	O
with	O
known	O
prognostic	O
criteria	O
]	O

Body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
fat	O
,	O
lean	O
body	O
mass	O
,	O
blood	O
-	O
glucose	O
,	O
cholesterol	O
,	O
HDL	O
-	O
cholesterol	O
,	O
triglyceride	O
,	O
beta	O
-	O
lipoproteins	O
,	O
insulin	O
,	O
gonadotropin	O
,	O
estradiol	O
,	O
testosterone	O
,	O
SHBG	O
,	O
T3	O
,	O
T4	O
and	O
TSH	O
levels	O
as	O
well	O
as	O
estradiol	O
and	O
progesterone	O
receptor	O
levels	O
in	O
excised	O
tumor	O
were	O
studied	O
in	O
40	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
conservative	O
treatment	O
.	O

Said	O
anthropometric	O
,	O
metabolic	O
and	O
hormonal	O
parameters	O
were	O
compared	O
with	O
the	O
index	O
of	O
lymphocytic	O
infiltration	O
of	O
tumor	O
selected	O
as	O
a	O
prognostic	O
factor	O
.	O

A	O
significant	O
correlation	O
between	O
high	O
lymphocytic	O
infiltration	O
(	O
2.5	O
points	O
)	O
,	O
low	O
body	O
mass	O
and	O
fat	O
was	O
identified	O
.	O

Also	O
,	O
smoking	O
contributed	O
to	O
loss	O
of	O
body	O
mass	O
and	O
fat	O
;	O
however	O
,	O
it	O
caused	O
lymphocytic	O
infiltration	O
to	O
rise	O
.	O

Moderate	O
body	O
mass	O
,	O
relatively	O
low	O
fat	O
level	O
and	O
positive	O
receptor	O
status	O
are	O
among	O
factors	O
of	O
good	O
prognosis	O
in	O
breast	O
cancer	O
of	O
early	O
stages	O
.	O

Myb	O
-	O
transformed	O
hematopoietic	O
cells	O
as	O
a	O
model	O
for	O
monocyte	O
differentiation	O
into	O
dendritic	O
cells	O
and	O
macrophages	O
.	O

Immune	O
induction	O
is	O
effected	O
through	O
the	O
interaction	O
of	O
antigen	O
-	O
presenting	O
cells	O
with	O
specific	O
receptors	O
on	O
the	O
surface	O
of	O
thymus	O
-	O
derived	O
lymphocytes	O
.	O

Cells	O
most	O
able	O
to	O
ingest	O
,	O
process	O
,	O
and	O
present	O
antigen	O
appear	O
to	O
be	O
related	O
to	O
the	O
mononuclear	O
phagocyte	O
/	O
neutrophil	O
series	O
.	O

For	O
example	O
dendritic	O
cells	O
(	O
DC	O
)	O
can	O
be	O
found	O
in	O
colonies	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
bone	O
marrow	O
cells	O
,	O
and	O
under	O
experimental	O
conditions	O
are	O
routinely	O
expanded	O
as	O
a	O
population	O
in	O
vitro	O
from	O
GM	O
-	O
CSF	O
-	O
responsive	O
progenitor	O
cells	O
.	O

To	O
address	O
the	O
question	O
of	O
DC	O
lineage	O
and	O
to	O
determine	O
what	O
genes	O
are	O
involved	O
in	O
lineage	O
commitment	O
,	O
we	O
have	O
generated	O
a	O
series	O
of	O
GM	B
-	I
CSF	I
-	I
responsive	I
cell	I
lines	I
that	O
can	O
be	O
induced	O
to	O
differentiate	O
in	O
a	O
homogeneous	O
manner	O
in	O
vitro	O
.	O

The	O
cloned	B
cell	I
lines	I
are	O
derived	O
from	O
12-day	O
fetal	O
liver	O
and	O
are	O
transformed	O
with	O
a	O
truncated	O
form	O
of	O
c	O
-	O
myb	O
,	O
which	O
lacks	O
the	O
normal	O
autoregulatory	O
sequences	O
.	O

As	O
far	O
as	O
we	O
know	O
,	O
these	O
myb	B
-	I
transformed	I
hemopoi	I
-	I
etic	I
cells	I
(	O
MTHC	B
)	O
differ	O
from	O
normal	O
only	O
in	O
the	O
unregulated	O
expression	O
of	O
myb	O
,	O
a	O
gene	O
whose	O
expression	O
is	O
obligatory	O
for	O
proliferation	O
of	O
hemopoietic	O
cells	O
.	O

MTHC	B
in	O
the	O
presence	O
of	O
TNF	O
-	O
alpha	O
and	O
IL-4	O
will	O
differentiate	O
into	O
cells	O
that	O
have	O
many	O
of	O
the	O
properties	O
of	O
macrophages	O
.	O

When	O
the	O
same	O
MTHC	B
lines	I
are	O
exposed	O
to	O
TNF	O
-	O
alpha	O
in	O
combination	O
with	O
IFN	O
-	O
gamma	O
,	O
the	O
cells	O
instead	O
become	O
DC	O
.	O

The	O
differentiated	O
DC	O
are	O
potent	O
presenters	O
of	O
antigen	O
in	O
mixed	O
lymphocyte	O
reactions	O
and	O
of	O
soluble	O
antigen	O
to	O
specific	O
T	B
cell	I
lines	I
.	O

Thus	O
,	O
cells	O
with	O
the	O
properties	O
of	O
both	O
macrophages	O
and	O
DC	O
can	O
be	O
derived	O
from	O
a	O
single	O
type	O
of	O
GM	O
-	O
CSF	O
-	O
responsive	O
progenitor	O
cell	O
.	O

We	O
have	O
used	O
this	O
MTHC	B
system	I
to	O
analyze	O
differences	O
in	O
gene	O
expression	O
as	O
the	O
cells	O
mature	O
along	O
the	O
DC	O
and	O
macrophage	O
pathways	O
.	O

A	O
distinctive	O
pattern	O
of	O
differentially	O
expressed	O
cDNAs	O
is	O
evident	O
where	O
macrophage	O
-	O
specific	O
cDNAs	O
are	O
homologous	O
to	O
genes	O
encoding	O
cytoskeletal	O
and	O
cell	O
-	O
surface	O
proteins	O
,	O
whereas	O
the	O
DC	O
-specific	O
cDNAs	O
are	O
homologous	O
to	O
signaling	O
,	O
chemokine	O
,	O
and	O
IFN	O
-	O
gamma	O
-	O
inducible	O
genes	O
.	O

We	O
discuss	O
the	O
utility	O
of	O
MTHC	B
in	O
analyzing	O
the	O
relationships	O
between	O
DC	O
and	O
macrophages	O
,	O
and	O
suggest	O
that	O
DC	O
and	O
macrophages	O
represent	O
extreme	O
phenotypes	O
in	O
a	O
spectrum	O
of	O
antigen	O
handling	O
cells	O
that	O
are	O
somewhat	O
interchangeable	O
,	O
depending	O
on	O
their	O
immediate	O
environment	O
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF	O
-	O
kappaB	O
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation	O
/	O
proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK	O
-	O
alpha	O
,	O
IKK	O
-	O
beta	O
,	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)	O
,	O
IKK	O
-	O
gamma	O
(	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	O
complex	O
-	O
associated	O
protein	O
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short	O
-	O
lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK	O
-	O
alpha	O
than	O
on	O
IKK	O
-	O
beta	O
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK	O
-	O
beta	O
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK	O
-	O
alpha	O
and	O
-beta	O
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK	O
-	O
alpha	O
/	O
beta	O
heterodimer	O
with	O
NIK	O
,	O
IkappaB	O
-	O
alpha	O
and	O
-epsilon	O
in	O
unstimulated	O
cells	O
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	O
to	O
differential	O
patterns	O
of	O
IkappaB	O
-	O
alpha	O
and	O
IkappaB	O
-	O
epsilon	O
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK	O
-	O
alpha	O
,	O
IKK	O
-	O
beta	O
,	O
and	O
NIK	O
remained	O
complex	O
-	O
associated	O
.	O

NIK	O
can	O
not	O
phosphorylate	O
IkappaB	O
-	O
alpha	O
directly	O
,	O
but	O
it	O
appears	O
to	O
be	O
a	O
functionally	O
important	O
subunit	O
,	O
because	O
mutated	O
NIK	O
inhibited	O
stimulus	O
-	O
induced	O
kappaB	O
-dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK	O
-	O
alpha	O
or	O
-beta	O
.	O

Overexpression	O
of	O
IKK	O
complex	O
-	O
associated	O
protein	O
inhibited	O
stimulus	O
-	O
mediated	O
transcription	O
,	O
whereas	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS-	O
and	O
TNF	O
-	O
induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis	O
-	O
associated	O
disease	O
.	O

Classification	O
of	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
as	O
a	O
polymorphism	O
of	O
BRCA1	O
.	O

Mutations	O
inactivating	O
the	O
tumor	O
suppressor	O
gene	O
BRCA1	O
may	O
be	O
responsible	O
for	O
disease	O
for	O
up	O
to	O
80	O
%	O
of	O
familial	O
ovarian	O
cancer	O
cases	O
.	O

In	O
this	O
syndrome	O
,	O
tumorigenesis	O
classically	O
initiates	O
from	O
an	O
inherited	O
mutation	O
in	O
one	O
allele	O
followed	O
by	O
somatic	O
deletion	O
of	O
the	O
normal	O
allele	O
.	O

Sequencing	O
of	O
BRCA1	O
amplified	O
from	O
genomic	O
DNA	O
of	O
lymphocytes	O
and	O
microdissected	O
ovarian	O
tumor	O
cells	O
of	O
a	O
familial	O
ovarian	O
cancer	O
patient	O
revealed	O
three	O
,	O
rare	O
heterozygous	O
DNA	O
variations	O
(	O
2418delA	O
,	O
233	O
G	O
--	O
>	O
A	O
,	O
and	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
)	O
in	O
both	O
tumor	O
and	O
constitutional	O
(	O
lymphocyte	O
)	O
DNA	O
.	O

Thus	O
,	O
both	O
copies	O
of	O
BRCA1	O
were	O
retained	O
in	O
tumor	O
.	O

Haplotype	O
analysis	O
of	O
the	O
patient	O
and	O
four	O
siblings	O
assigned	O
2418delA	O
to	O
one	O
copy	O
of	O
BRCA1	O
and	O
233	O
G	O
--	O
>	O
A	O
and	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
to	O
the	O
other	O
.	O

The	O
DNA	O
change	O
,	O
2418delA	O
,	O
is	O
considered	O
a	O
mutation	O
that	O
inactivated	O
one	O
BRCA1	O
allele	O
because	O
it	O
caused	O
a	O
frameshift	O
and	O
generation	O
of	O
a	O
premature	O
stop	O
codon	O
,	O
resulting	O
in	O
synthesis	O
of	O
a	O
truncated	O
peptide	O
as	O
evidenced	O
by	O
an	O
in	O
vitro	O
protein	O
truncation	O
test	O
.	O

The	O
DNA	O
variation	O
,	O
233	O
G	O
--	O
>	O
A	O
,	O
does	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
,	O
and	O
is	O
considered	O
a	O
benign	O
polymorphism	O
.	O

IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
is	O
a	O
unique	O
BRCA1	O
change	O
that	O
occurs	O
in	O
the	O
last	O
nucleotide	O
of	O
a	O
consensus	O
sequence	O
for	O
a	O
branch	O
site	O
critical	O
for	O
RNA	O
splicing	O
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
deleteriously	O
affected	O
BRCA1	O
splicing	O
or	O
expression	O
,	O
and	O
thereby	O
inactivated	O
the	O
other	O
BRCA1	O
allele	O
.	O

Using	O
the	O
technique	O
of	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
RNA	O
isolated	O
from	O
lymphoid	B
cell	I
lines	I
of	O
the	O
patient	O
and	O
of	O
controls	O
,	O
no	O
evidence	O
was	O
found	O
that	O
IVS1	O
-	O
10TC	O
abnormally	O
disrupted	O
mRNA	O
splicing	O
or	O
caused	O
the	O
absence	O
of	O
BRCA1	O
mRNA	O
.	O

Thus	O
,	O
IVS1	O
-	O
10	O
T	O
--	O
>	O
C	O
is	O
not	O
harmful	O
to	O
BRCA1	O
function	O
,	O
and	O
is	O
classified	O
a	O
benign	O
polymorphism	O
.	O

Retention	O
of	O
the	O
normal	O
BRCA1	O
allele	O
in	O
the	O
tumor	O
with	O
the	O
heterozygous	O
germline	O
BRCA1	O
mutation	O
,	O
2418delA	O
,	O
indicated	O
that	O
mutational	O
inactivation	O
of	O
both	O
BRCA1	O
alleles	O
was	O
not	O
required	O
for	O
tumorigenesis	O
.	O

It	O
is	O
possible	O
that	O
the	O
normal	O
allele	O
may	O
be	O
functionally	O
inactivated	O
by	O
a	O
nonmutational	O
mechanism	O
.	O

The	O
beta	O
-	O
globin	O
promoter	O
is	O
important	O
for	O
recruitment	O
of	O
erythroid	O
Kruppel	O
-	O
like	O
factor	O
to	O
the	O
locus	O
control	O
region	O
in	O
erythroid	O
cells	O
.	O

Erythroid	O
Kruppel	O
-	O
like	O
factor	O
(	O
EKLF	O
)	O
,	O
which	O
binds	O
to	O
the	O
CACCC	O
box	O
in	O
the	O
beta	O
-	O
globin	O
promoter	O
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
the	O
beta	O
-	O
globin	O
gene	O
in	O
adult	O
erythroid	O
cells	O
.	O

It	O
was	O
recently	O
demonstrated	O
that	O
EKLF	O
is	O
also	O
required	O
for	O
the	O
activity	O
of	O
the	O
beta	O
-	O
globin	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
5'HS3	O
.	O

Some	O
evidence	O
suggests	O
that	O
the	O
LCR	O
and	O
the	O
beta	O
-	O
globin	O
promoter	O
interact	O
in	O
adult	O
erythroid	O
cells	O
,	O
and	O
the	O
network	O
of	O
protein	O
-	O
protein	O
interactions	O
that	O
exists	O
between	O
these	O
two	O
elements	O
may	O
regulate	O
how	O
EKLF	O
is	O
recruited	O
to	O
the	O
LCR	O
.	O

In	O
this	O
report	O
,	O
we	O
use	O
the	O
PIN*POINT	O
assay	O
to	O
study	O
the	O
role	O
of	O
the	O
promoter	O
on	O
the	O
recruitment	O
of	O
EKLF	O
to	O
5'HS2	O
and	O
5'HS3	O
of	O
the	O
LCR	O
.	O

We	O
find	O
that	O
recruitment	O
of	O
EKLF	O
to	O
5'HS2	O
requires	O
the	O
TATA	O
box	O
,	O
but	O
recruitment	O
to	O
5'HS3	O
depends	O
on	O
the	O
CACCC	O
and	O
TATA	O
boxes	O
of	O
the	O
beta	O
-	O
globin	O
promoter	O
.	O

Furthermore	O
,	O
recruitment	O
of	O
EKLF	O
to	O
5'HS3	O
only	O
occurred	O
in	O
beta	O
-	O
globin	O
-	O
expressing	O
murine	O
erythroid	O
leukemia	O
cells	O
,	O
whereas	O
recruitment	O
of	O
EKLF	O
to	O
5'HS2	O
occurred	O
in	O
both	O
gamma	B
-	I
globin	I
-	I
expressing	I
K562	I
cells	I
and	O
murine	O
erythroid	O
leukemia	O
cells	O
.	O

Unlike	O
EKLF	O
,	O
Sp1	O
,	O
which	O
also	O
binds	O
to	O
CACCC	O
boxes	O
,	O
is	O
not	O
recruited	O
to	O
5'HS3	O
.	O

We	O
have	O
also	O
examined	O
how	O
one	O
5'HS	O
affects	O
the	O
recruitment	O
of	O
EKLF	O
to	O
another	O
5'HS	O
.	O

We	O
have	O
found	O
that	O
the	O
recruitment	O
of	O
EKLF	O
to	O
5'HS3	O
depends	O
on	O
the	O
presence	O
of	O
5'HS2	O
in	O
cis	O
,	O
but	O
the	O
recruitment	O
to	O
5'HS2	O
does	O
not	O
depend	O
on	O
5'HS3	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
present	O
a	O
model	O
that	O
illustrates	O
how	O
EKLF	O
may	O
be	O
recruited	O
to	O
the	O
beta	O
-	O
globin	O
locus	O
.	O

Interferons	O
inhibit	O
activation	O
of	O
STAT6	O
by	O
interleukin	O
4	O
in	O
human	O
monocytes	O
by	O
inducing	O
SOCS-1	O
gene	O
expression	O
.	O

Interferons	O
(	O
IFNs	O
)	O
inhibit	O
induction	O
by	O
IL-4	O
of	O
multiple	O
genes	O
in	O
human	O
monocytes	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
IFNs	O
mediate	O
this	O
inhibition	O
has	O
not	O
been	O
defined	O
.	O

IL-4	O
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	O
transcription	O
factor	O
,	O
STAT6	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-6	O
)	O
.	O

STAT6	O
-responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	O
of	O
IL-4-inducible	O
genes	O
.	O

Because	O
STAT6	O
activation	O
is	O
essential	O
for	O
IL-4	O
-induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
regulate	O
activation	O
of	O
STAT6	O
by	O
IL-4	O
in	O
primary	O
human	O
monocytes	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
IFN	O
-	O
beta	O
or	O
IFN	O
-	O
gamma	O
,	O
but	O
not	O
IL-1	O
,	O
IL-2	O
,	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
granulocyte	O
/	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
,	O
IL-6	O
,	O
or	O
transforming	O
growth	O
factor	O
beta	O
suppressed	O
activation	O
of	O
STAT6	O
by	O
IL-4	O
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	O
and	O
was	O
not	O
evident	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	O
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
by	O
IFN	O
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	O
of	O
the	O
JAK	O
/	O
STAT	O
inhibitory	O
gene	O
,	O
SOCS-1	O
.	O

Forced	O
expression	O
of	O
SOCS-1	O
in	O
a	O
macrophage	B
cell	I
line	I
,	O
RAW264	B
,	O
markedly	O
suppressed	O
trans	O
-	O
activation	O
of	O
an	O
IL-4-inducible	O
reporter	O
as	O
well	O
as	O
IL-6-	O
and	O
IFN	O
-	O
gamma	O
-	O
induced	O
reporter	O
gene	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	O
inhibit	O
IL-4	O
-induced	O
activation	O
of	O
STAT6	O
and	O
STAT6	O
-dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS-1	O
.	O

Vitamin	O
D	O
analogs	O
,	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
,	O
-trihomo-1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-vitamin	O
D3	O
,	O
1	O
,	O
24	O
(	O
OH	O
)	O
2	O
-	O
22-ene-24-cyclopropyl	O
-	O
vitamin	O
D3	O
and	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-lumisterol3	O
prime	O
NB4	B
leukemia	I
cells	I
for	O
monocytic	O
differentiation	O
via	O
nongenomic	O
signaling	O
pathways	O
,	O
involving	O
calcium	O
and	O
calpain	O
.	O

Side	O
-	O
chain	O
modified	O
vitamin	O
D	O
analogs	O
including	O
20-Epi-22-oxa-24a	O
,	O
26a	O
,	O
27a	O
-	O
trihomo-1alpha	O
,	O
2	O
5-dihydroxyvitamin	O
D3	O
(	O
KH1060	O
)	O
,	O
and	O
1	O
,	O
24-dihydroxy-22-ene-24-cyclopropyl	O
-	O
vitamin	O
D3	O
(	O
MC903	O
)	O
were	O
originally	O
designed	O
to	O
aid	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
including	O
psoriasis	O
and	O
cancer	O
.	O

Here	O
we	O
demonstrate	O
that	O
these	O
analogs	O
,	O
as	O
well	O
as	O
the	O
6-cis	O
-	O
locked	O
conformer	O
,	O
1alpha	B
,	I
25-dihydroxy	I
-	I
lumisterol3	I
(	I
JN	I
)	I
prime	I
NB4	I
cells	I
for	O
monocytic	O
differentiation	O
.	O

Previously	O
,	O
the	O
action	O
of	O
MC903	O
and	O
KH1060	O
was	O
presumed	O
to	O
be	O
mediated	O
by	O
the	O
nuclear	O
vitamin	O
D	O
receptor	O
(	O
VDRnuc	O
)	O
.	O

Differentiation	O
in	O
response	O
to	O
all	O
analogs	O
was	O
shown	O
to	O
be	O
inhibited	O
by	O
1beta	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
HL	O
)	O
,	O
the	O
antagonist	O
to	O
the	O
nongenomic	O
activities	O
of	O
1	O
,	O
25D3	O
.	O

These	O
data	O
suggest	O
that	O
although	O
MC903	O
and	O
KH1060	O
may	O
bind	O
the	O
VDRnuc	O
,	O
that	O
the	O
differentiative	O
activities	O
of	O
these	O
agents	O
requires	O
nongenomic	O
signaling	O
pathways	O
.	O

Here	O
we	O
show	O
that	O
1alpha	O
,	O
25	O
(	O
OH	O
)	O
2-d5-previtamin	O
D3	O
(	O
HF	O
)	O
,	O
JN	O
,	O
KH1060	O
,	O
and	O
MC903	O
induce	O
expression	O
of	O
PKC	O
alpha	O
and	O
PKC	O
delta	O
and	O
translocation	O
of	O
both	O
isoforms	O
to	O
the	O
particulate	O
fraction	O
,	O
and	O
PKC	O
alpha	O
to	O
the	O
nuclear	O
fraction	O
.	O

The	O
full	O
differentiation	O
response	O
with	O
combinations	O
of	O
analogs	O
and	O
TPA	O
was	O
inhibited	O
50	O
%	O
by	O
the	O
membrane	O
permeable	O
Ca2	O
+	O
chelator	O
,	O
1	O
,	O
2-bis	O
(	O
o	O
-	O
aminophenoxy	O
)	O
-ethane	O
-	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetraacetic	O
acid	O
(	O
BAPTA	O
-	O
AM	O
)	O
or	O
calpain	O
inhibitor	O
I	O
.	O

These	O
data	O
demonstrate	O
that	O
intracellular	O
free	O
calcium	O
and	O
the	O
calcium	O
-	O
dependent	O
protease	O
,	O
calpain	O
play	O
critical	O
roles	O
in	O
monocytic	O
differentiation	O
.	O

Intracellular	O
calcium	O
appears	O
to	O
be	O
most	O
critical	O
in	O
the	O
1	O
,	O
25D3-priming	O
stage	O
of	O
differentiation	O
,	O
while	O
calpain	O
is	O
essential	O
in	O
the	O
TPA	O
maturation	O
response	O
.	O

